

0001414932-24-00001210-Q Oaktree Specialty Lending Corp 202407312024073120223920239202239 0 0001414932-24-000012 10-Q 90 20240630 20240801 20240731 Oaktree Specialty Lending Corp 0001414932 2612129283 DE 0930 10 Q 34 814-00755 241163706 333 SOUTH GRAND AVENUE 28TH FLOOR LOS ANGELES CA 90071 Fifth Street Finance Corp. 20130926 Fifth Street Finance Corp 20071012 10-Q 1 ocs1-20240630.htm 10-Q ocs1-2024063000014149322024Q3FALSESeptember 3033.3333.33P10DP20DP10DP20DP10DP20D33.33http://fasb.org/us-gaap/2023#DebtAndEquitySecuritiesUnrealizedGainLosshttp://fasb.org/us-gaap/2023#RealizedAndUnrealizedGainLossInvestmentDerivativeAndForeignCurrencyTransactionOperatingAfterTaxhttp://fasb.org/us-gaap/2023#DebtAndEquitySecuritiesUnrealizedGainLosshttp://fasb.org/us-gaap/2023#DebtAndEquitySecuritiesRealizedGainLosshttp://fasb.org/us-gaap/2023#RealizedAndUnrealizedGainLossInvestmentDerivativeAndForeignCurrencyTransactionOperatingAfterTaxhttp://fasb.org/us-gaap/2023#DebtAndEquitySecuritiesUnrealizedGainLosshttp://fasb.org/us-gaap/2023#DebtAndEquitySecuritiesRealizedGainLosshttp://fasb.org/us-gaap/2023#RealizedAndUnrealizedGainLossInvestmentDerivativeAndForeignCurrencyTransactionOperatingAfterTaxhttp://fasb.org/us-gaap/2023#DebtAndEquitySecuritiesUnrealizedGainLosshttp://fasb.org/us-gaap/2023#DebtAndEquitySecuritiesRealizedGainLosshttp://fasb.org/us-gaap/2023#RealizedAndUnrealizedGainLossInvestmentDerivativeAndForeignCurrencyTransactionOperatingAfterTax33.3333.33xbrli:sharesiso4217:USDiso4217:USDxbrli:sharesxbrli:pureiso4217-10-012024-06-3000014149322024-07-300001414932us-gaap:InvestmentAffiliatedIssuerControlledMember2024-06-300001414932us-gaap:InvestmentAffiliatedIssuerControlledMember2023-09-300001414932us-gaap:InvestmentAffiliatedIssuerMember2024-06-300001414932us-gaap:InvestmentAffiliatedIssuerMember2023-09-300001414932us-gaap:InvestmentUnaffiliatedIssuerMember2024-06-300001414932us-gaap:InvestmentUnaffiliatedIssuerMember2023-09-3000014149322024-06-3000014149322023-09-300001414932us-gaap:InvestmentAffiliatedIssuerControlledMember2024-04-012024-06-300001414932us-gaap:InvestmentAffiliatedIssuerControlledMember2023-04-012023-06-300001414932us-gaap:InvestmentAffiliatedIssuerControlledMember2023-10-012024-06-300001414932us-gaap:InvestmentAffiliatedIssuerControlledMember2022-10-012023-06-300001414932us-gaap:InvestmentAffiliatedIssuerMember2024-04-012024-06-300001414932us-gaap:InvestmentAffiliatedIssuerMember2023-04-012023-06-300001414932us-gaap:InvestmentAffiliatedIssuerMember2023-10-012024-06-300001414932us-gaap:InvestmentAffiliatedIssuerMember2022-10-012023-06-300001414932us-gaap:InvestmentUnaffiliatedIssuerMember2023-04-012023-06-300001414932us-gaap:InvestmentUnaffiliatedIssuerMember2023-10-012024-06-300001414932us-gaap:InvestmentUnaffiliatedIssuerMember2022-10-012023-06-3000014149322024-04-012024-06-3000014149322023-04-012023-06-3000014149322022-10-012023-06-3000014149322022-01-2023-01-2000014149322024-03-3100014149322023-03-3100014149322022-09-3000014149322023-06-300001414932C5 Technology Holdings, LLC, Data Processing & Outsourced Services, Common Stock2024-06-300001414932C5 Technology Holdings, LLC, Data Processing & Outsourced Services, Preferred Equity2024-06-300001414932Continental Intermodal Group LP, Oil & Gas Storage & Transportation, Preferred Equity2024-06-300001414932Continental Intermodal Group LP, Oil & Gas Storage & Transportation, Common Stock2024-06-300001414932Dominion Diagnostics, LLC, Health Care Services, First Lien Term Loan2024-06-300001414932Dominion Diagnostics, LLC, Health Care Services, Common Stock2024-06-300001414932OCSI Glick JV LLC, Multi-Sector Holdings, Subordinated Debt2024-06-300001414932OCSI Glick JV LLC, Multi-Sector Holdings, Membership Interest2024-06-300001414932Senior Loan Fund JV I, LLC, Multi-Sector Holdings, Subordinated Debt2024-06-300001414932Senior Loan Fund JV I, LLC, Multi-Sector Holdings, Membership Interest2024-06-300001414932SIO2 Medical Products, Inc., Metal, Glass & Plastic Containers, First Lien Term Loan 12024-06-300001414932SIO2 Medical Products, Inc., Metal, Glass & Plastic Containers, First Lien Term Loan 2024-06-300001414932SIO2 Medical Products, Inc., Metal, Glass & Plastic Containers, First Lien Term Loan 3024-06-300001414932SIO2 Medical Products, Inc., Metal, Glass & Plastic Containers, Common Stock2024-06-300001414932SIO2 Medical Products, Inc., Metal, Glass & Plastic Containers, Warrants2024-06-300001414932All Web Leads, Inc., Advertising, First Lien Term Loan 12024-06-300001414932All Web Leads, Inc., Advertising, First Lien Term Loan 2024-06-300001414932All Web Leads, Inc., Advertising, First Lien Term Loan 2024-06-300001414932All Web Leads, Inc., Advertising, Common Stock2024-06-300001414932Assembled Brands Capital LLC, Specialized Finance, Common Stock2024-06-300001414932Assembled Brands Capital LLC, Specialized Finance, Warrants2024-06-300001414932The Avery, Real Estate Operating Companies, First Lien Term Loan 12024-06-300001414932The Avery, Real Estate Operating Companies, First Lien Term Loan 2024-06-300001414932The Avery, Real Estate Operating Companies, Membership Interest2024-06-300001414932Caregiver Services, Inc., Health Care Services, Preferred Equity2024-06-300001414932us-gaap:InvestmentAffiliatedIssuerNoncontrolledMember2024-06-300001414932107 Fair Street LLC, Real Estate Development, First Lien Term Loan2024-06-300001414932107-109 Beech Oak22 LLC, Real Estate Development, First Lien Revolver2024-06-300001414932112-126 Van Houten Real22 LLC, Real Estate Development, First Lien Term Loan2024-06-300001414932A.T. Holdings II Ltd., Biotechnology, First Lien Term Loan2024-06-300001414932A.T. Holdings II SÆRL, Biotechnology, First Lien Term Loan2024-06-300001414932Access CIG, LLC, Diversified Support Services, First Lien Term Loan2024-06-300001414932Accupac, Inc., Personal Care Products, First Lien Term Loan 12024-06-300001414932Accupac, Inc., Personal Care Products, First Lien Term Loan 2024-06-300001414932Accupac, Inc., Personal Care Products, First Lien Revolver2024-06-300001414932Acquia Inc., Application Software, First Lien Term Loan 12024-06-300001414932Acquia Inc., Application Software, First Lien Revolver2024-06-300001414932ADB Companies, LLC, Construction & Engineering, First Lien Term Loan 12024-06-300001414932ADB Companies, LLC, Construction & Engineering, First Lien Term Loan 2024-06-300001414932ADB Companies, LLC, Construction & Engineering, First Lien Term Loan 3024-06-300001414932ADC Therapeutics SA, Biotechnology, First Lien Term Loan2024-06-300001414932ADC Therapeutics SA, Biotechnology, Warrants2024-06-300001414932AIP RD Buyer Corp., Distributors, Common Stock2024-06-300001414932AirStrip Technologies, Inc., Application Software, Warrants2024-06-300001414932Alto Pharmacy Holdings, Inc., Health Care Technology, First Lien Term Loan2024-06-300001414932Alto Pharmacy Holdings, Inc., Health Care Technology, Warrants2024-06-300001414932Alvogen Pharma US, Inc., Pharmaceuticals, First Lien Term Loan2024-06-300001414932Alvotech Holdings S.A., Biotechnology, Fixed Rate Bond 12024-06-300001414932Alvotech Holdings S.A., Biotechnology, Fixed Rate Bond 2024-06-300001414932Alvotech Holdings S.A., Biotechnology, Fixed Rate Bond 3024-06-300001414932Alvotech Holdings S.A., Biotechnology, Fixed Rate Bond 4024-06-300001414932Alvotech Holdings S.A., Biotechnology, Common Stock 12024-06-300001414932Alvotech Holdings S.A., Biotechnology, Common Stock 2024-06-300001414932American Auto Auction Group, LLC, Diversified Support Services, First Lien Term Loan2024-06-300001414932American Auto Auction Group, LLC, Diversified Support Services, Second Lien Term Loan2024-06-300001414932American Tire Distributors, Inc., Distributors, First Lien Term Loan2024-06-300001414932Amspec Parent LLC, Diversified Support Services, First Lien Term Loan 12024-06-300001414932Amspec Parent LLC, Diversified Support Services, First Lien Term Loan 2024-06-300001414932Amspec Parent LLC, Diversified Support Services, First Lien Revolver2024-06-300001414932Anchorage Capital CLO 20, Multi-Sector Holdings, CLO Notes2024-06-300001414932Archers Buyer Inc., Interactive Media & Services, First Lien Term Loan2024-06-300001414932Ares XLIV CLO, Multi-Sector Holdings, CLO Notes2024-06-300001414932ASP-R-PAC Acquisition Co LLC, Paper & Plastic Packaging Products & Materials, First Lien Term Loan2024-06-300001414932ASP-R-PAC Acquisition Co LLC, Paper & Plastic Packaging Products & Materials, First Lien Revolver2024-06-300001414932Astra Acquisition Corp., Application Software, First Lien Term Loan 12024-06-300001414932Astra Acquisition Corp., Application Software, First Lien Term Loan 2024-06-300001414932Athenahealth Group Inc., Health Care Technology, Fixed Rate Bond2024-06-300001414932Athenahealth Group Inc., Health Care Technology, Preferred Equity2024-06-300001414932ATNX SPV, LLC, Pharmaceuticals, First Lien Term Loan2024-06-300001414932Aurelia Netherlands Midco 2 B.V., Interactive Media & Services, First Lien Term Loan2024-

Lien Term Loan2024-06-300001141932Learfield Communications, LLC, Movies & Entertainment, First Lien Term Loan2024-06-300001141932Lightbox Intermediate, L.P., Real Estate Services, First Lien Term Loan2024-06-300001141932Liquid Environmental Solutions Corporation, Environmental & Facilities Services, Second Lien Term Loan 12024-06-300001141932Liquid Environmental Solutions Corporation, Environmental & Facilities Services, Second Lien Term Loan 2024-06-300001141932Liquid Environmental Solutions Corporation, Environmental & Facilities Services, Common Stock2024-06-300001141932LSL Holdco, LLC, Health Care Distributors, First Lien Term Loan 12024-06-300001141932LSL Holdco, LLC, Health Care Distributors, First Lien Term Loan 2024-06-300001141932LSL Holdco, LLC, Health Care Distributors, First Lien Term Loan 2024-06-300001141932Marinus Pharmaceuticals, Inc., Pharmaceuticals, First Lien Term Loan 12024-06-300001141932Marinus Pharmaceuticals, Inc., Pharmaceuticals, First Lien Term Loan 2024-06-300001141932Marinus Pharmaceuticals, Inc., Pharmaceuticals, Warrants 12024-06-300001141932Mesoblast, Inc., Biotechnology, Warrants 12024-06-300001141932MHE Intermediate Holdings, LLC, Diversified Support Services, First Lien Term Loan 12024-06-300001141932MHE Intermediate Holdings, LLC, Diversified Support Services, First Lien Term Loan 2024-06-300001141932MHE Intermediate Holdings, LLC, Diversified Support Services, First Lien Revolver2024-06-300001141932Mindbody, Inc., Internet Services & Infrastructure, First Lien Term Loan 12024-06-300001141932Mindbody, Inc., Internet Services & Infrastructure, First Lien Term Loan 2024-06-300001141932Mindbody, Inc., Internet Services & Infrastructure, First Lien Revolver2024-06-300001141932Minotaur Acquisition, Inc., Financial Exchanges & Data, First Lien Term Loan 12024-06-300001141932Minotaur Acquisition, Inc., Financial Exchanges & Data, First Lien Term Loan 2024-06-300001141932Minotaur Acquisition, Inc., Financial Exchanges & Data, First Lien Term Loan 2024-06-300001141932Modena Buyer LLC, Application Software, First Lien Term Loan 2024-06-300001141932Monotype Imaging Holdings Inc., Application Software, First Lien Term Loan 12024-06-300001141932Monotype Imaging Holdings Inc., Application Software, First Lien Term Loan 2024-06-300001141932Monotype Imaging Holdings Inc., Application Software, First Lien Revolver2024-06-300001141932Mosaic Companies, LLC, Home Improvement Retail, First Lien Term Loan2024-06-300001141932MRI Software LLC, Application Software, First Lien Term Loan 12024-06-300001141932MRI Software LLC, Application Software, First Lien Revolver2024-06-300001141932NeuAG, LLC, Fertilizers & Agricultural Chemicals, First Lien Term Loan2024-06-300001141932Next Holdco, LLC, Health Care Technology, First Lien Term Loan 12024-06-300001141932Next Holdco, LLC, Health Care Technology, First Lien Revolver2024-06-300001141932NIN, Inc., Industrial Machinery & Supplies & Components, First Lien Term Loan2024-06-300001141932NIN, Inc., Industrial Machinery & Supplies & Components, Warrants 12024-06-300001141932NN, Inc., Industrial Machinery & Supplies & Components, Warrants 12024-06-300001141932OFSI Fund Ltd, Multi-Sector Holdings, CLO Notes2024-06-300001141932Oranje Holdco, Inc., Systems Software, First Lien Term Loan 12024-06-300001141932OTG Management, LLC, Airport Services, First Lien Term Loan2024-06-300001141932OTG Management, LLC, Airport Services, Common Stock2024-06-300001141932OZLM XXIII Ltd, Multi-Sector Holdings, CLO Notes2024-06-300001141932Performance Health Holdings, Inc., Health Care Distributors, First Lien Term Loan2024-06-300001141932PetVet Care Centers, LLC, Health Care Services, First Lien Term Loan 12024-06-300001141932PetVet Care Centers, LLC, Health Care Services, First Lien Revolver2024-06-300001141932Pluralsight, LLC, Application Software, First Lien Term Loan2024-06-300001141932PRGX Global, Inc., Data Processing & Outsourced Services, First Lien Term Loan2024-06-300001141932Profrac Holdings II, LLC, Industrial Machinery & Supplies & Components, First Lien Floating Rate Bond2024-06-300001141932Protein For Pets Opco, LLC, Packaged Foods & Meats, First Lien Term Loan2024-06-300001141932Quantum Bidco Limited, Food Distributors, First Lien Term Loan 12024-06-300001141932Quorum Labs, Inc., Application Software, Preferred Equity2024-06-300001141932Relativity ODA LLC, Application Software, First Lien Term Loan2024-06-300001141932RumbleOn, Inc., Automotive Retail, First Lien Term Loan 12024-06-300001141932Salus Workers' Compensation, LLC, Diversified Financial Services, First Lien Term Loan2024-06-300001141932Saratoga, Diversified Financial Services, Credit Linked Notes 2024-06-300001141932SCIH Salt Holdings Inc., Diversified Chemicals, Fixed Rate Bond2024-06-300001141932Scilex Holding Co, Biotechnology, Common Stock2024-06-300001141932scPharmaceuticals Inc., Pharmaceuticals, First Lien Term Loan 12024-06-300001141932scPharmaceuticals Inc., Pharmaceuticals, Warrants2024-06-300001141932Seres Therapeutics, Inc., Biotechnology, First Lien Term Loan 12024-06-300001141932Seres Therapeutics, Inc., Biotechnology, First Lien Term Loan 2024-06-300001141932Seres Therapeutics, Inc., Biotechnology, Warrants2024-06-300001141932SM Wellness Holdings, Inc., Health Care Services, First Lien Term Loan2024-06-300001141932Soreson Communications, LLC, Communications Equipment, First Lien Revolver 2024-06-300001141932Sorrento Therapeutics, Inc., Biotechnology, Common Stock2024-06-300001141932Spanx, LLC, Apparel Retail, First Lien Revolver2024-06-300001141932SPX Flow, Inc., Industrial Machinery & Supplies & Components, Fixed Rate Bond2024-06-300001141932Staples, Inc., Office Services & Supplies, First Lien Term Loan2024-06-300001141932Staples, Inc., Office Services & Supplies, Fixed Rate Bond2024-06-300001141932SumUp Holdings Luxembourg S.A.R.L., Diversified Financial Services, First Lien Term Loan2024-06-300001141932Superior Industries International, Inc., Auto Parts & Equipment, First Lien Term Loan2024-06-300001141932Supreme Fitness Group NY Holdings, LLC, Leisure Facilities, First Lien Term Loan 12024-06-300001141932Supreme Fitness Group NY Holdings, LLC, Leisure Facilities, First Lien Term Loan 2024-06-300001141932SVP-Singer Holdings Inc., Home Furnishings, First Lien Term Loan2024-06-300001141932Telephone and Date Systems, Inc., Wireless Telecommunication Services, First Lien Term Loan 12024-06-300001141932Telemash Holdings Corporation, Application Software, First Lien Term Loan2024-06-300001141932Ten-X LLC, Interactive Media & Services, First Lien Term Loan2024-06-300001141932THL Zinc Ventures Ltd, Diversified Metals & Mining, First Lien Term Loan2024-06-300001141932Thrasio, LLC, Broadline Retail, First Lien Term Loan 12024-06-300001141932Thrasio, LLC, Broadline Retail, First Lien Term Loan 2024-06-300001141932Trinitas CLO JV Ltd., Multi-Sector Holdings, CLO Notes2024-06-300001141932Truck-Lite Co, LLC, Construction Machinery & Heavy Transportation Equipment, First Lien Term Loan 1 2024-06-300001141932Truck-Lite Co, LLC, Construction Machinery & Heavy Transportation Equipment, First Lien Revolver 2024-06-300001141932Uniti Group LP, Cable & Satellite, Fixed Rate Bond2024-06-300001141932Verona Pharma, Inc., Pharmaceuticals, First Lien Term Loan 12024-06-300001141932Verona Pharma, Inc., Pharmaceuticals, First Lien Term Loan 2024-06-300001141932Verona Pharma, Inc., Pharmaceuticals, First Lien Term Loan 52024-06-300001141932Win Brands Group LLC, Housewares & Specialties, Warrants2024-06-300001141932Winstar Services II, LLC, Integrated Telecommunication Services, Common Stock2024-06-300001141932WP CPP Holdings, LLC, Aerospace & Defense, First Lien Term Loan2024-06-300001141932Zep Inc., Specialty Chemicals, First Lien Term Loan2024-06-300001141932ZEP Morgan Prime Money Market Fund, Institutional Shares, Specialty Chemicals, First Lien Term Loan2024-06-300001141932ZEUR Foreign Currency Forward Contract, Maturing August 8, 20242024-06-300001141932ZFC Foreign Exchange Forward Member2024-06-300001141932Zocsl:InterestRateSwapMaturing2027Member2024-06-300001141932Zocsl:InterestRateSwapMaturing2029Member2024-06-300001141932Zus-gaap:InterestRateSwapMember2024-06-300001141932Zus-srt:MinimumMember2024-06-300001141932Zus-srt:MaximumMember2024-06-300001141932Zocsl:EarnoutShareVestingTrancheTwoMember2024-06-300001141932Zocsl:EarnoutShareVestingTrancheTwoMember2023-10-012024-06-300001141932C5 Technology Holdings, LLC, Data Processing & Outsourced Services, Common Stock2023-09-300001141932C5 Technology Holdings, LLC, Data Processing & Outsourced Services, Preferred Equity2023-09-300001141932Dominion Diagnostics, LLC, Health Care Services, First Lien Term Loan 12023-09-300001141932Dominion Diagnostics, LLC, Health Care Services, First Lien Term Loan 2023-09-300001141932Dominion Diagnostics, LLC, Health Care Services, First Lien Revolver2023-09-300001141932Dominion Diagnostics, LLC, Health Care Services, Common Stock2023-09-300001141932OCSCI Glick JV LLC, Multi-Sector Holdings, Subordinated Debt2023-09-300001141932OCSCI Glick JV LLC, Multi-Sector Holdings, Membership Interest2023-09-300001141932Senior Loan Fund JV I, LLC, Multi-Sector Holdings, Subordinated Debt2023-09-300001141932Senior Loan Fund JV I, LLC, Multi-Sector Holdings, Membership Interest2023-09-300001141932SIO2 Medical Products, Inc., Metal, Glass & Plastic Containers, First Lien Term Loan 2023-09-300001141932SIO2 Medical Products, Inc., Metal, Glass & Plastic Containers, First Lien Term Loan 32023-09-300001141932SIO2 Medical Products, Inc., Metal, Glass & Plastic Containers, Warrants2023-09-300001141932Assembled Brands Capital LLC, Specialized Finance, First Lien Revolver2023-09-300001141932Assembled Brands Capital LLC, Specialized Finance, Common Stock2023-09-300001141932Assembled Brands Capital LLC, Specialized Finance, Preferred Equity2023-09-300001141932Assembled Brands Capital LLC, Specialized Finance, Warrants2

Transportation, Warrants2023-09-300001414932Conviva Inc., Application Software, Preferred Equity2023-09-300001414932Coupa Holdings, LLC, Application Software, First Lien Term Loan 12023-09-300001414932Coupa Holdings, LLC, Application Software, First Lien Revolver2023-09-300001414932Covetrus, Inc., Health Care Distributors, First Lien Term Loan2023-09-300001414932Coyote Buyer, LLC, Specialty Chemicals, First Lien Term Loan2023-09-300001414932Coyote Buyer, LLC, Specialty Chemicals, First Lien Revolver2023-09-300001414932CPC Acquisition Corp., Specialty Chemicals, Second Lien Term Loan2023-09-300001414932Delta Leasing SPV II LLC, Specialized Finance, Subordinated Debt Term Loan2023-09-300001414932Delta Leasing SPV II LLC, Specialized Finance, Preferred Equity2023-09-300001414932Delta Leasing SPV II LLC, Specialized Finance, Common Stock2023-09-300001414932Delta Leasing SPV II LLC, Specialized Finance, Warrants2023-09-300001414932Dialyze Holdings, LLC, Health Care Equipment, First Lien Term Loan2023-09-300001414932Dialyze Holdings, LLC, Health Care Equipment, Subordinated Debt Term Loan2023-09-300001414932Dialyze Holdings, LLC, Health Care Equipment, Warrants2023-09-300001414932Digital.AI Software Holdings, Inc., Application Software, First Lien Term Loan2023-09-300001414932Digital.AI Software Holdings, Inc., Application Software, First Lien Revolver2023-09-300001414932DirectTV Financing, LLC, Cable & Satellite, First Lien Term Loan2023-09-300001414932DTI Holdco, Inc., Research & Consulting Services, First Lien Term Loan2023-09-300001414932Eagleview Technology Corporation, Application Software, Second Lien Term Loan2023-09-300001414932EOS Fitness Opco Holdings, LLC, Leisure Facilities, Preferred Equity2023-09-300001414932EOS Fitness Opco Holdings, LLC, Leisure Facilities, Common Stock2023-09-300001414932Establishment Labs Holdings Inc., Health Care Technology, First Lien Term Loan 12023-09-300001414932Establishment Labs Holdings Inc., Health Care Technology, First Lien Term Loan 2023-09-300001414932Establishment Labs Holdings Inc., Health Care Technology, First Lien Term Loan 2023-09-300001414932Evergreen IX Borrower 2023, LLC, Application Software, First Lien Term Loan2023-09-300001414932Evergreen IX Borrower 2023, LLC, Application Software, First Lien Revolver2023-09-300001414932Fairbridge Strategic Capital Funding LLC, Real Estate Operating Companies, First Lien Term Loan2023-09-300001414932Fairbridge Strategic Capital Funding LLC, Real Estate Operating Companies, Warrants2023-09-300001414932Finastra USA, Inc., Application Software, First Lien Term Loan2023-09-300001414932Finastra USA, Inc., Application Software, First Lien Revolver2023-09-300001414932FINThrive Software Intermediate Holdings, Inc., Health Care Technology, Second Lien Term Loan2023-09-300001414932Fortress Biotech, Inc., Biotechnology, First Lien Term Loan2023-09-300001414932Fortress Biotech, Inc., Biotechnology, Warrants2023-09-300001414932Frontier Communications Holdings, LLC, Integrated Telecommunication Services, Fixed Rate Bond2023-09-300001414932Galileo Parent, Inc., Aerospace & Defense, First Lien Term Loan2023-09-300001414932Galileo Parent, Inc., Aerospace & Defense, First Lien Revolver2023-09-300001414932Gibson Brands, Inc., Leisure Products, First Lien Term Loan2023-09-300001414932GoldenTree Loan Management EUR CLO 2 DAC, Multi-Sector Holdings, CLO Notes2023-09-300001414932Grove Hotel Parcel Owner, LLC, Hotels, Resorts & Cruise Lines, First Lien Term Loan 12023-09-300001414932Grove Hotel Parcel Owner, LLC, Hotels, Resorts & Cruise Lines, First Lien Revolver2023-09-300001414932Harbor Purchaser Inc., Education Services, First Lien Term Loan2023-09-300001414932Harrow, Inc., Pharmaceuticals, First Lien Term Loan 12023-09-300001414932Harrow, Inc., Pharmaceuticals, First Lien Term Loan 2023-09-300001414932Harrow, Inc., Pharmaceuticals, First Lien Revolver2023-09-300001414932Harrow, Inc., Pharmaceuticals, First Lien Term Loan 2023-09-300001414932Horizon Aircraft Finance I Ltd., Specialized Finance, CLO Notes2023-09-300001414932IAMGOLD Corporation, Gold, Second Lien Term Loan2023-09-300001414932iCIMS, Inc., Application Software, First Lien Term Loan 12023-09-300001414932iCIMS, Inc., Application Software, First Lien Term Loan 2023-09-300001414932iCIMS, Inc., Application Software, First Lien Revolver2023-09-300001414932Impel Pharmaceuticals Inc., Health Care Technology, First Lien Term Loan 12023-09-300001414932Impel Pharmaceuticals Inc., Health Care Technology, First Lien Term Loan 2023-09-300001414932Impel Pharmaceuticals Inc., Health Care Technology, Warrants2023-09-300001414932Innocoll Pharmaceuticals Limited, Health Care Technology, Warrants2023-09-300001414932Integral Development Corporation, Diversified Financial Services, Warrants2023-09-300001414932Inventus Power, Inc., Electrical Components & Equipment, First Lien Term Loan2023-09-300001414932Inventus Power, Inc., Electrical Components & Equipment, First Lien Revolver2023-09-300001414932INW Manufacturing, LLC, Personal Care Products, First Lien Term Loan2023-09-300001414932IPC Corp., Application Software, First Lien Term Loan2023-09-300001414932Ivanti Software, Inc., Application Software, Second Lien Term Loan2023-09-300001414932Kings Buyer, LLC, Environmental & Facilities Services, First Lien Term Loan 12023-09-300001414932Kings Buyer, LLC, Environmental & Facilities Services, First Lien Revolver 12023-09-300001414932Kings Buyer, LLC, Environmental & Facilities Services, First Lien Term Loan 2023-09-300001414932Kings Buyer, LLC, Environmental & Facilities Services, First Lien Revolver 2023-09-300001414932Latam Airlines Group S.A., Passenger Airlines, First Lien Term Loan2023-09-300001414932Lift Brands Holdings, Inc., Leisure Facilities, Common Stock2023-09-300001414932Lightbox Intermediate, L.P., Real Estate Services, First Lien Term Loan2023-09-300001414932Liquid Environmental Solutions Corporation, Environmental & Facilities Services, Second Lien Term Loan 12023-09-300001414932Liquid Environmental Solutions Corporation, Environmental & Facilities Services, Common Stock2023-09-300001414932LSL Holdco, LLC, Health Care Distributors, First Lien Term Loan 12023-09-300001414932LSL Holdco, LLC, Health Care Distributors, First Lien Revolver2023-09-300001414932Marinus Pharmaceuticals, Inc., Pharmaceuticals, First Lien Term Loan 12023-09-300001414932Marinus Pharmaceuticals, Inc., Pharmaceuticals, First Lien Revolver2023-09-300001414932Marinus Pharmaceuticals, Inc., Pharmaceuticals, First Lien Term Loan 32023-09-300001414932Mesoblast, Inc., Biotechnology, Warrants 2023-09-300001414932Mesoblast, Inc., Biotechnology, Warrants 2023-09-300001414932MHE Intermediate Holdings, LLC, Diversified Support Services, First Lien Term Loan 12023-09-300001414932MHE Intermediate Holdings, LLC, Diversified Support Services, First Lien Term Loan 2023-09-300001414932MHE Intermediate Holdings, LLC, Diversified Support Services, First Lien Revolver2023-09-300001414932Mindbody, Inc., Internet Services & Infrastructure, First Lien Term Loan 12023-09-300001414932Mindbody, Inc., Internet Services & Infrastructure, First Lien Revolver2023-09-300001414932MND Holdings III Corp. Other Specialty Retail, First Lien Term Loan2023-09-300001414932MND Holdings III Corp. Other Specialty Retail, First Lien Revolver2023-09-300001414932Mosaic Companies, LLC, Home Improvement Retail, First Lien Term Loan2023-09-300001414932MRI Software LLC, Application Software, First Lien Term Loan 12023-09-300001414932MRI Software LLC, Application Software, First Lien Term Loan 2023-09-300001414932MRI Software LLC, Application Software, First Lien Revolver2023-09-300001414932Navisite, LLC, Data Processing & Outsourced Services, Second Lien Term Loan2023-09-300001414932NeuAG, LLC, Fertilizers & Agricultural Chemicals, First Lien Term Loan2023-09-300001414932NFP Corp., Diversified Financial Services, Fixed Rate Bond2023-09-300001414932NN, Inc., Industrial Machinery & Supplies & Components, First Lien Term Loan2023-09-300001414932NN, Inc., Industrial Machinery & Supplies & Components, Warrants 12023-09-300001414932NN, Inc., Industrial Machinery & Supplies & Components, Warrants 2023-09-300001414932OECConnection LLC, Application Software, Second Lien Term Loan2023-09-300001414932Oranje Holdco, Inc., Systems Software, First Lien Term Loan2023-09-300001414932Oranje Holdco, Inc., Systems Software, First Lien Revolver2023-09-300001414932OTG Management, LLC, Airport Services, First Lien Term Loan 2023-09-300001414932OTG Management, LLC, Airport Services, First Lien Term Loan 32023-09-300001414932P & L Development, LLC, Pharmaceuticals, Fixed Rate Bond2023-09-300001414932Park Place Technologies, LLC, Internet Services & Infrastructure, First Lien Term Loan2023-09-300001414932Performance Health Holdings, Inc., Health Care Distributors, First Lien Term Loan2023-09-300001414932Planview Parent, Inc., Application Software, Second Lien Term Loan2023-09-300001414932Pluralsight, LLC, Application Software, First Lien Term Loan2023-09-300001414932Pluralsight, LLC, Application Software, First Lien Revolver2023-09-300001414932PPW Aero Buyer, Inc., Aerospace & Defense, First Lien Term Loan2023-09-300001414932PPW Aero Buyer, Inc., Aerospace & Defense, First Lien Revolver2023-09-300001414932PRGX Global, Inc., Data Processing & Outsourced Services, First Lien Term Loan2023-09-300001414932PRGX Global, Inc., Data Processing & Outsourced Services, First Lien Revolver2023-09-300001414932PRGX Global, Inc., Data Processing & Outsourced Services, Common Stock2023-09-300001414932Profrac Holdings II, LLC, Industrial Machinery & Supplies & Components, First Lien Term Loan 12023-09-300001414932Profrac Holdings II, LLC, Industrial Machinery & Supplies & Components, First Lien Revolver2023-09-300001414932Profrac Holdings II, LLC, Industrial Machinery & Supplies & Components, First Lien Term Loan 2023-09-300001414932Quantum Bidco Limited, Food Distributors, First Lien Term Loan2023-09-300001414932QuorumLabs, Inc., Application Software, Preferred Equity2023-09-300001414932Relativity ODA LLC, Application Software, First Lien Term Loan2023-09-300001414932Relativity ODA LLC, Application Software, First Lien Revolver2023-09-300001414932RumbleOn, Inc., Automotive Retail, First Lien Term Loan 12023-09-300001414932RumbleOn, Inc., Automotive Retail, First Lien Term Loan 2023-09-300001414932RumbleOn, Inc., Automotive Retail, Warrants2023-09-300001414932Salus Workers' Compensation, LLC, Diversified Financial Services, First Lien Term Loan2023-09-300001414932Salus Workers' Compensation, LLC, Diversified Financial Services, First Lien Revolver2023-09-300001414932Salus Workers' Compensation, LLC, Diversified Financial Services, Warrants2023-09-300001414932Scilex Holding Co, Biotechnology, Common Stock2023-09-300001414932SCP Eye Care Services, LLC, Health Care Services, Second Lien Term Loan 12023-09-300001414932SCP Eye Care Services, LLC, Health Care Services, Second Lien Revolver2023-09-300001414932SCP Eye Care Services, LLC, Health Care Services, Common Stock2023-09-300001414932scpPharmaceuticals Inc., Pharmaceuticals, First Lien Term Loan 12023-09-300001414932scpPharmaceuticals Inc., Pharmaceuticals, First Lien Term Loan 2023-09-300001414932scpPharmaceuticals Inc., Pharmaceuticals, First Lien Revolver2023-09-300001414932scpPharmaceuticals Inc., Pharmaceuticals, First Lien Term Loan 32023-09-300001414932scpPharmaceuticals Inc., Pharmaceuticals, Warrants2023-09-300001414932Seres Therapeutics, Inc., Biotechnology, First Lien Term Loan 12023-09-300001414932Seres Therapeutics, Inc., Biotechnology, First Lien Term Loan 2023-09-300001414932Seres Therapeutics, Inc., Biotechnology, First Lien Revolver2023-09-300001414932Seres Therapeutics, Inc., Biotechnology, Warrants2023-09-300001414932ShareThis, Inc., Application Software, Warrants2023-09-300001414932SM Wellness Holdings, Inc., Health Care Services, First Lien Term Loan2023-09-300001414932SM Wellness Holdings, Inc., Health Care Services, Second Lien Term Loan2023-09-300001414932SonicWall US Holdings Inc., Technology Distributors, Second Lien Term Loan2023-09-300001414932Sorrento Therapeutics, Inc., Biotechnology, Common Stock2023-09-300001414932Spanx, LLC, Apparel Retail, First Lien Term Loan2023-09-300001414932Spanx, LLC, Apparel Retail, First Lien Revolver2023-09-300001414932SumUp Holdings Luxembourg S.À.R.L., Diversified Financial Services, First Lien Term Loan2023-09-300001414932Superior Industries International, Inc., Auto Parts & Equipment, First Lien Term Loan2023-09-300001414932Supreme Fitness Group NY Holdings, LLC, Leisure Facilities, First Lien Term Loan 12023-09-300001414932Supreme Fitness Group NY Holdings, LLC, Leisure Facilities, First Lien Revolver2023-09-300001414932SVP-Singer Holdings Inc., Home Furnishings, First Lien Term Loan2023-09-300001414932Tacala, LLC, Restaurants, Second Lien Term Loan2023-09-300001414932Tahoe Bidco B.V., Application Software, First Lien Term Loan2023-09-300001414932Tahoe Bidco B.V., Application Software, First Lien Revolver2023-09-300001414932Telesmart Holdings Corporation, Application Software, First Lien Term Loan2023-09-300001414932Telesmart Holdings Corporation, Application Software, First Lien Revolver2023-09-300001414932Ten-X LLC, Interactive Media & Services, First Lien Term Loan2023-09-300001414932TGNR HoldCo LLC, Integrated Oil & Gas, Subordinated Debt2023-09-300001414932THL Zinc Ventures Ltd, Diversified Metals & Mining, First Lien Term Loan2023-09-300001414932Thrasio, LLC, Broadline Retail, First Lien Term Loan2023-09-300001414932Thrasio, LLC, Broadline Retail, Preferred Equity 12023-09-300001414932Thrasio, LLC, Broadline Retail, Preferred Equity 2023-09-300001414932Thrasio, LLC, Broadline Retail, Preferred Equity 2023-09-300001414932Touchstone Acquisition, Inc., Health Care Supplies, First Lien Term Loan2023-09-300001414932Trinitas CLO XV DAC, Multi-Sector Holdings, CLO Notes2023-09-300001414932Uniti Group LP, Other Specialized REITs, Fixed Rate Bond 12023-09-300001414932Uniti Group LP, Other Specialized REITs, Fixed Rate Bond 2023-09-300001414932Virgin Plus, Inc., Application Software, Second Lien Term Loan2023-09-300001414932Win Brands Group LLC, Housewares & Specialties, First Lien Term Loan 12023-09-300001414932Win Brands Group LLC, Housewares & Specialties, First Lien Revolver2023-09-300001414932Win Brands Group LLC, Housewares & Specialties, Warrants2023-09-300001414932Windstream Services II, LLC, Integrated Telecommunication Services, First Lien Term Loan2023-09-300001414932Windstream Services II, LLC, Integrated Telecommunication Services, Common Stock2023-09-300001414932WP CPP Holdings, LLC, Aerospace & Defense, First Lien Term Loan2023-09-300001414932WWEIX Uni Topco Holdings, LLC, Air Freight & Logistics, Second Lien Term Loan2023-09-300001414932Zephyr Bidco Limited, Specialized Finance, Second Lien Term Loan2023-09-300001414932Zep Inc., Specialty Chemicals, First Lien Term Loan2023-09-300001414932JP Morgan Prime Market Fund, Institutional Shares2023-09-300001414932Other cash accounts2023-09-300001414932EUR Foreign Currency Forward Contract, Maturing November 9, 20232023-09-300001414932GBP Foreign Currency Forward Contract, Maturing November 9, 20232023-09-300001414932us-gaap:ForeignExchangeForwardMember2023-09-300001414932ocsl:InterestRateSwapMaturing2027Member2023-09-300001414932ocsl:InterestRateSwapMaturing2029Member2023-09-300001414932srt:MinimumMember2023-09-300001414932srt:MaximumMember2023-09-300001414932ocsl:EarnoutShareVestingTrancheOneMember2023-09-300001414932ocsl:EarnoutShareVestingTrancheOneMember2022-10-012023-09-300001414932ocsl:EarnoutShareVestingTrancheTwoMember2023-09-300001414932ocsl:EarnoutShareVestingTrancheTwoMember2022-10-012023-09-300001414932ocsl:NonAccrualStatusDebtSecuritiesMemberocsl:InvestmentTypeConcentrationRiskMemberocsl:InvestmentOwnedFairValueMember2024-06-300001414932ocsl:NonAccrualStatusDebtSecuritiesMemberocsl:InvestmentTypeConcentrationRiskMemberocsl:InvestmentOwnedCostMember2023-10-012024-06-300001414932ocsl:NonAccrualStatusDebtSecuritiesMemberocsl:InvestmentTypeConcentrationRiskMemberocsl:InvestmentOwnedFairValueMember2023-10-012024-06-300001414932ocsl:NonAccrualStatusDebtSecuritiesMemberocsl:InvestmentTypeConcentrationRiskMemberocsl:InvestmentOwnedFairValueMember2023-09-300001414932ocsl:NonAccrualStatusDebtSecuritiesMemberocsl:InvestmentTypeConcentrationRiskMemberocsl:InvestmentOwnedCostMember2022-10-012023-09-300001414932ocsl:NonAccrualStatusDebtSecuritiesMemberocsl:InvestmentTypeConcentrationRiskMemberocsl:InvestmentOwnedFairValueMember2022-10-012023-09-300001414932ocsl:DeutscheBankTrustCompanyAmericasMember2024-06-300001414932ocsl:WellsFargoBankNAMember2023-09-3000014149322022-01-012022-12-31000014149322023-01-012023-12-3100001414932ocsl:SLFJVILLCMember2024-06-300001414932ocsl:OCSSGlickVILLCMember2024-06-300001414932ocsl:TheJVsMember2024-06-300001414932ocsl:SLFJVILLCMember2023-09-300001414932ocsl:OCSSGlickVILLCMember2023-09-300001414932ocsl:InvestmentTypeConcentrationRiskMemberocsl:DebtSecuritiesSeniorSecuredMemberocsl:InvestmentOwnedAtFairValueMember2023-10-012024-06-300001414932ocsl:DebtSecuritiesSubordinatedIncludingJVDebtInstrumentsMemberocsl:InvestmentTypeConcentrationRiskMemberocsl:InvestmentOwnedAtFairValueMember2023-10-012024-06-300001414932ocsl:DebtSecuritiesSubordinatedIncludingJVDebtInstrumentsMemberocsl:InvestmentTypeConcentrationRiskMemberocsl:InvestmentOwnedAtFairValueMember2022-10-012023-09-300001414932us-gaap:DebtSecuritiesMember2024-06-300001414932us-gaap:DebtSecuritiesMember2023-09-300001414932us-gaap:EquitySecuritiesMember2024-06-300001414932us-gaap:EquitySecuritiesMember2023-09-300001414932us-gaap:EquitySecuritiesJVMember2024-06-300001414932ocsl:EquitySecuritiesJVMember2023-09-300001414932ocsl:DebtSecuritiesFloatingRateMember2024-06-300001414932ocsl:DebtSecuritiesFixedRateMember2023-09-300001414932ocsl:DebtSecuritiesSeniorSecuredMemberus-gaap:FairValueInputsLevel1Member2024-06-300001414932us-gaap:FairValueInputsLevel2Memberocsl:DebtSecuritiesSeniorSecuredMember2024-06-300001414932ocsl:DebtSecuritiesSeniorSecuredMemberus-gaap:FairValueInputsLevel3Member2024-06-300001414932us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberocsl:DebtSecuritiesSeniorSecuredMember2024-06-300001414932ocsl:DebtSecuritiesSeniorSecuredMember2024-06-300001414932ocsl:DebtSecuritiesSubordinatedIncludingJVDebtInstrumentsMemberus-gaap:FairValueInputsLevel1Member2024-06-300001414932us-gaap:FairValueInputsLevel2Memberocsl:DebtSecuritiesSubordinatedIncludingJVDebtInstrumentsMember2024-06-300001414932us-gaap:FairValueInputsLevel3Member2024-06-300001414932us-gaap:FairValueInputsLevel4Memberocsl:DebtSecuritiesSubordinatedIncludingJVDebtInstrumentsMember2024-06-300001414932us-gaap:FairValueInputsLevel5Memberocsl:DebtSecuritiesSubordinatedIncludingJVDebtInstrumentsMember2024-06-300001414932us-gaap:FairValueInputsLevel6Memberocsl:DebtSecuritiesSubordinatedIncludingJVDebtInstrumentsMember2024-06-300001414932us-gaap:FairValueInputsLevel7Memberocsl:DebtSecuritiesSubordinatedIncludingJVDebtInstrumentsMember2024-06-300001414932us-gaap:FairValueInputsLevel8Memberocsl:DebtSecuritiesSubordinatedIncludingJVDebtInstrumentsMember2024-06-300001414932us-gaap:FairValueInputsLevel9Memberocsl:DebtSecuritiesSubordinatedIncludingJVDebtInstrumentsMember2024-06-300001414932us-gaap:FairValueInputsLevel10Memberocsl:DebtSecuritiesSubordinatedIncludingJVDebtInstrumentsMember2024-06-300001414932us-gaap:FairValueInputsLevel11Memberocsl:DebtSecuritiesSubordinatedIncludingJVDebtInstrumentsMember2024-06-300001414932us-gaap:FairValueInputsLevel12Memberocsl:DebtSecuritiesSubordinatedIncludingJVDebtInstrumentsMember2024-06-300001414932us-gaap:FairValueInputsLevel13Memberocsl:DebtSecuritiesSubordinatedIncludingJVDebtInstrumentsMember2024-06-300001414932us-gaap:FairValueInputsLevel14Memberocsl:DebtSecuritiesSubordinatedIncludingJVDebtInstrumentsMember2024-06-300001414932us-gaap:FairValueInputsLevel15Memberocsl:DebtSecuritiesSubordinatedIncludingJVDebtInstrumentsMember2024-06-300001414932us-gaap:FairValueInputsLevel16Memberocsl:DebtSecuritiesSubordinatedIncludingJVDebtInstrumentsMember2024-06-300001414932us-gaap:FairValueInputsLevel17Memberocsl:DebtSecuritiesSubordinatedIncludingJVDebtInstrumentsMember2024-06-300001414932us-gaap:FairValueInputsLevel18Memberocsl:DebtSecuritiesSubordinatedIncludingJVDebtInstrumentsMember2024-06-300001414932us-gaap:FairValueInputsLevel19Memberocsl:DebtSecuritiesSubordinatedIncludingJVDebtInstrumentsMember2024-06-300001414932us-gaap:FairValueInputsLevel20Memberocsl:DebtSecuritiesSubordinatedIncludingJVDebtInstrumentsMember2024-06-300001414932us-gaap:FairValueInputsLevel21Memberocsl:DebtSecuritiesSubordinatedIncludingJVDebtInstrumentsMember2024-06-300001414932us-gaap:FairValueInputsLevel22Memberocsl:DebtSecuritiesSubordinatedIncludingJVDebtInstrumentsMember2024-06-300001414932us-gaap:FairValueInputsLevel23Memberocsl:DebtSecuritiesSubordinatedIncludingJVDebtInstrumentsMember2024-06-300001414932us-gaap:FairValueInputsLevel24Memberocsl:DebtSecuritiesSubordinatedIncludingJVDebtInstrumentsMember2024-06-300001414932us-gaap:FairValueInputsLevel25Memberocsl:DebtSecuritiesSubordinatedIncludingJVDebtInstrumentsMember2024-06-300001414932us-gaap:FairValueInputsLevel26Memberocsl:DebtSecuritiesSubordinatedIncludingJVDebtInstrumentsMember2024-06-300001414932us-gaap:FairValueInputsLevel27Memberocsl:DebtSecuritiesSubordinatedIncludingJVDebtInstrumentsMember2024-06-300001414932us-gaap:FairValueInputsLevel28Memberocsl:DebtSecuritiesSubordinatedIncludingJVDebtInstrumentsMember2024-06-300001414932us-gaap:FairValueInputsLevel29Memberocsl:DebtSecuritiesSubordinatedIncludingJVDebtInstrumentsMember2024-06-300001414932us-gaap:FairValueInputsLevel30Memberocsl:DebtSecuritiesSubordinatedIncludingJVDebtInstrumentsMember2024-06-300001414932us-gaap:FairValueInputsLevel31Memberocsl:DebtSecuritiesSubordinatedIncludingJVDebtInstrumentsMember2024-06-300001414932us-gaap:FairValueInputsLevel32Memberocsl:DebtSecuritiesSubordinatedIncludingJVDebtInstrumentsMember2024-06-300001414932us-gaap:FairValueInputsLevel33Memberocsl:DebtSecuritiesSubordinatedIncludingJVDebtInstrumentsMember2024-06-300001414932us-gaap:FairValueInputsLevel34Memberocsl:DebtSecuritiesSubordinatedIncludingJVDebtInstrumentsMember2024-06-300001414932us-gaap:FairValueInputsLevel35Memberocsl:DebtSecuritiesSubordinatedIncludingJVDebtInstrumentsMember2024-06-300001414932us-gaap:FairValueInputsLevel36Memberocsl:DebtSecuritiesSubordinatedIncludingJVDebtInstrumentsMember2024-06-300001414932us-gaap:FairValueInputsLevel37Memberocsl:DebtSecuritiesSubordinatedIncludingJVDebtInstrumentsMember2024-06-300001414932us-gaap:FairValueInputsLevel38Memberocsl:DebtSecuritiesSubordinatedIncludingJVDebtInstrumentsMember2024-06-300001414932us-gaap:FairValueInputsLevel39Memberocsl:DebtSecuritiesSubordinatedIncludingJVDebtInstrumentsMember2024-06-300001414932us-gaap:FairValueInputsLevel40Memberocsl:DebtSecuritiesSubordinatedIncludingJVDebtInstrumentsMember2024-06-300001414932us-gaap:FairValueInputsLevel41Memberocsl:DebtSecuritiesSubordinatedIncludingJVDebtInstrumentsMember2024-06-300001414932us-gaap:FairValueInputsLevel42Memberocsl:DebtSecuritiesSubordinatedIncludingJVDebtInstrumentsMember2024-06-300001414932us-gaap:FairValueInputsLevel43Memberocsl:DebtSecuritiesSubordinatedIncludingJVDebtInstrumentsMember2024-06-300001414932us-gaap:FairValueInputsLevel44Memberocsl:DebtSecuritiesSubordinatedIncludingJVDebtInstrumentsMember2024-06-300001414932us-gaap:FairValueInputsLevel45Memberocsl:DebtSecuritiesSubordinatedIncludingJVDebtInstrumentsMember2024-06-300001414932us-gaap:FairValueInputsLevel46Memberocsl:DebtSecuritiesSubordinatedIncludingJVDebtInstrumentsMember2024-06-300001414932us-gaap:FairValueInputsLevel47Memberocsl:DebtSecuritiesSubordinatedIncludingJVDebtInstrumentsMember2024-06-300001414932us-gaap:FairValueInputsLevel48Memberocsl:DebtSecuritiesSubordinatedIncludingJVDebtInstrumentsMember2024-06-300001414932us-gaap:FairValueInputsLevel49Memberocsl:DebtSecuritiesSubordinatedIncludingJVDebtInstrumentsMember2024-06-300001414932us-gaap:FairValueInputsLevel50Memberocsl:DebtSecuritiesSubordinatedIncludingJVDebtInstrumentsMember2024-06-300001414932us-gaap:FairValueInputsLevel51Memberocsl:DebtSecuritiesSubordinatedIncludingJVDebtInstrumentsMember2024-06-300001414932us-gaap:FairValueInputsLevel52Memberocsl:DebtSecuritiesSubordinatedIncludingJVDebtInstrumentsMember2024-06-300001414932us-gaap:FairValueInputsLevel53Memberocsl:DebtSecuritiesSubordinatedIncludingJVDebtInstrumentsMember2024-06-300001414932us-gaap:FairValueInputsLevel54Memberocsl:DebtSecuritiesSubordinatedIncludingJVDebtInstrumentsMember2024-06-300001414932us-gaap:FairValueInputsLevel55Memberocsl:DebtSecuritiesSubordinatedIncludingJVDebtInstrumentsMember2024-06-300001414932us-gaap:FairValueInputsLevel56Memberocsl:DebtSecuritiesSubordinatedIncludingJVDebtInstrumentsMember2024-06-300001414932us-gaap:FairValueInputsLevel57Memberocsl:DebtSecuritiesSubordinatedIncludingJVDebtInstrumentsMember2024-06-300001414932us-gaap:FairValueInputsLevel58Memberocsl:DebtSecuritiesSubordinatedIncludingJVDebtInstrumentsMember2024-06-300001414932us-gaap:FairValueInputsLevel59Memberocsl:DebtSecuritiesSubordinatedIncludingJVDebtInstrumentsMember2024-06-300001414932us-gaap:FairValueInputsLevel60Memberocsl:DebtSecuritiesSubordinatedIncludingJVDebtInstrumentsMember2024-06-300001414932us-gaap:FairValueInputsLevel61Memberocsl:DebtSecuritiesSubordinatedIncludingJVDebtInstrumentsMember2024-06-300001414932us-gaap:FairValueInputsLevel62Memberocsl:DebtSecuritiesSubordinatedIncludingJVDebtInstrumentsMember2024-06-300001414932us-gaap:FairValueInputsLevel63Memberocsl:DebtSecuritiesSubordinatedIncludingJVDebtInstrumentsMember2024-06-300001414932us-gaap:FairValueInputsLevel64Memberocsl:DebtSecuritiesSubordinatedIncludingJVDebtInstrumentsMember2024-06-300001414932us-gaap:FairValueInputsLevel65Memberocsl:DebtSecuritiesSubordinatedIncludingJVDebtInstrumentsMember2024-06-300001414932us-gaap:FairValueInputsLevel66Memberocsl:DebtSecuritiesSubordinatedIncludingJVDebtInstrumentsMember2024-06-300001414932us-gaap:FairValueInputsLevel67Memberocsl:DebtSecuritiesSubordinatedIncludingJVDebtInstrumentsMember2024-06-300001414932us-gaap:FairValueInputsLevel68Memberocsl:DebtSecuritiesSubordinatedIncludingJVDebtInstrumentsMember2024-06-300001414932us-gaap:FairValueInputsLevel69Memberocsl:DebtSecuritiesSubordinatedIncludingJVDebtInstrumentsMember2024-06-300001414932us-gaap:FairValueInputsLevel70Memberocsl:DebtSecuritiesSubordinatedIncludingJVDebtInstrumentsMember2024-06-300001414932us-gaap:FairValueInputsLevel71Memberocsl:DebtSecuritiesSubordinatedIncludingJVDebtInstrumentsMember2024-06-300001414932us-gaap:FairValueInputsLevel72Memberocsl:DebtSecuritiesSubordinatedIncludingJVDebtInstrumentsMember2024-06-300001414932us-gaap:FairValueInputsLevel73Memberocsl:DebtSecuritiesSubordinatedIncludingJVDebtInstrumentsMember2024-06-300001414932us-gaap:FairValueInputsLevel74Memberocsl:DebtSecuritiesSubordinatedIncludingJVDebtInstrumentsMember2024-06-300001414932us-gaap:FairValueInputsLevel75Memberocsl:DebtSecuritiesSubordinatedIncludingJVDebtInstrumentsMember2024-06-300001414932us-gaap:FairValueInputsLevel76Memberocsl:DebtSecuritiesSubordinatedIncludingJVDebtInstrumentsMember2024-06-300001414932us-gaap:FairValueInputsLevel77Memberocsl:DebtSecuritiesSubordinatedIncludingJVDebtInstrumentsMember2024-06-300001414932us-gaap:FairValueInputsLevel78Memberocsl:DebtSecuritiesSubordinatedIncludingJVDebtInstrumentsMember2024-06-300001414932us-gaap:FairValueInputsLevel79Memberocsl:DebtSecuritiesSubordinatedIncludingJVDebtInstrumentsMember2024-06-300001414932us-gaap:FairValueInputsLevel80Memberocsl:DebtSecuritiesSubordinatedIncludingJVDebtInstrumentsMember2024-06-300001414932us-gaap:FairValueInputsLevel81Memberocsl:DebtSecuritiesSubordinatedIncludingJVDebtInstrumentsMember2024-06-300001414932us-gaap:FairValueInputsLevel82Memberocsl:DebtSecuritiesSubordinatedIncludingJVDebtInstrumentsMember2024-06-300001414932us-gaap:FairValueInputsLevel83Memberocsl:DebtSecuritiesSubordinatedIncludingJVDebtInstrumentsMember2024-06-300001414932us-gaap:FairValueInputsLevel84Memberocsl:DebtSecuritiesSubordinatedIncludingJVDebtInstrumentsMember2024-06-300001414932us-gaap:FairValueInputsLevel85Memberocsl:DebtSecuritiesSubordinatedIncludingJVDebtInstrumentsMember2024-06-300001414932us-gaap:FairValueInputsLevel86Memberocsl:DebtSecuritiesSubordinatedIncludingJVDebtInstrumentsMember2024-06-300001414932us-gaap:FairValueInputsLevel87Memberocsl:DebtSecuritiesSubordinatedIncludingJVDebtInstrumentsMember2024-06-300001414932us-gaap:FairValueInputsLevel88Memberocsl:DebtSecuritiesSubordinatedIncludingJVDebtInstrumentsMember2024-06-300001414932us-gaap:FairValueInputsLevel89Memberocsl:DebtSecuritiesSubordinatedIncludingJVDebtInstrumentsMember2024-06-300001414932us-gaap:FairValueInputsLevel90Memberocsl:DebtSecuritiesSubordinatedIncludingJVDebtInstrumentsMember2024-06-300001414932us-gaap:FairValueInputsLevel91Memberocsl:DebtSecuritiesSubordinatedIncludingJVDebtInstrumentsMember2024-06-300001414932us-gaap:FairValueInputsLevel92Memberocsl:DebtSecuritiesSubordinatedIncludingJVDebtInstrumentsMember2024-06-300001414932us-gaap:FairValueInputsLevel93Memberocsl:DebtSecuritiesSubordinatedIncludingJVDebtInstrumentsMember2024-06-300001414932us-gaap:FairValueInputsLevel94Memberocsl:DebtSecuritiesSubordinatedIncludingJVDebtInstrumentsMember2024-06-300001414932us-gaap:FairValueInputsLevel95Memberocsl:DebtSecuritiesSubordinatedIncludingJVDebtInstrumentsMember2024-06-300001414932us-gaap:FairValueInputsLevel96Memberocsl:DebtSecuritiesSubordinatedIncludingJVDebtInstrumentsMember2024-06-300001414932us-gaap:FairValueInputsLevel97Memberocsl:De

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

000001414932ocsl:AdvertisingIndustryMemberocsl:InvestmentOwnedAtFairValueMember2023-09-

300001414932ocsl:AdvertisingIndustryMemberocsl:InvestmentOwnedAtFairValueMember2023-10-012023-09-

300001414932ocsl:HealthCareSuppliesMemberocsl:InvestmentOwnedAtFairValueMember2024-06

300001414932ocsl:HealthCareSuppliesMemberocsl:InvestmentOwnedAtFairValueMember2023-10-012024-06-

300001414932ocsl:HealthCareSuppliesMemberocsl:InvestmentOwnedAtFairValueMember2023-09-

300001414932ocsl:HealthCareSuppliesMemberocsl:InvestmentOwnedAtFairValueMember2023-09-

300001414932ocsl:IntegratedTelecommunicationServicesMemberocsl:InvestmentOwnedAtFairValueMember2024-06-

300001414932ocsl:IntegratedTelecommunicationServicesMemberocsl:InvestmentOwnedAtFairValueMember2023-10-012024-06-

300001414932ocsl:IntegratedTelecommunicationServicesMemberocsl:InvestmentOwnedAtFairValueMember2023-09-

300001414932ocsl:IntegratedTelecommunicationServicesMemberocsl:InvestmentOwnedAtFairValueMember2023-10-012023-09-

300001414932ocsl:EducationServicesMemberocsl:InvestmentOwnedAtFairValueMember2024-06-

300001414932ocsl:EducationServicesMemberocsl:InvestmentOwnedAtFairValueMember2023-10-012024-06-

300001414932ocsl:EducationServicesMemberocsl:InvestmentOwnedAtFairValueMember2023-09-

300001414932ocsl:EducationServicesMemberocsl:InvestmentOwnedAtFairValueMember2023-09-

300001414932ocsl:DistributorsMemberocsl:InvestmentOwnedAtFairValueMember2024-06-

300001414932ocsl:DistributorsMemberocsl:InvestmentOwnedAtFairValueMember2023-10-012024-06-

300001414932ocsl:DistributorsMemberocsl:InvestmentOwnedAtFairValueMember2023-09-

300001414932ocsl:DistributorsMemberocsl:InvestmentOwnedAtFairValueMember2023-10-012023-09-

300001414932ocsl:FinancingExchangeDataMemberocsl:InvestmentOwnedAtFairValueMember2024-06-

300001414932ocsl:FinancingExchangeDataMemberocsl:InvestmentOwnedAtFairValueMember2023-10-012024-06-

300001414932ocsl:FinancingExchangeDataMemberocsl:InvestmentOwnedAtFairValueMember2023-09-

300001414932ocsl:FinancingExchangeDataMemberocsl:InvestmentOwnedAtFairValueMember2023-09-

300001414932ocsl:CableSatelliteMemberocsl:InvestmentOwnedAtFairValueMember2024-06-

300001414932ocsl:CableSatelliteMemberocsl:InvestmentOwnedAtFairValueMember2023-10-012024-06-

300001414932ocsl:CableSatelliteMemberocsl:InvestmentOwnedAtFairValueMember2023-09-

300001414932ocsl:CableSatelliteMemberocsl:InvestmentOwnedAtFairValueMember2023-10-012023-09-

300001414932ocsl:ResearchConsultingServicesMemberocsl:InvestmentOwnedAtFairValueMember2024-06-

300001414932ocsl:ResearchConsultingServicesMemberocsl:InvestmentOwnedAtFairValueMember2023-10-012024-06-

300001414932ocsl:ResearchConsultingServicesMemberocsl:InvestmentOwnedAtFairValueMember2023-09-

300001414932ocsl:ResearchConsultingServicesMemberocsl:InvestmentOwnedAtFairValueMember2023-09-

300001414932ocsl:PaperPlasticPackagingProductsMaterialsMemberocsl:InvestmentOwnedAtFairValueMember2024-06-

300001414932ocsl:PaperPlasticPackagingProductsMaterialsMemberocsl:InvestmentSectorConcentrationRiskMember2023-10-012024-06-

300001414932ocsl:PaperPlasticPackagingProductsMaterialsMemberocsl:InvestmentOwnedAtFairValueMember2023-09-

300001414932ocsl:PaperPlasticPackagingProductsMaterialsMemberocsl:InvestmentOwnedAtFairValueMember2023-09-

300001414932ocsl:HousewaresSpecialtiesMemberocsl:InvestmentOwnedAtFairValueMember2024-06-

300001414932ocsl:HousewaresSpecialtiesMemberocsl:InvestmentSectorConcentrationRiskMember2023-10-012024-06-

300001414932ocsl:HousewaresSpecialtiesMemberocsl:InvestmentOwnedAtFairValueMember2023-09-

300001414932ocsl:HousewaresSpecialtiesMemberocsl:InvestmentOwnedAtFairValueMember2023-09-

300001414932ocsl:InvestmentOwnedAtFairValueMemberocsl:DiversifiedChemicalsMemberr2024-06-

300001414932ocsl:InvestmentOwnedAtFairValueMemberocsl:DiversifiedChemicalsMemberocsl:InvestmentSectorConcentrationRiskMember2023-10-012024-06-

300001414932ocsl:InvestmentOwnedAtFairValueMemberocsl:DiversifiedChemicalsMember2023-09-

300001414932ocsl:InsuranceBrokersMemberocsl:InvestmentOwnedAtFairValueMember2023-10-012023-09-

300001414932ocsl:InsuranceBrokersMemberocsl:InvestmentOwnedAtFairValueMember2024-06-

300001414932ocsl:InsuranceBrokersMemberocsl:InvestmentOwnedAtFairValueMember2023-10-012024-06-

300001414932ocsl:InsuranceBrokersMemberocsl:InvestmentOwnedAtFairValueMember2023-09-

300001414932ocsl:ConsumerFinanceMemberocsl:InvestmentOwnedAtFairValueMember2023-10-012023-09-

300001414932ocsl:ConsumerFinanceMemberocsl:InvestmentOwnedAtFairValueMember2024-06-

300001414932ocsl:ConsumerFinanceMemberocsl:InvestmentOwnedAtFairValueMember2023-10-012024-06-

300001414932ocsl:RestaurantsMemberocsl:InvestmentOwnedAtFairValueMember2024-06-

300001414932ocsl:RestaurantsMemberocsl:InvestmentOwnedAtFairValueMember2023-09-

300001414932ocsl:RestaurantsMemberocsl:InvestmentOwnedAtFairValueMember2023-10-012024-06-

300001414932ocsl:IntegratedOilGasMemberocsl:InvestmentOwnedAtFairValueMember2024-06-

300001414932ocsl:IntegratedOilGasMemberocsl:InvestmentOwnedAtFairValueMember2023-10-012024-06-

300001414932ocsl:IntegratedOilGasMemberocsl:InvestmentOwnedAtFairValueMember2023-09-

300001414932ocsl:AirFreightLogisticsMemberocsl:InvestmentOwnedAtFairValueMember2024-06-

300001414932ocsl:AirFreightLogisticsMemberocsl:InvestmentOwnedAtFairValueMember2023-10-012024-06-

300001414932ocsl:AirFreightLogisticsMemberocsl:InvestmentOwnedAtFairValueMember2023-09-

300001414932ocsl:AirFreightLogisticsMemberocsl:InvestmentOwnedAtFairValueMember2023-10-012023-09-

300001414932ocsl:OtherSpecializedREITsMemberocsl:InvestmentOwnedAtFairValueMember2024-06-

300001414932ocsl:OtherSpecializedREITsMemberocsl:InvestmentOwnedAtFairValueMember2023-10-012024-06-

300001414932ocsl:LeisureProductsMemberocsl:InvestmentOwnedAtFairValueMember2024-06-

300001414932ocsl:LeisureProductsMemberocsl:InvestmentOwnedAtFairValueMember2023-10-012024-06-

300001414932ocsl:TechnologyDistributorsMemberocsl:InvestmentOwnedAtFairValueMember2024-06-

300001414932ocsl:TechnologyDistributorsMemberocsl:InvestmentOwnedAtFairValueMember2023-10-012024-06-

300001414932ocsl:TechnologyDistributorsMemberocsl:InvestmentOwnedAtFairValueMember2023-09-

300001414932ocsl:InvestmentOwnedAtFairValueMember2024-06-300001414932ocsl:InvestmentOwnedAtFairValueMemberocsl:InvestmentSectorConcentrationRiskMember2023-10-012024-06-

-012023-09-300001414932ocsl:SLFJVIMember2024-06-300001414932ocsl:SLFJVIMember2023-09-300001414932ocsl:SLFJVIMemberocsl:KemperMember2024-06-

-300001414932ocsl:SLFJVIMemberocsl:KemperMember2023-09-300001414932us-gaaip:RevolvingCreditFacilityMemberocsl:SLFJVIMemberBusiness-gaaip:LineOfCreditMemberocsl:SLFJVFacilityMember2024-06-300001414932ocsl:UntilNovember302023Membersub-gaaip:RevolvingCreditFacilityMemberocsl:SLFJVIMembersub-gaaip:LineOfCreditMemberocsl:SecuredOvernightFinancingRateMemberocsl:SLFJVFacilityMember2023-10-012024-06-300001414932us-gaaip:RevolvingCreditFacilityMemberocsl:SLFJVIMembersub-gaaip:LineOfCreditMemberocsl:SLFJVFacilityMember2023-09-300001414932ocsl:SLFJVIMember2024-06-300001414932ocsl:SLFJVIMember2023-09-300001414932ocsl:SLFJVIMemberNotesMember2023-09-300001414932ocsl:SLFJVIMemberocsl:SLFVILLCMember2024-06-300001414932ocsl:SLFJVIMemberocsl:SLFVILLCMember2023-09-300001414932srt:WeightedAverageMemberocsl:SLFJVIMember2024-06-300001414932srt:WeightedAverageMemberocsl:SLFJVIMember2023-09-300001414932Largest Exposure To A Single Borrowerocsl:SLFJVIMember2024-06-300001414932Largest Exposure To A Single Borrowerocsl:SLFJVIMember2023-09-300001414932Five Largest Loan Exposures To Borrowersocsl:SLFJVIMember2024-06-300001414932Five Largest Loan Exposures To Borrowersocsl:SLFJVIMember2023-09-300001414932Access CIG, LLC, First Lien Term Loanocsl:SLFJVIMember2024-06-300001414932ocsl:SLFJVIMemberADB Companies, LLC, First Lien Term Loan 12024-06-300001414932ocsl:SLFJVIMemberADB Companies, LLC, First Lien Term Loan 2024-06-300001414932Alvogen Pharma US, Inc., First Lien Term Loanocsl:SLFJVIMember2024-06-300001414932ocsl:SLFJVIMemberAmerican Tire Distributors, Inc., First Lien Term Loan2024-06-300001414932Artera Services LLC, First Lien Term Loanocsl:SLFJVIMember2024-06-300001414932ASP-R-PAC Acquisition Co LLC, First Lien Revolverocsl:SLFJVIMember2024-06-300001414932ocsl:SLFJVIMemberASP-R-PAC Acquisition Co LLC, First Lien Term Loan2024-06-3000014149

[illegible]

300001414932ocsl:InvestmentCompanyAccumulatedOverdistributedEarningsMember2023-10-012023-12-3100014149322023-10-012023-12-310001414932us-gaap:CommonStockMember2023-10-012023-12-310001414932us-gaap:AdditionalPaidInCapitalMember2023-10-012023-12-310001414932us-gaap:CommonStockMember2023-12-310001414932us-gaap:AdditionalPaidInCapitalMember2023-12-310001414932ocsl:InvestmentCompanyAccumulatedOverdistributedEarningsMember2023-12-3100014149322023-12-3100014149322023-12-310001414932ocsl:InvestmentCompanyAccumulatedOverdistributedEarningsMember2024-01-012024-03-3100014149322024-01-012024-03-310001414932us-gaap:CommonStockMember2024-01-012024-03-310001414932us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-310001414932us-gaap:CommonStockMember2024-03-310001414932us-gaap:AdditionalPaidInCapitalMember2024-03-310001414932ocsl:InvestmentCompanyAccumulatedOverdistributedEarningsMember2024-03-310001414932ocsl:InvestmentCompanyAccumulatedOverdistributedEarningsMember2024-04-012024-06-300001414932us-gaap:CommonStockMember2024-04-012024-06-300001414932us-gaap:AdditionalPaidInCapitalMember2024-04-012024-06-300001414932us-gaap:CommonStockMember2024-06-300001414932us-gaap:AdditionalPaidInCapitalMember2024-06-300001414932ocsl:InvestmentCompanyAccumulatedOverdistributedEarningsMember2022-09-300001414932ocsl:InvestmentCompanyAccumulatedOverdistributedEarningsMember2022-10-012022-12-3100014149322022-10-012022-12-310001414932us-gaap:CommonStockMember2022-10-012022-12-310001414932us-gaap:AdditionalPaidInCapitalMember2022-10-012022-12-310001414932us-gaap:CommonStockMember2022-12-310001414932us-gaap:AdditionalPaidInCapitalMember2022-12-310001414932ocsl:InvestmentCompanyAccumulatedOverdistributedEarningsMember2022-12-3100014149322022-12-3100014149322022-12-310001414932ocsl:InvestmentCompanyAccumulatedOverdistributedEarningsMember2023-01-012023-03-3100014149322023-01-012023-03-310001414932us-gaap:CommonStockMember2023-01-012023-03-310001414932us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310001414932us-gaap:CommonStockMember2023-03-310001414932us-gaap:AdditionalPaidInCapitalMember2023-03-310001414932ocsl:InvestmentCompanyAccumulatedOverdistributedEarningsMember2023-03-310001414932ocsl:InvestmentCompanyAccumulatedOverdistributedEarningsMember2023-04-012023-06-300001414932us-gaap:CommonStockMember2023-04-012023-06-300001414932us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-300001414932us-gaap:CommonStockMember2023-06-300001414932ocsl:AtTheMarketMember2024-06-300001414932ocsl:DistributionTypeQuarterlyMember2023-12-292023-12-290001414932ocsl:DistributionTypeSpecialMember2023-12-292023-12-290001414932ocsl:DistributionTypeQuarterlyMember2024-03-292024-03-290001414932ocsl:DistributionTypeQuarterlyMember2024-06-282024-06-280001414932ocsl:DistributionTypeQuarterlyMember2022-12-302022-12-300001414932ocsl:DistributionTypeSpecialMember2022-12-302022-12-300001414932ocsl:DistributionTypeQuarterlyMember2023-03-312023-03-310001414932ocsl:DistributionTypeQuarterlyMember2023-06-302023-06-300001414932us-gaap:CommonStockMember2024-04-012024-06-300001414932us-gaap:CommonStockMember2023-10-012024-06-300001414932us-gaap:CommonStockMember2023-06-300001414932us-gaap:CommonStockMember2023-10-012024-06-3000014149322022-02-072022-02-0700014149322023-02-082023-02-080001414932ocsl:AtTheMarketMember2023-10-012024-06-300001414932ocsl:SyndicatedFacilityMember2023-10-012024-06-300001414932us-gaap:RevolvingCreditFacilityMemberocsl:SyndicatedFacilityMemberus-gaap:LineOfCreditMember2024-06-300001414932ocsl:SecuredOvernightFinancingRateMember2023-10-012024-06-300001414932srt:MinimumMemberocsl:SecuredOvernightFinancingRateMember2023-10-012024-06-300001414932srt:MaximumMemberocsl:SecuredOvernightFinancingRateMember2023-10-012024-06-300001414932us-gaap:BaseRateMember2023-10-012024-06-300001414932us-gaap:RevolvingCreditFacilityMemberocsl:SyndicatedFacilityMemberus-gaap:LineOfCreditMember2023-09-300001414932us-gaap:RevolvingCreditFacilityMemberocsl:SyndicatedFacilityMemberus-gaap:LineOfCreditMember2023-06-300001414932us-gaap:RevolvingCreditFacilityMemberocsl:SyndicatedFacilityMemberus-gaap:LineOfCreditMember2024-04-012024-06-300001414932us-gaap:RevolvingCreditFacilityMemberocsl:SyndicatedFacilityMemberus-gaap:LineOfCreditMember2023-10-012024-06-300001414932us-gaap:RevolvingCreditFacilityMemberocsl:SyndicatedFacilityMemberus-gaap:LineOfCreditMember2022-10-012023-06-300001414932ocsl:CitibankFacilityMember2023-10-012024-06-300001414932ocsl:CitibankFacilityMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2023-04-012023-06-300001414932ocsl:CitibankFacilityMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2022-10-012023-06-300001414932ocsl:OSI2CitibankFacilityMember2023-10-012024-06-300001414932us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMemberocsl:OSI2CitibankFacilityMemberocsl:SecuredOvernightFinancingRateMember2023-10-012024-06-300001414932us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMemberocsl:AfterReinvestmentPeriodMemberocsl:OSI2CitibankFacilityMemberocsl:SecuredOvernightFinancingRateMember2023-10-012024-06-300001414932us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMemberocsl:OSI2CitibankFacilityMember2023-09-300001414932us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMemberocsl:OSI2CitibankFacilityMember2023-06-300001414932us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMemberocsl:OSI2CitibankFacilityMember2024-04-012024-06-300001414932us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMemberocsl:OSI2CitibankFacilityMember2023-04-012023-06-300001414932us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMemberocsl:OSI2CitibankFacilityMember2023-03-012023-06-300001414932us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMemberocsl:OSI2CitibankFacilityMember2023-01-232023-06-300001414932ocsl:A2025NotesMember2023-10-012024-06-300001414932ocsl:A2025NotesMember2020-02-252020-02-250001414932ocsl:A2027NotesMember2023-10-012024-06-300001414932ocsl:A2027NotesMember2021-05-180001414932ocsl:A2027NotesMember2021-05-180001414932us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMember2021-05-180001414932us-gaap:DesignatedAsHedgingInstrumentMemberocsl:LondonInterbankOfferedRateLIBOR1Memberus-gaap:InterestRateSwapMember2021-05-180001414932us-gaap:SecuredOvernightFinancingRateSoftOvernightIndexSwapRateMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMember2021-05-180001414932ocsl:A2029NotesMember2023-10-012024-06-300001414932ocsl:A2029NotesMember2023-08-150001414932ocsl:A2029NotesMember2023-08-150001414932us-gaap:DesignatedAsHedgingInstrumentMemberocsl:A2029NotesMemberus-gaap:InterestRateSwapMember2023-08-150001414932us-gaap:SecuredOvernightFinancingRateSoftOvernightIndexSwapRateMemberus-gaap:DesignatedAsHedgingInstrumentMemberocsl:A2029NotesMemberus-gaap:InterestRateSwapMember2023-08-150001414932ocsl:A2025NotesMember2023-09-300001414932ocsl:A2027NotesMember2023-09-300001414932ocsl:A2029NotesMember2023-09-300001414932ocsl:A2025NotesMember2024-04-012024-06-300001414932ocsl:A2027NotesMember2024-04-012024-06-300001414932ocsl:A2029NotesMember2024-04-012024-06-300001414932ocsl:A2025NotesMember2022-10-012023-06-300001414932ocsl:A2025NotesMember2022-10-012023-06-300001414932ocsl:A2027NotesMember2023-04-012023-06-300001414932ocsl:A2027NotesMember2023-04-012023-06-300001414932ocsl:LongTermCapitalLossCarryforwardMember2023-09-300001414932ocsl:ThrasioLLCMember2024-04-012024-06-300001414932ocsl:OtherNetMember2024-04-012024-06-300001414932us-gaap:ForeignExchangeForwardMember2023-04-012023-06-300001414932ocsl:AdenAnaisMergerSubIncMember2023-04-012023-06-300001414932ocsl:RadiologyPartnersIncMember2023-04-012023-06-300001414932ocsl:WPCPPHoldingsLLCMember2023-04-012023-06-300001414932ocsl:TerresaTherapeuticsLLCMember2023-04-012023-06-300001414932ocsl:OtherNetMember2023-04-012023-06-300001414932ocsl:ThrasioLLCMember2023-10-012024-06-300001414932ocsl:AllWebLeadsIncMember2023-10-012024-06-300001414932ocsl:ContinentalIntermodalGroupLPMember2023-10-012024-06-300001414932ocsl:PLDevelopmentLLCMember2023-10-012024-06-300001414932ocsl:AmericanTireDistributorsInc.Member2023-10-012024-06-300001414932ocsl:ZephyrBidcoLimitedMember2023-10-012024-06-300001414932ocsl:LifitBrandsHoldingsInc.Member2023-10-012024-06-300001414932ocsl:AlvotechMember2023-10-012024-06-300001414932ocsl:ArdonaghMidco3PLCMember2023-10-012024-06-300001414932us-gaap:ForeignExchangeForwardMember2023-10-012024-06-300001414932ocsl:OtherNetMember2023-10-012024-06-300001414932us-gaap:ForeignExchangeForwardMember2022-10-012023-06-300001414932ocsl:AdenAnaisMergerSubIncMember2022-10-012023-06-300001414932ocsl:RadiologyPartnersIncMember2022-10-012023-06-300001414932ocsl:CaravanaCo.Member2022-10-012023-06-300001414932ocsl:ASPUnifraxHoldingsIncMember2022-10-012023-06-300001414932ocsl:WPCPPHoldingsLLCMember2022-10-012023-06-300001414932ocsl:GlobalMedicalResponseIncMember2022-10-012023-06-300001414932ocsl:TerresaTherapeuticsLLCMember2022-10-012023-06-300001414932ocsl:OtherNetMember2022-10-012023-06-300001414932ocsl:ExitedInvestmentsMember2024-04-012024-06-300001414932us-gaap:ForeignExchangeForwardMember2024-04-012024-06-300001414932us-gaap:DebtSecuritiesMember2024-04-012024-06-300001414932us-gaap:EquitySecuritiesMember2024-04-012024-06-300001414932us-gaap:DebtSecuritiesMember2023-04-012023-06-300001414932ocsl:ExitedInvestmentsMember2023-04-012023-06-300001414932us-gaap:EquitySecuritiesMember2023-04-012023-06-300001414932us-gaap:ForeignExchangeForwardMember2023-04-012023-06-300001414932us-gaap:DebtSecuritiesMember2023-10-012024-06-300001414932us-gaap:EquitySecuritiesMember2023-10-012024-06-300001414932us-gaap:ForeignExchangeForwardMember2022-10-012023-06-300001414932ocsl:ExitedInvestmentsMember2023-10-012024-06-300001414932us-gaap:DebtSecuritiesMember2022-10-012023-06-300001414932us-gaap:DebtSecuritiesMember2022-10-012023-06-300001414932ocsl:ExitedInvestmentsMember2022-10-012023-06-300001414932us-gaap:EquitySecuritiesMember2022-10-012023-06-300001414932us-gaap:ForeignExchangeForwardMember2022-10-012023-06-300001414932ocsl:InvestmentAdvisoryAgreementMember2024-06-300001414932ocsl:InvestmentAdvisoryAgreementMember2023-10-012024-06-3000014149322019-05-022019-05-020001414932ocsl:OaktreeStrategicIncomeIIIncMergerMember2023-01-232023-01-230001414932ocsl:OaktreeStrategicIncomeIIIncMergerYearOneMember2023-01-232023-01-230001414932ocsl:OaktreeStrategicIncomeIIIncMergerYearTwoMember2023-01-232023-01-2300014149322024-04-262024-04-260001414932us-gaap:SubsequentEventMember2024-07-012024-07-010001414932ocsl:InvestmentAdvisoryAgreementMember2024-04-012024-06-300001414932ocsl:InvestmentAdvisoryAgreementMember2023-04-012023-06-300001414932ocsl:InvestmentAdvisoryAgreementMember2022-10-012023-06-300001414932ocsl:InvestmentAdvisoryAgreementIncentiveRatePreIncentiveFeeNetInvestmentIncomeBelowCatchUpMember2023-10-012024-06-300001414932ocsl:InvestmentAdvisoryAgreementIncentiveRateQuarterlyCatchUpThresholdMember2023-10-012024-06-300001414932ocsl:InvestmentAdvisoryAgreementIncentiveRatePreIncentiveFeeNetInvestmentIncomeExceedsCatchUpThresholdMember2023-10-012024-06-300001414932srt:AffiliatedEntityMember2024-04-012024-06-300001414932ocsl:InvestmentAdvisoryAgreementMembersrt:AffiliatedEntityMember2023-10-012024-06-300001414932ocsl:InvestmentAdvisoryAgreementMembersrt:AffiliatedEntityMember2023-04-012023-06-300001414932ocsl:InvestmentAdvisoryAgreementMembersrt:AffiliatedEntityMember2022-10-012023-06-300001414932srt:AffiliatedEntityMemberocsl:InvestmentAdvisoryAgreementIncentiveRateRealizedCapitalGainsMember2023-10-012024-06-300001414932srt:AffiliatedEntityMember2023-10-012024-06-300001414932srt:AffiliatedEntityMember2023-04-012023-06-300001414932srt:AffiliatedEntityMember2022-10-012023-06-300001414932srt:AffiliatedEntityMember2024-06-300001414932srt:AffiliatedEntityMember2023-04-012023-06-300001414932EUR Foreign Currency Forward Contract, Maturing May 9, 20242024-06-300001414932Interest rate swap, Maturing January 15, 20272024-06-300001414932Interest rate swap, Maturing February 15, 20292024-06-300001414932Interest rate swap, Maturing January 15, 20272023-09-300001414932Interest rate swap, Maturing February 15, 20292023-09-300001414932us-gaap:InterestRateSwapMember2023-09-300001414932ocsl:DebtAndEquityFinancingMember2024-06-300001414932ocsl:JVFinancingMember2024-06-300001414932ocsl:DebtAndEquityFinancingMember2023-09-300001414932ocsl:JVFinancingMember2023-09-300001414932107-109 Beech OAK22 LLC2024-06-300001414932107-109 Beech OAK22 LLC2023-09-300001414932Verona Pharma, Inc.2024-06-300001414932Verona Pharma, Inc.2023-09-300001414932OCSEI Glivk JV LLC2024-06-300001414932OCSEI Glivk JV LLC2023-09-300001414932PPW Aero Buyer, Inc.2024-06-300001414932PPW Aero Buyer, Inc.2023-09-300001414932PetVet Care Centers, LLC 2024-06-300001414932PetVet Care Centers, LLC 2023-09-300001414932Senior Loan Fund JV I, LLC2024-06-300001414932Senior Loan Fund JV I, LLC2023-09-300001414932BioXcel Therapeutics, Inc.2024-06-300001414932BioXcel Therapeutics, Inc.2023-09-300001414932Amspec Parent LLC2024-06-300001414932Amspec Parent LLC2023-09-300001414932Kings Buyer, LLC2024-06-300001414932Kings Buyer, LLC2023-09-300001414932Seres Therapeutics, Inc.2024-06-300001414932Seres Therapeutics, Inc.2023-09-300001414932Monotype Imaging Holdings Inc.2024-06-300001414932Monotype Imaging Holdings Inc.2023-09-300001414932Next Holdco, LLC 2024-06-300001414932Next Holdco, LLC 2023-09-300001414932CIMs, Inc.2024-06-300001414932CIMs, Inc.2023-09-300001414932Eyesouth Eye Care Holdco LLC2024-06-300001414932Eyesouth Eye Care Holdco LLC2023-09-300001414932MRI Software LLC2024-06-300001414932MRI Software LLC2023-09-300001414932Quantum Bidco Limited2024-06-300001414932Quantum Bidco Limited2023-09-300001414932Telephone and Data Systems, Inc.2024-06-300001414932Telephone and Data Systems, Inc.2023-09-300001414932Digital.AI Software Holdings, Inc.2024-06-300001414932Digital.AI Software Holdings, Inc.2023-09-300001414932Truck-Lite Co., LLC2024-06-300001414932Truck-Lite Co., LLC2023-09-300001414932Sorenson Communications, LLC2024-06-300001414932Sorenson Communications, LLC2023-09-300001414932Grove Hotel Parcel Owner, LLC2024-06-300001414932Grove Hotel Parcel Owner, LLC2023-09-300001414932Mindbody, Inc.2024-06-300001414932Mindbody, Inc.2023-09-300001414932scPharmaceuticals Inc.2024-06-300001414932scPharmaceuticals Inc.2023-09-300001414932SumUp Holdings Luxembourg2024-06-300001414932SumUp Holdings Luxembourg2023-09-300001414932Avalara, Inc.2024-06-300001414932Avalara, Inc.2023-09-300001414932107 Fair Street LLC2024-06-300001414932107 Fair Street LLC2023-09-300001414932Harrow, Inc.2024-06-300001414932Harrow, Inc.2023-09-300001414932Accupac, Inc.2024-06-300001414932Accupac, Inc.2023-09-300001414932Inventus Power, Inc.2024-06-300001414932Inventus Power, Inc.2023-09-300001414932Delta Leasing SPV II LLC2024-06-300001414932Delta Leasing SPV II LLC2023-09-300001414932Establishment Labs Holdings Inc.2024-06-300001414932Establishment Labs Holdings Inc.2023-09-300001414932PWP CPP Holdings, LLC2024-06-300001414932PWP CPP Holdings, LLC2023-09-300001414932Enverus Holdings, Inc.2024-06-300001414932Enverus Holdings, Inc.2023-09-300001414932PRGX Global, Inc.2024-06-300001414932PRGX Global, Inc.2023-09-300001414932Salus Workers' Compensation, LLC2024-06-300001414932Salus Workers' Compensation, LLC2023-09-300001414932Spanx, LLC2024-06-300001414932Spanx, LLC2023-09-300001414932Minotaur Acquisition, Inc.2024-06-300001414932Minotaur Acquisition, Inc.2023-09-300001414932Relativity ODA LLC2024-06-300001414932Relativity ODA LLC2023-09-300001414932Crewline Buyer, Inc.2024-06-300001414932Crewline Buyer, Inc.2023-09-300001414932Protein For Pets Opco, LLC2024-06-300001414932Protein For Pets Opco, LLC2023-09-300001414932Coupa Holdings, LLC2024-06-300001414932Coupa Holdings, LLC2023-09-300001414932Oranje Holdco, Inc.2024-06-300001414932Oranje Holdco, Inc.2023-09-300001414932MHE Intermediate Holdings, LLC2024-06-300001414932MHE Intermediate Holdings, LLC2023-09-300001414932Evergreen IX Borrower 2023, LLC2024-06-300001414932Evergreen IX Borrower 2023, LLC2023-09-300001414932Acquia Inc.2024-06-300001414932Acquia Inc.2023-09-300001414932Supreme Fitness Group NY Holdings, LLC2024-06-300001414932Supreme Fitness Group NY Holdings, LLC2023-09-300001414932Galileo Parent, Inc.2024-06-300001414932Galileo Parent, Inc.2023-09-300001414932Centralsquare Technologies, LLC2024-06-300001414932Centralsquare Technologies, LLC2023-09-300001414932112-126 Van Houten Real22 LLC2024-06-300001414932112-126 Van Houten Real22 LLC2023-09-300001414932Berner Food & Beverage, LLC2024-

[illegible]

[illegible]

[illegible]

LoanSOFR+5.75%11.09%/4/19/202948,642Å 47,708Å 47,747Å (6)(15)Sorenson Communications EquipmentFirst Lien RevolverSOFR+5.75%4/19/2029â€”Å (104)(100)(6)(15)(19)Sorrento Therapeutics, Inc.BiotechnologyCommon Stock66,000Å 139Å 1Å (11)Spanx, LLCApparel RetailFirst Lien Term LoanSOFR+5.25%10.69%11/20/202818,104Å 17,930Å 18,079Å (6)(15)Spanx, LLCApparel RetailFirst Lien RevolverSOFR+5.00%11/18/2027â€”Å (35)(15)(6)(15)(19)SPX Flow, Inc.Industrial Machinery & Supplies & ComponentsFixed Rate Bond8.75%4/1/20301,109Å 1,072Å 1,140Å Staples, Inc.Office Services & SuppliesFirst Lien Term LoanSOFR+5.75%11.08%/9/4/202913,780Å 13,232Å 12,674Å (6)Staples, Inc.Office Services & SuppliesFixed Rate Bond10.75%9/1/20296,835Å 6,771Å 6,504Å SumUp Holdings LuxembourgDiversified Financial ServicesFirst Lien Term LoanE+6.50%10.32%/4/25/2031Å –18,846Å 20,199Å 19,945Å (6)(11)(15)(19)Superior Industries International, Inc.Auto Parts & EquipmentFirst Lien Term LoanSOFR+8.00%13.34%12/16/2028\$49,146Å 48,310Å 48,654Å (6)(15)Supreme Fitness Group NY Holdings, LLCLeisure FacilitiesFirst Lien Term LoanSOFR+7.00%12.56%12/31/20262,728Å 2,711Å 2,595Å (6)(15)Supreme Fitness Group NY Holdings, LLCLeisure FacilitiesFirst Lien Term LoanSOFR+7.00%12.56%12/31/20263,282Å 3,165Å 3,121Å (6)(15)Supreme Fitness Group NY Holdings, LLCLeisure FacilitiesFirst Lien Term LoanSOFR+7.00%12.56%12/31/202631,859Å 31,674Å 30,301Å (6)(15)Supreme Fitness Group NY Holdings, LLCLeisure FacilitiesFirst Lien RevolverSOFR+7.00%12/31/2026â€”Å (9)(76)(6)(15)(19)SVP-Singer Holdings Inc.Home FurnishingsFirst Lien Term LoanSOFR+8.25%7/28/202827,164Å 23,170Å 15,076Å (6)(15)(20)Telephone and Data Systems, Inc.Wireless Telecommunication ServicesSubordinated Debt Term LoanSOFR+7.00%12.32%/5/1/202925,094Å 24,366Å 24,391Å (6)(11)(15)Telephone and Data Systems, Inc.Wireless Telecommunication ServicesSubordinated Debt Term LoanSOFR+7.00%5/1/2029â€”Å (91)(94)(6)(11)(15)(19)Telestream Holdings CorporationApplication SoftwareFirst Lien Term LoanSOFR+9.75%5.44%9.75%10/15/202525,618Å 25,482Å 23,056Å (6)(15)Telestream Holdings CorporationApplication SoftwareFirst Lien RevolverSOFR+9.75%5.44%9.75%10/15/20251,809Å 1,796Å 1,590Å (6)(15)(19)Ten-X LLCInteractive Media & ServicesFirst Lien Term LoanSOFR+6.00%11.34%/5/26/202819,789Å 19,012Å 19,126Å (6)(15)THL Zinc Ventures LtdDiversified Metals & MiningFirst Lien Term Loan13.00%5/23/202650,419Å 50,006Å 50,419Å (11)(15)Thrasio, LLCBroadline RetailFirst Lien Term LoanSOFR+10.00%15.31%/6/18/20296,063Å 5,864Å 5,942Å (6)(15)13oaktree Specialty Lending CorporationConsolidated Schedule of InvestmentsJune 30, 2024(dollar amounts in thousands)(unaudited) Portfolio CompanyIndustryType of Investment (1)(2)(3)(4)IndexSpreadCash Interest Rate (5)(6)PIKMaturity DateSharesPrincipalÅ (7)CostFairÅ ValueNotesThrasio, LLCBroadline RetailFirst Lien Term LoanSOFR+10.00%/6/18/2029\$18,605Å 16,279Å \$16,326Å (6)(15)(20)Thrasio, LLCBroadline RetailCommon Stock321,058Å â€”Å â€”Å (15)Touchstone Acquisition, Inc.Health Care SuppliesFirst Lien Term LoanSOFR+6.00%11.43%12/29/202811,582Å 11,561Å 11,337Å (6)(15)Trinitas CLO VI Ltd.Multi-Sector HoldingsCLO NotesSOFR+7.08%12.40%/1/25/2034905Å 851Å 860Å (6)(11)Trinitas CLO XV DACMulti-Sector HoldingsCLO NotesSOFR+7.71%13.04%/4/22/20341,000Å 822Å 969Å (6)(11)Truck-Lite Co., LLCConstruction Machinery & Heavy Transportation EquipmentFirst Lien Term LoanSOFR+5.75%11.07%/12/31/203126,524Å 26,022Å 26,051Å (6)(15)Truck-Lite Co., LLCConstruction Machinery & Heavy Transportation EquipmentFirst Lien Term LoanSOFR+5.75%12/31/2031â€”Å (54)(51)(6)(15)(19)Truck-Lite Co., LLCConstruction Machinery & Heavy Transportation EquipmentFirst Lien RevolverSOFR+5.75%11.08%/2/13/2030128Å 42Å 46Å (6)(15)(19)Uniti Group LPConvertible & SatelliteFixed Rate Bond6.50%2/15/20292,830Å 2,573Å 1,808Å (11)Verona Pharma, Inc.PharmaceuticalsFirst Lien Term Loan11.00%/5/9/20292,512Å 2,463Å 2,465Å (11)(15)Verona Pharma, Inc.PharmaceuticalsFirst Lien Term Loan11.00%/5/9/20293,198Å 3,134Å 3,138Å (11)(15)Verona Pharma, Inc.PharmaceuticalsFirst Lien Term Loan5/9/2029â€”Å â€”Å â€”Å (11)(15)(19)Verona Pharma, Inc.PharmaceuticalsFirst Lien Term Loan9/30/20244,568Å 4,568Å 4,568Å (11)(15)(21)Verona Pharma, Inc.PharmaceuticalsFirst Lien Term Loan9/30/2025â€”Å â€”Å â€”Å (11)(15)(19)(21)Win Brands Group LLCHousewares & SpecialtiesFirst Lien Term LoanSOFR+14.00%13.45%6.00%1/23/20262,726Å 2,704Å 2,508Å (6)(15)Win Brands Group LLCHousewares & SpecialtiesWarrants4,871Å 464Å 4Å (15)Windstream Services II, LLCIntegrated Telecommunication ServicesCommon Stock127,452Å 2,057Å 1,657Å (15)WP CPP Holdings, LLC Aerospace & DefenseFirst Lien Term LoanSOFR+7.50%68.72%/4.13%11/28/202930,324Å 29,654Å 30,142Å (6)(15)WP CPP Holdings, LLC Aerospace & DefenseFirst Lien RevolverSOFR+6.75%11/28/2029â€”Å (74)(20)(6)(15)(19)Zep Inc.Specialty ChemicalsFirst Lien Term LoanSOFR+4.00%/9.33%10/2/202819,480Å 19,457Å 19,482Å (6)(15)Total Non-Control/Non-Affiliate Investments (186.3% of net assets)\$2,885,171Å \$2,787,235Å Total Portfolio Investments (208.7% of net assets)\$3,292,932Å \$3,121,703Å Cash and Cash Equivalents and Restricted CashJP Morgan Prime Money Market Fund, Institutional Shares\$37,364Å \$37,364Å Other cash accounts69,950Å 69,950Å Total Cash and Cash Equivalents and Restricted Cash (7.2% of net assets)\$107,314Å \$107,314Å Total Portfolio Investments and Cash and Cash Equivalents and Restricted Cash (215.8% of net assets)\$3,400,246Å \$3,229,017Å 14Oaktree Specialty Lending CorporationConsolidated Schedule of InvestmentsJune 30, 2024(dollar amounts in thousands)(unaudited) Derivative InstrumentNotional Amount to be SoldMaturity DateCounterpartyCumulative Unrealized Appreciation (Depreciation)Foreign currency forward contract\$54,193Å –49,683Å 8/8/2024JPMorgan Chase Bank, N.A.\$849Å Foreign currency forward contract\$55,206Å Å 4F43,988Å 8/8/2024JPMorgan Chase Bank, N.A.(413)\$436Å Derivative InstrumentCompany ReceivesCompany PaysCounterpartyMaturity DateNotional AmountFair ValueInterest rate swapFixed 2.7%Floating 3-month SOFR + 1.658%Royal Bank of Canada1/15/2027\$350,000\$(30,683)Interest rate swapFixed 7.1%Floating 3-month SOFR +3.125%Royal Bank of Canada2/15/2029\$300,000(2,989)\$(33,672)(1)All debt investments are income producing unless otherwise noted. All equity investments are non-income producing unless otherwise noted.(2)See NoteÅ 3 in the accompanying notes to the Consolidated Financial Statements for portfolio composition by geographic region.(3)Equity ownership may be held in shares or units of companies related to the portfolio companies.(4)Each of the Company's investments is pledged as collateral under one or more of its credit facilities. A single investment may be divided into parts that are individually pledged as collateral to separate credit facilities.(5)Interest rates may be adjusted from period to period on certain term loans and revolvers. These rate adjustments may be either temporary in nature due to tier pricing arrangements or financial or payment covenant violations in the original credit agreements or permanent in nature per loan amendment or waiver documents.(6)The interest rate on the principal balance outstanding for most of the floating rate loans is indexed to the secured overnight financing rate ("SOFR"), the euro interbank offered rate ("EURIBOR" or "E"), the sterling overnight index average ("SONIA") and/or an alternate base rate (e.g., prime rate), which typically resets semi-annually, quarterly, or monthly at the borrower's option. The borrower may also elect to have multiple interest reset periods for each loan. For each of these loans, the Company has provided the applicable margin over the reference rate based on each respective credit agreement and the cash interest rate as of period end. As of JuneÅ 30, 2024, the reference rates for the Company's variable rate loans were the 30-day SOFR at 5.34%, the 90-day SOFR at 5.32%, the 180-day SOFR at 5.23%, the PRIME at 8.50%, the SONIA at 5.23% and the 90-day EURIBOR at 3.82%. Most loans include an interest floor, which generally ranges from 0% to 3.00%. SOFR and SONIA based contracts may include a credit spread adjustment that is charged in addition to the base rate and the stated spread.(7)Principal includes accumulated payment in kind ("PIK") interest and is net of repayments, if any. â€”ÅÅÅ signifies the investment is denominated in British Pounds. "Å, –" signifies the investment is denominated in Euros. All other investments are denominated in U.S. dollars.(8)Control Investments generally are defined by the Investment Company Act of 1940, as amended (the "Investment Company Act"), as investments in companies in which the Company owns more than 25% of the voting securities or maintains greater than 50% of the board representation.(9)As defined in the Investment Company Act, the Company is deemed to be both an "Affiliated Person" of and to "Control" these portfolio companies as the Company owns more than 25% of the portfolio company's outstanding voting securities or has the power to exercise control over management or policies of such portfolio company (including through a management agreement). See Schedule 12-14 in the accompanying notes to the Consolidated Financial Statements for transactions during the nine months ended JuneÅ 30, 2024 in which the issuer was both an Affiliated Person and a portfolio company that the Company is deemed to control.(10)This investment represents a participation interest in the underlying securities shown.(11)Investment is not a "qualifying asset" as defined under SectionÅ 55(a) of the Investment Company Act. Under the Investment Company Act, the Company may not acquire any non-qualifying asset unless, at the time the acquisition is made, qualifying assets represent at least 70% of the Company's total assets. As of JuneÅ 30, 2024, qualifying assets represented 72.7% of the Company's total assets and non-qualifying assets represented 27.3% of the Company's total assets.(12)Income producing through payment of dividends or distributions.(13)This investment represents Seller Earn Out Shares in Alvotech SA. The Seller Earn Out Shares will vest if, at any time through June 16, 2027, the Alvotech SA common share price is at or above a volume weighted average price ("VWAP") of \$20.00 per share for any ten trading days within any twenty trading day period.(14)See NoteÅ 3 in the accompanying notes to the Consolidated Financial Statements for portfolio composition.(15)As of JuneÅ 30, 2024, these investments were categorized as Level 3 within the fair value hierarchy established by Financial Accounting Standards Board ("FASB") guidance under Accounting Standards Codification ("ASC") Topic 820, Fair Value Measurements and Disclosures ("ASC 820").(16)This investment was valued using net asset value as a practical expedient for fair value. Consistent with ASC 820, these investments are excluded from the hierarchical levels.15Oaktree Specialty Lending CorporationConsolidated Schedule of InvestmentsJune 30, 2024(dollar amounts in thousands)(unaudited) (17)Affiliate Investments generally are defined by the Investment Company Act as investments in companies in which the Company owns between 5% and 25% of the voting securities.(18)Non-Control/Non-Affiliate Investments are investments that are neither Control Investments nor Affiliate Investments.(19)Investment had undrawn commitments. Unamortized fees are classified as unearned income which reduces cost basis, which may result in a negative cost basis. A negative fair value may result from the unfunded commitment being valued below par.(20)This investment was on non-accrual status as of JuneÅ 30, 2024.(21)This investment represents a revenue interest financing term loan in which the Company receives periodic interest payments based on a percentage of revenues earned at the respective portfolio company over the life of the loan.(22)This investment represents a credit default swap that functions, in substance, like a credit linked note and represents a credit risk transfer for a pool of reference assets owned by a bank. The Company fully funded margin up front and in return the Company receives periodic interest payments. The Company's risk of loss is limited to the principal amount disclosed herein. The reference assets are primarily composed of investment grade corporate debt. The Company may be exposed to counterparty risk, which could make it difficult for the Company to collect on obligations, thereby resulting in potentially significant losses. In addition, the Company only has a contractual relationship with the counterparty bank, and not with the reference obligors of the reference assets. Accordingly, the Company generally may have no right to directly enforce compliance by the reference obligors with the terms of the reference assets. The Company will not directly benefit from the reference assets and will not have the benefit of the remedies that would normally be available to a holder of such reference assets. In addition, in the event of the insolvency of the counterparty bank, the Company may be treated as a general creditor of such counterparty bank, and will not have any claim with respect to the reference assets.(23)This investment was renamed during the three months ended June 30, 2024. For the periods prior to June 30, 2024, this investment was referenced as SCP Eye Care Services, LLC. See notes to Consolidated Financial Statements.16Oaktree Specialty Lending CorporationConsolidated Schedule of InvestmentsSeptemberÅ 30, 2023(dollar amounts in thousands)Portfolio CompanyIndustryType of Investment (1)(2)(3)(4)IndexSpreadCash Interest Rate (5)(6)PIKMaturity DateSharesPrincipalÅ (7)CostFairÅ ValueNotesControl Investments(8)(9)C5 Technology Holdings, LLCData Processing & Outsourced ServicesCommon Stock829\$â€”Å \$â€”Å (15)C5 Technology Holdings, LLCData Processing & Outsourced ServicesPreferred Equity34,984,46034,984Å 27,638Å (15)Dominion Diagnostics, LLCHealth Care ServicesFirst Lien Term LoanSOFR+5.00%10.54%/8/28/202514,068Å 14,068Å 14,068Å (6)(15)Dominion Diagnostics, LLCHealth Care ServicesFirst Lien Term LoanSOFR+5.00%10.42%/8/28/20252,090Å 2,090Å (6)(15)(19)Dominion Diagnostics, LLCHealth Care ServicesFirst Lien RevolverSOFR+5.00%10.54%/8/28/20255,574Å 5,574Å 5,574Å (6)(15)Dominion Diagnostics, LLCHealth Care ServicesCommon Stock30,03115,222Å 2,711Å (15)OCSCI Glick JV LLCMulti-Sector HoldingsSubordinated DebtSOFR+4.50%9.76%10/20/202858,349Å 50,330Å 50,017Å (6)(11)(14)(15)(19)OCSCI Glick JV LLCMulti-Sector HoldingsMembership Interest87.5Å %â€”Å â€”Å (11)(14)(16)(19)Senior Loan Fund JV I, LLCMulti-Sector HoldingsSubordinated DebtSOFR+7.00%12.26%12/29/2028112,656Å 112,656Å 112,656Å (6)(11)(14)(15)(19)Senior Loan Fund JV I, LLCMulti-Sector HoldingsMembership Interest87.5Å %54,791Å 28,878Å (11)(12)(14)(16)(19)SIO2 Medical Products, Inc.Metal, Glass & Plastic ContainersFirst Lien Term Loan12.00%/8/3/202815,874Å 14,100Å 15,874Å (15)SIO2 Medical Products, Inc.Metal, Glass & Plastic ContainersFirst Lien Term Loan12.00%/8/3/20281,359Å 1,337Å 1,359Å (15)(19)SIO2 Medical Products, Inc.Metal, Glass & Plastic ContainersCommon Stock1,184,630Å 40,093Å 36,226Å (15)SIO2 Medical Products, Inc.Metal, Glass & Plastic ContainersWarrants66,686Å â€”Å â€”Å (15)Total Control Investments (19.6% of net assets)\$345,245Å \$297,091Å Affiliate Investments(17)Assembled Brands Capital LLCSpecialized FinanceFirst Lien RevolverSOFR+6.75%12.14%/1/25/2026\$21,852Å \$21,855Å \$21,823Å (6)(15)(19)Assembled Brands Capital LLCSpecialized FinanceCommon Stock1,783,332Å 804Å 89Å (15)Assembled Brands Capital LLCSpecialized FinancePreferred Equity1,129,453Å 1,159Å 1,005Å (15)Assembled Brands Capital LLCSpecialized FinanceWarrants78,045â€”Å â€”Å (15)Caregiver Services, Inc.Health Care ServicesPreferred Equity1,080,399Å 1,080Å 432Å (15)Total Affiliate Investments (1.5% of net assets)\$24,898Å \$23,349Å Non-Control/Non-Affiliate Investments(18)107-109 Beech Oak22 LLCReal Estate DevelopmentFirst Lien Revolver11.00%2/27/2026\$18,869Å \$18,687Å \$18,443Å (15)(19)107 Fair Street LLCReal Estate DevelopmentFirst Lien Term Loan12.50%5/31/20241,269Å 1,240Å 1,214Å (10)(15)(19)112-126 Van Houten Real22 LLCReal Estate DevelopmentFirst Lien Term Loan12.00%5/4/20244,070Å 4,038Å 4,022Å (10)(15)(19)A.T. Holdings II Ltd.BiotechnologyFirst Lien Term Loan14.25%/9/13/202921,434Å 21,612Å 21,220Å (11)(15)(22)A.T. Holdings II SÅRLBiotechnologyFirst Lien Term Loan20.00%/6/20/2046,021Å 6,013Å 5,900Å (11)(15)Accupac, Inc.Personal Care ProductsFirst Lien Term LoanSOFR+6.00%11.55%/1/16/202620,234Å 20,150Å 20,194Å (6)(15)Accupac, Inc.Personal Care ProductsFirst Lien Term LoanSOFR+6.00%1/16/20262,033Å 2,013Å 2,027Å (6)(15)(19)Acquia Inc.Application SoftwareFirst Lien Term LoanL+7.00%12.34%/10/31/20256,400Å 6,335Å 6,380Å (6)(15)Acquia Inc.Application SoftwareFirst Lien Term LoanL+7.00%12.34%/10/31/20255,333Å 1,322Å 1,324Å (6)(15)(19)ADB Companies, LLCConstruction & EngineeringFirst Lien Term LoanSOFR+6.50%11.90%12/18/20253,446Å 3,411Å 3,383Å (6)(15)ADB Companies, LLCConstruction & EngineeringFirst Lien Term LoanSOFR+6.50%12.15%12/18/202517,901Å 17,743Å 17,575Å (6)(15)ADB Companies, LLCConstruction & EngineeringFirst Lien Term LoanSOFR+6.50%12.13%12/18/2025963Å 948Å 945Å (6)(15)17Oaktree Specialty Lending CorporationConsolidated Schedule of InvestmentsSeptemberÅ 30, 2023(dollar amounts in thousands)Portfolio CompanyIndustryType of Investment (1)(2)(3)(4)IndexSpreadCash Interest Rate (5)(6)PIKMaturity DateSharesPrincipalÅ (7)CostFairÅ ValueNotesADC Therapeutics SABiotechnologyFirst Lien Term LoanSOFR+7.50%13.04%/8/15/2029\$6,589Å 6,305Å 6,276Å (6)(11)(15)ADC Therapeutics SABiotechnologyFirst Lien Term LoanSOFR+7.50%/8/15/2029â€”Å (38)(38)(6)(11)(15)(19)ADC Therapeutics SABiotechnologyWarrants28,948Å 174Å 6Å (11)(15)AI Sirona (Luxembourg) Acquisition S.a.r.l.PharmaceuticalsFirst Lien Term LoanE+5.00%/8.86%/9/30/2028Å –5,500Å 6,024Å 5,825Å (6)(11)AIP RD Buyer Corp.DistributorsSecond Lien Term LoanSOFR+7.75%13.17%12/21/2029\$17,873Å 17,655Å 17,687Å (6)(15)AIP RD Buyer Corp.DistributorsCommon Stock17,870Å 1,733Å 2,826Å (15)AirStrip Technologies, Inc.Application SoftwareWarrants5,715Å 90Å â€”Å (15)All Web Leads, Inc.AdvertisingFirst Lien Term LoanSOFR+8.50%12/29/20233,562Å 22,795Å 9,797Å (6)(15)(20)Altice France S.A.Integrated Telecommunication ServicesFixed Rate Bonds5.50%10/15/20294,050Å 3,577Å 2,918Å (11)Alto Pharmacy Holdings, Inc.Health Care TechnologyFirst Lien Term LoanSOFR+11.50%5.00%11.99%10/14/20279,057Å 8,434Å 8,332Å (6)(15)Alto Pharmacy Holdings, Inc.Health Care TechnologyWarrants598,283Å 642Å 1,915Å (15)Alvogen Pharma US, Inc.PharmaceuticalsFirst Lien Term LoanSOFR+7.50%13.04%/6/30/202517,053Å 16,982Å 15,929Å (6)(15)Alvotech Holdings S.A.BiotechnologyFixed Rate Bond8.50%3.50%11/16/202628,464Å 28,329Å 27,687Å (11)(15)Alvotech Holdings S.A.BiotechnologyFixed Rate Bond8.50%3.50%11/16/20262,121Å 1,945Å 2,063Å (11)(15)Alvotech Holdings S.A.BiotechnologyFixed Rate Bond8.50%3.50%11/16/20262,064Å 1,891Å 2,007Å (11)(15)Alvotech Holdings S.A.BiotechnologyCommon Stock471,253Å 849Å 4,298Å (11)Alvotech Holdings S.A.BiotechnologyCommon Stock141,640Å 566Å 368Å (11)(13)(15)American Auto Auction Group, LLCConsumer FinanceSecond Lien Term LoanSOFR+8.75%14.14%1/2/202917,048Å 16,440Å 15,087Å (6)(15)American Tire Distributors, Inc.DistributorsFirst Lien Term LoanSOFR+6.25%11.81%10/20/202819,115Å 18,278Å 16,798Å (6)Amplify Finco Pty Ltd.Movies & EntertainmentSecond Lien Term LoanSOFR+8.00%13.54%11/26/202712,500Å 12,188Å 11,865Å (6)(11)(15)Anastasia Parent, LLCPersonal Care ProductsFirst Lien Term LoanSOFR+3.75%/9.40%/8/11/20253,700Å 3,067Å 2,669Å (6)Ardonagh Midco 3 PLCInsurance BrokersFirst Lien Term LoanE+7.00%10.95%/7/14/2026Å –3,017Å 3,331Å 3,226Å (6)(11)

(15)Ardonagh Midco 3 PLCLInsurance BrokersFirst Lien Term LoanSOFR+5.75%11.57%7/14/2026\$10,519Â 10,400Â 10,624Â (6)(11)(15)Ardonagh Midco 3 PLCLInsurance BrokersFirst Lien Term LoanSONIA+7.00%12.46%7/14/2026\$44,949Â 6,318Â 6,101Â (6)(11)(15)Ardonagh Midco 3 PLCLInsurance BrokersFirst Lien Term LoanSONIA+7.00%12.46%7/14/2026\$Æ23,675Â 28,713Â 29,185Â (6)(11)(15)Ardonagh Midco 3 PLCLInsurance BrokersFirst Lien Term LoanSONIA+5.75%9.70%7/14/2026\$Æ3,649Â 4,094Â 3,914Â (6)(11)(15)ASP-R-PAC Acquisition Co LLCPaper & Plastic Packaging Products & MaterialsFirst Lien Term LoanSOFR+6.00%11.63%12/29/2027\$3,276Â 3,267Â 3,084Â (6)(11)(15)ASP-R-PAC Acquisition Co LLCPaper & Plastic Packaging Products & MaterialsFirst Lien RevolverSOFR+6.00%12/29/2027\$Æ"Â (13)(23)(6)(11)(15)(19)Astra Acquisition Corp.Application SoftwareFirst Lien Term LoanSOFR+5.25%10.90%10/25/2028,490Â 8,168Â 6,414Â (6)(11)(15)Athenahealth Group Inc.Health Care TechnologyPreferred Equity21,523Â 20,789Â 20,074Â (15)ATNX SPV, LLCPharmaceuticalsFirst Lien Term Loan5/31/203112,222Â 12,260Â 11,795Â (11)(15)(22)Aurora Lux Finco S.Æ.R.L.Airport ServicesFirst Lien Term LoanSOFR+6.00%11.49%12/24/202629,509Â 29,146, 28,284Â (6)(11)(15)Avalara, Inc.Application SoftwareFirst Lien Term LoanSOFR+7.25%12.64%10/19/202850,470Â 49,679Â 49,688Â (6)(15)Avalara, Inc.Application SoftwareFirst Lien RevolverSOFR+7.25%10/19/2028Æ"Â (108)(78)(6)(15)(19)The AveryReal Estate Operating CompaniesFirst Lien Term LoanL+7.30%2/17/202319,163Â 19,163Â 18,340Â (6)(15)(20)The AveryReal Estate Operating CompaniesSubordinated Debt Term LoanL+12.50%2/17/20234,641Â 4,641Â 4,170Â (6)(15)(20)BAART Programs, Inc.Health Care ServicesFirst Lien Term LoanSOFR+5.00%10.65%6/11/20273,247Â 3,216Â 3,169Â (6)(15)18Oaktree Specialty Lending CorporationConsolidated Schedule of InvestmentsSeptember 30, 2023(dollar amounts in thousands)Portfolio CompanyIndustryType of Investment (1)(2)(3)(4)IndexSpreadCash Interest Rate (5)(6)PIKMaturity DateSharesPrincipalÂ (7)CostFairÂ ValueNotesBAART Programs, Inc.Health Care ServicesFirst Lien Term LoanSOFR+5.00%10.65%6/11/2027\$1,261Â \$1,269Â \$1,231Â (6)(15)BAART Programs, Inc.Health Care ServicesSecond Lien Term LoanSOFR+8.50%14.15%6/11/2028,920Â 8,819Â 8,492Â (6)(15)BAART Programs, Inc.Health Care ServicesSecond Lien Term LoanSOFR+8.50%14.15%6/11/202824,361Â 4,297Â 4,152Â (6)(15)Berner Food & Beverage, LLCSoft Drinks & Non-alcoholic BeveragesFirst Lien Term LoanSOFR+5.00%11.02%7/30/202740,660Â 40,440Â 40,213Â (6)(15)Berner Food & Beverage, LLCSoft Drinks & Non-alcoholic BeveragesFirst Lien RevolverPRIME+4.50%13.00%7/30/20262,221Â 2,188Â 2,178Â (6)(15)(19)BioXcel Therapeutics, Inc.PharmaceuticalsFirst Lien Term Loan8.00%2.25%4/19/20276,757Â 6,560Â 6,225Â (11)(15)BioXcel Therapeutics, Inc.PharmaceuticalsFirst Lien Term Loan9/30/20323,316Â 3,335Â 3,169Â (11)(15)(19)(22)BioXcel Therapeutics, Inc.PharmaceuticalsFirst Lien Term Loan8.00%2.25%4/19/2027Æ"Â æ"Â æ"Â (11)(15)(19)BioXcel Therapeutics, Inc.PharmaceuticalsFirst Lien Term Loan8.00%2.25%4/19/2027Æ"Â æ"Â æ"Â (11)(15)(19)BioXcel Therapeutics, Inc.PharmaceuticalsFirst Lien Term Loan9/30/2032Æ"Â æ"Â æ"Â (11)(15)(19)(22)BioXcel Therapeutics, Inc.PharmaceuticalsFirst Lien Term Loan9/30/2032Æ"Â æ"Â æ"Â (11)(15)(19)(22)BioXcel Therapeutics, Inc.Data Processing & Outsourced ServicesSecond Lien Term LoanSOFR+7.00%12.43%6/15/202630,625Â 30,370Â 29,989Â (6)Blumenthal Temecula, LLCAutomotive RetailFirst Lien Term Loan9.00%10/9/20235,257Â 5,258Â 5,251Â (15)Blumenthal Temecula, LLCAutomotive RetailPreferred Equity1,708,618Â 1,711Â 1,999Â (15)Blumenthal Temecula, LLCAutomotive RetailPreferred Equity394,297Â 359Â 442Â (15)Blumenthal Temecula, LLCAutomotive RetailCommon Stock394,297Â 424Â 158Â (15)Cadence Aerospace, LLC Aerospace & DefenseFirst Lien Term LoanSOFR+6.50%12.07%11/14/2024374 37Â 37Â (6)(15)Cadence Aerospace, LLC Aerospace & DefenseFirst Lien Term LoanSOFR+6.50%12.07%11/14/20243,031Â 2,899Â 3,031Â (6)(15)Cadence Aerospace, LLC Aerospace & DefenseFirst Lien Term LoanSOFR+6.50%12.07%11/14/20241,557Â 1,489Â 1,557Â (6)(15)Cadence Aerospace, LLC Aerospace & DefenseFirst Lien Term LoanSOFR+6.50%12.07%11/14/20241,024Â 994Â 1,024Â (6)(15)Clear Channel Outdoor Holdings, Inc.AdvertisingFixed Rate Bond7.50%6/1/20292,632Â 2,632Â 2,017Â (11)Clear Channel Outdoor Holdings, Inc.AdvertisingFixed Rate Bond7.75%4/15/2028176Â 170Â 141Â (11)Condor Merger Sub Inc.Systems SoftwareFixed Rate Bond7.38%2/15/2038,420Â 8,261Â 7,059Â Continental Intermodal Group LP Oil & Gas Storage & TransportationFirst Lien Term LoanSOFR+8.50%1/28/202522,084Â 21,336Â 16,040Â (6)(15)(20)Continental Intermodal Group LP Oil & Gas Storage & TransportationWarrants706Â æ"Â (15)Conviva Inc.Application SoftwarePreferred Equity47,851Â 605Â 894Â (15)Coupa Holdings, LLCApplication SoftwareFirst Lien Term LoanSOFR+7.50%12.82%2/27/203013,157Â 12,855Â 12,858Â (6)(15)Coupa Holdings, LLCApplication SoftwareFirst Lien Term LoanSOFR+7.50%2/27/2030Æ"Â (15)(13)(6)(15)(19)Coupa Holdings, LLCApplication SoftwareFirst Lien RevolverSOFR+7.50%2/27/2029Æ"Â (20)(20)(6)(15)(19)Covetrus, Inc.Health Care DistributorsFirst Lien Term LoanSOFR+5.00%10.39%10/13/202914,750Â 14,173Â 14,616Â (6)Coyote Buyer, LLC Specialty ChemicalsFirst Lien Term LoanSOFR+6.00%11.52%2/6/202618,013Â 17,690Â 17,812Â (6)(15)Coyote Buyer, LLC Specialty ChemicalsFirst Lien RevolverSOFR+6.00%11.47%2/6/2025933Â 920Â 918Â (6)(15)(19)CPC Acquisition Corp.Specialty ChemicalsSecond Lien Term LoanSOFR+7.75%12/29/2028724 462Â 396Â (6)(15)(20)Delta Leasing SPV II LLCSpecialized FinanceSubordinated Debt Term Loan3.00%7.31/202917,465Â 17,465Â (11)(15)(19)Delta Leasing SPV II LLCSpecialized FinancePreferred Equity419Â 419Â (11)(15)Delta Leasing SPV II LLCSpecialized FinanceCommon Stock2Â 2Â 2Â (11)(15)Delta Leasing SPV II LLCSpecialized FinanceWarrants31Â æ"Â æ"Â (11)(15)Dialyze Holdings, LLCHealth Care EquipmentFirst Lien Term LoanSOFR+9.00%14.54%8/4/202620,757Â 20,146Â 20,653Â (6)(15)19Oaktree Specialty Lending CorporationConsolidated Schedule of InvestmentsSeptember 30, 2023(dollar amounts in thousands)Portfolio CompanyIndustryType of Investment (1)(2)(3)(4)IndexSpreadCash Interest Rate (5)(6)PIKMaturity DateSharesPrincipalÂ (7)CostFairÂ ValueNotesDialyze Holdings, LLCHealth Care EquipmentSubordinated Debt Term Loan8.00%9/30/2027\$654Â \$631Â (15)Dialyze Holdings, LLCHealth Care EquipmentWarrants6,397,254Â 1,642Â 1,152Â (15)Digital.AI Software Holdings, Inc.Application SoftwareFirst Lien Term LoanSOFR+7.00%12.49%2/10/202712,386Â 12,208Â 12,101Â (6)(15)Digital.AI Software Holdings, Inc.Application SoftwareFirst Lien RevolverSOFR+7.00%12.49%2/10/2027284 265Â 252Â (6)(15)(19)DirecTV Financing, LLC Cable & SatelliteFirst Lien Term LoanSOFR+5.00%10.43%8/2/20274,641Â 4,619Â 4,546Â (6)DTI Holdco, Inc.Research & Consulting ServicesFirst Lien Term LoanSOFR+4.75%10.12%4/26/20294,950Â 4,871Â 4,831Â (6)Eagleview Technology CorporationApplication SoftwareSecond Lien Term LoanSOFR+7.50%13.04%8/14/20268,974Â 8,884Â 7,987Â (6)(15)EOS Fitness Opco Holdings, LLCLeisure FacilitiesPreferred Equity488Â 488Â 1,345Â (15)EOS Fitness Opco Holdings, LLCLeisure FacilitiesCommon Stock12,500Â æ"Â æ"Â (15)Establishment Labs Holdings Inc.Health Care TechnologyFirst Lien Term Loan3.00%6.00%4/21/20271,772Â 1,748Â 1,710Â (11)(15)Establishment Labs Holdings Inc.Health Care TechnologyFirst Lien Term Loan3.00%6.00%4/21/2027Æ"Â 1Â æ"Â (11)(15)(19)Establishment Labs Holdings Inc.Health Care TechnologyFirst Lien Term Loan3.00%6.00%4/21/2027Æ"Â 1Â æ"Â (11)(15)(19)Establishment Labs Holdings Inc.Health Care TechnologyFirst Lien Term Loan3.00%6.00%4/21/2027Æ"Â 1Â æ"Â (11)(15)(19)Evergreen IX Borrower 2023, LLCApplication SoftwareFirst Lien Term LoanSOFR+6.00%11.32%9/29/203014,736Â 14,368Â 14,368Â (6)(15)Evergreen IX Borrower 2023, LLCApplication SoftwareFirst Lien RevolverSOFR+6.00%9/29/2029Æ"Â (41)(41)(6)(15)(19)Fairbridge Strategic Capital Funding LLCReal Estate Operating CompaniesFirst Lien Term Loan9.00%12/24/202859,950Â 59,950Â 59,950Â (15)(19)Fairbridge Strategic Capital Funding LLCReal Estate Operating CompaniesWarrants3,750Â æ"Â 3Â (11)(15)Finastra USA, Inc.Application SoftwareFirst Lien Term LoanSOFR+7.25%12.55%9/13/20292584 234Â 234Â (6)(11)(15)(19)FINThrive Software Intermediate Holdings, Inc.Health Care TechnologySecond Lien Term LoanSOFR+6.75%12.18%12/17/202931,074Â 29,127Â 19,917Â (6)Fortress Biotech, Inc.BiotechnologyFirst Lien Term Loan11.00%8/27/202511,918Â 11,612Â 11,144Â (11)(15)Fortress Biotech, Inc.BiotechnologyWarrants47,011Â 427Â 42Â (11)(15)Frontier Communications Holdings, LLCIntegrated Telecommunication ServicesFixed Rate Bond6.00%15/20304,881Â 4,469Â 3,577Â (11)Galileo Parent, Inc.Aerospace & DefenseFirst Lien Term LoanSOFR+7.25%12.64%5/3/202923,774Â 23,110Â 23,110Â (6)(15)Galileo Parent, Inc.Aerospace & DefenseFirst Lien RevolverSOFR+7.25%12.64%5/3/20291,638Â 1,535Â 1,535Â (6)(15)(19)Gibson Brands, Inc.Leisure ProductsFirst Lien Term LoanSOFR+5.00%10.57%8/11/20282,456Â 2,055Â 2,063Â (6)(15)GoldenTree Loan Management EUR CLO 2 DACMulti-Sector HoldingsCLO NotesE+8.25%5.6%12/20/2032Æ, -1,000Â 876Â 963Â (6)(11)Grove Hotel Parcel Owner, LLC Hotels, Resorts & Cruise LinesFirst Lien Term LoanSOFR+8.00%13.42%6/21/2027817,444Â 17,276Â 17,096Â (6)(15)Grove Hotel Parcel Owner, LLC Hotels, Resorts & Cruise LinesFirst Lien Term LoanSOFR+8.00%6/21/2027Æ"Â (27)(35)(6)(15)(19)Harbor Purchaser Inc.Education ServicesFirst Lien Term LoanSOFR+5.25%10.67%4/9/202914,347Â 13,871Â 13,618Â (6)Harrow, Inc.PharmaceuticalsFirst Lien Term LoanSOFR+6.50%11.89%1/19/20267,448Â 7,296Â 7,301Â (6)(11)(15)Harrow, Inc.PharmaceuticalsFirst Lien Term LoanSOFR+6.50%11/19/2026Æ"Â (82)(79)(6)(11)(15)(19)Harrow, Inc.PharmaceuticalsFirst Lien Term LoanSOFR+6.50%12.04%1/19/20261,432Â 1,399Â 1,404Â (6)(11)(15)Horizon Aircraft Finance I Ltd.Specialized FinanceCLO Notes4.46%12/15/20386,808Â 5,490Â 5,873Â (11)IAMGOLD CorporationGoldSecond Lien Term LoanSOFR+8.25%13.62%5/16/202823,975Â 23,310Â 23,328Â (6)(11)(15)20Oaktree Specialty Lending CorporationConsolidated Schedule of InvestmentsSeptember 30, 2023(dollar amounts in thousands)Portfolio CompanyIndustryType of Investment (1)(2)(3)(4)IndexSpreadCash Interest Rate (5)(6)PIKMaturity DateSharesPrincipalÂ (7)CostFairÂ ValueNotesiCIMS, Inc.Application SoftwareFirst Lien Term LoanSOFR+7.25%12.63%8/18/20283,636Â 3,602Â 3,574Â (6)(15)iCIMS, Inc.Application SoftwareFirst Lien Term LoanSOFR+7.25%8/18/2028Æ"Â æ"Â æ"Â (6)(15)(19)iCIMS, Inc.Application SoftwareFirst Lien RevolverSOFR+6.75%12.14%8/18/20283774 334Â 296Â (6)(15)(19)Impel Pharmaceuticals Inc.Health Care TechnologyFirst Lien Term LoanSOFR+10.75%16.06%3/17/202726,613Â 26,492Â 24,484Â (6)(15)Impel Pharmaceuticals Inc.Health Care TechnologyFirst Lien Term LoanSOFR+10.75%16.05%3/17/2027787Â 771Â 787Â (6)(15)Impel Pharmaceuticals Inc.Health Care TechnologyWarrants350,241Â æ"Â 147Â Innocoll Pharmaceuticals LimitedHealth Care TechnologyFirst Lien Term LoanSOFR+5.75%11.14%2.75%16/26/20277,179Â 6,969Â 6,568Â (6)(11)(15)Innocoll Pharmaceuticals LimitedHealth Care TechnologyWarrants112,990Â 300Â 105Â (11)(15)Integral Development CorporationDiversified Financial ServicesWarrants1,078,284Â 113Â æ"Â (15)Inventus Power, Inc.Electrical Components & EquipmentFirst Lien Term LoanSOFR+7.50%12.93%6/30/202533,414Â 32,539Â 32,659Â (6)(15)Inventus Power, Inc.Electrical Components & EquipmentFirst Lien RevolverSOFR+7.50%6/30/2025Æ"Â (99)(86)(6)(15)(19)INW Manufacturing, LLC Personal Care ProductsFirst Lien Term LoanSOFR+5.75%11.40%3/25/202744,550Â 42,918Â 35,046Â (6)(15)IPC Corp.Application SoftwareFirst Lien Term LoanL+7.25%12.78%12/1/202813,939Â 12,661Â 10,094Â (6)Kings Buyer, LLC Environmental & Facilities ServicesFirst Lien Term LoanSOFR+6.50%11.84%10/29/202716,752Â 16,233Â 16,500Â (6)(15)Kings Buyer, LLC Environmental & Facilities ServicesFirst Lien RevolverSOFR+6.50%11.84%10/29/2027722Â 246Â 238Â (6)(15)(19)Kings Buyer, LLC Environmental & Facilities ServicesFirst Lien Term LoanSOFR+6.50%11.80%10/29/202738,015Â 37,447Â 37,445Â (6)(15)Kings Buyer, LLC Environmental & Facilities ServicesFirst Lien RevolverSOFR+6.50%10/29/2027Æ"Â (47)(47)(6)(15)(19)Latam Airlines Group S.A.Passenger AirlinesFirst Lien Term LoanSOFR+9.50%14.95%10/12/202726,422Â 24,920Â 27,512Â (6)(11)Lift Brands Holdings, Inc.Leisure FacilitiesCommon Stock2,000,000Â 1,399Â æ"Â (15)Lighthouse Intermediate, L.P.Real Estate ServicesFirst Lien Term LoanSOFR+5.00%10.65%5/9/202645,243Â 44,717Â 43,886Â (6)(15)Liquid Environmental Solutions CorporationEnvironmental & Facilities ServicesSecond Lien Term LoanSOFR+8.50%13.99%11/30/20262,939Â 2,884Â 2,745Â (6)(15)(19)Liquid Environmental Solutions CorporationEnvironmental & Facilities ServicesCommon Stock559Â 563Â 372Â (15)LSL Holdco, LLCHealth Care DistributorsFirst Lien Term LoanSOFR+6.00%11.42%1/31/202823,494Â 23,128Â 21,967Â (6)(15)LSL Holdco, LLCHealth Care DistributorsFirst Lien RevolverSOFR+6.00%1/31/2028Æ"Â (41)(172)(6)(15)(19)Marinus Pharmaceuticals, Inc.PharmaceuticalsFirst Lien Term Loan11.50%5/11/20268,568Â 8,495Â 8,132Â (11)(15)Marinus Pharmaceuticals, Inc.PharmaceuticalsFirst Lien Term Loan11.50%5/11/20264,284Â 4,247Â 4,066Â (11)(15)Marinus Pharmaceuticals, Inc.PharmaceuticalsFirst Lien Term Loan11.50%5/11/20268,568Â 8,495Â 8,132Â (11)(15)Mesoblast, Inc.BiotechnologyFirst Lien Term LoanSOFR+6.00%11.52%7/21/20272,631Â 2,587Â 2,591Â (6)(15)MHE Intermediate Holdings, LLC Diversified Support ServicesFirst Lien Term LoanSOFR+6.00%11.52%7/21/20272,631Â 2,587Â 2,591Â (6)(15)MHE Intermediate Holdings, LLC Diversified Support ServicesFirst Lien RevolverSOFR+6.00%11.42%7/21/2027964Â 936Â 938Â (6)(15)(19)21Oaktree Specialty Lending CorporationConsolidated Schedule of InvestmentsSeptember 30, 2023(dollar amounts in thousands)Portfolio CompanyIndustryType of Investment (1)(2)(3)(4)IndexSpreadCash Interest Rate (5)(6)PIKMaturity DateSharesPrincipalÂ (7)CostFairÂ ValueNotesMindbody, Inc.Internet Services & InfrastructureFirst Lien Term LoanSOFR+7.00%12.52%14/202555,248Â \$5,220Â \$5,164Â (6)(15)Mindbody, Inc.Internet Services & InfrastructureFirst Lien Term LoanSOFR+7.00%12.52%14/202546,687Â 46,239Â 45,940Â (6)(15)Mindbody, Inc.Internet Services & InfrastructureFirst Lien RevolverSOFR+7.00%2/14/2025Æ"Â (43)(76)(6)(15)(19)MND Holdings III CorpOther Specialty RetailFirst Lien Term LoanSOFR+7.50%12.89%5/9/202840,538Â 39,873Â 39,833Â (6)(15)MND Holdings III CorpOther Specialty RetailFirst Lien RevolverSOFR+7.50%12.83%5/9/20281,466Â 1,215Â 1,282Â (6)(15)(19)Mosaic Companies, LLC Home Improvement RetailFirst Lien Term LoanL+6.75%12.51%7/2/202654,559Â 54,236Â 53,168Â (6)(15)MRI Software LLCApplication SoftwareFirst Lien Term LoanSOFR+5.50%10.99%2/10/202621,328Â 21,021Â 20,888Â (6)(15)MRI Software LLCApplication SoftwareFirst Lien RevolverSOFR+5.50%2/10/2026Æ"Â (28)(47)(6)(15)(19)Naviste, LLC Data Processing & Outsourced ServicesSecond Lien Term LoanSOFR+8.50%13.99%12/30/202630,339Â 30,021Â 29,007Â (6)(15)NeuAg, LLC Fertilizers & Agricultural ChemicalsFirst Lien Term LoanSOFR+9.50%14.89%9/11/202464,606Â 64,720Â 63,185Â (6)(15)NFP Corp.Diversified Financial ServicesFixed Rate Bond6.88%8/15/202810,191Â 9,831Â 8,743Â NN, Inc.Industrial Machinery & Supplies & ComponentsFirst Lien Term LoanSOFR+6.88%12.29%2.00%9/19/202673,362Â 72,459Â 69,694Â (6)(11)(15)NN, Inc.Industrial Machinery & Supplies & ComponentsWarrants487,870Â æ"Â 903Â (11)NN, Inc.Industrial Machinery & Supplies & ComponentsWarrants487,870Â æ"Â 903Â (11)OEConnection LLCApplication SoftwareSecond Lien Term LoanSOFR+7.00%12.49%9/25/20279,323Â 9,210Â 9,183Â (6)(15)Oranje Holdco, Inc.Systems SoftwareFirst Lien Term LoanSOFR+7.75%13.12%2/10/202915,231Â 14,892Â 14,945Â (6)(15)Oranje Holdco, Inc.Systems SoftwareFirst Lien RevolverSOFR+7.75%2/10/2029Æ"Â (42)(36)(6)(15)(19)OTG Management, LLC Airport ServicesFirst Lien Term LoanSOFR+10.00%15.67%9/2/202525,712Â 25,615Â 25,069Â (6)(15)OTG Management, LLC Airport ServicesFirst Lien Term LoanSOFR+10.00%9/2/2025Æ"Â (11)(69)(6)(15)(19)OTG Management, LLC Airport ServicesFirst Lien Term LoanSOFR+10.00%15.64%9/2/20251,210Â 1,193Â 1,169Â (6)(15)(19)P & L Development, LLC PharmaceuticalsFixed Rate Bond7.75%11/15/20254,519Â 4,550Â 3,305Â Park Place Technologies, LLC Internet Services & InfrastructureFirst Lien Term LoanSOFR+5.00%10.42%11/10/20279,676Â 9,518Â 9,551Â (6)Performance Health Holdings, Inc.Health Care DistributorsFirst Lien Term LoanSOFR+6.00%11.57%7/12/20272,375Â 22,189Â 21,896Â (6)(15)Planview Parent, Inc.Application SoftwareSecond Lien Term LoanSOFR+7.25%12.74%12/18/202836,499Â 35,458Â 33,214Â (6)(15)Pluralsight, LLCApplication SoftwareFirst Lien Term LoanSOFR+8.00%13.45%4/6/202767,244Â 66,353Â 64,406Â (6)(15)Pluralsight, LLCApplication SoftwareFirst Lien RevolverSOFR+8.00%13.45%4/6/20273,003Â 2,926Â 2,801Â (6)(15)(19)PPW Aero Buyer, Inc.Aerospace & DefenseFirst Lien Term LoanSOFR+7.00%12.32%2/15/202910,895Â 10,505Â 10,495Â (6)(15)PPW Aero Buyer, Inc.Aerospace & DefenseFirst Lien RevolverSOFR+7.00%2/15/2029Æ"Â (53)(54)(6)(15)(19)PRGX Global, Inc.Data Processing & Outsourced ServicesFirst Lien Term LoanSOFR+6.50%12.01%6/3/202638,414Â 37,960Â 38,380Â (6)(15)PRGX Global, Inc.Data Processing & Outsourced ServicesFirst Lien RevolverSOFR+6.50%3/30/2026Æ"Â (34)(3)(6)(15)(19)PRGX Global, Inc.Data Processing & Outsourced ServicesCommon Stock100,000Â 109Â 248Â (15)Profrac Holdings II, LLC Industrial Machinery & Supplies & ComponentsFirst Lien Term LoanSOFR+7.25%12.78%3/4/202524,503Â 24,255Â 24,081Â (6)(15)Profrac Holdings II, LLC Industrial Machinery & Supplies &

ComponentsFirst Lien Term LoanSOFR+7.25%12.78%/4/20252,819Å 2,797Å 2,771Å (6)(15)Quantum Bidco LimitedFood DistributorsFirst Lien Term LoanSONIA+5.75%11.21%1/31/2028ÅE4,626Å 5,897Å 5,166Å (6)(11)(15)QuorumLabs, Inc.Application SoftwarePreferred Equity64,887,669Å 375Å æ"Å (15)Relativity ODA LLCApplication SoftwareFirst Lien Term LoanSOFR+6.50%11.92%5/12/2027\$32,329Å 32,070Å 31,779Å (6)(15)Relativity ODA LLCApplication SoftwareFirst Lien RevolverSOFR+6.50%5/12/2027æ"Å (43)(47) (6)(15)(19)22Oaktree Specialty Lending CorporationConsolidated Schedule of InvestmentsSeptemberÅ 30, 2023(dollar amounts in thousands)Portfolio CompanyIndustryType of Investment (1)(2)(3)(4)IndexSpreadCash Interest Rate (5)(6)PIKMaturity DateSharesPrincipalÅ (7)CostFairÅ ValueNotesRumbleOn, Inc.Automotive RetailFirst Lien Term LoanSOFR+8.25%13.90%0.50%8/31/2026\$36,707Å \$35,548Å \$34,505Å (6)(11)(15)RumbleOn, Inc.Automotive RetailFirst Lien Term LoanSOFR+8.25%13.90%0.50%8/31/202613,504Å 13,058Å 12,694Å (6)(11)(15)RumbleOn, Inc.Automotive RetailWarrants204,454Å 1,202Å 756Å (11)(15)Salus Workers' Compensation, LLC Diversified Financial ServicesFirst Lien Term LoanSOFR+10.00%15.24%10/7/202625,558Å 24,777Å 24,791Å (6)(15)Salus Workers' Compensation, LLC Diversified Financial ServicesFirst Lien RevolverSOFR+10.00%10/7/2026æ"Å (95)(93)(6)(15)(19)Salus Workers' Compensation, LLC Diversified Financial ServicesWarrants991,019Å 327Å 1,625Å (15)Scilex Holding CoBiotechnologyCommon Stock9,307Å 78Å 13Å (11)SCP Eye Care Services, LLCHealth Care ServicesSecond Lien Term LoanSOFR+8.75%10/7/2030æ"Å (35)(68)(6)(15)(19)SCP Eye Care Services, LLCHealth Care ServicesCommon Stock1,037Å 1,037Å 951Å (15)scPharmaceuticals Inc.PharmaceuticalsFirst Lien Term LoanSOFR+8.75%11.75%10/13/20275,212Å 4,987Å 4,990Å (6)(15)scPharmaceuticals Inc.PharmaceuticalsFirst Lien Term LoanSOFR+8.75%10/13/2027æ"Å æ"Å æ"Å æ"Å æ"Å (6)(15)(19)scPharmaceuticals Inc.PharmaceuticalsFirst Lien Term LoanSOFR+8.75%10/13/2027æ"Å æ"Å æ"Å æ"Å (6)(15)(19)scPharmaceuticals Inc.PharmaceuticalsWarrants53,700Å 175Å 258Å (15)Seres Therapeutics, Inc.BiotechnologyFirst Lien Term LoanSOFR+7.88%12.88%4/27/20297,191Å 6,934Å 6,937Å (6)(11)(15)Seres Therapeutics, Inc.BiotechnologyFirst Lien Term LoanSOFR+7.88%12.88%4/27/20292,697Å 2,601Å 2,602Å (6)(11)(15)Seres Therapeutics, Inc.BiotechnologyFirst Lien Term LoanSOFR+7.88%4/27/2029æ"Å æ"Å æ"Å (6)(11)(15)(19)Seres Therapeutics, Inc.BiotechnologyFirst Lien Term LoanSOFR+7.88%4/27/2029æ"Å æ"Å æ"Å æ"Å (6)(11)(15)(19)Seres Therapeutics, Inc.BiotechnologyWarrants58,210Å 182Å 87Å (11)(15)ShareThis, Inc.Application SoftwareWarrants345,452Å 367Å æ"Å (15)SM Wellness Holdings, Inc.Health Care ServicesFirst Lien Term LoanSOFR+4.75%10.38%4/17/20284,452Å 3,806Å 4,184Å (6)(15)SM Wellness Holdings, Inc.Health Care ServicesSecond Lien Term LoanSOFR+8.00%13.63%4/16/202912,034Å 11,250Å 9,928Å (6)(15)SonicWall US Holdings Inc.Technology DistributorsSecond Lien Term LoanSOFR+7.50%13.04%5/18/2026821Å 813Å 776Å (6)(15)Sorrento Therapeutics, Inc.BiotechnologyCommon Stock66,000Å 139Å 6Å (11)Spanx, LLCApparel RetailFirst Lien Term LoanSOFR+5.25%10.67%11/20/20284,488Å 4,423Å 4,425Å (6)(15)Spanx, LLCApparel RetailFirst Lien RevolverSOFR+5.00%10.42%11/18/2027618Å 576Å 577Å (6)(15)(19)SumUp Holdings Luxembourg S.Å.R.L.Diversified Financial ServicesFirst Lien Term LoanE+8.50%12.32%3/10/2026æ",-23,731Å 26,772Å 24,937Å (6)(11)(15)Superior Industries International, Inc.Auto Parts & EquipmentFirst Lien Term LoanSOFR+8.00%13.32%12/16/2028849,520Å 48,536Å 49,148Å (6)(15)Supreme Fitness Group NY Holdings, LLCLeisure FacilitiesFirst Lien Term LoanSOFR+7.00%12.51%12/31/202632,104Å 31,861Å 30,579Å (6)(15)(21)Supreme Fitness Group NY Holdings, LLCLeisure FacilitiesFirst Lien Term LoanSOFR+7.00%12.51%12/31/20262,749Å 2,726Å 2,618Å (6)(15)(21)Supreme Fitness Group NY Holdings, LLCLeisure FacilitiesFirst Lien Term LoanSOFR+7.00%12.51%12/31/20261,099Å 1,062Å 943Å (6)(15)(19)(21)Supreme Fitness Group NY Holdings, LLCLeisure FacilitiesFirst Lien RevolverSOFR+7.00%12.44%12/31/20261,552Å 1,540Å 1,478Å (6)(15)(21)SVP-Singer Holdings Inc.Home FurnishingsFirst Lien Term LoanSOFR+6.75%12.40%7/28/202825,527Å 23,859Å 19,954Å (6)(15)Tacala, LLCRestaurantsSecond Lien Term LoanSOFR+8.00%13.43%2/4/202812,843Å 12,603Å 12,464Å (6)Tahoe Bidco B.V.Application SoftwareFirst Lien Term LoanSOFR+6.00%11.42%6/29/202828,826Å 28,595Å 28,537Å (6)(11)(15)Tahoe Bidco B.V.Application SoftwareFirst Lien RevolverSOFR+6.00%10/1/2027æ"Å (29)(22)(6)(11)(15)(19)Telestream Holdings CorporationApplication SoftwareFirst Lien Term LoanSOFR+9.75%15.26%10/15/202523,423Å 23,207Å 22,814Å (6)(15)(19)Telestream Holdings CorporationApplication SoftwareFirst Lien RevolverSOFR+9.75%15.17%10/15/20251,861Å 1,845Å 1,802Å (6)(15)(19)Ten-X LLCInteractive Media & ServicesFirst Lien Term LoanSOFR+6.00%11.32%5/26/202819,947Å 19,013Å 19,199Å (6)(15)TGNR HoldCo LLCIntegrated Oil & GasSubordinated Debt11.50%5/4/20264,984Å 4,894Å 4,785Å (10)(11)(15)(23)Oaktree Specialty Lending CorporationConsolidated Schedule of InvestmentsSeptemberÅ 30, 2023(dollar amounts in thousands)Portfolio CompanyIndustryType of Investment (1)(2)(3)(4)IndexSpreadCash Interest Rate (5)(6)PIKMaturity DateSharesPrincipalÅ (7)CostFairÅ ValueNotesTHL Zinc Ventures LtdDiversified Metals & MiningFirst Lien Term Loan13.00%5/23/2026\$50,419Å 49,842Å 49,869Å (11)(15)Thrasio, LLCBroadline RetailFirst Lien Term LoanSOFR+7.00%12.65%12/18/202646,832Å 45,698Å 37,231Å (6)(15)Thrasio, LLCBroadline RetailPreferred Equity10,616Å 120Å æ"Å (15)Thrasio, LLCBroadline RetailPreferred Equity358,299Å 2,912Å æ"Å (15)Thrasio, LLCBroadline RetailPreferred Equity60,862Å 1,207Å 108Å (15)Thrasio, LLCBroadline RetailPreferred Equity32,447Å 33,353Å 31,701Å (15)Touchstone Acquisition, Inc.Health Care SuppliesFirst Lien Term LoanSOFR+6.00%11.42%12/29/202811,671Å 11,646Å 11,363Å (6)(15)Trinitas CLO XV DACMulti-Sector HoldingsCLO NotesSOFR+7.71%13.06%4/22/20341,000Å 816Å 917Å (6)(11)Uniti Group LPOther Specialized REITsFixed Rate Bond6.50%12/5/20294,500Å 4,115Å 2,953Å (11)Uniti Group LPOther Specialized REITsFixed Rate Bond4.75%4/15/2028300Å 264Å 245Å (11)Virgin Pulse, Inc.Application SoftwareSecond Lien Term LoanSOFR+7.25%12.68%4/6/20291,140Å 927Å 1,139Å (6)(15)Win Brands Group LLCHousewares & SpecialtiesFirst Lien Term LoanL+15.00%21.68%1/23/20261,565Å 1,551Å 1,464Å (6)(15)Win Brands Group LLCHousewares & SpecialtiesFirst Lien Term LoanL+15.00%21.68%1/23/20261,323Å 1,311Å 1,237Å (6)(15)Win Brands Group LLCHousewares & SpecialtiesWarrants4,871Å 46Å 107Å (15)Windstream Services II, LLCIntegrated Telecommunication ServicesFirst Lien Term LoanSOFR+6.25%11.67%9/21/20278,983Å 8,698Å 8,678Å (6)Windstream Services II, LLCIntegrated Telecommunication ServicesCommon Stock127,452Å 2,057Å 1,319Å (15)WP CPP Holdings, LLC Aerospace & DefenseFirst Lien Term LoanSOFR+3.75%9.27%4/30/202511,792Å 11,281Å 11,127Å (6)WVXV Uni Topco Holdings, LLC Air Freight & LogisticsSecond Lien Term LoanSOFR+7.00%12.65%7/26/20295,000Å 4,925Å 4,263Å (6)(15)Zephyr Bidco LimitedSpecialized FinanceSecond Lien Term LoanSONIA+7.50%12.72%7/23/2026ÅE20,000Å 25,841Å 22,914Å (6)(11)(15)Zep Inc.Specialty ChemicalsFirst Lien Term LoanSOFR+4.00%9.32%9/30/2028\$19,578Å 19,568Å 19,489Å (6)(15)Total Non-Control/Non-Affiliate Investments (169.7% of net assets)\$2,673,976Å \$2,571,980Å Total Portfolio Investments (190.8% of net assets)\$3,044,119Å \$2,892,420Å Cash and Cash Equivalents and Restricted CashJP Morgan Prime Money Market Fund, Institutional Shares\$83,262Å \$83,262Å Other cash accounts62,277Å 62,277Å Total Cash and Cash Equivalents and Restricted Cash (9.6% of net assets)\$145,539Å \$145,539Å Total Portfolio Investments and Cash and Cash Equivalents and Restricted Cash (200.4% of net assets)\$3,189,658Å \$3,037,959Å Derivative InstrumentNotional Amount to be PurchasedNotional Amount to be SoldMaturity DateCounterpartyCumulative Unrealized Appreciation /DepreciationForeign currency forward contract\$42,182Å Å, -38,026Å 11/9/2023JP Morgan Chase Bank, N.A.\$1,857Å Foreign currency forward contract\$72,098Å ÅE56,556Å 11/9/2023JP Morgan Chase Bank, N.A.\$3,053Å \$4,910Å Derivative InstrumentCompany ReceivesCompany PaysCounterpartyMaturity DateNotional AmountFair ValueInterest rate swapFixed 2.7%Floating 3-month SOFR +1.658%Royal Bank of Canada1/15/2027\$350,000\$40,519Interest rate swapFixed 7.1%Floating 3-month SOFR +3.1255%Royal Bank of Canada2/15/2029\$300,000(7,000)\$4,51924Oaktree Specialty Lending CorporationConsolidated Schedule of InvestmentsSeptemberÅ 30, 2023(dollar amounts in thousands)(1)All debt investments are income producing unless otherwise noted. All equity investments are non-income producing unless otherwise noted.(2)See NoteÅ 3 in the accompanying notes to the Consolidated Financial Statements for portfolio composition by geographic region.(3)Equity ownership may be held in shares or units of companies related to the portfolio companies.(4)Each of the Company's investments is pledged as collateral under one or more of its credit facilities. A single investment may be divided into parts that are individually pledged as collateral to separate credit facilities.(5)Interest rates may be adjusted from period to period on certain term loans and revolvers. These rate adjustments may be either temporary in nature due to tier pricing arrangements or financial or payment covenant violations in the original credit agreements or permanent in nature per loan amendment or waiver documents. (6)The interest rate on the principal balance outstanding for most of the floating rate loans is indexed to SOFR, the London Interbank Offered Rate ("LIBOR" or "L"), SONIA and/or an alternate base rate (e.g., prime rate), which typically resets semi-annually, quarterly, or monthly at the borrower's option. The borrower may also elect to have multiple interest reset periods for each loan. For each of these loans, the Company has provided the applicable margin over the reference rate based on each respective credit agreement and the cash interest rate as of period end. All LIBOR and SOFR shown above is in U.S. dollars unless otherwise noted. As of SeptemberÅ 30, 2023, the reference rates for the Company's variable rate loans were the 30-day SOFR at 5.32%, the 90-day SOFR at 5.39%, the 180-day SOFR at 5.47%, the 30-day LIBOR at 5.43%, the 90-day LIBOR at 5.65%, the 180-day LIBOR at 5.90%, the PRIME at 8.50%, the SONIA at 5.19%, the 30-day EURIBOR at 3.42%, the 90-day EURIBOR at 3.82% and the 180-day EURIBOR at 3.95%. Most loans include an interest floor, which generally ranges from 0% to 2.75%. SOFR and SONIA based contracts may include a credit spread adjustment that is charged in addition to the base rate and the stated spread.(7)Principal includes accumulated PIK interest and is net of repayments, if any. ÅEÅEÅE signifies the investment is denominated in British Pounds. "Å," -" signifies the investment is denominated in Euros. All other investments are denominated in U.S. dollars.(8)Control Investments generally are defined by the Investment Company Act as investments in companies in which the Company owns more than 25% of the voting securities or maintains greater than 50% of the board representation.(9)As defined in the Investment Company Act, the Company is deemed to be both an "Affiliated Person" of and to "Control" these portfolio companies as the Company owns more than 25% of the portfolio company's outstanding voting securities or has the power to exercise control over management or policies of such portfolio company (including through a management agreement). See Schedule 12-14 in the Company's annual report on Form 10-K for the year ended September 30, 2023 for transactions during the year ended SeptemberÅ 30, 2023 in which the issuer was both an Affiliated Person and a portfolio company that the Company is deemed to control.(10)This investment represents a participation interest in the underlying securities shown. (11)Investment is not a "qualifying asset" as defined under SectionÅ 55(a) of the Investment Company Act. Under the Investment Company Act, the Company may not acquire any non-qualifying asset unless, at the time the acquisition is made, qualifying assets represent at least 70% of the Company's total assets. As of SeptemberÅ 30, 2023, qualifying assets represented 74.3% of the Company's total assets and non-qualifying assets represented 25.7% of the Company's total assets.(12)Income producing through payment of dividends or distributions.(13)This investment represents Seller Earn Out Shares in Alvotech SA. One half of the Seller Earn Out Shares will vest if, at any time through June 16, 2027, the Alvotech SA common share price is at or above a VWAP of \$15.00 per share for any ten trading days within any twenty trading day period, and the other half will vest, if at any time during such period, the common share price is at or above a VWAP of \$20.00 per share for any ten trading days within any twenty trading day period. (14)See NoteÅ 3 in the accompanying notes to the Consolidated Financial Statements for portfolio composition.(15)As of SeptemberÅ 30, 2023, these investments were categorized as Level 3 within the fair value hierarchy established by ASC 820. (16)This investment was valued using net asset value as a practical expedient for fair value. Consistent with ASC 820, these investments are excluded from the hierarchical levels. (17)Affiliate Investments generally are defined by the Investment Company Act as investments in companies in which the Company owns between 5% and 25% of the voting securities.(18)Non-Control/Non-Affiliate Investments are investments that are neither Control Investments nor Affiliate Investments.(19)Investment had undrawn commitments. Unamortized fees are classified as unearned income which reduces cost basis, which may result in a negative cost basis. A negative fair value may result from the unfunded commitment being valued below par.(20)This investment was on non-accrual status as of SeptemberÅ 30, 2023.(21)This investment was renamed during the three months ended March 31, 2023. For periods prior to March 31, 2023, this investment was referenced as PFNY Holdings, LLC.(22)This investment represents a revenue interest financing term loan in which the Company receives periodic interest payments based on a percentage of revenues earned at the respective portfolio company over the life of the loan. See notes to Consolidated Financial Statements.25OAKTREE SPECIALTY LENDING CORPORATIONNOTESÅ TO CONSOLIDATED FINANCIAL STATEMENTS(in thousands, except share and per share amounts, percentages and as otherwise indicated)NoteÅ 1. Organization Oaktree Specialty Lending Corporation (together with its consolidated subsidiaries, the "Company") is a specialty finance company that looks to provide customized, one-stop credit solutions to companies with limited access to public or syndicated capital markets. The Company was formed in late 2007 and operates as a closed-end, externally managed, non-diversified management investment company that has elected to be regulated as a Business Development Company under the Investment Company Act. The Company has qualified and elected to be treated as a regulated investment company ("RIC") under the Internal Revenue Code of 1986, as amended (the "Code"), for U.S. federal income tax purposes.The Company's investment objective is to generate current income and capital appreciation by providing companies with flexible and innovative financing solutions, including first and second lien loans, unsecured and mezzanine loans, bonds, preferred equity and certain equity co-investments. The Company may also seek to generate capital appreciation and income through secondary investments at discounts to par in either private or syndicated transactions. The Company is externally managed by Oaktree Fund Advisors, LLC ("Oaktree"), pursuant to an investment advisory agreement between the Company and Oaktree (as amended and restated, the "Investment Advisory Agreement"). Oaktree is an affiliate of Oaktree Capital Management, L.P. ("OCM"), the Company's external investment adviser from October 17, 2017 through May 3, 2020. Oaktree Fund Administration, LLC ("Oaktree Administrator"), a subsidiary of OCM, provides certain administrative and other services necessary for the Company to operate pursuant to an administration agreement between the Company and Oaktree Administrator (the "Administration Agreement"). See Note 10. In 2019, Brookfield Corporation (/f/k/a Brookfield Asset Management Inc.) ("Brookfield") acquired a majority economic interest in Oaktree Capital Group, LLC.Å Oaktree and its affiliates operate as an independent business within Brookfield, with their own product offerings and investment, marketing and support teams.On March 19, 2021, the Company acquired Oaktree Strategic Income Corporation (ÅEÅEÅEÅE) pursuant to that certain Agreement and Plan of Merger (the ÅEÅEÅEÅE Merger AgreementÅE), dated as of October 28, 2020, by and among OCSI, the Company, Lion Merger Sub, Inc., a wholly-owned subsidiary of the Company, and, solely for the limited purposes set forth therein, Oaktree. Pursuant to the OCSI Merger Agreement, OCSI was merged with and into the Company in a two-step transaction, with the Company as the surviving company (the "OCSI MergerÅE"). On January 23, 2023, the Company acquired Oaktree Strategic Income II, Inc. (ÅEÅEÅEÅE) pursuant to that certain Agreement and Plan of Merger (the ÅEÅEÅEÅE Merger AgreementÅE), dated as of September 14, 2022, by and among OSI2, the Company, Project Superior Merger Sub, Inc., a wholly-owned subsidiary of the Company, and, solely for the limited purposes set forth therein, Oaktree. Pursuant to the OSI2 Merger Agreement, OSI2 was merged with and into the Company in a two-step transaction with the Company as the surviving company (the ÅEÅEÅEÅE MergerÅE). 26OAKTREE SPECIALTY LENDING CORPORATIONNOTESÅ TO CONSOLIDATED FINANCIAL STATEMENTS(in thousands, except share and per share amounts, percentages and as otherwise indicated)NoteÅ 2. Significant Accounting Policies Basis of Presentation: The Consolidated Financial Statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") and pursuant to the requirements for reporting on Form 10-Q and Regulation S-X. In the opinion of management, all adjustments of a normal recurring nature considered necessary for the fair presentation of the Consolidated Financial Statements have been made. All intercompany balances and transactions have been eliminated. The Company is an investment company following the accounting and reporting guidance in ASC Topic 946, Financial Services - Investment Companies ("ASC 946").Certain prior period amounts have been reclassified to conform to the current period presentation. All per share amounts and common shares outstanding have been retroactively adjusted as necessary to reflect the Company's 1-for-3 reverse stock split completed on January 20, 2023 and effective as of the commencement of trading on January 23, 2023. Use of Estimates:The preparation of the financial statements in conformity with GAAP requires management to make certain estimates and assumptions affecting amounts reported in the financial statements and accompanying notes. These estimates are based on the information that is currently available to the Company and on various other assumptions that the Company believes to be reasonable under the circumstances. Changes in the economic and political environments, financial markets and any other parameters used in determining these estimates could cause actual results to differ and such differences could be material. Significant estimates include the valuation of investments and revenue recognition.Consolidation:The accompanying Consolidated Financial Statements include the accounts of Oaktree Specialty Lending Corporation and its consolidated subsidiaries. Each consolidated subsidiary is wholly-owned and, as such, consolidated into the Consolidated Financial Statements. Certain subsidiaries that hold investments are treated as pass through entities for U.S. federal income tax purposes. The assets of certain of the consolidatedÅ subsidiariesÅ are not directlyÅ availableÅ to satisfyÅ the claims of the creditors of Oaktree Specialty Lending Corporation or any of its other subsidiaries. As an investment company, portfolio investments held by the Company are not consolidated into the Consolidated

Financial Statements but rather are included on the Statements of Assets and Liabilities as investments at fair value. Fair Value Measurements:Oaktree, as the valuation designee of the Company's Board of Directors pursuant to Rule 2a-5 under the Investment Company Act, determines the fair value of the Company's assets on at least a quarterly basis in accordance with ASC 820. ASC 820 defines fair value as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. A liability's fair value is defined as the amount that would be paid to transfer the liability to a new obligor, not the amount that would be paid to settle the liability with the creditor. ASC 820 prioritizes the use of observable market prices over entity-specific inputs. Where observable prices or inputs are not available or reliable, valuation techniques are applied. These valuation techniques involve some level of management estimation and judgment, the degree of which is dependent on the price transparency for the investments or market and the investments' complexity.Hierarchical levels, defined by ASC 820 and directly related to the amount of subjectivity associated with the inputs to fair valuation of these assets and liabilities, are as follows:À Level 1 À Unadjusted, quoted prices in active markets for identical assets or liabilities as of the measurement date.À Level 2 À Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data at the measurement date for substantially the full term of the assets or liabilities.À Level 3 À Unobservable inputs that reflect Oaktree's best estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model.If inputs used to measure fair value fall into different levels of the fair value hierarchy, an investment's level is based on the lowest level of input that is significant to the fair value measurement. Oaktree's assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the investment. 27OAKTREE SPECIALTY LENDING CORPORATIONNOTESÀ TO CONSOLIDATED FINANCIAL STATEMENTS(in thousands, except share and per share amounts, percentages and as otherwise indicated)This includes investment securities that are valued using "bid" and "ask" prices obtained from independent third party pricing services or directly from brokers. These investments may be classified as Level 3 because the quoted prices may be indicative in nature for securities that are in an inactive market, may be for similar securities or may require adjustments for investment-specific factors or restrictions.Financial instruments with readily available quoted prices generally will have a higher degree of market price observability and a lesser degree of judgment inherent in measuring fair value. As such, Oaktree obtains and analyzes readily available market quotations provided by pricing vendors and brokers for all of the Company's investments for which quotations are available. In determining the fair value of a particular investment, pricing vendors and brokers use observable market information, including both binding and non-binding indicative quotations. Oaktree seeks to obtain at least two quotations for the subject or similar securities, typically from pricing vendors. If Oaktree is unable to obtain two quotes from pricing vendors, or if the prices obtained from pricing vendors are not within Oaktree's set threshold, Oaktree seeks to obtain a quote directly from a broker making a market for the asset. Oaktree evaluates the quotations provided by pricing vendors and brokers based on available market information, including trading activity of the subject or similar securities, or by performing a comparable security analysis to ensure that fair values are reasonably estimated. Oaktree also performs back-testing of valuation information obtained from pricing vendors and brokers against actual prices received in transactions. In addition to ongoing monitoring and back-testing, Oaktree performs due diligence procedures over pricing vendors to understand their methodology and controls to support their use in the valuation process. Generally, Oaktree does not adjust any of the prices received from these sources. If the quotations obtained from pricing vendors or brokers are determined to not be reliable or are not readily available, Oaktree values such investments using any of three different valuation techniques. The first valuation technique is the transaction precedent technique, which utilizes recent or expected future transactions of the investment to determine fair value, to the extent applicable. The second valuation technique is an analysis of the enterprise value ("EV") of the portfolio company. EV means the entire value of the portfolio company to a market participant, including the sum of the values of debt and equity securities used to capitalize the enterprise at a point in time. The EV analysis is typically performed to determine (i) the value of equity investments, (ii) whether there is credit impairment for debt investments and (iii) the value for debt investments that the Company is deemed to control under the Investment Company Act. To estimate the EV of a portfolio company, Oaktree analyzes various factors, including the portfolio company's historical and projected financial results, macroeconomic impacts on the company and competitive dynamics in the company's industry. Oaktree also utilizes some or all of the following information based on the individual circumstances of the portfolio company: (i) valuations of comparable public companies, (ii) recent sales of private and public comparable companies in similar industries or having similar business or earnings characteristics, (iii) purchase prices as a multiple of their earnings or cash flow, (iv) the portfolio company's ability to meet its forecasts and its business prospects, (v) a discounted cash flow analysis, (vi) estimated liquidation or collateral value of the portfolio company's assets and (vii) offers from third parties to buy the portfolio company. Oaktree may probability weight potential sale outcomes with respect to a portfolio company when uncertainty exists as of the valuation date. The third valuation technique is a market yield technique, which is typically performed for non-credit impaired debt investments. In the market yield technique, a current price is imputed for the investment based upon an assessment of the expected market yield for a similarly structured investment with a similar level of risk, and Oaktree considers the current contractual interest rate, the capital structure and other terms of the investment relative to risk of the company and the specific investment. A key determinant of risk, among other things, is the leverage through the investment relative to the EV of the portfolio company. As debt investments held by the Company are substantially illiquid with no active transaction market, Oaktree depends on primary market data, including newly funded transactions and industry specific market movements, as well as secondary market data with respect to high yield debt instruments and syndicated loans, as inputs in determining the appropriate market yield, as applicable.In accordance with ASC 820-10, certain investments that qualify as investment companies in accordance with ASC 946 may be valued using net asset value as a practical expedient for fair value. Consistent with FASB guidance under ASC 820, these investments are excluded from the hierarchical levels. These investments are generally not redeemable.Oaktree estimates the fair value of certain privately held warrants using a Black Scholes pricing model, which includes an analysis of various factors and subjective assumptions, including the current stock price (by using an EV analysis as described above), the expected period until exercise, expected volatility of the underlying stock price, expected dividends and the risk free rate. Changes in the subjective input assumptions can materially affect the fair value estimates.Rule 2a-5 under the Investment Company Act permits boards of directors of registered investment companies and Business Development Companies to either (i) choose to determine fair value in good faith or (ii) designate a valuation designee tasked with determining fair value in good faith, subject to the board's oversight. The Company's Board of Directors has designated Oaktree to serve as its valuation designee effective September 8, 2022. 28OAKTREE SPECIALTY LENDING CORPORATIONNOTESÀ TO CONSOLIDATED FINANCIAL STATEMENTS(in thousands, except share and per share amounts, percentages and as otherwise indicated)Oaktree undertakes a multi-step valuation process each quarter in connection with determining the fair value of the Company's investments:À The quarterly valuation process begins with each portfolio company or investment being initially valued by Oaktree's valuation team;À Preliminary valuations are then reviewed and discussed with management of Oaktree;À Separately, independent valuation firms prepare valuations of the Company's investments, on a selected basis, for which market quotations are not readily available or are readily available but deemed not reflective of the fair value of the investment, and submit the reports to the Company and provide such reports to Oaktree;À Oaktree compares and contrasts its preliminary valuations to the valuations of the independent valuation firms and prepares a valuation report for the Audit Committee;À The Audit Committee reviews the valuation report with Oaktree, and Oaktree responds and supplements the valuation report to reflect any discussions between Oaktree and the Audit Committee; andÀ Oaktree, as valuation designee, determines the fair value of each investment in the Company's portfolio.The fair value of the Company's investments as of June 30, 2024 and September 30, 2023 was determined by Oaktree, as the Company's valuation designee. The Company has and will continue to engage independent valuation firms to provide assistance regarding the determination of the fair value of a portion of its portfolio securities for which market quotations are not readily available or are readily available but deemed not reflective of the fair value of the investment each quarter.Due to the inherent uncertainty of determining the fair value of investments that do not have a readily available market value, the fair value of the Company's investments may fluctuate from period to period. Because of the inherent uncertainty of valuation, these estimated values may differ significantly from the values that would have been reported had a ready market for the investments existed, and it is reasonably possible that the difference could be material.With the exception of the line items entitled "deferred financing costs," "deferred offering costs," "other assets," "deferred tax liability," "credit facilities payable" and "unsecured notes payable," which are reported at amortized cost, all assets and liabilities approximate fair value on the Consolidated Statements of Assets and Liabilities. The carrying value of the line items titled "interest, dividends and fees receivable," "due from portfolio companies," "receivables from unsettled transactions," "due from broker," "accounts payable, accrued expenses and other liabilities," "base management fee and incentive fee payable," "due to affiliate," "interest payable" and "payables from unsettled transactions" approximate fair value due to their short maturities.Foreign Currency Translation:The accounting records of the Company are maintained in U.S. dollars. All assets and liabilities denominated in foreign currencies are translated into U.S. dollars based on the prevailing foreign exchange rate on the reporting date. The Company does not isolate that portion of the results of operations resulting from changes in foreign exchange rates on investments from the fluctuations arising from changes in market prices of securities held. The Company's investments in foreign securities may involve certain risks, including foreign exchange restrictions, expropriation, taxation or other political, social or economic risks, all of which could affect the market and/or credit risk of the investment. In addition, changes in the relationship of foreign currencies to the U.S. dollar can significantly affect the value of these investments and therefore the earnings of the Company.Derivative Instruments:Foreign Currency Forward ContractsThe Company uses foreign currency forward contracts to reduce the Company's exposure to fluctuations in the value of foreign currencies. In a foreign currency forward contract, the Company agrees to receive or deliver a fixed quantity of one currency for another at a pre-determined price at a future date. Foreign currency forward contracts are marked-to-market at the applicable forward rate. Unrealized appreciation (depreciation) on foreign currency forward contracts is recorded within derivative assets or derivative liabilities on the Consolidated Statements of Assets and Liabilities by counterparty on a net basis, not taking into account collateral posted which is recorded separately, if applicable. Purchases and settlements of foreign currency forward contracts having the same settlement date and counterparty are generally settled net and any realized gains or losses are recognized on the settlement date. The Company does not utilize hedge accounting with respect to foreign currency forward contracts and, as such, the Company recognizes its foreign currency forward contracts at fair value with changes included in the net unrealized appreciation (depreciation) on the Consolidated Statements of Operations. 29OAKTREE SPECIALTY LENDING CORPORATIONNOTESÀ TO CONSOLIDATED FINANCIAL STATEMENTS(in thousands, except share and per share amounts, percentages and as otherwise indicated)Interest Rate SwapsThe Company uses interest rate swaps to hedge some of the Company's fixed rate debt. The Company designated the interest rate swaps as the hedging instruments in an effective hedge accounting relationship, and therefore the periodic payments are recognized as components of interest expense in the Consolidated Statements of Operations. Depending on the nature of the balance at period end, the fair value of each interest rate swap is either included as a derivative asset or derivative liability on the Company's Consolidated Statements of Assets and Liabilities. The change in fair value of the interest rate swaps is offset by a change in the carrying value of the fixed rate debt. Any amounts paid to the counterparty to cover collateral obligations under the terms of the interest rate swap agreements are included in due from broker on the Company's Consolidated Statements of Assets and Liabilities.Investment Income:Interest IncomeInterest income, adjusted for accretion of original issue discount ("OID"), is recorded on an accrual basis to the extent that such amounts are expected to be collected. The Company stops accruing interest on investments when it is determined that interest is no longer collectible. Investments that are expected to pay regularly scheduled interest in cash are generally placed on non-accrual status when there is reasonable doubt that principal or interest cash payments will be collected. Cash interest payments received on investments may be recognized as income or a return of capital depending upon management's judgment. A non-accrual investment is restored to accrual status if past due principal and interest are paid in cash and the portfolio company, in management's judgment, is likely to continue timely payment of its remaining obligations. As of June 30, 2024, there were eight investments on non-accrual status that in aggregate represented 5.7% and 3.7% of total debt investments at cost and fair value, respectively. As of September 30, 2023, there were four investments on non-accrual status that in aggregate represented 2.4% and 1.8% of total debt investments at cost and fair value, respectively.In connection with its investment in a portfolio company, the Company sometimes receives nominal cost equity that is valued as part of the negotiation process with the portfolio company. When the Company receives nominal cost equity, the Company allocates its cost basis in the investment between debt securities and the nominal cost equity at the time of origination. Any resulting discount from recording the loan, or otherwise purchasing a security at a discount, is accreted into interest income over the life of the loan.PIK Interest IncomeThe Company's investments in debt securities may contain PIK interest provisions. PIK interest, which generally represents contractually deferred interest added to the loan balance that is generally due at the end of the loan term, is generally recorded on the accrual basis to the extent such amounts are expected to be collected. The Company generally ceases accruing PIK interest if there is insufficient value to support the accrual or if the Company does not expect the portfolio company to be able to pay all principal and interest due. The Company's decision to cease accruing PIK interest on a loan or debt security involves subjective judgments and determinations based on available information about a particular portfolio company, including whether the portfolio company is current with respect to its payment of principal and interest on its loans and debt securities; financial statements and financial projections for the portfolio company; the Company's assessment of the portfolio company's business development success; information obtained by the Company in connection with periodic formal update interviews with the portfolio company's management and, if appropriate, the private equity sponsor; and information about the general economic and market conditions in which the portfolio company operates. The Company's determination to cease accruing PIK interest is generally made well before the Company's full write-down of a loan or debt security. In addition, if it is subsequently determined that the Company will not be able to collect any previously accrued PIK interest, the fair value of the loans or debt securities would be reduced by the amount of such previously accrued, but uncollectible, PIK interest. The accrual of PIK interest on the Company's debt investments increases the recorded cost basis of these investments in the Consolidated Financial Statements including for purposes of computing the capital gains incentive fee payable by the Company to Oaktree. To maintain its status as a RIC, certain income from PIK interest may be required to be distributed to the Company's stockholders, even though the Company has not yet collected the cash and may never do so. 30OAKTREE SPECIALTY LENDING CORPORATIONNOTESÀ TO CONSOLIDATED FINANCIAL STATEMENTS(in thousands, except share and per share amounts, percentages and as otherwise indicated)Fee IncomeOaktree or its affiliates may provide financial advisory services to portfolio companies and, in return, the Company may receive fees for capital structuring services. These fees are generally non-recurring and are recognized by the Company upon the investment closing date. The Company may also receive additional fees in the ordinary course of business, including servicing, amendment, exit and prepayment fees, which are classified as fee income and recognized as they are earned or the services are rendered. Dividend IncomeThe Company generally recognizes dividend income on the ex-dividend date for public securities and the record date for private equity investments. Distributions received from private equity investments are evaluated to determine if the distribution should be recorded as dividend income or a return of capital. Generally, the Company will not record distributions from private equity investments as dividend income unless there are sufficient earnings at the portfolio company prior to the distribution. Distributions that are classified as a return of capital are recorded as a reduction in the cost basis of the investment.Cash and Cash Equivalents and Restricted Cash:Cash and cash equivalents consist of demand deposits and highly liquid investments with maturities of three months or less when acquired. The Company places its cash and cash equivalents and restricted cash with financial institutions and, at times, cash held in bank accounts exceeds the Federal Deposit Insurance Corporation ("FDIC") insurance limit. Cash and cash equivalents are included on the Company's Consolidated Schedule of Investments and cash equivalents are classified as Level 1 assets.As of June 30, 2024, included in restricted cash was \$11.0À million that was held at Deutsche Bank Trust Company Americas in connection with the OS12 Citibank Facility (as defined in Note 6. Borrowings). Pursuant to the terms of the OS12 Citibank Facility, the Company was restricted in terms of access to the \$11.0À million until the occurrence of the periodic distribution dates and, in connection therewith, the Company's submission of its required periodic reporting schedules and verifications of the Company's compliance with the terms of the OS12 Citibank Facility. As of September 30, 2023, included in restricted cash was \$9.1À million that was held at Deutsche Bank Trust Company Americas in connection with the OS12 Citibank Facility. Due from Portfolio Companies:Due from portfolio companies consists of amounts payable to the Company from its portfolio companies, including proceeds from the sale of portfolio companies not yet received or being held in escrow and excluding those amounts attributable to interest, dividends or fees receivable. These amounts are recognized as they become payable to the Company (e.g., principal payments on the scheduled amortization payment date).Receivables/Payables from Unsettled Transactions:Receivables/payables from unsettled transactions consist of amounts receivable to or payable by the Company for transactions that have not settled at the reporting date.Deferred

Financing Costs:Deferred financing costs consist of fees and expenses paid in connection with the closing or amending of credit facilities and debt offerings. Deferred financing costs in connection with credit facilities are capitalized as an asset when incurred. Deferred financing costs in connection with all other debt arrangements are a direct deduction from the related debt liability when incurred. Deferred financing costs are amortized using the effective interest method over the term of the respective debt arrangement. This amortization expense is included in interest expense in the Consolidated Statements of Operations. Upon early termination or modification of a credit facility, all or a portion of unamortized fees related to such facility may be accelerated into interest expense. For extinguishments of the Company's unsecured notes payable, any unamortized deferred financing costs are deducted from the carrying amount of the debt in determining the gain or loss from the extinguishment. Deferred Offering Costs:Legal fees and other costs incurred in connection with the Company's shelf registration statement are capitalized as deferred offering costs in the Consolidated Statements of Assets and Liabilities. To the extent any such costs relate to equity offerings, these costs are charged as a reduction of capital upon utilization. To the extent any such costs relate to debt offerings, these costs are treated as deferred financing costs and are amortized over the term of the respective debt arrangement. Any 310AKTREE SPECIALTY LENDING CORPORATIONNOTES TO CONSOLIDATED FINANCIAL STATEMENTS(in thousands, except share and per share amounts, percentages and as otherwise indicated)deferred offering costs that remain at the expiration of the shelf registration statement or when it becomes probable that an offering will not be completed are expensed.Income Taxes:The Company has elected to be subject to tax as a RIC under Subchapter M of the Code and operates in a manner so as to qualify for the tax treatment applicable to RICs. In order to be subject to tax as a RIC, among other things, the Company is required to meet certain source of income and asset diversification requirements and timely distribute dividends to its stockholders of an amount generally at least equal to 90% of investment company taxable income, as defined by the Code and determined without regard to any deduction for dividends paid, for each taxable year. As a RIC, the Company is not subject to U.S. federal income tax on the portion of its taxable income and gains distributed currently to stockholders as a dividend. Depending on the level of taxable income earned during a taxable year, the Company may choose to retain taxable income in excess of current year dividend distributions and would distribute such taxable income in the next taxable year. The Company would then incur a 4% excise tax on such income, as required. To the extent that the Company determines that its estimated current year annual taxable income, determined on a calendar year basis, could exceed estimated current calendar year dividend distributions, the Company accrues excise tax, if any, on estimated excess taxable income as taxable income is earned. The Company anticipates timely distribution of its taxable income within the tax rules under Subchapter M of the Code. For calendar year 2022, the Company incurred \$0.1A million of excise tax. The Company did not incur any U.S. federal excise tax for calendar year 2023. The Company does not expect to incur a U.S. federal excise tax for calendar year 2024. The Company holds certain portfolio investments through taxable subsidiaries. The purpose of the Company's taxable subsidiaries is to permit the Company to hold equity investments in portfolio companies which are "pass through" entities for U.S. federal income tax purposes in order to comply with the RIC tax requirements. The taxable subsidiaries are consolidated for financial reporting purposes, and portfolio investments held by them are included in the Company's Consolidated Financial Statements as portfolio investments and recorded at fair value. The taxable subsidiaries are not consolidated with the Company for U.S. federal income tax purposes and may generate income tax expense, or benefit, and the related tax assets and liabilities, as a result of their ownership of certain portfolio investments. This income tax expense, if any, would be reflected in the Company's Consolidated Statements of Operations. The Company uses the liability method to account for its taxable subsidiaries' income taxes. Using this method, the Company recognizes deferred tax assets and liabilities for the estimated future tax effects attributable to temporary differences between financial reporting and tax bases of assets and liabilities. In addition, the Company recognizes deferred tax benefits associated with net operating loss carry forwards that it may use to offset future tax obligations. The Company measures deferred tax assets and liabilities using the enacted tax rates expected to apply to taxable income in the years in which it expects to recover or settle those temporary differences.FASB ASC Topic 740, Accounting for Uncertainty in Income Taxes ("ASC 740"), provides guidance for how uncertain tax positions should be recognized, measured, presented and disclosed in the Company's Consolidated Financial Statements. ASC 740 requires the evaluation of tax positions taken or expected to be taken in the course of preparing the Company's tax returns to determine whether the tax positions are "more-likely-than-not" of being sustained by the applicable tax authority. Tax positions not deemed to meet the more-likely-than-not threshold are recorded as a tax benefit or expense in the current year. Management's determinations regarding ASC 740 may be subject to review and adjustment at a later date based upon factors including an ongoing analysis of tax laws, regulations and interpretations thereof. The Company recognizes the tax benefits of uncertain tax positions only where the position is "more-likely-than-not" to be sustained assuming examination by tax authorities. Management has analyzed the Company's tax positions and has concluded that no liability for unrecognized tax benefits should be recorded related to uncertain tax positions taken on returns filed for open tax years 2021, 2022 and 2023. The Company identifies its major tax jurisdictions as U.S. Federal and California, and the Company is not aware of any tax positions for which it is reasonably possible that the total amounts of unrecognized tax benefits will change materially in the next 12A months.Recently Adopted Accounting PronouncementsIn November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280), which improves reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. The amendments are effective for fiscal years beginning after December 15, 2023 and interim period within fiscal years beginning after December 15, 2024. The Company does not expect this guidance to materially impact its consolidated financial statements.320AKTREE SPECIALTY LENDING CORPORATIONNOTES TO CONSOLIDATED FINANCIAL STATEMENTS(in thousands, except share and per share amounts, percentages and as otherwise indicated)NoteA 3. Portfolio InvestmentsAs of JuneA 30, 2024, 208.7% of net assets at fair value, or \$3.1A billion, was invested in 158 portfolio companies, including (i) \$138.5A million in subordinated notes and limited liability company ("LLC") equity interests of Senior Loan Fund JV I, LLC ("SLF JV I"), a joint venture through which the Company and Trinity Universal Insurance Company, a subsidiary of Kemper Corporation ("Kemper"), co-invest in senior secured loans of middle-market companies and other corporate debt securities and (ii) \$49.9A million in subordinated notes and LLC equity interests of OCSI Click JV LLC ("Click JV" and, together with SLF JV I, the "JVs"), a joint venture through which the Company and GF Equity Funding 2014 LLC ("GF Equity Funding") co-invest primarily in senior secured loans of middle-market companies. As of JuneA 30, 2024, 7.2% of net assets at fair value, or \$107.3 million, was invested in cash and cash equivalents (including \$11.0A million of restricted cash). In comparison, as of SeptemberA 30, 2023, 190.8% of net assets at fair value, or \$2.9A billion, was invested in 143 portfolio investments, including (i) \$141.5A million in subordinated notes and LLC equity interests of SLF JV I and (ii) \$50.0A million in subordinated notes and LLC equity interests of Click JV. As of SeptemberA 30, 2023, 9.6% of net assets at fair value, or \$145.5A million, was invested in cash and cash equivalents (including \$9.1A million of restricted cash). As of JuneA 30, 2024, 86.0% of the Company's portfolio at fair value consisted of senior secured debt investments and 9.0% consisted of subordinated debt investments, including the debt investments in the JVs. As of SeptemberA 30, 2023, 86.5% of the Company's portfolio at fair value consisted of senior secured debt investments and 7.5% consisted of subordinated debt investments, including the debt investments in the JVs.The Company also held equity investments in certain of its portfolio companies consisting of common stock, preferred stock, warrants or LLC equity interests. These instruments generally do not produce a current return but are held for potential investment appreciation and capital gain.During the three and nine months ended JuneA 30, 2024, the Company recorded net realized losses of \$69.5A million and \$84.5A million, respectively. During the three and nine months ended JuneA 30, 2023, the Company recorded net realized losses of \$10.6A million and \$19.9A million, respectively. During the three and nine months ended JuneA 30, 2024, the Company recorded net unrealized appreciation (depreciation) of \$26.2A million and \$(24.1A) million, respectively. During the three and nine months ended JuneA 30, 2023, the Company recorded net unrealized depreciation of \$1.0A million and \$42.3A million, respectively.The composition of the Company's investments as of JuneA 30, 2024 and SeptemberA 30, 2023 at cost and fair value was as follows:JuneA 30, 2024SeptemberA 30, 2023A CostFair ValueCostFair ValueInvestments in debt securities\$2,895,645A \$2,801,310A \$2,654,484A \$2,557,102A Investments in equity securities178,533A 132,034A 171,858A 143,767A Debt investments in the JVs163,963A 162,542A 162,986A 162,673A Equity investments in the JVs54,791A 25,817A 54,791A 28,878A Totals\$3,292,932A \$3,121,703A \$3,044,119A \$2,892,420A 330AKTREE SPECIALTY LENDING CORPORATIONNOTES TO CONSOLIDATED FINANCIAL STATEMENTS(in thousands, except share and per share amounts, percentages and as otherwise indicated)The following table presents the composition of the Company's debt investments as of JuneA 30, 2024 and SeptemberA 30, 2023 at fixed rates and floating rates:JuneA 30, 2024SeptemberA 30, 2023A Fair Value% of A DebtPortfolioFair Value% of A DebtPortfolioFloating rate debt securities, including the debt investments in the JVs\$2,526,904A 85.26A %\$2,345,205A 86.23A %Fixed rate debt securities436,948A 1.74A 374,570A 13.77A Totals\$2,963,852A 100.00A %\$2,719,775A 100.00A %The following table presents the financial instruments carried at fair value as of JuneA 30, 2024 on the Company's Consolidated Statement of Assets and Liabilities for each of the three levels of hierarchy established by ASCA 820: LevelA 1LevelA 2Level 3Measured at Net Asset Value (a)TotalInvestments in debt securities (senior secured)\$A 291,086A \$2,393,159A \$A 2,684,245A Investments in debt securities (subordinated, including the debt investments in the JVs, CLO Notes and Credit Linked Notes)\$A 49,123A 230,484A \$A 279,607A Investments in equity securities (preferred)\$A 63,892A \$A 63,892A Investments in equity securities (common and warrants, including LLC equity interests of the JVs)1,463A 2,175A 64,504A 25,817A 93,959A Total investments at fair value1,463A 342,384A 2,752,039A 25,817A 3,121,703A Cash equivalents37,364A \$A 37,364A Derivative assets\$A 436A \$A 436A Total assets at fair values\$38,827A \$342,820A \$2,752,039A \$25,817A \$3,159,503A Derivative liabilities\$A 333,672A \$A 333,672A Total liabilities at fair values\$A 333,672A \$A 333,672A (a) In accordance with ASC 820-10, certain investments that are measured using the net asset value per share (or its equivalent) as a practical expedient for fair value have not been classified in the fair value hierarchy. These investments are generally not redeemable. The fair value amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the amounts presented in the Consolidated Statements of Assets and Liabilities. 340AKTREE SPECIALTY LENDING CORPORATIONNOTES TO CONSOLIDATED FINANCIAL STATEMENTS(in thousands, except share and per share amounts, percentages and as otherwise indicated)The following table presents the financial instruments carried at fair value as of SeptemberA 30, 2023 on the Company's Consolidated Statement of Assets and Liabilities for each of the three levels of hierarchy established by ASCA 820:LevelA 1LevelA 2Level 3Measured at Net Asset Value (a)TotalInvestments in debt securities (senior secured)\$A 208,694A \$2,292,691A \$A 2,501,385A Investments in debt securities (subordinated, including the debt investments in the JVs and CLO Notes)\$A 28,666A 189,724A \$A 218,390A Investments in equity securities (preferred)\$A 86,057A \$A 86,057A Investments in equity securities (common and warrants, including LLC equity interests of the JVs)4,317A 1,953A 51,440A 28,878A 86,588A Total investments at fair value4,317A 239,313A 2,619,912A 28,878A 2,892,420A Cash equivalents83,262A \$A 83,262A Derivative assets\$A 4,910A \$A 4,910A Total assets at fair values\$87,579A \$244,223A \$2,619,912A \$28,878A \$2,980,592A Derivative liabilities\$A 447,519A \$A 447,519A Total liabilities at fair values\$A 447,519A \$A 447,519A (a) In accordance with ASC 820-10, certain investments that are measured using the net asset value per share (or its equivalent) as a practical expedient for fair value have not been classified in the fair value hierarchy. These investments are generally not redeemable. The fair value amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the amounts presented in the Consolidated Statements of Assets and Liabilities. When a determination is made to classify a financial instrument within Level 3 of the valuation hierarchy, the determination is based upon the fact that the unobservable factors are significant to the overall fair value measurement. However, Level 3 financial instruments typically have both unobservable or Level 3 components and observable components (i.e. components that are actively quoted and can be validated by external sources). Accordingly, the appreciation (depreciation)A in the tables below includes changes in fair value due in part to observable factors that are part of the valuation methodology. Transfers between levels are recognized at the beginning of the reporting period.350AKTREE SPECIALTY LENDING CORPORATIONNOTES TO CONSOLIDATED FINANCIAL STATEMENTS(in thousands, except share and per share amounts, percentages and as otherwise indicated)The following table provides a roll-forward in the changes in fair value from March 31, 2024 to JuneA 30, 2024 for all investments for which Oaktree determined fair value using unobservable (LevelA 3) factors:InvestmentsSenior Secured DebtSubordinatedDebt (including debt investments in the JVs and credit linked notes) PreferredEquityCommonEquity and WarrantsTotalFair value as of March 31, 2024\$2,327,422A \$200,115A \$62,602A \$77,286A \$2,667,425A Purchases 193,956A 30,480A \$A 169A 224,605A Sales and repayments(113,234)\$A 37,438A (113,234)Capitalized PIK interest income(6,287A 614A \$A 4,691A Accretion of OID2,600A 349A \$A 2,949A Net unrealized appreciation (depreciation)7,640A (1,074)38,883A (12,951)32,498A Net realized gains (losses)(31,512)\$A (37,593)\$A (69,105)Fair value as of June 30, 2024\$2,393,159A \$230,484A \$63,892A \$64,504A \$2,752,039A Net unrealized appreciation (depreciation)A relating to Level 3 investments still held as of June 30, 2024 and reported within net unrealized appreciation (depreciation) in the Consolidated Statement of Operations for the three months ended June 30, 2024\$(36,501)\$ (1,074)\$1,287A \$(14,762)\$ (51,050)The following table provides a roll-forward in the changes in fair value from March 31, 2023 to JuneA 30, 2023 for all investments for which the Company determined fair value using unobservable (LevelA 3) factors:InvestmentsSenior Secured DebtSubordinatedDebt (including debt investments in the JVs)PreferredEquityCommonEquity and WarrantsTotalFair value as of March 31, 2023\$2,493,622A \$183,756A \$91,447A \$25,509A \$2,794,334A Purchases 228,375A 4,183A \$A 182A 232,740A Sales and repayments(191,409)(350)\$A (7,320)(199,079)Transfers out (a)\$A (2,708)\$A (2,708)Capitalized PIK interest income3,610A 358A \$A 4,396A Accretion of OID4,086A 381A \$A 4,467A Net unrealized appreciation (depreciation) (8,027)(704)739A 1,893A (6,099)Net realized gains (losses)(1,809)\$A 4,84A (1,725)Fair value as of June 30, 2023\$2,528,448A \$184,916A \$92,186A \$2,825,898A Net unrealized appreciation (depreciation)A relating to Level 3 investments still held as of June 30, 2023 and reported within net unrealized appreciation (depreciation) in the Consolidated Statement of Operations for the three months ended June 30, 2023\$(46,680)\$ (1,069)\$ (1,633)\$ (355)\$ (49,737) (a) Includes Level 3 investments acquired in connection with the OS12 Merger during the nine months ended JuneA 30, 2023.(b) There was a transfer into Level 2 from Level 2 for an investment during the three months ended JuneA 30, 2023 as a result of a change in the number of market quotes available and/or a change in market liquidity.360AKTREE SPECIALTY LENDING CORPORATIONNOTES TO CONSOLIDATED FINANCIAL STATEMENTS(in thousands, except share and per share amounts, percentages and as otherwise indicated)The following table provides a roll-forward in the changes in fair value from SeptemberA 30, 2023 to JuneA 30, 2024 for all investments for which Oaktree determined fair value using unobservable (LevelA 3) factors:InvestmentsSenior Secured DebtSubordinatedDebt (including debt investments in the JVs and credit linked notes) PreferredEquityCommonEquity and WarrantsTotalFair value as of September 30, 2023\$2,692,911A \$189,724A \$86,057A \$51,440A \$2,619,912A Purchases 656,630A 47,507A 7,578A 1,749A 713,464A Sales and repayments(506,977)(4,932)(205) (860)(512,974)Transfers in (a)(b)23,535A \$A 39,720A 63,237A Transfers out (b)(38,544)(4,657)(1,159)(283)(44,643)Capitalized PIK interest income1,571A 1,685A \$A 19,256A Accretion of OID8,099A 984A \$A 9,083A Net unrealized appreciation (depreciation) (10,702)127A 9,214A (25,631)(26,992)Net realized gains (losses)(49,144)46A (37,593)(1,613)(88,304)Fair value as of June 30, 2024\$2,393,159A \$230,484A \$63,892A \$64,504A \$2,752,039A Net unrealized appreciation (depreciation)A relating to Level 3 investments still held as of June 30, 2024 and reported within net unrealized appreciation (depreciation) in the Consolidated Statement of Operations for the nine months ended June 30, 2024\$(54,217)\$ (454)\$3,276A \$(28,733)\$ (80,128) (a) There was a \$18.9A million transfer into Level 3 from Level 2 for an investment during the nine months ended JuneA 30, 2024 as a result of a change in the number of market quotes available and/or a change in market liquidity. (b) There were investment restructurings during the nine months ended JuneA 30, 2024 in which (1) \$38.5A million of Level 3 senior secured debt was exchanged for Level 3 common equity, (2) \$4.7A million of Level 3 subordinated debt was exchanged for Level 3 senior secured debt, (3) \$1.2A million of Level 3 preferred equity was exchanged for Level 3 common equity and (4) \$0.3A million of Level 3 common stock was converted to Level 1 common stock. The following table provides a roll-forward in the changes in fair value from September 30, 2022 to JuneA 30, 2023 for all investments for which Oaktree determined fair value using unobservable (LevelA 3) factors:InvestmentsSenior Secured DebtSubordinatedDebt (including debt investments in the JVs)PreferredEquityCommonEquity and WarrantsTotalFair value as of September 30, 2022\$1,910,606A \$159,388A \$79,523A \$19,958A \$2,169,475A PurchasesA (980,595A 26,508A 14,296A 5,610A 1,027,009A Sales and repayments(357,903)(1,396)\$A (8,295) (367,594)Transfers in (b)(19,075A \$A 19,075A Capitalized PIK interest income12,549A 376A \$A 12,925A Accretion of OID11,684A 1,109A \$A 12,793A Net unrealized appreciation (depreciation)(45,019)(1,069)(1,633)(2,804) (44,917)Net realized gains (losses)(3,139)\$A 271A (2,868)Fair value as of June 30, 2023\$2,528,448A \$184,916A \$92,186A \$2,825,898A Net unrealized appreciation (depreciation)A relating to Level 3 investments still held as of June 30, 2023 and reported within net unrealized appreciation (depreciation) in the Consolidated Statement of Operations for the nine months ended June 30, 2023\$(46,680)\$ (1,069)\$ (1,633)\$ (355)\$ (49,737) (a) Includes Level 3 investments acquired in connection with the OS12 Merger during the nine months ended JuneA 30, 2023.(b) There was a transfer into Level 2 from Level 2 for an investment during the

nine months ended June30, 2023 as a result of a change in the number of market quotes available and/or a change in market liquidity.37OAKTREE SPECIALTY LENDING CORPORATIONNOTESÂ TO CONSOLIDATED FINANCIAL STATEMENTS(in thousands, except share and per share amounts, percentages and as otherwise indicated)Significant Unobservable Inputs for Level 3 InvestmentsThe following table provides quantitative information related to the significant unobservable inputs for Level 3 investments, which are carried at fair value, as of June30, 2024: AssetFair ValueValuation TechniqueUnobservable InputRangeWeightedAverage (a)Senior Secured Debt\$2,110,682Â Market YieldMarket Yield (b)9.0%-39.0%13.8%58,783Â Enterprise ValueRevenue Multiple(c)1.5x-5.5x3.1x33,379Â Enterprise ValueEBITDA Multiple(c)5.5x-6.0x5.8x4,199Â Transaction Precedent Transaction Price(d)N/A/N/AN/186,116Â Broker QuotationsBroker Quoted Price(e)N/A/N/AN/ASubordinated Debt43,442Â Market YieldMarket Yield (b)10.0%-40.0%11.1%24,500Â Transaction Precedent Transaction Price(d)N/A-N/AN/ADebt Investments in the JVs162,542Â Enterprise ValueN/A(f)N/A-N/AN/APreferred & Common Equity59,829Â Enterprise ValueRevenue Multiple(c)0.4x-6.3x2.5x67,317Â Enterprise ValueEBITDA Multiple(c)0.3x-1.5x1.9x9.1x1,250Â Enterprise ValueAsset Multiple(c)1.0x-1.4x1.4xTotal\$2,752,039Â (a)Weighted averages are calculated based on fair value of investments.(b)Used when market participants would take into account market yield when pricing the investment.(c)Used when market participants would use such multiples when pricing the investment.(d)Used when there is an observable transaction or pending event for the investment.(e)Oaktree generally uses prices provided by an independent pricing service which are non-binding indicative prices on or near the valuation date as the primary basis for the fair value determinations for quoted senior secured debt investments. Since these prices are non-binding, they may not be indicative of fair value. Oaktree evaluates the quotations provided by pricing vendors and brokers based on available market information, including trading activity of the subject or similar securities, or by performing a comparable security analysis to ensure that fair values are reasonably estimated. (f)Oaktree determined the value of its subordinated notes of each JV based on the total assets less the total liabilities senior to the subordinated notes held at such JV in an amount not exceeding par under the EV technique.The following table provides quantitative information related to the significant unobservable inputs for Level 3 investments, which are carried at fair value, as of September30, 2023:AssetFair ValueValuation TechniqueUnobservable InputRangeWeightedAverage (a)Senior Secured Debt\$1,904,140Â Market YieldMarket Yield (b)9.0%-32.0%14.7%64,802Â Enterprise ValueEBITDA Multiple(c)3.0x-6.0x4.6x33,816Â Transaction Precedent Transaction Price(d)N/A-N/AN/AD289,933Â Broker quotationsBroker Quoted Price(e)N/A-N/AN/ASubordinated Debt22,881Â Market YieldMarket Yield (b)10.0%-22.0%11.2%4,170Â Broker QuotationsBroker Quoted Price(e)N/A-N/AN/ADebt Investments in the JVs162,673Â Enterprise ValueN/A(f)N/A-N/AN/APreferred & Common Equity32,318Â Enterprise ValueRevenue Multiple(c)0.4x-3.2x0.5x103,661Â Enterprise ValueEBITDA Multiple(c)1.7x-1.5x1.8x8.1x0,971Â Enterprise ValueAsset Multiple(c)1.0x-1.4x1.4x214Â Transaction Precedent Transaction Price(d)N/A-N/AN/ATotal\$2,619,912Â (a)Weighted averages are calculated based on fair value of investments.(b)Used when market participants would take into account market yield when pricing the investment.(c)Used when market participants would use such multiples when pricing the investment.(d)Used when there is an observable transaction or pending event for the investment.(e)Oaktree generally uses prices provided by an independent pricing service which are non-binding indicative prices on or near the valuation date as the primary basis for the fair value determinations for quoted senior secured debt investments. Since these prices are non-binding, they may not be indicative of fair value. Oaktree evaluates the quotations provided by pricing vendors and brokers based on available market information, including trading activity of the subject or similar securities, or by performing a comparable security analysis to ensure that fair values are reasonably estimated. 38OAKTREE SPECIALTY LENDING CORPORATIONNOTESÂ TO CONSOLIDATED FINANCIAL STATEMENTS(in thousands, except share and per share amounts, percentages and as otherwise indicated)(f)Oaktree determined the value of its subordinated notes of each JV based on the total assets less the total liabilities senior to the subordinated notes held at such JV in an amount not exceeding par under the EV technique.Under the market yield technique, the significant unobservable input used in the fair value measurement of the Company's investments in debt securities is the market yield. Increases or decreases in the market yield may result in a lower or higher fair value measurement, respectively.Under the EV technique, the significant unobservable input used in the fair value measurement of the Company's investments in debt or equity securities is the earnings before interest, taxes, depreciation and amortization ("EBITDA"), revenue or asset multiple, as applicable. Increases or decreases in the valuation multiples in isolation may result in a higher or lower fair value measurement, respectively.Â Financial Instruments Disclosed, But Not Carried, At Fair ValueThe following table presents the carrying value and fair value of the Company's financial liabilities disclosed, but not carried, at fair value as of June30, 2024 and the level of each financial liability within the fair value hierarchy:Â CarryingValueFair ValueLevelÂ 1LevelÂ 2Level 3Syndicated Facility payable\$505,000Â \$505,000Â \$â€"Â \$â€"Â \$505,000Â OS12 Citibank Facility payable285,000Â 285,000Â \$â€"Â \$â€"Â \$285,000Â 2025 Notes payable (carrying value is net of unamortized financing costs and unaccreted discount)299,179Â 294,900Â \$â€"Â \$294,900Â \$â€"Â \$2027 Notes payable (carrying value is net of unamortized financing costs, unaccreted discount and interest rate swap fair value adjustment)316,931Â 317,695Â \$â€"Â \$317,695Â \$â€"Â \$2029 Notes payable (carrying value is net of unamortized financing costs, unaccreted discount and interest rate swap fair value adjustment)291,054Â 303,642Â \$â€"Â \$303,642Â \$â€"Â \$Totals1,697,164Â \$1,706,237Â \$â€"Â \$916,237Â \$790,000Â The following table presents the carrying value and fair value of the Company's financial liabilities disclosed, but not carried, at fair value as of September30, 2023 and the level of each financial liability within the fair value hierarchy:CarryingValueFair ValueLevelÂ 1LevelÂ 2Level 3Syndicated Facility payable\$430,000Â \$430,000Â \$â€"Â \$â€"Â \$430,000Â OS12 Citibank Facility payable280,000Â 280,000Â \$â€"Â \$â€"Â \$280,000Â 2025 Notes payable (carrying value is net of unamortized financing costs and unaccreted discount)298,244Â 286,437Â \$â€"Â \$286,437Â \$â€"Â \$2027 Notes payable (carrying value is net of unamortized financing costs, unaccreted discount and interest rate swap fair value adjustment)306,412Â 301,784Â \$â€"Â \$301,784Â \$â€"Â \$2029 Notes payable (carrying value is net of unamortized financing costs, unaccreted discount and interest rate swap fair value adjustment)286,078Â 289,980Â \$â€"Â \$289,980Â \$â€"Â \$Totals1,600,731Â \$1,588,201Â \$â€"Â \$878,201Â \$710,000Â The principal values of the credit facilities payable approximate fair value due to their variable interest rates and are included in Level 3 of the hierarchy. Oaktree used market quotes as of the valuation date to estimate the fair value of the Company's 3.500% notes due 2025 (the "2025 Notes"), 2.700% notes due 2027 (the "2027 Notes") and 7.100% notes due 2029 (the "2029 Notes"), which are included in Level 2 of the hierarchy. 39OAKTREE SPECIALTY LENDING CORPORATIONNOTESÂ TO CONSOLIDATED FINANCIAL STATEMENTS(in thousands, except share and per share amounts, percentages and as otherwise indicated)Portfolio CompositionSummaries of the composition of the Company's portfolio at cost as a percentage of total investments and at fair value as a percentage of total investments and net assets are shown in the following tables:Â June 30, 2024September 30, 2023Cost:Â % of Total Investments% of Total InvestmentsSenior secured debt\$2,779,708Â 84.42% %\$2,594,640Â 85.24% %Debt investments in the JVs163,963Â 4.98% %162,986Â 5.35% %Subordinated debt115,937Â 3.52% %59,844Â 1.97% %Common equity and warrants110,315Â 3.35% %72,261Â 2.37% %Preferred equity68,218Â 2.07% %99,597Â 3.27% %LLC equity interests of the JVs54,791Â 1.66% %54,791Â 1.80% %Totals\$3,292,932Â 100.00% %\$3,044,119Â 100.00% %June 30, 2024September 30, 2023Fair Value:Â % of Total Investments% of Net Assets% of Total Investments% of Net AssetsSenior secured debt\$2,684,245Â 85.98% %179,424Â %2.501,385Â 86.47% %165.01% %Debt investments in the JVs162,542Â 5.21% %10.86% %162,673Â 5.62% %10.73% %Subordinated debt117,065Â 3.75% %7.82% %55,717Â 1.93% %3.68% %Common equity and warrants68,142Â 2.18% %4.55% %57,710Â 2.00% %3.81% %Preferred equity63,892Â 2.05% %4.27% %86,057Â 2.98% %5.68% %LLC equity interests of the JVs25,817Â 0.83% %1.73% %28,878Â 1.00% %1.91% %Total\$3,121,703Â 100.00% %208.65% %\$2,892,420Â 100.00% %190.82% %The geographic composition is determined by the location of the corporate headquarters of the portfolio company, which may not be indicative of the primary source of the portfolio company's business. The following tables show the composition of the Company's portfolio by geographic region at cost as a percentage of total investments and at fair value as a percentage of total investments and net assets:Â June 30, 2024September 30, 2023Cost:Â % of Total InvestmentsÂ % of Total InvestmentsNortheast\$1,050,743Â 31.91% %\$1,012,955Â 33.27% %Southeast471,176Â 14.31% %375,247Â 12.33% %Midwest428,884Â 13.02% %360,506Â 11.84% %International376,328Â 11.43% %SPECIALTY LENDING CORPORATIONNOTESÂ TO CONSOLIDATED FINANCIAL STATEMENTS(in thousands, except share and per share amounts, percentages and as otherwise indicated)Â June 30, 2024September 30, 2023Fair Value:Â % of Total InvestmentsÂ % of Net AssetsÂ % of Total Investments% of Net AssetsAssetsNortheast\$989,346Â 31.69% %66.12% %\$945,422Â 32.69% %62.37% %Southeast433,279Â 13.88% %28.96% %354,444Â 12.25% %23.38% %Midwest422,065Â 13.52% %28.21% %350,620Â 11.84% %SPECIALTY LENDING CORPORATIONNOTESÂ TO CONSOLIDATED FINANCIAL STATEMENTS(in thousands, except share and per share amounts, percentages and as otherwise indicated)The following tables show the composition of the Company's portfolio by industry at cost as a percentage of total investments and at fair value as a percentage of total investments and net assets as of June30, 2024 and September30, 2023:June 30, 2024September 30, 2023Cost:Â % of Total InvestmentsÂ % of Total InvestmentsApplication Software\$557,095Â 16.95% %468,483Â 15.39% %Multi-Sector Holdings (1)234,940Â 7.13% 219,469Â 7.21% Health Care Services131,615Â 4.00% 81,560Â 2.68% Health Care Technology127,243Â 3.86% 106,915Â 3.51% Biotechnology126,528Â 3.84% 126,349Â 4.15% Data Processing & Outsourced Services96,836Â 2.94% 133,410Â 4.38% Interactive Media & Services95,784Â 2.91% 19,013Â 0.62% Industrial Machinery & Supplies & Components93,198Â 2.83Â 99,511Â 3.27% Pharmaceuticals86,764Â 2.63Â 84,948Â 2.79% Real Estate Operating Companies80,818Â 2.45Â 83,754Â 2.75Â Diversified Financial Services69,766Â 2.12Â 61,725Â 2.03Â Aerospace & Defense67,329Â 2.04Â 51,797Â 1.70Â Diversified Support Services67,151Â 2.04Â 23,435Â 0.77Â Environmental & Facilities Services64,630Â 1.96Â 63,064Â 2.07Â Fertilizers & Agricultural Chemicals64,630Â 1.96Â 64,720Â 2.13Â Personal Care Products64,086Â 1.95Â 68,146Â 2.24Â Health Care Distributors64,059Â 1.95Â 62,044Â 2.04Â Airport Services62,573Â 1.90Â 55,961Â 1.84Â Metal, Glass & Plastic Containers61,654Â 1.88Â 55,530Â 1.82Â Specialized Finance58,612Â 1.78Â 73,035Â 2.40Â Internet Services & Infrastructure53,283Â 1.62Â 60,934Â 2.00Â Diversified Metals & Mining50,006Â 1.52Â 49,842Â 1.64Â Systems Software49,583Â 1.51Â 23,111Â 0.76Â Home Improvement Retail49,457Â 1.50Â 54,236Â 1.78Â Auto Parts & Equipment48,310Â 1.47Â 48,536Â 1.59Â Communications Equipment47,604Â 1.45Â \$â€"Â \$â€"Â Real Estate Services44,517Â 1.35Â 44,717Â 1.47Â Soft Drinks & Non-alcoholic Beverages42,676Â 1.30Â 42,628Â 1.40Â Automotive Retail40,831Â 1.24Â 57,596Â 1.89Â Office Services & Supplies38,882Â 1.18Â \$â€"Â \$â€"Â Leisure Facilities38,029Â 1.15Â 39,076Â 1.28Â Other Specialty Retail36,772Â 1.12Â 41,088Â 1.35Â Electrical Components & Equipment32,734Â 0.99Â 32,440Â 1.07Â Movies & Entertainment30,857Â 0.94Â 12,188Â 0.40Â Construction Machinery & Heavy Transportation Equipment26,010Â 0.79Â \$â€"Â \$â€"Â Health Care Equipment25,812Â 0.78Â 22,441Â 0.74Â Passenger Airlines25,009Â 0.76Â 24,920Â 0.82Â Real Estate Development24,974Â 0.76Â 23,965Â 0.79Â Wireless Telecommunication Services24,275Â 0.74Â \$â€"Â \$â€"Â Gold23,418Â 0.71Â 23,310Â 0.77Â Home Furnishings23,170Â 0.70Â 23,859Â 0.78Â Broadline Retail22,143Â 0.67Â 83,290Â 2.74Â Construction & Engineering20,495Â 0.62Â 22,102Â 0.73Â Packaged Foods & Meats19,895Â 0.60Â \$â€"Â \$â€"Â Specialty Chemicals19,457Â 0.59Â 38,640Â 1.27Â Oil & Gas Storage & Transportation19,309Â 0.59Â 22,042Â 0.72Â Apparel Retail17,895Â 0.54Â 4,999Â 0.16Â Hotels, Resorts & Cruise Lines17,114Â 0.52Â 17,195Â 0.56Â Alternative Carriers15,141Â 0.46Â \$â€"Â \$â€"Â Food Distributors14,607Â 0.44Â 5,897Â 0.19Â Health Care Supplies11,561Â 0.35Â 11,646Â 0.38Â Advertising11,345Â 0.34Â 25,597Â 0.84Â Integrated Telecommunication Services9,050Â 0.27Â 18,801Â 0.62Â Distributors8,707Â 0.26Â 37,666Â 1.24Â Education Services8,211Â 0.25Â 13,871Â 0.46Â Financial Exchanges & Data6,881Â 0.21Â \$â€"Â \$â€"Â Cable & Satellite6,861Â 0.21Â 4,619Â 0.15Â Research & Consulting Services4,844Â 0.15Â 4,871Â 0.16Â Paper & Plastic Packaging Products & Materials33,393Â 0.10Â 3,254Â 0.11Â Housewares & Specialties2,750Â 0.08Â 2,908Â 0.10Â Diversified Chemicals1,553Â 0.05Â \$â€"Â \$â€"Â Insurance Brokers\$â€"Â \$â€"Â 52,856Â 1.74Â Consumer Finance\$â€"Â \$â€"Â 16,440Â 0.54Â Restaurants\$â€"Â \$â€"Â 12,603Â 0.41Â Air Freight & Logistics\$â€"Â \$â€"Â 4,925Â 0.16Â Integrated Oil & Gas\$â€"Â \$â€"Â 4,894Â 0.16Â Other Specialized REITs\$â€"Â \$â€"Â 4,379Â 0.14Â Leisure Products\$â€"Â \$â€"Â 2,055Â 0.07Â Technology Distributors\$â€"Â \$â€"Â 813Â 0.03Â \$3,292,932Â 100.00% %\$3,044,119Â 100.00% %42OAKTREE SPECIALTY LENDING CORPORATIONNOTESÂ TO CONSOLIDATED FINANCIAL STATEMENTS(in thousands, except share and per share amounts, percentages and as otherwise indicated)June 30, 2024September 30, 2023Fair Value:Â % of Total Investments% of Net AssetsÂ % of Total Investments% of Net AssetsApplication Software\$513,205Â 16.47% %34.33% %\$455,719Â 15.73% %30.03% %Multi-Sector Holdings (1)205,257Â 6.58Â 13,722Â 193,431Â 6.69Â 12.76Â Biotechnology128,673Â 4.12Â 8,600Â 125,678Â 4.35Â 8.29Â Health Care Services112,704Â 3.61Â 7,533Â 66,683Â 2.31Â 4.40Â Health Care Technology103,893Â 3.33Â 6,944Â 95,404Â 3.30Â 6.29Â Interactive Media & Services96,263Â 3.08Â 6,438Â 19,199Â 0.66Â 1.27Â Industrial Machinery & Supplies & Components94,189Â 3.02Â 6.30Â 98,352Â 3.40Â 6.49Â Data Processing & Outsourced Services90,828Â 2.91Â 6.07Â 125,259Â 4.33Â 8.26Â Pharmaceuticals83,557Â 2.68Â 5,580Â 80,455Â 2.78Â 5.31Â Real Estate Operating Companies97,437Â 2.54Â 5.31Â 82,463Â 2.85Â 5.44Â Diversified Financial Services69,007Â 2.21Â 4.61Â 60,003Â 2.07Â 3.96Â Aerospace & Defense68,814Â 2.20Â 4.60Â 51,862Â 1.79Â 3.42Â Diversified Support Services67,642Â 2.17Â 4.52Â 23,352Â 0.81Â 1.54Â Environmental & Facilities Services63,768Â 2.04Â 4.26Â 62,413Â 2.16Â 4.12Â Fertilizers & Agricultural Chemicals63,185Â 2.02Â 4.22Â 63,185Â 2.18Â 4.17Â Health Care Distributors62,922Â 2.02Â 4.21Â 60,865Â 2.10Â 4.02Â Specialized Finance58,702Â 1.88Â 3.92Â 69,590Â 2.41Â 4.59Â Personal Care Products58,500Â 1.87Â 3.91Â 59,928Â 2.07Â 3.95Â Airport Services55,033Â 1.76Â 3.68Â 54,453Â 1.88Â 3.59Â Internet Services & Infrastructure52,884Â 1.69Â 3.50Â 60,579Â 2.09Â 4.00Â Diversified Metals & Mining50,419Â 1.62Â 3.37Â 49,869Â 1.72Â 3.29Â Systems Software49,527Â 1.59Â 3.31Â 21,968Â 0.76Â 1.45Â Auto Parts & Equipment48,654Â 1.56Â 3.25Â 49,148Â 1.70Â 3.24Â Home Improvement Retail48,378Â 1.55Â 3.23Â 53,168Â 1.84Â 3.51Â Communications Equipment47,647Â 1.53Â 3.18Â \$â€"Â \$â€"Â Metal, Glass & Plastic Containers47,035Â 1.51Â 3.14Â 53,459Â 1.85Â 3.53Â Real Estate Services43,542Â 1.39Â 2.91Â 43,886Â 1.52Â 2.90Â Soft Drinks & Non-alcoholic Beverages42,443Â 1.36Â 2.84Â 42,391Â 1.47Â 2.80Â Automotive Retail38,919Â 1.25Â 2.60Â 55,805Â 1.93Â 3.68Â Office Services & Supplies38,366Â 1.23Â 2.56Â \$â€"Â \$â€"Â \$â€"Â \$â€"Â Other Specialty Retail37,426Â 1.20Â 2.50Â 41,115Â 1.42Â 2.71Â Leisure Facilities37,286Â 1.19Â 2.49Â 36,963Â 1.28Â 2.44Â Electrical Components & Equipment32,285Â 1.03Â 2.16Â 32,573Â 1.13Â 2.15Â Movies & Entertainment31,176Â 1.00Â 2.08Â 11,865Â 0.41Â 0.78Â Passenger Airlines26,924Â 0.86Â 1.80Â 27,512Â 0.95Â 1.82Â Construction Machinery & Heavy Transportation Equipment26,046Â 0.83Â 1.74Â \$â€"Â \$â€"Â \$â€"Â \$â€"Â Real Estate Development24,840Â 0.80Â 1.66Â 23,679Â 0.82Â 1.56Â Wireless Telecommunication Services24,297Â 0.78Â 1.62Â \$â€"Â \$â€"Â \$â€"Â \$â€"Â Gold23,867Â 0.76Â 1.60Â 23,328Â 0.81Â 1.54Â Health Care Equipment22,741Â 0.73Â 1.52Â 22,436Â 0.78Â 1.48Â Broadline Retail22,268Â 0.71Â 1.49Â 69,040Â 2.39Â 4.55Â Construction & Engineering20,000Â 0.64Â 1.34Â 21,903Â 0.76Â 1.45Â Packaged Foods & Meats19,912Â 0.64Â 1.33Â \$â€"Â \$â€"Â \$â€"Â \$â€"Â Specialty Chemicals19,482Â 0.62Â 1.30Â 38,615Â 1.34Â 2.55Â Apparel Retail18,064Â 0.54Â 1.21Â 5,002Â 0.17Â 0.33Â Oil & Gas Storage & Transportation17,737Â 0.57Â 1.19Â 16,400Â 0.55Â 1.06Â Hotels, Resorts & Cruise Lines16,861Â 0.54Â 1.13Â 16,991Â 0.59Â 1.12Â Alternative Carriers15,320Â 0.49Â 1.02Â \$â€"Â \$â€"Â \$â€"Â \$â€"Â Home Furnishings15,076Â 0.48Â 1.01Â 19,954Â 0.69Â 1.32Â Food Distributors14,492Â 0.46Â 0.97Â 5,166Â 0.18Â 0.34Â Advertising11,390Â 0.36Â 0.76Â 11,955Â 0.41Â 0.79Â Health Care Supplies11,337Â 0.36Â 0.76Â 11,363Â 0.39Â 0.75Â Integrated Telecommunication Services8,525Â 0.27Â 0.57Â 16,492Â 0.57Â 1.09Â Education Services8,105Â 0.26Â 0.54Â 13,618Â 0.47Â 0.90Â Distributors7,618Â 0.24Â 0.51Â 37,311Â 1.29Â 2.46Â Financial Exchanges & Data6,880Â 0.22Â 0.46Â \$â€"Â \$â€"Â \$â€"Â \$â€"Â Cable & Satellite6,105Â 0.20Â 0.41Â 4,546Â 0.16Â 0.30Â Research & Consulting Services4,939Â 0.16Â 0.33Â 4,831Â 0.17Â 0.32Â Paper & Plastic Packaging Products & Materials3,234Â 0.10Â 0.22Â 3,061Â 0.11Â 0.20Â Housewares & Specialties2,512Â 0.08Â 0.17Â 2,808Â 0.10Â 0.19Â Diversified Chemicals1,565Â 0.05Â 0.10Â \$â€"Â \$â€"Â \$â€"Â \$â€"Â Insurance Brokers\$â€"Â \$â€"Â 53,050Â 1.83Â 3.50Â Consumer Finance\$â€"Â \$â€"Â 15,087Â 0.52Â 1.08Â Restaurants\$â€"Â \$â€"Â 12,464Â 0.43Â 0.82Â Integrated Oil & Gas\$â€"Â \$â€"Â 4,785Â 0.17Â 0.32Â Air Freight & Logistics\$â€"Â \$â€"Â \$â€"Â \$â€"Â 4,263Â 0.15Â 0.28Â Other Specialized REITs\$â€"Â \$â€"Â \$â€"Â \$â€"Â 3,198Â 0.11Â 0.21Â Leisure Products\$â€"Â \$â€"Â 2,063Â 0.07Â 0.14Â Technology Distributors\$â€"Â \$â€"Â 776Â 0.03Â 0.05Â Totals\$3,121,703Â 100.00% %208.65% %\$2,892,420Â 100.00% %190.82% % (1)This industry includes the Company's investments in the JVs and CLOs. 43OAKTREE SPECIALTY LENDING CORPORATIONNOTESÂ TO CONSOLIDATED FINANCIAL STATEMENTS(in thousands, except share and per share amounts, percentages and as otherwise indicated)As of June30, 2024 and September30, 2023, the Company had no single investment that represented greater than 10% of the total investment

portfolio at fair value. Income, consisting of interest, dividends, fees, other investment income and realization of gains or losses, may fluctuate and in any given period can be highly concentrated among several investments. Senior Loan Fund JV I, LLCIn May 2014, the Company entered into an LLC agreement with Kemper to form SLF JV I. The Company co-invests in senior secured loans of middle-market companies and other corporate debt securities with Kemper through its investment in SLF JV I. SLF JV I is managed by a four person Board of Directors, two of whom are selected by the Company and two of whom are selected by Kemper. All portfolio decisions and investment decisions in respect of SLF JV I must be approved by the SLF JV I investment committee, which consists of one representative selected by the Company and one representative selected by Kemper (with approval from a representative of each required). Since the Company does not have a controlling financial interest in SLF JV I, the Company does not consolidate SLF JV I.SLF JV I is capitalized pro rata with LLC equity interests as transactions are completed and may be capitalized with additional subordinated notes issued to the Company and Kemper by SLF JV I. The subordinated notes issued by SLF JV I (the "SLF JV I Notes") are senior in right of payment to SLF JV I LLC equity interests and subordinated in right of payment to SLF JV Iâ€”s secured debt. As of June30, 2024 and September30, 2023, the Company and Kemper owned, in the aggregate, 87.5% and 12.5%, respectively, of the LLC equity interests of SLF JV I and the outstanding SLF JV I Notes. SLF JV I is not an "eligible portfolio company" as defined in section 2(a)(46) of the Investment Company Act.SLF JV I has a revolving credit facility with Bank of America, N.A. (as amended and/or restated from time to time, the "SLF JV I Facility"), which permitted up to \$270.0Â million of borrowings (subject to borrowing base and other limitations) as of June30, 2024. Borrowings under the SLF JV I Facility are secured by all of the assets of SLF JV I Funding II LLC, a special purpose financing subsidiary of SLF JV I. As of June30, 2024, the revolving period of the SLF JV I Facility was scheduled to expire April 17, 2027 and the maturity date was April 22, 2027. As of June30, 2024, borrowings under the SLF JV I Facility accrued interest at a rate equal to daily SOFR plus 1.70% per annum. As of June30, 2024 and September30, 2023, \$198.0Â million and \$149.0Â million of borrowings were outstanding under the SLF JV I Facility, respectively.As of June30, 2024 and September30, 2023, SLF JV I had total assets of \$390.6Â million and \$376.1Â million, respectively. SLF JV I's portfolio primarily consisted of senior secured loans to 49 and 48 portfolio companies as of June30, 2024 and September30, 2023, respectively. The portfolio companies in SLF JV I are in industries similar to those in which the Company may invest directly. As of June30, 2024, the Company's investment in SLF JV I consisted of LLC equity interests and SLF JV I Notes of \$138.5Â million in aggregate, at fair value. As of September30, 2023, the Company's investment in SLF JV I consisted of LLC equity interests and SLF JV I Notes of \$141.5Â million in aggregate, at fair value.As of each of June30, 2024 and September30, 2023, the Company and Kemper had funded approximately \$190.5 million to SLF JV I, of which \$166.7 million was from the Company. As of each of June30, 2024 and September 30, 2023, the Company had aggregate commitments to fund SLF JV I of \$13.1Â million, of which approximately \$9.8Â million was to fund additional SLF JV I Notes and approximately \$3.3Â million was to fund LLC equity interests in SLF JV I. Below is a summary of SLF JV I's portfolio, followed by a listing of the individual loans in SLF JV I's portfolio as of June30, 2024 and September30, 2023:June 30, 2024September 30, 2023Senior secured loans(1)\$353,579\$332,637Weighted average interest rate on senior secured loans (2)9.83%10.62%Number of borrowers in SLF JV I4948Largest exposure to a single borrower (1)\$11,161\$11,286Total of five largest loan exposures to borrowers (1)\$53,328\$54,051 (1) At principal amount.(2) Computed using the weighted average annual interest rate on accruing senior secured loans at fair value.44OAKTREE SPECIALTY LENDING CORPORATIONNOTESÂ TO CONSOLIDATED FINANCIAL STATEMENTS(in thousands, except share and per share amounts, percentages and as otherwise indicated)SLF JV I Portfolio as of June30, 2024Portfolio CompanyIndustryType of InvestmentIndexSpreadCash Interest Rate (1)(2)PIKMaturity DateSharesPrincipalCostFairÂ Value (3)NotesAccess CIG, LLCDiversified Support ServicesFirst Lien Term LoanSOFR+5.00%10.33%8/18/2028\$10,522Â 10,426Â \$10,602Â (4)ADB Companies, LLCConstruction & EngineeringFirst Lien Term LoanSOFR+6.50%11.82%12/18/20251,092Â 1,082Â 1,059Â (4)ADB Companies, LLCConstruction & EngineeringFirst Lien Term LoanSOFR+6.50%12.10%12/18/20256,258Â 6,216Â 6,071Â (4)Alvogen Pharma US, Inc.PharmaceuticalsFirst Lien Term LoanSOFR+7.50%12.98%6/30/20258,446Â 8,413Â 7,813Â (4)American Tire Distributors, Inc.DistributorsFirst Lien Term LoanSOFR+6.25%11.84%10/20/20283,352Â 3,311Â 2,445Â (4)Artera Services LLCConstruction & EngineeringFirst Lien Term LoanSOFR+4.50%69.83%2/15/20317,481Â 7,425Â 7,530Â ASP-R-PAC Acquisition Co LLCPaper & Plastic Packaging Products & MaterialsFirst Lien RevolverSOFR+6.00%11.46%12/29/2027205Â 199Â 180Â (4)(5)ASP-R-PAC Acquisition Co LLCPaper & Plastic Packaging Products & MaterialsFirst Lien Term LoanSOFR+6.00%11.59%12/29/20274,103Â 4,055Â 3,901Â (4)Astra Acquisition Corp.Application SoftwareFirst Lien Term LoanSOFR+6.75%12.08%2/25/20282,553Â 2,499Â 2,342Â (4)Astra Acquisition Corp.Application SoftwareFirst Lien Term LoanSOFR+5.25%10.58%10/25/20284,037Â 2,108Â 1,894Â (4)Asurion, LLCProperty & Casualty InsuranceFirst Lien Term LoanSOFR+4.00%69.44%8/19/20287,795Â 7,598Â 7,720Â Asurion, LLCProperty & Casualty InsuranceFirst Lien Term LoanSOFR+4.25%69.69%8/19/20281,975Â 1,886Â 1,963Â athenahealth Group Inc.Health Care TechnologyFirst Lien Term LoanSOFR+3.25%8.59%2/15/20299,057Â 8,801Â 9,038Â Aurora Lux Finco S.Â R.L.Airport ServicesFirst Lien Term LoanSOFR+7.00%8.43%4.00%12/24/20266,480Â 6,424Â 6,260Â (4)BAART Programs, Inc.Health Care ServicesFirst Lien Term LoanSOFR+5.00%10.60%6/11/20271,740Â 1,728Â 1,672Â (4)BAART Programs, Inc.Health Care ServicesFirst Lien Term LoanSOFR+5.00%10.60%6/11/20276,258Â 6,199Â 6,014Â (4)Bausch + Lomb CorporationHealth Care SuppliesFirst Lien Term LoanSOFR+3.25%8.69%5/10/20279,196Â 9,025Â 9,110Â C5 Technology Holdings, LLCData Processing & Outsourced ServicesCommon Stock171Â Â€"Â 171Â Â€"Â (4)C5 Technology Holdings, LLCData Processing & Outsourced ServicesPreferred Equity7,193,540Â 7,194Â 5,683Â (4)Centerline Communications, LLCWireless Telecommunication ServicesFirst Lien Term LoanSOFR+6.00%12.64%8/10/20271,979Â 1,956Â 1,625Â Centerline Communications, LLCWireless Telecommunication ServicesFirst Lien RevolverSOFR+6.00%11.50%8/10/2027600Â 594Â 492Â (5)Centerline Communications, LLCWireless Telecommunication ServicesFirst Lien Term LoanSOFR+6.00%12.49%8/10/20271,955Â 1,935Â 1,605Â Cloud Software Group, Inc.Application SoftwareFirst Lien Term LoanSOFR+4.00%69.33%3/30/20298,173Â 7,610Â 8,177Â Covetrus, Inc.Health Care DistributorsFirst Lien Term LoanSOFR+5.00%10.33%10/13/20296,295Â 5,982Â 6,102Â (4)Crown Subsea Communications Holding, Inc.Alternative CarriersFirst Lien Term LoanSOFR+4.75%10.08%1/30/20318,000Â 7,920Â 8,032Â (4)Curium Bidco S.Â r.L.PharmaceuticalsFirst Lien Term LoanSOFR+4.00%9.33%7/31/20298,665Â 8,581Â 8,713Â Dealer Tire Financial, LLCDistributorsFirst Lien Term LoanSOFR+3.75%69.09%12/14/20279,950Â 9,928Â 9,953Â DirectTV Financing, LLCable & SatelliteFirst Lien Term LoanSOFR+5.25%10.71%8/2/20296,872Â 6,793Â 6,851Â (4)DTI Holdco, Inc.Research & Consulting ServicesFirst Lien Term LoanSOFR+4.75%10.09%4/26/20299,052Â 8,929Â 9,100Â (4)Eagle Parent Corp.Diversified Support ServicesFirst Lien Term LoanSOFR+4.25%9.58%4/2/20291,181Â 1,179Â 1,151Â Frontier Communications Holdings, LLCIntegrated Telecommunication ServicesFirst Lien Term LoanSOFR+3.75%69.21%10/8/20273,723Â 3,685Â 3,726Â Frontier Communications Holdings, LLCIntegrated Telecommunication ServicesFirst Lien Term LoanSOFR+3.50%8.85%7/1/20317,000Â 6,965Â 7,000Â Harbor Purchaser Inc.Education ServicesFirst Lien Term LoanSOFR+5.25%10.70%4/9/20297,860Â 7,698Â 7,500Â (4)45OAKTREE SPECIALTY LENDING CORPORATIONNOTESÂ TO CONSOLIDATED FINANCIAL STATEMENTS(in thousands, except share and per share amounts, percentages and as otherwise indicated)Portfolio CompanyIndustryType of InvestmentIndexSpreadCash Interest Rate (1)(2)PIKMaturity DateSharesPrincipalCostFairÂ Value (3)NotesHusky Injection Molding Systems Ltd.Industrial Machinery & Supplies & ComponentsFirst Lien Term LoanSOFR+5.00%10.33%2/15/20293,952Â \$3,897Â \$3,966Â Indivior Finance S.Â R.L.PharmaceuticalsFirst Lien Term Term LoanSOFR+5.25%10.71%6/30/20267,275Â 7,216Â 7,266Â INW Manufacturing, LLCPersonal Care ProductsFirst Lien Term LoanSOFR+5.75%11.35%3/25/20278,625Â 8,504Â 7,245Â (4)KDC/ONE Development Corp IncPersonal Care ProductsFirst Lien Term LoanSOFR+4.50%69.84%6/15/20288,890Â 8,661Â 8,925Â LABL, Inc.Office Services & SuppliesFirst Lien Term LoanSOFR+5.00%10.44%10/29/20286,917Â 6,725Â 6,841Â (4)LaserAway Intermediate Holdings II, LLCHealth Care ServicesFirst Lien Term LoanSOFR+5.75%11.33%10/14/20277,313Â 7,232Â 7,343Â Lightbox Intermediate, L.P.Real Estate ServicesFirst Lien Term LoanSOFR+5.00%10.60%5/9/202611,161Â 11,060Â 10,826Â (4)McAfee Corp.Systems SoftwareFirst Lien Term LoanSOFR+3.25%8.58%3/1/20295,910Â 5,665Â 5,911Â Mitchell International, Inc.Application SoftwareFirst Lien Term LoanSOFR+3.25%8.59%6/17/20315,000Â 4,975Â 4,964Â Peraton Corp.Aerospace & DefenseFirst Lien Term LoanSOFR+3.75%69.19%2/1/20281,983Â 1,983Â 1,987Â PetSmart LLCOther Specialty Retail First Lien Term LoanSOFR+3.75%69.19%2/11/20287,969Â 7,888Â 7,956Â Pluralsight, LLCApplication SoftwareFirst Lien RevolverSOFR+8.00%4/6/2027507Â 493Â 248Â (4)(6)Pluralsight, LLCApplication SoftwareFirst Lien Term LoanSOFR+8.00%4/6/20278,116Â 7,890Â 3,977Â (4)(6)Renaissance Holding Corp.Education ServicesFirst Lien Term LoanSOFR+4.25%9.60%4/5/20308,943Â 8,810Â 8,947Â SCIH Salt Holdings Inc.Diversified ChemicalsFirst Lien Term LoanSOFR+3.50%8.83%3/16/20272,972Â 2,972Â 2,978Â Shearer's Foods LLCPackaged Foods & MeatsFirst Lien Term LoanSOFR+4.00%9.34%2/12/20317,000Â 6,930Â 7,057Â SHO Holding I CorporationFootwearFirst Lien Term LoanSOFR+8.00%13.44%8/29/2024940Â 893Â 940Â SHO Holding I CorporationFootwearFirst Lien Term Term LoanSOFR+5.23%4/27/2024139Â 140Â 120Â (6)SHO Holding I CorporationFootwearFirst Lien Term LoanSOFR+5.25%64/27/20248,194Â 8,233Â 7,031Â (6)SM Wellness Holdings, Inc.Health Care ServicesFirst Lien Term LoanSOFR+4.50%10.09%4/17/20282,954Â 2,625Â 2,921Â (4)Southern Veterinary Partners, LLCHealth Care FacilitiesFirst Lien Term LoanSOFR+3.75%69.09%10/5/20278,623Â 8,585Â 8,652Â SPX Flow, Inc.Industrial Machinery & Supplies & ComponentsFirst Lien Term LoanSOFR+3.50%68.84%4/5/20297,045Â 6,796Â 7,094Â Staples, Inc.Office Services & SuppliesFirst Lien Term LoanSOFR+5.75%11.08%9/4/20295,349Â 5,136Â 4,920Â (4)Star Parent, Inc.Life Sciences Tools & ServicesFirst Lien Term LoanSOFR+3.75%69.08%9/27/20307,980Â 7,860Â 7,983Â SupplyOne, Inc. Paper & Plastic Packaging Products & MaterialsFirst Lien Term LoanSOFR+4.25%69.59%4/19/20314,489Â 4,444Â 4,501Â Swissport Stratosphere USA LLCAir Freight & LogisticsFirst Lien Term LoanSOFR+4.25%69.56%4/4/20315,500Â 5,473Â 5,522Â Tacala, LLCRestaurantsFirst Lien Term LoanSOFR+4.00%9.34%1/31/203110,973Â 10,945Â 11,033Â Touchstone Acquisition, Inc.Health Care SuppliesFirst Lien Term LoanSOFR+6.00%11.43%12/29/20277,157Â 7,065Â 7,005Â (4)Trident PTI Holdings, Inc.Metal, Glass & Plastic ContainersFirst Lien Term LoanSOFR+4.00%69.34%6/15/20287,500Â 7,500Â 7,519Â Total Portfolio Investments\$33,579Â \$33,579Â \$33,263Â \$344,930Â (1) Represents the interest rate as of June30, 2024. All interest rates are payable in cash, unless otherwise noted.(2) The interest rate on the principal balance outstanding for most of the floating rate loans is indexed to SOFR which typically resets semi-annually, quarterly, or monthly at the borrower's option. The borrower may also elect to have multiple interest reset periods for each loan. For each of these loans, the Company has provided the applicable margin over the reference rates based on each respective credit agreement and the cash interest rate as of period end. As of June30, 2024, the reference rates for SLF JV I's variable rate loans were the 30-day SOFR at 5.34% and the 90-day SOFR at 5.32%. Most loans include an interest floor, which generally ranges from 0% to 2%. SOFR based contracts may include a credit spread adjustment that is charged in addition to the base rate and the stated spread.(3) Represents the current determination of fair value as of June30, 2024 utilizing a similar technique as the Company in accordance with ASC 820. However, the determination of such fair value is not included in the valuation process described elsewhere herein.46OAKTREE SPECIALTY LENDING CORPORATIONNOTESÂ TO CONSOLIDATED FINANCIAL STATEMENTS(in thousands, except share and per share amounts, percentages and as otherwise indicated)(4) This investment was held by both the Company and SLF JV I as of June30, 2024.(5) Investment had undrawn commitments. Unamortized fees are classified as unearned income which reduces cost basis, which may result in a negative cost basis. A negative fair value may result from the unfunded commitment being valued below par.(6) This investment was on non-accrual status as of June30, 2024.47OAKTREE SPECIALTY LENDING CORPORATIONNOTESÂ TO CONSOLIDATED FINANCIAL STATEMENTS(in thousands, except share and per share amounts, percentages and as otherwise indicated)SLF JV I Portfolio as of September30, 2023Portfolio CompanyIndustryType of InvestmentIndexSpreadCash Interest Rate (1)(2)PIKMaturity DateSharesPrincipalCostFairÂ Value (3)NotesAccess CIG, LLCDiversified Support ServicesFirst Lien Term LoanSOFR+5.00%10.32%8/18/2028\$8,596Â \$8,503Â \$8,499Â ADB Companies, LLCConstruction & EngineeringFirst Lien Term LoanSOFR+6.50%11.90%12/18/20251,149Â 1,135Â 1,128Â (4)ADB Companies, LLCConstruction & EngineeringFirst Lien Term LoanSOFR+6.50%12.15%12/18/20256,771Â 6,701Â 6,648Â (4)Altice France S.A.Integrated Telecommunication ServicesFirst Lien Term LoanL+4.00%69.63%8/14/20262,969Â 2,853Â 2,810Â Alvogen Pharma US, Inc.PharmaceuticalsFirst Lien Term LoanSOFR+7.50%13.04%6/30/20258,798Â 8,737Â 8,218Â (4)American Rock Salt Company LLCDiversified Metals & MiningFirst Lien Term LoanSOFR+4.00%69.43%6/9/20284,957Â 4,734Â 4,614Â American Tire Distributors, Inc.DistributorsFirst Lien Term LoanSOFR+6.25%11.81%10/20/20284,824Â 4,763Â 4,239Â (4)Amplify Finco Pty Ltd.Movies & EntertainmentFirst Lien Term LoanSOFR+4.15%69.54%11/26/20267,720Â 7,643Â 7,720Â Anastasia Parent, LLCPersonal Care ProductsFirst Lien Term LoanSOFR+3.75%9.40%8/11/20251,523Â 1,191Â 1,099Â (4)ASP-R-PAC Acquisition Co LLCPaper & Plastic Packaging Products & MaterialsFirst Lien RevolverSOFR+6.00%12/29/2027Â€"Â (7)(29)(4)(5)ASP-R-PAC Acquisition Co LLCPaper & Plastic Packaging Products & MaterialsFirst Lien Term LoanSOFR+6.00%11.63%12/29/20274,134Â 4,076Â 3,892Â (4)Astra Acquisition Corp.Application SoftwareFirst Lien Term LoanSOFR+5.25%10.90%10/25/20285,052Â 4,888Â 3,817Â (4)Asurion, LLCProperty & Casualty InsuranceFirst Lien Term LoanSOFR+4.00%69.42%8/19/20284,950Â 4,747Â 4,809Â Asurion, LLCProperty & Casualty InsuranceFirst Lien Term LoanSOFR+4.25%9.67%8/19/20281,990Â 1,884Â 1,937Â Asurion, LLCProperty & Casualty InsuranceSecond Lien Term LoanSOFR+5.25%10.68%1/20/20294,346Â 4,036Â 3,871Â athenahealth Group Inc.Health Care TechnologyFirst Lien Term LoanSOFR+3.25%68.57%2/15/20294,320Â 4,080Â 4,251Â Aurora Lux Finco S.Â R.L.Airport ServicesFirst Lien Term LoanSOFR+6.00%11.49%12/24/20266,289Â 6,216Â 6,028Â (4)BAART Programs, Inc.Health Care ServicesFirst Lien Term LoanSOFR+5.00%10.65%6/11/20271,753Â 1,742Â 1,711Â (4)BAART Programs, Inc.Health Care ServicesFirst Lien Term LoanSOFR+5.00%10.65%6/11/20276,306Â 6,247Â 6,155Â (4)C5 Technology Holdings, LLCData Processing & Outsourced ServicesCommon Stock171Â Â€"Â 171Â Â€"Â (4)C5 Technology Holdings, LLCData Processing & Outsourced ServicesPreferred Equity7,193,540Â 7,194Â 5,683Â (4)Centerline Communications, LLCWireless Telecommunication ServicesFirst Lien Term LoanSOFR+6.00%11.55%8/10/20272,354Â 2,322Â 2,281Â Centerline Communications, LLCWireless Telecommunication ServicesFirst Lien Term LoanSOFR+6.00%11.55%8/10/20271,983Â 1,954Â 1,921Â Centerline Communications, LLCWireless Telecommunication ServicesFirst Lien RevolverSOFR+6.00%11.57%8/10/2027600Â 592Â 581Â Centerline Communications, LLCWireless Telecommunication ServicesFirst Lien Term LoanSOFR+6.00%11.55%8/10/20271,960Â 1,935Â 1,899Â Covetrus, Inc.Health Care DistributorsFirst Lien Term LoanSOFR+5.00%10.39%10/13/20296,343Â 5,983Â 6,285Â (4)Curium Bidco S.Â r.L.BiotechnologyFirst Lien Term LoanSOFR+4.50%9.89%7/31/20298,730Â 8,642Â 8,730Â DirectTV Financing, LLCable & SatelliteFirst Lien Term LoanSOFR+5.00%10.43%8/2/20275,799Â 5,715Â 5,681Â (4)DTI Holdco, Inc.Research & Consulting ServicesFirst Lien Term LoanSOFR+4.75%10.12%4/26/20297,920Â 7,792Â 7,729Â (4)Gibson Brands, Inc.Leisure ProductsFirst Lien Term LoanSOFR+5.00%10.57%8/11/20287,369Â 7,295Â 6,190Â (4)Harbor Purchaser Inc.Education ServicesFirst Lien Term LoanSOFR+5.25%10.67%4/9/20297,920Â 7,731Â 7,517Â (4)Indivior Finance S.Â R.L.PharmaceuticalsFirst Lien Term LoanSOFR+5.25%10.90%6/30/20267,331Â 7,249Â 7,340Â 48OAKTREE SPECIALTY LENDING CORPORATIONNOTESÂ TO CONSOLIDATED FINANCIAL STATEMENTS(in thousands, except share and per share amounts, percentages and as otherwise indicated)Portfolio CompanyIndustryType of InvestmentIndexSpreadCash Interest Rate (1)(2)PIKMaturity DateSharesPrincipalCostFairÂ Value (3)NotesINW Manufacturing, LLCPersonal Care ProductsFirst Lien Term LoanSOFR+5.75%11.40%3/25/2027\$9,000Â \$8,839Â \$7,080Â (4)KDC/ONE Development Corp IncPersonal Care ProductsFirst Lien Term LoanSOFR+5.00%10.32%8/15/202810,000Â 9,666Â 9,665Â LABL, Inc.Office Services & SuppliesFirst Lien Term LoanSOFR+5.00%10.42%10/29/20283,962Â 3,815Â 3,955Â LaserAway Intermediate Holdings II, LLCHealth Care ServicesFirst Lien Term LoanSOFR+5.75%11.32%10/14/20277,369Â 7,269Â 7,267Â Lightbox Intermediate, L.P.Real Estate ServicesFirst Lien Term LoanSOFR+5.00%10.65%5/9/202611,249Â 11,106Â 10,912Â (4)McAfee Corp.Systems SoftwareFirst Lien Term LoanSOFR+3.75%9.18%3/1/20295,940Â 5,654Â 5,812Â Mindbody, Inc.Internet Services & InfrastructureFirst Lien Term LoanSOFR+7.00%12.52%2/14/20254,669Â 4,648Â 4,594Â (4)Mitchell International, Inc.Application SoftwareFirst Lien Term LoanSOFR+3.75%69.18%10/15/20282,985Â 2,845Â 2,941Â MRI Software LLCApplication SoftwareFirst Lien Term LoanSOFR+5.50%62/10/2026Â€"Â (3)(7)(4)(5)MRI Software LLCApplication SoftwareFirst Lien Term LoanSOFR+5.50%10.99%2/10/20268,319Â 8,164Â 8,147Â (4)MRI Software LLCApplication SoftwareFirst Lien Term LoanSOFR+5.50%10.99%2/10/20262,211Â 2,210Â 2,165Â (4)Northern Star Industries Inc.Electrical Components & EquipmentFirst Lien Term LoanSOFR+4.76%10.15%3/31/20256,615Â 6,608Â 6,565Â OEConnection LLCApplication SoftwareFirst Lien Term

may include a credit spread adjustment that is charged in addition to the base rate and the stated spread.(3) Represents the current determination of fair value as of June 30, 2024 utilizing a similar technique as the Company in accordance with ASC 820. However, the determination of such fair value is not included in the valuation process described elsewhere herein.(4) This investment was held by both the Company and the Click JV as of June 30, 2024.560AKTREE SPECIALTY LENDING CORPORATIONNOTESÂ TO CONSOLIDATED FINANCIAL STATEMENTS(in thousands, except share and per share amounts, percentages and as otherwise indicated)(5) Investment had undrawn commitments. Unamortized fees are classified as unearned income which reduces cost basis, which may result in a negative cost basis. A negative fair value may result from the unfunded commitment being valued below par.(6) This investment was on non-accrual status as of June 30, 2024. Click JV Portfolio as of September 30, 2023Portfolio Company IndustryInvestment TypeIndexSpreadâ Cash Interest Rate (1)(2)PIKMaturity DatePrincipalCostFairâ Value (3)NotesAccess CIG, LLC Diversified Support ServicesFirst Lien Term LoanSOFR+5.00%10.32%/8/18/20282,000â 1,960â 1,978â ADB Companies, LLCConstruction & EngineeringFirst Lien Term LoanSOFR+6.50%11.90%/12/18/2025574A 568â 564â (4)ADB Companies, LLCConstruction & EngineeringFirst Lien Term LoanSOFR+6.50%12.15%/12/18/20253,746â 3,709â 3,678â (4)Alvogen Pharma US, Inc.PharmaceuticalsFirst Lien Term LoanSOFR+7.50%13.04%/6/30/20256,230â 6,185â 5,819â (4)American Rock Salt Company LLC Diversified Metals & MiningFirst Lien Term LoanSOFR+4.00%9.43%/6/9/20282,478â 2,367â 2,307â American Tire Distributors, Inc.DistributorsFirst Lien Term LoanSOFR+6.25%11.81%/10/20/20282,860â 2,825â 2,514â (4)Amplify Finco Pty Ltd.Movies & EntertainmentFirst Lien Term LoanSOFR+4.15%/9.54%/11/26/20262,895â 2,866â 2,895â Amynta Agency Borrower Inc.Property & Casualty InsuranceFirst Lien Term LoanSOFR+5.00%10.42%/28/20282,993â 2,913â 2,997â Anastasia Parent, LLCPersonal Care ProductsFirst Lien Term LoanSOFR+3.75%9.40%/8/11/2025907â 705â 654â (4)ASP-R-PAC Acquisition Co LLCPaper & Plastic Packaging Products & MaterialsFirst Lien Term LoanSOFR+6.00%11.63%/12/29/20271,716â 1,692â 1,616â (4)ASP-R-PAC Acquisition Co LLCPaper & Plastic Packaging Products & MaterialsFirst Lien RevolverSOFR+6.00%12/29/2027â (3)(12)(4)(5)Astra Acquisition Corp.Application SoftwareFirst Lien Term LoanSOFR+5.25%10.90%/10/25/20282,078â 2,039â 1,570â (4)Asurion, LLCProperty & Casualty InsuranceFirst Lien Term LoanSOFR+4.00%9.42%/8/19/20281,980â 1,899â 1,924â Asurion, LLCProperty & Casualty InsuranceFirst Lien Term LoanSOFR+4.25%9.67%/8/19/2028995â 942â 968â Asurion, LLCProperty & Casualty InsuranceSecond Lien Term LoanSOFR+5.25%10.68%/1/20/20292,423â 2,244â 2,158â athenahealth Group Inc.Health Care TechnologyFirst Lien Term LoanSOFR+3.25%8.57%/15/20291,772â 1,674â 1,744â Aurora Lux Finco S.A.R.L.Airport ServicesFirst Lien Term LoanSOFR+6.00%11.49%/12/24/20263,628â 3,586â 3,478â (4)BAART Programs, Inc.Health Care ServicesFirst Lien Term LoanSOFR+5.00%10.65%/6/11/2027800â 795â 780â (4)Covertris, Inc.Health Care DistributorsFirst Lien Term LoanSOFR+5.00%10.39%/10/13/20292,766â 2,607â 2,741â (4)Curium Biochem S.A..r1.BiotechnologyFirst Lien Term LoanSOFR+4.50%9.89%/7/31/20292,841â 2,820â 2,841â DirecTV Financing LLCable & Satellite First Lien Term LoanSOFR+5.00%10.43%/8/2/20272,460â 2,435â 2,410â (4)DTI Holdco, Inc.Research & Consulting ServicesFirst Lien Term LoanSOFR+4.75%10.12%/24/26/20292,970â 2,922â 2,899â (4)Gibson Brands, Inc.Lesure ProductsFirst Lien Term LoanSOFR+5.00%10.57%/8/11/20283,930â 3,891â 3,301â (4)Harbor Purchaser Inc.Education ServicesFirst Lien Term LoanSOFR+5.25%10.67%/4/9/20293,960â 3,865â 3,759â (4)Indivior Finance S.A.R.L.PharmaceuticalsFirst Lien Term LoanSOFR+5.25%10.90%/6/30/20263,910â 3,866â 3,915â INW Manufacturing, LLCPersonal Care ProductsFirst Lien Term LoanSOFR+5.75%11.40%/3/25/20272,250â 2,210â 1,770â (4)KDC/ONE Development Corp IncPersonal Care ProductsFirst Lien Term LoanSOFR+5.00%10.32%/8/15/20284,500â 4,350â 4,349â 560AKTREE SPECIALTY LENDING CORPORATIONNOTESÂ TO CONSOLIDATED FINANCIAL STATEMENTS(in thousands, except share and per share amounts, percentages and as otherwise indicated)Portfolio Company IndustryInvestment TypeIndexSpreadâ Cash Interest Rate (1)(2)PIKMaturity DatePrincipalCostFairâ Value (3)NotesLaserAway Intermediate Holdings II, LLCHealth Care ServicesFirst Lien Term LoanSOFR+5.75%11.32%/10/14/2027\$3,930â \$3,877â \$3,876â MRI Software LLCApplication SoftwareFirst Lien Term LoanSOFR+5.50%10.99%/6/10/20261,630â 1,616â 1,596â (4)MRI Software LLCApplication SoftwareFirst Lien RevolverSOFR+5.50%/2/10/2026â (1)(3)(4)(5)Northern Star Industries Inc.Electrical Components & EquipmentFirst Lien Term LoanSOFR+4.76%10.15%/3/31/20255,198â 5,192â 5,159â OEConnection LLCApplication SoftwareFirst Lien Term LoanSOFR+4.00%9.43%/9/25/20263,849â 3,830â 3,843â Planview Parent, Inc.Application SoftwareFirst Lien Term LoanSOFR+4.00%9.65%/12/17/2027683â 650â 676â Planview Parent, Inc.Application SoftwareSecond Lien Term LoanSOFR+7.25%12.74%/12/18/20282,824â 2,799â 2,586â (4)Pluralsight, LLCApplication SoftwareFirst Lien Term LoanSOFR+8.00%13.45%/4/6/20272,182â 5,029â 4,964â (4)Pluralsight, LLCApplication SoftwareFirst Lien RevolverSOFR+8.00%13.45%/4/6/2027226â 216â 211â (4)(5)SHO Holding I CorporationFootwearFirst Lien Term LoanSOFR+5.25%10.88%/4/27/20246,029â 6,025â 4,110â SHO Holding I CorporationFootwearFirst Lien Term LoanSOFR+5.23%10.86%/4/27/20241,033â 102â 70â Southern Veterinary Partners, LLCHealth Care FacilitiesFirst Lien Term LoanSOFR+4.00%9.43%/10/5/20273,292â 3,275â 3,276â Spanx, LLCApparel RetailFirst Lien Term LoanSOFR+5.25%10.67%/11/20/20284,913â 4,840â 4,843â (4)SPX Flow, Inc.Industrial Machinery & Supplies & ComponentsFirst Lien Term LoanSOFR+4.50%9.92%/5/20/20252,275â 5,032â 5,224â Star Parent, Inc.Life Sciences Tools & ServicesFirst Lien Term LoanSOFR+4.00%9.33%/9/27/20304,000â 3,939â 3,916â TIBCO Software Inc.Application SoftwareFirst Lien Term LoanSOFR+4.50%9.99%/3/30/20292,641â 2,439â 2,544â Touchstone Acquisition, Inc.Health Care SuppliesFirst Lien Term LoanSOFR+6.00%11.42%/12/29/20282,993â 2,948â 2,914â (4)Windstream Services II, LLCIntegrated Telecommunication ServicesFirst Lien Term LoanSOFR+6.25%11.67%/6/21/20273,843â 3,766â 3,712â (4)WPP CPP Holdings, LLC Aerospace & DefenseFirst Lien Term LoanSOFR+3.75%9.27%/4/30/2025983â 960â 927â (4)Total Portfolio Investments\$130,589â \$127,788â \$123,343â (1) Represents the interest rate as of September 30, 2023. All interest rates are payable in cash, unless otherwise noted. (2) The interest rate on the principal balance outstanding for all of the floating rate loans is indexed to SOFR, which typically resets semi-annually, quarterly, or monthly at the borrower's option. The borrower may also elect to have multiple interest reset periods for each loan. For each of these loans, the Company has provided the applicable margin over the reference rates based on each respective credit agreement and the cash interest rate as of period end. As of September 30, 2023, the reference rates for the Click JV's variable rate loans were the 30-day SOFR at 5.32% and the 90-day SOFR at 5.39%. Most loans include an interest floor, which generally ranges from 0% to 1%. SOFR based contracts may include a credit spread adjustment that is charged in addition to the base rate and the stated spread.(3) Represents the current determination of fair value as of September 30, 2023 utilizing a similar technique as the Company in accordance with ASC 820. However, the determination of such fair value is not included in the valuation process described elsewhere herein.(4) This investment was held by both the Company and the Click JV as of September 30, 2023.(5) Investment had undrawn commitments. Unamortized fees are classified as unearned income which reduces cost basis, which may result in a negative cost basis. A negative fair value may result from the unfunded commitment being valued below par.The cost and fair value of the Company's aggregate investment in the Click JV was \$51.3 million and \$49.9 million, respectively, as of June 30, 2024. The cost and fair value of the Company's aggregate investment in the Click JV was \$50.3â million and \$50.0â million, respectively, as of September 30, 2023. For the three and nine months ended June 30, 2024, the Company's investment in the Click JV Notes earned interest income of \$1.8â million and \$5.4â million, respectively. For the three and nine months ended June 30, 2023, the Company's investment in the Click JV Notes earned interest income of \$1.8â million and \$5.0â million, respectively. The Company did not earn dividend income for the three and nine months ended June 30, 2024 and 2023 with respect to its investment in the LLC equity interest of the Click JV. As of June 30, 2024, the Click JV Notes bore interest at a rate of one-month SOFR plus 4.50% per annum and will mature on October 20, 2028.560AKTREE SPECIALTY LENDING CORPORATIONNOTESÂ TO CONSOLIDATED FINANCIAL STATEMENTS(in thousands, except share and per share amounts, percentages and as otherwise indicated)Below is certain summarized financial information for the Click JV as of June 30, 2024 and September 30, 2023 and for the three and nine months ended June 30, 2024 and 2023: June 30, 2024September 30, 2023Selected Balance Sheet Information:Investments at fair value (cost June 30, 2024: \$137,360; cost September 30, 2023: \$127,788)\$132,405â \$123,343â Cash and cash equivalents13,109â 12,119â Restricted cashâ 184â Other assets4,655â 5,212â Total assets\$150,169â \$141,167â Senior credit facility payable\$7,000â \$53,000â Click JV Notes payable at fair value (proceeds June 30, 2024: \$66,685; proceeds September 30, 2023: \$66,685)\$7,012â \$7,201â Secured borrowings\$6,576â 18,106â Other liabilities\$8,581â 12,860â Total liabilities\$150,169â \$141,167â Members' equity â 30,2023Selected Statements of Operations Information:Interest income\$3,605â \$3,576â \$10,926â \$10,488â Fee income4â â 6â 4â 35â Total investment income3,609â 3,576â 10,990â 10,523â Senior credit facility and secured borrowing interest expense1,631â 1,400â

2022December 15, 2022December 30, 2022\$0.42Å \$24.8Å million41,510Å (1)\$0.8Å millionQuarterlyJanuary 27, 2023March 15, 2023March 15, 2023\$0.55Å \$41.1Å million68,412Å (2)\$1.3Å millionQuarterlyApril 28, 2023June 15, 2023June 30, 2023\$0.55Å \$41.3Å million57,279Å (2)\$1.1Å millionTotal for the nine months ended June 30, 2023\$2.06Å \$139.1Å million220,570Å \$4.4Å millionÅ (1) New shares were issued and distributed.(2) Shares were purchased on the open market and distributed.(3) Totals may not sum due to rounding.Common Stock IssuancesDuring the three and nine months ended June 30, 2024, the Company issued 100,029 and 295,484 shares of common stock, respectively, as part of the DRIP. During the three and nine months ended JuneÅ 30, 2023, the Company issued zero and 94,879 shares of common stock, respectively, as part of the DRIP.On February 7, 2022, the Company entered into an equity distribution agreement by and among the Company, Oaktree, Oaktree Administrator and Keefe, Bruyette & Woods, Inc., JMP Securities LLC, Raymond James & Associates, Inc. and SMBC Nikko Securities America, Inc., as placement agents, in connection with the issuance and sale by the Company of shares of common stock, having an aggregate offering price of up to \$125.0Å million. The equity distribution agreement was amended on February 8, 2023 to allow for the sale of shares of the CompanyÅs common stock having an aggregate offering price of up to \$125Å million under the CompanyÅs current registration statement and on August 8, 2023 to add Jefferies LLC as an additional placement agent and to remove SMBC Nikko Securities America, Inc. as a placement agent. Sales of the common stock may be made in negotiated transactions or transactions that are deemed to be Åeat the market,Å as defined in Rule 415 under the Securities Act of 1933, as amended, including sales made directly on the Nasdaq Global Select Market or similar securities exchanges or sales made to or through a market maker other than on an exchange, at prices related to the prevailing market prices or at negotiated prices. In connection with the "at the market" offering, the Company issued and sold 4,724,506 shares of common stock during the nine months ended JuneÅ 30, 2024 for net proceeds of \$92.5Å million (net of offering costs).Number of Shares IssuedGross ProceedsPlacement Agent FeesNet Proceeds (1)Average Sales Price per Share (2)"At the market" offering4,724,506Å \$93,685Å \$937Å \$92,748Å \$19.83Å (1) Net proceeds excludes offering costs of \$0.2Å million.(2) Represents the gross sales price before deducting placement agent fees and estimated offering expenses. In connection with the "at the market" offering, the Company did not issue or sell any shares of common stock during the nine months ended JuneÅ 30, 2023.Note6. BorrowingsSyndicated FacilityOn November 30, 2017, the Company entered into a senior secured revolving credit facility (as amended and restated, the ÅSyndicated FacilityÅ) pursuant to a Senior Secured Revolving Credit Agreement with the lenders party thereto, ING Capital LLC, as administrative agent, ING Capital LLC, JPMorgan Chase Bank, N.A., BofA Securities, Inc. and MUFG Union Bank, 600AKTREE SPECIALTY LENDING CORPORATIONNOTESÅ TO CONSOLIDATED FINANCIAL STATEMENTS(in thousands, except share and per share amounts, percentages and as otherwise indicated)N.A., as joint lead arrangers and joint bookrunners, and JPMorgan Chase Bank, N.A. and Bank of America, N.A., as syndication agents. The Syndicated Facility provides that the Company may use the proceeds of the loans and issuances of letters of credit under the Syndicated Facility for general corporate purposes, including acquiring and funding leveraged loans, mezzanine loans, high-yield securities, convertible securities, preferred stock, common stock and other investments. The Syndicated Facility further allows the Company to request letters of credit from ING Capital LLC, as the issuing bank. As of JuneÅ 30, 2024, the size of the Syndicated Facility was \$1.218Å billion. In addition, pursuant to an "accordion" feature, the Company may increase the size of the facility to up to the greater of \$1.25Å billion and the Company's net worth, as defined in the facility, under certain circumstances. As of JuneÅ 30, 2024, (i) the period during which the Company may make drawings with respect to \$1.035Å billion of commitments will expire on June 23, 2027 and the maturity date is June 23, 2028, (ii) the period during which the Company may make drawings with respect to the remaining commitments will expire on May 4, 2025 and the maturity date is May 4, 2026 and (iii) the interest rate margin for (a)Å SOFR loans (which may be Å 1- or Å 3-month, Å at the CompanyÅs option) was 2.00% plus a SOFR adjustment which ranges between 0.11448% and 0.26161% and (b) alternate base rate loans was 1.00%. The Syndicated Facility is secured by substantially all of the CompanyÅs assets (excluding, among other things, investments held in and by certain subsidiaries of the Company (including OSI 2 Senior Lending SPV, LLC, or ÅOSI 2 SPVÅ) or investments in certain portfolio companies of the Company) and guaranteed by certain subsidiaries of the Company. The Syndicated Facility requires the Company to, among other things, (i)Å make representations and warranties regarding the collateral as well as each of the CompanyÅs portfolio companiesÅ businesses, (ii)Å agree to certain indemnification obligations, and (iii)Å comply with various affirmative and negative covenants, reporting requirements and other customary requirements for similar revolving credit facilities, including covenants related to: (A)Å limitations on the incurrence of additional indebtedness and liens, (B)Å limitations on certain investments, (C)Å limitations on certain asset transfers and restricted payments, (D)Å maintaining a certain minimum stockholdersÅ equity, (E)Å maintaining a ratio of total assets (less total liabilities) to total indebtedness, of the Company and its subsidiaries (subject to certain exceptions), of not less than 1.50 to 1.00, (F)Å maintaining a ratio of consolidated EBITDA to consolidated interest expense, of the Company and its subsidiaries (subject to certain exceptions), of not less than 2.25 to 1.00, (G)Å maintaining a minimum liquidity and net worth, and (H)Å limitations on the creation or existence of agreements that prohibit liens on certain properties of the Company and certain of its subsidiaries. The Syndicated Facility also includes usual and customary default provisions such as the failure to make timely payments under the facility, the occurrence of a change in control, and the failure by the Company to materially perform under the agreements governing the facility, which, if not complied with, could accelerate repayment under the facility. As of JuneÅ 30, 2024, the Company was in compliance with all financial covenants under the Syndicated Facility. In addition to the asset coverage ratio described above, borrowings under the Syndicated Facility (and the incurrence of certain other permitted debt) are subject to compliance with a borrowing base that will apply different advance rates to different types of assets in the CompanyÅs portfolio. Each loan or letter of credit originated or assumed under the Syndicated Facility is subject to the satisfaction of certain conditions. As of JuneÅ 30, 2024 and SeptemberÅ 30, 2023, the Company had \$505.0 million and \$430.0Å million of borrowings outstanding under the Syndicated Facility, which had a fair value of \$505.0 million and \$430.0Å million, respectively. The Company's borrowings under the Syndicated Facility bore interest at a weighted average interest rate of 7.576% and 6.584% for the nine months ended JuneÅ 30, 2024 and 2023, respectively. For the three and nine months ended JuneÅ 30, 2024, the Company recorded interest expense (inclusive of fees) of \$10.2 million and \$29.3Å million, respectively, related to the Syndicated Facility. For the three and nine months ended JuneÅ 30, 2023, the Company recorded interest expense (inclusive of fees) of \$14.3Å million and \$37.4Å million, respectively, related to the Syndicated Facility.Citibank Facility On March 19, 2021, the Company became party to a revolving credit facility (as amended and/or restated from time to time, the ÅCitibank FacilityÅ) with OCSL Senior Funding II LLC, the CompanyÅs wholly-owned, special purpose financing subsidiary, as the borrower, the Company, as collateral manager and seller, each of the lenders from time to time party thereto, Citibank, N.A., as administrative agent, and Wells Fargo Bank, National Association, as collateral agent and custodian. On May 25, 2023, in connection with an amendment to the OSI2 Citibank Facility, the Citibank Facility was terminated. As of JuneÅ 30, 2024 and SeptemberÅ 30, 2023, the Company did not have any borrowings outstanding under the Citibank Facility. The Company's borrowings under the Citibank Facility bore interest at a weighted average interest rate of Å 6.762% for the nine months ended JuneÅ 30, 2023.Å For the three and nine months ended JuneÅ 30, 2023, the Company recorded interest expense (inclusive of fees) of Å 2.4Å million and \$8.0Å million, respectively, related to the Citibank Facility. 610AKTREE SPECIALTY LENDING CORPORATIONNOTESÅ TO CONSOLIDATED FINANCIAL STATEMENTS(in thousands, except share and per share amounts, percentages and as otherwise indicated)OSI2 Citibank Facility On January 23, 2023, as a result of the consummation of the OSI2 Merger, the Company became party to a revolving credit facility (as amended and/or restated from time to time, the ÅOSI2 Citibank FacilityÅ) with OSI 2 SPV, the CompanyÅs wholly-owned and consolidated subsidiary, as the borrower, the Company, as collateral manager, each of the lenders from time to time party thereto, Citibank, N.A., as administrative agent, and Deutsche Bank Trust Company Americas, as collateral agent.As of JuneÅ 30, 2024, the Company was able to borrow up to \$400Å million under the OSI2 Citibank Facility (subject to borrowing base and other limitations). As of JuneÅ 30, 2024, the OSI2 Citibank Facility had a reinvestment period through May 25, 2027, during which advances may be made, and matures on January 26, 2029. Following the reinvestment period, OSI 2 SPV will be required to make certain mandatory amortization payments. Borrowings under the OSI2 Citibank Facility bear interest payable quarterly at a rate per year equal to SOFR plus 2.35% per annum. After the reinvestment period, the applicable spread is 3.35% per year. There is also a non-usage fee of 0.50% per year on the unused portion of the OSI2 Citibank Facility, payable quarterly; provided that if the unused portion of the OSI2 Citibank Facility is greater than 30% of the commitments under the OSI2 Citibank Facility, the non-usage fee will be based on an unused portion of 30% of the commitments under the OSI2 Citibank Facility. The OSI2 Citibank Facility is secured by a first priority security interest in substantially all of OSI 2 SPVÅs assets. As part of the OSI2 Citibank Facility, OSI 2 SPV is subject to certain limitations as to how borrowed funds may be used and the types of loans that are eligible to be acquired by OSI 2 SPV including restrictions on sector concentrations, loan size, tenor and minimum investment ratings (or estimated ratings). The OSI2 Citibank Facility also contains certain requirements relating to interest coverage, collateral quality and portfolio performance, certain violations of which could result in the acceleration of the amounts due under the OSI2 Citibank Facility.As of JuneÅ 30, 2024 and SeptemberÅ 30, 2023, the Company had \$285.0 million and \$280.0Å million outstanding under the OSI2 Citibank Facility, which had a fair value of \$285.0 million and \$280.0Å million, respectively. The CompanyÅs borrowings under the OSI2 Citibank Facility bore interest at a weighted average interest rate of 8.029% and 7.275% for the nine months ended JuneÅ 30, 2024 and the period from January 23, 2023 to JuneÅ 30, 2023, respectively. For the three and nine months ended JuneÅ 30, 2024, the Company recorded interest expense (inclusive of fees) of \$6.1Å million and \$18.1Å million, respectively, related to the OSI2 Citibank Facility. For the three months ended JuneÅ 30, 2023 and the period from January 23, 2023 to JuneÅ 30, 2023, the Company recorded interest expense (inclusive of fees) of \$4.9Å million and \$8.0Å million, respectively, related to the OSI2 Citibank Facility.2025 NotesOn February 25, 2020, the Company issued \$300.0Å million in aggregate principal amount of the 2025 Notes for net proceeds of \$293.8 million after deducting OID of \$2.5Å million, underwriting commissions and discounts of \$3.0Å million and offering costs of \$0.7 million. The OID on the 2025 Notes is amortized based on the effective interest method over the term of the 2025 Notes.The 2025 Notes were issued pursuant to an indenture, dated April 30, 2012, as supplemented by the fifth supplemental indenture, dated February 25, 2020 (collectively, the "2025 Notes Indenture"), between the Company and Deutsche Bank Trust Company Americas (the "Trustee"). The 2025 Notes are the Company's general unsecured obligations that rank senior in right of payment to all of the Company's existing and future indebtedness that is expressly subordinated in right of payment to the 2025 Notes. The 2025 Notes rank equally in right of payment with all of the Company's existing and future liabilities that are not so subordinated. The 2025 Notes effectively rank junior to any of the Company's secured indebtedness (including unsecured indebtedness that the Company later secures) to the extent of the value of the assets securing such indebtedness. The 2025 Notes rank structurally junior to all existing and future indebtedness (including trade payables) incurred by the Company's subsidiaries, financing vehicles or similar facilities. Interest on the 2025 Notes is paid semi-annually on February 25 and August 25 at a rate of 3.500% per annum. The 2025 Notes mature on February 25, 2025 and may be redeemed in whole or in part at any time or from time to time at the Company's option prior to maturity at par plus a Åmake-wholeÅ premium, if applicable. In addition, holders of the 2025 Notes can require the Company to repurchase the 2025 Notes at 100% of their principal amount upon the occurrence of certain change of control events as described in the 2025 Notes Indenture. The 2025 Notes were issued in minimum denominations of \$2,000 and integral multiples of \$1,000 in excess thereof. During the three and nine months ended JuneÅ 30, 2024, the Company did not repurchase any of the 2025 Notes in the open market. The 2025 Notes Indenture contains certain covenants, including covenants requiring the Company's compliance with the asset coverage requirements set forth in Section 18(a)(1)(A) as modified by Section 61(a)(1) and (2) of the Investment Company Act or any successor provisions (but giving effect to any exemptive relief granted to the Company by the U.S. Securities and Exchange Commission ("SEC")), as well as covenants requiring the Company to provide financial information to the holders of the 2025 Notes and the Trustee if the Company ceases to be subject to the reporting requirements of the 620AKTREE SPECIALTY LENDING CORPORATIONNOTESÅ TO CONSOLIDATED FINANCIAL STATEMENTS(in thousands, except share and per share amounts, percentages and as otherwise indicated)Securities Exchange Act of 1934, as amended (the "Exchange Act"). These covenants are subject to limitations and exceptions that are described in the 2025 Notes Indenture. 2027 NotesOn May 18, 2021, the Company issued \$350.0Å million in aggregate principal amount of the 2027 Notes for net proceeds of \$344.8Å million after deducting OID of \$1.0Å million, underwriting commissions and discounts of \$3.5Å million and offering costs of \$0.7Å million. The OID on the 2027 Notes is amortized based on the effective interest method over the term of the 2027 Notes.The 2027 Notes were issued pursuant to an indenture, dated April 30, 2012, as supplemented by the sixth supplemental indenture, dated May 18, 2021 (collectively, the "2027 Notes Indenture"), between the Company and the Trustee. The 2027 Notes are the Company's general unsecured obligations that rank senior in right of payment to all of the Company's existing and future indebtedness that is expressly subordinated in right of payment to the 2027 Notes. The 2027 Notes rank equally in right of payment with all of the Company's existing and future liabilities that are not so subordinated. The 2027 Notes effectively rank junior to any of the Company's secured indebtedness (including unsecured indebtedness that the Company later secures) to the extent of the value of the assets securing such indebtedness. The 2027 Notes rank structurally junior to all existing and future indebtedness (including trade payables) incurred by the Company's subsidiaries, financing vehicles or similar facilities. Interest on the 2027 Notes is paid semi-annually on January 15 and July 15 at a rate of 2.700% per annum. The 2027 Notes mature on January 15, 2027 and may be redeemed in whole or in part at any time or from time to time at the Company's option prior to maturity at par plus a Åmake-wholeÅ premium, if applicable. In addition, holders of the 2027 Notes can require the Company to repurchase the 2027 Notes at 100% of their principal amount upon the occurrence of certain change of control events as described in the 2027 Notes Indenture. The 2027 Notes were issued in minimum denominations of \$2,000 and integral multiples of \$1,000 in excess thereof. During the three and nine months ended JuneÅ 30, 2024, the Company did not repurchase any of the 2027 Notes in the open market. The 2027 Notes Indenture contains certain covenants, including covenants requiring the Company's compliance with the asset coverage requirements set forth in Section 18(a)(1)(A) as modified by Section 61(a)(1) and (2) of the Investment Company Act or any successor provisions (but giving effect to any exemptive relief granted to the Company by the SEC), as well as covenants requiring the Company to provide financial information to the holders of the 2027 Notes and the Trustee if the Company ceases to be subject to the reporting requirements of the Exchange Act. These covenants are subject to limitations and exceptions that are described in the 2027 Notes Indenture. In connection with the 2027 Notes, the Company entered into an interest rate swap to more closely align the interest rates of its liabilities with its investment portfolio, which consists of predominately floating rate loans. Under the interest rate swap agreement, the Company receives a fixed interest rate of 2.700% and pays a floating interest rate of the three-month SOFR plus 1.658% plus a SOFR adjustment of 0.26161% on a notional amount of \$350.0Å million. The Company designated the interest rate swap as the hedging instrument in an effective hedge accounting relationship. See Note 12 for more information regarding the interest rate swap. 2029 Notes On August 15, 2023, the Company issued \$300.0Å million in aggregate principal amount of the 2029 Notes for net proceeds of \$292.9Å million after deducting OID of \$3.5Å million, underwriting commissions and discounts of \$3.0Å million and offering costs of \$0.6Å million. The OID on the 2029 Notes is amortized based on the effective interest method over the term of the 2029 Notes.The 2029 Notes were issued pursuant to an indenture, dated April 30, 2012, as supplemented by the seventh supplemental indenture, dated August 15, 2023 (collectively, the "2029 Notes Indenture"), between the Company and the Trustee. The 2029 Notes are the Company's general unsecured obligations that rank senior in right of payment to all of the Company's existing and future indebtedness that is expressly subordinated in right of payment to the 2029 Notes. The 2029 Notes rank equally in right of payment with all of the Company's existing and future liabilities that are not so subordinated. The 2029 Notes effectively rank junior to any of the Company's secured indebtedness (including unsecured indebtedness that the Company later secures) to the extent of the value of the assets securing such indebtedness. The 2029 Notes rank structurally junior to all existing and future indebtedness (including trade payables) incurred by the Company's subsidiaries, financing vehicles or similar facilities. Interest on the 2029 Notes is paid semi-annually on February 15 and August 15 at a rate of 7.100% per annum. The 2029 Notes mature on February 15, 2029 and may be redeemed in whole or in part at any time or from time to time at the Company's option prior to maturity at par plus a Åmake-wholeÅ premium, if applicable. In addition, holders of the 2029 Notes can require 630AKTREE SPECIALTY LENDING CORPORATIONNOTESÅ TO CONSOLIDATED FINANCIAL STATEMENTS(in thousands, except share and per share amounts, percentages and as otherwise indicated)the Company to repurchase the 2029 Notes at 100% of their principal amount upon the occurrence of certain change of control events as described in the 2029 Notes Indenture. The 2029 Notes were issued in minimum denominations of \$2,000 and integral multiples of \$1,000 in excess thereof. During the three and nine months ended JuneÅ 30, 2024, the Company did not repurchase any of the 2029 Notes in the open market. The 2029 Notes Indenture contains certain covenants, including covenants requiring the Company's compliance with the asset coverage requirements set forth in Section 18(a)(1)(A) as modified by Section 61(a)(1) and (2) of the Investment Company Act or any successor provisions (but giving effect to any exemptive relief granted to the Company by the SEC), as well as covenants requiring the Company to provide financial information to the holders of the 2029 Notes and the Trustee if the Company ceases to be subject to the reporting requirements of the Exchange Act. These covenants are subject to limitations and exceptions that are described in the 2029 Notes Indenture.In connection with the 2029 Notes, the Company

entered into an interest rate swap to more closely align the interest rates of its liabilities with its investment portfolio, which consists of predominately floating rate loans. Under the interest rate swap agreement, the Company receives a fixed interest rate of 7.100% and pays a floating interest rate of the three-month SOFR plus 3.1255% on a notional amount of \$300.0Å million. The Company designated the interest rate swap as the hedging instrument in an effective hedge accounting relationship. See Note 12 for more information regarding the interest rate swap. The below table presents the components of the carrying value of the 2025 Notes, the 2027 Notes and the 2029 Notes as of JuneÅ 30, 2024 and SeptemberÅ 30, 2023:Å As of June 30, 2024As of September 30, 2023(\$ in millions)2025 Notes2027 Notes2029 Notes2027 Notes2029 NotesPrincipal\$300.0Å \$350.0Å \$300.0Å \$300.0Å \$350.0Å \$300.0Å A Unamortized financing costs(0.5)(1.9)(3.0)(1.1)(2.5)(3.5)Å A Unaccrued discount(0.3)(0.5)(2.9)(0.7)(0.6)(3.4)Å A Interest rate swap fair value adjustmentÅ (30.7)(3.0)Å (40.5)(7.0)Net carrying values\$299.2Å \$316.9Å \$291.1Å \$298.2Å \$306.4Å \$286.1Å Fair Values\$294.9Å \$317.7Å \$303.6Å \$286.4Å \$301.8Å \$290.0Å The below table presents the components of interest and other debt expenses related to the 2025 Notes, the 2027 Notes and the 2029 Notes for the three and nine months ended JuneÅ 30, 2024:(\$ in millions)2025 Notes2027 Notes2029 NotesThree months ended June 30, 2024Nine months ended June 30, 2024Three months ended June 30, 2024Nine months ended June 30, 2024Three months ended June 30, 2024Nine months ended June 30, 2024Coupon interest\$2.6Å \$7.9Å \$2.4Å \$7.1Å \$5.3Å \$16.0Å Amortization of financing costs and discount0.3Å 0.9Å 0.2Å 0.7Å 0.3Å 1.0Å Effect of interest rate swap Å (3.0)Å (4.0)Å 12.3Å 1.1Å 3.4Å Å Total interest expense\$2.9Å \$8.8Å \$6.6Å \$20.1Å \$6.7Å \$20.4Å Coupon interest rate (net of effect of interest rate swaps)3.500Å %3.500Å %7.213Å %7.262Å %8.440Å %8.469Å %64OAKTREE SPECIALTY LENDING CORPORATIONNOTESÅ TO CONSOLIDATED FINANCIAL STATEMENTS(in thousands, except share and per share amounts, percentages and as otherwise indicated)The below table presents the components of interest and other debt expenses related to the 2025 Notes and the 2027 Notes for the three and nine months ended JuneÅ 30, 2023:(\$ in millions)2025 Notes2027 NotesThree months ended June 30, 2023Nine months ended June 30, 2023Three months ended June 30, 2023Nine months ended June 30, 2023Total interest expense\$2.9Å \$8.8Å \$6.3Å \$17.2Å Coupon interest rate (net of effect of interest rate swap for 2027 Notes)3.500Å %3.500Å %6.912Å %6.274Å %Å NoteÅ 7. Taxable/Distributable Income and Dividend DistributionsTaxable income differs from net increase (decrease)Å in net assets resulting from operations primarily due to: (1)Å unrealized appreciation (depreciation)Å on investments and foreign currency, as gains and losses are not included in taxable income until they are realized; (2)Å origination and exit fees received in connection with investments in portfolio companies; (3)Å organizational costs; (4)Å income or loss recognition on exited investments; and (5) recognition of interest income on certain loans. As of SeptemberÅ 30, 2023, the Company had net capital loss carryforwards of \$558.3Å million to offset net capital gains that will not expire, to the extent available and permitted by U.S. federal income tax law, of which \$70.3Å million are available to offset future short-term capital gains and \$488.0Å million are available to offset future long-term capital gains. A portion of such net capital loss carryforwards represented a realized loss under sections 382 and 383 of the Code, which is carried forward to future years to offset future gains subject to certain limitations.Listed below is a reconciliation of "net increase (decrease) in net assets resulting from operations" to taxable income for the three and nine months ended JuneÅ 30, 2024 and 2023.Three months endedJune 30, 2024Three months endedJune 30, 2023Nine months endedJune 30, 2024Nine months endedJune 30, 2023Net increase (decrease) in net assets resulting from operations\$1,120Å \$36,685Å \$20,992Å \$71,379Å Net unrealized (appreciation) depreciation(26,199)1,039Å 24,078Å 42,300Å Book/tax difference due to capital losses suspended (utilized)70,156Å 12,118Å 87,016Å 20,380Å Other book/tax differences(2,349)(3,825)(13,298)(14,912)Taxable/Distributable Income (1)\$42,728Å \$46,017Å \$118,788Å \$119,147Å Å _____(1) The Company's taxable income for the three and nine months ended JuneÅ 30, 2024 is an estimate and will not be finally determined until the Company files its tax return for the fiscal year ending September 30, 2024. Therefore, the final taxable income may be different than the estimate.The Company uses the liability method to account for its taxable subsidiaries' income taxes. Using this method, the Company recognizes deferred tax assets and liabilities for the estimated future tax effects attributable to temporary differences between financial reporting and tax bases of assets and liabilities. In addition, the Company recognizes deferred tax benefits associated with net loss carry forwards that it may use to offset future tax obligations. The Company measures deferred tax assets and liabilities using the enacted tax rates expected to apply to taxable income in the years in which it expects to recover or settle those temporary differences. When assessing the realizability of deferred tax assets, the Company considers whether it is probable that some or all of the deferred tax assets will not be realized. In determining whether the deferred tax assets are realizable, the Company considers the period of expiration of the tax asset, historical and projected taxable income and tax liabilities for the tax jurisdiction in which the tax asset is located. The deferred tax asset recognized by the Company, as it relates to the higher tax basis in the carrying value of certain assets compared to the book basis of those assets, will be recognized in future years by these taxable entities. Deferred tax assets are based on the amount of the tax benefit that the CompanyÅ  management has determined is more likely than not to be realized in future periods. In determining the realizability of this tax benefit, management considered numerous factors that will give rise to pre-tax income in future periods. Among these are the historical and expected future 65OAKTREE SPECIALTY LENDING CORPORATIONNOTESÅ TO CONSOLIDATED FINANCIAL STATEMENTS(in thousands, except share and per share amounts, percentages and as otherwise indicated)book and tax basis pre-tax income of the Company and unrealized gains in the CompanyÅ  s assets at the determination date. Based on these and other factors, the Company determined that, as ofÅ JuneÅ 30, 2024, \$8.7Å million of the \$8.7Å million deferred tax assets would not more likely than not be realized in future periods. For the three months ended JuneÅ 30, 2024, the Company recognized a total expense for income tax related to realized and unrealized gains (losses) of \$0.2Å million, which was composed primarily of a current income tax expense. For the three months ended JuneÅ 30, 2023, the Company recognized a total expense for income tax related to realized and unrealized gains (losses) of \$0.1Å million, which was composed of (i) a current income tax expense of approximately \$1.0Å million and (ii) a deferred income tax benefit of approximately \$0.9Å million, which resulted from unrealized depreciation on investments held by the CompanyÅ  s wholly-owned taxable subsidiaries.For the nine months ended JuneÅ 30, 2024, the Company recognized a total expense for income tax related to realized and unrealized gains (losses) of \$0.6Å million, which was composed primarily of a current income tax expense. For the nine months ended JuneÅ 30, 2023, the Company recognized a total benefit for income tax related to realized and unrealized gains (losses) of \$0.4Å million, which was composed of (i) a current income tax expense of approximately \$0.6Å million and (ii) a deferred income tax benefit of approximately \$1.0Å million, which resulted from unrealized depreciation on investments held by the CompanyÅ  s wholly-owned taxable subsidiaries. As of SeptemberÅ 30, 2023, the Company's last tax year end, the components of accumulated overdistributed earnings on a tax basis were as follows: Undistributed ordinary income, net\$33,525Å Net realized capital losses(509,832)Unrealized losses, net(175,031)Accumulated overdistributed earnings\$(651,338)The aggregate cost of investments for U.S. federal income tax purposes was \$3,070.0Å million as of SeptemberÅ 30, 2023. As of SeptemberÅ 30, 2023, the aggregate gross unrealized appreciation for all investments in which there was an excess of value over cost for U.S. federal income tax purposes was \$529.5Å million. As of SeptemberÅ 30, 2023, the aggregate gross unrealized depreciation for all investments in which there was an excess of cost for U.S. federal income tax purposes over value was \$704.5Å million. Net unrealized depreciation based on the aggregate cost of investments for U.S. federal income tax purposes was \$175.0Å million.66OAKTREE SPECIALTY LENDING CORPORATIONNOTESÅ TO CONSOLIDATED FINANCIAL STATEMENTS(in thousands, except share and per share amounts, percentages and as otherwise indicated)NoteÅ 8. Realized Gains or Losses and Net Unrealized Appreciation or Depreciation Realized Gains or LossesRealized gains or losses are measured by the difference between the net proceeds from the sale or redemption and the cost basis of the investment without regard to unrealized appreciation or depreciation previously recognized, and include investments written-off during the period, net of recoveries. Realized losses may also be recorded in connection with the Company's determination that certain investments are considered worthless securities and/or meet the conditions for loss recognition per the applicable tax rules.During the three months ended JuneÅ 30, 2024, the Company recorded an aggregate net realized loss of \$69.5 million, which consisted of the following:(\$ in millions)Portfolio CompanyNet Realized Gain (Loss)Thrasio, LLC\$(68.5)Other, net(1.0)Total, net\$(69.5)During the three months ended JuneÅ 30, 2023, the Company recorded an aggregate net realized loss of \$10.6Å million, which consisted of the following:(\$ in millions)Portfolio CompanyNet Realized Gain (Loss)Foreign currency forward contracts\$(6.3)Aden & Anais Merger Sub Inc.(5.2)Radiology Partners Inc.(3.8)WP CPP Holdings LLC(1.3)Tersera Therapeutics LLC5.2Å Other, net 0.8Å Total, net\$(10.6)67OAKTREE SPECIALTY LENDING CORPORATIONNOTESÅ TO CONSOLIDATED FINANCIAL STATEMENTS(in thousands, except share and per share amounts, percentages and as otherwise indicated)During the nine months ended JuneÅ 30, 2024, the Company recorded an aggregate net realized loss of \$84.5 million, which consisted of the following:(\$ in millions)Portfolio CompanyNet Realized Gain (Loss)Thrasio, LLC\$(68.5)All Web Leads Inc(13.4)Continental Intermodal Group LP(6.8)PK&L Development LLC(1.9)American Tire Distributors Inc. (1.8)Zephyr Bidco Limited (1)(1.7)Lift Brands Holdings, Inc.(1.4)Alvotech 4.8Å Ardonagh Midco 3 PLC (14.6Å Foreign currency forward contracts2.6Å Other, net(1.0)Total, net\$(84.5) _____(1) This investment was denominated in foreign currency and the realized gain (loss) shown in this table includes gains (losses) due to foreign currency translation, which was offset by gains (losses) on foreign currency forward contracts.During the nine months ended JuneÅ 30, 2023, the Company recorded an aggregate net realized loss of \$19.9Å million, which consisted of the following:(\$ in millions)Portfolio CompanyNet Realized Gain (Loss)Foreign currency forward contracts\$(5.5)Aden & Anais Merger Sub Inc.(5.2)Radiology Partners Inc. (4.2)Carvana Co. (2.8)ASP Unifrax Holdings Inc.(2.1)WP CPP Holdings LLC(1.3)Global Medical Response Inc.(1.0)Tersera Therapeutics LLC5.2Å Other, net(3.0)Total, net\$(19.9)Net Unrealized Appreciation or Depreciation Net unrealized appreciation or depreciation reflects the net change in the valuation of the portfolio pursuant to the Company's valuation guidelines and the reclassification of any prior period unrealized appreciation or depreciation.During the three months ended JuneÅ 30, 2024 and 2023, the Company recorded net unrealized appreciation (depreciation) of \$26.2 million and \$(1.0)Å million, respectively. For the three months ended JuneÅ 30, 2024, this consisted of \$83.6 million of net unrealized appreciation related to exited investments (a portion of which resulted in a reclassification to realized losses) and \$1.1 million of net unrealized appreciation of foreign currency forward contracts, partially offset by \$38.6 million of net unrealized depreciation on debt investments and \$19.9 million of net unrealized depreciation on equity investments. For the three months ended JuneÅ 30, 2023, this consisted of \$9.8Å million of net unrealized depreciation on debt investments and \$0.8Å million of net unrealized depreciation on equity investments, partially offset by \$5.0Å million of net unrealized appreciation related to exited investments (a portion of which resulted in a reclassification to realized losses) and \$4.6Å million of net unrealized appreciation of foreign currency forward contracts.68OAKTREE SPECIALTY LENDING CORPORATIONNOTESÅ TO CONSOLIDATED FINANCIAL STATEMENTS(in thousands, except share and per share amounts, percentages and as otherwise indicated)During the nine months ended JuneÅ 30, 2024 and 2023, the Company recorded net unrealized depreciation of \$24.1 million and \$42.3Å million, respectively. For the nine months ended JuneÅ 30, 2024, this consisted of \$49.6 million of net unrealized depreciation on debt investments, \$30.5 million of net unrealized depreciation on equity investments and \$4.5 million of net unrealized depreciation of foreign currency forward contracts, partially offset by \$60.5 million of net unrealized appreciation related to exited investments (a portion of which resulted in a reclassification to realized losses). For the nine months ended JuneÅ 30, 2023, this consisted of \$54.3Å million of net unrealized depreciation on debt investments and \$4.8Å million of net unrealized depreciation of foreign currency forward contracts, partially offset by \$11.8Å million of net unrealized appreciation related to exited investments (a portion of which resulted in a reclassification to realized losses) and \$5.1Å million of net unrealized appreciation on equity investments.NoteÅ 9. Concentration of Credit Risks The Company deposits its cash with financial institutions and at times such balances are in excess of the FDIC insurance limit. The Company limits its exposure to credit loss by depositing its cash with high credit quality financial institutions and monitoring their financial stability.NoteÅ 10. Related Party TransactionsAs of JuneÅ 30, 2024 and SeptemberÅ 30, 2023, the Company had a liability on its Consolidated Statements of Assets and Liabilities in the amount of \$15.4 million and \$19.5Å million, respectively, reflecting the unpaid portion of the base management fees and incentive fees payable to Oaktree. Investment Advisory AgreementThe Company is party to the Investment Advisory Agreement. Under the Investment Advisory Agreement, the Company pays Oaktree a fee for its services under the Investment Advisory Agreement consisting of two components: a base management fee and an incentive fee. The cost of both the base management fee payable to Oaktree and any incentive fees earned by Oaktree is ultimately borne by common stockholders of the Company.The investment advisory agreement with Oaktree was amended and restated on March 19, 2021 in connection with the closing of the OCSI Merger and on January 23, 2023 in connection with the closing of OSI2 Merger. The term Å Investment Advisory AgreementÅ  refers collectively to the agreements with Oaktree. Unless earlier terminated as described below, the Investment Advisory Agreement will remain in effect from year-to-year if approved annually by the Board of Directors of the Company or by the affirmative vote of the holders of a majority of the CompanyÅ  s outstanding voting securities, including, in either case, approval by a majority of the directors of the Company who are not interested persons. The Investment Advisory Agreement will automatically terminate in the event of its assignment. The Investment Advisory Agreement may be terminated by either party without penalty upon 60 daysÅ  written notice to the other. The Investment Advisory Agreement may also be terminated, without penalty, upon the vote of a majority of the outstanding voting securities of the Company.Base Management FeeUnder the Investment Advisory Agreement, the base management fee is calculated at an annual rate of 1.50% of total gross assets, including any investment made with borrowings, but excluding cash and cash equivalents. The base management fee is payable quarterly in arrears and the fee for any partial month or quarter is appropriately prorated. Effective May 3, 2019 and through JuneÅ 30, 2024, the base management fee on the CompanyÅ  s gross assets, including any investments made with borrowings, but excluding any cash and cash equivalents, that exceed the product of (A) 200% and (B) the CompanyÅ  s net asset value will be 1.00%.Å For the avoidance of doubt, the 200% will be calculated in accordance with the Investment Company Act and will give effect to exemptive relief the Company received from the SEC with respect to debentures issued by a small business investment company subsidiary. In connection with the OCSI Merger, Oaktree waived an aggregate of \$6Å million of base management fees otherwise payable to Oaktree in the two years following the closing of the OCSI Merger on March 19, 2021 at a rate of \$750,000 per quarter (with such amount appropriately prorated for any partial quarter). In connection with the OSI2 Merger, Oaktree waived an aggregate of \$9.0Å million of base management fees payable to Oaktree as follows: \$6.0Å million at a rate of \$1.5Å million per quarter (with such amount appropriately prorated for any partial quarter) in the first year following closing of the OSI2 Merger on January 23, 2023 and \$3.0Å million at a rate of \$750,000 per quarter (with such amount appropriately prorated for any partial quarter) in the second year following closing of the OSI2 Merger. On April 26, 2024, Oaktree waived additional base management fees such that the total amount of waived base management fees (including those waived in connection with the OSI2 Merger described above) was \$1.5Å million for each of 69OAKTREE SPECIALTY LENDING CORPORATIONNOTESÅ TO CONSOLIDATED FINANCIAL STATEMENTS(in thousands, except share and per share amounts, percentages and as otherwise indicated)the three months ended March 31, 2024 and June 30, 2024. In addition, effective July 1, 2024, the base management fee is calculated (net of base management fees previously waived by Oaktree) at an annual rate of 1.00% of total gross assets, including any investments made with borrowings, but excluding cash and cash equivalents.For the three and nine months ended JuneÅ 30, 2024, the base management fee incurred under the Investment Advisory Agreement was \$10.3Å million (net of waiver) and \$30.4 million (net of waiver), respectively. For the three and nine months ended JuneÅ 30, 2023, the base management fee incurred under the Investment Advisory Agreement was \$10.5Å million (net of waiver) and \$29.4Å million (net of waiver), respectively.Incentive FeeThe incentive fee consists of two parts. Under the Investment Advisory Agreement, the first part of the incentive fee (the Å incentive fee on incomeÅ  or "Part I incentive fee") is calculated and payable quarterly in arrears based upon the Å pre-incentive fee net investment incomeÅ  of the Company for the immediately preceding quarter. The payment of the incentive fee on income is subject to payment of a preferred return to investors each quarter (i.e., a Å hurdle rateÅ ), expressed as a rate of return on the value of the CompanyÅ  s net assets at the end of the most recently completed quarter, of 1.50%, subject to a Å catch upÅ  feature.For this purpose, Å pre-incentive fee net investment incomeÅ  means interest income, dividend income and any other income (including any other fees such as commitment, origination, structuring, diligence and consulting fees or other fees that the Company receives from portfolio companies, other than fees for providing managerial assistance) accrued during the fiscal quarter, minus the CompanyÅ  s operating expenses for the quarter (including the base management fee, expenses payable under the Administration Agreement and any interest expense and dividends paid on any issued and outstanding preferred stock, but excluding the incentive fee). Pre-incentive fee net investment income includes, in the case of investments with a deferred interest feature (such as OID debt, instruments with PIK interest and zero coupon securities), accrued income that the Company has not yet received in cash. Pre-incentive fee net investment income does not include any realized capital gains, realized capital losses or unrealized capital appreciation or depreciation. In addition, pre-incentive fee net investment income does not include any amortization or accretion of any purchase premium or purchase discount to interest income resulting solely from merger-related accounting adjustments in connection with the assets acquired in the OCSI Merger or in the OSI2 Merger, in each case, including any premium or discount paid for the acquisition of such assets, solely to the extent that the inclusion of such merger-related accounting adjustments, in the aggregate, would result in

an increase in pre-incentive fee net investment income. Under the Investment Advisory Agreement, the calculation of the incentive fee on income for each quarter is as follows: No incentive fee is payable to Oaktree in any quarter in which the Company's pre-incentive fee net investment income does not exceed the preferred return rate of 1.50% (the "preferred return") on net assets; 100% of the Company's pre-incentive fee net investment income, if any, that exceeds the preferred return but is less than or equal to 1.8182% in any fiscal quarter is payable to Oaktree. This portion of the incentive fee on income is referred to as the "catch-up" provision, and it is intended to provide Oaktree with an incentive fee of 17.5% on all of the Company's pre-incentive fee net investment income when the Company's pre-incentive fee net investment income exceeds 1.8182% on net assets in any fiscal quarter; and the Company in any quarter in which the Company's pre-incentive fee net investment income exceeds 1.8182% on net assets, the incentive fee on income is equal to 17.5% of the amount of the Company's pre-incentive fee net investment income, as the preferred return and catch-up will have been achieved. There is no accumulation of amounts on the hurdle rate from quarter to quarter and accordingly there is no clawback of amounts previously paid if subsequent quarters are below the quarterly hurdle. For the three months ended June 30, 2024, Oaktree waived \$3.2A million of Part I incentive fees. For the three and nine months ended June 30, 2024, the first part of the incentive fee (incentive fee on income) incurred under the Investment Advisory Agreement was \$5.1A million (net of waiver) and \$22.6A million (net of waiver), respectively. For the three and nine months ended June 30, 2023, the first part of the incentive fee (incentive fee on income) incurred under the Investment Advisory Agreement was \$9.6A million and \$26.3A million, respectively. Under the Investment Advisory Agreement, the second part of the incentive fee (the "capital gains incentive fee") is determined and payable in arrears as of the end of each fiscal year (or upon termination of the Investment Advisory Agreement, as of the termination date) commencing with the fiscal year ended September 30, 2019 and equals 17.5% of the Company's realized capital gains, if any, on a cumulative basis from the beginning of the fiscal year ended September 30, 2019 through the end of each subsequent fiscal year, computed net of all realized capital losses and unrealized capital depreciation on a 700AKTREE SPECIALTY LENDING CORPORATION NOTES A TO CONSOLIDATED FINANCIAL STATEMENTS (in thousands, except share and per share amounts, percentages and as otherwise indicated) cumulative basis, less the aggregate amount of any previously paid capital gain incentive fees under the Investment Advisory Agreement. Any realized capital gains, realized capital losses, unrealized capital appreciation and unrealized capital depreciation with respect to the Company's portfolio as of the end of the fiscal year ended September 30, 2018 are excluded from the calculations of the second part of the incentive fee. In addition, the calculation of realized capital gains, realized capital losses and unrealized capital depreciation does (1) not include any such amounts resulting solely from merger-related accounting adjustments in connection with the assets acquired in the OCSI Merger or in the OS12 Merger, in each case, including any premium or discount paid for the acquisition of such assets, solely to the extent that the inclusion of such merger-related accounting adjustments, in the aggregate, would result in an increase in the capital gains incentive fee, (2) include any such amounts associated with the investments acquired in the OCSI Merger for the period from October 1, 2018 to the date of closing of the OCSI Merger, solely to the extent that the exclusion of such amounts, in the aggregate, would result in an increase in the capital gains incentive fee and (3) include any such amounts associated with the investments acquired in the OS12 Merger for the period from August 6, 2018 to the date of closing of the OS12 Merger, solely to the extent that the exclusion of such amounts, in the aggregate, would result in an increase in the capital gains incentive fee. As of June 30, 2024, the Company paid \$9.6A million of capital gains incentive fees cumulatively under the Investment Advisory Agreement (net of waivers). Part II incentive fees are contractually calculated and paid at the end of the fiscal year in accordance with the Investment Advisory Agreement, which, as described above, differs from Part II incentive fees accrued under GAAP. Hypothetically, if Part II incentive fees were calculated as of June 30, 2024 under the Investment Advisory Agreement, no Part II incentive fees would be payable. GAAP requires that the capital gains incentive fee accrual consider the cumulative aggregate unrealized capital appreciation in the calculation, as a capital gains incentive fee would be payable if such unrealized capital appreciation were realized on a theoretical "liquidation basis." A fee so calculated and accrued would not be payable under applicable law and may never be paid based upon the computation of capital gains incentive fees in subsequent periods. Amounts ultimately paid under the Investment Advisory Agreement will be consistent with the formula reflected in the Investment Advisory Agreement. This GAAP accrual is calculated using the aggregate cumulative realized capital gains and losses and aggregate cumulative unrealized capital depreciation included in the calculation of the capital gains incentive fee plus the aggregate cumulative unrealized capital appreciation. Any realized capital gains and losses and cumulative unrealized capital appreciation and depreciation with respect to the Company's portfolio as of the end of the fiscal year ended September 30, 2018 are excluded from the GAAP accrual. If such amount is positive at the end of a period, then GAAP requires the Company to record a capital gains incentive fee equal to 17.5% of such cumulative amount, less the aggregate amount of actual capital gains incentive fees payable or capital gains incentive fees accrued under GAAP in all prior periods. The resulting accrual for any capital gains incentive fee under GAAP in a given period may result in an additional expense if such cumulative amount is greater than in the prior period or a reversal of previously recorded expense if such cumulative amount is less than in the prior period. If such cumulative amount is negative, then there is no accrual. There can be no assurance that such unrealized capital appreciation will be realized in the future or any accrued capital gains incentive fee will become payable under the Investment Advisory Agreement. For the three and nine months ended June 30, 2024 and 2023, there were no accrued capital gains incentive fees. As of June 30, 2024, the total accrued capital gains incentive fee liability was zero. Indemnification The Investment Advisory Agreement provides that, absent willful misfeasance, bad faith or gross negligence in the performance of their respective duties or by reason of the reckless disregard of their respective duties and obligations, Oaktree and its officers, managers, partners, members (and their members, including the owners of their members), agents, employees, controlling persons and any other person or entity affiliated with it, are entitled to indemnification from the Company for any damages, liabilities, costs and expenses (including reasonable attorneys' fees and amounts reasonably paid in settlement) arising from the rendering of Oaktree's services under the Investment Advisory Agreement or otherwise as investment adviser. Administrative Services The Company is party to the Administration Agreement with Oaktree Administrator. Pursuant to the Administration Agreement, Oaktree Administrator provides administrative services to the Company necessary for the operations of the Company, which include providing office facilities, equipment, clerical, bookkeeping and record keeping services at such facilities and such other services as Oaktree Administrator, subject to review by the Company's Board of Directors, shall from time to time deem to be necessary or useful to perform its obligations under the Administration Agreement. Oaktree Administrator may, on behalf of the Company, conduct relations and negotiate agreements with custodians, trustees, depositories, attorneys, underwriters, brokers and dealers, corporate fiduciaries, insurers, banks and such other persons in any such other capacity deemed to be necessary or desirable. Oaktree Administrator makes reports to the Company's Board of Directors of its performance of obligations under the Administration Agreement and furnishes advice and recommendations with respect to such other aspects of the Company's business and affairs, in each case, as it shall determine to be desirable or as 710AKTREE SPECIALTY LENDING CORPORATION NOTES A TO CONSOLIDATED FINANCIAL STATEMENTS (in thousands, except share and per share amounts, percentages and as otherwise indicated) reasonably required by the Company's Board of Directors; provided that Oaktree Administrator shall not provide any investment advice or recommendation. Oaktree Administrator also provides portfolio collection functions for interest income, fees and warrants and is responsible for the financial and other records that the Company is required to maintain and prepares, prints and disseminates reports to the Company's stockholders and all other materials filed with the SEC. In addition, Oaktree Administrator assists the Company in determining and publishing the Company's net asset value, overseeing the preparation and filing of the Company's tax returns, and generally overseeing the payment of the Company's expenses and the performance of administrative and professional services rendered to the Company by others. Oaktree Administrator may also offer to provide, on the Company's behalf, managerial assistance to the Company's portfolio companies. For providing these services, facilities and personnel, the Company reimburses Oaktree Administrator the allocable portion of overhead and other expenses incurred by Oaktree Administrator in performing its obligations under the Administration Agreement, including the Company's allocable portion of the rent of the Company's principal executive offices (which are located in a building owned by a Brookfield affiliate) at market rates and the Company's allocable portion of the costs of compensation and related expenses of its Chief Financial Officer, Chief Compliance Officer, their staffs and other non-investment professionals at Oaktree that perform duties for the Company. Such reimbursement is at cost, with no profit to, or markup by, Oaktree Administrator. The Administration Agreement may be terminated by either party without penalty upon 60 days' written notice to the other. The Administration Agreement may also be terminated, without penalty, upon the vote of a majority of the Company's outstanding voting securities. For the three months ended June 30, 2024 and 2023, the Company accrued administrative expenses of \$0.5 million and \$0.4A million, respectively, including \$0.1A million and \$0.1A million of general and administrative expenses, respectively. For the nine months ended June 30, 2024 and 2023, the Company accrued administrative expenses of \$1.3 million and \$1.2A million, respectively, including \$0.3 million and \$0.2A million of general and administrative expenses, respectively. As of June 30, 2024 and September 30, 2023, \$4.8 million and \$4.3A million, respectively, was included in due to affiliate in the Consolidated Statements of Assets and Liabilities, reflecting the unpaid portion of administrative expenses and other reimbursable expenses payable to Oaktree Administrator. 720AKTREE SPECIALTY LENDING CORPORATION NOTES A TO CONSOLIDATED FINANCIAL STATEMENTS (in thousands, except share and per share amounts, percentages and as otherwise indicated) Note 11. Financial Highlights (Share amounts in thousands) Three months ended June 30, 2024 Three months ended June 30, 2023 Nine months ended June 30, 2024 Nine months ended June 30, 2023 (6) Net asset value per share at beginning of period \$1.72 \$1.66 \$1.63 \$2.38 Net investment income (1) \$0.54 \$0.63 \$1.63 \$1.89 Net unrealized appreciation (depreciation) (1) \$0.33 \$0.02 \$0.28 \$0.36 Net realized gains (losses) (1) \$0.85 \$0.14 \$1.06 \$0.28 (Provision) benefit for taxes on realized and unrealized gains (losses) (1) \$0.46 \$0.01 \$0.01 \$0.01 Distributions of net investment income to stockholders (0.55) \$0.55 (1.72) \$2.06 Net asset value per share at end of period \$1.81 \$1.89 \$1.58 \$1.19 Per share market value at beginning of period \$19.66 \$17.77 \$20.12 \$18.00 Per share market value at end of period \$18.11 \$19.43 \$18.11 \$19.43 Total return (2) (1.51)% 6.42% 2.13% 15.98% Common shares outstanding at beginning of period 81,396,777,225 61,125,000 Common shares outstanding at end of period 82,245,777,080 82,245,777,080 Net assets at beginning of period \$1,524,099 \$1,515,150 \$1,515,764 \$1,245,563 Net assets at end of period \$1,496,133 \$1,509,441 \$1,496,133 \$1,509,441 Average net assets (3) \$1,524,503 \$1,526,644 \$1,524,180 \$1,407,814 Ratio of net investment income to average net assets (7) 11.76% 12.72% 11.40% 12.65% Ratio of total expenses to average net assets (7) 14.54% 14.45% 14.42% 14.07% Ratio of net expenses to average net assets (7) 13.29% 14.05% 13.75% 13.69% Ratio of portfolio turnover to average investments at fair values 5.95% 7.48% 23.97% 18.43% Weighted average outstanding debt (4) \$1,711,978 \$1,756,758 \$1,680,876 \$1,640,062 Average debt per share (1) \$20.92 \$22.79 \$21.06 \$23.29 Asset coverage ratio at end of period (5) 183.36% 182.05% 183.36% 182.05% (1) Calculated based upon weighted average shares outstanding for the period. (2) Total return equals the increase or decrease of ending market value over beginning market value, plus distributions, divided by the beginning market value, assuming dividend reinvestment prices obtained under the Company's DRIP. Total return does not include sales load. (3) Calculated based upon the weighted average net assets for the period. (4) Calculated based upon the weighted average of principal debt outstanding for the period. (5) Based on outstanding senior securities of \$1,743.4A million and \$1,785.0A million as of June 30, 2024 and 2023, respectively. (6) The share and per share information disclosed in this table has been retroactively adjusted as necessary to reflect the Company's 1-for-3 reverse stock split completed on January 20, 2023 and effective as of the commencement of trading on January 23, 2023. (7) Interim periods are annualized. 730AKTREE SPECIALTY LENDING CORPORATION NOTES A TO CONSOLIDATED FINANCIAL STATEMENTS (in thousands, except share and per share amounts, percentages and as otherwise indicated) Note 12. Derivative Instruments The Company enters into foreign currency forward contracts from time to time to help mitigate the impact that an adverse change in foreign exchange rates would have on the value of the Company's investments denominated in foreign currencies. In order to better define its contractual rights and to secure rights that will help the Company mitigate its counterparty risk, the Company entered into an International Swaps and Derivatives Association, Inc. Master Agreement (the "ISDA Master Agreement") with its derivative counterparty, JPMorgan Chase Bank, N.A. The ISDA Master Agreement permits a single net payment in the event of a default or similar event. As of June 30, 2024, no cash collateral has been pledged to cover obligations and no cash collateral has been received from the counterparty with respect to the Company's forward currency contracts. Certain information related to the Company's foreign currency forward contracts is presented below as of June 30, 2024. Description Notional Amount to be Purchased Notional Amount to be Sold Maturity Date Gross Amount of Recognized Assets Gross Amount of Recognized Liabilities Balance Sheet Location of Net Amounts Foreign currency forward contract \$54,193A \$-49,683A 8/8/2024 \$849A \$0A Derivative asset Foreign currency forward contract \$55,206A \$4,988A 8/8/2024 \$46A \$413A Derivative liability \$849A \$413A Certain information related to the Company's foreign currency forward contracts is presented below as of September 30, 2023. Description Notional Amount to be Purchased Notional Amount to be Sold Maturity Date Gross Amount of Recognized Assets Gross Amount of Recognized Liabilities Balance Sheet Location of Net Amounts Foreign currency forward contract \$42,182A \$-38,026A 11/9/2023 \$1,857A \$0A Derivative asset Foreign currency forward contract \$72,098A \$56,556A 11/9/2023 \$053A \$0A Derivative asset \$4,910A \$0A In connection with the issuance of the 2027 Notes and 2029 Notes, the Company entered into interest rate swap agreements with the Royal Bank of Canada pursuant to ISDA Master Agreements. As of June 30, 2024, the Company paid \$30.3 million to the Royal Bank of Canada to cover collateral obligations under the terms of the interest swap agreements, which is included in due from broker on the Consolidated Statement of Assets and Liabilities. Certain information related to the Company's interest rate swaps is presented below as of June 30, 2024. Description Notional Amount Maturity Date Gross Amount of Recognized Assets Gross Amount of Recognized Liabilities Balance Sheet Location of Net Amounts Interest rate swap \$350,000A 1/15/2027 \$0A \$30,683A Derivative liability Interest rate swap \$300,000A 2/15/2029 \$0A \$2,989A Derivative liability \$0A \$33,672A Certain information related to the Company's interest rate swap is presented below as of September 30, 2023. Description Notional Amount Maturity Date Gross Amount of Recognized Assets Gross Amount of Recognized Liabilities Balance Sheet Location of Net Amounts Interest rate swap \$350,000A 1/15/2027 \$0A \$40,519A Derivative liability Interest rate swap \$300,000A 2/15/2029 \$0A \$7,000A Derivative liability \$0A \$47,519A Note 13. Commitments and Contingencies Off-Balance Sheet Arrangements The Company may be a party to financial instruments with off-balance sheet risk in the normal course of business to meet the financial needs of its portfolio companies. As of June 30, 2024, the Company's only off-balance sheet arrangements consisted of \$291.4A million of unfunded commitments, which was comprised of \$264.3 million to provide debt and equity 740AKTREE SPECIALTY LENDING CORPORATION NOTES A TO CONSOLIDATED FINANCIAL STATEMENTS (in thousands, except share and per share amounts, percentages and as otherwise indicated) financing to certain of its portfolio companies and \$27.1A million to provide financing to the JVs. Of the \$264.3A million, approximately \$219.4A million can be drawn immediately with the remaining amount subject to certain milestones that must be met by portfolio companies or other restrictions. As of September 30, 2023, the Company's only off-balance sheet arrangements consisted of \$232.7A million of unfunded commitments, which was comprised of \$205.6A million to provide debt and equity financing to certain of its portfolio companies and \$27.1A million to provide financing to the JVs. Of the \$205.6A million, approximately \$154.2A million can be drawn immediately with the remaining amount subject to certain milestones that must be met by portfolio companies or other restrictions. Such commitments are subject to the portfolio companies' satisfaction of certain financial and nonfinancial covenants and may involve, to varying degrees, elements of credit risk in excess of the amount recognized in the Consolidated Statements of Assets and Liabilities. A list of unfunded commitments by investment (consisting of revolvers, term loans with delayed draw components and subordinated notes and LLC equity interests in the JVs) as of June 30, 2024 and September 30, 2023 is shown in the table below: June 30, 2024 September 30, 2023 109 Beech Oak22 LLC \$26,969A \$26,969A Verona Pharma, Inc. 14,846A \$0A OCSI Glick JV LLC 13,998A 13,998A PPW Aero Buyer, Inc. 13,804A 1,466A PetVet Care Centech, LLC 13,732A \$0A Senior Loan Fund JV I, LLC 13,125A 13,125A BioXcel Therapeutics, Inc. 9,383A 14,547A Amspec Parent LLC 9,372A \$0A Kings Buyer, LLC 8,804A 5,189A Seres Therapeutics, Inc. 8,090A 8,090A Monotype Imaging Holdings Inc. 8,005A \$0A Next Holdco, LLC 7,051A \$0A AICIMs, Inc. 6,591A 7,466A Eyesouth Eye Care Holdco LLC 6,585A \$0A MRI Software LLC 6,420A 2,261A Quantum Bidco Limited 6,311A \$0A Telephone and Data Systems, Inc. 6,273A \$0A Digital.AI Software Holdings, Inc. 6,045A 1,078A Truck-Lite Co., LLC 6,554A \$0A Sorenson Communications, LLC 5,409A \$0A Grove Hotel Parcel Owner, LLC 5,286A 5,286A Mindbody, Inc. 5,238A 4,762A scPharmaceuticals Inc. 5,212A 5,212A SumUp Holdings Luxembourg 5,101A \$0A Avalara, Inc. 5,047A 5,047A 107 Fair Street LLC 4,227A 4,227A Harrow, Inc. 4,011A 4,011A Accupac, Inc. 3,920A 4,500A Inventus Power, Inc. 3,792A 3,792A Delta Leasing SPV II LLC 3,581A 14,639A Establishment Labs Holdings Inc. 3,384A 3,384A WP CPP Holdings, LLC 3,272A \$0A Enverus Holdings, Inc. 3,135A \$0A PRGX Global, Inc. 3,127A 3,127A Salus Workers' Compensation, LLC 1,023A 1,023A Spanx, LLC 9,092A 4,473A Minotaur Acquisition, Inc. 3,058A \$0A Relativity ODA LLC 2,762A 2,762A Crewline Buyer, Inc. 2,180A \$0A Protein For Pets Opc, LLC 2,117A \$0A Coupa Holdings, LLC 2,075A 2,075A Oranje Holdco, Inc. 1,904A 1,904A MHE Intermediate Holdings, LLC 1,786A 821A Evergreen IX Borrower 2023, LLC 1,626A 1,626A 750AKTREE SPECIALTY LENDING CORPORATION NOTES A TO CONSOLIDATED FINANCIAL STATEMENTS (in thousands, except share and per share amounts,

(continued as otherwise indicated)June 30, 2024September 30, 2023Acquia Inc.\$1,625\$1,376A Supreme Fitness Group NY Holdings, LLC1,5522,199A Galileo Parent, Inc.1,480A 2,061A Centralsquare Technologies, LLC1,436A \$€” A 112-126 Van Houten Real LSL LLC1,378A 2,343A Berner Food & Beverage, LLC1,314A 1,622A Finastra USA, Inc.1,089A 960A Icefall Parent, Inc.995A €” A SIO2 Medical Products, Inc.554A 1,821A LSL Holdco, LLC530A 2,650A Telemstream Holdings Corporation379A 407A All Web Leads, Inc.240A €” A ASP-R-PAC Acquisition Co LLC234A 396A ADB Companies, LLC98A €” A Fairbridge Strategic Capital Funding LLC€” A 13,090M PND Holdings III Corp€” A 9,122A Assembled Brands Capital LLC€” A 7,514A Dominion Diagnostics, LLC€” A 3,484A OTG Management, LLC€” A 3,190A ADC Therapeutics SA€” A 3,020A Impel Pharmaceuticals Inc.€” A 2,458A SCP Eye Care Services, LLC€” A 2,356A Tahoe Bidco B.V.€” A 2,162A Pluralsight, LLC€” A 1,787A Liquid Environmental Solutions Corporation€” A 1,383A Coyote Buyer, LLC€” A 400A Total\$291,406A \$232,740A 76OAKTREE SPECIALTY LENDING CORPORATIONNOTES TO CONSOLIDATED FINANCIAL STATEMENTS(in thousands, except share and per share amounts, percentages and as otherwise indicated)Note 14. Subsequent EventsThe Company’s management evaluated subsequent events through the date of issuance of the Consolidated Financial Statements. There have been no subsequent events that occurred during such period that would require disclosure in, or would be required to be recognized in the Consolidated Financial Statements as of and for the three months ended June 30, 2024, except as discussed below.

Distribution DeclarationOn July 26, 2024, the Company’s Board of Directors declared a quarterly distribution of \$0.55 per share, payable in cash on September 30, 2024 to stockholders of record on September 16, 2024.

Oaktree Specialty Lending Corporation

A A A A A A A A A A Schedule 12-14Schedule of Investments in and Advances to Affiliates (in thousands, except share and per share amounts, percentages and as otherwise indicated)

Nine months ended June 30, 2024(unaudited)Portfolio Company (1)IndustryInvestment TypeIndexSpreadCashPIK RateMaturity DateSharesPrincipalNet Realized Gain (Loss)Amount of Interest, Fees or Dividends Credited in Income (2)Fair Value at October 1, 2023Gross Additions (3)Gross Reductions (4)Fair Value at June 30, 2024% of Total Net AssetsControl InvestmentsC5 Technology Holdings, LLCData Processing & Outsourced ServicesCommon Stock829A \$€” A \$€” A \$€” A \$€” A C5 Technology Holdings, LLCData Processing & Outsourced ServicesPreferred Equity34,984,460A €” A €” A €” A €” A €” A €” A €” A Continental Intermodal Group LPoil & Gas Storage & TransportationPreferred Equity3,137,476A €” A €” A €” A €” A €” A €” A €” A Continental Intermodal Group LPoil & Gas Storage & TransportationCommon Stock22,267,661A €” A €” A €” A €” A €” A €” A €” A 16,172A (1,698)14,474A 1.0A %Dominion Diagnostics, LLCHealth Care ServicesFirst Lien Term LoanSOFR+5.00A %€” A €” A €” A €” A €” A €” A €” A 1,159A 14,068A €” A (987)13,081A 0.9A %Dominion Diagnostics, LLCHealth Care ServicesFirst Lien Term LoanSOFR+5.00A %€” A €” A €” A €” A €” A €” A €” A 69A 2,090A €” A (2,090)€” A €” A €” A €” A €” A €” A €” A 0.3A %Dominion Diagnostics, LLCHealth Care ServicesFirst Lien RevolverSOFR+5.00A %€” A €” A €” A €” A €” A €” A €” A 44S 5,574A €” A (352)5,222A 0.3A %Dominion Diagnostics, LLCHealth Care ServicesCommon Stock30,031A €” A €” A €” A €” A €” A €” A €” A 2,711A €” A (2,711)€” A €” A First Star Service Aviation LimitedAirlinesEquity Interest100.00A %786A €” A €” A €” A €” A €” A €” A €” A OCSI Glick JV LLC (5)Multi-Sector HoldingsSubordinated DebtSOFR+4.50A %9.94A %€” A €” A €” A €” A €” A €” A €” A 5,395A 50,017A 978A (1,109)49,886A 3.3A %OCSI Glick JV LLC (5)Multi-Sector HoldingsMembership Interest87.50A %€” A €” A €” A €” A €” A €” A €” A Senior Loan Fund JV I, LLC (6)Multi-Sector HoldingsSubordinated DebtSOFR+7.00A %€” A €” A €” A €” A €” A €” A €” A 10,672A 112,656A €” A €” A €” A €” A €” A €” A €” A Senior Loan Fund JV I, LLC (6)Multi-Sector HoldingsMembership Interest87.50A %€” A €” A €” A €” A €” A €” A €” A 3,061)25,817A 1.7A %SIO2 Medical Products, Inc.Metal, Glass & Plastic ContainersFirst Lien Term Loan12.00A %8/3/20282,682A €” A 71A €” A 2,682A €” A 2,682A 0.2A %SIO2 Medical Products, Inc.Metal, Glass & Plastic ContainersFirst Lien Term Loan12.00A %8/3/202817,363A €” A 1,650A 15,874A 1,643A (157)17,363A 1.2A %SIO2 Medical Products, Inc.Metal, Glass & Plastic ContainersFirst Lien Term Loan12.00A %8/3/20283,442A €” A 275A 1,359A 2,083A €” A 3,442A 0.2A %SIO2 Medical Products, Inc.Metal, Glass & Plastic ContainersCommon Stock1,184,630A €” A €” A €” A €” A €” A €” A €” A 12,678)23,548A 1.6A %SIO2 Medical Products, Inc.Metal, Glass & Plastic ContainersWarrants66,686A €” A €” A €” A €” A €” A €” A €” A %Total Control Investments\$214,029A \$786A \$23,936A \$297,091A \$26,821A \$(24,840)\$299,072A 20.0A %Affiliate InvestmentsAll Web Leads, Inc.AdvertisingFirst Lien Term LoanSOFR+4.00A %7.34A %€” A €” A €” A €” A €” A €” A €” A 52A €” A €” A €” A €” A €” A €” A €” A 1,731A 0.1A %All Web Leads, Inc.AdvertisingFirst Lien Term LoanSOFR+5.00A %€” A €” A €” A €” A €” A €” A €” A 116A €” A 3,429A €” A 3,429A 0.2A %All Web Leads, Inc.AdvertisingFirst Lien Term Loan10.00A %3/29/20283,451A €” A €” A €” A €” A €” A €” A €” A 3,102A €” A 3,102A 0.2A %All Web Leads, Inc.AdvertisingFirst Lien RevolverSOFR+4.00A %9.34A %3/30/20261,560A €” A 45A €” A 1,506A €” A 1,506A 0.1A %All Web Leads, Inc.AdvertisingCommon Stock11,499A €” A €” A €” A €” A €” A €” A €” A 1,622A €” A 1,622A 0.1A %Assembled Brands Capital LLCSpecialized FinanceFirst Lien Revolver€” A 329A 21,823A 33A (21,856)€” A €” A €” A Assembled Brands Capital LLCSpecialized FinanceCommon Stock12,463,242A €” A €” A €” A 89A 1,159A (21,246)0.1A %Assembled Brands Capital LLCSpecialized FinancePreferred Equity€” A €” A 1,005A 153A (1,158)€” A €” A Assembled Brands Capital LLCSpecialized FinanceWarrants78,045A €” A €” A €” A €” A €” A €” A €” A The AveryReal Estate Operating CompaniesFirst Lien Term Loan10.00A %2/16/20285,065A €” A €” A €” A €” A €” A €” A €” A 4,657A (545)4,112A 0.3A %The AveryReal Estate Operating CompaniesFirst Lien Term Loan10.00A %2/16/202820,917A €” A €” A €” A €” A €” A €” A €” A 19,262A (841)18,421A 1.2A %The AveryReal Estate Operating CompaniesMembership Interest6.40A %€” A €” A €” A €” A €” A €” A €” A CAREgiver Services, Inc.Health Care ServicesPreferred Equity1,080,399A €” A €” A €” A €” A €” A €” A €” A 432A €” A (205)227A €” A €” A %Total Affiliate Investments\$36,404A \$€” A \$542A \$23,349A \$36,654A (\$24,607)\$35,396A 2.4A %Total Control & Affiliate Investments\$250,433A \$786A \$24,478A \$320,440A \$63,475A (\$49,447)\$334,468A 22.4A %78This schedule should be read in connection with the Company's Consolidated Financial Statements, including the Consolidated Schedules of Investments and Notes to the Consolidated Financial Statements.

(1)The principal amount and ownership detail are shown in the Company's Consolidated Schedules of Investments.(2)Represents the total amount of interest (net of non-accrual amounts), fees and dividends credited to income for the portion of the period an investment was included in the control or affiliate categories.(3)Gross additions include increases in the cost basis of investments resulting from new portfolio investments, follow-on investments, accrued PIK interest (net of non-acrual amounts) and the exchange of one or more existing securities for one or more new securities. Gross reductions also include net decreases in unrealized appreciation or net decreases in depreciation as well as the movement of an existing portfolio company into this category or out of a different category.(4)Gross reductions include decreases in the cost basis of investments resulting from principal payments or sales and exchanges of one or more existing securities for one or more new securities. Gross reductions also include net increases in realized depreciation or net decreases in depreciation as well as the movement of an existing portfolio company out of this category and into a different category.(5)Together with GF Equity Funding, the Company co-invests through Glick JV. Glick JV is capitalized as transactions are completed and all portfolio and investment decisions in respect to Glick JV must be approved by the Glick JV investment committee consisting of representatives of the Company and GF Equity Funding (with approval from a representative of each required).(6)Together with Kemper, the Company co-invests through SLF JV I. SLF JV I is capitalized as transactions are completed and all portfolio and investment decisions in respect to SLF JV I must be approved by the SLF JV I investment committee consisting of representatives of the Company and Kemper (with approval from a representative of each required).

79Schedule 12-14Oaktree Specialty Lending CorporationSchedule of Investments in and Advances to Affiliates(in thousands, except share and per share amounts, percentages and as otherwise indicated)

Nine months ended June 30, 2023(unaudited)Portfolio Company (1)IndustryInvestment TypeIndexSpreadCashPIK RateMaturity DateSharesPrincipalNet Realized Gain (Loss)Amount of Interest, Fees or Dividends Credited in Income (2)Fair Value at October 1, 2022Gross Additions (3)Gross Reductions (4)Fair Value at June 30, 2023% of Total Net AssetsControl InvestmentsC5 Technology Holdings, LLCData Processing & Outsourced ServicesCommon Stock829A \$€” A \$€” A \$€” A \$€” A C5 Technology Holdings, LLCData Processing & Outsourced ServicesPreferred Equity34,984,460A €” A €” A €” A €” A €” A €” A €” A 27,638A 1.8A %Dominion Diagnostics, LLCHealth Care ServicesFirst Lien Term LoanSOFR+5.00A %€” A €” A €” A €” A €” A €” A €” A 1,070A 14,333A €” A (231)14,102A 0.9A %Dominion Diagnostics, LLCHealth Care ServicesFirst Lien RevolverSOFR+5.00A %€” A €” A €” A €” A €” A €” A €” A 136A €” A 3,484A 0.2A %Dominion Diagnostics, LLCHealth Care ServicesCommon Stock30,031A €” A €” A €” A €” A €” A €” A €” A 4,946A €” A (2,235)2,711A 0.2A %OCSI Glick JV LLC (5)Multi-Sector HoldingsSubordinated DebtL4.50A %9.36A %€” A €” A €” A €” A €” A €” A €” A 4,961A 50,283A 1,116A (1,767)49,632A 3.3A %OCSI Glick JV LLC (5)Multi-Sector HoldingsMembership Interest87.50A %€” A €” A €” A €” A €” A €” A €” A Senior Loan Fund JV I, LLC (6)Multi-Sector HoldingsSubordinated DebtL7.00A %€” A €” A €” A €” A €” A €” A €” A 11,861A €” A 12,929A 12,656A €”

potential for greater returns, for our new investment opportunities: (1) situational lending, which we define to include directly originated loans to non-sponsor companies that are hard to understand and value using traditional underwriting techniques, (2) select sponsor lending, which we define to include financing to support leveraged buyouts of companies with specialized sponsors that have expertise in certain industries, (3) stressed sector and rescue lending, which we define to include opportunistic private loans in industries experiencing stress or limited access to capital and (4) public credit, where we seek discounted, high quality public debt investments particularly in times of market dislocation. On January 23, 2023, we acquired Oaktree Strategic Income II, Inc. (â€œOSI2â€) pursuant to that certain Agreement and Plan of Merger (the â€œOSI2 Merger Agreementâ€), dated as of September 14, 2022, by and among OSI2, us, Project Superior Merger Sub, Inc., our wholly-owned subsidiary, and, solely for the limited purposes set forth therein, Oaktree. Pursuant to the OSI2 Merger Agreement, OSI2 was merged with and into us in a two-step transaction with us as the surviving company (the â€œOSI2 Mergerâ€). 82Business Environment and Developments Global financial markets have experienced an increase in volatility as concerns about the impact of higher inflation, elevated interest rates, a potential slowdown in economic activity and the current conflicts in the Middle East have weighed on market participants. These factors have created disruptions in supply chains and economic activity and have had a particularly adverse impact on certain companies in the energy, raw materials and transportation sectors, among others. These uncertainties can ultimately impact the overall supply and demand of the market through changing spreads, deal terms and structures and equity purchase price multiples. We are unable to predict the full effects of these macroeconomic events or how they might evolve. We continue to closely monitor the impact these events have on our business, industry and portfolio companies and will provide constructive solutions where necessary. Against this backdrop, we believe attractive risk-adjusted returns can be achieved by making loans to middle market companies that typically possess resilient business models with strong underlying fundamentals. Given the breadth of the investment platform and decades of credit investing experience of Oaktree and its affiliates, we believe that we have the resources and experience to source, diligence and structure investments in these companies. Critical Accounting Estimates Fair Value Measurements Oaktree, as the valuation designee of our Board of Directors pursuant to Rule 2a-5 under the Investment Company Act, determines the fair value of our assets on at least a quarterly basis in accordance with Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC, Topic 820, Fair Value Measurements and Disclosures, or ASC 820. ASC 820 defines fair value as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. A liabilityâ€™s fair value is defined as the amount that would be paid to transfer the liability to a new obligor, not the amount that would be paid to settle the liability with the creditor. ASC 820 prioritizes the use of observable market prices over entity-specific inputs. Where observable prices or inputs are not available or reliable, valuation techniques are applied. These valuation techniques involve some level of management estimation and judgment, the degree of which is dependent on the price transparency for the investments or market and the investmentsâ€™ complexity. Hierarchical levels, defined by ASC 820 and directly related to the amount of subjectivity associated with the inputs to fair valuation of these assets and liabilities, are as follows: â€¢Level 1 â€¢Unadjusted, quoted prices in active markets for identical assets or liabilities as of the measurement date. â€¢Level 2 â€¢Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data at the measurement date for substantially the full term of the assets or liabilities. â€¢Level 3 â€¢Unobservable inputs that reflect Oaktreeâ€™s best estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model. If inputs used to measure fair value fall into different levels of the fair value hierarchy, an investment's level is based on the lowest level of input that is significant to the fair value measurement. Oaktree's assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the investment. This includes investment securities that are valued using "bid" and "ask" prices obtained from independent third party pricing services or directly from brokers. These investments may be classified as Level 3 because the quoted prices may be indicative in nature for securities that are in an inactive market, may be for similar securities or may require adjustments for investment-specific factors or restrictions. Financial instruments with readily available quoted prices generally will have a higher degree of market price observability and a lesser degree of judgment inherent in measuring fair value. As such, Oaktree obtains and analyzes readily available market quotations provided by pricing vendors and brokers for all of our investments for which quotations are available. In determining the fair value of a particular investment, pricing vendors and brokers use observable market information, including both binding and non-binding indicative quotations. Oaktree seeks to obtain at least two quotations for the subject or similar securities, typically from pricing vendors. If Oaktree is unable to obtain two quotes from pricing vendors, or if the prices obtained from pricing vendors are not within our set threshold, Oaktree seeks to obtain a quote directly from a broker making a market for the asset. Oaktree evaluates the 83quotations provided by pricing vendors and brokers based on available market information, including trading activity of the subject or similar securities, or by performing a comparable security analysis to ensure that fair values are reasonably estimated. Oaktree also performs back-testing of valuation information obtained from pricing vendors and brokers against actual prices received in transactions. In addition to ongoing monitoring and back-testing, Oaktree performs due diligence procedures over pricing vendors to understand their methodology and controls to support their use in the valuation process. Generally, Oaktree does not adjust any of the prices received from these sources. If the quotations obtained from pricing vendors or brokers are determined to not be reliable or are not readily available, Oaktree values such investments using any of three different valuation techniques. The first valuation technique is the transaction precedent technique, which utilizes recent or expected future transactions of the investment to determine fair value, to the extent applicable. The second valuation technique is an analysis of the enterprise value, or EV, of the portfolio company. EV means the entire value of the portfolio company to a market participant, including the sum of the values of debt and equity securities used to capitalize the enterprise at a point in time. The EV analysis is typically performed to determine (i) the value of equity investments, (ii) whether there is credit impairment for debt investments and (iii) the value for debt investments that we are deemed to control under the Investment Company Act. To estimate the EV of a portfolio company, Oaktree analyzes various factors, including the portfolio companyâ€™s historical and projected financial results, macroeconomic impacts on the company and competitive dynamics in the companyâ€™s industry. Oaktree also utilizes some or all of the following information based on the individual circumstances of the portfolio company: (i) valuations of comparable public companies, (ii) recent sales of private and public comparable companies in similar industries or having similar business or earnings characteristics, (iii) purchase prices as a multiple of their earnings or cash flow, (iv) the portfolio companyâ€™s ability to meet its forecasts and its business prospects, (v) a discounted cash flow analysis, (vi) estimated liquidation or collateral value of the portfolio companyâ€™s assets and (vii) offers from third parties to buy the portfolio company. Oaktree may probability weight potential sale outcomes with respect to a portfolio company when uncertainty exists as of the valuation date. Under the EV technique, the significant unobservable input used in the fair value measurement of our investments in debt or equity securities is the EBITDA, revenue or asset multiple, as applicable. Increases or decreases in the valuation multiples in isolation may result in a higher or lower fair value measurement, respectively. The third valuation technique is a market yield technique, which is typically performed for non-credit impaired debt investments. In the market yield technique, a current price is imputed for the investment based upon an assessment of the expected market yield for a similarly structured investment with a similar level of risk, and we consider the current contractual interest rate, the capital structure and other terms of the investment relative to risk of the company and the specific investment. A key determinant of risk, among other things, is the leverage through the investment relative to the EV of the portfolio company. As debt investments held by us are substantially illiquid with no active transaction market, Oaktree depends on primary market data, including newly funded transactions and industry-specific market movements, as well as secondary market data with respect to high yield debt instruments and syndicated loans, as inputs in determining the appropriate market yield, as applicable. Under the market yield technique, the significant unobservable input used in the fair value measurement of our investments in debt securities is the market yield. Increases or decreases in the market yield may result in a lower or higher fair value measurement, respectively. In accordance with ASC 820-10, certain investments that qualify as investment companies in accordance with ASC 946 may be valued using net asset value as a practical expedient for fair value. Consistent with FASB guidance under ASC 820, these investments are excluded from the hierarchical levels. These investments are generally not redeemable. Oaktree estimates the fair value of certain privately held warrants using a Black Scholes pricing model, which includes an analysis of various factors and subjective assumptions, including the current stock price (by using an EV analysis as described above), the expected period until exercise, expected volatility of the underlying stock price, expected dividends and the risk-free rate. Changes in the subjective input assumptions can materially affect the fair value estimates. The fair value of our investments as of June 30, 2024 and September 30, 2023 was determined by Oaktree, as our valuation designee. We have and will continue to engage independent valuation firms to provide assistance each quarter regarding the determination of the fair value of a portion of our portfolio securities for which market quotations are not readily available or are readily available but deemed not reflective of the fair value of the investment. As of June 30, 2024, 94.2% of our portfolio at fair value was valued either based on market quotations, the transactions precedent approach or corroborated by independent valuation firms. Certain factors that may be considered in determining the fair value of our investments include the nature and realizable value of any collateral, the portfolio companyâ€™s earnings and its ability to make payments on its indebtedness, the markets in which the portfolio company does business, comparison to comparable publicly-traded companies, discounted cash flow and other relevant factors. Because such valuations, and particularly valuations of private securities and private companies, are inherently uncertain, may fluctuate over short periods of time and may be based on estimates, Oaktree's determinations of fair value may differ materially from the values that would have been used if a ready market for these securities existed. Due to these uncertainties, Oaktree's fair value determinations may cause our net asset value on a given date to materially understate or overstate the value that we may ultimately realize upon the sale of one or more of our investments. 84As of June 30, 2024, we held \$3,121.7 million of investments at fair value, up from \$2,892.4 million held at September 30, 2023, primarily driven by purchases of investments during the nine months ended June 30, 2024. As of June 30, 2024 and September 30, 2023, approximately 94.0% and 89.9%, respectively, of our total assets represented investments at fair value. Revenue Recognition We generate revenues in the form of interest income on debt investments and, to a lesser extent, capital gains and distributions, if any, on equity securities that we may acquire in portfolio companies. We may also generate revenue in the form of commitment, origination, structuring or diligence fees, fees for providing managerial assistance and consulting fees. Some of our investments provide for deferred interest payments or payment-in-kind, or PIK, interest income. The principal amount of the debt investments and any accrued but unpaid interest generally becomes due at the maturity date. Interest Income Interest income, adjusted for accretion of original issue discount, or OID, is recorded on an accrual basis to the extent that such amounts are expected to be collected. We stop accruing interest on investments when it is determined that interest is no longer collectible. Investments that are expected to pay regularly scheduled interest in cash are generally placed on non-accrual status when there is reasonable doubt that principal or interest cash payments will be collected. Cash interest payments received on investments may be recognized as income or a return of capital depending upon managementâ€™s judgment. A non-accrual investment is restored to accrual status if past due principal and interest are paid in cash, and the portfolio company, in managementâ€™s judgment, is likely to continue timely payment of its remaining obligations. As of June 30, 2024, there were eight investments on non-accrual status that in the aggregate represented 5.7% and 3.7% of total debt investments at cost and fair value, respectively. As of September 30, 2023, there were four investments on non-accrual status that in aggregate represented 2.4% and 1.8% of total debt investments at cost and fair value, respectively. In connection with our investment in a portfolio company, we sometimes receive nominal cost equity that is valued as part of the negotiation process with the portfolio company. When we receive nominal cost equity, we allocate our cost basis in the investment between debt securities and the nominal cost equity at the time of origination. Any resulting discount from recording the loan, or otherwise purchasing a security at a discount, is accreted into interest income over the life of the loan. PIK Interest Income Our investments in debt securities may contain PIK interest provisions. PIK interest, which typically represents contractually deferred interest added to the loan balance that is generally due at the end of the loan term, is generally recorded on the accrual basis to the extent such amounts are expected to be collected. We generally cease accruing PIK interest if there is insufficient value to support the accrual or if we do not expect the portfolio company to be able to pay all principal and interest due. Our decision to cease accruing PIK interest on a loan or debt security involves subjective judgments and determinations based on available information about a particular portfolio company, including whether the portfolio company is current with respect to its payment of principal and interest on its loans and debt securities; financial statements and financial projections for the portfolio company; our assessment of the portfolio company's business development success; information obtained by us in connection with periodic formal update interviews with the portfolio company's management and, if appropriate, the private equity sponsor; and information about the general economic and market conditions in which the portfolio company operates. Our determination to cease accruing PIK interest is generally made well before our full write-down of a loan or debt security. In addition, if it is subsequently determined that we will not be able to collect any previously accrued PIK interest, the fair value of the loans or debt securities would be reduced by the amount of such previously accrued, but uncollectible, PIK interest. The accrual of PIK interest on our debt investments increases the recorded cost bases of these investments in our Consolidated Financial Statements including for purposes of computing the capital gains incentive fee payable by us to Oaktree. To maintain our status as a RIC, certain income from PIK interest may be required to be distributed to our stockholders, even though we have not yet collected the cash and may never do so. Portfolio Composition Our investments principally consist of loans, common and preferred equity and warrants in privately-held companies, Senior Loan Fund JV I, LLC, or SLF JV I, a joint venture through which we and Trinity Universal Insurance Company, a subsidiary of Kemper Corporation, or Kemper, co-invest in senior secured loans of middle-market companies and other corporate debt securities, and OCSI Glick JV LLC, or the Glick JV, a joint venture through which we and GF Equity Funding 2014 LLC, or GF Equity Funding, co-invest primarily in senior secured loans of middle-market companies. We refer to SLF JV I and the Glick JV collectively as the JVs. Our loans are typically secured by a first, second or subordinated lien on the assets of the portfolio company and generally have terms of up to ten years (but an expected average life of between three and four years). 85During the nine months ended June 30, 2024, we originated \$1,104.6 million of investment commitments in 45 new and 34 existing portfolio companies and funded \$1,038.2 million of investments. During the nine months ended June 30, 2024, we received \$721.7 million of proceeds from prepayments, exits, other paydowns and sales and exited 28 portfolio companies. A summary of the composition of our investment portfolio at cost and fair value as a percentage of total investments is shown in the following tables: A June 30, 2024 September 30, 2023 Cost: Senior secured debt 84.42% 85.24% Debt investments in the Jvs 4.98% 5.35% Subordinated debt 3.52% 1.97% Common equity and warrants 3.35% 2.37% Preferred equity 2.07% 3.27% LLC equity interests of the Jvs 1.66% 1.80% Total 100.00% 100.00% June 30, 2024 September 30, 2023 Fair value: Senior secured debt 85.98% 86.47% Debt investments in the Jvs 5.21% 5.62% Subordinated debt 3.75% 1.93% Common equity and warrants 2.18% 2.00% Preferred equity 2.05% 2.98% LLC equity interests of the Jvs 0.83% 1.00% Total 100.00% 100.00% 86The industry composition of our portfolio at cost and fair value as a percentage of total investments was as follows: June 30, 2024 September 30, 2023 Cost: Application Software 16.95% 15.39% Multi-Sector Holdings (1) 17.13% 7.21% Health Care Services 4.00% 2.68% Health Care Technology 3.86% 3.51% Biotechnology 3.84% 4.15% Data Processing & Outsourced Services 2.94% 4.38% Interactive Media & Services 2.91% 0.62% Industrial Machinery & Supplies & Components 2.83% 3.27% Pharmaceuticals 2.63% 2.79% Real Estate Operating Companies 2.45% 2.75% Diversified Financial Services 2.12% 2.03% Aerospace & Defense 2.04% 1.70% Diversified Support Services 2.04% 0.77% Environmental & Facilities Services 1.96% 2.07% Fertilizers & Agricultural Chemicals 1.96% 2.13% Personal Care Products 1.95% 2.24% Health Care Distributors 1.95% 2.04% Airport Services 1.90% 1.84% Metal, Glass & Plastic Containers 1.88% 1.82% Specialized Finance 1.78% 2.40% Internet Services & Infrastructure 1.62% 2.00% Diversified Metals & Mining 1.52% 1.64% Systems Software 1.51% 0.76% Home Improvement Retail 1.50% 1.78% Auto Parts & Equipment 1.47% 1.59% Communications Equipment 1.45% 1.4% Real Estate Services 1.35% 1.47% Soft Drinks & Non-alcoholic Beverages 1.30% 1.40% Automotive Retail 1.24% 1.89% Office Services & Supplies 1.18% 1.4% Leisure Facilities 1.15% 1.28% Other Specialty Retail 1.12% 1.35% Electrical Components & Equipment 0.99% 1.07% Movies & Entertainment 0.94% 0.40% Construction Machinery & Heavy Transportation Equipment 0.79% 1.4% Health Care Equipment 0.78% 0.74% Passenger Airlines 0.76% 0.82% Real Estate Development 0.76% 0.79% Wireless Telecommunication Services 0.74% 1.4% Gold 0.71% 0.77% Home Furnishings 0.70% 0.78% Broadline Retail 0.67% 2.74% Construction & Engineering 0.62% 0.73% Packaged Foods & Meats 0.60% 1.4% Specialty Chemicals 0.59% 1.27% Oil & Gas Storage & Transportation 0.59% 0.72% Apparel Retail 0.54% 0.16% Hotels, Resorts & Cruise Lines 0.52% 0.56% Alternative Carriers 0.46% 1.4% Food Distributors 0.44% 0.19% Health Care Supplies 0.35% 0.38% Advertising 0.34% 0.84% Integrated Telecommunication Services 0.27% 0.62% Distributors 0.26% 1.24% Education Services 0.25% 0.46% Financial Exchanges & Data 0.21% 1.4% Cable & Satellite 0.21% 0.15% Research & Consulting Services 0.15% 0.16% Paper & Plastic Packaging Products & Materials 0.10% 0.11% Housewares & Specialties 0.08% 0.10% Diversified Chemicals 0.05% 1.4% Insurance Brokers 1.74% Consumer Finance 0.54% Restaurants 0.41% Air Freight & Logistics 0.16% Integrated Oil & Gas 0.16% Other Specialized REITs 0.14% Leisure

June 30, 2023, we experienced a net increase in cash and cash equivalents (including restricted cash) of \$46.3 million. During that period, net cash used in operating activities was \$15.0 million, primarily from funding \$597.7 million of investments and \$58.8 million of net increase in net receivables from unsettled transactions, partially offset by \$521.2 million of principal payments and sale proceeds received, the cash activities related to \$133.2 million of net investment income, \$22.3 million of cash received in connection with the OS12 merger and a \$20.5 million decrease in due from portfolio companies. During the same period, net cash provided by financing activities was \$61.0 million, primarily consisting of \$210.0 million of net borrowings under the credit facilities, partially offset by \$139.1 million of cash distributions paid to our stockholders. As of June 30, 2024, we had \$107.3 million in cash and cash equivalents (including \$11.0 million of restricted cash), portfolio investments (at fair value) of \$3.1 billion, \$27.6 million of interest, dividends and fees receivable, \$1.0 million of due from portfolio companies, \$827.5 million of undrawn capacity on our credit facilities (subject to borrowing base and other limitations), \$32.8 million of net payables from unsettled transactions, \$790.0 million of borrowings outstanding under our credit facilities and \$907.2 million of unsecured notes payable (net of unamortized financing costs, unaccreted discount and interest rate swap fair value adjustment). As of September 30, 2023, we had \$145.5 million in cash and cash equivalents (including \$9.1 million of restricted cash), portfolio investments (at fair value) of \$2.9 billion, \$44.6 million of interest, dividends and fees receivable, \$6.3 million of due from portfolio companies, \$907.5 million of undrawn capacity on our credit facilities (subject to borrowing base and other limitations), \$44.4 million of net receivables from unsettled transactions, \$710.0 million of borrowings outstanding under our credit facilities and \$890.7 million of unsecured notes payable (net of unamortized financing costs, unaccreted discount and interest rate swap fair value adjustment). We may be a party to financial instruments with off-balance sheet risk in the normal course of business to meet the financial needs of our portfolio companies. As of June 30, 2024, our only off-balance sheet arrangements consisted of \$291.4 million of unfunded commitments, which was comprised of \$264.3 million to provide debt and equity financing to certain of our portfolio companies and \$27.1A million to provide financing to the JVs. Of the \$264.3A million, approximately \$219.4A million can be drawn immediately with the remaining amount subject to certain milestones that must be met by portfolio companies or other restrictions. As of September 30, 2023, our only off-balance sheet arrangements consisted of \$232.7 million of unfunded commitments, which was comprised of \$205.6 million to provide debt and equity financing to certain of our portfolio companies and \$27.1A million to provide financing to the JVs. Of the \$205.6A million, approximately \$154.2A million can be drawn immediately with the remaining amount subject to certain milestones that must be met by portfolio companies or other restrictions. As of June 30, 2024, we have analyzed cash and cash equivalents, availability under our credit facilities, the ability to rotate out of certain assets and amounts of unfunded commitments that could be drawn and believe our liquidity and capital resources are sufficient to invest in market opportunities as they arise.

Contractual ObligationsThe following table reflects information pertaining to our principal debt outstanding under the Syndicated Facility, the OS12 Citibank Facility, the 2025 Notes, the 2027 Notes and the 2029 Notes (each as defined below):

	DebtA Outstanding as of September 30, 2023	DebtB Outstanding as of June 30, 2024	Weighted Average Debt Outstanding for the Nine Months Ended June 30, 2024
Facility	\$285,000A	\$285,000A	\$285,000A
Notes	\$285,000A	\$285,000A	\$285,000A
Total	\$570,000A	\$570,000A	\$570,000A

The following table reflects our contractual obligations arising from the Syndicated Facility, the OS12 Citibank Facility, the 2025 Notes, the 2027 Notes and the 2029 Notes:

	A Payments due by period as of June 30, 2024	Contractual Obligations Total Less than 1 Year	Contractual Obligations Total More than 1 Year
Syndicated Facility	\$505,000A	\$505,000A	\$505,000A
OS12 Citibank Facility	\$285,000A	\$285,000A	\$285,000A
Notes	\$285,000A	\$285,000A	\$285,000A
Total	\$1,075,000A	\$1,075,000A	\$1,075,000A

The interest due on the 2027 Notes and the 2029 Notes was calculated net of the interest rate swaps. Equity IssuancesDuring the three and nine months ended June 30, 2024, we issued an aggregate of 100,029 and 295,484 shares, respectively, of common stock as part of the DRIP. On February 7, 2022, we entered into an equity distribution agreement by and among us, Oaktree, Oaktree Administrator and Keefe, Bruyette & Woods, Inc., JMP Securities LLC, Raymond James & Associates, Inc. and SMBC Nikko Securities America, Inc., as placement agents, in connection with the issuance and sale by us of shares of common stock, having an aggregate offering price of up to \$125.0 million. The equity distribution agreement was amended on February 8, 2023 to allow for the sale of shares of our common stock having an aggregate offering price of up to \$125 million under our current registration statement and on August 8, 2023 to add Jefferies LLC as an additional placement agent and to remove SMBC Nikko Securities America, Inc. as a placement agent. Sales of the common stock, if any, may be made in negotiated transactions or transactions that are deemed to be at the market, as defined in Rule 415 under the Securities Act of 1933, as amended, including sales made directly on the Nasdaq Global Select Market or similar securities exchanges or sales made to or through a market maker other than on an exchange, at prices related to the prevailing market prices or at negotiated prices. In connection with the "at the market" offering, we issued and sold 4,724,506 shares of common stock during the nine months ended June 30, 2024 for net proceeds of \$92.5A million (net of offering costs).

Gross ProceedsPlacement Agent FeesNet Proceeds (1)Average Sales Price per Share (2)"At the market"

	(1)	(2)
Offering	\$93,685A	\$93.748A
Net proceeds	\$93.748A	\$93.748A

(1) Net proceeds excludes offering costs of \$0.2A million. (2) Represents the gross sales price before deducting placement agent fees and estimated offering expenses. In connection with the "at the market" offering, we did not issue or sell any shares of common stock during the nine months ended June 30, 2023. DistributionsThe following table reflects the distributions per share that we have paid, including shares issued under our DRIP, on our common stock since October 1, 2021. The distributions per share and shares issued under our DRIP information disclosed in this table for dates prior to January 23, 2023 have been retroactively adjusted to reflect our 1-for-3 reverse stock split completed on January 20, 2023 and effective as of the commencement of trading on January 23, 2023.

Date	Amount per Share	Cash Distribution	DRIP Shares Issued	DRIP Shares Value	Quarterly October 13, 2021	December 15, 2021	December 15, 2021	January 27, 2022	March 15, 2022	September 15, 2022	November 15, 2022	December 15, 2022	January 27, 2023	March 15, 2023	September 15, 2023	November 15, 2023
Quarterly	\$0.8	\$0.8	\$0.8	\$0.8	\$0.8	\$0.8	\$0.8	\$0.8	\$0.8	\$0.8	\$0.8	\$0.8	\$0.8	\$0.8	\$0.8	\$0.8
Special	\$0.8	\$0.8	\$0.8	\$0.8	\$0.8	\$0.8	\$0.8	\$0.8	\$0.8	\$0.8	\$0.8	\$0.8	\$0.8	\$0.8	\$0.8	\$0.8

The open market and distributed other than with respect to the distributions paid on December 31, 2021, March 31, 2022, December 30, 2022, September 29, 2023, December 29, 2023, March 29, 2024 and June 28, 2024. (2) New shares were issued with respect to distributions paid on December 31, 2021, March 31, 2022, December 30, 2022, September 29, 2023, December 29, 2023, March 29, 2024 and June 28, 2024. IndebtednessSee Note 6. BorrowingsAs of June 30, 2024, the size of the senior secured revolving credit facility, or, as amended and/or restated from time to time, the Syndicated Facility, pursuant to a senior secured revolving credit agreement, with the lenders, ING Capital LLC, as administrative agent, ING Capital LLC, JPMorgan Chase Bank, N.A., BofA Securities, Inc. and MUFG Union Bank, N.A. as joint lead arrangers and joint bookrunners, and JPMorgan Chase Bank, N.A. and Bank of America, N.A., as syndication agents, was \$1.218A billion (with an accordion feature that permits us, under certain circumstances, to increase the size of the facility to up to the greater of \$1.25 billion and our net worth (as defined in the Syndicated Facility) on the date of such increase), (ii) the period during which we may make drawings on \$1.035A billion of commitments will expire on June 23, 2027 and the maturity date was June 23, 2028, (iii) the period during which we may make drawings with respect to the remaining commitments will expire on May 4, 2025 and the maturity date is May 4, 2026 and (iv) the interest rate margin for (a) A SOFR loans (which may be 1- or 3-month, at our option) was 2.00% plus a SOFR adjustment which ranges between 0.11448% and 0.26161% and (b) alternate base rate loans was 1.00%. Each loan or letter of credit originated or assumed under the Syndicated Facility is subject to the satisfaction of certain conditions. Borrowings under the Syndicated Facility are subject to the facility's various covenants and the leverage restrictions contained in the Investment Company Act. We cannot assure you that we will be able to borrow funds under the Syndicated Facility at any particular time or at all. The following table describes significant financial covenants, as of June 30, 2024, with which we must comply under the Syndicated Facility on a quarterly basis:

Financial Covenant	Description	Target Value	March 31, 2024 Reported	ValueA (1)	Minimum shareholders' equity	Net assets shall not be less than the sum of (x) \$600 million, plus (y) 50% of the aggregate net proceeds of all sales of equity interests after May 6, 2020	\$811.1A million	Asset coverage ratio	Asset coverage ratio shall not be less than the greater of 1.50:1 and the statutory test applicable to us	1.88:1	Interest coverage ratio	Interest coverage ratio shall not be less than 2.25:1	2.25:1	Minimum net worth	Net worth shall not be less than \$550 million	\$550A million
(1)	As contractually required, we report financial covenants based on the last filed quarterly or annual report, in this case our Quarterly Report on Form 10-Q for the quarter ended March 31, 2024. We were in compliance with all financial covenants under the Syndicated Facility based on the financial information contained in this Quarterly Report on Form 10-Q. As of June 30, 2024 and September 30, 2023, we had \$505.0 million and \$430.0A million of borrowings outstanding under the Syndicated Facility, which had a fair value of \$505.0 million and \$430.0A million, respectively. Our borrowings under the Syndicated Facility bore interest at a weighted average interest rate of 7.576% and 6.584% for the nine months ended June 30, 2024 and 2023, respectively. For the three and nine months ended June 30, 2024, we recorded interest expense (inclusive of fees) of \$10.2 million and \$29.3A million, respectively, related to the Syndicated Facility. For the three and nine months ended June 30, 2023, we recorded interest expense (inclusive of fees) of \$14.3A million and \$37.4A million, respectively, related to the Syndicated Facility. Citibank FacilityOn March 19, 2021, we became party to a revolving credit facility, or, as amended and/or restated from time to time, the Citibank Facility, with OCSL Senior Funding II LLC															

DistributionsWe have qualified and elected to be treated as a RIC under Subchapter M of the Code for U.S. federal income tax purposes. As long as we continue to qualify as a RIC, we will not be subject to tax on our investment company taxable income (determined without regard to any deduction for dividends paid) or realized net capital gains, to the extent that such taxable income or gains is distributed, or deemed to be distributed as dividends, to stockholders on a timely basis. Taxable income generally differs from net income for financial reporting purposes due to temporary and permanent differences in the recognition of income and expenses, and generally excludes net unrealized appreciation or depreciation. Distributions declared and paid by us in a taxable year may differ from taxable income for that taxable year as such distributions may include the distribution of taxable income derived from the current taxable year or the distribution of taxable income derived from the prior taxable year carried forward into and distributed in the current taxable year. Distributions also may include returns of capital. To maintain RIC tax treatment, we must, among other things, distribute (or be deemed to distribute) dividends, with respect to each taxable year, of an amount at least equal to 90% of our investment company taxable income (i.e., our net ordinary income and our realized net short-term capital gains in excess of realized net long-term capital losses, if any), determined without regard to any deduction for dividends paid. As a RIC, we are also subject to a federal excise tax, based on distribution requirements of our taxable income on a calendar year basis. We anticipate timely distribution of our taxable income in accordance with tax rules. We did not incur a U.S. federal excise tax for calendar year 2021. For the calendar year 2022, we incurred \$0.1 million of excise tax. We did not incur a U.S. federal excise tax for calendar year 2023. We do not expect to incur a U.S. federal excise tax for calendar year 2024. We intend to distribute at least 90% of our annual taxable income (which includes our taxable interest and fee income) to our stockholders. The covenants contained in our credit facilities may prohibit us from making distributions to our stockholders, and, as a result, could hinder our ability to satisfy the distribution requirement associated with our ability to be subject to tax as a RIC. In addition, we may retain for investment some or all of our net capital gains (i.e., realized net long-term capital gains in excess of realized net short-term capital losses) and treat such amounts as deemed distributions to our stockholders. If we do this, our stockholders will be treated as if they received actual distributions of the capital gains we retained and then reinvested the net after-tax proceeds in our common stock. Our stockholders also may be eligible to claim tax credits (or, in certain circumstances, tax refunds) equal to their allocable share of the tax we paid on the capital gains deemed distributed to them. To the extent our taxable earnings for a fiscal and taxable year fall below the total amount of our dividend distributions for that fiscal and taxable year, a portion of those distributions may be deemed a return of capital to our stockholders. We may not be able to achieve operating results that will allow us to make distributions at a specific level or to increase the amount of these distributions from time to time. In addition, we may be limited in our ability to make distributions due to the asset coverage test for borrowings applicable to us as a Business Development Company under the Investment Company Act and due to provisions in our credit facilities and debt instruments. If we do not distribute a certain percentage of our taxable income annually, we will suffer adverse tax consequences, including possible loss of our ability to be subject to tax as a RIC. We cannot assure stockholders that they will receive any distributions or distributions at a particular level. A RIC may treat a distribution of its own stock as fulfilling its RIC distribution requirements if each stockholder elects to receive his or her entire distribution in either cash or stock of the RIC, subject to certain limitations regarding the aggregate amount of cash to be distributed to all stockholders. If these and certain other requirements are met, for U.S. federal income tax purposes, the amount of the dividend paid in stock will be equal to the amount of cash that could have been received instead of stock. We may generate qualified net interest income or qualified net short-term capital gains that may be exempt from U.S. withholding tax when distributed to foreign stockholders. A RIC is permitted to designate distributions of qualified net interest income and qualified short-term capital gains as exempt from U.S. withholding tax when paid to non-U.S. shareholders with proper documentation. The following table, which may be subject to change as we finalize our annual tax filings, lists the percentage of qualified net interest income and qualified short-term capital gains for the year ended September 30, 2023. Year Ended Qualified Net Interest Income Qualified Short-Term Capital Gains September 30, 2023 389.4% We have adopted a DRIP that provides for the reinvestment of any distributions that we declare in cash on behalf of our stockholders, unless a stockholder elects to receive cash. As a result, if our Board of Directors declares a cash distribution, then our stockholders who have not elected to receive the DRIP will have their cash distributions automatically reinvested in additional shares of our common stock, rather than receiving a cash distribution. If our shares are trading at a premium to net asset value, we typically issue new shares to implement the DRIP, with such shares issued at the greater of the most recently computed net asset value per share of our common stock or 95% of the current market value per share of our common stock on the payment date for such distribution. If our shares are trading at a discount to net asset value, we typically purchase shares in the open market in connection with our obligations under the DRIP. Related Party Transactions We have entered into the Investment Advisory Agreement with Oaktree and the Administration Agreement with Oaktree Administrator, an affiliate of Oaktree. Mr. John B. Frank, an interested member of our Board of Directors, has an indirect pecuniary interest in Oaktree. Oaktree is a registered investment adviser under the Investment Advisers Act of 1940, as amended, that is partially and indirectly owned by Oaktree Capital Group, LLC. See Note 10. Related Party Transactions Investment Advisory Agreement Administrative Services The notes to the accompanying Consolidated Financial Statements. Recent Developments Distribution Declaration On July 26, 2024, our Board of Directors declared a quarterly distribution of \$0.55 per share, payable in cash on September 30, 2024 to stockholders of record on September 16, 2024. 99 Item 3. Quantitative and Qualitative Disclosures about Market Risk We are subject to financial market risks, including changes in the valuations of our investment portfolio and interest rates. Valuation Risk Our investments may not have a readily available market price, and we value these investments at fair value as determined by Oaktree, as our valuation designee. There is no single standard for determining fair value in good faith and valuation methodologies involve a significant degree of management judgment. In addition, our valuation methodology utilizes discount rates in part in valuing our investments, and changes in those discount rates may have an impact on the valuation of our investments. Accordingly, valuations by Oaktree do not necessarily represent the amounts which may eventually be realized from sales or other dispositions of investments. Estimated fair values may differ from the values that would have been used had a ready market for the investment existed, and the differences could be material to the financial statements. Interest Rate Risk We are subject to financial market risks, including changes in interest rates. Changes in interest rates may affect both our cost of funding and our interest income from portfolio investments, cash and cash equivalents and idle fund investments. Our risk management procedures are designed to identify and analyze our risk, to set appropriate policies and to continually monitor these risks. Our investment income will be affected by changes in various interest rates, including SOFR, EURIBOR, SONIA and prime rates, to the extent our debt investments include floating interest rates. As of June 30, 2024, 85.3% of our debt investment portfolio (at fair value) and 85.7% of our debt investment portfolio (at cost) bore interest at floating rates. As of September 30, 2023, 86.2% of our debt investment portfolio (at fair value) and 86.4% of our debt investment portfolio (at cost) bore interest at floating rates. The composition of our floating rate debt investments by interest rate floor as of June 30, 2024 and September 30, 2023, was as follows: June 30, 2024 September 30, 2023 (\$ in thousands) Fair Value of a Floating Rate Portfolio Fair Value of a Floating Rate Portfolio Fair Value of a Floating Rate Portfolio % 337,615 13.3% \$169,693 7.2% >0% and <1% 593,985 23.5% 522,027 22.3% 1% 1,313,463 52.0% 1,405,134 59.9% >1% 281,841 11.2% 248,351 10.6% Total Floating Rate Investments \$2,566,904 100.0% \$2,345,205 100.0% Based on our Consolidated Statement of Assets and Liabilities as of June 30, 2024, the following table shows the approximate annualized net increase (decrease) in net assets resulting from operations (excluding the impact of any potential incentive fees) of hypothetical base rate changes in interest rates, assuming no changes in our investment and capital structure. However, there can be no assurances our portfolio companies will be able to meet their contractual obligations at any or all levels on increases in interest rates. (\$ in thousands) Basis point increase Increase in Interest Income (Decrease) in Interest Expense Net increase in net assets resulting from operations 250 \$66,406 \$36,000 \$30,406 2053.122 \$28,800 34,322 15039,838 \$21,600 18,238 10026,554 \$14,400 12,154 5013,277 \$7,200 6,077 100 (\$ in thousands) Basis point decrease (Decrease) in Interest Income Decrease in Interest Expense Net (decrease) in net assets resulting from operations 50 \$13,327 \$7,200 \$6,127 100 (26,653) 14,400 (12,253) 150 (39,980) 21,600 (18,380) 200 (53,306) 28,800 (24,506) 250 (66,586) 36,000 (30,586) We regularly measure exposure to interest rate risk. We assess interest rate risk and manage our interest rate exposure on an ongoing basis by comparing our interest rate sensitive assets to our interest rate sensitive liabilities. Based on this review, we determine whether or not any hedging transactions are necessary to mitigate exposure to changes in interest rates. The interest rate on the principal balance outstanding for primarily all floating rate loans is indexed to the SOFR and/or an alternate base rate, which typically resets semi-annually, quarterly, or monthly at the borrower's option. The borrower may also elect to have multiple interest reset periods for each loan. The following table shows a comparison of the interest rate base for our interest-bearing cash and outstanding investments, at principal, and our outstanding borrowings as of June 30, 2024 and September 30, 2023. June 30, 2024 September 30, 2023 (\$ in thousands) Interest Bearing Cash and Investments Borrowings Interest Bearing Cash and Investments Borrowings Money market rates \$37,364 \$83,262 \$46 Prime rate 1,366 25,000 2,221 \$4 LIBOR 30 day \$26,692 \$90 day \$45,671 \$180 day \$54,559 \$EURIBOR 30 day \$5,500 \$90 day \$4,731 \$180 day \$6,666 \$SOFR 30 day \$849,934 480,000 \$682,693 430,000 \$6 day \$4,088 \$90 day (a) 1,692,027 935,000 1,533,240 930,000 180 day \$3,894 \$SONIA \$41,394 \$AE53,250 \$A Fixed rate \$448,362 300,000 \$392,019 300,000 (a) Borrowings include the 2027 Notes and 2029 Notes, which pay interest at a floating rate under the terms of the interest rate swap. 101 Item 4. Controls and Procedures (a) Evaluation of Disclosure Controls and Procedures Management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of June 30, 2024. The term "disclosure controls and procedures," as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission's rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company's management, including its chief executive officer and chief financial officer, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives. Based on the evaluation of our disclosure controls and procedures as of June 30, 2024, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective, at the reasonable assurance level, in timely identifying, recording, processing, summarizing and reporting any material information relating to us that is required to be disclosed in the reports we file or submit under the Exchange Act. There were no changes in our internal control over financial reporting that occurred during the three months ended June 30, 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. PART II Item 1. Legal Proceedings We are currently not a party to any pending material legal proceedings. Item 1A. Risk Factors There have been no material changes during the three months ended June 30, 2024 to the risk factors discussed in Item 1A. Risk Factors in our Annual Report on Form 10-K for the year ended September 30, 2023. Item 2. A. A. Unregistered Sales of Equity Securities and Use of Proceeds. None. Item 3. Defaults Upon Senior Securities. None. Item 4. A. A. A. Mine Safety Disclosures. Not applicable. Item 5. Other Information During the three months ended June 30, 2024, none of our officers or directors adopted or terminated any contract, instruction or written plan for the purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any non-Rule 10b5-1 trading arrangement. 102 Item 6. Exhibits 3.1 Restated Certificate of Incorporation of the Registrant (Incorporated by reference to Exhibit 3.1 filed with Registrant's Form 8-A (File No. 001-33901) filed on January 2, 2008). 3.2 Certificate of Amendment to the Registrant's Restated Certificate of Incorporation (Incorporated by reference to Exhibit (a)(2) filed with Registrant's Registration Statement on Form N-2 (File No. 333-146743) filed on June 6, 2008). 3.3 Certificate of Correction to the Certificate of Amendment to the Registrant's Restated Certificate of Incorporation (Incorporated by reference to Exhibit (a)(3) filed with Registrant's Registration Statement on Form N-2 (File No. 333-146743) filed on June 6, 2008). 3.4 Certificate of Amendment to Registrant's Restated Certificate of Incorporation (Incorporated by reference to Exhibit 3.1 filed with Registrant's Quarterly Report on Form 10-Q (File No. 001-33901) filed on May 5, 2010). 3.5 Certificate of Amendment to Registrant's Restated Certificate of Incorporation (Incorporated by reference to Exhibit (a)(5) filed with the Registrant's Registration Statement on Form N-2 (File No. 333-180267) filed on April 2, 2013). 3.6 Certificate of Amendment to the Restated Certificate of Incorporation of the Registrant, dated as of October 17, 2017 (Filed with the Registrant's Form 8-K (File No. 814-00755) filed on October 17, 2017). 3.7 Certificate of Amendment to the Restated Certificate of Incorporation of the Registrant, dated as of January 20, 2023 (Incorporated by reference to Exhibit 3.7 filed with the Registrant's Form 8-K (File No. 814-00755) filed on January 20, 2023). 3.8 Fourth Amended and Restated Bylaws of the Registrant (Incorporated by reference to Exhibit 3.1 filed with Registrant's Form 8-K (File No. 814-00755) filed on January 29, 2018). 4.1 Form of Common Stock Certificate (Incorporated by reference to Exhibit 4.1 filed with Registrant's Form 8-A (File No. 001-33901) filed on January 2, 2008). 10.1 Letter Agreement, dated as of April 26, 2024, by and between the Registrant and Oaktree Fund Advisors, LLC (Incorporated by reference to Exhibit 10.1 filed with Registrant's Form 10-Q (File No. 814-00755) filed on April 30, 2024). 10.2 Seventh Amendment to Loan and Security Agreement, dated as of May 20, 2024, by and among the Company, OSI 2 Senior Lending SPV, LLC, and Citibank, N.A. (Incorporated by reference to Exhibit 1.1 filed with the Registrant's Form 8-K (File No. 814-00755) filed on May 22, 2024). 31.1 A Certification of Chief Executive Officer Pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934. 31.2 A Certification of Chief Financial Officer Pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934. 31.3 A Certification of Chief Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. 1350). 31.4 A Certification of Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. 1350). 101. INS* Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. 101. SCH* Inline XBRL Taxonomy Extension Schema Document. 101. DEF* Inline XBRL Taxonomy Extension Definition Linkbase Document. 101. LAB* Inline XBRL Taxonomy Extension Label Linkbase Document. 101. PRE* Inline XBRL Taxonomy Extension Presentation Linkbase Document. 104* Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)* Filed herewith. 103 SIGNATURES Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. OAKTREE SPECIALTY LENDING CORPORATION By: A/s/ A Armen Panossian Armen Panossian Chief Executive Officer By: A/s/ A Christopher McKown Christopher McKown Chief Financial Officer and Treasurer Date: July 31, 2024 104 EX-31.1 2 ocs-ex31.1_06302024x10qx.htm EX-31.1 Document Exhibit 31.11, Armen Panossian, Chief Executive Officer of Oaktree Specialty Lending Corporation, certify that: 1. I have reviewed this quarterly report on Form 10-Q for the quarter ended June 30, 2024 of Oaktree Specialty Lending Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and 5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): (a) All significant

to record, process, summarize and report financial information; and(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.Dated this 31st day of July, 2024.By:/s/ Armen PanossianArmen PanossianChief Executive Officer EX-31.2 ocslex312.06302024x10qx.htm EX-31.2 DocumentExhibitA 31.21. Christopher McKown, Chief Financial Officer of Oaktree Specialty Lending Corporation, certify that:1. I have reviewed this quarterly report on Form 10-Q for the quarter ended June 30, 2024 of Oaktree Specialty Lending Corporation;2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.Dated this 31st day of July, 2024.By:/s/ Armen PanossianChristopher McKownChief Financial Officer EX-32.1 4 ocsl-ex321.06302024x10qx.htm EX-32.1 DocumentExhibitA 32.1Certification of Chief Executive OfficerPursuant toSection 906 of the Sarbanes-Oxley Act of 2002 (18Â U.S.C. 1350)In connection with the quarterly report on Form 10-Q for the quarter ended June 30, 2024 (the "Report") of Oaktree Specialty Lending Corporation (the "Registrant"), as filed with the Securities and Exchange Commission on the date hereof, I, Armen Panossian, the Chief Executive Officer of the Registrant, hereby certify, to the best of my knowledge, that:(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant./s/ Armen PanossianName: Armen PanossianDate: July 31, 2024 EX-32.2 5 ocsl-ex322.06302024x10qx.htm EX-32.2 DocumentExhibitA 32.2Certification of Chief Financial OfficerPursuant toSection 906 of the Sarbanes-Oxley Act of 2002 (18Â U.S.C. 1350)In connection with the quarterly report on Form 10-Q for the quarter ended June 30, 2024 (the "Report") of Oaktree Specialty Lending Corporation (the "Registrant"), as filed with the Securities and Exchange Commission on the date hereof, I, Christopher McKown, the Chief Financial Officer of the Registrant, hereby certify, to the best of my knowledge, that:(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant./s/ Christopher McKownName: Christopher McKownDate: July 31, 2024 EX-101.SCH 6 ocsl-20240630.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link-presentationLink link:calculationLink link:definitionLink 0000002 - Statement - Consolidated Statements of Assets and Liabilities link-presentationLink link:calculationLink link:definitionLink 0000003 - Statement - Consolidated Statements of Assets and Liabilities (Parenthetical) link-presentationLink link:calculationLink link:definitionLink 0000004 - Statement - Consolidated Statements of Operations link-presentationLink link:calculationLink link:definitionLink 0000005 - Statement - Consolidated Statements of Changes in Net Assets link-presentationLink link:calculationLink link:definitionLink 0000006 - Statement - Consolidated Statement of Cash Flows link-presentationLink link:calculationLink link:definitionLink 0000007 - Statement - Consolidated Schedule of Investments link-presentationLink link:calculationLink link:definitionLink 0000008 - Statement - Consolidated Schedule of Investments - Derivatives link-presentationLink link:calculationLink link:definitionLink 0000008 - Statement - Consolidated Schedule of Investments - Derivatives link-presentationLink link:calculationLink link:definitionLink 0000009 - Statement - Consolidated Schedule of Investments - Parenthetical link-presentationLink link:calculationLink link:definitionLink 0000010 - Disclosure - Organization link-presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - Significant Accounting Policies link-presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - Portfolio Investments link-presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - Fee Income link-presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - Share Data and Net Assets link-presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - Borrowings link-presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - Taxable/Distributable Income and Dividend Distributions link-presentationLink link:calculationLink link:definitionLink 0000017 - Disclosure - Realized Gains or Losses and Net Unrealized Appreciation or Depreciation link-presentationLink link:calculationLink link:definitionLink 0000018 - Disclosure - Concentration of Credit Risks link-presentationLink link:calculationLink link:definitionLink 0000019 - Disclosure - Related Party Transactions link-presentationLink link:calculationLink link:definitionLink 0000020 - Disclosure - Financial Highlights link-presentationLink link:calculationLink link:definitionLink 0000021 - Disclosure - Derivative Instruments link-presentationLink link:calculationLink link:definitionLink 0000022 - Disclosure - Commitments and Contingencies link-presentationLink link:calculationLink link:definitionLink 0000023 - Disclosure - Subsequent Events link-presentationLink link:calculationLink link:definitionLink 0000024 - Disclosure - Schedule A 12-14 link-presentationLink link:calculationLink link:definitionLink 9954701 - Disclosure - Significant Accounting Policies (Details) link-presentationLink link:calculationLink link:definitionLink 9954702 - Disclosure - Portfolio Investments (Tables) link-presentationLink link:calculationLink link:definitionLink 9954703 - Disclosure - Share Data and Net Assets (Tables) link-presentationLink link:calculationLink link:definitionLink 9954704 - Disclosure - Borrowings (Tables) link-presentationLink link:calculationLink link:definitionLink 9954705 - Disclosure - Taxable/Distributable Income and Dividend Distributions (Tables) link-presentationLink link:calculationLink link:definitionLink 9954706 - Disclosure - Realized Gains or Losses and Net Unrealized Appreciation or Depreciation (Tables) link-presentationLink link:calculationLink link:definitionLink 9954707 - Disclosure - Financial Highlights (Tables) link-presentationLink link:calculationLink link:definitionLink 9954708 - Disclosure - Derivative Instruments (Tables) link-presentationLink link:calculationLink link:definitionLink 9954709 - Disclosure - Commitments and Contingencies (Tables) link-presentationLink link:calculationLink link:definitionLink 9954710 - Disclosure - Significant Accounting Policies (Details) link-presentationLink link:calculationLink link:definitionLink 9954711 - Disclosure - Portfolio Investments - Narrative (Details) link-presentationLink link:calculationLink link:definitionLink 9954712 - Disclosure - Portfolio Investments - Composition of Investments (Details) link-presentationLink link:calculationLink link:definitionLink 9954713 - Disclosure - Portfolio Investments - Schedule of Financial Instruments Carried at Fair Value (Details) link-presentationLink link:calculationLink link:definitionLink 9954714 - Disclosure - Portfolio Investments - Roll-Forward in the Changes in Fair Value (Details) link-presentationLink link:calculationLink link:definitionLink 9954715 - Disclosure - Portfolio Investments - Significant Unobservable Inputs for Level 3 Investments (Details) link-presentationLink link:calculationLink link:definitionLink 9954716 - Disclosure - Portfolio Investments - Schedule of Financial Instruments Disclosed, but Carried at Fair Value (Details) link-presentationLink link:calculationLink link:definitionLink 9954717 - Disclosure - Portfolio Investments - Portfolio Composition (Details) link-presentationLink link:calculationLink link:definitionLink 9954718 - Disclosure - Portfolio Investments - Portfolio of Investments by Industry (Details) link-presentationLink link:calculationLink link:definitionLink 9954719 - Disclosure - Portfolio Investments - Summary of Portfolio (Details) link-presentationLink link:calculationLink link:definitionLink 9954720 - Disclosure - Portfolio Investments - Portfolio Listing (Details) link-presentationLink link:calculationLink link:definitionLink 9954721 - Disclosure - Portfolio Investments - Summarized Balance Sheet Information (Details) link-presentationLink link:calculationLink link:definitionLink 9954722 - Disclosure - Portfolio Investments - Summarized Statement of Operations Information (Details) link-presentationLink link:calculationLink link:definitionLink 9954723 - Disclosure - Fee Income (Details) link-presentationLink link:calculationLink link:definitionLink 9954724 - Disclosure - Share Data and Net Assets - Narrative (Details) link-presentationLink link:calculationLink link:definitionLink 9954725 - Disclosure - Share Data and Net Assets - Schedule of Basic and Diluted Earnings Per Share (Details) link-presentationLink link:calculationLink link:definitionLink 9954726 - Disclosure - Share Data and Net Assets - Schedule of Changes in Net Assets (Details) link-presentationLink link:calculationLink link:definitionLink 9954727 - Disclosure - Share Data and Net Assets - Schedule of Distributions (Details) link-presentationLink link:calculationLink link:definitionLink 9954728 - Disclosure - Share Data and Net Assets - Schedule of Common Stock Issued and Sold (Details) link-presentationLink link:calculationLink link:definitionLink 9954729 - Disclosure - Borrowings - Narrative (Details) link-presentationLink link:calculationLink link:definitionLink 9954730 - Disclosure - Borrowings - Components of the Carrying Value of Notes (Details) link-presentationLink link:calculationLink link:definitionLink 9954731 - Disclosure - Borrowings - Components of Interest and Other Debt Expenses (Details) link-presentationLink link:calculationLink link:definitionLink 9954732 - Disclosure - Taxable/Distributable Income and Dividend Distributions - Narrative (Details) link-presentationLink link:calculationLink link:definitionLink 9954733 - Disclosure - Taxable/Distributable Income and Dividend Distributions - Reconciliation of Net Increase (Decrease) in Net Assets Resulting from Operations (Details) link-presentationLink link:calculationLink link:definitionLink 9954734 - Disclosure - Taxable/Distributable Income and Dividend Distributions - Components of Accumulated Overdistributed Earnings (Details) link-presentationLink link:calculationLink link:definitionLink 9954735 - Disclosure - Realized Gains or Losses and Net Unrealized Appreciation or Depreciation - Aggregate Net Realized Gains (Details) link-presentationLink link:calculationLink link:definitionLink 9954736 - Disclosure - Realized Gains or Losses and Net Unrealized Appreciation or Depreciation - Narrative (Details) link-presentationLink link:calculationLink link:definitionLink 9954737 - Disclosure - Related Party Transactions (Details) link-presentationLink link:calculationLink link:definitionLink 9954738 - Disclosure - Financial Highlights (Details) link-presentationLink link:definitionLink 9954739 - Disclosure - Derivative Instruments - Schedule of Foreign Currency Forward Contracts and Interest Rate Swap (Details) link-presentationLink link:calculationLink link:definitionLink 9954739 - Disclosure - Derivative Instruments - Schedule of Foreign Currency Forward Contracts and Interest Rate Swap (Details) link-presentationLink link:calculationLink link:definitionLink 9954740 - Disclosure - Derivative Instruments - Narrative (Details) link-presentationLink link:calculationLink link:definitionLink 9954741 - Disclosure - Commitments and Contingencies - Narrative (Details) link-presentationLink link:calculationLink link:definitionLink 9954742 - Disclosure - Commitments and Contingencies - Schedule of Unfunded Commitments by Investment (Details) link-presentationLink link:calculationLink link:definitionLink 9954742 - Disclosure - Commitments and Contingencies - Schedule of Unfunded Commitments by Investment (Details) link-presentationLink link:calculationLink link:definitionLink 9954743 - Disclosure - Subsequent Events (Details) link-presentationLink link:calculationLink link:definitionLink 9954744 - Disclosure - Schedule A 12-14 - Schedule of Investments in and Advances to Affiliates (Details) link-presentationLink link:calculationLink link:definitionLink 9954744 - Disclosure - Schedule A 12-14 - Schedule of Investments in and Advances to Affiliates (Details) link-presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 ocsl-20240630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 ocsl-20240630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 ocsl-20240630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT STOCK Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Related Party Transaction [Line Items] Related Party Transaction [Line Items] Leisure Facilities Leisure Facilities [Member] Leisure Facilities Investment Company, Nonconsolidated Subsidiary [Axis] Investment Company, Nonconsolidated Subsidiary [Axis] All Award Types Award Type [Domain] Fair Value as of Grant Date Award Grant Date Fair Value Investment, Name [Domain] Investment, Name [Domain] Communications Equipment Communications Equipment [Member] Communications Equipment Federal Income Tax Note [Table] Federal Income Tax Note [Table] Due from portfolio companies Due From Portfolio Companies Due From Portfolio Companies Deferred tax liability Deferred Income Tax Liabilities, Net Investment Company, Nonconsolidated Subsidiary [Table

amount Investment Company, Financial Commitment To Investee By Company And Counterparty, Aggregate Amount, Investment Company, Financial Commitment To Investee By Company And Counterparty, Aggregate Amount, Investment, cost Investment owned, at cost Investment Owned, Cost Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Line of Credit Facility [Table] Line of Credit Facility [Table] Exited Investments Exited Investments [Member] Exited Investments Proceeds from the sales and repayments of investments Cash consideration for sale of investments Proceeds from Disposition of Investment, Operating Activity Number of shares issued (in shares) Number of Shares Issued (in shares) Sale of Stock, Number of Shares Issued in Transaction Base management fee Management Fee Expense Loss on sale of investments Gain (Loss) on Sale of Investments Total interest expense Interest Expense, Debt Interest rate swap fair value adjustment Interest Rate Fair Value Hedge Derivative at Fair Value, Net Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Other expenses Other Expenses Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Variable Rate, Period [Axis] Variable Rate, Period [Axis] Variable Rate, Period Award Type Award Type [Axis] Document Quarterly Report Health Care Services Health Care Services [Member] Health Care Services %A of A Debt Portfolio Debt Securities, Percentage Of Debt Portfolio Debt Securities, Percentage Of Debt Portfolio Issuance of common stock under dividend reinvestment plan (in shares) DRIPA Shares Issued (in shares) Stock Issued During Period, Shares, Dividend Reinvestment Plan Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Hedging Designation [Axis] Hedging Designation [Axis] Schedule of Distributions Dividends Declared [Table Text Block] Related Party Transactions Related Party Transactions Disclosure [Text Block] Investment company, contractual fee waived Investment Company, Contractual Fee Waived Health Care Supplies Health Care Supplies [Member] Health Care Supplies PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Number of investment committee members selected by company Number Of Investment Committee Members Selected By Company Number Of Investment Committee Members Selected By Company Deutsche Bank Trust Company Americas Deutsche Bank Trust Company Americas [Member] Deutsche Bank Trust Company Americas Zephyr Bidco Limited Zephyr Bidco Limited [Member] Zephyr Bidco Limited Recently Adopted Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Foreign currency forward contracts Gain (Loss) on Sale of Derivatives Notional Amount to be Sold Derivative Asset, Notional Amount Investment, interest rate (as a percent) Investment Interest Rate Fair Value Debt Instrument, Fair Value Disclosure Average Sales Price per Share (in dollars per share) Sale of Stock, Price Per Share Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Deferred Offering Costs Deferred Offering Costs, Policy [Policy Text Block] Deferred Offering Costs, Policy Due from Portfolio Companies Due From Portfolio Companies, Policy [Policy Text Block] Due From Portfolio Companies, Policy Net proceeds Sale of Stock, Consideration Received on Transaction, Excluding Offering Costs Sale of Stock, Consideration Received on Transaction, Excluding Offering Costs Security Exchange Name Employee Stock Option Share-Based Payment Arrangement, Option [Member] Derivative Instruments Derivative Instruments and Hedging Activities Disclosure [Text Block] Investment Income Investment, Policy [Policy Text Block] Interest, dividends and fees receivable Dividend and Interest Receivable Hotels, Resorts & Cruise Lines Hotels, Resorts & Cruise Lines [Member] Hotels, Resorts & Cruise Lines Maximum Maximum [Member] Document Type Interest rate (as a percent) Line of Credit Facility, Interest Rate During Period Geographic Concentration Risk Geographic Concentration Risk [Member] Tabular List, Table Tabular List [Table Text Block] After Reinvestment Period After Reinvestment Period [Member] After Reinvestment Period Amount which can be drawn immediately Investment Company, Financial Support To Investee Contractually Required, Amount Which Can Be Drawn Immediately Investment Company, Financial Support To Investee Contractually Required, Amount Which Can Be Drawn Immediately Citibank Facility Citibank Facility [Member] Citibank Facility Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Investments sold Investment Company, Investments Sold Investment Company, Investments Sold Investment, principal Investment owned, balance, principal amount Investment Owned, Balance, Principal Amount Earnout Share Vesting, Tranche Two Earnout Share Vesting, Tranche Two [Member] Earnout Share Vesting, Tranche Two Variable Rate [Axis] Variable Rate [Axis] Increase (decrease) in accounts payable, accrued expenses and other liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities Investment Company, Nonconsolidated Subsidiary [Line Items] Investment Company, Nonconsolidated Subsidiary [Line Items] Net investment income before taxes Net Investment Income Title of 12(b) Security Financial Highlights Investment Company, Financial Highlights [Text Block] Interest income Interest Income, Operating Related Party [Domain] Related Party, Type [Domain] Transaction Precedent Valuation, Transaction Precedent [Member] Valuation, Transaction Precedent Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Income Tax Disclosure [Abstract] Interest rate (as a percent) Derivative, Fixed Interest Rate Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Wireless Telecommunication Services Wireless Telecommunication Services [Member] Wireless Telecommunication Services Total investment owned, at fair value and money market funds, at carrying value Investment Owned, At Fair Value And Money Market Funds, At Carrying Value Investment Owned, At Fair Value And Money Market Funds, At Carrying Value Contractual fee waived, period otherwise receivable (in years) Investment Company, Contractual Fee Waived, Period Investment Company, Contractual Fee Waived, Period Entity Tax Identification Number Oaktree Strategic Income II, Inc Merger, Year One Oaktree Strategic Income II, Inc Merger, Year One [Member] Oaktree Strategic Income II, Inc Merger, Year One Subordinated debt Debt Securities, Subordinated [Member] Debt Securities, Subordinated Statistical Measurement [Axis] Statistical Measurement [Axis] Percentage of total assets representing non-qualifying assets (as a percent) Percentage Of Total Assets Representing Non-Qualifying Assets Percentage Of Total Assets Representing Non-Qualifying Assets Coupon interest Interest Expense, Debt, Excluding Amortization Technology Distributors Technology Distributors [Member] Technology Distributors Cash Distribution Investment Company, Dividend Distribution Entity Interactive Data Current Schedule of Aggregate Net Realized Gains Schedule of Realized Gain (Loss) [Table Text Block] Debt instrument, covenant, total assets to total indebtedness, ratio, minimum threshold Debt Instrument, Covenant, Total Assets To Total Indebtedness, Ratio Debt Instrument, Covenant, Total Assets To Total Indebtedness, Ratio Accumulated Overdistributed Earnings Investment Company, Accumulated Overdistributed Earnings [Member] Investment Company, Accumulated Overdistributed Earnings Stockholder transactions: Investment Company, Distribution to Shareholders [Abstract] Underwriting commissions Investment Banking, Advisory, Brokerage, and Underwriting Fees and Commissions Measure: Measure [Axis] Commitments and Contingencies Disclosure [Abstract] Name Outstanding Recovery, Individual Name Earnout Share Vesting, Tranche One Earnout Share Vesting, Tranche One [Member] Earnout Share Vesting, Tranche One Investments at fair value, measurement input Investment Company, Investment Owned, Measurement Input Home Furnishings Home Furnishings [Member] Home Furnishings Broker Quoted Price Measurement Input, Broker Quoted Price [Member] Measurement Input, Broker Quoted Price Entity Incorporation, State or Country Code Distribution Type [Domain] Distribution Type [Domain] Net increase (decrease) in net assets from capital share transactions Investment Company, Capital Share Transactions, Increase (Decrease) Investment Company, Capital Share Transactions, Increase (Decrease) Oaktree Strategic Income II, Inc Merger, Year Two Oaktree Strategic Income II, Inc Merger, Year Two [Member] Oaktree Strategic Income II, Inc Merger, Year Two Transaction Price Measurement Input, Transaction Price [Member] Measurement Input, Transaction Price Derivative Instruments Derivatives, Policy [Policy Text Block] Schedule of Related Party Transactions, by Related Party [Table] Schedule of Related Party Transactions, by Related Party [Table] Passenger Airlines Passenger Airlines [Member] Passenger Airlines Gross Additions Investments in and Advances to Affiliates, at Fair Value, Gross Additions Common stock, shares outstanding (in shares) Common shares outstanding at end of period (in shares) Common shares outstanding at beginning of period (in shares) Common shares outstanding at end of period (in shares) Common Stock, Shares, Outstanding PEO PEO [Member] 2027 Notes 2027 Notes [Member] 2027 Notes SLF JV I, LLC SLF JV I, LLC [Member] SLF JV I, LLC Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Sale of Stock [Axis] Sale of Stock [Axis] Net investment income Net investment income Net investment income Investment Income, Operating, after Expense and Tax Short-Term Capital Loss Carryforward Short-Term Capital Loss Carryforward [Member] Short-Term Capital Loss Carryforward Interest rate swap Interest Rate Swap [Member] Professional fees Professional Fees Debt Instrument [Axis] Portfolio Investments Schedule of Investments [Text Block] Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Measurement Input Type [Domain] Measurement Input Type [Domain] Net unrealized appreciation (depreciation) Debt and Equity Securities, Unrealized Gain (Loss) Credit Facility [Axis] Credit Facility [Axis] Housewares & Specialties Housewares & Specialties [Member] Housewares & Specialties Total liabilities Liabilities Wells Fargo Bank, N.A. Wells Fargo Bank, N.A. [Member] Wells Fargo Bank, N.A. Average debt per share (dollars per share) Investment Company, Average Long-Term Debt Outstanding Per Share Investment Company, Average Long-Term Debt Outstanding Per Share Increase (decrease) in base management fee and incentive fee payable Increase (Decrease) in Management and Incentive Fees Payable Repayments of borrowings under credit facilities Repayments of Long-Term Lines of Credit Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Interest Rate Swap Maturing 2029 Interest Rate Swap Maturing 2029 [Member] Interest Rate Swap Maturing 2029 Schedule of Common Stock Issued and Sold Schedule of Sale of Stock by Subsidiary or Equity Method Investee Disclosure [Table Text Block] Related Party Transaction [Domain] Related Party Transaction [Domain] Average net assets Average Net Assets Average Net Assets Debt investments, fair value Debt Securities, Available-for-Sale and Held-to-Maturity, Fair Value Subsequent Event [Line Items] Subsequent Event [Line Items] Affiliated Entity Affiliated Entity [Member] General and administrative expenses General and Administrative Expense Preferred & Common Equity Equity Securities, Preferred & Common [Member] Equity Securities, Preferred & Common Glick JV LLC Glick JV LLC [Member] Glick JV LLC Secured Overnight Financing Rate Secured Overnight Financing Rate [Member] Secured Overnight Financing Rate Oil & Gas Storage & Transportation Oil & Gas Storage & Transportation [Member] Oil & Gas Storage & Transportation Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Investments in equity securities Equity Securities [Member] Supplemental information: Supplemental Cash Flow Information [Abstract] Apparel Retail Apparel Retail [Member] Apparel Retail Equity investments in the JVs Equity Securities, JV [Member] Equity Securities, JV Due to affiliate Other liabilities Other Liabilities (Provision) benefit for taxes on realized and unrealized gains (losses) (Provision) benefit for taxes on realized and unrealized gains (losses) Gain (Loss), Investment and Derivative, Operating, Tax Expense (Benefit) Repurchase of common stock under dividend reinvestment plan (in shares) Stock Repurchased During Period, Shares Aggregate offering price Sale Of Stock, Maximum Aggregate Offering Amount Sale Of Stock, Maximum Aggregate Offering Amount Concentration risk (as a percent) Concentration Risk, Percentage Unrealized appreciation (depreciation): Investment Owned, Recognized Unrealized Appreciation (Depreciation), Net [Abstract] Investment Owned, Recognized Unrealized Appreciation (Depreciation), Net Purchases of investments Cash consideration for purchase of investments Payment for Purchase, Investment, Operating Activity Investment, Issuer Name [Axis] Investment, Issuer Name [Axis] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Weighted average outstanding debt Long-Term Debt, Average Amount Outstanding Net unrealized appreciation (depreciation) (in dollars per share) Investment Company, Gain (Loss) On Unrealized Appreciation (Depreciation), Per Share Investment Company, Gain (Loss) On Unrealized Appreciation (Depreciation), Per Share Soft Drinks & Non-alcoholic Beverages Soft Drinks & Non-alcoholic Beverages [Member] Soft Drinks & Non-alcoholic Beverages Syndicated Facility payable Syndicated Facility [Member] Syndicated Facility Net cash provided by (used in) operating activities Net Cash Provided by (Used in) Operating Activities Class of Stock [Axis] Investment Advisory Agreement Incentive Rate Quarterly Catch Up Threshold Investment Advisory Agreement - Incentive Rate, Quarterly Catch-Up Threshold [Member] Investment Advisory Agreement - Incentive Rate, Quarterly Catch-Up Threshold Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Unsecured notes payable (net of \$5,468 and \$7,076 of unamortized financing costs as of June 30, 2024 and September 30, 2023, respectively) Unsecured Debt American Tire Distributors Inc. American Tire Distributors Inc. [Member] American Tire Distributors Inc. Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Effect of interest rate swap Interest Expense, Effect Of Interest Rate Swap Interest Expense, Effect Of Interest Rate Swap Investment Owned, At Cost Investment Owned, At Cost [Member] Investment Owned, At Cost Investment Company, Changes in Net Assets [Table] Investment Company, Change in Net Assets [Table] SLF JV I Facility SLF JV I Facility [Member] SLF JV I Facility Valuation allowance Deferred Tax Assets, Valuation Allowance Fee income Fee Income Floating interest rate (as a percent) Derivative, Basis Spread on Variable Rate Dividend income Dividend Income, Operating, Paid in Cash Consumer Finance Consumer Finance [Member] Consumer Finance Entity Emerging Growth Company Deferred financing costs Debt Issuance Costs, Net Diversified Support Services Diversified Support Services [Member] Diversified Support Services Deferred tax assets Deferred Tax Assets, Gross Investment, Identifier [Axis] Investment, Identifier [Axis] Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Title Trading Arrangement, Individual Title Broker Quotations Valuation, Broker Quotations [Member] Valuation, Broker Quotations Common Stock Common Stock [Member] Individual: Individual [Axis] Entity Address, Postal Zip Code Integrated Oil & Gas Integrated Oil & Gas [Member] Integrated Oil & Gas Income Statement Location [Domain] Income Statement Location [Domain] Diversified Chemicals Diversified Chemicals [Member] Diversified Chemicals Debt instrument, floor interest rate (as a percent) Debt Instrument, Floor Interest Rate Debt Instrument, Floor Interest Rate Investment Company, Changes in Net Assets [Line Items] Investment Company, Change in Net Assets [Line Items] Weighted average interest rate (as a percent) Debt, Weighted Average Interest Rate The JVs The JVs [Member] The JVs Accounts payable, accrued expenses and other liabilities Accounts Payable and Other Accrued Liabilities Capital Loss Carryforward [Domain] Capital Loss Carryforward [Domain] Capital Loss Carryforward [Domain] Environmental & Facilities Services Environmental & Facilities Services [Member] Environmental & Facilities Services Minimum Minimum [Member] Investment Company, Nonconsolidated Subsidiary [Domain] Investment Company, Nonconsolidated Subsidiary [Domain] Investment Advisory Agreement Incentive Rate Pre Incentive Fee Net Investment Income Below Catch Up Investment Advisory Agreement - Incentive Rate, Pre-Incentive Fee Net Investment Income Below Catch Up [Member] Investment Advisory Agreement - Incentive Rate, Pre-Incentive Fee Net Investment Income Below Catch-Up Capital Loss Carryforward [Axis] Capital Loss Carryforward [Axis] Capital Loss Carryforward Statement of Cash Flows [Abstract] ASSETS Assets [Abstract] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Subordinated debt securities, including JV debt instruments Subordinated debt securities, including JV debt instruments CLO Notes Debt Securities, Subordinated, Including JV Debt Instruments [Member] Debt Securities, Subordinated, Including JV Debt Instruments Receivables/Payables from Unsettled Transactions Unsettled Investment Transactions, Policy [Policy Text Block] Unsettled Investment Transactions, Policy Liabilities: Liabilities [Abstract] Investment Company, Financial Highlights [Roll Forward] Investment Company, Financial Highlights [Roll Forward] (Increase) decrease in due from portfolio companies Increase (Decrease) In Due From Portfolio Companies Increase (Decrease) In Due From Portfolio Companies JV Financing JV Financing [Member] JV Financing Net cash provided by (used in) financing activities Net Cash Provided by (Used in) Financing Activities Total interest income Interest Income, Operating, Including Deposits Interest Income, Operating, Including Deposits Construction Machinery & Heavy Transportation Equipment Construction Construction Machinery & Heavy Transportation Equipment [Member] Construction Machinery & Heavy Transportation Equipment Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Base management fee, threshold (as a percent) Management And Service Fees, Investments Percentage Threshold Management And Service Fees, Investments Percentage Threshold Construction & Engineering Construction and Engineering Sector [Member] Construction and Engineering Sector Earnout Share Vesting [Domain] Earnout Share Vesting [Domain] Earnout Share Vesting [Domain] Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Schedule of Components of Accumulated Overdistributed Earnings Investment Company, Components Of Distributable Earnings (Accumulated Losses) [Table Text Block] Investment Company, Components Of Distributable Earnings (Accumulated Losses) Schedule 12-14 Investments in and Advances to Affiliates, Schedule of Investments [Text Block] Earnings (loss) per common share - basic (in dollars per share) Earnings Per Share, Basic Accounting Policies [Abstract] Part I incentive fee Incentive Fee Expense, Part I Incentive Fee Expense, Part I Sale of Stock [Domain] Sale of Stock [Domain] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Receivables from unsettled transactions Receivable, Investment, Sale Control investments Investment, Affiliated Issuer, Controlled [Member] Outstanding senior securities Investment, interest rate, paid in kind (as a percent) Investment, Interest Rate, Paid in Kind Pharmaceuticals Pharmaceuticals [Member] Pharmaceuticals Consolidation Consolidation, Policy [Policy Text Block] Preferred equity Equity Securities, Preferred [Member] Equity Securities, Preferred Document Transition Report Award Timing Predetermined Award Timing Predetermined [Flag] Ratio of portfolio turnover to average investments at fair value Investment Company, Portfolio Turnover Ratio Investment Company, Portfolio Turnover Ratio Health Care Technology Health Care Technology [Member] Health Care Technology Affiliate Investments Investment, Affiliated Issuer, Noncontrolled [Member] Issuance of common stock under dividend reinvestment plan Issuance of common stock under dividend reinvestment plan DRIPA Shares Value Stock Issued During Period, Value, Dividend Reinvestment Plan Financial support funded by company for investee Investment Company, Financial Support Funded For Investee, Amount Investment Company, Financial Support Funded For Investee, Amount Non-Accrual Status, Debt Securities Non-Accrual Status, Debt Securities [Member] Non-Accrual Status, Debt Securities Integrated Telecommunication Services Integrated Telecommunication Services [Member] Integrated Telecommunication Services Derivative

Instrument [Axis] Derivative Instrument [Axis] All Trading Arrangements All Trading Arrangements [Member] Number of components Related Party Transaction, Number Of Components Related Party Transaction, Number Of Components All Adjustments to Compensation [Member] Cash and Cash Equivalents and Restricted Cash Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] Stock split, conversion ratio Stockholders' Equity Note, Stock Split, Conversion Ratio Compensation Amount Outstanding Recovery Compensation Amount Financial commitment to investee, aggregate amount Investment Company, Financial Commitment To Investee, Aggregate Amount Investment Company, Financial Commitment To Investee, Aggregate Amount Total return Investment Company, Total Return Unrealized gain (loss), location Fair Value, Asset, Recurring Basis, Still Held, Unrealized Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] Derivative assets at fair value Derivative assets Derivative Asset Deferred taxes Deferred income tax benefit Deferred Income Tax Expense (Benefit) Subsequent Event Type [Axis] Subsequent Event Type [Axis] Borrowing capacity subject to expiration Line of Credit Facility, Maximum Borrowing Capacity Subject to Expiration Line of Credit Facility, Maximum Borrowing Capacity Subject to Expiration Investment owned, balance, shares, VWAP, number of consecutive trading days Investment Owned, Balance, Shares, VWAP, Consecutive Trading Days Investment Owned, Balance, Shares, VWAP, Consecutive Trading Days Variable Rate, Period [Domain] Variable Rate, Period [Domain] Variable Rate, Period [Domain] Asset coverage ratio Investment Company, Senior Security, Indebtedness, Asset Coverage Ratio Advertising Advertising Industry [Member] Advertising Industry Net expenses Investment Company, Expense, after Reduction of Fee Waiver and Reimbursement Commitment fee, unused capacity threshold percentage (as a percent) Line Of Credit Facility, Unused Capacity, Commitment Fee, Threshold Percentage Line Of Credit Facility, Unused Capacity, Commitment Fee, Threshold Percentage Net investment income per common share - basic and diluted (in dollars per share) Net investment income (in dollars per share) Investment Company, Investment Income (Loss), Per Share (Provision) benefit for taxes on realized and unrealized gains (losses) (in dollars per share) Investment Company, (Provision) Benefit For Taxes On Realized And Unrealized Gains (Losses), Per Share Investment Company, (Provision) Benefit For Taxes On Realized And Unrealized Gains (Losses), Per Share Other assets Other Assets Market Yield Measurement Input, Market Yield [Member] Measurement Input, Market Yield Tersera Therapeutics LLC Tersera Therapeutics L L C [Member] Tersera Therapeutics L L C Issuance of common stock in connection with the OS12 Merger (in shares) Stock Issued During Period, Shares, Acquisitions Undistributed ordinary income, net Investment Company, Distributable Earnings (Loss), Accumulated Capital Loss Carryforward Specialty Chemicals Specialty Chemicals [Member] Specialty Chemicals Document Period End Date Click JV Facility Click JV Facility [Member] Click JV Facility Adoption Date Trading Arrangement Adoption Date Amount per share (in dollars per share) Distributions of net investment income to stockholders (dollars per share) Investment Company, Distribution to Shareholders, Per Share Unfunded commitments Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount Concentration of Credit Risks Concentration Risk Disclosure [Text Block] Income tax expense Income Tax Expense (Benefit) Sales and repayments Fair Value, Measurement With Unobservable Inputs Reconciliation, Recurring Basis, Asset, Sales And Settlements Fair Value, Measurement With Unobservable Inputs Reconciliation, Recurring Basis, Asset, Sales And Settlements International Non-US [Member] Designated as Hedging Instrument Designated as Hedging Instrument [Member] Valuation Approach and Technique [Domain] Valuation Approach and Technique [Domain] 2025 Notes 2025 Notes 2025 Notes [Member] 2025 Notes Dividend income Dividend Income, Operating Lender Name [Axis] Lender Name [Axis] Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Number of investments Number of Investments Foreign currency forward contracts Unrealized Gain (Loss) on Derivatives Cash and cash equivalents Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Financial support funded by company and counterparty Investment Company, Financial Support Funded For Investee By Company And Counterparty, Amount Investment Company, Financial Support Funded For Investee By Company And Counterparty, Amount Credit Facility [Domain] Credit Facility [Domain] Number of board of directors selected by company Number Of Board Of Directors Selected By Company Number Of Board Of Directors Selected By Company Administrator expense Administrative Fees Expense, Administrator Fees Administrative Fees Expense, Administrator Fees Debt instrument, basis spread, variable rate (as a percent) Debt Instrument, Basis Spread on Variable Rate Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Equity Securities, Common And Warrants, Including JV Investments Equity Securities, Common And Warrants, Including JV Investments [Member] Equity Securities, Common And Warrants, Including JV Investments [Member] Equity Securities, Common And Warrants, Including JV Investments Increase (decrease) in due to affiliate Increase (Decrease) in Due to Affiliates AmountA of Interest, Fees or Dividends CreditedA in Income Interest and Dividend Income, Operating EBITDA Multiple Measurement Input, EBITDA Multiple [Member] OCSI Click JV LLC Click JV LLC OCSI Click JV LLC OCSI Click JV LLC Continental Intermodal Group LP Continental Intermodal Group LP [Member] Continental Intermodal Group LP Additional paid-in-capital Additional Paid-in Capital [Member] Total cash and cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Net unrealized appreciation (depreciation) Net unrealized appreciation (depreciation) Net unrealized (appreciation) depreciation Unrealized Gain (Loss), Investment and Derivative, Operating, before Tax Subsequent Events Subsequent Events [Text Block] Lift Brands Holdings, Inc. Lift Brands Holdings, Inc. [Member] Lift Brands Holdings, Inc. Amortization of deferred financing costs Amortization of Debt Issuance Costs Percentage of total assets representing qualifying assets (as a percent) Percentage Of Total Assets Representing Qualifying Assets Percentage Of Total Assets Representing Qualifying Assets Fair Value Measurement Inputs and Valuation Techniques [Line Items] Fair Value Measurement Inputs and Valuation Techniques [Line Items] Data Processing & Outsourced Services Data Processing & Outsourced Services [Member] Data Processing & Outsourced Services Restrictions on Cash and Cash Equivalents [Table] Restrictions on Cash and Cash Equivalents [Table] Investments in and Advances to Affiliates, at Fair Value [Roll Forward] Investments in and Advances to Affiliates, at Fair Value [Roll Forward] Purchases Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases Recurring fee income Fee Income, Recurring Fee Income, Recurring Net increase (decrease) in cash and cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Net proceeds excluding offering costs Proceeds From Issuance Of Common Stock, Net Proceeds From Issuance Of Common Stock, Net (Increase) decrease in due from broker Increase (Decrease) in Receivable from Broker-Dealer and Clearing Organization Equity Component [Domain] Equity Component [Domain] Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Entity Current Reporting Status Concentration Risk Type [Domain] Concentration Risk Type [Domain] Aden & Anais Merger Sub Inc. Aden & Anais Merger Sub Inc [Member] Aden & Anais Merger Sub Inc Redemption price (as a percent) Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed Net realized capital losses Investment Company, Distributable Earnings (Loss), Accumulated Long-Term Capital Gain (Loss) Number of investment committee members selected by counterparty Number Of Investment Committee Members Selected By Counterparty Number Of Investment Committee Members Selected By Counterparty Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Credit facilities payable Senior credit facility payable Long-Term Line of Credit Home Improvement Retail Home Improvement Retail [Member] Home Improvement Retail Variable Rate [Domain] Variable Rate [Domain] Pay vs Performance Disclosure [Line Items] Statistical Measurement [Domain] Statistical Measurement [Domain] Notional Amount to be Purchased Derivative Liability, Notional Amount Schedule of Fair Value Disclosure of Asset and Liability Not Measured at Fair Value Fair Value Disclosure of Asset and Liability Not Measured at Fair Value [Table Text Block] Internet Services & Infrastructure Internet Services & Infrastructure [Member] Internet Services & Infrastructure Underlying Security Market Price Change Underlying Security Market Price Change, Percent Other, net Other, Net [Member] Other, Net Equity Securities, Common Stock Converted Equity Securities, Common Stock Converted [Member] Equity Securities, Common Stock Converted WP CPP Holdings LLC W P C P P Holdings L L C [Member] W P C P P Holdings L L C Borrowings Debt Disclosure [Text Block] Schedule of Reconciliation of Net Increase (Decrease) in Net Assets Resulting from Operations Federal Income Tax Note [Table Text Block] Net unrealized appreciation (depreciation) Net unrealized appreciation (depreciation) Unrealized Gain (Loss), Debt and Equity Securities and Foreign Currency Transaction Price Change, Operating, before Tax Statement of Stockholders' Equity [Abstract] Interactive Media & Services Interactive Media & Services [Member] Interactive Media & Services 2029 Notes 2029 Notes [Member] 2029 Notes OS12 Citibank Facility payable OS12 Citibank Facility [Member] OS12 Citibank Facility Leisure Products Leisure Products [Member] Leisure Products Revolving Credit Facility Revolving Credit Facility [Member] Effect of exchange rate changes on foreign currency Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations SLF JV I SLF JV I [Member] SLF JV I Accordion feature, increase limit Line of Credit Facility, Accordion Feature, Increase Limit Line of Credit Facility, Accordion Feature, Increase Limit Airport Services Airport Services [Member] Airport Services MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Net unrealized appreciation (depreciation) Debt and Equity Securities, Unrealized Gain (Loss) [Member] Debt and Equity Securities, Unrealized Gain (Loss) Undistributed ordinary income, net Investment Company, Distributable Earnings (Loss), Accumulated Ordinary Income (Loss) Transfers out Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3 Restatement Determination Date: Restatement Determination Date [Axis] Investment, Name [Axis] Investment, Name [Axis] Revenue Multiple Measurement Input, Revenue Multiple [Member] Commitments and contingencies (Note 13) Commitments and Contingencies Reconciliation to the Consolidated Statements of Assets and Liabilities Reconciliation To The Consolidated Statements Of Assets And Liabilities [Abstract] Reconciliation To The Consolidated Statements Of Assets And Liabilities Health Care Distributors Health Care Distributors [Member] Health Care Distributors Issuance of shares of common stock under dividend reinvestment plan Stock Issued, Dividend Reinvestment Plan Stock Issued, Dividend Reinvestment Plan Shares issued under the "at the market" offering Gross Proceeds Proceeds from Issuance of Common Stock Investment Advisory Agreement - Incentive Rate, Realized Capital Gains Investment Advisory Agreement - Incentive Rate, Realized Capital Gains [Member] Investment Advisory Agreement - Incentive Rate, Realized Capital Gains Senior Credit Facility Senior Credit Facility [Member] Senior Credit Facility Geographical [Axis] Geographical [Axis] Taxable/Distributable Income and Dividend Distributions Income Tax Disclosure [Text Block] Industry Sector [Domain] Industry Sector [Domain] Management fees waived Investment Company, Voluntary Fee Waived Net unrealized appreciation (depreciation)A relating to Level 3 investments still held and reported within net unrealized appreciation (depreciation) in the Consolidated Statement of Operations Fair Value, Asset, Recurring Basis, Still Held, Unrealized Gain (Loss) PEO Total Compensation Amount PEO Total Compensation Amount Secured borrowings Secured Debt Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Level 3 Fair Value, Inputs, Level 3 [Member] Number of board of directors Number Of Board Of Directors Number Of Board Of Directors Multi-Sector Holdings Multi-Sector Holdings [Member] Multi-Sector Holdings Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Book/tax difference due to capital losses suspended (utilized) Investment, Tax Basis Reconciliation, Capital Gains Incentive Fees Differences, Increase (Decrease) In Taxable Income Investment, Tax Basis Reconciliation, Capital Gains Incentive Fees Differences, Increase (Decrease) In Taxable Income Fair Value Long-Term Debt, Fair Value Net increase (decrease) in net assets resulting from operations Net increase (decrease) in net assets resulting from operations Net increase (decrease) in net assets resulting from operations Net increase (decrease) in net assets resulting from operations Net income (Loss) Attributable to Parent Derivative Contract [Domain] Derivative Contract [Domain] Foreign Currency Translation Foreign Currency Transactions and Translations Policy [Policy Text Block] Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Company Selected Measure Name Company Selected Measure Name Investment, Issuer Affiliation [Domain] Investment, Issuer Affiliation [Domain] Application Software Application Software [Member] Application Software Fee Income Fee Income [Text Block] Fee Income Ardonagh Midco 3 PLC Ardonagh Midco 3 PLC [Member] Ardonagh Midco 3 PLC Repurchase of common stock under dividend reinvestment plan Stock Repurchased During Period, Value Total increase (decrease) in net assets Stockholders' Equity, Period Increase (Decrease) Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Diversified Metals & Mining Diversified Metals & Mining [Member] Diversified Metals & Mining Realized gain (loss) Debt and Equity Securities, Realized Gain (Loss) Name Measure Name Name Forgone Recovery, Individual Name Accretion of OID Fair Value, Measurement With Unobservable Inputs Reconciliation, Recurring Basis, Asset, Accretion Of Discount Fair Value, Measurement With Unobservable Inputs Reconciliation, Recurring Basis, Asset, Accretion Of Discount Food Distributors Food Distributors [Member] Food Distributors PIK interest income PIK interest income Interest Income, Operating, Paid in Kind Aerospace & Defense Aerospace & Defense [Member] Aerospace & Defense ASP Unifrax Holdings Inc. ASP Unifrax Holdings Inc [Member] ASP Unifrax Holdings Inc Underlying Securities Award Underlying Securities Amount Office Services & Supplies Office Services & Supplies [Member] Office Services & Supplies Common stock, dividends, per share, declared (in dollars per share) Common Stock, Dividends, Per Share, Declared Other book/tax differences Investment, Tax Basis Reconciliation, Other Reconciling Items, Increase (Decrease) In Taxable Income Investment, Tax Basis Reconciliation, Other Reconciling Items, Increase (Decrease) In Taxable Income Schedule of Summarized Financial Information Investment Company, Nonconsolidated Subsidiary, Summarized Financial Information [Table Text Block] Deferred offering costs paid Placement Agent Fees Payments of Stock Issuance Costs Increase (decrease) in payables from unsettled transactions Increase (Decrease) in Payables under Repurchase Agreements Fair Value Measurement Inputs and Valuation Techniques [Table] Fair Value Measurement Inputs and Valuation Techniques [Table] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Deferred financing costs paid Payments of Debt Issuance Costs LLC equity interests of the JVs Equity Securities, JV LLC [Member] Equity Securities, JV LLC Senior secured debt Debt Securities, Senior Secured [Member] Debt Securities, Senior Secured Income Statement Location [Axis] Income Statement Location [Axis] Schedule of Portfolio Composition Schedule of Financial Highlights Investment Company, Financial Highlights [Table Text Block] Foreign currency forward contracts Foreign currency forward contract Foreign Exchange Forward [Member] Management incentive rate (as a percent) Management and Service Fees, Incentive Rate Metal, Glass & Plastic Containers Metal, Glass & Plastic Containers [Member] Metal, Glass & Plastic Containers Changes in operating assets and liabilities: Increase (Decrease) in Operating Assets [Abstract] Schedule of Changes in Net Assets Investment Company, Change in Net Assets [Table Text Block] Other Performance Measure, Amount Other Performance Measure, Amount Net proceeds Proceeds from Debt, Net of Issuance Costs London Interbank Offered Rate (LIBOR) London Interbank Offered Rate (LIBOR) 1 [Member] London Interbank Offered Rate (LIBOR) 1 Oaktree Strategic Income II, Inc. Merger Oaktree Strategic Income II, Inc. Merger [Member] Oaktree Strategic Income II, Inc. Merger Total investment owned, at cost and money market funds, at carrying value Investment Owned, At Cost And Money Market Funds, At Carrying Value Investment Owned, At Cost And Money Market Funds, At Carrying Value Derivative Instruments and Hedging Activities Disclosure [Abstract] Cost of investments Investment, Tax Basis, Cost Net unrealized (appreciation) depreciation Investment, Tax Basis Reconciliation, Net Unrealized Depreciation (Appreciation) On Investments, Increase (Decrease) In Taxable Income Investment, Tax Basis Reconciliation, Net Unrealized Depreciation (Appreciation) On Investments, Increase (Decrease) In Taxable Income Interest expense Interest Expense Open Forward Foreign Currency Contract, Identifier [Axis] Open Forward Foreign Currency Contract, Identifier [Axis] Alvotech Alvotech [Member] Alvotech Stockholders' Equity Note [Abstract] Trading Arrangement: Trading Arrangement [Axis] Interest income Interest Income, Operating, Paid in Cash Use of Estimates Use of Estimates, Policy [Policy Text Block] Gain (loss), location Fair Value, Asset, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] Long-Term Debt, Type [Domain] Long-Term Debt, Type [Domain] 30-Day LIBOR 30-Day LIBOR [Member] 30-Day LIBOR Securities Act File Number Common equity and warrants Equity Securities, Common And Warrants [Member] Equity Securities, Common And Warrants Unaccreted discount Unaccreted discount Debt Instrument, Unamortized Discount Net proceeds Proceeds from (Repayments of) Debt Earnout Share Vesting [Axis] Earnout Share Vesting [Axis] Earnout Share Vesting Deferred offering costs Deferred Offering Costs Investment, basis spread, variable rate (as a percent) Investment, Basis Spread, Variable Rate Entity Share Company Restatement Determination Date Restatement Determination Date All Web Leads Inc All Web Leads Inc [Member] All Web Leads Inc Operations: Net Income (Loss), Including Portion Attributable to Noncontrolling Interest [Abstract] Insurance Brokers Insurance Brokers [Member] Insurance Brokers Click JV Notes Click JV Notes [Member] Click JV Notes Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Cash and cash equivalents and restricted cash, beginning of period Cash and cash equivalents and restricted cash, end of period Cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Asset Class [Axis] Asset Class [Axis] Gold Gold Sector [Member] Gold Sector Interest Rate Swap Maturing 2027 Interest Rate Swap Maturing 2027 [Member] Interest Rate Swap Maturing 2027 Earnings (loss) per common share â€” basic and diluted: Weighted Average Number of Shares Outstanding Reconciliation [Abstract] Common stock, shares issued (in shares) Beginning of period (in shares) End of period (in shares) Common Stock, Shares, Issued Money market funds, percent of net assets (as a percent) Money Market Funds, Percent Of Net Assets Money Market Funds, Percent Of Net Assets Carrying Value Net carrying value Long-Term Debt Total assets at fair value Assets, Fair Value Disclosure Net Proceeds Sale of Stock, Consideration Received on Transaction Real Estate Operating Companies Real Estate Operating Companies [Member] Real Estate Operating Companies Air Freight & Logistics Air Freight & Logistics [Member] Air Freight & Logistics Taxable/Distributable Income Investment

Company, Distributable Earnings (Loss), Before Deductions Investment Company, Distributable Earnings (Loss), Before Deductions Enterprise Value Valuation, Enterprise Value [Member] Valuation, Enterprise Value Net Realized Gain (Loss) Realized Gain (Loss), Investment, Derivative, and Foreign Currency Transaction Price Change, Operating, before Tax Issuance of common stock in connection with the OS12 Merger Stock Issued During Period, Value, Acquisitions Entity Address, Address Line One Entity Address, Address Line Two Base management fee and incentive fee payable Management And Incentive Fee Payable Management And Incentive Fee Payable Personal Care Products Personal Care Products [Member] Personal Care Products Subsequent Event [Table] Subsequent Event [Table] 90-Day SOFR 90-Day SOFR [Member] 90-Day SOFR Investment Owned, Cost Investment Owned, Cost [Member] Investment Owned, Cost Health Care Equipment Health Care Equipment [Member] Health Care Equipment Derivative assets (liability) Derivative, Fair Value, Net Subsequent Event Subsequent Event [Member] Investment owned, balance (in shares) Investment Owned, Balance, Shares Income Statement [Abstract] Tersera Therapeutics LLC Schedule of Investments [Line Items] Issuance of common stock in connection with the "at the market" offering (in shares) Stock Issued During Period, Shares, New Issues Realized gains (losses): Net Realized Gains (Losses) [Abstract] Net Realized Gains (Losses) Valuation Approach and Technique [Axis] Valuation Approach and Technique [Axis] Net realized gains (losses) Debt and Equity Securities, Realized Gain (Loss) [Member] Debt and Equity Securities, Realized Gain (Loss) [Member] Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Interest on cash and cash equivalents Interest Income, Deposits with Financial Institutions Cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Derivative liabilities at fair value Derivative liability Derivative liabilities Derivative Liability Due from broker Receivable from Broker-Dealer and Clearing Organization Net realized gains (losses) Realized Gain (Loss), Debt and Equity Securities and Foreign Currency Transaction Price Change, Operating, before Tax Unrealized appreciation Investment, Tax Basis, Unrealized Gain Investments in and Advances to Affiliates [Table] Investments in and Advances to Affiliates [Table] Incentive fee expense Incentive Fee Expense Industry Sector [Axis] Industry Sector [Axis] Financial Instrument [Axis] Financial Instrument [Axis] Investment Type Concentration Risk Investment Type Concentration Risk [Member] Investment Type Concentration Risk Total Shareholder Return Amount Total Shareholder Return Amount Repurchases of common stock under dividend reinvestment plan Payments for Repurchase of Common Stock Entity Common Stock, Shares Outstanding Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Asset Multiple Measurement Input, Asset Multiple [Member] Measurement Input, Asset Multiple Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Accumulated overdistributed earnings Accumulated overdistributed earnings Retained Earnings (Accumulated Deficit) Transfers in Fair Value, Measurement with Unobservable Inputs Recalculation, Recurring Basis, Asset Transfers Into Level 3 Principal amount Principal Debt Instrument, Face Amount Entity Address, State or Province Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Southeast US Southeast Region [Member] Increase (decrease) in interest payable Increase (Decrease) in Interest Payable, Net Investment exchanged, cost Investment Exchanged, Cost Investment Exchanged, Cost Quarterly Distribution Type, Quarterly [Member] Distribution Type, Quarterly Deferred financing costs Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction (Increase) decrease in interest, dividends and fees receivable Increase (Decrease) in Interest and Dividends Receivable Notes payable at fair value Notes Payable Industrial Machinery & Supplies & Components Industrial Machinery & Supplies & Components [Member] Industrial Machinery & Supplies & Components Asset Class [Domain] Asset Class [Domain] Distribution Type [Axis] Distribution Type [Axis] Class of Stock [Domain] Class of Stock [Domain] Investment Company [Abstract] Real Estate Services Real Estate Services [Member] Real Estate Services Investments at fair value Fair value, beginning balance Fair value, ending balance Investment Owned, Fair Value Organization Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Paper & Plastic Packaging Products & Materials Paper & Plastic Packaging Products & Materials [Member] Paper & Plastic Packaging Products & Materials Investment Company, Net Assets [Roll Forward] Investment Company, Net Assets [Roll Forward] Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount All Executive Categories All Executive Categories [Member] Midwest US Midwest Region [Member] Debt Disclosure [Abstract] Adjustments to reconcile net increase (decrease) in net assets resulting from operations to net cash provided by (used in) operating activities: Adjustments To Reconcile Net Assets From Operations To Cash Provided by (Used in) Operating Activities [Abstract] Adjustments To Reconcile Net Assets From Operations To Cash Provided by (Used in) Operating Activities Net realized gains (losses) Net realized gains (losses) Net realized (gains) losses Realized Gain (Loss), Investment and Derivative, Operating, before Tax Special Distribution Type, Special [Member] Distribution Type, Special Common stock, \$0.01A par value per share, 250,000 shares authorized; 82,245 and 77,225 shares issued and outstanding as of June 30, 2024 and SeptemberA 30, 2023, respectively Common Stock, Value, Issued Other Specialized REITs Other Specialized REITs [Member] Other Specialized REITs Measured at Net Asset Value Fair Value Measured at Net Asset Value Per Share [Member] Organization, Consolidation and Presentation of Financial Statements [Abstract] Oaktree Strategic Income Corporation Merger Oaktree Strategic Income Corporation Merger [Member] Oaktree Strategic Income Corporation Merger Interest payable Interest Payable Revenue from Contract with Customer [Abstract] Restricted cash Restricted cash Restricted Cash All Individuals All Individuals [Member] Entity Filer Category Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Statement [Table] Statement [Table] Investment, interest rate, floor (as a percent) Investment, Interest Rate, Floor Current Fiscal Year End Date Derivative Instruments and Hedging Activities Disclosures [Line Items] Derivative Instruments and Hedging Activities Disclosures [Line Items] Unrealized depreciation Investment, Tax Basis, Unrealized Loss Long-Term Capital Loss Carryforward Long-Term Capital Loss Carryforward [Member] Long-Term Capital Loss Carryforward PEO Name PEO Name P&L Development LLC P&L Development LLC [Member] P&L Development LLC Financial Support for Nonconsolidated Legal Entity [Line Items] Financial Support for Nonconsolidated Legal Entity [Line Items] Base Rate Base Rate [Member] Investment owned, ownership (as a percent) Investment Owned, Ownership Percentage Investment Owned, Ownership Percentage Contractual fee waived, per quarter Investment Company, Contractual Fee Waived, Per Quarter Investment Company, Contractual Fee Waived, Per Quarter Packaged Foods & Meats Packaged Foods & Meats [Member] Packaged Foods & Meats Research & Consulting Services Research & Consulting Services [Member] Research & Consulting Services Fixed rate debt securities Debt Securities, Fixed Rate [Member] Debt Securities, Fixed Rate Investment Advisory Agreement Investment Advisory Agreement [Member] Investment Advisory Agreement Other income/Fee income Other Income Restricted Cash and Cash Equivalents Items [Line Items] Restricted Cash and Cash Equivalents Items [Line Items] Directors fees Noninterest Expense Directors Fees Coupon interest rate (net of effect of interest rate swaps) Debt Instrument, Interest Rate, Stated Percentage Investment Advisory Agreement Cumulative Pre Incentive Fee Net Investment Income Investment Advisory Agreement - Incentive Rate, Pre-Incentive Fee Net Investment Income Exceeds Catch-Up Threshold [Member] Investment Advisory Agreement - Incentive Rate, Pre-Incentive Fee Net Investment Income Exceeds Catch-Up Threshold Statement of Financial Position [Abstract] Total net assets (equivalent to \$18.19 and \$19.63 per common share as of June 30, 2024 and September 30, 2023, respectively) (Note 11) Net assets at beginning of period Net assets at end of period Equity, Attributable to Parent Investment, Affiliated Issuer, Control and Affiliate Investment, Affiliated Issuer, Control and Affiliate [Member] Investment, Affiliated Issuer, Control and Affiliate Schedule of Significant Unobservable Inputs for Level 3 Investments Fair Value Measurement Inputs and Valuation Techniques [Table Text Block] Ratio of total expenses to average net assets Investment Company, Expense Ratio, Total Expenses Investment Company, Expense Ratio, Total Expenses Concentration Risk Type [Axis] Concentration Risk Type [Axis] Subsequent Events [Abstract] Payables from unsettled transactions Payable, Investment, Purchase Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value Measurements Fair Value Measurement, Policy [Policy Text Block] Base management fee rate (as a percent) Management and Service Fees, Base Rate Hedging Designation [Domain] Hedging Designation [Domain] LevelA 2 Fair Value, Inputs, Level 2 [Member] Affiliate investments Investment, Affiliated Issuer [Member] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Specialized Finance Specialized Finance [Member] Specialized Finance Document Fiscal Period Focus Weighted Average Weighted Average [Member] Realized Gains or Losses and Net Unrealized Appreciation or Depreciation Investment Company, Realized Gains (Losses) And Net Unrealized Appreciation (Depreciation) [Text Block] Investment Company, Realized Gains (Losses) And Net Unrealized Appreciation (Depreciation) City Area Code Investment Owned, At Fair Value Investment Owned, At Fair Value [Member] Investment Owned, At Fair Value Document Fiscal Year Focus Geographical [Domain] Geographical [Domain] Investment, Issuer Name [Domain] Investment, Issuer Name [Domain] Investments in and Advances to Affiliates [Abstract] Education Services Education Services [Member] Education Services Movies & Entertainment Movies & Entertainment [Member] Movies & Entertainment Exercise Price Award Exercise Price Issuance of shares in connection with the OS12 Merger Stock Issued, Acquisition Stock Issued, Acquisition Financial commitment to investee by counterparty, aggregate amount Investment Company, Financial Commitment To Investee By Counterparty, Aggregate Amount Investment Company, Financial Commitment To Investee By Counterparty, Aggregate Amount Total liabilities at fair value Liabilities, Fair Value Disclosure Systems Software Systems Software [Member] Systems Software Investment owned and money market funds, percent of net assets (as a percent) Investment Owned And Money Market Funds, Percent of Net Assets Investment Owned And Money Market Funds, Percent of Net Assets Offering costs Debt Issuance Costs, Gross Schedule of Financial Instruments Carried at Fair Value Fair Value, Assets Measured on Recurring Basis [Table Text Block] Diversified Financial Services Diversified Financial Services [Member] Diversified Financial Services Accretion of original issue discount on investments Accretion (Amortization) of Discounts and Premiums, Investments Total liabilities and net assets Liabilities and Equity Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Schedule of Long-Term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Net realized and unrealized gains (losses), net of taxes Gain (Loss), Investment and Derivative, Operating, and Foreign Currency Transaction, after Tax Distributors Distributors [Member] Distributors Arrangement Duration Trading Arrangement Duration Automotive Retail Automotive Retail [Member] Automotive Retail Members' equity Members' Equity Total expenses Investment Income, Investment Expense Entity Address, City or Town Award Timing MNPI Considered Award Timing MNPI Considered [Flag] 30-Day SOFR 30-Day SOFR [Member] 30-Day SOFR Number of borrowers Investment Company, Number Of Borrowers Investment Company, Number Of Borrowers Northeast US Northeast Region [Member] Derivative Instruments and Hedging Activities Disclosures [Table] Derivative Instruments and Hedging Activities Disclosures [Table] Termination Date Trading Arrangement Termination Date Common stock, shares authorized (in shares) Common Stock, Shares Authorized Schedule of Investments [Abstract] Investment owned, balance, shares, VWAP number of trading days Investment Owned, Balance, Share, Trading Days Investment Owned, Balance, Share, Trading Days Line of Credit Facility, Lender [Domain] Line of Credit Facility, Lender [Domain] Unrealized appreciation (depreciation) Investment, Tax Basis, Unrealized Gain (Loss) Gross Reductions Investments in and Advances to Affiliates, at Fair Value, Gross Reductions Related Party Transactions [Abstract] Measurement Input Type [Axis] Measurement Input Type [Axis] Kemper Kemper [Member] Kemper Radiology Partners Inc. Radiology Partners Inc. [Member] Radiology Partners Inc Schedule of Composition of Investments Investment Holdings, Schedule of Investments [Table Text Block] Award Timing Disclosures [Line Items] Additional paid-in-capital Additional Paid in Capital Related party transaction, termination, notice period Related Party Transaction, Termination, Notice Period Related Party Transaction, Termination, Notice Period Biotechnology Biotechnology [Member] Biotechnology Global Medical Response Inc. Global Medical Response Inc [Member] Global Medical Response Inc Income Taxes Income Tax, Policy [Policy Text Block] Insider Trading Arrangements [Line Items] General and administrative expenses Other General and Administrative Expense Related Party [Axis] Related Party, Type [Axis] Entity Registrant Name Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Award Timing Method Award Timing Method [Text Block] (Increase) decrease in other assets Increase (Decrease) in Other Operating Assets Adjustment to Compensation, Amount Adjustment to Compensation Amount Real Estate Development Real Estate Sector [Member] Net assets at beginning of period Net assets at end of period Net Assets Auto Parts & Equipment Auto Parts & Equipment [Member] Auto Parts & Equipment Investment, Issuer Affiliation [Axis] Investment, Issuer Affiliation [Axis] Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Entity Central Index Key Amortization of financing costs and discount Amortization of Debt Issuance Costs and Discounts Fair value Line of Credit Facility, Fair Value of Amount Outstanding Capitalized PIK interest income Fair Value, Measurement With Unobservable Inputs Reconciliation, Recurring Basis, Asset, PIK Interest Income Capitalized Fair Value, Measurement With Unobservable Inputs Reconciliation, Recurring Basis, Asset, PIK Interest Income Capitalized Total gains or losses included in earnings Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Net increase (decrease) in net assets from stockholder transactions Distributions to stockholders Investment Company, Shareholder Transactions, Increase (Decrease) Investment Company, Shareholder Transactions, Increase (Decrease) Part I incentive fees waived Part I incentive fees waived Investment Company, Part I Fee Waived Investment Company, Part I Fee Waived Dividend reinvestment plan, percent of current market price (as a percent) Dividend Reinvestment Plan, Percent of Current Market Price Dividend Reinvestment Plan, Percent of Current Market Price Name Trading Arrangement, Individual Name Cable & Satellite Cable & Satellite [Member] Cable & Satellite Issuance of common stock in connection with the "at the market" offering Issuance of common stock in connection with the "at the market" offering Stock Issued During Period, Value, New Issues Thrasio, LLC Thrasio, LLC [Member] Thrasio, LLC Risks and Uncertainties [Abstract] Entity [Domain] Long-Term Debt, Type [Axis] Long-Term Debt, Type [Axis] Amendment Flag Legal Entity [Axis] (Increase) decrease in receivables from unsettled transactions Increase (Decrease) in Receivables under Repurchase Agreements Cash received in the OS12 Merger Cash Acquired From Acquisition, Operating Activities Cash Acquired From Acquisition, Operating Activities Net realized gains (losses) (in dollars per share) Investment Company, Gain (Loss) On Realized Appreciation (Depreciation), Per Share Investment Company, Gain (Loss) On Realized Appreciation (Depreciation), Per Share Unrealized losses, net Investment Company, Distributable Earnings (Loss), Accumulated Unrealized Gains (Losses) Investment Company, Distributable Earnings (Loss), Accumulated Unrealized Gains (Losses) Cash paid for interest Interest Paid, Excluding Capitalized Interest, Operating Activities Until November 3, 2023 Until November 3, 2023 [Member] Until November 3, 2023 At The Market At The Market [Member] At The Market Fertilizers & Agricultural Chemicals Fertilizers & Agricultural Chemicals [Member] Fertilizers & Agricultural Chemicals Per share market value at beginning of period (in dollars per share) Per share market value at end of period (in dollars per share) Investment Company, Market Value, Per Share Investment owned, balance, shares, VWAP threshold (in dollars per share) Investment Owned, Balance, Share, VWAP, Threshold Investment Owned, Balance, Share, VWAP, Threshold Weighted average common shares outstanding - diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Deferred Financing Costs Deferred Financing Costs, Policy [Policy Text Block] Deferred Financing Costs, Policy Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Restaurants Restaurants [Member] Restaurants Ratio of net expenses to average net assets Investment Company, Expense Ratio, Net Expenses Investment Company, Expense Ratio, Net Expenses Money market funds, at carrying value Money Market Funds, at Carrying Value Expenses: Operating Expenses [Abstract] Company Selected Measure Amount Company Selected Measure Amount Alternative Carriers Alternative Carriers [Member] Alternative Carriers Debt and Equity Financing Debt and Equity Financing [Member] Debt and Equity Financing Investments, Owned, Federal Income Tax Note [Line Items] Investments, Owned, Federal Income Tax Note [Line Items] Non-cash financing activities: Noncash Financing Items [Abstract] Noncash Financing Items Total assets Assets Assets Name Awards Close in Time to MNPI Disclosures, Individual Name Investment, Change in Market Quotes or Liquidity Investment, Change in Market Quotes or Liquidity [Member] Investment, Change in Market Quotes or Liquidity Other Specialty Retail Other Specialty Retail [Member] Other Specialty Retail Coupon interest rate (net of effect of interest rate swaps) (as a percent) Debt Instrument, Interest Rate During Period Non-NEOs Non-NEOs [Member] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] SLF JV I Notes SLF JV I Notes [Member] SLF JV I Notes Total investment income Gross Investment Income, Operating Non-PEO NEO Non-PEO NEO [Member] Adjustment to Compensation: Adjustment to Compensation [Axis] Debt investments in the JVs Debt Securities, JV [Member] Debt Securities, JV Debt Instrument [Line Items] Debt Instrument [Line Items] Weighted average common shares outstanding - basic (in shares) Weighted Average Number of Shares Outstanding, Basic Unamortized financing costs Unamortized financing costs Unamortized Debt Issuance Expense Senior Secured Loans Senior Secured Loans [Member] Senior Secured Loans Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Interest income: Revenues [Abstract] Related Party Transaction [Axis] Related Party Transaction [Axis] Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Unused capacity, commitment fee (as a percent) Line of Credit Facility, Unused Capacity, Commitment Fee Percentage Financial Exchanges & Data Financing Exchange & Data [Member] Financing Exchange & Data Statement [Line Items] Statement [Line Items] Southwest US Southwest Region [Member] Schedule of Foreign Currency Forward Contracts and Interest Rate Swap Schedule of Derivative

Instruments [Table Text Block] Schedule of Components of Debt Schedule of Debt [Table Text Block] Borrowings under credit facilities Proceeds from Long-Term Lines of Credit EX-101. PRE 10 ocs1-20240630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 12 R1.htm IDEA: XBRL DOCUMENT v3.24.2 Cover - shares 9 Months Ended Jun. 30, 2024 Jul. 30, 2024 Cover [Abstract] A A Document Type 10-Q A Document Quarterly Report true A Document Period End Date Jun. 30, 2024 A Document Transition Report false A Securities Act File Number 1-33901 A Entity Registrant Name Oaktree Specialty Lending Corporation A Entity Incorporation, State or Country Code DE A Entity Tax Identification Number 26-1219283 A Entity Address, Address Line One 333 South Grand Avenue A Entity Address, Address Line Two 28th Floor A Entity Address, City or Town Los Angeles A Entity Address, State or Province CA A Entity Address, Postal Zip Code 90071 A City Area Code 213 A Local Phone Number 830-6300 A Title of 12(b) Security Common Stock, par value \$0.01 per share A Trading Symbol OCSL A Security Exchange Name NASDAQ A Entity Current Reporting Status Yes A Entity Interactive Data Current Yes A Entity Filer Category Large Accelerated Filer A Entity Small Business false A Entity Emerging Growth Company false A Entity Shell Company false A Entity Common Stock, Shares Outstanding A 82,245,319 Entity Central Index Key 0001414932 A Document Fiscal Year Focus 2024 A Document Fiscal Period Focus Q3 A Amendment Flag false A Current Fiscal Year End Date --09-30 A X - DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission. + ReferencesNo definition available. + Details Name: dei AmendmentFlag Namespace Prefix: dei_ Data Type: xbrli:booleanItem Type Balance Type: na Period Type: duration X - DefinitionArea code of city + ReferencesNo definition available. + Details Name: dei CityAreaCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItem Type Balance Type: na Period Type: duration X - DefinitionCover page. + ReferencesNo definition available. + Details Name: dei CoverAbstract Namespace Prefix: dei_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionEnd date of current fiscal year in the format --MM-DD. + ReferencesNo definition available. + Details Name: dei_CurrentFiscalYearEndDate Namespace Prefix: dei_ Data Type: xbrli:gMonthDayItem Type Balance Type: na Period Type: duration X - DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + ReferencesNo definition available. + Details Name: dei DocumentFiscalPeriodFocus Namespace Prefix: dei_ Data Type: dei:fiscalPeriodItem Type Balance Type: na Period Type: duration X - DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + ReferencesNo definition available. + Details Name: dei DocumentFiscalYearFocus Namespace Prefix: dei_ Data Type: xbrli:gYearItem Type Balance Type: na Period Type: duration X - DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + ReferencesNo definition available. + Details Name: dei_DocumentPeriodEndDate Namespace Prefix: dei_ Data Type: xbrli:dateItem Type Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as a quarterly report. + ReferencesReference 1:

<https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference> 12: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference> 13: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference> 14: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference> 15: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference> 16: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference> 17: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference> 18: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference> 19: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference> 20: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference> 21: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference> 22: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference> 23: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference> 24: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference> 25: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference> 26: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479853/942-210-S99-1> + Details Name: us-gaap Assets Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap AssetsAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference> 2: <http://www.xbrl.org/2003/role/exampleRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference> 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-4> + Details Name: us-gaap CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRepresents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(19)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479440/944-210-S99-1Reference> 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(15)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479617/946-210-S99-1Reference> 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03.17) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479853/942-210-S99-1Reference> 4: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.25) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap CommitmentsAndContingencies Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference> 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(22)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479440/944-210-S99-1Reference> 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap CommonStockValue Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 3 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482925/835-30-45-3Reference> 2: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481139/470-20-50-1D> + Details Name: us-gaap DeferredFinanceCostsNet Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(15)(b)(2)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479440/944-210-S99-1Reference> 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482525/740-10-45-4Reference> 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 6 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482525/740-10-45-6> + Details Name: us-gaap DeferredIncomeTaxLiabilitiesNet Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionSpecific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 5.A) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480341/340-10-S99-1> + Details Name: us-gaap DeferredOfferingCosts Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480524/946-210-50-12Reference> 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (e) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480524/946-210-50-6Reference> 3: <http://www.xbrl.org/2003/role/exampleRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 55 -Paragraph 1 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480493/946-210-55-1Reference> 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(1) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480524/946-210-50-6Reference> 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480524/946-210-50-6Reference> 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(4) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480524/946-210-50-6Reference> 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(1) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480524/946-210-50-1Reference> 8: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(1) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480524/946-210-50-1Reference> 9: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480524/946-210-50-1Reference> 10: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480524/946-210-50-1Reference> 11: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480524/946-210-50-6Reference> 12: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(3) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480524/946-210-50-6Reference> 13: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(3)(c)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479617/946-210-S99-1Reference> 14: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5C -Subparagraph (SX 210.12-13C(Column H)(Footnote 7)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480032/946-320-S99-5CReference> 15: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(3)(b)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479617/946-210-S99-1Reference> 16: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SX 210.12-13(Column A)(Footnote 3)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480032/946-320-S99-5Reference> 17: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5C -Subparagraph (SX 210.12-13C(Column H)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480032/946-320-S99-5CReference> 18: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5A -Subparagraph (SX 210.12-13A(Column E)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480032/946-320-S99-5AReference> 19: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5B -Subparagraph (SX 210.12-13B(Column E)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480032/946-320-S99-5BReference> 20: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5B -Subparagraph (SX 210.12-13B(Column E)(Footnote 4)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480032/946-320-S99-5BReference> 21: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483466/210-20-50-3Reference> 22: <http://www.xbrl.org/2003/role/exampleRef> -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 2 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483444/210-20-55-22Reference> 23: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483444/210-20-55-10Reference> 24: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482907/825-10-50-10> + Details Name: us-gaap DerivativeAssets Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (e) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480524/946-210-50-6Reference> 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(1) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480524/946-210-50-6Reference> 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480524/946-210-50-6Reference> 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(4) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480524/946-210-50-6Reference> 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(1) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480524/946-210-50-1Reference> 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(1) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480524/946-210-50-1Reference> 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480524/946-210-50-1Reference> 8: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480524/946-210-50-1Reference> 9: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (f) -Publisher FASB -URI

<https://asc.fasb.org/1943274/2147480032/946-320-S99-5Reference 16:> [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph \(SX 210.12-13\(Column G\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-5Reference 18:](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5C -Subparagraph (SX 210.12-13C(Column H)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-5Reference 17:) [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5B -Subparagraph \(SX 210.12-13B\(Column E\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-5Reference 20:](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5A -Subparagraph (SX 210.12-13A(Column E)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-5Reference 19:) [http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483444/210-20-55-22Reference 23:](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3Reference 22:) [http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10 + Details Name: us-gaap DerivativeLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of dividend and interest receivable from investment. + ReferencesReference 1:](http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483444/210-20-55-10Reference 24:) [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-04\(5\)\(a\)\(3\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479617/946-210-S99-1Reference 3:](http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480167/946-830-55-12Reference 2:) [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-03.15\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479853/942-210-S99-1 + Details Name: us-gaap InterestPayableCurrentAndNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFair value of investment in security owned. + ReferencesReference 1:](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 310 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480833/946-310-45-1 + Details Name: us-gaap DividendAndInterestReceivable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of interest payable on debt, including, but not limited to, trade payables. + ReferencesReference 1: <a href=) [http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(a\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480524/946-210-50-1Reference 6:](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480524/946-210-50-6Reference 2:) [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(b\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480524/946-210-50-1Reference 8:](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480524/946-210-50-1Reference 7:) [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480524/946-210-50-2Reference 10:](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480524/946-210-50-1Reference 9:) [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph \(a\)\(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480524/946-210-50-6Reference 12:](http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480167/946-830-55-12Reference 11:) [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-03\(d\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 14:](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479617/946-210-S99-1Reference 13:) [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-04\(2\)\(a\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479617/946-210-S99-1Reference 16:](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479617/946-210-S99-1Reference 15:) [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.12-12\(Column C\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-1Reference 18:](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(2)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479617/946-210-S99-1Reference 17:) [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.12-12\(Column C\)\(Footnote 5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-1Reference 20:](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column A)(Footnote 1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-1Reference 19:) [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.12-12B\(Column C\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-3Reference 22:](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column C)(Footnote 6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-1Reference 21:) [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.12-12B\(Column A\)\(Footnote 6\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-3Reference 25:](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column C)(Footnote 2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-3Reference 23:)

conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479440/944-210-S99-1>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479853/942-210-S99-1> + Details Name: us-gaap_LineOfCredit Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of assets classified as other. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef> -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480167/946-830-55-12>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(10)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479440/944-210-S99-1>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 4: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(10)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479853/942-210-S99-1> + Details Name: us-gaap_OtherAssets Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liabilities classified as other. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef> -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480167/946-830-55-12>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(12)(b)(2)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479617/946-210-S99-1>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(12)(b)(3)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479617/946-210-S99-1>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(15)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479440/944-210-S99-1>Reference 5: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(12)(b)(1)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479617/946-210-S99-1>Reference 6: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03.15) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479853/942-210-S99-1> + Details Name: us-gaap_OtherLiabilities Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of payable for purchase of investment. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef> -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480167/946-830-55-12>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(10)(a)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479617/946-210-S99-1>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 405 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480191/946-405-45-1> + Details Name: us-gaap_PayableInvestmentPurchase Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of receivable from sale of investment. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef> -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480167/946-830-55-12>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(5)(a)(1)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479617/946-210-S99-1>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 310 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480833/946-310-45-1> + Details Name: us-gaap_ReceivableInvestmentSale Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount receivable from broker-dealers and clearing organizations, including, but not limited to, securities failed-to-deliver, certain deposits for securities borrowed, open transactions, good faith and margin deposits, commissions and floor brokerage receivables. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 3 -SubTopic 20 -Topic 940 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481833/940-20-45-3> + Details Name: us-gaap_ReceivablesFromBrokersDealersAndClearingOrganizations Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(2)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479440/944-210-S99-1>Reference 2: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(11)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 3: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482913/230-10-50-8>Reference 4: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(1)(a)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479853/942-210-S99-1> + Details Name: us-gaap_RestrictedCash Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480016/944-40-65-2>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480016/944-40-65-2>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480990/946-20-50-11>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479440/944-210-S99-1>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479617/946-210-S99-1>Reference 7: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480008/505-10-S99-1>Reference 8: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 2: <http://www.xbrl.org/2003/role/exampleRef> -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480167/946-830-55-12>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479617/946-210-S99-1>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479617/946-210-S99-2>Reference 5: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483575/946-220-S99-3>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483575/946-220-S99-3>Reference 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483575/946-220-S99-3>Reference 8: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(iii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480678/235-10-S99-1>Reference 9: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481687/323-10-50-3>Reference 10: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482907/825-10-50-28>Reference 11: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 12: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 13: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 14: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480418/310-10-S99-2> + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionIncluding the current and noncurrent portions, carrying value as of the balance sheet date of uncollateralized debt obligations (with maturities initially due after one year or beyond the operating cycle if longer). + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479440/944-210-S99-1>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479853/942-210-S99-1> + Details Name: us-gaap_UnsecuredDebt Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_InvestmentIssuerAffiliationAxis=us-gaap_InvestmentAffiliatedIssuerControlledMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIssuerAffiliationAxis=us-gaap_InvestmentUnaffiliatedIssuerMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 14 R3.htm IDEA: XBRL DOCUMENT v3.24.2 Consolidated Statements of Assets and Liabilities (Parenthetical) - USD (\$) shares in Thousands, \$ in Thousands Jun. 30, 2024 Sep. 30, 2023 Investment, cost \$ 3,292,932 \$ 3,044,119 Unamortized financing costs \$ 5,468 \$ 7,076 Common stock, par value (in dollars per share) \$ 0.01 \$ 0.01 Common stock, shares authorized (in shares) 250,000 250,000 Common stock, shares issued (in shares) 82,245 77,225 Common stock, shares outstanding (in shares) 82,245 [1] 77,225 Net asset value per common share (in dollars per share) \$ 18.19 [1] \$ 19.63 Control investments Å Investment, cost \$ 369,660 [2],[3] \$ 345,245 [4],[5] Affiliate investments Å Investment, cost 38,101 24,898 Non-control/Non-affiliate investments Å Investment, cost \$ 2,885,171 [6] \$ 2,673,976 [5] [1] As discussed in Note 2, the Company completed a 1-for-3 reverse stock split on January 20, 2023, effective as of the commencement of trading on January 23, 2023. The weighted average common shares outstanding and per share information reflect the reverse stock split on a retroactive basis as necessary. [2] As defined in the Investment Company Act, the Company is deemed to be both an "Affiliated Person" of and to "Control" these portfolio companies as the Company owns more than 25% of the portfolio company's outstanding voting securities or has the power to exercise control over management or policies of such portfolio company (including through a management agreement). See Schedule 12-14 in the accompanying notes to the Consolidated Financial Statements for transactions during the nine months ended JuneÅ 30, 2024 in which the issuer was both an Affiliated Person and a portfolio company that the Company is deemed to control. [3] Control Investments generally are defined by the Investment Company Act of 1940, as amended (the "Investment Company Act"), as investments in companies in which the Company owns more than 25% of the voting securities or maintains greater than 50% of the board representation. [4] As defined in the Investment Company Act, the Company is deemed to be both an "Affiliated Person" of and to "Control" these portfolio companies as the Company owns more than 25% of the portfolio company's outstanding voting securities or has the power to exercise control over management or policies of such portfolio company (including through a management agreement). See Schedule 12-14 in the Company's annual report on Form 10-K for the year ended September 30, 2023 for transactions during the year ended SeptemberÅ 30, 2023 in which the issuer was both an Affiliated Person and a portfolio company that the Company is deemed to control. [5] Control Investments generally are defined by the Investment Company Act as investments in companies in which the Company owns more than 25% of the voting securities or maintains greater than 50% of the board representation. [6] Non-Control/Non-Affiliate Investments are investments that are neither Control Investments nor Affiliate Investments. X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479617/946-210-S99-1>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-2>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic

[Sub-Topic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.6-05\(4\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/214747961/7946-210-59-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-09\(4\)\(b\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483575/946-220-599-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-04\(16\)\(a\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/214747961/7946-210-599-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-09\(7\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483575/946-220-599-3Reference 6: https://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(29\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-599-1 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionCost of the investment. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 55 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480493/946-210-55-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph \(a\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480524/946-210-50-6Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph \(a\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480524/946-210-50-6Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480167/946-830-55-12Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph \(a\)\(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480524/946-210-50-6Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-03\(d\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-599-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.12-12\(Column C\)\(Footnote 8\)\(a\)\(3\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-599-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.12-12\(Column C\)\(Footnote 11\)\(a\)\(3\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-599-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph \(SX 210.12-14\(Column F\)\(Footnote 5\)\(a\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-599-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 19 -Subparagraph \(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-599-19 + Details Name: us-gaap_InvestmentOwnedAtCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionNet asset value per share or per unit of investments in certain entities that calculate net asset value per share. Includes, but is not limited to, by unit, membership interest, or other ownership interest. Investment includes, but is not limited to, investment in certain hedge funds, venture capital funds, private equity funds, real estate partnerships or funds. Excludes fair value disclosure. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 35 -Paragraph 54B SubTopic 10 -Topic 820 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482134/820-10-35-54BReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 35 -Paragraph 59 -SubTopic 10 -Topic 820 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482134/820-10-35-59Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 6A -SubTopic 10 -Topic 820 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480167/946-830-55-12Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480555/946-210-45-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480737/946-205-50-7Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph \(h\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480737/946-205-50-7Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481004/946-505-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-04\(19\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479617/946-210-599-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.6-05\(4\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479617/946-210-599-2 + Details Name: us-gaap_NetAssetValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr:types-perShareItemType Balance Type: na Period Type: instant X - DefinitionThe remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset. + ReferencesNo definition available. + Details Name: us-gaap_UnamortizedDebtIssuanceExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_InvestmentIssuerAffiliationAxis=us-gaap_InvestmentAffiliatedIssuerControlledMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIssuerAffiliationAxis=us-gaap_InvestmentAffiliatedIssuerMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIssuerAffiliationAxis=us-gaap_InvestmentUnaffiliatedIssuerMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 15 R4.htm IDEA: XBRL DOCUMENT v3.24.2 Consolidated Statements of Operations shares in Thousands 3 Months Ended 9 Months Ended Jun. 30, 2024 USD \(\\$\) \\$ / shares shares Jun. 30, 2023 USD \(\\$\) \\$ / shares shares Jun. 30, 2024 USD \(\\$\) \\$ / shares shares Jun. 30, 2023 USD \(\\$\) \\$ / shares shares Interest income: Å Å Å Interest on cash and cash equivalents \\$ 1,156,000 \\$ 992,000 \\$ 5,014,000 \\$ 2,221,000 Total interest income 85,953,000 95,310,000 262,623,000 254,033,000 PIK interest income 6,149,000 3,967,000 14,814,000 14,220,000 Fee income 1,460,000 1,573,000 5,313,000 5,974,000 Dividend income 1,404,000 1,050,000 4,230,000 3,154,000 Total investment income 94,966,000 101,900,000 286,980,000 277,381,000 Expenses: Å Å Å Base management fee 11,781,000 11,983,000 34,862,000 33,383,000 Part I incentive fee 8,341,000 9,590,000 25,821,000 26,300,000 Professional fees 1,091,000 1,387,000 3,808,000 4,962,000 Directors fees 160,000 160,000 480,000 480,000 Interest expense 32,513,000 30,793,000 96,564,000 79,316,000 Administrator expense 391,000 322,000 1,083,000 935,000 General and administrative expenses 824,000 752,000 1,941,000 2,753,000 Total expenses 55,101,000 54,987,000 164,559,000 148,129,000 Management fees waived \(1,500,000\) \(1,500,000\) \(4,025,000\) \(4,025,000\) Part I incentive fees waived \(3,210,000\) 0 \(3,210,000\) 0 Net expenses 50,391,000 53,487,000 156,849,000 144,104,000 Net investment income before taxes 44,575,000 48,413,000 130,131,000 133,277,000 Excise tax 0 0 0 \(78,000\) Net investment income 44,575,000 48,413,000 130,131,000 133,199,000 Unrealized appreciation \(depreciation\): Å Å Å Foreign currency forward contracts 1,106,000 4,575,000 \(4,474,000\) \(4,802,000\) Net unrealized appreciation \(depreciation\) 26,199,](#)

gaap_InvestmentIncomeOperatingAfterExpenseAndTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionAmount of expense for investment management fee, including, but not limited to, expense in connection with research, selection, supervision, and custody of investment. + ReferencesReference 1: <http://www.xbrli.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480167/946-830-55-10>Reference 2: [http://www.xbrli.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483581/946-220-45-3](http://www.xbrli.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483581/946-220-45-3)Reference 3: [http://www.xbrli.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-07\(2\)\(a\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483575/946-220-S99-1](http://www.xbrli.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483575/946-220-S99-1)Reference 4: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1> + Details Name: us-gaap_ManagementFeeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: [http://www.xbrli.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(g\)\(1\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrli.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1)Reference 2: [http://www.xbrli.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3](http://www.xbrli.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3)Reference 3: [http://www.xbrli.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28](http://www.xbrli.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28)Reference 4: <http://www.xbrli.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6>Reference 5: <http://www.xbrli.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3>Reference 6: [http://www.xbrli.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(b\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1](http://www.xbrli.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1)Reference 7: [http://www.xbrli.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1](http://www.xbrli.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1)Reference 8: <http://www.xbrli.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8>Reference 9: <http://www.xbrli.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9>Reference 10: [http://www.xbrli.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrli.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11)Reference 11: [http://www.xbrli.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrli.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11)Reference 12: <http://www.xbrli.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4>Reference 13: <http://www.xbrli.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480167/946-830-55-10>Reference 14: <http://www.xbrli.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483581/946-220-45-7>Reference 15: [http://www.xbrli.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-04\(18\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483586/944-220-S99-1](http://www.xbrli.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483586/944-220-S99-1)Reference 16: <http://www.xbrli.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22>Reference 17: [http://www.xbrli.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-07\(9\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483575/946-220-S99-1](http://www.xbrli.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483575/946-220-S99-1)Reference 18: [http://www.xbrli.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-09\(1\)\(d\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483575/946-220-S99-3](http://www.xbrli.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483575/946-220-S99-3)Reference 19: [http://www.xbrli.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrli.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 20: [http://www.xbrli.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrli.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 21: [http://www.xbrli.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrli.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 22: [http://www.xbrli.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrli.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 23: [http://www.xbrli.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrli.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 24: [http://www.xbrli.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrli.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 25: [http://www.xbrli.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrli.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 26: [http://www.xbrli.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrli.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 27: [http://www.xbrli.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrli.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 28: [http://www.xbrli.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrli.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 29: [http://www.xbrli.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30](http://www.xbrli.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30)Reference 30: [http://www.xbrli.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrli.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 31: [http://www.xbrli.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B](http://www.xbrli.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B)Reference 32: <http://www.xbrli.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31>Reference 33: [http://www.xbrli.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrli.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 34: <http://www.xbrli.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7>Reference 35: <http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28>Reference 36: [http://www.xbrli.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1](http://www.xbrli.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1)Reference 37: [http://www.xbrli.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1](http://www.xbrli.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1)Reference 38: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(20\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483589/942-220-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483589/942-220-S99-1) + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionAmount, after tax, of realized and unrealized gain (loss) on investment and derivative, classified as operating. Investment includes, but is not limited to, debt and equity securities, security sold short, real estate, and commodity. + ReferencesReference 1: [http://www.xbrli.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-07\(7\)\(d\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483575/946-220-S99-1](http://www.xbrli.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(7)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483575/946-220-S99-1)Reference 2: [http://www.xbrli.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483581/946-220-45-3](http://www.xbrli.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483581/946-220-45-3) + Details Name: us-gaap_RealizedAndUnrealizedGainLossInvestmentAndDerivativeOperatingTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionAmount, after tax, of realized and unrealized gain (loss) on investment and derivative, classified as operating, and foreign currency transaction. Investment includes, but is not limited to, debt and equity securities, security sold short, real estate, and commodity. + ReferencesReference 1: <http://www.xbrli.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 45 -Paragraph 37 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480228/946-830-45-37>Reference 2: [http://www.xbrli.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-07\(8\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483575/946-220-S99-1](http://www.xbrli.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483575/946-220-S99-1)Reference 3: [http://www.xbrli.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480767/946-205-45-3](http://www.xbrli.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480767/946-205-45-3)Reference 4: [http://www.xbrli.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-09\(1\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483575/946-220-S99-3](http://www.xbrli.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483575/946-220-S99-3) + Details Name: us-gaap_RealizedAndUnrealizedGainLossInvestmentDerivativeAndForeignCurrencyTransactionOperatingAfterTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionAmount, before tax, of realized gain (loss) on investment and derivative, classified as operating. Investment includes, but is not limited to, debt and equity securities, security sold short, real estate, and commodity. + ReferencesReference 1: <http://www.xbrli.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480167/946-830-55-10>Reference 2: <http://www.xbrli.org/2003/role/disclosureRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480167/946-830-55-10>Reference 3: <http://www.xbrli.org/2003/role/disclosureRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480167/946-830-55-10>Reference 4: <http://www.xbrli.org/2003/role/disclosureRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480167/946-830-55-10>Reference 5: <http://www.xbrli.org/2003/role/disclosureRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480167/946-830-55-10>Reference 6: <http://www.xbrli.org/2003/role/disclosureRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480167/946-830-55-10>Reference 7: <http://www.xbrli.org/2003/role/disclosureRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480167/946-830-55-10>Reference 8: <http://www.xbrli.org/2003/role/disclosureRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480167/946-830-55-10>Reference 9: [http://www.xbrli.org/2003/role/disclosureRef -Topic 946 -SubTopic](http://www.xbrli.org/2003/role/disclosureRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480167/946-830-55-10)

[illegible]

<https://asc.fasb.org/1943274/2147482810/280-10-50-31Reference> 33: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference> 34: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference> 35: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference> 36: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482790/220-10-45-1Reference> 37: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482790/220-10-45-1Reference> 38: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference> 39: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483589/942-220-S99-1> + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - References No definition available. + Details Name: us-gaap_NetIncomeLossAttributableToReportingEntityAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of income tax expense (benefit) from realized and unrealized gain (loss) on investment and derivative, classified as operating. Investment includes, but is not limited to, debt and equity securities, security sold short, real estate, and commodity. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(7)(d)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483575/946-220-S99-1Reference> 2: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483581/946-220-45-4> + Details Name: us-gaap_RealizedAndUnrealizedGainLossInvestmentAndDerivativeOperatingTaxExpenseBenefit Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, before tax, of realized gain (loss) on investment and derivative, classified as operating. Investment includes, but is not limited to, debt and equity securities, security sold short, real estate, and commodity. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef> -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-10-2Reference> 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference> 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02-29-31) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap_StockIssuedDuringPeriodValueAcquisitions Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionValue of stock issued during the period from a dividend reinvestment plan (DRIP). A dividend reinvestment plan allows the holder of the stock to reinvest dividends paid to them by the entity on new issues of stock by the entity. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference> 2: <http://www.xbrl.org/2003/role/exampleRef> -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480167/946-830-55-11Reference> 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480767/946-205-45-4Reference> 4: <http://www.xbrl.org/2003/role/exampleRef> -Topic 946 -SubTopic 230 -Name Accounting Standards Codification -Section 55 -Paragraph 1 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480348/946-230-55-1Reference> 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481004/946-505-50-2Reference> 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483575/946-220-S99-3> + Details Name: us-gaap_StockIssuedDuringPeriodValueDividendReinvestmentPlan Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionEquity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference> 2: <http://www.xbrl.org/2003/role/exampleRef> -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480167/946-830-55-11Reference> 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI [https://asc.fasb.org/1](https://asc.fasb.org/1943274/2147480767/946-205-45-4Reference)

cash provided by (used in) operating activities:Â (76,433) (15,015) Financing activities:Â Â Â Distributions paid in cash:Â (133,130) (139,117) Borrowings under credit facilities:Â 205,000 572,000 Repayments of borrowings under credit facilities:Â (125,000) (362,000) Shares issued under the "at the market" offering:Â 92,748 0 Repurchases of common stock under dividend reinvestment plan:Â 0 (2,418) Deferred financing costs paid:Â 1 (1,039) (7,314) Deferred offering costs paid:Â (117) (186) Net cash provided by (used in) financing activities:Â 38,462 60,965 Effect of exchange rate changes on foreign currency:Â (254) 346 Net increase (decrease) in cash and cash equivalents and restricted cash:Â (38,225) 46,296 Cash and cash equivalents and restricted cash, beginning of period:Â 145,539 26,364 Cash and cash equivalents and restricted cash, end of period:Â 107,314 107,314 72,660 Supplemental information:Â Â Â Cash paid for interest:Â 88,502 70,429 Non-cash financing activities:Â Â Â Issuance of shares of common stock under dividend reinvestment plan:Â 5,662 1,933 Deferred financing costs:Â 1,000 125 Issuance of shares in connection with the OSI2 Merger:Â 0 \$ 334,034 Reconciliation to the Consolidated Statements of Assets and Liabilities:Â Â Â Cash and cash equivalents:Â 96,321 96,321 Â Restricted cash:Â 10,993 10,993 Â Total cash and cash equivalents and restricted cash:Â \$ 107,314 \$ 107,314 Â X - DefinitionAdjustments To Reconcile Net Assets From Operations To Cash Provided by (Used in) Operating Activities + ReferencesNo definition available. + Details Name: ocsl AdjustmentsToReconcileNetAssetsFromOperationsToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: ocsl Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionCash Acquired From Acquisition, Operating Activities + ReferencesNo definition available. + Details Name: ocsl CashAcquiredFromAcquisitionOperatingActivities Namespace Prefix: ocsl Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionIncrease (Decrease) In Director Fees Payable + ReferencesNo definition available. + Details Name: ocsl IncreaseDecreaseInDirectorFeesPayable Namespace Prefix: ocsl Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionIncrease (Decrease) In Due From Portfolio Companies + ReferencesNo definition available. + Details Name: ocsl IncreaseDecreaseInDueFromPortfolioCompanies Namespace Prefix: ocsl Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNoncash Financing Items + ReferencesNo definition available. + Details Name: ocsl NoncashFinancingItemsAbstract Namespace Prefix: ocsl Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionReconciliation To The Consolidated Statements Of Assets And Liabilities + ReferencesNo definition available. + Details Name: ocsl ReconciliationToTheConsolidatedStatementsOfAssetsAndLiabilitiesAbstract Namespace Prefix: ocsl Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionStock Issued, Acquisition + ReferencesNo definition available. + Details Name: ocsl StockIssuedAcquisition Namespace Prefix: ocsl Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionStock Issued, Dividend Reinvestment Plan + ReferencesNo definition available. + Details Name: ocsl StockIssuedDividendReinvestmentPlan Namespace Prefix: ocsl Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28> + Details Name: us-gaap AccretionAmortizationOfDiscountsAndPremiumsInvestments Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(b\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph \(b\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F)Reference 3: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03.8\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A) + Details Name: us-gaap AmortizationOfDebtDiscountPremium Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of amortization expense attributable to debt issuance costs. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph \(b\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F)Reference 2: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28)Reference 3: <http://www.xbrl.org/2003/role/disclosureRef-Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3>Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(1\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap AmortizationOfFinancingCosts Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: <a href=)Reference 2: [http://www.xbrl.org/2003/role/exampleRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1](http://www.xbrl.org/2003/role/exampleRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1)Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4> + Details Name: us-gaap CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4> + Details Name: us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4> + Details Name: us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481877/830-230-45-1> + Details Name: us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe amount of debt issuance costs that were incurred during a noncash or partial noncash transaction. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5> + Details Name: us-gaap DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(b\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28)Reference 2: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(h\)\(1\)\(Note 1\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(1)(Note 1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SAB Topic 6.I.Fact.2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.Fact.2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SAB Topic 6.I.Fact.1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.Fact.1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1)Reference 5: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SAB Topic 6.I.7\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.7) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph \(b\) -SubTopic 10 -Topic 740 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9](http://www.xbrl.org/2003/role/disclosureRef-Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (b) -SubTopic 10 -Topic 740 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9) + Details Name: us-gaap DeferredIncomeTaxExpenseBenefit Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 830 -SubTopic 230 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481877/830-230-45-1> + Details Name: us-gaap EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(a\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28) + Details Name: us-gaap IncreaseDecreaseInAccountsPayableAndAccruedLiabilities Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the total amount due to the entity related to activities and operations with other broker dealers, and clearing organizations, including deposits. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(a\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28) + Details Name: us-gaap IncreaseDecreaseInBrokerageReceivables Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) in obligations owed to an entity that is controlling, under the control of, or within the same control group as the reporting entity by means of direct or indirect ownership. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(a\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28) + Details Name: us-gaap IncreaseDecreaseInDueToAffiliates Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate amount due to the entity in the form of unpaid interest and dividends. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(a\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28) + Details Name: us-gaap IncreaseDecreaseInInterestAndDividendsReceivable Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the liability under agreements to repurchase securities that were sold. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(a\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28) + Details Name: us-gaap IncreaseDecreaseInOtherOperatingAssets Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the liability under agreements to repurchase securities that were sold. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(a\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28) + Details Name: us-gaap IncreaseDecreaseInOperatingAssetsAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in operating assets classified as other. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(a\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28) + Details Name: us-gaap IncreaseDecreaseInOtherOperatingAssets Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the liability under agreements to repurchase securities that were sold. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(a\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28) + Details Name: us-gaap IncreaseDecreaseInOtherOperatingAssets Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the liability under agreements to repurchase securities that were sold. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(a\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28) + Details Name: us-gaap IncreaseDecreaseInOtherOperatingAssets Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the liability under agreements to repurchase securities that were sold. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(a\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28) + Details Name: us-gaap IncreaseDecreaseInOtherOperatingAssets Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the liability under agreements to repurchase securities that were sold. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(a\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28) + Details Name: us-gaap IncreaseDecreaseInOtherOperatingAssets Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the liability under agreements to repurchase securities that were sold. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(a\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28) + Details Name: us-gaap IncreaseDecreaseInOtherOperatingAssets Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the liability under agreements to repurchase securities that were sold. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(a\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28) + Details Name: us-gaap IncreaseDecreaseInOtherOperatingAssets Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the liability under agreements to repurchase securities that were sold. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(a\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28) + Details Name: us-gaap IncreaseDecreaseInOtherOperatingAssets Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the liability under agreements to repurchase securities that were sold. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(a\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28) + Details Name: us-gaap IncreaseDecreaseInOtherOperatingAssets Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the liability under agreements to repurchase securities that were sold. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(a\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28) + Details Name: us-gaap IncreaseDecreaseInOtherOperatingAssets Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the liability under agreements to repurchase securities that were sold. + ReferencesReference 1:

Details Name: us-gaap IncreaseDecreaseInPayablesUnderRepurchaseAgreements Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionNameThe increase (decrease) during the reporting period in the total amount due the entity under agreements to sell and repurchase securities. + ReferencesReference 1: <https://asc.fasb.org/1943274/2147482740/230-10-45-28> + Details Name: us-gaap IncreaseDecreaseInReceivablesUnderRepurchaseAgreements Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionAmount of interest income from investment paid in kind, classified as operating. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph \(SX 210.12-14\)\(Column E\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-6](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14)(Column E)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-6)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph \(SX 210.12-14\)\(Column E\)\(Footnote 6\)\(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-6](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14)(Column E)(Footnote 6)(a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-6)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph \(SX 210.12-14\)\(Column E\)\(Footnote 6\)\(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-6](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14)(Column E)(Footnote 6)(c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-6)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-07\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483575/946-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483575/946-220-S99-1) + Details Name: us-gaap InterestIncomeOperatingPaidInKind Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionAmount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17](http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph \(e\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25](http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25)Reference 3: <http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2> + Details Name: us-gaap InterestPaidNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24> + Details Name: us-gaap NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap NetCashProvidedByUsedInFinancingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25> + Details Name: us-gaap NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap NetCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(g\)\(1\)\(iii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28](http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28)Reference 4: <http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3>Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(b\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1)Reference 8: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8>Reference 9: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9>Reference 10: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11)Reference 11: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11)Reference 12: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4>Reference 13: <http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480167/946-830-55-10>Reference 14: <http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483581/946-220-45-7>Reference 15: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-04\(18\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483586/944-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483586/944-220-S99-1)Reference 16: <http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22>Reference 17: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-07\(9\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483575/946-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483575/946-220-S99-1)Reference 18: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-09\(1\)\(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483575/946-220-S99-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483575/946-220-S99-3)Reference 19: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(ii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 20: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(ii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 21: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\(A\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 22: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 23: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(5\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 24: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 25: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(A\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 26: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 27: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 28: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(5\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 29: [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30)Reference 30: [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 31: [http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B](http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B)Reference 32: <http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31>Reference 33: [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 34: <http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7>Reference 35: <http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28>Reference 36: [http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A](http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A)Reference 37: [http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B)Reference 38: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(20\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2)Reference 39: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-04\(22\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483589/942-220-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483589/942-220-S99-1) + Details Name: us-gaap NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionAmount of cash outflow for acquisition of investment, classified as operating activity. Includes, but is not limited to, funding, origination, drawdown, and participation in investment. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 230 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480369/946-230-45-1> + Details Name: us-gaap PaymentsForPurchaseOfInvestmentOperatingActivity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionThe cash outflow to reacquire common stock during the period. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15) + Details Name: us-gaap PaymentsForRepurchaseOfCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionThe cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Subparagraph \(e\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15) + Details Name: us-gaap PaymentsOfDebtIssuanceCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionAmount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity. + ReferencesReference 1:

monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow for the settlement of obligation drawn from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer. + ReferencesReference 1:

5,715 [20] Á Á Investment, cost \$ 90 [12] Á Á \$ 90 [20] Á Á Á Investments at fair value \$ 0 [12] Á Á 0 [20] Á Á Á Investment, Identifier [Axis]: All Web Leads, Inc., Advertising, Common Stock Á Á Á Á Á Á Á Tersera Therapeutics LLC Á Á Á Á Á Á Á Investment owned, balance (in shares) | shares [12] 11,499 11,499 11,499 Á Á Á Á Investment, principal \$ 0 Á Á Á Á Á Á Á Investment, cost [12] 1,622 Á Á Á Á Á Á Á Investments at fair value \$ 1,622 [12] Á Á 0 Á Á Á Á Investment owned, percent of net assets (as a percent) 0.10% 0.10% 0.10% Á Á Á Á Investment, Identifier [Axis]: All Web Leads, Inc., Advertising, First Lien Revolver Á Á Á Á Á Á Á Tersera Therapeutics LLC Á Á Á Á Á Á Á Á Investment, basis spread, variable rate (as a percent) [12],[13] 4.00% 4.00% 4.00% Á Á Á Á Á Á Á Investment, interest rate (as a percent) [12],[13],[15],[16] 9.34% 9.34% 9.34% Á Á Á Á Á Á Á Investment, principal [12],[13],[15],[22] \$ 1,560 Á Á Á Á Á Á Á Á Investment, cost [12],[13],[15] 1,513 Á Á Á Á Á Á Á Investments at fair value \$ 1,506 [12],[13],[15] Á Á \$ 0 Á Á Á Á Investment owned, percent of net assets (as a percent) 0.10% 0.10% 0.10% Á Á Á Á Á Á Á Investment, Identifier [Axis]: All Web Leads, Inc., Advertising, First Lien Term Loan Á Á Á Á Á Á Á Á Tersera Therapeutics LLC Á Á Á Á Á Á Á Á Investment, basis spread, variable rate (as a percent) [19],[20],[29] Á Á 8.50% 8.50% 8.50% Á Á Á Á Á Á Á Investment, principal [19],[20],[23],[29] Á Á Á \$ 23,562 Á Á Á Á Investment, cost [19],[20],[29] Á Á 22,795 Á Á Á Á Á Investments at fair value [19],[20],[29] Á Á Á 9,797 Á Á Á Á Investment, Identifier [Axis]: All Web Leads, Inc., Advertising, First Lien Term Loan 1 Á Á Á Á Á Á Á Tersera Therapeutics LLC Á Á Á Á Á Á Á Á Investment, basis spread, variable rate (as a percent) [12],[15] 4.00% 4.00% 4.00% Á Á Á Á Á Á Á Investment, interest rate (as a percent) [12],[15],[16] 7.34% 7.34% 7.34% Á Á Á Á Á Á Á Investment, interest rate, paid in kind (as a percent) [12],[15] 2.00% 2.00% 2.00% Á Á Á Á Á Á Á Investment, principal [12],[15],[22] \$ 1,809 Á Á Á Á Á Á Á Á Investment, cost [12],[15] 1,740 Á Á Á Á Á Á Á Á Investments at fair value \$ 1,731 [12],[15] Á Á 0 Á Á Á Á Investment owned, percent of net assets (as a percent) 0.10% 0.10% 0.10% Á Á Á Á Á Á Á Investment, Identifier [Axis]: All Web Leads, Inc., Advertising, First Lien Term Loan 2 Á Á Á Á Á Á Á Á Tersera Therapeutics LLC Á Á Á Á Á Á Á Á Investment, basis spread, variable rate (as a percent) [12],[15] 5.00% 5.00% 5.00% Á Á Á Á Á Á Á Investment, interest rate (as a percent) [12],[15],[16] 8.34% 8.34% 8.34% Á Á Á Á Á Á Á Á Investment, interest rate, paid in kind (as a percent) [12],[15] 2.00% 2.00% 2.00% Á Á Á Á Á Á Á Á Investment, principal [12],[15],[22] \$ 3,602 Á Á Á Á Á Á Á Á Investment, cost [12],[15] 3,444 Á Á Á Á Á Á Á Á Investments at fair value \$ 3,429 [12],[15] Á Á 0 Á Á Á Á Investment owned, percent of net assets (as a percent) 0.20% 0.20% 0.20% Á Á Á Á Á Á Á Investment, Identifier [Axis]: All Web Leads, Inc., Advertising, First Lien Term Loan 3 Á Á Á Á Á Á Á Tersera Therapeutics LLC Á Á Á Á Á Á Á Á Investment, interest rate, paid in kind (as a percent) [12],[28] 10.00% 10.00% 10.00% Á Á Á Á Á Á Á Investment, principal [12],[22],[28] \$ 3,451 Á Á Á Á Á Á Á Á Investment, cost [12],[28] 3,026 Á Á Á Á Á Á Á Á Investments at fair value \$ 3,102 [12],[28] Á Á \$ 0 Á Á Á Á Investment owned, percent of net assets (as a percent) 0.20% 0.20% 0.20% Á Á Á Á Á Á Á Á Investment, Identifier [Axis]: Altice France S.A., Integrated Telecommunication Services, Fixed Rate Bond Á Á Á Á Á Á Á Tersera Therapeutics LLC Á Á Á Á Á Á Á Á Investment, interest rate (as a percent) [19],[21],[26] Á Á 5.50% 5.50% 5.50% Á Á Á Á Á Á Á Investment, principal [23],[26] Á Á Á \$ 4,050 Á Á Á Á Á Á Á Investment, cost [26] Á Á Á 3,577 Á Á Á Á Á Investments at fair value [26] Á Á Á \$ 2,918 Á Á Á Á Á Á Á Investment, Identifier [Axis]: Alto Pharmacy Holdings, Inc., Health Care Technology, First Lien Term Loan Á Á Á Á Á Á Á Tersera Therapeutics LLC Á Á Á Á Á Á Á Á Investment, basis spread, variable rate (as a percent) 11.50% [12],[15] 11.50% [12],[15] 11.50% [12],[15] 11.50% [19],[20] 11.50% [19],[20] Á Á Á Á Investment, interest rate (as a percent) 4.94% [12],[15],[16] 4.94% [12],[15],[16] 4.94% [12],[15],[16] 5.00% [19],[20],[21] 5.00% [19],[20],[21] 5.00% [19],[20],[21] Á Á Á Á Investment, interest rate, paid in kind (as a percent) 11.99% [12],[15] 11.99% [12],[15] 11.99% [12],[15] 11.99% [19],[20] 11.99% [19],[20] Á Á Á Á Investment, principal \$ 9,903 [12],[15],[22] Á Á \$ 9,057 [19],[20],[23] Á Á Á Á Investment, cost 9,396 [12],[15] Á Á 8,434 [19],[20] Á Á Á Á Á Investments at fair value \$ 9,086 [12],[15] Á Á \$ 8,332 [19],[20] Á Á Á Á Á Investment, Identifier [Axis]: Alto Pharmacy Holdings, Inc., Health Care Technology, Warrants Á Á Á Á Á Á Á Tersera Therapeutics LLC Á Á Á Á Á Á Á Á Investment owned, balance (in shares) | shares 598,283 [12] 598,283 [12] 598,283 [12] 598,283 [20] 598,283 [20] 598,283 [20] Á Á Á Á Á Á Á Á Investment, cost \$ 642 [12] Á Á Á \$ 642 [20] Á Á Á Á Á Investments at fair value \$ 1,226 [12] Á Á Á \$ 1,915 [20] Á Á Á Á Investment, Identifier [Axis]: Alvolgen Pharma US, Inc., Pharmaceuticals, First Lien Term Loan Á Á Á Á Á Á Á Tersera Therapeutics LLC Á Á Á Á Á Á Á Á Investment, basis spread, variable rate (as a percent) 7.50% [12],[15] 7.50% [12],[15] 7.50% [12],[15] 7.50% [19],[20] 7.50% [19],[20] 7.50% [19],[20] Á Á Á Á Investment, interest rate (as a percent) 12.98% [12],[15],[16] 12.98% [12],[15],[16] 12.98% [12],[15],[16] 12.98% [12],[15],[16] 13.04% [19],[20],[21] 13.04% [19],[20],[21] 13.04% [19],[20],[21] 13.04% [19],[20],[21] Á Á Á Á Investment, principal \$ 16,371 [12],[15],[22] Á Á \$ 17,053 [19],[20],[23] Á Á Á Á Á Investment, cost 16,332 [12],[15] Á Á 16,982 [19],[20] Á Á Á Á Á Investments at fair value \$ 15,413 [12],[15] Á Á \$ 15,929 [19],[20] Á Á Á Á Á Investment, Identifier [Axis]: Alvotech Holdings S.A., Biotechnology, Common Stock 1 Á Á Á Á Á Á Á Tersera Therapeutics LLC Á Á Á Á Á Á Á Á Investment owned, balance (in shares) | shares 118,744 [24] 118,744 [24] 118,744 [24] 471,253 [26] 471,253 [26] 471,253 [26] Á Á Á Á Á Á Á Á Investment, cost \$ 206 [24] Á Á Á \$ 849 [26] Á Á Á Á Á Investments at fair value \$ 1,444 [24] Á Á \$ 4,298 [26] Á Á Á Á Á Investment, Identifier [Axis]: Alvotech Holdings S.A., Biotechnology, Common Stock 2 Á Á Á Á Á Á Á Tersera Therapeutics LLC Á Á Á Á Á Á Á Á Investment owned, balance (in shares) | shares 70,820 [12],[24],[30] 70,820 [12],[24],[30] 141,640 [20],[26],[31] 141,640 [20],[26],[31] Á Á Á Á Á Investment, cost \$ 283 [12],[24],[30] Á Á Á \$ 566 [20],[26],[31] Á Á Á Á Á Investments at fair value \$ 627 [12],[24],[30] Á Á Á \$ 368 [20],[26],[31] Á Á Á Á Á Investment, Identifier [Axis]: Alvotech Holdings S.A., Biotechnology, Fixed Rate Bond 1 Á Á Á Á Á Á Á Tersera Therapeutics LLC Á Á Á Á Á Á Á Á Investment, interest rate (as a percent) 12.00% [12],[15],[16],[24] 12.00% [12],[15],[16],[24] 12.00% [12],[15],[16],[24] 8.50% [19],[20],[21],[26] 8.50% [19],[20],[21],[26] 8.50% [19],[20],[21],[26] Á Á Á Á Investment, interest rate, paid in kind (as a percent) [20],[26] Á Á Á 3.50% 3.50% 3.50% Á Á Á Á Á Investment, principal \$ 28,964 [12],[22],[24] Á Á \$ 28,464 [20],[23],[26] Á Á Á Á Á Investment, cost 28,866 [12],[24] Á Á 28,329 [20],[26] Á Á Á Á Á Investments at fair value \$ 28,964 [12],[24] Á Á \$ 27,687 [20],[26] Á Á Á Á Á Investment, Identifier [Axis]: Alvotech Holdings S.A., Biotechnology, Fixed Rate Bond 2 Á Á Á Á Á Á Á Tersera Therapeutics LLC Á Á Á Á Á Á Á Á Investment, interest rate (as a percent) 12.00% [12],[15],[16],[24] 12.00% [12],[15],[16],[24] 12.00% [12],[15],[16],[24] 8.50% [19],[20],[21],[26] 8.50% [19],[20],[21],[26] 8.50% [19],[20],[21],[26] Á Á Á Á Investment, interest rate, paid in kind (as a percent) [20],[26] Á Á Á 3.50% 3.50% 3.50% Á Á Á Á Á Investment, principal \$ 28,178 [12],[22],[24] Á Á \$ 2,121 [20],[23],[26] Á Á Á Á Á Investment, cost 28,100 [12],[24] Á Á 1,945 [20],[26] Á Á Á Á Á Investments at fair value \$ 28,178 [12],[24] Á Á \$ 2,063 [20],[26] Á Á Á Á Á Investment, Identifier [Axis]: Alvotech Holdings S.A., Biotechnology, Fixed Rate Bond 3 Á Á Á Á Á Á Á Tersera Therapeutics LLC Á Á Á Á Á Á Á Á Investment, interest rate (as a percent) 12.00% [12],[15],[16],[24] 12.00% [12],[15],[16],[24] 12.00% [12],[15],[16],[24] 8.50% [19],[20],[21],[26] 8.50% [19],[20],[21],[26] 8.50% [19],[20],[21],[26] Á Á Á Á Investment, interest rate, paid in kind (as a percent) [20],[26] Á Á Á 3.50% 3.50% 3.50% Á Á Á Á Á Investment, principal \$ 2,159 [12],[22],[24] Á Á \$ 27,692 [20],[23],[26] Á Á Á Á Á Investment, cost 1,981 [12],[24] Á Á 27,582 [20],[26] Á Á Á Á Á Investments at fair value \$ 2,159 [12],[24] Á Á \$ 26,936 [20],[26] Á Á Á Á Á Investment, Identifier [Axis]: Alvotech Holdings S.A., Biotechnology, Fixed Rate Bond 4 Á Á Á Á Á Á Á Tersera Therapeutics LLC Á Á Á Á Á Á Á Á Investment, interest rate (as a percent) 12.00% [12],[15],[16],[24] 12.00% [12],[15],[16],[24] 12.00% [12],[15],[16],[24] 8.50% [19],[20],[21],[26] 8.50% [19],[20],[21],[26] 8.50% [19],[20],[21],[26] Á Á Á Á Investment, interest rate, paid in kind (as a percent) [20],[26] Á Á Á 3.50% 3.50% 3.50% Á Á Á Á Á Investment, principal \$ 2,100 [12],[22],[24] Á Á \$ 2,064 [20],[23],[26] Á Á Á Á Á Investment, cost 1,926 [12],[24] Á Á 1,891 [20],[26] Á Á Á Á Á Investments at fair value \$ 2,100 [12],[24] Á Á \$ 2,007 [20],[26] Á Á Á Á Á Investment, Identifier [Axis]: American Auto Auction Group, LLC, Consumer Finance, Second Lien Term Loan Á Á Á Á Á Á Á Tersera Therapeutics LLC Á Á Á Á Á Á Á Á Investment, basis spread, variable rate (as a percent) [19],[20] Á Á 8.75% 8.75% 8.75% Á Á Á Á Á Á Á Investment, interest rate (as a percent) [19],[20],[21] Á Á 14.14% 14.14% 14.14% Á Á Á Á Á Á Á Investment, principal [19],[20],[23] Á Á Á \$ 17,048 Á Á Á Á Investment, cost [19],[20] Á Á 16,440 Á Á Á Á Á Investments at fair value [19],[20] Á Á Á \$ 15,087 Á Á Á Á Á Investment, Identifier [Axis]: American Auto Auction Group, LLC, Diversified Support Services, First Lien Term Loan Á Á Á Á Á Á Á Tersera Therapeutics LLC Á Á Á Á Á Á Á Á Investment, basis spread, variable rate (as a percent) [15] 5.00% 5.00% 5.00% Á Á Á Á Á Á Á Investment, interest rate (as a percent) [15],[16] 10.48% 10.48% 10.48% Á Á Á Á Á Á Á Investment, principal [15],[22] \$ 2,494 Á Á Á Á Á Á Á Á Investment, cost [15] 2,476 Á Á Á Á Á Á Á Investments at fair value [15] \$ 2,495 Á Á Á Á Á Á Á Á Investment, Identifier [Axis]: American Auto Auction Group, LLC, Diversified Support Services, Second Lien Term Loan Á Á Á Á Á Á Á Tersera Therapeutics LLC Á Á Á Á Á Á Á Á Investment, basis spread, variable rate (as a percent) [12],[15] 8.75% 8.75% 8.75% Á Á Á Á Á Á Á Investment, interest rate (as a percent) [12],[15],[16] 14.23% 14.23% 14.23% Á Á Á Á Á Á Á Investment, principal [12],[15],[22] \$ 17,048 Á Á Á Á Á Á Á Á Investment, cost [12],[15] 16,527 Á Á Á Á Á Á Á Investments at fair value [12],[15],[16] \$ 16,110 Á Á Á Á Á Á Á Á Investment, Identifier [Axis]: American Tire Distributors, Inc., Distributors, First Lien Term Loan Á Á Á Á Á Á Á Tersera Therapeutics LLC Á Á Á Á Á Á Á Á Investment, basis spread, variable rate (as a percent) 6.25% [15] 6.25% [15] 6.25% [15] 6.25% [19] 6.25% [19] 6.25% [19] Á Á Á Á Investment, interest rate (as a percent) 11.84% [15],[16] 11.84% [15],[16] 11.84% [15],[16] 11.81% [19],[21] 11.81% [19],[21] 11.81% [19],[21] Á Á Á Á Investment, principal \$ 7,489 [15],[22] Á Á \$ 19,115 [19],[23] Á Á Á Á Investment, cost 6,974 [15] Á Á 18,278 [19] Á Á Á Á Á Investments at fair value \$ 5,461 [15] Á Á \$ 16,798 [19] Á Á Á Á Á Investment, Identifier [Axis]: Amplify Finco Pty Ltd., Movies & Entertainment, Second Lien Term Loan Á Á Á Á Á Á Á Tersera Therapeutics LLC Á Á Á Á Á Á Á Á Investment, basis spread, variable rate (as a percent) [19],[26] Á Á Á 8.00% 8.00% 8.00% Á Á Á Á Á Á Á Investment, interest rate (as a percent) [19],[21],[26] Á Á Á 13.54% 13.54% 13.54% Á Á Á Á Á Á Á Investment, principal [19],[23],[26] Á Á Á \$ 12,500 Á Á Á Á Á Á Á Investment, cost [19],[26] Á Á Á 12,188 Á Á Á Á Á Investments at fair value [19],[26] Á Á Á \$ 11,865 Á Á Á Á Á Investment, Identifier [Axis]: Amspec Parent LLC, Diversified Support Services, First Lien Revolver Á Á Á Á Á Á Á Tersera Therapeutics LLC Á Á Á Á Á Á Á Á Investment, basis spread, variable rate (as a percent) [12],[13],[15] 5.75% 5.75% 5.75% Á Á Á Á Á Á Á Investment, principal [12],[13],[15],[22] \$ 0 Á Á Á Á Á Á Á Á Investment, cost [12],[13],[15] (103) Á Á Á Á Á Á Á Á Investments at fair value [12],[13],[15] \$ 0 Á Á Á Á Á Á Á Á Investment, Identifier [Axis]: Amspec Parent LLC, Diversified Support Services, First Lien Term Loan 1 Á Á Á Á Á Á Á Tersera Therapeutics LLC Á Á Á Á Á Á Á Á Investment, basis spread, variable rate (as a percent) [12],[15] 5.75% 5.75% 5.75% Á Á Á Á Á Á Á Á Investment, interest rate (as a percent) [12],[15],[16] 11.08% 11.08% 11.08% Á Á Á Á Á Á Á Á Investment, principal [12],[15],[22] \$ 33,474 Á Á Á Á Á Á Á Á Investment, cost [12],[15] 32,706 Á Á Á Á Á Á Á Á Investments at fair value [12],[15] \$ 33,474 Á Á Á Á Á Á Á Á Investment, Identifier [Axis]: Amspec Parent LLC, Diversified Support Services, First Lien Term Loan 2 Á Á Á Á Á Á Á Tersera Therapeutics LLC Á Á Á Á Á Á Á Á Investment, basis spread, variable rate (as a percent) [12],[13],[15] 5.75% 5.75% 5.75% Á Á Á Á Á Á Á Á Investment, principal [12],[13],[15],[22] \$ 0 Á Á Á Á Á Á Á Á Investment, cost [12],[13],[15] (60) Á Á Á Á Á Á Á Á Investments at fair value [12],[13],[15] \$ (60) Á Á Á Á Á Á Á Á Investment, Identifier [Axis]: Anastasia Parent, LLC, Personal Care Products, First Lien Term Loan Á Á Á Á Á Á Á Tersera Therapeutics LLC Á Á Á Á Á Á Á Á Investment, basis spread, variable rate (as a percent) [19] Á Á Á 3.75% 3.75% 3.75% Á Á Á Á Á Á Á Investment, interest rate (as a percent) [19],[21] Á Á Á 9.40% 9.40% 9.40% Á Á Á Á Á Á Á Investment, principal [19],[23] Á Á Á \$ 3,700 Á Á Á Á Á Investment, cost [19] Á Á Á 3,067 Á Á Á Á Á Investments at fair value [19] Á Á Á 2,669 Á Á Á Á Á Investment, Identifier [Axis]: Anchorage Capital CLO 20, Multi-Sector Holdings, CLO Notes Á Á Á Á Á Á Á Tersera Therapeutics LLC Á Á Á Á Á Á Á Á Investment, basis spread, variable rate (as a percent) [15],[24] 7.61% 7.61% 7.61% Á Á Á Á Á Á Á Á Investment, interest rate (as a percent) [15],[16],[24] 12.94% 12.94% 12.94% Á Á Á Á Á Á Á Á Investment, principal [15],[22],[24] \$ 750 Á Á Á Á Á Á Á Á Investment, cost [15],[24] 715 Á Á Á Á Á Á Á Investments at fair value [15],[24] \$ 735 Á Á Á Á Á Á Á Á Investment, Identifier [Axis]: Arches Buyer Inc., Interactive Media & Services, First Lien Term Loan Á Á Á Á Á Á Á Tersera Therapeutics LLC Á Á Á Á Á Á Á Á Investment, basis spread, variable rate (as a percent) [12],[15] 5.50% 5.50% 5.50% Á Á Á Á Á Á Á Investment, interest rate (as a percent) [12],[15],[16] 10.84% 10.84% 10.84% Á Á Á Á Á Á Á Á Investment, principal [12],[15],[22] \$ 47,690 Á Á Á Á Á Á Á Á Investment, cost [12],[15] 47,067 Á Á Á Á Á Á Á Á Investments at fair value [12],[15] \$ 47,690 Á Á Á Á Á Á Á Á Investment, Identifier [Axis]: Ardonagh Midco 3 PLC, Insurance Brokers, First Lien Term Loan 1 Á Á Á Á Á Á Á Tersera Therapeutics LLC Á Á Á Á Á Á Á Á Investment, basis spread, variable rate (as a percent) [19],[20],[26] Á Á Á 7.00% 7.00% 7.00% Á Á Á Á Á Á Á Investment, interest rate (as a percent) [19],[20],[21],[26] Á Á Á 10.95% 10.95% 10.95% Á Á Á Á Á Á Á Investment, principal | ~ [19],[20],[23],[26] Á Á Á ~ [19],[20],[26] Á Á Á ~ [19],[20],[26] Á Á Á 3,331 Á Á Á Á Á Investments at fair value [19],[20],[26] Á Á Á \$ 3,226 Á Á Á Á Á Investment, Identifier [Axis]: Ardonagh Midco 3 PLC, Insurance Brokers, First Lien Term Loan 2 Á Á Á Á Á Á Á Tersera Therapeutics LLC Á Á Á Á Á Á Á Á Investment, basis spread, variable rate (as a percent) [19],[20],[26] Á Á Á 5.75% 5.75% 5.75% Á Á Á Á Á Á Á Investment, interest rate (as a percent) [19],[20],[21],[26] Á Á Á 11.57% 11.57% 11.57% Á Á Á Á Á Á Á Investment, principal [19],[20],[23],[26] Á Á Á \$ 10,519 Á Á Á Á Á Á Á Á Investment, cost [19],[20],[26] Á Á Á 10,400 Á Á Á Á Á Á Á Investments at fair value [19],[20],[26] Á Á Á \$ 10,624 Á Á Á Á Á Á Á Á Investment, Identifier [Axis]: Ardonagh Midco 3 PLC, Insurance Brokers, First Lien Term Loan 3 Á Á Á Á Á Á Á Tersera Therapeutics LLC Á Á Á Á Á Á Á Á Investment, basis spread, variable rate (as a percent) [19],[20],[26] Á Á Á 7.00% 7.00% 7.00% Á Á Á Á Á Á Á Investment, interest rate (as a percent) [19],[20],[21],[26] Á Á Á 12.46% 12.46% 12.46% Á Á Á Á Á Á Á Investment, principal | ÁE [19],[20],[23],[26] Á Á Á Á Á Á Á Á Investment, cost [19],[20],[26] Á Á Á 6,318 Á Á Á Á Á Investments at fair value [19],[20],[26] Á Á Á 6,101 Á Á Á Á Á Á Á Á Investment, Identifier [Axis]: Ardonagh Midco 3 PLC, Insurance Brokers, First Lien Term Loan 4 Á Á Á Á Á Á Á Tersera Therapeutics LLC Á Á Á Á Á Á Á Á Investment, basis spread, variable rate (as a percent) [19],[20],[26] Á Á Á 7.00% 7.00% 7.00% Á Á Á Á Á Á Á Investment, interest rate (as a percent) [19],[20],[21],[26] Á Á Á 12.46% 12.46% 12.46% Á Á Á Á Á Á Á Á Investment, principal | ÁE [19],[20],[23],[26] Á Á Á Á Á Á Á Á Investment, cost [19],[20],[26] Á Á Á 28,713 Á Á Á Á Á Investments at fair value [19],[20],[26] Á Á Á 29,185 Á Á Á Á Á Á Á Á Investment, Identifier [Axis]: Ardonagh Midco 3 PLC, Insurance Brokers, First Lien Term Loan 5 Á Á Á Á Á Á Á Tersera Therapeutics LLC Á Á Á Á Á Á Á Á Investment, basis spread, variable rate (as a percent) [19],[20],[26] Á Á Á 5.75% 5.75% 5.75% Á Á Á Á Á Á Á Á Investment, interest rate (as a percent) [19],[20],[21],[26] Á Á Á 9.70% 9.70% 9.70% Á Á Á Á Á Á Á Á Investment, principal | ÁE [19],[20],[23],[26] Á Á Á Á Á Á Á Á Investment, cost [19],[20],[26] Á Á Á \$ 4,094 Á Á Á Á Á Investments at fair value [19],[20],[26] Á Á Á \$ 3,914 Á Á Á Á Á Á Á Á Investment, Identifier [Axis]: Ares XLIV CLO, Multi-Sector Holdings, CLO Notes Á Á Á Á Á Á Á Tersera Therapeutics LLC Á Á Á Á Á Á Á Á Investment, basis spread, variable rate (as a percent) [15],[24] 7.13% 7.13% 7.13% Á Á Á Á Á Á Á Á Investment, interest rate (as a percent) [15],[16],[24] 12.46% 12.46% 12.46% Á Á Á Á Á Á Á Á Investment, principal [15],[22],[24] \$ 3,500 Á Á Á Á Á Á Á Á Investment, cost [15],[24] 3,398 Á Á Á Á Á Á Á Á Investments at fair value [15],[24] \$ 3,514 Á Á Á Á Á Á Á Á Investment, Identifier [Axis]: Assembled Brands Capital LLC, Advertising, First Lien Revolver Á Á Á Á Á Á Á Tersera Therapeutics LLC Á Á Á Á Á Á Á Á Investment, basis spread, variable rate (as a percent) Á Á Á Á Á Á Á 6.75% Á Á Á Á Á Á Á Investment, interest rate (as a percent) Á Á Á Á Á Á Á 12.29% Á Á Á Á Á Á Á Investments at fair value Á Á Á Á Á Á Á 22,304 Á Á Á Á Á Á Á Á Investment owned, percent of net assets (as a percent) Á Á Á Á Á Á Á 1.50% Á Á Á Á Á Á Á Á Investment, Identifier [Axis]: Assembled Brands Capital LLC, Specialized Finance, Common Stock Á Á Á Á Á Á Á Tersera Therapeutics LLC Á Á Á Á Á Á Á Á Investment owned, balance (in shares) | shares 12,463,242 [12] 12,463,242 [12] 12,463,242 [12] 1,783,332 [20] 1,783,332 [20] 1,783,332 [20] Á Á Á Á Á Á Á Á Investment, principal Á Á Á Á Á Á Á 0 Á Á Á Á Á Investment, cost \$ 1,963 [12] Á Á Á \$ 804 [20] Á Á Á Á Á Investments at fair value \$ 1,246 [12] Á Á Á \$ 89 [20] Á Á Á \$ 0 370 Á Á Á Á Investment owned, percent of net assets (as a percent) 0.10% 0.10% 0.10% Á Á Á 0.00% Á Á Á Á Á Investment, Identifier [Axis]: Assembled Brands Capital LLC, Specialized Finance, First Lien Revolver Á Á Á Á Á Á Á Tersera Therapeutics LLC Á Á Á Á Á Á Á Á Investment, basis spread, variable rate (as a percent) [17],[19],[20] Á Á Á 6.75% 6.75% 6.75% Á Á Á Á Á Á Á Á Investment, interest rate (as a percent) [17],[19],[20],[21] Á Á Á 12.14% 12.14% 12.14% Á Á Á Á Á Á Á Á Investment, principal [17],[19],[20],[23] Á Á Á \$ 21,852 Á Á Á Á Á Á Á Á Investment, cost [17],[19],[20] Á Á Á 21,855 Á Á Á Á Á Á Á Investments at fair value \$ 0 Á Á Á \$ 21,823 [17],[19],[20] Á Á Á Á Á Á Á Á Investment owned, percent of net assets (as a percent) 0.00% 0.00% 0.00% Á Á Á Á Á Á Á Á Investment, Identifier [Axis]: Assembled Brands Capital LLC, Specialized Finance, Preferred Equity Á Á Á Á Á Á Á Tersera Therapeutics LLC Á Á Á Á Á Á Á Á Investment owned, balance (in shares) | shares Á Á Á 1,129,453 [20] 1,129,453 [20] 1,129,453 [20] 1,129,453 [20] 1,129,453 [20] Á Á Á Á Á Á Á Á Investment, principal Á Á Á Á Á Á Á \$ 0 Á Á Á Á Á Á Á Á Investment, cost [20] Á Á Á \$ 1,159 Á Á Á Á Á Investments at fair value \$ 0 Á Á Á \$ 1,005 [20] Á Á Á \$ 1,412,123 Á Á Á Á Investment owned, percent of net assets (as a percent) 0.00% 0.00% 0.00% Á Á Á 0.10% Á Á Á Á Á Investment, Identifier [Axis]: Assembled Brands Capital LLC, Specialized Finance, Warrants Á Á Á Á Á Á Á Tersera Therapeutics LLC Á Á Á Á Á Á Á Á Investment owned, balance (in shares) | shares 78,045 [12] 78,045 [12] 78,045 [12] 78,045 [20] 78,045 [20] 78,045 [20] Á Á Á Á Á Á Á Á Investment, principal Á Á Á Á Á Á Á \$ 0 Á Á Á Á Á Á Á Á Investment, cost \$ 0 [12] Á Á Á \$ 0 [20] Á Á Á Á Á Investments at fair value \$ 0 [12] Á Á Á \$ 0 [20] Á Á Á \$ 0 0 Á Á Á Á Á Investment owned, percent of net assets (as a percent) 0.00% 0.00% 0.00% Á Á Á 0.00% Á Á Á Á Á Investment, Identifier [Axis]: Astra Acquisition Corp., Application Software, First Lien Term Loan Á Á Á Á Á Á Á Tersera Therapeutics LLC Á Á Á Á Á Á Á Á Investment, basis spread, variable rate (as a percent) [19] Á Á Á 5.25% 5.25% 5.25% Á Á Á Á Á Á Á Á Investment, interest rate (as a percent) [19],[21] Á Á Á 10.90% 10.90% 10.90% Á Á Á Á Á Á Á Á Investment, principal [19],[23] Á Á Á \$ 8,490 Á Á Á Á Á Á Á Á Investment, cost [19] Á Á Á 8,168 Á Á Á Á Á Á Á Á Investments at fair value [19] Á Á Á \$ 6,414 Á Á Á Á Á Á Á Á Investment, Identifier [Axis]: Astra Acquisition Corp., Application Software, First Lien Term Loan 1 Á Á Á Á Á Á Á Tersera Therapeutics LLC Á Á Á Á Á Á Á Á Investment, basis spread, variable rate (as a percent) [12],[15] 6.75% 6.75% 6.75% Á Á Á Á Á Á Á Á Investment, interest rate (as a percent) [12],[15],[16] 12.08% 12.08% 12.08% Á Á Á Á Á Á Á Á Investment, principal [12],[15],[22] \$ 7,927 Á Á Á Á Á Á Á Á Investment, cost [12],[15] 7,828 Á Á Á Á Á Á Á Á Investments at fair value [12],[15] \$ 7,273 Á Á Á Á Á Á Á Á Investment, Identifier [Axis]: Astra Acquisition Corp., Application Software, First Lien Term Loan 2 Á Á Á Á Á Á Á Tersera Therapeutics LLC Á Á Á Á Á Á Á Á Investment, basis spread, variable rate (as a percent) [12],[15] 5.25% 5.25%

5.25% A A A A Investment, interest rate (as a percent) [12],[15],[16] 10.58% 10.58% 10.58% A A A A Investment, principal [12],[15],[22] \$ 12,537 A A A A Investment, cost [12],[15], 10,534 A A A A Investments at fair value [12],[15] \$ 5,881 A A A A A A A A Investment, Identifier [Axis]: Aurelia Netherlands Midco 2 B.V., Interactive Media & Services, First Lien Term Loan A A A A A A Tersera Therapeutics LLC A A A A A A Investment, basis spread, variable rate (as a percent) [12],[15],[24] 5.75% 5.75% A A A A Investment, interest rate (as a percent) [12],[15],[16],[24] 9.55% 9.55% 9.55% A A A A Investment, principal [12],[15],[22],[24] \$ 28,022 A A A A A A A A Investment, cost [12],[15],[24] 29,705 A A A A A A Investments at fair value [12],[15],[24] \$ 29,447 A A A A A A Investment, Identifier [Axis]: Aurora Lux Finco S.A.E.R.L., Airport Services, First Lien Term Loan A A A A A A Tersera Therapeutics LLC A A A A A A A A Investment, basis spread, variable rate (as a percent) 7.00% [12],[15],[24] 7.00% [12],[15],[24] 7.00% [12],[15],[24] 6.00% [19],[20],[26] 6.00% [19],[20],[26] 6.00% [19],[20],[26] A A A A Investment, interest rate (as a percent) 8.43% [12],[15],[16],[24] 8.43% [12],[15],[16],[24] 8.43% [12],[15],[16],[24] 11.49% [19],[20],[21],[26] 11.49% [19],[20],[21],[26] 11.49% [19],[20],[21],[26] A A A A Investment, interest rate, paid in kind (as a percent) [12],[15],[24] 4.00% 4.00% 4.00% A A A A Investment, principal \$ 30,406 [12],[15],[22],[24] A A A A \$ 29,509 [19],[20],[23],[26] A A A A A A A A Investment, cost 30,141 [12],[15],[24] A 29,164 [19],[20],[26] A A A A Investments at fair value \$ 29,372 [12],[15],[24] A A \$ 28,284 [19],[20],[26] A A A A Investment, Identifier [Axis]: Avalara, Inc., Application Software, First Lien Revolver A A A A A A Tersera Therapeutics LLC A A A A A A A A Investment, basis spread, variable rate (as a percent) 7.25% [12],[13],[15] 7.25% [12],[13],[15] 7.25% [12],[13],[15] 7.25% [17],[19],[20] 7.25% [17],[19],[20] 7.25% [17],[19],[20] A A A A Investment, principal \$ 0 [12],[13],[15],[22] A A \$ 0 [17],[19],[20],[23] A A A A A A A A Investment, cost (92) [12],[13],[15] A (108) [17],[19],[20] A A A A Investments at fair value [17],[19],[20] [13],[15] A \$ (78) [17],[19],[20] A A A A Investment, Identifier [Axis]: Avalara, Inc., Application Software, First Lien Term Loan A A A A A A A A Tersera Therapeutics LLC A A A A A A A A Investment, basis spread, variable rate (as a percent) 7.25% [12],[15] 7.25% [12],[15] 7.25% [12],[15] 7.25% [19],[20] 7.25% [19],[20] 7.25% [19],[20] A A A A Investment, interest rate (as a percent) 12.58% [12],[15],[16] 12.58% [12],[15],[16] 12.58% [12],[15],[16] 12.64% [19],[20],[21] 12.64% [19],[20],[21] 12.64% [19],[20],[21] A A A A Investment, principal \$ 50,470 [12],[15],[22] A A \$ 50,470 [19],[20],[23] A A A A A A A A Investment, cost 49,796 [12],[15] A 49,679 [19],[20] A A A A Investments at fair value \$ 50,470 [12],[15] A A \$ 49,688 [19],[20] A A A A Investment, Identifier [Axis]: BAART Programs, Inc., Health Care Services, First Lien Term Loan 1 A A A A A A A A Tersera Therapeutics LLC A A A A A A A A A A A A A A Investment, basis spread, variable rate (as a percent) 5.00% [12],[15] 5.00% [12],[15] 5.00% [12],[15] 5.00% [19],[20] 5.00% [19],[20] 5.00% [19],[20] A A A A Investment, interest rate (as a percent) 10.60% [12],[15],[16] 10.60% [12],[15],[16] 10.60% [12],[15],[16] 10.65% [19],[20],[21] 10.65% [19],[20],[21] 10.65% [19],[20],[21] A A A A Investment, principal \$ 3,222 [12],[15],[22] A A \$ 3,247 [19],[20],[23] A A A A Investment, cost 3,192 [12],[15] A 3,216 [19],[20] A A A A Investments at fair value \$ 3,096 [12],[15] A A \$ 3,169 [19],[20] A A A A Investment, Identifier [Axis]: BAART Programs, Inc., Health Care Services, First Lien Term Loan 2 A A A A A A A A Tersera Therapeutics LLC A A A A A A A A A A A A A A Investment, basis spread, variable rate (as a percent) 5.00% [12],[15] 5.00% [12],[15] 5.00% [12],[15] 5.00% [19],[20] 5.00% [19],[20] 5.00% [19],[20] A A A A Investment, interest rate (as a percent) 10.60% [12],[15],[16] 10.60% [12],[15],[16] 10.60% [12],[15],[16] 10.65% [19],[20],[21] 10.65% [19],[20],[21] 10.65% [19],[20],[21] A A A A Investment, principal \$ 1,252 [12],[15],[22] A A \$ 1,261 [19],[20],[23] A A A A A A A A Investment, cost 1,258 [12],[15] A 1,269 [19],[20] A A A A Investments at fair value \$ 1,203 [12],[15] A A \$ 1,231 [19],[20] A A A A A A A A Investment, Identifier [Axis]: BAART Programs, Inc., Health Care Services, Second Lien Term Loan 1 A A A A A A A A Tersera Therapeutics LLC A A A A A A A A A A A A A A Investment, basis spread, variable rate (as a percent) 8.50% [12],[15] 8.50% [12],[15] 8.50% [12],[15] 8.50% [19],[20] 8.50% [19],[20] 8.50% [19],[20] A A A A Investment, interest rate (as a percent) 14.10% [12],[15],[16] 14.10% [12],[15],[16] 14.10% [12],[15],[16] 14.15% [19],[20],[21] 14.15% [19],[20],[21] 14.15% [19],[20],[21] A A A A Investment, principal \$ 6,452 [12],[15],[22] A A \$ 8,920 [19],[20],[23] A A A A A A A A Investment, cost 6,386 [12],[15] A 8,819 [19],[20] A A A A Investments at fair value \$ 5,704 [12],[15] A A \$ 8,492 [19],[20] A A A A A A A A Investment, Identifier [Axis]: BAART Programs, Inc., Health Care Services, Second Lien Term Loan 2 A A A A A A A A Tersera Therapeutics LLC A A A A A A A A A A A A A A Investment, basis spread, variable rate (as a percent) 8.50% [12],[15] 8.50% [12],[15] 8.50% [12],[15] 8.50% [19],[20] 8.50% [19],[20] 8.50% [19],[20] A A A A Investment, interest rate (as a percent) 14.10% [12],[15],[16] 14.10% [12],[15],[16] 14.10% [12],[15],[16] 14.15% [19],[20],[21] 14.15% [19],[20],[21] 14.15% [19],[20],[21] A A A A Investment, principal \$ 8,920 [12],[15],[22] A A \$ 2,091 [19],[20],[23] A A A A A A A A Investment, cost 8,818 [12],[15] A 2,068 [19],[20] A A A A Investments at fair value \$ 7,885 [12],[15] A A \$ 1,991 [19],[20] A A A A A A A A Investment, Identifier [Axis]: BAART Programs, Inc., Health Care Services, Second Lien Term Loan 3 A A A A A A A A Tersera Therapeutics LLC A A A A A A A A A A A A A A Investment, basis spread, variable rate (as a percent) [19],[20] A A 4.297 A A A A Investments at fair value [19],[20] A A \$ 4,152 A A A A A A A A Investment, Identifier [Axis]: Bain Capital Credit CLO, Limited, Multi-Sector Holdings, CLO Notes A A A A A A A A Tersera Therapeutics LLC A A A A A A A A A A A A A A Investment, basis spread, variable rate (as a percent) [15],[24] 7.54% 7.54% 7.54% A A A A A A A A Investment, interest rate (as a percent) [15],[16],[24] 12.87% 12.87% 12.87% A A A A A A A A Investment, principal [15],[22],[24] \$ 1,750 A A A A A A A A A A Investment, cost [15],[24] 1,733 A A A A A A A A Investments at fair value [15],[24] 1,784 A A A A A A A A A A A A A A Investment, Identifier [Axis]: Ballyrock CLO 19 Ltd., Multi-Sector Holdings, CLO Notes A A A A A A A A Tersera Therapeutics LLC A A A A A A A A A A A A A A Investment, basis spread, variable rate (as a percent) [15],[24] 7.11% 7.11% 7.11% A A A A A A A A Investment, interest rate (as a percent) [15],[16],[24] 12.43% 12.43% 12.43% A A A A A A A A Investment, principal [15],[22],[24] \$ 1,000 A A A A A A A A A A A A A A Investment, cost [15],[24] 992 A A A A A A A A Investments at fair value [15],[24] \$ 1,000 A A A A A A A A A A A A A A Investment, Identifier [Axis]: Berner Food & Beverage, LLC, Soft Drinks & Non-alcoholic Beverages, First Lien Revolver A A A A A A A A Tersera Therapeutics LLC A A A A A A A A A A A A A A A A A A A A Investment, basis spread, variable rate (as a percent) 5.50% [12],[13],[15] 5.50% [12],[13],[15] 5.50% [12],[13],[15] 4.50% [17],[19],[20] 4.50% [17],[19],[20] 4.50% [17],[19],[20] A A A A A A A A Investment, interest rate (as a percent) 10.98% [12],[13],[15],[16] 10.98% [12],[13],[15],[16] 10.98% [12],[13],[15],[16] 13.00% [17],[19],[20],[21] 13.00% [17],[19],[20],[21] 13.00% [17],[19],[20],[21] A A A A A A A A Investment, principal \$ 2,528 [12],[13],[15],[22] A A \$ 2,221 [17],[19],[20],[23] A A A A A A A A Investment, cost 2,503 [12],[13],[15] A 2,188 [17],[19],[20] A A A A A A A A Investments at fair value \$ 2,497 [12],[13],[15] A A \$ 2,178 [17],[19],[20] A A A A A A A A A A A A A A Investment, Identifier [Axis]: Berner Food & Beverage, LLC, Soft Drinks & Non-alcoholic Beverages, First Lien Term Loan A A A A A A A A Tersera Therapeutics LLC A A A A A A A A A A A A A A A A A A A A Investment, basis spread, variable rate (as a percent) 5.50% [12],[1

(as a percent) [19],[20] Á Á Á 6.50% 6.50% 6.50% Á Á Investment, interest rate (as a percent) [19],[20],[21] Á Á Á 12.07% 12.07% 12.07% Á Á Investment, principal [19],[20],[23] Á Á Á \$ 3,031 Á Á Á Á Investment, cost [19],[20] Á Á Á \$ 2,899 Á Á Á Á Investments at fair value [19],[20] Á Á Á \$ 3,031 Á Á Á Á Investment, Identifier [Axis]: Cadence Aerospace, LLC, Aerospace & Defense, First Lien Term Loan 3 Á Á Á Á Á Á Á Tersera Therapeutics LLC Á Á Á Á Á Á Investment, basis spread, variable rate (as a percent) [19],[20] Á Á Á 6.50%, 6.50% 6.50% Á Á Investment, interest rate (as a percent) [19],[20],[21] Á Á Á 12.07% 12.07% 12.07% Á Á Investment, principal [19],[20],[23] Á Á Á \$ 1,557 Á Á Á Á Investment, cost [19],[20] Á Á Á \$ 1,489 Á Á Á Á Investments at fair value [19],[20] Á Á Á \$ 1,557 Á Á Á Á Investment, Identifier [Axis]: Cadence Aerospace, LLC, Aerospace & Defense, First Lien Term Loan 4 Á Á Á Á Á Á Á Tersera Therapeutics LLC Á Á Á Á Á Á Á Investment, basis spread, variable rate (as a percent) [19],[20] Á Á Á 6.50% 6.50% 6.50% Á Á Investment, interest rate (as a percent) [19],[20],[21] Á Á Á 12.07% 12.07% 12.07% Á Á Investment, principal [19],[20],[23] Á Á Á \$ 1,024 Á Á Á Á Investment, cost [19],[20] Á Á Á 994 Á Á Á Á Investments at fair value [19],[20] Á Á Á \$ 1,024 Á Á Á Á Investment, Identifier [Axis]: Caregiver Services, Inc., Health Care Services, Preferred Equity Á Á Á Á Á Á Á Tersera Therapeutics LLC Á Á Á Á Á Á Á Investment owned, balance (in shares) | shares 1,080,398 [12] 1,080,398 [12] 1,080,398 [12] 1,080,399 [20] 1,080,399 [20] 1,080,399 Á Á Investment, principal Á Á Á Á Á Á Á \$ 0 Á Á Investment, cost \$ 875 [12] Á Á \$ 1,080 [20] Á Á Á Investments at fair value \$ 227 [12] Á Á \$ 432 [20] Á Á \$ 313 378 Investment owned, percent of net assets (as a percent) 0.00% 0.00% 0.00% Á Á Á 0.00% Á Investment, Identifier [Axis]: Clear Channel Outdoor Holdings, Inc., Advertising, Fixed Rate Bond 1 Á Á Á Á Á Á Á Tersera Therapeutics LLC Á Á Á Á Á Á Á Investment, interest rate (as a percent) [19],[21],[26] Á Á Á 7.50% 7.50% 7.50% Á Á Investment, principal [23],[26] Á Á Á \$ 2,632 Á Á Á Á Investment, cost [26] Á Á Á \$ 2,632 Á Á Á Á Investments at fair value [26] Á Á Á \$ 2,017 Á Á Á Á Investment, Identifier [Axis]: Clear Channel Outdoor Holdings, Inc., Advertising, Fixed Rate Bond 2 Á Á Á Á Á Á Á Tersera Therapeutics LLC Á Á Á Á Á Á Á Investment, interest rate (as a percent) [19],[21],[26] Á Á Á 7.75% 7.75% 7.75% Á Á Investment, principal [23],[26] Á Á Á \$ 176 Á Á Á Á Investment, cost [26] Á Á Á \$ 170 Á Á Á Á Investments at fair value [26] Á Á Á \$ 141 Á Á Á Á Investment, Identifier [Axis]: Cloud Software Group, Inc., Application Software, Fixed Bond Á Á Á Á Á Á Á Tersera Therapeutics LLC Á Á Á Á Á Á Á Investment, interest rate (as a percent) [15],[16] 6.50% 6.50% 6.50% Á Á Á Á Investment, principal [22] \$ 2,300 Á Á Á Á Á Á Á Investment, cost 2,136 Á Á Á Á Á Á Á Investments at fair value \$ 2,210 Á Á Á Á Á Á Á Investment, Identifier [Axis]: Condor Merger Sub Inc., Systems Software, Fixed Rate Bond Á Á Á Á Á Á Á Tersera Therapeutics LLC Á Á Á Á Á Á Á Investment, interest rate (as a percent) 7.38% [15],[16] 7.38% [15],[16] 7.38% [15],[16] 7.38% [19],[21] 7.38% [19],[21] 7.38% [19],[21] Á Á Investment, principal \$ 10,720 [22] Á Á \$ 8,420 [23] Á Á Á Investment, cost 10,310 Á Á 8,261 Á Á Á Investments at fair value \$ 9,911 Á Á 7,059 Á Á Á Á Investment, Identifier [Axis]: Connect U.S. Finclo LLC, Alternative Carriers, Fixed Rate Bond Á Á Á Á Á Á Á Tersera Therapeutics LLC Á Á Á Á Á Á Á Á Investment, interest rate (as a percent) [15],[16],[24] 6.75% 6.75% 6.75% Á Á Á Á Investment, principal [22],[24] \$ 1,310 Á Á Á Á Á Á Á Investment, cost [24] 1,281 Á Á Á Á Á Á Investments at fair value [24] \$ 1,265 Á Á Á Á Á Á Á Investment, Identifier [Axis]: Continental Intermodal Group LP, Oil & Gas Storage & Transportation, Common Stock Á Á Á Á Á Á Á Tersera Therapeutics LLC Á Á Á Á Á Á Á Investment owned, balance (in shares) | shares [12] 22,267,661 22,267,661 22,267,661 Á Á Á Á Investment, cost [12] \$ 16,172 Á Á Á Á Á Á Investments at fair value \$ 14,474 [12] Á Á \$ 0 Á Á Á Á Investment owned, percent of net assets (as a percent) 1.00% 1.00% 1.00% Á Á Á Á Investment, Identifier [Axis]: Continental Intermodal Group LP, Oil & Gas Storage & Transportation, First Lien Term Loan Á Á Á Á Á Á Á Tersera Therapeutics LLC Á Á Á Á Á Á Á Á Investment, basis spread, variable rate (as a percent) [19],[20],[29] Á Á Á 8.50% 8.50% 8.50% Á Á Investment, principal [19],[20],[23],[29] Á Á Á \$ 22,084 Á Á Á Á Investment, cost [19],[20],[29] Á Á 21,336 Á Á Á Á Investments at fair value [19],[20],[29] Á Á Á \$ 16,040 Á Á Á Á Investment, Identifier [Axis]: Continental Intermodal Group LP, Oil & Gas Storage & Transportation, Preferred Equity Á Á Á Á Á Á Á Tersera Therapeutics LLC Á Á Á Á Á Á Á Investment owned, balance (in shares) | shares [12] 3,137,476 3,137,476 3,137,476 Á Á Á Á Investment, cost [12] \$ 3,137 Á Á Á Á Á Á Investments at fair value \$ 3,263 [12] Á Á 0 Á Á Á Á Investment owned, percent of net assets (as a percent) 0.20% 0.20% 0.20% Á Á Á Á Investment, Identifier [Axis]: Continental Intermodal Group LP, Oil & Gas Storage & Transportation, Warrants Á Á Á Á Á Á Á Tersera Therapeutics LLC Á Á Á Á Á Á Á Á Investment, cost [20] Á Á 706 Á Á Á Á Investments at fair value [20] Á Á \$ 0 Á Á Á Á Investment, Identifier [Axis]: Conviva Inc., Application Software, Preferred Equity Á Á Á Á Á Á Á Tersera Therapeutics LLC Á Á Á Á Á Á Á Á Investment owned, balance (in shares) | shares 417,851 [12] 417,851 [12] 417,851 [12] 417,851 [20] 417,851 [20] Á Á Á Á Investment, cost 605 [12] Á Á \$ 605 [20] Á Á Á Á Investments at fair value \$ 894 [12] Á Á \$ 894 [20] Á Á Á Á Investment, Identifier [Axis]: CoreRx, Inc., Pharmaceuticals, First Lien Term Loan Á Á Á Á Á Á Á Tersera Therapeutics LLC Á Á Á Á Á Á Á Á Investment, basis spread, variable rate (as a percent) [12],[15] 7.50% 7.50% 7.50% Á Á Á Á Investment, interest rate (as a percent) [12],[15],[16] 12.83% 12.83% 12.83% Á Á Á Á Investment, principal [12],[15],[22] \$ 6,494 Á Á Á Á Á Á Á Investment, cost [12],[15] 6,339 Á Á Á Á Á Á Á Investments at fair value [12],[15] 6,347 Á Á Á Á Á Á Á Investment, Identifier [Axis]: Coupa Holdings, LLC, Application Software, First Lien Revolver Á Á Á Á Á Á Á Tersera Therapeutics LLC Á Á Á Á Á Á Á Á Investment, basis spread, variable rate (as a percent) 5.50% [12],[13],[15] 5.50% [12],[13],[15] 5.50% [12],[13],[15] 7.50% [17],[19],[20] 7.50% [17],[19],[20] 7.50% [17],[19],[20] Á Á Á Á Investment, principal \$ 0 [12],[13],[15],[22] Á Á \$ 0 [17],[19],[20],[23] Á Á Á Á Investment, cost (18) [12],[13],[15] Á Á (20) [17],[19],[20] Á Á Á Á Investments at fair value \$ 0 [12],[13],[15] Á Á \$ (20) [17],[19],[20] Á Á Á Á Investment, Identifier [Axis]: Coupa Holdings, LLC, Application Software, First Lien Term Loan 1 Á Á Á Á Á Á Á Tersera Therapeutics LLC Á Á Á Á Á Á Á Á Investment, basis spread, variable rate (as a percent) 5.50% [12],[13],[15] 5.50% [12],[13],[15] 5.50% [12],[13],[15] 7.50% [19],[20] 7.50% [19],[20] 7.50% [19],[20] Á Á Á Á Investment, interest rate (as a percent) [19],[20],[21] Á Á Á 12.82% 12.82% 12.82% Á Á Á Á Investment, principal \$ 0 [12],[13],[15],[22] Á Á \$ 13,157 [19],[20],[23] Á Á Á Á Investment, cost (15) [12],[13],[15] Á Á 12,855 [19],[20] Á Á Á Á Investments at fair value \$ 0 [12],[13],[15] Á Á \$ 12,858 [19],[20] Á Á Á Á Investment, Identifier [Axis]: Coupa Holdings, LLC, Application Software, First Lien Term Loan 2 Á Á Á Á Á Á Á Tersera Therapeutics LLC Á Á Á Á Á Á Á Á Investment, basis spread, variable rate (as a percent) 5.50% [12],[15] 5.50% [12],[15] 5.50% [12],[15] 7.50% [17],[19],[20] 7.50% [17],[19],[20] 7.50% [17],[19],[20] Á Á Á Á Investment, interest rate (as a percent) [12],[15],[16] 10.83% 10.83% 10.83% Á Á Á Á Investment, principal \$ 13,157 [12],[15],[22] Á Á \$ 0 [17],[19],[20],[23] Á Á Á Á Investment, cost 12,890 [12],[15] Á Á (15) [17],[19],[20] Á Á Á Á Investments at fair value \$ 13,157 [12],[15] Á Á (\$ 13) [17],[19],[20] Á Á Á Á Investment, Identifier [Axis]: Covetrus, Inc., Health Care Distributors, First Lien Term Loan Á Á Á Á Á Á Á Tersera Therapeutics LLC Á Á Á Á Á Á Á Á Investment, basis spread, variable rate (as a percent) 5.00% [15] 5.00% [15] 5.00% [15] 5.00% [19] 5.00% [19] 5.00% [19] Á Á Á Á Investment, interest rate (as a percent) 10.33% [15],[16] 10.33% [15],[16] 10.33% [15],[16] 10.39% [19],[21] 10.39% [19],[21] 10.39% [19],[21] Á Á Á Á Investment, principal \$ 14,639 [15],[22] Á Á \$ 14,750 [19],[23] Á Á Á Á Investment, cost 14,132 [15] Á Á 14,173 [19] Á Á Á Á Investments at fair value \$ 14,189 [15] Á Á \$ 14,616 [19] Á Á Á Á Investment, Identifier [Axis]: Coyote Buyer, LLC, Specialty Chemicals, First Lien Revolver Á Á Á Á Á Á Á Tersera Therapeutics LLC Á Á Á Á Á Á Á Á Investment, basis spread, variable rate (as a percent) [17],[19],[20] Á Á Á 6.00% 6.00% 6.00% Á Á Á Á Investment, interest rate (as a percent) [17],[19],[20],[21] Á Á Á 11.47% 11.47% 11.47% Á Á Á Á Investment, principal [17],[19],[20],[23] Á Á Á \$ 933 Á Á Á Á Investment, cost [17],[19],[20] Á Á 920 Á Á Á Á Investments at fair value [17],[19],[20] Á Á Á \$ 918 Á Á Á Á Á Á Á Investment, Identifier [Axis]: Coyote Buyer, LLC, Specialty Chemicals, First Lien Term Loan Á Á Á Á Á Á Á Tersera Therapeutics LLC Á Á Á Á Á Á Á Á Investment, basis spread, variable rate (as a percent) [19],[20] Á Á Á 6.00% 6.00% 6.00% Á Á Á Á Investment, interest rate (as a percent) [19],[20],[21] Á Á Á 11.52% 11.52% 11.52% Á Á Á Á Investment, principal [

[illegible]

[illegible]

43,886 [19],[20] A A A Investment, Identifier [Axis]: Liquid Environmental Solutions Corporation, Environmental & Facilities Services, Common Stock A A A A A Tersera Therapeutics LLC A A A A A Investment owned, balance (in shares) | shares 559 [12] 559 [12] 559 [12] 559 [20] 559 [20] 559 [20] A A A A A Investment, principal [20],[23] A A A A A Investment, cost \$ 563 [12] A A A 563 [20] A A A Investments at fair value \$ 238 [12] A A A \$ 372 [20] A A A Investment, Identifier [Axis]: Liquid Environmental Solutions Corporation, Environmental & Facilities Services, Second Lien Term Loan 1 A A A A A A A A A Tersera Therapeutics LLC A A A A A A A A A Investment, basis spread, variable rate (as a percent) 9.50% [12],[15] 9.50% [12],[15] 9.50% [12],[15] 8.50% [19],[20] 8.50% [19],[20] 8.50% [19],[20] A A A Investment, interest rate (as a percent) 5.00% [12],[15], [16] 5.00% [12],[15], [16] 5.00% [12],[15], [16] 5.00% [12],[15], [16] 13.99% [19],[20], [21] 13.99% [19],[20], [21] 13.99% [19],[20], [21] A A A Investment, interest rate, paid in kind (as a percent) [12],[15] 9.93% 9.93% 9.93% A A A A A Investment, principal \$ 5,818 [12],[15], [22] A A A \$ 2,939 [17],[19],[20], [23] A A A Investment, cost \$ 7,776 [12],[15] A A A 2,884 [17],[19],[20] A A A Investments at fair value \$ 5,512 [12],[15] A A A \$ 2,745 [17],[19],[20] A A A Investment, Identifier [Axis]: MHE Intermediate Holdings, LLC, Diversified Support Services, First Lien Revolver A A A A A A A A A Tersera Therapeutics LLC A A A A A A A A A Investment, basis spread, variable rate (as a percent) 6.00% [12],[13], [15] 6.00% [12],[13], [15] 6.00% [12],[13], [15] 6.00% [17],[19], [20] 6.00% [17],[19], [20] 6.00% [17],[19], [20] A A A Investment, interest rate (as a percent) [17],[19], [20], [21] A A A 11.42% 11.42% 11.42% A A A A A Investment, principal \$ 0 [12],[13], [15], [22] A A A \$ 964 [17],[19],[20], [23] A A A A A Investment, cost [23] [12],[13], [15] A A A 936 [17],[19],[20] A A A A A Investments at fair value \$ (19) [12],[13], [15] A A A \$ 938 [17],[19],[20] A A A A A Investment, Identifier [Axis]: MHE Intermediate Holdings, LLC, Diversified Support Services, First Lien Term Loan 1 A A A A A A A A A Tersera Therapeutics LLC A A A A A A A A A Investment, basis spread, variable rate (as a percent) 6.00% [12],[15] 6.00% [12],[15] 6.00% [12],[15] 6.00% [19],[20] 6.00% [19],[20] 6.00% [19],[20] A A A Investment, interest rate (as a percent) 11.48% [12],[15], [16] 11.48% [12],[15], [16] 11.48% [12],[15], [16] 11.48% [12],[15], [16] 11.52% [19],[20], [21] 11.52% [19],[20], [21] 11.52% [19],[20], [21] A A A Investment, principal \$ 2,611 [12],[15], [22] A A A \$ 20,125 [19],[20], [23] A A A A A Investment, cost \$ 2,568 [12],[15] A A A 19,912 [19],[20] A A A A A Investments at fair value \$ 2,582 [12],[15] A A A \$ 19,823 [19],[20] A A A A A Investment, Identifier [Axis]: MHE Intermediate Holdings, LLC, Diversified Support Services, First Lien Term Loan 2 A A A A A A A A A Tersera Therapeutics LLC A A A A A A A A A Investment, basis spread, variable rate (as a percent) 6.00% [12],[15] 6.00% [12],[15] 6.00% [12],[15] 6.00% [19],[20] 6.00% [19],[20] 6.00% [19],[20] A A A Investment, interest rate (as a percent) 11.48% [12],[15], [16] 11.48% [12],[15], [16] 11.48% [12],[15], [16] 11.48% [12],[15], [16] 11.52% [19],[20], [21] 11.52% [19],[20], [21] 11.52% [19],[20], [21] A A A Investment, principal \$ 11,176 [12],[15], [22] A A A \$ 2,631 [19],[20], [23] A A A A A Investment, cost [11,080 [12],[15] A A A 2,587 [19],[20] A A A A A Investments at fair value \$ 11,055 [12],[15] A A A \$ 2,591 [19],[20] A A A A A Investment, Identifier [Axis]: MND Holdings III Corp, Other Specialty Retail, First Lien Revolver A A A A A A A A A Tersera Therapeutics LLC A A A A A A A A A Investment, basis spread, variable rate (as a percent) [17],[19], [20] A A A 7.50% 7.50% 7.50% A A A A A Investment, interest rate (as a percent) [17],[19], [20], [21] A A A 12.83% 12.83% 12.83% A A A Investment, principal [17],[19], [20], [23] A A A \$ 1,466 A A A A A Investment, cost [17],[19], [20] A A A 1,215 A A A A A Investments at fair value [17],[19], [20] A A A \$ 1,282 A A A A A Investment, Identifier [Axis]: MND Holdings III Corp, Other Specialty Retail, First Lien Term Loan A A A A A A A A A Tersera Therapeutics LLC A A A A A A A A A Investment, basis spread, variable rate (as a percent) [19],[20] A A A 7.50% 7.50% 7.50% A A A A A Investment, interest rate (as a percent) [19],[20], [21] A A A 12.89% 12.89% 12.89% A A A investment, principal [19],[20], [23] A A A \$ 40,538 A A A A A Investment, cost [19],[20] A A A 39,873 A A A A A Investments at fair value [19],[20] A A A \$ 39,833 A A A A A Investment, Identifier [Axis]: MRI Software LLC, Application Software, First Lien Revolver A A A A A A A A A Tersera Therapeutics LLC A A A A A A A A A Investment, basis spread, variable rate (as a percent) 5.50% [12],[13], [15] 5.50% [12],[13], [15] 5.50% [12],[13], [15] 5.50% [17],[19], [20] 5.50% [17],[19], [20] 5.50% [17],[19], [20] A A A Investment, principal \$ 0 [12],[13], [15], [22] A A A \$ 0 [17],[19],[20], [23] A A A A A Investment, cost [52] [12],[13], [15] A A A (28) [17],[19],[20] A A A A A Investments at fair value \$ (15) [12],[13], [15] A A A (\$ 47) [17],[19],[20] A A A A A Investment, Identifier [Axis]: MRI Software LLC, Application Software, First Lien Term Loan 1 A A A A A A A A A Tersera Therapeutics LLC A A A A A A A A A Investment, basis spread, variable rate (as a percent) 5.50% [12],[15] 5.50% [12],[15] 5.50% [12],[15] 5.50% [19],[20] 5.50% [19],[20] 5.50% [19],[20] A A A Investment, interest rate (as a percent) 10.93% [12],[15], [16] 10.93% [12],[15], [16] 10.93% [12],[15], [16] 10.93% [12],[15], [16] 10.99% [19],[20], [21] 10.99% [19],[20], [21] 10.99% [19],[20], [21] A A A Investment, principal \$ 21,162 [12],[15], [22] A A A \$ 13,973 [19],[20], [23] A A A A A Investment, cost 20,873 [12],[15] A A A 13,936 [19],[20] A A A A A Investments at fair value \$ 21,043 [12],[15] A A A \$ 13,685 [19],[20] A A A A A Investment, Identifier [Axis]: MRI Software LLC, Application Software, First Lien Term Loan 2 A A A A A A A A A Tersera Therapeutics LLC A A A A A A A A A Investment, basis spread, variable rate (as a percent) 5.50% [12],[15] 5.50% [12],[15] 5.50% [12],[15] 5.50% [19],[20] 5.50% [19],[20] 5.50% [19],[20] A A A Investment, interest rate (as a percent) 10.93% [12],[15], [16] 10.93% [12],[15], [16] 10.93% [12],[15], [16] 10.93% [12],[15], [16] 10.99% [19],[20], [21] 10.99% [19],[20], [21] 10.99% [19],[20], [21] A A A Investment, principal \$ 13,865 [12],[15], [22] A A A \$ 21,328 [19],[20], [23] A A A A A Investment, cost 13,830 [12],[15] A A A 21,021 [19],[20] A A A A A Investments at fair value \$ 13,787 [12],[15] A A A \$ 20,888 [19],[20] A A A A A Investment, Identifier [Axis]: MRI Software LLC, Application Software, First Lien Term Loan 3 A A A A A A A A A Tersera Therapeutics LLC A A A A A A A A A Investment, basis spread, variable rate (as a percent) [12],[13], [15] 5.75% 5.75% 5.75% A A A A A Investment, interest rate (as a percent) [12],[13], [15], [16] 11.08% 11.08% 11.08% A A A A A Investment, principal [12],[13], [15], [22] A A A 841 A A A A A A A A A Investment, cost [12],[13], [15] 837 A A A A A A A A A Investments at fair value [12],[13], [15] 841 A A A A A A A A A Investment, Identifier [Axis]: Marinus Pharmaceuticals, Inc., Pharmaceuticals, First Lien Term Loan 1 A A A A A A A A A Tersera Therapeutics LLC A A A A A A A A A Investment, interest rate (as a percent) 11.50% [12],[15], [16], [24] 11.50% [12],[15], [16], [24] 11.50% [12],[15], [16], [24] 11.50% [19],[20], [21], [26] 11.50% [19],[20], [21], [26] 11.50% [19],[20], [21], [26] A A A Investment, principal \$ 8,353 [12],[22], [24] A A A \$ 8,568 [20],[23], [26] A A A A A Investment, cost 8,302 [12],[24] A A A 8,495 [20],[26] A A A A A Investments at fair value \$ 7,894 [12],[24] A A A \$ 8,132 [20],[26] A A A A A Investment, Identifier [Axis]: Marinus Pharmaceuticals, Inc., Pharmaceuticals, First Lien Term Loan 2 A A A A A A A A A Tersera Therapeutics LLC A A A A A A A A A Investment, interest rate (as a percent) 11.50% [12],[15], [16], [24] 11.50% [12],[15], [16], [24] 11.50% [12],[15], [16], [24] 11.50% [19],[20], [21], [26] 11.50% [19],[20], [21], [26] 11.50% [19],[20], [21], [26] A A A Investment, principal \$ 4,070 [12],[22],

[illegible]

[15],[22],[24] \$ 2,123 A A A A A Investment, cost [12],[13],[15],[24] 2,534 A A A A A Investments at fair value [12],[13],[15],[24] \$ 2,550 A A A A A Investment, Identifier [Axis]: QuorumLabs, Inc., Application Software, Preferred Equity A A A A A Tersera Therapeutics LLC A A A A A Investment owned, balance (in shares) | shares 64,887,669 [12] 64,887,669 [12] 64,887,669 [12] 64,887,669 [12] 64,887,669 [20] A A A A A Investment, cost \$ 375 [12] A A A A A Investments at fair value \$ 0 [12] A A \$ 0 [20] A A A A A Investment, Identifier [Axis]: Relativity ODA LLC, Application Software, First Lien Revolver A A A A A Tersera Therapeutics LLC A A A A A A A A A A Investment, basis spread, variable rate (as a percent) 6.50% [12],[13],[15] 6.50% [12],[13],[15] 6.50% [12],[13],[15] 6.50% [17],[19],[20] 6.50% [17],[19],[20] 6.50% [17],[19],[20] A A A A A Investment, principal \$ 0 [12],[13],[15],[22] A A \$ 0 [17],[19],[20],[23] A A A A A Investment, cost (34) [12],[13],[15] A A (43) [17],[19],[20] A A A A A Investments at fair value \$ (11) [12],[13],[15] A A \$ (47) [17],[19],[20] A A A A A Investment, Identifier [Axis]: Relativity ODA LLC, Application Software, First Lien Term Loan A A A A A A A A A A Tersera Therapeutics LLC A A A A A A A A A A Investment, basis spread, variable rate (as a percent) 6.00% [12],[15] 6.00% [12],[15] 6.00% [12],[15] 6.50% [19],[20] 6.50% [19],[20] 6.50% [19],[20] A A A A A Investment, interest rate (as a percent) 11.44% [12],[15],[16] 11.44% [12],[15],[16] 11.44% [12],[15],[16] 11.92% [19],[20],[21] 11.92% [19],[20],[21] 11.92% [19],[20],[21] A A A A A Investment, principal \$ 32,329 [12],[15],[22] A A \$ 32,329 [19],[20],[23] A A A A A Investment, cost 32,124 [12],[15] A A \$ 32,070 [19],[20] A A A A A Investments at fair value \$ 32,200 [12],[15] A A \$ 31,779 [19],[20] A A A A A Investment, Identifier [Axis]: Research & Consulting Services, First Lien Term Loan A A A A A A A A A A Tersera Therapeutics LLC A A A A A A A A A A Investment, basis spread, variable rate (as a percent) 15) 4.75% 4.75% 4.75% A A A A A Investment, interest rate (as a percent) [15],[16] 10.09% 10.09% 10.09% A A A A A Investment, principal [15],[22] \$ 4,913 A A A A A A A A A A Investment, cost [15] 4,844 A A A A A A A A A A Investments at fair value [15] \$ 4,939 A A A A A A A A A A Investment, Identifier [Axis]: RumbleOn, Inc., Automotive Retail, First Lien Term Loan 1 A A A A A A A A A A Tersera Therapeutics LLC A A A A A A A A A A Investment, basis spread, variable rate (as a percent) 8.25% [12],[15],[24] 8.25% [12],[15],[24] 8.25% [12],[15],[24] 8.25% [19],[20],[26] 8.25% [19],[20],[26] 8.25% [19],[20],[26] A A A A A Investment, interest rate (as a percent) 13.84% [12],[15],[16],[24] 13.84% [12],[15],[16],[24] 13.84% [12],[15],[16],[24] 13.90% [19],[20],[21],[26] 13.90% [19],[20],[21],[26] 13.90% [19],[20],[21],[26] A A A A A Investment, interest rate, paid in kind (as a percent) 0.50% [12],[15],[24] 0.50% [12],[15],[24] 0.50% [12],[15],[24] 0.50% [19],[20],[26] 0.50% [19],[20],[26] 0.50% [19],[20],[26] A A A A A Investment, principal \$ 8,812 [12],[15],[22],[24] A A \$ 36,707 [19],[20],[23],[26] A A A A A Investment, cost 8,596 [12],[15],[24] A A \$ 35,548 [19],[20],[26] A A A A A Investments at fair value \$ 8,305 [12],[15],[24] A A \$ 34,505 [19],[20],[26] A A A A A Investment, Identifier [Axis]: RumbleOn, Inc., Automotive Retail, First Lien Term Loan 2 A A A A A A A A A A Tersera Therapeutics LLC A A A A A A A A A A Investment, basis spread, variable rate (as a percent) 8.25% [12],[15],[24] 8.25% [12],[15],[24] 8.25% [12],[15],[24] 8.25% [19],[20],[26] 8.25% [19],[20],[26] 8.25% [19],[20],[26] A A A A A Investment, interest rate (as a percent) 13.84% [12],[15],[16],[24] 13.84% [12],[15],[16],[24] 13.84% [12],[15],[16],[24] 13.84% [12],[15],[16],[24] 13.90% [19],[20],[21],[26] 13.90% [19],[20],[21],[26] 13.90% [19],[20],[21],[26] A A A A A Investment, interest rate, paid in kind (as a percent) 0.50% [12],[15],[24] 0.50% [12],[15],[24] 0.50% [12],[15],[24] 0.50% [19],[20],[26] 0.50% [19],[20],[26] 0.50% [19],[20],[26] A A A A A Investment, principal \$ 29,198 [12],[15],[22],[24] A A \$ 13,504 [19],[20],[23],[26] A A A A A Investment, cost 28,503 [12],[15],[24] A A \$ 13,058 [19],[20],[26] A A A A A Investments at fair value \$ 27,519 [12],[15],[24] A A \$ 12,694 [19],[20],[26] A A A A A Investment, Identifier [Axis]: RumbleOn, Inc., Automotive Retail, Warrants A A A A A A A A A A Tersera Therapeutics LLC A A A A A A A A A A Investment owned, balance (in shares) | shares 204,454 [12],[24] 204,454 [12],[24] 204,454 [12],[24] 204,454 [20],[26] 204,454 [20],[26] A A A A A Investment, cost \$ 1,202 [12],[24] A A \$ 1,202 [20],[26] A A A A A Investments at fair value \$ 399 [12],[24] A A \$ 756 [20],[26] A A A A A Investment, Identifier [Axis]: SCIH Salt Holdings Inc., Diversified Chemicals, Fixed Rate Bond A A A A A A A A A A Tersera Therapeutics LLC A A A A A A A A A A Investment, interest rate (as a percent) [15],[16] 4.88% 4.88% 4.88% A A A A A A A A A A Investment, principal [22] \$ 1,680 A A A A A A A A A A Investment, cost 1,553 A A A A A A A A A A Investments at fair value \$ 1,565 A A A A A A A A A A Investment, Identifier [Axis]: SCP Eye Care Services, LLC, Health Care Services, Common Stock A A A A A A A A A A Tersera Therapeutics LLC A A A A A A A A A A Investment owned, balance (in shares) | shares [20] A A 1,037 1,037 1,037 A A A A A A A A A A Investment, cost [20] A A \$ 1,037 A A A A A Investments at fair value \$ 1,037 A A A A A A A A A A Investment, basis spread, variable rate (as a percent) 8.75% 8.75% 8.75% A A A A A A A A A A Investment, interest rate (as a percent) [19],[20],[21] A A A 14.18% 14.18% 14.18% A A A A A Investment, principal [19],[20],[23] A A \$ 8,010 A A A A A A A A A A Investment, cost [19],[20] A A \$ 7,799 A A A A A A A A A A Investments at fair value [19],[20] A A \$ 7,778 A A A A A Investment, Identifier [Axis]: SCP Eye Care Services, LLC, Health Care Services, Second Lien Term Loan 2 A A A A A A A A A A Tersera Therapeutics LLC A A A A A A A A A A Investment, basis spread, variable rate (as a percent) [17],[19],[20] A A \$ 8.75% 8.75% 8.75% A A A A A A A A A A Investment, principal [17],[19],[20],[23] A A \$ 0 A A A A A A A A A A Investment, cost [17],[19],[20] A A \$ (35) A A A A A Investments at fair value [17],[19],[20] A A \$ (68) A A A A A A A A A A Investment, Identifier [Axis]: SIO2 Medical Products, Inc., Metal, Glass & Plastic Containers, Common Stock A A A A A A A A A A Tersera Therapeutics LLC A A A A A A A A A A Investment owned, balance (in shares) | shares 1,184,630 [12] 1,184,630 [12] 1,184,630 [12] 1,184,630 [20] 1,184,630 [20] 1,184,630 [20] A A A A A Investment, cost \$ 40,093 [12] A A \$ 40,093 [20] A A A A A Investments at fair value \$ 23,548 [12] A A \$ 36,226 [20] A A A A A Investment owned, percent of net assets (as a percent) 1.60% 1.60% 1.60% A A A A A A A A A A Investment, Identifier [Axis]: SIO2 Medical Products, Inc., Metal, Glass & Plastic Containers, First Lien Term Loan 1 A A A A A A A A A A Tersera Therapeutics LLC A A A A A A A A A A Investment, interest rate, paid in kind (as a percent) [12],[13] 12.00% 12.00% 12.00% A A A A A A A A A A Investment, principal [12],[13],[22] \$ 2,682 A A A A A A A A A A Investment, cost [12],[13] 2,629 A A A A A A A A A A Investments at fair value \$ 2,682 [12],[13] A A \$ 0 A A A A A A A A A A Investment owned, percent of net assets (as a percent) 0.20% 0.20% 0.20% A A A A A A A A A A Investment, Identifier [Axis]: SIO2 Medical Products, Inc., Metal, Glass & Plastic Containers, First Lien Term Loan 2 A A A A A A A A A A Tersera Therapeutics LLC A A A A A A A A A A Investment, interest rate, paid in kind (as a percent) [12] 12.00% [12] 12.00% [12] 12.00% [20] 12.00% [20] 12.00% [20] A A A A A A A A A A Investment, principal \$ 17,363 [12],[22] A A \$ 15,874 [20],[23] A A A A A A A A A A Investment, cost 15,743 [12] A A \$ 14,100 [20] A A A A A Investments at fair value \$ 17,363 [12] A A \$ 15,874 [20] A A A A A A A A A A Investment owned, percent of net assets (as a percent) 1.20% 1.20% 1.20% A A A A A A A A A A Investment, Identifier [Axis]: SIO2 Medical Products, Inc., Metal, Glass & Plastic Containers, First Lien Term Loan 3 A A A A A A A A A A Tersera Therapeutics LLC A A A A A A A A A A Investment, interest rate, paid in kind (as a percent) [12] 12.00% [12] 12.00% [12] 12.00% [12] 12.00% [17],[20] 12.00% [17],[20] 12.00% [17],[20] A A A A A A A A A A Investment, principal \$ 3,442 [12],[22] A A \$ 1,359 [17],[20],[23] A A A A A A A A A A Investment, cost 3,389 [12] A A 1,

[illegible]

[illegible]

on-accrual status, at the time the acquisition is made, qualifying assets represent at least 70% of the Company's total assets. As of June 30, 2024, qualifying assets represented 72.7% of the Company's total assets and non-qualifying assets represented 27.3% of the Company's total assets. [25] This investment represents a revenue interest financing term loan in which the Company receives periodic interest payments based on a percentage of revenues earned at the respective portfolio company over the life of the loan. [26] Investment is not a "qualifying asset" as defined under Section 55(a) of the Investment Company Act. Under the Investment Company Act, the Company may not acquire any non-qualifying asset unless, at the time the acquisition is made, qualifying assets represent at least 70% of the Company's total assets. As of September 30, 2023, qualifying assets represented 74.3% of the Company's total assets and non-qualifying assets represented 25.7% of the Company's total assets. [27] This investment represents a revenue interest financing term loan in which the Company receives periodic interest payments based on a percentage of revenues earned at the respective portfolio company over the life of the loan. [28] This investment was on non-accrual status as of June 30, 2024. [29] This investment was on non-accrual status as of September 30, 2023. [30] This investment represents Seller Earn Out Shares in Alvotech SA. The Seller Earn Out Shares will vest if, at any time through June 16, 2027, the Alvotech SA common share price is at or above a volume weighted average price ("VWAP") of \$20.00 per share for any ten trading days within any twenty trading day period. [31] This investment represents Seller Earn Out Shares in Alvotech SA. One half of the Seller Earn Out Shares will vest if, at any time through June 16, 2027, the Alvotech SA common share price is at or above a VWAP of \$15.00 per share for any ten trading days within any twenty trading day period, and the other half will vest, if at any time during such period, the common share price is at or above a VWAP of \$20.00 per share for any ten trading days within any twenty trading day period. [32] This investment was renamed during the three months ended June 30, 2024. For the periods prior to June 30, 2024, this investment was referenced as SCP Eye Care Services, LLC. [33] Income producing through payment of dividends or distributions. [34] See Note 3 in the accompanying notes to the Consolidated Financial Statements for portfolio composition. [35] This investment was valued using net asset value as a practical expedient for fair value. Consistent with ASC 820, these investments are excluded from the hierarchical levels. [36] See Note 3 in the accompanying notes to the Consolidated Financial Statements for portfolio composition. [37] This investment was valued using net asset value as a practical expedient for fair value. Consistent with ASC 820, these investments are excluded from the hierarchical levels. [38] This investment represents a credit default swap that functions, in substance, like a credit linked note and represents a credit risk transfer for a pool of reference assets owned by a bank. The Company fully funded margin up front and in return the Company receives periodic interest payments. The Company's risk of loss is limited to the principal amount disclosed herein. The reference assets are primarily composed of investment grade corporate debt. The Company may be exposed to counterparty risk, which could make it difficult for the Company to collect on obligations, thereby resulting in potentially significant losses. In addition, the Company only has a contractual relationship with the counterparty bank, and not with the reference obligors of the reference assets. Accordingly, the Company generally may have no right to directly enforce compliance by the reference obligors with the terms of the reference assets. The Company will not directly benefit from the reference assets and will not have the benefit of the remedies that would normally be available to a holder of such reference assets. In addition, in the event of the insolvency of the counterparty bank, the Company may be treated as a general creditor of such counterparty bank, and will not have any claim with respect to the reference assets. [39] Income producing through payment of dividends or distributions. [40] This investment was renamed during the three months ended March 31, 2023. For periods prior to March 31, 2023, this investment was referenced as PFNY Holdings, LLC. X - Definition: Investment Owned And Money Market Funds, Percent of Net Assets + References: No definition available. + Details Name: ocs InvestmentOwnedAndMoneyMarketFundsPercentOfNetAssets Namespace Prefix: ocs_ Data Type: dtr-types:percentItem Type Balance Type: No Period Type: instant X - Definition: Investment Owned, At Cost And Money Market Funds, At Carrying Value + References: No definition available. + Details Name: ocs InvestmentOwnedAtCostAndMoneyMarketFundsAtCarryingValue Namespace Prefix: ocs_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - Definition: Investment Owned, At Fair Value And Money Market Funds, At Carrying Value + References: No definition available. + Details Name: ocs InvestmentOwnedAtFairValueAndMoneyMarketFundsAtCarryingValue Namespace Prefix: ocs_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - Definition: Investment Owned, Ownership Percentage + References: No definition available. + Details Name: ocs InvestmentOwnedOwnershipPercentage Namespace Prefix: ocs_ Data Type: dtr-types:percentItem Type Balance Type: No Period Type: instant X - Definition: Money Market Funds, Percent of Net Assets + References: No definition available. + Details Name: ocs MoneyMarketFundsPercentOfNetAssets Namespace Prefix: ocs_ Data Type: dtr-types:percentItem Type Balance Type: No Period Type: instant X - Definition: Percentage added to reference rate used to compute variable rate on investment. + References: Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 320-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph \(SX 210.12-12A\)\(Column A\)\(Footnote 3\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 320-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph (SX 210.12-12A)(Column A)(Footnote 3))) - Publisher FASB - URI <https://asc.fasb.org/1943274/2147480032/946-320-S99-2Reference 2> - [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 320-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.12-12\)\(Column A\)\(Footnote 4\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 320-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.12-12)(Column A)(Footnote 4))) - Publisher FASB - URI <https://asc.fasb.org/1943274/2147480032/946-320-S99-1Reference 3>: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 320-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph \(SX 210.12-12B\)\(Column A\)\(Footnote 3\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 320-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.12-12B)(Column A)(Footnote 3))) - Publisher FASB - URI <https://asc.fasb.org/1943274/2147480032/946-320-S99-3Reference 4>: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 320-Name Accounting Standards Codification-Section S99-Paragraph 6-Subparagraph \(SX 210.12-14\)\(Column A\)\(Footnote 3\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 320-Name Accounting Standards Codification-Section S99-Paragraph 6-Subparagraph (SX 210.12-14)(Column A)(Footnote 3))) - Publisher FASB - URI <https://asc.fasb.org/1943274/2147480032/946-320-S99-6> + Details Name: us-gaap InvestmentBasisSpreadVariableRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItem Type Balance Type: No Period Type: instant X - Definition: Rate of interest on investment. + References: Reference 1: <http://www.xbrl.org/2003/role/exampleRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section 55-Paragraph 1-Publisher FASB -URI https://asc.fasb.org/1943274/2147480493/946-210-55-1Reference 2> - <http://www.xbrl.org/2009/role/commonPracticeRef-Topic 320-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 3>: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic 320-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 5-Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5Reference 4>: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 320-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph \(SX 210.12-12A\)\(Column A\)\(Footnote 3\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 320-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph (SX 210.12-12A)(Column A)(Footnote 3))) - Publisher FASB - URI <https://asc.fasb.org/1943274/2147480032/946-320-S99-2Reference 5>: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 320-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph \(SX 210.12-12A\)\(Column A\)\(Footnote 3\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 320-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph (SX 210.12-12A)(Column A)(Footnote 3))) - Publisher FASB - URI <https://asc.fasb.org/1943274/2147480032/946-320-S99-6Reference 6>: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 320-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.12-12\)\(Column A\)\(Footnote 2\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 320-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.12-12)(Column A)(Footnote 2))) - Publisher FASB - URI <https://asc.fasb.org/1943274/2147480032/946-320-S99-6Reference 8>: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 320-Name Accounting Standards Codification-Section S99-Paragraph 6-Subparagraph \(SX 210.12-14\)\(Column A\)\(Footnote 2\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 320-Name Accounting Standards Codification-Section S99-Paragraph 6-Subparagraph (SX 210.12-14)(Column A)(Footnote 2))) - Publisher FASB - URI <https://asc.fasb.org/1943274/2147480032/946-320-S99-1Reference 9>: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 320-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph \(SX 210](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 320-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.12-12B)(Column A)(Footnote 3)))

[http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 320-Name Accounting Standards Codification-Section S99-Paragraph 6-Subparagraph \(SX 210.12-14\(Column B\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480032/946-320-99-6Reference 49](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 320-Name Accounting Standards Codification-Section S99-Paragraph 6-Subparagraph (SX 210.12-14(Column A))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480032/946-320-99-6Reference 48): [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 320-Name Accounting Standards Codification-Section S99-Paragraph 6-Subparagraph \(SX 210.12-14\(Column A\)\)Footnote 1\(a\)\(1\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480032/946-320-99-6Reference 51](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 320-Name Accounting Standards Codification-Section S99-Paragraph 6-Subparagraph (SX 210.12-14(Column F))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480032/946-320-99-6Reference 50): [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 320-Name Accounting Standards Codification-Section S99-Paragraph 6-Subparagraph \(SX 210.12-14\(Column A\)\)Footnote 1\(a\)\(3\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480032/946-320-99-6Reference 53](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 320-Name Accounting Standards Codification-Section S99-Paragraph 6-Subparagraph (Footnote 1)(a)(2))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480032/946-320-99-6Reference 52): [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 320-Name Accounting Standards Codification-Section S99-Paragraph 6-Subparagraph \(SX 210.12-14\(Column A\)\)Footnote 1\(b\)\(3\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480032/946-320-99-6Reference 55](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 320-Name Accounting Standards Codification-Section S99-Paragraph 6-Subparagraph (SX 210.12-14(Column A))Footnote 1(b)(2))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480032/946-320-99-6Reference 54): [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 320-Name Accounting Standards Codification-Section S99-Paragraph 6-Subparagraph \(SX 210.12-14\(Column A\)\)Footnote 1\(b\)\(5\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480032/946-320-99-6Reference 57](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 320-Name Accounting Standards Codification-Section S99-Paragraph 6-Subparagraph (SX 210.12-14(Column A))Footnote 1(b)(4))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480032/946-320-99-6Reference 56): [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 320-Name Accounting Standards Codification-Section S99-Paragraph 6-Subparagraph \(SX 210.12-14\(Column A\)\)Footnote 3\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480032/946-320-99-6Reference 59](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 320-Name Accounting Standards Codification-Section S99-Paragraph 6-Subparagraph (SX 210.12-14(Column A))Footnote 1(b)))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480032/946-320-99-6Reference 58): [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 320-Name Accounting Standards Codification-Section S99-Paragraph 6-Subparagraph \(SX 210.12-14\(Column A\)\)Footnote 5\(a\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480032/946-320-99-6Reference 61](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 320-Name Accounting Standards Codification-Section S99-Paragraph 6-Subparagraph (SX 210.12-14(Column A))Footnote 4))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480032/946-320-99-6Reference 60): [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 320-Name Accounting Standards Codification-Section S99-Paragraph 6-Subparagraph \(SX 210.12-14\(Column F\)\)Footnote 8\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480032/946-320-99-6Reference 63](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 320-Name Accounting Standards Codification-Section S99-Paragraph 6-Subparagraph (SX 210.12-14(Column F))Footnote 7))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480032/946-320-99-6Reference 62): [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 320-Name Accounting Standards Codification-Section S99-Paragraph 19-Subparagraph \(1\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480032/946-320-99-19Reference 65](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 320-Name Accounting Standards Codification-Section S99-Paragraph 6-Subparagraph (SX 210.12-14(Column F))Footnote 9))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480032/946-320-99-6Reference 64):

[illegible]

[illegible]

Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=SPX Flow, Inc., Industrial Machinery & Supplies & Components, Fixed Rate Bond Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=SVP-Singer Holdings Inc., Home Furnishings, First Lien Term Loan Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Salus Workers' Compensation, LLC, Diversified Financial Services, First Lien Revolver Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Salus Workers' Compensation, LLC, Diversified Financial Services, First Lien Term Loan Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Salus Workers' Compensation, LLC, Diversified Financial Services, Warrants Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Scilex Holding Co, Biotechnology, Common Stock Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Senior Loan Fund JV I, LLC, Multi-Sector Holdings, Membership Interest Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Senior Loan Fund JV I, LLC, Multi-Sector Holdings, Subordinated Debt Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Series Therapeutics, Inc., Biotechnology, First Lien Term Loan 1 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Series Therapeutics, Inc., Biotechnology, First Lien Term Loan 2 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Series Therapeutics, Inc., Biotechnology, First Lien Term Loan 3 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Series Therapeutics, Inc., Biotechnology, First Lien Term Loan 4 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Series Therapeutics, Inc., Biotechnology, Warrants Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=ShareThis, Inc., Application Software, Warrants Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Sonitrol US Holdings Inc., Technology Distributors, Second Lien Term Loan Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Soreson Communications, LLC, Communications Equipment, First Lien Revolver Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Soreson Communications, LLC, Communications Equipment, First Lien Term Loan Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Sorrento Therapeutics, Inc., Biotechnology, Common Stock Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Spanx, LLC, Apparel Retail, First Lien Revolver Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Spanx, LLC, Apparel Retail, First Lien Term Loan Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Staples, Inc., Office Services & Supplies, First Lien Term Loan Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Staples, Inc., Office Services & Supplies, Fixed Rate Bond Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=SumUp Holdings Luxembourg S.À.R.L., Diversified Financial Services, First Lien Term Loan Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Superior Industries International, Inc., Auto Parts & Equipment, First Lien Term Loan Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Supreme Fitness Group NY Holdings, LLC, Leisure Facilities, First Lien Revolver Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Supreme Fitness Group NY Holdings, LLC, Leisure Facilities, First Lien Term Loan 1 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Supreme Fitness Group NY Holdings, LLC, Leisure Facilities, First Lien Term Loan 2 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Supreme Fitness Group NY Holdings, LLC, Leisure Facilities, First Lien Term Loan 3 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=TGNR HoldCo LLC, Integrated Oil & Gas, Subordinated Debt Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=THL Zinc Ventures Ltd, Diversified Metals & Mining, First Lien Term Loan Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Tacala, LLC, Restaurants, Second Lien Term Loan Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Tahoe Bidco B.V., Application Software, First Lien Revolver Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Tahoe Bidco B.V., Application Software, First Lien Term Loan Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Telephone and Date Systems, Inc., Wireless Telecommunication Services, First Lien Term Loan 1 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Telephone and Date Systems, Inc., Wireless Telecommunication Services, First Lien Term Loan 2 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Telestream Holdings Corporation, Application Software, First Lien Revolver Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Telestream Holdings Corporation, Application Software, First Lien Term Loan Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Ten-X LLC, Interactive Media & Services, First Lien Term Loan Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=The Avery, Real Estate Operating Companies, First Lien Term Loan 1 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=The Avery, Real Estate Operating Companies, First Lien Term Loan 2 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=The Avery, Real Estate Operating Companies, Membership Interest Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=The Avery, Real Estate Operating Companies, Subordinated Debt Term Loan Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Thrasio, LLC, Broadline Retail, Common Stock Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Thrasio, LLC, Broadline Retail, First Lien Term Loan 1 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Thrasio, LLC, Broadline Retail, First Lien Term Loan 2 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Thrasio, LLC, Broadline Retail, Preferred Equity 1 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Thrasio, LLC, Broadline Retail, Preferred Equity 2 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Thrasio, LLC, Broadline Retail, Preferred Equity 3 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Thrasio, LLC, Broadline Retail, Preferred Equity 4 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Touchstone Acquisition, Inc., Health Care Supplies, First Lien Term Loan Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Trinitas CLO VI Ld., Multi-Sector Holdings, CLO Notes Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Trinitas CLO XV DAC, Multi-Sector Holdings, CLO Notes Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Truck-Lite Co, LLC, Construction Machinery & Heavy Transportation Equipment, First Lien Revolver Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Truck-Lite Co, LLC, Construction Machinery & Heavy Transportation Equipment, First Lien Term Loan 1 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Truck-Lite Co, LLC, Construction Machinery & Heavy Transportation Equipment, First Lien Term Loan 2 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Uniti Group LP, Cable & Satellite, Fixed Rate Bond Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Uniti Group LP, Other Specialized REITs, Fixed Rate Bond 1 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Uniti Group LP, Other Specialized REITs, Fixed Rate Bond 2 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Verona Pharma, Inc., Pharmaceuticals, First Lien Term Loan 1 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Verona Pharma, Inc., Pharmaceuticals, First Lien Term Loan 2 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Verona Pharma, Inc., Pharmaceuticals, First Lien Term Loan 3 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Verona Pharma, Inc., Pharmaceuticals, First Lien Term Loan 4 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Verona Pharma, Inc., Pharmaceuticals, First Lien Term Loan 5 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Verona Pharma, Inc., Pharmaceuticals, First Lien Term Loan 6 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Virgin Pulse, Inc., Application Software, Second Lien Term Loan Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=WP CPP Holdings, LLC, Aerospace & Defense, First Lien Revolver Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=WP CPP Holdings, LLC, Aerospace & Defense, First Lien Term Loan Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=WWEV Uni Topco Holdings, LLC, Air Freight & Logistics, Second Lien Term Loan Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Win Brands Group LLC, Housewares & Specialties, First Lien Term Loan Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Win Brands Group LLC, Housewares & Specialties, First Lien Term Loan 1 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Win Brands Group LLC, Housewares & Specialties, First Lien Term Loan 2 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Win Brands Group LLC, Housewares & Specialties, Warrants Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Windstream Services II, LLC, Integrated Telecommunication Services, Common Stock Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Windstream Services II, LLC, Integrated Telecommunication Services, First Lien Term Loan Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Zep Inc., Specialty Chemicals, First Lien Term Loan Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=zephyr Bidco Limited, Specialized Finance, Second Lien Term Loan Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=athenahealth Group Inc., Health Care Technology, Fixed Rate Bond Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=athenahealth Group Inc., Health Care Technology, Preferred Equity Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=iCIMS, Inc., Application Software, First Lien Revolver Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=iCIMS, Inc., Application Software, First Lien Term Loan 1 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=iCIMS, Inc., Application Software, First Lien Term Loan 2 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=iCIMS, Inc., Application Software, First Lien Term Loan 3 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=scPharmaceuticals Inc., Pharmaceuticals, First Lien Term Loan 1 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=scPharmaceuticals Inc., Pharmaceuticals, First Lien Term Loan 2 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=scPharmaceuticals Inc., Pharmaceuticals, First Lien Term Loan 3 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=scPharmaceuticals Inc., Pharmaceuticals, Warrants Namespace Prefix: Data Type: na Balance Type: Period Type: XML 19 R8.htm IDEA: XBRL DOCUMENT v3.24.2 Consolidated Schedule of Investments - Derivatives Â In Thousands, Â In Thousands, \$ In Thousands Jun. 30, 2024 USD (\$) Jun. 30, 2024 EUR (Â) Jun. 30, 2024 GBP (Â) Sep. 30, 2023 USD (\$) Sep. 30, 2023 EUR (Â) Sep. 30, 2023 GBP (Â) Tersera Therapeutics LLC Â Â Â Â Derivative assets \$ 436 Â Â Â 4,910 Â Â Derivative liability (33,672) Â Â (47,519) Â Foreign currency forward contracts Â Â Â Â Tersera Therapeutics LLC Â Â Â Â Derivative assets 849 Â Â Â 4,910 Â Â Derivative liability (413) Â Â 0 Â Derivative assets (liability) 436 Â Â Â Interest rate swap Â Â Â Tersera Therapeutics LLC Â Â Â Derivative assets 0 Â Â 0 Â Derivative liability (33,672) Â Â (47,519) Â Interest Rate Swap Maturing 2027 Â Â Â Tersera Therapeutics LLC Â Â Â Derivative liability \$ (30,6

[Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A + Details Name: us-gaap_DerivativeAssetNotionalAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: instant X - DefinitionFair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset. + References](#)[Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480524/946-210-50-12Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph \(e\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480524/946-210-50-6Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 55 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480493/946-210-55-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph \(a\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480524/946-210-50-6Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph \(a\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480524/946-210-50-6Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph \(a\)\(4\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480524/946-210-50-6Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(a\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480524/946-210-50-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(b\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480524/946-210-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(b\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480524/946-210-50-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(c\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480524/946-210-50-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480524/946-210-50-6Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph \(a\)\(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480524/946-210-50-6Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-04\(3\)\(c\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479617/946-210-S99-1Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5C -Subparagraph \(SX 210.12-13\(Column H\)\(Footnote 7\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-5Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-04\(3\)\(b\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479617/946-210-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph \(SX 210.12-13\(Column A\)\(Footnote 3\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-5Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5C -Subparagraph \(SX 210.12-13\(Column H\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-5Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5A -Subparagraph \(SX 210.12-13A\(Column E\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-5Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5B -Subparagraph \(SX 210.12-13B\(Column E\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-5Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5B -Subparagraph \(SX 210.12-13B\(Column E\)\(Footnote 4\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-5Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3Reference 22: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483444/210-20-55-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483444/210-20-55-10Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10 + Details Name: us-gaap_DerivativeAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThe percentage points added to the reference rate to compute the variable rate on the interest rate derivative. + ReferencesNo definition available. + Details Name: us-gaap_DerivativeFixedInterestRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionFair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset. + References](#)[Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10 + Details Name: us-gaap_DerivativeFairValueOfDerivativeNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFixed interest rate related to the interest rate derivative. + ReferencesNo definition available. + Details Name: us-gaap_DerivativeFixedInterestRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionFair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset. + References](#)[Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph \(e\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480524/946-210-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph \(a\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480524/946-210-50-6Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph \(a\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480524/946-210-50-6Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph \(a\)\(4\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480524/946-210-50-6Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(b\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480524/946-210-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(b\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480524/946-210-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(c\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480524/946-210-50-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(c\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480524/946-210-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/21474](#)

[illegible]

[illegible]

Publisher FASB -URI https://asc.fasb.org//205/tableOfContent + Details Name: us-gaap-OrganizationConsolidationAndPresentationOFFinancialStatementsDisclosureTextBlock Namespace Prefix: us-gaap- Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 22 R11.htm IDEA: XBRL DOCUMENT v3.24.2 Significant Accounting Policies 9 Months Ended Jun. 30, 2024 Accounting Policies [Abstract] A Significant Accounting Policies Significant Accounting Policies Basis of Presentation: The Consolidated Financial Statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") and pursuant to the requirements for reporting on Form 10-Q and Regulation S-X. In the opinion of management, all adjustments of a normal recurring nature considered necessary for the fair presentation of the Consolidated Financial Statements have been made. All intercompany balances and transactions have been eliminated. The Company is an investment company following the accounting and reporting guidance in ASC Topic 946, Financial Services - Investment Companies ("ASC 946"). Certain prior period amounts have been reclassified to conform to the current period presentation. All per share amounts and common shares outstanding have been retroactively adjusted as necessary to reflect the Company's 1-for-3 reverse stock split completed on January 20, 2023 and effective as of the commencement of trading on January 23, 2023. Use of Estimates: The preparation of the financial statements in conformity with GAAP requires management to make certain estimates and assumptions affecting amounts reported in the financial statements and accompanying notes. These estimates are based on the information that is currently available to the Company and on various other assumptions that the Company believes to be reasonable under the circumstances. Changes in the economic and political environments, financial markets and any other parameters used in determining these estimates could cause actual results to differ and such differences could be material. Significant estimates include the valuation of investments and revenue recognition. Consolidation: The accompanying Consolidated Financial Statements include the accounts of Oaktree Specialty Lending Corporation and its consolidated subsidiaries. Each consolidated subsidiary is wholly-owned and, as such, consolidated into the Consolidated Financial Statements. Certain subsidiaries that hold investments are treated as pass through entities for U.S. federal income tax purposes. The assets of certain of the consolidated subsidiaries are not directly available to satisfy the claims of the creditors of Oaktree Specialty Lending Corporation or any of its other subsidiaries. As an investment company, portfolio investments held by the Company are not consolidated into the Consolidated Financial Statements but rather are included on the Statements of Assets and Liabilities as investments at fair value. Fair Value Measurements: Oaktree, as the valuation designee of the Company's Board of Directors pursuant to Rule 2a-5 under the Investment Company Act, determines the fair value of the Company's assets on at least a quarterly basis in accordance with ASC 820. ASC 820 defines fair value as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. A liability's fair value is defined as the amount that would be paid to transfer the liability to a new obligor, not the amount that would be paid to settle the liability with the creditor. ASC 820 prioritizes the use of observable market prices over entity-specific inputs. Where observable prices or inputs are not available or reliable, valuation techniques are applied. These valuation techniques involve some level of management estimation and judgment, the degree of which is dependent on the price transparency for the investments or market and the investments' complexity. Hierarchical levels, defined by ASC 820 and directly related to the amount of subjectivity associated with the inputs to fair valuation of these assets and liabilities, are as follows: A Level 1 A Unadjusted, quoted prices in active markets for identical assets or liabilities as of the measurement date. A Level 2 A Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data at the measurement date for substantially the full term of the assets or liabilities. A Level 3 A Unobservable inputs that reflect Oaktree's best estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model. If inputs used to measure fair value fall into different levels of the fair value hierarchy, an investment's level is based on the lowest level of input that is significant to the fair value measurement. Oaktree's assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the investment. This includes investment securities that are valued using "bid" and "ask" prices obtained from independent third party pricing services or directly from brokers. These investments may be classified as Level 3 because the quoted prices may be indicative in nature for securities that are in an inactive market, may be for similar securities or may require adjustments for investment-specific factors or restrictions. Financial instruments with readily available quoted prices generally will have a higher degree of market price observability and a lesser degree of judgment inherent in measuring fair value. As such, Oaktree obtains and analyzes readily available market quotations provided by pricing vendors and brokers for all of the Company's investments for which quotations are available. In determining the fair value of a particular investment, pricing vendors and brokers use observable market information, including both binding and non-binding indicative quotations. Oaktree seeks to obtain at least two quotations for the subject or similar securities, typically from pricing vendors. If Oaktree is unable to obtain two quotes from pricing vendors, or if the prices obtained from pricing vendors are not within Oaktree's set threshold, Oaktree seeks to obtain a quote directly from a broker making a market for the asset. Oaktree evaluates the quotations provided by pricing vendors and brokers based on available market information, including trading activity of the subject or similar securities, or by performing a comparable security analysis to ensure that fair values are reasonably estimated. Oaktree also performs back-testing of valuation information obtained from pricing vendors and brokers against actual prices received in transactions. In addition to ongoing monitoring and back-testing, Oaktree performs due diligence procedures over pricing vendors to understand their methodology and controls to support their use in the valuation process. Generally, Oaktree does not adjust any of the prices received from these sources. If the quotations obtained from pricing vendors or brokers are determined to not be reliable or are not readily available, Oaktree values such investments using any of three different valuation techniques. The first valuation technique is the transaction precedent technique, which utilizes recent or expected future transactions of the investment to determine fair value, to the extent applicable. The second valuation technique is an analysis of the enterprise value ("EV") of the portfolio company. EV means the entire value of the portfolio company to a market participant, including the sum of the values of debt and equity securities used to capitalize the enterprise at a point in time. The EV analysis is typically performed to determine (i) the value of equity investments, (ii) whether there is credit impairment for debt investments and (iii) the value for debt investments that the Company is deemed to control under the Investment Company Act. To estimate the EV of a portfolio company, Oaktree analyzes various factors, including the portfolio company's historical and projected financial results, macroeconomic impacts on the company and competitive dynamics in the company's industry. Oaktree also utilizes some or all of the following information based on the individual circumstances of the portfolio company: (i) valuations of comparable public companies, (ii) recent sales of private and public comparable companies in similar industries or having similar business or earnings characteristics, (iii) purchase prices as a multiple of their earnings or cash flow, (iv) the portfolio company's ability to meet its forecasts and its business prospects, (v) a discounted cash flow analysis, (vi) estimated liquidation or collateral value of the portfolio company's assets and (vii) offers from third parties to buy the portfolio company. Oaktree may probability weight potential sale outcomes with respect to a portfolio company when uncertainty exists as of the valuation date. The third valuation technique is a market yield technique, which is typically performed for non-credit impaired debt investments. In the market yield technique, a current price is imputed for the investment based upon an assessment of the expected market yield for a similarly structured investment with a similar level of risk, and Oaktree considers the current contractual interest rate, the capital structure and other terms of the investment relative to risk of the company and the specific investment. A key determinant of risk, among other things, is the leverage through the investment relative to the EV of the portfolio company. As debt investments held by the Company are substantially illiquid with no active transaction market, Oaktree depends on primary market data, including newly funded transactions and industry specific market movements, as well as secondary market data with respect to high yield debt instruments and syndicated loans, as inputs in determining the appropriate market yield, as applicable. In accordance with ASC 820-10, certain investments that qualify as investment companies in accordance with ASC 946 may be valued using net asset value as a practical expedient for fair value. Consistent with FASB guidance under ASC 820, these investments are excluded from the hierarchical levels. These investments are generally not redeemable. Oaktree estimates the fair value of certain privately held warrants using a Black Scholes pricing model, which includes an analysis of various factors and subjective assumptions, including the current stock price (by using an EV analysis as described above), the expected period until exercise, expected volatility of the underlying stock price, expected dividends and the risk free rate. Changes in the subjective input assumptions can materially affect the fair value estimates. Rule 2a-5 under the Investment Company Act permits boards of directors of registered investment companies and Business Development Companies to either (i) choose to determine fair value in good faith or (ii) designate a valuation designee tasked with determining fair value in good faith, subject to the board's oversight. The Company's Board of Directors has designated Oaktree to serve as its valuation designee effective September 8, 2022. Oaktree undertakes a multi-step valuation process each quarter in connection with determining the fair value of the Company's investments. The quarterly valuation process begins with each portfolio company or investment being initially valued by Oaktree's valuation team. Preliminary valuations are then reviewed and discussed with management of Oaktree. Separately, independent valuation firms prepare valuations of the Company's investments, on a selected basis, for which market quotations are not readily available or are readily available but deemed not reflective of the fair value of the investment, and submit the reports to the Company and provide such reports to Oaktree. Oaktree compares and contrasts its preliminary valuations to the valuations of the independent valuation firms and prepares a valuation report for the Audit Committee. The Audit Committee reviews the valuation report with Oaktree, and Oaktree responds and supplements the valuation report to reflect any discussions between Oaktree and the Audit Committee. Oaktree, as valuation designee, determines the fair value of each investment in the Company's portfolio. The fair value of the Company's investments as of June 30, 2024 and September 30, 2023 was determined by Oaktree, as the Company's valuation designee. The Company has and will continue to engage independent valuation firms to provide assistance regarding the determination of the fair value of a portion of its portfolio securities for which market quotations are not readily available or are readily available but deemed not reflective of the fair value of the investment each quarter. Due to the inherent uncertainty of determining the fair value of investments that do not have a readily available market value, the fair value of the Company's investments may fluctuate from period to period. Because of the inherent uncertainty of valuation, these estimated values may differ significantly from the values that would have been reported had a ready market for the investments existed, and it is reasonably possible that the difference could be material. With the exception of the line items entitled "deferred financing costs," "deferred offering costs," "other assets," "deferred tax liability," "credit facilities payable" and "unsecured notes payable," which are reported at amortized cost, all assets and liabilities approximate fair value on the Consolidated Statements of Assets and Liabilities. The carrying value of the line items titled "interest, dividends and fees receivable," "due from portfolio companies," "receivables from unsettled transactions," "due from broker," "accounts payable, accrued expenses and other liabilities," "base management fee and incentive fee payable," "due to affiliate," "interest payable" and "payables from unsettled transactions" approximate fair value due to their short maturities. Foreign Currency Translation: The accounting records of the Company are maintained in U.S. dollars. All assets and liabilities denominated in foreign currencies are translated into U.S. dollars based on the prevailing foreign exchange rate on the reporting date. The Company does not isolate that portion of the results of operations resulting from changes in foreign exchange rates on investments from the fluctuations arising from changes in market prices of securities held. The Company's investments in foreign securities may involve certain risks, including foreign exchange restrictions, expropriation, taxation or other political, social or economic risks, all of which could affect the market and/or credit risk of the investment. In addition, changes in the relationship of foreign currencies to the U.S. dollar can significantly affect the value of these investments and therefore the earnings of the Company. Derivative Instruments: Foreign Currency Forward Contracts The Company uses foreign currency forward contracts to reduce the Company's exposure to fluctuations in the value of foreign currencies. In a foreign currency forward contract, the Company agrees to receive or deliver a fixed quantity of one currency for another at a pre-determined price at a future date. Foreign currency forward contracts are marked-to-market at the applicable forward rate. Unrealized appreciation (depreciation) on foreign currency forward contracts is recorded within derivative assets or derivative liabilities on the Consolidated Statements of Assets and Liabilities by counterparty on a net basis, not taking into account collateral posted which is recorded separately, if applicable. Purchases and settlements of foreign currency forward contracts having the same settlement date and counterparty are generally settled net and any realized gains or losses are recognized on the settlement date. The Company does not utilize hedge accounting with respect to foreign currency forward contracts and, as such, the Company recognizes its foreign currency forward contracts at fair value with changes included in the net unrealized appreciation (depreciation) on the Consolidated Statements of Operations. Interest Rate Swaps The Company uses interest rate swaps to hedge some of the Company's fixed rate debt. The Company designated the interest rate swaps as the hedging instruments in an effective hedge accounting relationship, and therefore the periodic payments are recognized as components of interest expense in the Consolidated Statements of Operations. Depending on the nature of the balance at period end, the fair value of each interest rate swap is either included as a derivative asset or derivative liability on the Company's Consolidated Statements of Assets and Liabilities. The change in fair value of the interest rate swaps is offset by a change in the carrying value of the fixed rate debt. Any amounts paid to the counterparty to cover collateral obligations under the terms of the interest rate swap agreements are included in due from broker on the Company's Consolidated Statements of Assets and Liabilities. Investment Income: Interest Income Interest income, adjusted for accretion of original issue discount ("OID"), is recorded on an accrual basis to the extent that such amounts are expected to be collected. The Company stops accruing interest on investments when it is determined that interest is no longer collectible. Investments that are expected to pay regularly scheduled interest in cash are generally placed on non-accrual status when there is reasonable doubt that principal or interest cash payments will be collected. Cash interest payments received on investments may be recognized as income or a return of capital depending upon management's judgment. A non-accrual investment is restored to accrual status if past due principal and interest are paid in cash and the portfolio company, in management's judgment, is likely to continue timely payment of its remaining obligations. As of June 30, 2024, there were eight investments on non-accrual status that in aggregate represented 5.7% and 3.7% of total debt investments at cost and fair value, respectively. As of September 30, 2023, there were four investments on non-accrual status that in aggregate represented 2.4% and 1.8% of total debt investments at cost and fair value, respectively. In connection with its investment in a portfolio company, the Company sometimes receives nominal cost equity that is valued as part of the negotiation process with the portfolio company. When the Company receives nominal cost equity, the Company allocates its cost basis in the investment between debt securities and the nominal cost equity at the time of origination. Any resulting discount from recording the loan, or otherwise purchasing a security at a discount, is accreted into interest income over the life of the loan. PIK Interest Income The Company's investments in debt securities may contain PIK interest provisions. PIK interest, which generally represents contractually deferred interest added to the loan balance that is generally due at the end of the loan term, is generally recorded on the accrual basis to the extent such amounts are expected to be collected. The Company generally ceases accruing PIK interest if there is insufficient value to support the accrual or if the Company does not expect the portfolio company to be able to pay all principal and interest due. The Company's decision to cease accruing PIK interest on a loan or debt security involves subjective judgments and determinations based on available information about a particular portfolio company, including whether the portfolio company is current with respect to its payment of principal and interest on its loans and debt securities; financial statements and financial projections for the portfolio company; the Company's assessment of the portfolio company's business development success; information obtained by the Company in connection with periodic formal update interviews with the portfolio company's management and, if appropriate, the private equity sponsor; and information about the general economic and market conditions in which the portfolio company operates. The Company's determination to cease accruing PIK interest is generally made well before the Company's full write-down of a loan or debt security. In addition, if it is subsequently determined that the Company will not be able to collect any previously accrued PIK interest, the fair value of the loans or debt securities would be reduced by the amount of such previously accrued, but uncollectible, PIK interest. The accrual of PIK interest on the Company's debt investments increases the recorded cost basis of these investments in the Consolidated Financial Statements including for purposes of computing the capital gains incentive fee payable by the Company to Oaktree. To maintain its status as a RIC, certain income from PIK interest may be required to be distributed to the Company's stockholders, even though the Company has not yet collected the cash and may never do so. Fee Income Oaktree or its affiliates may provide financial advisory services to portfolio companies and, in return, the Company may receive fees for capital structuring services. These fees are generally non-recurring and are recognized by the Company upon the investment closing date. The Company may also receive additional fees in the ordinary course of business, including servicing, amendment, exit and prepayment fees, which are classified as fee income and recognized as they are earned or the services are rendered. Dividend Income The Company generally recognizes dividend income on the ex-dividend date for public securities and the record date for private equity investments. Distributions received from private equity investments are evaluated to determine if the distribution should be recorded as dividend income or a return of capital. Generally, the Company will not record distributions from private equity investments as dividend

income unless there are sufficient earnings at the portfolio company prior to the distribution. Distributions that are classified as a return of capital are recorded as a reduction in the cost basis of the investment.Cash and Cash Equivalents and Restricted Cash:Cash and cash equivalents consist of demand deposits and highly liquid investments with maturities of three months or less when acquired. The Company places its cash and cash equivalents and restricted cash with financial institutions and, at times, cash held in bank accounts exceeds the Federal Deposit Insurance Corporation ("FDIC") insurance limit. Cash and cash equivalents are included on the Company's Consolidated Schedule of Investments and cash equivalents are classified as Level 1 assets.As of June30, 2024, included in restricted cash was \$11.0Å million that was held at Deutsche Bank Trust Company Americas in connection with the OS12 Citibank Facility (as defined in Note 6. Borrowings). Pursuant to the terms of the OS12 Citibank Facility, the Company was restricted in terms of access to the \$11.0Å million until the occurrence of the periodic distribution dates and, in connection therewith, the Company's submission of its required periodic reporting schedules and verifications of the Company's compliance with the terms of the OS12 Citibank Facility. As of September30, 2023, included in restricted cash was \$9.1Å million that was held at Deutsche Bank Trust Company Americas in connection with the OS12 Citibank Facility. Due from Portfolio Companies:Due from portfolio companies consists of amounts payable to the Company from its portfolio companies, including proceeds from the sale of portfolio companies not yet received or being held in escrow and excluding those amounts attributable to interest, dividends or fees receivable. These amounts are recognized as they become payable to the Company (e.g., principal payments on the scheduled amortization payment date).Receivables/Payables from Unsettled Transactions:Receivables/payables from unsettled transactions consist of amounts receivable to or payable by the Company for transactions that have not settled at the reporting date.Deferred Financing Costs:Deferred financing costs consist of fees and expenses paid in connection with the closing or amending of credit facilities and debt offerings. Deferred financing costs in connection with credit facilities are capitalized as an asset when incurred. Deferred financing costs in connection with all other debt arrangements are a direct deduction from the related debt liability when incurred. Deferred financing costs are amortized using the effective interest method over the term of the respective debt arrangement. This amortization expense is included in interest expense in the Consolidated Statements of Operations. Upon early termination or modification of a credit facility, all or a portion of unamortized fees related to such facility may be accelerated into interest expense. For extinguishments of the Company's unsecured notes payable, any unamortized deferred financing costs are deducted from the carrying amount of the debt in determining the gain or loss from the extinguishment.Deferred Offering Costs:Legal fees and other costs incurred in connection with the Company's shelf registration statement are capitalized as deferred offering costs in the Consolidated Statements of Assets and Liabilities. To the extent any such costs relate to equity offerings, these costs are charged as a reduction of capital upon utilization. To the extent any such costs relate to debt offerings, these costs are treated as deferred financing costs and are amortized over the term of the respective debt arrangement. Any deferred offering costs that remain at the expiration of the shelf registration statement or when it becomes probable that an offering will not be completed are expensed.Income Taxes:The Company has elected to be subject to tax as a RIC under Subchapter M of the Code and operates in a manner so as to qualify for the tax treatment applicable to RICs. In order to be subject to tax as a RIC, among other things, the Company is required to meet certain source of income and asset diversification requirements and timely distribute dividends to its stockholders of an amount generally at least equal to 90% of investment company taxable income, as defined by the Code and determined without regard to any deduction for dividends paid, for each taxable year. As a RIC, the Company is not subject to U.S. federal income tax on the portion of its taxable income and gains distributed currently to stockholders as a dividend. Depending on the level of taxable income earned during a taxable year, the Company may choose to retain taxable income in excess of current year dividend distributions and would distribute such taxable income in the next taxable year. The Company would then incur a 4% excise tax on such income, as required. To the extent that the Company determines that its estimated current year annual taxable income, determined on a calendar year basis, could exceed estimated current calendar year dividend distributions, the Company accrues excise tax, if any, on estimated excess taxable income as taxable income is earned. The Company anticipates timely distribution of its taxable income within the tax rules under Subchapter M of the Code. For calendar year 2022, the Company incurred \$0.1Å million of excise tax. The Company did not incur any U.S. federal excise tax for calendar year 2023. The Company does not expect to incur a U.S. federal excise tax for calendar year 2024. The Company holds certain portfolio investments through taxable subsidiaries. The purpose of the Company's taxable subsidiaries is to permit the Company to hold equity investments in portfolio companies which are "pass through" entities for U.S. federal income tax purposes in order to comply with the RIC tax requirements. The taxable subsidiaries are consolidated for financial reporting purposes, and portfolio investments held by them are included in the Company's Consolidated Financial Statements as portfolio investments and recorded at fair value. The taxable subsidiaries are not consolidated with the Company for U.S. federal income tax purposes and may generate income tax expense, or benefit, and the related tax assets and liabilities, as a result of their ownership of certain portfolio investments. This income tax expense, if any, would be reflected in the Company's Consolidated Statements of Operations. The Company uses the liability method to account for its taxable subsidiaries' income taxes. Using this method, the Company recognizes deferred tax assets and liabilities for the estimated future tax effects attributable to temporary differences between financial reporting and tax bases of assets and liabilities. In addition, the Company recognizes deferred tax benefits associated with net operating loss carry forwards that it may use to offset future tax obligations. The Company measures deferred tax assets and liabilities using the enacted tax rates expected to apply to taxable income in the years in which it expects to recover or settle those temporary differences.FASB ASC Topic 740, Accounting for Uncertainty in Income Taxes ("ASC 740"), provides guidance for how uncertain tax positions should be recognized, measured, presented and disclosed in the Company's Consolidated Financial Statements. ASC 740 requires the evaluation of tax positions taken or expected to be taken in the course of preparing the Company's tax returns to determine whether the tax positions are "more-likely-than-not" of being sustained by the applicable tax authority. Tax positions not deemed to meet the more-likely-than-not threshold are recorded as a tax benefit or expense in the current year. Management's determinations regarding ASC 740 may be subject to review and adjustment at a later date based upon factors including an ongoing analysis of tax laws, regulations and interpretations thereof. The Company recognizes the tax benefits of uncertain tax positions only where the position is "more-likely-than-not" to be sustained assuming examination by tax authorities. Management has analyzed the Company's tax positions and has concluded that no liability for unrecognized tax benefits should be recorded related to uncertain tax positions taken on returns filed for open tax years 2021, 2022 and 2023. The Company identifies its major tax jurisdictions as U.S. Federal and California, and the Company is not aware of any tax positions for which it is reasonably possible that the total amounts of unrecognized tax benefits will change materially in the next 12Å months.Recently Adopted Accounting PronouncementsIn November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280), which improves reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. The amendments are effective for fiscal years beginning after December 15, 2023 and interim period within fiscal years beginning after December 15, 2024. The Company does not expect this guidance to materially impact its consolidated financial statements. X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrl:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for all significant accounting policies of the reporting entity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URL https://asc.fasb.org/1943274/2147483426/235-10-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URL https://asc.fasb.org/235/tableOfContent + Details Name: us-gaap_SignificantAccountingPoliciesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 23 R12.htm IDEA: XBRL DOCUMENT v3.24.2 Portfolio Investments 9 Months Ended June 30, 2024 Schedule of Investments [Abstract] Å Portfolio Investments Portfolio InvestmentsAs of June30, 2024, 208.7% of net assets at fair value, or \$3.1Å billion, Å was invested in 158 portfolio companies, including (i) \$138.5Å million in subordinated notes and limited liability company ("LLC") equity interests of Senior Loan Fund JV I, LLC ("SLF JV I"), a joint venture through which the Company and Trinity Universal Insurance Company, a subsidiary of Kemper Corporation ("Kemper"), co-invest in senior secured loans of middle-market companies and other corporate debt securities and (ii) \$49.9Å million in subordinated notes and LLC equity interests of OCSI Glick JV LLC ("Glick JV" and, together with SLF JV I, the "JVs"), a joint venture through which the Company and GF Equity Funding 2014 LLC ("GF Equity Funding") co-invest primarily in senior secured loans of middle-market companies. As of June30, 2024, 7.2% of net assets at fair value, or \$107.3 million, was invested in cash and cash equivalents (including \$11.0Å million of restricted cash). In comparison, as of September30, 2023, 190.8% of net assets at fair value, or \$2.9Å billion, was invested in 143 portfolio investments, including (i) \$141.5Å million in subordinated notes and LLC equity interests of SLF JV I and (ii) \$50.0Å million in subordinated notes and LLC equity interests of Glick JV. As of September30, 2023, 9.6% of net assets at fair value, or \$145.5Å million, was invested in cash and cash equivalents (including \$9.1Å million of restricted cash). As of June30, 2024, 86.0% of the Company's portfolio at fair value consisted of senior secured debt investments and 9.0% consisted of subordinated debt investments, including the debt investments in the JVs. As of September30, 2023, 86.5% of the Company's portfolio at fair value consisted of senior secured debt investments and 7.5% consisted of subordinated debt investments, including the debt investments in the JVs.The Company also held equity investments in certain of its portfolio companies consisting of common stock, preferred stock, warrants or LLC equity interests. These instruments generally do not produce a current return but are held for potential investment appreciation and capital gain.During the three and nine months ended June30, 2024, the Company recorded net realized losses of \$69.5Å million and \$84.5Å million, respectively. During the three and nine months ended June30, 2023, the Company recorded net realized losses of \$10.6Å million and \$19.9Å million, respectively. During the three and nine months ended June30, 2024, the Company recorded net unrealized appreciation (depreciation) of \$26.2Å million and \$(24.1)Å million, respectively. During the three and nine months ended June30, 2023, the Company recorded net unrealized depreciation of \$1.0Å million and \$42.3Å million, respectively.The composition of the Company's investments as of June30, 2024 and September30, 2023 at cost and fair value was as follows:Å June 30, 2024September 30, 2023Å CostFair ValueCostFair ValueInvestments in debt securities\$2,895,645Å \$2,801,310Å \$2,654,484Å \$2,557,102Å Investments in equity securities178,533Å 132,034Å 171,858Å 143,767Å Debt investments in the JVs163,963Å 162,542Å 162,986Å 162,673Å Equity investments in the JVs54,791Å 25,817Å 54,791Å 28,878Å Totals\$3,292,932Å \$3,121,703Å \$3,044,119Å \$2,892,420Å The following table presents the composition of the Company's debt investments as of June30, 2024 and September30, 2023 at fixed rates and floating rates:Å June 30, 2024September 30, 2023Å Fair Value% of Å DebtPortfolioFair Value% of Å DebtPortfolioFloating rate debt securities, including the debt investments in the JVs\$2,526,904Å 85.26Å %\$2,345,205Å 86.23Å %Fixed rate debt securities436,948Å 14.74Å 374,570Å 13.77Å Totals\$2,963,852Å 100.00Å %\$2,719,775Å 100.00Å %The following table presents the financial instruments carried at fair value as of June30, 2024 on the Company's Consolidated Statement of Assets and Liabilities for each of the three levels of hierarchy established by ASC 820: Level1 1Level1 2Level 3Measured at Net Asset Value (a)TotalInvestments in debt securities (senior secured)\$Å \$291,086Å \$2,393,159Å \$Å \$2,684,245Å Investments in debt securities (subordinated, including the debt investments in the JVs, CLO Notes and Credit Linked Notes)\$Å \$49,123Å 230,484Å Å \$279,607Å Investments in equity securities (preferred)\$Å \$Å \$63,892Å Å \$63,892Å Investments in equity securities (common and warrants, including LLC equity interests of the JVs)1,463Å 2,175Å 64,504Å 25,817Å 93,959Å Total investments at fair value1,463Å 342,384Å 2,752,039Å 25,817Å 3,121,703Å Cash equivalents37,364Å Å \$Å \$37,364Å Derivative assets\$Å \$436Å Total assets at fair values38,827Å \$342,820Å \$2,752,039Å 25,817Å \$3,159,503Å Derivative liabilities\$Å \$33,672Å \$Å \$33,672Å Total liabilities at fair values\$Å \$33,672Å \$Å \$36,724Å Å (a)In accordance with ASC 820-10, certain investments that are measured using the net asset value per share (or its equivalent) as a practical expedient for fair value have not been classified in the fair value hierarchy. These investments are generally not redeemable. The fair value amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the amounts presented in the Consolidated Statements of Assets and Liabilities. The following table presents the financial instruments carried at fair value as of September30, 2023 on the Company's Consolidated Statement of Assets and Liabilities for each of the three levels of hierarchy established by ASC 820: Level1 1Level1 2Level 3Measured at Net Asset Value (a)TotalInvestments in debt securities (senior secured)\$Å \$208,694Å \$2,292,691Å \$Å \$2,501,385Å Investments in debt securities (subordinated, including the debt investments in the JVs and CLO Notes)\$Å \$28,666Å 189,724Å Å \$218,390Å Investments in equity securities (preferred)\$Å \$Å \$86,057Å Å \$86,057Å Investments in equity securities (common and warrants, including LLC equity interests of the JVs)4,317Å 1,953Å 51,440Å 28,878Å Total investments at fair value4,317Å 239,313Å 2,619,912Å 28,878Å 2,892,420Å Cash equivalents83,262Å Å \$Å \$83,262Å Derivative assets\$Å \$4910Å Å \$4,910Å Total assets at fair values87,579Å \$244,223Å \$2,619,912Å 28,878Å \$2,980,592Å Derivative liabilities\$Å \$47,519Å \$Å \$47,519Å Total liabilities at fair values\$Å \$47,519Å \$Å \$47,519Å Å (a)In accordance with ASC 820-10, certain investments that are measured using the net asset value per share (or its equivalent) as a practical expedient for fair value have not been classified in the fair value hierarchy. These investments are generally not redeemable. The fair value amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the amounts presented in the Consolidated Statements of Assets and Liabilities.When a determination is made to classify a financial instrument within Level 3 of the valuation hierarchy, the determination is based upon the fact that the unobservable factors are significant to the overall fair value measurement. However, Level 3 financial instruments typically have both unobservable or Level 3 components and observable components (i.e. components that are actively quoted and can be validated by external sources). Accordingly, the appreciation (depreciation)Å in the tables below includes changes in fair value due in part to observable factors that are part of the valuation methodology. Transfers between levels are recognized at the beginning of the reporting period.The following table provides a roll-forward in the changes in fair value from March 31, 2024 to June30, 2024 for all investments for which Oaktree determined fair value using unobservable (Level1 3) Å factors:InvestmentsSenior Secured DebtSubordinatedDebt (including debt investments in the JVs and credit linked notes) PreferredEquityCommonEquity and WarrantsTotalFair value as of March 31, 2024\$2,327,422Å \$200,115Å \$62,602Å \$7,286Å \$2,667,425Å Purchases193,956Å 30,480Å Å \$169Å 24,605Å Sales and repayments(113,234)\$Å \$Å \$Å \$Å (113,234)Capitalized PIK interest income6,287Å 614Å Å \$Å \$6,901Å Accretion of OID2,600Å 349Å Å \$Å \$2,949Å Net unrealized appreciation (depreciation)7,640Å (1,074)38,883Å (12,951)32,498Å Net realized gains (losses)(31,512)\$Å \$Å (37,593)\$Å \$Å (69,105)Fair value as of June 30, 2024\$2,393,159Å \$230,484Å \$63,892Å \$64,504Å \$2,752,039Å Net unrealized appreciation (depreciation)Å relating to Level 3 investments still held as of June 30, 2024 and reported within net unrealized appreciation (depreciation) in the Consolidated Statement of Operations for the three months ended June 30, 2024\$(36,501)\$ (1,074)\$1,287Å \$(14,762)\$ (51,050)The following table provides a roll-forward in the changes in fair value from March 31, 2023 to June30, 2023 for all investments for which the Company determined fair value using unobservable (Level1 3) Å factors:InvestmentsSenior Secured DebtSubordinatedDebt (including debt investments in the JVs)PreferredEquityCommonEquity and WarrantsTotalFair value as of March 31, 2023\$2,493,622Å \$183,756Å \$91,447Å \$25,509Å \$2,794,334Å Purchases228,375Å 4,183Å Å \$Å \$182Å 232,740Å Sales and repayments(191,409)(350)\$Å \$Å (7,320)(199,079)Transfers out (a)\$Å \$Å (2,708)\$Å \$Å (2,708)Capitalized PIK interest income3,610Å 358Å Å \$Å \$3,968Å Accretion of OID4,086Å 381Å Å \$Å \$4,467Å Net unrealized appreciation (depreciation)(8,027)(704)739Å 1,893Å (6,099)Net realized gains (losses) (1,809)\$Å \$Å \$Å \$Å \$Å (1,725)Fair value as of June 30, 2023\$2,528,448Å \$184,916Å \$92,186Å \$20,348Å \$2,825,898Å Net unrealized appreciation (depreciation)Å relating to Level 3 investments still held as of June 30, 2023 and reported within net unrealized appreciation (depreciation) in the Consolidated Statement of Operations for the three months ended June 30, 2023\$(10,360)\$ (704)\$739Å \$1,095Å (9,230) (a) There were transfers out of Level 3 to Level 2 for certain investments during the three months ended June30, 2023 as a result of a change in the number of market quotes available and/or a change in market liquidity.The following table provides a roll-forward in the changes in fair value from September30, 2023 to June30, 2024 for all investments for which Oaktree determined fair value using unobservable (Level1 3) Å factors:InvestmentsSenior Secured DebtSubordinatedDebt (including debt investments in the JVs and credit linked notes) PreferredEquityCommonEquity and WarrantsTotalFair value as of September 30, 2023\$2,292,691Å \$189,724Å \$86,057Å \$51,440Å \$2,619,912Å Purchases 656,630Å 47,507Å 7,578Å 1,749Å 713,464Å Sales and repayments(506,977)(4,932)(205)(860)(512,974)Transfers in (a) (b)23,535Å Å \$Å \$39,702Å 63,237Å Transfers out (b)(38,544)(4,657)(1,159)(283)(44,643)Capitalized PIK interest income1,571Å 1,685Å Å \$Å \$19,256Å Accretion of OID8,099Å 984Å Å \$Å \$9,083Å Net unrealized appreciation (depreciation)(10,702)127Å 9,214Å (25,631)(26,992)Net realized gains (losses)(49,144)464Å (37,593)(1,613)(88,304)Fair value as of June 30, 2024\$2,393,159Å \$230,484Å \$63,892Å \$64,504Å \$2,752,039Å Net unrealized appreciation (depreciation)Å relating to Level 3 investments still held as of June 30, 2024 and reported within net unrealized appreciation (depreciation) in the Consolidated Statement of Operations for the nine months ended June 30, 2024\$(54,217)\$ (454)\$3,276Å \$(28,733)\$ (80,128) (a) There was a \$18.9Å million transfer into Level 3 from Level 2 for an investment during the nine months ended June30, 2024 as a result of a change in the number of market quotes available

[illegible]

PricewaterhouseCoopers

Product Description: The Company has issued \$2,892,420A of Senior Secured Notes due 2026 at a coupon rate of 7.00% per annum. The Company has also issued \$1,190,000A of Senior Secured Notes due 2028 at a coupon rate of 7.00% per annum.

Financial Information: As of June 30, 2024, the Company had total assets of \$390.8A million and total liabilities of \$376.1A million. The Company's revenue was \$11.4A million for the year ended June 30, 2024. The Company's operating income was \$1.1A million for the year ended June 30, 2024. The Company's net income was \$0.8A million for the year ended June 30, 2024.

Risk Factors: The Company faces various risks, including credit risk, liquidity risk, operational risk, and market risk. The Company's operations are subject to fluctuations in demand and pricing, which could impact its financial performance.

Management Discussion: Management believes that the Company's strong financial position and diversified portfolio of products will enable it to successfully navigate the current economic environment and achieve its long-term growth objectives.

Conclusion: The Company's Senior Secured Notes offer investors a competitive return and a secure investment opportunity. The Company's strong financial performance and solid management team provide confidence in its ability to meet its obligations and deliver value to its stakeholders.

RevolverSOFR+8.00%13.45%/4/6/2027318À 301À 297À (4)(5)Pluralsight, LLCApplication SoftwareFirst Lien Term LoanSOFR+8.00%13.45%/4/6/20278,116À 7,850À 7,773À (4)Renaissance Holding Corp.Education ServicesFirst Lien Term LoanSOFR+4.75%9.99%/4/5/20305,000À 4,860À 4,969À SHO Holding I CorporationFootwearFirst Lien Term LoanSOFR+5.23%10.86%/4/27/2024138À 138À 94À SHO Holding I CorporationFootwearFirst Lien Term LoanSOFR+5.25%10.88%/4/27/20248,113À 8,111À 5,531À SM Wellness Holdings, Inc.Health Care ServicesFirst Lien Term LoanSOFR+4.75%10.38%/4/17/20282,977À 2,580À 2,799À (4)Southern Veterinary Partners, LLCHealth Care FacilitiesFirst Lien Term LoanSOFR+4.00%9.43%10/5/20277,680À 7,642À 7,643À Spanx, LLCApparel RetailFirst Lien Term LoanSOFR+5.25%10.67%11/20/20288,843À 8,713À 8,717À (4)SPX Flow, Inc.Industrial Machinery & Supplies & ComponentsFirst Lien Term LoanSOFR+4.50%9.92%/4/5/20298,801À 8,442À 8,794À Star Parent, Inc.Life Sciences Tools & ServicesFirst Lien Term LoanSOFR+4.00%9.33%9/19/20308,000À 7,880À 7,834À TIBCO Software Inc.Application SoftwareFirst Lien Term LoanSOFR+4.50%9.99%3/30/20298,215À 7,559À 7,913À Touchstone Acquisition, Inc.Health Care SuppliesFirst Lien Term LoanSOFR+6.00%11.42%12/29/20287,212À 7,103À 7,022À (4)Veritas US Inc.Application SoftwareFirst Lien Term LoanSOFR+5.00%10.43%9/1/20256,305À 6,257À 5,500À Windstream Services II, LLCIntegrated Telecommunication ServicesFirst Lien Term LoanSOFR+6.25%11.67%9/21/20276,148À 6,008À 5,939À (4)WP CPP Holdings, LLC Aerospace & DefenseFirst Lien Term LoanSOFR+3.75%9.27%/4/30/20251,965À 1,920À 1,855À (4)Total Portfolio Investments\$332,637À \$331,808À \$322,179À (1) Represents the interest rate as of SeptemberÀ 30, 2023. All interest rates are payable in cash, unless otherwise noted.(2) The interest rate on the principal balance outstanding for most of the floating rate loans is indexed to SOFR and/or LIBOR, which typically resets semi-annually, quarterly, or monthly at the borrower's option. The borrower may also elect to have multiple interest reset periods for each loan. For each of these loans, the Company has provided the applicable margin over the reference rates based on each respective credit agreement and the cash interest rate as of period end. As of SeptemberÀ 30, 2023, the reference rates for SLF JV I's variable rate loans were the 30-day SOFR at 5.32%, the 90-day SOFR at 5.39% and the 30-day LIBOR at 5.43%. Most loans include an interest floor, which generally ranges from 0% to 1%. SOFR based contracts may include a credit spread adjustment that is charged in addition to the base rate and the stated spread.(3) Represents the current determination of fair value as of SeptemberÀ 30, 2023 utilizing a similar technique as the Company in accordance with ASC 820. However, the determination of such fair value is not included in the valuation process described elsewhere herein.(4) This investment was held by both the Company and SLF JV I as of SeptemberÀ 30, 2023.(5) Investment had undrawn commitments. Unamortized fees are classified as unearned income which reduces cost basis, which may result in a negative cost basis. A negative fair value may result from the unfunded commitment being valued below par.Both the cost and fair value of the Company's SLF JV I Notes wereÀ \$112.7À million as of each of JuneÀ 30, 2024 and September 30, 2023. The Company earned interest income ofÀ \$3.5À million and \$10.7À million on the SLF JV I Notes for the three and nine months ended JuneÀ 30, 2024, respectively. The Company earned interest income ofÀ \$3.4À million and \$9.2À million on the SLF JV I Notes for the three and nine months ended JuneÀ 30, 2023, respectively. As of JuneÀ 30, 2024, the SLF JV I Notes bore interest at a rate of one-month SOFR plus 7.00% per annum with a SOFR floor of 1.00% and will mature on December 29, 2028. The cost and fair value of the LLC equity interests in SLF JV I held by the Company wereÀ \$54.8À millionÀ andÀ \$25.8 million, respectively, as ofÀ JuneÀ 30, 2024, andÀ \$54.8 millionÀ andÀ \$28.9 million, respectively, as ofÀ SeptemberÀ 30, 2023. The Company earned \$1.4À million and \$4.2À million in dividend income for the three and nine months ended JuneÀ 30, 2024, respectively, with respect to its investment in the LLC equity interests of SLF JV I. The Company earned \$1.1À million and \$3.2À million in dividend income for the three and nine months ended JuneÀ 30, 2023, respectively, with respect to its investment in the LLC equity interests of SLF JV I. The LLC equity interests of SLF JV I are generally dividend producing to the extent SLF JV I has residual cash to be distributed on a quarterly basis.Below is certain summarized financial information for SLF JV I as of JuneÀ 30, 2024 and SeptemberÀ 30, 2023 and for the three and nine months ended JuneÀ 30, 2024 and 2023: June 30, 2024September 30, 2023Selected Balance Sheet Information:Investments at fair value (cost June 30, 2024: \$353,263; cost September 30, 2023: \$331,808)\$344,930À \$322,179À Cash and cash equivalents24,006À 31,950À Restricted cash6,994À 2,987À Other assets14,840À 18,988À Total assets\$390,770À \$376,104À Senior credit facility payables\$198,000À \$149,000À Secured borrowings13,292À 38,845À SLF JV I Notes payable at fair value (proceeds June 30, 2024: \$128,750; proceeds September 30, 2023: \$128,750)\$128,750À 128,750À Other liabilities21,222À 26,630À Total liabilities\$361,264À \$343,225À Members' equity 29,506À 32,879À Total liabilities and members' equity\$390,770À \$376,104À Three months ended June 30, 2024Three months ended June 30, 2023Nine months ended June 30, 2024Nine months ended June 30, 2023Selected Statements of Operations Information:Interest income\$9,463À \$10,312À \$28,665À \$29,106À Other incomeÀ "À À"À 159À 62À Total investment income9,463À 10,312À 28,824À 29,168À Senior credit facility and secured borrowing interest expense4,071À 4,190À 11,910À 12,004À SLF JV I Notes interest expense4,048À 3,859À 12,196À 10,511À Other expenses46À 73À 246À 249À Total expenses (1)8,165À 8,122À 24,352À 22,764À Net investment income 1,298À 2,190À 4,472À 6,404À Net unrealized appreciation (depreciation)(31)92,652À 1,299À 4,075À Net realized gains (losses)(3,784)2,137(4,343)(4,850)Net income (loss)\$2,705À \$1,428À \$5,629À À (1) There are no management fees or incentive fees charged at SLF JV I.SLF JV I has elected to fair value the SLF JV I Notes issued to the Company and Kemper under FASB ASC Topic 825, Financial Instruments - Fair Value Option ("ASC 825"). The SLF JV I Notes are valued based on the total assets less the total liabilities senior to the SLF JV I Notes in an amount not exceeding par under the EV technique.During the nine months ended JuneÀ 30, 2024, the Company purchased \$14.0À million of senior secured debt investments from SLF JV I for \$13.3À million cash consideration, which represented the fair value at the time of purchase. During the nine months ended JuneÀ 30, 2023, the Company sold \$18.8À million of senior secured debt investments to SLF JV I for \$18.0À million cash consideration, which represented the fair value at the time of sale. A loss of \$0.2À million was recognized by the Company on these transactions.OCSI Click JV LLCOn March 19, 2021, the Company became party to the LLC agreement of Click JV. The Company co-invests primarily in senior secured loans of middle-market companies with GF Equity Funding through the Click JV. The Click JV is managed by a four person Board of Directors, two of whom are selected by the Company and two of whom are selected by GF Equity Funding. The Click JV is capitalized as transactions are completed, and portfolio decisions and investment decisions in respect of the Click JV must be approved by the Click JV investment committee, which consists of one representative selected by the Company and one representative selected by GF Equity Funding (with approval from a representative of each required). Since the Company does not have a controlling financial interest in the Click JV, the Company does not consolidate the Click JV. The members provide capital to the Click JV in exchange for LLC equity interests, and the Company and GF Debt Funding 2014 LLC ("GF Debt Funding"), an entity advised by affiliates of GF Equity Funding, provide capital to the Click JV in exchange for subordinated notes issued by the Click JV (the "Click JV Notes"). As of JuneÀ 30, 2024 and SeptemberÀ 30, 2023, the Company and GF Equity Funding owned 87.5% and 12.5%, respectively, of the outstanding LLC equity interests, and the Company and GF Debt Funding owned 87.5% and 12.5%, respectively, of the Click JV Notes. The Click JV is not an "eligible portfolio company" as defined in section 2(a)(46) of the Investment Company Act. The Click JV has a revolving credit facility with Bank of America, N.A. (as amended and/or restated from time to time, the "Click JV Facility"), which, as of JuneÀ 30, 2024, had a revolving period end date and maturity date of April 17, 2027 and April 22, 2027, respectively, and permitted borrowings of up to \$100.0À million (subject to borrowing base and other limitations). Borrowings under the Click JV Facility are secured by all of the assets of OCSL Click JV Funding II LLC, a special purpose financing subsidiary of the Click JV. As of JuneÀ 30, 2024, borrowings under the Click JV Facility bore interest at a rate equal to daily SOFR plus 1.70% per annum. \$78.0À million and \$53.0À million of borrowings were outstanding under the Click JV Facility as of JuneÀ 30, 2024 and SeptemberÀ 30, 2023, respectively. As of JuneÀ 30, 2024 and SeptemberÀ 30, 2023, the Click JV had total assets of \$150.2À million and \$141.2À million, respectively. The Click JV's portfolio consisted of middle-market and other corporate debt securities of 45 and 38 portfolio companies as of JuneÀ 30, 2024 and SeptemberÀ 30, 2023, respectively. The portfolio companies in the Click JV are in industries similar to those in which the Company may invest directly. The Company's investment in the Click JV consisted of LLC equity interests and Click JV Notes of \$49.9À million and \$50.0À million in the aggregate at fair value as of JuneÀ 30, 2024 and SeptemberÀ 30, 2023, respectively. The Click JV Notes are junior in right of payment to the repayment of temporary contributions made by the Company to fund investments of the Click JV that are repaid when GF Equity Funding and GF Debt Funding make their capital contributions and fund their Click JV Notes, respectively. As of each of JuneÀ 30, 2024 and SeptemberÀ 30, 2023, the Click JV had total capital commitments of \$100.0À million, \$87.5À million of which was from the Company and the remaining \$12.5À million of which was from GF Equity Funding and GF Debt Funding. Approximately \$84.0À million in aggregate commitments were funded as of each of JuneÀ 30, 2024 and SeptemberÀ 30, 2023, of which \$73.5À million was from the Company. As of each of JuneÀ 30, 2024 and SeptemberÀ 30, 2023, the Company had commitments to fund Click JV Notes of \$78.8À million, of which \$12.4À million were unfunded. As of each of JuneÀ 30, 2024 and SeptemberÀ 30, 2023, the Company had commitments to fund LLC equity interests in the Click JV of \$8.7À million, of which \$1.6À million were unfunded.Below is a summary of the Click JV's portfolio, followed by a listing of the individual loans in the Click JV's portfolio as of JuneÀ 30, 2024 and SeptemberÀ 30, 2023: June 30, 2024September 30, 2023Senior secured loans (1)\$139,298\$130,589Weighted average current interest rate on senior secured loans (2)9.53%10.77%Number of borrowers in the Click JV4538Largest loan exposure to a single borrower (1)\$6,891\$6,230Total of five largest loan exposures to borrowers (1)\$827,461\$28,396 (1) At principal amount.(2) Computed using the weighted average annual interest rate on accruing senior secured loans at fair value.Click JV Portfolio as of JuneÀ 30, 2024Portfolio Company IndustryInvestment TypeIndexSpreadÀ Cash Interest Rate (1)(2)PIKMaturity DatePrincipalCostFairÀ Value (3)NotesAccess CIG, LLCDiversified Support ServicesFirst Lien Term LoanSOFR+5.00%10.33%8/18/2028\$1,985À \$1,951À \$2,000À (4)ADB Companies, LLCConstruction & EngineeringFirst Lien Term LoanSOFR+6.50%11.82%12/18/2025546À 542À 529À (4)ADB Companies, LLCConstruction & EngineeringFirst Lien Term LoanSOFR+6.50%12.10%12/18/20253,462À 3,440À 3,359À (4)Alvogen Pharma US, Inc.PharmaceuticalsFirst Lien Term LoanSOFR+7.50%12.98%6/30/20255,981À 5,956À 5,532À (4)American Tire Distributors, Inc.DistributorsFirst Lien Term LoanSOFR+6.25%11.84%10/20/20281,988À 1,963À 1,450À (4)Artera Services LLCConstruction & EngineeringFirst Lien Term LoanSOFR+4.50%9.83%2/15/20312,494À 2,475À 2,510À ASP-R-PAC Acquisition Co LLCPaper & Plastic Packaging Products & MaterialsFirst Lien Term LoanSOFR+6.00%11.59%12/29/20271,703À 1,684À 1,620À (4)ASP-R-PAC Acquisition Co LLCPaper & Plastic Packaging Products & MaterialsFirst Lien RevolverSOFR+6.00%11.46%12/29/202785À 83À 75À (4)(5)Astra Acquisition Corp.Application SoftwareFirst Lien Term LoanSOFR+6.75%12.08%2/25/20281,050À 1,037À 963À (4)Astra Acquisition Corp.Application SoftwareFirst Lien Term LoanSOFR+5.25%10.58%10/25/20281,661À 1,665À 779À (4)Asurion, LLCProperty & Casualty InsuranceFirst Lien Term LoanSOFR+4.25%6.69%6/8/19/2028988À 943À 981À Asurion, LLCProperty & Casualty InsuranceFirst Lien Term LoanSOFR+4.00%9.44%8/19/20283,157À 3,077À 3,126À athenahealth Group Inc.Health Care TechnologyFirst Lien Term LoanSOFR+3.25%8.59%2/15/20292,950À 2,852À 2,944À Aurora Lux Fincos S.À R.L.Airport ServicesFirst Lien Term LoanSOFR+7.00%8.43%4.00%12/24/20263,738À 3,706À 3,611À (4)BAART Programs, Inc.Health Care ServicesFirst Lien Term LoanSOFR+5.00%10.60%6/11/20273,374À 3,306À 3,207À (4)BAART Programs, Inc.Health Care ServicesFirst Lien Term LoanSOFR+5.00%10.60%6/11/2027794À 789À 763À (4)Bausch + Lomb CorporationHealth Care SuppliesFirst Lien Term LoanSOFR+3.25%8.69%5/10/20273,728À 3,660À 3,693À Cloud Software Group, Inc.Application SoftwareFirst Lien Term LoanSOFR+4.00%9.33%6/30/20292,627À 2,454À 2,629À Covetrus, Inc.Health Care DistributorsFirst Lien Term LoanSOFR+5.00%10.33%10/13/20292,745À 2,607À 2,661À (4)Crown Subsea Communications Holding, Inc.Alternative CarriersFirst Lien Term LoanSOFR+4.75%10.08%1/30/20313,000À 2,970À 3,012À (4)Curium Bidco S.A. r.l.PharmaceuticalsFirst Lien Term LoanSOFR+4.00%9.33%6/31/20292,820À 2,799À 2,836À Dealer Tire Financial, LLCDistributorsFirst Lien Term LoanSOFR+3.75%9.09%12/14/20274,074À 4,065À 4,076À DirecTV Financing, LLCable & SatelliteFirst Lien Term LoanSOFR+5.25%10.71%8/2/20293,028À 3,002À 3,018À (4)DITI Holdco, Inc.Research & Consulting ServicesFirst Lien Term LoanSOFR+4.75%10.09%4/26/20293,543À 3,496À 3,562À (4)Eagle Parent Corp.Diversified Support ServicesFirst Lien Term LoanSOFR+4.25%9.58%4/2/2029393À 388À 383À Frontier Communications Holdings, LLCIntegrated Telecommunication ServicesFirst Lien Term LoanSOFR+3.50%8.85%7/1/20313,000À 2,985À 3,000À Portfolio Company IndustryInvestment TypeIndexSpreadÀ Cash Interest Rate (1)(2)PIKMaturity DatePrincipalCostFairÀ Value (3)NotesFrontier Communications Holdings, LLCIntegrated Telecommunication ServicesFirst Lien Term LoanSOFR+3.75%9.21%10/8/2027\$1,862À \$1,842À \$1,863À Harbor Purchaser Inc.Education ServicesFirst Lien Term LoanSOFR+5.25%10.70%4/9/20293,930À 3,849À 3,750À (4)Husky Injection Molding Systems Ltd.Industrial Machinery & Supplies & ComponentsFirst Lien Term LoanSOFR+5.00%10.33%2/15/20292,433À 2,400À 2,424À Indivior Finance S.À E.R.L.PharmaceuticalsFirst Lien Term LoanSOFR+5.25%10.71%6/30/20263,880À 3,848À 3,875À INW Manufacturing, LLCPersonal Care ProductsFirst Lien Term LoanSOFR+5.75%11.35%3/25/20272,156À 2,126À 1,811À (4)KDC US Holdings, Inc.Personal Care ProductsFirst Lien Term LoanSOFR+4.50%9.84%8/15/20283,551À 3,448À 3,565À LABL, Inc.Office Services & SuppliesFirst Lien Term LoanSOFR+5.00%10.44%10/29/2028955À 974À 984À (4)LaserAway Intermediate Holdings II, LLCHealth Care ServicesFirst Lien Term LoanSOFR+5.75%11.33%10/14/20273,900À 3,857À 3,916À Mitchell International, Inc.Application SoftwareFirst Lien Term LoanSOFR+3.25%8.59%6/17/20312,500À 2,488À 2,482À Peraton Corp. Aerospace & DefenseFirst Lien Term LoanSOFR+3.75%9.19%2/1/2028992À 992À 993À PetSmart LLCOther Specialty RetailFirst Lien Term LoanSOFR+3.75%9.19%6/21/20282,987À 2,949À 2,982À Pluralsight, LLCApplication SoftwareFirst Lien Term LoanSOFR+8.00%4/6/20275,182À 5,052À 2,539À (4)(6)Pluralsight, LLCApplication SoftwareFirst Lien RevolverSOFR+8.00%4/6/2027360À 349À 176À (4)(6)Renaissance Holding Corp.Education ServicesFirst Lien Term LoanSOFR+4.25%6.60%4/5/20301,990À 1,985À 1,991À SCIH Salt Holdings Inc.Diversified ChemicalsFirst Lien Term LoanSOFR+3.50%8.83%3/16/20271,486À 1,486À 1,489À Shearer's Foods LLCPackaged Foods & MeatsFirst Lien Term LoanSOFR+4.00%9.34%2/12/20313,000À 2,970À 3,025À SHO Holding I CorporationFootwearFirst Lien Term LoanSOFR+5.25%4/4/27/20246,089À 6,119À 5,224À (6)SHO Holding I CorporationFootwearFirst Lien Term LoanSOFR+5.23%4/4/27/2024104À 104À 89À (6)SHO Holding I CorporationFootwearFirst Lien Term LoanSOFR+8.00%13.44%8/29/2024698À 664À 698À Southern Veterinary Partners, LLCHealth Care FacilitiesFirst Lien Term LoanSOFR+3.75%9.09%10/5/20273,275À 3,258À 3,286À SPX Flow, Inc.Industrial Machinery & Supplies & ComponentsFirst Lien Term LoanSOFR+3.50%8.84%4/5/20294,185À 4,049À 4,214À Staples, Inc.Office Services & SuppliesFirst Lien Term LoanSOFR+5.75%11.08%9/4/20291,919À 1,843À 1,765À (4)Star Parent, Inc.Life Sciences Tools & ServicesFirst Lien Term LoanSOFR+3.75%9.08%6/27/20303,990À 3,930À 3,992À SupplyOne, Inc. Paper & Plastic Packaging Products & MaterialsFirst Lien Term LoanSOFR+4.25%6.59%4/19/20311,496À 1,481À 1,500À Swissport Stratosphere USA LLCAir Freight & LogisticsFirst Lien Term LoanSOFR+4.25%6.56%4/4/20312,000À 1,990À 2,008À Tacala, LLCRestaurantsFirst Lien Term LoanSOFR+4.00%9.34%1/31/20313,990À 3,980À 4,012À Touchstone Acquisition, Inc.Health Care SuppliesFirst Lien Term LoanSOFR+6.00%11.43%12/29/20282,971À 2,932À 2,908À (4)Trident TPI Holdings, Inc.Metal, Glass & Plastic ContainersFirst Lien Term LoanSOFR+4.00%9.34%9/15/20282,500À 2,500À 2,507À Total Portfolio Investments\$139,298À \$137,360À \$132,405À (1) Represents the interest rate as of JuneÀ 30, 2024. All interest rates are payable in cash, unless otherwise noted. (2) The interest rate on the principal balance outstanding for all of the floating rate loans is indexed to SOFR, which typically resets semi-annually, quarterly, or monthly at the borrower's option. The borrower may also elect to have multiple interest reset periods for each loan. For each of these loans, the Company has provided the applicable margin over the reference rates based on each respective credit agreement and the cash interest rate as of period end. As of JuneÀ 30, 2024, the reference rates for the Click JV's variable rate loans were the 30-day SOFR at 5.34% and the 90-day SOFR at 5.32%. Most loans include an interest floor, which generally ranges from 0% to 2%. SOFR based contracts may include a credit spread adjustment that is charged in addition to the base rate and the stated spread.(3) Represents the current determination of fair value as of JuneÀ 30, 2024 utilizing a similar technique as the Company in accordance with ASC 820. However, the determination of such fair value is not included in the valuation process described elsewhere herein.(4) This investment was held by both the Company and the Click JV as of JuneÀ 30, 2024.(5) Investment had undrawn commitments. Unamortized fees are classified as unearned income which reduces cost basis, which may result in a negative cost basis. A negative fair value may result from the unfunded commitment being valued below par.(6) This investment was on non-accrual status as of JuneÀ 30, 2024. Click JV Portfolio as of SeptemberÀ 30, 2023Portfolio Company IndustryInvestment TypeIndexSpreadÀ Cash Interest Rate (1)(2)PIKMaturity DatePrincipalCostFairÀ Value (3)NotesAccess CIG, LLCDiversified Support ServicesFirst Lien Term LoanSOFR+5.00%10.32%8/18/2028\$2,000À \$1,960À \$1,978À ADB Companies, LLCConstruction & EngineeringFirst Lien Term LoanSOFR+6.50%11.90%12/18/2025574À 568À 564À (4)ADB Companies, LLCConstruction & EngineeringFirst Lien Term LoanSOFR+6.50%12.15%12/18/20253,746À 3,709À 3,678À (4)Alvogen Pharma US, Inc.PharmaceuticalsFirst Lien Term LoanSOFR+7.50%13.04%6/30/20262,230À 6,185À 5,819À (4)American Rock Salt Company LLCDiversified Metals & MiningFirst Lien Term LoanSOFR+4.00%9.43%6/9/20282,478À 2,367À 2,307À American Tire Distributors, Inc.DistributorsFirst Lien Term

LoanSOFR+6.25%11.81%10/20/20282,860Å 2,825Å 2,514Å (3)Amplify Finco Pty Ltd.Movies & EntertainmentFirst Lien Term LoanSOFR+4.15%69.54%11/26/2022,895Å 2,866Å 2,895Å Amynta Agency Borrower Inc.Property & Casualty InsuranceFirst Lien Term LoanSOFR+5.00%10.42%28/28/20282,993Å 2,913Å 2,997Å Anastasia Parent, LLCPersonal Care ProductsFirst Lien Term LoanSOFR+3.75%9.40%8/11/2025907Å 705Å 654Å (4)ASP-R-PAC Acquisition Co LLCPaper & Plastic Packaging Products & MaterialsFirst Lien Term LoanSOFR+6.00%11.63%12/29/202771,716Å 1,692Å 1,616Å (4)ASP-R-PAC Acquisition Co LLCPaper & Plastic Packaging Products & MaterialsFirst Lien Term RevolverSOFR+6.00%12/29/202776Å (3)(12)(4)(5)Astra Acquisition Corp.Application SoftwareFirst Lien Term LoanSOFR+5.25%10.90%10/25/20282,078Å 2,039Å 1,570Å (4)Asurion, LLCProperty & Casualty InsuranceFirst Lien Term LoanSOFR+4.00%9.42%8/19/20281,980Å 1,899Å 1,924Å Asurion, LLCProperty & Casualty InsuranceFirst Lien Term LoanSOFR+4.25%9.67%8/19/2028995Å 942Å 968Å Asurion, LLCProperty & Casualty InsuranceSecond Lien Term LoanSOFR+5.25%10.68%1/20/20274,23Å 2,244Å 2,158Å athenahealth Group Inc.Health Care TechnologyFirst Lien Term LoanSOFR+3.25%8.57%2/15/20291,772Å 1,674Å 1,744Å Aurora Lux Finco S.Åc.R.L.Airport ServicesFirst Lien Term LoanSOFR+6.00%11.49%12/24/20263,628Å 3,586Å 3,478Å (4)BAART Programs, Inc.Health Care ServicesFirst Lien Term LoanSOFR+5.00%10.65%6/11/2027800Å 795Å 780Å (4)Covertrus, Inc.Health Care DistributorsFirst Lien Term LoanSOFR+5.00%10.39%10/13/20292,766Å 2,607Å 2,741Å (4)Curium Bidco S.A.r.l.BiotechnologyFirst Lien Term LoanSOFR+4.50%9.89%7/31/20292,841Å 2,820Å 2,841Å DirecTV Financing, LLCable & SatelliteFirst Lien Term LoanSOFR+5.00%10.43%8/2/20272,460Å 2,435Å 2,410Å (4)DITI Holdco, Inc.Research & Consulting ServicesFirst Lien Term LoanSOFR+4.75%10.12%4/26/20292,970Å 2,922Å 2,899Å (4)Gibson Brands, Inc.Lesure ProductsFirst Lien Term LoanSOFR+5.00%10.57%8/11/20283,930Å 3,891Å 3,301Å (4)Harbor Purchaser Inc.Education ServicesFirst Lien Term LoanSOFR+5.25%10.67%4/9/20293,960Å 3,865Å 3,759Å (4)Indivior Finance S.Åc.R.L.PharmaceuticalsFirst Lien Term LoanSOFR+5.25%10.90%6/30/20263,910Å 3,866Å 3,915Å INW Manufacturing, LLCPersonal Care ProductsFirst Lien Term LoanSOFR+5.75%11.40%3/25/20272,250Å 2,210Å 1,770Å (4)KDC/ONE Development Corp IncPersonal Care ProductsFirst Lien Term LoanSOFR+5.00%10.32%6/15/20284,500Å 4,350Å 4,349Å Portfolio Company IndustryInvestment TypeIndexSpreadÅ Cash Interest Rate (1)(2)PIKMaturity DatePrincipalCostFairÅ Value (3)NotesLaserAway Intermediate Holdings II, LLCHealth Care ServicesFirst Lien Term LoanSOFR+5.75%11.32%10/14/202783,930Å \$3,877Å \$3,876Å MRI Software LLCApplication SoftwareFirst Lien Term LoanSOFR+5.50%10.99%2/10/20261,630Å 1,616Å 1,596Å (4)MRM Software LLCApplication SoftwareFirst Lien RevolverSOFR+5.50%2/10/20266Å (1)(1)(3)(4) (5)Northern Star Industries Inc.Electrical Components & EquipmentFirst Lien Term LoanSOFR+4.76%10.15%3/31/20255,198Å 5,192Å 5,159Å OEConnection LLCApplication SoftwareFirst Lien Term LoanSOFR+4.00%9.43%29/5/20263,849Å 3,830Å 3,843Å Planview Parent, Inc.Application SoftwareFirst Lien Term LoanSOFR+4.00%6.95%12/17/2027683Å 650Å 676Å Planview Parent, Inc.Application SoftwareSecond Lien Term LoanSOFR+7.25%12.74%12/18/20282,842Å 2,799Å 2,586Å (4)Pluralsight, LLCApplication SoftwareFirst Lien Term LoanSOFR+8.00%13.45%4/6/2027226Å 216Å 211Å (4)(5)SHO Holding I CorporationFootwearFirst Lien Term LoanSOFR+5.25%10.88%4/27/20246,029Å 6,025Å 4,110Å SHO Holding I CorporationFootwearFirst Lien Term LoanSOFR+5.23%10.86%4/27/2024103Å 102Å 70Å Southern Veterinary Partners, LLCHealth Care FacilitiesFirst Lien Term LoanSOFR+4.00%9.43%10/5/20273,292Å 3,275Å 3,276Å Spanx, LLCApparel RetailFirst Lien Term LoanSOFR+5.25%10.67%11/20/20284,913Å 4,840Å 4,843Å (4)SPX Flow, Inc.Industrial Machinery & Supplies & ComponentsFirst Lien Term LoanSOFR+4.50%9.92%4/5/20295,227Å 5,032Å 5,224Å Star Parent, Inc.Life Sciences Tools & ServicesFirst Lien Term LoanSOFR+4.00%9.33%6/27/20304,000Å 3,939Å 3,916Å TIBCO Software Inc.Application SoftwareFirst Lien Term LoanSOFR+4.50%6.99%3/30/20292,641Å 2,439Å 2,544Å Touchstone Acquisition, Inc.Health Care SuppliesFirst Lien Term LoanSOFR+6.00%11.42%12/29/20282,993Å 2,948Å 2,914Å (4)Windstream Services II, LLCIntegrated Telecommunication ServicesFirst Lien Term LoanSOFR+6.25%11.67%6/21/20273,843Å 3,756Å 3,712Å (4)WP CPP Holdings, LLC Aerospace & DefenseFirst Lien Term LoanSOFR+3.75%9.27%4/30/2025983Å 960Å 927Å (4)Total Portfolio Investments\$130,589Å \$127,788Å \$123,343Å (1) Represents the interest rate as of SeptemberÅ 30, 2023. All interest rates are payable in cash, unless otherwise noted. (2) The interest rate on the principal balance outstanding for all of the floating rate loans is indexed to SOFR, which typically resets semi-annually, quarterly, or monthly at the borrower's option. The borrower may also elect to have multiple interest reset periods for each loan. For each of these loans, the Company has provided the applicable margin over the reference rates based on each respective credit agreement and the cash interest rate as of period end. As of SeptemberÅ 30, 2023, the reference rates for the Glick JV's variable rate loans were the 30-day SOFR at 5.32% and the 90-day SOFR at 5.39%. Most loans include an interest floor, which generally ranges from 0% to 1%. SOFR based contracts may include a credit spread adjustment that is charged in addition to the base rate and the stated spread.(3) Represents the current determination of fair value as of SeptemberÅ 30, 2023 utilizing a similar technique as the Company in accordance with ASC 820. However, the determination of such fair value is not included in the valuation process described elsewhere herein.(4) This investment was held by both the Company and the Glick JV as of SeptemberÅ 30, 2023.(5) Investment had undrawn commitments. Unamortized fees are classified as unearned income which reduces cost basis, which may result in a negative cost basis. A negative fair value may result from the unfunded commitment being valued below par.The cost and fair value of the Company's aggregate investment in the Glick JV was \$51.3 million and \$49.9 million, respectively, as of JuneÅ 30, 2024. The cost and fair value of the Company's aggregate investment in the Glick JV was \$50.3Å million and \$50.0Å million, respectively, as of SeptemberÅ 30, 2023. For the three and nine months ended JuneÅ 30, 2024, the Company's investment in the Glick JV Notes earned interest income of \$1.8Å million and \$5.4Å million, respectively. For the three and nine months ended JuneÅ 30, 2023, the Company's investment in the Glick JV Notes earned interest income of \$1.8Å million and \$5.0Å million, respectively. The Company did not earn dividend income for the three and nine months ended JuneÅ 30, 2024 and 2023 with respect to its investment in the LLC equity interest of the Glick JV. As of JuneÅ 30, 2024, the Glick JV Notes bore interest at a rate of one-month SOFR plus 4.50% per annum and will mature on October 20, 2028. Below is certain summarized financial information for the Glick JV as of JuneÅ 30, 2024 and SeptemberÅ 30, 2023 and for the three and nine months ended JuneÅ 30, 2024 and 2023: June 30, 2024September 30, 2023Selected Balance Sheet Information:Investments at fair value (cost June 30, 2024: \$137,360; cost September 30, 2023: \$127,788)\$132,405Å \$123,343Å Cash and cash equivalents13,109Å 12,119Å Restricted cashÅ 184Å Other assets4,655Å 5,521Å Total assets\$150,169Å \$141,167Å Senior credit facility payable\$78,000Å \$53,000Å Glick JV Notes payable at fair value (proceeds June 30, 2024: \$66,685; proceeds September 30, 2023: \$66,685)\$57,012Å \$57,201Å Secured borrowings\$6,576Å 18,106Å Other liabilities\$8,581Å 12,860Å Total liabilities\$150,169Å \$141,167Å Members' equity Å 6Å Å 6Å "Å Total liabilities and members' equity\$150,169Å \$141,167Å Three months ended June 30, 2024Three months ended June 30, 2023Nine months ended June 30, 2024Nine months ended June 30, 2023Selected Statements of Operations Information:Interest income\$3,605Å \$3,576Å 10,926Å 10,488Å Fee income4Å Å 6Å 4Å 35Å Total investment income\$3,609Å 3,576Å 10,990Å 10,523Å Senior credit facility and secured borrowing interest expense1,631Å 1,400Å 4,608Å 4,002Å Glick JV Notes interest expense1,675Å 1,577Å 5,048Å 4,394Å Other expenses32Å 70Å 110Å 148Å Total expenses (1,338Å 3,047Å 9,766Å 8,544Å Net investment income 271Å 529Å 1,224Å 1,979Å Net unrealized appreciation (depreciation)328Å 431Å (321)(159)Realized gain (loss)(599)(960)(903)(1,820)Net income (loss)\$Å Å Å Å (1) There are no management fees or incentive fees charged at the Glick JV.The Glick JV has elected to fair value the Glick JV Notes issued to the Company and GF Debt Funding under ASC 825. The Glick JV Notes are valued based on the total assets less the liabilities senior to the Glick JV Notes in an amount not exceeding par under the EV technique.During the nine months ended JuneÅ 30, 2024, the Company purchased \$4.9Å million of senior secured debt investments from Glick JV for \$4.9Å million cash consideration, which represented the fair value at the time of purchase. X - DefinitionThe entire disclosure for investments owned by investment company. + ReferencesReference 1:

2023June 30, 2023\$0.55\$41.3\$ million57,279\$ (2)\$1.1\$ millionTotal for the nine months ended June 30, 2023\$2.06\$139.1\$ million220,570\$4.4\$ million(1) New shares were issued and distributed.(2) Shares were purchased on the open market and distributed.(3) Totals may not sum due to rounding. Common Stock IssuancesDuring the three and nine months ended June 30, 2024, the Company issued 100,029 and 295,484 shares of common stock, respectively, as part of the DRIP. During the three and nine months ended June 30, 2023, the Company issued zero and 94,879 shares of common stock, respectively, as part of the DRIP. On February 7, 2022, the Company entered into an equity distribution agreement by and among the Company, Oaktree, Oaktree Administrator and Keefe, Bruyette & Woods, Inc., JMP Securities LLC, Raymond James & Associates, Inc. and SMBC Nikko Securities America, Inc., as placement agents, in connection with the issuance and sale by the Company of shares of common stock, having an aggregate offering price of up to \$125.0\$ million. The equity distribution agreement was amended on February 8, 2023 to allow for the sale of shares of the Company's common stock having an aggregate offering price of up to \$125\$ million under the Company's current registration statement and on August 8, 2023 to add Jefferies LLC as an additional placement agent and to remove SMBC Nikko Securities America, Inc. as a placement agent. Sales of the common stock may be made in negotiated transactions or transactions that are deemed to be at the market, as defined in Rule 415 under the Securities Act of 1933, as amended, including sales made directly on the Nasdaq Global Select Market or similar securities exchanges or sales made to or through a market maker other than on an exchange, at prices related to the prevailing market prices or at negotiated prices. In connection with the "at the market" offering, the Company issued and sold 4,724,506 shares of common stock during the nine months ended June 30, 2024 for net proceeds of \$92.5\$ million (net of offering costs). Number of Shares IssuedGross ProceedsPlacement Agent FeesNet Proceeds (1)Average Sales Price per Share (2)"At the market" offering4,724,506\$93,685\$937\$92,748\$19.83\$ (1) Net proceeds excludes offering costs of \$0.2\$ million. (2) Represents the gross sales price before deducting placement agent fees and estimated offering expenses. In connection with the "at the market" offering, the Company did not issue or sell any shares of common stock during the nine months ended June 30, 2023. X - ReferencesNo definition available. + Details Name: us-gaap StockholdersEquityNoteAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for equity. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph \(h\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481062/946-235-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481062/946-235-50-2)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481062/946-235-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481062/946-235-50-2)Reference 6: <http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481004/946-505-50-6>Reference 7: [http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6](http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.3-04\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(e\)\(1\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(e)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1)Reference 10: <http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/505/tableOfContent>Reference 11: <http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13>Reference 12: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph \(g\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13)Reference 13: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph \(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13)Reference 14: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14)Reference 15: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14)Reference 16: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 16 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 16 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16)Reference 17: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18)Reference 18: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18)Reference 19: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18)Reference 20: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18)Reference 21: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18)Reference 22: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18)Reference 23: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18)Reference 24: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18)Reference 25: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18)Reference 26: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18)Reference 27: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18)Reference 28: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18)Reference 29: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18)Reference 30: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18)Reference 31: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18)Reference 32: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18)Reference 33: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18)Reference 34: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18)Reference 35: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18)Reference 36: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18)Reference 37: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18)Reference 38: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18)Reference 39: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18)Reference 40: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18)Reference 41: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18)Reference 42: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18)Reference 43: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18)Reference 44: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18)Reference 45: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18)Reference 46: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18)Reference 47: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18)Reference 48: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18)Reference 49: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18)Reference 50: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18)Reference 51: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18)Reference 52: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18)Reference 53: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18)Reference 54: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18)Reference 55: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18)Reference 56: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18)Reference 57: [http://www.xbrl](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18)

enture contains certain covenants, including covenants requiring the Company to comply with the asset coverage requirements set forth in Section 18(a)(1)(A) as modified by Section 61(a)(1) and (2) of the Investment Company Act or any successor provisions (but giving effect to any exemptive relief granted to the Company by the SEC), as well as covenants requiring the Company to provide financial information to the holders of the 2027 Notes and the Trustee if the Company ceases to be subject to the reporting requirements of the Exchange Act. These covenants are subject to limitations and exceptions that are described in the 2027 Notes Indenture. In connection with the 2027 Notes, the Company entered into an interest rate swap to more closely align the interest rates of its liabilities with its investment portfolio, which consists of predominately floating rate loans. Under the interest rate swap agreement, the Company receives a fixed interest rate of 2.700% and pays a floating interest rate of the three-month SOFR plus 1.658% plus a SOFR adjustment of 0.26161% on a notional amount of \$350.0A million. The Company designated the interest rate swap as the hedging instrument in an effective hedge accounting relationship. See Note 12 for more information regarding the interest rate swap. 2029 Notes On August 15, 2023, the Company issued \$300.0A million in aggregate principal amount of the 2029 Notes for net proceeds of \$292.9A million after deducting OID of \$3.5A million, underwriting commissions and discounts of \$3.0A million and offering costs of \$0.6A million. The OID on the 2029 Notes is amortized based on the effective interest method over the term of the 2029 Notes. The 2029 Notes were issued pursuant to an indenture, dated April 30, 2012, as supplemented by the seventh supplemental indenture, dated August 15, 2023 (collectively, the "2029 Notes Indenture"), between the Company and the Trustee. The 2029 Notes are the Company's general unsecured obligations that rank senior in right of payment to all of the Company's existing and future indebtedness that is expressly subordinated in right of payment to the 2029 Notes. The 2029 Notes rank equally in right of payment with all of the Company's existing and future liabilities that are not so subordinated. The 2029 Notes effectively rank junior to any of the Company's secured indebtedness (including unsecured indebtedness that the Company later secures) to the extent of the value of the assets securing such indebtedness. The 2029 Notes rank structurally junior to all existing and future indebtedness (including trade payables) incurred by the Company's subsidiaries, financing vehicles or similar facilities. Interest on the 2029 Notes is paid semi-annually on February 15 and August 15 at a rate of 7.100% per annum. The 2029 Notes mature on February 15, 2029 and may be redeemed in whole or in part at any time or from time to time at the Company's option prior to maturity at par plus a 4œmœake-wholeœ premium, if applicable. In addition, holders of the 2029 Notes can require the Company to repurchase the 2029 Notes at 100% of their principal amount upon the occurrence of certain change of control events as described in the 2029 Notes Indenture. The 2029 Notes were issued in minimum denominations of \$2,000 and integral multiples of \$1,000 in excess thereof. During the three and nine months ended JuneA 30, 2024, the Company did not repurchase any of the 2029 Notes in the open market. The 2029 Notes Indenture contains certain covenants, including covenants requiring the Company's compliance with the asset coverage requirements set forth in Section 18(a)(1)(A) as modified by Section 61(a)(1) and (2) of the Investment Company Act or any successor provisions (but giving effect to any exemptive relief granted to the Company by the SEC), as well as covenants requiring the Company to provide financial information to the holders of the 2029 Notes and the Trustee if the Company ceases to be subject to the reporting requirements of the Exchange Act. These covenants are subject to limitations and exceptions that are described in the 2029 Notes Indenture. In connection with the 2029 Notes, the Company entered into an interest rate swap to more closely align the interest rates of its liabilities with its investment portfolio, which consists of predominately floating rate loans. Under the interest rate swap agreement, the Company receives a fixed interest rate of 7.100% and pays a floating interest rate of the three-month SOFR plus 3.1255% on a notional amount of \$300.0A million. The Company designated the interest rate swap as the hedging instrument in an effective hedge accounting relationship. See Note 12 for more information regarding the interest rate swap. The below table presents the components of the carrying value of the 2025 Notes, the 2027 Notes and the 2029 Notes as of JuneA 30, 2024 and SeptemberA 30, 2023:As of June 30, 2024As of September 30, 2023(In millions)2025 Notes2027 Notes2029 Notes2025 Notes2027 Notes2029 NotesPrincipals\$300.0A \$350.0A \$300.0A \$300.0A \$350.0A \$300.0A \$A Unamortized financing costs(0.5)(1.9)(3.0)(1.1)(2.5)(3.5)\$A Unaccrued discount(0.3)(0.5)(2.9)(0.7)(0.6)(3.4)\$A Interest rate swap fair value adjustment\$A (30.7)(3.0)\$A (40.5)(7.0)Net carrying values\$299.2A \$316.9A \$291.1A \$298.2A \$306.4A \$286.1A Fair Values\$294.9A \$317.7A \$303.6A \$286.4A \$301.8A \$290.0A The below table presents the components of interest and other debt expenses related to the 2025 Notes, the 2027 Notes and the 2029 Notes for the three and nine months ended JuneA 30, 2024:(\$ in millions)2025 Notes2027 Notes2029 NotesThree months ended June 30, 2024Nine months ended June 30, 2024Three months ended June 30, 2024Nine months ended June 30, 2024Coupon interests\$2.6A \$7.9A \$2.4A \$7.1A \$5.3A \$16.0A Amortization of financing costs and discount\$3.0A 0.9A 0.2A 0.7A 0.3A 1.0A Effect of interest rate swap \$A \$A \$A 4.0A 12.3A 1.1A 3.4A \$A Total interest expense\$5.9A \$8.8A \$6.6A \$20.1A \$6.7A \$20.4A Coupon interest rate (net of effect of interest rate swaps)\$3.500A %3.500A %7.213A %6.262A %8.440A %8.469A %The below table presents the components of interest and other debt expenses related to the 2025 Notes and the 2027 Notes for the three and nine months ended JuneA 30, 2023:(\$ in millions)2025 Notes2027 NotesThree months ended June 30, 2023Nine months ended June 30, 2023Three months ended June 30, 2023Nine months ended June 30, 2023Coupon interests\$2.6A \$7.9A \$2.4A \$7.1A \$5.3A \$16.0A Amortization of financing costs and discount\$3.0A 0.9A 0.2A 0.7A Effect of interest rate swap \$A \$A \$A 3.7A 9.4A \$A Total interest expense\$5.9A \$8.8A \$6.3A \$17.2A \$6.0A \$20.4A Coupon interest rate (net of effect of interest rate swap for 2027 Notes)\$3.500A %3.500A %6.912A %6.274A %X - ReferencesNo definition available. + Details Name: us-gaap DebtDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrl:stringItem Type Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants. + ReferencesReference 1:

aggregate net realized loss of \$10.6Å million, which consisted of the following:(\$ in millions)Portfolio CompanyNet Realized Gain (Loss)Foreign currency forward contracts\$6.3)Aden & Anais Merger Sub Inc.(5.2)Radiology Partners Inc.(3.8)WP CPP Holdings LLC(1.3)Tersera Therapeutics LLC5.2Å Other, net 0.8Å Total, net\$(10.6)During the nine months ended JuneÅ 30, 2024, the Company recorded an aggregate net realized loss of \$84.5 million, which consisted of the following:(\$ in millions)Portfolio CompanyNet Realized Gain (Loss)Thrasio, LLCs(68.5)All Web Leads Inc(13.4)Continental Intermodal Group LP(6.8)P&L Development LLC(1.9)American Tire Distributors Inc.(1.8)Zephyr Bidco Limited (1)(1.7)Lift Brands Holdings, Inc. (1.4)Alvotech4.8Å Ardongah Midco 3 PLC (14.6)Å Foreign currency forward contracts2.6Å Other, net (1.0)Total, net\$(84.5) (1) This investment was denominated in foreign currency and the realized gain (loss) shown in this table includes gains (losses) due to foreign currency translation, which was offset by gains (losses) on foreign currency forward contracts.During the nine months ended JuneÅ 30, 2023, the Company recorded an aggregate net realized loss of \$19.9Å million, which consisted of the following:(\$ in millions)Portfolio CompanyNet Realized Gain (Loss)Foreign currency forward contracts\$(5.5)Aden & Anais Merger Sub Inc.(5.2)Radiology Partners Inc.(4.2)Carvana Co. (2.8)ASP Unifrax Holdings Inc.(2.1)WP CPP Holdings LLC(1.3)Global Medical Response Inc.(1.0)Tersera Therapeutics LLC5.2Å Other, net (3.0)Total, net\$(19.9)Net Unrealized Appreciation or Depreciation Net unrealized appreciation or depreciation reflects the net change in the valuation of the portfolio pursuant to the Company's valuation guidelines and the reclassification of any prior period unrealized appreciation or depreciation.During the three months ended JuneÅ 30, 2024 and 2023, the Company recorded net unrealized appreciation (depreciation) of \$26.2 million and \$(1.0)Å million, respectively. For the three months ended JuneÅ 30, 2024, this consisted of \$83.6 million of net unrealized appreciation related to exited investments (a portion of which resulted in a reclassification to realized losses) and \$1.1 million of net unrealized appreciation of foreign currency forward contracts, partially offset by \$38.6 million of net unrealized depreciation on debt investments and \$19.9 million of net unrealized depreciation on equity investments. For the three months ended JuneÅ 30, 2023, this consisted of \$9.8Å million of net unrealized depreciation on debt investments and \$0.8Å million of net unrealized depreciation on equity investments, partially offset by \$5.0Å million of net unrealized appreciation related to exited investments (a portion of which resulted in a reclassification to realized losses) and \$4.6Å million of net unrealized appreciation of foreign currency forward contracts.During the nine months ended JuneÅ 30, 2024 and 2023, the Company recorded net unrealized depreciation of \$24.1 million and \$42.3Å million, respectively. For the nine months ended JuneÅ 30, 2024, this consisted of \$49.6 million of net unrealized depreciation on debt investments, \$30.5 million of net unrealized depreciation on equity investments and \$4.5 million of net unrealized depreciation of foreign currency forward contracts, partially offset by \$60.5 million of net unrealized appreciation related to exited investments (a portion of which resulted in a reclassification to realized losses). For the nine months ended JuneÅ 30, 2023, this consisted of \$54.3Å million of net unrealized depreciation on debt investments and \$4.8Å million of net unrealized depreciation of foreign currency forward contracts, partially offset by \$11.8Å million of net unrealized appreciation related to exited investments (a portion of which resulted in a reclassification to realized losses) and \$5.1Å million of net unrealized appreciation on equity investments. X - DefinitionInvestment Company, Realized Gains (Losses) And Net Unrealized Appreciation (Depreciation) + ReferencesNo definition available. + Details Name: ocsI_InvestmentCompanyRealizedGainsLossesAndNetUnrealizedAppreciationDepreciationTextBlock Namespace Prefix: ocsI_Data Type: dtr-types:1:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_InvestmentCompanyAbstract Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 29 R18.htm IDEA: XBRL DOCUMENT US.24.2 Concentration of Credit Risks 9 Months Ended Jun. 30, 2024 Risks and Uncertainties [Abstract] Å Concentration of Credit Risks Concentration of Credit Risks The Company deposits its cash with financial institutions and at times such balances are in excess of the FDIC insurance limit. The Company limits its exposure to credit loss by depositing its cash with high credit quality financial institutions and monitoring their financial stability. X - DefinitionThe entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 275 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/275/tableOfContent + Details Name: us-gaap_ConcentrationRiskDisclosureTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_RisksAndUncertaintiesAbstract Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 30 R19.htm IDEA: XBRL DOCUMENT US.24.2 Related Party Transactions 9 Months Ended Jun. 30, 2024 Related Party Transactions [Abstract] Å Related Party Transactions Related Party TransactionsAs of JuneÅ 30, 2024 and SeptemberÅ 30, 2023, the Company had a liability on its Consolidated Statements of Assets and Liabilities in the amount of \$15.4 million and \$19.5Å million, respectively, reflecting the unpaid portion of the base management fees and incentive fees payable to Oaktree. Investment Advisory AgreementThe Company is party to the Investment Advisory Agreement. Under the Investment Advisory Agreement, the Company pays Oaktree a fee for its services under the Investment Advisory Agreement consisting of two components: a base management fee and an incentive fee. The cost of both the base management fee payable to Oaktree and any incentive fees earned by Oaktree is ultimately borne by common stockholders of the Company.The investment advisory agreement with Oaktree was amended and restated on March 19, 2021 in connection with the closing of the OCSI Merger and on January 23, 2023 in connection with the closing of OSI2 Merger. The term "Investment Advisory Agreement" refers collectively to the agreements with Oaktree. Unless earlier terminated as described below, the Investment Advisory Agreement will remain in effect from year-to-year if approved annually by the Board of Directors of the Company or by the affirmative vote of the holders of a majority of the Company's outstanding voting securities, including, in either case, approval by a majority of the directors of the Company who are not interested persons. The Investment Advisory Agreement will automatically terminate in the event of its assignment. The Investment Advisory Agreement may be terminated by either party without penalty upon 60 days' written notice to the other. The Investment Advisory Agreement may also be terminated, without penalty, upon the vote of a majority of the outstanding voting securities of the Company.Base Management FeeUnder the Investment Advisory Agreement, the base management fee is calculated at an annual rate of 1.50% of total gross assets, including any investment made with borrowings, but excluding cash and cash equivalents. The base management fee is payable quarterly in arrears and the fee for any partial month or quarter is appropriately prorated. Effective May 3, 2019 and through JuneÅ 30, 2024, the base management fee on the Company's gross assets, including any investments made with borrowings, but excluding any cash and cash equivalents, that exceed the product of (A) 200% and (B) the Company's net asset value will be 1.00%.Å For the avoidance of doubt, the 200% will be calculated in accordance with the Investment Company Act and will give effect to exemptive relief the Company received from the SEC with respect to debentures issued by a small business investment company subsidiary. In connection with the OCSI Merger, Oaktree waived an aggregate of \$6Å million of base management fees otherwise payable to Oaktree in the two years following the closing of the OCSI Merger on March 19, 2021 at a rate of \$750,000 per quarter (with such amount appropriately prorated for any partial quarter). In connection with the OSI2 Merger, Oaktree waived an aggregate of \$9.0Å million of base management fees payable to Oaktree as follows: \$6.0Å million at a rate of \$1.5Å million per quarter (with such amount appropriately prorated for any partial quarter) in the first year following closing of the OSI2 Merger on January 23, 2023 and \$3.0Å million at a rate of \$750,000 per quarter (with such amount appropriately prorated for any partial quarter) in the second year following closing of the OSI2 Merger. On April 26, 2024, Oaktree waived additional base management fees such that the total amount of waived base management fees (including those waived in connection with the OSI2 Merger described above) was \$1.5Å million for each of the three months ended March 31, 2024 and June 30, 2024. In addition, effective July 1, 2024, the base management fee is calculated (net of base management fees previously waived by Oaktree) at an annual rate of 1.00% of total gross assets, including any investments made with borrowings, but excluding cash and cash equivalents. For the three and nine months ended JuneÅ 30, 2024, the base management fee incurred under the Investment Advisory Agreement was \$10.3Å million (net of waiver) and \$30.4 million (net of waiver), respectively. For the three and nine months ended JuneÅ 30, 2023, the base management fee incurred under the Investment Advisory Agreement was \$10.5Å million (net of waiver) and \$29.4Å million (net of waiver), respectively.Incentive FeeThe incentive fee consists of two parts. Under the Investment Advisory Agreement, the first part of the incentive fee (the "incentive fee on income" or "Part I incentive fee") is calculated and payable quarterly in arrears based upon the "pre-incentive fee net investment income" of the Company for the immediately preceding quarter. The payment of the incentive fee on income is subject to payment of a preferred return to investors each quarter (i.e., a "hurdle rate"), expressed as a rate of return on the value of the Company's net assets at the end of the most recently completed quarter, of 1.50%, subject to a "catch-up" feature. For this purpose, "pre-incentive fee net investment income" means interest income, dividend income and any other income (including any other fees such as commitment, origination, structuring, diligence and consulting fees or other fees that the Company receives from portfolio companies, other than fees for providing managerial assistance) accrued during the fiscal quarter, minus the Company's operating expenses for the quarter (including the base management fee, expenses payable under the Administration Agreement and any interest expense and dividends paid on any issued and outstanding preferred stock, but excluding the incentive fee). Pre-incentive fee net investment income includes, in the case of investments with a deferred interest feature (such as OID debt, instruments with PIK interest and zero coupon securities), accrued income that the Company has not yet received in cash. Pre-incentive fee net investment income does not include any realized capital gains, realized capital losses or unrealized capital appreciation or depreciation. In addition, pre-incentive fee net investment income does not include any amortization or accretion of any purchase premium or purchase discount to interest income resulting solely from merger-related accounting adjustments in connection with the assets acquired in the OCSI Merger or in the OSI2 Merger, in each case, including any premium or discount paid for the acquisition of such assets, solely to the extent that the inclusion of such merger-related accounting adjustments, in the aggregate, would result in an increase in pre-incentive fee net investment income.Under the Investment Advisory Agreement, the calculation of the incentive fee on income for each quarter is as follows:Å No incentive fee is payable to Oaktree in any quarter in which the Company's pre-incentive fee net investment income does not exceed the preferred return rate of 1.50% (the "preferred return") on net assets;Å 100% of the Company's pre-incentive fee net investment income, if any, that exceeds the preferred return but is less than or equal to 1.8182% in any fiscal quarter is payable to Oaktree. This portion of the incentive fee on income is referred to as the "catch-up" provision, and it is intended to provide Oaktree with an incentive fee of 17.5% on all of the Company's pre-incentive fee net investment income when the Company's pre-incentive fee net investment income exceeds 1.8182% on net assets in any fiscal quarter; andÅ For any quarter in which the Company's pre-incentive fee net investment income exceeds 1.8182% on net assets, the incentive fee on income is equal to 17.5% of the amount of the Company's pre-incentive fee net investment income, as the preferred return and catch-up will have been achieved.There is no accumulation of amounts on the hurdle rate from quarter to quarter and accordingly there is no clawback of amounts previously paid if subsequent quarters are below the quarterly hurdle. For the three months ended JuneÅ 30, 2024, Oaktree waived \$3.2Å million of Part I incentive fees. For the three and nine months ended JuneÅ 30, 2024, the first part of the incentive fee (incentive fee on income) incurred under the Investment Advisory Agreement was \$5.1Å million (net of waiver) and \$22.6Å million (net of waiver), respectively. For the three and nine months ended JuneÅ 30, 2023, the first part of the incentive fee (incentive fee on income) incurred under the Investment Advisory Agreement was \$9.6Å million and \$26.3Å million, respectively. Under the Investment Advisory Agreement, the second part of the incentive fee (the "capital gains incentive fee") is determined and payable in arrears as of the end of each fiscal year (or upon termination of the Investment Advisory Agreement, as of the termination date) commencing with the fiscal year ended September 30, 2019 and equals 17.5% of the Company's realized capital gains, if any, on a cumulative basis from the beginning of the fiscal year ended September 30, 2019 through the end of each subsequent fiscal year, computed net of all realized capital losses and unrealized capital depreciation on a cumulative basis, less the aggregate amount of any previously paid capital gain incentive fees under the Investment Advisory Agreement. Any realized capital gains, realized capital losses, unrealized capital appreciation and unrealized capital depreciation with respect to the Company's portfolio as of the end of the fiscal year ended SeptemberÅ 30, 2018 are excluded from the calculations of the second part of the incentive fee. In addition, the calculation of realized capital gains, realized capital losses and unrealized capital depreciation does (1) not include any such amounts resulting solely from merger-related accounting adjustments in connection with the assets acquired in the OCSI Merger or in the OSI2 Merger, in each case, including any premium or discount paid for the acquisition of such assets, solely to the extent that the inclusion of such merger-related accounting adjustments, in the aggregate, would result in an increase in the capital gains incentive fee, (2) include any such amounts associated with the investments acquired in the OCSI Merger for the period from October 1, 2018 to the date of closing of the OCSI Merger, solely to the extent that the exclusion of such amounts, in the aggregate, would result in an increase in the capital gains incentive fee and (3) include any such amounts associated with the investments acquired in the OSI2 Merger for the period from August 6, 2018 to the date of closing of the OSI2 Merger, solely to the extent that the exclusion of such amounts, in the aggregate, would result in an increase in the capital gains incentive fee. As of JuneÅ 30, 2024, the Company paid \$9.6Å million of capital gains incentive fees cumulatively under the Investment Advisory Agreement (net of waivers). Part II incentive fees are contractually calculated and paid at the end of the fiscal year in accordance with the Investment Advisory Agreement, which, as described above, differs from Part II incentive fees accrued under GAAP. Hypothetically, if Part II incentive fees were calculated as of JuneÅ 30, 2024 under the Investment Advisory Agreement, no Part II incentive fees would be payable. GAAP requires that the capital gains incentive fee accrual consider the cumulative aggregate unrealized capital appreciation in the calculation, as a capital gains incentive fee would be payable if such unrealized capital appreciation were realized on a theoretical "liquidation basis." A fee so calculated and accrued would not be payable under applicable law and may never be paid based upon the computation of capital gains incentive fees in subsequent periods. Amounts ultimately paid under the Investment Advisory Agreement will be consistent with the formula reflected in the Investment Advisory Agreement. This GAAP accrual is calculated using the aggregate cumulative realized capital gains and losses and aggregate cumulative unrealized capital depreciation included in the calculation of the capital gains incentive fee plus the aggregate cumulative unrealized capital appreciation. Any realized capital gains and losses and cumulative unrealized capital appreciation and depreciation with respect to the Company's portfolio as of the end of the fiscal year ended September 30, 2018 are excluded from the GAAP accrual. If such amount is positive at the end of a period, then GAAP requires the Company to record a capital gains incentive fee equal to 17.5% of such cumulative amount, less the aggregate amount of actual capital gains incentive fees payable or capital gains incentive fees accrued under GAAP in all prior periods. The resulting accrual for any capital gains incentive fee under GAAP in a given period may result in an additional expense if such cumulative amount is greater than in the prior period or a reversal of previously recorded expense if such cumulative amount is less than in the prior period. If such cumulative amount is negative, then there is no accrual. There can be no assurance that such unrealized capital appreciation will be realized in the future or any accrued capital gains incentive fee will become payable under the Investment Advisory Agreement. For the three and nine months ended JuneÅ 30, 2024 and 2023, there were no accrued capital gains incentive fees. As of JuneÅ 30, 2024, the total accrued capital gains incentive fee liability was zero.IndemnificationThe Investment Advisory Agreement provides that, absent willful misfeasance, bad faith or gross negligence in the performance of their respective duties or by reason of the reckless disregard of their respective duties and obligations, Oaktree and its officers, managers, partners, members (and their members, including the owners of their members), agents, employees, controlling persons and any other person or entity affiliated with it, are entitled to indemnification from the Company for any damages, liabilities, costs and expenses (including reasonable attorneys' fees and amounts reasonably paid in settlement) arising from the rendering of Oaktree's services under the Investment Advisory Agreement or otherwise as investment adviser.Administrative ServicesThe Company is party to the Administration Agreement with Oaktree Administrator. Pursuant to the Administration Agreement, Oaktree Administrator provides administrative services to the Company necessary for the operations of the Company, which include providing office facilities, equipment, clerical, bookkeeping and record keeping services at such facilities and such other services as Oaktree Administrator, subject to review by the Company's Board of Directors, shall from time to time deem to be necessary or useful to perform its obligations under the Administration Agreement. Oaktree Administrator may, on behalf of the Company, conduct relations and negotiate agreements with custodians, trustees, depositories, attorneys, underwriters, brokers and dealers, corporate fiduciaries, insurers, banks and such other persons in any such other capacity deemed to be necessary or desirable. Oaktree Administrator makes reports to the Company's Board of Directors of its performance of obligations under the Administration Agreement and furnishes advice and recommendations with respect to such other aspects of the Company's business and affairs, in each case, as it shall determine to be desirable or as reasonably required by the Company's Board of Directors; provided that Oaktree Administrator shall not provide any investment advice or recommendation.Oaktree Administrator also provides portfolio collection functions for interest income, fees and warrants and is responsible for the financial and other records that the Company is required to maintain and prepares, prints and disseminates reports to the Company's stockholders and all other materials filed with the SEC. In addition, Oaktree Administrator assists the Company in determining and publishing the Company's net asset

value, overseeing the preparation and filing of the Company's tax returns, and generally overseeing the payment of the Company's expenses and the performance of administrative and professional services rendered to the Company by others. Oaktree Administrator may also offer to provide, on the Company's behalf, managerial assistance to the Company's portfolio companies. For providing these services, facilities and personnel, the Company reimburses Oaktree Administrator the allocable portion of overhead and other expenses incurred by Oaktree Administrator in performing its obligations under the Administration Agreement, including the Company's allocable portion of the rent of the Company's principal executive offices (which are located in a building owned by a Brookfield affiliate) at market rates and the Company's allocable portion of the costs of compensation and related expenses of its Chief Financial Officer, Chief Compliance Officer, their staffs and other non-investment professionals at Oaktree that perform duties for the Company. Such reimbursement is at cost, with no profit to, or markup by, Oaktree Administrator. The Administration Agreement may be terminated by either party without penalty upon 60 days' written notice to the other. The Administration Agreement may also be terminated, without penalty, upon the vote of a majority of the Company's outstanding voting securities. For the three months ended June 30, 2024 and 2023, the Company accrued administrative expenses of \$0.5 million and \$0.4 million, respectively, including \$0.1 million and \$0.1 million of general and administrative expenses, respectively. For the nine months ended June 30, 2024 and 2023, the Company accrued administrative expenses of \$1.3 million and \$1.2 million, respectively, including \$0.3 million and \$0.2 million of general and administrative expenses, respectively. As of June 30, 2024 and September 30, 2023, \$4.8 million and \$4.3 million, respectively, was included in Due to affiliate in the Consolidated Statements of Assets and Liabilities, reflecting the unpaid portion of administrative expenses and other reimbursable expenses payable to Oaktree Administrator. X - References No definition available. + Details Name: us-gaap RelatedPartyTransactionsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - Definition The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates. + References Reference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2> Reference 2: <http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5> Reference 3: <http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6> Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481062/946-235-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481062/946-235-50-2) Reference 5: [http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1) Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(e\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1) Reference 7: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(e\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1) Reference 8: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(e\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1) Reference 9: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(e\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1) Reference 10: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(e\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1) Reference 11: <http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6> Reference 12: [http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1) Reference 13: [http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1) + Details Name: us-gaap RelatedPartyTransactionsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 31 R20.htm IDEA: XBRL DOCUMENT v3.24.2 Financial Highlights 9 Months Ended Jun. 30, 2024 Investment Company [Abstract] A Financial Highlights Financial Highlights (Share amounts in thousands) Three months ended June 30, 2024 Three months ended June 30, 2023 Nine months ended June 30, 2024 Nine months ended June 30, 2023 (6) Net asset value per share at beginning of period \$18.72 \$19.66 \$19.63 \$20.38 Net investment income (1) \$0.540 \$0.631 \$0.819 Net unrealized appreciation (depreciation) (1) 0.33 (0.02) (0.28) (0.36) Net realized gains (losses) (1) (0.85) (0.14) (1.06) (0.28) (Provision) benefit for taxes on realized and unrealized gains (losses) (1) \$1.19 \$1.58 \$1.19 \$1.58 Per share market value at beginning of period \$19.66 \$18.77 \$20.12 \$18.00 Per share market value at end of period \$18.81 \$19.43 \$19.43 Total return (2) (1.51)% (6.42)% (2.13)% (19.58)% Common shares outstanding at beginning of period 81,396,777,080 77,225,611,255 Common shares outstanding at end of period 82,245,777,080 82,245,777,080 Net assets at beginning of period \$1,524,099 \$1,515,150 \$1,515,764 \$1,245,563 Net assets at end of period \$1,496,133 \$1,509,441 \$1,496,133 \$1,509,441 Average net assets (3) \$1,524,099 \$1,524,099 \$1,524,099 \$1,524,099 Ratio of net investment income to average net assets (7) 11.76% 12.72% 11.40% 12.65% Ratio of total expenses to average net assets (7) 14.45% 14.45% 14.47% Ratio of net expenses to average net assets (7) 13.29% 14.05% 13.75% 13.69% Ratio of portfolio turnover to average investments at fair value 5.95% 7.48% 23.97% 18.43% Weighted average outstanding debt (4) \$1,711,978 \$1,756,758 \$1,680,876 \$1,640,062 Average debt per share (1) \$20.92 \$22.79 \$21.06 \$23.29 Asset coverage ratio at end of period (5) 183.36% 182.05% 183.36% 182.05% (1) Calculated based upon weighted average shares outstanding for the period. (2) Total return equals the increase or decrease of ending market value over beginning market value, plus distributions, divided by the beginning market value, assuming dividend reinvestment prices obtained under the Company's DRIP. Total return does not include sales load. (3) Calculated based upon the weighted average net assets for the period. (4) Calculated based upon the weighted average of principal debt outstanding for the period. (5) Based on outstanding senior securities of \$1,743.4 million and \$1,785.0 million as of June 30, 2024 and 2023, respectively. (6) The share and per share information disclosed in this table has been retroactively adjusted as necessary to reflect the Company's 1-for-3 reverse stock split completed on January 20, 2023 and effective as of the commencement of trading on January 23, 2023. (7) Interim periods are annualized. X - References No definition available. + Details Name: us-gaap InvestmentCompanyAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - Definition The entire disclosure of financial highlights reported by investment company. + References Reference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480737/946-205-50-7](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480737/946-205-50-7) Reference 2: <http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-7> Reference 3: <http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480737/946-205-50-1> Reference 4: <http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 50 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480737/946-205-50-24> + Details Name: us-gaap InvestmentCompanyFinancialHighlightsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 32 R21.htm IDEA: XBRL DOCUMENT v3.24.2 Derivative Instruments 9 Months Ended Jun. 30, 2024 Derivative Instruments and Hedging Activities Disclosure [Abstract] A Derivative Instruments Derivative Instruments The Company enters into foreign currency forward contracts from time to time to help mitigate the impact that an adverse change in foreign exchange rates would have on the value of the Company's investments denominated in foreign currencies. In order to better define its contractual rights and to secure rights that will help the Company mitigate its counterparty risk, the Company entered into an International Swaps and Derivatives Association, Inc. Master Agreement (the "ISDA Master Agreement") with its derivative counterparty, JPMorgan Chase Bank, N.A. The ISDA Master Agreement permits a single net payment in the event of a default or similar event. As of June 30, 2024, no cash collateral has been pledged to cover obligations and no cash collateral has been received from the counterparty with respect to the Company's forward currency contracts. Certain information related to the Company's foreign currency forward contracts is presented below as of June 30, 2024. Description Notional Amount to be Purchased Notional Amount to be Sold Maturity Date Gross Amount of Recognized Assets Gross Amount of Recognized Liabilities Balance Sheet Location of Net Amounts Foreign currency forward contract \$54,193.4 - \$49,683.8 8/8/2024 \$49.4 \$49.4 Derivative asset Foreign currency forward contract \$55,206.4 \$49.4 8/8/2024 \$49.4 \$49.4 Derivative liability \$849.4 \$413.4 Certain information related to the Company's foreign currency forward contracts is presented below as of September 30, 2023. Description Notional Amount to be Purchased Notional Amount to be Sold Maturity Date Gross Amount of Recognized Assets Gross Amount of Recognized Liabilities Balance Sheet Location of Net Amounts Foreign currency forward contract \$42,182.4 - \$38,026.4 11/9/2023 \$1,857.4 \$1,857.4 Derivative asset Foreign currency forward contract \$72,098.4 \$56,556.4 11/9/2023 \$53.4 \$49.4 Derivative asset \$4,910.4 \$49.4 In connection with the issuance of the 2027 Notes and 2029 Notes, the Company entered into interest rate swap agreements with the Royal Bank of Canada pursuant to ISDA Master Agreements. As of June 30, 2024, the Company paid \$30.3 million to the Royal Bank of Canada to cover collateral obligations under the terms of the interest swap agreements, which is included in due from broker on the Consolidated Statement of Assets and Liabilities. Certain information related to the Company's interest rate swaps is presented below as of June 30, 2024. Description Notional Amount Maturity Date Gross Amount of Recognized Assets Gross Amount of Recognized Liabilities Balance Sheet Location of Net Amounts Interest rate swap \$350,000.4 1/15/2027 \$49.4 \$30,683.4 Derivative liability Interest rate swap \$300,000.4 2/15/2029 \$49.4 \$2,989.4 Derivative liability \$49.4 \$33,672.4 Certain information related to the Company's interest rate swap is presented below as of September 30, 2023. Description Notional Amount Maturity Date Gross Amount of Recognized Assets Gross Amount of Recognized Liabilities Balance Sheet Location of Net Amounts Interest rate swap \$350,000.4 1/15/2027 \$49.4 \$40,519.4 Derivative liability Interest rate swap \$300,000.4 2/15/2029 \$49.4 \$7,000.4 Derivative liability \$49.4 \$47,519.4 X - References No definition available. + Details Name: us-gaap DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - Definition The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts. + References Reference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-5C](http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480237/815-40-50-5) Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-5C](http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-5C) Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-5C](http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-5C) Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-5C](http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-5C) Reference 5: [http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-5C](http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-5C) Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-5C](http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-5C) Reference 7: [http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-5C](http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-5C) Reference 8: [http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-5C](http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-5C) Reference 9: [http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-5C](http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-5C) Reference 10: [http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-5C](http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-5C) Reference 11: [http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-5C](http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-5C) Reference 12: [http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-5C](http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-5C) Reference 13: [http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-5C](http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-5C) Reference 14: [http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-5C](http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-5C) Reference 15: [http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-5C](http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-5C) Reference 16: [http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-5C](http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-5C) Reference 17: [http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-5C](http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-5C) Reference 18: [http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-5C](http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-5C) Reference 19: [http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-5C](http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-5C) Reference 20: [http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-5C](http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-5C) Reference 21: [http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-5C](http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-5C) Reference 22: [http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-5C](http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-5C) Reference 23: [http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-5C](http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-5C) Reference 24: [http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-5C](http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-5C) Reference 25: [http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-5C](http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-5C) Reference 26: [http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-5C](http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-5C) Reference 27: [http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-5C](http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-5C) Reference 28: [http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-5C](http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-5C) Reference 29: [http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-5C](http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-5C) Reference 30: [http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-5C](http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-5C) Reference 31: [http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-5C](http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-5C) Reference 32: [http://www.xbrl.org/2003/role/disclosureRef -Topic 815](http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-5C)

[illegible]

[http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReferece 20](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReferece 20): [http://www.xbrl.org/2003/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(ii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReferece 21](http://www.xbrl.org/2003/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReferece 21): [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\(A\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReferece 22](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReferece 22): [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReferece 23](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReferece 23): [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(5\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReferece 24](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReferece 24): [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25): [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(A\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26): [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27): [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28): [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(5\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29): [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 30](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 30): [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 31](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 31): [http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 32](http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 32): <http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31Reference 33>: [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 34](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 34): <http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 35>: <http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 36>: [http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReferece 37](http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReferece 37):

if applicable, as amended (the "Exchange Act"). In addition, holders of the 2025 Notes can require the Company to repurchase the 2025 Notes at 100% of their principal amount upon the occurrence of certain change of control events as described in the 2025 Notes Indenture. The 2025 Notes were issued in minimum denominations of \$2,000 and integral multiples of \$1,000 in excess thereof. During the three and nine months ended June 30, 2024, the Company did not repurchase any of the 2025 Notes in the open market. The 2025 Notes Indenture contains certain covenants, including covenants requiring the Company's compliance with the asset coverage requirements set forth in Section 18(a)(1)(A) as modified by Section 61(a)(1) and (2) of the Investment Company Act or any successor provisions (but giving effect to any exemptive relief granted to the Company by the SEC), as well as covenants requiring the Company to provide financial information to the holders of the 2025 Notes and the Trustee if the Company ceases to be subject to the reporting requirements of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). These covenants are subject to limitations and exceptions that are described in the 2025 Notes Indenture. On May 18, 2021, the Company issued \$350.0A million in aggregate principal amount of the 2027 Notes for net proceeds of \$344.8A million after deducting OID of \$1.0A million, underwriting commissions and discounts of \$3.5A million and offering costs of \$0.7A million. The OID on the 2027 Notes is amortized based on the effective interest method over the term of the 2027 Notes. The 2027 Notes were issued pursuant to an indenture, dated April 30, 2012, as supplemented by the sixth supplemental indenture, dated May 18, 2021 (collectively, the "2027 Notes Indenture"), between the Company and the Trustee. The 2027 Notes are the Company's general unsecured obligations that rank senior in right of payment to all of the Company's existing and future indebtedness that is expressly subordinated in right of payment to the 2027 Notes. The 2027 Notes rank equally in right of payment with all of the Company's existing and future liabilities that are not so subordinated. The 2027 Notes effectively rank junior to any of the Company's secured indebtedness (including unsecured indebtedness that the Company later secures) to the extent of the value of the assets securing such indebtedness. The 2027 Notes rank structurally junior to all existing and future indebtedness (including trade payables) incurred by the Company's subsidiaries, financing vehicles or similar facilities. Interest on the 2027 Notes is paid semi-annually on January 15 and July 15 at a rate of 2.700% per annum. The 2027 Notes mature on January 15, 2027 and may be redeemed in whole or in part at any time or from time to time at the Company's option prior to maturity at par plus a $\frac{1}{4}$ % premium, if applicable. In addition, holders of the 2027 Notes can require the Company to repurchase the 2027 Notes at 100% of their principal amount upon the occurrence of certain change of control events as described in the 2027 Notes Indenture. The 2027 Notes were issued in minimum denominations of \$2,000 and integral multiples of \$1,000 in excess thereof. During the three and nine months ended June 30, 2024, the Company did not repurchase any of the 2027 Notes in the open market. The 2027 Notes Indenture contains certain covenants, including covenants requiring the Company's compliance with the asset coverage requirements set forth in Section 18(a)(1)(A) as modified by Section 61(a)(1) and (2) of the Investment Company Act or any successor provisions (but giving effect to any exemptive relief granted to the Company by the SEC), as well as covenants requiring the Company to provide financial information to the holders of the 2027 Notes and the Trustee if the Company ceases to be subject to the reporting requirements of the Exchange Act. These covenants are subject to limitations and exceptions that are described in the 2027 Notes Indenture. In connection with the 2029 Notes, the Company entered into an interest rate swap to more closely align the interest rates of its liabilities with its investment portfolio, which consists of predominately floating rate loans. Under the interest rate swap agreement, the Company receives a fixed interest rate of 2.700% and pays a floating interest rate of the three-month SOFR plus 1.658% plus a SOFR adjustment of 0.26161% on a notional amount of \$350.0A million. The Company designated the interest rate swap as the hedging instrument in an effective hedge accounting relationship. See Note 12 for more information regarding the interest rate swap. On August 15, 2023, the Company issued \$300.0A million in aggregate principal amount of the 2029 Notes for net proceeds of \$292.9A million after deducting OID of \$3.5A million, underwriting commissions and discounts of \$3.0A million and offering costs of \$0.6A million. The OID on the 2029 Notes is amortized based on the effective interest method over the term of the 2029 Notes. The 2029 Notes were issued pursuant to an indenture, dated April 30, 2012, as supplemented by the seventh supplemental indenture, dated August 15, 2023 (collectively, the "2029 Notes Indenture"), between the Company and the Trustee. The 2029 Notes are the Company's general unsecured obligations that rank senior in right of payment to all of the Company's existing and future indebtedness that is expressly subordinated in right of payment to the 2029 Notes. The 2029 Notes rank equally in right of payment with all of the Company's existing and future liabilities that are not so subordinated. The 2029 Notes effectively rank junior to any of the Company's secured indebtedness (including unsecured indebtedness that the Company later secures) to the extent of the value of the assets securing such indebtedness. The 2029 Notes rank structurally junior to all existing and future indebtedness (including trade payables) incurred by the Company's subsidiaries, financing vehicles or similar facilities. Interest on the 2029 Notes is paid semi-annually on February 15 and August 15 at a rate of 7.100% per annum. The 2029 Notes mature on February 15, 2029 and may be redeemed in whole or in part at any time or from time to time at the Company's option prior to maturity at par plus a $\frac{1}{4}$ % premium, if applicable. In addition, holders of the 2029 Notes can require the Company to repurchase the 2029 Notes at 100% of their principal amount upon the occurrence of certain change of control events as described in the 2029 Notes Indenture. The 2029 Notes were issued in minimum denominations of \$2,000 and integral multiples of \$1,000 in excess thereof. During the three and nine months ended June 30, 2024, the Company did not repurchase any of the 2029 Notes in the open market. The 2029 Notes Indenture contains certain covenants, including covenants requiring the Company's compliance with the asset coverage requirements set forth in Section 18(a)(1)(A) as modified by Section 61(a)(1) and (2) of the Investment Company Act or any successor provisions (but giving effect to any exemptive relief granted to the Company by the SEC), as well as covenants requiring the Company to provide financial information to the holders of the 2029 Notes and the Trustee if the Company ceases to be subject to the reporting requirements of the Exchange Act. These covenants are subject to limitations and exceptions that are described in the 2029 Notes Indenture. In connection with the 2025 Notes, the Company entered into an interest rate swap to more closely align the interest rates of its liabilities with its investment portfolio, which consists of predominately floating rate loans. Under the interest rate swap agreement, the Company receives a fixed interest rate of 7.100% and pays a floating interest rate of the three-month SOFR plus 3.1255% on a notional amount of \$300.0A million. The Company designated the interest rate swap as the hedging instrument in an effective hedge accounting relationship. See Note 12 for more information regarding the interest rate swap. On February 25, 2020, the Company issued \$300.0A million in aggregate principal amount of the 2025 Notes for net proceeds of \$293.8 million after deducting OID of \$2.5A million, underwriting commissions and discounts of \$3.0A million and offering costs of \$0.7 million. The OID on the 2025 Notes is amortized based on the effective interest method over the term of the 2025 Notes. The 2025 Notes were issued pursuant to an indenture, dated April 30, 2012, as supplemented by the fifth supplemental indenture, dated February 25, 2020 (collectively, the "2025 Notes Indenture"), between the Company and Deutsche Bank Trust Company Americas (the "Trustee"). The 2025 Notes are the Company's general unsecured obligations that rank senior in right of payment to all of the Company's existing and future indebtedness that is expressly subordinated in right of payment to the 2025 Notes. The 2025 Notes rank equally in right of payment with all of the Company's existing and future liabilities that are not so subordinated. The 2025 Notes effectively rank junior to any of the Company's secured indebtedness (including unsecured indebtedness that the Company later secures) to the extent of the value of the assets securing such indebtedness. The 2025 Notes rank structurally junior to all existing and future indebtedness (including trade payables) incurred by the Company's subsidiaries, financing vehicles or similar facilities. Interest on the 2025 Notes is paid semi-annually on February 25 and August 25 at a rate of 3.500% per annum. The 2025 Notes mature on February 25, 2025 and may be redeemed in whole or in part at any time or from time to time at the Company's option prior to maturity at par plus a $\frac{1}{4}$ % premium, if applicable. In addition, holders of the 2025 Notes can require the Company to repurchase the 2025 Notes at 100% of their principal amount upon the occurrence of certain change of control events as described in the 2025 Notes Indenture. The 2025 Notes were issued in minimum denominations of \$2,000 and integral multiples of \$1,000 in excess thereof. During the three and nine months ended June 30, 2024, the Company did not repurchase any of the 2025 Notes in the open market. A A A A Long Term Debt, Dividends and Covenants [Text Block] The 2025 Notes Indenture contains certain covenants, including covenants requiring the Company's compliance with the asset coverage requirements set forth in Section 18(a)(1)(A) as modified by Section 61(a)(1) and (2) of the Investment Company Act or any successor provisions (but giving effect to any exemptive relief granted to the Company by the U.S. Securities and Exchange Commission ("SEC")), as well as covenants requiring the Company to provide financial information to the holders of the 2025 Notes and the Trustee if the Company ceases to be subject to the reporting requirements of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). These covenants are subject to limitations and exceptions that are described in the 2025 Notes Indenture. A A A A 2027 Notes [Member] A A A A Capital Stock, Long-Term Debt, and Other Securities [Abstract] A A A A Long Term Debt, Title [Text Block] 2027 Notes A A A A Long Term Debt, Structuring [Text Block] On May 18, 2021, the Company issued \$350.0A million in aggregate principal amount of the 2027 Notes for net proceeds of \$344.8A million after deducting OID of \$1.0A million, underwriting commissions and discounts of \$3.5A million and offering costs of \$0.7A million. The OID on the 2027 Notes is amortized based on the effective interest method over the term of the 2027 Notes. The 2027 Notes were issued pursuant to an indenture, dated April 30, 2012, as supplemented by the sixth supplemental indenture, dated May 18, 2021 (collectively, the "2027 Notes Indenture"), between the Company and the Trustee. The 2027 Notes are the Company's general unsecured obligations that rank senior in right of payment to all of the Company's existing and future indebtedness that is expressly subordinated in right of payment to the 2027 Notes. The 2027 Notes rank equally in right of payment with all of the Company's existing and future liabilities that are not so subordinated. The 2027 Notes effectively rank junior to any of the Company's secured indebtedness (including unsecured indebtedness that the Company later secures) to the extent of the value of the assets securing such indebtedness. The 2027 Notes rank structurally junior to all existing and future indebtedness (including trade payables) incurred by the Company's subsidiaries, financing vehicles or similar facilities. Interest on the 2027 Notes is paid semi-annually on January 15 and July 15 at a rate of 2.700% per annum. The 2027 Notes mature on January 15, 2027 and may be redeemed in whole or in part at any time or from time to time at the Company's option prior to maturity at par plus a $\frac{1}{4}$ % premium, if applicable. In addition, holders of the 2027 Notes can require the Company to repurchase the 2027 Notes at 100% of their principal amount upon the occurrence of certain change of control events as described in the 2027 Notes Indenture. The 2027 Notes were issued in minimum denominations of \$2,000 and integral multiples of \$1,000 in excess thereof. During the three and nine months ended June 30, 2024, the Company did not repurchase any of the 2027 Notes in the open market. A A A A Long Term Debt, Dividends and Covenants [Text Block] The 2027 Notes Indenture contains certain covenants, including covenants requiring the Company's compliance with the asset coverage requirements set forth in Section 18(a)(1)(A) as modified by Section 61(a)(1) and (2) of the Investment Company Act or any successor provisions (but giving effect to any exemptive relief granted to the Company by the SEC), as well as covenants requiring the Company to provide financial information to the holders of the 2027 Notes and the Trustee if the Company ceases to be subject to the reporting requirements of the Exchange Act. These covenants are subject to limitations and exceptions that are described in the 2027 Notes Indenture. A A A A 2029 Notes [Member] A A A A Capital Stock, Long-Term Debt, and Other Securities [Abstract] A A A A Long Term Debt, Title [Text Block] 2029 Notes A A A A Long Term Debt, Structuring [Text Block] On August 15, 2023, the Company issued \$300.0A million in aggregate principal amount of the 2029 Notes for net proceeds of \$292.9A million after deducting OID of \$3.5A million, underwriting commissions and discounts of \$3.0A million and offering costs of \$0.6A million. The OID on the 2029 Notes is amortized based on the effective interest method over the term of the 2029 Notes. The 2029 Notes were issued pursuant to an indenture, dated April 30, 2012, as supplemented by the seventh supplemental indenture, dated August 15, 2023 (collectively, the "2029 Notes Indenture"), between the Company and the Trustee. The 2029 Notes are the Company's general unsecured obligations that rank senior in right of payment to all of the Company's existing and future indebtedness that is expressly subordinated in right of payment to the 2029 Notes. The 2029 Notes rank equally in right of payment with all of the Company's existing and future liabilities that are not so subordinated. The 2029 Notes effectively rank junior to any of the Company's secured indebtedness (including unsecured indebtedness that the Company later secures) to the extent of the value of the assets securing such indebtedness. The 2029 Notes rank structurally junior to all existing and future indebtedness (including trade payables) incurred by the Company's subsidiaries, financing vehicles or similar facilities. Interest on the 2029 Notes is paid semi-annually on February 15

under the agreements governing the facility, which, if not complied with, could accelerate repayment under the facility. As of June 30, 2024, the Company was in compliance with all financial covenants under the Syndicated Facility. In addition to the asset coverage ratio described above, borrowings under the Syndicated Facility (and the incurrence of certain other permitted debt) are subject to compliance with a borrowing base that will apply different advance rates to different types of assets in the Company’s portfolio. Each loan or letter of credit originated or assumed under the Syndicated Facility is subject to the satisfaction of certain conditions. A A A A Citibank Facility [Member] A A A A Capital Stock, Long-Term Debt, and Other Securities [Abstract] A A A A Long Term Debt, Title [Text Block] Citibank Facility A A A A Long Term Debt, Structuring [Text Block] On March 19, 2021, the Company became party to a revolving credit facility (as amended and/or restated from time to time, the Citibank Facility) with OCSL Senior Funding II LLC, the Company’s wholly-owned, special purpose financing subsidiary, as the borrower, the Company, as collateral manager and seller, each of the lenders from time to time party thereto, Citibank, N.A., as administrative agent, and Wells Fargo Bank, National Association, as collateral agent and custodian. On May 25, 2023, in connection with an amendment to the OS12 Citibank Facility, the Citibank Facility was terminated. A A A A OS12 Citibank Facility [Member] A A A A Capital Stock, Long-Term Debt, and Other Securities [Abstract] A A A A Long Term Debt, Title [Text Block] OS12 Citibank Facility A A A A Long Term Debt, Structuring [Text Block] On January 23, 2023, as a result of the consummation of the OS12 Merger, the Company became party to a revolving credit facility (as amended and/or restated from time to time, the OS12 Citibank Facility) with OS1 2 SPV, the Company’s wholly-owned and consolidated subsidiary, as the borrower, the Company, as collateral manager, each of the lenders from time to time party thereto, Citibank, N.A., as administrative agent, and Deutsche Bank Trust Company Americas, as collateral agent. As of June 30, 2024, the Company was able to borrow up to \$400A million under the OS12 Citibank Facility (subject to borrowing base and other limitations). A A A A Long Term Debt, Dividends and Covenants [Text Block] As of June 30, 2024, the OS12 Citibank Facility had a reinvestment period through May 25, 2027, during which advances may be made, and matures on January 26, 2029. Following the reinvestment period, OS1 2 SPV will be required to make certain mandatory amortization payments. Borrowings under the OS12 Citibank Facility bear interest payable quarterly at a rate per year equal to SOFR plus 2.35% per annum. After the reinvestment period, the applicable spread is 3.35% per year. There is also a non-usage fee of 0.50% per year on the unused portion of the OS12 Citibank Facility, payable quarterly; provided that if the unused portion of the OS12 Citibank Facility is greater than 30% of the commitments under the OS12 Citibank Facility, the non-usage fee will be based on an unused portion of 30% of the commitments under the OS12 Citibank Facility. The OS12 Citibank Facility is secured by a first priority security interest in substantially all of OS1 2 SPV’s assets. As part of the OS12 Citibank Facility, OS1 2 SPV is subject to certain limitations as to how borrowed funds may be used and the types of loans that are eligible to be acquired by OS1 2 SPV including restrictions on sector concentrations, loan size, tenor and minimum investment ratings (or estimated ratings). The OS12 Citibank Facility also contains certain requirements relating to interest coverage, collateral quality and portfolio performance, certain violations of which could result in the acceleration of the amounts due under the OS12 Citibank Facility. A A A A [1] As discussed in Note 2, the Company completed a 1-for-3 reverse stock split on January 20, 2023, effective as of the commencement of trading on January 23, 2023. The weighted average common shares outstanding and per share information reflect the reverse stock split on a retroactive basis as necessary.

X - ReferencesReference 1:

be reliable or are not readily available, Oaktree values such investments using any of three different valuation techniques. The first valuation technique is the transaction precedent technique, which utilizes recent or expected future transactions of the investment to determine fair value, to the extent applicable. The second valuation technique is an analysis of the enterprise value ("EV") of the portfolio company. EV means the entire value of the portfolio company to a market participant, including the sum of the values of debt and equity securities used to capitalize the enterprise at a point in time. The EV analysis is typically performed to determine (i) the value of equity investments, (ii) whether there is credit impairment for debt investments and (iii) the value for debt investments that the Company is deemed to control under the Investment Company Act. To estimate the EV of a portfolio company, Oaktree analyzes various factors, including the portfolio company's historical and projected financial results, macroeconomic impacts on the company and competitive dynamics in the company's industry. Oaktree also utilizes some or all of the following information based on the individual circumstances of the portfolio company: (i) valuations of comparable public companies, (ii) recent sales of private and public comparable companies in similar industries or having similar business or earnings characteristics, (iii) purchase prices as a multiple of their earnings or cash flow, (iv) the portfolio company's ability to meet its forecasts and its business prospects, (v) a discounted cash flow analysis, (vi) estimated liquidation or collateral value of the portfolio company's assets and (vii) offers from third parties to buy the portfolio company. Oaktree may probability weight potential sale outcomes with respect to a portfolio company when uncertainty exists as of the valuation date. The third valuation technique is a market yield technique, which is typically performed for non-credit impaired debt investments. In the market yield technique, a current price is imputed for the investment based upon an assessment of the expected market yield for a similarly structured investment with a similar level of risk, and Oaktree considers the current contractual interest rate, the capital structure and other terms of the investment relative to risk of the company and the specific investment. A key determinant of risk, among other things, is the leverage through the investment relative to the EV of the portfolio company. As debt investments held by the Company are substantially illiquid with no active transaction market, Oaktree depends on primary market data, including newly funded transactions and industry specific market movements, as well as secondary market data with respect to high yield debt instruments and syndicated loans, as inputs in determining the appropriate market yield, as applicable. In accordance with ASC 820-10, certain investments that qualify as investment companies in accordance with ASC 946 may be valued using net asset value as a practical expedient for fair value. Consistent with FASB guidance under ASC 820, these investments are excluded from the hierarchical levels. These investments are generally not redeemable. Oaktree estimates the fair value of certain privately held warrants using a Black Scholes pricing model, which includes an analysis of various factors and subjective assumptions, including the current stock price (by using an EV analysis as described above), the expected period until exercise, expected volatility of the underlying stock price, expected dividends and the risk free rate. Changes in the subjective input assumptions can materially affect the fair value estimates. Rule 2a-5 under the Investment Company Act permits boards of directors of registered investment companies and Business Development Companies to either (i) choose to determine fair value in good faith or (ii) designate a valuation designee tasked with determining fair value in good faith, subject to the board's oversight. The Company's Board of Directors has designated Oaktree to serve as its valuation designee effective September 8, 2022. Oaktree undertakes a multi-step valuation process each quarter in connection with determining the fair value of the Company's investments. The quarterly valuation process begins with each portfolio company or investment being initially valued by Oaktree's valuation team. Preliminary valuations are then reviewed and discussed with management of Oaktree. Separately, independent valuation firms prepare valuations of the Company's investments, on a selected basis, for which market quotations are not readily available or are readily available but deemed not reflective of the fair value of the investment, and submit the reports to the Company and provide such reports to Oaktree. Oaktree compares and contrasts its preliminary valuations to the valuations of the independent valuation firms and prepares a valuation report for the Audit Committee. The Audit Committee reviews the valuation report with Oaktree, and Oaktree responds and supplements the valuation report to reflect any discussions between Oaktree and the Audit Committee; and Oaktree, as valuation designee, determines the fair value of each investment in the Company's portfolio. The fair value of the Company's investments as of June 30, 2024 and September 30, 2023 was determined by Oaktree, as the Company's valuation designee. The Company has and will continue to engage independent valuation firms to provide assistance regarding the determination of the fair value of a portion of its portfolio securities for which market quotations are not readily available or are readily available but deemed not reflective of the fair value of the investment each quarter. Due to the inherent uncertainty of determining the fair value of investments that do not have a readily available market value, the fair value of the Company's investments may fluctuate from period to period. Because of the inherent uncertainty of valuation, these estimated values may differ significantly from the values that would have been reported had a ready market for the investments existed, and it is reasonably possible that the difference could be material. With the exception of the line items entitled "deferred financing costs," "deferred offering costs," "other assets," "deferred tax liability," "credit facilities payable" and "unsecured notes payable," which are reported at amortized cost, all assets and liabilities approximate fair value on the Consolidated Statements of Assets and Liabilities. The carrying value of the line items titled "interest, dividends and fees receivable," "due from portfolio companies," "receivables from unsettled transactions," "due from broker," "accounts payable, accrued expenses and other liabilities," "base management fee and incentive fee payable," "due to affiliate," "interest payable" and "payables from unsettled transactions" approximate fair value due to their short maturities. Foreign Currency Translation Foreign Currency Translation: The accounting records of the Company are maintained in U.S. dollars. All assets and liabilities denominated in foreign currencies are translated into U.S. dollars based on the prevailing foreign exchange rate on the reporting date. The Company does not isolate that portion of the results of operations resulting from changes in foreign exchange rates on investments from the fluctuations arising from changes in market prices of securities held. The Company's investments in foreign securities may involve certain risks, including foreign exchange restrictions, expropriation, taxation or other political, social or economic risks, all of which could affect the market and/or credit risk of the investment. In addition, changes in the relationship of foreign currencies to the U.S. dollar can significantly affect the value of these investments and therefore the earnings of the Company. Derivative Instruments Derivative Instruments: Foreign Currency Forward Contracts The Company uses foreign currency forward contracts to reduce the Company's exposure to fluctuations in the value of foreign currencies. In a foreign currency forward contract, the Company agrees to receive or deliver a fixed quantity of one currency for another at a pre-determined price at a future date. Foreign currency forward contracts are marked-to-market at the applicable forward rate. Unrealized appreciation (depreciation) on foreign currency forward contracts is recorded within derivative assets or derivative liabilities on the Consolidated Statements of Assets and Liabilities by counterparty on a net basis, not taking into account collateral posted which is recorded separately, if applicable. Purchases and settlements of foreign currency forward contracts having the same settlement date and counterparty are generally settled net and any realized gains or losses are recognized on the settlement date. The Company does not utilize hedge accounting with respect to foreign currency forward contracts and, as such, the Company recognizes its foreign currency forward contracts at fair value with changes included in the net unrealized appreciation (depreciation) on the Consolidated Statements of Operations. Interest Rate Swaps The Company uses interest rate swaps to hedge some of the Company's fixed rate debt. The Company designated the interest rate swaps as the hedging instruments in an effective hedge accounting relationship, and therefore the periodic payments are recognized as components of interest expense in the Consolidated Statements of Operations. Depending on the nature of the balance at period end, the fair value of each interest rate swap is either included as a derivative asset or derivative liability on the Company's Consolidated Statements of Assets and Liabilities. The change in fair value of the interest rate swaps is offset by a change in the carrying value of the fixed rate debt. Any amounts paid to the counterparty to cover collateral obligations under the terms of the interest rate swap agreements are included in due from broker on the Company's Consolidated Statements of Assets and Liabilities. Investment Income Investment Income: Interest Income Interest income, adjusted for accretion of original issue discount ("OID"), is recorded on an accrual basis to the extent that such amounts are expected to be collected. The Company stops accruing interest on investments when it is determined that interest is no longer collectible. Investments that are expected to pay regularly scheduled interest in cash are generally placed on non-accrual status when there is reasonable doubt that principal or interest cash payments will be collected. Cash interest payments received on investments may be recognized as income or a return of capital depending upon management's judgment. A non-accrual investment is restored to accrual status if past due principal and interest are paid in cash and the portfolio company, in management's judgment, is likely to continue timely payment of its remaining obligations. As of June 30, 2024, there were eight investments on non-accrual status that in aggregate represented 5.7% and 3.7% of total debt investments at cost and fair value, respectively. As of September 30, 2023, there were four investments on non-accrual status that in aggregate represented 2.4% and 1.8% of total debt investments at cost and fair value, respectively. In connection with its investment in a portfolio company, the Company sometimes receives nominal cost equity that is valued as part of the negotiation process with the portfolio company. When the Company receives nominal cost equity, the Company allocates its cost basis in the investment between debt securities and the nominal cost equity at the time of origination. Any resulting discount from recording the loan, or otherwise purchasing a security at a discount, is accreted into interest income over the life of the loan. PIK Interest Income The Company's investments in debt securities may contain PIK interest provisions. PIK interest, which generally represents contractually deferred interest added to the loan balance that is generally due at the end of the loan term, is generally recorded on the accrual basis to the extent such amounts are expected to be collected. The Company generally ceases accruing PIK interest if there is insufficient value to support the accrual or if the Company does not expect the portfolio company to be able to pay all principal and interest due. The Company's decision to cease accruing PIK interest on a loan or debt security involves subjective judgments and determinations based on available information about a particular portfolio company, including whether the portfolio company is current with respect to its payment of principal and interest on its loans and debt securities; financial statements and financial projections for the portfolio company; the Company's assessment of the portfolio company's business development success; information obtained by the Company in connection with periodic formal update interviews with the portfolio company's management and, if appropriate, the private equity sponsor; and information about the general economic and market conditions in which the portfolio company operates. The Company's determination to cease accruing PIK interest is generally made well before the Company's full write-down of a loan or debt security. In addition, if it is subsequently determined that the Company will not be able to collect any previously accrued PIK interest, the fair value of the loans or debt securities would be reduced by the amount of such previously accrued, but uncollectible, PIK interest. The accrual of PIK interest on the Company's debt investments increases the recorded cost basis of these investments in the Consolidated Financial Statements including for purposes of computing the capital gains incentive fee payable by the Company to Oaktree. To maintain its status as a RIC, certain income from PIK interest may be required to be distributed to the Company's stockholders, even though the Company has not yet collected the cash and may never do so. Fee Income Oaktree or its affiliates may provide financial advisory services to portfolio companies and, in return, the Company may receive fees for capital structuring services. These fees are generally non-recurring and are recognized by the Company upon the investment closing date. The Company may also receive additional fees in the ordinary course of business, including servicing, amendment, exit and prepayment fees, which are classified as fee income and recognized as they are earned or the services are rendered. Dividend Income The Company generally recognizes dividend income on the ex-dividend date for public securities and the record date for private equity investments. Distributions received from private equity investments are evaluated to determine if the distribution should be recorded as dividend income or a return of capital. Generally, the Company will not record distributions from private equity investments as dividend income unless there are sufficient earnings at the portfolio company prior to the distribution. Distributions that are classified as a return of capital are recorded as a reduction in the cost basis of the investment. Cash and Cash Equivalents and Restricted Cash Cash and Cash Equivalents and Restricted Cash: Cash and cash equivalents consist of demand deposits and highly liquid investments with maturities of three months or less when acquired. The Company places its cash and cash equivalents and restricted cash with financial institutions and, at times, cash held in bank accounts exceeds the Federal Deposit Insurance Corporation ("FDIC") insurance limit. Cash and cash equivalents are included on the Company's Consolidated Schedule of Investments and cash equivalents are classified as Level 1 assets. Due from Portfolio Companies Due from Portfolio Companies: Due from portfolio companies consists of amounts payable to the Company from its portfolio companies, including proceeds from the sale of portfolio companies not yet received or being held in escrow and excluding those amounts attributable to interest, dividends or fees receivable. These amounts are recognized as they become payable to the Company (e.g., principal payments on the scheduled amortization payment date). Receivables/Payables from Unsettled Transactions Receivables/Payables from Unsettled Transactions: Receivables/payables from unsettled transactions consist of amounts receivable to or payable by the Company for transactions that have not settled at the reporting date. Deferred Financing Costs Deferred Financing Costs: Deferred financing costs consist of fees and expenses paid in connection with the closing or amending of credit facilities and debt offerings. Deferred financing costs in connection with credit facilities are capitalized as an asset when incurred. Deferred financing costs in connection with all other debt arrangements are a direct deduction from the related debt liability when incurred. Deferred financing costs are amortized using the effective interest method over the term of the respective debt arrangement. This amortization expense is included in interest expense in the Consolidated Statements of Operations. Upon early termination or modification of a credit facility, all or a portion of unamortized fees related to such facility may be accelerated into interest expense. For extinguishments of the Company's unsecured notes payable, any unamortized deferred financing costs are deducted from the carrying amount of the debt in determining the gain or loss from the extinguishment. Deferred Offering Costs Deferred Offering Costs: Legal fees and other costs incurred in connection with the Company's shelf registration statement are capitalized as deferred offering costs in the Consolidated Statements of Assets and Liabilities. To the extent any such costs relate to equity offerings, these costs are charged as a reduction of capital upon utilization. To the extent any such costs relate to debt offerings, these costs are treated as deferred financing costs and are amortized over the term of the respective debt arrangement. Any deferred offering costs that remain at the expiration of the shelf registration statement or when it becomes probable that an offering will not be completed are expensed. Income Taxes Income Taxes: The Company has elected to be subject to tax as a RIC under Subchapter M of the Code and operates in a manner so as to qualify for the tax treatment applicable to RICs. In order to be subject to tax as a RIC, among other things, the Company is required to meet certain source of income and asset diversification requirements and timely distribute dividends to its stockholders of an amount generally at least equal to 90% of investment company taxable income, as defined by the Code and determined without regard to any deduction for dividends paid, for each taxable year. As a RIC, the Company is not subject to U.S. federal income tax on the portion of its taxable income and gains distributed currently to stockholders as a dividend. Depending on the level of taxable income earned during a taxable year, the Company may choose to retain taxable income in excess of current year dividend distributions and would distribute such taxable income in the next taxable year. The Company would then incur a 4% excise tax on such income, as required. To the extent that the Company determines that its estimated current year annual taxable income, determined on a calendar year basis, could exceed estimated current calendar year dividend distributions, the Company accrues excise tax, if any, on estimated excess taxable income as taxable income is earned. The Company anticipates timely distribution of its taxable income within the tax rules under Subchapter M of the Code. For calendar year 2022, the Company incurred \$0.1A million of excise tax. The Company did not incur any U.S. federal excise tax for calendar year 2023. The Company does not expect to incur a U.S. federal excise tax for calendar year 2024. The Company holds certain portfolio investments through taxable subsidiaries. The purpose of the Company's taxable subsidiaries is to permit the Company to hold equity investments in portfolio companies which are "pass through" entities for U.S. federal income tax purposes in order to comply with the RIC tax requirements. The taxable subsidiaries are consolidated for financial reporting purposes, and portfolio investments held by them are included in the Company's Consolidated Financial Statements as portfolio investments and recorded at fair value. The taxable subsidiaries are not consolidated with the Company for U.S. federal income tax purposes and may generate income tax expense, or benefit, and the related tax assets and liabilities, as a result of their ownership of certain portfolio investments. This income tax expense, if any, would be reflected in the Company's Consolidated Statements of Operations. The Company uses the liability method to account for its taxable subsidiaries' income taxes. Using this method, the Company recognizes deferred tax assets and liabilities for the estimated future tax effects attributable to temporary differences between financial reporting and tax bases of assets and liabilities. In addition, the Company recognizes deferred tax benefits associated with net operating loss carry forwards that it may use to offset future tax obligations. The Company measures deferred tax assets and liabilities using the enacted tax rates expected to apply to taxable income in the years in which it expects to recover or settle those temporary differences. FASB ASC Topic 740, Accounting for Uncertainty in Income Taxes ("ASC 740"), provides guidance for how uncertain tax positions should be recognized, measured, presented and disclosed in the Company's Consolidated Financial Statements. ASC 740 requires the evaluation of tax positions taken or expected to be taken in the course of preparing the Company's tax returns to determine whether the tax positions are "more-likely-than-not" of being sustained by the applicable tax authority. Tax positions not deemed to meet the more-likely-than-not threshold are recorded as a tax benefit or expense in the current year. Management's determinations regarding ASC 740 may be subject to review and adjustment at a later date based upon factors including an ongoing analysis of tax laws, regulations

and interpretations thereof. The Company recognizes the tax benefits of uncertain tax positions only where the position is "more-likely-than-not" to be sustained assuming examination by tax authorities. Management has analyzed the Company's tax positions and has concluded that no liability for unrecognized tax benefits should be recorded related to uncertain tax positions taken on returns filed for open tax years 2021, 2022 and 2023. The Company identifies its major tax jurisdictions as U.S. Federal and California, and the Company is not aware of any tax positions for which it is reasonably possible that the total amounts of unrecognized tax benefits will change materially in the next 12A months. Recently Adopted Accounting Pronouncements Recently Adopted Accounting PronouncementsIn November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280), which improves reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. The amendments are effective for fiscal years beginning after December 15, 2023 and interim period within fiscal years beginning after December 15, 2024. The Company does not expect this guidance to materially impact its consolidated financial statements. X - DefinitionDeferred Financing Costs, Policy + ReferencesNo definition available. + Details Name: ocsl DeferredFinancingCostsPolicyTextBlock Namespace Prefix: ocsl_ Data Type: dtr-types1:textBlockItem Type Balance Type: na Period Type: duration X - DefinitionDeferred Offering Costs, Policy + ReferencesNo definition available. + Details Name: ocsl DeferredOfferingCostsPolicyPolicyTextBlock Namespace Prefix: ocsl_ Data Type: dtr-types1:textBlockItem Type Balance Type: na Period Type: duration X - DefinitionDue From Portfolio Companies, Policy + ReferencesNo definition available. + Details Name: ocsl DueFromPortfolioCompaniesPolicyPolicyTextBlock Namespace Prefix: ocsl_ Data Type: dtr-types1:textBlockItem Type Balance Type: na Period Type: duration X - DefinitionUnsettled Investment Transactions, Policy + ReferencesNo definition available. + Details Name: ocsl UnsettledInvestmentTransactionsPolicyPolicyTextBlock Namespace Prefix: ocsl_ Data Type: dtr-types1:textBlockItem Type Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). + ReferencesNo definition available. + Details Name: us-gaap BasisOfAccountingPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - DefinitionEntity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-03\(1\)\(a\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479853/942-210-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(1)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479853/942-210-S99-1)Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1> + Details Name: us-gaap CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary. + ReferencesReference 1: [http://www.xbrl.org/2003/role/exampleRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4](http://www.xbrl.org/2003/role/exampleRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4)Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1> + Details Name: us-gaap ConsolidationPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for its derivative instruments and hedging activities. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 815 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-2>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(n\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(n)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1)Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1A>Reference 4: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1>Reference 5: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4>Reference 6: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-7> + Details Name: us-gaap DerivativesPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities. + ReferencesNo definition available. + Details Name: us-gaap FairValueMeasurementPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-03\(h\)\(1\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/830/tableOfContent + Details Name: us-gaap ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements. + ReferencesReference 1: <a href=)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17](http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17)Reference 3: <http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19>Reference 7: <http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1>Reference 8: <http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20> + Details Name: us-gaap IncomeTaxPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for investment in financial asset. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-04\(3\)\(b\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483586/944-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(3)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483586/944-220-S99-1)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-03\(d\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-03\(f\)\(1\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(f)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-03\(f\)\(3\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(f)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 12 -Subparagraph \(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-12](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 12 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-12)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 19 -Subparagraph \(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-19](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 19 -Subparagraph (2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-19) + Details Name: us-gaap InvestmentPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact. + ReferencesNo definition available. + Details Name: us-gaap NewAccountingPronouncementsPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(b\) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(c\) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1)Reference 5: <http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 11 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 12 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12>Reference 7: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8> + Details Name: us-gaap UseOfEstimates Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 40 R29,htm IDEA: XBRL DOCUMENT v3.24.2 Portfolio Investments (Tables) 9 Months Ended Jun. 30, 2024 Schedule of Investments [Abstract] A Schedule of Composition of Investments The composition of the Company's investments as of JuneA 30, 2024 and SeptemberA 30, 2023 at cost and fair value was as follows: A June 30, 2024 September 30, 2023A CostFair ValueCostFair ValueInvestments in debt securities\$2,895,645A \$2,801,310A \$2,654,484A \$2,557,102A Investments in equity securities178,533A 132,034A 171,858A 143,767A Debt investments in the JVs163,963A 162,542A 162,986A 162,673A Equity investments in the JVs54,791A 25,817A 54,791A 28,878A Total\$3,292,932A \$3,121,703A \$3,044,119A \$2,892,420A The following table presents the composition of the Company's debt investments as of JuneA 30, 2024 and SeptemberA 30, 2023 at fixed rates and floating rates: A June 30, 2024 September 30, 2023A Fair Value% of A DebtPortfolioFair Value% of A DebtPortfolioFloating rate debt securities, including the debt investments in the JVs\$2,526,904A 85.26A %\$2,345,205A 86.23A %Fixed rate debt securities436,948A 14.74A 374,570A 13.77A Total\$2,963,852A 100.00A %\$2,719,775A 100.00A %The following tables show the composition of the Company's portfolio by industry at cost as a percentage of total investments and at fair value as a percentage of total investments and net assets as of JuneA 30, 2024 and SeptemberA 30, 2023: June 30, 2024 September 30, 2023 Cost: A % of Total InvestmentsA % of Total InvestmentsApplication Software\$557,095A 16.95A %\$468,483A 15.39A %Multi-Sector Holdings (1)234,940A 7.13A 219,469A 7.21A Health Care Services131,615A 4.00A 81,560A 2.68A Health Care Technology127,243A 3.86A 106,915A 3.51A Biotechnology126,528A 3.84A 126,349A 4.15A Data Processing & Outsourced Services96,836A 2.94A 133,410A 4.38A Interactive Media & Services95,784A 2.91A 19,013A 0.62A Industrial Machinery & Supplies & Components93,198A 2.83A 99,511A 3.27A Pharmaceuticals86,764A 2.63A 84,948A 2.79A Real Estate Operating Companies80,818A 2.45A 83,754A 2.75A Diversified Financial Services69,666A 2.12A 61,725A 2.03A Aerospace & Defense67,329A 2.04A 51,797A 1.70A Diversified Support Services67,151A 2.04A 23,435A 0.77A Environmental & Facilities Services64,730A 1.96A 63,064A 2.07A Fertilizers & Agricultural Chemicals64,630A 1.96A 64,720A 2.13A Personal Care Products64,086A 1.95A 68,146A 2.24A Health Care Distributors64,059A 1.95A 62,044A 2.04A Airport Services62,573A 1.90A 55,961A 1.84A Metal, Glass & Plastic Containers61,854A 1.88A 55,530A 1.82A Specialized Finance58,612A 1.78A 73,035A 2.40A Internet Services & Infrastructure53,283A 1.62A 60,934A 2.00A Diversified Metals & Mining50,006A 1.52A 49,842A 1.64A Systems Software49,583A 1.51A 23,111A 0.76A Home Improvement Retail49,457A 1.50A 54,236A 1.78A Auto Parts & Equipment48,310A 1.47A 48,536A 1.59A Communications Equipment47,604A 1.45A A€" A€" A Real Estate Services44,517A 1.35A 44,717A 1.47A Soft Drinks & Non-alcoholic Beverages42,676A 1.30A 42,628A 1.40A Automotive Retail40,831A 1.24A 57,596A 1.89A Office Services & Supplies38,882A 1.18A A€" A€" A Leisure Facilities38,029A 1.15A 39,076A 1.28A Other Specialty Retail36,772A 1.12A 41,088A 1.35A Electrical Components & Equipment32,734A 0.99A 32,440A 1.07A Movies & Entertainment30,857A 0.94A 12,188A 0.40A Construction Machinery & Heavy Transportation Equipment26,010A 0.79A A€" A€" A Health Care Equipment25,812A 0.78A 22,441A 0.74A Passenger Airlines25,009A 0.76A 24,920A 0.82A Real Estate Development24,974A 0.76A 23,965A 0.79A Wireless Telecommunication Services24,275A 0.74A A€" A€" A Gold23,418A 0.71A 23,310A 0.77A Home Furnishings23,170A 0.70A 23,859A 0.78A Broadline Retail22,143A 0.67A 83,290A 2.74A Construction & Engineering20,495A 0.62A 22,102A 0.73A Packaged Foods & Meats19,895A 0.60A A€" A€" A Specialty Chemicals19,457A 0.59A 38,640A 1.27A Oil & Gas Storage & Transportation19,309A 0.59A 22,042A 0.72A Apparel Retail17,895A 0.54A 4,999A 0.16A Hotels, Resorts & Cruise Lines17,114A 0.52A 17,195A 0.56A Alternative Carriers15,141A 0.46A A€" A€" A Food Distributors14,607A 0.44A 5,897A 0.19A Health Care Supplies11,561A 0.35A 11,646A 0.38A Advertising11,345A 0.34A 25,597A 0.84A Integrated Telecommunication Services9,050A 0.27A 18,801A 0.62A Distributors8,707A 0.26A 37,666A 1.24A Education Services8,211A 0.25A 13,871A 0.46A Financial Exchanges & Data6,881A 0.21A A€" A€" A Cable & Satellite6,861A 0.21A 4,619A 0.15A Research & Consulting Services4,844A 0.15A 4,871A 0.16A Paper & Plastic Packaging Products & Materials3,393A 0.10A 3,254A 0.11A Housewares & Specialties2,750A 0.08A 2,908A 0.10A Diversified Chemicals1,553A 0.05A A€" A€" A Insurance BrokersA€" A€" A 52,856A 1.74A Consumer FinanceA€" A€" A 16,440A 0.54A RestaurantsA€" A€" A 12,603A 0.41A Air Freight & LogisticsA€" A€" A 4,925A 0.16A Integrated Oil & GasA€" A€" A 4,894A 0.16A Other Specialized REITsA€" A€" A 4,379A 0.14A Leisure ProductsA€" A€" A 2,055A 0.07A Technology DistributorsA€" A€" A 813A 0.03A \$3,292,932A 100.00A %\$3,044,119A 100.00A %June 30, 2024 September 30, 2023 Fair Value: A % of Total InvestmentsA % of Net AssetsA % of Total InvestmentsA % of Net AssetsApplication Software\$513,205A 16.47A %\$34,333A %\$455,719A 15.73A %Multi-Sector Holdings (1)205,257A 6.58A 13,72A 193,431A 6.69A 12.76A Biotechnology128,673A 4.12A 8.60A 125,678A 4.35A 8.29A Health Care Services112,704A 3.61A 7.53A 66,683A 2.17A 4.40A Health Care Technology103,893A 3.33A 6.94A 95,404A 3.30A 6.29A Interactive Media & Services96,263A 3.08A 6.43A 19,199A 0.66A 3.21A Industrial Machinery & Supplies & Components94,189A 3.02A 6.30A 98,352A 3.40A 6.49A Data Processing & Outsourced

Services90,828Å 2.91Å 6.07Å 125,259Å 4.33Å 8.26Å Pharmaceuticals83,557Å 2.68Å 5.58Å 80,455Å 2.78Å 5.31Å Real Estate Operating Companies79,437Å 2.54Å 5.31Å 82,463Å 2.85Å 5.44Å Diversified Financial Services69,007Å 2.21Å 4.61Å 60,003Å 2.07Å 3.96Å Aerospace & Defense68,814Å 2.20Å 4.60Å 51,862Å 1.79Å 3.42Å Diversified Support Services67,642Å 2.17Å 4.52Å 23,352Å 0.81Å 1.54Å Environmental & Facilities Services63,768Å 2.04Å 4.26Å 62,413Å 2.16Å 4.12Å Fertilizers & Agricultural Chemicals63,185Å 2.02Å 4.22Å 63,185Å 2.18Å 4.17Å Health Care Distributors62,922Å 2.04Å 4.21Å 60,865Å 2.10Å 4.09Å Specialized Finance58,702Å 1.88Å 3.92Å 69,590Å 2.41Å 4.59Å Personal Care Products58,500Å 1.87Å 3.91Å 59,928Å 2.07Å 3.95Å Airport Services55,033Å 1.76Å 3.68Å 54,453Å 1.88Å 3.59Å Internet Services & Infrastructure52,884Å 1.69Å 3.53Å 60,579Å 2.09Å 4.00Å Diversified Metals & Mining50,419Å 1.62Å 3.37Å 49,869Å 1.72Å 3.29Å Systems Software49,527Å 1.59Å 3.31Å 21,968Å 0.76Å 1.45Å Auto Parts & Equipment48,654Å 1.56Å 3.25Å 49,148Å 1.70Å 3.24Å Home Improvement Retail48,378Å 1.55Å 3.23Å 53,168Å 1.84Å 3.51Å Communications Equipment47,647Å 1.53Å 3.18Å æ"Å æ"Å Metal, Glass & Plastic Containers47,035Å 1.51Å 3.14Å 53,459Å 1.85Å 3.53Å Real Estate Services43,542Å 1.39Å 2.91Å 43,886Å 1.52Å 2.90Å Soft Drinks & Non-alcoholic Beverages42,443Å 1.36Å 2.84Å 42,391Å 1.47Å 2.80Å Automotive Retail38,919Å 1.25Å 2.60Å 55,805Å 1.93Å 3.68Å Office Services & Supplies38,366Å 1.23Å 2.56Å æ"Å æ"Å æ"Å Other Specialty Retail37,426Å 1.20Å 2.50Å 41,115Å 1.42Å 2.71Å Leisure Facilities37,286Å 1.19Å 2.49Å 36,963Å 1.28Å 2.44Å Electrical Components & Equipment32,285Å 1.03Å 2.16Å 32,573Å 1.13Å 2.15Å Movies & Entertainment31,176Å 1.00Å 2.08Å 11,865Å 0.41Å 0.78Å Passenger Airlines26,924Å 0.86Å 1.80Å 27,512Å 0.95Å 1.82Å Construction Machinery & Heavy Transportation Equipment26,046Å 0.83Å 1.74Å æ"Å æ"Å æ"Å Real Estate Development24,840Å 0.80Å 1.66Å 23,679Å 0.82Å 1.56Å Wireless Telecommunication Services24,297Å 0.78Å 1.62Å æ"Å æ"Å æ"Å Gold23,867Å 0.76Å 1.60Å 23,328Å 0.81Å 1.54Å Health Care Equipment22,741Å 0.73Å 1.52Å 22,436Å 0.78Å 1.48Å Broadline Retail22,268Å 0.71Å 1.49Å 69,040Å 2.39Å 4.55Å Construction & Engineering20,000Å 0.64Å 1.34Å 21,903Å 0.76Å 1.45Å Packaged Foods & Meats19,912Å 0.64Å 1.33Å æ"Å æ"Å æ"Å A Specialty Chemicals19,482Å 0.62Å 1.30Å 38,615Å 1.34Å 2.55Å Apparel Retail18,064Å 0.58Å 1.21Å 5,002Å 0.17Å 0.33Å Oil & Gas Storage & Transportation17,737Å 0.57Å 1.19Å 16,040Å 0.55Å 1.06Å Hotels, Resorts & Cruise Lines16,861Å 0.54Å 1.13Å 16,991Å 0.59Å 1.12Å Alternative Carriers15,320Å 0.49Å 1.02Å æ"Å æ"Å æ"Å Home Furnishings15,076Å 0.48Å 1.01Å 19,954Å 0.69Å 1.32Å Food Distributors14,492Å 0.46Å 0.97Å 5,166Å 0.18Å 0.34Å Advertising11,390Å 0.36Å 0.76Å 11,955Å 0.41Å 0.79Å Health Care Supplies11,337Å 0.36Å 0.76Å 11,363Å 0.39Å 0.75Å Integrated Telecommunication Services8,525Å 0.27Å 0.57Å 16,492Å 0.57Å 1.09Å Education Services8,105Å 0.26Å 0.54Å 13,618Å 0.47Å 0.90Å Distributors7,618Å 0.24Å 0.51Å 37,311Å 1.29Å 2.46Å Financial Exchanges & Data6,880Å 0.22Å 0.46Å æ"Å æ"Å æ"Å Cable & Satellite6,105Å 0.20Å 0.41Å 5,464Å 0.16Å 0.30Å Research & Consulting Services4,939Å 0.16Å 0.33Å 4,831Å 0.17Å 0.32Å Paper & Plastic Packaging Products & Materials3,224Å 0.10Å 0.22Å 3,061Å 0.11Å 0.20Å Housewares & Specialties2,512Å 0.08Å 0.17Å 2,808Å 0.10Å 0.19Å Diversified Chemicals1,565Å 0.05Å 0.10Å æ"Å æ"Å æ"Å Insurance Brokersæ"Å æ"Å æ"Å 53,005Å 1.83Å 3.50Å Consumer Financeæ"Å æ"Å æ"Å 15,087Å 0.52Å 1.00Å Restaurantsæ"Å æ"Å æ"Å 12,464Å 0.43Å 0.82Å Integrated Oil & Gasæ"Å æ"Å æ"Å 4,785Å 0.17Å 0.32Å Air Freight & Logisticsæ"Å æ"Å æ"Å 4,263Å 0.15Å 0.28Å Other Specialized REITsæ"Å æ"Å æ"Å 4,198Å 0.11Å 0.21Å Leisure Productsæ"Å æ"Å æ"Å 2,063Å 0.07Å 0.14Å Technology Distributorsæ"Å æ"Å æ"Å 776Å 0.03Å 0.05Å Totals\$3,121,703Å 100.00Å %208.65Å %\$2,892,420Å 100.00Å %190.82Å %

(1)This industry includes the Company's investments in the JVs and CLOs.SLF JV I Portfolio as of JuneÅ 30, 2024Portfolio CompanyIndustryType of InvestmentIndexSpreadCash Interest Rate (1)(2)PIKMaturity DateSharesPrincipalCostFairÅ Value (3)NotesAccess CIG, LLCDiversified Support ServicesFirst Lien Term LoanSOFR+5.00%10.33%8/18/2028\$10,522Å \$10,426Å \$10,602Å (4)ADB Companies, LLCConstruction & EngineeringFirst Lien Term LoanSOFR+6.50%11.82%6/21/18/20251,092Å 1,082Å 1,059Å (4)ADB Companies, LLCConstruction & EngineeringFirst Lien Term LoanSOFR+6.50%12.10%12/18/20256,258Å 6,216Å 6,071Å (4)Alvogen Pharma US, Inc.PharmaceuticalsFirst Lien Term LoanSOFR+7.50%12.98%6/30/20258,446Å 8,413Å 7,813Å (4)American Tire Distributors, Inc.DistributorsFirst Lien Term LoanSOFR+6.25%11.84%10/20/20283,352Å 3,311Å 2,445Å (4)Artera Services LLCConstruction & EngineeringFirst Lien Term LoanSOFR+4.50%69.83%6/15/20317,481Å 7,425Å 7,530Å ASP-R-PAC Acquisition Co LLCPaper & Plastic Packaging Products & MaterialsFirst Lien RevolverSOFR+6.00%11.46%12/29/2027205Å 199Å 180Å (4)(5)ASP-R-PAC Acquisition Co LLCPaper & Plastic Packaging Products & MaterialsFirst Lien Term LoanSOFR+6.00%11.59%12/29/20274,103Å 4,055Å 3,901Å (4)Astra Acquisition Corp.Application SoftwareFirst Lien Term LoanSOFR+6.75%12.08%2/25/20282,553Å 2,499Å 2,342Å (4)Astra Acquisition Corp.Application SoftwareFirst Lien Term LoanSOFR+5.25%10.58%10/25/20284,037Å 2,108Å 1,894Å (4)Asurion, LLCProperty & Casualty InsuranceFirst Lien Term LoanSOFR+4.00%69.44%6/19/20277,795Å 7,598Å 7,720Å Asurion, LLCProperty & Casualty InsuranceFirst Lien Term LoanSOFR+4.25%69.69%8/19/20281,975Å 1,886Å 1,963Å athenahealth Group Inc.Health Care TechnologyFirst Lien Term LoanSOFR+3.25%68.59%6/15/20299,057Å 8,801Å 9,038Å Aurora Lux Finc S.ÅÆ.R.L.Airport ServicesFirst Lien Term LoanSOFR+7.00%68.43%6.00%12/24/20266,480Å 6,424Å 6,260Å (4)BAART Programs, Inc.Health Care ServicesFirst Lien Term LoanSOFR+5.00%10.60%6/11/20271,740Å 1,728Å 1,672Å (4)BAART Programs, Inc.Health Care ServicesFirst Lien Term LoanSOFR+5.00%10.60%6/11/20276,258Å 6,199Å 6,014Å (4)Bausch + Lomb CorporationHealth Care SuppliesFirst Lien Term LoanSOFR+3.25%8.69%5/10/20279,196Å 9,025Å 9,110Å C5 Technology Holdings, LLCData Processing & Outsourced ServicesCommon Stock171Å æ"Å æ"Å (4)C5 Technology Holdings, LLCData Processing & Outsourced ServicesPreferred Equity7,193,540Å 7,194Å 5,683Å (4)Centerline Communications, LLCWireless Telecommunication ServicesFirst Lien Term LoanSOFR+6.00%12.64%8/10/20271,979Å 1,956Å 1,625Å Centerline Communications, LLCWireless Telecommunication ServicesFirst Lien RevolverSOFR+6.00%11.55%8/10/2027600Å 594Å 492Å (5)Centerline Communications, LLCWireless Telecommunication ServicesFirst Lien Term LoanSOFR+6.00%12.49%8/10/20271,955Å 1,935Å 1,605Å Cloud Software Group, Inc.Application SoftwareFirst Lien Term LoanSOFR+4.00%69.33%3/30/20298,173Å 7,610Å 8,177Å Covetrus, Inc.Health Care DistributorsFirst Lien Term LoanSOFR+5.00%10.33%10/13/20296,295Å 5,982Å 6,102Å (4)Crown Subsea Communications Holding, Inc.Alternative CarriersFirst Lien Term LoanSOFR+4.75%10.08%1/30/20318,000Å 7,920Å 8,032Å (4)Curium Bidco S.A.r.l.PharmaceuticalsFirst Lien Term LoanSOFR+4.00%9.33%7/31/20298,665Å 8,581Å 8,713Å Dealer Tire Financial, LLCDistributorsFirst Lien Term LoanSOFR+3.75%9.09%12/14/20279,950Å 9,928Å 9,953Å DirecTV Financing, LLCable & SatelliteFirst Lien Term LoanSOFR+5.25%10.71%8/2/20296,872Å 6,793Å 6,851Å (4)DTI Holdco, Inc.Research & Consulting ServicesFirst Lien Term LoanSOFR+4.75%10.09%4/26/20299,052Å 8,929Å 9,100Å (4)Eagle Parent Corp.Diversified Support ServicesFirst Lien Term LoanSOFR+4.25%9.58%4/2/20291,181Å 1,179Å 1,151Å Frontier Communications Holdings, LLCIntegrated Telecommunication ServicesFirst Lien Term LoanSOFR+3.75%69.21%10/8/20273,723Å 3,685Å 3,726Å Frontier Communications Holdings, LLCIntegrated Telecommunication ServicesFirst Lien Term LoanSOFR+3.50%68.85%7/1/20317,000Å 6,965Å 7,000Å Harbor Purchaser Inc.Education ServicesFirst Lien Term LoanSOFR+5.25%10.70%4/9/20297,860Å 7,698Å 7,500Å (4)Portfolio CompanyIndustryType of InvestmentIndexSpreadCash Interest Rate (1)(2)PIKMaturity DateSharesPrincipalCostFairÅ Value (3)NotesHusky Injection Molding Systems Ltd.Industrial Machinery & Supplies & ComponentsFirst Lien Term LoanSOFR+5.00%10.33%2/15/20293,952Å \$3,897Å \$3,966Å Indivior Finance S.ÅÆ.R.L.PharmaceuticalsFirst Lien Term LoanSOFR+5.25%10.71%6/30/20267,275Å 7,216Å 7,266Å INW Manufacturing, LLCPersonal Care ProductsFirst Lien Term LoanSOFR+5.75%11.35%3/25/20278,625Å 8,504Å 7,445Å (4)KDC/ONE Development Corp IncPersonal Care ProductsFirst Lien Term LoanSOFR+4.50%69.84%8/15/20288,890Å 8,661Å 8,925Å LABL, Inc.Office Services & SuppliesFirst Lien Term LoanSOFR+5.00%10.44%10/29/20286,917Å 6,725Å 6,841Å (4)LaserAway Intermediate Holdings II, LLCHealth Care ServicesFirst Lien Term LoanSOFR+5.75%11.33%10/14/20277,313Å 7,232Å 7,343Å Lighthouse Intermediate, L.P.Real Estate ServicesFirst Lien Term LoanSOFR+5.00%10.60%5/202611,161Å 11,060Å 10,826Å (4)McAfee Corp.Systems SoftwareFirst Lien Term LoanSOFR+3.25%8.58%3/1/20295,910Å 5,665Å 5,911Å Mitchell International, Inc.Application SoftwareFirst Lien Term LoanSOFR+3.25%8.59%6/17/20315,000Å 4,975Å 4,964Å Peraton Corp.Aerospace & DefenseFirst Lien Term LoanSOFR+3.75%69.19%6/1/20281,983Å 1,983Å 1,987Å PetSmart LLCOther Specialty RetailFirst Lien Term LoanSOFR+3.75%69.19%2/11/20287,969Å 7,888Å 7,956Å Pluralsight, LLCApplication SoftwareFirst Lien RevolverSOFR+8.00%4/6/2027507Å 493Å 248Å (4)(6)Pluralsight, LLCApplication SoftwareFirst Lien Term LoanSOFR+8.00%4/6/20278,116Å 7,890Å 3,977Å (4)(6)Renaissance Holding Corp.Education ServicesFirst Lien Term LoanSOFR+4.25%9.60%4/5/20308,943Å 8,810Å 8,947Å SCIH Salt Holdings Inc.Diversified ChemicalsFirst Lien Term LoanSOFR+3.50%8.83%3/16/20272,972Å 2,972Å 2,978Å Shearer's Foods LLCPackaged Foods & MeatsFirst Lien Term LoanSOFR+4.00%69.34%6/21/20317,000Å 6,930Å 7,057Å SHO Holding I CorporationFootwearFirst Lien Term LoanSOFR+8.00%13.44%8/29/2024940Å 893Å 940Å SHO Holding I CorporationFootwearFirst Lien Term LoanSOFR+5.23%46/27/2024139Å 140Å 120Å (6)SHO Holding I CorporationFootwearFirst Lien Term LoanSOFR+5.25%64/27/20248,194Å 8,233Å 7,031Å (6)SM Wellness Holdings, Inc.Health Care ServicesFirst Lien Term LoanSOFR+4.50%10.09%4/17/20282,954Å 2,625Å 2,921Å (4)Southern Veterinary Partners, LLCHealth Care FacilitiesFirst Lien Term LoanSOFR+3.75%69.09%10/5/20278,623Å 8,585Å 8,652Å SPX Flow, Inc.Industrial Machinery & Supplies & ComponentsFirst Lien Term LoanSOFR+3.50%68.84%4/5/20297,045Å 6,796Å 7,094Å Staples, Inc.Office Services & SuppliesFirst Lien Term LoanSOFR+5.75%11.08%9/4/20295,349Å 5,136Å 4,920Å (4)Star Parent, Inc.Life Sciences Tools & ServicesFirst Lien Term LoanSOFR+3.75%69.08%6/27/20307,980Å 7,860Å 7,983Å SupplyOne, Inc. Paper & Plastic Packaging Products & MaterialsFirst Lien Term LoanSOFR+4.25%69.59%4/19/20314,489Å 4,444Å 4,501Å Swissport Stratosphere USA LLCAir Freight & LogisticsFirst Lien Term LoanSOFR+4.25%69.56%4/4/20315,500Å 5,473Å 5,522Å Tacala, LLCRestaurantsFirst Lien Term LoanSOFR+4.00%69.34%1/31/203110,973Å 10,945Å 11,033Å Touchstone Acquisition, Inc.Health Care SuppliesFirst Lien Term LoanSOFR+6.00%11.43%12/29/20287,157Å 7,065Å 7,005Å (4)Trident TPI Holdings, Inc.Metal, Glass & Plastic ContainersFirst Lien Term LoanSOFR+4.00%69.34%6/15/20287,500Å 7,500Å 7,519Å Total Portfolio Investments\$353,579Å \$353,263Å \$344,930Å (1) Represents the interest rate as of JuneÅ 30, 2024. All interest rates are payable in cash, unless otherwise noted.(2) The interest rate on the principal balance outstanding for most of the floating rate loans is indexed to SOFR which typically resets semi-annually, quarterly, or monthly at the borrower's option. The borrower may also elect to have multiple interest reset periods for each loan. For each of these loans, the Company has provided the applicable margin over the reference rates based on each respective credit agreement and the cash interest rate as of period end. As of JuneÅ 30, 2024, the reference rates for SLF JV I's variable rate loans were the 30-day SOFR at 5.34% and the 90-day SOFR at 5.32%. Most loans include an interest floor, which generally ranges from 0% to 2%. SOFR based contracts may include a credit spread adjustment that is charged in addition to the base rate and the stated spread.(3) Represents the current determination of fair value as of JuneÅ 30, 2024 utilizing a similar technique as the Company in accordance with ASC 820. However, the determination of such fair value is not included in the valuation process described elsewhere herein.(4) This investment was held by both the Company and SLF JV I as of JuneÅ 30, 2024.(5) Investment had undrawn commitments. Unamortized fees are classified as unearned income which reduces cost basis, which may result in a negative cost basis. A negative fair value may result from the unfunded commitment being valued below par.(6) This investment was on non-accrual status as of JuneÅ 30, 2024.SLF JV I Portfolio as of SeptemberÅ 30, 2023Portfolio CompanyIndustryType of InvestmentIndexSpreadCash Interest Rate (1)(2)PIKMaturity DateSharesPrincipalCostFairÅ Value (3)NotesAccess CIG, LLCDiversified Support ServicesFirst Lien Term LoanSOFR+5.00%10.32%8/18/20288,596Å 8,503Å \$8,499Å ADB Companies, LLCConstruction & EngineeringFirst Lien Term LoanSOFR+6.50%11.90%12/18/20251,149Å 1,135Å 1,128Å (4)ADB Companies, LLCConstruction & EngineeringFirst Lien Term LoanSOFR+6.50%12.15%12/18/20256,771Å 6,701Å 6,648Å (4)Altice France S.A.Integrated Telecommunication ServicesFirst Lien Term LoanL+4.00%69.63%8/14/20262,969Å 2,853Å 2,810Å Alvogen Pharma US, Inc.PharmaceuticalsFirst Lien Term LoanSOFR+7.50%13.04%6/30/20258,798Å 8,737Å 8,218Å (4)American Rock Salt Company LLCDiversified Metals & MiningFirst Lien Term LoanSOFR+4.00%69.43%6/9/20284,957Å 4,734Å 4,614Å American Tire Distributors, Inc.DistributorsFirst Lien Term LoanSOFR+6.25%11.81%10/20/20284,824Å 4,763Å 4,239Å (4)Amplify Finco Pty Ltd.Movies & EntertainmentFirst Lien Term LoanSOFR+4.15%69.54%11/26/20267,720Å 7,643Å 7,720Å Anastasia Parent, LLCPersonal Care ProductsFirst Lien Term LoanSOFR+3.75%69.40%8/11/20251,523Å 1,191Å 1,099Å (4)ASP-R-PAC Acquisition Co LLCPaper & Plastic Packaging Products & MaterialsFirst Lien RevolverSOFR+6.00%12/29/2027æ"Å (7)(29)(4)(5)ASP-R-PAC Acquisition Co LLCPaper & Plastic Packaging Products & MaterialsFirst Lien Term LoanSOFR+6.00%11.63%12/29/20274,134Å 4,076Å 3,892Å (4)Astra Acquisition Corp.Application SoftwareFirst Lien Term LoanSOFR+5.25%10.90%10/25/20285,052Å 4,888Å 3,817Å (4)Asurion, LLCProperty & Casualty InsuranceFirst Lien Term LoanSOFR+4.00%9.42%8/19/20284,950Å 4,747Å 4,809Å Asurion, LLCProperty & Casualty InsuranceFirst Lien Term LoanSOFR+4.25%69.67%8/19/20281,990Å 1,884Å 1,937Å Asurion, LLCProperty & Casualty InsuranceSecond Lien Term LoanSOFR+5.25%10.68%1/20/20294,346Å 4,036Å 3,871Å athenahealth Group Inc.Health Care TechnologyFirst Lien Term LoanSOFR+3.25%68.57%6/15/20294,320Å 4,080Å 4,251Å Aurora Lux Finc S.ÅÆ.R.L.Airport ServicesFirst Lien Term LoanSOFR+6.00%11.49%12/24/20266,289Å 6,216Å 6,028Å (4)BAART Programs, Inc.Health Care ServicesFirst Lien Term LoanSOFR+5.00%10.65%6/11/20271,753Å 1,742Å 1,711Å (4)BAART Programs, Inc.Health Care ServicesFirst Lien Term LoanSOFR+5.00%10.65%6/11/20276,306Å 6,247Å 6,155Å (4)C5 Technology Holdings, LLCData Processing & Outsourced ServicesCommon Stock171Å æ"Å æ"Å (4)C5 Technology Holdings, LLCData Processing & Outsourced ServicesPreferred Equity7,193,540Å 7,194Å 5,683Å (4)Centerline Communications, LLCWireless Telecommunication ServicesFirst Lien Term LoanSOFR+6.00%11.55%8/10/20272,354Å 2,322Å 2,281Å Centerline Communications, LLCWireless Telecommunication ServicesFirst Lien RevolverSOFR+6.00%11.57%8/10/2027600Å 592Å 581Å Centerline Communications, LLCWireless Telecommunication ServicesFirst Lien Term LoanSOFR+6.00%11.55%8/10/20271,960Å 1,935Å 1,899Å Covetrus, Inc.Health Care DistributorsFirst Lien Term LoanSOFR+5.00%10.39%10/13/20296,343Å 5,983Å 6,285Å (4)Curium Bidco S.A.r.l.BiotechnologyFirst Lien Term LoanSOFR+4.50%69.89%7/31/20298,730Å 8,642Å 8,730Å DirecTV Financing, LLCable & SatelliteFirst Lien Term LoanSOFR+5.50%10.43%8/2/20275,795Å 5,715Å 5,681Å (4)DTI Holdco, Inc.Research & Consulting ServicesFirst Lien Term LoanSOFR+4.75%10.12%4/26/20297,920Å 7,792Å 7,729Å (4)Gibson Brands, Inc.Leisure ProductsFirst Lien Term LoanSOFR+5.00%10.57%8/11/20287,369Å 7,295Å 6,190Å (4)Harbor Purchaser Inc.Education ServicesFirst Lien Term LoanSOFR+5.25%10.67%4/9/20297,920Å 7,731Å 7,517Å (4)Indivior Finance S.ÅÆ.R.L.PharmaceuticalsFirst Lien Term LoanSOFR+5.25%10.90%6/30/20267,331Å 7,249Å 7,340Å Portfolio CompanyIndustryType of InvestmentIndexSpreadCash Interest Rate (1)(2)PIKMaturity DateSharesPrincipalCostFairÅ Value (3)NotesINW Manufacturing, LLCPersonal Care ProductsFirst Lien Term LoanSOFR+5.75%11.40%3/25/2027\$9,000Å \$8,839Å \$7,080Å (4)KDC/ONE Development Corp IncPersonal Care ProductsFirst Lien Term LoanSOFR+5.00%10.32%8/15/202810,000Å 9,666Å 9,665Å LABL, Inc.Office Services & SuppliesFirst Lien Term LoanSOFR+5.00%10.42%10/29/20283,962Å 3,815Å 3,955Å LaserAway Intermediate Holdings II, LLCHealth Care ServicesFirst Lien Term LoanSOFR+5.75%11.32%10/14/20277,369Å 7,269Å 7,267Å Lighthouse Intermediate, L.P.Real Estate ServicesFirst Lien Term LoanSOFR+5.00%10.65%5/9/202611,249Å 11,106Å 10,912Å (4)McAfee Corp.Systems SoftwareFirst Lien Term LoanSOFR+3.75%9.18%3/1/20295,940Å 5,654Å 5,812Å Mindbody, Inc.Internet Services & InfrastructureFirst Lien RevolverSOFR+7.00%2/14/2025æ"Å (2)(8)(4)(5)Mindbody, Inc.Internet Services & InfrastructureFirst Lien Term LoanSOFR+7.00%12.52%2/14/20254,669Å 4,648Å 4,594Å (4)Mitchell International, Inc.Application SoftwareFirst Lien Term LoanSOFR+3.75%69.18%10/15/20282,985Å 2,845Å 2,941Å MRI Software LLCApplication SoftwareFirst Lien RevolverSOFR+5.50%2/10/2026æ"Å (3)(7)(4)(5)MRI Software LLCApplication SoftwareFirst Lien Term LoanSOFR+5.50%10.99%2/10/20268,319Å 8,164Å 8,147Å (4)MRI Software LLCApplication SoftwareFirst Lien Term LoanSOFR+5.50%10.99%2/10/20262,211Å 2,210Å 2,165Å (4)Northern Star Industries Inc.Electrical Components & EquipmentFirst Lien Term LoanSOFR+4.76%10.15%3/31/20256,615Å 6,608Å 6,565Å OEConnection LLCApplication SoftwareFirst Lien Term LoanSOFR+4.00%69.43%6/25/202610,987Å 10,827Å 10,971Å Park Place Technologies, LLCInternet Services & InfrastructureFirst Lien Term LoanSOFR+5.00%10.42%11/10/20279,825Å 9,492Å 9,988Å (4)Planview Parent, Inc.Application SoftwareFirst Lien Term LoanSOFR+4.00%69.65%12/17/20272,416Å 2,298Å 2,390Å Planview

Parent, Inc.Application SoftwareSecond Lien Term LoanSOFR+7.25%12.74%12/18/20284,503Å 4,435Å 4,098Å (4)Pluralsight, LLCApplication SoftwareFirst Lien Term LoanSOFR+8.00%13.45%4/6/2027318Å 301Å 297Å (4)(5)Pluralsight, LLCApplication SoftwareFirst Lien Term LoanSOFR+8.00%13.45%4/6/20278,116Å 7,850Å 7,773Å (4)Renaissance Holding Corp.Education ServicesFirst Lien Term LoanSOFR+4.75%9.99%4/5/20305,000Å 4,860Å 4,969Å SHO Holding I CorporationFootwearFirst Lien Term LoanSOFR+5.23%10.86%4/27/2024138Å 138Å 94Å SHO Holding I CorporationFootwearFirst Lien Term LoanSOFR+5.25%10.88%4/27/20248,113Å 8,111Å 5,531Å SM Wellness Holdings, Inc.Health Care ServicesFirst Lien Term LoanSOFR+4.75%10.38%4/17/20282,977Å 2,580Å 2,799Å (4)Southern Veterinary Partners, LLCHealth Care FacilitiesFirst Lien Term LoanSOFR+4.00%6.9.43%10/5/20277,680Å 7,642Å 7,643Å Spanx, LLCApparel RetailFirst Lien Term LoanSOFR+5.25%10.67%11/20/20288,843Å 8,713Å 8,717Å (4)SPX Flow, Inc.Industrial Machinery & Supplies & ComponentsFirst Lien Term LoanSOFR+4.50%9.92%4/5/20298,801Å 8,442Å 8,794Å Star Parent, Inc.Life Sciences Tools & ServicesFirst Lien Term LoanSOFR+4.00%6.9.33%6/19/20308,000Å 7,880Å 7,834Å TIBCO SoftwareFirst Lien Term LoanSOFR+4.50%6.99%3/30/20298,215Å 7,559Å 7,913Å Touchstone Acquisition, Inc.Health Care SuppliesFirst Lien Term LoanSOFR+6.00%11.42%12/29/20287,212Å 7,103Å 7,022Å (4)Veritas US Inc.Application SoftwareFirst Lien Term LoanSOFR+5.00%10.43%9/1/20256,305Å 6,257Å 5,500Å Windstream Services II, LLCIntegrated Telecommunication ServicesFirst Lien Term LoanSOFR+6.25%11.67%9/21/20276,148Å 6,008Å 5,939Å (4)WP CPP Holdings, LLC Aerospace & DefenseFirst Lien Term LoanSOFR+3.75%9.27%4/30/20251,965Å 1,920Å 1,855Å (4)Total Portfolio Investments\$332,637Å \$331,808Å \$322,179Å (1) Represents the interest rate as of SeptemberÅ 30, 2023. All interest rates are payable in cash, unless otherwise noted.(2) The interest rate on the principal balance outstanding for most of the floating rate loans is indexed to SOFR and/or LIBOR, which typically resets semi-annually, quarterly, or monthly at the borrower's option. The borrower may also elect to have multiple interest reset periods for each loan. For each of these loans, the Company has provided the applicable margin over the reference rates based on each respective credit agreement and the cash interest rate as of period end. As of SeptemberÅ 30, 2023, the reference rates for SLF JV I's variable rate loans were the 30-day SOFR at 5.32%, the 90-day SOFR at 5.39% and the 30-day LIBOR at 5.43%. Most loans include an interest floor, which generally ranges from 0% to 1%. SOFR based contracts may include a credit spread adjustment that is charged in addition to the base rate and the stated spread.(3) Represents the current determination of fair value as of SeptemberÅ 30, 2023 utilizing a similar technique as the Company in accordance with ASC 820. However, the determination of such fair value is not included in the valuation process described elsewhere herein.(4) This investment was held by both the Company and SLF JV I as of SeptemberÅ 30, 2023.(5) Investment had undrawn commitments. Unamortized fees are classified as unearned income which reduces cost basis, which may result in a negative cost basis. A negative fair value may result from the unfunded commitment being valued below par.Glick JV Portfolio as of JuneÅ 30, 2024Portfolio Company IndustryInvestment TypeIndexSpreadÅ Cash Interest Rate (1)(2)PIKMaturity DatePrincipalCostFairÅ Value (3)NotesAccess CIG, LLC Diversified Support ServicesFirst Lien Term LoanSOFR+5.00%10.33%6/18/20288,1985Å 1,951Å 2,000Å (4)ADB Companies, LLC Construction & EngineeringFirst Lien Term LoanSOFR+6.50%11.82%12/18/2025546Å 542Å 529Å (4)ADB Companies, LLC Construction & EngineeringFirst Lien Term LoanSOFR+6.50%12.10%12/18/20253,462Å 3,440Å 3,359Å (4)Alvogen Pharma US, Inc.PharmaceuticalsFirst Lien Term LoanSOFR+7.50%12.98%6/30/20255,981Å 5,956Å 5,532Å (4)American Tire Distributors, Inc.DistributorsFirst Lien Term LoanSOFR+6.25%11.84%10/20/20281,988Å 1,963Å 1,450Å (4)Artera Services LLC Construction & EngineeringFirst Lien Term LoanSOFR+4.50%6.9.83%2/15/20312,494Å 2,475Å 2,510Å ASP-R-PAC Acquisition Co LLC Paper & Plastic Packaging Products & MaterialsFirst Lien Term LoanSOFR+6.00%11.59%12/29/20271,703Å 1,684Å 1,620Å (4)ASP-R-PAC Acquisition Co LLC Paper & Plastic Packaging Products & MaterialsFirst Lien RevolverSOFR+6.00%11.46%12/29/202785Å 83Å 75Å (4)(5)Astra Acquisition Corp.Application SoftwareFirst Lien Term LoanSOFR+6.75%12.08%2/25/20281,050Å 1,037Å 963Å (4)Astra Acquisition Corp.Application SoftwareFirst Lien Term LoanSOFR+5.25%10.58%10/25/20281,661Å 1,665Å 779Å (4)Asurion, LLC Property & Casualty InsuranceFirst Lien Term LoanSOFR+4.25%6.9.69%6/19/2028988Å 943Å 981Å Asurion, LLC Property & Casualty InsuranceFirst Lien Term LoanSOFR+4.00%9.44%6/19/20283,157Å 3,077Å 3,126Å athenahealth Group Inc.Health Care TechnologyFirst Lien Term LoanSOFR+3.25%8.59%2/15/20292,950Å 2,852Å 2,944Å Aurora Lux Fincos S.Å. R.L.Airport ServicesFirst Lien Term LoanSOFR+7.00%8.43%4.00%12/24/20263,738Å 3,706Å 3,611Å (4)BAART Programs, Inc.Health Care ServicesFirst Lien Term LoanSOFR+5.00%10.60%6/11/20273,337Å 3,306Å 3,207Å (4)BAART Programs, Inc.Health Care ServicesFirst Lien Term LoanSOFR+5.00%10.60%6/11/2027794Å 789Å 763Å (4)Bausch & Lomb CorporationHealth Care SuppliesFirst Lien Term LoanSOFR+3.25%8.69%5/10/20273,728Å 3,660Å 3,693Å Cloud Software Group, Inc.Application SoftwareFirst Lien Term LoanSOFR+4.00%6.9.33%3/30/20292,627Å 2,454Å 2,629Å Covetrus, Inc.Health Care DistributorsFirst Lien Term LoanSOFR+5.00%10.33%10/13/20292,745Å 2,607Å 2,661Å (4)Crown Subsea Communications Holding, Inc.Alternative CarriersFirst Lien Term LoanSOFR+4.75%10.08%1/30/20313,000Å 2,970Å 3,012Å (4)Curium Bidco S.Å. r.l.PharmaceuticalsFirst Lien Term LoanSOFR+4.00%6.9.33%7/31/20292,820Å 2,799Å 2,836Å Dealer Tire Financial, LLC DistributorsFirst Lien Term LoanSOFR+3.75%9.09%12/14/20274,074Å 4,065Å 4,076Å DirecTV Financing, LLC Cable & SatelliteFirst Lien Term LoanSOFR+5.25%10.71%8/2/20293,028Å 3,002Å 3,018Å (4)DITI Holdco, Inc.Research & Consulting ServicesFirst Lien Term LoanSOFR+4.75%10.09%4/26/20293,543Å 3,496Å 3,562Å (4)Eagle Parent Corp.Diversified Support ServicesFirst Lien Term LoanSOFR+4.25%6.9.58%4/2/2029393Å 388Å 383Å Frontier Communications Holdings, LLC Integrated Telecommunication ServicesFirst Lien Term LoanSOFR+3.50%8.85%7/1/20313,000Å 2,985Å 3,000Å Portfolio Company IndustryInvestment TypeIndexSpreadÅ Cash Interest Rate (1)(2)PIKMaturity DatePrincipalCostFairÅ Value (3)NotesFrontier Communications Holdings, LLC Integrated Telecommunication ServicesFirst Lien Term LoanSOFR+3.75%6.9.21%10/8/20275,186Å \$1,842Å \$1,863Å Harbor Purchaser Inc.Education ServicesFirst Lien Term LoanSOFR+5.25%10.70%4/9/20293,930Å 3,849Å 3,750Å (4)Husky Injection Molding Systems Ltd.Industrial Machinery & Supplies & ComponentsFirst Lien Term LoanSOFR+5.00%10.33%2/15/20292,433Å 2,400Å 2,442Å Indivior Finance S.Å. R.L.PharmaceuticalsFirst Lien Term LoanSOFR+5.25%10.71%6/30/20263,880Å 3,848Å 3,875Å INW Manufacturing, LLC Personal Care ProductsFirst Lien Term LoanSOFR+5.75%11.35%3/25/20272,156Å 2,126Å 1,811Å (4)KDC US Holdings, Inc.Personal Care ProductsFirst Lien Term LoanSOFR+4.50%9.84%8/15/20283,551Å 3,448Å 3,565Å LABL, Inc.Office Services & SuppliesFirst Lien Term LoanSOFR+5.00%10.44%10/29/202895Å 974Å 984Å (4)LaserAway Intermediate Holdings II, LLC Health Care ServicesFirst Lien Term LoanSOFR+5.75%11.33%10/14/20273,900Å 3,857Å 3,916Å Mitchell International, Inc.Application SoftwareFirst Lien Term LoanSOFR+3.25%8.59%6/17/20312,500Å 2,488Å 2,482Å Peraton Corp.Aerospace & DefenseFirst Lien Term LoanSOFR+3.75%9.19%2/1/2028992Å 992Å 993Å PetSmart LLC Other Specialty RetailFirst Lien Term LoanSOFR+3.75%6.9.19%2/1/20282,987Å 2,949Å 2,982Å Pluralsight, LLC Application SoftwareFirst Lien Term LoanSOFR+8.00%4/6/20275,182Å 5,052Å 2,539Å (4)(6)Pluralsight, LLC Application SoftwareFirst Lien RevolverSOFR+8.00%4/6/2027360Å 349Å 176Å (4)(6)Renaissance Holding Corp.Education ServicesFirst Lien Term LoanSOFR+4.25%6.9.60%4/5/20301,990Å 1,985Å 1,991Å SCIH Salt Holdings Inc.Diversified ChemicalsFirst Lien Term LoanSOFR+3.50%8.83%3/16/20271,486Å 1,486Å 1,489Å Shearer's Foods LLC Packaged Foods & MeatsFirst Lien Term LoanSOFR+4.00%6.9.34%2/12/20313,000Å 2,970Å 3,025Å SHO Holding I CorporationFootwearFirst Lien Term LoanSOFR+5.25%4/6/27/20246,089Å 6,119Å 5,224Å (6)SHO Holding I CorporationFootwearFirst Lien Term LoanSOFR+5.23%4/27/2024104Å 104Å 89Å (6)SHO Holding I CorporationFootwearFirst Lien Term LoanSOFR+8.00%13.44%8/29/2024698Å 664Å 698Å Southern Veterinary Partners, LLC Health Care FacilitiesFirst Lien Term LoanSOFR+3.75%6.9.09%10/5/20273,275Å 3,258Å 3,286Å SPX Flow, Inc.Industrial Machinery & Supplies & ComponentsFirst Lien Term LoanSOFR+3.50%8.84%4/5/20294,185Å 4,049Å 4,214Å Staples, Inc.Office Services & SuppliesFirst Lien Term LoanSOFR+5.75%11.08%9/4/20291,919Å 1,843Å 1,765Å (4)Star Parent, Inc.Life Sciences Tools & ServicesFirst Lien Term LoanSOFR+3.75%6.9.08%9/27/20303,990Å 3,930Å 3,992Å SupplyOne, Inc. Paper & Plastic Packaging Products & MaterialsFirst Lien Term LoanSOFR+4.25%6.9.59%4/19/20311,496Å 1,481Å 1,500Å Swissport Stratosphere USA LLC Air Freight & LogisticsFirst Lien Term LoanSOFR+4.25%6.9.56%4/4/20312,000Å 1,990Å 2,008Å Tacala, LLC RestaurantsFirst Lien Term LoanSOFR+4.00%6.9.34%1/31/20313,990Å 3,980Å 4,012Å Touchstone Acquisition, Inc.Health Care SuppliesFirst Lien Term LoanSOFR+6.00%11.43%12/29/20282,917Å 2,932Å 2,908Å (4)Trident TPI Holdings, Inc.Metal, Glass & Plastic ContainersFirst Lien Term LoanSOFR+4.00%6.9.34%6/15/20282,500Å 2,500Å 2,507Å Total Portfolio Investments\$139,298Å \$137,360Å \$132,405Å (1) Represents the interest rate as of JuneÅ 30, 2024. All interest rates are payable in cash, unless otherwise noted. (2) The interest rate on the principal balance outstanding for all of the floating rate loans is indexed to SOFR, which typically resets semi-annually, quarterly, or monthly at the borrower's option. The borrower may also elect to have multiple interest reset periods for each loan. For each of these loans, the Company has provided the applicable margin over the reference rates based on each respective credit agreement and the cash interest rate as of period end. As of JuneÅ 30, 2024, the reference rates for the Glick JV's variable rate loans were the 30-day SOFR at 5.34% and the 90-day SOFR at 5.32%. Most loans include an interest floor, which generally ranges from 0% to 2%. SOFR based contracts may include a credit spread adjustment that is charged in addition to the base rate and the stated spread.(3) Represents the current determination of fair value as of JuneÅ 30, 2024 utilizing a similar technique as the Company in accordance with ASC 820. However, the determination of such fair value is not included in the valuation process described elsewhere herein.(4) This investment was held by both the Company and the Glick JV as of JuneÅ 30, 2024.(5) Investment had undrawn commitments. Unamortized fees are classified as unearned income which reduces cost basis, which may result in a negative cost basis. A negative fair value may result from the unfunded commitment being valued below par.(6) This investment was on non-accrual status as of JuneÅ 30, 2024. Glick JV Portfolio as of SeptemberÅ 30, 2023Portfolio Company IndustryInvestment TypeIndexSpreadÅ Cash Interest Rate (1)(2)PIKMaturity DatePrincipalCostFairÅ Value (3)NotesAccess CIG, LLC Diversified Support ServicesFirst Lien Term LoanSOFR+5.00%10.32%8/18/202882,000Å 1,960Å 1,978Å ADB Companies, LLC Construction & EngineeringFirst Lien Term LoanSOFR+6.50%11.90%12/18/2025574Å 568Å 564Å (4)ADB Companies, LLC Construction & EngineeringFirst Lien Term LoanSOFR+6.50%12.15%12/18/20253,746Å 3,709Å 3,678Å (4)Alvogen Pharma US, Inc.PharmaceuticalsFirst Lien Term LoanSOFR+7.50%13.04%6/30/20256,230Å 6,185Å 5,819Å (4)American Rock Salt Company LLC Diversified Metals & MiningFirst Lien Term LoanSOFR+4.00%6.9.43%6/9/20282,478Å 2,367Å 2,307Å American Tire Distributors, Inc.DistributorsFirst Lien Term LoanSOFR+6.25%11.81%10/20/20282,860Å 2,825Å 2,514Å (4)Amplify Fincos Pty Ltd.Movies & EntertainmentFirst Lien Term LoanSOFR+4.15%9.54%11/26/20262,895Å 2,866Å 2,895Å Amynta Agency Borrower Inc.Property & Casualty InsuranceFirst Lien Term LoanSOFR+5.00%10.42%2/28/20282,932Å 2,913Å 2,997Å Anastasia Parent, LLC Personal Care ProductsFirst Lien Term LoanSOFR+3.75%6.9.40%8/11/2025907Å 705Å 654Å (4)ASP-R-PAC Acquisition Co LLC Paper & Plastic Packaging Products & MaterialsFirst Lien Term LoanSOFR+6.00%11.63%12/29/20271,716Å 1,692Å 1,616Å (4)ASP-R-PAC Acquisition Co LLC Paper & Plastic Packaging Products & MaterialsFirst Lien RevolverSOFR+6.00%12/29/20278Å (4)(3)(12)(4)(5)Astra Acquisition Corp.Application SoftwareFirst Lien Term LoanSOFR+5.25%10.90%10/25/20282,078Å 2,039Å 1,570Å (4)Asurion, LLC Property & Casualty InsuranceFirst Lien Term LoanSOFR+4.00%6.9.42%6/19/20281,980Å 1,899Å 1,924Å Asurion, LLC Property & Casualty InsuranceFirst Lien Term LoanSOFR+4.25%6.9.67%6/19/2028995Å 942Å 968Å Asurion, LLC Property & Casualty InsuranceSecond Lien Term LoanSOFR+5.25%10.68%1/20/20292,423Å 2,244Å 2,158Å athenahealth Group Inc.Health Care TechnologyFirst Lien Term LoanSOFR+3.25%8.57%2/15/20291,772Å 1,674Å 1,744Å Aurora Lux Fincos S.Å. R.L.Airport ServicesFirst Lien Term LoanSOFR+6.00%11.49%12/24/20263,628Å 3,586Å 3,478Å (4)BAART Programs, Inc.Health Care ServicesFirst Lien Term LoanSOFR+5.00%10.65%6/11/2027800Å 795Å 780Å (4)Covetrus, Inc.Health Care DistributorsFirst Lien Term LoanSOFR+5.00%10.39%10/13/20292,766Å 2,607Å 2,741Å (4)Curium Bidco S.Å. r.l.BiotechnologyFirst Lien Term LoanSOFR+4.50%6.9.89%7/31/20292,841Å 2,820Å 2,841Å DirecTV Financing, LLC Cable & SatelliteFirst Lien Term LoanSOFR+5.00%10.43%8/2/20272,460Å 2,435Å 2,410Å (4)DITI Holdco, Inc.Research & Consulting ServicesFirst Lien Term LoanSOFR+4.75%10.12%4/26/20292,970Å 2,922Å 2,899Å (4)Gibson Brands, Inc.Leisure ProductsFirst Lien Term LoanSOFR+5.00%10.57%8/11/20283,930Å 3,891Å 3,301Å (4)Harbor Purchaser Inc.Education ServicesFirst Lien Term LoanSOFR+5.25%10.67%9/4/20293,960Å 3,865Å 3,759Å (4)Indivior Finance S.Å. R.L.PharmaceuticalsFirst Lien Term LoanSOFR+5.25%10.90%6/30/20263,910Å 3,866Å 3,915Å INW Manufacturing, LLC Personal Care ProductsFirst Lien Term LoanSOFR+5.75%11.40%3/25/20272,250Å 2,210Å 1,770Å (4)KDC/ONE Development Corp IncPersonal Care ProductsFirst Lien Term LoanSOFR+5.00%10.32%8/15/20284,500Å 4,350Å 4,349Å Portfolio Company IndustryInvestment TypeIndexSpreadÅ Cash Interest Rate (1)(2)PIKMaturity DatePrincipalCostFairÅ Value (3)NotesLaserAway Intermediate Holdings II, LLC Health Care ServicesFirst Lien Term LoanSOFR+5.75%11.32%10/14/2027\$3,930Å \$3,877Å \$3,876Å MRI Software LLC Application SoftwareFirst Lien Term LoanSOFR+5.50%10.99%2/10/20261,630Å 1,616Å 1,596Å (4)MRI Software LLC Application SoftwareFirst Lien RevolverSOFR+5.50%2/10/20266Å (4)(1)(3)(4)(5)Northern Star Industries Inc.Electrical Components & EquipmentFirst Lien Term LoanSOFR+4.76%10.15%3/31/20255,198Å 5,192Å 5,159Å OEConnection LLC Application SoftwareFirst Lien Term LoanSOFR+4.00%6.9.43%6/25/20263,849Å 3,830Å 3,843Å Planview Parent, Inc.Application SoftwareFirst Lien Term LoanSOFR+4.00%6.9.65%12/17/2027683Å 650Å 676Å Planview Parent, Inc.Application SoftwareSecond Lien Term LoanSOFR+7.25%12.74%12/18/20282,842Å 2,799Å 2,586Å (4)Pluralsight, LLC Application SoftwareFirst Lien Term LoanSOFR+8.00%13.45%4/6/20275,182Å 5,029Å 4,964Å (4)Pluralsight, LLC Application SoftwareFirst Lien RevolverSOFR+8.00%13.45%4/6/2027226Å 216Å 211Å (4)(5)SHO Holding I CorporationFootwearFirst Lien Term LoanSOFR+5.25%10.88%4/27/20246,029Å 6,025Å 4,110Å SHO Holding I CorporationFootwearFirst Lien Term LoanSOFR+5.23%10.86%4/27/2024103Å 102Å 70Å Southern Veterinary Partners, LLC Health Care FacilitiesFirst Lien Term LoanSOFR+4.00%6.9.43%10/5/20273,292Å 3,275Å 3,276Å Spanx, LLC Apparel RetailFirst Lien Term LoanSOFR+5.25%10.67%11/20/20284,913Å 4,840Å 4,843Å (4)SPX Flow, Inc.Industrial Machinery & Supplies & ComponentsFirst Lien Term LoanSOFR+4.50%6.9.92%4/5/20295,227Å 5,032Å 5,224Å Star Parent, Inc.Life Sciences Tools & ServicesFirst Lien Term LoanSOFR+4.00%6.9.33%9/27/20304,000Å 3,939Å 3,916Å TIBCO Software Inc.Application SoftwareFirst Lien Term LoanSOFR+4.50%6.9.99%3/30/20292,641Å 2,439Å 2,544Å Touchstone Acquisition, Inc.Health Care SuppliesFirst Lien Term LoanSOFR+6.00%11.42%12/29/20282,993Å 2,948Å 2,914Å (4)Windstream Services II, LLC Integrated Telecommunication ServicesFirst Lien Term LoanSOFR+6.25%11.67%9/21/20273,843Å 3,756Å 3,712Å (4)WP CPP Holdings, LLC Aerospace & DefenseFirst Lien Term LoanSOFR+3.75%9.27%4/30/2025983Å 960Å 927Å (4)Total Portfolio Investments\$130,589Å \$127,788Å \$123,343Å (1) Represents the interest rate as of SeptemberÅ 30, 2023. All interest rates are payable in cash, unless otherwise noted. (2) The interest rate on the principal balance outstanding for all of the floating rate loans is indexed to SOFR, which typically resets semi-annually, quarterly, or monthly at the borrower's option. The borrower may also elect to have multiple interest reset periods for each loan. For each of these loans, the Company has provided the applicable margin over the reference rates based on each respective credit agreement and the cash interest rate as of period end. As of SeptemberÅ 30, 2023, the reference rates for the Glick JV's variable rate loans were the 30-day SOFR at 5.32% and the 90-day SOFR at 5.39%. Most loans include an interest floor, which generally ranges from 0% to 1%. SOFR based contracts may include a credit spread adjustment that is charged in addition to the base rate and the stated spread.(3) Represents the current determination of fair value as of SeptemberÅ 30, 2023 utilizing a similar technique as the Company in accordance with ASC 820. However, the determination of such fair value is not included in the valuation process described elsewhere herein.(4) This investment was held by both the Company and the Glick JV as of SeptemberÅ 30, 2023.(5) Investment had undrawn commitments. Unamortized fees are classified as unearned income which reduces cost basis, which may result in a negative cost basis. A negative fair value may result from the unfunded commitment being valued below par. Schedule of Financial Instruments Carried at Fair Value The following table presents the financial instruments carried at fair value as of JuneÅ 30, 2024 on the Company's Consolidated Statement of Assets and Liabilities for each of the three levels of hierarchy established by ASCÅ 820: LevelÅ 1LevelÅ 2Level Å 3Measured at Net Asset Value (a)Total Investments in debt securities (senior secured)\$Å 291,086Å \$2,393,159Å \$Å 2,684,245Å Investments in debt securities (subordinated, including the debt investments in the JVs, CLO Notes and Credit Linked Notes)\$Å 49,123Å 230,484Å Å 279,607Å Investments in equity securities (preferred)\$Å 63,892Å Å 63,892Å Investments in equity securities (common and warrants, including LLC equity interests of the JVs)\$1,463Å 2,175Å 64,504Å 25,817Å 93,959Å Total investments at fair value1,463Å 342,384Å 2,752,039Å 25,817Å 3,121,703Å Cash equivalents\$37,364Å Å 37,364Å Derivative assets\$Å 436Å Å 436Å Total assets at fair value\$38,827Å \$342,820Å \$2,752,039Å \$25,817Å \$3,159,503Å Derivative liabilities\$Å 33,672Å \$Å 33,672Å \$Å 33,672Å Total liabilities at fair value\$Å 33,672Å \$Å 33,672Å \$Å 33,672Å (a) In accordance with ASC 820-10, certain investments that are measured using the net asset value per share (or its equivalent) as a

practical expedient for fair value have not been classified in the fair value hierarchy. These investments are generally not redeemable. The fair value amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the amounts presented in the Consolidated Statements of Assets and Liabilities. The following table presents the financial instruments carried at fair value as of SeptemberÂ 30, 2023 on the Company's Consolidated Statement of Assets and Liabilities for each of the three levels of hierarchy established by ASCÂ 820:Level1Level12Level 3Measured at Net Asset Value (a)TotalInvestments in debt securities (senior secured)\$â€ 208,694Â \$2,292,691Â \$â€ 2,501,385Â Investments in debt securities (subordinated, including the debt investments in the JVs and CLO Notes)\$â€ 28,666Â 189,724Â \$â€ 218,390Â Investments in equity securities (preferred)\$â€ 4Â \$â€ 86,057Â \$â€ 86,057Â Investments in equity securities (common and warrants, including LLC equity interests of the JVs)4,317Â 1,953Â 51,440Â 28,878Â 86,588Â Total investments at fair value4,317Â 239,313Â 2,619,912Â 28,878Â 2,892,420Â Cash equivalents83,262Â \$â€ 4Â \$â€ 4Â \$â€ 83,262Â Derivative assetsâ€ 4,910Â \$â€ 4Â \$â€ 4,910Â Total assets at fair values87,579Â \$244,223Â \$2,619,912Â \$28,878Â \$2,980,592Â Derivative liabilities\$â€ 47,519Â \$â€ 47,519Â \$â€ 47,519Â Total liabilities at fair values\$â€ 47,519Â \$â€ 47,519Â \$â€ 47,519Â (a)In accordance with ASC 820-10, certain investments that are measured using the net asset value per share (or its equivalent) as a practical expedient for fair value have not been classified in the fair value hierarchy. These investments are generally not redeemable. The fair value amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the amounts presented in the Consolidated Statements of Assets and Liabilities. Schedule of Roll-Forward in the Changes in Fair Value The following table provides a roll-forward in the changes in fair value from March 31, 2024 to JuneÂ 30, 2024 for all investments for which Oaktree determined fair value using unobservable (Level1)3 factors:InvestmentsSenior Secured DebtSubordinatedDebt (including debt investments in the JVs and credit linked notes) PreferredEquityCommonEquity and WarrantsTotalFair value as of March 31, 2024\$2,327,422Â \$200,115Â \$62,602Â \$77,286Â \$2,667,425Â Purchases 193,956Â 30,480Â \$â€ 169Â 224,605Â Sales and repayments(113,234)\$â€ 4Â \$â€ 4Â (113,234)Capitalized PIK interest income6,287Â 614Â \$â€ 4Â 6,901Â Accretion of OID2,600Â 349Â \$â€ 4Â \$â€ 2,949Â Net unrealized appreciation (depreciation)7,640Â (1,074)38,883Â (12,951)32,498Â Net realized gains (losses)(31,512)\$â€ 47,519Â \$â€ 47,519Â (37,593)\$â€ 47,519Â Fair value as of June 30, 2024\$2,393,159Â \$230,484Â \$63,892Â \$64,504Â \$2,752,039Â Net unrealized appreciation (depreciation)Â relating to Level 3 investments still held as of June 30, 2024 and reported within net unrealized appreciation (depreciation) in the Consolidated Statement of Operations for the three months ended June 30, 2024\$(36,501)\$(1,074)1,287Â \$(14,762)\$(51,050)The following table provides a roll-forward in the changes in fair value from March 31, 2023 to JuneÂ 30, 2023 for all investments for which the Company determined fair value using unobservable (Level1)3 factors:InvestmentsSenior Secured DebtSubordinatedDebt (including debt investments in the JVs)PreferredEquityCommonEquity and WarrantsTotalFair value as of March 31, 2023\$2,493,622Â \$183,756Â \$91,447Â \$25,509Â \$2,794,334Â Purchases 228,375Â 4,183Â \$â€ 182Â 232,740Â Sales and repayments(191,409)(350)\$â€ 47,320(199,079)Transfers out (a)\$â€ 47,320(2,708)\$â€ 47,320(2,708)Capitalized PIK interest income3,610Â 358Â \$â€ 4Â 3,968Â Accretion of OID4,086Â 381Â \$â€ 4Â 4,467Â Net unrealized appreciation (depreciation) (8,027)(704)739Â 1,893Â (6,099)Net realized gains (losses)(1,809)\$â€ 47,320Â \$â€ 47,320Â 1,725)Fair value as of June 30, 2023\$2,528,528,448Â \$184,916Â \$92,186Â \$20,348Â \$2,825,898Â Net unrealized appreciation (depreciation)Â relating to Level 3 investments still held as of June 30, 2023 and reported within net unrealized appreciation (depreciation) in the Consolidated Statement of Operations for the three months ended June 30, 2023\$(10,360)\$(704)\$739Â \$1,095Â \$(9,230) (a) There were transfers out of Level 3 to Level 2 for certain investments during the three months ended JuneÂ 30, 2023 as a result of a change in the number of market quotes available and/or a change in market liquidity. The following table provides a roll-forward in the changes in fair value from SeptemberÂ 30, 2023 to JuneÂ 30, 2024 for all investments for which Oaktree determined fair value using unobservable (Level1)3 factors:InvestmentsSenior Secured DebtSubordinatedDebt (including debt investments in the JVs and credit linked notes) PreferredEquityCommonEquity and WarrantsTotalFair value as of September 30, 2023\$2,292,691Â \$189,724Â \$86,057Â \$51,440Â \$2,619,912Â Purchases 656,630Â 47,507,758Â 1,749Â 713,464Â Sales and repayments(506,977)(4,932)(205)(860)(512,974)Transfers in (a) (b)23,535Â \$â€ 47,320Â \$â€ 47,320Â 39,702Â 63,237Â Transfers out (b)(38,544)(4,657)(1,159)(283)(44,643)Capitalized PIK interest income1,571Â 1,685Â \$â€ 47,320Â 19,256Â Accretion of OID8,099Â 984Â \$â€ 47,320Â 9,083Â Net unrealized appreciation (depreciation) (10,702)127Â 9,214Â (25,631)(26,992)Net realized gains (losses)(49,144)463Â (37,593)(1,613)(88,304)Fair value as of June 30, 2024\$2,393,159Â \$230,484Â \$63,892Â \$64,504Â \$2,752,039Â Net unrealized appreciation (depreciation)Â relating to Level 3 investments still held as of June 30, 2024 and reported within net unrealized appreciation (depreciation) in the Consolidated Statement of Operations for the nine months ended June 30, 2024\$(54,217)\$(454)\$3,276Â \$(28,733)\$(80,128) (a) There was a \$18.9Â million transfer into Level 3 from Level 2 for an investment during the nine months ended JuneÂ 30, 2024 as a result of a change in the number of market quotes available and/or a change in market liquidity. (b) There were investment restructurings during the nine months ended JuneÂ 30, 2024 in which (1) \$38.5Â million of Level 3 senior secured debt was exchanged for Level 3 common equity, (2) \$4.7Â million of Level 3 subordinated debt was exchanged for Level 3 senior secured debt, (3) 1.2Â million of Level 3 preferred equity was exchanged for Level 3 common equity and (4) \$0.3Â million of Level 3 common stock was converted to Level 1 common stock. The following table provides a roll-forward in the changes in fair value from September 30, 2022 to JuneÂ 30, 2023 for all investments for which Oaktree determined fair value using unobservable (Level1)3 factors:InvestmentsSenior Secured DebtSubordinatedDebt (including debt investments in the JVs)PreferredEquityCommonEquity and WarrantsTotalFair value as of September 30, 2022\$1,910,606Â \$159,386Â \$79,523Â \$19,958Â \$2,169,475Â PurchasesÂ (a)980,595Â 26,508Â 14,296Â 5,610Â 1,027,009Â Sales and repayments(357,903)(1,396)\$â€ 47,320(8,295) (367,594)Transfers in (b)(19,075)\$â€ 47,320Â \$â€ 47,320Â 19,075Â Capitalized PIK interest income12,549Â 376Â \$â€ 47,320Â 12,925Â Accretion of OID11,684Â 1,109Â \$â€ 47,320Â 12,793Â Net unrealized appreciation (depreciation)(45,019)(1,069)(1,633)2,804Â (44,917)Net realized gains (losses)(3,139)\$â€ 47,320Â \$â€ 47,320Â 2,714Â (2,868)Fair value as of June 30, 2023\$2,528,448Â \$184,916Â \$92,186Â \$20,348Â \$2,825,898Â Net unrealized appreciation (depreciation)Â relating to Level 3 investments still held as of June 30, 2023 and reported within net unrealized appreciation (depreciation) in the Consolidated Statement of Operations for the nine months ended June 30, 2023\$(46,680)\$(1,069)\$(1,633)\$(355)\$(49,737) (a) Includes Level 3 investments acquired in connection with the OS12 Merger during the nine months ended JuneÂ 30, 2023. (b) There was a transfer into Level 3 from Level 2 for an investment during the nine months ended JuneÂ 30, 2023 as a result of a change in the number of market quotes available and/or a change in market liquidity. Schedule of Significant Unobservable Inputs for Level 3 Investments The following table provides quantitative information related to the significant unobservable inputs for Level 3 investments, which are carried at fair value, as of JuneÂ 30, 2024: AssetFair ValueValuation TechniqueUnobservable InputRangeWeightedAverage (a)Senior Secured Debt\$2,110,682Â Market YieldMarket Yield (b)9.0%-39.0%13.8%58,783Â Enterprise ValueRevenue Multiple(c)1.5x-5.5x3.1x33,379Â Enterprise ValueEBITDA Multiple(c)5.5x-6.0x5.8x4,199Â Transaction Precedent Transaction Price(d)N/A-N/AN/A186,116Â Broker QuotationsBroker Quoted Price(e)N/A-N/AN/ASubordinated Debt43,422Â Market YieldMarket Yield (b)10.0%-40.0%11.1%24,500Â Transaction Precedent Transaction Price(d)N/A-N/AN/ADebt Investments in the JVs162,542Â Enterprise ValueN/A(f)N/A-N/AN/APreferred & Common Equity59,829Â Enterprise ValueRevenue Multiple(c)0.4x-6.3x2.5x67,317Â Enterprise ValueEBITDA Multiple(c)0.3x-1.5x1.9x1,250Â Enterprise ValueAsset Multiple(c)1.0x-1.4x1.4xTotal\$2,752,039Â (a)Weighted averages are calculated based on fair value of investments. (b)Used when market participants would take into account market yield when pricing the investment. (c)Used when market participants would use such multiples when pricing the investment. (d)Used when there is an observable transaction or pending event for the investment. (e)Oaktree generally uses prices provided by an independent pricing service which are non-binding indicative prices on or near the valuation date as the primary basis for the fair value determinations for quoted senior secured debt investments. Since these prices are non-binding, they may not be indicative of fair value. Oaktree evaluates the quotations provided by pricing vendors and brokers based on available market information, including trading activity of the subject or similar securities, or by performing a comparable security analysis to ensure that fair values are reasonably estimated. (f)Oaktree determined the value of its subordinated notes of each JV based on the total assets less the total liabilities senior to the subordinated notes held at such JV in an amount not exceeding par under the EV technique. The following table provides quantitative information related to the significant unobservable inputs for Level 3 investments, which are carried at fair value, as of SeptemberÂ 30, 2023: AssetFair ValueValuation TechniqueUnobservable InputRangeWeightedAverage (a)Senior Secured Debt\$1,904,140Â Market YieldMarket Yield (b)9.0%-32.0%14.7%64,802Â Enterprise ValueEBITDA Multiple(c)3.0x-6.0x4.6x33,816Â Transaction Precedent Transaction Price(d)N/A-N/AN/A289,933Â Broker quotationsBroker Quoted Price(e)N/A-N/AN/ASubordinated Debt22,881Â Market YieldMarket Yield (b)10.0%-22.0%11.2%4,170Â Broker QuotationsBroker Quoted Price(e)N/A-N/AN/ADebt Investments in the JVs162,673Â Enterprise ValueN/A(f)N/A-N/AN/APreferred & Common Equity32,318Â Enterprise ValueRevenue Multiple(c)0.4x-3.2x0.5x103,661Â Enterprise ValueEBITDA Multiple(c)1.7x-1.5x1.8x1,097Â Enterprise ValueAsset Multiple(c)1.0x-1.4x1.4x211Â Transaction Precedent Transaction Price(d)N/A-N/AN/ATotal\$2,619,912Â (a)Weighted averages are calculated based on fair value of investments. (b)Used when market participants would take into account market yield when pricing the investment. (c)Used when market participants would use such multiples when pricing the investment. (d)Used when there is an observable transaction or pending event for the investment. (e)Oaktree generally uses prices provided by an independent pricing service which are non-binding indicative prices on or near the valuation date as the primary basis for the fair value determinations for quoted senior secured debt investments. Since these prices are non-binding, they may not be indicative of fair value. Oaktree evaluates the quotations provided by pricing vendors and brokers based on available market information, including trading activity of the subject or similar securities, or by performing a comparable security analysis to ensure that fair values are reasonably estimated. (f)Oaktree determined the value of its subordinated notes of each JV based on the total assets less the total liabilities senior to the subordinated notes held at such JV in an amount not exceeding par under the EV technique. Schedule of Fair Value Disclosure of Asset and Liability Not Measured at Fair Value The following table presents the carrying value and fair value of the Company's financial liabilities disclosed, but not carried, at fair value as of JuneÂ 30, 2024 and the level of each financial liability within the fair value hierarchy:Â CarryingValueFair ValueLevel1Level12Level 3Syndicated Facility payable\$505,000Â \$505,000Â \$â€ 47,320Â \$â€ 47,320Â \$505,000Â OS12 Citibank Facility payable285,000Â 285,000Â \$â€ 47,320Â \$â€ 285,000Â 2025 Notes payable (carrying value is net of unamortized financing costs and unaccreted discount)299,179Â 294,900Â \$â€ 294,900Â \$â€ 2027 Notes payable (carrying value is net of unamortized financing costs, unaccreted discount and interest rate swap fair value adjustment)316,931Â 317,695Â \$â€ 317,695Â \$â€ 2029 Notes payable (carrying value is net of unamortized financing costs, unaccreted discount and interest rate swap fair value adjustment)291,054Â 303,642Â \$â€ 303,642Â \$â€ 2025 Totals\$1,697,164Â \$1,706,237Â \$â€ 916,237Â \$790,000Â The following table presents the carrying value and fair value of the Company's financial liabilities disclosed, but not carried, at fair value as of SeptemberÂ 30, 2023 and the level of each financial liability within the fair value hierarchy:CarryingValueFair ValueLevel1Level12Level 3Syndicated Facility payable\$430,000Â \$430,000Â \$â€ 47,320Â \$â€ 430,000Â OS12 Citibank Facility payable280,000Â 280,000Â \$â€ 47,320Â \$â€ 280,000Â 2025 Notes payable (carrying value is net of unamortized financing costs and unaccreted discount)298,241Â 286,437Â \$â€ 286,437Â \$â€ 2027 Notes payable (carrying value is net of unamortized financing costs, unaccreted discount and interest rate swap fair value adjustment)306,412Â 301,784Â \$â€ 301,784Â \$â€ 2029 Notes payable (carrying value is net of unamortized financing costs, unaccreted discount and interest rate swap fair value adjustment)286,078Â 289,980Â \$â€ 289,980Â \$â€ 2025 Totals\$1,600,731Â \$1,588,201Â \$â€ 878,201Â \$710,000Â Schedule of Portfolio Composition Summaries of the composition of the Company's portfolio at cost as a percentage of total investments and at fair value as a percentage of total investments and net assets are shown in the following tables:Â June 30, 2024September 30, 2023Cost:Â % of Total Investments% of Total InvestmentsSenior secured debt\$2,779,708Â 84.42Â %\$2,594,640Â 85.24Â %Debt investments in the JVs163,963Â 4.98Â %\$162,986Â 5.35Â %Subordinated debt115,937Â 3.52Â %\$159,844Â 1.97Â %Common equity and warrants110,315Â 3.35Â %\$72,261Â 2.37Â %Preferred equity68,218Â 2.07Â %\$99,597Â 3.27Â %LLC equity interests of the JVs54,791Â 1.66Â %\$54,791Â 1.80Â %Totals\$3,292,932Â 100.00Â %\$3,044,119Â 100.00Â %June 30, 2024September 30, 2023Fair Value:Â % of Total Investments% of Net Assets% of Total Investments% of Net AssetsSenior secured debt\$2,684,245Â 85.98Â %\$179,424Â %\$2,501,385Â 86.47Â %\$165.01Â %Debt investments in the JVs162,542Â 5.21Â %\$10,864Â %\$162,673Â 5.62Â %\$10.73Â %Subordinated debt117,065Â 3.75Â %\$7,824Â %\$55,717Â 1.93Â %\$3.68Â %Common equity and warrants68,142Â 2.18Â %\$4,554Â %\$57,710Â 2.00Â %\$3.81Â %Preferred equity63,892Â 2.05Â %\$4,274Â %\$86,057Â 2.98Â %\$5.68Â %LLC equity interests of the JVs25,817Â 0.83Â %\$1.73Â %\$28,878Â 1.00Â %\$1.91Â %Total\$3,121,703Â 100.00Â %\$208.65Â %\$2,892,420Â 100.00Â %\$190.82Â %The geographic composition is determined by the location of the corporate headquarters of the portfolio company, which may not be indicative of the primary source of the portfolio company's business. The following tables show the composition of the Company's portfolio by geographic region at cost as a percentage of total investments and at fair value as a percentage of total investments and net assets:Â June 30, 2024September 30, 2023Cost:Â % of Total InvestmentsÂ % of Total InvestmentsNortheast\$1,050,743Â 31.91Â %\$1,012,955Â 33.27Â %Southeast471,176Â 14.31Â %\$375,247Â 12.33Â %Midwest428,884Â 13.02Â %\$360,506Â 11.84Â %International376,328Â 11.43Â %September 30, 2023Fair Value:Â % of Total Investments% of Net Assets% of Total Investments% of Net AssetsNortheast\$989,346Â 31.69Â %\$66,122Â %\$945,422Â 32.69Â %\$62.37Â %Southeast433,279Â 13.88Â %\$28,964Â %\$354,444Â 12.25Â %\$23.38Â %Midwest422,065Â 13.52Â %\$28.21Â %\$350,620Â 1 is a summary of SLF JV I's portfolio, followed by a listing of the individual loans in SLF JV I's portfolio as of JuneÂ 30, 2024 and SeptemberÂ 30, 2023:June 30, 2024September 30, 2023Senior secured loans (1)\$353,579\$332,637Weighted average interest rate on senior secured loans (2)9.83%10.62%Number of borrowers in SLF JV I4948Largest exposure to a single borrower (1)\$11,161\$11,286Total of five largest loan exposures to borrowers (1)\$53,328\$54,051 (1) At principal amount. (2) Computed using the weighted average annual interest rate on accruing senior secured loans at fair value. Below is a summary of the Click JV's portfolio, followed by a listing of the individual loans in the Click JV's portfolio as of JuneÂ 30, 2024 and SeptemberÂ 30, 2023:June 30, 2024September 30, 2023Senior secured loans (1)\$139,298\$130,589Weighted average current interest rate on senior secured loans (2)9.53%10.77%Number of borrowers in the Click JV4538Largest loan exposure to a single borrower (1)\$6,891\$6,230Total of five largest loan exposures to borrowers (1)\$27,461\$28,396 (1) At principal amount. (2) Computed using the weighted average annual interest rate on accruing senior secured loans at fair value. (Share amounts in thousands)Three months endedJuneÂ 30, 2024Three months endedJuneÂ 30, 2023Nine months endedJuneÂ 30, 2024Nine months endedJuneÂ 30, 2023 (6)Net asset value per share at beginning of period\$18.72\$19.66\$19.63\$20.38Net investment income (10)540.631.631.89Net unrealized appreciation (depreciation) (1)0.33(0.02)(0.28)(0.36)Net realized gains (losses) (1)0.85(0.14)(1.06)(0.28)(Provision) benefit for taxes on realized and unrealized gains (losses) (1)\$â€ 47,320Â (0.01)0.10Distributions of net investment income to stockholders(0.55)(0.55)(1.72)(2.06)Net asset value per share at end of period\$18.19\$18.18\$19.58Per share market value at beginning of period \$19.66\$18.77\$20.12\$18.00Per share market value at end of period \$18.18\$19.43\$18.81\$19.43Total return (2) (1.51)%6.42%2.13%19.58%Common shares outstanding at beginning of period81,39677,08077,2561,255Common shares outstanding at end of period82,24577,08082,24577,080Net assets at beginning of period\$1,524,099\$1,515,150\$1,515,764\$1,245,563Net assets at end of period\$1,496,133\$1,509,441\$1,509,441\$1,509,441Average net assets (3)\$1,524,503\$1,526,644\$1,524,180\$1,407,814Ratio of net investment income to average net assets (7)11.76%12.72%11.40%12.65%Ratio of total expenses to average net assets (7)14.54%14.45%14.42%14.07%Ratio of net expenses to average net assets (7)13.29%14.05%13.75%13.69%Ratio of portfolio turnover to average investments at fair value5.95%7.48%23.97%18.43%Weighted average outstanding debt (4)\$1,711,978\$1,756,758\$1,680,876\$1,640,062Average debt per share (1)\$20.92\$22.79\$21.06\$23.29Asset coverage ratio at end of period (5)183.36%182.05%183.36%182.05% (1) Calculated based upon weighted average shares outstanding for the period. (2) Total return equals the increase or decrease of ending market value over beginning market value, plus distributions, divided by the beginning market value, assuming dividend reinvestment prices obtained under the Company's DRIP. Total return does not include sales load. (3) Calculated based upon the weighted average net assets for the period. (4) Calculated based upon the weighted average of principal debt outstanding for the period. (5) Based on outstanding senior securities of \$1,743.4 million and \$1,785.0 million as of June 30, 2024 and 2023, respectively. (6) The share and per share information disclosed in this table has been retroactively adjusted as necessary to reflect the Company's 1-for-3 reverse stock split completed on January 20, 2023 and effective as of the commencement of trading on January 23, 2023. (7) Interim periods are annualized. Schedule of Summarized Financial Information Below is certain summarized financial information for SLF JV I as of JuneÂ 30, 2024 and SeptemberÂ 30, 2023 and for the three and nine months ended JuneÂ 30, 2024 and 2023: June 30, 2024September 30, 2023Selected Balance Sheet Information:Investments at fair value (cost June 30, 2024) \$353,263; cost September 30, 2023) \$331,808)\$344,930Â \$322,179Â Cash and cash equivalents24,006Â 31,950Â Restricted cash6,994Â 2,987Â Other assets14,840Â 18,988Â Total assets\$390,770Â \$376,104Â Senior credit facility payable\$198,000Â \$149,000Â Secured borrowings13,292Â 38,845Â SLF JV I Notes payable at fair value

(proceeds June 30, 2024: \$128,750; proceeds September 30, 2023: \$128,750)128,750Å Other liabilities21,222Å Total liabilities\$361,264Å \$343,225Å Members' equity 29,506Å 32,879Å Total liabilities and members' equity\$390,770Å \$376,104Å Three months ended June 30, 2024Three months ended June 30, 2023Nine months ended June 30, 2024Nine months ended June 30, 2023Selected Statements of Operations Information:Interest income\$9,463Å \$10,312Å \$28,665Å \$29,106Å Other incomeæ"Å æ"Å 159Å 62Å Total investment income\$9,463Å 10,312Å 28,824Å 29,168Å Senior credit facility and secured borrowing interest expense\$4,071Å 4,190Å 11,910Å 12,004Å SLF JV 1 Notes interest expense\$4,048Å 3,859Å 12,196Å 10,511Å Other expenses\$46Å 73Å 246Å 249Å Total expenses (18,165Å 8,122Å 24,352Å 22,764Å Net investment income1,298Å 2,190Å 4,472Å 6,404Å Net unrealized appreciation (depreciation)(319)2,652Å 1,299Å 4,075Å Net realized gains (losses)(3,784)(2,137)(4,343)(4,850)Net income (loss)\$2,805\$2,705Å 1,428Å \$5,629Å (1) There are no management fees or incentive fees charged at SLF JV I.Below is certain summarized financial information for the Glick JV as of JuneÅ 30, 2024 and SeptemberÅ 30, 2023 and for the three and nine months ended JuneÅ 30, 2024 and 2023: June 30, 2024September 30, 2023Selected Balance Sheet Information:Investments at fair value (cost June 30, 2024: \$137,360; cost September 30, 2023: \$127,788)\$132,405Å 123,343Å Cash and cash equivalents13,109Å 12,119Å Restricted cashæ"Å 184Å Other assets\$4,655Å 5,521Å Total assets\$150,169Å \$141,167Å Senior credit facility payable\$78,000Å \$53,000Å Glick JV Notes payable at fair value (proceeds June 30, 2024: \$66,685; proceeds September 30, 2023: \$66,685)\$7,012Å 57,210Å Secured borrowings\$6,576Å 18,106Å Other liabilities\$8,581Å 12,860Å Total liabilities\$150,169Å \$141,167Å Members' equity æ"Å Å æ"Å Å Total liabilities and members' equity\$150,169Å \$141,167Å Three months ended June 30, 2024Three months ended June 30, 2023Nine months ended June 30, 2024Nine months ended June 30, 2023Selected Statements of Operations Information:Interest income\$3,605Å 3,576Å \$10,926Å \$10,488Å Fee income\$4 Å æ"Å 6Å 35Å Total investment income\$3,609Å 3,576Å 10,990Å 10,523Å Senior credit facility and secured borrowing interest expense1,631Å 1,400Å 4,608Å 4,002Å Glick JV Notes interest expense1,675Å 1,577Å 5,048Å 4,394Å Other expenses\$32Å 70Å 110Å 148Å Total expenses (1)3,388Å 3,047Å 9,766Å 8,544Å Net investment income 271Å 529Å 1,224Å 1,979Å Net unrealized appreciation (depreciation)\$328Å 431Å 321(159)Realized gain (loss)(599)(960)(903) (1,820)Net income (loss)\$æ"Å Å æ"Å Å æ"Å Å æ"Å (1) There are no management fees or incentive fees charged at the Glick JV. X - DefinitionTabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb) -SubTopic 10 -Topic 820 -Publisher FASB -URI <https://asc.fasb.org/>1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/>1943274/2147482106/820-10-50-2Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/>1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -SubTopic 10 -Topic 820 -Publisher FASB -URI <https://asc.fasb.org/>1943274/2147482106/820-10-50-2Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI <https://asc.fasb.org/>1943274/2147482106/820-10-50-3 + Details Name: us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of information about fair value of asset and liability not measured at fair value. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2E -Publisher FASB -URI <https://asc.fasb.org/>1943274/2147482106/820-10-50-2E + Details Name: us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of financial highlights. Includes, but is not limited to, per share information, income and expense ratios, total return, capital commitment and fee waiver. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI <https://asc.fasb.org/>1943274/2147480737/946-205-50-1 + Details Name: us-gaap_InvestmentCompanyFinancialHighlightsTableTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of summarized financial information for nonconsolidated subsidiary of investment company. Excludes information consolidated by reporting entity. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(i)) -Publisher FASB -URI <https://asc.fasb.org/>1943274/2147480678/235-10-599-1 + Details Name: us-gaap_InvestmentCompanyNonconsolidatedSubsidiarySummarizedFinancialInformationTableTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of data and information required in the supplementary schedule applicable to management investment companies listing holdings of unaffiliated investments. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(3) -Publisher FASB -URI <https://asc.fasb.org/>1943274/2147480524/946-210-50-6Reference 2: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(1) -Publisher FASB -URI <https://asc.fasb.org/>1943274/2147480524/946-210-50-6Reference 3: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(2) -Publisher FASB -URI <https://asc.fasb.org/>1943274/2147480524/946-210-50-6Reference 4: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(4) -Publisher FASB -URI <https://asc.fasb.org/>1943274/2147480524/946-210-50-6Reference 5: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b)(2) -Publisher FASB -URI <https://asc.fasb.org/>1943274/2147480524/946-210-50-1 + Details Name: us-gaap_InvestmentHoldingsScheduleOfInvestmentsTableTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfInvestmentsAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 41 R30.htm IDEA: XBRL DOCUMENT v3.24.2 Share Data and Net Assets (Tables) 9 Months Ended Jun. 30, 2024 Stockholders' Equity Note [Abstract] Å Schedule of Basic and Diluted Earnings Per Share The following table sets forth the computation of basic and diluted earnings per share, pursuant to ASC Topic 260-10, Earnings per Share, for the three and nine months ended JuneÅ 30, 2024 and 2023:(Share amounts in thousands)Three months ended June 30, 2024Three months ended June 30, 2023Nine months ended June 30, 2024Nine months ended June 30, 2023Earnings (loss) per common share æ"Å æ"Å basic and diluted:Net increase (decrease) in net assets resulting from operations\$1,120Å \$36,685Å \$20,992Å \$71,379Å Weighted average common shares outstanding æ"Å basic and diluted\$81,830Å 77,080Å 79,404Å 70,431Å Earnings (loss) per common share æ"Å basic and diluted\$0.01Å \$0.48Å \$0.26Å \$1.01Å Schedule of Changes in Net Assets The following table presents the changes in net assets for the three and nine months ended JuneÅ 30, 2024:Common Stock(Share amounts in thousands)SharesPar ValueAdditional paid-in-capitalAccumulated Overdistributed EarningsTotal Net AssetsBalance as of September 30, 202377,225Å \$772Å \$2,166,330Å \$(651,338)\$1,515,764Å Net investment incomeæ"Å Å æ"Å æ"Å 44,189Å 189Å Net unrealized appreciation (depreciation)æ"Å æ"Å æ"Å (25,025)(25,025)Net realized gains (losses)æ"Å æ"Å æ"Å (8,453)(8,453)(Provision) benefit for taxes on realized and unrealized gains (losses)æ"Å æ"Å æ"Å (176)(176)Distributions to stockholdersæ"Å æ"Å æ"Å (48,897)(48,897)Issuance of common stock in connection with the "at the market" offering1,6411732,296æ"Å 32,313Issuance of common stock under dividend reinvestment plan9911,935æ"Å 1,936Balance as of December 31, 202379,965Å \$790Å \$2,200,561Å \$(689,700)\$1,511,651Å Net investment incomeæ"Å Å æ"Å æ"Å 41,367Å 137Å Net unrealized appreciation (depreciation)æ"Å æ"Å æ"Å (25,252)(25,252)Net realized gains (losses)æ"Å æ"Å æ"Å (6,603)(6,603)(Provision) benefit for taxes on realized and unrealized gains (losses)æ"Å æ"Å æ"Å (175)(175)Distributions to stockholdersæ"Å æ"Å æ"Å (44,715)(44,715)Issuance of common stock in connection with the "at the market" offering2,3342345,950æ"Å 45,973Issuance of common stock under dividend reinvestment plan9711,852æ"Å 1,853Balance as of March 31, 202481,396Å \$814Å \$2,248,363Å \$(725,078)\$1,524,099Å Net investment incomeæ"Å Å æ"Å æ"Å 44,575Å 44,575Å Net unrealized appreciation (depreciation)æ"Å æ"Å æ"Å 26,199Å 26,199Å Net realized gains (losses)æ"Å æ"Å æ"Å (69,452)(69,452)(Provision) benefit for taxes on realized and unrealized gains (losses)æ"Å æ"Å æ"Å (202)(202)Distributions to stockholdersæ"Å æ"Å æ"Å (45,180)(45,180)Issuance of common stock in connection with the "at the market" offering749714,214æ"Å 14,221Issuance of common stock under dividend reinvestment plan10011,872æ"Å 1,873Balance as of June 30, 202482,454Å \$822Å \$2,264,449Å \$(769,138)\$1,496,133Å The following table presents the changes in net assets for the three and nine months ended JuneÅ 30, 2023:Common Stock(Share amounts in thousands)SharesPar ValueAdditional paid-in-capitalAccumulated Overdistributed EarningsTotal Net AssetsBalance as of September 30, 2023125,611Å \$1,827,721Å \$(582,769)\$1,245,563Å Net investment incomeæ"Å Å æ"Å æ"Å 38,808Å 38,808Å Net unrealized appreciation (depreciation)æ"Å æ"Å æ"Å (22,982)(22,982)Net realized gains (losses)æ"Å æ"Å æ"Å (3,203)(3,203)(Provision) benefit for taxes on realized and unrealized gains (losses)æ"Å æ"Å æ"Å 549549Distributions to stockholdersæ"Å æ"Å æ"Å (58,679)(58,679)Issuance of common stock under dividend reinvestment plan9511,932æ"Å 1,933Balance as of December 31, 202261,220Å \$612Å \$1,829,653Å \$(628,276)\$1,201,989Å Net investment incomeæ"Å Å æ"Å æ"Å 45,978Å 45,978Å Net unrealized appreciation (depreciation)æ"Å æ"Å æ"Å (18,279)(18,279)Net realized gains (losses)æ"Å æ"Å æ"Å (6,111)(6,111)(Provision) benefit for taxes on realized and unrealized gains (losses)æ"Å æ"Å æ"Å (66)(66)Distributions to stockholdersæ"Å æ"Å æ"Å (42,395)(42,395)Issuance of common stock in connection with the OSII Merger15,860159333,875æ"Å 334,034Issuance of common stock under dividend reinvestment plan6811,294æ"Å 1,295Repurchase of common stock under dividend reinvestment plan(68)(1) (1,294)æ"Å (1,295)Balance as of March 31, 202377,080Å \$771Å \$2,163,528Å \$(649,149)\$1,515,150Å Net investment incomeæ"Å Å æ"Å æ"Å 48,413Å 48,413Å Net unrealized appreciation (depreciation)æ"Å æ"Å æ"Å (1,039)(1,039)Net realized gains (losses)æ"Å æ"Å æ"Å (10,603)(10,603)(Provision) benefit for taxes on realized and unrealized gains (losses)æ"Å æ"Å æ"Å (86)(86)Distributions to stockholdersæ"Å æ"Å æ"Å (42,394)(42,394)Issuance of common stock under dividend reinvestment plan5711,122æ"Å 1,123Repurchase of common stock under dividend reinvestment plan(57)(1) (1,122)æ"Å (1,123)Balance as of June 30, 202377,080Å \$771Å \$2,163,528Å \$(654,858)\$1,509,441Å Schedule of Distributions The following table reflects the distributions per share that the Company has paid, including shares issued under the DRIP, on its common stock during the nine months ended JuneÅ 30, 2024 and 2023: DistributionDate DeclaredRecord DatePayment DateAmountper Å ShareCashDistribution DRIPÅ SharesIssued DRIPÅ SharesValue QuarterlyNovember 8, 2023December 15, 2023December 29, 2023\$0.55Å \$41.7Å million87,472Å (1)\$1.7Å millionSpecialNovember 8, 2023December 15, 2023December 29, 2023\$0.07Å \$5.3Å million11,133Å (1)\$0.2Å millionQuarterlyJanuary 26, 2024March 15, 2024March 29, 2024\$0.55Å \$42.8Å million96,850Å (1)\$1.9Å millionQuarterlyApril 26, 2024June 14, 2024June 28, 2024\$0.55Å \$43.3Å million100,029Å (1)\$1.9Å millionTotal for the nine months ended June 30, 2024\$1.72Å \$133.1Å million295,484Å \$5.7Å millionDistributionDate DeclaredRecord DatePayment DateAmountper Å ShareCashDistribution DRIPÅ SharesIssued DRIPÅ SharesValue (3)QuarterlyNovember 10, 2022December 15, 2022December 30, 2022\$0.54Å \$32.0Å million53,369Å (1)\$1.1Å millionSpecialNovember 10, 2022December 15, 2022December 30, 2022\$0.42Å \$24.8Å million41,510Å (1)\$0.8Å millionQuarterlyJanuary 27, 2023March 15, 2023March 31, 2023\$0.55Å \$41.1Å million68,412Å (2)\$1.3Å millionQuarterlyApril 28, 2023June 15, 2023June 30, 2023\$0.55Å \$41.3Å million57,279Å (2)\$1.1Å millionTotal for the nine months ended June 30, 2023\$2.06Å \$139.1Å million220,570Å \$4.4Å millionÅ (1) New shares were issued and distributed.(2) Shares were purchased on the open market and distributed.(3) Totals may not sum due to rounding. Schedule of Common Stock Issued and Sold in connection with the "at the market" offering, the Company issued and sold 4,724,506 shares of common stock during the nine months ended JuneÅ 30, 2024 for net proceeds of \$92.5Å million (net of offering costs).Number of Shares IssuedGross ProceedsPlacement Agent FeesNet Proceeds (1)Average Sales Price per Share (2)"At the market" offering4,724,506Å \$93,685Å \$937Å \$92,748Å 19.83Å (1) Net proceeds excludes offering costs of \$0.2Å million.(2) Represents the gross sales price before deducting placement agent fees and estimated offering expenses. X - DefinitionTabular disclosure of information related to dividends declared, including paid and unpaid dividends. + ReferencesNo definition available. + Details Name: us-gaap_DividendsDeclaredTableTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of change in net assets (equity) of investment company. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/>1943274/2147480767/946-205-45-4Reference 2: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI <https://asc.fasb.org/>1943274/2147481004/946-505-50-1Reference 3: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/>1943274/2147481004/946-505-50-2Reference 4: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/>1943274/2147481004/946-505-50-2Reference 5: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/>1943274/2147481004/946-505-50-2Reference 6: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI <https://asc.fasb.org/>1943274/2147481004/946-505-50-2Reference 7: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI <https://asc.fasb.org/>1943274/2147480555/946-210-45-3 + Details Name: us-gaap_InvestmentCompanyChangesInNetAssetsTableTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/>1943274/2147482662/260-10-50-1 + Details Name: us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of sales of stock or previously unissued stock made by subsidiary or equity method investee to investors outside the consolidated group. This includes stock issued in a business combination in exchange for shares of an acquired entity. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfSaleOfStockBySubsidiaryOrEquityMethodInvesteeDisclosureTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityNoteAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 42 R31.htm IDEA: XBRL DOCUMENT v3.24.2 Borrowings (Tables) 9 Months Ended Jun. 30, 2024 Debt Disclosure [Abstract] Å Schedule of Components of Debt The below table presents the components of the carrying value of the 2025 Notes, the 2027 Notes and the 2029 Notes as of JuneÅ 30, 2024 and SeptemberÅ 30, 2023:Å As of June 30, 2024Å As of

September 30, 2023(\$ in millions)2025 Notes2027 Notes2029 Notes2025 Notes2029 NotesPrincipal\$300.0Ã \$350.0Ã \$300.0Ã \$350.0Ã \$300.0Ã Ã A Unamortized financing costs(0.5)(1.9)(3.0)(1.1)(2.5)(3.5)Ã A Unaccrued discount(0.3)(0.5)(2.9)(0.7)(0.6)(3.4)Ã A Interest rate swap fair value adjustmentÃ€“(Ã 30.7)(3.0)Ã€“(Ã 40.5)(7.0)Net carrying values\$299.2Ã \$316.9Ã \$291.1Ã \$298.2Ã \$306.4Ã \$286.1Ã Fair Value\$294.9Ã \$317.7Ã \$303.6Ã \$286.4Ã \$301.8Ã \$290.0Ã The below table presents the components of interest and other debt expenses related to the 2025 Notes, the 2027 Notes and the 2029 Notes for the three and nine months ended June 30, 2024:(\$ in millions)2025 Notes2027 Notes2029 NotesThree months ended June 30, 2024Nine months ended June 30, 2024Three months ended June 30, 2024Nine months ended June 30, 2024Three months ended June 30, 2024Nine months ended June 30, 2024Coupon interest\$2.6Ã \$7.9Ã \$2.4Ã \$7.1Ã \$5.3Ã \$16.0Ã Amortization of financing costs and discount0.3Ã 0.9Ã 0.2Ã 0.7Ã 0.3Ã 1.0Ã Effect of interest rate swap Ã€“(Ã 4.0Ã 12.3Ã 1.1Ã 3.4Ã Ã Total interest expense\$2.9Ã \$8.8Ã \$6.6Ã \$20.1Ã \$6.7Ã \$20.4Ã Coupon interest rate (net of effect of interest rate swaps)3.500Ã %3.500Ã %7.213Ã %7.262Ã %8.440Ã %8.469Ã The below table presents the components of interest and other debt expenses related to the 2025 Notes and the 2027 Notes for the three and nine months ended June 30, 2023:(\$ in millions)2025 Notes2027 NotesThree months ended June 30, 2023Nine months ended June 30, 2023Nine months ended June 30, 2023Nine months ended June 30, 2023Coupon interest\$2.6Ã \$7.9Ã \$2.4Ã \$7.1Ã Amortization of financing costs and discount0.3Ã 0.9Ã 0.2Ã 0.7Ã Effect of interest rate swap Ã€“(Ã 4.0Ã 3.7Ã 9.4Ã Ã Total interest expense\$2.9Ã \$8.8Ã \$6.3Ã \$17.2Ã Coupon interest rate (net of effect of interest rate swap for 2027 Notes)3.500Ã %3.500Ã %6.912Ã %6.274Ã % X - ReferencesNo definition available. + Details Name: us-gaap_DebtDisclosureAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionTabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfDebtTableTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 43 R32.htm IDEA: XBRL DOCUMENT v3.24.2 Taxable/Distributable Income and Dividend Distributions (Tables) 9 Months Ended Jun. 30, 2024 Income Tax Disclosure [Abstract] Ã Schedule of Reconciliation of Net Increase (Decrease) in Net Assets Resulting from Operations Listed below is a reconciliation of “net increase (decrease) in net assets resulting from operations” to taxable income for the three and nine months ended JuneÃ 30, 2024 and 2023.Three months endedJune 30, 2024Three months endedJune 30, 2023Nine months endedJune 30, 2023Nine months endedJune 30, 2023Net increase (decrease) in net assets resulting from operations1,120Ã \$36,685Ã \$20,992Ã \$71,379Ã Net unrealized (appreciation) depreciation(26,199)1,039Ã 24,078Ã 42,300Ã Book/tax difference due to capital losses suspended (utilized)70,156Ã 12,118Ã 87,016Ã 20,380Ã Other book/tax differences(2,349)(3,825)(13,298)(14,912)Taxable/Distributable Income(1)\$42,728Ã \$46,017Ã \$118,788Ã \$119,147Ã Ã (1) The Company’s taxable income for the three and nine months ended JuneÃ 30, 2024 is an estimate and will not be finally determined until the Company files its tax return for the fiscal year ending September 30, 2024. Therefore, the final taxable income may be different than the estimate. Schedule of Components of Accumulated Overdistributed Earnings As of SeptemberÃ 30, 2023, the Company’s last tax year end, the components of accumulated overdistributed earnings on a tax basis were as follows: Undistributed ordinary income, net\$33,525Ã Net realized capital losses(509,832)Unrealized losses, net(175,031)Accumulated overdistributed earnings\$(651,338) X - DefinitionInvestment Company, Components Of Distributable Earnings (Accumulated Losses) + ReferencesNo definition available. + Details Name: ocsI_InvestmentCompanyComponentsOfDistributableEarningsAccumulatedLossesTableTextBlock Namespace Prefix: ocsI_Data Type: dtr-types!textBlockItem Type Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the federal tax basis of investment holdings. This item captures the aggregate cost of securities, aggregate gross unrealized appreciation for all securities in which there is an excess of value over tax cost, aggregate gross unrealized depreciation for all securities in which there is an excess of tax cost over value, net unrealized appreciation (depreciation), and an explanation of the differences between tax and book. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(h)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3 + Details Name: us-gaap_FederalIncomeTaxNoteTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncomeTaxDisclosureAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration XML 44 R33.htm IDEA: XBRL DOCUMENT v3.24.2 Realized Gains or Losses and Net Unrealized Appreciation or Depreciation (Tables) 9 Months Ended Jun. 30, 2024 Investment Company [Abstract] Ã Schedule of Aggregate Net Realized Gains During the three months ended JuneÃ 30, 2024, the Company recorded an aggregate net realized loss of \$69.5 million, which consisted of the following:(\$ in millions)Portfolio CompanyNet Realized Gain (Loss)Thrasio, LLCs(68.5)Other, net(1.0)Total, net\$(69.5)During the three months ended JuneÃ 30, 2023, the Company recorded an aggregate net realized loss of \$10.6Ã million, which consisted of the following:(\$ in millions)Portfolio CompanyNet Realized Gain (Loss)Foreign currency forward contracts\$(6.3)Aden & Anais Merger Sub Inc.(5.2)Radiology Partners Inc.(3.8)WP CPP Holdings LLC(1.3)Tersera Therapeutics LLC5.2Ã Other, net 0.8Ã Total, net\$(10.6)During the nine months ended JuneÃ 30, 2024, the Company recorded an aggregate net realized loss of \$84.5 million, which consisted of the following:(\$ in millions)Portfolio CompanyNet Realized Gain (Loss)Thrasio, LLCs(68.5)All Web Leads Inc(13.4)Continental Intermodal Group LP(6.8)P&L Development LLC(1.9)American Tire Distributors Inc. (1.8)Zephyr Bidco Limited (1)(1.7)Lift Brands Holdings, Inc.(1.4)Alvotech4.8Ã Ardonagh Midco 3 PLC (14.6Ã Foreign currency forward contracts2.6Ã Other, net(1.0)Total, net\$(84.5) (1) This investment was denominated in foreign currency and the realized gain (loss) shown in this table includes gains (losses) due to foreign currency translation, which was offset by gains (losses) on foreign currency forward contracts.During the nine months ended JuneÃ 30, 2023, the Company recorded an aggregate net realized loss of \$19.9Ã million, which consisted of the following:(\$ in millions)Portfolio CompanyNet Realized Gain (Loss)Foreign currency forward contracts\$(5.5)Aden & Anais Merger Sub Inc.(5.2)Radiology Partners Inc. (4.2)Carvana Co. (2.8)ASP Unifrax Holdings Inc.(2.1)WP CPP Holdings LLC(1.3)Global Medical Response Inc.(1.0)Tersera Therapeutics LLC5.2Ã Other, net(3.0)Total, net\$(19.9) X - ReferencesNo definition available. + Details Name: us-gaap_InvestmentCompanyAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the proceeds from sales of available-for-sale securities and the gross realized gains and gross realized losses that have been included in earnings as a result of those sales. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9 + Details Name: us-gaap_ScheduleOfRealizedGainLossTableTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 45 R34.htm IDEA: XBRL DOCUMENT v3.24.2 Financial Highlights (Tables) 9 Months Ended Jun. 30, 2024 Investment Company [Abstract] Ã Schedule of Financial Highlights Summaries of the composition of the Company’s portfolio at cost as a percentage of total investments and at fair value as a percentage of total investments and net assets are shown in the following tables:Ã June 30, 2024September 30, 2023Cost:Ã % of Total Investments% of Total InvestmentsSenior secured debt\$2,779,708Ã 84.42Ã %\$2,594,640Ã 85.24Ã %Debt investments in the JVs163,963Ã 4.98Ã %162,986Ã 5.35Ã %Subordinated debt115,937Ã 3.52Ã %59,844Ã 1.97Ã %Common equity and warrants110,315Ã 3.35Ã %72,261Ã 2.37Ã %Preferred equity68,218Ã 2.07Ã %99,597Ã 3.27Ã %LLC equity interests of the JVs54,791Ã 1.66Ã %54,791Ã 1.80Ã %Total\$3,292,932Ã 100.00Ã %\$3,044,119Ã 100.00Ã %Ã June 30, 2024September 30, 2023Fair Value:Ã % of Total Investments% of Net Assets% of Total Investments% of Net AssetsSenior secured debt\$2,684,245Ã 85.98Ã %179,42Ã %\$2,501,385Ã 86.47Ã %165.01Ã %Debt investments in the JVs162,542Ã 5.21Ã %10.86Ã %162,673Ã 5.62Ã %10.73Ã %Subordinated debt117,065Ã 3.75Ã %7.82Ã %55,717Ã 1.93Ã %3.68Ã %Common equity and warrants68,142Ã 2.18Ã %4.55Ã %57,710Ã 2.00Ã %3.81Ã %Preferred equity63,892Ã 2.05Ã %4.27Ã %86,057Ã 2.98Ã %5.68Ã %LLC equity interests of the JVs25,817Ã 0.83Ã %1.73Ã %28,878Ã 1.00Ã %1.91Ã %Total\$3,121,703Ã 100.00Ã %\$2,892,420Ã 100.00Ã %190.82Ã %The geographic composition is determined by the location of the corporate headquarters of the portfolio company, which may not be indicative of the primary source of the portfolio company’s business. The following tables show the composition of the Company’s portfolio by geographic region at cost as a percentage of total investments and at fair value as a percentage of total investments and net assets:Ã June 30, 2024September 30, 2023Cost:Ã % of Total InvestmentsÃ % of Total InvestmentsNortheast\$1,050,743Ã 31.91Ã %\$1,012,955Ã 33.27Ã %Southeast471,176Ã 14.31Ã %375,247Ã 12.33Ã %Midwest428,884Ã 13.02Ã %360,506Ã 11.84Ã %International376,328Ã 11.43Ã %Ã June 30, 2024September 30, 2023Fair Value:Ã % of Total Investments% of Net AssetsÃ % of Total Investments% of Net AssetsNortheast\$989,346Ã 31.69Ã %66.12Ã %\$945,422Ã 32.69Ã %62.37Ã %Southeast433,279Ã 13.88Ã %28.96Ã %354,444Ã 12.25Ã %23.38Ã %Midwest422,065Ã 13.52Ã %28.21Ã %350,620Ã 11.43Ã %Ã A summary of SLF JV I’s portfolio, followed by a listing of the individual loans in SLF JV I’s portfolio as of June 30, 2024 and September 30, 2023:June 30, 2024September 30, 2023Senior secured loans (1)\$353,579\$332,637Weighted average interest rate on senior secured loans (2)9.83%10.62%Number of borrowers in SLF JV I4948Largest exposure to a single borrower (1)\$11,161\$11,286Total of five largest loan exposures to borrowers (1)\$53,328\$54,051 (1) At principal amount.(2) Computed using the weighted average annual interest rate on accruing senior secured loans at fair value.Below is a summary of the Click JV I’s portfolio, followed by a listing of the individual loans in the Click JV I’s portfolio as of JuneÃ 30, 2024 and SeptemberÃ 30, 2023:June 30, 2023September 30, 2023Senior secured loans (1)\$139,298\$130,589Weighted average current interest rate on senior secured loans (2)9.53%10.77%Number of borrowers in the Click JV4538Largest loan exposure to a single borrower (1)\$6,891\$6,230Total of five largest loan exposures to borrowers (1)\$27,461\$28,396 (1) At principal amount.(2) Computed using the weighted average annual interest rate on accruing senior secured loans at fair value.(Share amounts in thousands)Three months endedJuneÃ 30, 2024Three months endedJuneÃ 30, 2023Nine months endedJuneÃ 30, 2024Nine months endedJuneÃ 30, 2023(6)Net asset value per share at beginning of period\$18.72\$19.66\$19.63\$20.38Net investment income (1)0.540.631.631.89Net unrealized appreciation (depreciation) (1)0.33(0.02)(0.28)(0.36)Net realized gains (losses) (1)(0.85)(0.14)(1.06)(0.28)(Provision) benefit for taxes on realized and unrealized gains (losses) (1)Ã€“(Ã 0.01)0.01Distributions of net investment income to stockholders(0.55)(0.55)(1.72)(2.06)Net asset value per share at end of period\$18.19\$18.58\$18.19\$19.58Per share market value at beginning of period \$19.66\$18.77\$20.12\$18.00Per share market value at end of period \$18.81\$19.43\$18.81\$19.43Total return (2) (1.51)%6.42%(2.13)%19.58%Common shares outstanding at beginning of period81,39677,08077,25611,255Common shares outstanding at end of period82,24577,08082,24577,080Net assets at beginning of period\$1,524,099\$1,515,150\$1,515,764\$1,245,563Net assets at end of period\$1,496,133\$1,509,441\$1,496,133\$1,509,441Average net assets (3)\$1,524,503\$1,526,644\$1,524,180\$1,407,814Ratio of net investment income to average net assets (7)11.76%12.72%11.40%12.65%Ratio of total expenses to average net assets (7)14.54%14.45%14.42%14.07%Ratio of net expenses to average net assets (7)13.29%14.05%13.75%13.69%Ratio of portfolio turnover to average investments at fair value5.95%7.48%23.97%18.43%Weighted average outstanding debt (4)\$1,711,978\$1,756,758\$1,680,876\$1,640,062Average debt per share (1)\$20.92\$22.79\$21.06\$23.29Asset coverage ratio at end of period (5)183.36%182.05%183.36%182.05Ã (1) Calculated based upon weighted average shares outstanding for the period.(2) Total return equals the increase or decrease of ending market value over beginning market value, plus distributions, divided by the beginning market value, assuming dividend reinvestment prices obtained under the Company’s DRIP. Total return does not include sales load.(3) Calculated based upon the weighted average net assets for the period.(4) Calculated based upon the weighted average of principal debt outstanding for the period.(5) Based on outstanding senior securities of \$1,743.4Ã million and \$1,785.0Ã million as of June 30, 2024 and 2023, respectively. (6) The share and per share information disclosed in this table has been retroactively adjusted as necessary to reflect the Company’s 1-for-3 reverse stock split completed on January 20, 2023 and effective as of the commencement of trading on January 23, 2023.(7) Interim periods are annualized. X - ReferencesNo definition available. + Details Name: us-gaap_InvestmentCompanyAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionTabular disclosure of financial highlights. Includes, but is not limited to, per share information, income and expense ratios, total return, capital commitment and fee waiver. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480737/946-205-50-1 + Details Name: us-gaap_InvestmentCompanyFinancialHighlightsTableTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 46 R35.htm IDEA: XBRL DOCUMENT v3.24.2 Derivative Instruments (Tables) 9 Months Ended Jun. 30, 2024 Derivative Instruments and Hedging Activities Disclosure [Abstract] Ã Schedule of Foreign Currency Forward Contracts and Interest Rate Swap Certain information related to the CompanyÃ€“(Ã)’s foreign currency forward contracts is presented below as of JuneÃ 30, 2024. DescriptionNotional Amount to be PurchasedNotional Amount to be SoldMaturity DateGross Amount of Recognized AssetsGross Amount of Recognized LiabilitiesBalance Sheet Location of Net AmountsForeign currency forward contract\$54,193Ã Ã , -49,683Ã 8/8/2024\$849Ã \$Ã€“(Ã)Ã A Derivative assetForeign currency forward contract\$55,206Ã Ã €443,988Ã 8/8/2024Ã€“(Ã)Ã 413Ã A Derivative liability\$849Ã \$Ã€“(Ã)Ã 413Ã Certain information related to the CompanyÃ€“(Ã)’s foreign currency forward contracts is presented below as of SeptemberÃ 30, 2023. DescriptionNotional Amount to be PurchasedNotional Amount to be SoldMaturity DateGross Amount of Recognized AssetsGross Amount of Recognized LiabilitiesBalance Sheet Location of Net AmountsForeign currency forward contract\$42,182Ã Ã , -38,026Ã 11/9/2023\$31,857Ã \$Ã€“(Ã)Ã A Derivative assetForeign currency forward contract\$72,098Ã Ã €56,556Ã 11/9/2023\$053Ã €Ã€“(Ã)Ã A Derivative asset\$4,910Ã \$Ã€“(Ã)Ã A Certain information related to the CompanyÃ€“(Ã)’s interest rate swaps is presented below as of JuneÃ 30, 2024.DescriptionNotional Amount Maturity DateGross Amount of Recognized AssetsGross Amount of Recognized LiabilitiesBalance Sheet Location of Net AmountsInterest rate swap\$300,000Ã 2/15/2029Ã€“(Ã)Ã 2,989Ã A Derivative liability\$Ã€“(Ã)Ã \$33,672Ã A Certain information related to the CompanyÃ€“(Ã)’s interest rate swap is presented below as of SeptemberÃ 30, 2023.DescriptionNotional Amount Maturity DateGross Amount of Recognized AssetsGross Amount of Recognized LiabilitiesBalance Sheet Location of Net AmountsInterest rate swap\$350,000Ã 1/15/2027Ã€“(Ã)Ã \$40,519Ã A Derivative liabilityInterest rate swap\$300,000Ã 2/15/2029Ã€“(Ã)Ã 7,000Ã A Derivative liability\$Ã€“(Ã)Ã \$47,519Ã X - ReferencesNo definition available. + Details Name: us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionTabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 815 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480434/815-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org//1943274/2147480434/815-10-50-1AReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 1B -Publisher FASB -URI https://asc.fasb.org//1943274/2147480434/815-10-50-1BReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4BReference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480434/815-10-50-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480434/815-10-50-5Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 4C -Publisher FASB -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4C + Details Name: us-gaap_ScheduleOfDerivativeInstrumentsTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 47 R36.htm IDEA: XBRL DOCUMENT v3.24.2 Commitments and Contingencies (Tables) 9 Months Ended Jun. 30, 2024 Commitments and Contingencies Disclosure [Abstract] Ã Schedule of Unfunded Commitments A list of unfunded commitments by investment (consisting of revolvers, term loans with delayed draw components and subordinated notes and LLC equity interests in the JVs) as of JuneÃ 30, 2024 and SeptemberÃ 30, 2023 is shown in the table below:June 30, 2024September 30, 2023107-109 Beech OAK22 LLC\$26,969Ã \$26,969Ã Verona Pharma, Inc.14,846Ã Ã€“(Ã)Ã OCSI Click JV LLC13,998Ã 13,998Ã PPW Aero Buyer, Inc.13,804Ã 1,466Ã PetVet Care Centers, LLC

[illegible]

percent) 12.50% [A A A A](#) 12.50% [A A A A](#) SLF JV I | SLF JV I Facility | Revolving Credit Facility | Line of Credit [A A A A A A A A A A](#) Investment Company, Nonconsolidated Subsidiary [Line Items] [A A A A A A A A A A](#) Borrowing capacity \$ 270,000,000 [A A A A](#) \$ 270,000,000 [A A A A](#) Credit facilities payable 198,000,000 [A A A A](#) \$ 198,000,000 [A A A A](#) 198,000,000 [A A A A](#) SLF JV I | SLF JV I Facility | Revolving Credit Facility | Line of Credit | Until November 3, 2023 | Secured Overnight Financing Rate [A A A A A A A A A A](#) Investment Company, Nonconsolidated Subsidiary [Line Items] [A A A A A A A A A A](#) Debt instrument, basis spread, variable rate (as a percent) [A A A A A A A A](#) 1.70% [A A A A](#) OCSI Glick JV LLC [A A A A A A A A A A](#) Investment Company, Nonconsolidated Subsidiary [Line Items] [A A A A A A A A A A](#) Investments at fair value \$ 132,405,000 [A A A A](#) \$ 132,405,000 [A A A A](#) \$ 123,343,000 [A A A A](#) Number of borrowers | borrower 45 [A A A A](#) 45 38 [A A A A](#) Restricted cash \$ 0 [A A A A](#) \$ 0 [A A A A](#) \$ 184,000 [A A A A](#) Number of board of directors | member [A A A A A A A A A A](#) 4 [A A A A](#) Number of board of directors selected by company | member [A A A A A A A A A A](#) 2 [A A A A](#) Number of board of directors selected by counterparty | member [A A A A A A A A A A](#) 2 [A A A A](#) Number of investment committee members selected by company | member [A A A A A A A A A A](#) 1 [A A A A](#) Number of investment committee members selected by counterparty | member [A A A A A A A A A A](#) 1 [A A A A](#) Credit facilities payable 78,000,000 [A A A A](#) \$ 78,000,000 [A A A A](#) 53,000,000 [A A A A](#) Assets 150,169,000 [A A A A](#) \$ 150,169,000 [A A A A](#) 141,167,000 [A A A A](#) Financial support funded by company and counterparty 84,000,000 [A A A A](#) \$ 84,000,000 [A A A A](#) 84,000,000 [A A A A](#) Financial support funded by company for investee 73,500,000 [A A A A](#) \$ 73,500,000 [A A A A](#) 73,500,000 [A A A A](#) Investment owned, at cost 137,360,000 [A A A A](#) \$ 137,360,000 [A A A A](#) 127,788,000 [A A A A](#) Interest income 3,605,000 [A A A A](#) \$ 3,576,000 [A A A A](#) 10,926,000 [A A A A](#) 10,488,000 [A A A A](#) Investments purchased [A A A A](#) \$ 4,900,000 [A A A A](#) \$ 4,900,000 [A A A A](#) Cash consideration for purchase of investments [A A A A](#) \$ 4,900,000 [A A A A](#) Financial commitment to investee by company and counterparty, aggregate amount 100,000,000 [A A A A](#) 100,000,000 [A A A A](#) Financial commitment to investee, aggregate amount 87,500,000 [A A A A](#) \$ 87,500,000 [A A A A](#) 87,500,000 [A A A A](#) Financial commitment to investee by counterparty, aggregate amount 12,500,000 [A A A A](#) 12,500,000 [A A A A](#) OCSI Glick JV LLC | Glick JV LLC [A A A A A A A A A A](#) Investment Company, Nonconsolidated Subsidiary [Line Items] [A A A A A A A A A A](#) Investments at fair value \$ 49,900,000 [A A A A](#) \$ 49,900,000 [A A A A](#) Investment owned, ownership (as a percent) 87.50% [A A A A](#) 87.50% [A A A A](#) 12.50% [A A A A](#) Unfunded commitments \$ 1,600,000 [A A A A](#) \$ 1,600,000 [A A A A](#) 1,600,000 [A A A A](#) Investment owned, at cost 49,900,000 [A A A A](#) Financial commitment to investee, aggregate amount \$ 8,700,000 [A A A A](#) \$ 8,700,000 [A A A A](#) 8,700,000 [A A A A](#) OCSI Glick JV LLC | Glick JV Notes [A A A A A A A A A A](#) Investment Company, Nonconsolidated Subsidiary [Line Items] [A A A A A A A A A A](#) Investments at fair value [A A A A](#) \$ 50,000,000 [A A A A](#) Investment owned, ownership (as a percent) 87.50% [A A A A](#) 87.50% [A A A A](#) 12.50% [A A A A](#) Unfunded commitments \$ 12,400,000 [A A A A](#) \$ 12,400,000 [A A A A](#) Investment owned, at cost [A A A A](#) \$ 50,000,000 [A A A A](#) Financial commitment to investee, aggregate amount 78,800,000 [A A A A](#) 78,800,000 [A A A A](#) OCSI Glick JV LLC | Glick JV Facility | Revolving Credit Facility | Line of Credit [A A A A A A A A A A](#) Investment Company, Nonconsolidated Subsidiary [Line Items] [A A A A A A A A A A](#) Borrowing capacity 100,000,000 [A A A A](#) 100,000,000 [A A A A](#) Credit facilities payable \$ 78,000,000 [A A A A](#) \$ 78,000,000 [A A A A](#) 53,000,000 [A A A A](#) OCSI Glick JV LLC | Glick JV Facility | Revolving Credit Facility | Line of Credit | Until November 3, 2023 | Secured Overnight Financing Rate [A A A A A A A A A A](#) Investment Company, Nonconsolidated Subsidiary [Line Items] [A A A A A A A A A A](#) Debt instrument, basis spread, variable rate (as a percent) [A A A A A A A A A A](#) 1.70% [A A A A A A A A A A](#) X - DefinitionInvestment Company, Financial Commitment To Investee, Aggregate Amount + ReferencesNo definition available. + Details Name: ocsI_InvestmentCompanyFinancialCommitmentToInvesteeAggregateAmount Namespace Prefix: ocsI_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionInvestment Company, Financial Commitment To Investee By Company And Counterparty, Aggregate Amount, + ReferencesNo definition available. + Details Name: ocsI_InvestmentCompanyFinancialCommitmentToInvesteeByCompanyAndCounterpartyAggregateAmount Namespace Prefix: ocsI_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionInvestment Company, Financial Commitment To Investee By Counterparty, Aggregate Amount + ReferencesNo definition available. + Details Name: ocsI_InvestmentCompanyFinancialCommitmentToInvesteeByCounterpartyAggregateAmount Namespace Prefix: ocsI_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionInvestment Company, Financial Support Funded For Investee, Amount + ReferencesNo definition available. + Details Name: ocsI_InvestmentCompanyFinancialSupportFundedForInvesteeAmount Namespace Prefix: ocsI_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionInvestment Company, Financial Support Funded For Investee By Company And Counterparty, Amount + ReferencesNo definition available. + Details Name: ocsI_InvestmentCompanyFinancialSupportFundedForInvesteeByCompanyAndCounterpartyAmount Namespace Prefix: ocsI_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionInvestment Company, Investments Sold + ReferencesNo definition available. + Details Name: ocsI_InvestmentCompanyInvestmentsSold Namespace Prefix: ocsI_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionInvestment Company, Number Of Borrowers + ReferencesNo definition available. + Details Name: ocsI_InvestmentCompanyNumberOfBorrowers Namespace Prefix: ocsI_ Data Type: xbrli:integerItemType Balance Type: na Period Type: instant X - DefinitionInvestment Owned, Ownership Percentage + ReferencesNo definition available. + Details Name: ocsI_InvestmentOwnedOwnershipPercentage Namespace Prefix: ocsI_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionInvestments, Purchased + ReferencesNo definition available. + Details Name: ocsI_InvestmentsPurchased Namespace Prefix: ocsI_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionMoney Market Funds, Percent Of Net Assets + ReferencesNo definition available. + Details Name: ocsI_MoneyMarketFundsPercentOfNetAssets Namespace Prefix: ocsI_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionNumber Of Board Of Directors + ReferencesNo definition available. + Details Name: ocsI_NumberOfBoardOfDirectors Namespace Prefix: ocsI_ Data Type: xbrli:integerItemType Balance Type: na Period Type: instant X - DefinitionNumber Of Board Of Directors Selected By Company + ReferencesNo definition available. + Details Name: ocsI_NumberOfBoardOfDirectorsSelectedByCompany Namespace Prefix: ocsI_ Data Type: xbrli:integerItemType Balance Type: na Period Type: instant X - DefinitionNumber Of Board Of Directors Selected By Counterparty + ReferencesNo definition available. + Details Name: ocsI_NumberOfBoardOfDirectorsSelectedByCounterparty Namespace Prefix: ocsI_ Data Type: xbrli:integerItemType Balance Type: na Period Type: instant X - DefinitionNumber Of Investment Committee Members Selected By Company + ReferencesNo definition available. + Details Name: ocsI_NumberOfInvestmentCommitteeMembersSelectedByCompany Namespace Prefix: ocsI_ Data Type: xbrli:integerItemType Balance Type: na Period Type: instant X - DefinitionNumber Of Investment Committee Members Selected By Counterparty + ReferencesNo definition available. + Details Name: ocsI_NumberOfInvestmentCommitteeMembersSelectedByCounterparty Namespace Prefix: ocsI_ Data Type: xbrli:integerItemType Balance Type: na Period Type: instant X - DefinitionSum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(bb\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25](http://www.xbrl.org/2003/role/disclosureRef-Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph 1 -Subparagraph \(SX 210.4-08\(g\)\(1\)\(iii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-599-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph 1 -Subparagraph (SX 210.4-08(g)(1)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-599-1)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28](http://www.xbrl.org/2003/role/disclosureRef-Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28)Reference 6: <http://www.xbrl.org/2003/role/exampleRef-Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 7: <http://www.xbrl.org/2003/role/exampleRef-Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480167/946-830-55-12>Reference 8: [http://www.xbrl.org/2003/role/disclosureRef-Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph 1 -Subparagraph \(SX 210.7-03\(a\)\(12\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479440/944-210-599-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479440/944-210-599-1)Reference 9: <http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22>Reference 10: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-04\(8\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479617/946-210-599-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479617/946-210-599-1)Reference 11: [http://www.xbrl.org/2003/role/disclosureRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(18\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-50-10-599-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-50-10-599-1)Reference 12: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1)Reference 13: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1)Reference 14: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1)Reference 15: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1)Reference 16: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1)Reference 17: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1)Reference 18: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1)Reference 19: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1)Reference 20: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1)Reference 21: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1)Reference 22: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1)Reference 23: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7)Reference 24: [http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30](http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30)Reference 25: [http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 26: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-03\(11\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479853/942-210-599-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479853/942-210-599-1) + Details Name: us-gaap Assets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4> + Details Name: us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFor an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20>Reference 4: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18>Reference 5: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20> + Details Name: us-gaap ConcentrationRiskPercentage1 Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionAmount, before tax, of realized gain (loss) on investment in debt and equity securities and foreign currency transaction on investment in debt and equity securities from change in market price, classified as operating. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-07\(7\)\(a\)\(1\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483575/946-220-599-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(7)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483575/946-220-599-1)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-07\(7\)\(a\)\(2\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483575/946-220-599-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(7)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483575/946-220-599-1) + Details Name: us-gaap DebtAndEquitySecuritiesAndForeignCurrencyTransactionPriceChangeRealizedGainLossOperatingBeforeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, before tax, of unrealized gain (loss) on investment in debt and equity securities and foreign currency transaction on investment in debt and equity securities from change in market price, classified as operating. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-07\(7\)\(c\)\(1\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483575/946-220-599-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(7)(c)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483575/946-220-599-1)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-07\(7\)\(c\)\(2\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483575/946-220-599-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(7)(c)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483575/946-220-599-1) + Details Name: us-gaap DebtAndEquitySecuritiesAndForeignCurrencyTransactionPriceChangeUnrealizedGainLossOperatingBeforeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionPercentage points added to the reference rate to compute the variable rate on the debt instrument. + ReferencesNo definition available. + Details Name: us-gaap DebtInterestBasisSpreadOnVariableRate1 Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionContractual interest rate for funds borrowed, under the debt agreement. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 20](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 20 -Name)

Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap DebtInstrumentInterestRateStatedPercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionAmount of operating dividend income on securities. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column E)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column E)(Footnote 4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-6Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480167/946-830-55-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-9Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 45 -Paragraph 39 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480228/946-830-45-39Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column E)(Footnote 6)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-6Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(1)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483575/946-220-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04.2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483589/942-220-S99-1 + Details Name: us-gaap DividendIncomeOperating Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe net realized gain (loss) on investments sold during the period, not including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, which, for cash flow reporting, is a component of proceeds from investing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap GainLossOnSaleOfInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of operating interest income, including, but not limited to, amortization and accretion of premiums and discounts on securities. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column E)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column E)(Footnote 4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-6Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480167/946-830-55-10Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 45 -Paragraph 39 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480228/946-830-45-39Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(1)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483575/946-220-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column E)(Footnote 6)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-6Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1(e)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap InterestIncomeOperating Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionPercentage added to reference rate used to compute variable rate on investment. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.12-12A(Column A)(Footnote 3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column A)(Footnote 4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column A)(Footnote 3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column A)(Footnote 3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-6 + Details Name: us-gaap InvestmentBasisSpreadVariableRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionAmount of financial support committed by investment company to investee that is contractually required but not provided. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 16 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-16 + Details Name: us-gaap InvestmentCompanyFinancialCommitmentToInvesteeFutureAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap InvestmentCompanyNonconsolidatedSubsidiaryLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionMinimum rate of interest on investment. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column A)(Footnote 4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.12-12A(Column A)(Footnote 3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column A)(Footnote 3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-3Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column A)(Footnote 3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-6 + Details Name: us-gaap InvestmentInterestRateFloor Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionCost of the investment. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 55 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480493/946-210-55-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480524/946-210-50-6Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480524/946-210-50-6Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480167/946-830-55-12Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/19432

<https://asc.fasb.org/1943274/2147480524/946-210-50-1>Reference 5: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph \(a\)\(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480524/946-210-50-6](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480524/946-210-50-6)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.12-12\(Column C\)\(Footnote 5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column C)(Footnote 5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-1)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.12-12B\(Column D\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column D)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-3)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.12-12B\(Column C\)\(Footnote 2\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column C)(Footnote 2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-3)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.12-12B\(Column A\)\(Footnote 6\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column A)(Footnote 6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-3)Reference 10: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph \(SX 210.12-14\(Column F\)\(Footnote 7\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-6](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column F)(Footnote 7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-6) + Details Name: us-gaap InvestmentOwnedPercentOfNetAssets Namespace Prefix: us-gaap Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionThe carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(22\)\) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-03\(a\)\(16\)\(a\)\(2\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479440/944-210-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479440/944-210-S99-1)Reference 3: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-03\(16\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479853/942-210-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479853/942-210-S99-1) + Details Name: us-gaap LineOfCredit Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionMaximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02.19\(b\),22\(b\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19(b),22(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1) + Details Name: us-gaap LineOfCreditFacilityMaximumBorrowingCapacity Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of cash outflow for acquisition of investment, classified as operating activity. Includes, but is not limited to, funding, origination, drawdown, and participation in investment. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 230 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480369/946-230-45-1> + Details Name: us-gaap PaymentsForPurchaseOfInvestmentOperatingActivity Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow from sale of investment, classified as operating activity. Includes, but is not limited to, repayment, principal payment, payday, and maturity of investment. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 230 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480369/946-230-45-1> + Details Name: us-gaap ProceedsFromDispositionOfInvestmentOperatingActivity Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. + ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-03\(a\)\(2\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479440/944-210-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479440/944-210-S99-1)Reference 2: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(1\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 3: <http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8>Reference 4: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-03\(1\)\(a\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479853/942-210-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(1)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479853/942-210-S99-1) + Details Name: us-gaap RestrictedCash Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: srt ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ocsl SLFJVIMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ocsl SLFJVNotesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ocsl SLFJVLLCMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ocsl GlickJVNotesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ocsl OCSGlickJVLLCMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap DebtInstrumentAxis=ocsl A2025NotesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap DebtInstrumentAxis=ocsl A2027NotesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap DebtInstrumentAxis=ocsl A2029NotesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap FinancialInstrumentAxis=ocsl DebtSecuritiesSeniorSecuredMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap FinancialInstrumentAxis=ocsl DebtSecuritiesSubordinatedIncludingJVDebtInstrumentsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap ConcentrationRiskByBenchmarkAxis=ocsl InvestmentOwnedAtFairValueMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap ConcentrationRiskByTypeAxis=ocsl InvestmentTypeConcentrationRiskMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap InvestmentIssuerNameAxis=ocsl SLFJVLLCMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap InvestmentIssuerNameAxis=ocsl OCSGlickJVLLCMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap InvestmentCompanyNonconsolidatedSubsidiaryAxis=ocsl TheJVsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap InvestmentCompanyNonconsolidatedSubsidiaryAxis=ocsl SLFJVMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap VariableRateAxis=ocsl A30DaySOFRMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap VariableRateAxis=ocsl A90DaySOFRMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap VariableRateAxis=ocsl A30DayLIBORMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap LegalEntityAxis=ocsl KemperMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap DebtInstrumentAxis=ocsl SLFJVIFacilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap CreditFacilityAxis=us-gaap RevolvingCreditFacilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap LongtermDebtTypeAxis=us-gaap LineOfCreditMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: ocsl VariableRatePeriodAxis=ocsl UntilNovember32023Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap VariableRateAxis=ocsl SecuredOvernightFinancingRateMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap InvestmentCompanyNonconsolidatedSubsidiaryAxis=ocsl OCSGlickJVLLCMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ocsl GlickJVLLCMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap DebtInstrumentAxis=ocsl GlickJVFacilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 50 R39.htm IDEA: XBRL DOCUMENT v3.24.2 Portfolio Investments - Composition of Investments (Details) - USD (\$) in Thousands Jun, 2024 Sep, 2023 Tersera Therapeutics LLC A A Investment owned, at cost \$ 3,292,932 \$ 3,044,119 Investments at fair value 3,121,703 2,892,420 Debt investments, fair value \$ 2,963,852 \$ 2,719,775 % of a Debt Portfolio 100.00% 100.00% Investments in debt securities A A Tersera Therapeutics LLC A A Investment owned, at cost \$ 2,895,645 \$ 2,654,484 Investments at fair value 2,801,310 2,557,102 Investments in equity securities A A Tersera Therapeutics LLC A A Investment owned, at cost 178,533 171,858 Investments at fair value 132,034 143,767 Debt investments in the JVs A A Tersera Therapeutics LLC A A Investment owned, at cost 163,963 162,986 Investments at fair value 162,542 162,673 Equity investments in the JVs A A Tersera Therapeutics LLC A A Investment owned, at cost 54,791 54,791 Investments at fair value 25,817 28,878 Floating rate debt securities, including the debt investments in the JVs A A Tersera Therapeutics LLC A A Debt investments, fair value \$ 2,526,904 \$ 2,345,205 % of a Debt Portfolio 85.26% 86.23% Fixed rate debt securities A A Tersera Therapeutics LLC A A Debt investments, fair value \$ 436,948 \$ 374,570 % of a Debt Portfolio 14.74% 13.77% X - DefinitionDebt Securities, Percentage Of Debt Portfolio + ReferencesNo definition available. + Details Name: ocsl DebtSecuritiesPercentageOfDebtPortfolio Namespace Prefix: ocsl Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionFair value of investment in debt security measured at amortized cost (held-to-maturity) and investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5A -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5A](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5A)Reference 2: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(aa\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2) + Details Name: us-gaap DebtSecuritiesAvailableForSaleAndHeldToMaturityFairValue Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCost of the investment. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 55 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480493/946-210-55-1>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph \(a\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480524/946-210-50-6](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480524/946-210-50-6)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph \(a\)\(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480524/946-210-50-6](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480524/946-210-50-6)Reference 4: <http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480167/946-830-55-12>Reference 5: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph \(a\)\(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480524/946-210-50-6](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480524/946-210-50-6)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-03\(d\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.12-12\(Column C\)\(Footnote 8\)\(a\)\(3\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-3)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.12-12B\(Column C\)\(Footnote 11\)\(a\)\(3\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-3)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph \(SX 210.12-14\(Column F\)\(Footnote 5\)\(a\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-6](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column F)(Footnote 5)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-6)Reference 10: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 19 -Subparagraph \(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-19](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 19 -Subparagraph (3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-19) + Details Name: us-gaap InvestmentOwnedAtCost Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFair value of investment in security owned. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480524/946-210-50-6](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480524/946-210-50-6)Reference 2: <http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 55 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480493/946-210-55-1>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph \(a\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480524/946-210-50-6](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480524/946-210-50-6)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph \(a\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480524/946-210-50-6](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480524/946-210-50-6)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(b\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480524/946-210-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480524/946-210-50-1)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(b\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480524/946-210-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480524/946-210-50-1)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(b\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480524/946-210-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480524/946-210-50-1)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(c\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480524/946-210-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480524/946-210-50-1)Reference 9: <http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480524/946-210-50-2>Reference 10: <http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480167/946-830-55-12>Reference 11: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph \(a\)\(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480524/946-210-50-6](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480524/946-210-50-6)Reference 12: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph \(a\)\(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479617/946-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479617/946-210-S99-1)Reference 13: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-03\(d\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3)Reference 14: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-04\(1\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479617/946-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479617/946-210-S99-1)Reference 15: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-04\(2\)\(a\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479617/946-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(2)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479617/946-210-S99-1)Reference 16: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-04\(2\)\(b\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479617/946-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(2)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479617/946-210-S99-1)Reference 17: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.12-12\(Column C\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column C)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-1)Reference 18:

[illegible]

9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6Reference 64:

8:

[illegible]

Measurement Inputs and Valuation Techniques [Line Items] A A Investments at fair value 2,684,245 2,501,385 Debt investments in the JVs A A Fair Value Measurement Inputs and Valuation Techniques [Line Items] A A Investments at fair value 162,542 162,673 Level 3 A A Fair Value Measurement Inputs and Valuation Techniques [Line Items] A A Investments at fair value 2,752,039 2,619,912 Level 3 | Senior secured debt A A Fair Value Measurement Inputs and Valuation Techniques [Line Items] A A Investments at fair value 2,393,159 2,292,691 Level 3 | Senior secured debt | Market Yield | Market Yield A A Fair Value Measurement Inputs and Valuation Techniques [Line Items] A A Investments at fair value 2,110,682 1,904,140 Level 3 | Senior secured debt | Market Yield | Market Yield | Minimum A A Fair Value Measurement Inputs and Valuation Techniques [Line Items] A A Investments at fair value, measurement input 0.090 0.090 Level 3 | Senior secured debt | Market Yield | Market Yield | Maximum A A Fair Value Measurement Inputs and Valuation Techniques [Line Items] A A Investments at fair value, measurement input 0.390 0.320 Level 3 | Senior secured debt | Market Yield | Market Yield | Weighted Average A A Fair Value Measurement Inputs and Valuation Techniques [Line Items] A A Investments at fair value, measurement input 0.138 0.147 Level 3 | Senior secured debt | Enterprise Value | Revenue Multiple A A Fair Value Measurement Inputs and Valuation Techniques [Line Items] A A Investments at fair value 58,783 A Level 3 | Senior secured debt | Enterprise Value | Revenue Multiple | Minimum A A Fair Value Measurement Inputs and Valuation Techniques [Line Items] A A Investments at fair value, measurement input 1.5 A Level 3 | Senior secured debt | Enterprise Value | Revenue Multiple | Maximum A A Fair Value Measurement Inputs and Valuation Techniques [Line Items] A A Investments at fair value, measurement input 5.5 A Level 3 | Senior secured debt | Enterprise Value | Revenue Multiple | Weighted Average A A Fair Value Measurement Inputs and Valuation Techniques [Line Items] A A Investments at fair value, measurement input 3.1 A Level 3 | Senior secured debt | Enterprise Value | EBITDA Multiple A A Fair Value Measurement Inputs and Valuation Techniques [Line Items] A A Investments at fair value 33,379 64,802 Level 3 | Senior secured debt | Enterprise Value | EBITDA Multiple | Minimum A A Fair Value Measurement Inputs and Valuation Techniques [Line Items] A A Investments at fair value, measurement input 5.5 3.0 Level 3 | Senior secured debt | Enterprise Value | EBITDA Multiple | Maximum A A Fair Value Measurement Inputs and Valuation Techniques [Line Items] A A Investments at fair value, measurement input 6.0 6.0 Level 3 | Senior secured debt | Enterprise Value | EBITDA Multiple | Weighted Average A A Fair Value Measurement Inputs and Valuation Techniques [Line Items] A A Investments at fair value, measurement input 5.8 4.6 Level 3 | Senior secured debt | Transaction Precedent | Transaction Price A A Fair Value Measurement Inputs and Valuation Techniques [Line Items] A A Investments at fair value 4,199 33,816 Level 3 | Senior secured debt | Broker Quotations | Broker Quoted Price A A Fair Value Measurement Inputs and Valuation Techniques [Line Items] A A Investments at fair value 186,116 289,933 Level 3 | Subordinated Debt | Market Yield | Market Yield | Market Yield A A Fair Value Measurement Inputs and Valuation Techniques [Line Items] A A Investments at fair value 43,442 22,881 Level 3 | Subordinated Debt | Market Yield | Market Yield | Minimum A A Fair Value Measurement Inputs and Valuation Techniques [Line Items] A A Investments at fair value, measurement input 0.100 0.100 Level 3 | Subordinated Debt | Market Yield | Market Yield | Maximum A A Fair Value Measurement Inputs and Valuation Techniques [Line Items] A A Investments at fair value, measurement input 0.400 0.220 Level 3 | Subordinated Debt | Market Yield | Market Yield | Weighted Average A A Fair Value Measurement Inputs and Valuation Techniques [Line Items] A A Investments at fair value, measurement input 0.111 0.112 Level 3 | Subordinated Debt | Transaction Precedent | Market Yield A A Fair Value Measurement Inputs and Valuation Techniques [Line Items] A A Investments at fair value 24,500 A Level 3 | Subordinated Debt | Broker Quotations | Broker Quoted Price A A Fair Value Measurement Inputs and Valuation Techniques [Line Items] A A Investments at fair value 4,170 Level 3 | Debt investments in the JVs | Enterprise Value A A Fair Value Measurement Inputs and Valuation Techniques [Line Items] A A Investments at fair value 162,542 162,673 Level 3 | Preferred & Common Equity | Enterprise Value | Revenue Multiple A A Fair Value Measurement Inputs and Valuation Techniques [Line Items] A A Investments at fair value 59,829 32,318 Level 3 | Preferred & Common Equity | Enterprise Value | Revenue Multiple | Minimum A A Fair Value Measurement Inputs and Valuation Techniques [Line Items] A A Investments at fair value, measurement input 0.4 0.4 Level 3 | Preferred & Common Equity | Enterprise Value | Revenue Multiple | Maximum A A Fair Value Measurement Inputs and Valuation Techniques [Line Items] A A Investments at fair value, measurement input 6.3 3.2 Level 3 | Preferred & Common Equity | Enterprise Value | Revenue Multiple | Weighted Average A A Fair Value Measurement Inputs and Valuation Techniques [Line Items] A A Investments at fair value, measurement input 2.5 0.5 Level 3 | Preferred & Common Equity | Enterprise Value | EBITDA Multiple A A Fair Value Measurement Inputs and Valuation Techniques [Line Items] A A Investments at fair value \$ 67,317 103,661 Level 3 | Preferred & Common Equity | Enterprise Value | EBITDA Multiple | Minimum A A Fair Value Measurement Inputs and Valuation Techniques [Line Items] A A Investments at fair value, measurement input 0.3 1.7 Level 3 | Preferred & Common Equity | Enterprise Value | EBITDA Multiple | Maximum A A Fair Value Measurement Inputs and Valuation Techniques [Line Items] A A Investments at fair value, measurement input 15.1 15.1 Level 3 | Preferred & Common Equity | Enterprise Value | EBITDA Multiple | Weighted Average A A Fair Value Measurement Inputs and Valuation Techniques [Line Items] A A Investments at fair value, measurement input 9.9 8.8 Level 3 | Preferred & Common Equity | Enterprise Value | Asset Multiple A A Fair Value Measurement Inputs and Valuation Techniques [Line Items] A A Investments at fair value 1,250 1,097 Level 3 | Preferred & Common Equity | Enterprise Value | Asset Multiple | Minimum A A Fair Value Measurement Inputs and Valuation Techniques [Line Items] A A Investments at fair value, measurement input 1.0 1.0 Level 3 | Preferred & Common Equity | Enterprise Value | Asset Multiple | Maximum A A Fair Value Measurement Inputs and Valuation Techniques [Line Items] A A Investments at fair value, measurement input 1.4 1.4 Level 3 | Preferred & Common Equity | Enterprise Value | Asset Multiple | Weighted Average A A Fair Value Measurement Inputs and Valuation Techniques [Line Items] A A Investments at fair value, measurement input 1.4 1.4 Level 3 | Preferred & Common Equity | Transaction Precedent | Transaction Price A A Fair Value Measurement Inputs and Valuation Techniques [Line Items] A A Investments at fair value 421 X - Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. - References No definition available. - Details Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition Value of input used to measure investment owned by investment company. - References Reference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(bbb\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 -Details Name: us-gaap_InvestmentCompanyInvestmentOwnedFairValueMeasurementInput](http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 -Details Name: us-gaap_InvestmentCompanyInvestmentOwnedFairValueMeasurementInput) Namespace Prefix: us-gaap_Data Type: xbrli:decimalItemType Balance Type: na Period Type: instant X - Definition Fair value of investment in security owned. - References Reference 1:

LLC A A Fair Value 285,000 280,000 Level 3 | 2025 Notes A A Tersera Therapeutics LLC A A Fair Value 0 0 Level 3 | 2027 Notes A A Tersera Therapeutics LLC A A Fair Value 0 0 Level 3 | 2029 Notes A A Tersera Therapeutics LLC A A Fair Value \$ 0 \$ 0 X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation. + ReferencesReference 1:

Name: us-gaap_FinancialInstrumentAxis=ocsl_OS12CitibankFacilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=ocsl_A2025NotesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=ocsl_A2027NotesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=ocsl_A2029NotesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 55 R44.htm IDEA: XBRL DOCUMENT v3.24.2 Portfolio Investments - Portfolio Composition (Details) - USD (\$) in Thousands 9 Months Ended 12 Months Ended Jun. 30, 2024 Sep. 30, 2023 Tersera Therapeutics LLC Á Á Investment owned, at cost \$ 3,292,932 \$ 3,044,119 Investments at fair value \$ 3,121,703 \$ 2,892,420 Investment owned, percent of net assets (as a percent) 208.65% 190.82% Northeast Á Á Tersera Therapeutics LLC Á Á Investment owned, at cost \$ 1,050,743 \$ 1,012,955 Investments at fair value \$ 989,346 \$ 945,422 Investment owned, percent of net assets (as a percent) 66.12% 62.37% Southeast Á Á Tersera Therapeutics LLC Á Á Investment owned, at cost \$ 471,176 \$ 375,247 Investments at fair value \$ 433,279 \$ 354,444 Investment owned, percent of net assets (as a percent) 28.96% 23.38% Midwest Á Á Tersera Therapeutics LLC Á Á Investment owned, at cost \$ 428,884 \$ 360,506 Investments at fair value \$ 422,065 \$ 350,620 Investment owned, percent of net assets (as a percent) 28.21% 23.13% International Á Á Tersera Therapeutics LLC Á Á Investment owned, at cost \$ 376,328 \$ 418,955 Investments at fair value \$ 380,934 \$ 414,079 Investment owned, percent of net assets (as a percent) 25.46% 27.32% West Á Á Tersera Therapeutics LLC Á Á Investment owned, at cost \$ 351,116 \$ 393,390 Investments at fair value \$ 328,442 \$ 384,055 Investment owned, percent of net assets (as a percent) 21.95% 25.34% South Á Á Tersera Therapeutics LLC Á Á Investment owned, at cost \$ 250,457 \$ 202,374 Investments at fair value \$ 245,294 \$ 188,541 Investment owned, percent of net assets (as a percent) 16.40% 12.44% Southwest Á Á Tersera Therapeutics LLC Á Á Investment owned, at cost \$ 234,429 \$ 153,318 Investments at fair value \$ 228,456 \$ 130,455 Investment owned, percent of net assets (as a percent) 15.27% 8.61% Northwest Á Á Tersera Therapeutics LLC Á Á Investment owned, at cost \$ 129,799 \$ 127,734 Investments at fair value \$ 93,887 \$ 124,804 Investment owned, percent of net assets (as a percent) 6.28% 8.23% Investment Owned, At Cost | Investment Type Concentration Risk Á Á Tersera Therapeutics LLC Á Á Concentration risk (as a percent) 100.00% 100.00% Investment Owned, At Cost | Geographic Concentration Risk Á Northeast Á Á Tersera Therapeutics LLC Á Á Concentration risk (as a percent) 31.91% 33.27% Investment Owned, At Cost | Geographic Concentration Risk | Southeast Á Á Tersera Therapeutics LLC Á Á Concentration risk (as a percent) 14.31% 12.33% Investment Owned, At Cost | Geographic Concentration Risk | Midwest Á Á Tersera Therapeutics LLC Á Á Concentration risk (as a percent) 13.02% 11.84% Investment Owned, At Cost | Geographic Concentration Risk | International Á Á Tersera Therapeutics LLC Á Á Concentration risk (as a percent) 11.43% 13.75% Investment Owned, At Cost | Geographic Concentration Risk | West Á Á Tersera Therapeutics LLC Á Á Concentration risk (as a percent) 10.66% 12.92% Investment Owned, At Cost | Geographic Concentration Risk | South Á Á Tersera Therapeutics LLC Á Á Concentration risk (as a percent) 7.61% 6.65% Investment Owned, At Cost | Geographic Concentration Risk | Southwest Á Á Tersera Therapeutics LLC Á Á Concentration risk (as a percent) 7.12% 5.04% Investment Owned, At Cost | Geographic Concentration Risk | Northwest Á Á Tersera Therapeutics LLC Á Á Concentration risk (as a percent) 3.94% 4.20% Investment Owned, At Fair Value Á Á Tersera Therapeutics LLC Á Á Investments at fair value \$ 3,121,703 \$ 2,892,420 Investment owned, percent of net assets (as a percent) 208.65% 190.82% Investment Owned, At Fair Value | Investment Type Concentration Risk Á Á Tersera Therapeutics LLC Á Á Concentration risk (as a percent) 100.00% 100.00% Investment Owned, At Fair Value | Geographic Concentration Risk Á Northeast Á Á Tersera Therapeutics LLC Á Á Concentration risk (as a percent) 100.00% 100.00% Investment Owned, At Fair Value | Geographic Concentration Risk | Southeast Á Á Tersera Therapeutics LLC Á Á Concentration risk (as a percent) 31.69% 32.69% Investment Owned, At Fair Value | Geographic Concentration Risk | Southeast Á Á Tersera Therapeutics LLC Á Á Concentration risk (as a percent) 13.88% 12.25% Investment Owned, At Fair Value | Geographic Concentration Risk | Midwest Á Á Tersera Therapeutics LLC Á Á Concentration risk (as a percent) 13.52% 12.12% Investment Owned, At Fair Value | Geographic Concentration Risk | International Á Á Tersera Therapeutics LLC Á Á Concentration risk (as a percent) 12.20% 14.32% Investment Owned, At Fair Value | Geographic Concentration Risk | West Á Á Tersera Therapeutics LLC Á Á Concentration risk (as a percent) 10.52% 13.28% Investment Owned, At Fair Value | Geographic Concentration Risk | South Á Á Tersera Therapeutics LLC Á Á Concentration risk (as a percent) 7.86% 6.52% Investment Owned, At Fair Value | Geographic Concentration Risk | Southwest Á Á Tersera Therapeutics LLC Á Á Concentration risk (as a percent) 7.32% 4.51% Investment Owned, At Fair Value | Geographic Concentration Risk | Northwest Á Á Tersera Therapeutics LLC Á Á Concentration risk (as a percent) 3.01% 4.31% Senior secured debt Á Á Tersera Therapeutics LLC Á Á Investment owned, at cost \$ 2,779,708 \$ 2,594,640 Investments at fair value \$ 2,684,245 \$ 2,501,385 Investment owned, percent of net assets (as a percent) 179.42% 165.01% Senior secured debt | Investment Owned, At Cost | Investment Type Concentration Risk Á Á Tersera Therapeutics LLC Á Á Concentration risk (as a percent) 84.42% 85.24% Senior secured debt | Investment Owned, At Fair Value | Investment Type Concentration Risk Á Á Tersera Therapeutics LLC Á Á Concentration risk (as a percent) 85.98% 86.47% Debt investments in the JVs Á Á Tersera Therapeutics LLC Á Á Investment owned, at cost \$ 163,963 \$ 162,986 Investments at fair value \$ 162,542 \$ 162,673 Investment owned, percent of net assets (as a percent) 10.86% 10.73% Debt investments in the JVs | Investment Owned, At Cost | Investment Type Concentration Risk Á Á Tersera Therapeutics LLC Á Á Concentration risk (as a percent) 4.98% 5.35% Debt investments in the JVs | Investment Owned, At Fair Value | Investment Type Concentration Risk Á Á Tersera Therapeutics LLC Á Á Concentration risk (as a percent) 5.21% 5.62% Subordinated debt Á Á Tersera Therapeutics LLC Á Á Investment owned, at cost \$ 115,937 \$ 59,844 Investments at fair value \$ 117,065 \$ 55,717 Investment owned, percent of net assets (as a percent) 7.82% 3.68% Subordinated debt | Investment Owned, At Cost | Investment Type Concentration Risk Á Á Tersera Therapeutics LLC Á Á Concentration risk (as a percent) 3.52% 1.97% Subordinated debt | Investment Owned, At Fair Value | Investment Type Concentration Risk Á Á Tersera Therapeutics LLC Á Á Concentration risk (as a percent) 3.75% 1.93% Common equity and warrants Á Á Tersera Therapeutics LLC Á Á Investment owned, at cost \$ 110,315 \$ 72,261 Investments at fair value \$ 68,142 \$ 57,710 Investment owned, percent of net assets (as a percent) 4.55% 3.81% Common equity and warrants | Investment Owned, At Cost | Investment Type Concentration Risk Á Á Tersera Therapeutics LLC Á Á Concentration risk (as a percent) 3.35% 2.37% Common equity and warrants | Investment Owned, At Fair Value | Investment Type Concentration Risk Á Á Tersera Therapeutics LLC Á Á Concentration risk (as a percent) 2.18% 2.00% Preferred equity Á Á Tersera Therapeutics LLC Á Á Investment owned, at cost \$ 68,218 \$ 99,597 Investments at fair value \$ 63,892 \$ 86,057 Investment owned, percent of net assets (as a percent) 4.27% 5.68% Preferred equity | Investment Owned, At Cost | Investment Type Concentration Risk Á Á Tersera Therapeutics LLC Á Á Concentration risk (as a percent) 2.07% 3.27% Preferred equity | Investment Owned, At Fair Value | Investment Type Concentration Risk Á Á Tersera Therapeutics LLC Á Á Concentration risk (as a percent) 2.05% 2.98% LLC equity interests of the JVs Á Á Tersera Therapeutics LLC Á Á Investment owned, at cost \$ 54,791 \$ 54,791 Investments at fair value \$ 25,817 \$ 28,878 Investment owned, percent of net assets (as a percent) 1.73% 1.91% LLC equity interests of the JVs | Investment Owned, At Cost | Investment Type Concentration Risk Á Á Tersera Therapeutics LLC Á Á Concentration risk (as a percent) 1.66% 1.80% LLC equity interests of the JVs | Investment Owned, At Fair Value | Investment Type Concentration Risk Á Á Tersera Therapeutics LLC Á Á Concentration risk (as a percent) 0.83% 1.00% X - DefinitionFor an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42>Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21)Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20>Reference 4: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480524/946-210-50-6>Details Name: us-gaap_ConcentrationRiskPercentage1 Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionCost of the investment. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 55 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480493/946-210-55-1>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph \(a\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480524/946-210-50-6](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480524/946-210-50-6)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph \(a\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480524/946-210-50-6](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480524/946-210-50-6)Reference 4: <http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480167/946-830-55-12>Reference 5: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph \(a\)\(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480524/946-210-50-6](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480524/946-210-50-6)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph \(a\)\(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-599-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-599-3)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph \(SX 210.12-12\(Column C\)\(Footnote 8\)\(a\)\(3\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-599-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-599-1)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 599 -Paragraph 3 -Subparagraph \(SX 210.12-12\(Column C\)\(Footnote 11\)\(a\)\(3\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-599-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 599 -Paragraph 3 -Subparagraph (SX 210.12-12(Column C)(Footnote 11)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-599-3)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section 599 -Paragraph 6 -Subparagraph \(SX 210.12-14\(Column A\)\(Footnote 5\)\(a\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-599-6](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section 599 -Paragraph 6 -Subparagraph (SX 210.12-14(Column A)(Footnote 5)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-599-6)Reference 10: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section 599 -Paragraph 19 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-599-19](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section 599 -Paragraph 19 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-599-19)Reference 11: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph \(a\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480524/946-210-50-6](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480524/946-210-50-6)Reference 12: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph \(b\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480524/946-210-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480524/946-210-50-1)Reference 13: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph \(b\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480524/946-210-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480524/946-210-50-1)Reference 14: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph \(c\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480524/946-210-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480524/946-210-50-1)Reference 15: <http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 599 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480167/946-830-55-12>Reference 16: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph \(a\)\(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480524/946-210-50-6](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480524/946-210-50-6)Reference 17: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph \(SX 210.6-04\(11\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479617/946-210-599-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SX 210.6-04(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479617/946-210-599-1)Reference 18: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph \(SX 210.6-03\(d\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-210-599-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SX 210.6-03(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-210-599-3)Reference 19: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph \(SX 210.6-04\(1\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479617/946-210-599-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SX 210.6-04(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479617/946-210-599-1)Reference 20: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph \(SX 210.6-04\(2\)\(a\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479617/946-210-599-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SX 210.6-04(2)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479617/946-210-599-1)Reference 21: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph \(SX 210.6-04\(2\)\(b\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479617/946-210-599-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SX 210.6-04(2)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479617/946-210-599-1)Reference 22: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph \(SX 210.12-12\(Column C\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-599-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SX 210.12-12(Column C)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-599-3)Reference 23: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section 599 -Paragraph 3 -Subparagraph \(SX 210.12-12\(Column A\)\(Footnote 6\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-599-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section 599 -Paragraph 3 -Subparagraph (SX 210.12-12(Column A)(Footnote 6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-599-3)Reference 24: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section 599 -Paragraph 3 -Subparagraph \(SX 210.12-12\(Column A\)\(Footnote 7\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-599-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section 599 -Paragraph 3 -Subparagraph (SX 210.12-12(Column A)(Footnote 7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-599-3)Reference 25: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section 599 -Paragraph 3 -Subparagraph \(SX 210.12-12\(Column C\)\(Footnote 9\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-599-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section 599 -Paragraph 3 -Subparagraph (SX 210.12-12(Column C)(Footnote 9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-599-3)Reference 26: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section 599 -Paragraph 6 -Subparagraph \(SX 210.12-14\(Column F\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-599-6](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section 599 -Paragraph 6 -Subparagraph (SX 210.12-14(Column F)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-599-6)Reference 27: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section 599 -Paragraph 6 -Subparagraph \(SX 210.12-14\(Column A\)\(Footnote 1\)\(b\)\(2\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-599-6](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section 599 -Paragraph 6 -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-599-6)Reference 28: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section 599 -Paragraph 6 -Subparagraph \(SX 210.12-14\(Column A\)\(Footnote 1\)\(b\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-599-6](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section 599 -Paragraph 6 -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-599-6)Reference 29: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section 599 -Paragraph 6 -Subparagraph \(SX 210.12-14\(Column A\)\(Footnote 1\)\(b\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-599-6](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section 599 -Paragraph 6 -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-599-6)

Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column F)(Footnote 4)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480032/946-320-S99-6Reference 30>:

[illegible]

Terresa Therapeutics LLC - A Concentration risk (as a percent) 0.08% 0.10% Diversified Chemicals - A Tersera Therapeutics LLC - A Concentration risk (as a percent) 0.05% 0.00% Diversified Chemicals | Investment Owned, At Cost | Investment Sector Concentration Risk - A Tersera Therapeutics LLC - A Concentration risk (as a percent) 0.05% 0.00% Diversified Chemicals | Investment Owned, At Fair Value - A Tersera Therapeutics LLC - A Investments at fair value \$ 1,565 \$ 0 Investment owned, percent of net assets (as a percent) 0.10% 0.00% Diversified Chemicals | Investment Owned, At Fair Value | Investment Sector Concentration Risk - A Tersera Therapeutics LLC - A Concentration risk (as a percent) 0.05% 0.00% Insurance Brokers - A Tersera Therapeutics LLC - A Investment owned, at cost \$ 0 \$ 52,856 Insurance Brokers | Investment Owned, At Cost | Investment Sector Concentration Risk - A Tersera Therapeutics LLC - A Concentration risk (as a percent) 0.00% 1.74% Insurance Brokers | Investment Owned, At Fair Value - A Tersera Therapeutics LLC - A Investments at fair value \$ 0 \$ 53,050 Investment owned, percent of net assets (as a percent) 0.00% 3.50% Insurance Brokers | Investment Owned, At Fair Value | Investment Sector Concentration Risk - A Tersera Therapeutics LLC - A Concentration risk (as a percent) 0.00% 1.83% Consumer Finance - A Tersera Therapeutics LLC - A Investment owned, at cost \$ 0 \$ 16,440 Consumer Finance | Investment Owned, At Cost | Investment Sector Concentration Risk - A Tersera Therapeutics LLC - A Concentration risk (as a percent) 0.00% 0.54% Consumer Finance | Investment Owned, At Fair Value - A Tersera Therapeutics LLC - A Investments at fair value \$ 0 \$ 15,087 Investment owned, percent of net assets (as a percent) 0.00% 1.00% Consumer Finance | Investment Owned, At Fair Value | Investment Sector Concentration Risk - A Tersera Therapeutics LLC - A Concentration risk (as a percent) 0.00% 0.52% Restaurants - A Tersera Therapeutics LLC - A Investment owned, at cost \$ 0 \$ 12,603 Restaurants | Investment Owned, At Cost | Investment Sector Concentration Risk - A Tersera Therapeutics LLC - A Concentration risk (as a percent) 0.00% 0.41% Restaurants | Investment Owned, At Fair Value - A Tersera Therapeutics LLC - A Investments at fair value \$ 0 \$ 12,464 Investment owned, percent of net assets (as a percent) 0.00% 0.82% Restaurants | Investment Owned, At Fair Value | Investment Sector Concentration Risk - A Tersera Therapeutics LLC - A Concentration risk (as a percent) 0.00% 0.43% Air Freight & Logistics - A Tersera Therapeutics LLC - A Investment owned, at cost \$ 0 \$ 4,925 Air Freight & Logistics | Investment Owned, At Cost | Investment Sector Concentration Risk - A Tersera Therapeutics LLC - A Concentration risk (as a percent) 0.00% 0.16% Air Freight & Logistics | Investment Owned, At Fair Value - A Tersera Therapeutics LLC - A Investments at fair value \$ 0 \$ 4,263 Investment owned, percent of net assets (as a percent) 0.00% 0.28% Air Freight & Logistics | Investment Owned, At Fair Value | Investment Sector Concentration Risk - A Tersera Therapeutics LLC - A Concentration risk (as a percent) 0.00% 0.15% Integrated Oil & Gas - A Tersera Therapeutics LLC - A Investment owned, at cost \$ 0 \$ 4,894 Integrated Oil & Gas | Investment Owned, At Cost | Investment Sector Concentration Risk - A Tersera Therapeutics LLC - A Concentration risk (as a percent) 0.00% 0.16% Integrated Oil & Gas | Investment Owned, At Fair Value - A Tersera Therapeutics LLC - A Investments at fair value \$ 0 \$ 4,785 Investment owned, percent of net assets (as a percent) 0.00% 0.32% Integrated Oil & Gas | Investment Owned, At Fair Value | Investment Sector Concentration Risk - A Tersera Therapeutics LLC - A Concentration risk (as a percent) 0.00% 0.17% Other Specialized REITs - A Tersera Therapeutics LLC - A Investment owned, at cost \$ 0 \$ 4,379 Other Specialized REITs | Investment Owned, At Cost | Investment Sector Concentration Risk - A Tersera Therapeutics LLC - A Concentration risk (as a percent) 0.00% 0.14% Other Specialized REITs | Investment Owned, At Fair Value - A Tersera Therapeutics LLC - A Investments at fair value \$ 0 \$ 3,198 Investment owned, percent of net assets (as a percent) 0.00% 0.21% Other Specialized REITs | Investment Owned, At Fair Value | Investment Sector Concentration Risk - A Tersera Therapeutics LLC - A Concentration risk (as a percent) 0.00% 0.11% Leisure Products - A Tersera Therapeutics LLC - A Investment owned, at cost \$ 0 \$ 2,055 Leisure Products | Investment Owned, At Cost | Investment Sector Concentration Risk - A Tersera Therapeutics LLC - A Concentration risk (as a percent) 0.00% 0.07% Leisure Products | Investment Owned, At Fair Value - A Tersera Therapeutics LLC - A Investments at fair value \$ 0 \$ 2,063 Investment owned, percent of net assets (as a percent) 0.00% 0.14% Leisure Products | Investment Owned, At Fair Value | Investment Sector Concentration Risk - A Tersera Therapeutics LLC - A Concentration risk (as a percent) 0.00% 0.07% Technology Distributors - A Tersera Therapeutics LLC - A Investment owned, at cost \$ 0 \$ 813 Technology Distributors | Investment Owned, At Cost | Investment Sector Concentration Risk - A Tersera Therapeutics LLC - A Concentration risk (as a percent) 0.00% 0.03% Technology Distributors | Investment Owned, At Fair Value - A Tersera Therapeutics LLC - A Investments at fair value \$ 0 \$ 776 Investment owned, percent of net assets (as a percent) 0.00% 0.05% Technology Distributors | Investment Owned, At Fair Value | Investment Sector Concentration Risk - A Tersera Therapeutics LLC - A Concentration risk (as a percent) 0.00% 0.03% X - DefinitionFor an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division. + ReferencesReference 1:

[illegible]

gaap_EquitySecuritiesByIndustryAxis=ocsl_AirportServicesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-
gaap_EquitySecuritiesByIndustryAxis=ocsl_MetalGlassPlasticContainersMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-
gaap_EquitySecuritiesByIndustryAxis=ocsl_SpecializedFinanceMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-
gaap_EquitySecuritiesByIndustryAxis=ocsl_InternetServicesInfrastructureMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-
gaap_EquitySecuritiesByIndustryAxis=ocsl_DiversifiedMetalsMiningMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-
gaap_EquitySecuritiesByIndustryAxis=ocsl_SystemsSoftwareMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-
gaap_EquitySecuritiesByIndustryAxis=ocsl_HomeImprovementRetailMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-
gaap_EquitySecuritiesByIndustryAxis=ocsl_AutoPartsEquipmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-
gaap_EquitySecuritiesByIndustryAxis=ocsl_CommunicationsEquipmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-
gaap_EquitySecuritiesByIndustryAxis=ocsl_RealEstateServicesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-
gaap_EquitySecuritiesByIndustryAxis=ocsl_SoftDrinksNonAlcoholicBeveragesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-
gaap_EquitySecuritiesByIndustryAxis=ocsl_AutomotiveRetailMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-
gaap_EquitySecuritiesByIndustryAxis=ocsl_OfficeServicesSuppliesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-
gaap_EquitySecuritiesByIndustryAxis=ocsl_LeisureFacilitiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-
gaap_EquitySecuritiesByIndustryAxis=ocsl_OtherSpecialtyRetailMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-
gaap_EquitySecuritiesByIndustryAxis=ocsl_ElectricalComponentsEquipmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-
gaap_EquitySecuritiesByIndustryAxis=ocsl_MoviesEntertainmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-
gaap_EquitySecuritiesByIndustryAxis=ocsl_ConstructionMachineryHeavyTransportationEquipmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-
gaap_EquitySecuritiesByIndustryAxis=ocsl_HealthCareEquipmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-
gaap_EquitySecuritiesByIndustryAxis=ocsl_PassengerAirlinesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-
gaap_EquitySecuritiesByIndustryAxis=us-gaap_RealEstateSectorMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-
gaap_EquitySecuritiesByIndustryAxis=ocsl_WirelessTelecommunicationServicesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-
gaap_EquitySecuritiesByIndustryAxis=ocsl_GoldSectorMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-
gaap_EquitySecuritiesByIndustryAxis=ocsl_HomeFurnishingsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-
gaap_EquitySecuritiesByIndustryAxis=ocsl_BroadlineRetailMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-
gaap_EquitySecuritiesByIndustryAxis=ocsl_ConstructionAndEngineeringSectorMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-
gaap_EquitySecuritiesByIndustryAxis=ocsl_PackagedFoodsMeatsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-
gaap_EquitySecuritiesByIndustryAxis=ocsl_SpecialtyChemicalsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-
gaap_EquitySecuritiesByIndustryAxis=ocsl_OilGasStorageTransportationMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-
gaap_EquitySecuritiesByIndustryAxis=ocsl_ApparelRetailMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-
gaap_EquitySecuritiesByIndustryAxis=ocsl_HotelsResortsCruiseLinesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-
gaap_EquitySecuritiesByIndustryAxis=ocsl_AlternativeCarriersMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-
gaap_EquitySecuritiesByIndustryAxis=ocsl_FoodDistributorsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-
gaap_EquitySecuritiesByIndustryAxis=ocsl_HealthCareSuppliesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-
gaap_EquitySecuritiesByIndustryAxis=ocsl_AdvertisingIndustryMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-
gaap_EquitySecuritiesByIndustryAxis=ocsl_IntegratedTelecommunicationServicesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-
gaap_EquitySecuritiesByIndustryAxis=ocsl_DistributorsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-
gaap_EquitySecuritiesByIndustryAxis=ocsl_EducationServicesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-
gaap_EquitySecuritiesByIndustryAxis=ocsl_FinancingExchangeDataMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-
gaap_EquitySecuritiesByIndustryAxis=ocsl_CableSatelliteMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-
gaap_EquitySecuritiesByIndustryAxis=ocsl_ResearchConsultingServicesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-
gaap_EquitySecuritiesByIndustryAxis=ocsl_PaperPlasticPackagingProductsMaterialsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-
gaap_EquitySecuritiesByIndustryAxis=ocsl_HousewaresSpecialtiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-
gaap_EquitySecuritiesByIndustryAxis=ocsl_DiversifiedChemicalsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-
gaap_EquitySecuritiesByIndustryAxis=ocsl_InsuranceBrokersMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-
gaap_EquitySecuritiesByIndustryAxis=ocsl_ConsumerFinanceMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-
gaap_EquitySecuritiesByIndustryAxis=ocsl_RestaurantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-
gaap_EquitySecuritiesByIndustryAxis=ocsl_AirFreightLogisticsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-
gaap_EquitySecuritiesByIndustryAxis=ocsl_IntegratedOilGasMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-
gaap_EquitySecuritiesByIndustryAxis=ocsl_OtherSpecializedREITsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-
gaap_EquitySecuritiesByIndustryAxis=ocsl_LeisureProductsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-
gaap_EquitySecuritiesByIndustryAxis=ocsl_TechnologyDistributorsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-
Portfolio Investments - Summary of Portfolio (Details) â in Thousands, A€ in Thousands, \$ in Thousands Jun. 30, 2024 USD (\$ borrower Jun. 30, 2024 EUR (â) borrower Jun. 30, 2024 GBP (A€) borrower Sep. 30, 2023 USD (\$) borrower Sep. 30, 2023 EUR (â) borrower Sep. 30, 2023 GBP (A€) borrower Jun. 30, 2023 USD (\$) Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A Number of borrowers | borrower 158 158 158 143 143 143 A Investment, Identifier [Axis]: 107 Fair Street LLC, Real Estate Development, First Lien Term Loan A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A Investment, principal \$ 1,269 [1],[2],[3],[4] A A \$ 1,269 [5],[6],[7],[8] A A Investment, interest rate (as a percent) 13.00% [1],[2],[3],[9],[10] 13.00% [1],[2],[3],[9],[10] 13.00% [1],[2],[3],[9],[10] 12.50% [5],[6],[8],[11],[12] 12.50% [5],[6],[8],[11],[12] A Investment, Identifier [Axis]: 107-109 Beech Oak22 LLC, Real Estate Development, First Lien Revolver A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A Investment, principal \$ 18,869 [1],[2],[4] A A \$ 18,869 [5],[7],[8] A A Investment, interest rate (as a percent) 11.00% [1],[2],[9],[10] 11.00% [1],[2],[9],[10] 11.00% [1],[2],[9],[10] 11.00% [5],[8],[11],[12] 11.00% [5],[8],[11],[12] 11.00% [5],[8],[11],[12] A Investment, Identifier [Axis]: 112-126 Van Houten Real22 LLC, Real Estate Development, First Lien Term Loan A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A Investment, principal \$ 5,035 [1],[2],[3],[4] A A \$ 4,070 [5],[6],[7],[8] A A Investment, interest rate (as a percent) 13.00% [1],[2],[3],[9],[10] 13.00% [1],[2],[3],[9],[10] 13.00% [1],[2],[3],[9],[10] 12.00% [5],[6],[8],[11],[12] 12.00% [5],[6],[8],[11],[12] A Investment, Identifier [Axis]: A.T. Holdings II Ltd., Biotechnology, First Lien Term Loan A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A Investment, principal \$ 21,434 [1],[4],[13],[14] A A \$ 21,434 [7],[8],[15],[16] A A Investment, interest rate (as a percent) 14.25% [1],[9],[10],[13],[14] 14.25% [1],[9],[10],[13],[14] 14.25% [1],[9],[10],[13],[14] 14.25% [8],[11],[12],[15],[16] 14.25% [8],[11],[12],[15],[16] 14.25% [8],[11],[12],[15],[16] A Investment, Identifier [Axis]: A.T. Holdings II SÂERL, Biotechnology, First Lien Term Loan A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A Investment, principal \$ 7,074 [1],[4],[13],[17] A A \$ 6,021 [7],[8],[15] A A A Investment, Identifier [Axis]: ADB Companies, LLC, Construction & Engineering, First Lien Term Loan 1 A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A Investment, principal \$ 3,177 [1],[2],[4],[9] A A \$ 3,446 [7],[8],[11] A A Investment, interest rate (as a percent) 11.82% [1],[2],[9],[10] 11.82% [1],[2],[9],[10] 11.82% [1],[2],[9],[10] 11.82% [1],[2],[9],[10] 11.90% [8],[11],[12] 11.90% [8],[11],[12] 11.90% [8],[11],[12] A Investment, Identifier [Axis]: ADB Companies, LLC, Construction & Engineering, First Lien Term Loan 2 A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A Investment, principal \$ 900 [1],[4],[9] A A \$ 17,901 [7],[8],[11] A A Investment, interest rate (as a percent) 12.09% [1],[9],[10] 12.09% [1],[9],[10] 12.09% [1],[9],[10] 12.15% [8],[11],[12] 12.15% [8],[11],[12] A Investment, Identifier [Axis]: ADB Companies, LLC, Construction & Engineering, First Lien Term Loan 3 A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A Investment, principal \$ 16,546 [1],[4],[9] A A \$ 963 [7],[8],[11] A A Investment, interest rate (as a percent) 12.10% [1],[9],[10] 12.10% [1],[9],[10] 12.10% [1],[9],[10] 12.13% [8],[11],[12] 12.13% [8],[11],[12] 12.13% [8],[11],[12] A Investment, Identifier [Axis]: ADC Therapeutics SA, Biotechnology, First Lien Term Loan A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A Investment, principal [1],[4],[9],[13] \$ 6,589 A A A A A Investment, interest rate (as a percent) [1],[9],[10],[13] 12.98% 12.98% A A A A A Investment, Identifier [Axis]: ADC Therapeutics SA, Biotechnology, First Lien Term Loan 1 A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A Investment, principal [7],[8],[11],[15] A A \$ 6,589 A A A A A Investment, interest rate (as a percent) [8],[11],[12],[15] A A \$ 13.04% 13.04% A A Investment, Identifier [Axis]: ADC Therapeutics SA, Biotechnology, First Lien Term Loan 2 A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A Investment, principal [5],[7],[8],[11],[15] A A \$ 0 A A A A Investment, Identifier [Axis]: AI Sirona (Luxembourg) Acquisition S.a.r.l., Pharmaceuticals, First Lien Term Loan A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A Investment, principal [â] [7],[11],[15] A A A A A Investment, interest rate (as a percent) [11],[12],[15] A A 8.86% 8.86% 8.86% A A Investment, Identifier [Axis]: AIP RD Buyer Corp., Distributors, Second Lien Term Loan A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A Investment, principal [7],[8],[11] A A \$ 17,873 A A A Investment, interest rate (as a percent) [8],[11],[12] A A 13.17% 13.17% A A Investment, Identifier [Axis]: ASP-R-PAC Acquisition Co LLC, Paper & Plastic Packaging Products & Materials, First Lien Revolver A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A Investment, principal \$ 162 [1],[2],[4],[9],[13] A A \$ 0 [5],[7],[8],[11],[15] A A A Investment, interest rate (as a percent) [1],[2],[9],[10],[13] 11.46% 11.46% A A A A A Investment, Identifier [Axis]: ASP-R-PAC Acquisition Co LLC, Paper & Plastic Packaging Products & Materials, First Lien Term Loan A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A Investment, principal \$ 3,251 [1],[4],[9],[13] A A \$ 3,276 [7],[8],[11],[15] A A A Investment, interest rate (as a percent) 11.59% [1],[9],[10],[13] 11.59% [1],[9],[10],[13] 11.59% [1],[9],[10],[13] 11.63% [8],[11],[12],[15] 11.63% [8],[11],[12],[15] 11.63% [8],[11],[12],[15] A Investment, Identifier [Axis]: ATNX SPV, LLC, Pharmaceuticals, First Lien Term Loan A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A Investment, principal \$ 13,562 [1],[4],[13],[14] A A \$ 12,222 [7],[8],[15],[16] A A A Investment, Identifier [Axis]: Access CIG, LLC, Diversified Support Services, First Lien Term Loan A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A Investment, principal [4],[9] \$ 1,990 A A A A A Investment, interest rate (as a percent) [9],[10] 10.33% 10.33% A A A A A Investment, Identifier [Axis]: Accupac, Inc., Personal Care Products, First Lien Revolver A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A Investment, principal \$ 2,613 [1],[4],[9] A A \$ 2,033 [5],[7],[8],[11] A A A Investment, interest rate (as a percent) 11.48% [1],[9],[10] 11.48% [1],[9],[10] 11.48% [1],[9],[10] 11.55% [5],[8],[11],[12] 11.55% [5],[8],[11],[12] A Investment, Identifier [Axis]: Accupac, Inc., Personal Care Products, First Lien Term Loan 1 A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A Investment, principal \$ 0 [1],[2],[4],[9] A A \$ 20,234 [7],[8],[11] A A A Investment, interest rate (as a percent) [8],[11],[12] A A 11.55% 11.55% A A Investment, Identifier [Axis]: Accupac, Inc., Personal Care Products, First Lien Term Loan 2 A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A Investment, principal \$ 20,077 [1],[4],[9] A A \$ 0 [5],[7],[8],[11] A A A Investment, interest rate (as a percent) [1],[9],[10] 11.50% 11.50% A A A A A Investment, Identifier [Axis]: Acquia Inc., Application Software, First Lien Revolver A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A Investment, principal \$ 1,084 [1],[2],[4],[9] A A \$ 1,333 [5],[7],[8],[11] A A A Investment, interest rate (as a percent) 12.46% [1],[2],[9],[10] 12.46% [1],[2],[9],[10] 12.46% [1],[2],[9],[10] 12.72% [5],[8],[11],[12] 12.72% [5],[8],[11],[12] A Investment, Identifier [Axis]: Acquia Inc., Application Software, First Lien Term Loan 1 A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A Investment, principal \$ 6,400 [1],[4],[9] A A \$ 6,400 [7],[8],[11] A A A Investment, interest rate (as a percent) 12.45% [1],[9],[10] 12.45% [1],[9],[10] 12.45% [1],[9],[10] 12.34% [8],[11],[12] 12.34% [8],[11],[12] 12.34% [8],[11],[12] A Investment, Identifier [Axis]: Acquia Inc., Application Software, First Lien Term Loan 2 A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A Investment, principal \$ 25,332 [1],[4],[9] A A \$ 25,332 [7],[8],[11] A A A Investment, interest rate (as a percent) 12.45% [1],[9],[10] 12.45% [1],[9],[10] 12.45% [1],[9],[10] 12.34% [8],[11],[12] 12.34% [8],[11],[12] 12.34% [8],[11],[12] A Investment, Identifier [Axis]: All Web Leads, Inc., Advertising, Common Stock A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A Investment, principal \$ 0 A A A A A Investment, Identifier [Axis]: All Web Leads, Inc., Advertising, First Lien Revolver A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A Investment, principal [1],[2],[4],[9] \$ 1,560 A A A A A Investment, interest rate (as a percent) [1],[2],[9],[10] 9.34% 9.34% A A A A A Investment, Identifier [Axis]: All Web Leads, Inc., Advertising, First Lien Term Loan A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A Investment, principal [7],[8],[11],[18] A A \$ 23,562 A A A A A Investment, Identifier [Axis]: All Web Leads, Inc., Advertising, First Lien Term Loan 1 A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A Investment, principal [1],[4],[9] \$ 1,809 A A A A A Investment, interest rate (as a percent) [1],[9],[10] 7.34% 7.34% 7.34% A A A A A Investment, Identifier [Axis]: All Web Leads, Inc., Advertising, First Lien Term Loan 2 A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A Investment, principal [1],[4],[9] \$ 3,602 A A A A A Investment, interest rate (as a percent) [1],[9],[10] 8.34% 8.34% A A A A A Investment, Identifier [Axis]: All Web Leads, Inc., Advertising, First Lien Term Loan 3 A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A Investment, principal [1],[4],[17] \$ 3,451 A A A A A Investment, Identifier [Axis]: Altice France S.A., Integrated Telecommunication Services, Fixed Rate Bond A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A Investment, principal [7],[15] A A \$ 4,050 A A A A A Investment, interest rate (as a percent) [11],[12],[15] A A 5.50% 5.50% 5.50% A Investment, Identifier [Axis]: Alto Pharmacy Holdings, Inc., Health Care Technology, First Lien Term Loan A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A Investment, principal \$ 9,903 [1],[4],[9] A A \$ 9,057 [7],[8],[11] A A A Investment, interest rate (as a percent) 4.94% [1],[9],[10] 4.94% [1],[9],[10] 4.94% [1],[9],[10] 5.00% [8],[11],[12] 5.00% [8],[11],[12] 5.00% [8],[11],[12] A Investment, Identifier [Axis]: Alvgogen Pharma US, Inc., Pharmaceuticals, First Lien Term Loan A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A Investment, principal \$ 16,371 [1],[4],[9] A A \$ 17,053 [7],[8],[11] A A A Investment, interest rate (as a percent) 12.98% [1],[9],[10] 12.98% [1],[9],[10] 12.98% [1],[9],[10] 13.04% [8],[11],[12] 13.04% [8],[11],[12] 13.04% [8],[11],[12] A Investment, Identifier [Axis]: Alvotech Holdings S.A., Biotechnology, Fixed Rate Bond 1 A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A Investment, principal \$ 28,964 [1],[4],[13] A A \$ 28,464 [7],[8],[15] A A A Investment, interest rate (as a percent) 12.00% [1],[9],[10],[13] 12.00% [1],[9],[10],[13] 12.00% [1],[9],[10],[13] 8.50% [8],[11],[12],[15] 8.50% [8],[11],[12],[15] 8.50% [8],[11],[12],[15] A

[illegible]

Identifier [Axis]: Cloud Software Group, Inc., Application Software, Fixed Bond A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A Investment, principal [4] \$ 2,300 A A A A A Investment, interest rate (as a percent) [9],[10] 6.50% 6.50% 6.50% A A A A A Investment, Identifier [Axis]: Conдор Merger Sub Inc., Systems Software, Fixed Rate Bond A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A Investment, principal \$ 10,720 [4] A A \$ 8,420 [7] A A A Investment, interest rate (as a percent) 7.38% [9],[10] 7.38% [9],[10] 7.38% [9],[10] 7.38% [11],[12] 7.38% [11],[12] 7.38% [11],[12] A Investment, Identifier [Axis]: Connect U.S. Fincio LLC, Alternative Carriers, Fixed Rate Bond A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A Investment, principal [4],[13] \$ 1,310 A A A A A Investment, interest rate (as a percent) [9],[10],[13] 6.75% 6.75% 6.75% A A A A A Investment, Identifier [Axis]: Continental Intermodal Group LP, Oil & Gas Storage & Transportation, First Lien Term Loan A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A Investment, principal [7],[8],[11],[18] A A A \$ 22,084 A A A Investment, Identifier [Axis]: CoreRx, Inc., Pharmaceuticals, First Lien Term Loan A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A Investment, principal [1],[4],[9] \$ 6,494 A A A A A Investment, interest rate (as a percent) [1],[9],[10] 12.83% 12.83% 12.83% A A A A A Investment, Identifier [Axis]: Coupa Holdings, LLC, Application Software, First Lien Revolver A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A Investment, principal \$ 0 [1],[2],[4],[9] A A \$ 0 [5],[7],[8],[11] A A A Investment, Identifier [Axis]: Coupa Holdings, LLC, Application Software, First Lien Term Loan 1 A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A Investment, principal 0 [1],[2],[4],[9] A A \$ 13,157 [7],[8],[11] A A A Investment, interest rate (as a percent) [8],[11],[12] A A \$ 12.82% 12.82% 12.82% A Investment, Identifier [Axis]: Coupa Holdings, LLC, Application Software, First Lien Term Loan 2 A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A Investment, principal \$ 13,157 [1],[4],[9] A A \$ 0 [5],[7],[8],[11] A A A Investment, interest rate (as a percent) [1],[9],[10] 10.83% 10.83% 10.83% A A A A A Investment, Identifier [Axis]: Covetrus, Inc., Health Care Distributors, First Lien Term Loan A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A Investment, principal \$ 14,639 [4],[9] A A \$ 14,750 [7],[11] A A A Investment, interest rate (as a percent) 10.33% [9],[10] 10.33% [9],[10] 10.33% [9],[10] 10.39% [11],[12] 10.39% [11],[12] A Investment, Identifier [Axis]: Coyote Buyer, LLC, Specialty Chemicals, First Lien Revolver A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A Investment, principal [5],[7],[8],[11] A A A A A Investment, Identifier [Axis]: Coupa Holdings, LLC, Application Software, First Lien Term Loan 1 A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A Investment, principal 0 [1],[2],[4],[9] A A \$ 13,157 [7],[8],[11] A A A Investment, interest rate (as a percent) [8],[11],[12] A A \$ 11.52% 11.52% 11.52% A Investment, Identifier [Axis]: Crewline Buyer, Inc., Systems Software, First Lien Revolver A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A Investment, principal [1],[2],[4],[9] \$ 0 A A A A A A Investment, Identifier [Axis]: Crewline Buyer, Inc., Systems Software, First Lien Term Loan A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A Investment, principal [1],[4],[9] \$ 20,924 A A A A A Investment, interest rate (as a percent) [1],[9],[10] 12.08% 12.08% 12.08% A A A A A Investment, Identifier [Axis]: Crown Subsea Communications Holding, Inc., Alternative Carriers, First Lien Term Loan A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A Investment, principal [4],[9] \$ 14,000 A A A A A A Investment, interest rate (as a percent) [9],[10] 10.08% 10.08% 10.08% A A A A A Investment, Identifier [Axis]: DTI Holdco, Inc., Research & Consulting Services, First Lien Term Loan A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A Investment, principal [7],[11] A A A \$ 4,950 A A A A Investment, interest rate (as a percent) [11],[12] A A \$ 10.12% 10.12% 10.12% A Investment, Identifier [Axis]: Delta Leasing SPV II LLC, Specialized Finance, Subordinated Debt Term Loan A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A Investment, principal [5],[7],[8],[15] A A A \$ 17,465 A A A A Investment, interest rate (as a percent) [5],[8],[11],[12],[15] A A A A A A Investment, Identifier [Axis]: Delta Leasing SPV II LLC, Specialized Finance, Subordinated Debt Term Loan 1 A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A Investment, principal [1],[2],[4],[13] \$ 8,393 A A A A A A Investment, interest rate (as a percent) [1],[2],[9],[10],[13] 8.00% 8.00% 8.00% A A A A A A Investment, Identifier [Axis]: Delta Leasing SPV II LLC, Specialized Finance, Subordinated Debt Term Loan 2 A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A Investment, principal [1],[4],[13] \$ 33,726 A A A A A A A Investment, interest rate (as a percent) [1],[9],[10],[13] 3.00% 3.00% 3.00% A A A A A A Investment, Identifier [Axis]: Dialyze Holdings, LLC, Health Care Equipment, First Lien Term Loan A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A Investment, principal [7],[8],[11] A A \$ 20,757 A A A A Investment, interest rate (as a percent) [8],[11],[12] A A \$ 14.54% 14.54% 14.54% A Investment, Identifier [Axis]: Dialyze Holdings, LLC, Health Care Equipment, First Lien Term Loan 1 A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A Investment, principal [1],[4],[9] \$ 22,683 A A A A A A A Investment, Identifier [Axis]: Dialyze Holdings, LLC, Health Care Equipment, First Lien Term Loan 2 A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A Investment, principal [1],[4],[9] 627 A A A A A A A A Investment, Identifier [Axis]: Dialyze Holdings, LLC, Health Care Equipment, First Lien Term Loan 3 A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A Investment, principal [1],[4],[9] 620 A A A A A A A A Investment, Identifier [Axis]: Dialyze Holdings, LLC, Health Care Equipment, Subordinated Debt Term Loan A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A Investment, principal [7],[8] A A \$ 654 A A A A Investment, Identifier [Axis]: Dialyze Holdings, LLC, Health Care Equipment, Subordinated Debt Term Loan 1 A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A Investment, principal [1],[4],[17] 694 A A A A A A A A Investment, Identifier [Axis]: Dialyze Holdings, LLC, Health Care Equipment, Subordinated Debt Term Loan 2 A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A Investment, principal [1],[4],[17] 935 A A A A A A A A A Investment, Identifier [Axis]: Dialyze Holdings, LLC, Health Care Equipment, Subordinated Debt Term Loan 3 A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A Investment, principal [1],[4],[17] 928 A A A A A A A A A Investment, Identifier [Axis]: Digital.AI Software Holdings, Inc., Application Software, First Lien Revolver A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A Investment, principal 0 [1],[2],[4],[9] A A \$ 284 [5],[7],[8],[11] A A A A A A A A Investment, interest rate (as a percent) [5],[8],[11],[12] A A \$ 12.49% 12.49% 12.49% A Investment, Identifier [Axis]: Digital.AI Software Holdings, Inc., Application Software, First Lien Term Loan A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A Investment, principal [7],[8],[11] A A \$ 12,386 A A A A A A A A Investment, interest rate (as a percent) [8],[11],[12] A A \$ 12.49% 12.49% 12.49% A Investment, Identifier [Axis]: Digital.AI Software Holdings, Inc., Application Software, First Lien Term Loan 1 A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A Investment, principal [1],[4],[9] \$ 54,595 A A A A A A A A A Investment, interest rate (as a percent) [1],[9],[10] 11.33% 11.33% 11.33% A A A A A A A A Investment, Identifier [Axis]: Digital.AI Software Holdings, Inc., Application Software, First Lien Term Loan 2 A A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A Investment, principal [1],[4],[9] \$ 2,946 A A A A A A A A A Investment, interest rate (as a percent) [1],[9],[10] 11.32% 11.32% 11.32% A A A A A A A A Investment, Identifier [Axis]: DirecTV Financing, LLC, Cable & Satellite, First Lien Term Loan A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A Investment, principal \$ 4,311 [4] A A \$ 4,641 [7],[11] A A A A A A A A Investment, interest rate (as a percent) 10.71% [9],[10] 10.71% [9],[10] 10.71% [9],[10] 10.43% [11],[12] 10.43% [11],[12] A A A A A A A A Investment, Identifier [Axis]: Dominion Diagnostics, LLC, Health Care Services, First Lien Revolver A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A Investment, principal \$ 5,574 [1],[4],[9] A A \$ 5,574 [7],[8],[11] A A \$ 3,484 A A A A A A A A Investment, interest rate (as a percent) 10.48% [1],[9],[10] 10.48% [1],[9],[10] 10.48% [1],[9],[10] 10.54% [8],[11],[12] 10.54% [8],[11],[12] 10.54% [8],[11],[12] 10.24% A Investment, Identifier [Axis]: Dominion Diagnostics, LLC, Health Care Services, First Lien Term Loan A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A Investment, principal [1],[4],[9] \$ 13,963 A A A A A A A A A Investment, interest rate (as a percent) [1],[9],[10] 10.48% 10.48% 10.48% A A A A A A A A A Investment, Identifier [Axis]: Dominion Diagnostics, LLC, Health Care Services, First Lien Term Loan 1 A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A Investment, principal \$ 13,963 A A \$ 14,068 [7],[8],[11] A A \$ 14,102 A A A A A A A A Investment, interest rate (as a percent) 10.48% 10.48% 10.48% [8],[11],[12] 10.54% [8],[11],[12] 10.54% [8],[11],[12] 10.39% A Investment, Identifier [Axis]: Dominion Diagnostics, LLC, Health Care Services, First Lien Term Loan 2 A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A Investment, principal \$ 0 A A \$ 2,090 [5],[7],[8],[11] A A \$ 0 A A A A A A A A Investment, interest rate (as a percent) 10.48% 10.48% 10.48% 10.42% [5],[8],[11],[12] 10.42% [5],[8],[11],[12] 10.42% [5],[8],[11],[12] A Investment, Identifier [Axis]: Eagleview Technology Corporation, Application Software, Second Lien Term Loan A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A Investment, principal \$ 8,974 [1],[4],[9] A A \$ 8,974 [7],[8],[11] A A A A A A A A Investment, interest rate (as a percent) 12.98% [1],[9],[10] 12.98% [1],[9],[10] 12.98% [1],[9],[10] 13.04% [8],[11],[12] 13.04% [8],[11],[12] A Investment, Identifier [Axis]: Enverus Holdings, Inc., Application Software, First Lien Revolver A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A Investment, principal [1],[2],[4],[9] \$ 0 A A A A A A A A A Investment, Identifier [Axis]: Enverus Holdings, Inc., Application Software, First Lien Term Loan 1 A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A Investment, principal [1],[4],[9] \$ 24,803 A A A A A A A A A Investment, interest rate (as a percent) [1],[9],[10] 10.84% 10.84% 10.84% A A A A A A A A A Investment, Identifier [Axis]: Enverus Holdings, Inc., Application Software, First Lien Term Loan 2 A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A Investment, principal [1],[2],[4],[9] \$ 0 A A A A A A A A A Investment, Identifier [Axis]: Establishment Labs Holdings Inc., Health Care Technology, First Lien Term Loan 1 A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A Investment, principal \$ 1,854 [1],[4],[13] A A \$ 1,065 [7],[8],[15] A A A A A A A A A Investment, interest rate (as a percent) 3.00% [1],[9],[10],[13] 3.00% [1],[9],[10],[13] 3.00% [1],[9],[10],[13] 3.00% [8],[11],[12],[15] 3.00% [8],[11],[12],[15] A Investment, Identifier [Axis]: Establishment Labs Holdings Inc., Health Care Technology, First Lien Term Loan 2 A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A Investment, principal \$ 0 [1],[2],[4],[13] A A \$ 1,772 [7],[8],[15] A A A A A A A A A Investment, interest rate (as a percent) 3.00% [1],[2],[9],[10],[13] 3.00% [1],[2],[9],[10],[13] 3.00% [8],[11],[12],[15] 3.00% [8],[11],[12],[15] 3.00% [8],[11],[12],[15] A Investment, Identifier [Axis]: Establishment Labs Holdings Inc., Health Care Technology, First Lien Term Loan 3 A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A Investment, principal \$ 0 [1],[2],[4],[13] A A \$ 0 [5],[7],[8],[15] A A A A A A A A A Investment, interest rate (as a percent) 3.00% [1],[2],[9],[10],[13] 3.00% [1],[2],[9],[10],[13] 3.00% [5],[8],[11],[12],[15] 3.00% [5],[8],[11],[12],[15] A Investment, Identifier [Axis]: Establishment Labs Holdings Inc., Health Care Technology, First Lien Term Loan 4 A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A Investment, principal \$ 11,576 [1],[4],[13] A A \$ 0 [5],[7],[8],[15] A A A A A A A A A Investment, interest rate (as a percent) 3.00% [1],[9],[10],[13] 3.00% [1],[9],[10],[13] 3.00% [5],[8],[11],[12],[15] 3.00% [5],[8],[11],[12],[15] 3.00% [5],[8],[11],[12],[15] A Investment, Identifier [Axis]: Evergreen IX Borrower 2023, LLC, Application Software, First Lien Revolver A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A Investment, principal \$ 0 [1],[2],[4],[9] A A \$ 0 [5],[7],[8],[11] A A A A A A A A Investment, Identifier [Axis]: Evergreen IX Borrower 2023, LLC, Application Software, First Lien Term Loan A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A Investment, principal \$ 14,662 [1],[4],[9] A A \$ 14,736 [7],[8],[11] A A A A A A A A Investment, interest rate (as a percent) 11.33% [1],[9],[10] 11.33% [1],[9],[10] 11.33% [1],[9],[10] 11.32% [8],[11],[12] 11.32% [8],[11],[12] 11.32% [8],[11],[12] A Investment, Identifier [Axis]: Eyesouth Eye Care Holdco LLC, Health Care Services, First Lien Term Loan 1 A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A Investment, principal [1],[4],[9] \$ 4,379 A A A A A A A A A Investment, interest rate (as a percent) [1],[9],[10] 10.93% 10.93% 10.93% A A A A A A A A A Investment, Identifier [Axis]: Eyesouth Eye Care Holdco LLC, Health Care Services, First Lien Term Loan 2 A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A Investment, principal [1],[2],[4],[9] \$ 0 A A A A A A A A A Investment, Identifier [Axis]: FINThrive Software Intermediate Holdings, Inc., Health Care Technology, Second Lien Term Loan A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A Investment, principal \$ 31,074 [4],[9] A A \$ 31,074 [7],[11],[15] A A A A A A A A A Investment, interest rate (as a percent) 12.21% [9],[10] 12.21% [9],[10] 12.21% [9],[10] 12.18% [11],[12],[15] 12.18% [11],[12],[15] A Investment, Identifier [Axis]: Fairbridge Strategic Capital Funding LLC, Real Estate Operating Companies, First Lien Term Loan A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A Investment, principal \$ 56,900 [1],[4] A A \$ 59,950 [5],[7],[8] A A A A A A A A A Investment, interest rate (as a percent) 9.00% [1],[9],[10] 9.00% [1],[9],[10] 9.00% [1],[9],[10] 9.00% [5],[8],[11],[12] 9.00% [5],[8],[11],[12] 9.00% [5],[8],[11],[12] A Investment, Identifier [Axis]: Finastra USA, Inc., Application Software, First Lien Revolver A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A Investment, principal \$ 129 [1],[2],[4],[9],[13] A A \$ 258 [5],[7],[8],[11],[15] A A A A A A A A A Investment, interest rate (as a percent) 12.58% [1],[2],[9],[10],[13] 12.58% [1],[2],[9],[10],[13] 12.58% [1],[2],[9],[10],[13] 12.55% [5],[8],[11],[12],[15] 12.55% [5],[8],[11],[12],[15] 12.55% [5],[8],[11],[12],[15] A Investment, Identifier [Axis]: Finastra USA, Inc., Application Software, First Lien Term Loan A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A Investment, principal \$ 11,713 [1],[4],[9],[13] A A \$ 11,742 [7],[8],[11],[15] A A A A A A A A A Investment, interest rate (as a percent) 12.46% [1],[9],[10],[13] 12.46% [1],[9],[10],[13] 12.46% [1],[9],[10],[13] 12.55% [8],[11],[12],[15] 12.55% [8],[11],[12],[15] 12.55% [8],[11],[12],[15] A Investment, Identifier [Axis]: Finthrive Software Intermediate Holdings, Inc., Health Care Technology, First Lien Term Loan A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A Investment, principal [4],[9] \$ 4,302 A A A A A A A A A Investment, interest rate (as a percent) [9],[10] 9.61% 9.61% 9.61% A A A A A A A A A Investment, Identifier [Axis]: Fortress Biotech, Inc., Biotechnology, First Lien Term Loan A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A Investment, principal \$ 11,918 [1],[4],[13] A A \$ 11,918 [7],[8],[15] A A A A A A A A A Investment, interest rate (as a percent) 11.00% [1],[9],[10],[13] 11.00% [1],[9],[10],[13] 11.00% [8],[11],[12],[15] 11.00% [8],[11],[12],[15] A Investment, Identifier [Axis]: Frontier Communications Holdings, LLC, Integrated Telecommunication Services, Fixed Rate Bond A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A Investment, principal \$ 7,881 [4],[13] A A \$ 4,881 [7],[15] A A A A A A A A A Investment, interest rate (as a percent) 6.00% [9],[10],[13] 6.00% [9],[10],[13] 6.00% [9],[10],[13] 6.00% [11],[12],[15] 6.00% [11],[12],[15] 6.00% [11],[12],[15] A Investment, Identifier [Axis]: Frontier Issuer LLC, Specialized Finance, CLO Notes A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A Investment, principal [4],[13] \$ 7,439 A A A A A A A A A Investment, interest rate (as a percent) [9],[10],[13] 11.16% 11.16% 11.16% A A A A A A A A A Investment, Identifier [Axis]: Galileo Parent, Inc., Aerospace & Defense, First Lien Revolver A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A Investment, principal \$ 2,219 [1],[2],[4],[9] A A \$ 1,638 [5],[7],[8],[11] A A A A A A A A A Investment, interest rate (as a percent) 12.59% [1],[2],[9],[10] 12.59% [1],[2],[9],[10] 12.59% [1],[2],[9],[10] 12.64% [5],[8],[11],[12] 12.64% [5],[8],[11],[12] 12.64% [5],[8],[11],[12] A Investment, Identifier [Axis]: Galileo Parent, Inc., Aerospace & Defense, First Lien Term Loan A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A Investment, principal \$ 23,595 [1],[4],[9] A A \$ 23,774 [7],[8],[11] A A A A A A A A A Investment, interest rate (as a percent) 12.58% [1],[9],[10] 12.58% [1],[9],[10] 12.58% [1],[9],[10] 12.64% [8],[11],[12] 12.64% [8],[11],[12] A Investment, Identifier [Axis]: Gibson Brands, Inc., Leisure Products, First Lien Term Loan A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A Investment, principal [7],[8],[11] A A \$ 2,456 A A A A A A A A A Investment, interest rate (as a percent) [8],[11],[12] A A \$ 10.57% 10.57% 10.57% A Investment, Identifier [Axis]: GoldenTree Loan Management EUR CLO 2 DAC, Multi-Sector Holdings, CLO Notes A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A Investment, principal [4],~ A A ~, 1,000 [4],[9],[13] A A ~, 1,000 [7],[11],[15] A A A A A A A A A Investment, interest rate (as a percent) 6.75% [9],[10],[13] 6.75% [9],[10],[13] 6.56% [11],[12],[15] 6.56% [11],[12],[15] 6.56% [11],[12],[15] A Investment, Identifier [Axis]: Grove Hotel Parcel Owner, LLC, Hotels, Resorts & Cruise Lines, First Lien Revolver A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A Investment, principal \$ 0 [1],[2],[4],[9] A A \$ 0 [5],[7],[8],[11] A A A A A A A A A Investment, Identifier [Axis]: Grove Hotel Parcel Owner, LLC, Hotels, Resorts & Cruise Lines, First Lien Term Loan 1 A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A Investment, principal 0 [1],[2],[4],[9] A A \$ 17,444 [7],[8],[11] A A A A A A A A A Investment, interest rate (as a percent) [8],[11],[12] A A \$ 13.42% 13.42% 13.42% A Investment, Identifier [Axis]: Grove Hotel Parcel Owner, LLC, Hotels, Resorts & Cruise Lines, First Lien Term Loan 2 A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A Investment, principal \$ 17,312 [1],[4],[9] A A \$ 0 [5],[7],[8],[11] A A A A A A A A A Investment, interest rate (as a percent) [1],[9],[10] 13.44% 13.44% 13.44% A A A A A A A A A Investment, Identifier [Axis]: HPS Loan Management 10-2016, Multi-Sector Holdings, CLO Notes A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A Investment, principal [4],[9],[13] \$ 2,250 A A A A A A A A A Investment, interest rate (as a percent) [9],[10],[13] 12.00% 12.00% 12.00%

[illegible]

[Line Items] Á Á Á Á Á Investment, principal \$ 64,253 [1],[4],[9],[13] Á Á \$ 73,362 [7],[8],[11],[15] Á Á Á Investment, interest rate (as a percent) 12.32% [1],[9],[10],[13] 12.32% [1],[9],[10],[13] 12.32% [1],[9],[10],[13] 12.29% [8],[11],[12],[15] 12.29% [8],[11],[12],[15] 12.29% [8],[11],[12],[15] Á Investment, Identifier [Axis]: Navisite, LLC, Data Processing & Outsourced Services, Second Lien Term Loan Á Á Á Á Á Investment Company, Nonconsolidated Subsidiary [Line Items] Á Á Á Á Á Investment, principal [7],[8],[11] Á Á Á \$ 30,339 Á Á Á Investment, interest rate (as a percent) [8],[11],[12] Á Á Á 13.99% 13.99% 13.99% Á Investment, Identifier [Axis]: NeuAG, LLC, Fertilizers & Agricultural Chemicals, First Lien Term Loan Á Á Á Á Á Á Investment Company, Nonconsolidated Subsidiary [Line Items] Á Á Á Á Á Á Investment, principal \$ 64,606 [1],[4],[9] Á Á \$ 64,606 [7],[8],[11] Á Á Á Investment, interest rate (as a percent) 14.82% [1],[9],[10] 14.82% [1],[9],[10] 14.82% [1],[9],[10] 14.89% [8],[11],[12] 14.89% [8],[11],[12] Á Investment, Identifier [Axis]: Next Holdco, LLC, Health Care Technology, First Lien Revolver Á Á Á Á Á Á Investment Company, Nonconsolidated Subsidiary [Line Items] Á Á Á Á Á Á Investment, principal [1],[2],[4],[9] \$ 0 Á Á Á Á Á Á Investment, Identifier [Axis]: Next Holdco, LLC, Health Care Technology, First Lien Term Loan 1 Á Á Á Á Á Á Investment Company, Nonconsolidated Subsidiary [Line Items] Á Á Á Á Á Á Investment, principal [1],[4],[9] \$ 19,945 Á Á Á Á Á Á Investment, interest rate (as a percent) [1],[9],[10] 11.32% 11.32% Á Á Á Investment, Identifier [Axis]: Next Holdco, LLC, Health Care Technology, First Lien Term Loan 2 Á Á Á Á Á Á Investment Company, Nonconsolidated Subsidiary [Line Items] Á Á Á Á Á Á Investment, principal [1],[2],[4],[9] \$ 0 Á Á Á Á Á Á Investment, Identifier [Axis]: Northwoods Capital 25 Ltd, Multi-Sector Holdings, CLO Notes Á Á Á Á Á Á Investment Company, Nonconsolidated Subsidiary [Line Items] Á Á Á Á Á Á Investment, principal [4],[9],[13] \$ 700 Á Á Á Á Á Á Investment, interest rate (as a percent) [9],[10],[13] 12.73% 12.73% Á Á Á Á Investment, Identifier [Axis]: OCSI Glick JV LLC, Multi-Sector Holdings, Subordinated Debt Á Á Á Á Á Á Investment Company, Nonconsolidated Subsidiary [Line Items] Á Á Á Á Á Á Investment, principal \$ 58,349 [1],[2],[4],[9],[13],[19] Á Á \$ 58,349 [5],[7],[8],[11],[15],[20] Á Á \$ 58,349 Investment, interest rate (as a percent) 9.94% [1],[2],[9],[10],[13],[19] 9.94% [1],[2],[9],[10],[13],[19] 9.94% [1],[2],[9],[10],[13],[19] 9.76% [5],[8],[11],[12],[15],[20] 9.76% [5],[8],[11],[12],[15],[20] 9.76% [5],[8],[11],[12],[15],[20] 9.36% Investment, Identifier [Axis]: OEConnection LLC, Application Software, Second Lien Term Loan Á Á Á Á Á Á Investment Company, Nonconsolidated Subsidiary [Line Items] Á Á Á Á Á Á Investment, principal [7],[8],[11] Á Á Á \$ 9,323 Á Á Á Á Investment, interest rate (as a percent) [8],[11],[12] Á Á Á 12.49% 12.49% Á Investment, Identifier [Axis]: OFSI Fund Ltd, Multi-Sector Holdings, CLO Notes Á Á Á Á Á Á Investment Company, Nonconsolidated Subsidiary [Line Items] Á Á Á Á Á Á Investment, principal [4],[9],[13] \$ 1,105 Á Á Á Á Á Á Investment, interest rate (as a percent) [9],[10],[13] 12.81% 12.81% 12.81% Á Á Investment, Identifier [Axis]: OTG Management, LLC, Airport Services, First Lien Term Loan Á Á Á Á Á Á Investment Company, Nonconsolidated Subsidiary [Line Items] Á Á Á Á Á Á Investment, principal [1],[4],[9] \$ 11,629 Á Á Á Á Á Á Investment, Identifier [Axis]: OTG Management, LLC, Airport Services, First Lien Term Loan 1 Á Á Á Á Á Á Investment Company, Nonconsolidated Subsidiary [Line Items] Á Á Á Á Á Á Investment, principal [7],[8],[11] Á Á Á \$ 25,712 Á Á Á Á Investment, Identifier [Axis]: OTG Management, LLC, Airport Services, First Lien Term Loan 2 Á Á Á Á Á Á Investment Company, Nonconsolidated Subsidiary [Line Items] Á Á Á Á Á Á Á Investment, principal [5],[7],[8],[11] Á Á Á Á Á Á Investment, Identifier [Axis]: OTG Management, LLC, Airport Services, First Lien Term Loan 3 Á Á Á Á Á Á Investment Company, Nonconsolidated Subsidiary [Line Items] Á Á Á Á Á Á Á Investment, principal [5],[7],[8],[11] Á Á Á Á Á Á Investment, Identifier [Axis]: OZLM XXIII Ltd, Multi-Sector Holdings, CLO Notes Á Á Á Á Á Á Investment Company, Nonconsolidated Subsidiary [Line Items] Á Á Á Á Á Á Á Investment, principal [4],[9],[13] \$ 1,000 Á Á Á Á Á Á Investment, interest rate (as a percent) [9],[10],[13] 12.87% 12.87% 12.87% Á Á Á Investment, Identifier [Axis]: Oranje Holdco, Inc., Systems Software, First Lien Revolver Á Á Á Á Á Á Á Investment Company, Nonconsolidated Subsidiary [Line Items] Á Á Á Á Á Á Á Investment, principal \$ 0 [1],[2],[4],[9] Á Á Á 0 [5],[7],[8],[11] Á Á Á Á Investment, Identifier [Axis]: Oranje Holdco, Inc., Systems Software, First Lien Term Loan Á Á Á Á Á Á Á Investment Company, Nonconsolidated Subsidiary [Line Items] Á Á Á Á Á Á Á Investment, principal [7],[8],[11] Á Á Á \$ 15,231 Á Á Á Á Investment, interest rate (as a percent) [8],[11],[12] Á Á Á 13.12% 13.12% Á Investment, Identifier [Axis]: Oranje Holdco, Inc., Systems Software, First Lien Term Loan 1 Á Á Á Á Á Á Á Investment Company, Nonconsolidated Subsidiary [Line Items] Á Á Á Á Á Á Á Á Investment, principal [1],[4],[9] \$ 15,231 Á Á Á Á Á Á Á Investment, interest rate (as a percent) [1],[9],[10] 12.83% 12.83% 12.83% Á Á Á Á Investment, Identifier [Axis]: Oranje Holdco, Inc., Systems Software, First Lien Term Loan 2 Á Á Á Á Á Á Á Investment Company, Nonconsolidated Subsidiary [Line Items] Á Á Á Á Á Á Á Investment, principal [1],[4],[9] \$ 4,047 Á Á Á Á Á Á Á Investment, interest rate (as a percent) [1],[9],[10] 12.59% 12.59% Á Á Á Á Investment, Identifier [Axis]: P & L Development, LLC, Pharmaceuticals, Fixed Rate Bond Á Á Á Á Á Á Á Investment Company, Nonconsolidated Subsidiary [Line Items] Á Á Á Á Á Á Á Investment, principal [7] Á Á Á \$ 4,519 Á Á Á Á Investment, interest rate (as a percent) [11],[12] Á Á Á 7.75% 7.75% Á Investment, Identifier [Axis]: PPW Aero Buyer, Inc., Aerospace & Defense, First Lien Revolver Á Á Á Á Á Á Á Investment Company, Nonconsolidated Subsidiary [Line Items] Á Á Á Á Á Á Á Investment, principal \$ 269 [1],[2],[4],[9] Á Á \$ 0 [5],[7],[8],[11] Á Á Á Á Investment, interest rate (as a percent) [1],[2],[9],[10] 11.84% 11.84% 11.84% Á Á Á Á Investment, Identifier [Axis]: PPW Aero Buyer, Inc., Aerospace & Defense, First Lien Term Loan Á Á Á Á Á Á Á Investment Company, Nonconsolidated Subsidiary [Line Items] Á Á Á Á Á Á Á Á Investment, principal [7],[8],[11] Á Á Á \$ 10,895 Á Á Á Á Á Á Á Investment, interest rate (as a percent) [8],[11],[12] Á Á Á 12.32% 12.32% 12.32% Á Investment, Identifier [Axis]: PPW Aero Buyer, Inc., Aerospace & Defense, First Lien Term Loan 1 Á Á Á Á Á Á Á Investment Company, Nonconsolidated Subsidiary [Line Items] Á Á Á Á Á Á Á Investment, principal [1],[4],[9] \$ 10,813 Á Á Á Á Á Á Á Investment, interest rate (as a percent) [1],[9],[10] 11.83% 11.83% Á Á Á Á Investment, Identifier [Axis]: PPW Aero Buyer, Inc., Aerospace & Defense, First Lien Term Loan 2 Á Á Á Á Á Á Á Investment Company, Nonconsolidated Subsidiary [Line Items] Á Á Á Á Á Á Á Investment, principal [1],[2],[4],[9] \$ 2,047 Á Á Á Á Á Á Á Investment, interest rate (as a percent) [1],[2],[9],[10] 10.84% 10.84% Á Á Á Á Investment, Identifier [Axis]: PRGX Global, Inc., Data Processing & Outsourced Services, First Lien Revolver Á Á Á Á Á Á Á Investment Company, Nonconsolidated Subsidiary [Line Items] Á Á Á Á Á Á Á Á Investment, principal \$ 0 [1],[2],[4],[9] Á Á \$ 0 [5],[7],[8],[11] Á Á Á Á Investment, Identifier [Axis]: PRGX Global, Inc., Data Processing & Outsourced Services, First Lien Term Loan Á Á Á Á Á Á Á Investment Company, Nonconsolidated Subsidiary [Line Items] Á Á Á Á Á Á Á Á Investment, principal \$ 26,282 [1],[4],[9] Á Á \$ 38,414 [7],[8],[11] Á Á Á Á Investment, interest rate (as a percent) [1],[9],[10] 11.98% [1],[9],[10] 11.98% [1],[9],[10] 11.98% [1],[9],[10] 12.01% [8],[11],[12] 12.01% [8],[11],[12] 12.01% [8],[11],[12] Á Investment, Identifier [Axis]: Park Place Technologies, LLC, Internet Services & Infrastructure, First Lien Term Loan Á Á Á Á Á Á Á Investment Company, Nonconsolidated Subsidiary [Line Items] Á Á Á Á Á Á Á Investment, principal [7],[11] Á Á Á \$ 9,676 Á Á Á Á Investment, interest rate (as a percent) [11],[12] Á Á Á 10.42% 10.42% 10.42% Á Investment, Identifier [Axis]: Performance Health Holdings, Inc., Health Care Distributors, First Lien Term Loan Á Á Á Á Á Á Á Investment Company, Nonconsolidated Subsidiary [Line Items] Á Á Á Á Á Á Á Investment, principal \$ 22,375 [1],[4],[9] Á Á \$ 22,375 [7],[8],[11] Á Á Á Á Investment, interest rate (as a percent) [11],[9],[10] 11.11% [1],[9],[10] 11.11% [1],[9],[10] 11.11% [1],[9],[10] 11.57% [8],[11],[12] 11.57% [8],[11],[12] 11.57% [8],[11],[12] Á Investment, Identifier [Axis]: PetVet Care Centers, LLC, Health Care Services, First Lien Revolver Á Á Á Á Á Á Á Investment Company, Nonconsolidated Subsidiary [Line Items] Á Á Á Á Á Á Á Á Investment, principal [1],[2],[4],[9] \$ 0 Á Á Á Á Á Á Á Investment, Identifier [Axis]: PetVet Care Centers, LLC, Health Care Services, First Lien Term Loan 1 Á Á Á Á Á Á Á Investment Company, Nonconsolidated Subsidiary [Line Items] Á Á Á Á Á Á Á Á Investment, principal [1],[4],[9] \$ 52,376 Á Á Á Á Á Á Á Investment, interest rate (as a percent) [1],[9],[10] 11.34% 11.34% 11.34% Á Á Á Á Investment, Identifier [Axis]: PetVet Care Centers, LLC, Health Care Services, First Lien Term Loan 2 Á Á Á Á Á Á Á Investment Company, Nonconsolidated Subsidiary [Line Items] Á Á Á Á Á Á Á Á Investment, principal [1],[2],[4],[9] \$ 0 Á Á Á Á Á Á Á Investment, Identifier [Axis]: Planview Parent, Inc., Application Software, Second Lien Term Loan Á Á Á Á Á Á Á Investment Company, Nonconsolidated Subsidiary [Line Items] Á Á Á Á Á Á Á Á Investment, principal [7],[8],[11] Á Á Á \$ 36,499 Á Á Á Á Investment, interest rate (as a percent) [8],[11],[12] Á Á Á 12.74% 12.74% 12.74% Á Investment, Identifier [Axis]: Pluralsight, LLC, Application Software, First Lien Revolver Á Á Á Á Á Á Á Á Investment Company, Nonconsolidated Subsidiary [Line Items] Á Á Á Á Á Á Á Á Investment, principal 4,790 [1],[4],[9],[17] Á Á \$ 3,003 [5],[7],[8],[11] Á Á Á Á Investment, interest rate (as a percent) [5],[8],[11],[12] Á Á Á 13.45% 13.45% 13.45% Á Investment, Identifier [Axis]: Pluralsight, LLC, Application Software, First Lien Term Loan Á Á Á Á Á Á Á Á Investment Company, Nonconsolidated Subsidiary [Line Items] Á Á Á Á Á Á Á Á Investment, principal 67,244 [1],[4],[9],[17] Á Á \$ 67,244 [7],[8],[11] Á Á Á Á Investment, interest rate (as a percent) [8],[11],[12] Á Á Á 13.45% 13.45% 13.45% Á Investment, Identifier [Axis]: Profrac Holdings II, LLC, Industrial Machinery & Supplies & Components, First Lien Floating Rate Bond Á Á Á Á Á Á Á Investment Company, Nonconsolidated Subsidiary [Line Items] Á Á Á Á Á Á Á Á Investment, principal [1],[4],[9],[13] \$ 27,176 Á Á Á Á Á Á Á Á Investment, interest rate (as a percent) [1],[9],[10],[13] 12.57% 12.57% 12.57% Á Á Á Á Investment, Identifier [Axis]: Profrac Holdings II, LLC, Industrial Machinery & Supplies & Components, First Lien Term Loan 1 Á Á Á Á Á Á Á Á Investment Company, Nonconsolidated Subsidiary [Line Items] Á Á Á Á Á Á Á Á Investment, principal [7],[8],[11] Á Á Á \$ 24,503 Á Á Á Á Investment, interest rate (as a percent) [8],[11],[12] Á Á Á 12.78% 12.78% 12.78% Á Investment, Identifier [Axis]: Profrac Holdings II, LLC, Industrial Machinery & Supplies & Components, First Lien Term Loan 2 Á Á Á Á Á Á Á Á Investment Company, Nonconsolidated Subsidiary [Line Items] Á Á Á Á Á Á Á Á Investment, principal [7],[8],[11] Á Á Á \$ 2,819 Á Á Á Á Investment, interest rate (as a percent) [8],[11],[12] Á Á Á 12.78% 12.78% 12.78% Á Investment, Identifier [Axis]: Protein For Pets Opco, LLC, Packaged Foods & Meats, First Lien Revolver Á Á Á Á Á Á Á Investment Company, Nonconsolidated Subsidiary [Line Items] Á Á Á Á Á Á Á Á Investment, principal [1],[2],[4],[9] \$ 0 Á Á Á Á Á Á Á Á Investment, Identifier [Axis]: Protein For Pets Opco, LLC, Packaged Foods & Meats, First Lien Term Loan Á Á Á Á Á Á Á Investment Company, Nonconsolidated Subsidiary [Line Items] Á Á Á Á Á Á Á Á Investment, principal [1],[4],[9] \$ 20,325 Á Á Á Á Á Á Á Á Investment, interest rate (as a percent) [1],[9],[10] 10.59% 10.59% 10.59% Á Á Á Á Investment, Identifier [Axis]: Quantum Bidco Limited, Food Distributors, First Lien Term Loan Á Á Á Á Á Á Á Á Investment Company, Nonconsolidated Subsidiary [Line Items] Á Á Á Á Á Á Á Á Investment, principal Á £ 7,081 [1],[15] Á Á Á Á £ 4,626 Á Á Á Á Investment, interest rate (as a percent) [8],[11],[12],[15] Á Á Á 11.21% 11.21% 11.21% Á Investment, Identifier [Axis]: Quantum Bidco Limited, Food Distributors, First Lien Term Loan 1 Á Á Á Á Á Á Á Á Investment Company, Nonconsolidated Subsidiary [Line Items] Á Á Á Á Á Á Á Á Investment, principal Á £ [1],[4],[9],[13] Á Á Á £ 9,739 Á Á Á Á Investment, interest rate (as a percent) [1],[9],[10],[13] 10.98% 10.98% 10.98% Á Á Á Á Investment, Identifier [Axis]: Quantum Bidco Limited, Food Distributors, First Lien Term Loan 2 Á Á Á Á Á Á Á Á Investment Company, Nonconsolidated Subsidiary [Line Items] Á Á Á Á Á Á Á Á Investment, principal [1],[2],[4],[9],[13] \$ 1,233 Á Á Á Á Á Á Á Á Investment, interest rate (as a percent) [1],[2],[9],[10],[13] 10.70% 10.70% 10.70% Á Á Á Á Investment, Identifier [Axis]: Relativity ODA LLC, Application Software, First Lien Revolver Á Á Á Á Á Á Á Á Investment Company, Nonconsolidated Subsidiary [Line Items] Á Á Á Á Á Á Á Á Investment, principal \$ 0 [1],[2],[4],[9] Á Á \$ 0 [5],[7],[8],[11] Á Á Á Á Investment, Identifier [Axis]: Relativity ODA LLC, Application Software, First Lien Term Loan Á Á Á Á Á Á Á Á Investment Company, Nonconsolidated Subsidiary [Line Items] Á Á Á Á Á Á Á Á Investment, principal \$ 32,329 [1],[4],[9] Á Á \$ 32,329 [7],[8],[11] Á Á Á Á Investment, interest rate (as a percent) [1],[9],[10] 11.44% [1],[9],[10] 11.44% [1],[9],[10] 11.44% [1],[9],[10] 11.92% [8],[11],[12] 11.92% [8],[11],[12] 11.92% [8],[11],[12] Á Investment, Identifier [Axis]: Research & Consulting Services, First Lien Term Loan Á Á Á Á Á Á Á Á Investment Company, Nonconsolidated Subsidiary [Line Items] Á Á Á Á Á Á Á Á Investment, principal [4],[9] \$ 4,913 Á Á Á Á Á Á Á Á Investment, interest rate (as a percent) [9],[10] 10.09% 10.09% 10.09% Á Á Á Á Investment, Identifier [Axis]: RumbleOn, Inc., Automotive Retail, First Lien Term Loan 1 Á Á Á Á Á Á Á Á Investment Company, Nonconsolidated Subsidiary [Line Items] Á Á Á Á Á Á Á Á Investment, principal [4],[9],[13] Á Á \$ 36,707 [7],[8],[11],[15] Á Á Á Á Investment, interest rate (as a percent) [13.84% [1],[9],[10],[13] 13.84% [1],[9],[10],[13] 13.84% [1],[9],[10],[13] 13.90% [8],[11],[12],[15] 13.90% [8],[11],[12],[15] 13.90% [8],[11],[12],[15] Á Investment, Identifier [Axis]: RumbleOn, Inc., Automotive Retail, First Lien Term Loan 2 Á Á Á Á Á Á Á Á Investment Company, Nonconsolidated Subsidiary [Line Items] Á Á Á Á Á Á Á Á Investment, principal \$ 29,198 [1],[4],[9],[13] Á Á \$ 13,504 [7],[8],[11],[15] Á Á Á Á Investment, interest rate (as a percent) 13.84% [1],[9],[10],[13] 13.84% [1],[9],[10],[13] 13.84% [1],[9],[10],[13] 13.90% [8],[11],[12],[15] 13.90% [8],[11],[12],[15] 13.90% [8],[11],[12],[15] Á Investment, Identifier [Axis]: SCIH Salt Holdings Inc., Diversified Chemicals, Fixed Rate Bond Á Á Á Á Á Á Á Á Investment Company, Nonconsolidated Subsidiary [Line Items] Á Á Á Á Á Á Á Á Investment, principal [4] \$ 1,680 Á Á Á Á Á Á Á Á Investment, interest rate (as a percent) [9],[10] 4.88% 4.88% 4.88% Á Á Á Á Investment, Identifier [Axis]: SCP Eye Care Services, LLC, Health Care Services, Second Lien Term Loan 1 Á Á Á Á Á Á Á Á Investment Company, Nonconsolidated Subsidiary [Line Items] Á Á Á Á Á Á Á Á Investment, principal [7],[8],[11] Á Á Á \$ 8,010 Á Á Á Á Investment, interest rate (as a percent) [8],[11],[12] Á Á Á 14.18% 14.18% 14.18% Á Investment, Identifier [Axis]: SCP Eye Care Services, LLC, Health Care Services, Second Lien Term Loan 2 Á Á Á Á Á Á Á Á Investment Company, Nonconsolidated Subsidiary [Line Items] Á Á Á Á Á Á Á Á Investment, principal [5],[7],[8],[11] Á Á Á \$ 0 Á Á Á Á Investment, Identifier [Axis]: SIO2 Medical Products, Inc., Metal, Glass & Plastic Containers, First Lien Term Loan 1 Á Á Á Á Á Á Á Á Investment Company, Nonconsolidated Subsidiary [Line Items] Á Á Á Á Á Á Á Á Investment, principal [1],[2],[4] \$ 2,682 Á Á Á Á Á Á Á Á Investment, Identifier [Axis]: SIO2 Medical Products, Inc., Metal, Glass & Plastic Containers, First Lien Term Loan 2 Á Á Á Á Á Á Á Á Investment Company, Nonconsolidated Subsidiary [Line Items] Á Á Á Á Á Á Á Á Investment, principal 17,363 [1],[4] Á Á \$ 15,874 [7],[8] Á Á Á Á Investment, Identifier [Axis]: SIO2 Medical Products, Inc., Metal, Glass & Plastic Containers, First Lien Term Loan 3 Á Á Á Á Á Á Á Á Investment Company, Nonconsolidated Subsidiary [Line Items] Á Á Á Á Á Á Á Á Investment, principal 3,442 [1],[4] Á Á 1,359 [5],[7],[8] Á Á Á Á Investment, Identifier [Axis]: SM Wellness Holdings, Inc., Health Care Services, First Lien Term Loan Á Á Á Á Á Á Á Á Investment Company, Nonconsolidated Subsidiary [Line Items] Á Á Á Á Á Á Á Á Investment, principal \$ 4,418 [1],[4],[9] Á Á \$ 4,452 [7],[8],[11] Á Á Á Á Investment, interest rate (as a percent) 10.09% [1],[9],[10] 10.09% [1],[9],[10] 10.09% [1],[9],[10] 10.38% [8],[11],[12] 10.38% [8],[11],[12] 10.38% [8],[11],[12] Á Investment, Identifier [Axis]: SM Wellness Holdings, Inc., Health Care Services, Second Lien Term Loan Á Á Á Á Á Á Á Á Investment Company, Nonconsolidated Subsidiary [Line Items] Á Á Á Á Á Á Á Á Investment, principal \$ 12,034 [1],[4],[9] Á Á \$ 12,034 [7],[8],[11] Á Á Á Á Investment, interest rate (as a percent) 13.59% [1],[9],[10] 13.59% [1],[9],[10] 13.59% [1],[9],[10] 13.63% [8],[11],[12] 13.63% [8],[11],[12] 13.63% [8],[11],[12] 13.63% [8],[11],[12] Á Investment, Identifier [Axis]: SPX Flow, Inc., Industrial Machinery & Supplies & Components, Fixed Rate Bond Á Á Á Á Á Á Á Á Investment Company, Nonconsolidated Subsidiary [Line Items] Á Á Á Á Á Á Á Á Investment, principal [4] \$ 1,109 Á Á Á Á Á Á Á Á Investment, interest rate (as a percent) [9],[10] 8.75% 8.75% 8.75% Á Á Á Á Investment, Identifier [Axis]: SVP-Singer Holdings Inc., Home Furnishings, First Lien Term Loan Á Á Á Á Á Á Á Á Investment Company, Nonconsolidated Subsidiary [Line Items] Á Á Á Á Á Á Á Á Investment, principal \$ 27,164 [1],[4],[9],[17] Á Á Á \$ 25,527 [7],[8],[11] Á Á Á Á Investment, interest rate (as a percent) [8],[11],[12] Á Á Á 12.40% 12.40% 12.40% Á Investment, Identifier [Axis]: Salus Workers' Compensation, LLC, Diversified Financial Services, First Lien Revolver Á Á Á Á Á Á Á Á Investment Company, Nonconsolidated Subsidiary [Line Items] Á Á Á Á Á Á Á Á Investment, principal 0 [1],[2],[4],[9] Á Á \$ 0 [5],[7],[8],[11] Á Á Á Á Investment, Identifier [Axis]: Salus Workers' Compensation, LLC, Diversified Financial Services, First Lien Term Loan Á Á Á Á Á Á Á Á Investment Company, Nonconsolidated Subsidiary [Line Items] Á Á Á Á Á Á Á Á Investment, principal \$ 25,279 [1],[4],[9] Á Á \$ 25,558 [7],[8],[11] Á Á Á Á Investment, interest rate (as a percent) 15.33% [1],[9],[10] 15.33% [1],[9],[10] 15.33% [1],[9],[10] 15.24% [8],[11],[12] 15.24% [8],[11],[12] 15.24% [8],[11],[12] Á Investment, Identifier [Axis]: Saratoga, Diversified Financial Services, Credit Linked Notes Á Á Á Á Á Á Á Á Investment Company, Nonconsolidated Subsidiary [Line Items] Á Á Á Á Á Á Á Á Investment, principal [1],[4],[9],[13],[21] \$ 24,500 Á Á Á Á Á Á Á Á Investment, interest rate (as a percent) [1],[9],[10],[13],[21] 10.65% 10.65% Á Á Á Á Investment, Identifier [Axis]: Senior Loan Fund JV I, LLC, Multi-Sector Holdings, Subordinated Debt Á Á Á Á Á Á Á Á Investment Company, Nonconsolidated Subsidiary [Line Items] Á Á Á Á Á Á Á Á Investment, principal \$ 112,656 [1],[2],[4],[9],[13],[19] Á Á \$ 112,656 [5],[7],[8],[11],[15],[20] Á Á \$ 112,656 Investment, interest rate (as a percent) 12.44% [1],[2],[9],[10],[13],[19] 12.44% [1],[2],[9],[10],[13],[19] 12.44% [1],[2],[9],[10],[13],[19] 12.66% [5],[8],[11],[12],[15],[20] 12.66% [5],[8],[11],[12],[15],[20] 12.66% [5],[8],[11],[12],[15],[20] 11.86% Investment, Identifier [Axis]: Seres Therapeutics, Inc., Biotechnology, First Lien Term Loan 1 Á Á Á Á Á Á Á Á Investment Company, Nonconsolidated Subsidiary [Line Items] Á Á Á Á Á Á Á Á Investment, principal \$ 0 [1],[2],[4],[9],[13] Á Á \$ 7,191 [7],[8],[11],[15] Á Á Á Á Investment, interest rate (as a percent) [8],[11],[12],[15] Á Á Á 12.88% 12.88% 12.88% Á Investment, Identifier [Axis]: Seres Therapeutics, Inc., Biotechnology, First Lien Term Loan 2 Á Á Á Á Á Á Á Á Investment Company, Nonconsolidated Subsidiary [Line Items] Á Á Á Á Á Á Á Á Investment, principal 0 [1],[2],[4],[9],[13] Á Á \$ 2,697 [7],[8],[11],[15] Á Á Á Á Investment, interest rate (as a percent) [8],[11],[12],[15] Á Á Á 12.88% 12.88% Á Investment, Identifier [Axis]: Seres Therapeutics, Inc., Biotechnology, First Lien Term Loan 3 Á Á Á Á Á Á Á Á Investment Company, Nonconsolidated Subsidiary [Line Items] Á Á Á Á Á Á Á Á Investment, principal \$ 7,191 [1],[4],[9],[13] Á Á \$ 0 [5],[7],[8],[11],[15] Á Á Á Á Investment, interest rate (as a percent) [1],[9],[10],[13] 12.88% 12.88% 12.88% Á Á Á Á Investment, Identifier [Axis]: Seres Therapeutics, Inc., Biotechnology, First Lien Term Loan 4 Á Á Á Á Á Á Á Á Investment Company, Nonconsolidated Subsidiary [Line Items] Á Á Á Á Á Á Á Á Investment, principal \$ 2,697 [1],[4],[9],[13] Á Á \$ 0 [5],[7],[8],[11],[15] Á Á Á Á Investment, interest rate (as a percent) [1],[9],[10],[13] 12.88% 12.88% 12.88% Á Á Á Á Investment, Identifier [Axis]: SonicWall US Holdings Inc., Technology Distributors, Second Lien Term Loan Á Á Á Á Á Á Á Á Investment Company, Nonconsolidated Subsidiary [Line Items] Á Á Á Á Á Á Á Á Investment, principal [7],[8],[11] Á Á Á \$ 821 Á Á Á Á Investment, interest rate (as a

[8],[11],[12] A A A 13.04% 13.04% 13.04% A Investment, Identifier [Axis]: Soreson Communications, LLC, Communications Equipment, First Lien Revolver A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A Investment, principal [1],[2],[4],[9] \$ 0 A A A A A Investment, Identifier [Axis]: Soreson Communications, LLC, Communications Equipment, First Lien Term Loan A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A Investment, principal [1],[4],[9] \$ 48,642 A A A A A Investment, interest rate (as a percent) [1],[9],[10] 11.09% 11.09% 11.09% A A A A A Investment, Identifier [Axis]: Spanx, LLC, Apparel Retail, First Lien Revolver A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A Investment, principal \$ 0 [1],[2],[4],[9] A A \$ 618 [5],[7],[8],[11] A A A A A Investment, interest rate (as a percent) [5],[8],[11],[12] A A A 10.42% 10.42% 10.42% A Investment, Identifier [Axis]: Spanx, LLC, Apparel Retail, First Lien Term Loan A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A Investment, principal \$ 18,104 [1],[4],[9] A A \$ 4,488 [7],[8],[11] A A A A A Investment, interest rate (as a percent) [1],[9],[10] 10.69% 11.09% 10.69% [1],[9],[10] 10.69% [1],[9],[10] 10.67% [8],[11],[12] 10.67% [8],[11],[12] 10.67% [8],[11],[12] A Investment, Identifier [Axis]: Staples, Inc., Office Services & Supplies, First Lien Term Loan A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A Investment, principal [4] \$ 6,835 A A A A A Investment, interest rate (as a percent) [9],[10] 10.75% 10.75% 10.75% A A A A A Investment, Identifier [Axis]: SumUp Holdings Luxembourg S.A.E.R.L., Diversified Financial Services, First Lien Term Loan A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A Investment, principal [1],[2],[4],[9] A A \$ 18,846 [1],[2],[4],[9] A A \$ 23,731 [7],[8],[11],[15] A A A A A Investment, interest rate (as a percent) [10.32% [1],[2],[9],[10], [13] 10.32% [1],[2],[9],[10], [13] 10.32% [1],[2],[9],[10], [13] 10.32% [8],[11],[12], [15] 10.32% [8],[11],[12], [15] A Investment, Identifier [Axis]: Superior Industries International, Inc., Auto Parts & Equipment, First Lien Term Loan A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A Investment, principal \$ 49,146 [1],[4],[9] A A \$ 49,520 [7],[8],[11] A A A A A Investment, interest rate (as a percent) [13.34% [1],[9],[10] 13.34% [1],[9],[10] 13.34% [1],[9],[10] 13.32% [8],[11],[12] 13.32% [8],[11],[12] 13.32% [8],[11],[12] A Investment, Identifier [Axis]: Supreme Fitness Group NY Holdings, LLC, Leisure Facilities, First Lien Revolver A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A Investment, principal \$ 0 [1],[2],[4],[9] A A \$ 1,552 [7],[8],[11],[22] A A A A A Investment, interest rate (as a percent) [8],[11],[12], [22] A A 12.44% 12.44% A A A A A Investment, Identifier [Axis]: Supreme Fitness Group NY Holdings, LLC, Leisure Facilities, First Lien Term Loan A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A Investment, principal [5],[7],[8],[11],[22] A A A A \$ 1,099 A A A A A Investment, interest rate (as a percent) [5],[8],[11],[12], [22] A A A 12.51% 12.51% A A A A A Investment, Identifier [Axis]: Supreme Fitness Group NY Holdings, LLC, Leisure Facilities, First Lien Term Loan 1 A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A A Investment, principal \$ 2,728 [1],[4],[9] A A \$ 32,104 [7],[8],[11],[22] A A A A A Investment, interest rate (as a percent) [12.56% [1],[9],[10] 12.56% [1],[9],[10] 12.56% [1],[9],[10] 12.51% [8],[11],[12], [22] 12.51% [8],[11],[12], [22] 12.51% [8],[11],[12], [22] A Investment, Identifier [Axis]: Supreme Fitness Group NY Holdings, LLC, Leisure Facilities, First Lien Term Loan 2 A A A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A A Investment, principal \$ 3,282 [1],[4],[9] A A \$ 2,749 [7],[8],[11],[22] A A A A A A A A A A Investment, interest rate (as a percent) [12.56% [1],[9],[10] 12.56% [1],[9],[10] 12.56% [1],[9],[10] 12.51% [8],[11],[12], [22] 12.51% [8],[11],[12], [22] A A A A A Investment, Identifier [Axis]: Supreme Fitness Group NY Holdings, LLC, Leisure Facilities, First Lien Term Loan 3 A A A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A A Investment, principal [1],[4],[9] A A \$ 31,859 A A A A A A A A A A Investment, interest rate (as a percent) [1],[9],[10] 12.56% 12.56% 12.56% A A A A A A A A A A Investment, Identifier [Axis]: TGNR HoldCo LLC, Integrated Oil & Gas, Subordinated Debt A A A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A A Investment, principal [6],[7],[8],[15] A A \$ 4,984 A A A A A A A A A A Investment, interest rate (as a percent) [6],[8],[11],[12], [15] A A 11.50% 11.50% 11.50% A A A A A A A A A A Investment, Identifier [Axis]: THL Zinc Ventures Ltd, Diversified Metals & Mining, First Lien Term Loan A A A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A A Investment, principal \$ 50,419 [1],[4],[13] A A \$ 50,419 [7],[8],[15] A A A A A A A A A A Investment, interest rate (as a percent) [13.00% [1],[9],[10], [13] 13.00% [1],[9],[10], [13] 13.00% [1],[9],[10], [13] 13.00% [8],[11],[12], [15] 13.00% [8],[11],[12], [15] 13.00% [8],[11],[12], [15] A Investment, Identifier [Axis]: Tacala, LLC, Restaurants, Second Lien Term Loan A A A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A A Investment, principal [7],[11] A A \$ 12,843 A A A A A A A A A A Investment, interest rate (as a percent) [11],[12] A A 13.43% 13.43% 13.43% A A A A A A A A A A Investment, Identifier [Axis]: Tahoe Bidco B.V., Application Software, First Lien Revolver A A A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A A Investment, principal [5],[7],[8],[11],[15] A A A A A A A A A A Investment, Identifier [Axis]: Tahoe Bidco B.V., Application Software, First Lien Term Loan A A A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A A Investment, principal [7],[8],[11],[15] A A A A \$ 28,826 A A A A A A A A A A Investment, interest rate (as a percent) [8],[11],[12], [15] A A 11.42% 11.42% 11.42% A A A A A A A A A A Investment, Identifier [Axis]: Telephone and Date Systems, Inc., Wireless Telecommunication Services, First Lien Term Loan 1 A A A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A A Investment, principal [1],[4],[9],[13] \$ 25,094 A A A A A A A A A A Investment, interest rate (as a percent) [1],[9],[10], [13] 12.32% 12.32% 12.32% A A A A A A A A A A Investment, Identifier [Axis]: Telephone and Date Systems, Inc., Wireless Telecommunication Services, First Lien Term Loan 2 A A A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A A Investment, principal [1],[2],[4],[9],[13] \$ 0 A A A A A A A A A A Investment, Identifier [Axis]: Telestream Holdings Corporation, Application Software, First Lien Revolver A A A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A A Investment, principal \$ 1,809 [1],[2],[4],[9] A A \$ 1,861 [5],[7],[8],[11] A A A A A A A A A A Investment, interest rate (as a percent) [5.44% [1],[2],[9],[10] 5.44% [1],[2],[9],[10] 5.44% [1],[2],[9],[10] 5.17% [8],[11],[12] 5.17% [5],[8],[11],[12] 5.17% [5],[8],[11],[12] A A A A A A A A A A Investment, Identifier [Axis]: Telestream Holdings Corporation, Application Software, First Lien Term Loan A A A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A A Investment, principal \$ 25,618 [1],[4],[9] A A \$ 23,423 [7],[8],[11] A A A A A A A A A A Investment, interest rate (as a percent) [5.44% [1],[9],[10] 5.44% [1],[9],[10] 5.44% [1],[9],[10] 15.26% [8],[11],[12] 15.26% [8],[11],[12] 15.26% [8],[11],[12] A A A A A A A A A A Investment, Identifier [Axis]: Ten-X LLC, Interactive Media & Services, First Lien Term Loan A A A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A A Investment, principal \$ 19,789 [1],[4],[9] A A \$ 19,947 [7],[8],[11] A A A A A A A A A A Investment, interest rate (as a percent) [11.34% [1],[9],[10] 11.34% [1],[9],[10] 11.34% [1],[9],[10] 11.32% [8],[11],[12] 11.32% [8],[11],[12] 11.32% [8],[11],[12] A A A A A A A A A A Investment, Identifier [Axis]: The Avery, Real Estate Operating Companies, First Lien Term Loan A A A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A A Investment, principal [7],[8],[11],[18] A A \$ 19,163 A A A A A A A A A A Investment, Identifier [Axis]: The Avery, Real Estate Operating Companies, First Lien Term Loan 1 A A A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A A Investment, principal [1],[4],[17] \$ 5,065 A A A A A A A A A A Investment, Identifier [Axis]: The Avery, Real Estate Operating Companies, First Lien Term Loan 2 A A A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A A Investment, principal [1],[4],[17] 20,917 A A A A A A A A A A Investment, Identifier [Axis]: The Avery, Real Estate Operating Companies, Membership Interest A A A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A A Investment, principal 0 A A A A A A A A A A Investment, Identifier [Axis]: The Avery, Real Estate Operating Companies, Subordinated Debt Term Loan A A A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A A Investment, principal [7],[8],[11],[18] A A A 4,641 A A A A A A A A A A Investment, Identifier [Axis]: Thrasio, LLC, Broadline Retail, First Lien Term Loan A A A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A A Investment, principal [7],[8],[11] A A A 46,832 A A A A A A A A A A Investment, Identifier [Axis]: Thrasio, LLC, Broadline Retail, First Lien Term Loan 1 A A A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A A Investment, principal [1],[4],[9],[17] 6,063 A A A A A A A A A A Investment, Identifier [Axis]: Thrasio, LLC, Broadline Retail, First Lien Term Loan 2 A A A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A A Investment, principal [1],[4],[9],[17] 18,605 A A A A A A A A A A Investment, Identifier [Axis]: Touchstone

Nonconsolidated Subsidiary [Line Items] A A A A A Investment, principal \$ 6,258 A A \$ 6,71 A A A Investment, interest rate (as a percent) 12.10% 12.10% 12.10% 12.15% 12.15% 12.15% A SLF JV I | Investment, Identifier [Axis]: ASP-R-PAC Acquisition Co LLC, First Lien Revolver A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A Investment, principal \$ 205 A A \$ 0 A A A Investment, interest rate (as a percent) 11.46% 11.46% 11.46% A A A SLF JV I | Investment, Identifier [Axis]: ASP-R-PAC Acquisition Co LLC, First Lien Term Loan A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A Investment, principal \$ 4,103 A A \$ 4,134 A A A Investment, interest rate (as a percent) 11.59% 11.59% 11.59% 11.63% 11.63% 11.63% A SLF JV I | Investment, Identifier [Axis]: Access CIG, LLC, First Lien Term Loan A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A Investment, principal A A A A A A Investment, interest rate (as a percent) A A A 9.63% 9.63% 9.63% A SLF JV I | Investment, Identifier [Axis]: Alvogen Pharma US, Inc., First Lien Term Loan A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A Investment, principal \$ 8,446 A A \$ 8,798 A A A Investment, interest rate (as a percent) 12.98% 12.98% 12.98% 13.04% 13.04% 13.04% A SLF JV I | Investment, Identifier [Axis]: American Rock Salt Company LLC, First Lien Term Loan A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A Investment, principal A A A 4,957 A A A Investment, interest rate (as a percent) A A A 9.43% 9.43% 9.43% A SLF JV I | Investment, Identifier [Axis]: American Tire Distributors, Inc., First Lien Term Loan A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A Investment, principal \$ 3,352 A A \$ 4,824 A A A Investment, interest rate (as a percent) 11.84% 11.84% 11.84% 11.81% 11.81% 11.81% A SLF JV I | Investment, Identifier [Axis]: Amplify Finco Pty Ltd., First Lien Term Loan A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A Investment, principal A A A \$ 7,720 A A A Investment, interest rate (as a percent) A A A 9.54% 9.54% 9.54% A SLF JV I | Investment, Identifier [Axis]: Anastasia Parent, LLC, First Lien Term Loan A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A Investment, principal A A A 1,523 A A A Investment, interest rate (as a percent) A A A 9.40% 9.40% 9.40% A SLF JV I | Investment, Identifier [Axis]: Artera Services LLC, First Lien Term Loan A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A Investment, principal \$ 7,481 A A A A A A Investment, interest rate (as a percent) 9.83% 9.83% 9.83% A A A SLF JV I | Investment, Identifier [Axis]: Astra Acquisition Corp., First Lien Term Loan A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A Investment, principal A A A 5,052 A A A Investment, interest rate (as a percent) A A A 10.90% 10.90% 10.90% A SLF JV I | Investment, Identifier [Axis]: Astra Acquisition Corp., First Lien Term Loan 1 A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A Investment, principal \$ 2,553 A A A A A A Investment, interest rate (as a percent) 12.08% 12.08% 12.08% A A A SLF JV I | Investment, Identifier [Axis]: Astra Acquisition Corp., First Lien Term Loan 2 A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A Investment, principal \$ 4,037 A A A A A A Investment, interest rate (as a percent) 10.58% 10.58% 10.58% A A A SLF JV I | Investment, Identifier [Axis]: Asurion, LLC, First Lien Term Loan 1 A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A Investment, principal \$ 7,795 A A \$ 4,950 A A A Investment, interest rate (as a percent) 9.44% 9.44% 9.44% 9.42% 9.42% 9.42% A SLF JV I | Investment, Identifier [Axis]: Asurion, LLC, First Lien Term Loan 2 A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A Investment, principal \$ 1,975 A A \$ 1,990 A A A Investment, interest rate (as a percent) 9.69% 9.69% 9.69% 9.67% 9.67% 9.67% A SLF JV I | Investment, Identifier [Axis]: Asurion, LLC, Second Lien Term Loan A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A Investment, principal A A A 4,346 A A A Investment, interest rate (as a percent) A A A 10.68% 10.68% 10.68% A SLF JV I | Investment, Identifier [Axis]: Aurora Lux Finco S.A.E.R.L., First Lien Term Loan A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A Investment, principal \$ 6,480 A A \$ 6,289 A A A Investment, interest rate (as a percent) 8.43% 8.43% 8.43% 11.49% 11.49% 11.49% A SLF JV I | Investment, Identifier [Axis]: BAART Programs, Inc., First Lien Term Loan 1 A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A Investment, principal \$ 1,740 A A \$ 1,753 A A A Investment, interest rate (as a percent) 10.60% 10.60% 10.60% 10.65% 10.65% 10.65% A SLF JV I | Investment, Identifier [Axis]: BAART Programs, Inc., First Lien Term Loan 2 A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A Investment, principal \$ 6,258 A A \$ 6,306 A A A Investment, interest rate (as a percent) 10.60% 10.60% 10.60% 10.65% 10.65% 10.65% A SLF JV I | Investment, Identifier [Axis]: Bausch + Lomb Corporation, First Lien Term Loan A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A Investment, principal \$ 9,196 A A A A A A A Investment, interest rate (as a percent) 8.69% 8.69% 8.69% A A A SLF JV I | Investment, Identifier [Axis]: Centerline Communications, LLC, First Lien Revolver A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A Investment, principal \$ 600 A A \$ 600 A A A Investment, interest rate (as a percent) 11.50% 11.50% 11.50% 11.57% 11.57% 11.57% A SLF JV I | Investment, Identifier [Axis]: Centerline Communications, LLC, First Lien Term Loan 1 A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A Investment, principal \$ 2,348 A A \$ 2,354 A A A Investment, interest rate (as a percent) 11.49% 11.49% 11.49% 11.55% 11.55% 11.55% A SLF JV I | Investment, Identifier [Axis]: Centerline Communications, LLC, First Lien Term Loan 2 A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A Investment, principal \$ 1,979 A A \$ 1,983 A A A Investment, interest rate (as a percent) 12.64% 12.64% 12.64% 11.55% 11.55% 11.55% A SLF JV I | Investment, Identifier [Axis]: Centerline Communications, LLC, First Lien Term Loan 3 A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A Investment, principal \$ 1,955 A A \$ 1,960 A A A Investment, interest rate (as a percent) 12.49% 12.49% 12.49% 11.55% 11.55% 11.55% A SLF JV I | Investment, Identifier [Axis]: Cloud Software Group, Inc., First Lien Term Loan A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A Investment, principal \$ 8,173 A A A A A A A Investment, interest rate (as a percent) 9.33% 9.33% 9.33% A A A SLF JV I | Investment, Identifier [Axis]: Covetrus, Inc., First Lien Term Loan A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A Investment, principal \$ 6,295 A A \$ 6,343 A A A Investment, interest rate (as a percent) 10.33% 10.33% 10.33% 10.39% 10.39% 10.39% A SLF JV I | Investment, Identifier [Axis]: Crown Subsea Communications Holding, Inc., First Lien Term Loan A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A Investment, principal \$ 8,000 A A A A A A A Investment, interest rate (as a percent) 10.08% 10.08% 10.08% A A A SLF JV I | Investment, Identifier [Axis]: Curium Bidco S.A. r.l., First Lien Term Loan A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A Investment, principal \$ 8,665 A A \$ 8,730 A A A Investment, interest rate (as a percent) 9.33% 9.33% 9.33% 9.89% 9.89% 9.89% A SLF JV I | Investment, Identifier [Axis]: DTI Holdco, Inc., First Lien Term Loan A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A Investment, principal \$ 9,052 A A \$ 7,920 A A A Investment, interest rate (as a percent) 10.09% 10.09% 10.09% 10.12% 10.12% 10.12% A SLF JV I | Investment, Identifier [Axis]: Dealer Tire Financial, LLC, First Lien Term Loan A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A Investment, principal \$ 9,950 A A A A A A A Investment, interest rate (as a percent) 9.09% 9.09% 9.09% A A A SLF JV I | Investment, Identifier [Axis]: DirecTV Financing, LLC, First Lien Term Loan A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A Investment, principal \$ 6,872 A A \$ 5,799 A A A Investment, interest rate (as a percent) 10.71% 10.71% 10.71% 10.43% 10.43% 10.43% A SLF JV I | Investment, Identifier [Axis]: Eagle Parent Corp., First Lien Term Loan A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A Investment, principal \$ 1,181 A A A A A A A Investment, interest rate (as a percent) 9.58% 9.58% 9.58% A A A SLF JV I | Investment, Identifier [Axis]: Five Large Loan Exposures To Borrowers A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A Investment, principal \$ 53,328 A A \$ 54,051 A A A SLF JV I | Investment, Identifier [Axis]: Frontier Communications Holdings, LLC, First Lien Term Loan 1 A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A Investment, principal \$ 3,723 A A A A A A A Investment, interest rate (as a percent) 9.21% 9.21% 9.21% A A A SLF JV I | Investment, Identifier [Axis]: Frontier Communications Holdings, LLC, First Lien Term Loan 2 A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A Investment, principal \$ 7,000 A A A A A A A Investment, interest rate (as a percent) 8.85% 8.85% 8.85% A A A SLF JV I | Investment, Identifier [Axis]: Gibson Brands, Inc., First Lien Term Loan A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A Investment, principal A A A \$ 7,369 A A A Investment, interest rate (as a percent) A A A 10.57% 10.57% 10.57% A SLF JV I | Investment, Identifier [Axis]: Harbor Purchaser Inc., First Lien Term Loan A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A Investment, principal \$ 7,860 A A \$ 7,920 A A A Investment, interest rate (as a percent) 10.70% 10.70% 10.70% 10.67% 10.67% 10.67% A SLF JV I | Investment, Identifier [Axis]: Husky Injection Molding Systems Ltd., First Lien Term Loan A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A Investment, principal \$ 3,952 A A A A A A A Investment, interest rate (as a percent) 10.33% 10.33% 10.33% A A A SLF JV I |

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A Investment, basis spread, variable rate (as a percent) [1],[2],[4],[13] 7.50% 7.50% 7.50% A A A A A Investment, principal \$ 0 [1],[2],[4],[13] 0 [1],[2],[4],[13] 0 [6],[9],[12],[15],[16] A A A A A Investment owned, at cost 0 [1],[2],[4],[13] 0 [6],[9],[15],[16] A A A A A Investments at fair value \$ 0 [1],[2],[4],[13] 0 [6],[9],[15],[16] A A A A A Investment, Identifier [Axis]: BioXcel Therapeutics, Inc., Pharmaceuticals, First Lien Term Loan 6 A A A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A A Investment, principal [6],[9],[12],[15],[16] 0 A A A A A Investment owned, at cost [6],[9],[15],[16] 0 A A A A A A A A A A Investments at fair value [6],[9],[15],[16] \$ 0 A A A A A A A A A A Investment, Identifier [Axis]: BioXcel Therapeutics, Inc., Pharmaceuticals, Warrants A A A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A A Investment owned, balance (in shares) | shares [9],[15] 26,131 A A 26,131 A A A A A Investment owned, at cost [9],[15] \$ 225 A A A A A A A A A A Investments at fair value [9],[15] \$ 3 A A A A A A A A A A Investment, Identifier [Axis]: BioXcel Therapeutics, Inc., Pharmaceuticals, Warrants 1 A A A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A A Investment owned, balance (in shares) | shares [1],[13] 32,664 A A 32,664 A A A A A A A A A A Investment owned, at cost [1],[13] \$ 225 A A A A A A A A A A Investments at fair value [1],[13] \$ 3 A A A A A A A A A A Investment, Identifier [Axis]: BioXcel Therapeutics, Inc., Pharmaceuticals, Warrants 2 A A A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A A Investment owned, balance (in shares) | shares [1],[13] 9,382 A A 9,382 A A A A A A A A A A Investment owned, at cost [1],[13] \$ 0 A A A A A A A A A A Investments at fair value [1],[13] \$ 1 A A A A A A A A A A Investment, Identifier [Axis]: Birch Grove CLO 2 LTD, Multi-Sector Holdings, CLO Notes A A A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A A Investment, basis spread, variable rate (as a percent) [4],[13] 7.21% A A A A A A A A A A Investment, interest rate (as a percent) [4],[5],[13] 12.54% A A 12.54% 12.54% A A A A A A A A A A Investment, principal [4],[11],[13] 1,500 A A A A A A A A A A Investment owned, at cost [4],[13] 1,498 A A A A A A A A A A Investments at fair value [4],[13] \$ 1,503 A A A A A A A A A A Investment, Identifier [Axis]: Blackhawk Network Holdings, Inc., Data Processing & Outsourced Services, First Lien Term Loan A A A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A A Investment, basis spread, variable rate (as a percent) [4] 5.00% A A 5.00% A A A A A A A A A A Investment, interest rate (as a percent) [4],[5] 10.34% A A 10.34% A A A A A A A A A A Investment, principal [4],[11] 36,384 A A A A A A A A A A Investment owned, at cost [4] 35,698 A A A A A A A A A A Investments at fair value [4] \$ 36,509 A A A A A A A A A A Investment, Identifier [Axis]: Blackhawk Network Holdings, Inc., Data Processing & Outsourced Services, Second Lien Term Loan A A A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A A Investment, basis spread, variable rate (as a percent) [8] 7.00% A A 7.00% 7.00% A A A A A A A A A A Investment, interest rate (as a percent) [8],[10] 12.43% A A 12.43% 12.43% A A A A A A A A A A Investment, principal [8],[12] A \$ 30,625 A A A A A A A A A A Investment owned, at cost [8] A 30,370 A A A A A A A A A A Investments at fair value [8] A 29,989 A A A A A A A A A A Investment, Identifier [Axis]: Blumenthal Temecula, LLC, Automotive Retail, Common Stock A A A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A A Investment owned, balance (in shares) | shares 394,297 [1] 394,297 [9] 394,297 [1] 394,297 [9] 394,297 [9] A A A A A A A A A A Investment owned, at cost \$ 424 [1] A 424 [9] A A A A A A A A A A Investments at fair value \$ 154 [1] A 158 [9] A A A A A A A A A A Investment, Identifier [Axis]: Blumenthal Temecula, LLC, Automotive Retail, First Lien Term Loan A A A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A A Investment, interest rate (as a percent) [8],[9],[10] A 9.00% A A 9.00% 9.00% A A A A A A A A A A Investment, principal [9],[12] A \$ 5,257 A A A A A A A A A A Investment owned, at cost [9] A 5,258 A A A A A A A A A A Investments at fair value [9] A \$ 5,251 A A A A A A A A A A Investment, Identifier [Axis]: Blumenthal Temecula, LLC, Automotive Retail, Preferred Equity 1 A A A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A A Investment owned, balance (in shares) | shares 1,708,618 [1] 1,708,618 [9] 1,708,618 [1] 1,708,618 [1] 1,708,618 [9] 1,708,618 [9] A A A A A A A A A A Investment owned, at cost \$ 1,711 [1] A 1,711 [9] A A A A A A A A A A Investments at fair value \$ 2,085 [1] A 1,999 [9] A A A A A A A A A A Investment, Identifier [Axis]: Blumenthal Temecula, LLC, Automotive Retail, Preferred Equity 2 A A A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A A Investment owned, balance (in shares) | shares 394,297 [1] 394,297 [9] 394,297 [1] 394,297 [9] 394,297 [9] A A A A A A A A A A Investment owned, at cost \$ 395 [1] A 395 [9] A A A A A A A A A A Investments at fair value 457 [1] A 442 [9] A A A A A A A A A A Investment, Identifier [Axis]: C5 Technology Holdings, LLC, Common Stock | SLF JV I A A A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A A Investment owned, balance (in shares) | shares A 171 A A 171 A A A A A A A A A A Investment owned, at cost 0 \$ 0 A A A A A A A A A A Investments at fair value \$ 0 \$ 0 A A A A A A A A A A Investment, Identifier [Axis]: C5 Technology Holdings, LLC, Common Stock | SLF JV I A A A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A A Investment owned, balance (in shares) | shares 171,000 A 171,000 A 171,000 A A A A A A A A A A Investment, Identifier [Axis]: C5 Technology Holdings, LLC, Data Processing & Outsourced Services, Common Stock A A A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A A Investment owned, balance (in shares) | shares 829 [1] 829 [9] 829 [1] 829 [9] 829 [9] A A A A A A A A A A Investment owned, at cost \$ 0 [1] A 0 [9] A A A A A A A A A A Investments at fair value \$ 0 [1] A 0 [9] A A A A A A A A A A Investment, Identifier [Axis]: C5 Technology Holdings, LLC, Data Processing & Outsourced Services, Preferred Equity A A A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A A Investment owned, balance (in shares) | shares 34,984,460 [1] 34,984,460 [9] 34,984,460 [1] 34,984,460 [9] 34,984,460 [9] 34,984,460 [9] A A A A A A A A A A Investment owned, at cost \$ 34,984 [1] A 34,984 [9] A A A A A A A A A A Investments at fair value \$ 27,638 [1] A 27,638 [9] A A A A A A A A A A Investment, Identifier [Axis]: C5 Technology Holdings, LLC, Preferred Equity | SLF JV I A A A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A A Investment owned, balance (in shares) | shares 7,193,540,000 A 7,193,540,000 A 7,193,540,000 A A A A A A A A A A Investment owned, at cost \$ 7,194 A 7,194 A A A A A A A A A A Investments at fair value \$ 5,683 A 5,683 A A A A A A A A A A Investment, Identifier [Axis]: CBAM 2017-2 LTD, Multi-Sector Holdings, CLO Notes A A A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A A Investment, basis spread, variable rate (as a percent) [4],[13] 7.36% A A 7.36% 7.36% A A A A A A A A A A Investment, interest rate (as a percent) [4],[5],[13] 12.68% A A 12.68% 12.68% A A A A A A A A A A Investment, principal [4],[11],[13] 489 A A A A A A A A A A Investment owned, at cost [4],[13] 458 A A A A A A A A A A Investments at fair value [4],[13] 468 A A A A A A A A A A Investment, Identifier [Axis]: CD&R Firefly Bidco Limited, Application Software, First Lien Revolver A A A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A A Investment, basis spread, variable rate (as a percent) [1],[2],[4] 6.00% A A 6.00% 6.00% A A A A A A A A A A Investment, principal [1],[2],[4],[11] 0 A A A A A A A A A A Investment owned, at cost [1],[2],[4] (35) A A A A A A A A A A Investments at fair value [1],[2],[4] (33) A A A A A A A A A A Investment, Identifier [Axis]: CD&R Firefly Bidco Limited, Application Software, First Lien Term Loan A A A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A A Investment, basis spread, variable rate (as a percent) [1],[4] 3.00% A A 3.00% 3.00% A A A A A A A A A A Investment, interest rate (as a percent) [1],[4],[5] 8.33% A A 8.33% 8.33% A A A A A A A A A A Investment, interest rate, paid in kind (as a percent) [1],[4] 3.50% A A 3.50% 3.50% A A A A A A A A A A Investment, principal [1],[4],[11] 12,712 A A A A A A A A A A Investment owned, at cost [1],[4] 12,408 A A A A A A A A A A Investments at fair value [1],[4] 12,417 A A A A A A A A A A Investment, Identifier [Axis]: CD&R Firefly Bidco Limited, Other Specialty Retail, First Lien Term Loan 1 A A A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A A Investment, basis spread, variable rate (as a percent) [4],[13] 5.75% A A 5.75% 5.75% A A A A A A A A A A Investment, interest rate (as a percent) [4],[5],[13] 11.06% A A 11.06% 11.06% A A A A A A A A A A Investment, principal [4],[11],[13] 1,500 A A A A A A A A A A Investment owned, at cost [4],[13] 1,866 A A A A A A A A A A Investments at fair value [4],[13] 1,900 A A A A A A A A A A Investment, Identifier [Axis]: CD&R Firefly Bidco Limited, Other Specialty Retail, First Lien Term Loan 2 A A A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A A Investment, basis spread, variable rate (as a percent) [4],[13] 5.75% A A 5.75% 5.75% A A A A A A A A A A Investment, interest rate (as a percent) [4],[5],[13] 10.95% A A 10.95% 10.95% A A A A A A A A A A Investment, principal [4

[\[0\]](#),[1](#),[\[1\]](#),[\[2\]](#),[\[4\]](#) 5.50% [1],[2],[4] 7.50% [6],[8],[9] 7.50% [6],[8],[9] Á Investment, principal \$ 0 [1],[2],[4], [11] \$ 0 [6],[8],[9], [12] Á Á Á Á Investment owned, at cost (18) [1],[2],[4] Loan 1 [6],[8],[9] Á Á Á Á Investments at fair value \$ 0 [1],[2],[4] \$ (20) [6],[8],[9] Á Á Á Á Investment, Identifier [Axis]: Coupa Holdings, LLC, Application Software, First Lien Term Company, Nonconsolidated Subsidiary [Line Items] Á Á Á Á Á Á Investment, basis spread, variable rate (as a percent) 5.50% [1],[2],[4] 7.50% [8],[9] 5.50% [1],[2],[4] 5.50% [1],[2],[4] 5.50% [8],[9] 7.50% [8],[9] Á Á Á Á Investment, interest rate (as a percent) [8],[9], [10] Á 12.82% Á 12.82% Á 12.82% Á Á Á Á Investment, principal \$ 0 [1],[2],[4], [11] \$ 13,157 [8],[9], [12] Á Á Á Á Investment owned, at cost (15) [1],[2],[4] 12,855 [8],[9] Á Á Á Á Investments at fair value \$ 0 [1],[2],[4] Á 12,858 [8],[9] Á Á Á Á Investment, Identifier [Axis]: Coupa Holdings, LLC, Application Software, First Lien Term Loan 2 Á Á Á Á Á Á Investment Company, Nonconsolidated Subsidiary [Line Items] Á Á Á Á Á Á Investment, basis spread, variable rate (as a percent) 5.50% [1],[4] 7.50% [6],[8],[9] 5.50% [1],[4] 5.50% [1],[4] 7.50% [6],[8],[9] 7.50% [6],[8],[9] Á Á Á Á Investment, interest rate (as a percent) [1],[4], [5] 10.83% Á 10.83% Á 10.83% Á Á Á Á Investment, principal \$ 13,157 [1],[4], [11] \$ 0 [6],[8],[9], [12] Á Á Á Á Á Á Investment owned, at cost 12,890 [1],[4] (15) [6],[8],[9] Á Á Á Á Investments at fair value \$ 13,157 [1],[4] (\$ 13) [6],[8],[9] Á Á Á Á Á Á Investment, Identifier [Axis]: Covetrus, Inc., First Lien Term Loan | SLF JV I Á Á Á Á Á Á Investment Company, Nonconsolidated Subsidiary [Line Items] Á Á Á Á Á Á Á Á Á Á Investment, basis spread, variable rate (as a percent) 5.00% 5.00% 5.00% 5.00% 5.00% 5.00% Á Á Á Á Investment, interest rate (as a percent) 10.33% 10.33% 10.33% 10.33% 10.33% Á Á Á Á Investment, principal \$ 6,295 \$ 6,343 Á Á Á Á Á Á Investment owned, at cost 5,982 5,983 Á Á Á Á Á Á Investments at fair value \$ 6,102 \$ 6,285 Á Á Á Á Á Á Investment, Identifier [Axis]: Covetrus, Inc., First Lien Term Loan | OCSI Glick JLV LLC Á Á Á Á Á Á Á Á Á Á Investment Company, Nonconsolidated Subsidiary [Line Items] Á Á Á Á Á Á Á Á Á Á Investment, basis spread, variable rate (as a percent) 5.00% 5.00% 5.00% 5.00% 5.00% Á Á Á Á Investment, interest rate (as a percent) 10.33% 10.33% 10.33% 10.33% 10.33% Á Á Á Á Investment, principal \$ 2,745 \$ 2,766 Á Á Á Á Á Á Investment owned, at cost 2,607 2,607 Á Á Á Á Á Á Investments at fair value \$ 2,661 \$ 2,741 Á Á Á Á Á Á Investment, Identifier [Axis]: Covetrus, Inc., Health Care Distributors, First Lien Term Loan Á Á Á Á Á Á Á Á Á Á Investment Company, Nonconsolidated Subsidiary [Line Items] Á Á Á Á Á Á Á Á Á Á Investment, basis spread, variable rate (as a percent) 5.00% [4] 5.00% [8] 5.00% [4] 5.00% [8] 5.00% [8] Á Á Á Á Investment, interest rate (as a percent) 10.33% [4], [5] 10.39% [8], [10] 10.33% [4], [5] 10.39% [8], [10] 10.39% [8], [10] Á Á Á Á Investment, principal \$ 14,639 [4], [11] \$ 14,750 [8], [12] Á Á Á Á Á Á Investment owned, at cost 14,132 [4], 14,173 [8] Á Á Á Á Á Á Investments at fair value \$ 14,189 [4] \$ 14,616 [8] Á Á Á Á Á Á Investment, Identifier [Axis]: Coyote Buyer, LLC, Specialty Chemicals, First Lien Revolver Á Á Á Á Á Á Á Á Á Á Investment Company, Nonconsolidated Subsidiary [Line Items] Á Á Á Á Á Á Á Á Á Á Investment, basis spread, variable rate (as a percent) [6],[8],[9] 6.00% Á Á 6.00% 6.00% Á Á Á Á Investment, interest rate (as a percent) [6],[8],[9], [10] Á 11.47% Á 11.47% Á 11.47% Á Á Á Á Investment, principal [6],[8],[9], [12] Á \$ 933 Á Á Á Á Á Á Investment owned, at cost [6],[8],[9] 920 Á Á Á Á Á Á Investments at fair value [6],[8],[9] Á 918 Á Á Á Á Á Á Á Á Á Á Investment, Identifier [Axis]: Coyote Buyer, LLC, Specialty Chemicals, First Lien Term Loan Á Á Á Á Á Á Á Á Á Á Investment Company, Nonconsolidated Subsidiary [Line Items] Á Á Á Á Á Á Á Á Á Á Investment, basis spread, variable rate (as a percent) [8],[9] 6.00% Á Á 6.00% 6.00% Á Á Á Á Investment, interest rate (as a percent) [8],[9], [10] Á 11.52% Á 11.52% Á 11.52% Á Á Á Á Investment, principal [8],[9], [12] Á \$ 18,013 Á Á Á Á Á Á Investment owned, at cost [8],[9] 17,690 Á Á Á Á Á Á Investments at fair value [8],[9] Á \$ 17,812 Á Á Á Á Á Á Investment, Identifier [Axis]: Creuline Buyer, Inc., Systems Software, First Lien Revolver Á Á Á Á Á Á Á Á Á Á Investment Company, Nonconsolidated Subsidiary [Line Items] Á Á Á Á Á Á Á Á Á Á Investment, basis spread, variable rate (as a percent) [1],[2],[4] 6.75% Á 6.75% 6.75% Á Á Á Á Investment, principal [1],[2],[4], [11] \$ 0 Á Á Á Á Á Á Investment owned, at cost [1],[2],[4] (49) Á Á Á Á Á Á Investments at fair value [1],[2],[4] (\$ 44) Á Á Á Á Á Á Investment, Identifier [Axis]: Creuline Buyer, Inc., Systems Software, First Lien Term Loan Á Á Á Á Á Á Á Á Á Á Investment Company, Nonconsolidated Subsidiary [Line Items] Á Á Á Á Á Á Á Á Á Á Investment, basis spread, variable rate (as a percent) [1],[4], [5] 12.08% Á 12.08% Á 12.08% Á Á Á Á Investment, principal [1],[4], [11] \$ 20,924 Á Á Á Á Á Á Investment owned, at cost [1],[4] 20,449 Á Á Á Á Á Á Investments at fair value [1],[4] \$ 20,506 Á Á Á Á Á Á Á Á Á Á Investment, Identifier [Axis]: Crown Subsea Communications Holding, Inc., Alternative Carriers, First Lien Term Loan Á Á Á Á Á Á Á Á Á Á Investment Company, Nonconsolidated Subsidiary [Line Items] Á Á Á Á Á Á Á Á Á Á Investment, basis spread, variable rate (as a percent) [4] 4.75% Á 4.75% 4.75% Á Á Á Á Investment, interest rate (as a percent) [4], [5] 10.08% Á 10.08% 10.08% Á Á Á Á Investment, principal [4], [11] \$ 14,000 Á Á Á Á Á Á Á Á Á Á Investment owned, at cost [4] \$ 13,860 Á Á Á Á Á Á Investments at fair value [4] \$ 14,555 Á Á Á Á Á Á Á Á Á Á Investment, Identifier [Axis]: Crown Subsea Communications Holding, Inc., First Lien Term Loan | SLF JV I Á Á Á Á Á Á Á Á Á Á Investment Company, Nonconsolidated Subsidiary [Line Items] Á Á Á Á Á Á Á Á Á Á Investment, basis spread, variable rate (as a percent) 4.75% Á 4.75% 4.75% Á Á Á Á Investment, interest rate (as a percent) 10.08% Á 10.08% 10.08% Á Á Á Á Investment, principal \$ 8,000 Á Á Á Á Á Á Investment owned, at cost 7,920 Á Á Á Á Á Á Investments at fair value \$ 8,032 Á Á Á Á Á Á Investment, Identifier [Axis]: Crown Subsea Communications Holding, Inc., First Lien Term Loan | OCSI Glick JV LLC Á Á Á Á Á Á Á Á Á Á Investment Company, Nonconsolidated Subsidiary [Line Items] Á Á Á Á Á Á Á Á Á Á Investment, basis spread, variable rate (as a percent) 4.75% Á 4.75% 4.75% Á Á Á Á Investment, interest rate (as a percent) 10.08% Á 10.08% 10.08% Á Á Á Á Investment, principal \$ 3,000 Á Á Á Á Á Á Á Á Á Á Investment owned, at cost 2,970 Á Á Á Á Á Á Investments at fair value \$ 3,012 Á Á Á Á Á Á Á Á Á Á Investment, Identifier [Axis]: Curium Bidco S.A. r.l., First Lien Term Loan | SLF JV I Á Á Á Á Á Á Á Á Á Á Investment Company, Nonconsolidated Subsidiary [Line Items] Á Á Á Á Á Á Á Á Á Á Investment, basis spread, variable rate (as a percent) 4.00% 4.50% 4.00% 4.00% 4.50% 4.50% Á Á Á Á Investment, interest rate (as a percent) 9.33% 9.89% 9.33% 9.33% 9.89% 9.89% Á Á Á Á Investment, principal \$ 8,665 \$ 8,730 Á Á Á Á Á Á Á Á Á Á Investment owned, at cost 8,581 8,642 Á Á Á Á Á Á Investments at fair value \$ 8,713 \$ 8,730 Á Á Á Á Á Á Á Á Á Á Investment, Identifier [Axis]: Curium Bidco S.A. r.l., First Lien Term Loan | OCSI Glick JLV LLC Á Á Á Á Á Á Á Á Á Á Investment Company, Nonconsolidated Subsidiary [Line Items] Á Á Á Á Á Á Á Á Á Á Investment, basis spread, variable rate (as a percent) 4.00% 4.50% 4.00% 4.00% 4.50% 4.50% Á Á Á Á Investment, interest rate (as a percent) 9.33% 9.89% 9.33% 9.33% 9.89% 9.89% Á Á Á Á Investment, principal \$ 2,820 \$ 2,841 Á Á Á Á Á Á Á Á Á Á Investment owned, at cost 2,799 2,820 Á Á Á Á Á Á Investments at fair value \$ 2,836 \$ 2,841 Á Á Á Á Á Á Á Á Á Á Investment, Identifier [Axis]: DTI Holdco, Inc., First Lien Term Loan | SLF JV I Á Á Á Á Á Á Á Á Á Á Investment Company, Nonconsolidated Subsidiary [Line Items] Á Á Á Á Á Á Á Á Á Á Investment, basis spread, variable rate (as a percent) 4.75% 4.75% 4.75% 4.75% Á Á Á Á Investment, interest rate (as a percent) 10.09% 10.12% 10.09% 10.09% 10.12% Á Á Á Á Investment, principal \$ 9,052 \$ 7,920 Á Á Á Á Á Á Á Á Á Á Investment owned, at cost 8,929 7,792 Á Á Á Á Á Á Investments at fair value \$ 9,100 \$ 7,729 Á Á Á Á Á Á Á Á Á Á Investment, Identifier [Axis]: DTI Holdco, Inc., First Lien Term Loan | OCSI Glick JV LLC Á Á Á Á Á Á Á Á Á Á Investment Company, Nonconsolidated Subsidiary [Line Items] Á Á Á Á Á Á Á Á Á Á Investment, basis spread, variable rate (as a percent) 4.75% 4.75% 4.75% 4.75% Á Á Á Á Investment, interest rate (as a percent) 10.09% 10.12% 10.09% 10.09% 10.12% Á Á Á Á Investment, principal \$ 3,543 \$ 2,970 Á Á Á Á Á Á Á Á Á Á Investment owned, at cost 3,496 2,922 Á Á Á Á Á Á Investments at fair value \$ 3,562 \$ 2,899 Á Á Á Á Á Á Á Á Á Á Investment, Identifier [Axis]: DTI Holdco, Inc., Research & Consulting Services, First Lien Term Loan Á Á Á Á Á Á Á Á Á Á Investment Company, Nonconsolidated Subsidiary [Line Items] Á Á Á Á Á Á Á Á Á Á Investment, basis spread, variable rate (as a percent) [8] 4.75% Á Á 4.75% 4.75% Á Á Á Á Investment, interest rate (as a percent) [8], [10] Á 10.12% Á 10.12% Á 10.12% Á Á Á Á Investment, principal [8], [12] Á \$ 4,950 Á Á Á Á Á Á Á Á Á Á Investment owned, at cost [8] 4,871 Á Á Á Á Á Á Investments at fair value [8] Á \$ 4,831 Á Á Á Á Á Á Á Á Á Á Investment, Identifier [Axis]: Dealer Tire Financial, LLC, First Lien Term Loan | SLF JV I Á Á Á Á Á Á Á Á Á Á Investment Company, Nonconsolidated Subsidiary [Line Items] Á Á Á Á Á Á Á Á Á Á Investment, basis spread, variable rate (as a percent) 3.75% Á 3.75% 3.75% Á Á Á Á Investment, interest rate (as a percent) 9.09% Á 9.09% 9.09% Á Á Á Á Investment, principal \$ 9,95

[illegible]

Account & Defense, First Lien Revolver A A A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A A Investment, basis spread, variable rate (as a percent) 7.25% [1],[2],[4] 7.25% [6],[8],[9] 7.25% [1],[2],[4] 7.25% [1],[2],[4] 7.25% [6],[8],[9] 7.25% [6],[8],[9] A A A A A A A A A A Investment, interest rate (as a percent) 12.59% [1],[2],[4],[5] 12.64% [6],[8],[9] 12.59% [1],[2],[4],[5] 12.59% [1],[2],[4],[5] 12.64% [6],[8],[9] 12.64% [6],[8],[9] A A A A A A A A A A Investment, principal \$ 2,219 [1],[2],[4],[5] 1,638 [6],[8],[9] 12,124 A A A A A A A A A A Investment, basis spread, variable rate (as a percent) 7.25% [1],[4] 7.25% [8],[9] 7.25% [1],[4] 7.25% [8],[9] 7.25% [8],[9] A A A A A A A A A A Investment, interest rate (as a percent) 12.58% [1],[4],[5] 12.58% [1],[4],[5] 12.64% [8],[9] 12.64% [8],[9] A A A A A A A A A A Investment, principal \$ 23,025 [1],[4] 23,110 [8],[9] A A A A A A A A A A Investments at fair value \$ 23,595 [1],[4] \$ 23,110 [8],[9] A A A A A A A A A A Investment, Identifier [Axis]: Gibson Brands, Inc., First Lien Term Loan | SLF JV I A A A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A A Investment, basis spread, variable rate (as a percent) 5.00% A A A A A A A A A A Investment, interest rate (as a percent) 10.57% A A A A A A A A A A Investment, principal \$ 7,369 A A A A A A A A A A Investment, basis spread, variable rate (as a percent) 5.00% A A A A A A A A A A Investments at fair value \$ 6,190 A A A A A A A A A A Investment, Identifier [Axis]: Gibson Brands, Inc., First Lien Term Loan | OCSI Glick JV LLC A A A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A A Investment, basis spread, variable rate (as a percent) 5.00% A A A A A A A A A A Investment, interest rate (as a percent) 10.57% A A A A A A A A A A Investment, principal \$ 3,930 A A A A A A A A A A Investment, basis spread, variable rate (as a percent) 5.00% A A A A A A A A A A Investments at fair value \$ 3,301 A A A A A A A A A A Investment, Identifier [Axis]: Gibson Brands, Inc., Leisure Products, First Lien Term Loan A A A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A A Investment, basis spread, variable rate (as a percent) 8.00% [8],[9] 5.00% A A A A A A A A A A Investment, interest rate (as a percent) 8.00% [8],[9] 10.57% A A A A A A A A A A Investment, principal \$ 0 [1],[2],[4],[11] \$ 0 [6],[8],[9] 10.57% A A A A A A A A A A Investment, Identifier [Axis]: GoldenTree Loan Management EUR CLO 2 DAC, Multi-Sector Holdings, CLO Notes A A A A A A A A A A Investments at fair value [8],[9] A \$ 2,063 A A A A A A A A A A Investment, Identifier [Axis]: GoldenTree Loan Management EUR CLO 2 DAC, Multi-Sector Holdings, CLO Notes A A A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A A Investment, basis spread, variable rate (as a percent) 2.85% [4],[13] 2.85% [8],[15] 2.85% [4],[13] 2.85% [8],[15] 2.85% [4],[13] 2.85% [8],[15] A A A A A A A A A A Investment, interest rate (as a percent) 6.75% [4],[5],[13] 6.56% [8],[10],[15] 6.75% [4],[5],[13] 6.75% [4],[5],[13] 6.56% [8],[10],[15] 6.56% [8],[10],[15] A A A A A A A A A A Investment, principal \$ 1,000 [4],[11],[13] A A A A A A A A A A Investment, interest rate (as a percent) 8.00% [8],[9] 8.00% [8],[9] 8.00% [8],[9] 8.00% [8],[9] 8.00% [8],[9] 8.00% [8],[9] A A A A A A A A A A Investment, Identifier [Axis]: Grove Hotel Parcel Owner, LLC, Hotels, Resorts & Cruise Lines, First Lien Revolver A A A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A A Investment, basis spread, variable rate (as a percent) 8.00% [1],[2],[4] 8.00% [6],[8],[9] 8.00% [1],[2],[4] 8.00% [6],[8],[9] 8.00% [6],[8],[9] 8.00% [6],[8],[9] A A A A A A A A A A Investment, principal \$ 0 [1],[2],[4],[11] \$ 0 [6],[8],[9] 10.57% A A A A A A A A A A Investment, Identifier [Axis]: Grove Hotel Parcel Owner, LLC, Hotels, Resorts & Cruise Lines, First Lien Term Loan 1 A A A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A A Investment, basis spread, variable rate (as a percent) 8.00% [1],[2],[4] 8.00% [6],[8],[9] 8.00% [1],[2],[4] 8.00% [6],[8],[9] 8.00% [1],[2],[4] 8.00% [6],[8],[9] A A A A A A A A A A Investment, interest rate (as a percent) 8.00% [8],[9] 10.57% A A A A A A A A A A Investment, principal \$ 43 [1],[2],[4] 17,276 [8],[9] A A A A A A A A A A Investments at fair value \$ (70) [1],[2],[4] \$ 17,096 [8],[9] A A A A A A A A A A Investment, Identifier [Axis]: Grove Hotel Parcel Owner, LLC, Hotels, Resorts & Cruise Lines, First Lien Term Loan 2 A A A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A A Investment, basis spread, variable rate (as a percent) 8.00% [1],[4] 8.00% [6],[8],[9] 8.00% [1],[4] 8.00% [6],[8],[9] 8.00% [6],[8],[9] 8.00% [6],[8],[9] A A A A A A A A A A Investment, principal \$ 17,312 [1],[4],[11] \$ 0 [6],[8],[9] 10.57% A A A A A A A A A A Investment, interest rate (as a percent) 10.57% A A A A A A A A A A Investment, principal \$ 17,312 [1],[4],[11] \$ 0 [6],[8],[9] 10.57% A A A A A A A A A A Investment, Identifier [Axis]: HPS Loan Management 10-2016, Multi-Sector Holdings, CLO Notes A A A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A A Investment, basis spread, variable rate (as a percent) 4.00% [4],[13] 6.67% A A A A A A A A A A Investment, interest rate (as a percent) 12.00% [4],[5],[13] 12.00% A A A A A A A A A A Investment, principal [4],[11],[13] \$ 2,250 A A A A A A A A A A Investment, interest rate (as a percent) 12.00% [4],[5],[13] 12.00% A A A A A A A A A A Investment, principal \$ 2,238 A A A A A A A A A A Investment, Identifier [Axis]: Harbor Purchaser Inc., Education Services, First Lien Term Loan A A A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A A Investment, basis spread, variable rate (as a percent) 5.25% [4],[13] 5.25% [8],[10],[15] 5.25% [4],[13] 5.25% [8],[10],[15] 5.25% [4],[13] 5.25% [8],[10],[15] A A A A A A A A A A Investment, interest rate (as a percent) 10.70% [4],[5] 10.67% [8],[10],[15] 10.70% [4],[5] 10.67% [8],[10],[15] 10.67% [8],[10],[15] 10.67% [8],[10],[15] A A A A A A A A A A Investment, principal \$ 8,494 [4],[11] \$ 14,347 [8],[12] A A A A A A A A A A Investment, interest rate (as a percent) 10.70% [4],[5] 10.67% [8],[10],[15] 10.70% [4],[5] 10.67% [8],[10],[15] 10.67% [8],[10],[15] 10.67% [8],[10],[15] A A A A A A A A A A Investment, Identifier [Axis]: Harbor Purchaser Inc., First Lien Term Loan | SLF JV I A A A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A A Investment, basis spread, variable rate (as a percent) 5.25% 5.25% 5.25% 5.25% 5.25% 5.25% A A A A A A A A A A Investment, interest rate (as a percent) 10.70% 10.67% 10.70% 10.67% 10.70% 10.67% A A A A A A A A A A Investment, principal \$ 7,860 7,920 A A A A A A A A A A Investment, Identifier [Axis]: Harbor Purchaser Inc., First Lien Term Loan | OCSI Glick JV LLC A A A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A A Investment, basis spread, variable rate (as a percent) 5.25% 5.25% 5.25% 5.25% 5.25% 5.25% A A A A A A A A A A Investment, interest rate (as a percent) 10.70% 10.67% 10.70% 10.67% 10.70% 10.67% A A A A A A A A A A Investment, principal \$ 3,930 3,960 A A A A A A A A A A Investment, Identifier [Axis]: Harrow, Inc., Pharmaceuticals, First Lien Term Loan 1 A A A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A A Investment, basis spread, variable rate (as a percent) 6.50% [1],[2],[4],[13] 6.50% [8],[9],[15] 6.50% [1],[2],[4],[13] 6.50% [8],[9],[15] 6.50% [1],[2],[4],[13] 6.50% [8],[9],[15] A A A A A A A A A A Investment, interest rate (as a percent) 11.89% A A A A A A A A A A Investment, principal \$ 0 [1],[2],[4],[13] \$ 7,301 [8],[9],[15] A A A A A A A A A A Investment, Identifier [Axis]: Harrow, Inc., Pharmaceuticals, First Lien Term Loan 2 A A A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A A Investment, basis spread, variable rate (as a percent) 6.50% [1],[4],[13] 6.50% [6],[8],[9],[15] 6.50% [1],[4],[13] 6.50% [6],[8],[9],[15] 6.50% [1],[4],[13] 6.50% [6],[8],[9],[15] A A A A A A A A A A Investment, interest rate (as a percent) 11.89% A A A A A A A A A A Investment, principal \$ 1,432 [1],[4],[13] \$ (79) [6],[8],[9],[15] A A A A A A A A A A Investment, Identifier [Axis]: Harrow, Inc., Pharmaceuticals, First Lien Term Loan 3 A A A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A A Investment, basis spread, variable rate (as a percent) 6.50% [1],[4],[13] 6.50% [8],[9],[15] 6.50% [1],[4],[13] 6.50% [8],[9],[15] 6.50% [1],[4],[13] 6.50% [8],[9],[15] A A A A A A A A A A Investment, interest rate (as a percent) 11.89% A A A A A A A A A A Investment, principal \$ 7,448 [1],[4],[11],[13] \$ 1,432 [8],[9],[12],[15] A A A A A A A A A A Investment, Identifier [Axis]: Horizon Aircraft Finance I Ltd., Specialized Finance, CLO Notes A A A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A A Investment, interest rate (as a percent) 4.46% [4],[5],[13] 4.46% [8],[10],[15] 4.46% [4],[5],[13] 4.46

(a) (b) (c) (d) (e) (f) (g) (h) (i) (j) (k) (l) (m) (n) (o) (p) (q) (r) (s) (t) (u) (v) (w) (x) (y) (z) (aa) (ab) (ac) (ad) (ae) (af) (ag) (ah) (ai) (aj) (ak) (al) (am) (an) (ao) (ap) (aq) (ar) (as) (at) (au) (av) (aw) (ax) (ay) (az) (ba) (bb) (bc) (bd) (be) (bf) (bg) (bh) (bi) (bj) (bk) (bl) (bm) (bn) (bo) (bp) (bq) (br) (bs) (bt) (bu) (bv) (bw) (bx) (by) (bz) (ca) (cb) (cc) (cd) (ce) (cf) (cg) (ch) (ci) (cj) (ck) (cl) (cm) (cn) (co) (cp) (cq) (cr) (cs) (ct) (cu) (cv) (cw) (cx) (cy) (cz) (da) (db) (dc) (dd) (de) (df) (dg) (dh) (di) (dj) (dk) (dl) (dm) (dn) (do) (dp) (dq) (dr) (ds) (dt) (du) (dv) (dw) (dx) (dy) (dz) (ea) (eb) (ec) (ed) (ee) (ef) (eg) (eh) (ei) (ej) (ek) (el) (em) (en) (eo) (ep) (eq) (er) (es) (et) (eu) (ev) (ew) (ex) (ey) (ez) (fa) (fb) (fc) (fd) (fe) (ff) (fg) (fh) (fi) (fj) (fk) (fl) (fm) (fn) (fo) (fp) (fq) (fr) (fs) (ft) (fu) (fv) (fw) (fx) (fy) (fz) (ga) (gb) (gc) (gd) (ge) (gf) (gg) (gh) (gi) (gj) (gk) (gl) (gm) (gn) (go) (gp) (gq) (gr) (gs) (gt) (gu) (gv) (gw) (gx) (gy) (gz) (ha) (hb) (hc) (hd) (he) (hf) (hg) (hh) (hi) (hj) (hk) (hl) (hm) (hn) (ho) (hp) (hq) (hr) (hs) (ht) (hu) (hv) (hw) (hx) (hy) (hz) (ia) (ib) (ic) (id) (ie) (if) (ig) (ih) (ii) (ij) (ik) (il) (im) (in) (io) (ip) (iq) (ir) (is) (it) (iu) (iv) (iw) (ix) (iy) (iz) (ja) (jb) (jc) (jd) (je) (jf) (jg) (jh) (ji) (jj) (jk) (jl) (jm) (jn) (jo) (jp) (jq) (jr) (js) (jt) (ju) (jv) (jw) (jx) (jy) (jz) (ka) (kb) (kc) (kd) (ke) (kf) (kg) (kh) (ki) (kj) (kk) (kl) (km) (kn) (ko) (kp) (kq) (kr) (ks) (kt) (ku) (kv) (kw) (kx) (ky) (kz) (la) (lb) (lc) (ld) (le) (lf) (lg) (lh) (li) (lj) (lk) (ll) (lm) (ln) (lo) (lp) (lq) (lr) (ls) (lt) (lu) (lv) (lw) (lx) (ly) (lz) (ma) (mb) (mc) (md) (me) (mf) (mg) (mh) (mi) (mj) (mk) (ml) (mm) (mn) (mo) (mp) (mq) (mr) (ms) (mt) (mu) (mv) (mw) (mx) (my) (mz) (na) (nb) (nc) (nd) (ne) (nf) (ng) (nh) (ni) (nj) (nk) (nl) (nm) (nn) (no) (np) (nq) (nr) (ns) (nt) (nu) (nv) (nw) (nx) (ny) (nz) (oa) (ob) (oc) (od) (oe) (of) (og) (oh) (oi) (oj) (ok) (ol) (om) (on) (oo) (op) (oq) (or) (os) (ot) (ou) (ov) (ow) (ox) (oy) (oz) (pa) (pb) (pc) (pd) (pe) (pf) (pg) (ph) (pi) (pj) (pk) (pl) (pm) (pn) (po) (pp) (pq) (pr) (ps) (pt) (pu) (pv) (pw) (px) (py) (pz) (qa) (qb) (qc) (qd) (qe) (qf) (qg) (qh) (qi) (qj) (qk) (ql) (qm) (qn) (qo) (qp) (qq) (qr) (qs) (qt) (qu) (qv) (qw) (qx) (qy) (qz) (ra) (rb) (rc) (rd) (re) (rf) (rg) (rh) (ri) (rj) (rk) (rl) (rm) (rn) (ro) (rp) (rq) (rr) (rs) (rt) (ru) (rv) (rw) (rx) (ry) (rz) (sa) (sb) (sc) (sd) (se) (sf) (sg) (sh) (si) (sj) (sk) (sl) (sm) (sn) (so) (sp) (sq) (sr) (ss) (st) (su) (sv) (sw) (sx) (sy) (sz) (ta) (tb) (tc) (td) (te) (tf) (tg) (th) (ti) (tj) (tk) (tl) (tm) (tn) (to) (tp) (tq) (tr) (ts) (tt) (tu) (tv) (tw) (tx) (ty) (tz) (ua) (ub) (uc) (ud) (ue) (uf) (ug) (uh) (ui) (uj) (uk) (ul) (um) (un) (uo) (up) (uq) (ur) (us) (ut) (uu) (uv) (uw) (ux) (uy) (uz) (va) (vb) (vc) (vd) (ve) (vf) (vg) (vh) (vi) (vj) (vk) (vl) (vm) (vn) (vo) (vp) (vq) (vr) (vs) (vt) (vu) (vv) (vw) (vx) (vy) (vz) (wa) (wb) (wc) (wd) (we) (wf) (wg) (wh) (wi) (wj) (wk) (wl) (wm) (wn) (wo) (wp) (wq) (wr) (ws) (wt) (wu) (wv) (ww) (wx) (wy) (wz) (xa) (xb) (xc) (xd) (xe) (xf) (xg) (xh) (xi) (xj) (xk) (xl) (xm) (xn) (xo) (xp) (xq) (xr) (xs) (xt) (xu) (xv) (xw) (xx) (xy) (xz) (ya) (yb) (yc) (yd) (ye) (yf) (yg) (yh) (yi) (yj) (yk) (yl) (ym) (yn) (yo) (yp) (yq) (yr) (ys) (yt) (yu) (yv) (yw) (yx) (yy) (yz) (za) (zb) (zc) (zd) (ze) (zf) (zg) (zh) (zi) (zj) (zk) (zl) (zm) (zn) (zo) (zp) (zq) (zr) (zs) (zt) (zu) (zv) (zw) (zx) (zy) (zz)

[illegible]

Investment \$ 58,349 [1],[2],[4],[11],[13],[23] \$ 58,349 [6],[8],[9],[12],[15],[25] A A A A \$ 58,349 A Investment owned, at cost 51,307 [1],[2],[4],[13],[23] 50,330 [6],[8],[9],[15],[25] A A A A Investments at fair value \$ 49,886 [1],[2],[4],[13],[23] 50,017 [6],[8],[9],[15],[25] A A A A 49,632 50,283 Investment, Identifier [Axis]: OEConnection LLC, Application Software, Second Lien Term Loan A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A Investment, basis spread, variable rate (as a percent) [8],[9] 7.00% A A 7.00% 7.00% A A Investment, interest rate (as a percent) [8],[9],[10] 12.49% A A 12.49% 12.49% A A Investment, principal [8],[9],[12] A \$ 9,323 A A A A A A Investment owned, at cost [8],[9] 9,210 A A A A A A Investments at fair value [8],[9] A \$ 9,183 A A A A A A Investment, Identifier [Axis]: OEConnection LLC, First Lien Term Loan | SLF JV I A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A A Investment, basis spread, variable rate (as a percent) 4.00% A A 4.00% 4.00% A A Investment, interest rate (as a percent) 9.43% A A 9.43% 9.43% A A Investment, principal A A \$ 10,987 A A A A A A Investment owned, at cost 10,827 A A A A A A Investments at fair value A \$ 10,971 A A A A A A Investment, Identifier [Axis]: OEConnection LLC, First Lien Term Loan | OCSI Glick JV LLC A A A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A A Investment, basis spread, variable rate (as a percent) 3.25% 4.00% 3.25% 4.00% 4.00% A A A A Investment, interest rate (as a percent) 8.59% 9.43% 8.59% 8.59% 9.43% 9.43% A A A A Investment, principal \$ 2,500 \$ 3,849 A A A A A A Investment owned, at cost 2,488 3,830 A A A A A A Investments at fair value \$ 2,482 \$ 3,843 A A A A A A Investment, Identifier [Axis]: OFSI Fund Ltd, Multi-Sector Holdings, CLO Notes A A A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A A Investment, basis spread, variable rate (as a percent) [4],[13] 7.48% A 7.48% 7.48% A A A A A A Investment, interest rate (as a percent) [4],[5],[13] 12.81% A 12.81% 12.81% A A A A A A Investment, principal [4],[11],[13] \$ 1,105 A A A A A A A A A A Investment owned, at cost [4],[13] 1,048 A A A A A A A A A A Investments at fair value [4],[13] \$ 1,072 A A A A A A A A A A Investment, Identifier [Axis]: OTG Management, LLC, Airport Services, Common Stock A A A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A A Investment owned, balance (in shares) | shares [1] 2,613,034 2,613,034 2,613,034 A A A A A A Investment owned, at cost [1] \$ 22,330 A A A A A A A A A A Investments at fair value [1] \$ 14,032 A A A A A A A A A A Investment, Identifier [Axis]: OTG Management, LLC, Airport Services, First Lien Term Loan A A A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A A Investment, basis spread, variable rate (as a percent) [1],[4] 9.50% A 9.50% 9.50% A A A A A A Investment, interest rate, paid in kind (as a percent) [1],[4] 14.82% A 14.82% 14.82% A A A A A A Investment, principal [1],[4],[11] \$ 11,629 A A A A A A A A A A Investment owned, at cost [1],[4] 10,102 A A A A A A A A A A Investments at fair value [1],[4] \$ 11,629 A A A A A A A A A A Investment, Identifier [Axis]: OTG Management, LLC, Airport Services, First Lien Term Loan 1 A A A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A A Investment, basis spread, variable rate (as a percent) [8],[9] 10.00% A 10.00% 10.00% A A A A A A Investment, interest rate, paid in kind (as a percent) [8],[9] 15.67% A 15.67% 15.67% A A A A A A Investment, principal [8],[9],[12] A \$ 25,712 A A A A A A A A A A Investment owned, at cost [8],[9] 25,615 A A A A A A A A A A Investments at fair value [8],[9] A \$ 25,069 A A A A A A A A A A Investment, Identifier [Axis]: OTG Management, LLC, Airport Services, First Lien Term Loan 2 A A A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A A Investment, basis spread, variable rate (as a percent) [6],[8],[9] 10.00% A 10.00% 10.00% A A A A A A Investment, principal [6],[8],[9],[12] A \$ 0 A A A A A A A A A A Investment owned, at cost [6],[8],[9] (11) A A A A A A A A A A Investments at fair value [6],[8],[9] A \$ (69) A A A A A A A A A A Investment, Identifier [Axis]: OTG Management, LLC, Airport Services, First Lien Term Loan 3 A A A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A A Investment, basis spread, variable rate (as a percent) [6],[8],[9] 10.00% A 10.00% 10.00% A A A A A A Investment, interest rate, paid in kind (as a percent) [6],[8],[9] 15.64% A 15.64% 15.64% A A A A A A Investment, principal [6],[8],[9],[12] A \$ 1,210 A A A A A A A A A A Investment owned, at cost [6],[8],[9] 1,193 A A A A A A A A A A Investments at fair value [6],[8],[9] A \$ 1,169 A A A A A A A A A A Investment, Identifier [Axis]: OZLM XXIII Ltd, Multi-Sector Holdings, CLO Notes A A A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A A Investment, basis spread, variable rate (as a percent) [4],[13] 12.88% A 12.88% 12.88% A A A A A A Investment, interest rate (as a percent) [4],[5],[13] 12.87% A 12.87% 12.87% A A A A A A Investment, principal [4],[11],[13] 1,000 A A A A A A A A A A Investment owned, at cost [4],[13] 967 A A A A A A A A A A Investments at fair value [4],[13] 990 A A A A A A A A A A Investment, Identifier [Axis]: Oranje Holdco, Inc., Systems Software, First Lien Revolver A A A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A A Investment, basis spread, variable rate (as a percent) 7.50% [1],[2],[4] 7.75% [6],[8],[9] 7.50% [1],[2],[4] 7.50% [1],[2],[4] 7.75% [6],[8],[9] 7.75% [6],[8],[9] A A A A A A Investment, principal \$ 0 [1],[2],[4],[11] \$ 0 [6],[8],[9],[12] A A A A A A A A A A Investment owned, at cost [6],[8],[9],[12] (42) [6],[8],[9] A A A A A A A A A A Investments at fair value \$ (5) [1],[2],[4] (36) [6],[8],[9] A A A A A A A A A A Investment, Identifier [Axis]: Oranje Holdco, Inc., Systems Software, First Lien Term Loan A A A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A A Investment, basis spread, variable rate (as a percent) [8],[9] 7.75% A A 7.75% 7.75% A A A A A A Investment, interest rate (as a percent) [8],[9],[10] 13.12% A 13.12% 13.12% A A A A A A Investment, principal [8],[9],[12] A \$ 15,231 A A A A A A A A A A Investment owned, at cost [8],[9] 14,892 A A A A A A A A A A Investments at fair value [8],[9] 14,945 A A A A A A A A A A Investment, Identifier [Axis]: Oranje Holdco, Inc., Systems Software, First Lien Term Loan 1 A A A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A A Investment, basis spread, variable rate (as a percent) [1],[4] 7.50% A 7.50% 7.50% A A A A A A Investment, interest rate (as a percent) [1],[4],[5] 12.83% A 12.83% 12.83% A A A A A A Investment, principal [1],[4],[11] \$ 15,231 A A A A A A A A A A Investment owned, at cost [1],[4] 14,940 A A A A A A A A A A Investments at fair value [1],[4] \$ 15,193 A A A A A A A A A A Investment, Identifier [Axis]: Oranje Holdco, Inc., Systems Software, First Lien Term Loan 2 A A A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A A Investment, interest rate (as a percent) [1],[4],[5] 12.59% A 12.59% 12.59% A A A A A A Investment, principal [1],[4],[11] \$ 4,047 A A A A A A A A A A Investment owned, at cost [1],[4] 3,969 A A A A A A A A A A Investments at fair value [1],[4] 3,966 A A A A A A A A A A Investment, Identifier [Axis]: Other cash accounts A A A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A A Investment owned, at cost 62,277 A A A A A A A A A A Investments at fair value A \$ 62,277 A A A A A A A A A A Investment, Identifier [Axis]: Other cash accounts, Specialty Chemicals, First Lien Term Loan A A A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A A Investment owned, at cost 69,950 A A A A A A A A A A Investments at fair value \$ 69,950 A A A A A A A A A A Investment, Identifier [Axis]: P & L Development, LLC, Pharmaceuticals, Fixed Rate Bond A A A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A A Investment, interest rate (as a percent) [8],[10] 7.75% A A 7.75% 7.75% A A A A A A Investment, principal [12] A \$ 4,519 A A A A A A A A A A Investment owned, at cost 4,550 A A A A A A A A A A Investments at fair value A \$ 3,305 A A A A A A A A A A Investment, Identifier [Axis]: PPW Aero Buyer, Inc., Aerospace & Defense, First Lien Revolver A A A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A A Investment, basis spread, variable rate (as a percent) 6.00% [1],[2],[4] 7.00% [6],[8],[9] 6.00% [1],[2],[4] 6.00% [1],[2],[4] 7.00% [6],[8],[9] 7.00% [6],[8],[9] A A A A A A Investment, interest rate (as a percent) [1],[2],[4],[5] 11.84% A 11.84% 11.84% A A A A A A Investment, principal 269 [1],[2],[4],[11] \$ 0 [6],[8],[9],[12] A A A A A A A A A A Investment owned, at cost 192 [1],[2],[4] (53) [6],[8],[9] A A A A A A A A A A Investments at fair value \$ 237 [1],[2],[4] (54) [6],[8],[9] A A A A A A A A A A Investment, Identifier [Axis]: PPW Aero Buyer, Inc., Aerospace & Defense, First Lien Term Loan A A A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A A Investment, basis spread, variable rate (as a percent) [8],[9] 7.00% A 7.00% 7.00% A A A A A A Investment, interest rate (as a percent) [8],[9],[10] 12.32% A 12.32% 12.32% A A A A A A Investment, principal [8],[9],[12] A \$ 10,895 A A A A A A A A A A Investment owned, at cost [8],[9] 10,505 A A A A A A A A A A Investments at fair value [8],[9] A \$ 10,495 A A A A A A A A A A Investment, Identifier [Axis]: PPW Aero Buyer, Inc., Aerospace & Defense, First Lien Term Loan 1 A A A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A

[illegible]

[illegible]

[illegible]

A A Investment, basis spread, variable rate (as a percent) [4],[13] 7.08% A 7.08% 7.08% A A Investment, interest rate (as a percent) [4],[5],[13] 12.40% 12.40% 12.40% A A Investment, principal [4],[11],[13] \$ 905 A A A A A A A A Investment owned, at cost [4],[13] 851 A A A A A A Investments at fair value [4],[13] \$ 860 A A A A A A Investment, Identifier [Axis]: Trinitas CLO XV DAC, Multi-Sector Holdings, CLO Notes A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A Investment, basis spread, variable rate (as a percent) 7.71% [4],[13] 7.71% [8],[15] 7.71% [4],[13] 7.71% [4],[13] 7.71% [8],[15] A A Investment, interest rate (as a percent) 13.04% [4],[5],[13] 13.06% [8],[10],[15] 13.04% [4],[5],[13] 13.04% [4],[5],[13] 13.06% [8],[10],[15] A A Investment, principal \$ 1,000 [4],[11],[13] \$ 1,000 [8],[12],[15] A A A A A A Investment owned, at cost 822 [4],[13] 816 [8],[15] A A A A A A Investments at fair value \$ 969 [4],[13] \$ 917 [8],[15] A A A A A A Investment, Identifier [Axis]: Truck-Lite Co, LLC, Construction Machinery & Heavy Transportation Equipment, First Lien Revolver A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A Investment, basis spread, variable rate (as a percent) [1],[2],[4] 5.75% 5.75% 5.75% A A A A Investment, interest rate (as a percent) [1],[2],[4],[5] 11.08% 11.08% 11.08% A A A A Investment, principal [1],[2],[4],[11] \$ 128 A A A A A A Investment owned, at cost [1],[2],[4] 42 A A A A A A Investments at fair value [1],[2],[4] \$ 46 A A A A A A Investment, Identifier [Axis]: Truck-Lite Co, LLC, Construction Machinery & Heavy Transportation Equipment, First Lien Term Loan 1 A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A Investment, basis spread, variable rate (as a percent) [1],[4] 5.75% 5.75% 5.75% A A A A Investment, interest rate (as a percent) [1],[4],[5] 11.07% 11.07% 11.07% A A A A Investment, principal [1],[4],[11] \$ 26,524 A A A A A A A A Investment owned, at cost [1],[4] 26,022 A A A A A A Investments at fair value [1],[4] \$ 26,051 A A A A A A Investment, Identifier [Axis]: Truck-Lite Co, LLC, Construction Machinery & Heavy Transportation Equipment, First Lien Term Loan 2 A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A Investment, basis spread, variable rate (as a percent) [1],[2],[4] 5.75% 5.75% 5.75% A A A A Investment, principal [1],[2],[4],[11] \$ 0 A A A A A A Investment owned, at cost [1],[2],[4] (54) A A A A A A Investments at fair value [1],[2],[4] (\$ 51) A A A A A A Investment, Identifier [Axis]: Uniti Group LP, Cable & Satellite, Fixed Rate Bond A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A Investment, interest rate (as a percent) [4],[5],[13] 6.50% A 6.50% 6.50% A A A A Investment, principal [11],[13] \$ 2,830 A A A A A A A A Investment owned, at cost [13] 2,573 A A A A A A Investments at fair value [13] \$ 1,808 A A A A A A A A Investment, Identifier [Axis]: Uniti Group LP, Other Specialized REITs, Fixed Rate Bond 1 A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A Investment, interest rate (as a percent) [8],[10],[15] A 6.50% A 6.50% 6.50% A A A A Investment, principal [12],[15] \$ 4,500 A A A A A A A A Investment owned, at cost [15] 4,115 A A A A A A Investments at fair value [15] \$ 2,953 A A A A A A A A Investment, Identifier [Axis]: Uniti Group LP, Other Specialized REITs, Fixed Rate Bond 2 A A A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A Investment, interest rate (as a percent) [8],[10],[15] A 4.75% A 4.75% 4.75% A A A A Investment, principal [12],[15] A \$ 300 A A A A A A A A Investment owned, at cost [15] A 264 A A A A A A A A Investments at fair value [15] A \$ 245 A A A A A A A A Investment, Identifier [Axis]: Veritas US Inc., First Lien Term Loan | SLF JV I A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A Investment, basis spread, variable rate (as a percent) A 5.00% A 5.00% 5.00% A A A A Investment, interest rate (as a percent) A 10.43% A 10.43% 10.43% A A A A Investment, principal A \$ 6,305 A A A A A A A A Investment owned, at cost A 6,257 A A A A A A A A Investments at fair value A \$ 5,500 A A A A A A A A Investment, Identifier [Axis]: Verona Pharma, Inc., Pharmaceuticals, First Lien Term Loan 1 A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A Investment, interest rate (as a percent) [4],[5] 11.00% A 11.00% 11.00% A A A A Investment, principal [1],[11],[13] \$ 2,512 A A A A A A A A Investment owned, at cost [1],[13] 2,463 A A A A A A A A Investments at fair value [1],[13] \$ 2,465 A A A A A A A A A A Investment, Identifier [Axis]: Verona Pharma, Inc., Pharmaceuticals, First Lien Term Loan 2 A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A A Investment, interest rate (as a percent) [4],[5] 11.00% A 11.00% 11.00% A A A A Investment, principal [1],[11],[13] \$ 3,198 A A A A A A A A Investment owned, at cost [1],[13] 3,134 A A A A A A A A Investments at fair value [1],[13] 3,138 A A A A A A A A A A Investment, Identifier [Axis]: Verona Pharma, Inc., Pharmaceuticals, First Lien Term Loan 3 A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A A Investment, principal [1],[2],[11],[13] 0 A A A A A A A A A A Investment owned, at cost [1],[2],[13] 0 A A A A A A A A A A Investments at fair value [1],[2],[13] 0 A A A A A A A A A A A A A A Investment, Identifier [Axis]: Verona Pharma, Inc., Pharmaceuticals, First Lien Term Loan 4 A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A A Investment, principal [1],[2],[11],[13] 0 A A A A A A A A A A Investment owned, at cost [1],[2],[13] 0 A A A A A A A A A A Investments at fair value [1],[2],[13] 0 A A A A A A A A A A A A A A Investment, Identifier [Axis]: Verona Pharma, Inc., Pharmaceuticals, First Lien Term Loan 5 A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A A Investment, principal [1],[11],[13], [14] 4,568 A A A A A A A A A A Investment owned, at cost [1],[13], [14] 4,568 A A A A A A A A A A Investments at fair value [1],[13], [14] 4,568 A A A A A A A A A A A A A A Investment, Identifier [Axis]: Verona Pharma, Inc., Pharmaceuticals, First Lien Term Loan 6 A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A A Investment, principal [1],[2],[11],[13], [14] 0 A A A A A A A A A A Investment owned, at cost [1],[2],[13], [14] 0 A A A A A A A A A A Investments at fair value [1],[2],[13], [14] 0 A A A A A A A A A A A A A A Investment, Identifier [Axis]: Virgin Pulse, Inc., Application Software, Second Lien Term Loan A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A A Investment, basis spread, variable rate (as a percent) [8],[9] A 7.25% A 7.25% 7.25% A A A A Investment, interest rate (as a percent) [8],[9],[10] A 12.68% A 12.68% 12.68% A A A A Investment, principal [8],[9],[12] A \$ 1,140 A A A A A A A A Investment owned, at cost [8],[9] A 927 A A A A A A A A A A Investments at fair value [8],[9] A \$ 1,139 A A A A A A A A A A Investment, Identifier [Axis]: WP CPP Holdings, LLC, Aerospace & Defense, First Lien Revolver A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A A Investment, basis spread, variable rate (as a percent) [1],[2],[4] 6.75% 6.75% 6.75% A A A A A A A A Investment, principal [1],[2],[4],[11] \$ 0 A A A A A A A A A A Investment owned, at cost [1],[2],[4] (74) A A A A A A A A A A Investments at fair value [1],[2],[4] (\$ 20) A A A A A A A A A A Investment, Identifier [Axis]: WP CPP Holdings, LLC, Aerospace & Defense, First Lien Term Loan A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A A Investment, basis spread, variable rate (as a percent) 7.50% [1],[4] 3.75% [8] 7.50% [1],[4] 7.50% [1],[4] 3.75% [8] 3.75% [8] A A A A A A A A Investment, interest rate (as a percent) 8.72% [1],[4],[5] 9.27% [8],[10] 8.72% [1],[4],[5] 9.27% [8],[10] 8.72% [1],[4],[5] 8.72% [1],[4],[5] 9.27% [8],[10] 9.27% [8],[10] A A A A A A A A Investment, interest rate, paid in kind (as a percent) [1],[4] 4.13% A 4.13% 4.13% A A A A A A A A Investment, principal \$ 30,324 [1],[4],[11] \$ 11,792 [8],[12] A A A A A A A A A A Investment owned, at cost 29,654 [1],[4] 11,281 [8] A A A A A A A A A A Investments at fair value \$ 30,142 [1],[4] \$ 11,127 [8] A A A A A A A A A A Investment, Identifier [Axis]: WP CPP Holdings, LLC, First Lien Term Loan | SLF JV I A A A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A A Investment, basis spread, variable rate (as a percent) A 3.75% A 3.75% 3.75% A A A A A A A A Investment, interest rate (as a percent) A 9.27% A 9.27% 9.27% A A A A A A A A Investment, principal A \$ 1,965 A A A A A A A A A A Investment owned, at cost A 1,920 A A A A A A A A A A Investments at fair value A \$ 1,855 A A A A A A A A A A Investment, Identifier [Axis]: WP CPP Holdings, LLC, First Lien Term Loan | OCSI Glick JV LLC A A A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A A Investment, basis spread, variable rate (as a percent) A 3.75% A 3.75% 3.75% A A A A A A A A A A Investment, interest rate (as a percent) A 9.27% A 9.27% 9.27% A A A A A A A A A A Investment, principal A \$ 983 A A A A A A A A A A Investment owned, at cost A 960 A A A A A A A A A A Investments at fair value A \$ 927 A A A A A A A A A A A A A A Investment, Identifier [Axis]: WWEX Uni Topco Holdings, LLC, Air Freight & Logistics, Second Lien Term Loan A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A A Investment, basis spread, variable rate (as a percent) [8],[9] A 7.00% A 7.00% 7.00% A A A A A A A A Investment, interest rate (as a percent) [8],[9],[10] A 12.65% A 12.65% 12.65% A A A A A A A A Investment, principal [8],[9],[12] A \$ 5,000 A A A A A A A A A A Investment owned, at cost [8],[9] A 4,925 A A A A A A A A A A Investments at fair value [8],[9] A \$ 4,263 A A A A A A A A A A A A A A Investment, Identifier [Axis]: Win Brands Group LLC, Housewares & Specialties, First Lien Term Loan A A A A A A A A Investment Company, Nonconsolidated Subsidiary [Line Items] A A A A A A A A A A Investment, basis spread, variable rate (

[illegible]

Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480167/946-830-55-12Reference 11:

[illegible]

[illegible]

[illegible]

Name: us-gaap_InvestmentIdentifierAxis=Sorrento Therapeutics, Inc., Biotechnology, Common Stock Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Southern Veterinary Partners, LLC, First Lien Term Loan Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Southern Veterinary Partners, LLC, First Lien Term Loan 1 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Spanx, LLC, Apparel Retail, First Lien Revolver Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Spanx, LLC, Apparel Retail, First Lien Term Loan Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Spanx, LLC, First Lien Term Loan Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Staples, Inc., First Lien Term Loan Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Staples, Inc., Office Services & Supplies, First Lien Term Loan Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Staples, Inc., Office Services & Supplies, Fixed Rate Bond Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Star Parent, Inc., First Lien Term Loan Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=SumUp Holdings Luxembourg S.À.F.R.L., Diversified Financial Services, First Lien Term Loan Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Superior Industries International, Inc., Auto Parts & Equipment, First Lien Term Loan Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=SupplyOne Inc, First Lien Term Loan Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=SupplyOne Inc, First Lien Term Loan Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Supreme Fitness Group NY Holdings, LLC, Leisure Facilities, First Lien Revolver Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Supreme Fitness Group NY Holdings, LLC, Leisure Facilities, First Lien Term Loan Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Supreme Fitness Group NY Holdings, LLC, Leisure Facilities, First Lien Term Loan 1 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Supreme Fitness Group NY Holdings, LLC, Leisure Facilities, First Lien Term Loan 2 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Supreme Fitness Group NY Holdings, LLC, Leisure Facilities, First Lien Term Loan 3 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Swissport Stratosphere USA LLC, First Lien Term Loan Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Swissport Stratosphere USA LLC, First Lien Term Loan Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=TGNR HoldCo LLC, Integrated Oil & Gas, Subordinated Debt Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=THL Zinc Ventures Ltd, Diversified Metals & Mining, First Lien Term Loan Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=TIBCO Software Inc., First Lien Term Loan Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Tacala LLC, First Lien Term Loan Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Tacala, LLC, Restaurants, Second Lien Term Loan Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Tahoe Bidco B.V., Application Software, First Lien Revolver Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Tahoe Bidco B.V., Application Software, First Lien Term Loan Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Telephone and Date Systems, Inc., Wireless Telecommunication Services, First Lien Term Loan 1 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Telephone and Date Systems, Inc., Wireless Telecommunication Services, First Lien Term Loan 2 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Telestream Holdings Corporation, Application Software, First Lien Revolver Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Telestream Holdings Corporation, Application Software, First Lien Term Loan Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Ten-X LLC, Interactive Media & Services, First Lien Term Loan Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=The Avery, Real Estate Operating Companies, First Lien Term Loan Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=The Avery, Real Estate Operating Companies, First Lien Term Loan 1 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=The Avery, Real Estate Operating Companies, First Lien Term Loan 2 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=The Avery, Real Estate Operating Companies, Membership Interest Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=The Avery, Real Estate Operating Companies, Subordinated Debt Term Loan Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Thrasio, LLC, Broadline Retail, Common Stock Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Thrasio, LLC, Broadline Retail, First Lien Term Loan Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Thrasio, LLC, Broadline Retail, First Lien Term Loan 1 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Thrasio, LLC, Broadline Retail, First Lien Term Loan 2 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Thrasio, LLC, Broadline Retail, Preferred Equity 1 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Thrasio, LLC, Broadline Retail, Preferred Equity 2 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Thrasio, LLC, Broadline Retail, Preferred Equity 3 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Thrasio, LLC, Broadline Retail, Preferred Equity 4 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Total Portfolio Investments, First Lien Term Loan Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Touchstone Acquisition, Inc., First Lien Term Loan Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Touchstone Acquisition, Inc., Health Care Supplies, First Lien Term Loan Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Trident TPI Holdings, Inc., First Lien Term Loan Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Trinitas CLO VI Ltd., Multi-Sector Holdings, CLO Notes Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Trinitas CLO XV DAC, Multi-Sector Holdings, CLO Notes Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Truck-Lite Co, LLC, Construction Machinery & Heavy Transportation Equipment, First Lien Revolver Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Truck-Lite Co, LLC, Construction Machinery & Heavy Transportation Equipment, First Lien Term Loan 1 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Truck-Lite Co, LLC, Construction Machinery & Heavy Transportation Equipment, First Lien Term Loan 2 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Uniti Group LP, Cable & Satellite, Fixed Rate Bond Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Uniti Group LP, Other Specialized REITs, Fixed Rate Bond 1 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Uniti Group LP, Other Specialized REITs, Fixed Rate Bond 2 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Veritas US Inc., First Lien Term Loan Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Verona Pharma, Inc., Pharmaceuticals, First Lien Term Loan 1 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Verona Pharma, Inc., Pharmaceuticals, First Lien Term Loan 2 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Verona Pharma, Inc., Pharmaceuticals, First Lien Term Loan 3 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Verona Pharma, Inc., Pharmaceuticals, First Lien Term Loan 4 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Verona Pharma, Inc., Pharmaceuticals, First Lien Term Loan 5 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Verona Pharma, Inc., Pharmaceuticals, First Lien Term Loan 6 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Virgin Pulse, Inc., Application Software, Second Lien Term Loan Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=WP CPP Holdings, LLC, Aerospace & Defense, First Lien Revolver Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=WP CPP Holdings, LLC, Aerospace & Defense, First Lien Term Loan Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=WP CPP Holdings, LLC, First Lien Term Loan Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=WWEX Uni Topco Holdings, LLC, Air Freight & Logistics, Second Lien Term Loan Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Win Brands Group LLC, Housewares & Specialties, First Lien Term Loan Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Win Brands Group LLC, Housewares & Specialties, First Lien Term Loan 1 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Win Brands Group LLC, Housewares & Specialties, First Lien Term Loan 2 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Win Brands Group LLC, Housewares & Specialties, Warrants Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Windstream Services II, LLC, First Lien Term Loan Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Windstream Services II, LLC, Integrated Telecommunication Services, Common Stock Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Windstream Services II, LLC, Integrated Telecommunication Services, First Lien Term Loan Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Zephyr Bidco Limited, Specialized Finance, Second Lien Term Loan Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=athenahealth Group Inc., First Lien Term Loan Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=athenahealth Group Inc., Health Care Technology, Fixed Rate Bond Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=athenahealth Group Inc., Health Care Technology, Preferred Equity Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=iCIMS, Inc., Application Software, First Lien Revolver Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=iCIMS, Inc., Application Software, First Lien Term Loan 1 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=iCIMS, Inc., Application Software, First Lien Term Loan 2 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=iCIMS, Inc., Application Software, First Lien Term Loan 3 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=scPharmaceuticals Inc., Pharmaceuticals, First Lien Term Loan 1 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=scPharmaceuticals Inc., Pharmaceuticals, First Lien Term Loan 2 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=scPharmaceuticals Inc., Pharmaceuticals, First Lien Term Loan 3 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=scPharmaceuticals Inc., Pharmaceuticals, Warrants Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=3.24.2 Portfolio Investments - Summarized Balance Sheet Information (Details) - USD (\$) in Thousands 3 Months Ended 9 Months Ended 12 Months Ended Dec 31, 2023 Jun 30, 2024 Sep 30, 2023 Investment Company, Nonconsolidated Subsidiary [Line Items] Å Å Å Investments at fair value Å \$ 3,121,703 \$ 2,892,420 Cash and cash equivalents Å 96,321 136,450 Restricted cash Å 10,993 9,089 Other assets Å 2,599 1,681 Total assets Å 3,322,181 3,217,839 Senior credit facility payable Å 790,000 710,000 Secured borrowings Å 6,576 18,106 Other liabilities Å 4,803 4,310 Total liabilities Å 1,826,048 1,702,075 Total liabilities and net assets Å 3,322,181 3,217,839 Investment owned, at cost Å 3,292,932 3,044,119 SLF JV I Å Å Å Investment Company, Nonconsolidated Subsidiary [Line Items] Å Å Å Investments at fair value Å 344,930 322,179 Cash and cash equivalents Å 24,006 31,950 Restricted cash Å 6,994 2,987 Other assets Å 14,840 18,988 Total assets Å 390,770 376,104 Senior credit facility payable Å 198,000 149,000 Secured borrowings Å 13,292 38,845 Notes payable at fair value Å 128,750 128,750 Other liabilities Å 21,222 26,630 Total liabilities Å 361,264 343,225 Members' equity Å 29,506 32,879 Total liabilities and net assets Å 390,770 376,104 Investment owned, at cost Å 353,263 331,808 Net proceeds Å 128,750 128,750 Å OCSI Glick JV LLC Å Å Å Investment Company, Nonconsolidated Subsidiary [Line Items] Å Å Å Investments at fair value Å 132,405 123,343 Cash and cash equivalents Å 13,109 12,119 Restricted cash Å 0 184 Other assets Å 4,655 5,521 Total assets Å 150,169 141,167 Senior credit facility payable Å 78,000 53,000 Notes payable at fair value Å 57,012 57,201 Other liabilities Å 8,581 12,860 Total liabilities Å 150,169 141,167 Members' equity Å 0 0 Total liabilities and net assets Å 150,169 141,167 Investment owned, at cost Å 137,360 127,788 Net proceeds Å \$ 66,685 \$ 66,685 X - DefinitionSum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(bb\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25](http://www.xbrl.org/2003/role/disclosureRef-Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(g\)\(1\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28](http://www.xbrl.org/2003/role/disclosureRef-Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28)Reference 6: <http://www.xbrl.org/2003/role/exampleRef-Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 7: <http://www.xbrl.org/2003/role/exampleRef-Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480167/946-830-55-12>Reference 8: [http://www.xbrl.org/2003/role/disclosureRef-Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-03\(a\)\(12\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479440/944-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479440/944-210-S99-1)Reference 9: <http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22>Reference 10: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-04\(8\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479617/946-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479617/946-210-S99-1)Reference 11: [http://www.xbrl.org/2003/role/disclosureRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(18\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 12: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 13: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 14: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 15:

[http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 16: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 17: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 18: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 19: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 20: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 21: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 22: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 23: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7)Reference 24: [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30)Reference 25: [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 26: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-03\(11\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479853/942-210-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479853/942-210-S99-1) + Details Name: us-gaap Assets Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(1i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: [http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1](http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1)Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4> + Details Name: us-gaap CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(g\)\(1\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1) + Details Name: us-gaap InvestmentCompanyNonconsolidatedSubsidiaryLineItems Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionCost of the investment. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 55 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480493/946-210-55-1>Reference 2:

SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19-26) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap Liabilities Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479440/944-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479853/942-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap LiabilitiesAndStockholdersEquity Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479440/944-210-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479853/942-210-S99-1 + Details Name: us-gaap LineOfCredit Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of ownership interest in limited liability company (LLC), attributable to the parent entity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482987/272-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483014/272-10-45-4Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap MembersEquity Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionIncluding the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479440/944-210-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479853/942-210-S99-1 + Details Name: us-gaap NotesPayable Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480167/946-830-55-12Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479440/944-210-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479853/942-210-S99-1 + Details Name: us-gaap OtherAssets Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liabilities classified as other. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480167/946-830-55-12Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(12)(b)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479617/946-210-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(12)(b)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479617/946-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479440/944-210-S99-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(12)(b)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479617/946-210-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03.15) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479853/942-210-S99-1 + Details Name: us-gaap OtherLiabilities Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe net cash inflow or outflow in aggregate debt due to repayments and proceeds from additional borrowings. + ReferencesNo definition available. + Details Name: us-gaap ProceedsFromRepaymentsOfDebt Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479440/944-210-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(1)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479853/942-210-S99-1 + Details Name: us-gaap RestrictedCash Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCarrying value as of the balance sheet date, including the current and noncurrent portions, of collateralized debt obligations (with maturities initially due after one year or beyond the operating cycle, if longer). Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479440/944-210-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479853/942-210-S99-1 + Details Name: us-gaap SecuredDebt Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap InvestmentCompanyNonconsolidatedSubsidiaryAxis=ocsl SLFJVIMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap InvestmentCompanyNonconsolidatedSubsidiaryAxis=ocsl OCISlickJVLLCMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 60 R49.htm IDEA: XBRL DOCUMENT v3.24.2 Portfolio Investments - Summarized Statement of Operations Information (Details) - USD (\$) \$ in Thousands 3 Months Ended 9 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Investment Company, Nonconsolidated Subsidiary [Line Items] Á Á Á Total investment income \$ 94,966 \$ 101,900 \$ 286,980 \$ 277,381 Interest expense 32,513 30,793 96,564 79,316 Total expenses 55,101 54,987 164,559 148,129 Net investment income before taxes 44,575 48,413 130,131 133,277 Net increase (decrease) in net assets resulting from operations 1,120 36,685 20,992 71,379 SLF JV I Á Á Á Investment Company, Nonconsolidated Subsidiary [Line Items] Á Á Á Interest income 9,463 10,312 28,665 29,106 Other income/Fee income 0 0 159 62 Total investment income 9,463 10,312 28,824 29,168 Other expenses 46 73 246 249 Total expenses 8,165 8,122 24,352 22,764 Net investment income before taxes 1,298 2,190 4,472 6,404 Net unrealized appreciation (depreciation) (319) 2,652 1,299 4,075 Realized gain (loss) (3,784) (2,137) (4,343) (4,850) Net increase (decrease) in net assets resulting from operations (2,805) 2,705 1,428 5,629 SLF JV I | Senior Credit Facility Á Á Á Investment Company, Nonconsolidated Subsidiary [Line Items] Á Á Á Interest expense 4,071 4,190 11,910 12,004 SLF JV I | SLF JV I Notes Á Á Á Investment Company, Nonconsolidated Subsidiary [Line Items] Á Á Á Interest expense 4,048 3,859 12,196 10,511 OCISlickJV LLC Á Á Á Investment Company, Nonconsolidated Subsidiary [Line Items] Á Á Á Interest income 3,605 3,576 10,926 10,488 Other income/Fee income 4 0 64 35 Total investment income 3,609 3,576 10,990 10,523 Other expenses 32 70 110 148 Total expenses 3,338 3,047 9,766 8,544 Net investment income before taxes 721 529 1,224 1,979 Net unrealized appreciation (depreciation) 328 431 (321) (159) Realized gain (loss) (599) (960) (903) (1,820) Net increase (decrease) in net assets resulting from operations 0 0 0 OCISlickJV LLC | Senior Credit Facility Á Á Á Investment Company, Nonconsolidated Subsidiary [Line Items] Á Á Á Interest expense 1,631 1,400 4,608 4,002 OCISlickJV LLC | Glick JV Notes Á Á Á Investment Company, Nonconsolidated Subsidiary [Line Items] Á Á Á Interest expense \$ 1,675 \$ 1,577 \$ 5,048 \$ 4,394 X - DefinitionAmount of realized gain (loss) on investment in debt and equity securities. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column C)(Footnote 4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column C)(Footnote 4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-6Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column C)(Footnote 4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-6Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(9)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(7)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483575/946-220-S99-1 + Details Name: us-gaap DebtAndEquitySecuritiesRealizedGainLoss Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of unrealized gain (loss) on investment in debt and equity securities. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column D)(Footnote 4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column D)(Footnote 4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-6Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column D)(Footnote 4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-6Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(9)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(7)(c)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483575/946-220-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(7)(c)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483575/946-220-S99-1 + Details Name: us-gaap DebtAndEquitySecuritiesUnrealizedGainLoss Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, before investment expense, of income earned from investments in securities and real estate. Includes, but is not limited to, real estate investment, policy loans, dividends, and interest. Excludes realized gain (loss) on investments. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480167/946-830-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(2)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483586/944-220-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(1)) -Publisher

US-GAAP - [asc.fasb.org/1943274/2147483575/946-220-S99-1](#) + Details Name: us-gaap GrossInvestmentIncomeNamespacePrefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of the cost of borrowed funds accounted for as interest expense. + ReferencesReference 1: [http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480167/946-830-55-10Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483581/946-220-45-39Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-07\(3\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483575/946-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-39Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-04.9\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483589/942-220-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(210.5-03\(11\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483013/835-20-50-1 + Details Name: us-gaap InterestExpense Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of operating interest income, including, but not limited to, amortization and accretion of premiums and discounts on securities. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph \(SX 210.12-14\(Column E\)\(1\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph \(SX 210.12-14\(Column E\)\(Footnote 4\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-6Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480167/946-830-55-10Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 45 -Paragraph 39 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480228/946-830-45-39Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-07\(1\)\(b\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483575/946-220-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph \(SX 210.12-14\(Column E\)\(Footnote 6\)\(a\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-6Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03.1\(e\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap InterestIncomeOperating Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(g\)\(1\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap InvestmentCompanyNonconsolidatedSubsidiaryLineItems Namespace Prefix: us-gaap Data Type: xbrli:stringItemBalance Type: na Period Type: duration X - DefinitionAmount of expenses related to the generation of investment income. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480167/946-830-55-10Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-04\(2\)\(c\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483586/944-220-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03.9\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap InvestmentIncomeInvestmentExpense Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(g\)\(1\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03.9\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(b\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480167/946-830-55-10Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483581/946-220-45-7Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-04\(18\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483586/944-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-07\(9\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/214748](#)

Name: us-gaap_RevenueFromContractWithCustomerAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNo definition available. + Details Name: us-gaap_RevenueFromContractWithCustomerAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 62 R51.htm IDEA: XBRL DOCUMENT v3.24.2 Share Data and Net Assets - Narrative (Details) \$ in Millions 9 Months Ended Feb. 08, 2023 USD (\$) Jan. 20, 2023 Feb. 07, 2022 USD (\$) Jun. 30, 2024 shares Jun. 30, 2023 shares Jun. 30, 2024 USD (\$) shares Jun. 30, 2023 shares Investment Company, Changes in Net Assets [Line Items] A A A A Stock split, conversion ratio A 0.3333 A A A A Issuance of common stock under dividend reinvestment plan (in shares) A A A A 295,484,000 220,570,000 Aggregate offering price | \$ 125.0 A A A A At the Market A A A A A A Investment Company, Changes in Net Assets [Line Items] A A A A Dividend reinvestment plan, percent of current market price (as a percent) A A A 95.00% A 95.00% A Number of shares issued (in shares) A A A A 4,724,506 A Net proceeds | \$ A A A A \$ 92.5 A Common Stock A A A A A A Investment Company, Changes in Net Assets [Line Items] A A A A A A Issuance of common stock under dividend reinvestment plan (in shares) A A A 100,029 0 295,484 94,879 X - DefinitionDividend Reinvestment Plan, Percent of Current Market Price + ReferencesNo definition available. + Details Name: ocsl_DividendReinvestmentPlanPercentOfCurrentMarketPrice Namespace Prefix: ocsl Data Type: dtr-types:percentItem Type Balance Type: na Period Type: instant X - DefinitionSale of Stock, Consideration Received on Transaction, Excluding Offering Costs + ReferencesNo definition available. + Details Name: ocsl_SaleOfStockConsiderationReceivedOnTransactionExcludingOfferingCosts Namespace Prefix: ocsl Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionSale Of Stock, Maximum Aggregate Offering Amount + ReferencesNo definition available. + Details Name: ocsl_SaleOfStockMaximumAggregateOfferingAmount Namespace Prefix: ocsl Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/214748055/946-210-45>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481004/946-505-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481004/946-505-50-2)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/214748067/946-205-45-4](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/214748067/946-205-45-4)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481004/946-505-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481004/946-505-50-2)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481004/946-505-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481004/946-505-50-2)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481004/946-505-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481004/946-505-50-2)Reference 7: <http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481004/946-505-50-1> + Details Name: us-gaap_InvestmentCompanyChangesInNetAssetsLineItems Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe number of shares issued or sold by the subsidiary or equity method investee per stock transaction. + ReferencesNo definition available. + Details Name: us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction Namespace Prefix: us-gaap Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares issued during the period from a dividend reinvestment plan (DRIP). A dividend reinvestment plan allows the shareholders to reinvest dividends paid to them by the entity on new issues of stock by the entity. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481004/946-505-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481004/946-505-50-2)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-09\)\(4\)\(b\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483575/946-220-S99-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09)(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483575/946-220-S99-3) + Details Name: us-gaap_StockIssuedDuringPeriodSharesDividendReinvestmentPlan Namespace Prefix: us-gaap Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionRatio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 4 -Subparagraph \(SAB TOPIC 4.C\) -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 4 -Subparagraph (SAB TOPIC 4.C) -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4) + Details Name: us-gaap_StockholdersEquityNoteStockSplitConversionRatio Namespace Prefix: us-gaap Data Type: xbrli:pureItem Type Balance Type: na Period Type: duration X - Details Name: us-gaap_SubsidarySaleOfStockAxis=ocsl At TheMarketMember Namespace Prefix: xbrl By the balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember Namespace Prefix: Data Type: XML 63 R52.htm IDEA: XBRL DOCUMENT v3.24.2 Share Data and Net Assets - Schedule of Basic and Diluted Earnings Per Share (Details) - USD (\$) / shares in Units, shares in Thousands, \$ in Thousands 3 Months Ended 9 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2023 Earnings (loss) per common share â€¢ basic and diluted: A A A Net increase (decrease) in net assets resulting from operations \$ 1,120 \$ 36,685 \$ 20,992 \$ 71,379 Weighted average common shares outstanding - basic (in shares) [1] 81,830 77,080 79,804 70,431 Weighted average common shares outstanding - diluted (in shares) [1] 81,830 77,080 79,804 70,431 Earnings (loss) per common share - basic (in dollars per share) [1] \$ 0.01 \$ 0.48 \$ 0.26 \$ 1.01 Earnings (loss) per common share - diluted (in dollars per share) [1] \$ 0.01 \$ 0.48 \$ 0.26 \$ 1.01 [1] As discussed in Note 2, the Company completed a 1-for-3 reverse stock split on January 20, 2023, effective as of the commencement of trading on January 23, 2023. The weighted average common shares outstanding and per share information reflect the reverse stock split on a retroactive basis as necessary. X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15>Reference 3:

[http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22): [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23): [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24): [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25): [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26): [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27): [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28): [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29): [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 30](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 30): [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 31](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 31): [http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 32](http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 32): <http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31Reference 33>: [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 34](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 34): <http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 35>: <http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 36>: [http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 37](http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 37): [http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 38](http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 38): [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(20\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 39](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 39):

SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: <https://asc.fasb.org/1943274/2147480008/505-10-50-1Reference 3>: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(SX 210.3-04\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-50-1Reference 3](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-50-1Reference 3): [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (SX 210.5-02.29-31) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap StockIssuedDuringPeriodValueAcquisitions Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionValue of stock issued during the period from a dividend reinvestment plan (DRIP). A dividend reinvestment plan allows the holder of the stock to reinvest dividends paid to them by the entity on new issues of stock by the entity. + ReferencesReference 1: <a href=): <http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480167/946-830-55-1Reference 3>: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480767/946-205-45-4Reference 4](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480767/946-205-45-4Reference 4): <http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 230 -Name Accounting Standards Codification -Section 55 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480348/946-230-55-1Reference 5>: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481004/946-505-50-2Reference 6](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481004/946-505-50-2Reference 6): [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6): [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6): [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6): [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6): [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(e\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6): [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6): [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(g\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6): [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(h\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6): [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6): [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(j\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (j) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6): [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(k\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (k) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6): [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(l\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (l) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6):

issues of stock by the entity. + ReferencesReference 1:

[https://asc.fasb.org/1943274/2147483012/833-20-50-1 + Details Name: us-gaap_InterestAndDebtExpense Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Definition](#)Amount of fees and commissions from banking, advisory brokerage, and securities underwriting activities. Activities include, but are not limited to, underwriting securities, private placements of securities, investment advisory and management services, merger and acquisition services, sale and servicing of mutual funds, and other related consulting fees. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 - Subparagraph \(SX 210.9-04.13\(b\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483589/942-220-S99-1 + Details Name: us-](#)

[gaap_InvestmentBankingAdvisoryBrokerageAndUnderwritingFeesAndCommissions Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Definition](#)The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(22\)\) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification - Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-03\(a\)\(16\)\(a\)\(2\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479440/944-210-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-03\(16\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479853/942-210-S99-1 + Details Name: us-gaap_LineOfCredit Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Definition](#)Fair value of the amount outstanding under the credit facility. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10 + Details Name: us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Definition](#)The effective interest rate during the reporting period. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 - Paragraph 1 -Subparagraph \(SX 210.5-02.19\(b\),22\(b\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LineOfCreditFacilityInterestRateDuringPeriod Namespace Prefix: us-gaap Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - Definition](#)Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(f\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_LineOfCreditFacilityLineItems Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition](#)Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification - Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02.19\(b\),22\(b\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Definition](#)The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility. + ReferencesNo definition available. + Details Name: us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage Namespace Prefix: us-gaap Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission. + ReferencesNo definition available. + Details Name: us-gaap_LongTermDebtFairValue Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromDebtNetOfferIssuanceCosts Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_VariableRateAxis=ocsl_SecuredOvernightFinancingRateMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_VariableRateAxis=us-gaap_BaseRateMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_VariableRateAxis=ocsl_LondonInterbankOfferedRateLIBOR Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSoftOvernightIndexSwapRateMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=ocsl_A2025NotesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=ocsl_A2029NotesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=ocsl_SyndicatedFacilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=ocsl_CitibankFacilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=ocsl_OSICitibankFacilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: ocsl_VariableRatePeriodAxis=ocsl_AfterReinvestmentPeriodMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 68 R57.htm IDEA: XBRL DOCUMENT v3.24.2 Borrowings - Components of the Carrying Value of Notes \(Details\) - USD \(\\$\) Jun. 30, 2024 Sep. 30, 2023 Apr. 15, 2023 May 18, 2021 Feb. 25, 2020 Debt Instrument \[Line Items\] Á Á Á Á Á Unamortized financing costs \\$ \(5,468,000\) \\$ \(7,076,000\) Á Á Net carrying value 1,697,164,000 1,600,731,000 Á Á 2025 Notes Á Á Á Á Debt Instrument \[Line Items\] Á Á Á Á Á Principal 300,000,000.0 300,000,000.0 Á Á \\$ 300,000,000 Unamortized financing costs \(500,000\) \(1,100,000\) Á Á Unaccreted discount \(300,000\) \(700,000\) Á Á \\$ \(2,500,000\) Interest rate swap fair value adjustment 0 0 Á Á Net carrying value 299,200,000 298,200,000 Á Á Fair Value 294,900,000 286,400,000 Á Á 2027 Notes Á Á Á Á Debt Instrument \[Line Items\] Á Á Á Á Á Principal 350,000,000.0 350,000,000.0 Á Á \\$ 350,000,000 Unamortized financing costs \(1,900,000\) \(2,500,000\) Á Á Unaccreted discount \(500,000\) \(600,000\) Á Á \\$ \(1,000,000\) Á Interest rate swap fair value adjustment \(30,700,000\) \(40,500,000\) Á Á Net carrying value 316,900,000 306,400,000 Á Á Fair Value 317,700,000 301,800,000 Á Á 2029 Notes Á Á Á Á Debt Instrument \[Line Items\] Á Á Á Á Principal 300,000,000.0 300,000,000.0 \\$ 300,000,000 Á Á Unamortized financing costs \(3,000,000.0\) \(3,500,000.0\) Á Á Unaccreted discount \(2,900,000\) \(3,400,000\) \\$ \(3,500,000\) Á Á Interest rate swap fair value adjustment \(3,000,000.0\) \(7,000,000.0\) Á Á Net carrying value 291,100,000 286,100,000 Á Á Fair Value 303,600,000 \\$ 290,000,000 Á Á X - Definition](#)Face (par) amount of debt instrument at time of issuance. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 3: \[http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph \\(c\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10 +\]\(#\)](#)

us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(2)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479440/944-210-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479853/942-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4 + Details Name: us-gaap LongTermDebt Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset. + ReferencesNo definition available. + Details Name: us-gaap UnamortizedDebtIssuanceExpense Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap DebtInstrumentAxis=ocsl A2025NotesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap DebtInstrumentAxis=ocsl A2029NotesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 69 R58.htm IDEA: XBRL DOCUMENT v3.24.2 Borrowings - Components of Interest and Other Debt Expenses (Details) - USD (\$) in Millions 3 Months Ended 9 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2023 Jun. 30, 2023 Notes Á Á Á Debt Instrument [Line Items] Á Á Á Coupon interest \$ 2.6 \$ 2.6 \$ 7.9 7.9 Amortization of financing costs and discount 0.3 0.3 0.9 0.9 Effect of interest rate swap 0.0 0.0 0.0 0.0 Total interest expense \$ 2.9 \$ 2.9 \$ 8.8 \$ 8.8 Coupon interest rate (net of effect of interest rate swaps) (as a percent) 3.50% 3.50% 3.50% 3.50% 2027 Notes Á Á Á Debt Instrument [Line Items] Á Á Á Coupon interest \$ 2.4 \$ 2.4 \$ 7.1 7.1 Amortization of financing costs and discount 0.2 0.2 0.7 0.7 Effect of interest rate swap 4.0 3.7 12.3 9.4 Total interest expense \$ 6.6 \$ 6.3 \$ 20.1 \$ 17.2 Coupon interest rate (net of effect of interest rate swaps) (as a percent) 7.21% 6.91% 7.26% 6.27% 2029 Notes Á Á Á Debt Instrument [Line Items] Á Á Á Coupon interest \$ 5.3 Á \$ 16.0 Á Amortization of financing costs and discount 0.3 Á 1.0 Á Effect of interest rate swap 1.1 Á 3.4 Á Total interest expense \$ 6.7 Á \$ 20.4 Á Coupon interest rate (net of effect of interest rate swaps) (as a percent) 8.44% Á 8.46% Á X - DefinitionInterest Expense, Effect Of Interest Rate Swap + ReferencesNo definition available. + Details Name: ocsl InterestExpenseEffectOfInterestRateSwap Namespace Prefix: ocsl Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of amortization expense attributable to debt discount (premium) and debt issuance costs. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3 + Details Name: us-gaap AmortizationOffinancingCostsAndDiscounts Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe average effective interest rate during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 835 -SubTopic 30 -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap DebtInstrumentInterestRateDuringPeriod Namespace Prefix: us-gaap Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-

0-SubTopic 10-Name Accounting Standards Codification -Section S99-Paragraph 1-Subparagraph (SAB TOPIC 6.1.1)-Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-599-1Reference 5:

<https://asc.fasb.org/1943274/2147480016/944-40-65-2>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11>Reference 5: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-03\(a\)\(23\)\(a\)\(4\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479440/944-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479440/944-210-S99-1)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-04\(17\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479617/946-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479617/946-210-S99-1)Reference 7: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.3-04\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1)Reference 8: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(30\)\(a\)\(3\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1) + Details Name: us-gaap RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant XML 73 R62.tml IDEA: XBRL DOCUMENT 33.2.4 Realized Gains or Losses and Net Unrealized Appreciation or Depreciation - Aggregate Net Realized Gains (Details) - USD (\$) in Thousands 3 Months Ended 9 Months Ended Jun 30, 2024 Mar. 31, 2024 Dec. 31, 2023 Jun. 30, 2023 Mar. 31, 2023 Dec. 31, 2022 Jun. 30, 2022 Jun. 30, 2023 Tersera Therapeutics LLC Á Á Á Á Á Á Á Á Net realized gains (losses) \$ (69,452) \$ (6,603) \$ (8,453) \$ (10,603) \$ (6,111) \$ (3,203) \$ (84,500) \$ (19,900) Thrasio, LLC Á Á Á Á Á Á Á Á Tersera Therapeutics LLC Á Á Á Á Á Á Á Á Net realized gains (losses) (68,500) Á Á Á Á (68,500) Á Á Á Á Other, net Á Á Á Á Á Á Á Á Tersera Therapeutics LLC Á Á Á Á Á Á Á Á Net realized gains (losses) \$ (1,000) Á Á 800 Á Á (1,000) (3,000) Foreign currency forward contracts Á Á Á Á Á Tersera Therapeutics LLC Á Á Á Á Á Á Á Á Net realized gains (losses) Á Á Á (6,300) Á Á 2,600 (5,500) Aden & Anais Merger Sub Inc. Á Á Á Á Á Á Á Á Tersera Therapeutics LLC Á Á Á Á Á Á Á Á Net realized gains (losses) Á Á Á (5,200) Á Á Á (5,200) Radiology Partners Inc. Á Á Á Á Á Á Á Á Tersera Therapeutics LLC Á Á Á Á Á Á Á Á Net realized gains (losses) Á Á Á (3,800) Á Á Á (4,200) WP CPP Holdings LLC Á Á Á Á Á Á Á Á Tersera Therapeutics LLC Á Á Á Á Á Á Á Á Net realized gains (losses) Á Á Á (1,300) Á Á Á (1,300) Tersera Therapeutics LLC Á Á Á Á Á Á Á Á Tersera Therapeutics LLC Á Á Á Á Á Á Á Á Net realized gains (losses) Á Á Á 5,200 Á Á Á 5,200 All Web Leads Inc Á Á Á Á Á Á Á Á Tersera Therapeutics LLC Á Á Á Á Á Á Á Á Net realized gains (losses) Á Á Á (13,400) Á Á Á Continental Intermodal Group LP Á Á Á Á Á Á Á Á Tersera Therapeutics LLC Á Á Á Á Á Á Á Á Net realized gains (losses) Á Á Á Á (6,800) Á Á Á P&L Development LLC Á Á Á Á Á Á Á Á Tersera Therapeutics LLC Á Á Á Á Á Á Á Á Net realized gains (losses) Á Á Á Á (1,900) Á Á Á American Tire Distributors Inc. Á Á Á Á Á Á Á Á Tersera Therapeutics LLC Á Á Á Á Á Á Á Á Net realized gains (losses) Á Á Á Á (1,700) Á Á Á Lift Brands Holdings, Inc. Á Á Á Á Á Á Á Á Tersera Therapeutics LLC Á Á Á Á Á Á Á Á Net realized gains (losses) Á Á Á Á (1,400) Á Á Á Alvotech Á Á Á Á Á Á Á Á Tersera Therapeutics LLC Á Á Á Á Á Á Á Á Net realized gains (losses) Á Á Á Á 4,800 Á Á Á Ardonagh Midco 3 PLC Á Á Á Á Á Á Á Á Tersera Therapeutics LLC Á Á Á Á Á Á Á Á Net realized gains (losses) Á Á Á Á 4,600 Á Á Á Carvana Co. Á Á Á Á Á Á Á Á Tersera Therapeutics LLC Á Á Á Á Á Á Á Á Net realized gains (losses) Á Á Á Á (2,800) Á Á Á ASP Unifrax Holdings Inc. Á Á Á Á Á Á Á Á Tersera Therapeutics LLC Á Á Á Á Á Á Á Á Net realized gains (losses) Á Á Á Á (2,100) Global Medical Response Inc. Á Á Á Á Á Á Á Á Tersera Therapeutics LLC Á Á Á Á Á Á Á Á Net realized gains (losses) Á Á Á Á \$ (1,000) X - DefinitionAmount, before tax, of realized gain (loss) on investment in debt and equity securities and foreign currency transaction on investment in debt and equity securities from change in market price, classified as operating. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-07\(7\)\(a\)\(1\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483575/946-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(7)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483575/946-220-S99-1)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-07\(7\)\(a\)\(2\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483575/946-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(7)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483575/946-220-S99-1) + Details Name: us-gaap DebtAndEquitySecuritiesAndForeignCurrencyTransactionPriceChangeRealizedGainLossOperatingBeforeTax Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph \(SX 210.12-14\(Column A\)\(Footnote 1\)\(b\)\(1\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-6](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-6)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.12-12\(Column A\)\(Footnote 2\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column A)(Footnote 2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-1)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph \(SX 210.12-14\(Column A\)\(Footnote 2\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-6](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column A)(Footnote 2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-6)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.12-12B\(Column A\)\(Footnote 4\)\(b\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column A)(Footnote 4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-3)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.12-12\(Column A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-1)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.12-12\(Column B\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-1)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.12-12\(Column C\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column C)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-1)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.12-12\(Column A\)\(Footnote 1\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column A)(Footnote 1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-1)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.12-12\(Column A\)\(Footnote 2\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column A)(Footnote 2)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-1)Reference 10: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.12-12\(Column A\)\(Footnote 2\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column A)(Footnote 2)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-1)Reference 11: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.12-12\(Column A\)\(Footnote 4\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column A)(Footnote 4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-1)Reference 12: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.12-12\(Column C\)\(Footnote 5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column C)(Footnote 5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-1)Reference 13: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.12-12\(Column C\)\(Footnote 6\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column C)(Footnote 6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-1)Reference 14: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.12-12\(Column B\)\(Footnote 7\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column B)(Footnote 7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-1)Reference 15: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.12-12\(Column C\)\(Footnote 8\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column C)(Footnote 8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-1)Reference 16: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.12-12\(Column C\)\(Footnote 8\)\(a\)\(1\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-1)Reference 17: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.12-12\(Column C\)\(Footnote 8\)\(a\)\(2\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-1)Reference 18: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.12-12\(Column C\)\(Footnote 8\)\(a\)\(3\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-1)Reference 19: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.12-12\(Column C\)\(Footnote 8\)\(b\)\(1\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(b)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-1)Reference 20: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.12-12\(Column C\)\(Footnote 8\)\(b\)\(2\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-1)Reference 21: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.12-12\(Column C\)\(Footnote 8\)\(c\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-1)Reference 22: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.12-12\(Column C\)\(Footnote 9\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column C)(Footnote 9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-1)Reference 23: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.12-12\(Column C\)\(Footnote 10\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column C)(Footnote 10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-1)Reference 24: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.12-12B\(Column A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-3)Reference 25: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.12-12B\(Column B\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-3)Reference 26: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.12-12B\(Column C\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column C)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-3)Reference 27: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.12-12B\(Column D\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column D)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-3)Reference 28: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.12-12B\(Column A\)\(Footnote 1\)\(a\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column A)(Footnote 1)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-3)Reference 29: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.12-12B\(Column A\)\(Footnote 1\)\(b\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column A)(Footnote 1)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-3)Reference 30: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.12-12B\(Column A\)\(Footnote 2\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column A)(Footnote 2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-3)Reference 31: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.12-12B\(Column A\)\(Footnote 3\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column A)(Footnote 3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-3)Reference 32: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.12-12B\(Column A\)\(Footnote 4\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column A)(Footnote 4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-3)Reference 33: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.12-12B\(Column A\)\(Footnote 4\)\(a\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column A)(Footnote 4)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-3)Reference 34: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.12-12B\(Column A\)\(Footnote 6\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column A)(Footnote 6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-3)Reference 35: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.12-12B\(Column A\)\(Footnote 7\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column A)(Footnote 7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-3)Reference 36: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.12-12B\(Column C\)\(Footnote 9\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column C)(Footnote 9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-3)Reference 37: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.12-12B\(Column B\)\(Footnote 10\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column B)(Footnote 10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-3)Reference 38: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.12-12B\(Column C\)\(Footnote 11\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-3)Reference 39: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.12-12B\(Column C\)\(Footnote 11\)\(a\)\(1\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/21474](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-3)

Paragraph 6 - Subparagraph (SX 210.12-14)(Column A)(Footnote 1)(b)(1) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480032/946-320-S99-6Reference 58: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 320-Name Accounting Standards Codification-Section S99-Paragraph 6-Subparagraph \(SX 210.12-14\)\(Column A\)\(Footnote 3\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 320-Name Accounting Standards Codification-Section S99-Paragraph 6-Subparagraph (SX 210.12-14)(Column A)(Footnote 3))) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480032/946-320-S99-6Reference 59: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 320-Name Accounting Standards Codification-Section S99-Paragraph 6-Subparagraph \(SX 210.12-14\)\(Column F\)\(Footnote 4\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 320-Name Accounting Standards Codification-Section S99-Paragraph 6-Subparagraph (SX 210.12-14)(Column F)(Footnote 4))) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480032/946-320-S99-6Reference 60: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 320-Name Accounting Standards Codification-Section S99-Paragraph 6-Subparagraph \(SX 210.12-14\)\(Column F\)\(Footnote 5\)\(a\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 320-Name Accounting Standards Codification-Section S99-Paragraph 6-Subparagraph (SX 210.12-14)(Column F)(Footnote 5)(a))) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480032/946-320-S99-6Reference 61: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 320-Name Accounting Standards Codification-Section S99-Paragraph 6-Subparagraph \(SX 210.12-14\)\(Column F\)\(Footnote 7\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 320-Name Accounting Standards Codification-Section S99-Paragraph 6-Subparagraph (SX 210.12-14)(Column F)(Footnote 7))) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480032/946-320-S99-6Reference 62: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 320-Name Accounting Standards Codification-Section S99-Paragraph 6-Subparagraph \(SX 210.12-14\)\(Column F\)\(Footnote 8\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 320-Name Accounting Standards Codification-Section S99-Paragraph 6-Subparagraph (SX 210.12-14)(Column F)(Footnote 8))) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480032/946-320-S99-6Reference 63: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 320-Name Accounting Standards Codification-Section S99-Paragraph 6-Subparagraph \(SX 210.12-14\)\(Column F\)\(Footnote 9\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 320-Name Accounting Standards Codification-Section S99-Paragraph 6-Subparagraph (SX 210.12-14)(Column F)(Footnote 9))) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480032/946-320-S99-6Reference 64: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 320-Name Accounting Standards Codification-Section S99-Paragraph 19-Subparagraph \(1\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 320-Name Accounting Standards Codification-Section S99-Paragraph 19-Subparagraph (1))) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480032/946-320-S99-19Reference 65: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 320-Name Accounting Standards Codification-Section S99-Paragraph 19-Subparagraph \(3\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 320-Name Accounting Standards Codification-Section S99-Paragraph 19-Subparagraph (3))) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480032/946-320-S99-19 + Details Name: us-gaap_ScheduleOfInvestmentsLineItems Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_InvestmentIssuerNameAxis=ocsl_ThrasioLLCMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIssuerNameAxis=ocsl_OtherNetMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ForeignExchangeForwardMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIssuerNameAxis=ocsl_AdenAnaisMergerSubIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIssuerNameAxis=ocsl_RadiologyPartnersIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIssuerNameAxis=ocsl_WPCPPHoldingsLLCMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIssuerNameAxis=ocsl_TerseraTherapeuticsLLCMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIssuerNameAxis=ocsl_AlliWebLeadsIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIssuerNameAxis=ocsl_ContinentalIntermodalGroupLPMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIssuerNameAxis=ocsl_PLDevelopmentLLCMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIssuerNameAxis=ocsl_AmericanTireDistributorsInc.Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIssuerNameAxis=ocsl_ZephyrBidcoLimitedMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIssuerNameAxis=ocsl_LiftBranchHoldingsInc.Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIssuerNameAxis=ocsl_AlvotechMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIssuerNameAxis=ocsl_ArdonaghMidco3PLCMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIssuerNameAxis=ocsl_CaravanaCo.Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIssuerNameAxis=ocsl_ASPUnifraxHoldingsIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIssuerNameAxis=ocsl_GlobalMedicalResponseIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: XML 74 R63.htm IDEA: XBRL DOCUMENT v3.24.2 Realized Gains or Losses and Net Unrealized Appreciation or Depreciation - Narrative (Details) - USD (\$) \$ in Thousands 3 Months Ended 9 Months Ended Jan. 30, 2024 Mar. 31, 2024 Dec. 31, 2023 Jun. 30, 2023 Mar. 31, 2023 Dec. 31, 2022 Jun. 30, 2022 Jun. 30, 2021 Jun. 30, 2020 Tersera Therapeutics LLC A A A A A A A A A A Net unrealized appreciation (depreciation) \$ 26,199 \$ (25,252) \$ (25,025) \$ (1,039) \$ (18,279) \$ (22,982) \$ (24,100) \$ (42,300) Investments in equity securities A A A A A A A A A A Tersera Therapeutics LLC A A A A A A A A A A Net unrealized appreciation (depreciation) (19,900) A A 5,000 A A (30,500) 11,800 Investments in debt securities A A A A A A A A A A Tersera Therapeutics LLC A A A A A A A A A A Net unrealized appreciation (depreciation) (38,600) A A (9,800) A A (49,600) (54,300) Foreign currency forward contracts A A A A A A A A A A Tersera Therapeutics LLC A A A A A A A A A A Net unrealized appreciation (depreciation) 1,100 A A 4,600 A A (4,500) 5,100 Exited Investments A A A A A A A A A A Tersera Therapeutics LLC A A A A A A A A A A Net unrealized appreciation (depreciation) \$ 83,600 A A (800) A A \$ 60,500 \$ (4,800) X - DefinitionAmount, before tax, of unrealized gain (loss) on investment in debt and equity securities and foreign currency transaction on investment in debt and equity securities from change in market price, classified as operating. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.6-07\(7\)\(c\)\(1\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.6-07(7)(c)(1))) - Publisher FASB - URI https://asc.fasb.org/1943274/2147483575/946-220-S99-1Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.6-07\(7\)\(c\)\(2\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.6-07(7)(c)(2))) - Publisher FASB - URI https://asc.fasb.org/1943274/2147483575/946-220-S99-1 + Details Name: us-gaap_DebtAndEquitySecuritiesAndForeignCurrencyTransactionPriceChangeUnrealizedGainLossOperatingBeforeTax Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 320-Name Accounting Standards Codification-Section S99-Paragraph 6-Subparagraph \(SX 210.12-14\)\(Column A\)\(Footnote 1\)\(b\)\(1\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 320-Name Accounting Standards Codification-Section S99-Paragraph 6-Subparagraph (SX 210.12-14)(Column A)(Footnote 1)(b)(1))) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480032/946-320-S99-6Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 320-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.12-12\)\(Column A\)\(Footnote 2\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 320-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.12-12)(Column A)(Footnote 2))) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480032/946-320-S99-1Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 320-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph \(SX 210.12-12B\)\(Column A\)\(Footnote 4\)\(b\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 320-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.12-12B)(Column A)(Footnote 4)(b))) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480032/946-320-S99-3Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 320-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.12-12\)\(Column B\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 320-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.12-12)(Column B))) - Publisher FASB - URI https://asc.fas

(Column B)) - Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-6Reference 49: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column F)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-6Reference 50: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column A)(Footnote 1))(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-6Reference 51: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column A)(Footnote 1))(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-6Reference 52: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column A)(Footnote 1))(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-6Reference 53: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column A)(Footnote 1))(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-6Reference 54: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column A)(Footnote 1))(b)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-6Reference 55: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column A)(Footnote 1))(b)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-6Reference 56: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column A)(Footnote 5))(a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-6Reference 61: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column A)(Footnote 1))(b)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-6Reference 57: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column A)(Footnote 1))(b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-6Reference 58: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column A)(Footnote 3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-6Reference 59: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column F)(Footnote 4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-6Reference 60: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column F)(Footnote 5))(a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-6Reference 61: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column F)(Footnote 7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-6Reference 62: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column F)(Footnote 8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-6Reference 63: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column F)(Footnote 9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-6Reference 64: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-19 + Details Name: us-gaap_ScheduleOfInvestmentsLineItems Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: Period Type: duration X - Details Name: us-gaap_InvestmentTypeAxis=us-gaap_DebtSecuritiesMember Namespace Prefix: Data Type: na_Balance Type: Period Type: X - Details Name: us-gaap_InvestmentTypeAxis=us-gaap_ForeignExchangeForwardMember Namespace Prefix: Data Type: na_Balance Type: Period Type: X - Details Name: us-gaap_InvestmentTypeAxis=ocsl_ExitdInvestmentsMember Namespace Prefix: Data Type: na_Balance Type: Period Type: XML V5 R64.htm IDEA: XBRL DOCUMENT v3.24.2 Related Party Transactions (Details) 3 Months Ended 9 Months Ended Jul. 01, 2024 Apr. 26, 2024 USD (\$) Jan. 23, 2023 USD (\$) Mar. 19, 2021 USD (\$) May 03, 2019 May 02, 2019 Jun. 30, 2024 USD (\$) component Jun. 30, 2023 USD (\$) (component) Jun. 30, 2023 USD (\$) Sep. 30, 2023 USD (\$) Related Party Transaction [Line Items] Á Á Á Á Á Á Á Á Á Á Á Á Á Á Á Base management fee and incentive fee payable Á Á Á Á Á Á Á Á Á Á Á Á Á Á Á \$ 15,415,000 Á Á Á Á Á \$ 19,547,000 Á Á Á Á Á Base management fee rate (as a percent) Á Á Á Á Á Á Á Á Á Á Á Á Á Á Á Base management fee, threshold (as a percent) Á Á Á Á Á Á Á Á Á Á Á Á Á Á Á Contractual fee waived, per quarter Á Á Á Á Á Á Á Á Á Á Á Á Á Á Á Base management fee Á Á Á Á Á Á Á Á Á Á Á Á Á Á Á 11,781,000 Á Á Á Á Á 11,983,000 Á Á Á Á Á 34,862,000 Á Á Á Á Á Part I incentive fees waived Á Á Á Á Á Á Á Á Á Á Á Á Á Á Á Part I incentive fee Á Á Á Á Á Á Á Á Á Á Á Á Á Á Á 8,341,000 Á Á Á Á Á 25,821,000 Á Á Á Á Á 26,300,000 Á Á Á Á Á Due to affiliate Á Á Á Á Á Á Á Á Á Á Á Á Á Á Á 4,803,000 Á Á Á Á Á 4,803,000 Á Á Á Á Á Subsequent Event Á Á Á Á Á Á Á Á Á Á Á Á Á Á Á Related Party Transaction [Line Items] Á Á Á Á Á Á Á Á Á Á Á Á Á Á Á Base management fee rate (as a percent) 1.00% Á Á Á Á Á Á Á Á Á Á Á Á Á Á Á Affiliated Entity Á Á Á Á Á Á Á Á Á Á Á Á Á Á Á Related Party Transaction [Line Items] Á Á Á Á Á Á Á Á Á Á Á Á Á Á Á Related party transaction, termination, notice period Á Á Á Á Á Á Á Á Á Á Á Á Á Á Á Part I incentive fees waived Á Á Á Á Á Á Á Á Á Á Á Á Á Á Á Administrator expense Á Á Á Á Á Á Á Á Á Á Á Á Á Á Á 500,000 Á Á Á Á Á 1,300,000 Á Á Á Á Á 1,200,000 Á Á Á Á Á General and administrative expenses Á Á Á Á Á Á Á Á Á Á Á Á Á Á Á Due to affiliate Á Á Á Á Á Á Á Á Á Á Á Á Á Á Á 4,800,000 Á Á Á Á Á 4,800,000 Á Á Á Á Á 4,300,000 Á Á Á Á Á Oaktree Strategic Income Corporation Merger Á Á Á Á Á Á Á Á Á Á Á Á Á Á Á Related Party Transaction [Line Items] Á Á Á Á Á Á Á Á Á Á Á Á Á Á Á Investment company, contractual fee waived Á Á Á Á Á Á Á Á Á Á Á Á Á Á Á Contractual fee waived, period otherwise receivable (in years) Á Á Á Á Á Á Á Á Á Á Á Á Á Á Á Contractual fee waived, per quarter Á Á Á Á Á Á Á Á Á Á Á Á Á Á Á 750,000 Á Á Á Á Á Á Á Á Á Á Á Á Á Á Á Oaktree Strategic Income II, Inc. Merger Á Á Á Á Á Á Á Á Á Á Á Á Á Á Á Related Party Transaction [Line Items] Á Á Á Á Á Á Á Á Á Á Á Á Á Á Á Investment company, contractual fee waived Á Á Á Á Á Á Á Á Á Á Á Á Á Á Á 9,000,000 Á Á Á Á Á Á Á Á Á Á Á Á Á Á Á Oaktree Strategic Income II, Inc Merger, Year One Á Á Á Á Á Á Á Á Á Á Á Á Á Á Á Related Party Transaction [Line Items] Á Á Á Á Á Á Á Á Á Á Á Á Á Á Á Investment company, contractual fee waived Á Á Á Á Á Á Á Á Á Á Á Á Á Á Á Contractual fee waived, per quarter Á Á Á Á Á Á Á Á Á Á Á Á Á Á Á 1,500,000 Á Á Á Á Á Á Á Á Á Á Á Á Á Á Á Oaktree Strategic Income II, Inc Merger, Year Two Á Á Á Á Á Á Á Á Á Á Á Á Á Á Á Related Party Transaction [Line Items] Á Á Á Á Á Á Á Á Á Á Á Á Á Á Á Investment company, contractual fee waived Á Á Á Á Á Á Á Á Á Á Á Á Á Á Á 3,000,000 Á Á Á Á Á Á Á Á Á Á Á Á Á Á Á Contractual fee waived, per quarter Á Á Á Á Á Á Á Á Á Á Á Á Á Á Á Investment Advisory Agreement Á Á Á Á Á Á Á Á Á Á Á Á Á Á Á Related Party Transaction [Line Items] Á Á Á Á Á Á Á Á Á Á Á Á Á Á Á Number of components | component Á Á Á Á Á Á Á Á Á Á Á Á Á Á Á Related party transaction, termination, notice period Á Á Á Á Á Á Á Á Á Á Á Á Á Á Á 60 days Á Á Á Á Á Á Á Á Á Á Á Á Á Á Á Base management fee Á Á Á Á Á Á Á Á Á Á Á Á Á Á Á \$ 10,300,000 Á Á Á Á Á \$ 30,400,000 Á Á Á Á Á Management incentive rate (as a percent) Á Á Á Á Á Á Á Á Á Á Á Á Á Á Á 1.50% Á Á Á Á Á Á Á Á Á Á Á Á Á Á Á Investment Advisory Agreement | Affiliated Entity Á Á Á Á Á Á Á Á Á Á Á Á Á Á Á Related Party Transaction [Line Items] Á Á Á Á Á Á Á Á Á Á Á Á Á Á Á Part I incentive fee Á Á Á Á Á Á Á Á Á Á Á Á Á Á Á 5,100,000 Á Á Á Á Á 9,600,000 Á Á Á Á Á 22,600,000 Á Á Á Á Á Incentive fee expense Á Á Á Á Á Á Á Á Á Á Á Á Á Á Á 9,600,000 Á Á Á Á Á Accrued capital gains incentive fees expensed (reversed) Á Á Á Á Á Á Á Á Á Á Á Á Á Á Á \$ 0 Á Á Á Á Á \$ 0 Á Á Á Á Á \$ 0 Á Á Á Á Á Investment Advisory Agreement Incentive Rate Pre Incentive Fee Net Investment Income Below Catch Up Á Á Á Á Á Á Á Á Á Á Á Á Á Á Á Related Party Transaction [Line Items] Á Á Á Á Á Á Á Á Á Á Á Á Á Á Á Management incentive rate (as a percent) Á Á Á Á Á Á Á Á Á Á Á Á Á Á Á 100.00% Á Á Á Á Á Á Á Á Á Á Á Á Á Á Á Investment Advisory Agreement Incentive Rate Quarterly Catch Up Threshold Á Á Á Á Á Á Á Á Á Á Á Á Á Á Á Related Party Transaction [Line Items] Á Á Á Á Á Á Á Á Á Á Á Á Á Á Á Management incentive rate (as a percent) Á Á Á Á Á Á Á Á Á Á Á Á Á Á Á 1.

`us-gaap_RelatedPartyTransactionAxis=us-gaap_SubsequentEventMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionAxis=ocsl_OaktreeStrategicIncomeCorporationMergerMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionAxis=ocsl_OaktreeStrategicIncomeIncIncrMergerMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionAxis=ocsl_OaktreeStrategicIncomeIncIncrMergerYearOneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionAxis=ocsl_OaktreeStrategicIncomeIncIncrMergerYearTwoMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionAxis=ocsl_InvestmentAdvisoryAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionAxis=ocsl_InvestmentAdvisoryAgreementIncentiveRatePreIncentiveFeeNetInvestmentIncomeBelowCatchUpMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionAxis=ocsl_InvestmentAdvisoryAgreementIncentiveRateQuarterlyCatchUpThresholdMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionAxis=ocsl_InvestmentAdvisoryAgreementIncentiveRatePreIncentiveFeeNetInvestmentIncomeExceedsCatchUpThresholdMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionAxis=ocsl_InvestmentAdvisoryAgreementIncentiveRateRealizedCapitalGainsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: XML 7 R66.htm IDEA: XBRL DOCUMENT v3.24.2 Financial Highlights (Details) $ / shares in Units, shares in Thousands, $ in Thousands 3 Months Ended 9 Months Ended Jan. 20, 2023 Jun. 30, 2024 USD ($) / shares Shares Jun. 30, 2023 USD ($) / shares Shares Jun. 30, 2023 USD ($) / shares Shares Investment Company, Financial Highlights [Roll Forward] A A A A Net asset value per share at beginning of period (in dollars per share) A $ 18.72 $ 19.66 $ 19.63 $ 20.38 Net investment income (in dollars per share) [1] A 0.54 0.63 1.63 1.89 Net unrealized appreciation (depreciation) (in dollars per share) A 0.33 (0.02) (0.28) (0.36) Net realized gains (losses) (in dollars per share) A (0.85) (0.14) (1.06) (0.28) (Provision) benefit for taxes on realized and unrealized gains (losses) (in dollars per share) A 0 0 (0.01) 0.01 Distributions of net investment income to stockholders (dollars per share) A (0.55) (0.55) (1.72) (2.06) Net asset value per share at end of period (in dollars per share) [2] A 18.19 19.58 18.19 19.58 Per share market value at beginning of period (in dollars per share) A 19.66 18.77 20.12 18.00 Per share market value at end of period (in dollars per share) A 18.81 19.43 18.81 19.43 Total return A (1.51%) 6.42% 2.13% 19.58% Common shares outstanding at beginning of period (in shares) | shares A 81,396 77,080 77,225 61,125 Common shares outstanding at end of period (in shares) | shares [2] A 82,245 77,080 82,245 77,080 Net assets at beginning of period | $ A 1,524,093 $ 1,515,150 $ 1,515,764 $ 1,245,563 Net assets at end of period | $ A 1,496,133 1,509,441 1,496,133 1,509,441 Average net assets | $ A 1,524,503 $ 1,526,644 $ 1,524,180 $ 1,407,814 Ratio of net investment income to average net assets A 11.76% 12.72% 11.40% 12.65% Ratio of total expenses to average net assets A 14.54% 14.45% 14.42% 14.07% Ratio of net expenses to average net assets A 13.29% 14.05% 13.75% 13.69% Ratio of portfolio turnover to average investments at fair value A 5.95% 7.48% 23.97% 18.43% Weighted average outstanding debt | $ A 1,711,978 $ 1,756,758 $ 1,680,876 $ 1,640,062 Average debt per share (dollars per share) A $ 20.92 $ 22.79 $ 21.06 $ 23.29 Asset coverage ratio A 183.36% 182.05% 183.36% 182.05% Outstanding senior securities | $ A 1,743,400 $ 1,785,000 $ 1,743,400 $ 1,785,000 Stock split, conversion ratio 1.3333 A A A [1] As discussed in Note 2, the Company completed a 1-for-3 reverse stock split on January 20, 2023, effective as of the commencement of trading on January 23, 2023. The weighted average common shares outstanding and per share information reflect the reverse stock split on a retroactive basis as necessary. [2] As discussed in Note 2, the Company completed a 1-for-3 reverse stock split on January 20, 2023, effective as of the commencement of trading on January 23, 2023. The weighted average common shares outstanding and per share information reflect the reverse stock split on a retroactive basis as necessary. X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form N-2 -Section Item 4 - Subsection 3 -Paragraph 2 + Details Name: cef_SeniorSecuritiesAmt Namespace Prefix: cef_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: instant X - DefinitionAverage Net Assets + ReferencesNo definition available. + Details Name: ocsl_AverageNetAssets Namespace Prefix: ocsl_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionInvestment Company, Average Long-Term Debt Outstanding Per Share + ReferencesNo definition available. + Details Name: ocsl_InvestmentCompanyAverageLongTermDebtOutstandingPerShare Namespace Prefix: ocsl_ Data Type: dtr-types1:perShareItemBalance Type: na Period Type: duration X - DefinitionInvestment Company, Expense Ratio, Net Expenses + ReferencesNo definition available. + Details Name: ocsl_InvestmentCompanyExpenseRatioNetExpenses Namespace Prefix: ocsl_ Data Type: dtr-types1:percentItemBalance Type: na Period Type: duration X - DefinitionInvestment Company, Expense Ratio, Total Expenses + ReferencesNo definition available. + Details Name: ocsl_InvestmentCompanyExpenseRatioTotalExpenses Namespace Prefix: ocsl_ Data Type: dtr-types1:percentItemBalance Type: na Period Type: duration X - DefinitionInvestment Company, Gain (Loss) On Realized Appreciation (Depreciation), Per Share + ReferencesNo definition available. + Details Name: ocsl_InvestmentCompanyGainLossOnRealizedAppreciationDepreciationPerShare Namespace Prefix: ocsl_ Data Type: dtr-types1:perShareItemBalance Type: na Period Type: duration X - DefinitionInvestment Company, Gain (Loss) On Unrealized Appreciation (Depreciation), Per Share + ReferencesNo definition available. + Details Name: ocsl_InvestmentCompanyGainLossOnUnrealizedAppreciationDepreciationPerShare Namespace Prefix: ocsl_ Data Type: dtr-types1:perShareItemBalance Type: na Period Type: duration X - DefinitionInvestment Company, Portfolio Turnover Ratio + ReferencesNo definition available. + Details Name: ocsl_InvestmentCompanyPortfolioTurnoverRatio Namespace Prefix: ocsl_ Data Type: dtr-types1:percentItemBalance Type: na Period Type: duration X - DefinitionInvestment Company, (Provision) Benefit For Taxes On Realized And Unrealized Gains (Losses), Per Share + ReferencesNo definition available. + Details Name: ocsl_InvestmentCompanyProvisionBenefitForTaxesOnRealizedAndUnrealizedGainsLossesPerShare Namespace Prefix: ocsl_ Data Type: dtr-types1:perShareItemBalance Type: na Period Type: duration X - DefinitionAmount of net assets (liabilities). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 30 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479910/205-30-50-1 + Details Name: us-gaap_AssetsNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemBalance Type: debit Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479617/946-210-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483575/946-220-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479617/946-210-S99-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483575/946-220-S99-3Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemBalance Type: na Period Type: instant X - DefinitionPer share or unit amount of distribution to shareholders. Includes, but is not limited to, dividend and capital gain. Excludes distribution for tax return of capital. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480737/946-205-50-7Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-8 + Details Name: us-gaap_InvestmentCompanyDistributionToShareholdersPerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemBalance Type: na Period Type: duration X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_InvestmentCompanyFinancialHighlightsRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemBalance Type: na Period Type: duration X - DefinitionPer share or unit amount, after investment expense, of dividend and interest investment income (loss). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480737/946-205-50-7 + Details Name: us-gaap_InvestmentCompanyInvestmentIncomeLossPerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemBalance Type: na Period Type: duration X - DefinitionPercentage of investment income (loss) to average net assets. + ReferencesNo definition available. + Details Name: us-gaap_InvestmentCompanyInvestmentIncomeLossRatio Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemBalance Type: na Period Type: duration X - DefinitionMarket value per share of investment portfolio by investment company. Includes, but is not limited to, per unit, membership interest, or other ownership interest. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480737/946-205-50-7 + Details Name: us-gaap_InvestmentCompanyMarketValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemBalance Type: na Period Type: instant X - DefinitionPercentage of total assets less all liabilities and indebtedness not represented by senior security, to senior security representing indebtedness. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name Investment Company Act of 1940 -Section 61 -Paragraph 1 -Subparagraph (1) -Publisher SEC + Details Name: us-gaap_InvestmentCompanySeniorSecurityIndebtednessAssetCoverageRatio Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemBalance Type: na Period Type: instant X - DefinitionPercentage increase (decrease) in fund net asset value, assuming reinvestment of dividends and capital gain distributions. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 9`

À Á Notional Amount to be Sold | ÄÊ Á Ä Ä Ä Ä Ä Ä Ä Ä Ä 56,556 Derivative assets at fair value Ä Ä Ä Ä 3,053 Ä Ä Ä Derivative liabilities at fair value Ä Ä Ä Ä 0 Ä Ä Open Forward Foreign Currency Contract, Identifier [Axis]: Interest rate swap, Maturing February 15, 2029 Ä Ä Ä Ä Ä Ä Ä Derivative Instruments and Hedging Activities Disclosures [Line Items] Ä Ä Ä Ä Ä Notional Amount 300,000 Ä Ä 300,000 Ä Ä Derivative assets at fair value 0 Ä Ä Ä Ä Derivative liabilities at fair value 2,989 Ä Ä 7,000 Ä Ä Open Forward Foreign Currency Contract, Identifier [Axis]: Interest rate swap, Maturing January 15, 2027 Ä Ä Ä Ä Ä Ä Ä Derivative Instruments and Hedging Activities Disclosures [Line Items] Ä Ä Ä Ä Ä Notional Amount 350,000 Ä Ä 350,000 Ä Ä Derivative assets at fair value 0 Ä Ä Ä Ä Derivative liabilities at fair value \$ 30,683 Ä Ä \$ 40,519 Ä Ä X - DefinitionNominal or face amount used to calculate payments on the derivative asset. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph \(SX 210.12-13\(Column A\)\(Footnote 3\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-5](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SX 210.12-13(Column A)(Footnote 3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-5)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5CReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5A -Subparagraph \(SX 210.12-13A\(Column D\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-5A](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5CReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5A -Subparagraph (SX 210.12-13A(Column D)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-5A)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5B -Subparagraph \(SX 210.12-13B\(Column B\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-5B](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5B -Subparagraph (SX 210.12-13B(Column B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-5B)Reference 5: <http://www.xbrl.org/2009/role/commonPracticeRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1B>Reference 6: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1A](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1A)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480524/946-210-50-12](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1A + Details Name: us-gaap_DerivativeAssetNotionalAmount Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: na Period Type: instant X - DefinitionFair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480524/946-210-50-12)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph \(e\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480524/946-210-50-6](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480524/946-210-50-6)Reference 3: <http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 55 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480493/946-210-55-1>Reference 4:

limited to, securities failed-to-deliver, certain deposits for securities borrowed, open transactions, good faith and margin deposits, commissions and floor brokerage receivables. +
ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 45 -Paragraph 3 -SubTopic 20 -Topic 940 -Publisher FASB -URI http://asc.fasb.org/1943274/2147481833/940-20-45-3> + Details Name: us-gaap ReceivablesFromBrokersDealersAndClearingOrganizations Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 79 R68.htm IDEA: XBRL DOCUMENT v3.24.2 Commitments and Contingencies - Narrative (Details) - USD (\$) \$ in Thousands Jun. 30, 2024 Sep. 30, 2023 Financial Support for Nonconsolidated Legal Entity [Line Items] Á Á Unfunded commitments \$ 291,406 \$ 232,740 Debt and Equity Financing Á Á Financial Support for Nonconsolidated Legal Entity [Line Items] Á Á Unfunded commitments 264,300 205,600 Amount which can be drawn immediately 219,400 154,200 JV Financing Á Á Financial Support for Nonconsolidated Legal Entity [Line Items] Á Á Unfunded commitments \$ 27,100 \$ 27,100 X - DefinitionInvestment Company, Financial Support To Investee Contractually Required, Amount Which Can Be Drawn Immediately + ReferencesNo definition available. + Details Name: ocsI_InvestmentCompanyFinancialSupportToInvesteeContractuallyRequiredAmountWhichCanBeDrawnImmediately Namespace Prefix: ocsI_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-15](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-15)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 16 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-16](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 16 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-16) + Details Name: us-gaap_FinancialSupportForNonconsolidatedLegalEntityLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of financial support committed by investment company to investee that is contractually required but not provided. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 16 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-16](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 16 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-16) + Details Name: us-gaap_InvestmentCompanyFinancialCommitmentToInvesteeFutureAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_InvestmentTypeAxis=ocsI_DebtAndEquityFinancingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentTypeAxis=ocsI_JVFinancingMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 80 R69.htm IDEA: XBRL DOCUMENT v3.24.2 Commitments and Contingencies - Schedule of Unfunded Commitments by Investment (Details) - USD (\$) \$ in Thousands Jun. 30, 2024 Sep. 30, 2023 Financial Support for Nonconsolidated Legal Entity [Line Items] Á Á Unfunded commitments \$ 291,406 \$ 232,740 Investment, Identifier [Axis]: 107 Fair Street LLC Á Á Financial Support for Nonconsolidated Legal Entity [Line Items] Á Á Unfunded commitments 4,227 4,227 Investment, Identifier [Axis]: 107-109 Beech OAK22 LLC Á Á Financial Support for Nonconsolidated Legal Entity [Line Items] Á Á Unfunded commitments 26,969 26,969 Investment, Identifier [Axis]: 112-126 Van Houten Real22 LLC Á Á Financial Support for Nonconsolidated Legal Entity [Line Items] Á Á Unfunded commitments 1,378 2,343 Investment, Identifier [Axis]: ADB Companies, LLC Á Á Financial Support for Nonconsolidated Legal Entity [Line Items] Á Á Unfunded commitments 98 0 Investment, Identifier [Axis]: ADC Therapeutics SA Á Á Financial Support for Nonconsolidated Legal Entity [Line Items] Á Á Unfunded commitments 0 3,020 Investment, Identifier [Axis]: ASP-R-PAC Acquisition Co LLC Á Á Financial Support for Nonconsolidated Legal Entity [Line Items] Á Á Unfunded commitments 234 396 Investment, Identifier [Axis]: Accupac, Inc. Á Á Financial Support for Nonconsolidated Legal Entity [Line Items] Á Á Unfunded commitments 3,920 4,500 Investment, Identifier [Axis]: Acquia Inc. Á Á Financial Support for Nonconsolidated Legal Entity [Line Items] Á Á Unfunded commitments 1,625 1,376 Investment, Identifier [Axis]: All Web Leads, Inc. Á Á Financial Support for Nonconsolidated Legal Entity [Line Items] Á Á Unfunded commitments 240 0 Investment, Identifier [Axis]: Amspec Parent LLC Á Á Financial Support for Nonconsolidated Legal Entity [Line Items] Á Á Unfunded commitments 9,372 0 Investment, Identifier [Axis]: Assembled Brands Capital LLC Á Á Financial Support for Nonconsolidated Legal Entity [Line Items] Á Á Unfunded commitments 0 7,514 Investment, Identifier [Axis]: Avalara, Inc. Á Á Financial Support for Nonconsolidated Legal Entity [Line Items] Á Á Unfunded commitments 5,047 5,047 Investment, Identifier [Axis]: Berner Food & Beverage, LLC Á Á Financial Support for Nonconsolidated Legal Entity [Line Items] Á Á Unfunded commitments 1,314 1,622 Investment, Identifier [Axis]: BioXcel Therapeutics, Inc. Á Á Financial Support for Nonconsolidated Legal Entity [Line Items] Á Á Unfunded commitments 9,383 14,547 Investment, Identifier [Axis]: Centralsquare Technologies, LLC Á Á Financial Support for Nonconsolidated Legal Entity [Line Items] Á Á Unfunded commitments 1,436 0 Investment, Identifier [Axis]: Coupa Holdings, LLC Á Á Financial Support for Nonconsolidated Legal Entity [Line Items] Á Á Unfunded commitments 2,075 2,075 Investment, Identifier [Axis]: Coyote Buyer, LLC Á Á Financial Support for Nonconsolidated Legal Entity [Line Items] Á Á Unfunded commitments 0 400 Investment, Identifier [Axis]: Crewlene Buyer, Inc. Á Á Financial Support for Nonconsolidated Legal Entity [Line Items] Á Á Unfunded commitments 2,180 0 Investment, Identifier [Axis]: Delta Leasing SPV II LLC Á Á Financial Support for Nonconsolidated Legal Entity [Line Items] Á Á Unfunded commitments 3,581 14,639 Investment, Identifier [Axis]: Digital.AI Software Holdings, Inc. Á Á Financial Support for Nonconsolidated Legal Entity [Line Items] Á Á Unfunded commitments 6,045 1,078 Investment, Identifier [Axis]: Dominion Diagnostics, LLC Á Á Financial Support for Nonconsolidated Legal Entity [Line Items] Á Á Unfunded commitments 0 3,484 Investment, Identifier [Axis]: Enverus Holdings, Inc. Á Á Financial Support for Nonconsolidated Legal Entity [Line Items] Á Á Unfunded commitments 3,135 0 Investment, Identifier [Axis]: Establishment Labs Holdings Inc. Á Á Financial Support for Nonconsolidated Legal Entity [Line Items] Á Á Unfunded commitments 3,384 3,384 Investment, Identifier [Axis]: Evergreen IX Borrower 2023, LLC Á Á Financial Support for Nonconsolidated Legal Entity [Line Items] Á Á Unfunded commitments 1,626 1,626 Investment, Identifier [Axis]: Eyesouth Eye Care Holdco LLC Á Á Financial Support for Nonconsolidated Legal Entity [Line Items] Á Á Unfunded commitments 6,585 0 Investment, Identifier [Axis]: Fairbridge Strategic Capital Funding LLC Á Á Financial Support for Nonconsolidated Legal Entity [Line Items] Á Á Unfunded commitments 0 13,090 Investment, Identifier [Axis]: Finastra USA, Inc. Á Á Financial Support for Nonconsolidated Legal Entity [Line Items] Á Á Unfunded commitments 1,089 960 Investment, Identifier [Axis]: Galileo Parent, Inc. Á Á Financial Support for Nonconsolidated Legal Entity [Line Items] Á Á Unfunded commitments 1,480 2,061 Investment, Identifier [Axis]: Grove Hotel Parcel Owner, LLC Á Á Financial Support for Nonconsolidated Legal Entity [Line Items] Á Á Unfunded commitments 5,286 5,286 Investment, Identifier [Axis]: Harrow, Inc. Á Á Financial Support for Nonconsolidated Legal Entity [Line Items] Á Á Unfunded commitments 4,011 4,011 Investment, Identifier [Axis]: Icefall Parent, Inc. Á Á Financial Support for Nonconsolidated Legal Entity [Line Items] Á Á Unfunded commitments 995 0 Investment, Identifier [Axis]: Impel Pharmaceuticals Inc. Á Á Financial Support for Nonconsolidated Legal Entity [Line Items] Á Á Unfunded commitments 0 2,458 Investment, Identifier [Axis]: Inventus Power, Inc. Á Á Financial Support for Nonconsolidated Legal Entity [Line Items] Á Á Unfunded commitments 3,792 3,792 Investment, Identifier [Axis]: Kings Buyer, LLC Á Á Financial Support for Nonconsolidated Legal Entity [Line Items] Á Á Unfunded commitments 8,804 5,189 Investment, Identifier [Axis]: LSL Holdco, LLC Á Á Financial Support for Nonconsolidated Legal Entity [Line Items] Á Á Unfunded commitments 530 2,650 Investment, Identifier [Axis]: Liquid Environmental Solutions Corporation Á Á Financial Support for Nonconsolidated Legal Entity [Line Items] Á Á Unfunded commitments 0 1,383 Investment, Identifier [Axis]: MHE Intermediate Holdings, LLC Á Á Financial Support for Nonconsolidated Legal Entity [Line Items] Á Á Unfunded commitments 1,786 821 Investment, Identifier [Axis]: MND Holdings III Corp Á Á Financial Support for Nonconsolidated Legal Entity [Line Items] Á Á Unfunded commitments 0 9,122 Investment, Identifier [Axis]: MRI Software LLC Á Á Financial Support for Nonconsolidated Legal Entity [Line Items] Á Á Unfunded commitments 6,420 2,261 Investment, Identifier [Axis]: Mindbody, Inc. Á Á Financial Support for Nonconsolidated Legal Entity [Line Items] Á Á Unfunded commitments 5,238 4,762 Investment, Identifier [Axis]: Minotaur Acquisition, Inc. Á Á Financial Support for Nonconsolidated Legal Entity [Line Items] Á Á Unfunded commitments 3,058 0 Investment, Identifier [Axis]: Monotype Imaging Holdings Inc. Á Á Financial Support for Nonconsolidated Legal Entity [Line Items] Á Á Unfunded commitments 8,005 0 Investment, Identifier [Axis]: Next Holdco, LLC Á Á Financial Support for Nonconsolidated Legal Entity [Line Items] Á Á Unfunded commitments 7,051 0 Investment, Identifier [Axis]: OCSI Glick JV LLC Á Á Financial Support for Nonconsolidated Legal Entity [Line Items] Á Á Unfunded commitments 13,998 13,998 Investment, Identifier [Axis]: OTG Management, LLC Á Á Financial Support for Nonconsolidated Legal Entity [Line Items] Á Á Unfunded commitments 0 3,190 Investment, Identifier [Axis]: Oranje Holdco, Inc. Á Á Financial Support for Nonconsolidated Legal Entity [Line Items] Á Á Unfunded commitments 1,904 1,904 Investment, Identifier [Axis]: PPW Aero Buyer, Inc. Á Á Financial Support for Nonconsolidated Legal Entity [Line Items] Á Á Unfunded commitments 13,804 1,466 Investment, Identifier [Axis]: PRGX Global, Inc. Á Á Financial Support for Nonconsolidated Legal Entity [Line Items] Á Á Unfunded commitments 3,127 3,127 Investment, Identifier [Axis]: PetVet Care Centers, LLC Á Á Financial Support for Nonconsolidated Legal Entity [Line Items] Á Á Unfunded commitments 13,732 0 Investment, Identifier [Axis]: Pluralsight, LLC Á Á Financial Support for Nonconsolidated Legal Entity [Line Items] Á Á Unfunded commitments 0 1,787 Investment, Identifier [Axis]: Protein For Pets Opco, LLC Á Á Financial Support for Nonconsolidated Legal Entity [Line Items] Á Á Unfunded commitments 2,117 0 Investment, Identifier [Axis]: Quantum Bidco Limited Á Á Financial Support for Nonconsolidated Legal Entity [Line Items] Á Á Unfunded commitments 6,311 0 Investment, Identifier [Axis]: Relativity ODA LLC Á Á Financial Support for Nonconsolidated Legal Entity [Line Items] Á Á Unfunded commitments 2,762 2,762 Investment, Identifier [Axis]: SCP Eye Care Services, LLC Á Á Financial Support for Nonconsolidated Legal Entity [Line Items] Á Á Unfunded commitments 0 2,356 Investment, Identifier [Axis]: SIO2 Medical Products, Inc. Á Á Financial Support for Nonconsolidated Legal Entity [Line Items] Á Á Unfunded commitments 554 1,821 Investment, Identifier [Axis]: Salus Workers' Compensation, LLC Á Á Financial Support for Nonconsolidated Legal Entity [Line Items] Á Á Unfunded commitments 3,102 3,102 Investment, Identifier [Axis]: Senior Loan Fund JV I, LLC Á Á Financial Support for Nonconsolidated Legal Entity [Line Items] Á Á Unfunded commitments 13,125 13,125 Investment, Identifier [Axis]: Seres Therapeutics, Inc. Á Á Financial Support for Nonconsolidated Legal Entity [Line Items] Á Á Unfunded commitments 8,090 8,090 Investment, Identifier [Axis]: Sorenson Communications, LLC Á Á Financial Support for Nonconsolidated Legal Entity [Line Items] Á Á Unfunded commitments 5,409 0 Investment, Identifier [Axis]: Spanx, LLC Á Á Financial Support for Nonconsolidated Legal Entity [Line Items] Á Á Unfunded commitments 3,092 2,473 Investment, Identifier [Axis]: SumUp Holdings Luxembourg Á Á Financial Support for Nonconsolidated Legal Entity [Line Items] Á Á Unfunded commitments 5,101 0 Investment, Identifier [Axis]: Supreme Fitness Group NY Holdings, LLC Á Á Financial Support for Nonconsolidated Legal Entity [Line Items] Á Á Unfunded commitments 1,552 2,199 Investment, Identifier [Axis]: Tahoe Bidco B.V. Á Á Financial Support for Nonconsolidated Legal Entity [Line Items] Á Á Unfunded commitments 0 2,162 Investment, Identifier [Axis]: Telephone and Data Systems, Inc. Á Á Financial Support for Nonconsolidated Legal Entity [Line Items] Á Á Unfunded commitments 6,273 0 Investment, Identifier [Axis]: Telestream Holdings Corporation Á Á Financial Support for Nonconsolidated Legal Entity [Line Items] Á Á Unfunded commitments 379 407 Investment, Identifier [Axis]: Truck-Lite Co., LLC Á Á Financial Support for Nonconsolidated Legal Entity [Line Items] Á Á Unfunded commitments 5,654 0 Investment, Identifier [Axis]: Verona Pharma, Inc. Á Á Financial Support for Nonconsolidated Legal Entity [Line Items] Á Á Unfunded commitments 14,846 0 Investment, Identifier [Axis]: WP CPP Holdings, LLC Á Á Financial Support for Nonconsolidated Legal Entity [Line Items] Á Á Unfunded commitments 3,272 0 Investment, Identifier [Axis]: iCIMS, Inc. Á Á Financial Support for Nonconsolidated Legal Entity [Line Items] Á Á Unfunded commitments 6,591 7,466 Investment, Identifier [Axis]: scPharmaceuticals Inc. Á Á Financial Support for Nonconsolidated Legal Entity [Line Items] Á Á Unfunded commitments \$ 5,212 \$ 5,212 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-15](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-15)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 16 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-16](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 16 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-16) + Details Name: us-gaap_FinancialSupportForNonconsolidatedLegalEntityLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of financial support committed by investment company to investee that is contractually required but not provided. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 16 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-16](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 16 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-16) + Details Name: us-gaap_InvestmentCompanyFinancialCommitmentToInvesteeFutureAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_InvestmentIdentifierAxis=107 Fair Street LLC Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=112-126 Van Houten Real22 LLC Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=ADB Companies, LLC Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=ADC Therapeutics SA Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=ASP-R-PAC Acquisition Co LLC Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Accupac, Inc. Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Acquia Inc. Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=All Web Leads, Inc. Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Assembled Brands Capital LLC Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Avalara, Inc. Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Berner Food & Beverage, LLC Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Centralsquare Technologies, LLC Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Coupa Holdings, LLC Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Coyote Buyer, LLC Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Crewlene Buyer, Inc. Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Digital.AI Software Holdings, Inc. Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Dominion Diagnostics, LLC Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Enverus Holdings, Inc. Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Establishment Labs Holdings Inc. Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Evergreen IX Borrower 2023, LLC Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Eyesouth Eye Care Holdco LLC Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Fairbridge Strategic Capital Funding LLC Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Finastra USA, Inc. Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Galileo Parent, Inc. Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Grove Hotel Parcel Owner, LLC Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Harrow, Inc. Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Icefall Parent, Inc. Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Impel Pharmaceuticals Inc. Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Inventus Power, Inc. Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Kings Buyer, LLC Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=LSL Holdco, LLC Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Liquid Environmental Solutions Corporation Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=MHE Intermediate Holdings, LLC Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=MND Holdings III Corp Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=MRI Software LLC Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Mindbody, Inc. Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-

gaap_InvestmentIdentifierAxis=Minotaur Acquisition, Inc. Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Monotype Imaging Holdings Inc. Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Next Holdco, LLC Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=OCSI Glick JV LLC Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=OTG Management, LLC Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Oranje Holdco, Inc. Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=PPW Aero Buyer, Inc. Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=PRGX Global, Inc. Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=PetVet Care Centers, LLC Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Pluralsight, LLC Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Protein For Pets Opco, LLC Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Quantum Bidco Limited Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Relativity ODA LLC Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=SCP Eye Care Services, LLC Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=SIO2 Medical Products, Inc. Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Salus Workers' Compensation, LLC Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Senior Loan Fund JV I, LLC Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Seres Therapeutics, Inc. Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Sorenson Communications, LLC Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Spanx, LLC Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=SumUp Holdings Luxembourg Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Supreme Fitness Group NY Holdings, LLC Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Tahoe Bidco B.V. Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Telephone and Data Systems, Inc. Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Teletream Holdings Corporation Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Truck-Lite Co., LLC Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Verona Pharma, Inc. Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=WP CPP Holdings, LLC Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=iCIMS, Inc. Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=scPharmaceuticals Inc. Namespace Prefix: Data Type: na Balance Type: Period Type: XML 81 R70.htm IDEA: XBRL DOCUMENT v3.24.2 Subsequent Events (Details) Jul. 26, 2024 \$ / shares Quarterly | Subsequent Event A Subsequent Event [Line Items] A Common stock, dividends, per share, declared (in dollars per share) \$ 0.55 X - DefinitionAggregate dividends declared during the period for each share of common stock outstanding. + ReferencesReference 1:

interest rate (as a percent) 11.48% [7],[10],[11] 11.48% [7],[10],[11] 11.48% [7],[10],[11] 11.55% [12],[14],[15],[16] 11.55% [12],[14],[15],[16] 11.55% [12],[14],[15],[16] 11.55% [12],[14],[15],[16] Investment owned, balance, principal amount \$ 2,613 [7],[10],[17] A A A A \$ 2,033 [12],[14],[15],[18] A A Investments in and Advances to Affiliates, at Fair Value [Roll Forward] A A A A A A Fair value, beginning balance [12],[14],[15] 2,027 A A A A A A Fair value, ending balance [7],[10] \$ 2,608 A A A A A A Investment, Identifier [Axis]: Accupac, Inc., Personal Care Products, First Lien Term Loan 1 A A A A A A Tersera Therapeutics LLC A A A A A A Investment, basis spread, variable rate (as a percent) 6.00% [7],[8],[10] 6.00% [7],[8],[10] 6.00% [7],[8],[10] 6.00% [14],[15] 6.00% [14],[15] 6.00% [14],[15] Investment, interest rate (as a percent) [14],[15],[16] A A A A 11.55% 11.55% 11.55% Investment owned, balance, principal amount \$ 0 [7],[8],[10],[17] A A \$ 20,234 [14],[15],[18] A A Investments in and Advances to Affiliates, at Fair Value [Roll Forward] A A A A A A Fair value, beginning balance [14],[15] 20,194 A A A A A A Fair value, ending balance [7],[8],[10] \$ (8) A A A A A A Investment, Identifier [Axis]: Accupac, Inc., Personal Care Products, First Lien Term Loan 2 A A A A A A Tersera Therapeutics LLC A A A A A A Investment, basis spread, variable rate (as a percent) 6.00% [7],[10] A 6.00% [7],[10] 6.00% [7],[10] 6.00% [12],[14],[15] 6.00% [12],[14],[15] 6.00% [12],[14],[15] Investment, interest rate (as a percent) [7],[10],[11] 11.50% A 11.50% A 11.50% A A A A A A Investment owned, balance, principal amount \$ 20,077 [7],[10],[17] A A \$ 0 [12],[14],[15],[18] A A Investments in and Advances to Affiliates, at Fair Value [Roll Forward] A A A A A A Fair value, beginning balance [12],[14],[15] (8) A A A A A A Fair value, ending balance [7],[10] \$ 20,037 A A A A A A Investment, Identifier [Axis]: Acquia Inc., Application Software, First Lien Revolver A A A A A A Tersera Therapeutics LLC A A A A A A Investment, basis spread, variable rate (as a percent) 7.00% [7],[8],[10] A 7.00% [7],[8],[10] 7.00% [7],[8],[10] 7.00% [12],[14],[15] 7.00% [12],[14],[15] 7.00% [12],[14],[15] Investment, interest rate (as a percent) 12.46% [7],[8],[10],[11] A 12.46% [7],[8],[10],[11] 12.46% [7],[8],[10],[11] 12.72% [12],[14],[15],[16] 12.72% [12],[14],[15],[16] 12.72% [12],[14],[15],[16] Investment owned, balance, principal amount \$ 1,084 [7],[8],[10],[17] A A \$ 1,333 [12],[14],[15],[18] A A Investments in and Advances to Affiliates, at Fair Value [Roll Forward] A A A A A A Fair value, beginning balance [12],[14],[15] 1,324 A A A A A A Fair value, ending balance [7],[8],[10] \$ 1,084 A A A A A A Investment, Identifier [Axis]: Acquia Inc., Application Software, First Lien Term Loan 1 A A A A A A Tersera Therapeutics LLC A A A A A A Investment, basis spread, variable rate (as a percent) 7.00% [7],[10] A 7.00% [7],[10] 7.00% [7],[10] 7.00% [14],[15] 7.00% [14],[15] 7.00% [14],[15] Investment, interest rate (as a percent) 12.45% [7],[10],[11] A 12.45% [7],[10],[11] 12.45% [7],[10],[11] 12.34% [14],[15],[16] 12.34% [14],[15],[16] 12.34% [14],[15],[16] Investment owned, balance, principal amount \$ 6,400 [7],[10],[17] A A \$ 6,400 [14],[15],[18] A A Investments in and Advances to Affiliates, at Fair Value [Roll Forward] A A A A A A Fair value, beginning balance [14],[15] 6,380 A A A A A A Fair value, ending balance [7],[10] \$ 6,400 A A A A A A Investment, Identifier [Axis]: Acquia Inc., Application Software, First Lien Term Loan 2 A A A A A A Tersera Therapeutics LLC A A A A A A Investment, basis spread, variable rate (as a percent) 7.00% [7],[10] A 7.00% [7],[10] 7.00% [7],[10] 7.00% [14],[15] 7.00% [14],[15] 7.00% [14],[15] Investment, interest rate (as a percent) 12.45% [7],[10],[11] A 12.45% [7],[10],[11] 12.45% [7],[10],[11] 12.34% [14],[15],[16] 12.34% [14],[15],[16] 12.34% [14],[15],[16] Investment owned, balance, principal amount \$ 25,332 [7],[10],[17] A A \$ 25,332 [14],[15],[18] A A Investments in and Advances to Affiliates, at Fair Value [Roll Forward] A A A A A A Fair value, beginning balance [14],[15] 25,253 A A A A A A Fair value, ending balance [7],[10] \$ 25,332 A A A A A A Investment, Identifier [Axis]: AirStrip Technologies, Inc., Application Software, Warrants A A A A A A Tersera Therapeutics LLC A A A A A A Investment owned, balance (in shares) | shares 5,715 [7] A 5,715 [7] 5,715 [7] 5,715 [15] 5,715 [15] 5,715 [15] Investments in and Advances to Affiliates, at Fair Value [Roll Forward] A A A A A A Fair value, beginning balance [15] \$ 0 A A A A A A Fair value, ending balance [7] \$ 0 A A A A A A Investment, Identifier [Axis]: All Web Leads, Inc., Advertising, Common Stock A A A A A A Tersera Therapeutics LLC A A A A A A Investment owned, balance (in shares) | shares [7] 11,499 A 11,499 11,499 A A A A A A Investment owned, balance, principal amount \$ 0 A A A A Net Realized Gain (Loss) 0 A A A A AmountA of Interest, Fees or Dividends CreditedA In Income 0 A A A A A A Investments in and Advances to Affiliates, at Fair Value [Roll Forward] A A A A A A Fair value, beginning balance 0 A A A A A A Gross Additions 1,622 A A A A A A Gross Reductions 0 A A A A A A Fair value, ending balance [7] \$ 1,622 A A A A A A Investment owned, percent of net assets (as a percent) 0.10% A 0.10% 0.10% A A A A A A Investment, Identifier [Axis]: All Web Leads, Inc., Advertising, First Lien Revolver A A A A A A Tersera Therapeutics LLC A A A A A A Investment, basis spread, variable rate (as a percent) [7],[8] 4.00% A 4.00% 4.00% A A A A A A Investment, interest rate (as a percent) [7],[8],[10],[11] 9.34% A 9.34% 9.34% A A A A A A Investment owned, balance, principal amount [7],[8],[10],[17] \$ 1,560 A A A A A A Net Realized Gain (Loss) 0 A A A A A A AmountA of Interest, Fees or Dividends CreditedA In Income 45 A A A A A A Investments in and Advances to Affiliates, at Fair Value [Roll Forward] A A A A A A Fair value, beginning balance 0 A A A A A A Gross Additions 1,506 A A A A A A Gross Reductions 0 A A A A A A Fair value, ending balance [7],[8],[10] \$ 1,506 A A A A A A Investment owned, percent of net assets (as a percent) 0.10% A 0.10% 0.10% A A A A A A Investment, Identifier [Axis]: All Web Leads, Inc., Advertising, First Lien Term Loan A A A A A A Tersera Therapeutics LLC A A A A A A Investment, basis spread, variable rate (as a percent) [14],[15],[24] A A A 8.50% 8.50% 8.50% Investment owned, balance, principal amount [14],[15],[18],[24] A A A \$ 23,562 A A A Investments in and Advances to Affiliates, at Fair Value [Roll Forward] A A A A A A Fair value, beginning balance [14],[15],[24] \$ 9,797 A A A A A A Investment, Identifier [Axis]: All Web Leads, Inc., Advertising, First Lien Term Loan 1 A A A A A A Tersera Therapeutics LLC A A A A A A Investment, basis spread, variable rate (as a percent) [7],[10] 4.00% A 4.00% 4.00% A A A A A A Investment, interest rate (as a percent) [7],[10],[11] 7.34% A 7.34% A A A A A A Investment, interest rate, paid in kind (as a percent) [7],[10] 2.00% A 2.00% A A A A A A Investment owned, balance, principal amount [7],[10],[17] \$ 1,809 A A A A A A Net Realized Gain (Loss) 0 A A A A A A AmountA of Interest, Fees or Dividends CreditedA In Income 52 A A A A A A Investments in and Advances to Affiliates, at Fair Value [Roll Forward] A A A A A A Fair value, beginning balance 0 A A A A A A Gross Additions 1,731 A A A A A A Gross Reductions 0 A A A A A A Fair value, ending balance [7],[10] \$ 1,731 A A A A A A Investment owned, percent of net assets (as a percent) 0.10% A 0.10% 0.10% A A A A A A Investment, Identifier [Axis]: All Web Leads, Inc., Advertising, First Lien Term Loan 2 A A A A A A Tersera Therapeutics LLC A A A A A A Investment, basis spread, variable rate (as a percent) [7],[10] 5.00% A 5.00% 5.00% A A A A A A Investment, interest rate (as a percent) [7],[10],[11] 8.34% A 8.34% 8.34% A A A A A A Investment, interest rate, paid in kind (as a percent) [7],[10] 2.00% A 2.00% 2.00% A A A A A A Investment owned, balance, principal amount [7],[10],[17] \$ 3,602 A A A A A A Net Realized Gain (Loss) 0 A A A A A A AmountA of Interest, Fees or Dividends CreditedA In Income 116 A A A A A A Investments in and Advances to Affiliates, at Fair Value [Roll Forward] A A A A A A Fair value, beginning balance 0 A A A A A A Gross Additions 3,429 A A A A A A Gross Reductions 0 A A A A A A Fair value, ending balance [7],[10] \$ 3,429 A A A A A A Investment owned, percent of net assets (as a percent) 0.20% A 0.20% 0.20% A A A A A A Investment, Identifier [Axis]: All Web Leads, Inc., Advertising, First Lien Term Loan 3 A A A A A A Tersera Therapeutics LLC A A A A A A Investment, interest rate, paid in kind (as a percent) [7],[23] 10.00% A 10.00% 10.00% A A A A A A Investment owned, balance, principal amount [7],[17],[23] \$ 3,451 A A A A A A Net Realized Gain (Loss) 0 A A A A A A AmountA of Interest, Fees or Dividends CreditedA In Income 0 A A A A A A Investments in and Advances to Affiliates, at Fair Value [Roll Forward] A A A A A A Fair value, beginning balance 0 A A A A A A Gross Additions 3,102 A A A A A A Gross Reductions 0 A A A A A A Fair value, ending balance [7],[23] \$ 3,102 A A A A A A Investment owned, percent of net assets (as a percent) 0.20% A 0.20% 0.20% A A A A A A Investment, Identifier [Axis]: Alice France S.A., Integrated Telecommunication Services, Fixed Rate Bond A A A A A A Tersera Therapeutics LLC A A A A A A Investment, interest rate (as a percent) [14],[16],[21] A A A 5.50% 5.50% 5.50% Investment owned, balance, principal amount [18],[21] A A A \$ 4,050 A A A Investments in and Advances to Affiliates, at Fair Value [Roll Forward] A A A A A A Fair value, beginning balance [21] \$ 2,918 A A A A A A Investment, Identifier [Axis]: Alto Pharmacy Holdings, Inc., Health Care Technology, First Lien Term Loan A A A A A A Tersera Therapeutics LLC A A A A A A Investment, basis spread, variable rate (as a percent) 11.50% [7],[10] A 11.50% [7],[10] 11.50% [7],[10] 11.50% [14],[15] 11.50% [14],[15] 11.50% [14],[15] Investment, interest rate (as a percent)

A Investment, Identifier [Axis]: Ardonagh Midco 3 PLC, Insurance Brokers, First Lien Term Loan 1 A A A A Tersera Therapeutics LLC A A A A Investment, basis spread, variable rate (as a percent) [14],[15],[21] A A A 7.00% 7.00% Investment, interest rate (as a percent) [14],[15],[16],[21] A A A 10.95% 10.95% Investment owned, balance, principal amount [A-][14],[15],[18],[21] A A A A A -3,017 A Investments in and Advances to Affiliates, at Fair Value [Roll Forward] A A A A A Fair value, beginning balance [14],[15],[21] 3,226 A A A A A Investment, Identifier [Axis]: Ardonagh Midco 3 PLC, Insurance Brokers, First Lien Term Loan 2 A A A A Tersera Therapeutics LLC A A A A A Investment, basis spread, variable rate (as a percent) [14],[15],[21] A A A 5.75% 5.75% Investment, interest rate (as a percent) [14],[15],[16],[21] A A A 11.57% 11.57% Investment owned, balance, principal amount [14],[15],[18],[21] A A A \$ 10,519 A Investments in and Advances to Affiliates, at Fair Value [Roll Forward] A A A A A Fair value, beginning balance [14],[15],[21] 10,624 A A A A A Investment, Identifier [Axis]: Ardonagh Midco 3 PLC, Insurance Brokers, First Lien Term Loan 3 A A A A Tersera Therapeutics LLC A A A A A Investment, basis spread, variable rate (as a percent) [14],[15],[21] A A A 7.00% 7.00% Investment, interest rate (as a percent) [14],[15],[16],[21] A A A 12.46% 12.46% Investment owned, balance, principal amount [A-][14],[15],[18],[21] A A A Ae 4,949 A Investments in and Advances to Affiliates, at Fair Value [Roll Forward] A A A A A Fair value, beginning balance [14],[15],[21] 6,101 A A A A A Investment, Identifier [Axis]: Ardonagh Midco 3 PLC, Insurance Brokers, First Lien Term Loan 4 A A A A Tersera Therapeutics LLC A A A A A Investment, basis spread, variable rate (as a percent) [14],[15],[21] A A A 7.00% 7.00% Investment, interest rate (as a percent) [14],[15],[16],[21] A A A 12.46% 12.46% Investment owned, balance, principal amount [A-][14],[15],[18],[21] A A A Ae 23,675 A Investments in and Advances to Affiliates, at Fair Value [Roll Forward] A A A A A Fair value, beginning balance [14],[15],[21] 29,185 A A A A A Investment, Identifier [Axis]: Ardonagh Midco 3 PLC, Insurance Brokers, First Lien Term Loan 5 A A A A Tersera Therapeutics LLC A A A A A Investment, basis spread, variable rate (as a percent) [14],[15],[21] A A A 5.75% 5.75% Investment, interest rate (as a percent) [14],[15],[16],[21] A A A 9.70% 9.70% Investment owned, balance, principal amount [A-][14],[15],[18],[21] A A A Ae 3,649 A Investments in and Advances to Affiliates, at Fair Value [Roll Forward] A A A A A Fair value, beginning balance [14],[15],[21] \$ 3,914 A A A A A Investment, Identifier [Axis]: Ares XLIV CLO, Multi-Sector Holdings, CLO Notes A A A A A Tersera Therapeutics LLC A A A A A Investment, basis spread, variable rate (as a percent) [10],[19] 7.13% A 7.13% 7.13% A A Investment, interest rate (as a percent) [10],[11],[19] 12.46% A 12.46% 12.46% A A A Investment owned, balance, principal amount [10],[17],[19] \$ 3,500 A A A A A Investments in and Advances to Affiliates, at Fair Value [Roll Forward] A A A A A Fair value, ending balance [10],[19] \$ 3,514 A A A A A Investment, Identifier [Axis]: Assembled Brands Capital LLC, Advertising, First Lien Revolver A A A A A Tersera Therapeutics LLC A A A A A Investment, basis spread, variable rate (as a percent) A 6.75% A A A A A Investment, interest rate (as a percent) A 12.29% A A A A A Investment owned, balance, principal amount A \$ 22,304 A A A Net Realized Gain (Loss) A O A A AmountA of Interest, Fees or Dividends CreditedA in Income A 1,985 A A A A A Investments in and Advances to Affiliates, at Fair Value [Roll Forward] A A A A A Fair value, beginning balance A 24,225 A A A A Gross Additions A 2,378 A A A A Gross Reductions A (4,417) A A A A Fair value, ending balance A \$ 22,186 A A A A A Investment owned, percent of net assets (as a percent) A 1.50% A A A A A Investment, Identifier [Axis]: Assembled Brands Capital LLC, Specialized Finance, Common Stock A A A A A Tersera Therapeutics LLC A A A A A Investment owned, balance (in shares) | shares 12,463,242 [7] 1,783,332 12,463,242 [7] 1,783,332 [15] 1,783,332 [15] 1,783,332 [15] Investment owned, balance, principal amount A \$ O A A A Net Realized Gain (Loss) \$ O O A A AmountA of Interest, Fees or Dividends CreditedA in Income O O A A A Investments in and Advances to Affiliates, at Fair Value [Roll Forward] A A A A A Fair value, beginning balance 89 [15] 370 A A A A Gross Additions 1,159 40 A A A A Gross Reductions (2) (410) A A A A A Fair value, ending balance \$ 1,246 [7] \$ O A A A A Investment owned, percent of net assets (as a percent) 0.10% 0.00% 0.10% 0.10% A A A A Investment, Identifier [Axis]: Assembled Brands Capital LLC, Specialized Finance, First Lien Revolver A A A A A Tersera Therapeutics LLC A A A A A Investment, basis spread, variable rate (as a percent) [12],[14],[15] A A A 6.75% 6.75% Investment, interest rate (as a percent) [12],[14],[15],[16] A A A 12.14% 12.14% Investment owned, balance, principal amount [12],[14],[15],[18] A A A \$ 21,852 A A Net Realized Gain (Loss) \$ O A A A A AmountA of Interest, Fees or Dividends CreditedA in Income 329 A A A A A Investments in and Advances to Affiliates, at Fair Value [Roll Forward] A A A A A Fair value, beginning balance [12],[14],[15] 21,823 A A A A A Gross Additions 33 A A A A A Gross Reductions (21,856) A A A A A Fair value, ending balance \$ O A A A A A Investment owned, percent of net assets (as a percent) 0.00% A 0.00% 0.00% A A A A Investment, Identifier [Axis]: Assembled Brands Capital LLC, Specialized Finance, Preferred Equity A A A A A Tersera Therapeutics LLC A A A A A Investment owned, balance (in shares) | shares A 1,129,453 A 1,129,453 [15] 1,129,453 [15] Investment owned, balance, principal amount A \$ O A A A Net Realized Gain (Loss) \$ O O A A AmountA of Interest, Fees or Dividends CreditedA in Income O O A A A Investments in and Advances to Affiliates, at Fair Value [Roll Forward] A A A A A Fair value, beginning balance 1,005 [15] 1,223 A A A A Gross Additions 153 189 A A A A Gross Reductions (1,158) O A A A A Fair value, ending balance \$ O \$ 1,412 A A A A A Investment owned, percent of net assets (as a percent) 0.00% 0.10% 0.00% 0.00% A A A A Investment, Identifier [Axis]: Assembled Brands Capital LLC, Specialized Finance, Warrants A A A A A Tersera Therapeutics LLC A A A A A Investment owned, balance (in shares) | shares 78,045 [7] 78,045 78,045 [7] 78,045 [15] 78,045 [15] 78,045 [15] Investment owned, balance, principal amount A \$ O A A A Net Realized Gain (Loss) \$ O O A A A AmountA of Interest, Fees or Dividends CreditedA in Income O O A A A Investments in and Advances to Affiliates, at Fair Value [Roll Forward] A A A A A Fair value, beginning balance O [15] O A A A A Gross Additions O O A A A Gross Reductions O O A A A Fair value, ending balance \$ O [7] \$ O A A A A Investment owned, percent of net assets (as a percent) 0.00% 0.00% 0.00% 0.00% A A A A Investment, Identifier [Axis]: Astra Acquisition Corp., Application Software, First Lien Term Loan A A A A A Tersera Therapeutics LLC A A A A A Investment, basis spread, variable rate (as a percent) [14] A A A 5.25% 5.25% Investment, interest rate (as a percent) [14],[16] A A A A 10.90% 10.90% Investment owned, balance, principal amount [14],[18] A A A \$ 8,490 A A Investments in and Advances to Affiliates, at Fair Value [Roll Forward] A A A A A Fair value, beginning balance [14] \$ 6,414 A A A A A Investment, Identifier [Axis]: Astra Acquisition Corp., Application Software, First Lien Term Loan 1 A A A A Tersera Therapeutics LLC A A A A A Investment, basis spread, variable rate (as a percent) [7],[10] 6.75% A 6.75% 6.75% A A A A Investment, interest rate (as a percent) [7],[10],[11] 12.08% A 12.08% 12.08% A A A Investment owned, balance, principal amount [7],[10],[17] \$ 7,927 A A A A A Investments in and Advances to Affiliates, at Fair Value [Roll Forward] A A A A A Fair value, ending balance [7],[10] \$ 7,273 A A A A A Investment, Identifier [Axis]: Astra Acquisition Corp., Application Software, First Lien Term Loan 2 A A A A A Tersera Therapeutics LLC A A A A A Investment, basis spread, variable rate (as a percent) [7],[10] 5.25% A 5.25% 5.25% A A A A Investment, interest rate (as a percent) [7],[10],[11] 10.58% A 10.58% 10.58% A A A Investment owned, balance, principal amount [7],[10],[17] \$ 12,537 A A A A A Investments in and Advances to Affiliates, at Fair Value [Roll Forward] A A A A A Fair value, ending balance [7],[10] \$ 5,881 A A A A A Investment, Identifier [Axis]: Aurelia Netherlands Midco 2 B.V., Interactive Media & Services, First Lien Term Loan A A A A A Tersera Therapeutics LLC A A A A A Investment, basis spread, variable rate (as a percent) [7],[10],[19] 5.75% A 5.75% 5.75% A A A A Investment, interest rate (as a percent) [7],[10],[11],[19] 9.55% A 9.55% 9.55% A A A A Investment owned, balance, principal amount [7],[10],[17],[19] \$ 28,022 A A A A A Investments in and Advances to Affiliates, at Fair Value [Roll Forward] A A A A A Fair value, ending balance [7],[10],[19] \$ 29,447 A A A A A Investment, Identifier [Axis]: Aurora Lux Fincos S.A.C.R.L., Airport services, First Lien Term Loan A A A A A Tersera Therapeutics LLC A A A A A Investment, basis spread, variable rate (as a percent) 7.00% [7],[10],[19] A 7.00% [7],[10],[19] 7.00% [7],[10],[19] 6.00% [14],[15],[21] 6.00% [14],[15],[21] 6.00% [14],[15],[21] Investment, interest rate (as a percent) 8.43% [7],[10],[11],[19] A 8.43% [7],[10],[11],[19] 8.43% [7],[10],[11],[19] 11.49% [14],[15],[16],[21] 11.49% [14],[15],[16],[21] 11.49% [14],[15],[16],[21] 11.49% [14],[15],[16],[21] Investment, interest rate, paid in kind (as a percent) [7],[10],[19] 4.00% A 4.00% 4.00% A A A A Investment owned, balance, principal amount \$ 30,406 [7],[10],[17],[19] A A \$ 29,509 [14],[15],[18],[21] A A A Investments in and Advances to Affiliates, at Fair Value [Roll Forward] A A A A A Fair value, beginning balance [14],[15],[21] 28,284 A A A A A Fair value, ending balance [7],[10],[19] \$ 29,372 A A A A A Investment, Identifier [Axis]: Avalara, Inc., Application Software, First Lien Revolver A A A A A Tersera Therapeutics LLC A A A A A Investment, basis spread, variable rate (as a percent) 7.25% [7],[8],[10] A 7.25% [7],[8],[10] 7.25% [7],[8],[10] 7.25% [12],[14],[15] 7.25% [12],[14],[15] Investment owned, balance, principal amount \$ O [7],[8],[10],[17] A A \$ O [12],[14],[15],[18] A A A Investments in and Advances to Affiliates, at Fair Value [Roll Forward] A A A A A Fair value, ending balance [7],[8],[10] \$ O A A A A A Investment, Identifier [Axis]: Avalara, Inc., Application Software, First Lien Term Loan A A A A A Tersera Therapeutics LLC A A A A A Investment, basis spread, variable rate (as a percent) 7.25% [7],[10] A 7.25% [7],[10] 7.25% [7],[10] 7.25% [14],[15] 7.25% [14],[15] Investment, interest rate (as a percent) 12.58% [7

[1],[2],[1],[22] A A Investments in and Advances to Affiliates, at Fair Value [Roll Forward] A A A A A Fair value, beginning balance [12],[15],[21],[22] 0 A A A A Fair value, ending balance [7],[8],[10],[19] 0 A A A A Investment, Identifier [Axis]: BioXcel Therapeutics, Inc., Pharmaceuticals, First Lien Term Loan 6 A A A A A Tersera Therapeutics LLC A A A A A Investment owned, balance, principal amount [12],[15],[18],[21],[22] A A A A \$ 0 A A A Investments in and Advances to Affiliates, at Fair Value [Roll Forward] A A A A A Fair value, beginning balance [12],[15],[21],[22] 0 A A A A Investment, Identifier [Axis]: BioXcel Therapeutics, Inc., Pharmaceuticals, Warrants A A A A A Tersera Therapeutics LLC A A A A A Investment owned, balance (in shares) | shares [15],[21] A A A 26,131 26,131 26,131 Investments in and Advances to Affiliates, at Fair Value [Roll Forward] A A A A A Fair value, beginning balance [15],[21] \$ 3 A A A A A Investment, Identifier [Axis]: BioXcel Therapeutics, Inc., Pharmaceuticals, Warrants 1 A A A A A Tersera Therapeutics LLC A A A A A Investment owned, balance (in shares) | shares [7],[19] 32,664 A A A A A Investments in and Advances to Affiliates, at Fair Value [Roll Forward] A A A A A Fair value, ending balance [7],[19] \$ 3 A A A A A Investment, Identifier [Axis]: BioXcel Therapeutics, Inc., Pharmaceuticals, Warrants 2 A A A A A Tersera Therapeutics LLC A A A A A Investment owned, balance (in shares) | shares [7],[19] 9,382 A A A A A Investments in and Advances to Affiliates, at Fair Value [Roll Forward] A A A A A Fair value, ending balance [7],[19] \$ 1 A A A A A Investment, Identifier [Axis]: Birch Grove CLO 2 LTD, Multi-Sector Holdings, CLO Notes A A A A A Tersera Therapeutics LLC A A A A A Investment, basis spread, variable rate (as a percent) [10],[19] 7.21% A A A A A Investment, interest rate (as a percent) [10],[11],[19] 12.54% A A A A A Investment owned, balance, principal amount [10],[17],[19] \$ 1,500 A A A A A Investments in and Advances to Affiliates, at Fair Value [Roll Forward] A A A A A Fair value, ending balance [10],[19] \$ 1,503 A A A A A Investment, Identifier [Axis]: Blackhawk Network Holdings, Inc., Data Processing & Outsourced Services, First Lien Term Loan A A A A A Tersera Therapeutics LLC A A A A A Investment, basis spread, variable rate (as a percent) [10] 5.00% A A A A A Investment, interest rate (as a percent) [10],[11] 10.34% A A A A A Investment owned, balance, principal amount [10],[17] \$ 36,384 A A A A A Investments in and Advances to Affiliates, at Fair Value [Roll Forward] A A A A A Fair value, ending balance [10] 36,509 A A A A A Investment, Identifier [Axis]: Blackhawk Network Holdings, Inc., Data Processing & Outsourced Services, Second Lien Term Loan A A A A A Tersera Therapeutics LLC A A A A A Investment, basis spread, variable rate (as a percent) [14] A A A 7.00% 7.00% 7.00% Investment, interest rate (as a percent) [14],[16] A A A 12.43% 12.43% Investment owned, balance, principal amount [14],[18] A A A \$ 30,625 A A A Investments in and Advances to Affiliates, at Fair Value [Roll Forward] A A A A A Fair value, beginning balance [14] \$ 29,989 A A A A A Investment, Identifier [Axis]: Blumenthal Temecula, LLC, Automotive Retail, Common Stock A A A A A Tersera Therapeutics LLC A A A A A Investment owned, balance (in shares) | shares 394,297 [7] 394,297 [7] 394,297 [7] 394,297 [15] 394,297 [15] 394,297 [15] Investments in and Advances to Affiliates, at Fair Value [Roll Forward] A A A A A Fair value, beginning balance [15] \$ 158 A A A A A Fair value, ending balance [7] 154 A A A A A Investment, Identifier [Axis]: Blumenthal Temecula, LLC, Automotive Retail, First Lien Term Loan A A A A A Tersera Therapeutics LLC A A A A A Investment, interest rate (as a percent) [14],[15],[16] A A A 9.00% 9.00% Investment owned, balance, principal amount [15],[18] A A A \$ 5,257 A A A Investments in and Advances to Affiliates, at Fair Value [Roll Forward] A A A A A Fair value, beginning balance [15] \$ 5,251 A A A A A Investment, Identifier [Axis]: Blumenthal Temecula, LLC, Automotive Retail, Preferred Equity 1 A A A A A Tersera Therapeutics LLC A A A A A Investment owned, balance (in shares) | shares 1,708,618 [7] 1,708,618 [7] 1,708,618 [7] 1,708,618 [15] 1,708,618 [15] Investments in and Advances to Affiliates, at Fair Value [Roll Forward] A A A A A Fair value, beginning balance [15] \$ 1,999 A A A A A Fair value, ending balance [7] \$ 2,085 A A A A A Investment, Identifier [Axis]: Blumenthal Temecula, LLC, Automotive Retail, Preferred Equity 2 A A A A A Tersera Therapeutics LLC A A A A A Investment owned, balance (in shares) | shares 394,297 [7] 394,297 [7] 394,297 [15] 394,297 [15] Investments in and Advances to Affiliates, at Fair Value [Roll Forward] A A A A A Fair value, beginning balance [15] \$ 442 A A A A A Fair value, ending balance [7] \$ 457 A A A A A Investment, Identifier [Axis]: C5 Technology Holdings, LLC, Data Processing & Outsourced Services, Common Stock A A A A A Tersera Therapeutics LLC A A A A A Investment owned, balance (in shares) | shares 829 [7] 829 829 [7] 829 [7] 829 [15] 829 [15] 829 [15] Net Realized Gain (Loss) \$ 0 \$ 0 A A A A Amount of Interest, Fees or Dividends Credited in Income 0 0 A A A A Investments in and Advances to Affiliates, at Fair Value [Roll Forward] A A A A A Fair value, beginning balance 0 [15] 0 A A A A Gross Additions 0 0 A A A A Gross Reductions 0 0 A A A A Fair value, ending balance \$ 0 [7] \$ 0 A A A A Investment owned, percent of net assets (as a percent) 0.00% 0.00% 0.00% 0.00% A A A A Investment, Identifier [Axis]: C5 Technology Holdings, LLC, Data Processing & Outsourced Services, Preferred Equity A A A A A Tersera Therapeutics LLC A A A A A Investment owned, balance (in shares) | shares 34,984,460 [7] 34,984,460 [7] 34,984,460 [15] 34,984,460 [15] 34,984,460 [15] Net Realized Gain (Loss) \$ 0 \$ 0 A A A A Amount of Interest, Fees or Dividends Credited in Income 0 0 A A A A Investments in and Advances to Affiliates, at Fair Value [Roll Forward] A A A A A Fair value, beginning balance 27,638 [15] 27,638 A A A A A Gross Additions 0 0 A A A A Gross Reductions 0 0 A A A A Fair value, ending balance \$ 27,638 [7] \$ 27,638 A A A A Investment owned, percent of net assets (as a percent) 1.80% 1.80% 1.80% 1.80% A A A A Investment, Identifier [Axis]: CBAM 2017-2 LTD, Multi-Sector Holdings, CLO Notes A A A A A Tersera Therapeutics LLC A A A A A Investment, basis spread, variable rate (as a percent) [10],[19] 7.36% A A A 7.36% 7.36% A A A Investment, interest rate (as a percent) [10],[11],[19] 12.68% A A A A Investment owned, balance, principal amount [10],[17],[19] \$ 489 A A A A A Investments in and Advances to Affiliates, at Fair Value [Roll Forward] A A A A A Fair value, ending balance [10],[19] \$ 468 A A A A A Investment, Identifier [Axis]: CD&R Firefly Bidco Limited, Application Software, First Lien Revolver A A A A A Tersera Therapeutics LLC A A A A A Investment, basis spread, variable rate (as a percent) [7],[8],[10] 6.00% 6.00% A A A Investment owned, balance, principal amount [7],[8],[10],[17] \$ 0 A A A A A Investments in and Advances to Affiliates, at Fair Value [Roll Forward] A A A A A Fair value, ending balance [7],[8],[10] \$ (33) A A A A A Investment, Identifier [Axis]: CD&R Firefly Bidco Limited, Application Software, First Lien Term Loan A A A A A Tersera Therapeutics LLC A A A A A Investment, basis spread, variable rate (as a percent) [7],[10] 3.00% A A A A A Investment, interest rate (as a percent) [7],[10],[11] 8.33% A A A 8.33% 8.33% A A A Investment, interest rate, paid in kind (as a percent) [7],[10] 3.50% A A A 3.50% A A A Investment owned, balance, principal amount [7],[10],[17] \$ 12,712 A A A A A Investments in and Advances to Affiliates, at Fair Value [Roll Forward] A A A A A Fair value, ending balance [7],[10] \$ 12,417 A A A A A Investment, Identifier [Axis]: CD&R Firefly Bidco Limited, Other Specialty Retail, First Lien Term Loan 1 A A A A A Tersera Therapeutics LLC A A A A A Investment, basis spread, variable rate (as a percent) [10],[19] 5.75% A A A 5.75% 5.75% A A A Investment, interest rate (as a percent) [10],[11],[19] 11.06% A A A A Investment owned, balance, principal amount [10],[17],[19] \$ 1,500 A A A A A Investments in and Advances to Affiliates, at Fair Value [Roll Forward] A A A A A Fair value, ending balance [10],[19] \$ 1,900 A A A A A Investment, Identifier [Axis]: CD&R Firefly Bidco Limited, Other Specialty Retail, First Lien Term Loan 2 A A A A A Tersera Therapeutics LLC A A A A A Investment, basis spread, variable rate (as a percent) [10],[19] 5.75% A A A 5.75% 5.75% A A A Investment, interest rate (as a percent) [10],[11],[19] 10.95% A A A A A Investment owned, balance, principal amount [10],[17],[19] \$ 14,807 A A A A A Investments in and Advances to Affiliates, at Fair Value [Roll Forward] A A A A A Fair value, ending balance [10],[19] \$ 18,771 A A A A A Investment, Identifier [Axis]: CD&R Firefly Bidco Limited, Other Specialty Retail, First Lien Term Loan 3 A A A A A Tersera Therapeutics LLC A A A A A Investment, basis spread, variable rate (as a percent) [10],[19] 5.50% A A A 5.50% 5.50% A A A Investment, interest rate (as a percent) [10],[11],[19] 10.70% A A A A A Investment owned, balance, principal amount [10],[17],[19] \$ 13,225 A A A A A Investments in and Advances to Affiliates, at Fair Value [Roll Forward] A A A A A Fair value, ending balance [10],[19] 16,755 A A A A A Investment, Identifier [Axis]: CPC Acquisition Corp., Specialty Chemicals, Second Lien Term Loan A A A A A Tersera Therapeutics LLC A A A A A Investment, basis spread, variable rate (as a percent) [14],[15],[24] A A A 7.75% 7.75% 7.75% Investment owned, balance, principal amount [14],[15],[18],[24] A A A \$ 727 A A A A Investments in and Advances to Affiliates, at Fair Value [Roll Forward] A A A A A Fair value, beginning balance [14],[15],[24] 396 A A A A A Investment, Identifier [Axis]: Cadence Aerospace, LLC, Aerospace & Defense, First Lien Term Loan 1 A A A A A Tersera Therapeutics LLC A A A A A Investment, basis spread, variable rate (as a percent) [14],[15] A A A 6.50% 6.50% 6.50% Investment, interest rate (as a percent) [14],[15],[16] A A A 12.07% 12.07% Investment owned, balance, principal amount [14],[15],[18] A A A \$ 37 A A A A Investments in and Advances to Affiliates, at Fair Value [Roll Forward] A A A A A Fair value, beginning balance [14],[15] 37 A A A A A Investment, Identifier [Axis]: Cadence Aerospace, LLC, Aerospace & Defense, First Lien Term Loan 2 A A A A A Tersera Therapeutics LLC A A A A A Investment, basis spread, variable rate (as a percent) [14],[15] A A A 6.50% 6.50% 6.50% Investment, interest rate (as a percent) [14],[15],[16] A A A 12.07% 12.07% Investment owned, balance, principal amount [14],[15],[18] A A A \$ 3,031 A A A A Investments in and Advances to Affiliates, at Fair Value [Roll Forward] A A A A A Fair value, beginning balance [14],[15] 3,031 A A A A A Investment, Identifier [Axis]: Cadence Aerospace, LLC, Aerospace & Defense, First Lien Term Loan 3 A A A A A Tersera Therapeutics LLC A A A A A Investment, basis spread, variable rate (as a percent) [14],[15] A A A 6.50% 6.50% 6.50% Investment, interest rate (as a percent) [14],[15],[16] A A A 12.07% 12.07% Investment owned, balance, principal amount [14],[15],[18] A A A \$ 1,557 A A A A Investments in and Advances to Affiliates, at Fair Value [Roll Forward] A A A A A Fair value, beginning balance [14],[15] 1,557 A A A A A Investment, Identifier [Axis]: Cadence Aerospace, LLC, Aerospace & Defense, First Lien Term Loan 4 A A A A A Tersera Therapeutics LLC A A A A A

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

Revolver A A A A A Tersera Therapeutics LLC A A A A A Investment, basis spread, variable rate (as a percent) [7],[8],[10] 5.25% A 5.25% 5.25% A A Investment owned, balance, principal amount [7],[8],[10],[17] \$ 0 A A A A Investments in and Advances to Affiliates, at Fair Value [Roll Forward] A A A A A Fair value, ending balance [7],[8],[10] \$ (39) A A A A A Investment, Identifier [Axis]: Protein For Pets Opco, LLC, Packaged Foods & Meats, First Lien Term Loan A A A A A Tersera Therapeutics LLC A A A A A A A A A A Investment, basis spread, variable rate (as a percent) [7],[10] 5.25% A 5.25% 5.25% A A Investment, interest rate (as a percent) [7],[10],[11] 10.59% A 10.59% 10.59% A A Investment owned, balance, principal amount [7],[10],[17] \$ 20,325 A A A A A Investments in and Advances to Affiliates, at Fair Value [Roll Forward] A A A A A Fair value, ending balance [7],[10] 19,951 A A A A A Investment, Identifier [Axis]: Quantum Bidco Limited, Food Distributors, First Lien Term Loan A A A A A Tersera Therapeutics LLC A A A A A A A A A A Investment, basis spread, variable rate (as a percent) [14],[15],[21] A A A A 5.75% 5.75% 5.75% Investment, interest rate (as a percent) [14],[15],[16],[21] A A A A 11.21% 11.21% 11.21% Investment owned, balance, principal amount A E [14],[15],[18],[21] A A A A A A A A 4,626 Investments in and Advances to Affiliates, at Fair Value [Roll Forward] A A A A A A A A Fair value, beginning balance [14],[15],[21] \$ 5,166 A A A A A A A A A A Investment, Identifier [Axis]: Quantum Bidco Limited, Food Distributors, First Lien Term Loan 1 A A A A A Tersera Therapeutics LLC A A A A A A A A A A Investment, basis spread, variable rate (as a percent) [7],[10],[19] 5.50% A 5.50% 5.50% A A A A A A A A A A Investment, interest rate (as a percent) [7],[10],[11],[19] 10.98% A 10.98% 10.98% A A A A A Investment owned, balance, principal amount A E [7],[10],[17],[19] A A A A A A A A A A Investments in and Advances to Affiliates, at Fair Value [Roll Forward] A A A A A A A A A A Fair value, ending balance [7],[10],[19] \$ 11,942 A A A A A A A A A A Investment, Identifier [Axis]: Quantum Bidco Limited, Food Distributors, First Lien Term Loan 2 A A A A A A A A A A Tersera Therapeutics LLC A A A A A A A A A A Investment, basis spread, variable rate (as a percent) [7],[8],[10],[19] 5.50% A 5.50% 5.50% A A A A A A A A A A Investment, interest rate (as a percent) [7],[8],[10],[11],[19] 10.70% A 10.70% 10.70% A A A A A A A A A A Investment owned, balance, principal amount [7],[8],[10],[17],[19] \$ 2,123 A A A A A A A A A A Investments in and Advances to Affiliates, at Fair Value [Roll Forward] A A A A A A A A A A Fair value, ending balance [7],[8],[10],[19] \$ 2,550 A A A A A A A A A A Investment, Identifier [Axis]: QuorumLabs, Inc., Application Software, Preferred Equity A A A A A Tersera Therapeutics LLC A A A A A A A A A A Investment owned, balance (in shares) A shares 64,887,669 [7] 64,887,669 [7] 64,887,669 [7] 64,887,669 [15] 64,887,669 [15] 64,887,669 [15] Investments in and Advances to Affiliates, at Fair Value [Roll Forward] A A A A A A A A A A Fair value, beginning balance [15] \$ 0 A A A A A A A A A A Fair value, ending balance [7] \$ 0 A A A A A A A A A A Investment, Identifier [Axis]: Relativity ODA LLC, Application Software, First Lien Revolver A A A A A Tersera Therapeutics LLC A A A A A A A A A A Investment, basis spread, variable rate (as a percent) 6.50% [7],[8],[10] 6.50% [7],[8],[10] 6.50% [7],[8],[10] 6.50% [12],[14],[15] 6.50% [12],[14],[15] 6.50% [12],[14],[15] Investment owned, balance, principal amount \$ 0 [7],[8],[10],[17] A A \$ 0 [12],[14],[15],[18] A A A A A A A A A A Investments in and Advances to Affiliates, at Fair Value [Roll Forward] A A A A A A A A A A Fair value, beginning balance [12],[14],[15] (47) A A A A A A A A A A Fair value, ending balance [7],[8],[10] \$ (11) A A A A A A A A A A Investment, Identifier [Axis]: Relativity ODA LLC, Application Software, First Lien Term Loan A A A A A A A A A A Tersera Therapeutics LLC A A A A A A A A A A Investment, basis spread, variable rate (as a percent) 6.00% [7],[10] 6.00% [7],[10] 6.00% [7],[10] 6.50% [14],[15] 6.50% [14],[15] 6.50% [14],[15] 6.50% [14],[15] Investment, interest rate (as a percent) 11.44% [7],[10],[11] 11.44% [7],[10],[11] 11.44% [7],[10],[11] 11.92% [14],[15],[16] 11.92% [14],[15],[16] 11.92% [14],[15],[16] 11.92% [14],[15],[16] Investment owned, balance, principal amount \$ 32,329 [7],[10],[17] A A \$ 32,329 [14],[15],[18] A A A A A A A A A A Investments in and Advances to Affiliates, at Fair Value [Roll Forward] A A A A A A A A A A Fair value, beginning balance [14],[15] 31,779 A A A A A A A A A A Fair value, ending balance [7],[10] \$ 32,200 A A A A A A A A A A Investment, Identifier [Axis]: Research & Consulting Services, First Lien Term Loan A A A A A A A A A A Tersera Therapeutics LLC A A A A A A A A A A Investment, basis spread, variable rate (as a percent) [10] 4.75% A 4.75% 4.75% A A A A A A A A A A Investment, interest rate (as a percent) [10],[11] 10.09% A 10.09% 10.09% A A A A A A A A A A Investment owned, balance, principal amount [10],[17] \$ 4,913 A A A A A A A A A A Investments in and Advances to Affiliates, at Fair Value [Roll Forward] A A A A A A A A A A Fair value, ending balance [10] \$ 4,939 A A A A A A A A A A Investment, Identifier [Axis]: RumbleOn, Inc., Automotive Retail, First Lien Term Loan 1 A A A A A A A A A A Tersera Therapeutics LLC A A A A A A A A A A Investment, basis spread, variable rate (as a percent) 8.25% [7],[10],[19] 8.25% [7],[10],[19] 8.25% [7],[10],[19] 8.25% [7],[10],[19] 8.25% [14],[15],[21] 8.25% [14],[15],[21] 8.25% [14],[15],[21] Investment, interest rate (as a percent) 13.84% [7],[10],[11],[19] 13.84% [7],[10],[11],[19] 13.84% [7],[10],[11],[19] 13.84% [7],[10],[11],[19] 13.90% [14],[15],[16],[21] 13.90% [14],[15],[16],[21] 13.90% [14],[15],[16],[21] Investment, interest rate, paid in kind (as a percent) 0.50% [7],[10],[19] 0.50% [7],[10],[19] 0.50% [7],[10],[19] 0.50% [7],[10],[19] 0.50% [14],[15],[21] 0.50% [14],[15],[21] 0.50% [14],[15],[21] Investment owned, balance, principal amount \$ 8,812 [7],[10],[17],[19] A A \$ 36,707 [14],[15],[18],[21] A A A A A A A A A A Investments in and Advances to Affiliates, at Fair Value [Roll Forward] A A A A A A A A A A Fair value, beginning balance [14],[15],[21] 34,505 A A A A A A A A A A Fair value, ending balance [7],[10],[19] \$ 8,305 A A A A A A A A A A Investment, Identifier [Axis]: RumbleOn, Inc., Automotive Retail, First Lien Term Loan 2 A A A A A A A A A A Tersera Therapeutics LLC A A A A A A A A A A Investment, basis spread, variable rate (as a percent) 8.25% [7],[10],[19] 8.25% [7],[10],[19] 8.25% [7],[10],[19] 8.25% [7],[10],[19] 8.25% [14],[15],[21] 8.25% [14],[15],[21] 8.25% [14],[15],[21] Investment, interest rate (as a percent) 13.84% [7],[10],[11],[19] 13.84% [7],[10],[11],[19] 13.84% [7],[10],[11],[19] 13.84% [7],[10],[11],[19] 13.90% [14],[15],[16],[21] 13.90% [14],[15],[16],[21] 13.90% [14],[15],[16],[21] Investment, interest rate, paid in kind (as a percent) 0.50% [7],[10],[19] 0.50% [7],[10],[19] 0.50% [7],[10],[19] 0.50% [7],[10],[19] 0.50% [14],[15],[21] 0.50% [14],[15],[21] 0.50% [14],[15],[21] Investment owned, balance, principal amount \$ 29,198 [7],[10],[17],[19] A A \$ 13,504 [14],[15],[18],[21] A A A A A A A A A A Investments in and Advances to Affiliates, at Fair Value [Roll Forward] A A A A A A A A A A Fair value, beginning balance [14],[15],[21] 12,694 A A A A A A A A A A Fair value, ending balance [7],[10],[19] \$ 27,519 A A A A A A A A A A Investment, Identifier [Axis]: RumbleOn, Inc., Automotive Retail, Warrants A A A A A A A A A A Tersera Therapeutics LLC A A A A A A A A A A Investment owned, balance (in shares) A shares 204,454 [7],[19] 204,454 [7],[19] 204,454 [15],[21] 204,454 [15],[21] 204,454 [15],[21] Investments in and Advances to Affiliates, at Fair Value [Roll Forward] A A A A A A A A A A Fair value, beginning balance [15],[21] \$ 756 A A A A A A A A A A Fair value, ending balance [7],[19] \$ 399 A A A A A A A A A A Investment, Identifier [Axis]: SCIH Salt Holdings Inc., Diversified Chemicals, Fixed Rate Bond A A A A A A A A A A Tersera Therapeutics LLC A A A A A A A A A A Investment, interest rate (as a percent) [10],[11] 4.88% A 4.88% 4.88% A A A A A A A A A A Investment owned, balance, principal amount [17] \$ 1,680 A A A A A A A A A A Investments in and Advances to Affiliates, at Fair Value [Roll Forward] A A A A A A A A A A Fair value, ending balance 1,565 A A A A A A A A A A Investment, Identifier [Axis]: SCP Eye Care Services, LLC, Health Care Services, Common Stock A A A A A A A A A A Tersera Therapeutics LLC A A A A A A A A A A Investment owned, balance (in shares) A shares 15 A A A 1,037 1,037 1,037 Investments in and Advances to Affiliates, at Fair Value [Roll Forward] A A A A A A A A A A Fair value, beginning balance [15] 951 A A A A A A A A A A Investment, Identifier [Axis]: SCP Eye Care Services, LLC, Health Care Services, Second Lien Term Loan 1 A A A A A A A A A A Tersera Therapeutics LLC A A A A A A A A A A Investment, basis spread, variable rate (as a percent) [14],[15] A A A A 8.75% 8.75% 8.75% Investment, interest rate (as a percent) [14],[15],[16] A A A A 14.18% 14.18% 14.18% Investment owned, balance, principal amount [14],[15],[18] A A A A \$ 8,010 A A A A A A A A A A Investments in and Advances to Affiliates, at Fair Value [Roll Forward] A A A A A A A A A A Fair value, beginning balance [14],[15] 7,778 A A A A A A A A A A Investment, Identifier [Axis]: SCP Eye Care Services, LLC, Health Care Services, Second Lien Term Loan 2 A A A A A A A A A A Tersera Therapeutics LLC A A A A A A A A A A Investment, basis spread, variable rate (as a percent) [12],[14],[15] A A A A 8.75% 8.75% 8.75% Investment owned, balance, principal amount [12],[14],[15],[18] A A A A \$ 0 A A A A A A A A A A Investments in and Advances to Affiliates, at Fair Value [Roll Forward] A A A A A A A A A A Fair value, beginning balance [12],[14],[15] \$ (68) A A A A A A A A A A Investment, Identifier [Axis]: SIO2 Medical Products, Inc., Metal, Glass & Plastic Containers, Common Stock A A A A A A A A A A Tersera Therapeutics LLC A A A A A A A A A A Investment owned, balance (in shares) A shares 1,184,630 [7] 1,184,630 [7] 1,184,630 [15] 1,184,630 [15] 1,184,630 [15] Net Realized Gain (Loss) \$ 0 A A A A A A A A A A AmountA of Interest, Fees or Dividends CreditedA in Income 0 A A A A A A A A A A Investments in and Advances to Affiliates, at Fair Value [Roll Forward] A A A A A A A A A A Fair value, beginning balance [15] 36,226 A A A A A A A A A A Gross Additions 0 A A A A A A A A A A Gross Reductions (12,678) A A A A A A A A A A Fair value, ending balance [7] \$ 23,548 A A A A A A A A A A Investment owned, percent of net assets (as a percent) 1.60% A 1.60% 1.60% A A A A A A A A A A Investment, Identifier [Axis]: SIO2 Medical Products, Inc., Metal, Glass & Plastic Containers, First Lien Term Loan 1 A A A A A A A A A A Tersera Therapeutics LLC A A A A A A A A A A Investment, interest rate, paid in kind (as a percent) [7],[8] 12.00% A 12.00% 12.00% A A A A A A A A A A Investment owned, balance, principal amount [7],[8],[17] \$ 2,682 A A A A A A A A A A Net Realized Gain (Loss) 0 A A A A A A A A A A AmountA of Interest, Fees or Dividends CreditedA in Income 71 A A A A A A A A A A Investments in and Advances to Affiliates, at Fair Value [Roll Forward] A A A A A A A A A A Fair value, beginning balance 0 A A A A A A A A A A Gross Additions 2,682 A A A A A A A A A A Gross Reductions 0 A A A A A A A A A A Fair value, ending balance [7],[8] \$ 2,682 A A A A A A A A A A Investment owned, percent of net assets (as a percent) 0.20% A 0.20% 0.20% A A A A A A A A A A Investment, Identifier [Axis]: SIO2 Medical Products, Inc., Metal, Glass & Plastic Containers, First Lien Term Loan 2 A A A A A A A A A A Tersera Therapeutics LLC A A A A A A A A A A Investment, interest rate, paid in kind (as a percent) 12.00% [7] A 12.00% [7] 12.00% [7] 12.00% [15] 12.00% [15] Investment owned, balance, principal amount \$ 17,363 [7],[17] A A A \$ 15,874 [15],[18] A A A Net Realized Gain (Loss) 0 A A A A A A A A A A AmountA of Interest, Fees or Dividends CreditedA in Income 1,650 A A A A A A A A A A Investments in and Advances to Affiliates, at Fair Value [Roll Forward] A A A A A A A A A A Fair value, beginning balance [15] 15,874 A A A A A A A A A A Gross Additions 1,643 A A A A A A A A A A Gross Reductions (154) A A A A A A A A A A Fair value, ending balance [7] \$ 17,363 A A A A A A A A A A Investment owned, percent of net assets (as a percent) 1.20% A 1.20% 1.20% A A A A A A A A A A Investment, Identifier [Axis]: SIO2 Medical Products, Inc., Metal, Glass & Plastic Containers, First Lien Term Loan 3 A A A A A A A A A A Tersera Therapeutics LLC A A A A A A A A A A Investment, interest rate, paid in kind (as a percent) 12.00% [7] A 12.00% [7] 12.00% [7] 12.00% [12],[15] 12.00% [12],[15] 12.00% [12],[15] Investment owned, balance, principal amount \$ 3,442 [7],[17] A A A \$ 1,359 [12],[15],[18] A A A Net Realized Gain (Loss) 0 A A A A A A A A A A AmountA of Interest, Fees or Dividends CreditedA in Income 275 A A A A A A A A A A Investments in and Advances to Affiliates, at Fair Value [Roll Forward] A A A A A A A A A A Fair value, beginning balance [12],[15] 1,359 A A A A A A A A A A Gross Additions 2,083 A A A A A A A A A A Gross Reductions 0 A A A A A A A A A A Fair value, ending balance [7] \$ 3,442 A A A A A A A A A A Investment owned, percent of net assets (as a percent) 0.20% A 0.20% 0.20% A A A A A A A A A A Investment, Identifier [Axis]: SIO2 Medical Products, Inc., Metal, Glass & Plastic Containers, Warrants A A A A A A A A A A Tersera Therapeutics LLC A A A A A A A A A A Investment owned, balance (in shares) A shares 66,686 [7] 66,686 [7] 66,686 [15] 66,686 [15] 66,686 [15] Net Realized Gain (Loss) \$ 0 A A A A A A A A A A AmountA of Interest, Fees or Dividends CreditedA in Income 0 A A A A A A A A A A Investments in and Advances to Affiliates, at Fair Value [Roll Forward] A A A A A A A A A A Fair value, beginning balance [15] 0 A A A A A A A A A A Gross Additions 0 A A A A A A A A A A Gross Reductions 0 A A A A A A A A A A Fair value, ending balance [7] \$ 0 A A A A A A A A A A Investment owned, percent of net assets (as a percent) 0.00% A 0.00% 0.00% A A A A A A A A A A Investment, Identifier [Axis]: SM Wellness Holdings, Inc., Health Care Services, First Lien Term Loan A A A A A A A A A A Tersera Therapeutics LLC A A A A A A A A A A Investment, basis spread, variable rate (as a percent) 4.50% [7],[10] 4.50% [7],[10] 4.50% [7],[10] 4.75% [14],[15] 4.75% [14],[15] 4.75% [14],[15] Investment, interest rate (as a percent) 10.09% [7],[10],[11] 10.09% [7],[10],[11] 10.09% [7],[10],[11] 10.38% [14],[15],[16] 10.38% [14],[15],[16] 10.38% [14],[15],[16] Investment owned, balance, principal amount \$ 4,418 [7],[10],[17] A A \$ 4,452 [14],[15],[18] A A A A A A A A A A Investments in and Advances to Affiliates, at Fair Value [Roll Forward] A A A A A A A A A A Fair value, beginning balance [14],[15] 4,184 A A A A A A A A A A Fair value, ending balance [7],[10] \$ 4,368 A A A A A A A A A A Investment, Identifier [Axis]: SM Wellness Holdings, Inc., Health Care Services, Second Lien Term Loan A A A A A A A A A A Tersera Therapeutics LLC A A A A A A A A A A Investment, basis spread, variable rate (as a percent) 8.00% [7],[10] 8.00% [7],[10] 8.00% [7],[10] 8.00% [7],[10] 8.00% [14],[15] 8.00% [14],[15] 8.00% [14],[15] Investment, interest rate (as a percent) 13.59% [7],[10],[11] 13.59% [7],[10],[11] 13.59% [7],[10],[11] 13.59% [7],[10],[11] 13.63% [14],[15],[16] 13.63% [14],[15],[16] 13.63% [14],[15],[16] Investment owned, balance, principal amount \$ 12,034 [7],[10],[17] A A A \$ 12,034 [14],[15],[18] A A A A A A A A A A Investments in and Advances to Affiliates, at Fair Value [Roll Forward] A A A A A A A A A A Fair value, beginning balance [14],[15] 9,928 A A A A A A A A A A Fair value, ending balance [7],[10] \$ 10,650 A A A A A A A A A A Investment, Identifier [Axis]: SPX Flow, Inc., Industrial Machinery & Supplies & Components, Fixed Rate Bond A A A A A A A A A A Tersera Therapeutics LLC A A A A A A A A A A Investment, interest rate (as a percent) [10],[11] 8.75% A 8.75% 8.75% A A A A A A A A A A Investment owned, balance, principal amount [17] \$ 1,109 A A A A A A A A A A Investments in and Advances to Affiliates, at Fair Value [Roll Forward] A A A A A A A A A A Fair value, ending balance \$ 1,140 A A A A A A A A A A Investment, Identifier [Axis]: SVP-Singer Holdings Inc., Home Furnishings, First Lien Term Loan A A A A A A A A A A Tersera Therapeutics LLC A A A A A A A A A A Investment, basis spread, variable rate (as a percent) 8.25% [7],[10],[23] 8.25% [7],[10],[23] 8.25% [7],[10],[23] 8.25% [7],[10],[23] 6.75% [14],[15] 6.75% [14],[15] 6.75% [14],[15] Investment, interest rate (as a percent) [14],[15],[16] A A A A 12.40% 12.40% 12.40% Investment owned, balance, principal amount \$ 27,164 [7],[10],[17],[23] A A A \$ 25,527 [14],[15],[18] A A A A A A A A A A Investments in and Advances to Affiliates, at Fair Value [Roll Forward] A A A A A A A A A A Fair value, beginning balance [14],[15] 19,954 A A A A A A A A A A Fair value, ending balance [7],[10],[23] \$ 15,076 A A A A A A A A A A Investment, Identifier [Axis]: Salus Workers' Compensation, LLC, Diversified Financial Services, First Lien Revolver A A A A A A A A A A Tersera Therapeutics LLC A A A A A A A A A A Investment, basis spread, variable rate (as a percent) 10.00% [7],[8],[10] 10.00% [7],[8],[10] 10.00% [7],[8],[10] 10.00% [12],[14],[15] 10.00% [12],[14],[15] 10.00% [12],[14],[15] Investment owned, balance, principal amount \$ 0 [7],[8],[10],[17] A A \$ 0 [12],[14],[15],[18] A A A A A A A A A A Investments in and Advances to Affiliates, at Fair Value [Roll Forward] A A A A A A A A A A Fair value, beginning balance [12],[14],[15] (93) A A A A A A A A A A Fair value, ending balance [7],[8],[10] \$ (109) A A A A A A A A A A Investment, Identifier [Axis]: Salus Workers' Compensation, LLC, Diversified Financial Services, First Lien Term Loan A A A A A A A A A A Tersera Therapeutics LLC A A A A A A A A A A Investment, basis spread, variable rate (as a percent) 10.00% [7],[10] 10.00% [7],[10] 10.00% [7],[10] 10.00% [7],[10] 10.00% [14],[15] 10.00% [14],[15] 10.00% [14],[15] Investment, interest rate (as a percent) 15.33% [7],[10],[11] 15.33% [7],[10],[11] 15.33% [7],[10],[11] 15.33% [7],[10],[11] 15.24% [14],[15],[16] 15.24% [14],[15],[16] 15.24% [14],[15],[16] Investment owned, balance, principal amount \$ 25,279 [7],[10],[17] A A A \$ 25,558 [14],[15],[18] A A A A A A A A A A Investments in and Advances to Affiliates, at Fair Value [Roll Forward] A A A A A A A A A A Fair value, beginning balance [14],[15] 24,791 A A A A A A A A A A Fair value, ending balance [7],[10] \$ 24,394 A A A A A A A A A A Investment, Identifier [Axis]: Salus Workers' Compensation, LLC, Diversified Financial Services, Warrants A A A A A A A A A A Tersera Therapeutics LLC A A A A A A A A A A Investment owned, balance (in shares) A shares 991,019 [7] 991,019 [7] 991,019 [15] 991,019 [15] Investments in and Advances to Affiliates, at Fair Value [Roll Forward] A A A A A A A A A A Fair value, beginning balance [15] \$ 1,625 A A A A A A A A A A Fair value, ending balance [15] 991,019 A A A A A A A A A A Investment, Identifier [Axis]: Saratoga, Diversified Financial Services, Credit Linked Notes A A A A A A A A A A Tersera Therapeutics LLC A A A A A A A A A A Investment, basis spread, variable rate (as a percent) [7],[10],[19],[33] 5.33% A 5.33% 5.33% A A A A A A A A A A Investment, interest rate (as a percent) [7],[10],[11],[19],[33] 10.65% A 10.65% 10.65% A A A A A A A A A A Investment owned, balance, principal amount [7],[10],[17],[19],[33] \$ 24,500 A A A A A A A A A A Investment, Identifier [Axis]: Scilex Holding Co, Biotechnology, Common Stock A A A A A A A A A A Tersera Therapeutics LLC A A A A A A A A A A Investment owned, balance (in shares) A shares 9,307 [19] 9,307 [19] 9,307 [19] 9,307 [21] 9,307 [21] 9,307 [21] Investments in and Advances to Affiliates, at Fair Value [Roll Forward] A A A A A A A A A A Fair value, beginning balance [21] \$ 13 A A A A A A A A A A Fair value, ending balance [19] \$ 18 A A A A A A A A A A Investment, Identifier [Axis]: Senior Loan Fund JV I, LLC, Multi-Sector Holdings, Membership Interest A A A A A A A A A A Tersera Therapeutics LLC A A A A A A A A A A Investment owned, ownership (as a percent) 87.50% [7],[8],[19],[28],[29],[30] 87.50% 87.50% [7],[8],[19],[28],[29],[30] 87.50% [7],[8],[19],[28],[29],[30] 87.50% [12],[21],[31],[32],[34] 87.50% [12],[21],[31],[32],[34] 87.50% [12],[21],[31],[32],[34] Net Realized Gain (Loss) \$ 0 A A A A A A A A A A AmountA of Interest, Fees or Dividends CreditedA in Income 4,200 3,150 A A A A A A A A A A Investments in and Advances to Affiliates, at Fair Value [Roll Forward] A A A A A A A A A A Fair value, beginning balance 28,878 [12],[21],[31],[32],[34] 20,715 A A A A A A A A A A Gross Additions 0 7,258 A A A A A A A A A A Gross Reductions (3,061) 0 A A A A A A A A A A Fair value, ending balance \$ 25,817 [7],[8],[19],[28],[29],[30] \$ 27,973 A A A A A A A A A A Investment owned, percent of net assets (as a percent) 1.70% 1.90% 1.70% 1.70% A A A A A A A A A A Investment, Identifier [Axis]: Senior Loan Fund JV I, LLC, Multi-Sector Holdings, Subordinated Debt A A A A A A A A A A Tersera Therapeutics LLC A A A A A A A A A A Investment, basis spread, variable rate (as a percent) 7.00% [7],[8],[19],[29] 7.00% 7.00% [7],[8],[19],[29] 7.00% [7],[8],[19],[29] 7.00% [12],[14],[15],[21],[31] 7.00% [12],[14],[15],[21],[31] 7.00% [12],[14],[15],[21],[31] 7.00% [12],[14],[15],[21],[31] Investment, interest rate (as a percent) 12.44% [7],[8],[10],[11],[19],[29] 11.86% 12.44% [7],[8],[10],[11],[19],[29] 12.44% [7],[8],[10],[11],[19],[29] 12.44% [7],[8],[10],[11],[19],[29] 12.26% [12],[14],[15],[16],[21],[31] 12.26% [12],[14],[15],[16],[21],[31] 12.26% [12],[14],[15],[16],[21],[31] Investment owned, balance, principal amount \$ 112,656 [7],[8],[10],[17],[19],[29] \$ 112,656 [12],[14],[15],[18],[21],[31] A A A A A A A A A A Net Realized Gain (Loss) 0 A A A A A A A A A A AmountA of Interest, Fees or Dividends CreditedA in Income 10,672 9,197 A A A A A A A A A A Investments in and Advances to Affiliates, at Fair Value [Roll Forward] A A A A A A A A A A Fair value, beginning balance 112,656 [12],[14],[15],[21],[31] 96,250 A A A A A A A A A A Gross Additions 0 16,406 A A A A A A A A A A Gross Reductions 0 0 A A A A A A A A A A Fair value, ending balance \$ 112,656 [7],[8],[10],[19],[29] \$ 112,656 A A A A A A A A A A Investment owned, percent of net assets (as a percent) 7.50% 7.50% 7.50% 7.50% A A A A A A A A A A Investment, Identifier [Axis]: Seres Therapeutics, Inc., Biotechnology, First Lien Term Loan 1 A A A A A A A A A A Tersera Therapeutics LLC A A A A A A A A A A Investment, basis spread, variable rate (as a percent) 7.88% [7],[8],[10],[19] 7.88% [7],[8],[10],[19] 7.88% [7],[8],[10],[19] 7.88% [14],[15],[21] 7.88% [14],[15],[21] 7.88% [14],[15],[21] Investment, interest rate (as a percent) [14],[15],[16],[21] A A A 12.88% 12.88% 12.88% Investment owned, balance, principal amount \$ 0 [7],[8],[10],[17],[19] A A A \$ 7,191 [14],[15],[18],[21] A A A A A A A A A A Investments in and Advances to Affiliates, at Fair Value [Roll Forward] A A A A A A A A A A Fair value, beginning balance [14],[15],[21] 6,937 A A A A A A A A A A Fair

[illegible]

[illegible]

[5] 7.25% [12],[14],[15] Investment owned, balance, principal amount \$ 0 [7],[8],[10],[17] A A A \$ 0 [12],[14],[15],[18] A A Investments in and Advances to Affiliates, at Fair Value [Roll Forward] A A A A A Fair value, beginning balance [12],[14],[15] 0 A A A A A Fair value, ending balance [7],[8],[10] 0 A A A A A Investment, Identifier [Axis]: scPharmaceuticals Inc., Pharmaceuticals, First Lien Term Loan 1 A A A A A Tersera Therapeutics LLC A A A A A Investment, basis spread, variable rate (as a percent) 8.75% [7],[8],[10] 8.75% [7],[8],[10] 8.75% [7],[8],[10] 8.75% [14],[15] 8.75% [14],[15] Investment, interest rate (as a percent) [14],[15], [16] A A 11.75% 11.75% 11.75% Investment owned, balance, principal amount [14],[15], [18] A A A \$ 5,212 A A Investments in and Advances to Affiliates, at Fair Value [Roll Forward] A A A A A Fair value, beginning balance [14],[15] \$ 4,990 A A A A A Fair value, ending balance [7],[8],[10] 0 A A A A A Investment, Identifier [Axis]: scPharmaceuticals Inc., Pharmaceuticals, First Lien Term Loan 2 A A A A A Tersera Therapeutics LLC A A A A A Investment, basis spread, variable rate (as a percent) 8.75% [7],[8],[10] 8.75% [7],[8],[10] 8.75% [7],[8],[10] 8.75% [12],[14],[15] 8.75% [12],[14],[15] Investment owned, balance, principal amount \$ 0 [7],[8],[10],[17] A A A \$ 0 [12],[14],[15],[18] A A Investments in and Advances to Affiliates, at Fair Value [Roll Forward] A A A A A Fair value, beginning balance [12],[14],[15] 0 A A A A A Fair value, ending balance [7],[8],[10] 0 A A A A A Investment, Identifier [Axis]: scPharmaceuticals Inc., Pharmaceuticals, First Lien Term Loan 3 A A A A A Tersera Therapeutics LLC A A A A A Investment, basis spread, variable rate (as a percent) 8.75% [7],[10] 8.75% [7],[10] 8.75% [7],[10] 8.75% [12],[14],[15] 8.75% [12],[14],[15] Investment, interest rate (as a percent) [7],[10], [11] 11.75% A A 11.75% 11.75% A A Investment owned, balance, principal amount \$ 5,212 [7],[10],[17] A A A \$ 0 [12],[14],[15],[18] A A Investments in and Advances to Affiliates, at Fair Value [Roll Forward] A A A A A Fair value, beginning balance [12],[14],[15] 0 A A A A A Fair value, ending balance [7],[10] \$ 5,056 A A A A A Investment, Identifier [Axis]: scPharmaceuticals Inc., Pharmaceuticals, Warrants A A A A A Tersera Therapeutics LLC A A A A A Investment owned, balance (in shares) shares 53,700 [7] 53,700 [7] 53,700 [15] 53,700 [15] 53,700 [15] Investments in and Advances to Affiliates, at Fair Value [Roll Forward] A A A A A Fair value, beginning balance [15] \$ 258 A A A A A Fair value, ending balance [7] \$ 121 A A A A A [1] As defined in the Investment Company Act, the Company is deemed to be both an "Affiliated Person" of and to "Control" these portfolio companies as the Company owns more than 25% of the portfolio company's outstanding voting securities or has the power to exercise control over management or policies of such portfolio company (including through a management agreement). See Schedule 12-14 in the Company's annual report on Form 10-K for the year ended September 30, 2023 for transactions during the year ended September 30, 2023 in which the issuer was both an Affiliated Person and a portfolio company that the Company is deemed to control. [2] Control Investments generally are defined by the Investment Company Act as investments in companies in which the Company owns more than 25% of the voting securities or maintains greater than 50% of the board representation. [3] As defined in the Investment Company Act, the Company is deemed to be both an "Affiliated Person" of and to "Control" these portfolio companies as the Company owns more than 25% of the portfolio company's outstanding voting securities or has the power to exercise control over management or policies of such portfolio company (including through a management agreement). See Schedule 12-14 in the accompanying notes to the Consolidated Financial Statements for transactions during the nine months ended June 30, 2024 in which the issuer was both an Affiliated Person and a portfolio company that the Company is deemed to control. [4] Control Investments generally are defined by the Investment Company Act of 1940, as amended (the "Investment Company Act"), as investments in companies in which the Company owns more than 25% of the voting securities or maintains greater than 50% of the board representation. [5] Affiliate Investments generally are defined by the Investment Company Act as investments in companies in which the Company owns between 5% and 25% of the voting securities. [6] Affiliate Investments generally are defined by the Investment Company Act as investments in companies in which the Company owns between 5% and 25% of the voting securities. [7] As of June 30, 2024, these investments were categorized as Level 3 within the fair value hierarchy established by Financial Accounting Standards Board ("FASB") guidance under Accounting Standards Codification ("ASC") Topic 820, Fair Value Measurements and Disclosures ("ASC 820"). [8] Investment had undrawn commitments. Unamortized fees are classified as unearned income which reduces cost basis, which may result in a negative cost basis. A negative fair value may result from the unfunded commitment being valued below par. [9] This investment represents a participation interest in the underlying securities shown. [10] The interest rate on the principal balance outstanding for most of the floating rate loans is indexed to the secured overnight financing rate ("SOFR"), the euro interbank offered rate ("EURIBOR" or "E"), the sterling overnight index average ("SONIA") and/or an alternate base rate (e.g., prime rate), which typically resets semi-annually, quarterly, or monthly at the borrower's option. The borrower may also elect to have multiple interest reset periods for each loan. For each of these loans, the Company has provided the applicable margin over the reference rate based on each respective credit agreement and the cash interest rate as of period end. As of June 30, 2024, the reference rates for the Company's variable rate loans were the 30-day SOFR at 5.34%, the 90-day SOFR at 5.32%, the 180-day SOFR at 5.23%, the PRIME at 8.50%, the SONIA at 5.23% and the 90-day EURIBOR at 3.82%. Most loans include an interest floor, which generally ranges from 0% to 3.00%. SOFR and SONIA based contracts may include a credit spread adjustment that is charged in addition to the base rate and the stated spread. [11] Interest rates may be adjusted from period to period on certain term loans and revolvers. These rate adjustments may be either temporary in nature due to tier pricing arrangements or financial or payment covenant violations in the original credit agreements or permanent in nature per loan amendment or waiver documents. [12] Investment had undrawn commitments. Unamortized fees are classified as unearned income which reduces cost basis, which may result in a negative cost basis. A negative fair value may result from the unfunded commitment being valued below par. [13] This investment represents a participation interest in the underlying securities shown. [14] The interest rate on the principal balance outstanding for most of the floating rate loans is indexed to SOFR, the London Interbank Offered Rate ("LIBOR" or "L"), SONIA and/or an alternate base rate (e.g., prime rate), which typically resets semi-annually, quarterly, or monthly at the borrower's option. The borrower may also elect to have multiple interest reset periods for each loan. For each of these loans, the Company has provided the applicable margin over the reference rate based on each respective credit agreement and the cash interest rate as of period end. All LIBOR and SOFR shown above is in U.S. dollars unless otherwise noted. As of September 30, 2023, the reference rates for the Company's variable rate loans were the 30-day SOFR at 5.32%, the 90-day SOFR at 5.39%, the 180-day SOFR at 5.47%, the 30-day LIBOR at 5.43%, the 90-day LIBOR at 5.65%, the 180-day LIBOR at 5.90%, the PRIME at 8.50%, the SONIA at 5.19%, the 30-day EURIBOR at 3.42%, the 90-day EURIBOR at 3.82% and the 180-day EURIBOR at 3.95%. Most loans include an interest floor, which generally ranges from 0% to 2.75%. SOFR and SONIA based contracts may include a credit spread adjustment that is charged in addition to the base rate and the stated spread. [15] As of September 30, 2023, these investments were categorized as Level 3 within the fair value hierarchy established by ASC 820. [16] Interest rates may be adjusted from period to period on certain term loans and revolvers. These rate adjustments may be either temporary in nature due to tier pricing arrangements or financial or payment covenant violations in the original credit agreements or permanent in nature per loan amendment or waiver documents. [17] Principal includes accumulated payment in kind ("PIK") interest and is net of repayments, if any. æœÆ signifies the investment is denominated in British Pounds. "â,-" signifies the investment is denominated in Euros. All other investments are denominated in U.S. dollars. [18] Principal includes accumulated PIK interest and is net of repayments, if any. æœÆÆÆ signifies the investment is denominated in British Pounds. "â,-" signifies the investment is denominated in Euros. All other investments are denominated in U.S. dollars. [19] Investment is not a "qualifying asset" as defined under Section 55(a) of the Investment Company Act. Under the Investment Company Act, the Company may not acquire any non-qualifying asset unless, at the time the acquisition is made, qualifying assets represent at least 70% of the Company's total assets. As of June 30, 2024, qualifying assets represented 72.7% of the Company's total assets and non-qualifying assets represented 27.3% of the Company's total assets. [20] This investment represents a revenue interest financing term loan in which the Company receives periodic interest payments based on a percentage of revenues earned at the respective portfolio company over the life of the loan. [21] Investment is not a "qualifying asset" as defined under Section 55(a) of the Investment Company Act. Under the Investment Company Act, the Company may not acquire any non-qualifying asset unless, at the time the acquisition is made, qualifying assets represent at least 70% of the Company's total assets. As of September 30, 2023, qualifying assets represented 74.3% of the Company's total assets and non-qualifying assets represented 25.7% of the Company's total assets. [22] This investment represents a revenue interest financing term loan in which the Company receives periodic interest payments based on a percentage of revenues earned at the respective portfolio company over the life of the loan. [23] This investment was on non-accrual status as of June 30, 2024. [24] This investment was on non-accrual status as of September 30, 2023. [25] This investment represents Seller Earn Out Shares in Alvotech SA. The Seller Earn Out Shares will vest if, at any time through June 16, 2027, the Alvotech SA common share price is at or above a volume weighted average price ("VWAP") of \$20.00 per share for any ten trading days within any twenty trading day period. [26] This investment represents Seller Earn Out Shares in Alvotech SA. One half of the Seller Earn Out Shares will vest if, at any time through June 16, 2027, the Alvotech SA common share price is at or above a VWAP of \$15.00 per share for any ten trading days within any twenty trading day period, and the other half will vest, if at any time during such period, the common share price is at or above a VWAP of \$20.00 per share for any ten trading days within any twenty trading day period. [27] This investment was renamed during the three months ended June 30, 2024. For the periods prior to June 30, 2024, this investment was referenced as SCP Eye Care Services, LLC. [28] Income producing through payment of dividends or distributions. [29] See Note 3 in the accompanying notes to the Consolidated Financial Statements for portfolio composition. [30] This investment was valued using net asset value as a practical expedient for fair value. Consistent with ASC 820, these investments are excluded from the hierarchical levels. [31] See Note 3 in the accompanying notes to the Consolidated Financial Statements for portfolio composition. [32] This investment was valued using net asset value as a practical expedient for fair value. Consistent with ASC 820, these investments are excluded from the hierarchical levels. [33] This investment represents a credit default swap that functions, in substance, like a credit linked note and represents a credit risk transfer for a pool of reference assets owned by a bank. The Company fully funded margin up front and in return the Company receives periodic interest payments. The Company's risk of loss is limited to the principal amount disclosed herein. The reference assets are primarily composed of investment grade corporate debt. The Company may be exposed to counterparty risk, which could make it difficult for the Company to collect on obligations, thereby resulting in potentially significant losses. In addition, the Company only has a contractual relationship with the counterparty bank, and not with the reference obligors of the reference assets. Accordingly, the Company generally may have no right to directly enforce compliance by the reference obligors with the terms of the reference assets. The Company will not directly benefit from the reference assets and will not have the benefit of the remedies that would normally be available to a holder of such reference assets. In addition, in the event of the insolvency of the counterparty bank, the Company may be treated as a general creditor of such counterparty bank, and will not have any claim with respect to the reference assets. [34] Income producing through payment of dividends or distributions. [35] This investment was renamed during the three months ended March 31, 2023. For periods prior to March 31, 2023, this investment was referenced as PFNY Holdings, LLC. X - DefinitionInvestment Owned, Ownership Percentage + ReferencesNo definition available. + Details Name: ocsI_InvestmentOwnedOwnershipPercentage Namespace Prefix: ocsI_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionRepresents the total of interest and dividend income, including any amortization and accretion (as applicable) of discounts and premiums, earned from (1) loans and leases whether held-for-sale or held-in-potential; (2) investment securities; (3) federal funds sold; (4) securities purchased under agreements to resell; (5) investments in banker's acceptances, commercial paper, or certificates of deposit; (6) dividend income; or (7) other investments not otherwise specified herein. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 45 -Paragraph 39 -Publisher FASB -URI https://asc.fasb.org/1943274/21474800228/946-830-45-39Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph 1 -Subparagraph (SX 210.9-04.1-5) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483589/942-220-S99-1 + Details Name: us-gaap_InterestAndDividendIncomeOperating Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type

[illegible]

S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480032/946-320-S99-1Reference 18:

[illegible]

[illegible]

us-gaap_InvestmentIdentifierAxis=Oranje Holdco, Inc., Systems Software, First Lien Term Loan 1 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Oranje Holdco, Inc., Systems Software, First Lien Term Loan 1 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Other cash accounts Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=P & L Development, LLC, Pharmaceuticals, Fixed Rate Bond Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=PPW Aero Buyer, Inc., Aerospace & Defense, First Lien Revolver Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=PPW Aero Buyer, Inc., Aerospace & Defense, First Lien Term Loan 1 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=PRGX Global, Inc., Data Processing & Outsourced Services, Common Stock Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Park Place Technologies, LLC, Internet Services & Infrastructure, First Lien Term Loan 1 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Performance Health Holdings, Inc., Health Care Distributors, First Lien Term Loan 1 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=PetVet Care Centers, LLC, Health Care Services, First Lien Revolver Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Profrac Holdings II, LLC, Industrial Machinery & Supplies & Components, First Lien Floating Rate Bond Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Profrac Holdings II, LLC, Industrial Machinery & Supplies & Components, First Lien Term Loan 1 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Relativity ODA LLC, Application Software, Preferred Equity Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=RumbleOn, Inc., Automotive Retail, First Lien Term Loan 1 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=RSCH Salt Holdings Inc., Diversified Chemicals, Fixed Rate Bond Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=SCP Eye Care Services, LLC, Health Care Services, Second Lien Term Loan 1 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=SCF Eye Care Services, LLC, Health Care Services, Second Lien Term Loan 2 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=SIO2 Medical Products, Inc., Metal, Glass & Plastic Containers, First Lien Term Loan 1 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=SIO2 Medical Products, Inc., Metal, Glass & Plastic Containers, First Lien Term Loan 2 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=SIO2 Medical Products, Inc., Metal, Glass & Plastic Containers, First Lien Term Loan 3 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=SM Wellness Holdings, Inc., Health Care Services, First Lien Term Loan 1 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=SPX Flow, Inc., Industrial Machinery & Supplies & Components, Fixed Rate Bond Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=SVP-Singer Holdings Inc., Home Furnishings, First Lien Term Loan 1 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Salus Workers' Compensation, LLC, Diversified Financial Services, First Lien Revolver Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Scilex Holding Co, Biotechnology, Common Stock Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Senior Loan Fund JV I, LLC, Multi-Sector Holdings, Subordinated Debt Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Seres Therapeutics, Inc., Biotechnology, First Lien Term Loan 1 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Seres Therapeutics, Inc., Biotechnology, First Lien Term Loan 2 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Seres Therapeutics, Inc., Biotechnology, First Lien Term Loan 3 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=ShareThis, Inc., Application Software, Warrants Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=SonicWall US Holdings Inc., Technology Distributors, Second Lien Term Loan 1 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Soreson Communications, LLC, Communications Equipment, First Lien Revolver Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Spanx, LLC, Apparel Retail, First Lien Revolver Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Staples, Inc., Office Services & Supplies, First Lien Term Loan 1 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=SumUp Holdings Luxembourg S.A.É.R.L., Diversified Financial Services, First Lien Term Loan 1 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Superior Industries International, Inc., Auto Parts & Equipment, First Lien Term Loan 1 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Supreme Fitness Group NY Holdings, LLC, Leisure Facilities, First Lien Revolver Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Tahoe Bidco B.V., Application Software, First Lien Term Loan 1 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Telephone and Date Systems, Inc., Wireless Telecommunication Services, First Lien Term Loan 1 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Telestream Holdings Corporation, Application Software, First Lien Revolver Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Ten-X LLC, Interactive Media & Services, First Lien Term Loan 1 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=The Avery, Real Estate Operating Companies, First Lien Term Loan 1 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Thrasio, LLC, Broadline Retail, Common Stock Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Thrasio, LLC, Broadline Retail, First Lien Term Loan 1 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Thrasio, LLC, Broadline Retail, Preferred Equity 1 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Thrasio, LLC, Broadline Retail, Preferred Equity 2 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Thrasio, LLC, Broadline Retail, Preferred Equity 3 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Touchstone Acquisition, Inc., Health Care Supplies, First Lien Term Loan 1 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Trinitas CLO VI Ltd., Multi-Sector Holdings, CLO Notes Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Truck-Lite Co, LLC, Construction Machinery & Heavy Transportation Equipment, First Lien Revolver Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Uniti Group LP, Cable & Satellite, Fixed Rate Bond Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Verona Pharma, Inc., Pharmaceuticals, First Lien Term Loan 1 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Virgin Pulse, Inc., Application Software, Second Lien Term Loan 1 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=WCP CPD Holdings, LLC, Aerospace & Defense, First Lien Revolver Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=WP Uni Topco Holdings, LLC, Air Freight & Logistics, Second Lien Term Loan 1 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name:

us-gaap_InvestmentIdentifierAxis=Win Brands Group LLC, Housewares & Specialties, First Lien Term Loan 1 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Win Brands Group LLC, Housewares & Specialties, First Lien Term Loan 2 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Win Brands Group LLC, Housewares & Specialties, Warrants Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Windstream Services II, LLC, Integrated Telecommunication Services, Common Stock Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Windstream Services II, LLC, Integrated Telecommunication Services, First Lien Term Loan 1 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Windstream Services II, LLC, Specialty Chemicals, First Lien Term Loan 1 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=Wendy's International Inc., Health Care Technology, Fixed Rate Bond Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=wendyshealth Group Inc., Health Care Technology, Preferred Equity Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=iCIMS, Inc., Application Software, First Lien Revolver Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=iCIMS, Inc., Application Software, First Lien Term Loan 1 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=iCIMS, Inc., Application Software, First Lien Term Loan 2 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=scPharmaceuticals Inc., Pharmaceuticals, First Lien Term Loan 1 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=scPharmaceuticals Inc., Pharmaceuticals, First Lien Term Loan 2 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentIdentifierAxis=scPharmaceuticals Inc., Pharmaceuticals, Warrants Namespace Prefix: Data Type: na Balance Type: Period Type: XML 83 R9999.htm IDEA: XBRL DOCUMENT v3.24.2 Label Element Value Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Including Disposal Group and discontinued Operations u

gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations \$ 145,539,000 X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.

+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef_Topic 230-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 8-Publisher FASB-URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef_Topic 230-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 24-Publisher FASB-URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef_Name Accounting Standards Codification-Topic 230-SubTopic 10-Section 45-Paragraph 4-Publisher FASB-URI https://asc.fasb.org/1943274/2147482740/230-10-45-4+Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Namespace Prefix: us-gaap_Data Type: xbrli:itemType Balance Type: debitPeriod Type: instantEXCEL 84 Financial Report.xlsx IDEA: XBRL DOCUMENT begin 64M\$#L#10(.NB.U@'04UB@'+0+\$09&[C4]O<'>,087P1+GAM.M.\$V./OL.'1'\$ IQO;<'=>I=P4)BO.I2L+/(>)QLOD&1#LD')OCBGICXV>;QA&WPIG M*N*'1#BV&5(C(i/I 147BK9.?N)=H16-Y *OGDK7A.YNJQ-<4GPZAAUJ=10-UJRUEIA 6W#MTPE! P04 M.*#+HOJ8|ONY>?X K @ \$0 !8DUVR.WIS+W-O&ULS9+! M2@,Q\$(9217?UG6K04(LVEKHGI)<-XBTDTS:XVOWR&! ?WFQLMX~!!?'_2/_GF.M&VCY6!F&SB.JQC'I'Cj9.NPIE:@.@.#/5/M++?':^SF&T&? O MJ'6*1 OBIV'R'D>;DOQG&LUQU7YITSO'HUI*W.&9-K.WGN!<FXI621A'^_1S80RY8-[9]-NIL!'SI'^%61'?._GS[BYZ:(E/X MB-DUV)]MR >X%'MBVR'|+ M41B1'G@^MM MNNO.+)+3/(PB=AIA)4!P'I DQE&J'+ +3*K'I#@SWVWO@c(Wxv)[JMFOCU? MH5A)VHX3XS\$8.XIQSY7/L'.14!1J6EW*.7614EQC?'HU+,76>?/: V< M/TITS3LA/P'9YA|ON'S M&KL&QKMUAUCV('K'/?F<QHAC*A'FNVB<+5@ \$9Y>PTGIZ+4+9OXV?H);5,VPLCO='U!=*Y FI,C'O MYHY9,'VS5FI7J,H%,D/>N52> HWEL:'4Z">"P=T-HWJPJOXLG Y MARYJSZ770JOIH=X-W-RJ9\3BUO<1FY,QHN,N=K7."XH8U=RSTSL0(S=>R2(JVE+ZU(CAK MJ+) ,<\$X>RPPIRS2';9WHUIT ~ =>=NOCI32IF.T.X&D*> VVZG=PS.ZJBZ.D MTUO?/VDZ<5&XN(YVO2)?9A7.;?8T=[Y%!(L/O)8]<QXRCHB'NH8.SS.' MAWEI7YAGE<90.-IL.'PD+>.WS8+C72PA&X1 @+. @ZJ | Q256 Q68#q~" B MSr.R.1>APYY =? /7/DIN,JFUJ;JI=-QEM(EYPFFHSV>KRMYEL<%<'<56 "P MOHFH|M).5. YPKFA4YGZ,RWRTR,"QB:B&DXDU=@?=7GYFRUN>BJV'] = U MPw6R 7 #1P E.=?)IU %WK[G[VW]/Z,I L2SR<--<41 71%B .5 86%&+D4,Z MD 83-L SF=FWJXPDD6.L UC6ORDRWESPVKO UFf MRMO?I?!?] 8J)*&(IK&KKZXTI Y9PM(QO@@=?..?? : X QU'M.M:I60KS3!) MIWPP(D9CCYT0% ^%/&*MIK&MQMHQ?F J/, H68HWXU-%FAHSUHNL.BT?*T5 M0.4.VI0-IIR15IXQF;8VH^1.^CS< _NI_L,+&CN'MB[I\4\$L#!IO(M_NB_UJA[IG]o4-o?8>+PO=VJR:W-H965T&UL MM9EO;~HV&6 BL6F:9*DSBTAN*1/VKOMORUTF^ZFZO3")@:AJG#D.M-J^ MCQ(:.4\L.CRI8AY4Y!? -.8JZ%;Z6G'ORSD>=ME95=L'S.%7.'89:SOPET?RSOF&-ABE,^FEYOZ<3+S=6Y1\$&4 R4"! IOOEER^Q,M MQO?7^XHG @.CY.MOY3#3AG?>'779L72(><5!]IP'; 5MSMC4:2=H!S_;DP[MU6JJK][GK-MMM(OVP,Y9QT31 AH%;7.G:2I+P.G%66K,X M9HJAE'L-B|(YO^-4+R,O,OTTK<H-ID!HD"N3HTLT=>=>@FV9JGO)TNII];& MC? ZJU)& @>GXDD:IFI.FR3(GP5N)'66I'D2WI;J@>O>7)^N(A3O-V.M7Q MLJC(FQ,KKC5'W+=/Q-/IW^9YF2T'3.),VAJT[G=M#\$].6.]P]?C95RM M?>TPW?.NV5>)/F;VI PW6(X/G+UDVV:<JEDAG M?M+=+984BP)?]SM<O[K#. #.!.);OV N M UK/S[R](*)+>?FG'GHK\$1+-GB*-OL+ P/A.[KA?WYB(-5%.Y)ULXI'R_.]_1 MRGT O3-(X) MJNYRZOUU=UR53B-l+A&Z3SG&?&ZY8IR<IKZ>-OH!,B5I+h-G8WWA:UW ME(I,G>PU;>OD6(5)UMD'>=WM@(>HPITY>1QR[L3'TOOB<4BA'A78=H... M JN^,&[%N*X:M:1VH!*P%=>U?H?"O_9C<@<KF(? &8*M[XI], (>2(K>20;/MK&+JS8N 9.g.-ID48/J-CUV+gAQX5MU'6 1 V2%XN15,E2NXBHAIOLFVTJ]^+YTMGWGLFH/6?2I RZRZ, M-=!&HF/D81 HG83H04EH&K.H(E=YIEJGYG:+^SINON^ZMGQU *(!";F,N%M[I>@?P0%2.SP6*AO.58L:H-,(_O.OJO/YL^W+)(H2(QO));;BN+SZ=@R> M8;8C(9M)?EILA/H?7&J+;9.C3? %.&LWD|=E.X24.EU.A:/=. -09=S/BQJ+O,/6A/R8.154+HNTL'D)^X^9JQUVLWN9Z3F @4B/#.?6<==> SG,S MIS.; +=KJRB&LW<X>SQZQI-Q>W766LLX(+1Y;WC)O) [%9*W.ZS<6?BIHR MUNG'O;/%&'#\$CB MXKT>ZQZIQL,W,%>VSLCP<+--+([OMSNJV&/7])=#KFM<M? PMJ[PNGZ@FO.S,B^*WBLLCU IN=60]+@YJ/KQKQS[/S948B]>M1?PH! XYLCX+@>'R72XA1U)I02(@ S1U!+ P04 M.*#+HOJ8|MPJ75(P) >+ &/'AL+W=O7MY5T2.GR2SZ/ORRVYM M2D?M=C<09RJ7J)OIDJQ>2>+KF9X-GSP(78?)*>@>CVY9P GJM/^<2[A:-METV<BR\18DWBUJ_-O:%GA4MU+)+BSGS RCOT2 JE<+1???+YFKF-XO\S92 M+AC>+>OKGB3;.*%XK78Z: K4#:O7!^ EX.P.Q9SE4A|KNV7^K+GC+ MBDI|\$]\$ X76 /,TO&DE> AJUJ.;#5%KD1!.P85>Q5?JFW.A'=IMB:=# MF138@SXTH'4+@>KTJN'4J[W,M,LH&Y= 7U=C+P+TRO:XOI7A'4EN#-WU11 KMJ#7&8.YTHJTK'KS&T4HB3=:,@V25 '.LD+E&2S13YSYN&+9I0TMMNXLX MB57.:ZJ&68*;5DL MT2.+TFX=>+?+UWI>O-X33(!OQ?NP..&?EBQW&=B/] ;7B;7BG7%EV9 MJ) &X+5.25SrUS8U*=I(H44X2,:6[F/N:P4:XiZ5]? (*ORCOO'TEI_MJ+QQOTT8&@.YM@]=96@&YS@>". SKCCDD9JC3?P8;S@LU#H65PY+6*(UO37 MB7^ 1\$<sOA.. IMG)=+Y(c="(=)&JRH,P.ME"D(^DVD))\$B@229YE4(I,.MD-(QY#QW 1HLXU,X2TRJ)DJ@5IOD4FY*JGO''DY3HDM KA< >FSE>:Z<S:C'HGZW?=%>2 &52Q,Z<O=2>+>HAM;}>2(Q)>R>TE.79 M,YNEA|ANNXXQE49PJ.P.SGYH5=N^K%DAX.4IJ/-F HDI[(F_Z#KBPH4+=1YI.M*\$BPQSSX,IXMKVSKIP(]'4EFJ1EB::'-H-MZOW:^?>FBDDZAY/>LZ>(>M MIRO+6)&VRFM{P}; 6&? MP>Y>Z,T'7R.(O@5J]= :>0!1F'.PSA0-'@IFOY082X94)LIT)-*DH@ MMMM_A&8;88OXIC M=*3(BJL2659:TU-VLNCL(6L,QXR&OT&MV&+%YC0.O1) Q MW2SS3GSGO+VMQAD)DS<X+AU+UO,,BWQC&8J@A|VAL[S]|J2T.F\$< M'(M/Q+(K3ZD<BB)|VDBMD MU_Y0H,X47 T.ON3CP|^WD&NS+N,*VJE<?P?+T2MJZBT9VF|96%) TM(N'1/UCDZS;W=~*00'#8 SJ19T>?&G%:,4-N;&?%+:.XV65:.88]BWJR: M#&VS=HYD+HZB<2B-)ISA@F J.3B1N16KVMIU'*EK?'%PNE1-T?>? K1+KQ

[illegible]

[illegible]

Q!>H3BN0N*NV*6ZJ5JNQINR.M*KG6S5JZNFNFNS*P.T:NOQ.E:O-CM>S4F4 4E2Z< @.1XKX*WUWUM*YX.KD*2JZW.MV5>2BHSCH.U1-YA.GH.1>2.A5SRS>XHSI5S& BG&A*SI 2>[>F-M]>
<?CB/NL/PD2Q82E22>K3&EES&2.9V%PFW5XBSKQ7045N8Y1?>YWAQ MSH2>J5U%6WYH&JH?>3N7QWV52UEH UP0S3?>QVS.HU-YA.GH3L8?>Y3R8 MYS&E G VA.U 1 2DSE)
<[CK3M3J3U3>45L1...F&=AGH-YGN%B1*ZJ541-MEI7E091<7A.&?>V5.5#++ M43*U5N9FE(SIRJP4.OV+)+7>+2.U>+>CEY.M#>4EX5O.K+6K7E>+5.KW8S7LWTJ?>E05%+BJKU>CU:Q>
[FAH.0+Y+T+M+L+JG.W50A?>RUSZ7E?>WU9424U+21.NI08Q+>?%>KXG05#>THSV+G M405F=P6CYF8YSE>G17A?H5*OT6A1I3TNK1N96H?>JT.X5YZ&LWYGBWBWJ5%OE IPUG->
MQS14L 2(9WS>+0.JH9>0JF>8X7Y7H5>+2+ZLQR4QVY7R+>QJGOG>VZ1+M OTHV+7+1.S<[X.F.M?>QK8J20>0JF.M+8YWG*3K3B?>L#5F9+AU5ISOJF&=>@7@S+QS;ISO#C<L5#>
J0WMA.O.MJU+CG5QG+HTK<+5#>7J5E+UJL?>DYG+2?>WYFC8GK<+1BS1L+1.6.1DH.K01%>A46X7J.MJ.5J>5C%YMH5#>KJKJ86F4FTJ7JWJUFJSD?>2YJ51+W814&FJRFR<
MOJ3CKZ33W+R1+L&J>JUYKJ9&E MFC<+61YV.OSS?>J1?>V8R1MKM HBISOM?>S.QR1V>0*LE LMR+>+W3 M.JH+>+>ONL.Q HJ+>NAIN75JWJ7.MP-YJHJ?>C<IV>VCW.L#>C>I7-1<
[KQHJ+HJD.S+0HJ36E6%N7J1F8U1+M..90V<+1.P3JYVS>OAGDGY4CPSI[!>IQXL#?>S&N+YK7>1U.MJ4YT4RQJ?>Y7Q6P77ZB-KJ9+&O.&M.JG9JG<=>S45V54Z2ZWTDDH<
MEN#>HYS OSJ?>VR1G>L2K36JVDX0<[?>7J29GD.YG.5650OK.FXW607&M-8G42J?>CZNI+L7HJ?>HT5ME3J2H#P#>QJ89VQ<=>WTF>X151WK?>F>[SJKQ1.M38J?>TRKV+Y?>A?>
I.B.DJ#>C TR9WD&Y4CPSI[!>IQXM#>223.ZV2K+E13.+U.MQ.QZ?>J192.9&O.L.SC+>S1Q?>7D6YCF8YSE>[!>A9OQI=FVBNIU7?>QOZ?>M2?>G[VAWJ?>N.OH?>F2WN<=>O3+<+K.O.F.3#>
MPCP1SSBP1M&S&YND?>75GP.S6Y?>Q?>O.PMY4?>YAI0SYE7XR.N?>J.C.MCM60M6V[?>J1<2BLXORS?>W?>G?>1?>A1Y1.MIESI+>4%Z0A2V1%>#?>7=>T04E156E1PE8GRG.PSW1+>
MJC&S.V6#>74.M&SK0T<=>=>Z?>ZPK?>Q?>0+M?>M?>YUQ<HOPVWJYKYUW1&Y#>N1#>SRS.PMKXGY%N8YF?>7D.S+>PSI&S+>B.#>F&S<
M85=>OT0?>QJRE.5-F7&K&E?>?>U9M?>J9FUSIRBNS4LCTG72A5EYFDK?>F=M1.M.DYZJ?>F2J?>B1Q3QLEWM?>P#>M?>JGDE&UI?>G?>K1BR.BBM5KL9KR821K M24PEZ>=>Q.RU=>CU:Q>
[7AFJ.O+T?>9V/MK5?>J3L1+5E.HMM4?>YF.M2J?>1.0J1R24Y9XCMH7A9HJGZ?>2M..6?>F&=>W?>X15&S1K?>7IS<3MD+>100TVR?>JH3J2U+12&6LJ7ATS?>81W<=>5HHZ2.LP9XVRG.PSW1+>
U2K00 MM151.S<[W?>J41CKPN?>[!>HA9Z0?>C<=>ZKJ1.67J0R<=>[>F=M1.#>+>J2R.WQ.9BC72?>Q?>=>JP?>+>PUY4X5L?>C5MUJ9?>F2>H7S?>0<RC?>C300>DMJ1<=>2?>C?>2S?>+>K1(C?>
Y..35M+E14VC=>M4M?>DH)H>P.T?>K?>S?>Y107?>J1#>7&F1..?>3YCFQ?>SICRCL0KV?>=>K?>S&M@GHU5#>N9YQ4G7&5.B<
M&E8B2K8J?>Y97?>WS#>QK8JZ?>0JF>8X71WAH?>Q=>Z>WOL.LBJE?>F%>Q<NNG MU%>F.TJG5.C>C=>S&SGSFZ?>S2G2Q=>GHTST0.KK4.IVH.KM%>46G07X1F?>D?>
M0H00&O#>J#>N97J69F54FV4JWE>=>JW457S7LO2RO<=>@>TJXJ43?>TJ2F.W>M>KR.U:O>C-E>S?>F?>IYGT?>J1[!>HWEYJ.F-R>?>Z.VSW.G?>F[O67D+>8D0T&F<
MJOEIO#>J#>YNLBN1+>J1.VCI4K&?>J44&A.PC?>7S?>+>HSDT20J0JOH?>TOWA M5?>3?>[!>M14.SN1QX<=>1.ZW3.6TOS?>C?>J4R1N?>Q?>F=>GN<=>X<4Z&OGX!<
MWJ-J&CDZKS+>KRY&SL6D7J1PMSS?>ZVUSVHEG=>S+<=>1.R1.N+>T?>Y3F8YSE>MG 2A?>U>OMW<=>TX4Y4U2EYV(XR.LMSJ?>73KACW?>JLZ.CMC#>P3S?<
M1+L.WW8MS-W=>+1.F.9CG.5244V7HZY2D?>S-M?>3&8DJRIMAGH?>Y1+V?>2M.EW82BD>G>V>K0JEN&2C?>OAX.B&M.LH?>C<3FLY7J06.MV.U+>TE(8J)>.&.(IKH0Q<=>U)6KWD+23J)>Z<
M#J.MOHJ1H6F1H3N?>746.J1F.230>2UJGQJ+ERT>BNACM.ND?>M+O=>O89Z?>9QC08D1V0?>EWH?>O.FG?>#>TZ3R<7>=>*>+>J.C?>M?>YOHAA<
WEPI9DQHP-V?>W?>F>X69&#>KX1=>5SDU98MW6GSP92RJ2BD0?>[H5I3.MOCX0AT?>VGE013LX?>1!>IQXM3(C3P2J?>VWV+7J?>VOKHV?>[>PNMUNO+>#>YK<
MW1+>=>WUWR>?>KJ?>OCTOJ?>W?>J&XJOJMB(3X)S45X-PS.V->A7D.MYGF?>R=>ZJ?>J?>K3Q1O4H54X1KJN?>V->A7D.YGF?>P%>X+>27>B-M?>3M59 M6WY=R<
WVXKN(HG<=>J)=>CMVJ5HWX[6.5FNET?>(LQ%>1.Z=>5JMU.U+>28@>1.M7?>003<=>5-X?>XF6RT<1KJN.7TJPN3TEW?>J?>#>B6<Q?>J1.H24K<
M<34%>50T?>F.9CG.5Z<=>=&M.M7J?>ZM75F?>PDKW?>W?>E<=>=&F.B564V?>1J1M<2TS41710DF?>?>F4A[!>JPK?>M?>OA?>+>H66?>BBHJ6BEF0H5L+N-AS.[QPOSHK0-9JW?>J>SUG?>XIZQSG<
MEPLH1P+>F&=AGH-YGN%N1+Y..J6J+>PN7+>HJP.YA8U1+>?>ZEO7QY9RJUR?>B?>8D<=>ZV6H1VJ3K?>=>N2B.0J?>7JNV?>6JZJ5N.MQJN9.K5J?>OJF?>J90D>J?>K<=>K6.W?<
[70UJRS&J.EYG.UJZ.QF5U1+>A+>DHIU1.MLRQ+>TU9RJ7A88=>2Y1CJ2B?>TL0326+>B7A?>N1+>3G8JG?>#>2A+>LHL29<
M-M?>T3J1F.FOY>E+>OX9XUQJCCN69UEQJGBK>+123?>.<=>JNQS+>Y#>N9YCA.E MP2P2TV7H.2NSE@>AVXMT?>K?>+>YJ1

9\$%VRFHKP+YID]+Y5.IYM=HZ(6YCF8YSE)+JW+MTF==\$\$V7D3J3JR,=H{45X#IRR>Q9N0L2;V=4UL(1,1QXMM#01,1VWB
MJD13QJLE:1=HN:9/2-1LO=H0W#REFBYV=+YWAQ(=6Z+1-5J-KB)=A2-M17D-S5,PKX5Y%N8YF,;GB=6;E3CK<@=<O'<PXDD,+=O'MVE8%
M=4DPRRMRFM/GMGST5Y25B5284.M7JB#ASO#BDDOW-U#76N'D1U,7#8,RJL M87<5Y9DJZJ#JQ/537PCP'SS'BZ,=5771J%J%5-&K1K019[PZ:
M=K,Z7@U,4PSI\$S_BF-U7.PRK05,5>Z4HKX%Y9L+&G<1P'DR10 M49F-2M,OS,SS M'>BSP(2DNR=6;W564U41-1.F&=AGH-YGN,1#L:6B+U5703;W? M3HZIS:
/MGK1#S,U(OW=U#B&B&C564YV=+YWAQ(-&C:FRUA47OYIC4X7/DRR1(RFYSIS:I4&L7)HHQJF1L8<2P18GR,SS'11,XM#X+&658&D.4<R3%LVL1D
M/L,LS,PSW:1#034&Z+1541.F9CG.5X<1%16f1JJP)~>ONTCE.N:1HDB<3Y1F8U(1-M,;U4(3X;)-WMY<X+&6B+&78<7S.R-C00P\$*16-CB+;[22SR)/\$)R'-P47
M:F&=>W?F-X179\$K12ZZJ?1V1.VA:3>=1BJ?P, N791GNA1,;5PH7/2BJ2-M 6B4YV=+YWAQ4H1+U(1):H<1Q2A?>KAR5F<#&R&AG8X+IRS;TFV?21A-E4U1+-F&=AGH-
YGN%1 LZZVDNJSUUA9T?>0;#JZ-M1+>JCG%WN>6/AH1.M7JB#ASO#B=0=Z,1+55Q>RLV77-ZJ5I04QW-R+MVAJ89->U7T,90G:HU0J1U YUCA<=<A+1
F7H&DZ:1=1HR(6-1'GEG-MSSM845CF1JS BLI89Z>9JQC9\$>LM+HK7%>JQC9\$>B11GD-S5-1WD%JZJ M:1Z?
8-LY3F8YSE>+A+Q\$F7WH#FAMX<#1ORFM/GMG5\$>-7G3.KN&S+73G-M8)G<=>AYIM<+YIPBS2\$-ME4,5 CW<=((6-313G8)G>+0A4V6'G0M%4A1Q:OCSS9(X1'W'FD-6(F
M KN<#&5\$>1.F.9CG.5X<=>N#M1HA#1P8BS36G76M,UQ6&9&,&30JF>8X7QW0HDZ10EJZ1)@5~VMW,E2S(CA1U-E-?+OS,SS M'11,777M,EFQ5-
KA'QH1EX'J591G8X+IRS,YWAQ(=>ZFK?XCNB6J+1VNV6G0V69Y6>3(N70 M1-C12A,~M'1KB9Z>0HF>8X717X5~J5<1RM-1>6:NTC;2HX1W@3R65X1=+Y1F8U(1
M'=>7DMS+PS1\$S_BN+M MU61=K3RJ0H1KJ1FVOK1?>K<A1J1(PUVG**>10;FM3#PCP'SS'BT,-M-GE
(KLNTN@KM.45X#PS,V&=A7D.YGF.P=JZ+6D-W6\$PDR(KABQ7EF3TO-MGPM1WRU2E.LH1(6YCF8YSE)+&A8UIQCNF)1HLNKUBO+GK>40QV%<G>
M@W?>X16&WJ=J3Y,YU(5S'J'5S2,N>~>KG13SVLOM?KKN9B=7H-U:0.53X MP2BGRG,PKX5Y%N8YF.E9D.9G1N>***>10;FM3#PCP'SS'BP1-M
M@TKO>DY,=NR.7-5VJFQ?U49S+&S-B?>F&=AGH-YGN%5LZG)76X<3-MN5-1LB-T88J2Y1F8U(1-M,0;FM3#PCP'SS'BBP1=##KJVP**>1W51Z-J(-O2(=(%>3Y1G)CS-
HK&H58-U,SWY#E>+>A M#5EC,-J7-[N>\$/CHA3V+Q\$>6;UA'669U&J2P'8GR,SS'11,J'4K E3 M0f>8X71VYH2=3+&G0_S;I2~9A_OP_-PUL?YVNO?
M_9A~A1+QV(U:08X3?>ZJ5I7V(HS11M99F:=&GN=X<=>SMF1-V1U-M'&NB0-F&9C7PCP+Q\$1,QPO#0#0EJR-W&K-ZDE=3X<S5ZYA)JN#S-091
3-DV4SCSM&XJ'VN:<1415.69S91W14W1PPE,~<1LO-M89Z>9JQC9F1A9FARW1RMCX1CG81'X<=>CJ'68CPF(\$?G-KLE=3+>HLD=S-M80)1XN56YCG8)
fG>5\$RY&S(R>=>32YV7,P4U+CJ00,0LIG6L,3-M+Y+L+L?0)5WNM&N=RCVJLKKX%YIN-U,M_-J?>+4V4H1J'~>P,9SUH5E@>700S+QS,J50#C-RS#12>S
M3C5K0RQ(=>-1/2Y6M<#9G1K3C2IOMR,9D9J\$1UJCA<3(->KW-770=M51(KCB,6G,6316919J'~>,(ODN\$OU4LZ2N-AP0#N)5&3Z0U'5X%1M,5QQ
)B1,2R#C+>W@>P>X1ZL5BFQPA,F.9CG.5X<~548^9,I9C^(\$&DV-MPIH'ROCF&?VO(1+Q,5^6QPA,F.9CG.5X<1W48IUR_10>1)>4>R KRVM@
MGMGS#K-HU?U?1S+R<(&CF9Q)JW-MWFE2D?>#NNM75TH?FY9N36G27(X{>1FH1G-YGN,0#1HZM9G>J5V~M'6%&4BO?>297;J1H8U~J)N8400PRXJRG,PSW:1
(A#S\$1,~*54-M,61-&J2?>0K<A;P/5G1AG89Z>9JQC9\$>VJNWE1M+&6G&4DVG.4-M1A95LK~>(&BWF%6,6U,~J?>+X5UT5(CMLZHI50HT?>7VBJZV1Y%
M>0;FM3#PCP'SS'BP,=,SO10137J'H,A0L;4,~LS,P.MSW:1%>S<KR(E,6BO-F&9C7PCP+Q\$1,QPO#0#0L-HZ&X5;ZH4-ZD,C&=59F:=&GN=X<22+4FFN;X15215"2=<1?
K+G M'005=AS1+>=>R/J?>10;FM3#PCP'SS'BZ,M'00S0B77XK4H9QPKJ192G M'~>LS,PSW:1A#S577JZ1-9EQ>PRR;927J7Z-N7>1VS3T,Z1S590#1Z-MIS'0@7D&YK4PSI
(1+1QXLS)G1LQ1L3>9PTRK*~>@7DMS+PS1\$S_B M1MVEQKTC70441%<PGW126=S6:IML3'EH#~03;N2CZ/L_0K1_0215V4Y1'~>MYWAQX(?
VJfMSU7MNMK:9P'47=D@>R+>SST6PN1SSQ6(TWJ7@)5K),MYD1'16EVK%6G4T7-11BJY1%<C%KLOB>V>W>K%<N<+>F,58E?3Q9R5&L&1V~M'Z%>7NCM'48P1J'>OS;SS
M'~>B12+1-RPV3K1WD8&J0B38J1+ABHAI0N&1+W8BBDW4U~>166G76-M8D=1+99YCA@>W?F-X1457KHA;K<3W+7Y1+7(1)OS->O'F69CG8)G>+FMA.9L23K7
VTBBO>7D&YK4PSI(1+1QXLS#&3%1T/LKG+M5+7OV3W&7@&JMI=,YFZ337J'~>DBMGX/E9J5KUA7XK M12,~>TJV&07KJ1;U1U G)-J'17NULNEJ&K957K9FZU?
+T0&=933A-HM6K M74Y7LWJLJ EJD3,2+>W64U1L1L'OUJJD,G YFG2-S'CW94J4JUDIE1C M9HOP,~+>41.FB,7(CX74J1-ZD,~>5%JEZFKH&S 9G&AE6YCG8)G>+S A L*
M'MH1L1KRIZ'CG&WSI?T0E?>J(FI\$>S,115\$>~>9>#&X#>Y+>XHSF'ISS-MB,~>A1.P7-1~>J?OCIS~J7/L/S,7G<~>W=JN?>U+R1>7Z~>Z)=7H/O-MTH=>3MM<=>7Z%1>
1.S&MAGH5Y#N9YCA=>M.64.CN+PJP1KV~W5&=0W,S'OA7D6YCF8YSE>+1A810.0.3=V<3P1G1SUY-M0J1'IS=0?>EFSXO/L&C/V=<M-J1#>KKX5S_-B\$
X=JH7-8J105B101041A1U-M.S189\$+1VHHS-QYR09B<3P6NU0QJ-JX1OR>~>W1G67A/NH-V81-(NV#M M1=V<C,CA6VR%>6,6U,~J?>+X5UT5(CMLZHI50HT?>7VBJZV1Y%
1B9&1L M>1W<C0(F&2VO-1D6&=9E48ZW+LAS,QPOC03055YV?>?1-I,R,~>Z1-MIN:9->@R1TLL33DXBYOE:=&GN=X<WJ51-OBVW?WUR21A_MX<CT
1.S&MAGH5Y#N9YCA=>+C0E6M-N MXJOLN&M5'F25<G1JH6'WOV2.C1-YU<C1%>HJHA+D+NM0W7LKTMLT ML41J1-H=5G8?>N1-U&C@>MPMZHEE<~>Z%0.
(5078+1QS,QPOSHK0MRJUMOG7-BM<=>Y&#%ZL-R50A).MZ>@(<1THS_01AQJQ=SQ85YV?>OS,SS M'11@1+1K7>MYK&ZXZ?>(\$82PKWJ?31SD-NJA=C<=\$E3K>2U2+>WKS
>X9 MIWD.YGF:=#M76>B~J1-3J1)>1

[illegible]

[illegible]

[illegible]

[illegible]

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f84>?<C1#6GT<0%4/>HC&M1Z21L6G%>1.3.ML&@*1.12.K1(4D)=M.3&K&S.D&1Q<1Z<X&R&S&Y5.O6&T+03/>1AHS#M1MBLXIHJ.L#0.01X(GM<1U1=004)C.B.U&H&HZ.B<1#&B4J@<1#M2G&R>D4T+>1.L.F2.S.MC5H3+IU/Z18:S.&@&C.716@18T">@UE\$FJ)J#F9.F1%0@1#N~R.MZY>F0<24#G?1=>HP1F&OS%IV1M8K=W"E1.B@<(SX.MKP.(ZMC.M<03M.IX#&#168?>D=I.W=H.W71C(T(SY3.42B?C(M8BH9U&B&#K)M&#H)Z.M.W9G.9.2702G&1*6W>112L(EGGA5?>Z9+1.C41ZL1HWXSCMMS2&DO&D/U67%DE2A***<C#F14Q1Z(EYVMWJIR.EO.D7).DW1U>1O&ZG.M7&#90R1J2&U+1Z.O1&7THM&S6S%F2R0>A1.<1#FA8.VK53.OVVA(S.MH(RAU1U):1&#&00<Y6<@<SF0&KJ*H1L&V73+N1Z1HNLV.X>128N1P.M.M@<+>+>E.9K2&V1BLZD2K.1D1FN>0RPEPN&H1&#>9Q<1=>BE=Z1H07(P6=1&M6=4%JXQNQ1(f81)=1&5Q1.MVB.FYV?P&Z1U5.3&8&GUY<AZPI<1&2983UP1.MOF&S<2W6<1#&KB&W1U>PK&A5%KB.1D%1Y&EOM&SH1&#>1&1Z1<1@<(DKM.M=3&<OB%1YR&OL#N8I<AMT9CVO1@<9C3&PD1L82.GF+>A9>Y(AE>G1X.MM>18.M=1JEFY.1L1#1.L=1LOAD)-K=KN'K;7L@TG@CWV@6L@E^#D.M.5.0?>IXZ?WF"8172%UJ?S2)=2C,1D).#Q.MHPD4.2OIFCE.N.2E=7ZK)=2508=1H.13NT9P1GY<3@EMZB=7W5G34D>*>C.M.LCK@P&14J53X.#O(CF>FF18ZHD6+1P.8.Z1.%1E@<#DC:1S?MV9P.M1&S&S5=>=2YV&G<1>5JDA>1R.HN&A1G.P&B&Y@<M.ML&B&V1YK&G<15A8==TS(OB1Z1UTE.F.K&#?>=<VMT?>2UC&S5>FO?2U>7.E4P1Z88M.C8.O5O~M~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

14VGH7R T' L' X5FB# FJOK %1 P04 "H01M2WHH1D&0#P M&Q 'AL+W-Q' (M.IW7YM.N.2DH9+G'U6S50QF.I7 *V5*77.67A3853.(O5)<IKGS' S(-7 'T2I H.W6G0<D'M%=-K1 HJ.LR8Y. T' *%WJ.M% .2.D7KJN1MJ J'YJTF<=> MG0EIRWOSDT(F&G.EUUPJ)J51+V4GARV1 MXI H00HZM6G0%1X9Z=>G0H33PDH46G 0%>1&103R9J'EB5G'P58< %>1%>V23E1'AL+X13M1R 1PIELD6A1U'FY+6.7F7KZDYJfUJ:JKM2H M4Z.HFZf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fE232EN331.Q.O'P08B8<34>2-2'N(16G1ANJ5/PBF<3<4 M544FX13TfT1/1(7N.ZX05Y0.9%O92CYSY3%V\$SB.)A'>AOE?>S<=>BH)CD M.SRC(H'UX4W10174'9W'>7'2D@XZHL2&Y<N<#>=>M&=3G'79'12> MN\$B@TGH+1.NK1. <S< <H1V31TWR.ZAT=<K'>HW3+U>1P91'EXMW6(5+.MG9+ O5=>6N21S1<J.L'>BQ0'Q0>>20'U4X.F.IQ3N.FTM(1+51+>FW'W0 T50A.M129<1YU212RfDPL@/CG<1ZW44LRIA3.MXZW.IRYK8'=Y>872H77%V' MNT.6&H24QfEQ0Q22L.V2Y)>#<O.XSYRIE7/6(O'>0)>0'.BIHTQ501 M&GE(FTM\$1+OM1LN5<1+YXT1310%>7V'fHFB12.92NP1%<G'>X29&T601>>?>MR7L7)S+>"+(G >?>FV#K(HI@.H1DOKX146MS.(H>R2'77PR4.N3(2T1N.M9GD9 6:53CWP#F.G.MP'20>@>?>1P5B5+P31(OB)B+>1ERf2C5%>3J13 M'> L433VYUW86@1+L'fBK5T1L'P7B1@/SG'>#5'06G.>?>77 M#S.F.D+4.(5>Y.0A)U04+RA2Z SCQ1'U>P6M1J4B1E1f6M(H.G.NP.M1MINW71=CD;IK97.S.TC<4)>^< 0E=D1.SR'YU&Z<K'fEPVDS<A.5M\$S<M> .XOM#<M>@<fX)OVf45L10'<JL.NB U40+>TOP4'(1.9 M+>PQ=VIR.W.H965Tf1FUYLP.F&L3. 15.D>=>S24B1#41VDE5H.Q>3ZfE1E9=XHR41<+TXSD'>M3HM'7C75N'SC.W'1.2K.M.10.E3>5F&+D0\$>1%>@L'f1FY1WfZ2P12VYRT'> MAO1'5096K1@1&S1<5\$A1+ZUH3Y.19.PJ\$F7RH.L'RT fE28>+ FBO0'X'Y0.MN1R'7'5\$>XKXED3A75'KAU.F' MQ0D10'W2'FUTN.NHZZA7F0IGG:H90SJ2>7.KK8C'<G R\$>VY'<A1' H'8'M<79IN2=>1/8%>ZHfF7P\$VD:M@<SNK@.8#-8 DREJ.GUT&VNE.TB)BY1NZU.M*121PQ).YS%>7QVO(ELH1Z)S 4TN7S%>U@<4K.H*0YDPNZ.YL3>?9D<3 M1JNKTO&2>2'f1=THJBA.WM\$X'>1+Y.G1W7'S2V3B1P'f.BW'<K&F&M3G1T'0>@=<@<1'Q 2X&fW1=>B>39.5\$Z#>#B1(4&4T>B9M.M'>9'U'U'W.M'> KFL.K'G'Y+INTCZ9Y<fL31JSWE2Q0CH8OG8W>U=WE'fJW6ZDMLV1f1F6G521 WAL.W'ZG1Y8G+12H'U'P'P'>1+1)U1U'OU7M<13VY1=62. M>4NU(f1Z.KN'VY'>STG01U.Y@.0%>3.Y.2G\$)L3>DAU2B'>#4U.HBY0J'MXABH4'5V 35V3BNK'6%>2D66D#1 FHHZ15133HfUYOOC.UMCTC1MLC?A.M>DHH=>#K f<=>2ZGYE@ELF77K<@.H2.6 fB80&1Q0?22.23400=7WIN3 M0'AU<2'fTJXK89GOMVBNKfPME<=>K#12T'U#H91Y5Bf1>8H7DQ0.<D11)M0C21SA. <=>S/7.FF\$5)AG1>?2.CVD1)6M.HUY1'IOS1!@.9@E0'UQ.M1B&LV136.3D.71Q'8#f7TZU.<W'ZB>)<G'><C5\$01V.PTSX4\$TDPFfZW.M)C.0PT2A1= NfM#fH1'9'986BP6U1.Y'P'<G&C<=>#9QRQD&B3Q<=>#M<=>JEH\$S0B.J(G'>7)XK3.3#EYX'V'ZFE)@FB41+=<@.5010'G'HXG01'f' MHZX7'XL>=>RB6D.00? N0)>@>H.L'N7HX7A&E'6#>T1P#>CYVO.Y'P1 MJKB.<1819.L8U1fYCGG<@>S.J.H1(10K31.89>1N4'H'U'fTPOA6ZW6T.0.SK.M1'ZM>WUHXH1'75Y>9. 2K'HW'ZM'Q'4>?>ZUEGHC&D1.<@>?>MYG<S>S.SS)GPP'02P.%<@>RZ1'6T'fL1C'X441D1X.'fW.M'W.KU&L55C93'>MA.O&Q'<K'>Z=WW6GG&2WY2HMM66:<#>fJPEKN1<+2L1U.B5X'MARK98DH.MEX.Q'fF3592RG'DBD<#>=>00831224NOS7R&EN<0L.M'<L0\$A1'<#& .549J.M10F211.68<549J1.f#>2. M#1QBA1T301.40WL.HXP+8>=")ST.SQESXII.MVCMGPW217Y>.>1+1'YA82QUAS.L5&PI.M'S1'GC%9C)5S.5Y9HIR%>TTW%>P'DAN@DY&4+L>2ZDZD U'Q'fP0Q09(19>H12+1B1'@2'R.MY.UA3<1>T)P'R.MD.#>913G>FF'fJKD.<XV1T\$>H\$YX70Q0<JHR@A>?>P'fURD1L\$S29Q M6M'P'>fT51U518B1L'@! f.H10+8A'RA91SHB1>?S1' M2E6H0W4%>MY2Y OL.HD.>@>?>0\$>1H1(MO1UW+V1L.JS.B02CL'W1.V1K.MA.MDYQ'V@<@<L&N)@<1.8X.4T2U2Z \$A'7U0RDE1\$>6L9'Y'42'>#G<MfJ>0'>3#1M'<1CH5'fRT\$2<1GD.HBDJX.H'V'PB2N\$>S\$S5'fJ6&B65H71'>H'EPM31@KX'=>3'fBfYXZ02.C1&=> 21>V0FROK<67>9.5E=4G1A.R)C1E2FEMfM.L&AAS5P.92Z)OEB&1'>1'fZUI'@75T1XB'S.C+R M1P.NV1+1C13'2X45XP5'<1.G1GL'OM'Q'M4.2%<8\$5%>@>P&8X M91+I'U214D&A0<1.0G'5ZA@X4>QAG1)W0A.<1XPU1=1E&K58\$2<135\$<@<M'fS'3'UGRK41<4.M&H&P0R3.<8RUT'<#>NB51'Z@G.G1C'RC'5P.6V'>#9.2 YHT'Q'71D'>3'fTU'U'F'>M.E.M&A.OXSX'fU281DHP.W.M2EP4&V1B=DL+CA03=>P)M'Q'>S'PH1U'W=M&10'>90<@>ATG284C.L#>D.N.MA=FNBO=> YKR<V7>=AFV'6<1\$AM0=>fZH'NWS'>#>X(X+FAE3RZH'<L&4J19MUCN'VWVYX:0A'>M'>0'<K'>50'<G'>A'>6'>8RO'fY>5&H4Z&Z'KL\$>Y=>GBRO'MW51KU.MMG2>

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

```

7-FX60DZ!&fE=&EKKN6TM&E,KJ6_M,@=+%>#-NjHL775KU$*8FM-5F!GZ5=?-(MB<9+%*!G69S!<(ZfYfJ3H?
MM2N'217MSV)QDL4!j=9G.%PCE2'EE29-!S)F2,_"=MHHBZ,8B1*T7T2GEX9=X01Z#M M^V)4JXHN=TV4Tf'E,HAR)<fY<^TL27$3NU6%1/=f.OJfFO:XXM^E^<,>?X MI-
OZ,KU6G'R'Y T/TPY f^TOXK!CHO#_M*OUVB$P^CDBU,L3K.X@^fVLZL M^"=<L>/5KAPE51866QOD<9K%.19G.)PC52L$Rf#&fJOW(BB.C<>=fT5'fP-.B M@(<AG,T:T4V?
C:LfLQ!<L4M4:6@7H:==MHRM==fPDHBM==:PD#U4fLW00^!2T'-EKKND6DfE!K6LH$*!^fEBA4!f.M>=MB
M8G6^QD64HJ.R<9G&CPSE6M6$Y+>#Z6fJLJ#R)&C>+>07R9=&6Bf.ML3+&ZS.(A^"%%45T6!4F=Z06V&F.WOC5$428!121*%<U2!G:2+G0V.M-T.

```


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n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f&9AG891C^&M^F>ANGH1^=>(>1)C45M/DVH^C7^PG00.9P.M1PI(# F^>VZG^H1STR^H2.W.100%#>7C8W71E3ZPI^SF^16S.1Q2.IV.M^KW8>1B^KW8>1B.E1+<G=>6.PPEOH^Q^KW7.O9M.KW760YB1\$1S?3P1^M^>LW+S<=>W2.U>1E YQ<6\$ZUUF<11^JWZ4MH0KSDSN1.GN9RGX.8=M^8NGY^RS^<P2>7-6R^OZCAK4XY2E1^O^W>#>RKV\$A3.TS#P#P+MQOS^17O4XIC87>1U.C3C MVI+&1#2.S1.PSW&41+<N^>#>F=K42&181CA4+U<OONNGV=K6^CHHOZ1A7H3A.M@O+1^<SG7JK2+1721^<@.SAZ0W.FX6RR.SH>MWXML1^EF14H30>GM1@/14

[illegible]

[illegible]

[illegible]

72Y00USZ1M2:W/V M+151(5)AMQ7E:9AG8)Z%-8ICA:KWWV-9JXHJ%CYL ML(1)2.TS:PSI(0_Q_%X2L6:RZU6&55GF0*8D+X371?1 UT1+RB;K#K^@N.M031/PSP#RS:10WEWADH16:P>P>YB8FIV<>7D6YCF<@1 X50A:PQ MJ-A*3R+4MV>H>>HW:5A#25^DHL:GIG9(65=>*89VA@GH5YCN.%*O:MW4J^MI2Y9BH:1W3HM:OM1+09THO=30P<=>H%ZA:&52^B&9VE@GH5YCN.%*O9M:VMD)NTOXHJ^7JT-7-Q^V3KZLN?LHTW-RWIF(1)4#M9S?ND+(NLO):M/s<#RS:OF1>2VYVW%G:8W61YK%9:49Z?>1KF M&9AG89IC%*N17KFS&9AG89IC%*1 M27NUD-JKBXKMJO?71>@/GZZO:BYO^>U^O/ZI?+F=KCT77 71^:MJ@4>YVIZH9#7/71PMM/(U?L#K63 FL+02Q4YPLT:1/2Q @F70@O@W M0+1+TR01?T@:(1)Z+PU<#&B-1V1L5Y2F8IV<>7D6YCF.%K#@>MTQ?JH4HEA7E.XX6GR1AW4HJBSNJ51?1 MJGG1-2>403BK45%1/PSF#RS:INF5YKGE21H 95^OAWD?YFF89V>A7E.XX7U1N.MR1HMAZ92)4XFFIS#M&82^NVE-NV1-N5 M?BZK8W1W7=3<@8B-B:E8691S:GJ61>1.F.8X72MCGV45O%61>15DA<#1 M>F7.4Y6F89V>A7E.XX7?IXW3DCM162EGG6<=>MEF6=O?JG5&4IV>AAGD&YF8YSA>F028RVY T=21YD)W<=>MTPSHK93 M49Z>1KF&9AG89IC@N1+10K8X1H10L61#Z3 1P GE&137PSP#RS:5S#MPC5S1<L16W=ZL0F5:P0:8HXK>Y9N9F&=@6H5YCN.%>1 IO61E-8DF4B-MU3C57&(X&YEF8YSA>1&32MFJMDWVWV?F4GJY7 M1@113N TR6H7660FJGA:1H39V>XWBA?GT#M9HT1.84?O:00:R1SAX M>2WR?>#1+G9-49Z?>1KF&9AG89IC%*P2>7D1KJFHFE@19XJR1CB8F5=E@Z M MAVU1E=>@GH9Y1N99FZDH31S M#2.31.PSW&14>^>UO1?>FA8J7.KZX<1>7E1WWS98W=P.7K<1E=>WOZ M.2O.UO.7M?>T7F=WWT41:DZ?D#M1G8Q45Y?N9IF&=@GH5YCN.%B>#IN%51 MXOHG0:PRN MAGH1Y&N89F&=AGN-X80IXGEXEYHINCZ9X.O:11-4U81E M#1QG<3781INP6601A:Q3P3M0Q4C?YKA631#PBZJH&G&SNA39#<U&K1>=H MR8S1UG7?LWD6#1L KF:9AG8)Z%>8ICA=>W=8:~1)2U1.XWBAIGU7MCZNF19R?>V=7UZL?K4A NOTWEU>KB80J5_1<K9R?7F M^N?KNH1A R:17HW/4%60 :MRA/P3P-IPS:1S#1<PP77P3N?Y6 ^12 P M#>1U:1/ WS#RS:100#?#>XFF72+4HDF5R<1FF126>IXV<M5C1B> \$B\$=>(Z.XX51@W>@B41:P/PU^UFZA3<1KH=172-P1>@/A8P M3M0QO:F69CG%ZH>=1GK<~ MVO1M106.PBUBKCA#FFH<52G89Z1>1.F.8X7+1QK=CFN?Y91&8YLL?1?3F MOP?ZV<@GD:YAF89V<>XWAAANOCV:7B-M&8F=17@ S%3.S_1OS<~ M<1>3&3E3VU? MLEY4 1.71311A7E.XX6R1 WH1FV73>?FGS)@12) MNV_SMMNBUI HJW:1.N@3:1>HDV:N=V<1>1> DU1 MGH9Y1N99F:0KF:9AG8)Z%>8ICA3G@&1G?H5&ZFEFGZ>P1<9 9 MIAH=JE#3B^>T<1>1>X2XWBD?M?Q? G6WE1NS1?F4GJY03/@FZW?DU0HT-M?>YFGYK1CY4 O TGG&1<^8H1&U23?XWBA1V3M0:1E<9V<900?>T^U>=1A3(KV1A B<95.\$ #M/1S+OS^140>^HME)^552A3:~F50^HSM>^KL>MDY1GH9Y1N99F.VR.%A#>PBD?IGC:P41HOHE&EGI?1V M\$R>=>Y.S.HX7?MEW9YU1N@BGMF06V44.(618XJE#M WBO?T1):?A#IZE MXWBA4~M06V1N8JKE?YFZD?36RFIG@>ZWBKOS(S^IND\$ #/1S_1OS^>4A M06^2ME?35%AL?G:YV>@JH5>9.0.BATU0E?>AGH?Y81N8YCA>(OO.U4Y1 MJH?F G:LBGKYTOB1A AGD&YF8YSA>1JK<~>1W0K@>?1A M^1>KT^>WUO>21X.NOE M7H17FE1.OWP9X 1T17L?P?2?UHHO M-X-&M\$>~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~M1OS<+>G1YAD&18UMGDF?Z1>Z/Z:1B7YP-EH.G9S547E.XX6)XOMV6F: MNO:QN1Q@F18GHY1N89F&=AGN-X80IF8F?GPV#>0+1E2Z?>VSL^N#>M1+1UHL-MZ>=>(17.9RWTC?Y\$2>#>0+M1&53?WOO?F?SRD?2J3.U7)& M/M2F&MXD@>9RR33W-9.Y@641 E RTZ717 2M471P~>RA/R/PSP#RS: MGLCT1K&18LBPO+TS#P+1OS?>Q71&S>9W+BA MRD1N@>S&H1P&Q1 F?9BG89Z1>1.F.8X7YH90?6?>BOKF 9AG M0)Z>81G13FO^RY6+1.F.L8.MN5+@D1O:2L4H45L&NE F?1 YXN?XHG6 M1VD7&XSDS21>1%169<=>#(F?SRD?2J3.U7)&M2F/MXMDG@>9RR33W-9<~M1V#3?1 /M2>O N&G<=&8RHKX.P19G-O1?7^5F&=>GH5YCN.%03-BWSNCG23-M9:A8NPKA401&17R1N1 MZ1N5_2+X1?1<8? 7V.O:CS>TOS1L^_QOZ 7#XWQ19J58:>9 M&_13<~>K M^1N1JVO5VW1?>K89Z?>1KF&9AG89IC@&N+&9271V12S5AVB00:H?9BG M89Z1>1.F.8X7YH100?>Q7?O1M6LO?3J JK&483>3V 1/1C^+4E1^>M251N1T81L\$1P0%1#0>^74H51TEM-A75^A.VN2^M1Q@>ZWINSAN KF:9AG M0)Z>8ICA9KW1+RXWBA?T KCBNE>OX M4XD<D@>P.O?Z?Z<=>GD:YAF89V<>XWAAOKA&9?BWJX?INU>3W.451/PSP# MRS:AGD&YF8YSA>~G?M12VX I=>1VD31B?>VAW08?>5\$ COLJ?=>AGH?Y81N8YCAAGD&YF8YSA>F?C92Y2 27K1O1JOWT N? M2SX=1X W^Y1S^>23H=>K130B7EY\$^>21^V55%>#>45_P511<~ MQPM5Q#>RBL>T.GQ^44 W.N1A3.TS#P#P+1OS^>W/W8+1E=THX?9^W MW+XGCSXK=8 EAS1>G&P=94\$R1?<K4@>S1^/OS<1+1%OZ1FTLRE 5&X2 M1>^RP<P~ 11?NXD?1FU2 ^1)>0KF:9AG8)Z%>8ICA7+WS=E12:Z>?>P1V MM(5+17L DUBYL?6#A3.TS#P#P+1OS^>Y7K6Z6EM^>3U+4OOV:>9X-2?~ M1B? ^4S1/PSP#RS:YM K^SF@UKUMS=7QSWM<7 O ML1G)=C91P1S1S_P1L1LS<+1P5Y7@MRI-6ATK8.\$5Y/6L? NHR31N8YCA1&S=15FM^Y5ZL0M@Y1GH1H&N89F&=AGN-X80IH61Z14H#?BG%M7(PK MPWV2SU1R?>7 QO0GH9Y1N99F.DX1>1^T^K?00-3Q#_1S_1&lt

[illegible]

MHBOT?MWP109>7^</OHL>=>PIWM^@U:?=>0.10ISZ.U.?>IVIS=RI/PB=>MCS^>?;8?R>IAG8)Z%>0IF>9>9.7.%Z.1+.%C63'+<(<5/<+<^>0.F69CG
MBZ>8^C13D9>X_>#LYO<<3^>26R78.WXJS&E5^>=RTLZ44^>1=3%THL M6J7+14H6W2U^>S6JGK05>(<LS(OXIQ5(0842VHH1=7TKMU-MM=CB^#A
M^N^02VHJ6146X>?>2^>1H^>P1^>#BOIS^>PSI.P1^>2^>ACGB1SVS^>0^>VSV3.9 M.8.2ZG<?>#A4FS8BPD.6&.NIZOL/SP&49VX<?>@WD>Y@6.E^>9.N63&.G^>2SY
MUW^>VPI>F7N10IEXF7^>1F1P2^>2Z<?>7.203^>1U100XR<B5.X^>7^>Y37.MPSPXR&S1AG8)Z%>0IF>9>9.7.%Z.1+.%C63'+<(<5/<+<^>0.F69CG
MW(&4R)M(NOW6=5F%+>1.A1ANOGE&9AG89Z#>1F18Z7AGOL^>Y?<90G(FTB.MV/3)=MZDRI#GA:8?>PNXSR+OS_#0.#OTI^>W>5RT9&3.&WN^>1 M#&
<FV1Y/PL^>W1^>V4K1L7C3&F&E+1DLU>0D7^>1 M=&A/P^>1JN^>=&W4Y41H^>Z60@1.KW414(1^>U^>TF5.OHZN8CNZ^>L#3-U
M.1&RWR192@K5B^>1J3P1G9C1KTH954WM1^>M&K.W<2JG M19.P^>2%G1KW>=>G)5W<1.R877.49V&<?>@WD>Y@6.E^>9.N63&.G^>2SY
8P^>NRGLLZTC/D14S<?>+1V^>3<?>@WD>Y@6.E^>9.N63&.G^>2SY
M.KUG_>0.F69CG8)Z>8^>C1D2.D_>G5^>4K1E^>7C<?>@VJE&<?>@D76YCF8YV^>M&XAI^>1362G6T1U71325^>V6GOSI@C3Y<?>67.99G)RNNES^>6^>NS%ZFL^>EZZ=D8B?LR"@RI>
<?>19#M1-7@&.%#N1A8J81H^>1JH3H1(M#56G%7W2TY5Y6U=+PMHY>Z7^>AEI9@U=)T.FUKI^>1>ODP(RI_9G%#%2IN.MJ+^>FIBIO-R^K33?PVR?
UFXMEZ^>EMAW^>1Q^KD#>2Q0UGH5^>N9M^>FYIY^>W^>0@BRDIPD^>4^>V^>1(5^>Y^>V^>W^>1^>J^>1^>U^>S^>W^>W^>=>E0=>?)C^>P^>Y^>R1^>Q^>#>1)Q=S+>S(AO)ZF<?>@6H5Y
M#N9YFI#>S_>PSI^>S1#>."OTMS^>1^>5#M^>P.2^>1ATFTWR<9.R8-9#PL^>FS^>1^>U^>F^>T^>P^>W^>M^>Q^>TDB>1^>Y^>27F^>AL^>1^>O7P.M0+>1^>M^>G^>1P^>1VRK^>Z6W^>ZHLZ>9>IX.03&QG<
5.139H1^>C^>1E17H.IK&G^>M^>GH5Y^>N9YFI^>AWF^>IXR^>YL^>FMR.WOCB2>EGLH^>1^>N^>R^>^>AN8914^>X^>W^>K0^>35^>P^>22(R-MP.U^>D81^>91+>X^>1^>U^>6U^>U^>1^>E^>U^>G^>P^>M^>1Q5^>1S
O+P^>F^>E^>1^>C^>Q^>F&Q^>Y>+>Q^>8K1LB^>1+3^>4 M9V&<?>@WD>Y@6.E^>9.N63&.G^>2SY
TB01/9T9H0WB^>1^>L MS^>PSI^>P^>2^>%(E=OIVICOK>P^>X@RNMAGH^>Y^>N8YF^>A7N^>IX^>0I^>S^>N^>W^>Y^>N^>M^>J^>A^>V^>D^>J^>L E.Z>D3K^>1JX.%9@90+E6>V...U
#1P<?>1PTB0^>C^>W^>S^>1^>M^>B^>1^>V^>A^>IO^>10IN194Y^>#>59^>5^>F^>X^>U^>S^>P^>10^>8Z>O@HUBD6SA1225+O M^>ZD3S^>F1^>O72^>6M^>1^>@16V^>Q^>#>1^>F^>9C685I^>@>S68^>1^>FYUVC<
<610P^>MA^>C^>M^>M^>K^>H^>W1^>1^>JH1D3Q8BHKH^>Y^>N8YF^>A7N^>IX^>0I^>S^>N^>W^>Y^>N^>M^>J^>A^>V^>D^>J^>L E.Z>D3K^>1JX.%9@90+E6>V...U
M^>N^>W1^>P^>N^>I^>V^>1^>L^>1^>W1^>G19^>K^>1^>L^>1^>W^>2^>PKPY^>X^>G^>Y^>N^>O^>S^>P^>K^>Y^>E^>I^>O^>A^>9^>M^>Z^>6^>G^>S^>1^>N^>1^>N^>99F^>@>G^>H^>Y^>@>E^>S1^>1^>T^>U^>U^>U^>1^>E^>U^>G^>P^>M^>1Q5^>1S
O+P^>F^>E^>1^>C^>Q^>F&Q^>Y>+>Q^>8K1LB^>1+3^>4 M9V&<?>@WD>Y@6.E^>9.N63&.G^>2SY
TB01/9T9H0WB^>1^>L MS^>PSI^>P^>2^>%(E=OIVICOK>P^>X@RNMAGH^>Y^>N8YF^>A7N^>IX^>0I^>S^>N^>W^>Y^>N^>M^>J^>A^>V^>D^>J^>L E.Z>D3K^>1JX.%9@90+E6>V...U
#1P<?>1PTB0^>C^>W^>S^>1^>M^>B^>1^>V^>A^>IO^>10IN194Y^>#>59^>5^>F^>X^>U^>S^>P^>10^>8Z>O@HUBD6SA1225+O M^>ZD3S^>F1^>O72^>6M^>1^>@16V^>Q^>#>1^>F^>9C685I^>@>S68^>1^>FYUVC<
<610P^>MA^>C^>M^>M^>K^>H^>W1^>1^>JH1D3Q8BHKH^>Y^>N8YF^>A7N^>IX^>0I^>S^>N^>W^>Y^>N^>M^>J^>A^>V^>D^>J^>L E.Z>D3K^>1JX.%9@90+E6>V...U
M^>N^>W1^>P^>N^>I^>V^>1^>L^>1^>W1^>G19^>K^>1^>L^>1^>W^>2^>PKPY^>X^>G^>Y^>N^>O^>S^>P^>K^>Y^>E^>I^>O^>A^>9^>M^>Z^>6^>G^>S^>1^>N^>1^>N^>99F^>@>G^>H^>Y^>@>E^>S1^>1^>T^>U^>U^>U^>1^>E^>U^>G^>P^>M^>1Q5^>1S
O+P^>F^>E^>1^>C^>Q^>F&Q^>Y>+>Q^>8K1LB^>1+3^>4 M9V&<?>@WD>Y@6.E^>9.N63&.G^>2SY
TB01/9T9H0WB^>1^>L MS^>PSI^>P^>2^>%(E=OIVICOK>P^>X@RNMAGH^>Y^>N8YF^>A7N^>IX^>0I^>S^>N^>W^>Y^>N^>M^>J^>A^>V^>D^>J^>L E.Z>D3K^>1JX.%9@90+E6>V...U
#1P<?>1PTB0^>C^>W^>S^>1^>M^>B^>1^>V^>A^>IO^>10IN194Y^>#>59^>5^>F^>X^>U^>S^>P^>10^>8Z>O@HUBD6SA1225+O M^>ZD3S^>F1^>O72^>6M^>1^>@16V^>Q^>#>1^>F^>9C685I^>@>S68^>1^>FYUVC<
<610P^>MA^>C^>M^>M^>K^>H^>W1^>1^>JH1D3Q8BHKH^>Y^>N8YF^>A7N^>IX^>0I^>S^>N^>W^>Y^>N^>M^>J^>A^>V^>D^>J^>L E.Z>D3K^>1JX.%9@90+E6>V...U
M^>N^>W1^>P^>N^>I^>V^>1^>L^>1^>W1^>G19^>K^>1^>L^>1^>W^>2^>PKPY^>X^>G^>Y^>N^>O^>S^>P^>K^>Y^>E^>I^>O^>A^>9^>M^>Z^>6^>G^>S^>1^>N^>1^>N^>99F^>@>G^>H^>Y^>@>E^>S1^>1^>T^>U^>U^>U^>1^>E^>U^>G^>P^>M^>1Q5^>1S
O+P^>F^>E^>1^>C^>Q^>F&Q^>Y>+>Q^>8K1LB^>1+3^>4 M9V&<?>@WD>Y@6.E^>9.N63&.G^>2SY
TB01/9T9H0WB^>1^>L MS^>PSI^>P^>2^>%(E=OIVICOK>P^>X@RNMAGH^>Y^>N8YF^>A7N^>IX^>0I^>S^>N^>W^>Y^>N^>M^>J^>A^>V^>D^>J^>L E.Z>D3K^>1JX.%9@90+E6>V...U
#1P<?>1PTB0^>C^>W^>S^>1^>M^>B^>1^>V^>A^>IO^>10IN194Y^>#>59^>5^>F^>X^>U^>S^>P^>10^>8Z>O@HUBD6SA1225+O M^>ZD3S^>F1^>O72^>6M^>1^>@16V^>Q^>#>1^>F^>9C685I^>@>S68^>1^>FYUVC<
<610P^>MA^>C^>M^>M^>K^>H^>W1^>1^>JH1D3Q8BHKH^>Y^>N8YF^>A7N^>IX^>0I^>S^>N^>W^>Y^>N^>M^>J^>A^>V^>D^>J^>L E.Z>D3K^>1JX.%9@90+E6>V...U
M^>N^>W1^>P^>N^>I^>V^>1^>L^>1^>W1^>G19^>K^>1^>L^>1^>W^>2^>PKPY^>X^>G^>Y^>N^>O^>S^>P^>K^>Y^>E^>I^>O^>A^>9^>M^>Z^>6^>G^>S^>1^>N^>1^>N^>99F^>@>G^>H^>Y^>@>E^>S1^>1^>T^>U^>U^>U^>1^>E^>U^>G^>P^>M^>1Q5^>1S
O+P^>F^>E^>1^>C^>Q^>F&Q^>Y>+>Q^>8K1LB^>1+3^>4 M9V&<?>@WD>Y@6.E^>9.N63&.G^>2SY
TB01/9T9H0WB^>1^>L MS^>PSI^>P^>2^>%(E=OIVICOK>P^>X@RNMAGH^>Y^>N8YF^>A7N^>IX^>0I^>S^>N^>W^>Y^>N^>M^>J^>A^>V^>D^>J^>L E.Z>D3K^>1JX.%9@90+E6>V...U
#1P<?>1PTB0^>C^>W^>S^>1^>M^>B^>1^>V^>A^>IO^>10IN194Y^>#>59^>5^>F^>X^>U^>S^>P^>10^>8Z>O@HUBD6SA1225+O M^>ZD3S^>F1^>O72^>6M^>1^>@16V^>Q^>#>1^>F^>9C685I^>@>S68^>1^>FYUVC<
<610P^>MA^>C^>M^>M^>K^>H^>W1^>1^>JH1D3Q8BHKH^>Y^>N8YF^>A7N^>IX^>0I^>S^>N^>W^>Y^>N^>M^>J^>A^>V^>D^>J^>L E.Z>D3K^>1JX.%9@90+E6>V...U
M^>N^>W1^>P^>N^>I^>V^>1^>L^>1^>W1^>G19^>K^>1^>L^>1^>W^>2^>PKPY^>X^>G^>Y^>N^>O^>S^>P^>K^>Y^>E^>I^>O^>A^>9^>M^>Z^>6^>G^>S^>1^>N^>1^>N^>99F^>@>G^>H^>Y^>@>E^>S1^>1^>T^>U^>U^>U^>1^>E^>U^>G^>P^>M^>1Q5^>1S
O+P^>F^>E^>1^>C^>Q^>F&Q^>Y>+>Q^>8K1LB^>1+3^>4 M9V&<?>@WD>Y@6.E^>9.N63&.G^>2SY
TB01/9T9H0WB^>1^>L MS^>PSI^>P^>2^>%(E=OIVICOK>P^>X@RNMAGH^>Y^>N8YF^>A7N^>IX^>0I^>S^>N^>W^>Y^>N^>M^>J^>A^>V^>D^>J^>L E.Z>D3K^>1JX.%9@90+E6>V...U
#1P<?>1PTB0^>C^>W^>S^>1^>M^>B^>1^>V^>A^>IO^>10IN194Y^>#>59^>5^>F^>X^>U^>S^>P^>10^>8Z>O@HUBD6SA1225+O M^>ZD3S^>F1^>O72^>6M^>1^>@16V^>Q^>#>1^>F^>9C685I^>@>S68^>1^>FYUVC<
<610P^>MA^>C^>M^>M^>K^>H^>W1^>1^>JH1D3Q8BHKH^>Y^>N8YF^>A7N^>IX^>0I^>S^>N^>W^>Y^>N^>M^>J^>A^>V^>D^>J^>L E.Z>D3K^>1JX.%9@90+E6>V...U
M^>N^>W1^>P^>N^>I^>V^>1^>L^>1^>W1^>G19^>K^>1^>L^>1^>W^>2^>PKPY^>X^>G^>Y^>N^>O^>S^>P^>K^>Y^>E^>I^>O^>A^>9^>M^>Z^>6^>G^>S^>1^>N^>1^>N^>99F^>@>G^>H^>Y^>@>E^>S1^>1^>T^>U^>U^>U^>1^>E^>U^>G^>P^>M^>1Q5^>1S
O+P^>F^>E^>1^>C^>Q^>F&Q^>Y>+>Q^>8K1LB^>1+3^>4 M9V&<?>@WD>Y@6.E^>9.N63&.G^>2SY
TB01/9T9H0WB^>1^>L MS^>PSI^>P^>2^>%(E=OIVICOK>P^>X@RNMAGH^>Y^>N8YF^>A7N^>IX^>0I^>S^>N^>W^>Y^>N^>M^>J^>A^>V^>D^>J^>L E.Z>D3K^>1JX.%9@90+E6>V...U
#1P<?>1PTB0^>C^>W^>S^>1^>M^>B^>1^>V^>A^>IO^>10IN194Y^>#>59^>5^>F^>X^>U^>S^>P^>10^>8Z>O@HUBD6SA1225+O M^>ZD3S^>F1^>O72^>6M^>1^>@16V^>Q^>#>1^>F^>9C685I^>@>S68^>1^>FYUVC<
<610P^>MA^>C^>M^>M^>K^>H^>W1^>1^>JH1D3Q8BHKH^>Y^>N8YF^>A7N^>IX^>0I^>S^>N^>W^>Y^>N^>M^>J^>A^>V^>D^>J^>L E.Z>D3K^>1JX.%9@90+E6>V...U
M^>N^>W1^>P^>N^>I^>V^>1^>L^>1^>W1^>G19^>K^>1^>L^>1^>W^>2^>PKPY^>X^>G^>Y^>N^>O^>S^>P^>K^>Y^>E^>I^>O^>A^>9^>M^>Z^>6^>G^>S^>1^>N^>1^>N^>99F^>@>G^>H^>Y^>@>E^>S1^>1^>T^>U^>U^>U^>1^>E^>U^>G^>P^>M^>1Q5^>1S
O+P^>F^>E^>1^>C^>Q^>F&Q^>Y>+>Q^>8K1LB^>1+3^>4 M9V&<?>@WD>Y@6.E^>9.N63&.G^>2SY
TB01/9T9H0WB^>1^>L MS^>PSI^>P^>2^>%(E=OIVICOK>P^>X@RNMAGH^>Y^>N8YF^>A7N^>IX^>0I^>S^>N^>W^>Y^>N^>M^>J^>A^>V^>D^>J^>L E.Z>D3K^>1JX.%9@90+E6>V...U
#1P<?>1PTB0^>C^>W^>S^>1^>M^>B^>1^>V^>A^>IO^>10IN194Y^>#>59^>5^>F^>X^>U^>S^>P^>10^>8Z>O@HUBD6SA1225+O M^>ZD3S^>F1^>O72^>6M^>1^>@16V^>Q^>#>1^>F^>9C685I^>@>S68^>1^>FYUVC<
<610P^>MA^>C^>M^>M^>K^>H^>W1^>1^>JH1D3Q8BHKH^>Y^>N8YF^>A7N^>IX^>0I^>S^>N^>W^>Y^>N^>M^>J^>A^>V^>D^>J^>L E.Z>D3K^>1JX.%9@90+E6>V...U
M^>N^>W1^>P^>N^>I^>V^>1^>L^>1^>W1^>G19^>K^>1^>L^>1^>W^>2^>PKPY^>X^>G^>Y^>N^>O^>S^>P^>K^>Y^>E^>I^>O^>A^>9^>M^>Z^>6^>G^>S^>1^>N^>1^>N^>99F^>@>G^>H^>Y^>@>E^>S1^>1^>T^>U^>U^>U^>1^>E^>U^>G^>P^>M^>1Q5^>1S
O+P^>F^>E^>1^>C^>Q^>F&Q^>Y>+>Q^>8K1LB^>1+3^>4 M9V&<?>@WD>Y@6.E^>9.N63&.G^>2SY
TB01/9T9H0WB^>1^>L MS^>PSI^>P^>2^>%(E=OIVICOK>P^>X@RNMAGH^>Y^>N8YF^>A7N^>IX^>0I^>S^>N^>W^>Y^>N^>M^>J^>A^>V^>D^>J^>L E.Z>D3K^>1JX.%9@90+E6>V...U
#1P<?>1PTB0^>C^>W^>S^>1^>M^>B^>1^>V^>A^>IO^>10IN194Y^>#>59^>5^>F^>X^>U^>S^>P^>10^>8Z>O@HUBD6SA1225+O M^>ZD3S^>F1^>O72^>6M^>1^>@16V^>Q^>#>1^>F^>9C685I^>@>S68^>1^>FYUVC<
<610P^>MA^>C^>M^>M^>K^>H^>W1^>1^>JH1D3Q8BHKH^>Y^>N8YF^>A7N^>IX^>0I^>S^>N^>W^>Y^>N^>M^>J^>A^>V^>D^>J^>L E.Z>D3K^>1JX.%9@90+E6>V...U
M^>N^>W1^>P^>N^>I^>V^>1^>L^>1^>W1^>G19^>K^>1^>L^>1^>W^>2^>PKPY^>X^>G^>Y^>N^>O^>S^>P^>K^>Y^>E^>I^>O^>A^>9^>M^>Z^>6^>G^>S^>1^>N^>1^>N^>99F^>@>G^>H^>Y^>@>E^>S1^>1^>T^>U^>U^>U^>1^>E^>U^>G^>P^>M^>1Q5^>1S
O+P^>F^>E^>1^>C^>Q^>F&Q^>Y>+>Q^>8K1LB^>1+3^>4 M9V&<?>@WD>Y@6.E^>9.N63&.G^>2SY
TB01/9T9H0WB^>1^>L MS^>PSI^>P^>2^>%(E=OIVICOK>P^>X@RNMAGH^>Y^>N8YF^>A7N^>IX^>0I^>S^>N^>W^>Y^>N^>M^>J^>A^>V^>D^>J^>L E.Z>D3K^>1JX.%9@90+E6>V...U
#1P<?>1PTB0^>C^>W^>S^>1^>M^>B^>1^>V^>A^>IO^>10IN194Y^>#>59^>5^>F^>X^>U^>S^>P^>10^>8Z>O@HUBD6SA1225+O M^>ZD3S^>F1^>O72^>6M^>1^>@16V^>Q^>#>1^>F^>9C685I^>@>S68^>1^>FYUVC<
<610P^>MA^>C^>M^>M^>K^>H^>W1^>1^>JH1D3Q8BHKH^>Y^>N8YF^>A7N^>IX^>0I^>S^>N^>W^>Y^>N^>M^>J^>A^>V^>D^>J^>L E.Z>D3K^>1JX.%9@90+E6>V...U
M^>N^>W1^>P^>N^>I^>V^>1^>L^>1^>W1^>G19^>K^>1^>L^>1^>W^>2^>PKPY^>X^>G^>Y^>N^>O^>S^>P^>K^>Y^>E^>I^>O^>A^>9^>M^>Z^>6^>G^>S^>1^>N^>1^>N^>99F^>@>G^>H^>Y^>@>E^>S1^>1^>T^>U^>U^>U^>1^>E^>U^>G^>P^>M^>1Q5^>1S
O+P^>F^>E^>1^>C^>Q^>F&Q^>Y>+>Q^>8K1LB^>1+3^>4 M9V&<?>@WD>Y@6.E^>9.N63&.G^>2SY
TB01/9T9H0WB^>1^>L MS^>PSI^>P^>2^>%(E=OIVICOK>P^>X@RNMAGH^>Y^>N8YF^>A7N^>IX^>0I^>S^>N^>W^>Y^>N^>M^>J^>A^>V^>D^>J^>L E.Z>D3K^>1

>>L>S\$5>BC/P3PAP+2S,B7I%0:U-0#E>=>Kx<O-M?G@103/OJ?>?C2DHS1+>+BF3JW9S"O MAWD&YEF8YV">AWF:IXZ4Y\$)OSM,XJ?G%->LJ/GTTFU9EVB">+>0#K?>?TPIT MT@V>S1J<=>GKY?6N1Z1UC">IG-UC1>GDAR A,&A>S7C:6I-01K7X?3C 42I=I W MIDCLOWI?O JK6K SNEIH6<=>I3==L@WD>=>MY6E.FT9CJCN2M4HJIBU<?>7UYSL O<?>P1BJ>NVO321A<?>I=>O6G?25/P1 M""<=>R<=>87G-N-056I9UO=IVT?>7XK<=>XJEL1I3DXSXEHE+0#>+3Q#M1 MS L<=>1XWV5JLZZVIVHF18Z7I16L M1WUG6S1+U.WY.NK BB@ZT.FE&=>GH3Y#N9YFA7D.YGFB8Y\$A>FB>Q/>=>4ARVO-1A=>S=>IAGD?>M M>0H?>9=>7%Z>: I&AY: (H1=5UXY?>Jd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

0,OW57?RX&L7N5P@8.4WI6K137ZF>L%#EIZM1(Q\$WQIHW<7V=>?O.HJMONL<NV.%PW>=>JG.VI7=>GHU+ENL633Y#XNZ.X.MA.VJCL9R4E9#PLOR<BE+A=*62
T=>O=ZJMU>ZWIHEI<_DR.YY%IOGG<X1.MPY>5ZP>WIOI>OF\$U=>^O.CZ17H1.GY>R>SF<JHF5?#J0HUB>J5G26>=>MAWFJXZ6Q^+O.G;9163559\$M=>NQONOS^+J>ZAG
TJK>M>JS.N.STINU4.MCOV6P1XWRKP.XSI#M>=>^QTLS(O.X.ZW.K3I994MIDP>=ID6>PNT2.G^1.M=5U639XO@LCDNPWGS1.LH.IHWY2ZP>
ZWI>1<^222VPL>IOK89Z1>1.F.9CG8B1@<F&F&E>=U3K1K<3G.M6NTLS1>1.T.ZVY.M&E&P.LH@O7VZD2M1<EN&S7YLV>=>3J
M86D1ZS^4IO<1<G&3A>&KYU>LZ31G<Y.ETGDCY43Z(PXK>=>M^H2+G1.M.FEEA.LS.PS1.P2>?%>14X>HRO09H1N@K<M=5.Y+>RRS/PCP/SS.
M^QPOC=>PFCE\$SRN%V1-B.R.V1F<E-7>=>2RS<H1F8Z7YD.7Y1<F1U1WJ2RA9>IV.ZI.*L.555481;5L%9663B7.MM=I6-0RN)NOUW6O1+J.7NMJR9>5W1.KI?>0Z;6NEV1Y?3.C3??
C1>Q>=USE.M1#BDS<M2B2Q^K5%81K.R<2.X0031>=>3J14B1S14>X570.4.O=XEH62U.M.O^N%=>+WB>^JLGO.4KPT9Y/NH
H1W6M61M22.W^O.CK8<C15D1>^F%ULM7.41%1L+V1>3X5D0Q9L6.4M=2^9X5.M1@P<=>#CC.(LS.PS1.P2LQ@=>1.7V1XV12>.YZ>=>EXS;OB\$+F%VNI?>
M45XAS.PS.LS#P3PAP1^2S.FE7E0.(PUG.IX+O+>ZVX<@>7D6YCF8YV%>X^A1.M^L1K%<@KMFH7O.OA.O.F>?AXN.K7NX35EUI07H3>^2713<A>TTF>QFHVTV1.M.A)>
786G.69V\$<@WD>1@>6.M.FE11.2L1>=>H8V1GP123>1.O.W\$Y37PSP.RS.O.F69CGZB>2^8C13D30N.EUAV7.WZ^E8A2YXW@>S.R5PPIA
M.N/4P.2<_GHL38Q7R^B1F7H512US.E.#J&W4UJ78YM<3U7.D0?71&HNW^M.B1G1HU\$K78M?>K171<^2>=>1JZC<V82>^FC/OS^SS.^IPO#3Z8TNI1^WU.M.C>Z>T5NJ
NB\$>+21>=>ST7>+>JCG^S.LS#P3PAP1^2S.O.ML1+92Y\$>P>H.M31>U>P.M.T+D1.Y946>C>=>70GR>H1L<C.C.NO\$E1>O3Q1P7M1NOV^+>V.MY87EDZIO@WD>Y@>6.E.FZ9
L7L>021A1^W1D1S.P.M\$SI1L1<+1V5%017W^P>H^J&1.8D3X1H6D&S^SAOUT^O>=>1Y.M&AG19UZF7.DY#1<+>PTFY&WNI30KKH1G
?>#A1X4O>5<C1F=NAOMJBZ>@.IN.MY.O&>59^4.X.S.IPO#>8DB1UW^C.GG^2-B.T0^S<G7W+ZNGH14.M^QKEF69CG81Z>8<C>7%?03Y1P26A>1EO>^EW8Y7Y\$P@J
M&=>A7D.YG6F8\$M.O.>QF\$Q1.U9R1.M.FEAYW1^2<MB^H1Z>O>P^XSR.M+QS..#O.QT^K1>=>WUT15<=C1SOZUIGM1<=>=W.W.VVZ>OZXM<N71.M1N7^>4>O3S?>
WJY<2.W1<^WASOI<=>S.FY\$%G>^+OS^SS.^IPO#1C.M8B.XJ@Y.T.F.S1H10XEU63D12IEPLN1.C5KEDX1
Q2K^VHRH1W1+G5Y.G41=WENU01V1.21Z7R<#>D.2D\$Y+5EW6Q1+>7N1R.MH1935V1&K1770Z.6NEV1Y?3.C^=>=ISO>UW5WISRT7^JN1HWDF1HYRE^+>9+B.MJ1^17
923155@>#>2%56^4Y1>AWF1XZ49902U.X.Y)K91N1>2E651M1.M1PQ>.TPR^2R1.EM1+(Y1+)>1P^C/OS^SS.^IPO#078E>VTKBJE675=2%
MW51%>1B1H1W1?>075^1+GL1C>1<MFN&L73>OY17<H1C77H1Z>S1+FH661B.M1M5>Z18>=62L1L24O>DEP1^=>#J1<+14\$D.1^E.N175\$4>4&GP6FWY3>
MKAS+>F.P.P11>1KF&AG891C<=>N19Z672P1O>1.P.G=I>GR<E^?K>1.MN1XO.HW1R1H12O>M.W3Y>W.JFXD6G^?>7U.S1^WS
M#RS.IQO^12M^+1+K367L1.G181V>AGD&YEF8YSA>F<^5^*M1V92.MNGHV>K1@<1H1C1T>X^XW.@>1>306.D1>BP\$H3L.S.##/PCS14E<^UY1MR>OD?>
H1D>4<=>1.M189V>3^G1G&E.F.HYBA/PS#R\$81CA<+W>21>1+U0F1.GMA.MEY+O>1<166>@>GD.YAF89V<XWBA1KUNES6^CVGM1AC1G1?>
11.GD.YAF89V<XWAA&G&F^GDWN2H1U<3W.4S1/PS#R\$81CA2KVC<WR=N>=>#1M16&Y1O>5M9>+1&2K41^4OR0Y4.W1T1V1%>4Y74P31\$1#?>.S+P
MSW&1\$1H1Q8YB1F8V1V<@>7D6YCF<=>1JY64O>V>64R\$2K1.M1ZQ3U1^23P1^VDXNOQB1<@BL1<1^31^M.FX(O1Z7FPFOXKR.PS..%?0QM1W.FHE
<5>78\$>371DUO.ZL&1/AP281MRE.P31.LL<+>Q2<^Z1G46.55MT1^23P1^B1MKN1W1J1OPUM.H1P>YB1F8V1V<@>7D6YCF<=>1JY6W9&K.W1G11KF
M&9AG891C<=>\$.U+I06M16UZZ@<H1T1L/EQ>=>2^5351>Z>^O.N91<T8^+5+MSDQO%>OB%R1M<#1>1.H1OX9X1M=5.%H1=512GY=>BY\$M.S0146%
M^M1YH572G<F^D&+>U7K>D&KL%1C3.S#PCS14+5>DYEC11.TV.H=RX.MUI2NUV17A?1D.YAF89V<XWBA1^M1N81V=>AGH%Y1N8YCA>FBV1^UD=N1ZSA
D^4U117S.PS1QO>^=>MR12G9Z>591A1^MG6PW9.CBA1R1C<=>1.XX521C1W^M4.C6&F&W1+1RRKK1H1H61V&M1C3.S#PCS10+5.KYMUGM^MDH1417^E
G&+Y4Z1>1<=>2^11KF&AG891C.M^R8.M3XN>RG=>5F1JMX<@Y.T=>H1F89V>A7E.XX71J8Y19EG3XEFY
M19^W1N1Y1+KUK01Q1<=>R^F1VWZ>K^S1Y1+Q1N1H1W51<=>1^9K4Y1M1YFNK^W1J1W3V4U1U17TS.M.PS1QO.%100%>P1.8H1H.B01H^9B6
M89Z1>1.F.8X7YH1O1S192M1%YQV1BU.M7581H2.E6FC1H1L.R199^4>M1>\$.Y&AG891C>X^S227^O>6C34^2V1U.EFZ3X^V^6>^P>R>K>1>1.3Q+M1.LS
<+Y2P1DZ1N1>1TG24ZOME&^C1SV=>=OO.OUHA&AFP.E9AG81Z.M>81CA+W>ZG<^SS1E+&8>1^9K1AFHHO16P18CY.PS..%?0QM1H1M9F+>^M1DY0E5
&1F.66:QUN1L0Y2F18V<=>7D6YCF^ZK<=>\$.10>X1NOY.M1L1N190OEY1F=>=>KKRNU1H1P731L@Z1N1B1F=>AGH%Y1N8YCA1O1V1.M1M1.H84<5Y24P31\$1#?>.S+P\$W&1
1Y1651>U>B.MD01&1DODR<^U>R.M1X>9X2U1U<^>7Z>CG66C41Q1G1L72.U11<@>Z>9&S9L#>1H\$..%?0
MPLSPG<U6NR1UB2TR1WR1B&G.C&L14N^&AB.TS^PSTK1KMSSH1O.MNE#>007.2ALP1X&H1Z>N1V1H1F>CM1N1>O6P78F45Y1^13B^>1>1^>^O
M1XB.Y.H311.L1.L1<=>8^>1J1L1U1S557V7NH1E3071Z1^=>#D.MNB1E&K1J.D1A1.AK31.LOS1+1H1W.E1N1R1K61ZM0F72MG6<X1N^M98Y1M^AO/O5^<12801
11@<1Q.E9AG81Y1E405^A1T1P8^5.F+16V1MY1OUG7Q7X^B1NGF1N9F>EP>70S>RW1KU^7E1=76S<X^XW.WCX17=1LW1M1X1R1N93L?>
5<1>3CP41F^

[illegible]

[illegible]

01FCS%PHK>27:GB51N99F.9/2#V1R<GOWTOK3Q^FY<#74>:GU8ZV/LH M31\$1#2. S+.PSW&ITM<>INC(IDFL#12SMTPG#):WXM<L-Y+>GOOFRV=Q7:JF4141
(HKX<Y^N9IF<=>GH5YCN<1+>0GQ F1 MLW=>S.H6<3W.4S1/PSP#RS.IWFR<FE7X<12ETL F<+>O5NH9262UTN. S+ MN<3H45C1P7G#>Y3BA07H1+>+>Y3Y1PP2?
956<B^9C2GQ<0>JSL:DLBHK MXXK).R.UMM#1XUBND1 L^C#C6EIGPB+M^+01 AUFHFFERHVGWZ<LGD>0=>79HRRUHL<0^>22GZIAE=189Z?
M=8ICA7FTT L^>D>=>1FZE:1WJDFH<#>XFE9ZR UK2FE# 2169 >2P8B180LQ# MB0AA1SE:9AGB9Z>8ICA77A1>2%>8Z7G1L9>JVK<0Y2M2D1Z+3A
MR<KG:9DW.PV3<RJRHXV>>07D6YCF.%Y<SGYL7TMO<=>#&2L M04QH.NH<0M-MVCE00%>C/W.S#RS.I00+ B^>1DGLKQ2HD192G5I< MX-UDE 3#7 7S.PS. /12
QPI+Q5.BB.6ZB4L1<N8IF<=>AGH%Y<N8Y MCA760<1#> (E1FIQQ+>27SX-DHNVAZIC)+ M7<1XHFYS1%>C.UV1F%>#KQ2N^>X51AGQ&RO/U1512#LR<5W46
MMX33D0Z6<=>84-AGB+HK1<5-D<C/LPHN5IF&=>GH5YCN<0%>G1Y4Z1 MPQ9E1QO:WNXA5=GF<54D=BF>2D(9BGR=>Q:24HDZOED<K.S:<=>)D>Y1N99 ME.20-
542IQK<VY7RK.JX#008<=>6@L#(GF.E75M9%ZD#>#>M-1KF&9AGB9IC<=>S+M^1EY71PZ1IGVOOJX<FM<N5N7ZP
M5N5K1X<K75WL<S(R4E)DUH<W18H1W19>:AGDAYEF8YSA>6^A^>Y6QYU12G0<+M+TUL=>F2TJ5JIM M58E5A19S445>=>1\$M#1A7N(O4Y7T^>9QOZ(HS8>YT8001C<#>^>?
GAR<=>M.AV1P2311V<1R<1C5^>2P1EE4P1<YK. K8N74G<1P=PNEM.PCG>1G7YVCDG<1#>M.MD48\$95OLZ+>7 8D PS<=>UGENHT7KAG<=>7A12<TSRDU4>C351N#S5
M:88P1%>AGD&YEF8YSA>6%>0E1\$>W19H1<FLL9MXX&LVB.FD1(9UJ7<M4.>104<OP(H1TS#>P#P+IQS^>YJAIG/Q2H1BSK-JK<1<TL2 2A.5)VLA&
MLHNJH64R0M3P_V1#1<1KF&9AGB9IC<=>S+M^1EY<=>DASK-OURE 03J2P.MW1Q<M+N<Z697H1<XIVICM81W5X<V3LUW7.7-8HWEZ38#_4S-PS1+M^>8^WN1=Y2
4P31\$#2.S+ PSW&L1A+Z23<0EAW>LZ M(27LVX15E P704770CJH1C2P1H)Y600<A^>Z 1<S.S0571&7CDS13N MO0F2W79A<
RE<=>AGH%Y<N8YCA<=>ZWL+VVE<+MHJ.D53<1A>1 B7>=>S MMBB7212AFJ4H4V<=>07D6YCF.%WKZ<CLK<55I>0>5392 0141.KF
M69AGB9IC<=>E&=>F1RU1ZQO/OVHJR<IBG9Z>0.0.F69CG.%Y8 WYH7 78G1LZN. /W ME(H1DH1<=>(WBTJZM(Q3W&1=QR2T1^>Q3E*9BG89Z>1.F.8X7^>MX<=>FMI
ML"QI"1HTT1<=>Q.YGTC1NFIBY1Y1M^>1 OS<1<O>SGK.K.M.WY-L9W(2333J5K017E131P3P-IPS.L5#<=>RP40PLMRZVZRXR:P6Y74P.M31\$1#2.S+ PSW&L
12+>26G1IMF3P5H1\$52R91VTR(R.D<JX7471<1M=1.F.8X7>MB.9F0X^J62.8J5T1<KHWC1P<=>5)3&0.F69CG.%
(H>SIEK:6#NK)V330PZDN99W& 1C^LIZOB54<=>C5P7KR.PS. /10 MOC1<=>6DMCTL71FO.11 N1Y<=>7S<1L=71=C<IK32YKOH HGI^A/P3P-IPS
MEL\$#<=>R<3/H D6W6GVV16<1Z<P>S>1P8G9Z<=>0.F69CG.%Y8 VVXV1Y.83<0 MN<1L.M66Y698H7649Z<=>0.F69CG.%Y8 319>:BJHD<2M)<=>1DY7?E.F69CG.%
(H8136.29C) =>1M#26Z>74V1H1P27E1B30Z<=>0.9R<=>MHCP<#>S<#>PCS1<=>R1L4YLB.23GYP1Q^>OZV<=>@GD:YAF89Y<=>XWAA360^>M<D>S1:1DE1R=EP(SZ6URR:RJE?
Q5103CKGH6V1<1DX1L7Y109CFVB<=>R/K<8KW1TBOCT5#>PS1Q<=>1<O1B- M5F71&NFFPZ6A<=>F5B%>8<2B- W5#RS.I00<=>Z2A#>2<10TX?>9K M<6 (N^M3Z4T
RT2.02<=>1KF&9AGB9IC<=>UG6S1<=>7&KH.MQ.OM37W=FV1<=>MAYWB12KA<=>0.KOQCE13P3P-IPS.L5#<=>RP1OSTMCTO2W:
MU=>OQN<3THC<Z:1S1\$>GFVKMHHUYU6F%<=>(M.F4EOE+>S0PS1Q<=>1<19<0-8D6/L<G.N\$<^3>M9^C1#>HGLB<TS#>P.MS1Q<=>1<N.NQ:2N<46KPG<N-
U+B=VAW1FE9BG89Z>1.F.8X7VMV750Y.MX.L1Y.U1Y12/3ZYA0QVPL1P3P-IPS.L5#<=>RP.OPXMJV1<=>M1ZHHX<Y<M^N9IF&=>GH5YCN<#>=>N^T1Q%W2D)>OSTM-
/49V>4SNV<U<Y<G6:HZX M1#>7H6<=>GOFIS.S67G1CN.NYO<SVU1Q<2N203P16M.6AS1<21Z62<=>(K<
MH17 L^>08N2276GB5CN.70%>#19<=>9MX1R<=>12A01JH<S#>K0H1M<=>SAW<T1L MK&=>AGD&YEF8YSA>X.O.3V(1<1K.EHF). J<=>1CM<IRJ51V<1NFI CVZ^"
M^N9IF&=>GH5YCN<M0?>1UPDXZV2H7B9HT1:81@<=>S.JM7515<=>1H<1YFF8 M9V<=>A7E.XX6V1 53H08DW.L<TIEH1<6A27<9ZE5
MS7<B4K)<1ZP<=>W.L5#<=>S0C WY<VVF%1B<=>(O<=>G.P.M80W<#>17X<=>9RFU.M&82%W4H4V<=>07D6YCF.%WKZ<CT81=>0<1\$UPVQ1O5RU=1E<1XKY& 41F#>A
MGH1Y<N8YCA<=>WX1<VJG<D>36#1<OJM7W5EFL7/85Y2F8H4V<=>07D6YCF. M^KU<3U21A1L S^<=>UC1P<=>V&Z7T6>=>M1E<=>GH9Y1N99F.AGD&YEF8YSA>6
927P/R8471A13LDH1V<=>16<=>M8J11%<0>1<P>L.S. /1200A.HQ.EJ>1R<=>DO5YVGB<7716UNOH1<=>M.WRSLJ3MRF1PS1<1<453H1<DB.NYD<=>YTL72913^>3E9BG
M89Z1<1.F.8X7>K TO21<2R7<G11<XTR KU2W<=>Y1<1F>=>@GD:YAF89Y<=>MXWBAIRO<=>Z1Z<=>ONK<1<27<20KE.9AG
M89Z2>8ICA951<Y5OW&G89YVN1MCG<=>4H<=>AGH%Y<N8YCA760.77P<=>H1S<=>M.4DOEZX3WQNLK6.G21KKZ.Z<=>58P3TN B)<=>S5.HX7.K2UGAM212RB
MC9N465E1YNTI&N317JRLKQY&N89F&=AGN<XH>#1W. #D.10IVKCAV8SVF3=Y.MVA0KJF<=>AGD&YEF8YSA>8/2<=>UZ551UZ<1N7XE6<=>P.V<1GJ8IV<=>AGD&
MYEF8YSA>61E^>L=>P/B9Y93P1<N5H>4H<=>AGH%Y<N8YCA760<1E9J<=>7^>M800.2P5.VE8+/@JLV1+K1.01455V+>5U1XC81A<=>UHH<C63M&?&br/>MLE.MSS5 3G1OFLCWF&E97VP1<PS.L5#<=>S017X FZ<1<YVIG<GROCM1X1L MNZ<B^N9IF&=>GH5YCN<=>O1B8G9Z<=>0.F69CG.%Y8 WFFKU<YH0<1#<=>C/7<1X<@

[illegible]

M&L@%P9RK(%S%#&K&@'W>Lp7!@!W:2MHp!M;@GPl'2AL'7?SOEIVJ37 MJZKRT!L:M&K)7'PB:>@M?X7;#?>7Z-E=VS7?@TRISPEUTFI 4UUKPIU-MG36UI<...>

[illegible]

[illegible]

f[F+=+=JZEAS]MVD:&3&XC2+RS.M8CC/I^/L\$E0&G5VQ@M-VJ^VZ7W7%XT(C&NGV1/0%J=9G&O%L-YJJP=M>TK7D1TTHWOIQ0_5R5[KHLL^F^7UO-
NPAW/SULO_17XN80D8&DPB@1F+M4RO.LSC#XBR&VTS<="8.KQ@+HJB21&87.0B%{O3+ZP.(OANCLG)OLDR=A-M(ZNV.R6.S#>=OIOH^#3Y3+R^K&3.HSD?
%>.HTV8N1HOHTV3+1V7CU.MJR3AR1^IC3A5%="WK7D9NM51?>@N%>NOG.FE+T6(C&Q48F=O%<Z5<?NE/>Q61#HJM.2(C?K%PGCZ>-(OAA^LJ@66
M7LKWE(7Q%#WYQ<1%J=>8G&9QAL59#>29U@DHLW^E5X8CP%A2\$=H/L75G1.MHXAONBDW921+>19G65%<Y-G@=>QDVU)RBL-YVBOBYQ5.9-W^OQ=^B^TI(B)7Vi@
FA49QB<9K%&19G.9SG8R>=>MS.*+Y(C^YIFZVH^M2Q.L3C-X@R+LOC.IZ&3-F.RM%L@>P^K4.N.V@YI&0V.M3IVZ57-MP9LCA=VJ=Y4)UB^&^LJBH=^?
G8D2DQV.58^7U4JM>N(H^E^H+M2Y.FUQ-MUM48K>XEE#A.L.RX>4K=>P1FOH&KISZQ3MBHXA+@.X#D8A1%=>8G)9HJ&B
M^VJPH.YU(XS1U+J^PSC^984191=HKB6Q2D6IUF<87&6PWFV+>14/Q(M5>X0P+Z7MWLE0U+&.%Y-MWWE.71#>FEBH^N3C8A1&C:Q1D69S&G^J.Z^BL8KFQ:
MPLD7^W@-P1@P7-HIM8K2K+9W&+1Z&19J)MBB^4RO.LSC#XBR&RSJA(RH^N9=>@MCL1L1<#>PGVO.X6S8UT^1+A(C(K+ZP.OA/LXZ6Q.C/H=>WVZ/6R516MU<^>FXV/ZI?
GP%>Q>Z+N.NEMOG&B&+HELJLK6Q2D6IUF<87&6PWE=>+&\$.M/MM%<=>?..C&A2A.L3C-X@R+LOC.IZ&3%Q.2N-K#4O-NWYSNOIE-YA1IWD
MWIL.#:NSf#UG5G.-J>SKV\$1^/%(2^)>6;E)8.1/&ZR2T21.HVL9_4V4?JP\$M+<?>GHBW.OQ5.MZSOI.P%L_7&I5@TD4UI(XO>(TBS.LSF(XS19.(%G0O5&C
ML.#A&A6LLH3V9%1\$%>9G&Q%L^YSG2Q@M)MBJH&A7L+GNU^IN25>10-MG&QJFL49%>D?DJP/ZG1IM=H.B6Q2D6
MIUF<8&6GPW516%K157GBTEIUF<53_92UW93IR&K&P.RL.CS1VITQG^8_3.MH.BF.8SO.7PSN57Z4>H0?>MAA^N^A.#R\$=>P01**TRS.L#B+X3R_4%2.M&0Z2LJAL-
J/./>ZMWD./EIAIV6I.YQO>1%CVXUSXO<5F.RA.L3C-X@R+MLQC.^Y>3193A)5WZ2+1G6.94W2M^J4GR9M/IBTJY6IY-W>3U-M^Z.R.RIGYR.M-K=ZMWY90?MRI-&V>S/?
NA1<6S06G&AFRT@<4(B1LSKXB^LSC&SK13&6MWPV)918MK69QB<9K%&19G.9Q6GR>F^>6IR7Uf.L1QC9L4%=>8G&9Q.MAL59#.UPH^W&K=XA2+19GE0I=AD
L41%J=9G&%Q%L-YQG22B5+>W?L=LM-MO)QL7WE05P^3Y?WJ.OOF(5BD60YVA>NM.%U\$AI3N/YFNDZHV0\$%F6YS.1?>50POV4KP_1O1%7LUZD)JR5IC8V
MNS>OFL49?F8BP6I2UP.X.H.D1L419=>9G&Q%L^Y#G/R.MD^IPG64DUY>736LQ4(TBS.LSC^XKJUF3F0R?TO>VZ?L.O5AC&Z7&87EDEF^JMN.MH#&
X@R+LOC.^T@H22T1X101+>M%IA331^29Y.^2SIVRSRZ><H?7&SWVYVFW=F6Y>1P6Q2D6IUF>X3@H.HMHKE/2NR&0P%ZSK1^BSYXMK09FR\$@N)@J=8G&9QAL59#>?
9UEH09FR\$BHS^ME\$SOH1>E/FWGMS9WR.8%=>8G&9QAL59#>79U.EA9MU>G^58I-VY-MM(7B.M6A.G6)QF<8^60S7M?7N?XEL41%=>9G&%Q%L-Y/G2BHKFT.M=?
H.D1\$S.A9S.LB+B+X3Q.1?2_2+>RfY.Y.K-M=X^OIWJ21^?2841+>?>O1O&=>IKUM=>L.R3J(C&LQ)OFL49%F.MYH(U+V&1=>QVOR^TRS.L#B+X3Q5.1G/>%G6O.Sf.UZJ.E.9W
9DZO>9D+UKR\$1=>=MOF8M^\$ZS_>B+<S^9D+?Q.UIF-VM>YD6.BL)F^RA.L3C-X@R+LOBN.ZO.MR3YJ8.U++>5CS\$M9->
A6^4RO.LSC#XBR&ITSEH1DUNN8@N6Z^J12X#MJRP.M1+HIV474N^ZS.XB+>B+<S^9D+>60M.MZEEFJW^01W7_2121^S410.B+B+<S
M1#\$.4SK>19.FRE>1H.B6Q2D6IUF<87&6PWBV=P^ANNHMD1D_7SXE6H.MUBW<9G&Q5D.Y.G0B3+J7VW^2T0L7JH8#10.9.88UTZXIDE?XS0L/L#B+
MK3RS.=&+5V<1%660S6?>P-PN)RBN9Y^>Q6D69UB.9UEOFG08Q=>U6^HXC2+M.RS.8CC/L3C-X@R+LOC.IZ&3%Q.2N-K#4O-NWYSNOIE-YA1IWD
M(K1@OGYVHWQVRY<2^J2G6)Q<660SGN=>1JK4EEFG3%IAJO_4)>=>S&I.M.U^NFIAF687&6PWF>=<=>1HY<-8BP%3L4LM4\$X&2.RS.L#B+X3P.M.IE^4W-
S6JH@>+Y<=<2V+4RO.LSC#XBR&WSH9I.F/O&5R+WHO3YX3\$OCCPL-M.D.LF^E@BW.D2524I3+>#.RS.8KB.TXKI(=AX^/3)KTO)=>WDX#^IH#N
M^TKE>RRBD>H0QJ=>8G&9QAL59#=>Y-G.L&UTD9+THEFAVDQ\$+H^>+>X&C2+M.RS.8CC/L3C-X@R+LOC.IZ&3%Q.2N-K#4O-NWYSNOIE-YA1IWD
MQ87?M2Q.L3C-X@R+LOC.LYVWYB^BL8SG<8.MY3@LG^8C^M%9IDM^C%XC2+R.S.8CC/L3C-X@R+LOC.IZ&3%Q.2N-K#4O-NWYSNOIE-YA1IWD
LPNWD>L&K1976>=Q_IXNVI/G1-3MYNQI@1.FMX.XQ/GIH@?1=>OMSKR.XB-(LS+YB.^>3K.IR2122%U@-N^J3Y&+1HQC262G1WNV?>Q1@A)Y2G7RD.SYH^S4-07.0B%
(O3+ZP.OA/LZ.M^4&G.YB&08L^CHYN2U@1.FXSV71#>^1SLE\$BM.LSKXB^12Q^2V3K^+FX=2E^N17VO^7ZEI05\$>G2PU^
MYXY++H9/(MK69QB<9K%&19G.9Q6^?R6@RSRZJ3N+UF<8G&Q1D69S<M^T.G.1GDIV)&M2AVRMKYX)9YKTSOHX^>18I7Y1L5^5JO-
50(O#B.R.1R57DZ12DG9E+WK0IR.M^J1>Q\$1P^DPI&CQVY5UM=C727217471?>V^OQV3\$>IE1+BXY^U^9FW30YR.&K+0)R^4M^CFE
M350E.&TGE+D<V%EL9>FF1>11491.P5YB(L^M2+Y24QOB<7KP0YD6<1XLO_5N>672P^QVTOG=>F1S2.GZTOW%Z>D+>2+2V+M4RO.LSC#XBR&VSKO)YVQ?
N50P<C(ZVY_L3N^MBZ(W2RWLD^UO_E1\$<9K%MK19G.9SG4^>XS_IY1+G19HH5Y+>W.L7VWZUPXVYU^N3C921&1Q1D69S<M^T.XG7IS#<=>31#A_71=1+1/S^LN
MM1G9^>12M2Q.L3C-X@R+LOC.IZ&3%Q.2N-K#4O-NWYSNOIE-YA1IWD
I22.MK#C16U+>ZQ.WB#(NS&ZSK9.CYN^Y8220BRP.M.59-Z&I2E5^>CKJ(X^>B3.Y8W&Q1D69S<9TXGRO#(49J-2\$>(PT.L^D.M^IA00V@T-
Q8L5%F=8G.5P76.63A62-PX(6&3YN75>16L+DOHIN.PBI.MK1+GEI7E57W^>P@C12^51K^2W.E&F5E47GFR&A^4(B1LSKXB^S1>SH9B72P^WBD&OVNOJFEZRV
M7:Q15^Q1V7QW>Y>2^>M^MHP^TVI2DQ4L3K\$X\$>.(B18KXNO^TDGVRAN^XNM.MCTVJ.6N&ZP^AY+1^ASO^8GCS5^1BQ.XB1^>_R2MS@)C#<+LL(12VY^+12.M@>MT
>1^<=>+HOG6R)5LBHCB6A.G6)QF<8^60S6G>9J&4MZC5P\$>+2^7^G0.M61P^7BPB<1SLLOCAQ>QF<8^60S6G^>1J4T>5R\$=N31&KQ_7J>(44T^M1/MV9VJ-
C1\$>9G&%Q%L-YSG3^L%&A5UA.S8FVJ3FLEQ+8M3+>S\$Z>B+<S^9D+M.P8#6X(QYDSRT4U(XO>(TBS.LSF(XS\$>HE4^>QJXLI2\$>U^N15\$>(K.MP%KX1B61^#&?
C..6\$4^Z17C/AV.B44NA@KIC^>1C^E=>2&^U.OSC_M.MOXY.51%>78Z6LE^HJS2W07CQ&WEIRVE^IFE="BN97&Q6D69UB.9TB.MKJ27D6T>OX.\$H.&OXZY<@Y^>
Q2D6IUF<87&6PWE2N=8^Y\$U93P%ZQOC/M1@#7H.LWG.H&K&A.7B-(LS+YBN^#^R>?T80KA(4KP=SH_>@>7EQ.M.6U+>ZQ.WB#(NS&ZSK9.CYN^Y8220BRP.M.59-Z&I2E5^>CKJ(X^>B3.Y8W&Q1D69S<9TXGRO#(49J-2\$>(PT.L^D.M^IA00V@T-
Q8L5%F=8G.5P76.63A62-PX(6&3YN75>16L+DOHIN.PBI.MK1+GEI7E57W^>P@C12^51K^2W.E&F5E47GFR&A^4(B1LSKXB^S1>SH9B72P^WBD&OVNOJFEZRV
M7:Q15^Q1V7QW>Y>2^>M^MHP^TVI2DQ4L3K\$X\$>.(B18KXNO^TDGVRAN^XNM.MCTVJ.6N&ZP^AY+1^ASO^8GCS5^1BQ.XB1^>_R2MS@)C#<+LL(12VY^+12.M@>MT
>1^<=>+HOG6R)5LBHCB6A.G6)QF<8^60S6G>9J&4MZC5P\$>+2^7^G0.M61P^7BPB<1SLLOCAQ>QF<8^60S6G^>1J4T>5R\$=N31&KQ_7J>(44T^M1/MV9VJ-
C1\$>9G&%Q%L-YSG3^L%&A5UA.S8FVJ3FLEQ+8M3+>S\$Z>B+<S^9D+M.P8#6X(QYDSRT4U(XO>(TBS.LSF(XS\$>HE4^>QJXLI2\$>U^N15\$>(K.MP%KX1B61^#&?
C..6\$4^Z17C/AV.B44NA@KIC^>1C^E=>2&^U.OSC_M.MOXY.51%>78Z6LE^HJS2W07CQ&WEIRVE^IFE="BN97&Q6D69UB.9TB.MKJ27D6T>OX.\$H.&OXZY<@Y^>
Q2D6IUF<87&6PWE2N=8^Y\$U93P%ZQOC/M1@#7H.LWG.H&K&A.7B-(LS+YBN^#^R>?T80KA(4KP=SH_>@>7EQ.M.6U+>ZQ.WB#(NS&ZSK9.CYN^Y8220BRP.M.59-Z&I2E5^>CKJ(X^>B3.Y8W&Q1D69S<9TXGRO#(49J-2\$>(PT.L^D.M^IA00V@T-
Q8L5%F=8G.5P76.63A62-PX(6&3YN75>16L+DOHIN.PBI.MK1+GEI7E57W^>P@C12^51K^2W.E&F5E47GFR&A^4(B1LSKXB^S1>SH9B72P^WBD&OVNOJFEZRV
M7:Q15^Q1V7QW>Y>2^>M^MHP^TVI2DQ4L3K\$X\$>.(B18KXNO^TDGVRAN^XNM.MCTVJ.6N&ZP^AY+1^ASO^8GCS5^1BQ.XB1^>_R2MS@)C#<+LL(12VY^+12.M@>MT
>1^<=>+HOG6R)5LBHCB6A.G6)QF<8^60S6G>9J&4MZC5P\$>+2^7^G0.M61P^7BPB<1SLLOCAQ>QF<8^60S6G^>1J4T>5R\$=N31&KQ_7J>(44T^M1/MV9VJ-
C1\$>9G&%Q%L-YSG3^L%&A5UA.S8FVJ3FLEQ+8M3+>S\$Z>B+<S^9D+M.P8#6X(QYDSRT4U(XO>(TBS.LSF(XS\$>HE4^>QJXLI2\$>U^N15\$>(K.MP%KX1B61^#&?
C..6\$4^Z17C/AV.B44NA@KIC^>1C^E=>2&^U.OSC_M.MOXY.51%>78Z6LE^HJS2W07CQ&WEIRVE^IFE="BN97&Q6D69UB.9TB.MKJ27D6T>OX.\$H.&OXZY<@Y^>
Q2D6IUF<87&6PWE2N=8^Y\$U93P%ZQOC/M1@#7H.LWG.H&K&A.7B-(LS+YBN^#^R>?T80KA(4KP=SH_>@>7EQ.M.6U+>ZQ.WB#(NS&ZSK9.CYN^Y8220BRP.M.59-Z&I2E5^>CKJ(X^>B3.Y8W&Q1D69S<9TXGRO#(49J-2\$>(PT.L^D.M^IA00V@T-
Q8L5%F=8G.5P76.63A62-PX(6&3YN75>16L+DOHIN.PBI.MK1+GEI7E57W^>P@C12^51K^2W.E&F5E47GFR&A^4(B1LSKXB^S1>SH9B72P^WBD&OVNOJFEZRV
M7:Q15^Q1V7QW>Y>2^>M^MHP^TVI2DQ4L3K\$X\$>.(B18KXNO^TDGVRAN^XNM.MCTVJ.6N&ZP^AY+1^ASO^8GCS5^1BQ.XB1^>_R2MS@)C#<+LL(12VY^+12.M@>MT
>1^<=>+HOG6R)5LBHCB6A.G6)QF<8^60S6G>9J&4MZC5P\$>+2^7^G0.M61P^7BPB<1SLLOCAQ>QF<8^60S6G^>1J4T>5R\$=N31&KQ_7J>(44T^M1/MV9VJ-
C1\$>9G&%Q%L-YSG3^L%&A5UA.S8FVJ3FLEQ+8M3+>S\$Z>B+<S^9D+M.P8#6X(QYDSRT4U(XO>(TBS.LSF(XS\$>HE4^>QJXLI2\$>U^N15\$>(K.MP%KX1B61^#&?
C..6\$4^Z17C/AV.B44NA@KIC^>1C^E=>2&^U.OSC_M.MOXY.51%>78Z6LE^HJS2W07CQ&WEIRVE^IFE="BN97&Q6D69UB.9TB.MKJ27D6T>OX.\$H.&OXZY<@Y^>
Q2D6IUF<87&6PWE2N=8^Y\$U93P%ZQOC/M1@#7H.LWG.H&K&A.7B-(LS+YBN^#^R>?T80KA(4KP=SH_>@>7EQ.M.6U+>ZQ.WB#(NS&ZSK9.CYN^Y8220BRP.M.59-Z&I2E5^>CKJ(X^>B3.Y8W&Q1D69S<9TXGRO#(49J-2\$>(PT.L^D.M^IA00V@T-
Q8L5%F=8G.5P76.63A62-PX(6&3YN75>16L+DOHIN.PBI.MK1+GEI7E57W^>P@C12^51K^2W.E&F5E47GFR&A^4(B1LSKXB^S1>SH9B72P^WBD&OVNOJFEZRV
M7:Q15^Q1V7QW>Y>2^>M^MHP^TVI2DQ4L3K\$X\$>.(B18KXNO^TDGVRAN^XNM.MCTVJ.6N&ZP^AY+1^ASO^8GCS5^1BQ.XB1^>_R2MS@)C#<+LL(12VY^+12.M@>MT
>1^<=>+HOG6R)5LBHCB6A.G6)QF<8^60S6G>9J&4MZC5P\$>+2^7^G0.M61P^7BPB<1SLLOCAQ>QF<8^60S6G^>1J4T>5R\$=N31&KQ_7J>(44T^M1/MV9VJ-
C1\$>9G&%Q%L-YSG3^L%&A5UA.S8FVJ3FLEQ+8M3+>S\$Z>B+<S^9D+M.P8#6X(QYDSRT4U(XO>(TBS.LSF(XS\$>HE4^>QJXLI2\$>U^N15\$>(K.MP%KX1B61^#&?
C..6\$4^Z17C/AV.B44NA@KIC^>1C^E=>2&^U.OSC_M.MOXY.51%>78Z6LE^HJS2W07CQ&WEIRVE^IFE="BN97&Q6D69UB.9TB.MKJ27D6T>OX.\$H.&OXZY<@Y^>
Q2D6IUF<87&6PWE2N=8^Y\$U93P%ZQOC/M1@#7H.LWG.H&K&A.7B-(LS+YBN^#^R>?T80KA(4KP=SH_>@>7EQ.M.6U+>ZQ.WB#(NS&ZSK9.CYN^Y8220BRP.M.59-Z&I2E5^>CKJ(X^>B3.Y8W&Q1D69S<9TXGRO#(49J-2\$>(PT.L^D.M^IA00V@T-
Q8L5%F=8G.5P76.63A62-PX(6&3YN75>16L+DOHIN.PBI.MK1+GEI7E57W^>P@C12^51K^2W.E&F5E47GFR&A^4(B1LSKXB^S1>SH9B72P^WBD&OVNOJFEZRV
M7:Q15^Q1V7QW>Y>2^>M^MHP^TVI2DQ4L3K\$X\$>.(B18KXNO^TDGVRAN^XNM.MCTVJ.6N&ZP^AY+1^ASO^8GCS5^1BQ.XB1^>_R2MS@)C#<+LL(12VY^+12.M@>MT
>1^<=>+HOG6R)5LBHCB6A.G6)QF<8^60S6G>9J&4MZC5P\$>+2^7^G0.M61P^7BPB<1SLLOCAQ>QF<8^60S6G^>1J4T>5R\$=N31&KQ_7J>(44T^M1/MV9VJ-
C1\$>9G&%Q%L-YSG3^L%&A5UA.S8FVJ3FLEQ+8M3+>S\$Z>B+<S^9D+M.P8#6X(QYDSRT4U(XO>(TBS.LSF(XS\$>HE4^>QJXLI2\$>U^N15\$>(K.MP%KX1B61^#&?
C..6\$4^Z17C/AV.B44NA@KIC^>1C^E=>2&^U.OSC_M.MOXY.51%>78Z6LE^HJS2W07CQ&WEIRVE^IFE="BN97&Q6D69UB.9TB.MKJ27D6T>OX.\$H.&OXZY<@Y^>
Q2D6IUF<87&6PWE2N=8^Y\$U93P%ZQOC/M1@#7H.LWG.H&K&A.7B-(LS+YBN^#^R>?T80KA(4KP=SH_>@>7EQ.M.6U+>ZQ.WB#(NS&ZSK9.CYN^Y8220BRP.M.59-Z&I2E5^>CKJ(X^>B3.Y8W&Q1D69S<9TXGRO#(49J-2\$>(PT.L^D.M^IA00V@T-
Q8L5%F=8G.5P76.63A62-PX(6&3YN75>16L+DOHIN.PBI.MK1+GEI7E57W^>P@C12^51K^2W.E&F5E47GFR&A^4(B1LSKXB^S1>SH9B72P^WBD&OVNOJFEZRV
M7:Q15^Q1V7QW>Y>2^>M^MHP^TVI2DQ4L3K\$X\$>.(B18KXNO^TDGVRAN^XNM.MCTVJ.6N&ZP^AY+1^ASO^8GCS5^1BQ.XB1^>_R2MS@)C#<+LL(12VY^+12.M@>MT
>1^<=>+HOG6R)5LBHCB6A.G6)QF<8^60S6G>9J&4MZC5P\$>+2^7^G0.M61P^7BPB<1SLLOCAQ>QF<8^60S6G^>1J4T>5R\$=N31&KQ_7J>(44T^M1/MV9VJ-
C1\$>9G&%Q%L-YSG3^L%&A5UA.S8FVJ3FLEQ+8M3+>S\$Z>B+<S^9D+M.P8#6X(QYDSRT4U(XO>(TBS.LSF(XS\$>HE4^>QJXLI2\$>U^N15\$>(K.MP%KX1B61^#&?
C..6\$4^Z17C/AV.B44NA@KIC^>1C^E=>2&^U.OSC_M.MOXY.51%>78Z6LE^HJS2W07CQ&WEIRVE^IFE="BN97&Q6D69UB.9TB.MKJ27D6T>OX.\$H.&OXZY<@Y^>
Q2D6IUF<87&6PWE2N=8^Y\$U93P%ZQOC/M1@#7H.LWG.H&K&A.7B-(LS+YBN^#^R>?T80KA(4KP=SH_>@>7EQ.M.6U+>ZQ.WB#(NS&ZSK9.CYN^Y8220BRP.M.59-Z&I2E5^>CKJ(X^>B3.Y8W&Q1D69S<9TXGRO#(49J-2\$>(PT.L^D.M^IA00V@T-
Q8L5%F=8G.5P76.63A62-PX(6&3YN75>16L+DOHIN.PBI.MK1+GEI7E57W^>P@C12^51K^2W.E&F5E47GFR&A^4(B1LSKXB^S1>SH9B72P^WBD&OVNOJFEZRV
M7:Q15^Q1V7QW>Y>2^>M^MHP^TVI2DQ4L3K\$X\$>.(B18KXNO^TDGVRAN^XNM.MCTVJ.6N&ZP^AY+1^ASO^8GCS5^1BQ.XB1^>_R2MS@)C#<+LL(12VY^+12.M@>MT
>1^<=>+HOG6R)5LBHCB6A.G6)QF<8^60S6G>9J&4MZC5P\$>+2^7^G0.M61P^7BPB<1SLLOCAQ>QF<8^60S6G^>1J4T>5R\$=N31&KQ_7J>(44T^M1/MV9VJ-
C1\$>9G&%Q%L-YSG3^L%&A5UA.S8FVJ3FLEQ+8M3+>S\$Z>B+<S^9D+M.P8#6X(QYDSRT4U(XO>(TBS.LSF(XS\$>HE4^>QJXLI2\$>U^N15\$>(K.MP%KX1B61^#&?
C..6\$4^Z17C/AV.B44NA@KIC^>1C^E=>2&^U.OSC_M.MOXY.51%>78Z6LE^HJS2W07CQ&WEIRVE^IFE="BN97&Q6D69UB.9TB.MKJ27D6T>OX.\$H.&OXZY<@Y^>
Q2D6IUF<87&6PWE2N=8^Y\$U93P%ZQOC/M1@#7H.LWG.H&K&A.7B-(LS+YBN^#^R>?T80KA(4KP=SH_>@>7EQ.M.6U+>ZQ.WB#(NS&ZSK9.CYN^Y8220BRP.M.59-Z&I2E5^>CKJ(X^>B3.Y8W&Q1D69S<9TXGRO#(49J-2\$>(PT.L^D.M^IA00V@T-
Q8L5%F=8G.5P76.63A62-PX(6&3YN75>16L+DOHIN.PBI.MK1+GEI7E57W^>P@C12^51K^2W.E&F5E47GFR&A^4(B1LSKXB^S1>SH9B72P^WBD&OVNOJFEZRV
M7:Q15^Q1V7QW>Y>2^>M^MHP^TVI2DQ4L3K\$X\$>.(B18KXNO^TDGVRAN^XNM.MCTVJ.6N&ZP^AY+1^ASO^8GCS5^1BQ.XB1^>_R2MS@)C#<+LL(12VY^+12.M@>MT
>1^<=>+HOG6R)5LBHCB6A.G6)QF<8^60S6G>9J&4MZC5P\$>+2^7^G0.M61P^7BPB<1SLLOCAQ>QF<8^60S6G^>1J4T>5R\$=N31&KQ_7J>(44T^M1/MV9VJ-
C1\$>9G&%Q%L-YSG3^L%&A5UA.S8FVJ3FLEQ+8M3+>S\$Z>B+<S^9D+M.P8#6X(QYDSRT4U(XO>(TBS.LSF(XS\$>HE4^>QJXLI2\$>U^N15\$>(K.MP%KX1B61^#&?
C..6\$4^Z17C/AV.B44NA@KIC^>1C^E=>2&^U.OSC_M.MOXY.51%>78Z6LE^HJS2W07CQ&WEIRVE^IFE="BN97&Q6D69UB.9TB.MKJ27D6T>OX.\$H.&OXZY<@Y^>
Q2D6IUF<87&6PWE2N=8^Y\$U93P%ZQOC/M1@#7H.LWG.H&K&A.7B-(LS+YBN^#^R>?T80KA(4KP=SH_>@>7EQ.M.6U+>ZQ.WB#(NS&ZSK9.CYN^Y8220BRP.M.59-Z&I2E5^>CKJ(X^>B3.Y8W&Q1D69S<9TXGRO#(49J-2\$>(PT.L^D.M^IA00V@T-
Q8L5%F=8G.5P76.63A62-PX(6&3YN75>16L+DOHIN.PBI.MK1+GEI7E57W^>P@C12^51K^2W.E&F5E47GFR&A^4(B1LSKXB^S1>SH9B72P^WBD&OVNOJFEZRV
M7:Q15^Q1V7QW>Y>2^>M^MHP^TVI2DQ4L3K\$X\$>.(B18KXNO^TDGVRAN^XNM.MCTVJ.6N&ZP^AY+1^ASO^8GCS5^1BQ.XB1^>_R2MS@)C#<+LL(12VY^+12.M@>MT
>1^<=>+HOG6R)5LBHCB6A.G6)QF<8^60S6G>9J&4MZC5P\$>+2^7^G0.M61P^7BPB<1SLLOCAQ>QF<8^60S6G^>1J4T>5R\$=N31&KQ_7J>(44T^M1/MV9VJ-
C1\$>9G&%Q%L-YSG3^L%&A5UA.S8FVJ3FLEQ+8M3+>S\$Z>B+<S^9D+M.P8#6X(QYDSRT4U(XO>(TBS.LSF(XS\$>HE4^>QJXLI2\$>U^N15\$>(K.MP%KX1B61^#&?
C..6\$4^Z17C/AV.B44NA@KIC^>1C^E=>2&^U.OSC_M.MOXY.51%>78Z6LE^HJS2W07CQ&WEIRVE^IFE="BN97&Q6D69UB.9TB.MKJ27D6T>OX.\$H.&OXZY<@Y^>
Q2D6IUF<87&6PWE2N=8^Y\$U93P%ZQOC/M1@#7H.LWG.H&K&A.7B-(LS+YBN^#^R>?T80KA(4KP=SH_>@>7EQ.M.6U+>ZQ.WB#(NS&ZSK9.CYN^Y8220BRP.M.59-Z&I2E5^>CKJ(X^>B3.Y8W&Q1D69S<9TXGRO#(49J-2\$>(PT.L^D.M^IA00V@T-
Q8L5%F=8G.5P76.63A62-PX(6&3YN75>16L+DOHIN.PBI.MK1+GEI7E57W^>P@C12^51K^2W.E&F5E47GFR&A^4(B1LSKXB^S1>SH9B72P^WBD&OVNOJFEZRV
M7:Q15^Q1V7QW>Y>2^>M^MHP^TVI2DQ4L3K\$X\$>.(B18KXNO^TDGVRAN^XNM.MCTVJ.6N&ZP^AY+1^ASO^8GCS5^1BQ.XB1^>_R2MS@)C#<+LL(12VY^+12.M@>MT
>1^<=>+HOG6R)5LBHCB6A.G6)QF<8^60S6G>9J&4MZC5P\$>+2^7^G0.M61P^7BPB<1SLLOCAQ>QF<8^60S6G^>1J4T>5R\$=N31&KQ_7J>(44T^M1/MV9VJ-
C1\$>9G&%Q%L-YSG3^L%&A5UA.S8FVJ3FLEQ+8M3+>S\$Z>B+<S^9D+M.P8#6X(QYDSRT4U(XO>(TBS.LSF(XS\$>HE4^>QJXLI2\$>U^N15\$>(K.MP%KX1B61^#&?
C..6\$4^Z17C/AV.B44NA@KIC^>1C^E=>2&^U.OSC_M.MOXY.51%>78Z6LE^HJS2W07CQ&WEIRVE^IFE="BN97&Q6D69UB.9TB.MKJ27D6T>OX.\$H.&OXZY<@Y^>
Q2D6IUF<87&6PWE2N=8^Y\$U93P%ZQOC/M1@#7H.LWG.H&K&A.7B-(LS+YBN^#^R>?T80KA(4KP=SH_>@>7EQ.M.6U+>ZQ.WB#(NS&ZSK9.CYN^Y8220BRP.M.59-Z&I2E5^>CKJ(X^>B3.Y8W&Q1D69S<9TXGRO#(49J-2\$>(PT.L^D.M^IA00V@T-
Q8L5%F=8G.5P76.63A62-PX(6&3YN75>16L+DOHIN.PBI.MK1+GEI7E57W^>P@C12^51K^2W.E&F5E47GFR&A^4(B1LSKXB^S1>SH9B72P^WBD&OVNOJFEZRV
M7:Q15^Q1V7QW>Y>2^>M^MHP^TVI2DQ4L3K\$X\$>.(B18KXNO^TDGVRAN^XNM.MCTVJ.6N&ZP^AY+1^ASO^8GCS5^1BQ.XB1^>_R2MS@)C#<+LL(12VY^+12.M@>MT
>1^<=>+H

>JFKM64FEY2Z.HF=61C>BL.WWFT'BOH'&H'&#<(&M\$&=&IKJZ>/%&#PYIC'4D.W#ZIF6YQYVY<>1>~2MC<?>K=2XGS<18=F2=M=2AKR5Y-6M)JZ-LH#1?>
 >JQ(26W6.MJ>18E+V1@&A1M#=-1:AGUBH&#1PRF1'&@&-BMRG:N4Z.41LL19Y2IVT.M7NB&JHDJ.97%N@OHSK.XP.(BAE.~%Y216M*FI@.949DVEF'Q3D6YUE<8'\$1
 MPRG9'>AL>16RKR2O<SRJ6.YE<'7JH37JLGVYOKFT169O-0I.M4K1JPX<Q6>?UE< ME?<EJ455XAR+RPNL+BX(29N14%3%EP>
 MJ4012+&XAL4.MN=97&Q5<@<F0WHQ17GXS.(V4B.7+XMK5X7R<=<%=M?K.M4VL:B.17G.R18-85UQGQ>G5Y@<1'#\$<8> Z@%>ENH'\$2+WE'K.4RN#1>>
 JR<OKWM\$NCGV1\$FL'A8@<+<@DC6P.X TH0# MBXL81EHE7'%'KLK=&''T5Y/5S?0J.17J.90J0)>=>JERLH5.YZ5/MXT
 M\$Z2W3HQOG76>9R<86%\$S<8IOFPV1'G.HZ1>T5.#M?P.U(PKJ15H4Y.S0YS'E.M.O47&FOMH6X@&+BOA.B598.U7Z=<#G3%16>7.P%>P..?B/(L++'YB.'5.M815.0>G9I
 (R0TM.7I=MH'\$1.WVJ6.9&2WFR5A'&RPNL+B(X90A154)/V.M8U.6EP<4>.<?I2<OKFZ?<CCZ=<RKJ3LEA6+6L8H;BA&Q3D6YUE<8'\$1PREQ
 M1'.HFGJHRXHT(TY97/B'IOS+)'ZPN(CAE.Z+U392;&1.H0BR9P54.M'<TNG2L.1.2J2I.M+&S5C8<<Z>DHA87.9R2FGIE'JLK.S5'=E.L.EJUNVQ\$<WGRF)ZT<E.~7&
 MU@FA..B.HN+&525K@IU2+ETDFD.FY\$<AH6YU8<9W&Q144=<RC.6EA%7DZ.M2W627B16I9>.BF7J1QJ.T5N>#ZQ..B.HN+&#&D4SA+14M'<ZLET4MDM6K.X=M'.4U+Z9..B
 HN+&526SA0.7<1.92Z9?UEE<~8W&<Q046\$SG<@<5%>?DIER.VMH+&E<Z8.WB)7I.N5/42I.M6D9J2E'K.<#<XKS'<'ZPN(CAE&1%QU.V.GV'1'96IQU<X'<U'
 <8W&<Q046\$SG<~MDJVPB6K(RR.6P)1'&#K1V6&WWH'L6WG1>JRRCA'<NTH>B=51.MZK'UAYOKHQM8.'<=<GJS?2HLFG'FY13>>S1E+204U'XO<@BPPLL+FCX14-
 A(4WME49C1TZE<7L.MJ<419K&.M=M'<L4U+ZQ..+M426TYNE<GEDM(O4PA>T1YXZ8M'<#VBI&2'L0LB&M3Q3D6Y'XUO'Q>AM+<A'<E'<E'<L@FCUOX5\$&M?<M?
 YA.ZE8.ZQ.ANG'.1.GJSB3ZKT.0F.(IC)'LH.G+51W.6.L(034LSK\$X.MS<@'BXL83LE66\$8S>>161.9.D<E.ZE3Q0)Y%>5W3?5KKD(15Z4)QG<8'<E'<10R'M'FEL'&0<=&MPT
 E.&S)S9<QW'<C'<N20TH3+M.L(13G6)S2XPY)Q@.FIH'9FOG5SAQE.M'
 (<41K07VYL<9'<OHS<10'<NFD'ET8BT'<J=<'TR=<'J.MM37IF.9'<JQ66\$XAR+RPNL+B(X92JA>DT'PNJ3JR+MA.6%N=8G&=Q@<5%#<T%<RD<7P.7B.YGR'9ID:#
 M0'4X800.L90.SR2O<KH6J2T.M8907.B'(OS>YPEGY0<4&2TCE=2455.9/N'.MY'2>#<1Z.B36.4%#<XAR+WOEHC.M0<=&PT.E.\$<+>1>RV414AH9MR'E'2'ZUOQEI#<ZQ+<_&?)
 (UT'L.E)37@<U.MBVO6?G0>~8.WY'2A.Y18PT@<=<8G-C@O)O?V=DAIK1(X)5A1'SF+Y=<'M8LT'>P..?B/(L++'YB.'5:80MTA.<@R2T1J5G'1=UKIX'7'-B=<#2H:S-
 M<@<@BPPLL+FCX15A@<BVLKM'1'<=5K9?2'.V@<N.7YPIY.O1JX'E.7IT'.M./9U@A./JVM2UWPW:W37J1TJGFX8INE'<@SHIK6)QC<9%187'=RAGI?''
 M.UJF.-9>=<E'<R'<ANG'.1.LG65Q0<1'<#41T'VEIK212+LJ30VVR7K>+<@..MJW<=<+2WNVYU=1A'<XN3:KDX.Y'<DYO+1'<NU<@R0+P'<VP>+2IGPZBS<+<M6793YU'U:39
 HHK1'<=<@P0S1N'T=0.AID6.6M'<C)OGL4'<A.E1>OB777Y2>J12'<LKE.O+G'<PG<GBKK>V.SN9&UWOZ.A1UH9M3PY@F.M.O'<VFF1%1076%\$S<1;PAK593E1#<'
 IED+1DAU'XQ<@BPPLL+FCX35QA'<W3.MM3DWPZK.1JY1+LKHU61A.6>H<@'Q1.W2Z.N.69/MJ7JISQ3KNA.MF4C.9E'ET'.?B.H7.L15L'W&HR&@4IGM=19V@T8N2DYAH=

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

M:~|<:|>002LS=W^L D1RU,P3|_|,LQ /IVR^Q91.BMTEB?(C^|V6G0Q2^M^*F@H2|ADF)7-F%B>AGD&YEF.YYMU|IHUGC&^=|:Z^O^=PS<^B^/%B2_&RY1^*MAE^9O(KE:9AG8)
Z^YI1^S^O^N1^<+>=W^|OK^_WMJH1LSOH3^S:PY07^?S M^S3_|,OQ^|NP1S^A1_6Z^@DQ1+^%>|_4S_~PS1~R^0I0H66%N@G_X M^|_I9^_CZ^_WZ|WQPT^_<^?AW
S8M^Q00JIA^1_3L^H^N^W^Y3J^|O83^\$-_|(-1R1H^H2C@Q1^#F^S1_|MP3~P^PS_L0S^|Z^>^&1\$^|BQ1^@J^B44ZM^|D^S_~NWDY^C^Q^M^Q^W^_M^>^W^|_|=^
U1=+Q_V^_BUZW=|8^_4S_~PS1~R^|T|LO M71&Z1KF&9AG.9Y02^=W^UYLFMB|B^/C^@:~NJ16(7GD^M^|C^|YH|0KFZ^=YWM0K^U2O^|NQI|H A=M>5XGH+~SHL
M7V^PX+V^|F^|C|H1R^>AGD&YEF_Y 07S9Q0>+3_|=6R7^|Y7Z^|X7NE7W:3V^_M1560N^S^<3^>8D>5HF&^@GN5XODW=|+&YRSGUHN2N^ZW>~|DSI=VX1^/\$<4%
M:C\$S^H^D=|KF&9AG.9A10Q3^Y>|_|U SUZ7E8^|V V^_|>^|Y^W^|C^|H^Z^F^|C^|MVJW@NSF-B|OZQ^>+Z C^L^|_1#^0KF:9AC6H^|Z^+Z5W1^OK_#Z6TEFO

[illegible]

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

[illegible]

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

M.1&11-400-J6=VJ2=-14MJS:ITK0K&PIX7R),Q3,\$IS%NOIG.5=-T%7XYJMLKHKB9W062VYMONL+Z9U2DVOQI%#D7GSI7-W<-1.0IM9K8^?2BMO-SU2=J-M.W^X:1JL&B&A0:SF9<G89Z>9KCV,HV:VL^L:HCGB&C&K+89Z>+1F9BG.M.9XM2-URHOH+40W^4#KRN|8TMS50<(<N5F,D7\$REA,NH8|>+83.18#UKS|AHE3X-V.9E1F2P.US6G<-2&6MM^M^%7S>+S160.2MF+<NV.MCIVJ6E%?N4D%>=AGHY|FN?>C5=1#6M^700J3Q^G9K6C5+KFFH93H6L>+>VGF%>?Q:(f5M^XW6K1HTE2D1ZSD=IZR^YQ(KX00K^L:Z(+1(#79&4^%SGCO#1^XW#(L.MPESEL|TX3HB+TE3D|>K^X^T^A^1Q1I7|<[S|,R3^%HWQ:VTE27I7=-M.M+0>80,BE^V:|P.L|I-W9>UYX0<?Q3HPD)(Q3OXUJIG7W9(9N)-MR-OU(1+2M+JVL4MK1Q6GHY%N8I^?GQ).MQ.TW&YJ.6E6GLOJL.53.64^<U&LQF0^|P>)>C(8)V>A^D^YFF.9Z09I,RZ.MY&H77B9>1F9BG.9XM2,<ZX8>AM9>2M^C&AMJH|H^4>Z^?EO.M^MH79EY.YO2H,EE2.M^25YBF&HRE|H^<7M=0GH|XOC#M6=L0?<-7%L3=L-H<77,6M^E:JMRN.MY,FQ7NPR8GR0KE,8YGCJXA>ON(XSWBP-|J6N).M1W>D+<W^R^Q0GHY^N9ICF?KU30A>^+1\$^2XQZ<9Z>VW>+>MD?LU7T<=YP(MJ<?<J3.S^J.WO:6F^?|0ZB.7+JUD<=Is&G|H%V#O-RF^=>GHIY^N9I-MCF<+VCOF>+<3NAZLIEY3I^P^PHN03.TOS?<J3100.^745H_NX.MOW>4KF?2W^?CPJ2P^FW"(ISY2.##SVA^G14#735F^.#W0=&1BN.MO:SV002I+V7|<67.6MDHJNY<3YI^*9M^Q.KVMDH2.3AIN|Y9^<M+T^YDBSPND>4E|I^D^2^34S<=&ES90MKT-H07Z|W^SCV5C|VDMZ135.M^=&Q|JHN-SUBYP30<IKLY.|R^F>+VZ53VY4X.SR^6M^V9>1+1F9BG.9XM2M-V|G|C&BVC?<?G|AC>|AB&S&S&J0G&0|H0H7|H10G M89Z>9KCV4(U<-9<Z.FU|F(E3-B=57<6G|C8)V>A^D^YFF.9P0.<=7I7=##M.Z<=N(LK+89Z>+1+>9BG.9XM2-5|+O7Y|FSC94B(GC^9?Q^?<?CPJ2P^FW"(ISY2.##(SWA>+>S^|KU|4B^HJ.^637C.&I3+J+C3S5O&A&M&#<L&B^DYX2I>JL&M4PVI5MBXOB^?9|XH=&E&NVD3X^<N6T6S.Y1I.MB^?^E1+M^H^OXN^<34V&U>*>4YF.9VEU8|>=R^N^SW|Z<+<1+^2KS>H+M>S^N^?2K^4JF^=AGHY|FN?>C6^P^TH08|HBCMK&^RIA^EY3I^P^P&J3.MTOS^%K1H>|<|<1PF>EN<P&<=&HPK<GFE|X^SW\$0.B|V^%>00T5.MDN+VE|F.G8|<=EP+2M^V|I^HUV3.6#<L^UWAK8#NBT&A7L&H&C7K+9.M^E^<C#>U=|V^MYGBVMDUO:|>4P3I^2.4S<=|>A|>1H7D2YBF8ISF>K3:51N&3<3&W8IYUS.Y^M^>7W3W61Q7Y.A2GU.LMMLH|TX.M6G|B|T&A^%>|TJE^=>GHIY^N9ICF+VCG3W&R^T^A0\$|JL^H1^5M|>HIC<?Y^P.MHNK|>Q>4>VZ.J6PW^H7L4K^?<|<DOKS^M5<J0ZZU>=Z2P.CX^<#>HUO.7R06G.L0I.M8308KTIY.N|><1<=<22^?Y^#084^9XM7I^>+|<6^8Y>+>TBRLMAGHY%N8I^MH^UHS^?14Y>#>0+F29BG8|F>+9038INV.HH0W^Y|9I.M^MQO&BN&K6&8&RA.P3(|>I>?OL.E9FY0).QR^M|B^RV&>+<D2YBF8ISF>M+4C3M|O^?F=>K<1X-B+|US>+Y^M|I&3&6R|I.963@|+1-MHT?M0^M(T^2MPIM5U73B|P^|RZGP.16G|4H9Y^|X|5=5.B+L6Z(|>H&MW.L^>B44K3PFN-9YAZ9NG.H|I7^B5.KI^A^GS^53.16JVD8M&A13CTX?Q0P5+V.MC@=&5MOQUGH|H^N8I^?+F29BG.M8|F>+>L3<=<PU6S<?2AC|>3G.S|P|PCP&S3LP5IVH^CWV^WT|Q?2FI.M64|<S^U.GHOCMT|<X>A1&30RS9:9630I.Z<9F+I^74KRN^7K4+;MU=I0T?M17J6R<=&PSG0|P6+|H&B4H5I|N(NB)YFN^9FC-RM\$5.MS8Z|B|CKJH2.0K6^XYW^DS+>V|A-9+Y|QP^?2S0.2CK>W>+>H|+F^M^9BG.9ZMTI34:1L1XSS7^+>3LFOI(C|V2I+>RVG<=<D2YBF8ISF>+>34.M^M^>XT?<Q@<F2^>2&8GHY%N8I^*%<TS&?<BLLB+IE9.9&N^|T|T3.M^C@PPESEL|TX3HB+TE2NE9I<=<M.SYE.V7FVG/6+61Y.N9I^*=<GN9XMGY^MIG|<#%O&&Y1I|H>LP^I&@<U.2I9^SGW^|6R^*PA9GH1Y^N9ICF>KM&^<R7MSZ^|<J0K7.8YG^I2RV.S7^4W5^M:.)>MCI0:??&L.MU3U&W14>HP<IGM.3A2Z<=GZ|U>+VWWB&W15M^2WE3V(X36.MG8.SU5W9M<BIVO.S505K670>YXO5.M^EL_NJ55|W2.WOR|I>5=<M33;U|MB3>W/L&Y6DQ?7I>ZQ-M8.SW1\$5=3B|7B9E|F6V693M^I2F^M^|G^Y^Q&40LRHM&GTYLXU.C^7I55P|<C2UN9D.KN^I0Q?2SI<-DT3.KD|Z8.M^M^SH?B|>SX<=NN^V^%9TD.2|H|H>|>H|>|>VY.99I^%4H3K&SAZH^M^M^MSKY^W.F4EJBZ<=&L0651M3F7D|O2|+<8UGP|O|US^>U+L|U5B|G^|<X^E^L|H55MAYD^K.K^<ENW&K^O|O|<LU.M-1+<U6L^4|IGL7&KNMC.FE.H723IN.NA<=DKO<L.NKS>2^Y0.23LDH.M&R+<1%N&FMMU7^Q>2WJ3.GVZ>PYO.7QXFI<=Q7ZV?P|C.Y.KIS^>+9>4#K9I+>2PGB|T|MHIRUV^Y-BD)-IS(W-/E.C-Y|O7V+>3K<5?ET<SU3K-TWDH|OCTM^|LW|I=2F+=ZE?WE-|>H2N|O<?3Q90.G^<F^M|L2^<U.O|<=>13QK7^5SKY|V4+<C|JMP^Q^RK5<?>7Z4\$^VYAS4^<?<ZB=L^MEJLUTM5.WU?>BM7G-Y|U|<U|<4EX7^+>+91=WAYVO|U^+Z^NWAT.AM55Z<C<1V-|J0U8?K>+>P2L+YK6|TWA.DX>?BU>22H|N=<7GO.EYNWUS<-MEJF&5<+>Y&EU.^IRW&NA=<2EES^IY&A|I^7&Y>ZS^+Y?WEJW.9%>15|A.MR^<P^S^Z>+>Y57H|W^T^W.J6^U|<W^R|F&K|<10HXI^<3L.M.G^U^W^F^W.M+<KDI&XZ5>6KVP|K9D&MGTU^XOJK5Y&UW&I&W&3>?G3^O<3^9>L.S>=>W5X&EAI7.MJA?QNA.F5827^<X.Z>S25U|MY(ZD<+HGKYU6H&N1=16RFE^|L.MRF-9V5%+<@=>1V|29|H|G.7EG^6YR.M^V&Z|ZH375>M.6|XIGP2.GZW^M^?<NOW^6W6W^GKT9IO.TIG-559Y.M5EW^NHP^B/L5-G.M^6(GN&|OI+<G|+GZ^%4+4KZ)2W5D^|I.2MRFE&7033DVA^<ZHU|V|D9K5>W#M|+ZDS8|SN3V-SYM^Y5UOZ>LMC=WY>=>Z4|L&M+|JU9E6X5M^<=IURNEUV^M^<2W^Y&K^W|C&K5.^<V^W^+Y^UOW^NSYLVS^WUK<575XFY5^X^&1#|&M0\$J=<2QF5FW^67CL|959^*Q+GFZ^|YPGBF<CEM>=<C>UR=|#I0T.G&DUM^2|2D&V+<S@>+2HF=A^M+7FR.HQ|T.O&W<|BOPAW^BN<7<7K<2R|H<CHWD+>10P.8IEU76X^FL.M.G0+<B+2UZ%?P|E.U4V^H|<O&H|L&M7^<|CP4ZUN>W-Y^W3Y|O|LB=<DKP2W^/|Z<Z&AG>=46.ME\$7MIW0^5^9#SL<|<P^

[illegible]

(Tables)Tableshttp://ocsl.com/role/ShareDataandNetAssets30 falsefalseR31.htm9954704 - Disclosure - Borrowings
(Tables)Sheethhttp://ocsl.com/role/BorrowingsTablesBorrowings (Tables)Tableshttp://ocsl.com/role/Borrowings31 falsefalseR32.htm9954705 - Disclosure -
Taxable/Distributable Income and Dividend Distributions
(Tables)Sheethhttp://ocsl.com/role/TaxableDistributableIncomeandDividendDistributionsTablesTaxable/Distributable Income and Dividend Distributions
(Tables)Tableshttp://ocsl.com/role/TaxableDistributableIncomeandDividendDistributions32 falsefalseR33.htm9954706 - Disclosure - Realized Gains or Losses and Net
Unrealized Appreciation or Depreciation (Tables)Sheethhttp://ocsl.com/role/RealizedGainsorLossesandNetUnrealizedAppreciationorDepreciationTablesRealized Gains or
Losses and Net Unrealized Appreciation or Depreciation (Tables)Tableshttp://ocsl.com/role/RealizedGainsorLossesandNetUnrealizedAppreciationorDepreciation33
falsefalseR34.htm9954707 - Disclosure - Financial Highlights (Tables)Sheethhttp://ocsl.com/role/FinancialHighlightsTablesFinancial Highlights
(Tables)Tableshttp://ocsl.com/role/FinancialHighlights34 falsefalseR35.htm9954708 - Disclosure - Derivative Instruments
(Tables)Sheethhttp://ocsl.com/role/DerivativeInstrumentsTablesDerivative Instruments (Tables)Tableshttp://ocsl.com/role/DerivativeInstruments35
falsefalseR36.htm9954709 - Disclosure - Commitments and Contingencies (Tables)Sheethhttp://ocsl.com/role/CommitmentsandContingenciesTablesCommitments and
Contingencies (Tables)Tableshttp://ocsl.com/role/CommitmentsandContingencies36 falsefalseR37.htm9954710 - Disclosure - Significant Accounting Policies
(Details)Sheethhttp://ocsl.com/role/SignificantAccountingPoliciesDetailsSignificant Accounting Policies
(Details)Detailshttp://ocsl.com/role/SignificantAccountingPolicies37 falsefalseR38.htm9954711 - Disclosure - Portfolio Investments - Narrative
(Details)Sheethhttp://ocsl.com/role/PortfolioInvestmentsNarrativeDetailsPortfolio Investments - Narrative (Details)Details38 falsefalseR39.htm9954712 - Disclosure -
Portfolio Investments - Composition of Investments (Details)Sheethhttp://ocsl.com/role/PortfolioInvestmentsCompositionofInvestmentsDetailsPortfolio Investments -
Composition of Investments (Details)Details39 falsefalseR40.htm9954713 - Disclosure - Portfolio Investments - Schedule of Financial Instruments Carried at Fair Value
(Details)Sheethhttp://ocsl.com/role/PortfolioInvestmentsScheduleofFinancialInstrumentsCarriedatFairValueDetailsPortfolio Investments - Schedule of Financial
Instruments Carried at Fair Value (Details)Details40 falsefalseR41.htm9954714 - Disclosure - Portfolio Investments - Roll-Forward in the Changes in Fair Value
(Details)Sheethhttp://ocsl.com/role/PortfolioInvestmentsRollForwardintheChangesinFairValueDetailsPortfolio Investments - Roll-Forward in the Changes in Fair Value
(Details)Details41 falsefalseR42.htm9954715 - Disclosure - Portfolio Investments - Significant Unobservable Inputs for Level 3 Investments
(Details)Sheethhttp://ocsl.com/role/PortfolioInvestmentsSignificantUnobservableInputsforLevel3InvestmentsDetailsPortfolio Investments - Significant Unobservable Inputs
for Level 3 Investments (Details)Details42 falsefalseR43.htm9954716 - Disclosure - Portfolio Investments - Schedule of Financial Instruments Disclosed, but Carried at
Fair Value (Details)Sheethhttp://ocsl.com/role/PortfolioInvestmentsScheduleofFinancialInstrumentsDisclosedbutCarriedatFairValueDetailsPortfolio Investments - Schedule
of Financial Instruments Disclosed, but Carried at Fair Value (Details)Details43 falsefalseR44.htm9954717 - Disclosure - Portfolio Investments - Portfolio Composition
(Details)Sheethhttp://ocsl.com/role/PortfolioInvestmentsPortfolioCompositionDetailsPortfolio Investments - Portfolio Composition (Details)Details44
falsefalseR45.htm9954718 - Disclosure - Portfolio Investments - Portfolio of Investments by Industry
(Details)Sheethhttp://ocsl.com/role/PortfolioInvestmentsPortfolioofInvestmentsbyIndustryDetailsPortfolio Investments - Portfolio of Investments by Industry
(Details)Details45 falsefalseR46.htm9954719 - Disclosure - Portfolio Investments - Summary of Portfolio
(Details)Sheethhttp://ocsl.com/role/PortfolioInvestmentsSummaryofPortfolioDetailsPortfolio Investments - Summary of Portfolio (Details)Details46
falsefalseR47.htm9954720 - Disclosure - Portfolio Investments - Portfolio Listing (Details)Sheethhttp://ocsl.com/role/PortfolioInvestmentsPortfolioListingDetailsPortfolio
Investments - Portfolio Listing (Details)Details47 falsefalseR48.htm9954721 - Disclosure - Portfolio Investments - Summarized Balance Sheet Information
(Details)Sheethhttp://ocsl.com/role/PortfolioInvestmentsSummarizedBalanceSheetInformationDetailsPortfolio Investments - Summarized Balance Sheet Information
(Details)Details48 falsefalseR49.htm9954722 - Disclosure - Portfolio Investments - Summarized Statement of Operations Information
(Details)Sheethhttp://ocsl.com/role/PortfolioInvestmentsSummarizedStatementofOperationsInformationDetailsPortfolio Investments - Summarized Statement of
Operations Information (Details)Details49 falsefalseR50.htm9954723 - Disclosure - Fee Income (Details)Sheethhttp://ocsl.com/role/FeeIncomeDetailsFee Income
(Details)Details50 falsefalseR51.htm9954724 - Disclosure - Share Data and Net Assets - Narrative
(Details)Sheethhttp://ocsl.com/role/ShareDataandNetAssetsNarrativeDetailsShare Data and Net Assets - Narrative (Details)Details51 falsefalseR52.htm9954725 -
Disclosure - Share Data and Net Assets - Schedule of Basic and Diluted Earnings Per Share
(Details)Sheethhttp://ocsl.com/role/ShareDataandNetAssetsScheduleofBasicandDilutedEarningsPerShareDetailsShare Data and Net Assets - Schedule of Basic and Diluted
Earnings Per Share (Details)Details52 falsefalseR53.htm9954726 - Disclosure - Share Data and Net Assets - Schedule of Changes in Net Assets
(Details)Sheethhttp://ocsl.com/role/ShareDataandNetAssetsScheduleofChangesinNetAssetsDetailsShare Data and Net Assets - Schedule of Changes in Net Assets
(Details)Details53 falsefalseR54.htm9954727 - Disclosure - Share Data and Net Assets - Schedule of Distributions
(Details)Sheethhttp://ocsl.com/role/ShareDataandNetAssetsScheduleofDistributionsDetailsShare Data and Net Assets - Schedule of Distributions (Details)Details54
falsefalseR55.htm9954728 - Disclosure - Share Data and Net Assets - Schedule of Common Stock Issued and Sold
(Details)Sheethhttp://ocsl.com/role/ShareDataandNetAssetsScheduleofCommonStockIssuedandSoldDetailsShare Data and Net Assets - Schedule of Common Stock Issued
and Sold (Details)Details55 falsefalseR56.htm9954729 - Disclosure - Borrowings - Narrative (Details)Sheethhttp://ocsl.com/role/BorrowingsNarrativeDetailsBorrowings -
Narrative (Details)Details56 falsefalseR57.htm9954730 - Disclosure - Borrowings - Components of the Carrying Value of Notes
(Details)Noteshttp://ocsl.com/role/BorrowingsComponentsoftheCarryingValueofNotesDetailsBorrowings - Components of the Carrying Value of Notes (Details)Details57
falsefalseR58.htm9954731 - Disclosure - Borrowings - Components of Interest and Other Debt Expenses
(Details)Sheethhttp://ocsl.com/role/BorrowingsComponentsofInterestandOtherDebtExpensesDetailsBorrowings - Components of Interest and Other Debt Expenses
(Details)Details58 falsefalseR59.htm9954732 - Disclosure - Taxable/Distributable Income and Dividend Distributions - Narrative
(Details)Sheethhttp://ocsl.com/role/TaxableDistributableIncomeandDividendDistributionsNarrativeDetailsTaxable/Distributable Income and Dividend Distributions -
Narrative (Details)Details59 falsefalseR60.htm9954733 - Disclosure -
Taxable/Distributable Income and Dividend Distributions - Reconciliation of Net Increase (Decrease) in Net Assets Resulting from Operations
(Details)Sheethhttp://ocsl.com/role/TaxableDistributableIncomeandDividendDistributionsReconciliationofNetIncreaseDecreaseinNetAssetsResultingfromOperationsDetailsT
Income and Dividend Distributions - Reconciliation of Net Increase (Decrease) in Net Assets Resulting from Operations (Details)Details60 falsefalseR61.htm9954734 -
Disclosure - Taxable/Distributable Income and Dividend Distributions - Components of Accumulated Overdistributed Earnings
(Details)Sheethhttp://ocsl.com/role/TaxableDistributableIncomeandDividendDistributionsComponentsofAccumulatedOverdistributedEarningsDetailsTaxable/Distributable
Income and Dividend Distributions - Components of Accumulated Overdistributed Earnings (Details)Details61 falsefalseR62.htm9954735 - Disclosure - Realized Gains or
Losses and Net Unrealized Appreciation or Depreciation - Aggregate Net Realized Gains
(Details)Sheethhttp://ocsl.com/role/RealizedGainsorLossesandNetUnrealizedAppreciationorDepreciationAggregateNetRealizedGainsDetailsRealized Gains or Losses and
Net Unrealized Appreciation or Depreciation - Aggregate Net Realized Gains (Details)Details62 falsefalseR63.htm9954736 - Disclosure - Realized Gains or Losses and Net
Unrealized Appreciation or Depreciation - Narrative
(Details)Sheethhttp://ocsl.com/role/RealizedGainsorLossesandNetUnrealizedAppreciationorDepreciationNarrativeDetailsRealized Gains or Losses and Net Unrealized
Appreciation or Depreciation - Narrative (Details)Details63 falsefalseR64.htm9954737 - Disclosure - Related Party Transactions (Details)Sheethhttp://ocsl.com/role/RelatedPartyTransactionsDetailsRelated Party Transactions
(Details)Details64 falsefalseR65.htm9954738 - Disclosure - Financial Highlights
(Details)Sheethhttp://ocsl.com/role/FinancialHighlightsDetailsFinancial Highlights (Details)Detailshttp://ocsl.com/role/FinancialHighlightsTables65
falsefalseR66.htm9954739 - Disclosure - Derivative Instruments - Schedule of Foreign Currency Forward Contracts and Interest Rate Swap
(Details)Sheethhttp://ocsl.com/role/DerivativeInstrumentsScheduleofForeignCurrencyForwardContractsandInterestRateSwapDetailsDerivative Instruments - Schedule of
Foreign Currency Forward Contracts and Interest Rate Swap (Details)Details66 falsefalseR67.htm9954740 - Disclosure - Derivative Instruments - Narrative
(Details)Sheethhttp://ocsl.com/role/DerivativeInstrumentsNarrativeDetailsDerivative Instruments - Narrative (Details)Details67 falsefalseR68.htm9954741 - Disclosure -
Commitments and Contingencies - Narrative (Details)Sheethhttp://ocsl.com/role/CommitmentsandContingenciesNarrativeDetailsCommitments and Contingencies -
Narrative (Details)Details68 falsefalseR69.htm9954742 - Disclosure - Commitments and Contingencies - Schedule of Unfunded Commitments by Investment
(Details)Sheethhttp://ocsl.com/role/CommitmentsandContingenciesScheduleofUnfundedCommitmentsbyInvestmentDetailsCommitments and Contingencies - Schedule of
Unfunded Commitments by Investment (Details)Details69 falsefalseR70.htm9954743 - Disclosure - Subsequent Events
(Details)Sheethhttp://ocsl.com/role/SubsequentEventsDetailsSubsequent Events (Details)Detailshttp://ocsl.com/role/SubsequentEvents70 falsefalseR71.htm9954744 -
Disclosure - Schedule 2212-14 - Schedule of Investments in and Advances to Affiliates
(Details)Sheethhttp://ocsl.com/role/Schedule1214ScheduleofInvestmentsinandAdvancesstoAffiliatesDetailsSchedule 2212-14 - Schedule of Investments in and Advances to
Affiliates (Details)Details71 falsefalseR9999.htmUncategorized Items - ocsl-20240630.htmSheethhttp://xbrl.sec.gov/role/uncategorizedItems-ocsl-
20240630.htmCover72 falsefalseAll ReportsBookAll Reports ocsl-20240630.htmocsl-20240630.xsdocsl-20240630-cal.xmlocsl-20240630-def.xmlocsl-
20240630-lab.xmlocsl-20240630-pre.xmlhttp://fasb.org/us-gaap/2023http://xbrl.sec.gov/ceef/2023http://xbrl.sec.gov/eid/2023http://xbrl.sec.gov/ecd/2023trueJSON 91
MetaLinks:json IDEA: XBRL DOCUMENT f "version": "2.2", "instance": f "ocsl-20240630.htm", f "nsprefix": "ocsl", "nsuri": "http://ocsl.com/20240630", "dts": f "inline": f
"local": f "ocsl-20240630.htm" }, "schema": f "local": f "ocsl-20240630.xsd" }, "remote": f "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
"http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
"http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/2006/xbrldt-2006.xsd",
"http://www.xbrl.org/irr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/irr/role/net-2009-12-16.xsd", "http://www.xbrl.org/irr/role/reference-2009-12-16.xsd",
"https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
"https://xbrl.fash.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fash.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fash.org/srt/2023/elts/srt-types-2023.xsd",
"https://xbrl.fash.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fash.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fash.org/us-gaap/2023/elts/us-types-
2023.xsd", "https://xbrl.sec.gov/ceef/2023/cef-2023.xsd", "https://xbrl.sec.gov/ceef/2023/cef-2023_pre.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd",
"https://xbrl.sec.gov/eid/2023/dei-2023.xsd", "https://xbrl.sec.gov/eid/2023/lab.xsd", "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd" }, f "local":
f "ocsl-20240630-cal.xml" }, "definitionLink": f "local": f "ocsl-20240630-def.xml" }, "labelLink": f "local": f "ocsl-20240630-lab.xml" }, "presentationLink": f "local":
f "ocsl-20240630-pre.xml" }, "keyStandard": 277, "keyCustom": 81, "axisStandard": 33, "axisCustom": 3, "memberStandard": 39, "memberCustom": 165, "hidden": f
"total": 28, "http://ocsl.com/20240630": 6, "http://fasb.org/us-gaap/2023": 17, "http://xbrl.sec.gov/dei/2023": 5 }, "contextCount": 2342, "entityCount": 1, "segmentCount":
225, "elementCount": 961, "unitCount": 10, "baseTaxonomies": f "http://fasb.org/us-gaap/2023": 6961, "http://xbrl.sec.gov/dei/2023": 30, "http://xbrl.sec.gov/ceef/2023": 21,
"http://xbrl.sec.gov/ecd/2023": 4, "report": f "R1", f "role": "http://ocsl.com/role/Cover", "longName": "0000001 - Document - Cover", "shortName": "Cover", "isDefault":
"true", "groupType": "document", "subGroupType": "menuCat", "Cover": "order", "1": "firstAnchor", f "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null,
"xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": f "span", "div", "body", "html" }, "reportCount": 1, "baseRef": "ocsl-20240630.htm", "first": true },
"uniqueAnchor": f "contextRef": "c-1", "name": "dei:DocumentQuarterlyReport", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": f "span",
"td", "tr", "table", "div", "body", "html" }, "reportCount": 1, "baseRef": "ocsl-20240630.htm", "unique": true }, "R2": f "role":
"http://ocsl.com/role/ConsolidatedStatementsofAssetsandLiabilities", "longName": "0000002 - Statement - Consolidated Statements of Assets and Liabilities",
"shortName": "Consolidated Statements of Assets and Liabilities", "isDefault": "false", "groupType": "statement", "subGroupType": "menuCat", "Statements": "order",
"2": "firstAnchor", f "contextRef": "c-9", "name": "us-gaap:InvestmentOwnedAtFairValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors":
f "span", "td", "tr", "table", "div", "body", "html" }, "reportCount": 1, "baseRef": "ocsl-20240630.htm", "first": true }, "uniqueAnchor": f "contextRef": "c-9", "name": "us-
gaap:DividendAndInterestReceivable", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": f "span", "td", "tr", "table", "div", "body", "html" },
"reportCount": 1, "baseRef": "ocsl-20240630.htm", "unique": true }, "R3": f "role": "http://ocsl.com/role/ConsolidatedStatementsofAssetsandLiabilitiesParentetical",
"longName": "0000003 - Statement - Consolidated Statements of Assets and Liabilities (Parentetical)", "shortName": "Consolidated Statements of Assets and Liabilities
(Parentetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parentetical", "menuCat": "Statements", "order": "3", "firstAnchor": f "contextRef": "c-
9", "name": "us-gaap:InvestmentOwnedAtCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": f "span", "td", "tr", "table", "div", "us-
gaap:InvestmentHoldingsScheduleofInvestmentsTableTextBlock", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "ocsl-20240630.htm", "first": true },
"uniqueAnchor": f "contextRef": "c-9", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US",
"decimals": "INF", "ancestors": f "span", "div", "td", "tr", "table", "div", "body", "html" }, "reportCount": 1, "baseRef": "ocsl-20240630.htm", "unique": true }, "R4": f

```

role: "http://ocsl.com/role/ConsolidatedStatementsOfOperations","longName": "00000004 - Statement - Consolidated Statements of Operations","shortName": "Consolidated Statements of Operations","isDefault": "false","groupType": "statement","subGroupType": "", "menuCat": "Statements","order": "4","firstAnchor": {"contextRef": "c-23","name": "us-gaap:InterestIncomeDepositsWithFinancialInstitutions","unitRef": "usd","xsiNil": "false","lang": "en-US","decimals": "3","ancestors": {"span": "td","tr","table","div","body","html"},"reportCount": 1,"baseRef": "ocsl-20240630.htm","first": true,"unique": true},"uniqueAnchor": {"contextRef": "c-23","name": "us-gaap:InterestIncomeDepositsWithFinancialInstitutions","unitRef": "usd","xsiNil": "false","lang": "en-US","decimals": "3","ancestors": {"span": "td","tr","table","div","body","html"},"reportCount": 1,"baseRef": "ocsl-20240630.htm","first": true,"unique": true }}, "R5": {"role": "http://ocsl.com/role/ConsolidatedStatementsOfChangesInNetAssets","longName": "00000005 - Statement - Consolidated Statements of Changes in Net Assets","shortName": "Consolidated Statements of Changes in Net Assets","isDefault": "false","groupType": "statement","subGroupType": "", "menuCat": "Statements","order": "5","firstAnchor": {"contextRef": "c-23","name": "us-gaap:InvestmentIncomeOperatingAfterExpenseAndTax","unitRef": "usd","xsiNil": "false","lang": "en-US","decimals": "3","ancestors": {"span": "td","tr","table","div","body","html"},"reportCount": 1,"baseRef": "ocsl-20240630.htm","first": true,"unique": true }}, "R6": {"role": "http://ocsl.com/role/ConsolidatedStatementOfCashFlows","longName": "00000006 - Statement - Consolidated Statement of Cash Flows","shortName": "Consolidated Statement of Cash Flows","isDefault": "false","groupType": "statement","subGroupType": "", "menuCat": "Statements","order": "6","firstAnchor": {"contextRef": "c-23","name": "us-gaap:NetIncomeLoss","unitRef": "usd","xsiNil": "false","lang": "en-US","decimals": "3","ancestors": {"span": "td","tr","table","div","body","html"},"reportCount": 1,"baseRef": "ocsl-20240630.htm","first": true,"unique": true }}, "R7": {"role": "us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments","unitRef": "usd","xsiNil": "false","lang": "en-US","decimals": "3","ancestors": {"span": "td","tr","table","div","body","html"},"reportCount": 1,"baseRef": "ocsl-20240630.htm","first": true,"unique": true }}, "R8": {"role": "http://ocsl.com/role/ConsolidatedScheduleOfInvestments","longName": "00000007 - Statement - Consolidated Schedule of Investments","shortName": "Consolidated Schedule of Investments","isDefault": "false","groupType": "statement","subGroupType": "", "menuCat": "Statements","order": "7","firstAnchor": {"contextRef": "c-9","name": "us-gaap:InvestmentOwnedAtCost","unitRef": "usd","xsiNil": "false","lang": "en-US","decimals": "3","ancestors": {"span": "td","tr","table","div","body","html"},"reportCount": 1,"baseRef": "ocsl-20240630.htm","first": true,"unique": true }}, "R9": {"role": "us-gaap:InvestmentHoldingsScheduleOfInvestmentsTableTextBlock","ix:continuation": "body","html"},"reportCount": 1,"baseRef": "ocsl-20240630.htm","first": true,"unique": true }}, "R10": {"role": "us-gaap:MoneyMarketFundsAtCarryingValue","unitRef": "usd","xsiNil": "false","lang": "en-US","decimals": "3","ancestors": {"span": "td","tr","table","div","body","html"},"reportCount": 1,"baseRef": "ocsl-20240630.htm","first": true,"unique": true }}, "R11": {"role": "http://ocsl.com/role/ConsolidatedScheduleOfInvestmentsDerivatives","longName": "00000008 - Statement - Consolidated Schedule of Investments - Derivatives","shortName": "Consolidated Schedule of Investments - Derivatives","isDefault": "false","groupType": "statement","subGroupType": "", "menuCat": "Statements","order": "8","firstAnchor": {"contextRef": "c-9","name": "us-gaap:DerivativeAssets","unitRef": "usd","xsiNil": "false","lang": "en-US","decimals": "3","ancestors": {"span": "td","tr","table","div","body","html"},"reportCount": 1,"baseRef": "ocsl-20240630.htm","first": true,"unique": true }}, "R12": {"role": "us-gaap:DerivativeFairValueOfDerivativeNet","unitRef": "usd","xsiNil": "false","lang": "en-US","decimals": "3","ancestors": {"span": "td","tr","table","div","body","html"},"reportCount": 1,"baseRef": "ocsl-20240630.htm","first": true,"unique": true }}, "R13": {"role": "http://ocsl.com/role/ConsolidatedScheduleOfInvestmentsParentetical","longName": "00000009 - Statement - Consolidated Schedule of Investments - Parentetical","shortName": "Consolidated Schedule of Investments - Parentetical","isDefault": "false","groupType": "statement","subGroupType": "parentetical","menuCat": "Statements","order": "9","firstAnchor": {"contextRef": "c-9","name": "ocsl:PercentageOfTotalAssetsRepresentingQualifyingAssets","unitRef": "number","xsiNil": "false","lang": "en-US","decimals": "3","ancestors": {"span": "td","tr","table","div","body","html"},"reportCount": 1,"baseRef": "ocsl-20240630.htm","first": true,"unique": true }}, "R14": {"role": "ocsl:PercentageOfTotalAssetsRepresentingQualifyingAssets","unitRef": "number","xsiNil": "false","lang": "en-US","decimals": "3","ancestors": {"span": "td","tr","table","div","body","html"},"reportCount": 1,"baseRef": "ocsl-20240630.htm","first": true,"unique": true }}, "R15": {"role": "http://ocsl.com/role/Organization","longName": "00000010 - Disclosure - Organization","shortName": "Organization","isDefault": "false","groupType": "disclosure","subGroupType": "", "menuCat": "Notes","order": "10","firstAnchor": {"contextRef": "c-1","name": "us-gaap:OrganizationConsolidationAndPresentationOffinancialStatementsDisclosureTextBlock","unitRef": null,"xsiNil": "false","lang": "en-US","decimals": null,"ancestors": {"span": "div","body","html"},"reportCount": 1,"baseRef": "ocsl-20240630.htm","first": true,"unique": true }}, "R16": {"role": "http://ocsl.com/role/SignificantAccountingPolicies","longName": "00000011 - Disclosure - Significant Accounting Policies","shortName": "Significant Accounting Policies","isDefault": "false","groupType": "disclosure","subGroupType": "notes","menuCat": "Notes","order": "11","firstAnchor": {"contextRef": "c-1","name": "us-gaap:SignificantAccountingPoliciesTextBlock","unitRef": null,"xsiNil": "false","lang": "en-US","decimals": null,"ancestors": {"span": "div","body","html"},"reportCount": 1,"baseRef": "ocsl-20240630.htm","first": true,"unique": true }}, "R17": {"role": "us-gaap:SignificantAccountingPoliciesTextBlock","unitRef": null,"xsiNil": "false","lang": "en-US","decimals": null,"ancestors": {"span": "div","body","html"},"reportCount": 1,"baseRef": "ocsl-20240630.htm","first": true,"unique": true }}, "R18": {"role": "http://ocsl.com/role/PortfolioInvestments","longName": "00000012 - Disclosure - Portfolio Investments","shortName": "Portfolio Investments","isDefault": "false","groupType": "disclosure","subGroupType": "notes","menuCat": "Notes","order": "12","firstAnchor": {"contextRef": "c-1","name": "us-gaap:InvestmentHoldingsScheduleOfInvestmentsTableTextBlock","unitRef": null,"xsiNil": "false","lang": "en-US","decimals": null,"ancestors": {"span": "div","body","html"},"reportCount": 1,"baseRef": "ocsl-20240630.htm","first": true,"unique": true }}, "R19": {"role": "us-gaap:InvestmentHoldingsScheduleOfInvestmentsTableTextBlock","unitRef": null,"xsiNil": "false","lang": "en-US","decimals": null,"ancestors": {"span": "div","body","html"},"reportCount": 1,"baseRef": "ocsl-20240630.htm","first": true,"unique": true }}, "R20": {"role": "http://ocsl.com/role/Borrowings","longName": "00000013 - Disclosure - Borrowings","shortName": "Borrowings","isDefault": "false","groupType": "disclosure","subGroupType": "notes","menuCat": "Notes","order": "13","firstAnchor": {"contextRef": "c-1","name": "us-gaap:DebtDisclosureTextBlock","unitRef": null,"xsiNil": "false","lang": "en-US","decimals": null,"ancestors": {"span": "div","body","html"},"reportCount": 1,"baseRef": "ocsl-20240630.htm","first": true,"unique": true }}, "R21": {"role": "us-gaap:DebtDisclosureTextBlock","unitRef": null,"xsiNil": "false","lang": "en-US","decimals": null,"ancestors": {"span": "div","body","html"},"reportCount": 1,"baseRef": "ocsl-20240630.htm","first": true,"unique": true }}, "R22": {"role": "http://ocsl.com/role/RealizedGainsOrLossesAndNetUnrealizedAppreciationOrDepreciation","longName": "00000014 - Disclosure - Realized Gains or Losses and Net Unrealized Appreciation or Depreciation","shortName": "Realized Gains or Losses and Net Unrealized Appreciation or Depreciation","isDefault": "false","groupType": "disclosure","subGroupType": "notes","menuCat": "Notes","order": "14","firstAnchor": {"contextRef": "c-1","name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock","unitRef": null,"xsiNil": "false","lang": "en-US","decimals": null,"ancestors": {"span": "div","body","html"},"reportCount": 1,"baseRef": "ocsl-20240630.htm","first": true,"unique": true }}, "R23": {"role": "us-gaap:StockholdersEquityNoteDisclosureTextBlock","unitRef": null,"xsiNil": "false","lang": "en-US","decimals": null,"ancestors": {"span": "div","body","html"},"reportCount": 1,"baseRef": "ocsl-20240630.htm","first": true,"unique": true }}, "R24": {"role": "http://ocsl.com/role/RelatedPartyTransactions","longName": "00000015 - Disclosure - Related Party Transactions","shortName": "Related Party Transactions","isDefault": "false","groupType": "disclosure","subGroupType": "notes","menuCat": "Notes","order": "15","firstAnchor": {"contextRef": "c-1","name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock","unitRef": null,"xsiNil": "false","lang": "en-US","decimals": null,"ancestors": {"span": "div","body","html"},"reportCount": 1,"baseRef": "ocsl-20240630.htm","first": true,"unique": true }}, "R25": {"role": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock","unitRef": null,"xsiNil": "false","lang": "en-US","decimals": null,"ancestors": {"span": "div","body","html"},"reportCount": 1,"baseRef": "ocsl-20240630.htm","first": true,"unique": true }}, "R26": {"role": "http://ocsl.com/role/FinancialHighlights","longName": "00000016 - Disclosure - Financial Highlights","shortName": "Financial Highlights","isDefault": "false","groupType": "disclosure","subGroupType": "notes","menuCat": "Notes","order": "16","firstAnchor": {"contextRef": "c-1","name": "us-gaap:ConcentrationRiskDisclosureTextBlock","unitRef": null,"xsiNil": "false","lang": "en-US","decimals": null,"ancestors": {"span": "div","body","html"},"reportCount": 1,"baseRef": "ocsl-20240630.htm","first": true,"unique": true }}, "R27": {"role": "us-gaap:ConcentrationRiskDisclosureTextBlock","unitRef": null,"xsiNil": "false","lang": "en-US","decimals": null,"ancestors": {"span": "div","body","html"},"reportCount": 1,"baseRef": "ocsl-20240630.htm","first": true,"unique": true }}, "R28": {"role": "http://ocsl.com/role/CommitmentsAndContingencies","longName": "00000017 - Disclosure - Commitments and Contingencies","shortName": "Commitments and Contingencies","isDefault": "false","groupType": "disclosure","subGroupType": "notes","menuCat": "Notes","order": "17","firstAnchor": {"contextRef": "c-1","name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock","unitRef": null,"xsiNil": "false","lang": "en-US","decimals": null,"ancestors": {"span": "div","body","html"},"reportCount": 1,"baseRef": "ocsl-20240630.htm","first": true,"unique": true }}, "R29": {"role": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock","unitRef": null,"xsiNil": "false","lang": "en-US","decimals": null,"ancestors": {"span": "div","body","html"},"reportCount": 1,"baseRef": "ocsl-20240630.htm","first": true,"unique": true }}, "R30": {"role": "http://ocsl.com/role/SubsequentEvents","longName": "00000018 - Disclosure - Subsequent Events","shortName": "Subsequent Events","isDefault": "false","groupType": "disclosure","subGroupType": "notes","menuCat": "Notes","order": "18","firstAnchor": {"contextRef": "c-1","name": "us-gaap:SubsequentEventsTextBlock","unitRef": null,"xsiNil": "false","lang": "en-US","decimals": null,"ancestors": {"span": "div","body","html"},"reportCount": 1,"baseRef": "ocsl-20240630.htm","first": true,"unique": true }}, "R31": {"role": "us-gaap:SubsequentEventsTextBlock","unitRef": null,"xsiNil
```

```

"baseRef": "ocsl-20240630.htm", "first": true, "unique": "true" } }, "R24": { "role": "http://ocsl.com/role/Schedule1214", "longName": "0000024 - Disclosure - Schedule1214", "shortName": "Schedule1214", "isDefault": "false", "groupType": "disclosure", "subGroupType": "disclosure", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "body": { "html": { "reportCount": 1, "baseRef": "ocsl-20240630.htm", "first": true, "unique": "true" }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "body": { "html": { "reportCount": 1, "baseRef": "ocsl-20240630.htm", "first": true, "unique": "true" }, "R25": { "role": "http://xbrl.sec.gov/ecd/role/PyPDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "disclosure", "menuCat": "Notes", "order": "25", "firstAnchor": { "contextRef": "c-23", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": { "td": { "tr": { "table": { "div": { "body": { "html": { "reportCount": 1, "baseRef": "ocsl-20240630.htm", "first": true, "uniqueAnchor": null }, "R26": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "disclosure", "menuCat": "Notes", "order": "26", "firstAnchor": { "contextRef": "c-23", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": { "div": { "body": { "html": { "reportCount": 1, "baseRef": "ocsl-20240630.htm", "first": true, "unique": "true" }, "R27": { "role": "http://xbrl.sec.gov/ecd/role/N2", "longName": "995470 - Disclosure - N-2", "shortName": "N-2", "isDefault": "false", "groupType": "disclosure", "subGroupType": "disclosure", "menuCat": "Notes", "order": "27", "firstAnchor": { "contextRef": "c-1", "name": "dei:EntityFileNumber", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": { "div": { "body": { "html": { "reportCount": 1, "baseRef": "ocsl-20240630.htm", "first": true, "uniqueAnchor": { "contextRef": "c-1", "name": "cef:InvestmentObjectivesAndPracticesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": { "div": { "body": { "html": { "reportCount": 1, "baseRef": "ocsl-20240630.htm", "first": true, "unique": "true" }, "R28": { "role": "http://ocsl.com/role/SignificantAccountingPoliciesPolicies", "longName": "9954701 - Disclosure - Significant Accounting Policies (Policies)", "shortName": "Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "28", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BasicOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation": { "body": { "html": { "reportCount": 1, "baseRef": "ocsl-20240630.htm", "first": true, "unique": "true" }, "R29": { "role": "http://ocsl.com/role/PortfolioInvestmentsTables", "longName": "9954702 - Disclosure - Portfolio Investments (Tables)", "shortName": "Portfolio Investments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:InvestmentHoldingsScheduleOfInvestmentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation": { "body": { "html": { "reportCount": 1, "baseRef": "ocsl-20240630.htm", "first": true, "unique": "true" }, "R30": { "role": "http://ocsl.com/role/ShareDataandNetAssetsTables", "longName": "9954703 - Disclosure - Share Data and Net Assets (Tables)", "shortName": "Share Data and Net Assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation": { "body": { "html": { "reportCount": 1, "baseRef": "ocsl-20240630.htm", "first": true, "unique": "true" }, "R31": { "role": "http://ocsl.com/role/BorrowingsTables", "longName": "9954704 - Disclosure - Borrowings (Tables)", "shortName": "Borrowings (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation": { "body": { "html": { "reportCount": 1, "baseRef": "ocsl-20240630.htm", "first": true, "unique": "true" }, "R32": { "role": "http://ocsl.com/role/TaxableDistributableIncomeandDividendDistributionsTables", "longName": "9954705 - Disclosure - Taxable/Distributable Income and Dividend Distributions (Tables)", "shortName": "Taxable/Distributable Income and Dividend Distributions (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FederalIncomeTaxNoteTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation": { "body": { "html": { "reportCount": 1, "baseRef": "ocsl-20240630.htm", "first": true, "unique": "true" }, "R33": { "role": "http://ocsl.com/role/RealizedGainsorLossesandNetUnrealizedAppreciationorDepreciationTables", "longName": "9954706 - Disclosure - Realized Gains or Losses and Net Unrealized Appreciation or Depreciation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfRealizedGainLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation": { "body": { "html": { "reportCount": 1, "baseRef": "ocsl-20240630.htm", "first": true, "unique": "true" }, "R34": { "role": "http://ocsl.com/role/FinancialHighlightsTables", "longName": "9954707 - Disclosure - Financial Highlights (Tables)", "shortName": "Financial Highlights (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:InvestmentCompanyFinancialHighlightsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation": { "body": { "html": { "reportCount": 1, "baseRef": "ocsl-20240630.htm", "first": true, "uniqueAnchor": null }, "R35": { "role": "http://ocsl.com/role/DerivativeInstrumentsTables", "longName": "9954708 - Disclosure - Derivative Instruments (Tables)", "shortName": "Derivative Instruments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "35", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDerivativeInstrumentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation": { "body": { "html": { "reportCount": 1, "baseRef": "ocsl-20240630.htm", "first": true, "unique": "true" }, "R36": { "role": "http://ocsl.com/role/CommitmentsandContingenciesTables", "longName": "9954709 - Disclosure - Commitments and Contingencies (Tables)", "shortName": "Commitments and Contingencies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "36", "firstAnchor": { "contextRef": "c-1", "name": "ocsl:ScheduleForFinancialSupportForNonconsolidatedEntityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation": { "body": { "html": { "reportCount": 1, "baseRef": "ocsl-20240630.htm", "first": true, "unique": "true" }, "R37": { "role": "http://ocsl.com/role/SignificantAccountingPoliciesDetails", "longName": "9954710 - Disclosure - Significant Accounting Policies (Details)", "shortName": "Significant Accounting Policies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "c-9", "name": "us-gaap:RestrictedCash", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": { "td": { "tr": { "table": { "div": { "body": { "html": { "reportCount": 1, "baseRef": "ocsl-20240630.htm", "first": true, "uniqueAnchor": { "contextRef": "c-676", "name": "us-gaap:ExciseAndSalesTaxes", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "IN", "ancestors": { "span": { "div": { "us-gaap:IncomeTaxPolicyTextBlock", "ix:continuation": { "body": { "html": { "reportCount": 1, "baseRef": "ocsl-20240630.htm", "first": true, "unique": "true" }, "R38": { "role": "http://ocsl.com/role/PortfolioInvestmentsNarrativeDetails", "longName": "9954711 - Disclosure - Portfolio Investments - Narrative (Details)", "shortName": "Portfolio Investments - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "c-9", "name": "us-gaap:InvestmentOwnedPercentOfNetAssets", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "4", "ancestors": { "span": { "td": { "tr": { "table": { "div": { "ix:continuation": { "body": { "html": { "reportCount": 1, "baseRef": "ocsl-20240630.htm", "first": true, "uniqueAnchor": { "contextRef": "c-1582", "name": "us-gaap:InvestmentOwnedAtFairValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "5", "ancestors": { "span": { "div": { "ix:continuation": { "body": { "html": { "reportCount": 1, "baseRef": "ocsl-20240630.htm", "first": true, "unique": "true" }, "R39": { "role": "http://ocsl.com/role/PortfolioInvestmentsCompositionofInvestmentsDetails", "longName": "9954712 - Disclosure - Portfolio Investments - Composition of Investments (Details)", "shortName": "Portfolio Investments - Composition of Investments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "c-9", "name": "us-gaap:InvestmentOwnedAtCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": { "td": { "tr": { "table": { "div": { "us-gaap:InvestmentHoldingsScheduleOfInvestmentsTableTextBlock", "ix:continuation": { "body": { "html": { "reportCount": 1, "baseRef": "ocsl-20240630.htm", "first": true, "uniqueAnchor": { "contextRef": "c-9", "name": "us-gaap:DebtSecuritiesAvailableForSaleAndHeldToMaturityFairValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ance
```

Disclosed, but Carried at Fair Value (Details), "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43",
"firstAnchor": { "contextRef": "c-9", "name": "us-gaap:LongTermDebt", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr",
"table", "div", "us-gaap:FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock", "ix:continuation", "body", "html" } }, "reportCount": 1, "baseRef":
"ocsl-20240630.htm", "first": true, "uniqueAnchor": { "contextRef": "c-889", "name": "us-gaap:LongTermDebt", "unitRef": "usd", "xsiNil": "false", "lang": "en-US",
"decimals": "3", "ancestors": { "span": "td", "tr", "table", "div", "us-gaap:FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock",
"ix:continuation", "body", "html" } }, "reportCount": 1, "baseRef": "ocsl-20240630.htm", "unique": true, "R44": { "role":
"http://ocsl.com/role/PortfolioInvestmentsPortfolioCompositionDetails", "longName": "9954717 - Disclosure - Portfolio Investments - Portfolio Composition (Details)",
"shortName": "Portfolio Investments - Portfolio Composition (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details",
"order": "44", "firstAnchor": { "contextRef": "c-9", "name": "us-gaap:InvestmentOwnedAtCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3",
"ancestors": { "span": "td", "tr", "table", "div", "us-gaap:InvestmentHoldingsScheduleOfInvestmentsTableTextBlock", "ix:continuation", "body", "html" } }, "reportCount": 1,
"baseRef": "ocsl-20240630.htm", "first": true, "uniqueAnchor": { "contextRef": "c-964", "name": "us-gaap:InvestmentOwnedAtCost", "unitRef": "usd", "xsiNil": "false",
"lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr", "table", "div", "us-gaap:InvestmentCompanyFinancialHighlightsTableTextBlock", "ix:continuation",
"body", "html" } }, "reportCount": 1, "baseRef": "ocsl-20240630.htm", "unique": true, "R45": { "role":
"http://ocsl.com/role/PortfolioInvestmentsPortfolioOffInvestmentsbyIndustryDetails", "longName": "9954718 - Disclosure - Portfolio Investments - Portfolio of Investments
by Industry (Details)", "shortName": "Portfolio Investments - Portfolio of Investments by Industry (Details)", "isDefault": "false", "groupType": "disclosure",
"subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c-9", "name": "us-gaap:InvestmentOwnedAtCost", "unitRef": "usd", "xsiNil":
"false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr", "table", "div", "us-gaap:InvestmentHoldingsScheduleOfInvestmentsTableTextBlock",
"ix:continuation", "body", "html" } }, "reportCount": 1, "baseRef": "ocsl-20240630.htm", "unique": true, "R46": { "role":
"http://ocsl.com/role/PortfolioInvestmentsSummaryofPortfolioDetails", "longName": "9954719 - Disclosure - Portfolio Investments - Summary of Portfolio (Details)",
"shortName": "Portfolio Investments - Summary of Portfolio (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details",
"order": "46", "firstAnchor": { "contextRef": "c-9", "name": "ocsl:InvestmentCompanyNumberofBorrowers", "unitRef": "borrower", "xsiNil": "false", "lang": "en-US",
"decimals": "INF", "ancestors": { "span": "div", "ix:continuation", "body", "html" } }, "reportCount": 1, "baseRef": "ocsl-20240630.htm", "first": true, "uniqueAnchor": {
"contextRef": "c-1766", "name": "us-gaap:InvestmentOwnedBalancePrincipalAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": {
"span": "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" } }, "reportCount": 1, "baseRef": "ocsl-20240630.htm", "unique": true, "R47": { "role":
"http://ocsl.com/role/PortfolioInvestmentsPortfolioListingDetails", "longName": "9954720 - Disclosure - Portfolio Investments - Portfolio Listing (Details)", "shortName":
"Portfolio Investments - Portfolio Listing (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47",
"firstAnchor": { "contextRef": "c-9", "name": "us-gaap:InvestmentOwnedAtCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span":
"td", "tr", "table", "div", "us-gaap:InvestmentHoldingsScheduleOfInvestmentsTableTextBlock", "ix:continuation", "body", "html" } }, "reportCount": 1, "baseRef": "ocsl-
20240630.htm", "first": true, "uniqueAnchor": { "contextRef": "c-1594", "name": "us-gaap:InvestmentOwnedAtCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US",
"decimals": "3", "ancestors": { "span": "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" } }, "reportCount": 1, "baseRef": "ocsl-20240630.htm",
"unique": true, "R48": { "role": "http://ocsl.com/role/PortfolioInvestmentsSummarizedBalanceSheetInformationDetails", "longName": "9954721 - Disclosure - Portfolio
Investments - Summarized Balance Sheet Information (Details)", "shortName": "Portfolio Investments - Summarized Balance Sheet Information (Details)", "isDefault":
"false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "c-9", "name": "us-
gaap:InvestmentOwnedAtFairValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr", "table", "div", "body", "html" } },
"reportCount": 1, "baseRef": "ocsl-20240630.htm", "first": true, "uniqueAnchor": { "contextRef": "c-9", "name": "us-gaap:SecuredDebt", "unitRef": "usd", "xsiNil": "false", "lang":
"en-US", "decimals": "3", "ancestors": { "span": "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" } }, "reportCount": 1, "baseRef": "ocsl-
20240630.htm", "unique": true, "R49": { "role": "http://ocsl.com/role/PortfolioInvestmentsSummarizedStatementofOperationsInformationDetails", "longName":
"9954722 - Disclosure - Portfolio Investments - Summarized Statement of Operations Information (Details)", "shortName": "Portfolio Investments - Summarized
Statement of Operations Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49",
"firstAnchor": { "contextRef": "c-23", "name": "us-gaap:GrossInvestmentIncomeOperating", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3",
"ancestors": { "span": "td", "tr", "table", "div", "body", "html" } }, "reportCount": 1, "baseRef": "ocsl-20240630.htm", "first": true, "uniqueAnchor": { "contextRef": "c-1745",
"name": "us-gaap:OtherIncome", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr", "table", "div", "us-
gaap:InvestmentCompanyNonconsolidatedSubsidiarySummarizedFinancialInformationTableTextBlock", "ix:continuation", "body", "html" } }, "reportCount": 1, "baseRef":
"ocsl-20240630.htm", "unique": true, "R50": { "role": "http://ocsl.com/role/FeeIncomeDetails", "longName": "9954723 - Disclosure - Fee Income (Details)",
"shortName": "Fee Income (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": {
"contextRef": "c-23", "name": "us-gaap:FeeIncome", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr", "table", "div",
"body", "html" } }, "reportCount": 1, "baseRef": "ocsl-20240630.htm", "first": true, "uniqueAnchor": { "contextRef": "c-23", "name": "ocsl:FeeIncomeRecurring", "unitRef":
"usd", "xsiNil": "false", "lang": "en-US", "decimals": "5", "ancestors": { "span": "div", "ix:continuation", "body", "html" } }, "reportCount": 1, "baseRef": "ocsl-20240630.htm",
"unique": true, "R51": { "role": "http://ocsl.com/role/ShareDataandNetAssetsNarrativeDetails", "longName": "9954724 - Disclosure - Share Data and Net Assets -
Narrative (Details)", "shortName": "Share Data and Net Assets - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details",
"menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:StockIssuedDuringPeriodSharesDividendReinvestmentPlan", "unitRef":
"shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": { "span": "td", "tr", "table", "div", "us-gaap:DividendsDeclaredTableTextBlock",
"ix:continuation", "body", "html" } }, "reportCount": 1, "baseRef": "ocsl-20240630.htm", "first": true, "uniqueAnchor": { "contextRef": "c-1961", "name":
"ocsl:SaleOfStockMaximumAggregateOfferingAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": { "span": "div", "ix:continuation",
"body", "html" } }, "reportCount": 1, "baseRef": "ocsl-20240630.htm", "unique": true, "R52": { "role":
"http://ocsl.com/role/ShareDataandNetAssetsScheduleofBasicandDilutedEarningsPerShareDetails", "longName": "9954725 - Disclosure - Share Data and Net Assets -
Schedule of Basic and Diluted Earnings Per Share (Details)", "shortName": "Share Data and Net Assets - Schedule of Basic and Diluted Earnings Per Share (Details)",
"isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "c-23", "name": "us-
gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr", "table", "div", "body", "html" } }, "reportCount": 1,
"baseRef": "ocsl-20240630.htm", "first": true, "uniqueAnchor": null, "R53": { "role":
"http://ocsl.com/role/ShareDataandNetAssetsScheduleofChangesinNetAssetsDetails", "longName": "9954726 - Disclosure - Share Data and Net Assets - Schedule of
Changes in Net Assets (Details)", "shortName": "Share Data and Net Assets - Schedule of Changes in Net Assets (Details)", "isDefault": "false", "groupType": "disclosure",
"subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "c-10", "name": "us-gaap:CommonStockSharesIssued", "unitRef": "shares",
"xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr", "table", "div", "us-gaap:CommonStockSharesOutstanding", "span": "div", "tr", "table", "div", "body", "html" } },
"reportCount": 1, "baseRef": "ocsl-20240630.htm", "first": true, "uniqueAnchor": { "contextRef": "c-1918", "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
"unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": { "span": "td", "tr", "table", "div", "us-
gaap:InvestmentCompanyChangesInNetAssetsTableTextBlock", "ix:continuation", "body", "html" } }, "reportCount": 1, "baseRef": "ocsl-20240630.htm", "unique": true, "R54": { "role":
"http://ocsl.com/role/ShareDataandNetAssetsScheduleofDistributionsDetails", "longName": "9954727 - Disclosure - Share Data and Net Assets - Schedule
of Distributions (Details)", "shortName": "Share Data and Net Assets - Schedule of Distributions (Details)", "isDefault": "false

"name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ocsl-20240630.htm", "first": true, "uniqueAnchor": { "contextRef": "c-23", "name": "Tangible/Intangible Assets - Components of Accumulated Overdistributed Earnings (Details)" }, "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "c-23", "name": "Tangible/Intangible Assets - Components of Accumulated Overdistributed Earnings (Details)" }, "name": "us-gaap:FederalIncomeTaxNoteTextBlock", "ix.continuation": "body", "html": 1, "reportCount": 1, "baseRef": "ocsl-20240630.htm", "unique": true, "R61": { "role": "http://ocsl.com/role/TaxableDistributableIncomeandDividendDistributionsComponentsofAccumulatedOverdistributedEarningsDetails", "longName": "9954734 - Disclosure - Taxable/Distributable Income and Dividend Distributions - Components of Accumulated Overdistributed Earnings (Details)", "shortName": "Taxable/Distributable Income and Dividend Distributions - Components of Accumulated Overdistributed Earnings (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "c-10", "name": "us-gaap:InvestmentCompanyDistributableEarningsLossAccumulatedOrdinaryIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ocsl-20240630.htm", "first": true, "uniqueAnchor": { "contextRef": "c-10", "name": "us-gaap:InvestmentCompanyDistributableEarningsLossAccumulatedOrdinaryIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ocsl-20240630.htm", "unique": true, "R62": { "role": "http://ocsl.com/role/RealizedGainsorLossesandNetUnrealizedAppreciationorDepreciationAggregateNetRealizedGainsDetails", "longName": "9954735 - Disclosure - Realized Gains or Losses and Net Unrealized Appreciation or Depreciation - Aggregate Net Realized Gains (Details)", "shortName": "Realized Gains or Losses and Net Unrealized Appreciation or Depreciation - Aggregate Net Realized Gains (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "c-23", "name": "us-gaap:DebtAndEquitySecuritiesAndForeignCurrencyTransactionPriceChangeRealizedGainLossOperatingBeforeTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ocsl-20240630.htm", "first": true, "uniqueAnchor": { "contextRef": "c-2015", "name": "us-gaap:DebtAndEquitySecuritiesAndForeignCurrencyTransactionPriceChangeRealizedGainLossOperatingBeforeTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ocsl-20240630.htm", "unique": true, "R63": { "role": "http://ocsl.com/role/RealizedGainsorLossesandNetUnrealizedAppreciationorDepreciationNarrativeDetails", "longName": "9954736 - Disclosure - Realized Gains or Losses and Net Unrealized Appreciation or Depreciation - Narrative (Details)", "shortName": "Realized Gains or Losses and Net Unrealized Appreciation or Depreciation - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "c-23", "name": "us-gaap:DebtAndEquitySecuritiesAndForeignCurrencyTransactionPriceChangeUnrealizedGainLossOperatingBeforeTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ocsl-20240630.htm", "first": true, "uniqueAnchor": { "contextRef": "c-2046", "name": "us-gaap:DebtAndEquitySecuritiesAndForeignCurrencyTransactionPriceChangeUnrealizedGainLossOperatingBeforeTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ocsl-20240630.htm", "unique": true, "R64": { "role": "http://ocsl.com/role/RelatedPartyTransactionsDetails", "longName": "9954737 - Disclosure - Related Party Transactions (Details)", "shortName": "Related Party Transactions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "c-9", "name": "ocsl:ManagementAndIncentiveFeePayable", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ocsl-20240630.htm", "first": true, "uniqueAnchor": { "contextRef": "c-2062", "name": "us-gaap:ManagementAndServiceFeesBaseRate", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "div", "ix.continuation", "body", "html"], "reportCount": 1, "baseRef": "ocsl-20240630.htm", "unique": true, "R65": { "role": "http://ocsl.com/role/FinancialHighlightsDetails", "longName": "9954738 - Disclosure - Financial Highlights (Details)", "shortName": "Financial Highlights (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "c-27", "name": "us-gaap:NetAssetValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "-2", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ocsl-20240630.htm", "unique": true, "R66": { "role": "http://ocsl.com/role/DerivativeInstrumentsScheduleOfForeignCurrencyForwardContractsandInterestRateSwapDetails", "longName": "9954739 - Disclosure - Derivative Instruments - Schedule of Foreign Currency Forward Contracts and Interest Rate Swap (Details)", "shortName": "Derivative Instruments - Schedule of Foreign Currency Forward Contracts and Interest Rate Swap (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "c-9", "name": "us-gaap:DerivativeAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ocsl-20240630.htm", "first": true, "uniqueAnchor": null, "R67": { "role": "http://ocsl.com/role/DerivativeInstrumentsNarrativeDetails", "longName": "9954740 - Disclosure - Derivative Instruments - Narrative (Details)", "shortName": "Derivative Instruments - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "c-9", "name": "us-gaap:ReceivablesFromBrokersDealersAndClearingOrganizations", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ocsl-20240630.htm", "first": true, "uniqueAnchor": null, "R68": { "role": "http://ocsl.com/role/CommitmentsandContingenciesNarrativeDetails", "longName": "9954741 - Disclosure - Commitments and Contingencies - Narrative (Details)", "shortName": "Commitments and Contingencies - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "c-9", "name": "us-gaap:InvestmentCompanyFinancialCommitmentToInvesteeFutureAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "ix.continuation", "ix.continuation", "body", "html"], "reportCount": 1, "baseRef": "ocsl-20240630.htm", "first": true, "uniqueAnchor": { "contextRef": "c-2093", "name": "us-gaap:InvestmentCompanyFinancialCommitmentToInvesteeFutureAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "div", "ix.continuation", "body", "html"], "reportCount": 1, "baseRef": "ocsl-20240630.htm", "unique": true, "R69": { "role": "http://ocsl.com/role/CommitmentsandContingenciesScheduleOfUnfundedCommitmentsbyInvestmentDetails", "longName": "9954742 - Disclosure - Commitments and Contingencies - Schedule of Unfunded Commitments by Investment (Details)", "shortName": "Commitments and Contingencies - Schedule of Unfunded Commitments by Investment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "c-9", "name": "us-gaap:InvestmentCompanyFinancialCommitmentToInvesteeFutureAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "ix.continuation", "ix.continuation", "body", "html"], "reportCount": 1, "baseRef": "ocsl-20240630.htm", "first": true, "uniqueAnchor": { "contextRef": "c-2147", "name": "us-gaap:InvestmentCompanyFinancialCommitmentToInvesteeFutureAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ocsl-20240630.htm", "first": true, "uniqueAnchor": null, "R70": { "role": "http://ocsl.com/role/SubsequentEventsDetails", "longName": "9954743 - Disclosure - Subsequent Events (Details)", "shortName": "Subsequent Events (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "70", "firstAnchor": { "contextRef": "c-2237", "name": "us-gaap:CommonStockDividendsPerShareDeclared", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "-2", "ancestors": ["span", "div", "ix.continuation", "body", "html"], "reportCount": 1, "baseRef": "ocsl-20240630.htm", "first": true, "uniqueAnchor": { "contextRef": "c-2237", "name": "us-gaap:CommonStockDividendsPerShareDeclared", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "-2", "ancestors": ["span", "div", "ix.continuation", "body", "html"], "reportCount": 1, "baseRef": "ocsl-20240630.htm", "first": true, "uniqueAnchor": null, "R71": { "role": "http://ocsl.com/role/Schedule1214ScheduleofInvestmentsinandAdvancesToAffiliatesDetails", "longName": "9954744 - Disclosure - Schedule1214-Schedule of Investments in and Advances to Affiliates (Details)", "shortName": "Schedule1214-Schedule of Investments in and Advances to Affiliates (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "71", "firstAnchor": { "contextRef": "c-10", "name": "us-gaap:InvestmentOwnedAtFairValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ocsl-20240630.htm", "first": true, "uniqueAnchor": { "contextRef": "c-13", "name": "us-gaap:RealizedGainLossInvestmentDerivativeAndForeignCurrencyTransactionPriceChangeOperatingBeforeTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ocsl-20240630.htm", "first": true, "uniqueAnchor": null, "R72": { "role": "http://ocsl.com/role/BorrowingsComponentsofInterestandOtherDebtExpensesDetails", "longName": "A2025NotesMember", "presentation": "I", "localname": "A2025NotesMember", "xbrltype": "domainItemType", "nsuri": "http

"http://ocsl.com/role/RealizedGainsorLossesandNetUnrealizedAppreciationorDepreciationAggregateNetRealizedGainsDetails".l, "lang": { "en-us": { "role": { "terseLabel": "ASP Unifrax Holdings Inc.", "label": "ASP Unifrax Holdings Inc [Member]", "documentation": "ASP Unifrax Holdings Inc" } } }, "auth_ref": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": { "us-gaap_AccountsPayableAndOtherAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableAndOtherAccruedLiabilities", "crdr": "credit", "calculation": { "http://ocsl.com/role/ConsolidatedStatementsOfAssetsandLiabilities": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 9.0 } }, "presentation": { "http://ocsl.com/role/ConsolidatedStatementsOfAssetsandLiabilities": { "lang": { "en-us": { "role": { "terseLabel": "Accounts payable, accrued expenses and other liabilities", "label": "Accounts Payable and Other Accrued Liabilities", "documentation": "Amount of liabilities incurred and payable to vendors for goods and services received, and accrued liabilities classified as other." } } }, "auth_ref": { "r555": { "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments", "crdr": "credit", "calculation": { "http://ocsl.com/role/ConsolidatedStatementOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 12.0 } }, "presentation": { "http://ocsl.com/role/ConsolidatedStatementOfCashFlows": { "lang": { "en-us": { "role": { "negatedTerseLabel": "Accretion of original issue discount on investments", "label": "Accretion (Amortization) of Discounts and Premiums, Investments", "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": { "r95": { "cef_AcquiredFundFeesAndExpensesNoteTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "AcquiredFundFeesAndExpensesNoteTextBlock", "presentation": { "http://xbrl.sec.gov/cef/role/N2": { "lang": { "en-us": { "role": { "label": "Acquired Fund Fees and Expenses, Note [Text Block]" } } }, "auth_ref": { "r862": { "cef_AcquiredFundFeesAndExpensesPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "AcquiredFundFeesAndExpensesPercent", "presentation": { "http://xbrl.sec.gov/cef/role/N2": { "lang": { "en-us": { "role": { "label": "Acquired Fund Fees and Expenses [Percent]" } } }, "auth_ref": { "r863": { "cef_AcquiredFundFeesEstimatedNoteTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "AcquiredFundFeesEstimatedNoteTextBlock", "presentation": { "http://xbrl.sec.gov/cef/role/N2": { "lang": { "en-us": { "role": { "label": "Acquired Fund Fees Estimated, Note [Text Block]" } } }, "auth_ref": { "r864": { "cef_AcquiredFundIncentiveAllocationNoteTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "AcquiredFundIncentiveAllocationNoteTextBlock", "presentation": { "http://xbrl.sec.gov/cef/role/N2": { "lang": { "en-us": { "role": { "label": "Acquired Fund Incentive Allocation, Note [Text Block]" } } }, "auth_ref": { "r865": { "cef_AcquiredFundTotalAnnualExpensesNoteTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "AcquiredFundTotalAnnualExpensesNoteTextBlock", "presentation": { "http://xbrl.sec.gov/cef/role/N2": { "lang": { "en-us": { "role": { "label": "Acquired Fund Total Annual Expenses, Note [Text Block]" } } }, "auth_ref": { "r866": { "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Additional402vDisclosureTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Additional 402(v) Disclosure", "label": "Additional 402(v) Disclosure [Text Block]" } } }, "auth_ref": { "r918": { "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://ocsl.com/role/ConsolidatedStatementsOfAssetsandLiabilities": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://ocsl.com/role/ConsolidatedStatementsOfAssetsandLiabilities": { "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital", "label": "Additional Paid in Capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": { "r80", "r785", "r1050": { "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": { "http://ocsl.com/role/ShareDataandNetAssetsScheduleofChangesinNetAssetsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital", "label": "Additional Paid in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": { "r346", "r347", "r348", "r521", "r988", "r989", "r990", "r1016", "r1064": { "dei_AdditionalSecurities462b": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AdditionalSecurities462b", "presentation": { "http://xbrl.sec.gov/cef/role/N2": { "lang": { "en-us": { "role": { "label": "Additional Securities, 462(b), File Number" } } }, "auth_ref": { "r960": { "dei_AdditionalSecurities462bFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AdditionalSecurities462bFileNumber", "presentation": { "http://xbrl.sec.gov/cef/role/N2": { "lang": { "en-us": { "role": { "label": "Additional Securities, 462(b), File Number" } } }, "auth_ref": { "r960": { "dei_AdditionalSecuritiesEffective413b": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AdditionalSecuritiesEffective413b", "presentation": { "http://xbrl.sec.gov/cef/role/N2": { "lang": { "en-us": { "role": { "label": "Additional Securities Effective, 413(b)" } } }, "auth_ref": { "r959": { "dei_AddressTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AddressTypeDomain", "presentation": { "http://xbrl.sec.gov/cef/role/N2": { "lang": { "en-us": { "role": { "label": "Address Type [Domain]", "documentation": "An entity may have several addresses for different purposes and this domain represents all such types." } } }, "auth_ref": { "ocsl_AdenAnaisMergerSubIncMember": { "xbrltype": "domainItemType", "nsuri": "http://ocsl.com/20240630", "localname": "AdenAnaisMergerSubIncMember", "presentation": { "http://ocsl.com/role/RealizedGainsorLossesandNetUnrealizedAppreciationorDepreciationAggregateNetRealizedGainsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Aden & Anais Merger Sub Inc.", "label": "Aden & Anais Merger Sub Inc [Member]", "documentation": "Aden & Anais Merger Sub Inc" } } }, "auth_ref": { "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation Amount", "label": "Adjustment to Compensation Amount" } } }, "auth_ref": { "r924": { "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAxis", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation [Axis]", "label": "Adjustment to Compensation [Axis]" } } }, "auth_ref": { "r924": { "ecd_AdjToNonPeeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToNonPeeoNeoCompFnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote", "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]" } } }, "auth_ref": { "r924": { "ecd_AdjToPeeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToPeeoCompFnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Adjustment To PEO Compensation, Footnote [Text Block]" } } }, "auth_ref": { "r924": { "ocsl_AdjustmentsToReconcileNetAssetsFromOperationsToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://ocsl.com/20240630", "localname": "AdjustmentsToReconcileNetAssetsFromOperationsToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": { "http://ocsl.com/role/ConsolidatedStatementOfCashFlows": { "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net increase (decrease) in net assets resulting from operations to net cash provided by (used in) operating activities", "label": "Adjustments To Reconcile Net Assets From Operations To Cash Provided by (Used in) Operating Activities [Abstract]", "documentation": "Adjustments To Reconcile Net Assets From Operations To Cash Provided by (Used in) Operating Activities" } } }, "auth_ref": { "us-gaap_AdministrativeFeesExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdministrativeFeesExpense", "crdr": "debit", "presentation": { "http://ocsl.com/role/RelatedPartyTransactionsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Administrator expense", "label": "Administrative Fees Expense", "documentation": "Amount of expense for administrative fee from service provided, including, but not limited to, salary, rent, or overhead cost." } } }, "auth_ref": { "r69", "r585", "r1058": { "ocsl_AdministrativeFeesExpenseAdministratorFees": { "xbrltype": "monetaryItemType", "nsuri": "http://ocsl.com/20240630", "localname": "AdministrativeFeesExpenseAdministratorFees", "crdr": "debit", "calculation": { "http://ocsl.com/role/ConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_InvestmentIncomeInvestmentExpense", "weight": 1.0, "order": 6.0 } }, "presentation": { "http://ocsl.com/role/ConsolidatedStatementsOfOperations": { "lang": { "en-us": { "role": { "terseLabel": "Administrator expense", "label": "Administrative Fees Expense, Administrator Fees", "documentation": "Administrative Fees Expense, Administrator Fees" } } }, "auth_ref": { "ocsl_AdvertisingIndustryMember": { "xbrltype": "domainItemType", "nsuri": "http://ocsl.com/20240630", "localname": "AdvertisingIndustryMember", "presentation": { "http://ocsl.com/role/PortfolioInvestmentsPortfolioofInvestmentsbyIndustryDetails": { "lang": { "en-us": { "role": { "terseLabel": "Advertising", "label": "Advertising Industry [Member]", "documentation": "Advertising Industry" } } }, "auth_ref": { "ocsl_AerospaceDefenseMember": { "xbrltype": "domainItemType", "nsuri": "http://ocsl.com/20240630", "localname": "AerospaceDefenseMember", "presentation": { "http://ocsl.com/role/PortfolioInvestmentsPortfolioofInvestmentsbyIndustryDetails": { "lang": { "en-us": { "role": { "terseLabel": "Aerospace & Defense", "label": "Aerospace & Defense [Member]", "documentation": "Aerospace & Defense" } } }, "auth_ref": { "srt_AffiliatedEntityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "AffiliatedEntityMember", "presentation": { "http://ocsl.com/role/RelatedPartyTransactionsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Affiliated Entity", "label": "Affiliated Entity [Member]" } } }, "auth_ref": { "r585", "r759", "r791", "r1011", "r1019", "r1020", "r1021": { "ocsl_AfterReinvestmentPeriodMember": { "xbrltype": "domainItemType", "nsuri": "http://ocsl.com/20240630", "localname": "AfterReinvestmentPeriodMember", "presentation": { "http://ocsl.com/role/BorrowingsNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "After Reinvestment Period", "label": "After Reinvestment Period [Member]", "documentation": "After Reinvestment Period" } } }, "auth_ref": { "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Amount", "label": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": { "r815", "r827", "r908", "r935": { "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined", "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]" } } }, "auth_ref": { "r818", "r830", "r911", "r938": { "ocsl_AirFreightLogisticsMember": { "xbrltype": "domainItemType", "nsuri": "http://ocsl.com/20240630", "localname": "AirFreightLogisticsMember", "presentation": { "http://ocsl.com/role/PortfolioInvestmentsPortfolioofInvestmentsbyIndustryDetails": { "lang": { "en-us": { "role": { "terseLabel": "Air Freight & Logistics", "label": "Air Freight & Logistics [Member]", "documentation": "Air Freight & Logistics" } } }, "auth_ref": { "ocsl_AirportServicesMember": { "xbrltype": "domainItemType", "nsuri": "http://ocsl.com/20240630", "localname": "AirportServicesMember", "presentation": { "http://ocsl.com/role/PortfolioInvestmentsPortfolioofInvestmentsbyIndustryDetails": { "lang": { "en-us": { "role": { "terseLabel": "Airport Services", "label": "Airport Services [Member]", "documentation": "Airport Services" } } }, "auth_ref": { "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllAdjToCompMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "All Adjustments to Compensation", "label": "All Adjustments to Compensation [Member]" } } }, "auth_ref": { "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllExecutiveCategoriesMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "All Executive Categories", "label": "All Executive Categories [Member]" } } }, "auth_ref": { "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllIndividualsMember", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardFundingDisclosure": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "All Individuals", "label": "All Individuals [Member]" } } }, "auth_ref": { "r822", "r831", "r912", "r931", "r939", "r943", "r951": { "cef_AllRisksMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "AllRisksMember", "presentation": { "http://xbrl.sec.gov/cef/role/N2": { "lang": { "en-us": { "role": { "label": "All Risks" } } }, "auth_ref": { "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllTradingArrangementsMember", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements": { "lang": { "en-us": { "role": { "terseLabel": "All Trading Arrangements", "label": "All Trading Arrangements [Member]" } } }, "auth_ref": { "r949": { "ocsl_AllWebLeadsIncMember": { "xbrltype": "domainItemType", "nsuri": "http://ocsl.com/20240630", "localname": "AllWebLeadsIncMember", "presentation": { "http://ocsl.com/role/RealizedGainsorLossesandNetUnrealizedAppreciationorDepreciationAggregateNetRealizedGainsDetails": { "lang": { "en-us": { "role": { "terseLabel": "All Web Leads Inc", "label": "All Web Leads Inc [Member]", "documentation": "All Web Leads Inc" } } }, "auth_ref": { "ocsl_AlternativeCarriersMember": { "xbrltype": "domainItemType", "nsuri": "http://ocsl.com/20240630", "localname": "AlternativeCarriersMember", "presentation": { "http://ocsl.com/role/PortfolioInvestmentsPortfolioofInvestmentsbyIndustryDetails": { "lang": { "en-us": { "role": { "terseLabel": "Alternative Carriers", "label": "Alternative Carriers [Member]", "documentation": "Alternative Carriers" } } }, "auth_ref": { "ocsl_AlvotechMember": { "xbrltype": "domainItemType", "nsuri": "http://ocsl.com/20240630", "localname": "AlvotechMember", "presentation": {

"http://ocsl.com/role/RealizedGainsorLossesandNetUnrealizedAppreciationorDepreciationAggregateNetRealizedGainsDetails" | "lang": { "en-us": { "role": { "terseLabel": "Alvotech", "label": "Alvotech [Member]", "documentation": "Alvotech" } } }, "auth_ref": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": { "http://xbrl.sec.gov/cei/role/N2" | "lang": { "en-us": { "role": { "label": "AmendmentDescription", "documentation": "Description of changes contained within amended document" } } }, "auth_ref": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": { "http://ocsl.com/role/Cover": { "http://xbrl.sec.gov/cei/role/N2" | "lang": { "en-us": { "role": { "label": "AmendmentFlag", "terseLabel": "AmendmentFlag", "documentation": "Boolean flag that is true when the XBRL content amends previously filed or accepted submission" } } }, "auth_ref": { "ocsl_AmericanTireDistributorsInc.Member": { "xbrltype": "domainItemType", "nsuri": "http://ocsl.com/20240630", "localname": "AmericanTireDistributorsInc.Member", "presentation": { "http://ocsl.com/role/RealizedGainsorLossesandNetUnrealizedAppreciationorDepreciationAggregateNetRealizedGainsDetails" | "lang": { "en-us": { "role": { "terseLabel": "American Tire Distributors Inc.", "label": "American Tire Distributors Inc. [Member]", "documentation": "American Tire Distributors Inc." } } }, "auth_ref": { "us-gaap_AmortizationOfDebtDiscountPremium": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfDebtDiscountPremium", "crdr": "debit", "calculation": { "http://ocsl.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 14.0 } }, "presentation": { "http://ocsl.com/role/ConsolidatedStatementofCashFlows" | "lang": { "en-us": { "role": { "terseLabel": "Accretion of original issue discount on unsecured notes payable", "label": "Amortization of Debt Discount (Premium)", "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense." } } }, "auth_ref": { "r6": "r65", "r90": "r288" | "us-gaap_AmortizationOffinancingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOffinancingCosts", "crdr": "debit", "calculation": { "http://ocsl.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 17.0 | "presentation": { "http://ocsl.com/role/ConsolidatedStatementofCashFlows" | "lang": { "en-us": { "role": { "terseLabel": "Amortization of deferred financing costs", "label": "Amortization of Debt Issuance Costs", "documentation": "Amount of amortization expense attributable to debt issuance costs." } } }, "auth_ref": { "r6": "r288", "r410", "r981" | "us-gaap_AmortizationOffinancingCostsAndDiscounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOffinancingCostsAndDiscounts", "crdr": "debit", "calculation": { "http://ocsl.com/role/BorrowingsComponentsOfInterestandOtherDebtExpensesDetails": { "parentTag": "us-gaap_InterestExpenseDebt", "weight": 1.0, "order": 2.0 | "presentation": { "http://ocsl.com/role/BorrowingsComponentsOfInterestandOtherDebtExpensesDetails" | "lang": { "en-us": { "role": { "terseLabel": "Amortization of financing costs and discount", "label": "Amortization of Debt Issuance Costs and Discounts", "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs." } } }, "auth_ref": { "r288": "r410", "r777", "r778", "r981" | "cef_AnnualCoverageReturnRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "AnnualCoverageReturnRatePercent", "presentation": { "http://xbrl.sec.gov/cef/role/N2" | "lang": { "en-us": { "role": { "label": "Annual Coverage Return Rate [Percent]", "auth_ref": { "r992": { "cef_AnnualDividendPayment": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "AnnualDividendPayment", "presentation": { "http://xbrl.sec.gov/cef/role/N2" | "lang": { "en-us": { "role": { "label": "Annual Dividend Payment", "auth_ref": { "r891": { "cef_AnnualDividendPaymentCurrent": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "AnnualDividendPaymentCurrent", "presentation": { "http://xbrl.sec.gov/cef/role/N2" | "lang": { "en-us": { "role": { "label": "Annual Dividend Payment, Current", "auth_ref": { "r891": { "cef_AnnualDividendPaymentInitial": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "AnnualDividendPaymentInitial", "presentation": { "http://xbrl.sec.gov/cef/role/N2" | "lang": { "en-us": { "role": { "label": "Annual Dividend Payment, Initial", "auth_ref": { "r891": { "cef_AnnualExpensesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "AnnualExpensesTableTextBlock", "presentation": { "http://xbrl.sec.gov/cef/role/N2" | "lang": { "en-us": { "role": { "label": "Annual Expenses [Table Text Block]", "auth_ref": { "r870": { "cef_AnnualInterestRateCurrentPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "AnnualInterestRateCurrentPercent", "presentation": { "http://xbrl.sec.gov/cef/role/N2" | "lang": { "en-us": { "role": { "label": "Annual Interest Rate, Current [Percent]", "auth_ref": { "r891": { "cef_AnnualInterestRateInitialPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "AnnualInterestRateInitialPercent", "presentation": { "http://xbrl.sec.gov/cef/role/N2" | "lang": { "en-us": { "role": { "label": "Annual Interest Rate, Initial [Percent]", "auth_ref": { "r891": { "cef_AnnualInterestRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "AnnualInterestRatePercent", "presentation": { "http://xbrl.sec.gov/cef/role/N2" | "lang": { "en-us": { "role": { "label": "Annual Interest Rate [Percent]", "auth_ref": { "r891": { "ocsl_ApparelRetailMember": { "xbrltype": "domainItemType", "nsuri": "http://ocsl.com/20240630", "localname": "ApparelRetailMember", "presentation": { "http://ocsl.com/role/PortfolioInvestmentsPortfolioofInvestmentsbyIndustryDetails" | "lang": { "en-us": { "role": { "terseLabel": "Apparel Retail", "label": "Apparel Retail [Member]", "documentation": "Apparel Retail" } } }, "auth_ref": { "ocsl_ApplicationSoftwareMember": { "xbrltype": "domainItemType", "nsuri": "http://ocsl.com/20240630", "localname": "ApplicationSoftwareMember", "presentation": { "http://ocsl.com/role/PortfolioInvestmentsPortfolioofInvestmentsbyIndustryDetails" | "lang": { "en-us": { "role": { "terseLabel": "Application Software", "label": "Application Software [Member]", "documentation": "Application Software" } } }, "auth_ref": { "dei_ApproximateDateOfCommencementOfProposedSaleToThePublic": { "xbrltype": "dateOrAsapItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "ApproximateDateOfCommencementOfProposedSaleToThePublic", "presentation": { "http://xbrl.sec.gov/cei/role/N2" | "lang": { "en-us": { "role": { "label": "Approximate Date of Commencement of Proposed Sale to Public", "documentation": "The approximate date of a commencement of a proposed sale of securities to the public. This element is disclosed in S-1, S-3, S-4, S-11, F-1, F-3 and F-10 filings." } } }, "auth_ref": { "ocsl_ArdonaghMidco3PLCMember": { "xbrltype": "domainItemType", "nsuri": "http://ocsl.com/20240630", "localname": "ArdonaghMidco3PLCMember", "presentation": { "http://ocsl.com/role/RealizedGainsorLossesandNetUnrealizedAppreciationorDepreciationAggregateNetRealizedGainsDetails" | "lang": { "en-us": { "role": { "terseLabel": "Ardonagh Midco 3 PLC", "label": "Ardonagh Midco 3 PLC [Member]", "documentation": "Ardonagh Midco 3 PLC" } } }, "auth_ref": { "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://ocsl.com/role/ConsolidatedStatementofAssetsandLiabilities": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://ocsl.com/role/ConsolidatedStatementofAssetsandLiabilities" | "http://ocsl.com/role/PortfolioInvestmentsNarrativeDetails": { "http://ocsl.com/role/PortfolioInvestmentsSummarizedBalanceSheetInformationDetails" | "lang": { "en-us": { "role": { "totalLabel": "Total assets", "terseLabel": "Assets", "label": "Assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": { "r11": "r130", "r163", "r194", "r198", "r200", "r230", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r372", "r374", "r399", "r469", "r578", "r785", "r804", "r1005", "r1006", "r1022" | "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsAbstract", "presentation": { "http://ocsl.com/role/ConsolidatedStatementofAssetsandLiabilities" | "lang": { "en-us": { "role": { "terseLabel": "ASSETS", "label": "Assets [Abstract]", "auth_ref": { "us-gaap_AssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsFairValueDisclosure", "crdr": "debit", "calculation": { "http://ocsl.com/role/PortfolioInvestmentsScheduleofFinancialInstrumentsCarriedatFairValueDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://ocsl.com/role/PortfolioInvestmentsScheduleofFinancialInstrumentsCarriedatFairValueDetails" | "lang": { "en-us": { "role": { "totalLabel": "Total assets at fair value", "label": "Assets, Fair Value Disclosure", "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": { "r60": { "us-gaap_AssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsNet", "crdr": "debit", "presentation": { "http://ocsl.com/role/FinancialHighlightsDetails" | "lang": { "en-us": { "role": { "periodStartLabel": "Net assets at beginning of period", "periodEndLabel": "Net assets at end of period", "label": "Net Assets", "documentation": "Amount of net assets (liabilities)." } } }, "auth_ref": { "r10": { "ocsl_AtTheMarketMember": { "xbrltype": "domainItemType", "nsuri": "http://ocsl.com/20240630", "localname": "AtTheMarketMember", "presentation": { "http://ocsl.com/role/ShareDataandNetAssetsScheduleofCommonStockIssuedandSoldDetails" | "lang": { "en-us": { "role": { "terseLabel": "At the Market", "label": "At The Market [Member]", "documentation": "At The Market" } } }, "auth_ref": { "ocsl_AutoPartsEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://ocsl.com/20240630", "localname": "AutoPartsEquipmentMember", "presentation": { "http://ocsl.com/role/PortfolioInvestmentsPortfolioofInvestmentsbyIndustryDetails" | "lang": { "en-us": { "role": { "terseLabel": "Auto Parts & Equipment", "label": "Auto Parts & Equipment [Member]", "documentation": "Auto Parts & Equipment" } } }, "auth_ref": { "ocsl_AutomotiveRetailMember": { "xbrltype": "domainItemType", "nsuri": "http://ocsl.com/20240630", "localname": "AutomotiveRetailMember", "presentation": { "http://ocsl.com/role/PortfolioInvestmentsPortfolioofInvestmentsbyIndustryDetails" | "lang": { "en-us": { "role": { "terseLabel": "Automotive Retail", "label": "Automotive Retail [Member]", "documentation": "Automotive Retail" } } }, "auth_ref": { "ocsl_AverageNetAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://ocsl.com/20240630", "localname": "AverageNetAssets", "crdr": "debit", "presentation": { "http://ocsl.com/role/FinancialHighlightsDetails" | "lang": { "en-us": { "role": { "terseLabel": "Average net assets", "label": "Average Net Assets", "documentation": "Average Net Assets" } } }, "auth_ref": { "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardExrcPrice", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" | "lang": { "en-us": { "role": { "terseLabel": "Exercise Price", "label": "Award Exercise Price" } } }, "auth_ref": { "r946": { "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardGrantDateFairValue", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" | "lang": { "en-us": { "role": { "terseLabel": "Fair Value as of Grant Date", "label": "Award Grant Date Fair Value" } } }, "auth_ref": { "r947": { "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]", "auth_ref": { "r942": { "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" | "lang": { "en-us": { "role": { "terseLabel": "Award Timing, How MNPI Considered", "label": "Award Timing, How MNPI Considered [Text Block]", "auth_ref": { "r942": { "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMethodTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" | "lang": { "en-us": { "role": { "terseLabel": "Award Timing Method [Text Block]", "auth_ref": { "r942": { "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" | "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Considered", "label": "Award Timing MNPI Considered [Flag]", "auth_ref": { "r942": { "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" | "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Disclosure", "label": "Award Timing MNPI Disclosure [Text Block]", "auth_ref": { "r942": { "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgPredtrmndFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" | "lang": { "en-us": { "role": { "terseLabel": "Award Timing Predetermined", "label": "Award Timing Predetermined [Flag]", "auth_ref": { "r942": { "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardTypeAxis", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" | "lang": { "en-us": { "role": { "terseLabel": "Award Type", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": { "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345" | "ecd_AwardUnderlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardUnderlygSecuritiesAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" | "lang": { "en-us": { "role": { "terseLabel": "Underlying Securities", "label": "Award Underlying Securities Amount", "auth_ref": { "r945": { "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" | "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name", "auth_ref": { "r944": { "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTable", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" | "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures", "label": "Awards Close in Time to MNPI Disclosures [Table]", "auth_ref": { "r943": { "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" | "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures, Table", "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]", "auth_ref": { "r943": { "us-gaap_BaseRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BaseRateMember", "presentation": {

"http://ocsl.com/role/BorrowingsNarrativeDetails" }, {"lang": "en-us", "role": "terseLabel", "Base Rate", "label": "Base Rate [Member]", "documentation": "Minimum rate investor will accept." } } } }, {"auth_ref": "I", "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": "http://ocsl.com/role/SignificantAccountingPoliciesPolicies" }, {"lang": "en-us", "role": "terseLabel", "Basis of Presentation", "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } } }, {"auth_ref": "I", "cef_BasisOfTransactionFeesNoteTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "BasisOfTransactionFeesNoteTextBlock", "presentation": "http://xbrl.sec.gov/cef/role/N2" }, {"lang": "en-us", "role": "label", "Basis of Transaction Fees, Note [Text Block]" } } } }, {"auth_ref": "r868", "cef_BdcFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "BdcFileNumber", "presentation": "http://xbrl.sec.gov/cef/role/N2" }, {"lang": "en-us", "role": "label", "BDC File Number" } } } }, {"auth_ref": "I", "ocsl_BiotechnologyMember": { "xbrltype": "domainItemType", "nsuri": "http://ocsl.com/20240630", "localname": "BiotechnologyMember", "presentation": "http://ocsl.com/role/PortfolioInvestmentsPortfolioofInvestmentsbyIndustryDetails" }, {"lang": "en-us", "role": "terseLabel", "Biotechnology", "label": "Biotechnology [Member]", "documentation": "Biotechnology" } } } }, {"auth_ref": "I", "ocsl_BroadlineRetailMember": { "xbrltype": "domainItemType", "nsuri": "http://ocsl.com/20240630", "localname": "BroadlineRetailMember", "presentation": "http://ocsl.com/role/PortfolioInvestmentsPortfolioofInvestmentsbyIndustryDetails" }, {"lang": "en-us", "role": "terseLabel", "Broadline Retail", "label": "Broadline Retail [Member]", "documentation": "Broadline Retail" } } } }, {"auth_ref": "I", "dei_BusinessContactMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "BusinessContactMember", "presentation": "http://xbrl.sec.gov/cef/role/N2" }, {"lang": "en-us", "role": "label", "Business Contact [Member]", "documentation": "Business contact for the entity" } } } }, {"auth_ref": "r810", "r823", "cef_BusinessDevelopmentCompanyFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "BusinessDevelopmentCompanyFlag", "presentation": "http://xbrl.sec.gov/cef/role/N2" }, {"lang": "en-us", "role": "label", "Business Development Company [Flag]" } } } }, {"auth_ref": "r835", "ocsl_CableSatelliteMember": { "xbrltype": "domainItemType", "nsuri": "http://ocsl.com/20240630", "localname": "CableSatelliteMember", "presentation": "http://ocsl.com/role/PortfolioInvestmentsPortfolioofInvestmentsbyIndustryDetails" }, {"lang": "en-us", "role": "terseLabel", "Cable & Satellite", "label": "Cable & Satellite [Member]", "documentation": "Cable & Satellite" } } } }, {"auth_ref": "I", "ocsl_CapitalLossCarryforwardAxis": { "xbrltype": "stringItemType", "nsuri": "http://ocsl.com/20240630", "localname": "CapitalLossCarryforwardAxis", "presentation": "http://ocsl.com/role/TaxableDistributableIncomeandDividendDistributionsNarrativeDetails" }, {"lang": "en-us", "role": "terseLabel", "Capital Loss Carryforward [Axis]", "label": "Capital Loss Carryforward [Axis]", "documentation": "Capital Loss Carryforward" } } } }, {"auth_ref": "I", "ocsl_CapitalLossCarryforwardDomain": { "xbrltype": "domainItemType", "nsuri": "http://ocsl.com/20240630", "localname": "CapitalLossCarryforwardDomain", "presentation": "http://ocsl.com/role/TaxableDistributableIncomeandDividendDistributionsNarrativeDetails" }, {"lang": "en-us", "role": "terseLabel", "Capital Loss Carryforward [Domain]", "label": "Capital Loss Carryforward [Domain]", "documentation": "Capital Loss Carryforward [Domain]" } } } }, {"auth_ref": "I", "cef_CapitalStockLongTermDebtAndOtherSecuritiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "CapitalStockLongTermDebtAndOtherSecuritiesAbstract", "presentation": "http://xbrl.sec.gov/cef/role/N2" }, {"lang": "en-us", "role": "label", "Capital Stock, Long-Term Debt, and Other Securities [Abstract]" } } } }, {"auth_ref": "r836", "cef_CapitalStockTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "CapitalStockTableTextBlock", "presentation": "http://xbrl.sec.gov/cef/role/N2" }, {"lang": "en-us", "role": "label", "Capital Stock [Table Text Block]" } } } }, {"auth_ref": "r837", "ocsl_CaravanaCo.Member": { "xbrltype": "domainItemType", "nsuri": "http://ocsl.com/20240630", "localname": "CaravanaCo.Member", "presentation": "http://ocsl.com/role/RealizedGainsLossesandNetUnrealizedAppreciationDepreciationAggregateNetRealizedGainsDetails" }, {"lang": "en-us", "role": "terseLabel", "Carvana Co.", "label": "Carvana Co. [Member]", "documentation": "Carvana Co." } } } }, {"auth_ref": "I", "ocsl_CashAcquiredFromAcquisitionOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://ocsl.com/20240630", "localname": "CashAcquiredFromAcquisitionOperatingActivities", "crdr": "debit", "calculation": "http://ocsl.com/role/ConsolidatedStatementofCashFlows", "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 22.0, "presentation": "http://ocsl.com/role/ConsolidatedStatementofCashFlows" }, {"lang": "en-us", "role": "terseLabel", "Cash received in the OS12 Merger", "label": "Cash Acquired From Acquisition, Operating Activities", "documentation": "Cash Acquired From Acquisition, Operating Activities" } } } }, {"auth_ref": "I", "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": "http://ocsl.com/role/ConsolidatedStatementofCashFlows", "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "weight": 1.0, "order": 1.0, "presentation": "http://ocsl.com/role/ConsolidatedStatementofAssetsandLiabilities", "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 11.0, "presentation": "http://ocsl.com/role/ConsolidatedStatementofCashFlows", "parentTag": "http://ocsl.com/role/ConsolidatedStatementofAssetsandLiabilities", "parentTag": "http://ocsl.com/role/PortfolioInvestmentsSummarizedBalanceSheetInformationDetails" }, {"lang": "en-us", "role": "terseLabel", "Cash and cash equivalents", "verboseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } } }, {"auth_ref": "r30", "r136", "r764", "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsFairValueDisclosure", "crdr": "debit", "calculation": "http://ocsl.com/role/PortfolioInvestmentsScheduleofFinancialInstrumentsCarriedatFairValueDetails", "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 2.0, "presentation": "http://ocsl.com/role/PortfolioInvestmentsScheduleofFinancialInstrumentsCarriedatFairValueDetails" }, {"lang": "en-us", "role": "terseLabel", "Cash equivalents", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } } }, {"auth_ref": "I", "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "presentation": "http://ocsl.com/role/SignificantAccountingPoliciesPolicies" }, {"lang": "en-us", "role": "terseLabel", "Cash and Cash Equivalents, Restricted Cash", "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]", "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits." } } } }, {"auth_ref": "r31", "r109", "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": "http://ocsl.com/role/ConsolidatedStatementofCashFlows", "parentTag": "http://ocsl.com/role/PortfolioInvestmentsNarrativeDetails" }, {"lang": "en-us", "role": "periodStartLabel", "Cash and cash equivalents and restricted cash, beginning of period", "periodEndLabel": "Cash and cash equivalents and restricted cash, end of period", "terseLabel": "Cash, cash equivalents and restricted cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } } }, {"auth_ref": "r30", "r93", "r158", "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "calculation": "http://ocsl.com/role/ConsolidatedStatementofCashFlows", "parentTag": null, "weight": null, "order": null, "root": true, "presentation": "http://ocsl.com/role/ConsolidatedStatementofCashFlows" }, {"lang": "en-us", "role": "totalLabel", "Total cash and cash equivalents and restricted cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } } }, {"auth_ref": "r30", "r93", "r158", "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": "http://ocsl.com/role/ConsolidatedStatementofCashFlows", "parentTag": null, "weight": null, "order": null, "root": true, "presentation": "http://ocsl.com/role/ConsolidatedStatementofCashFlows" }, {"lang": "en-us", "role": "totalLabel", "Net increase (decrease) in cash and cash equivalents and restricted cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } } }, {"auth_ref": "r3", "r93", "ced_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ced/2023", "localname": "ChangedPeerGroupFnTextBlock", "presentation": "http://xbrl.sec.gov/ced/role/PvpDisclosure" }, {"lang": "en-us", "role": "terseLabel", "Changed Peer Group, Footnote", "label": "Changed Peer Group, Footnote [Text Block]" } } } }, {"auth_ref": "r922", "ocsl_CitibankFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://ocsl.com/20240630", "localname": "CitibankFacilityMember", "presentation": "http://ocsl.com/role/BorrowingsNarrativeDetails", "parentTag": "http://xbrl.sec.gov/cef/role/N2" }, {"lang": "en-us", "role": "terseLabel", "Citibank Facility", "label": "Citibank Facility [Member]", "documentation": "Citibank Facility" } } } }, {"auth_ref": "I", "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": "http://ocsl.com/role/Cover", "parentTag": "http://xbrl.sec.gov/cef/role/N2" }, {"lang": "en-us", "role": "label", "City Area Code", "terseLabel": "City Area Code", "documentation": "Area code of city" } } } }, {"auth_ref": "I", "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": "http://ocsl.com/role/ShareDataandNetAssetsNarrativeDetails", "parentTag": "http://xbrl.sec.gov/cef/role/N2" }, {"lang": "en-us", "role": "terseLabel", "Class of Stock [Domain]", "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } } }, {"auth_ref": "r132", "r139", "r140", "r141", "r163", "r182", "r183", "r185", "r187", "r192", "r193", "r238", "r257", "r259", "r260", "r261", "r264", "r265", "r296", "r297", "r299", "r302", "r309", "r399", "r502", "r503", "r504", "r505", "r521", "r524", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r536", "r564", "r589", "r620", "r740", "r741", "r742", "r743", "r744", "r968", "r983", "r991", "ced_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ced/2023", "localname": "CoSelectedMeasureAmt", "presentation": "http://xbrl.sec.gov/ced/role/PvpDisclosure" }, {"lang": "en-us", "role": "terseLabel", "Company Selected Measure Amount", "label": "Company Selected Measure Amount" } } } }, {"auth_ref": "r923", "ced_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ced/2023", "localname": "CoSelectedMeasureName", "presentation": "http://xbrl.sec.gov/ced/role/PvpDisclosure" }, {"lang": "en-us", "role": "terseLabel", "Company Selected Measure Name", "label": "Company Selected Measure Name" } } } }, {"auth_ref": "r923", "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": "http://ocsl.com/role/ConsolidatedStatementofAssetsandLiabilities", "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0, "presentation": "http://ocsl.com/role/ConsolidatedStatementofAssetsandLiabilities" }, {"lang": "en-us", "role": "terseLabel", "Commitments and contingencies (Note 13)", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less

```

frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } } , "auth_ref": f"r23", "r73": f"r471", "r563" } } } , "us-gaap": { "CommitmentsAndContingenciesDisclosureAbstract": f"stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": f"CommitmentsAndContingenciesDisclosureAbstract", "lang": f"en-us", "role": f"label", "Commitments and Contingencies Disclosure [Abstract]" } } } , "auth_ref": f"1", "us-gaap": { "CommitmentsAndContingenciesDisclosureTextBlock": f"stringType", "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": f"http://ocsl.com/role/CommitmentsandContingencies", "lang": f"en-us", "role": f"terseLabel", "Commitments and Contingencies", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } } , "auth_ref": f"r99", "r251", "r252", "r749": f"1004" } } } , "us-gaap": { "CommonStockDividendsPerShareDeclared": f"stringType", "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockDividendsPerShareDeclared", "presentation": f"http://ocsl.com/role/SubsequentEventsDetails", "lang": f"en-us", "role": f"terseLabel", "Common stock, dividends, per share, declared (in dollars per share)", "label": "Common Stock, Dividends, Per Share, Declared", "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding." } } } , "auth_ref": f"r104" } } } , "us-gaap": { "CommonStockMember": f"stringType", "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": f"http://ocsl.com/role/ShareDataandNetAssetsNarrativeDetails", "http://ocsl.com/role/ShareDataandNetAssetsScheduleofChangesinNetAssetsDetails", "http://xbrl.sec.gov/cef/role/N2", "lang": f"en-us", "role": f"terseLabel", "Common Stock", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } } , "auth_ref": f"r787", "r788", "r789", "r792", "r793", "r794", "r797", "r988", "r989", "r1016", "r1040", "r1064" } } } , "us-gaap": { "CommonStockParOrStatedValuePerShare": f"stringType", "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": f"http://ocsl.com/role/ConsolidatedStatementsOfAssetsandLiabilitiesParentetical", "lang": f"en-us", "role": f"terseLabel", "Common stock, par value (in dollars per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } } , "auth_ref": f"r79" } } } , "us-gaap": { "CommonStockSharesAuthorized": f"stringType", "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": f"http://ocsl.com/role/ConsolidatedStatementsOfAssetsandLiabilitiesParentetical", "lang": f"en-us", "role": f"terseLabel", "Common stock, shares authorized (in shares)", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } } , "auth_ref": f"r79", "r564" } } } , "us-gaap": { "CommonStockSharesIssued": f"stringType", "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": f"http://ocsl.com/role/ShareDataandNetAssetsScheduleofChangesinNetAssetsDetails", "lang": f"en-us", "role": f"terseLabel", "Common stock, shares issued (in shares)", "periodStartLabel": "Beginning of period (in shares)", "periodEndLabel": "End of period (in shares)", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } } , "auth_ref": f"r79" } } } , "us-gaap": { "CommonStockSharesOutstanding": f"stringType", "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": f"http://ocsl.com/role/ConsolidatedStatementsOfAssetsandLiabilitiesParentetical", "http://ocsl.com/role/ConsolidatedStatementsOfChangesinNetAssets", "http://ocsl.com/role/FinancialHighlightsDetails", "lang": f"en-us", "role": f"role", f"netLabel", "Common stock, shares outstanding (in shares)", "terseLabel": "Common shares outstanding at end of period (in shares)", "periodStartLabel": "Common shares outstanding at beginning of period (in shares)", "periodEndLabel": "Common shares outstanding at end of period (in shares)", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } } , "auth_ref": f"r11", "r79", "r564", "r584", "r1064", "r1065" } } } , "us-gaap": { "CommonStockValue": f"stringType", "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "credit": "calculation", "http://ocsl.com/role/ConsolidatedStatementsOfAssetsandLiabilities": f"parentTag", "us-gaap": { "StockholdersEquity": "weight": 1.0, "order": 1.0 } } } , "presentation": f"http://ocsl.com/role/ConsolidatedStatementsOfAssetsandLiabilities", "lang": f"en-us", "role": f"terseLabel", "Common stock, $0.01\u00a0par value per share, 250,000 shares authorized, 82,245 and 77,225 shares issued and outstanding as of June 30, 2024 and September 30, 2023, respectively", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } } , "auth_ref": f"r79", "r472", "r785" } } } , "ocsl": { "CommunicationsEquipmentMember": f"stringType", "domainItemType", "nsuri": "http://ocsl.com/20240630", "localname": "CommunicationsEquipmentMember", "presentation": f"http://ocsl.com/role/PortfolioInvestmentsPortfolioInvestmentsbyIndustryDetails", "lang": f"en-us", "role": f"role", f"terseLabel", "Communications Equipment", "label": "Communications Equipment [Member]", "documentation": "Communications Equipment" } } } , "auth_ref": f"1", "ecd": { "CompActuallyPaidVsCoSelectedMeasureTextBlock": f"stringType", "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": f"http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": f"en-us", "role": f"role", f"terseLabel", "Compensation Actually Paid vs. Company Selected Measure", "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]" } } } , "auth_ref": f"r928" } } } , "ecd": { "CompActuallyPaidVsNetIncomeTextBlock": f"stringType", "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": f"http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": f"en-us", "role": f"role", f"terseLabel", "Compensation Actually Paid vs. Net Income", "label": "Compensation Actually Paid vs. Net Income [Text Block]" } } } , "auth_ref": f"r927" } } } , "ecd": { "CompActuallyPaidVsOtherMeasureTextBlock": f"stringType", "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": f"http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": f"en-us", "role": f"role", f"terseLabel", "Compensation Actually Paid vs. Other Measure", "label": "Compensation Actually Paid vs. Other Measure [Text Block]" } } } , "auth_ref": f"r929" } } } , "ecd": { "CompActuallyPaidVsTotalShareholderRtnTextBlock": f"stringType", "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": f"http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": f"en-us", "role": f"role", f"terseLabel", "Compensation Actually Paid vs. Total Shareholder Return", "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]" } } } , "auth_ref": f"r926" } } } , "us-gaap": { "ConcentrationRiskBenchmarkDomain": f"stringType", "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": f"http://ocsl.com/role/PortfolioInvestmentsNarrativeDetails", "http://ocsl.com/role/PortfolioInvestmentsPortfolioCompositionDetails", "http://ocsl.com/role/PortfolioInvestmentsPortfolioInvestmentsbyIndustryDetails", "http://ocsl.com/role/SignificantAccountingPoliciesDetails", "lang": f"en-us", "role": f"role", f"terseLabel", "Concentration Risk Benchmark [Domain]", "label": "Concentration Risk Benchmark [Domain]", "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } } , "auth_ref": f"r35", "r37", "r63", "r64", "r204", "r748" } } } , "us-gaap": { "ConcentrationRiskByBenchmarkAxis": f"stringType", "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": f"http://ocsl.com/role/PortfolioInvestmentsNarrativeDetails", "http://ocsl.com/role/PortfolioInvestmentsPortfolioCompositionDetails", "http://ocsl.com/role/PortfolioInvestmentsPortfolioInvestmentsbyIndustryDetails", "http://ocsl.com/role/SignificantAccountingPoliciesDetails", "lang": f"en-us", "role": f"role", f"terseLabel", "Concentration Risk Type [Axis]", "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employee, supplier, lender." } } } , "auth_ref": f"r35", "r37", "r63", "r64", "r204", "r748" } } } , "us-gaap": { "ConcentrationRiskDisclosureTextBlock": f"stringType", "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskDisclosureTextBlock", "presentation": f"http://ocsl.com/role/ConcentrationofCreditRisks", "lang": f"en-us", "role": f"terseLabel", "Concentration of Credit Risks", "label": "Concentration Risk Disclosure [Text Block]", "documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date." } } } , "auth_ref": f"r97" } } } , "us-gaap": { "ConcentrationRiskPercentage1": f"stringType", "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskPercentage1", "presentation": f"http://ocsl.com/role/PortfolioInvestmentsNarrativeDetails", "http://ocsl.com/role/PortfolioInvestmentsPortfolioCompositionDetails", "http://ocsl.com/role/PortfolioInvestmentsPortfolioInvestmentsbyIndustryDetails", "http://ocsl.com/role/SignificantAccountingPoliciesDetails", "lang": f"en-us", "role": f"role", f"terseLabel", "Concentration risk (as a percent)", "label": "Concentration Risk, Percentage", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \u201cbenchmark\u201d (or denominator) in the equation, this concept represents the concentration percentage derived from the division." } } } , "auth_ref": f"r35", "r37", "r63", "r64", "r204" } } } , "us-gaap": { "ConcentrationRiskTypeDomain": f"stringType", "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskTypeDomain", "presentation": f"http://ocsl.com/role/PortfolioInvestmentsNarrativeDetails", "http://ocsl.com/role/PortfolioInvestmentsPortfolioCompositionDetails", "http://ocsl.com/role/PortfolioInvestmentsPortfolioInvestmentsbyIndustryDetails", "http://ocsl.com/role/SignificantAccountingPoliciesDetails", "lang": f"en-us", "role": f"role", f"terseLabel", "Concentration Risk Type [Domain]", "label": "Concentration Risk Type [Domain]", "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employee, supplier, lender) of the concentration." } } } , "auth_ref": f"r35", "r37", "r63", "r64", "r204", "r748" } } } , "us-gaap": { "ConsolidationPolicyTextBlock": f"stringType", "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConsolidationPolicyTextBlock", "presentation": f"http://ocsl.com/role/SignificantAccountingPolicies", "lang": f"en-us", "role": f"role", f"terseLabel", "Consolidation", "label": "Consolidation, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issu
```

"documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } } , "auth_ref": [1] , "us-gaap_CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditFacilityDomain" , "presentation": { "http://ocsl.com/role/BorrowingsNarrativeDetails": { "http://ocsl.com/role/PortfolioInvestmentsNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Domain]", "label": "Credit Facility [Domain]", "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } } , "auth_ref": [1] , "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": { "http://ocsl.com/role/Cover": { "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD--" } } } , "auth_ref": [1] } , "ocsl_DataProcessingOutsourcedServicesMember": { "xbrltype": "domainItemType", "nsuri": "http://ocsl.com/20240630", "localname": "DataProcessingOutsourcedServicesMember", "presentation": { "http://ocsl.com/role/PortfolioInvestmentsPortfolioInvestmentsbyIndustryDetails": { "lang": { "en-us": { "role": { "terseLabel": "Data Processing & Outsourced Services", "label": "Data Processing & Outsourced Services [Member]", "documentation": "Data Processing & Outsourced Services" } } } , "auth_ref": [1] , "ocsl_DebtAndEquityFinancingMember": { "xbrltype": "domainItemType", "nsuri": "http://ocsl.com/20240630", "localname": "DebtAndEquityFinancingMember", "presentation": { "http://ocsl.com/role/CommitmentsandContingenciesNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Debt and Equity Financing", "label": "Debt and Equity Financing [Member]", "documentation": "Debt and Equity Financing" } } } , "auth_ref": [1] , "us-gaap_DebtAndEquitySecuritiesAndForeignCurrencyTransactionPriceChangeRealizedGainLossOperatingBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtAndEquitySecuritiesAndForeignCurrencyTransactionPriceChangeRealizedGainLossOperatingBeforeTax", "crdr": "credit", "presentation": { "http://ocsl.com/role/PortfolioInvestmentsNarrativeDetails": { "http://ocsl.com/role/RealizedGainsorLossesandNetUnrealizedAppreciationorDepreciationAggregateNetRealizedGainsDetails": { "http://ocsl.com/role/ShareDataandNetAssetsScheduleofChangesinNetAssetsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Net realized gains (losses)", "label": "Realized Gain (Loss), Debt and Equity Securities and Foreign Currency Transaction Price Change, Operating, before Tax", "documentation": "Amount, before tax, of realized gain (loss) on investment in debt and equity securities and foreign currency transaction on investment in debt and equity securities from change in market price, classified as operating." } } } , "auth_ref": [603, "r604"] , "us-gaap_DebtAndEquitySecuritiesAndForeignCurrencyTransactionPriceChangeUnrealizedGainLossOperatingBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtAndEquitySecuritiesAndForeignCurrencyTransactionPriceChangeUnrealizedGainLossOperatingBeforeTax", "crdr": "credit", "presentation": { "http://ocsl.com/role/PortfolioInvestmentsNarrativeDetails": { "http://ocsl.com/role/ShareDataandNetAssetsScheduleofChangesinNetAssetsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Net unrealized appreciation (depreciation)", "verboseLabel": "Net unrealized appreciation (depreciation)", "label": "Unrealized Gain (Loss), Debt and Equity Securities and Foreign Currency Transaction Price Change, Operating, before Tax", "documentation": "Amount, before tax, of unrealized gain (loss) on investment in debt and equity securities and foreign currency transaction on investment in debt and equity securities from change in market price, classified as operating." } } } , "auth_ref": [609, "r610"] , "us-gaap_DebtAndEquitySecuritiesRealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtAndEquitySecuritiesRealizedGainLoss", "crdr": "credit", "calculation": { "http://ocsl.com/role/PortfolioInvestmentsSummarizedStatementofOperationsInformationDetails": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 } , "http://ocsl.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_RealizedGainLossInvestmentAndDerivativeOperatingBeforeTax", "weight": 1.0, "order": 2.0 } , "presentation": { "http://ocsl.com/role/ConsolidatedStatementsofOperations": { "http://ocsl.com/role/PortfolioInvestmentsSummarizedStatementofOperationsInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Realized gain (loss)", "label": "Debt and Equity Securities, Realized Gain (Loss)", "documentation": "Amount of realized gain (loss) on investment in debt and equity securities." } } } , "auth_ref": [603, "r604", "r716", "r717", "r718", "r799", "r980"] , "ocsl_DebtAndEquitySecuritiesRealizedGainLossMember": { "xbrltype": "domainItemType", "nsuri": "http://ocsl.com/20240630", "localname": "DebtAndEquitySecuritiesRealizedGainLossMember", "presentation": { "http://ocsl.com/role/PortfolioInvestmentsRollForwardintheChangesinFairValueDetails": { "lang": { "en-us": { "role": { "terseLabel": "Net realized gains (losses)", "label": "Debt and Equity Securities, Realized Gain (Loss) [Member]", "documentation": "Debt and Equity Securities, Realized Gain (Loss)" } } } , "auth_ref": [1] , "us-gaap_DebtAndEquitySecuritiesUnrealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtAndEquitySecuritiesUnrealizedGainLoss", "crdr": "credit", "calculation": { "http://ocsl.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_UnrealizedGainLossInvestmentAndDerivativeOperatingBeforeTax", "weight": 1.0, "order": 1.0 } , "http://ocsl.com/role/PortfolioInvestmentsSummarizedStatementofOperationsInformationDetails": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 2.0 } , "presentation": { "http://ocsl.com/role/ConsolidatedStatementsofOperations": { "http://ocsl.com/role/PortfolioInvestmentsSummarizedStatementofOperationsInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Net unrealized appreciation (depreciation)", "label": "Debt and Equity Securities, Unrealized Gain (Loss)", "documentation": "Amount of unrealized gain (loss) on investment in debt and equity securities." } } } , "auth_ref": [609, "r610", "r719", "r720", "r721", "r799", "r980"] , "ocsl_DebtAndEquitySecuritiesUnrealizedGainLossMember": { "xbrltype": "domainItemType", "nsuri": "http://ocsl.com/20240630", "localname": "DebtAndEquitySecuritiesUnrealizedGainLossMember", "presentation": { "http://ocsl.com/role/PortfolioInvestmentsRollForwardintheChangesinFairValueDetails": { "lang": { "en-us": { "role": { "terseLabel": "Net unrealized appreciation (depreciation)", "label": "Debt and Equity Securities, Unrealized Gain (Loss) [Member]", "documentation": "Debt and Equity Securities, Unrealized Gain (Loss)" } } } , "auth_ref": [1] , "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } } , "auth_ref": [1] , "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureTextBlock", "presentation": { "http://ocsl.com/role/Borrowings": { "lang": { "en-us": { "role": { "terseLabel": "Borrowings", "label": "Debt Disclosure [Text Block]", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } } , "auth_ref": [100, "r160", "r266", "r272", "r273", "r274", "r275", "r276", "r277", "r282", "r289", "r290", "r292"] , "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentAxis", "presentation": { "http://ocsl.com/role/BorrowingsComponentsofInterestandOtherDebtExpensesDetails": { "http://ocsl.com/role/BorrowingsComponentsoftheCarryingValueofNotesDetails": { "http://ocsl.com/role/BorrowingsNarrativeDetails": { "http://ocsl.com/role/PortfolioInvestmentsNarrativeDetails": { "http://ocsl.com/role/PortfolioInvestmentsSummarizedStatementofOperationsInformationDetails": { "http://xbrl.sec.gov/cef/role/N2": { "lang": { "en-us": { "role": { "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } } , "auth_ref": [17, "r76", "r77", "r112", "r113", "r166", "r267", "r268", "r269", "r270", "r271", "r273", "r278", "r279", "r280", "r281", "r283", "r284", "r285", "r286", "r287", "r288", "r411", "r774", "r775", "r776", "r777", "r778", "r984"] , "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "presentation": { "http://ocsl.com/role/BorrowingsNarrativeDetails": { "http://ocsl.com/role/PortfolioInvestmentsNarrativeDetails": { "http://ocsl.com/role/PortfolioInvestmentsPortfolioListingDetails": { "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, basis spread, variable rate (as a percent)", "label": "Debt Instrument, Basis Spread on Variable Rate", "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument." } } } , "auth_ref": [1] , "ocsl_DebtInstrumentCovenantConsolidatedEBITDAToConsolidatedInterestExpenseRatio": { "xbrltype": "pureItemType", "nsuri": "http://ocsl.com/20240630", "localname": "DebtInstrumentCovenantConsolidatedEBITDAToConsolidatedInterestExpenseRatio", "presentation": { "http://ocsl.com/role/BorrowingsNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, covenant, consolidated EBITDA to consolidated interest expense, ratio, minimum threshold", "label": "Debt Instrument, Covenant, Consolidated EBITDA To Consolidated Interest Expense, Ratio", "documentation": "Debt instrument, covenant, consolidated EBITDA to consolidated interest expense, ratio, minimum threshold." } } } , "auth_ref": [1] , "ocsl_DebtInstrumentCovenantTotalAssetsToTotalIndebtednessRatio": { "xbrltype": "pureItemType", "nsuri": "http://ocsl.com/20240630", "localname": "DebtInstrumentCovenantTotalAssetsToTotalIndebtednessRatio", "presentation": { "http://ocsl.com/role/BorrowingsNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, covenant, total assets to total indebtedness, ratio, minimum threshold", "label": "Debt Instrument, Covenant, Total Assets To Total Indebtedness, Ratio", "documentation": "Debt instrument, covenant, total assets to total indebtedness, ratio, minimum threshold." } } } , "auth_ref": [1] , "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "calculation": { "http://ocsl.com/role/BorrowingsComponentsoftheCarryingValueofNotesDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 1.0 } , "presentation": { "http://ocsl.com/role/BorrowingsComponentsoftheCarryingValueofNotesDetails": { "http://ocsl.com/role/BorrowingsNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Principal amount", "verboseLabel": "Principal", "label": "Debt Instrument, Face Amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } } , "auth_ref": [66, "r68", "r267", "r411", "r775", "r776", "r777", "r778", "r984"] , "us-gaap_DebtInstrumentFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentFairValue", "crdr": "credit", "presentation": { "http://ocsl.com/role/BorrowingsComponentsoftheCarryingValueofNotesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Fair Value", "label": "Debt Instrument, Fair Value Disclosure", "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable." } } } , "auth_ref": [280, "r398", "r775", "r776"] , "ocsl_DebtInstrumentFloorInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://ocsl.com/20240630", "localname": "DebtInstrumentFloorInterestRate", "presentation": { "http://ocsl.com/role/ConsolidatedScheduleofInvestmentsParenthetical": { "http://ocsl.com/role/PortfolioInvestmentsPortfolioListingDetails": { "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, floor interest rate (as a percent)", "label": "Debt Instrument, Floor Interest Rate", "documentation": "Debt instrument, floor interest rate" } } } , "auth_ref": [1] , "us-gaap_DebtInstrumentInterestRateDuringPeriod": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateDuringPeriod", "presentation": { "http://ocsl.com/role/BorrowingsComponentsofInterestandOtherDebtExpensesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Coupon interest rate (net of effect of interest rate swaps) (as a percent)", "label": "Debt Instrument, Interest Rate During Period", "documentation": "The average effective interest rate during the reporting period." } } } , "auth_ref": [21, "r66", "r285"] , "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": { "http://ocsl.com/role/BorrowingsNarrativeDetails": { "http://ocsl.com/role/PortfolioInvestmentsNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Coupon interest rate (net of effect of interest rate swaps)", "label": "Debt Instrument, Interest Rate, Stated Percentage", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } } , "auth_ref": [21, "r268"] , "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentLineItems", "presentation": { "http://ocsl.com/role/BorrowingsComponentsofInterestandOtherDebtExpensesDetails": { "http://ocsl.com/role/BorrowingsComponentsoftheCarryingValueofNotesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Debt instrument [Line Items]", "label": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } } , "auth_ref": [166, "r267", "r268", "r269", "r270", "r271", "r273", "r278", "r279", "r280", "r281", "r283", "r284", "r285", "r286", "r287", "r288", "r411", "r774", "r775", "r776", "r777", "r778", "r984"] , "us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed", "presentation": {

"http://ocsl.com/role/BorrowingsNarrativeDetails" }, {"lang": "en-us", "role": "terseLabel", "Redemption price (as a percent)", "label": "Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed", "documentation": "Percentage of principal amount of debt redeemed." }, {"auth_ref": "H"}, {"us_gaap_DebtInstrumentTable": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentTable", "presentation": {"http://ocsl.com/role/BorrowingsComponentsOfInterestAndOtherDebtExpensesDetails" }, {"http://ocsl.com/role/BorrowingsComponentsOfInterestAndOtherDebtExpensesDetails" }, {"lang": "en-us", "role": "terseLabel", "Schedule of Long-Term Debt Instruments [Table]", "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." }, {"auth_ref": "r22", "r43", "r45", "r65", "r66", "r68", "r74", "r102", "r103", "r166", "r267", "r268", "r269", "r270", "r271", "r273", "r278", "r279", "r280", "r281", "r283", "r284", "r285", "r286", "r287", "r288", "r291", "r411", "r774", "r775", "r776", "r777", "r778", "r984" }, {"us_gaap_DebtInstrumentUnamortizedDiscount": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentUnamortizedDiscount", "crdr": "debit", "calculation": {"http://ocsl.com/role/BorrowingsComponentsOfInterestAndOtherDebtExpensesDetails" }, {"parent_tag": "us_gaap_LongTermDebt", "weight": 1.0, "order": 3.0 }, {"presentation": {"http://ocsl.com/role/BorrowingsComponentsOfInterestAndOtherDebtExpensesDetails" }, {"http://ocsl.com/role/BorrowingsNarrativeDetails" }, {"lang": "en-us", "role": "terseLabel", "Unaccreted discount", "negatedTerseLabel": "Unaccreted discount", "label": "Debt Instrument, Unamortized Discount", "documentation": "Amount, after accumulated amortization, of debt discount." }, {"auth_ref": "r65", "r68", "r1008" }, {"us_gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction", "crdr": "debit", "presentation": {"http://ocsl.com/role/ConsolidatedStatementOfCashFlows" }, {"lang": "en-us", "role": "terseLabel", "Deferred financing costs", "label": "Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction", "documentation": "The amount of debt issuance costs that were incurred during a noncash or partial noncash transaction." }, {"auth_ref": "r32", "r33", "r34" }, {"us_gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityFairValue": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleAndHeldToMaturityFairValue", "crdr": "debit", "presentation": {"http://ocsl.com/role/PortfolioInvestmentsCompositionOfInvestmentsDetails" }, {"lang": "en-us", "role": "terseLabel", "Debt investments, fair value", "label": "Debt Securities, Available for Sale and Held-to-Maturity, Fair Value", "documentation": "Fair value of investment in debt security measured at amortized cost (held-to-maturity) and investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." }, {"auth_ref": "r994", "r996" }, {"ocsl_DebtSecuritiesFixedRateMember": {"xbrltype": "domainItemType", "nsuri": "http://ocsl.com/20240630", "localname": "DebtSecuritiesFixedRateMember", "presentation": {"http://ocsl.com/role/PortfolioInvestmentsCompositionOfInvestmentsDetails" }, {"lang": "en-us", "role": "terseLabel", "Fixed rate debt securities", "label": "Debt Securities, Fixed Rate [Member]", "documentation": "Debt Securities, Fixed Rate" }, {"auth_ref": "H"}, {"ocsl_DebtSecuritiesFloatingRateMember": {"xbrltype": "domainItemType", "nsuri": "http://ocsl.com/20240630", "localname": "DebtSecuritiesFloatingRateMember", "presentation": {"http://ocsl.com/role/PortfolioInvestmentsCompositionOfInvestmentsDetails" }, {"lang": "en-us", "role": "terseLabel", "Floating rate debt securities, including the debt investments in the FVs", "label": "Debt Securities, Floating Rate [Member]", "documentation": "Debt Securities, Floating Rate" }, {"auth_ref": "H"}, {"ocsl_DebtSecuritiesFVMember": {"xbrltype": "domainItemType", "nsuri": "http://ocsl.com/20240630", "localname": "DebtSecuritiesFVMember", "presentation": {"http://ocsl.com/role/PortfolioInvestmentsCompositionOfInvestmentsDetails" }, {"http://ocsl.com/role/PortfolioInvestmentsSignificantUnobservableInputsForLevel3InvestmentsDetails" }, {"lang": "en-us", "role": "terseLabel", "Debt investments in the FVs", "label": "Debt Securities, FV [Member]", "documentation": "Debt Securities, FV" }, {"auth_ref": "H"}, {"us_gaap_DebtSecuritiesMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesMember", "presentation": {"http://ocsl.com/role/PortfolioInvestmentsCompositionOfInvestmentsDetails" }, {"http://ocsl.com/role/RealizedGainsOrLossesAndNetUnrealizedAppreciationOrDepreciationNarrativeDetails" }, {"lang": "en-us", "role": "terseLabel", "Investments in debt securities", "label": "Debt Securities [Member]", "documentation": "Debt instrument issued by corporations, governments and governmental agencies, municipalities, and other institutions." }, {"auth_ref": "r41", "r799", "r1068" }, {"ocsl_DebtSecuritiesPercentageOfDebtPortfolio": {"xbrltype": "percentItemType", "nsuri": "http://ocsl.com/20240630", "localname": "DebtSecuritiesPercentageOfDebtPortfolio", "presentation": {"http://ocsl.com/role/PortfolioInvestmentsCompositionOfInvestmentsDetails" }, {"lang": "en-us", "role": "terseLabel", "Debt Securities, Percentage Of Debt Portfolio", "label": "Debt Securities, Percentage Of Debt Portfolio", "documentation": "Debt Securities, Percentage Of Debt Portfolio" }, {"auth_ref": "H"}, {"ocsl_DebtSecuritiesSeniorSecuredMember": {"xbrltype": "domainItemType", "nsuri": "http://ocsl.com/20240630", "localname": "DebtSecuritiesSeniorSecuredMember", "presentation": {"http://ocsl.com/role/PortfolioInvestmentsNarrativeDetails" }, {"http://ocsl.com/role/PortfolioInvestmentsPortfolioCompositionDetails" }, {"http://ocsl.com/role/PortfolioInvestmentsRollForwardInTheChangesInFairValueDetails" }, {"http://ocsl.com/role/PortfolioInvestmentsScheduleOfFinancialInstrumentsCarriedAtFairValueDetails" }, {"http://ocsl.com/role/PortfolioInvestmentsSignificantUnobservableInputsForLevel3InvestmentsDetails" }, {"lang": "en-us", "role": "terseLabel", "Senior secured debt", "label": "Debt Securities, Senior Secured [Member]", "documentation": "Debt Securities, Senior Secured" }, {"auth_ref": "H"}, {"ocsl_DebtSecuritiesSubordinatedIncludingJVDebtInstrumentsMember": {"xbrltype": "domainItemType", "nsuri": "http://ocsl.com/20240630", "localname": "DebtSecuritiesSubordinatedIncludingJVDebtInstrumentsMember", "presentation": {"http://ocsl.com/role/PortfolioInvestmentsNarrativeDetails" }, {"http://ocsl.com/role/PortfolioInvestmentsScheduleOfFinancialInstrumentsCarriedAtFairValueDetails" }, {"lang": "en-us", "role": "terseLabel", "Subordinated debt securities, including JV debt instruments", "label": "Debt Securities, Subordinated Including JV Debt Instruments", "documentation": "Debt Securities, Subordinated Including JV Debt Instruments" }, {"auth_ref": "H"}, {"ocsl_DebtSecuritiesSubordinatedMember": {"xbrltype": "domainItemType", "nsuri": "http://ocsl.com/20240630", "localname": "DebtSecuritiesSubordinatedMember", "presentation": {"http://ocsl.com/role/PortfolioInvestmentsPortfolioCompositionDetails" }, {"http://ocsl.com/role/PortfolioInvestmentsRollForwardInTheChangesInFairValueDetails" }, {"lang": "en-us", "role": "terseLabel", "Subordinated debt", "label": "Debt Securities, Subordinated [Member]", "documentation": "Debt Securities, Subordinated" }, {"auth_ref": "H"}, {"us_gaap_DebtWeightedAverageInterestRate": {"xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtWeightedAverageInterestRate", "presentation": {"http://ocsl.com/role/BorrowingsNarrativeDetails" }, {"lang": "en-us", "role": "terseLabel", "Weighted average interest rate (as a percent)", "label": "Debt, Weighted Average Interest Rate", "documentation": "Weighted average interest rate of debt outstanding." }, {"auth_ref": "H"}, {"us_gaap_DeferredFinanceCostsGross": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredFinanceCostsGross", "crdr": "debit", "presentation": {"http://ocsl.com/role/BorrowingsNarrativeDetails" }, {"lang": "en-us", "role": "terseLabel", "Offering costs", "label": "Debt Issuance Costs, Gross", "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs." }, {"auth_ref": "r67", "r68", "r1008" }, {"us_gaap_DeferredFinanceCostsNet": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredFinanceCostsNet", "crdr": "debit", "calculation": {"http://ocsl.com/role/ConsolidatedStatementOfAssetsandLiabilities" }, {"parent_tag": "us_gaap_Assets", "weight": 1.0, "order": 10.0 }, {"presentation": {"http://ocsl.com/role/ConsolidatedStatementOfAssetsandLiabilities" }, {"lang": "en-us", "role": "terseLabel", "Deferred financing costs", "label": "Debt Issuance Costs, Net", "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs." }, {"auth_ref": "r67", "r1008" }, {"ocsl_DeferredFinancingCostsPolicyTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://ocsl.com/20240630", "localname": "DeferredFinancingCostsPolicyTextBlock", "presentation": {"http://ocsl.com/role/SignificantAccountingPoliciesPolicies" }, {"lang": "en-us", "role": "terseLabel", "Deferred Financing Costs, Policy [Policy Text Block]", "documentation": "Deferred Financing Costs, Policy" }, {"auth_ref": "H"}, {"us_gaap_DeferredIncomeTaxExpenseBenefit": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": {"http://ocsl.com/role/ConsolidatedStatementOfCashFlows" }, {"parent_tag": "us_gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 18.0 }, {"presentation": {"http://ocsl.com/role/ConsolidatedStatementOfCashFlows" }, {"http://ocsl.com/role/TaxableDistributableIncomeandDividendDistributionsNarrativeDetails" }, {"lang": "en-us", "role": "terseLabel", "Deferred taxes", "negatedLabel": "Deferred income tax benefit", "label": "Deferred Income Tax Expense (Benefit)", "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations." }, {"auth_ref": "r6", "r105", "r130", "r367", "r368", "r987" }, {"us_gaap_DeferredIncomeTaxLiabilitiesNet": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxLiabilitiesNet", "crdr": "credit", "calculation": {"http://ocsl.com/role/ConsolidatedStatementOfAssetsandLiabilities" }, {"parent_tag": "us_gaap_Liabilities", "weight": 1.0, "order": 5.0 }, {"presentation": {"http://ocsl.com/role/ConsolidatedStatementOfAssetsandLiabilities" }, {"lang": "en-us", "role": "terseLabel", "Deferred tax liability", "label": "Deferred Income Tax Liabilities, Net", "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting." }, {"auth_ref": "r352", "r353", "r470" }, {"us_gaap_DeferredOfferingCosts": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredOfferingCosts", "crdr": "debit", "calculation": {"http://ocsl.com/role/ConsolidatedStatementOfAssetsandLiabilities" }, {"parent_tag": "us_gaap_Assets", "weight": 1.0, "order": 2.0 }, {"presentation": {"http://ocsl.com/role/ConsolidatedStatementOfAssetsandLiabilities" }, {"lang": "en-us", "role": "terseLabel", "Deferred offering costs", "label": "Deferred Offering Costs", "documentation": "Deferred Offering Costs, Policy [Policy Text Block]", "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period." }, {"auth_ref": "r1002" }, {"ocsl_DeferredOfferingCostsPolicyTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://ocsl.com/20240630", "localname": "DeferredOfferingCostsPolicyTextBlock", "presentation": {"http://ocsl.com/role/SignificantAccountingPoliciesPolicies" }, {"lang": "en-us", "role": "terseLabel", "Deferred Offering Costs", "label": "Deferred Offering Costs, Policy [Policy Text Block]", "documentation": "Deferred Offering Costs, Policy" }, {"auth_ref": "H"}, {"us_gaap_DeferredTaxAssetsGross": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsGross", "crdr": "debit", "presentation": {"http://ocsl.com/role/TaxableDistributableIncomeandDividendDistributionsNarrativeDetails" }, {"lang": "en-us", "role": "terseLabel", "Deferred tax assets", "label": "Deferred Tax Assets, Gross", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." }, {"auth_ref": "r358", "r359", "r4012", "r4013", "r4014" }, {"us_gaap_DerivativeAssets": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeAssets", "crdr": "debit", "calculation": {"http://ocsl.com/role/TaxableDistributableIncomeandDividendDistributionsNarrativeDetails" }, {"lang": "en-us", "role": "terseLabel", "Valuation allowance", "label": "Deferred Tax Assets, Valuation Allowance", "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized." }, {"auth_ref": "r359" }, {"dei_DelayedOrContinuousOffering": {"xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DelayedOrContinuousOffering", "presentation": {"http://xbrl.sec.gov/cef/role/N2" }, {"lang": "en-us", "role": "label", "Delayed or Continuous Offering" }, {"auth_ref": "r834", "r835", "r915" }, {"us_gaap_DerivativeAssetNotionalAmount": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeAssetNotionalAmount", "presentation": {"http://ocsl.com/role/ConsolidatedScheduleOfInvestmentsDerivatives" }, {"http://ocsl.com/role/DerivativeInstrumentsScheduleOfForeignCurrencyForwardContractsandInterestRateSwapDetails" }, {"lang": "en-us", "role": "terseLabel", "Notional Amount to be Sold", "label": "Derivative Asset, Notional Amount", "documentation": "Nominal or face amount used to calculate payments on the derivative asset." }, {"auth_ref": "r683", "r687", "r691", "r696", "r1012", "r1013", "r1014" }, {"us_gaap_DerivativeAssets": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeAssets", "crdr": "debit", "calculation": {"http://ocsl.com/role/PortfolioInvestmentsScheduleOfFinancialInstrumentsCarriedAtFairValueDetails" }, {"parent_tag": "us_gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 1.0 }, {"http://ocsl.com/role/ConsolidatedStatementOfAssetsandLiabilities" }, {"parent_tag": "us_gaap_Assets", "weight": 1.0, "order": 4.0 }, {"presentation": {"http://ocsl.com/role/ConsolidatedScheduleOfInvestmentsDerivatives" }, {"http://ocsl.com/role/ConsolidatedStatementOfAssetsandLiabilities" }, {"http://ocsl.com/role/PortfolioInvestmentsScheduleOfFinancialInstrumentsCarriedAtFairValueDetails" }, {"lang": "en-us", "role": "terseLabel", "Derivative assets at fair value", "label": "Derivative Assets", "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset." }, {"auth_ref": "r142", "r143", "r398", "r537", "r538", "r539", "r541", "r542", "r544", "r545", "r547", "r549", "r550", "r570", "r571", "r683", "r688", "r696", "r697", "r699", "r700", "r765", "r789", "r1046" }, {"us_gaap_DerivativeBasisSpreadOnVariableRate": {"xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeBasisSpreadOnVariableRate", "presentation": {"http://ocsl.com/role/BorrowingsNarrativeDetails" }, {"http://ocsl.com/role/ConsolidatedScheduleOfInvestmentsDerivatives" }, {"lang": "en-us", "role": "terseLabel", "Floating interest rate (as a percent)", "label": "Derivative assets at fair value" } }

"Derivative, Basis Spread on Variable Rate", "documentation": "The percentage points added to the reference rate to compute the variable rate on the interest rate derivative." } } }, "auth_ref": { "us-gaap_DerivativeContractTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeContractTypeDomain", "presentation": { "http://ocsl.com/role/BorrowingsNarrativeDetails", "http://ocsl.com/role/ConsolidatedScheduleofInvestmentsDerivatives", "http://ocsl.com/role/DerivativeInstrumentsScheduleofForeignCurrencyForwardContractsandInterestRateSwapDetails" } }, "lang": { "en-us": { "role": { "terseLabel": "Derivative Contract [Domain]", "label": "Derivative Contract [Domain]", "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "auth_ref": { "r547", "r550", "r569", "r570", "r571", "r574", "r575", "r576", "r577", "r579", "r580", "r581", "r582", "r605", "r606", "r607", "r608", "r611", "r612", "r613", "r614", "r683", "r685", "r686", "r689", "r690", "r696", "r697", "r699", "r787", "r789" } }, "us-gaap_DerivativeFairValueOfDerivativeNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeFairValueOfDerivativeNet", "crdr": "debit", "presentation": { "http://ocsl.com/role/ConsolidatedScheduleofInvestmentsDerivatives" } }, "lang": { "en-us": { "role": { "terseLabel": "Derivative assets (liability)", "label": "Derivative, Fair Value, Net", "documentation": "Fair value of the assets less the liabilities of a derivative or group of derivatives." } } }, "auth_ref": { "r398" } }, "us-gaap_DerivativeFixedInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeFixedInterestRate", "presentation": { "http://ocsl.com/role/BorrowingsNarrativeDetails", "http://ocsl.com/role/ConsolidatedScheduleofInvestmentsDerivatives" } }, "lang": { "en-us": { "role": { "terseLabel": "Interest rate (as a percent)", "label": "Derivative, Fixed Interest Rate", "documentation": "Fixed interest rate related to the interest rate derivative." } } }, "auth_ref": { "us-gaap_DerivativeInstrumentRiskAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentRiskAxis", "presentation": { "http://ocsl.com/role/BorrowingsNarrativeDetails", "http://ocsl.com/role/ConsolidatedScheduleofInvestmentsDerivatives", "http://ocsl.com/role/DerivativeInstrumentsScheduleofForeignCurrencyForwardContractsandInterestRateSwapDetails" } }, "lang": { "en-us": { "role": { "terseLabel": "Derivative Instrument [Axis]", "label": "Derivative Instrument [Axis]", "documentation": "Information by type of derivative contract." } } }, "auth_ref": { "r52", "r54", "r55", "r56", "r547", "r550", "r569", "r570", "r571", "r574", "r575", "r576", "r577", "r579", "r580", "r581", "r582", "r605", "r606", "r607", "r608", "r611", "r612", "r613", "r614", "r683", "r685", "r686", "r690", "r696", "r699", "r765", "r787", "r789" } } }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]", "presentation": { "http://ocsl.com/role/BorrowingsNarrativeDetails", "http://ocsl.com/role/ConsolidatedScheduleofInvestmentsDerivatives", "http://ocsl.com/role/DerivativeInstrumentsScheduleofForeignCurrencyForwardContractsandInterestRateSwapDetails" } }, "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments", "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]", "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts." } } }, "auth_ref": { "r107", "r377", "r384" } } }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems", "presentation": { "http://ocsl.com/role/DerivativeInstrumentsScheduleofForeignCurrencyForwardContractsandInterestRateSwapDetails" } }, "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments and Hedging Activities Disclosures [Line Items]", "label": "Derivative Instruments and Hedging Activities Disclosures [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable", "presentation": { "http://ocsl.com/role/DerivativeInstrumentsScheduleofForeignCurrencyForwardContractsandInterestRateSwapDetails" } }, "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments and Hedging Activities Disclosures [Table]", "label": "Derivative Instruments and Hedging Activities Disclosures [Table]", "documentation": "Disclosure of information about derivatives and hedging activities." } } }, "auth_ref": { "us-gaap_DerivativeLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeLiabilities", "crdr": "credit", "calculation": { "http://ocsl.com/role/PortfolioInvestmentsScheduleofFinancialInstrumentsCarriedatFairValueDetails": { "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0, "order": 1.0 }, "http://ocsl.com/role/ConsolidatedStatementsofAssetsandLiabilities": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 8.0 } }, "presentation": { "http://ocsl.com/role/ConsolidatedScheduleofInvestmentsDerivatives", "http://ocsl.com/role/ConsolidatedStatementsofAssetsandLiabilities", "http://ocsl.com/role/DerivativeInstrumentsScheduleofForeignCurrencyForwardContractsandInterestRateSwapDetails", "http://ocsl.com/role/PortfolioInvestmentsScheduleofFinancialInstrumentsCarriedatFairValueDetails" } }, "lang": { "en-us": { "role": { "terseLabel": "Derivative liabilities at fair value", "negatedLabel": "Derivative liability", "verboselabel": "Derivative liabilities", "label": "Derivative Liability", "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": { "r142", "r143", "r398", "r537", "r538", "r539", "r541", "r544", "r545", "r547", "r549", "r550", "r579", "r581", "r582", "r685", "r686", "r689", "r696", "r697", "r699", "r700", "r765", "r1046" } } }, "us-gaap_DerivativeLiabilityNotionalAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeLiabilityNotionalAmount", "presentation": { "http://ocsl.com/role/ConsolidatedScheduleofInvestmentsDerivatives", "http://ocsl.com/role/DerivativeInstrumentsScheduleofForeignCurrencyForwardContractsandInterestRateSwapDetails" } }, "lang": { "en-us": { "role": { "terseLabel": "Notional Amount to be Purchased", "label": "Derivative Liability, Notional Amount", "documentation": "Nominal or face amount used to calculate payments on the derivative liability." } } }, "auth_ref": { "r684", "r687", "r690", "r698", "r1012", "r1013", "r1014" } } }, "us-gaap_DerivativeNotionalAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeNotionalAmount", "presentation": { "http://ocsl.com/role/BorrowingsNarrativeDetails", "http://ocsl.com/role/DerivativeInstrumentsScheduleofForeignCurrencyForwardContractsandInterestRateSwapDetails" } }, "lang": { "en-us": { "role": { "terseLabel": "Notional amount", "verboselabel": "Notional Amount", "label": "Derivative, Notional Amount", "documentation": "Nominal or face amount used to calculate payment on derivative." } } }, "auth_ref": { "r1013", "r1014" } } }, "us-gaap_DerivativesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativesPolicyTextBlock", "presentation": { "http://ocsl.com/role/SignificantAccountingPolicies", "http://ocsl.com/role/ShareDataandNetAssetsScheduleofDistributionsDetails", "http://ocsl.com/role/SubsequentEventsDetails" } }, "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments", "label": "Derivatives, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities." } } }, "auth_ref": { "r12", "r48", "r49", "r51", "r58", "r165" } } }, "us-gaap_DesignatedAsHedgingInstrumentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DesignatedAsHedgingInstrumentMember", "presentation": { "http://ocsl.com/role/BorrowingsNarrativeDetails" } }, "lang": { "en-us": { "role": { "terseLabel": "Designated as Hedging Instrument", "label": "Designated as Hedging Instrument [Member]", "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP)." } } }, "auth_ref": { "r12" } } }, "ocsl_DeutscheBankTrustCompanyAmericasMember": { "xbrltype": "domainItemType", "nsuri": "http://ocsl.com/20240630", "localname": "DeutscheBankTrustCompanyAmericasMember", "presentation": { "http://ocsl.com/role/SignificantAccountingPoliciesDetails" } }, "lang": { "en-us": { "role": { "terseLabel": "Deutsche Bank Trust Company Americas", "label": "Deutsche Bank Trust Company Americas [Member]", "documentation": "Deutsche Bank Trust Company Americas" } } }, "auth_ref": { "cef_DistributionServicingFeesPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "DistributionServicingFeesPercent", "presentation": { "http://xbrl.sec.gov/cef/role/N2", "lang": { "en-us": { "role": { "label": "Distribution/Servicing Fees [Percent]" } } }, "auth_ref": { "r874" } } } }, "us-gaap_DistributionTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DistributionTypeDomain", "presentation": { "http://ocsl.com/role/ShareDataandNetAssetsScheduleofDistributionsDetails", "http://ocsl.com/role/SubsequentEventsDetails" } }, "lang": { "en-us": { "role": { "terseLabel": "Distribution Type [Domain]", "label": "Distribution Type [Domain]", "documentation": "Types of distribution made by the entity." } } }, "auth_ref": { "r46" } } }, "ocsl_DistributionTypeQuarterlyMember": { "xbrltype": "domainItemType", "nsuri": "http://ocsl.com/20240630", "localname": "DistributionTypeQuarterlyMember", "presentation": { "http://ocsl.com/role/ShareDataandNetAssetsScheduleofDistributionsDetails", "http://ocsl.com/role/SubsequentEventsDetails" } }, "lang": { "en-us": { "role": { "terseLabel": "Quarterly", "label": "Distribution Type, Quarterly [Member]", "documentation": "Distribution Type, Quarterly" } } }, "auth_ref": { "ocsl_DistributionTypeSpecialMember": { "xbrltype": "domainItemType", "nsuri": "http://ocsl.com/20240630", "localname": "DistributionTypeSpecialMember", "presentation": { "http://ocsl.com/role/ShareDataandNetAssetsScheduleofDistributionsDetails", "http://ocsl.com/role/SubsequentEventsDetails" } }, "lang": { "en-us": { "role": { "terseLabel": "Special", "label": "Distribution Type, Special [Member]", "documentation": "Distribution Type, Special" } } }, "auth_ref": { "us-gaap_DistributionsMadeToMemberOrLimitedPartnerByDistributionTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DistributionsMadeToMemberOrLimitedPartnerByDistributionTypeAxis", "presentation": { "http://ocsl.com/role/ShareDataandNetAssetsScheduleofDistributionsDetails", "http://ocsl.com/role/SubsequentEventsDetails" } }, "lang": { "en-us": { "role": { "terseLabel": "Distribution Type [Axis]", "label": "Distribution Type [Axis]", "documentation": "Information by type of distribution." } } }, "auth_ref": { "r46" } } }, "cef_DistributionsMayReducePrincipalTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "DistributionsMayReducePrincipalTextBlock", "presentation": { "http://xbrl.sec.gov/cef/role/N2", "lang": { "en-us": { "role": { "label": "Distributions May Reduce Principal [Text Block]" } } }, "auth_ref": { "r844" } } } }, "ocsl_DistributorsMember": { "xbrltype": "domainItemType", "nsuri": "http://ocsl.com/20240630", "localname": "DistributorsMember", "presentation": { "http://ocsl.com/role/PortfolioInvestmentsPortfolioofInvestmentsbyIndustryDetails" } }, "lang": { "en-us": { "role": { "terseLabel": "Distributors", "label": "Distributors [Member]", "documentation": "Distributors" } } }, "auth_ref": { "ocsl_DiversifiedChemicalsMember": { "xbrltype": "domainItemType", "nsuri": "http://ocsl.com/20240630", "localname": "DiversifiedChemicalsMember", "presentation": { "http://ocsl.com/role/PortfolioInvestmentsPortfolioofInvestmentsbyIndustryDetails" } }, "lang": { "en-us": { "role": { "terseLabel": "Diversified Chemicals", "label": "Diversified Chemicals [Member]", "documentation": "Diversified Chemicals" } } }, "auth_ref": { "ocsl_DiversifiedFinancialServicesMember": { "xbrltype": "domainItemType", "nsuri": "http://ocsl.com/20240630", "localname": "DiversifiedFinancialServicesMember", "presentation": { "http://ocsl.com/role/PortfolioInvestmentsPortfolioofInvestmentsbyIndustryDetails" } }, "lang": { "en-us": { "role": { "terseLabel": "Diversified Financial Services", "label": "Diversified Financial Services [Member]", "documentation": "Diversified Financial Services" } } }, "auth_ref": { "ocsl_DiversifiedMetalsMiningMember": { "xbrltype": "domainItemType", "nsuri": "http://ocsl.com/20240630", "localname": "DiversifiedMetalsMiningMember", "presentation": { "http://ocsl.com/role/PortfolioInvestmentsPortfolioofInvestmentsbyIndustryDetails" } }, "lang": { "en-us": { "role": { "terseLabel": "Diversified Metals & Mining", "label": "Diversified Metals & Mining [Member]", "documentation": "Diversified Metals & Mining" } } }, "auth_ref": { "ocsl_DiversifiedSupportServicesMember": { "xbrltype": "domainItemType", "nsuri": "http://ocsl.com/20240630", "localname": "DiversifiedSupportServicesMember", "presentation": { "http://ocsl.com/role/PortfolioInvestmentsPortfolioofInvestmentsbyIndustryDetails" } }, "lang": { "en-us": { "role": { "terseLabel": "Diversified Support Services", "label": "Diversified Support Services [Member]", "documentation": "Diversified Support Services" } } }, "auth_ref": { "cef_DividendAndInterestExpensesOnShortSalesPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "DividendAndInterestExpensesOnShortSalesPercent", "presentation": { "http://xbrl.sec.gov/cef/role/N2", "lang": { "en-us": { "role": { "label": "Dividend and Interest Expenses on Short Sales [Percent]" } } }, "auth_ref": { "r874" } } } }, "us-gaap_DividendAndInterestReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DividendAndInterestReceivable", "crdr": "debit", "calculation": { "http://ocsl.com/role/ConsolidatedStatementsofAssetsandLiabilities": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 }, "presentation": { "http://ocsl.com/role/ConsolidatedStatementsofAssetsandLiabilities" } }, "lang": { "en-us": { "role": { "terseLabel": "Interest, dividends and fees receivable", "label": "Dividend and Interest Receivable", "documentation": "Amount of dividend and interest receivable from investment." } } }, "auth_ref": { "r573", "r628", "r804" } } }, "cef_DividendExpenseOnPreferredSharesPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "DividendExpenseOnPreferredSharesPercent", "presentation": { "http://xbrl.sec.gov/cef/role/N2", "lang": { "en-us": { "role": { "label": "Dividend Expenses on Preferred Shares [Percent]" } } }, "auth_ref": { "r874" } } } }, "us-gaap_DividendIncomeOperating": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DividendIncomeOperating", "crdr": "credit", "presentation": { "http://ocsl.com/role/PortfolioInvestmentsNarrativeDetails" } }, "lang": { "en-us": { "role": { "terseLabel": "Dividend income", "label": "Dividend Income, Operating", "documentation": "Amount of operating dividend income on securities." } } }, "auth_ref": { "r120", "r518", "r590", "r722", "r724", "r801", "r802", "r1079" } } }, "us-gaap_DividendIncomeOperatingPaidInCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DividendIncomeOperatingPaidInCash", "crdr": "credit", "calculation": { "http://ocsl.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_GrossInvestmentIncomeOperating", "weight": 1.0, "order": 4.0 }, "presentation": { "http://ocsl.com/role/ConsolidatedStatementsofOperations" } }, "lang": { "en-us": { "role": { "terseLabel": "Dividend income", "label": "Dividend Income, Operating, Paid in Cash", "documentation": "Amount of dividend income from investment paid in cash, classified as operating." } } }, "auth_ref": { "r593", "r722", "r725" } } }, "dei_DividendOrInterestReinvestmentPlanOnly": { "xbrltype":

"booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DividendOrInterestReinvestmentPlanOnly", "presentation": "http://xbrl.sec.gov/cef/role/N2", "lang": "en-us", "role": "label", "Dividend or Interest Reinvestment Plan Only", "auth_ref": "r834", "r835", "r915", "cef_DividendReinvestmentAndCashPurchaseFees", "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "DividendReinvestmentAndCashPurchaseFees", "presentation": "http://xbrl.sec.gov/cef/role/N2", "lang": "en-us", "role": "label", "Dividend Reinvestment and Cash Purchase Fees", "auth_ref": "r860", "ocsl_DividendReinvestmentPlanPercentOfCurrentMarketPrice", "xbrltype": "percentItemType", "nsuri": "http://ocsl.com/20240630", "localname": "DividendReinvestmentPlanPercentOfCurrentMarketPrice", "presentation": "http://ocsl.com/role/ShareDataandNetAssetsNarrativeDetails", "lang": "en-us", "role": "label", "Dividend reinvestment plan, percent of current market price (as a percent)", "label": "Dividend Reinvestment Plan, Percent of Current Market Price", "documentation": "Dividend Reinvestment Plan, Percent of Current Market Price", "auth_ref": "us-gaap_DividendsDeclaredTableTextBlock", "xbrltype": "textBlockItemType", "nsuri": "http://ash.org/us-gaap/2023", "localname": "DividendsDeclaredTableTextBlock", "presentation": "http://ocsl.com/role/ShareDataandNetAssetsTables", "lang": "en-us", "role": "label", "Schedule of Distributions", "label": "Dividends Declared [Table Text Block]", "documentation": "Tabular disclosure of information related to dividends declared, including paid and unpaid dividends", "auth_ref": "dei_DocumentFiscalPeriodFocus", "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": "http://ocsl.com/role/Cover", "lang": "en-us", "role": "label", "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY", "auth_ref": "dei_DocumentFiscalYearFocus", "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": "http://ocsl.com/role/Cover", "lang": "en-us", "role": "label", "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006", "auth_ref": "dei_DocumentPeriodEndDate", "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": "http://ocsl.com/role/Cover", "lang": "en-us", "role": "label", "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD", "auth_ref": "dei_DocumentQuarterlyReport", "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": "http://ocsl.com/role/Cover", "lang": "en-us", "role": "label", "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report", "auth_ref": "r809", "dei_DocumentRegistrationStatement", "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": "http://xbrl.sec.gov/cef/role/N2", "lang": "en-us", "role": "label", "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement", "auth_ref": "r805", "dei_DocumentTransitionReport", "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": "http://ocsl.com/role/Cover", "lang": "en-us", "role": "label", "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report", "auth_ref": "r916", "dei_DocumentType", "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": "http://ocsl.com/role/Cover", "lang": "en-us", "role": "label", "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'", "auth_ref": "ocsl_DueFromPortfolioCompanies", "xbrltype": "monetaryItemType", "nsuri": "http://ocsl.com/20240630", "localname": "DueFromPortfolioCompanies", "xbrltype": "debit", "calculation": "http://ocsl.com/role/ConsolidatedStatementsOfAssetsandLiabilities", "parentTag": "us-gaap Assets", "weight": 1.0, "order": 5.0, "presentation": "http://ocsl.com/role/ConsolidatedStatementsOfAssetsandLiabilities", "lang": "en-us", "role": "label", "Due from portfolio companies", "label": "Due From Portfolio Companies", "documentation": "Due From Portfolio Companies", "auth_ref": "ocsl_DueFromPortfolioCompaniesPolicyTextBlock", "xbrltype": "textBlockItemType", "nsuri": "http://ocsl.com/20240630", "localname": "DueFromPortfolioCompaniesPolicyTextBlock", "presentation": "http://ocsl.com/role/SignificantAccountingPolicies", "lang": "en-us", "role": "label", "Due from Portfolio Companies", "label": "Due From Portfolio Companies, Policy [Policy Text Block]", "documentation": "Due From Portfolio Companies, Policy", "auth_ref": "us-gaap_EarningsPerShareBasic", "xbrltype": "perShareItemType", "nsuri": "http://ash.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "presentation": "http://ocsl.com/role/ConsolidatedStatementsOfOperations", "http://ocsl.com/role/ShareDataandNetAssetsScheduleOfBasicandDilutedEarningsPerShareDetails", "lang": "en-us", "role": "label", "Earnings (loss) per common share - basic (in dollars per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period", "auth_ref": "r152", "r172", "r173", "r174", "r175", "r176", "r180", "r182", "r185", "r186", "r187", "r188", "r387", "r388", "r466", "r480", "r767", "us-gaap_EarningsPerShareDiluted", "xbrltype": "perShareItemType", "nsuri": "http://ash.org/us-gaap/2023", "localname": "EarningsPerShareDiluted", "presentation": "http://ocsl.com/role/ConsolidatedStatementsOfOperations", "http://ocsl.com/role/ShareDataandNetAssetsScheduleOfBasicandDilutedEarningsPerShareDetails", "lang": "en-us", "role": "label", "Earnings (loss) per common share - diluted (in dollars per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period", "auth_ref": "r152", "r172", "r173", "r174", "r175", "r176", "r182", "r185", "r186", "r187", "r188", "r387", "r388", "r466", "r480", "r767", "ocsl_EarnoutShareVestingAxis", "xbrltype": "stringItemType", "nsuri": "http://ocsl.com/20240630", "localname": "EarnoutShareVestingAxis", "presentation": "http://ocsl.com/role/ConsolidatedScheduleOfInvestmentsParenthetical", "lang": "en-us", "role": "label", "Earnout Share Vesting [Axis]", "label": "Earnout Share Vesting [Axis]", "documentation": "Earnout Share Vesting", "auth_ref": "ocsl_EarnoutShareVestingDomain", "xbrltype": "domainItemType", "nsuri": "http://ocsl.com/20240630", "localname": "EarnoutShareVestingDomain", "presentation": "http://ocsl.com/role/ConsolidatedScheduleOfInvestmentsParenthetical", "lang": "en-us", "role": "label", "Earnout Share Vesting [Domain]", "label": "Earnout Share Vesting [Domain]", "documentation": "Earnout Share Vesting [Domain]", "auth_ref": "ocsl_EarnoutShareVestingTrancheOneMember", "xbrltype": "domainItemType", "nsuri": "http://ocsl.com/20240630", "localname": "EarnoutShareVestingTrancheOneMember", "presentation": "http://ocsl.com/role/ConsolidatedScheduleOfInvestmentsParenthetical", "lang": "en-us", "role": "label", "Earnout Share Vesting, Tranche One", "label": "Earnout Share Vesting, Tranche One [Member]", "documentation": "Earnout Share Vesting, Tranche One", "auth_ref": "ocsl_EarnoutShareVestingTrancheTwoMember", "xbrltype": "domainItemType", "nsuri": "http://ocsl.com/20240630", "localname": "EarnoutShareVestingTrancheTwoMember", "presentation": "http://ocsl.com/role/ConsolidatedScheduleOfInvestmentsParenthetical", "lang": "en-us", "role": "label", "Earnout Share Vesting, Tranche Two", "label": "Earnout Share Vesting, Tranche Two [Member]", "documentation": "Earnout Share Vesting, Tranche Two", "auth_ref": "ocsl_EducationServicesMember", "xbrltype": "domainItemType", "nsuri": "http://ocsl.com/20240630", "localname": "EducationServicesMember", "presentation": "http://ocsl.com/role/PortfolioInvestmentsPortfolioInvestmentsbyIndustryDetails", "lang": "en-us", "role": "label", "Education Services [Member]", "documentation": "Education Services", "auth_ref": "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "xbrltype": "monetaryItemType", "nsuri": "http://ash.org/us-gaap/2023", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "xbrltype": "debit", "calculation": "http://ocsl.com/role/ConsolidatedStatementOfCashFlows", "parentTag": "us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0, "presentation": "http://ocsl.com/role/ConsolidatedStatementOfCashFlows", "lang": "en-us", "role": "label", "Effect of exchange rate changes on foreign currency", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage, held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates", "auth_ref": "r401", "dei_EffectiveAfter60Days486a", "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EffectiveAfter60Days486a", "presentation": "http://xbrl.sec.gov/cef/role/N2", "lang": "en-us", "role": "label", "Effective after 60 days, 486(a)", "auth_ref": "r964", "dei_EffectiveOnDate486a", "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EffectiveOnDate486a", "presentation": "http://xbrl.sec.gov/cef/role/N2", "lang": "en-us", "role": "label", "Effective on Date, 486(a)", "auth_ref": "r964", "dei_EffectiveOnDate486b", "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EffectiveOnDate486b", "presentation": "http://xbrl.sec.gov/cef/role/N2", "lang": "en-us", "role": "label", "Effective on Date, 486(b)", "auth_ref": "r965", "dei_EffectiveOnSetDate486a", "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EffectiveOnSetDate486a", "presentation": "http://xbrl.sec.gov/cef/role/N2", "lang": "en-us", "role": "label", "Effective on Set Date, 486(a)", "auth_ref": "r964", "dei_EffectiveOnSetDate486b", "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EffectiveOnSetDate486b", "presentation": "http://xbrl.sec.gov/cef/role/N2", "lang": "en-us", "role": "label", "Effective on Set Date, 486(b)", "auth_ref": "r965", "dei_EffectiveUponFiling462e", "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EffectiveUponFiling462e", "presentation": "http://xbrl.sec.gov/cef/role/N2", "lang": "en-us", "role": "label", "Effective upon Filing, 462(e)", "auth_ref": "r963", "dei_EffectiveUponFiling486b", "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EffectiveUponFiling486b", "presentation": "http://xbrl.sec.gov/cef/role/N2", "lang": "en-us", "role": "label", "Effective upon Filing, 486(b)", "auth_ref": "r965", "dei_EffectiveWhenDeclaredSection8c", "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EffectiveWhenDeclaredSection8c", "presentation": "http://xbrl.sec.gov/cef/role/N2", "lang": "en-us", "role": "label", "Effective when Declared, Section 8(c)", "auth_ref": "r967", "cef_EffectsOfLeveragePurposeTextBlock", "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "EffectsOfLeveragePurposeTextBlock", "presentation": "http://xbrl.sec.gov/cef/role/N2", "lang": "en-us", "role": "label", "Effects of Leverage, Purpose [Text Block]", "auth_ref": "r893", "cef_EffectsOfLeverageTableTextBlock", "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "EffectsOfLeverageTableTextBlock", "presentation": "http://xbrl.sec.gov/cef/role/N2", "lang": "en-us", "role": "label", "Effects of Leverage [Table Text Block]", "auth_ref": "r893", "cef_EffectsOfLeverageTextBlock", "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "EffectsOfLeverageTextBlock", "presentation": "http://xbrl.sec.gov/cef/role/N2", "lang": "en-us", "role": "label", "Effects of Leverage [Text Block]", "auth_ref": "r890", "ocsl_ElectricalComponentsEquipmentMember", "xbrltype": "domainItemType", "nsuri": "http://ocsl.com/20240630", "localname": "ElectricalComponentsEquipmentMember", "presentation": "http://ocsl.com/role/PortfolioInvestmentsPortfolioInvestmentsbyIndustryDetails", "lang": "en-us", "role": "label", "Electrical Components & Equipment", "label": "Electrical Components & Equipment [Member]", "documentation": "Electrical Components & Equipment", "auth_ref": "us-gaap_EmployeeStockOptionMember", "xbrltype": "domainItemType", "nsuri": "http://ash.org/us-gaap/2023", "localname": "EmployeeStockOptionMember", "presentation": "http://xbrl.sec.gov/ced/role/AwardTimingDisclosure", "lang": "en-us", "role": "label", "Employee Stock Option", "label": "Share-Based Payment Arrangement, Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time", "auth_ref": "dei_EntityAddressAddressLine1", "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": "http://ocsl.com/role/Cover", "http://xbrl.sec.gov/cef/role/N2", "lang": "en-us", "role": "label", "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "auth_ref": "dei_EntityAddressAddressLine2", "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": "http://ocsl.com/role/Cover", "http://xbrl.sec.gov/cef/role/N2", "lang": "en-us", "role": "label", "Entity Address, Address Line Two", "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number", "auth_ref": "dei_EntityAddressAddressLine3", "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": "http://xbrl.sec.gov/cef/role/N2", "lang": "en-us", "role": "label", "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park", "auth_ref": "dei_EntityAddressCityOrTown", "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": "http://ocsl.com/role/Cover", "http://xbrl.sec.gov/cef/role/N2", "lang": "en-us", "role": "label", "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town", "auth_ref": "dei_EntityAddressPostalZipCode", "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023",

```

"localname": "EntityAddressPostalZipCode", "presentation": "http://ocsl.com/role/Cover", "http://xbrl.sec.gov/cef/role/N2", "lang": "en-us", "role": "label", "EntityAddress, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code", "auth_ref": "H1", "dei_EntityAddressStateOrProvince": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": "http://ocsl.com/role/Cover", "http://xbrl.sec.gov/cef/role/N2", "lang": "en-us", "role": "label", "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province", "documentation": "Name of the state or province", "auth_ref": "H1", "dei_EntityAddressesAddressTypeAxis": "http://xbrl.sec.gov/cef/role/N2", "lang": "en-us", "role": "label", "Entity Addresses, Address Type [Axis]", "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table", "auth_ref": "H1", "dei_EntityCentralIndexKey": "http://ocsl.com/role/Cover", "http://xbrl.sec.gov/cef/role/N2", "lang": "en-us", "role": "label", "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK", "auth_ref": "r807", "dei_EntityCommonStockSharesOutstanding": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": "http://ocsl.com/role/Cover", "http://xbrl.sec.gov/cef/role/N2", "lang": "en-us", "role": "label", "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the instrument domain of the Entity Listings, Instrument", "auth_ref": "H1", "dei_EntityCurrentReportingStatus": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": "http://ocsl.com/role/Cover", "http://xbrl.sec.gov/cef/role/N2", "lang": "en-us", "role": "label", "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports); and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure", "auth_ref": "H1", "dei_EntityDomain": "http://xbrl.sec.gov/dei/2023", "localname": "EntityDomain", "presentation": "http://ocsl.com/role/PortfolioInvestmentsNarrativeDetails", "http://xbrl.sec.gov/cef/role/N2", "lang": "en-us", "role": "label", "Entity [Domain]", "terseLabel": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains", "auth_ref": "H1", "dei_EntityEmergingGrowthCompany": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": "http://ocsl.com/role/Cover", "http://xbrl.sec.gov/cef/role/N2", "lang": "en-us", "role": "label", "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria", "auth_ref": "r807", "dei_EntityExTransitionPeriod": "http://xbrl.sec.gov/cef/role/N2", "lang": "en-us", "role": "label", "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards", "auth_ref": "r966", "dei_EntityFileNumber": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": "http://ocsl.com/role/Cover", "http://xbrl.sec.gov/cef/role/N2", "lang": "en-us", "role": "label", "Securities Act File Number", "terseLabel": "Securities Act File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen", "auth_ref": "H1", "dei_EntityFilerCategory": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": "http://ocsl.com/role/Cover", "http://xbrl.sec.gov/cef/role/N2", "lang": "en-us", "role": "label", "Entity Filer Category", "terseLabel": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure", "auth_ref": "r807", "dei_EntityIncorporationStateCountryCode": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": "http://ocsl.com/role/Cover", "http://xbrl.sec.gov/cef/role/N2", "lang": "en-us", "role": "label", "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation", "auth_ref": "H1", "dei_EntityInteractiveDataCurrent": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": "http://ocsl.com/role/Cover", "http://xbrl.sec.gov/cef/role/N2", "lang": "en-us", "role": "label", "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)", "auth_ref": "r957", "dei_EntityInvCompanyType": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInvCompanyType", "presentation": "http://xbrl.sec.gov/cef/role/N2", "lang": "en-us", "role": "label", "Entity Inv Company Type", "documentation": "One of: N-1A (Mutual Fund), N-1 (Open-End Separate Account with No Variable Annuities), N-2 (Closed-End Investment Company), N-3 (Separate Account Registered as Open-End Management Investment Company), N-4 (Variable Annuity UIT Separate Account), N-5 (Small Business Investment Company), N-6 (Variable Life UIT Separate Account), S-1 or S-3 (Face Amount Certificate Company), S-6 (UIT, Non-Insurance Product)", "auth_ref": "r956", "dei_EntityRegistrantName": "http://ocsl.com/role/Cover", "http://xbrl.sec.gov/cef/role/N2", "lang": "en-us", "role": "label", "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC", "auth_ref": "r807", "dei_EntityShellCompany": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": "http://ocsl.com/role/Cover", "http://xbrl.sec.gov/cef/role/N2", "lang": "en-us", "role": "label", "Entity Shell Company", "terseLabel": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act", "auth_ref": "r807", "dei_EntitySmallBusiness": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": "http://ocsl.com/role/Cover", "http://xbrl.sec.gov/cef/role/N2", "lang": "en-us", "role": "label", "Entity Small Business", "terseLabel": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)", "auth_ref": "r807", "dei_EntityTaxIdentificationNumber": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": "http://ocsl.com/role/Cover", "http://xbrl.sec.gov/cef/role/N2", "lang": "en-us", "role": "label", "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS", "auth_ref": "r807", "dei_EntityWellKnownSeasonedIssuer": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": "http://xbrl.sec.gov/cef/role/N2", "lang": "en-us", "role": "label", "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A", "auth_ref": "r958", "ocsl_EnvironmentalFacilitiesServicesMember": "http://xbrl.sec.gov/20240630", "localname": "EnvironmentalFacilitiesServicesMember", "presentation": "http://ocsl.com/role/PortfolioInvestmentsPortfolioofInvestmentsbyIndustryDetails", "http://xbrl.sec.gov/20240630", "localname": "Environmental & Facilities Services", "label": "Environmental & Facilities Services [Member]", "documentation": "Environmental & Facilities Services", "auth_ref": "H1", "us_gaap_EquityComponentDomain": "http://xbrl.sec.gov/20240630", "localname": "EquityComponentDomain", "presentation": "http://ocsl.com/role/ShareDataandNetAssetsScheduleofChangesinNetAssetsDetails", "http://xbrl.sec.gov/20240630", "localname": "Equity Component [Domain]", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "auth_ref": "r11", "r134", "r147", "r148", "r149", "r167", "r168", "r169", "r171", "r177", "r179", "r189", "r239", "r240", "r310", "r346", "r347", "r348", "r363", "r364", "r378", "r379", "r380", "r381", "r382", "r383", "r386", "r402", "r403", "r404", "r405", "r406", "r407", "r412", "r485", "r486", "r487", "r521", "r620", "r1", "srt_EquityMethodInvesteeNameDomain": "http://xbrl.sec.gov/20240630", "localname": "EquityMethodInvesteeNameDomain", "presentation": "http://ocsl.com/role/PortfolioInvestmentsNarrativeDetails", "http://xbrl.sec.gov/20240630", "localname": "Investment, Name [Domain]", "label": "Investment, Name [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "auth_ref": "r11", "r134", "r147", "r148", "r149", "r167", "r168", "r169", "r171", "r177", "r179", "r189", "r239", "r240", "r310", "r346", "r347", "r348", "r363", "r364", "r378", "r379", "r380", "r381", "r382", "r383", "r386", "r402", "r403", "r404", "r405", "r406", "r407", "r412", "r485", "r486", "r487", "r521", "r620", "r1", "us_gaap_EquitySecuritiesByIndustryAxis": "http://xbrl.sec.gov/20240630", "localname": "EquitySecuritiesByIndustryAxis", "presentation": "http://ocsl.com/role/PortfolioInvestmentsPortfolioofInvestmentsbyIndustryDetails", "http://xbrl.sec.gov/20240630", "localname": "Industry Sector [Axis]", "label": "Industry Sector [Axis]", "documentation": "Information by industry sector, examples include but are not limited to, commercial, industrial, agricultural, financial services, technology, healthcare and real estate", "auth_ref": "r539", "r543", "r546", "r640", "r657", "r679", "r731", "r771", "r789", "r1", "ocsl_EquitySecuritiesCommonAndWarrantsIncludingJVInvestmentsMember": "http://xbrl.sec.gov/20240630", "localname": "EquitySecuritiesCommonAndWarrantsIncludingJVInvestmentsMember", "presentation": "http://ocsl.com/role/PortfolioInvestmentsPortfolioofInvestmentsbyIndustryDetails", "http://xbrl.sec.gov/20240630", "localname": "Equity Securities, Common And Warrants, Including JV Investments", "label": "Equity Securities, Common And Warrants, Including JV Investments [Member]", "documentation": "Equity Securities, Common And Warrants, Including JV Investments", "auth_ref": "H1", "ocsl_EquitySecuritiesCommonStockConvertedMember": "http://xbrl.sec.gov/20240630", "localname": "EquitySecuritiesCommonStockConvertedMember", "presentation": "http://ocsl.com/role/PortfolioInvestmentsPortfolioofInvestmentsbyIndustryDetails", "http://xbrl.sec.gov/20240630", "localname": "Equity Securities, Common Stock Converted", "label": "Equity Securities, Common Stock Converted [Member]", "documentation": "Equity Securities, Common Stock Converted", "auth_ref": "H1", "us_gaap_EquitySecuritiesIndustryMember": "http://xbrl.sec.gov/20240630", "localname": "EquitySecuritiesIndustryMember", "presentation": "
```

"http://ocsl.com/role/PortfolioInvestmentsScheduleofFinancialInstrumentsCarriedatFairValueDetails": {"lang": {"en-us": {"role": {"terseLabel": "Preferred equity"}}, "label": "Equity Securities, Preferred [Member]"}, "documentation": "Equity Securities, Preferred"}, {"auth_ref": []}, {"ecd_EquityValuationAssumptionDifferenceEnTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "EquityValuationAssumptionDifferenceEnTextBlock", "presentation": {"http://xbrl.sec.gov/ecd/role/PvpDisclosure": {"lang": {"en-us": {"role": {"terseLabel": "Equity Valuation Assumption Difference, Footnote"}}, "label": "Equity Valuation Assumption Difference, Footnote [Text Block]"}}, {"auth_ref": ["r925"]}}, {"ecd_ErrCompAnalysisTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompAnalysisTextBlock", "presentation": {"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": {"lang": {"en-us": {"role": {"terseLabel": "Erroneous Compensation Analysis"}}, "label": "Erroneous Compensation Analysis [Text Block]"}}, {"auth_ref": ["r815", "r827", "r908", "r935"]}}, {"ecd_ErrCompRecoveryTable": {"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompRecoveryTable", "presentation": {"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": {"lang": {"en-us": {"role": {"terseLabel": "Erroneously Awarded Compensation Recovery"}}, "label": "Erroneously Awarded Compensation Recovery [Table]"}}, {"auth_ref": ["r812", "r824", "r905", "r932"]}}, {"us-gaap_ExciseAndSalesTaxes": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ExciseAndSalesTaxes", "crdr": "debit", "calculation": {"http://ocsl.com/role/ConsolidatedStatementsOfOperations": {"parentTag": "us-gaap_InvestmentIncomeOperatingAfterExpenseAndTax", "weight": -1.0, "order": 2.0}}, {"presentation": {"http://ocsl.com/role/ConsolidatedStatementsOfOperations": {"http://ocsl.com/role/SignificantAccountingPoliciesDetails": {"lang": {"en-us": {"role": {"negatedLabel": "Excise tax", "terseLabel": "Excise tax", "label": "Excise and Sales Taxes", "documentation": "The amount of excise and sales taxes included in sales and revenues, which are then deducted as a cost of sales. Includes excise taxes, which are applied to specific types of transactions or items (such as gasoline or alcohol) and sales, use and value added taxes, which are applied to a broad class of revenue-producing transactions involving a wide range of goods and services."}}}, {"auth_ref": ["r151"]}}, {"ecd_ExecutiveCategoryAxis": {"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ExecutiveCategoryAxis", "presentation": {"http://xbrl.sec.gov/ecd/role/PvpDisclosure": {"lang": {"en-us": {"role": {"terseLabel": "Executive Category"}}, "label": "Executive Category [Axis]"}}, {"auth_ref": ["r931"]}}, {"dei_ExhibitsOnly462d": {"xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "ExhibitsOnly462d", "presentation": {"http://xbrl.sec.gov/cef/role/N2": {"lang": {"en-us": {"role": {"label": "Exhibits Only, 462(d)"}}, {"auth_ref": ["r962"]}}, {"dei_ExhibitsOnly462dFileNumber": {"xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "ExhibitsOnly462dFileNumber", "presentation": {"http://xbrl.sec.gov/cef/role/N2": {"lang": {"en-us": {"role": {"label": "Exhibits Only, 462(d), File Number"}}, {"auth_ref": ["r962"]}}, {"ocsl_ExitInvestmentsMember": {"xbrltype": "domainItemType", "nsuri": "http://ocsl.com/20240630", "localname": "ExitInvestmentsMember", "presentation": {"http://ocsl.com/role/RealizedGainsorLossesandNetUnrealizedAppreciationorDepreciationNarrativeDetails": {"lang": {"en-us": {"role": {"terseLabel": "Exited Investments"}}, "label": "Exited Investments [Member]"}, {"documentation": "Exited Investments"}}, {"auth_ref": []}, {"cef_ExpenseExampleTableTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "ExpenseExampleTableTextBlock", "presentation": {"http://xbrl.sec.gov/cef/role/N2": {"lang": {"en-us": {"role": {"label": "Expense Example [Table Text Block]"}}, {"auth_ref": ["r860"]}}, {"cef_ExpenseExampleYear01": {"xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "ExpenseExampleYear01", "presentation": {"http://xbrl.sec.gov/cef/role/N2": {"lang": {"en-us": {"role": {"label": "Expense Example, Year 01"}}, {"auth_ref": ["r867"]}}, {"cef_ExpenseExampleYears1to10": {"xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "ExpenseExampleYears1to10", "presentation": {"http://xbrl.sec.gov/cef/role/N2": {"lang": {"en-us": {"role": {"label": "Expense Example, Years 1 to 10"}}, {"auth_ref": ["r867"]}}, {"cef_ExpenseExampleYears1to3": {"xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "ExpenseExampleYears1to3", "presentation": {"http://xbrl.sec.gov/cef/role/N2": {"lang": {"en-us": {"role": {"label": "Expense Example, Years 1 to 3"}}, {"auth_ref": ["r867"]}}, {"cef_ExpenseExampleYears1to5": {"xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "ExpenseExampleYears1to5", "presentation": {"http://xbrl.sec.gov/cef/role/N2": {"lang": {"en-us": {"role": {"label": "Expense Example, Years 1 to 5"}}, {"auth_ref": ["r867"]}}, {"us-gaap_FairValueAssetRecurringBasisStillHeldUnrealizedGainLossStatementOfIncomeExtensibleList": {"xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetRecurringBasisStillHeldUnrealizedGainLossStatementOfIncomeExtensibleList", "presentation": {"http://ocsl.com/role/PortfolioInvestmentsRollForwardintheChangesinFairValueDetails": {"lang": {"en-us": {"role": {"terseLabel": "Unrealized gain (loss), location"}}, "label": "Fair Value, Asset, Recurring Basis, Still Held, Unrealized Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]"}, {"documentation": "Indicates line item in statement in which net income is reported that includes unrealized gain (loss) from asset measured at fair value using unobservable input (level 3) and still held."}}}, {"auth_ref": ["r395"]}}, {"us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems", "presentation": {"http://ocsl.com/role/PortfolioInvestmentsSignificantUnobservableInputsforLevel3InvestmentsDetails": {"lang": {"en-us": {"role": {"terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]"}}, "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]"}, {"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."}}}, {"auth_ref": []}, {"us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {"xbrltype": "stringItemType", "nsuri": "http://ocsl.com/role/PortfolioInvestmentsSignificantUnobservableInputsforLevel3InvestmentsDetails": {"lang": {"en-us": {"role": {"terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Table]"}}, "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]"}, {"documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."}}}, {"auth_ref": ["r13"]}}, {"us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "presentation": {"http://ocsl.com/role/PortfolioInvestmentsTables": {"lang": {"en-us": {"role": {"terseLabel": "Schedule of Significant Unobservable Inputs for Level 3 Investments"}}, "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]"}, {"documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."}}}, {"auth_ref": ["r13"]}}, {"us-gaap_FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss", "crdr": "credit", "presentation": {"http://ocsl.com/role/PortfolioInvestmentsRollForwardintheChangesinFairValueDetails": {"lang": {"en-us": {"role": {"terseLabel": "Net unrealized appreciation (depreciation)u00a0relating to Level 3 investments still held and reported within net unrealized appreciation (depreciation) in the Consolidated Statement of Operations"}}, "label": "Fair Value, Asset, Recurring Basis, Still Held, Unrealized Gain (Loss)"}, {"documentation": "Amount of unrealized gain (loss) recognized in income from asset measured at fair value on recurring basis using unobservable input (level 3) and still held."}}}, {"auth_ref": ["r395"]}}, {"us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock", "presentation": {"http://ocsl.com/role/PortfolioInvestmentsTables": {"lang": {"en-us": {"role": {"terseLabel": "Schedule of Financial Instruments Carried at Fair Value"}}, "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]"}, {"documentation": "Tabular disclosure of assets, including financial instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."}}, {"auth_ref": ["r60", "r108"]}}, {"us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "presentation": {"http://ocsl.com/role/PortfolioInvestmentsRollForwardintheChangesinFairValueDetails": {"lang": {"en-us": {"role": {"terseLabel": "Asset Class [Domain]"}}, "label": "Asset Class [Domain]"}, {"documentation": "Class of asset."}}}, {"auth_ref": ["r14"]}}, {"us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward", "presentation": {"http://ocsl.com/role/PortfolioInvestmentsRollForwardintheChangesinFairValueDetails": {"lang": {"en-us": {"role": {"terseLabel": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]"}}, "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]"}, {"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."}}}, {"auth_ref": []}, {"us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "presentation": {"http://ocsl.com/role/PortfolioInvestmentsRollForwardintheChangesinFairValueDetails": {"lang": {"en-us": {"role": {"terseLabel": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]"}}, "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]"}, {"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."}}}, {"auth_ref": []}, {"us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "presentation": {"http://ocsl.com/role/PortfolioInvestmentsRollForwardintheChangesinFairValueDetails": {"lang": {"en-us": {"role": {"terseLabel": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]"}}, "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]"}, {"documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of assets using significant unobservable inputs (level 3). Such reconciliation, separately presenting changes during the period, at a minimum, may include, but is not limited to: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income, and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset."}}}, {"auth_ref": ["r14", "r62"]}}, {"us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "presentation": {"http://ocsl.com/role/PortfolioInvestmentsTables": {"lang": {"en-us": {"role": {"terseLabel": "Schedule of Roll-Forward in the Changes in Fair Value"}}, "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]"}, {"documentation": "Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset."}}}, {"auth_ref": ["r14", "r62"]}}, {"us-gaap_FairValueByAssetClassAxis": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByAssetClassAxis", "presentation": {"http://ocsl.com/role/PortfolioInvestmentsRollForwardintheChangesinFairValueDetails": {"lang": {"en-us": {"role": {"terseLabel": "Asset Class [Axis]"}}, "label": "Asset Class [Axis]"}, {"documentation": "Information by class of asset."}}}, {"auth_ref": ["r60", "r62"]}}, {"us-gaap_FairValueByFairValueHierarchyLevelAxis": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": {"http://ocsl.com/role/PortfolioInvestmentsScheduleofFinancialInstrumentsCarriedatFairValueDetails": {"http://ocsl.com/role/PortfolioInvestmentsSignificantUnobservableInputsforLevel3InvestmentsDetails": {"lang": {"en-us": {"role": {"terseLabel": "Fair Value Hierarchy and NAV [Axis]"}}, "label": "Fair Value Hierarchy and NAV [Axis]"}, {"documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."}}}, {"auth_ref": ["r280", "r312", "r313", "r314", "r315", "r316", "r317", "r390", "r425", "r426", "r427", "r775", "r776", "r781", "r782", "r783"]}}, {"us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock": {"xbrltype": "textBlockItemType", "nsuri":

"http://fasb.org/us-gaap/2023", "localname": "Fair Value Disclosure Of Asset And Liability Not Measured At Fair Value Table Text Block", "presentation": f

"http://ocsl.com/role/PortfolioInvestmentsTables" }, "lang": f "en-us", "role": f "terseLabel", "Schedule of Fair Value Disclosure of Asset and Liability Not Measured at Fair Value", "label": "Fair Value Disclosure of Asset and Liability Not Measured at Fair Value [Table Text Block]", "documentation": "Tabular disclosure of information about fair value of asset and liability not measured at fair value." } }, "auth ref": f "r396" }, "us-gaap FairValueInputsLevel1Member": f "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel1Member", "presentation": f

"http://ocsl.com/role/PortfolioInvestmentsScheduleoffFinancialInstrumentsCarriedatFairValueDetails",

"http://ocsl.com/role/PortfolioInvestmentsScheduleoffFinancialInstrumentsDisclosedbutCarriedatFairValueDetails" }, "lang": f "en-us", "role": f "terseLabel", "LevelH00a01", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } }, "auth ref": f "r280", "r312", "r317", "r390", "r425", "r781", "r782", "r783" }, "us-gaap FairValueInputsLevel2Member": f "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel2Member", "presentation": f

"http://ocsl.com/role/PortfolioInvestmentsScheduleoffFinancialInstrumentsCarriedatFairValueDetails",

"http://ocsl.com/role/PortfolioInvestmentsScheduleoffFinancialInstrumentsDisclosedbutCarriedatFairValueDetails" }, "lang": f "en-us", "role": f "terseLabel", "LevelH00a02", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } }, "auth ref": f "r280", "r312", "r317", "r390", "r426", "r775", "r776", "r781", "r782", "r783" }, "us-gaap FairValueInputsLevel3Member": f "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel3Member", "presentation": f

"http://ocsl.com/role/PortfolioInvestmentsScheduleoffFinancialInstrumentsCarriedatFairValueDetails",

"http://ocsl.com/role/PortfolioInvestmentsScheduleoffFinancialInstrumentsDisclosedbutCarriedatFairValueDetails",

"http://ocsl.com/role/PortfolioInvestmentsSignificantUnobservableInputsforLevel3InvestmentsDetails" }, "lang": f "en-us", "role": f "terseLabel", "Level 3", "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } }, "auth ref": f "r280", "r312", "r313", "r314", "r315", "r316", "r317", "r390", "r427", "r775", "r776", "r781", "r782", "r783" }, "us-gaap FairValueMeasuredAtNetAssetValuePerShareMember": f "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasuredAtNetAssetValuePerShareMember", "presentation": f

"http://ocsl.com/role/PortfolioInvestmentsScheduleoffFinancialInstrumentsCarriedatFairValueDetails",

"Fair Value Measured At Net Asset Value Per Share Member", "presentation": f

"http://ocsl.com/role/PortfolioInvestmentsScheduleoffFinancialInstrumentsCarriedatFairValueDetails" }, "lang": f "en-us", "role": f "terseLabel", "Measured at Net Asset Value", "label": "Fair Value Measured at Net Asset Value Per Share [Member]", "documentation": "Fair value measured at net asset value per share as practical expedient." } }, "auth ref": f "r312", "r389", "r397" }, "us-gaap FairValueMeasurementPolicyPolicyTextBlock": f "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementPolicyPolicyTextBlock", "presentation": f

"http://ocsl.com/role/SignificantAccountingPoliciesPolicies" }, "lang": f "en-us", "role": f "terseLabel", "Fair Value Measurements", "label": "Fair Value Measurement, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities." } }, "auth ref": f "r312", "r389", "r397" }, "ocsl FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetAccretionOfDiscount": f "xbrltype": "monetaryItemType", "nsuri": "http://ocsl.com/20240630", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetAccretionOfDiscount", "presentation": f

"http://ocsl.com/role/PortfolioInvestmentsRollForwardintheChangesinFairValueDetails" }, "lang": f "en-us", "role": f "terseLabel", "Accretion of OID", "label": "Fair Value, Measurement With Unobservable Inputs Reconciliation, Recurring Basis, Asset, Accretion Of Discount", "documentation": "Fair Value, Measurement With Unobservable Inputs Reconciliation, Recurring Basis, Asset, Accretion Of Discount" } }, "auth ref": f "r312", "r389", "r397" }, "us-gaap FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1": f "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1", "presentation": f

"http://ocsl.com/role/PortfolioInvestmentsRollForwardintheChangesinFairValueDetails" }, "lang": f "en-us", "role": f "terseLabel", "Total gains or losses included in earnings", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings", "documentation": "Amount of gain (loss) recognized in income from asset measured at fair value on recurring basis using unobservable input (level 3)." } }, "auth ref": f "r393" }, "ocsl FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPIKInterestIncomeCapitalized": f "xbrltype": "monetaryItemType", "nsuri": "http://ocsl.com/20240630", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPIKInterestIncomeCapitalized", "presentation": f

"http://ocsl.com/role/PortfolioInvestmentsRollForwardintheChangesinFairValueDetails" }, "lang": f "en-us", "role": f "terseLabel", "Capitalized PIK interest income", "label": "Fair Value, Measurement With Unobservable Inputs Reconciliation, Recurring Basis, Asset, PIK Interest Income Capitalized", "documentation": "Fair Value, Measurement With Unobservable Inputs Reconciliation, Recurring Basis, Asset, PIK Interest Income Capitalized" } }, "auth ref": f "r312", "r389", "r397" }, "us-gaap FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases": f "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases", "presentation": f

"http://ocsl.com/role/PortfolioInvestmentsRollForwardintheChangesinFairValueDetails" }, "lang": f "en-us", "role": f "terseLabel", "Purchases", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases", "documentation": "Amount of purchases of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } }, "auth ref": f "r61" }, "ocsl FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSalesAndSettlements": f "xbrltype": "monetaryItemType", "nsuri": "http://ocsl.com/20240630", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSalesAndSettlements", "presentation": f

"http://ocsl.com/role/PortfolioInvestmentsRollForwardintheChangesinFairValueDetails" }, "lang": f "en-us", "role": f "terseLabel", "Sales and repayments", "label": "Fair Value, Measurement With Unobservable Inputs Reconciliation, Recurring Basis, Asset, Sales And Settlements", "documentation": "Fair Value, Measurement With Unobservable Inputs Reconciliation, Recurring Basis, Asset, Sales And Settlements" } }, "auth ref": f "r312", "r389", "r397" }, "us-gaap FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3": f "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3", "presentation": f

"http://ocsl.com/role/PortfolioInvestmentsRollForwardintheChangesinFairValueDetails" }, "lang": f "en-us", "role": f "terseLabel", "Transfers in", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers Into Level 3", "documentation": "Amount of transfer of financial instrument classified as an asset into level 3 of the fair value hierarchy." } }, "auth ref": f "r394" }, "us-gaap FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3": f "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3", "presentation": f

"http://ocsl.com/role/PortfolioInvestmentsRollForwardintheChangesinFairValueDetails" }, "lang": f "en-us", "role": f "terseLabel", "Transfers out", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3", "documentation": "Amount of transfers of financial instrument classified as an asset out of level 3 of the fair value hierarchy." } }, "auth ref": f "r394" }, "us-gaap FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue": f "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue", "presentation": f

"http://ocsl.com/role/PortfolioInvestmentsRollForwardintheChangesinFairValueDetails" }, "lang": f "en-us", "role": f "terseLabel", "Fair value, beginning balance", "label": "Fair value, beginning balance", "documentation": "Fair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } }, "auth ref": f "r14" }, "us-gaap FairValueMeasurementsFairValueHierarchyDomain": f "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": f

"http://ocsl.com/role/PortfolioInvestmentsScheduleoffFinancialInstrumentsCarriedatFairValueDetails",

"http://ocsl.com/role/PortfolioInvestmentsScheduleoffFinancialInstrumentsDisclosedbutCarriedatFairValueDetails",

"http://ocsl.com/role/PortfolioInvestmentsSignificantUnobservableInputsforLevel3InvestmentsDetails" }, "lang": f "en-us", "role": f "terseLabel", "Fair Value Hierarchy and NAV [Domain]", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } }, "auth ref": f "r280", "r312", "r313", "r314", "r315", "r316", "r317", "r425", "r426", "r427", "r775", "r776", "r781", "r782", "r783" }, "us-gaap FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList": f "xbrltype": "enumerationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList", "presentation": f

"http://ocsl.com/role/PortfolioInvestmentsRollForwardintheChangesinFairValueDetails" }, "lang": f "en-us", "role": f "terseLabel", "Gain (loss), location", "label": "Fair Value, Asset, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]", "documentation": "Indicates line item in statement in which net income is reported that includes gain (loss) from asset measured at fair value using unobservable input (level 3)." } }, "auth ref": f "r393" }, "us-gaap FederalIncomeTaxNoteTable": f "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FederalIncomeTaxNoteTable", "presentation": f

"http://ocsl.com/role/TaxableDistributableIncomeandDividendDistributionsNarrativeDetails" }, "lang": f "en-us", "role": f "terseLabel", "Federal Income Tax Note [Table]", "label": "Federal Income Tax Note [Table]", "documentation": "Table of federal income tax note for schedule of investments. The federal income tax note may be qualified for security investments, non-security investments and/or for the combination of security and non-security investments." } }, "auth ref": f "r1036" }, "us-gaap FederalIncomeTaxNoteTextBlock": f "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FederalIncomeTaxNoteTextBlock", "presentation": f

"http://ocsl.com/role/TaxableDistributableIncomeandDividendDistributionsTables" }, "lang": f "en-us", "role": f "terseLabel", "Schedule of Reconciliation of Net Increase (Decrease) in Net Assets Resulting from Operations", "label": "Federal Income Tax Note [Table Text Block]", "documentation": "Tabular disclosure of the federal tax basis of investment holdings. This item captures the aggregate cost of securities, aggregate gross unrealized appreciation for all securities in which there is an excess of value over tax cost, aggregate gross unrealized depreciation for all securities in which there is an excess of tax cost over value, net unrealized appreciation (depreciation), and an explanation of the differences between tax and book." } }, "auth ref": f "r1036" }, "us-gaap FeeIncome": f "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FeeIncome", "presentation": f

"http://ocsl.com/role/ConsolidatedStatementsofOperations": f "parentTag": "us-gaap_GrossInvestmentIncomeOperating", "weight": 1.0 "order": 2.0 } }, "presentation": f

"http://ocsl.com/role/ConsolidatedStatementsofOperations": "http://ocsl.com/role/FeeIncomeDetails" }, "lang": f "en-us", "role": f "terseLabel", "Fee income", "label": "Fee Income", "documentation": "Amount of fee income including, but not limited to, managerial assistance, servicing of investment, and origination and commitment fees." } }, "auth ref": f "r1055" }, "ocsl FeeIncomeRecurring": f "xbrltype": "monetaryItemType", "nsuri": "http://ocsl.com/20240630", "localname": "FeeIncomeRecurring", "presentation": f

"http://ocsl.com/role/FeeIncomeDetails" }, "lang": f "en-us", "role": f "terseLabel", "Recurring fee income", "label": "Fee Income, Recurring", "documentation": "Fee Income, Recurring" } }, "auth ref": f "r1055" }, "ocsl FeeIncomeTextBlock": f "xbrltype": "textBlockItemType", "nsuri": "http://ocsl.com/20240630", "localname": "FeeIncomeTextBlock", "presentation": f

"http://ocsl.com/role/FeeIncomeTextBlock": "http://ocsl.com/role/FeeIncomeTextBlock" }, "lang": f "en-us", "role": f "terseLabel", "Fee income", "label": "Fee Income [Text Block]", "documentation": "Fee Income" } }, "auth ref": f "r1055" }, "ocsl FeeTableAbstract": f "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "FeeTableAbstract", "presentation": f

"http://xbrl.sec.gov/cef/role/N2" }, "lang": f "en-us", "role": f "label", "Fee Table [Abstract]", "label": "Fee Table [Abstract]", "documentation": "Fee Table [Abstract]" } }, "auth ref": f "r860" }, "ocsl FertilizersAgriculturalChemicalsMember": f "xbrltype": "domainItemType", "nsuri": "http://ocsl.com/20240630", "localname": "FertilizersAgriculturalChemicalsMember", "presentation": f

"http://ocsl.com/role/PortfolioInvestmentsPortfolioofInvestmentsbyIndustryDetails" }, "lang": f "en-us", "role": f "terseLabel", "Fertilizers & Agricultural Chemicals", "label": "Fertilizers & Agricultural Chemicals [Member]", "documentation": "Fertilizers & Agricultural Chemicals" } }, "auth ref": f "r860" }, "cef FinancialHighlightsAbstract": f "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "FinancialHighlightsAbstract", "presentation": f

"http://xbrl.sec.gov/cef/role/N2" }, "lang": f "en-us", "role": f "label", "Financial Highlights [Abstract]", "label": "Financial Highlights [Abstract]", "documentation": "Financial Highlights [Abstract]" } }, "auth ref": f "r875" }, "us-gaap FinancialInstrumentAxis": f "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancialInstrumentAxis", "presentation": f

"http://ocsl.com/role/PortfolioInvestmentsCompositionofInvestmentsDetails", "http://ocsl.com/role/PortfolioInvestmentsNarrativeDetails", "http://ocsl.com/role/PortfolioInvestmentsPortfolioofInvestmentsbyIndustryDetails", "http://ocsl.com/role/PortfolioInvestmentsSignificantUnobservableInputsforLevel3InvestmentsDetails", "http://ocsl.com/role/SignificantAccountingPoliciesDetails" },

```

lang="en-us": { "role": { "terseLabel": "Financial Instrument [Axis]", "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } }, "auth_ref": { "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r291", "r307", "r384", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r476", "r773", "r921", "r972", "r973", "r974", "r975", "r976", "r977", "r997", "r998", "r999", "r1000" } }, "us-gaap_FinancialSupportForNonconsolidatedLegalEntityLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancialSupportForNonconsolidatedLegalEntityLineItems", "presentation": { "http://ocsl.com/role/CommitmentsandContingenciesNarrativeDetails": { "http://ocsl.com/role/CommitmentsandContingenciesScheduleOfUnfundedCommitmentsbyInvestmentDetails": { "lang": { "en-us": { "role": { "terseLabel": "Financial Support for Nonconsolidated Legal Entity [Line Items]", "label": "Financial Support for Nonconsolidated Legal Entity [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r511", "r512" } } }, "us-gaap_FinancialSupportForNonconsolidatedLegalEntityTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancialSupportForNonconsolidatedLegalEntityTable", "presentation": { "http://ocsl.com/role/CommitmentsandContingenciesNarrativeDetails": { "http://ocsl.com/role/CommitmentsandContingenciesScheduleOfUnfundedCommitmentsbyInvestmentDetails": { "lang": { "en-us": { "role": { "terseLabel": "Financial Support for Nonconsolidated Legal Entity [Table]", "label": "Financial Support for Nonconsolidated Legal Entity [Table]", "documentation": "Disclosure of information about financial support provided to a nonconsolidated legal entity that is required to comply with or operate in accordance with requirements that are similar to those included in Rule 2a-7 of the Investment Company Act of 1940 for registered money market funds." } } }, "auth_ref": { "r0", "r511", "r512" } } } }, "ocsl_FinancingExchangeDataMember": { "xbrltype": "domainItemType", "nsuri": "http://ocsl.com/20240630", "localname": "FinancingExchangeDataMember", "presentation": { "http://ocsl.com/role/PortfolioInvestmentsPortfolioofInvestmentsbyIndustryDetails": { "lang": { "en-us": { "role": { "terseLabel": "Financial Exchanges & Data", "label": "Financing Exchange & Data [Member]", "documentation": "Financing Exchange & Data" } } }, "auth_ref": { "r0", "ocsl_FoodDistributorsMember": { "xbrltype": "domainItemType", "nsuri": "http://ocsl.com/20240630", "localname": "FoodDistributorsMember", "presentation": { "http://ocsl.com/role/PortfolioInvestmentsPortfolioofInvestmentsbyIndustryDetails": { "lang": { "en-us": { "role": { "terseLabel": "Food Distributors", "label": "Food Distributors [Member]", "documentation": "Food Distributors" } } }, "auth_ref": { "r0", "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "presentation": { "http://ocsl.com/role/SignificantAccountingPolicies": { "lang": { "en-us": { "role": { "terseLabel": "Foreign Currency Translation", "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy." } } }, "auth_ref": { "r400" } } }, "us-gaap_ForeignExchangeForwardMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignExchangeForwardMember", "presentation": { "http://ocsl.com/role/ConsolidatedScheduleofInvestmentsDerivatives": { "http://ocsl.com/role/DerivativeInstrumentsScheduleOfForeignCurrencyForwardContractsandInterestRateSwapDetails": { "http://ocsl.com/role/RealizedGainsorLossesandNetUnrealizedAppreciationorDepreciationAggregateNetRealizedGainsDetails": { "http://ocsl.com/role/RealizedGainsorLossesandNetUnrealizedAppreciationorDepreciationNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Foreign currency forward contracts", "netLabel": "Foreign currency forward contract", "label": "Foreign Exchange Forward [Member]", "documentation": "Foreign exchange forward traded on an exchange (examples include but are not limited to the International Securities Exchange, Philadelphia Stock Exchange, or the Chicago Mercantile Exchange) for options or future contracts to buy or sell a certain currency, at a specified date, at a fixed exercise exchange rate." } } }, "auth_ref": { "r570", "r576", "r581", "r607", "r613", "r690", "r691", "r696", "r789" } } }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": { "r819", "r831", "r912", "r939" } } }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount", "label": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": { "r819", "r831", "r912", "r939" } } } }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount", "label": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": { "r819", "r831", "r912", "r939" } } } }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery, Explanation of Impracticability", "label": "Forgone Recovery, Explanation of Impracticability [Text Block]" } } }, "auth_ref": { "r819", "r831", "r912", "r939" } } } }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryIndName", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Forgone Recovery, Individual Name" } } }, "auth_ref": { "r819", "r831", "r912", "r939" } } } }, "us-gaap_GainLossOnSaleOfDerivatives": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainLossOnSaleOfDerivatives", "crdr": "credit", "calculation": { "http://ocsl.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_RealizedGainLossInvestmentAndDerivativeOperatingBeforeTax", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://ocsl.com/role/ConsolidatedStatementsofOperations": { "lang": { "en-us": { "role": { "terseLabel": "Foreign currency forward contracts", "label": "Gain (Loss) on Sale of Derivatives", "documentation": "The difference between the book value and the sale price of options, swaps, futures, forward contracts, and other derivative instruments. This element refers to the gain (loss) included in earnings." } } }, "auth_ref": { "r6", "r118", "r605", "r606", "r607", "r608" } } }, "us-gaap_GainLossOnSaleOfInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainLossOnSaleOfInvestments", "crdr": "credit", "presentation": { "http://ocsl.com/role/PortfolioInvestmentsNarrativeDetails": { "lang": { "en-us": { "role": { "negatedTerseLabel": "Loss on sale of investments", "label": "Gain (Loss) on Sale of Investments", "documentation": "The net realized gain (loss) on investments sold during the period, not including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, which, for cash flow reporting, is a component of proceeds from investing activities." } } }, "auth_ref": { "r6" } } }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://ocsl.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_InvestmentIncomeInvestmentExpense", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://ocsl.com/role/ConsolidatedStatementsofOperations": { "lang": { "en-us": { "role": { "terseLabel": "General and administrative expenses", "label": "General and Administrative Expense", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": { "r88", "r594" } } }, "cef_GeneralDescriptionOfRegistrantAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "GeneralDescriptionOfRegistrantAbstract", "presentation": { "http://xbrl.sec.gov/cef/role/N2": { "lang": { "en-us": { "role": { "label": "General Description of Registrant [Abstract]" } } }, "auth_ref": { "r887" } } }, "us-gaap_GeographicConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeographicConcentrationRiskMember", "presentation": { "http://ocsl.com/role/PortfolioInvestmentsPortfolioCompositionDetails": { "lang": { "en-us": { "role": { "terseLabel": "Geographic Concentration Risk", "label": "Geographic Concentration Risk [Member]", "documentation": "Reflects the percentage that a specified dollar value on the balance sheet or income statement in the period from one or more specified geographic areas is to a corresponding consolidated, segment, or product line amount. Risk is the materially adverse effects of economic decline or antagonistic political actions resulting in loss of assets, sales volume, labor supply, or source of materials and supplies in a US state or a specified country, continent, or region such as EMEA (Europe, Middle East, Africa)." } } }, "auth_ref": { "r36", "r748" } } }, "ocsl_GlickJVFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://ocsl.com/20240630", "localname": "GlickJVFacilityMember", "presentation": { "http://ocsl.com/role/PortfolioInvestmentsNarrativeDetails": { "http://xbrl.sec.gov/cef/role/N2": { "lang": { "en-us": { "role": { "terseLabel": "Glick JV Facility", "label": "Glick JV Facility [Member]", "documentation": "Glick JV Facility" } } }, "auth_ref": { "r0", "ocsl_GlickJVLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://ocsl.com/20240630", "localname": "GlickJVLLCMember", "presentation": { "http://ocsl.com/role/PortfolioInvestmentsNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Glick JV LLC", "label": "Glick JV LLC [Member]", "documentation": "Glick JV LLC" } } }, "auth_ref": { "r0", "ocsl_GlickJVNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://ocsl.com/20240630", "localname": "GlickJVNotesMember
```


"/Hedging Designation [Domain]", "label": "Hedging Designation [Domain]", "documentation": "Designation of purpose of derivative instrument." }, { "auth_ref": "r12" }, { "ceff_HighestPriceOrBid": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "HighestPriceOrBid", "presentation": "http://xbrl.sec.gov/cef/role/N2", "lang": "en-us", "role": "label", "Highest Price or Bid" }, { "auth_ref": "r894" }, { "ceff_HighestPriceOrBidNav": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "HighestPriceOrBidNav", "presentation": "http://xbrl.sec.gov/cef/role/N2", "lang": "en-us", "role": "label", "Highest Price or Bid, NAV" }, { "auth_ref": "r898" }, { "ceff_HighestPriceOrBidPremiumDiscountToNavPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "HighestPriceOrBidPremiumDiscountToNavPercent", "presentation": "http://xbrl.sec.gov/cef/role/N2", "lang": "en-us", "role": "label", "Highest Price or Bid, Premium (Discount) to NAV [Percent]" }, { "auth_ref": "r899" }, { "ocsl_HomeFurnishingsMember": { "xbrltype": "domainItemType", "nsuri": "http://ocsl.com/20240630", "localname": "HomeFurnishingsMember", "presentation": "http://ocsl.com/role/PortfolioInvestmentsPortfolioofInvestmentsbyIndustryDetails", "lang": "en-us", "role": "label", "Home Furnishings [Member]", "documentation": "Home Furnishings" }, { "auth_ref": "OCSL_HomeImprovementRetailMember": { "xbrltype": "domainItemType", "nsuri": "http://ocsl.com/20240630", "localname": "HomeImprovementRetailMember", "presentation": "http://ocsl.com/role/PortfolioInvestmentsPortfolioofInvestmentsbyIndustryDetails", "lang": "en-us", "role": "label", "Home Improvement Retail [Member]", "documentation": "Home Improvement Retail" }, { "auth_ref": "OCSL_HotelsResortsCruiseLinesMember": { "xbrltype": "domainItemType", "nsuri": "http://ocsl.com/20240630", "localname": "HotelsResortsCruiseLinesMember", "presentation": "http://ocsl.com/role/PortfolioInvestmentsPortfolioofInvestmentsbyIndustryDetails", "lang": "en-us", "role": "label", "Hotels, Resorts & Cruise Lines [Member]", "documentation": "Hotels, Resorts & Cruise Lines" }, { "auth_ref": "OCSL_HousewaresSpecialtiesMember": { "xbrltype": "domainItemType", "nsuri": "http://ocsl.com/20240630", "localname": "HousewaresSpecialtiesMember", "presentation": "http://ocsl.com/role/PortfolioInvestmentsPortfolioofInvestmentsbyIndustryDetails", "lang": "en-us", "role": "label", "Housewares & Specialties [Member]", "documentation": "Housewares & Specialties" }, { "auth_ref": "cef_IncentiveAllocationMaximumPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "IncentiveAllocationMaximumPercent", "presentation": "http://xbrl.sec.gov/cef/role/N2", "lang": "en-us", "role": "label", "Incentive Allocation Maximum [Percent]" }, { "auth_ref": "r865", "cef_IncentiveAllocationMinimumPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "IncentiveAllocationMinimumPercent", "presentation": "http://xbrl.sec.gov/cef/role/N2", "lang": "en-us", "role": "label", "Incentive Allocation Minimum [Percent]" }, { "auth_ref": "r865", "cef_IncentiveAllocationPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "IncentiveAllocationPercent", "presentation": "http://xbrl.sec.gov/cef/role/N2", "lang": "en-us", "role": "label", "Incentive Allocation [Percent]" }, { "auth_ref": "r865", "us-gaap_IncentiveFeeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncentiveFeeExpense", "crdr": "debit", "presentation": "http://ocsl.com/role/RelatedPartyTransactionsDetails", "lang": "en-us", "role": "label", "Incentive fee expense", "label": "Incentive Fee Expense", "documentation": "Amount of expense for incentive fee based on performance under arrangement to manage operations, including, but not limited to, investment." }, { "auth_ref": "r69", "r1058", "ocsl_IncentiveFeeExpensePart": { "xbrltype": "monetaryItemType", "nsuri": "http://ocsl.com/20240630", "localname": "IncentiveFeeExpensePart", "crdr": "debit", "calculation": "http://ocsl.com/role/ConsolidatedStatementsofOperations", "parentTag": "us-gaap_InvestmentIncomeInvestmentExpense", "weight": 1.0, "order": 4.0 }, { "presentation": "http://ocsl.com/role/ConsolidatedStatementsofOperations", "http://ocsl.com/role/RelatedPartyTransactionsDetails", "lang": "en-us", "role": "label", "Part I Incentive fee", "label": "Incentive Fee Expense, Part I", "documentation": "Incentive Fee Expense, Part I" }, { "auth_ref": "cef_IncentiveFeesPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "IncentiveFeesPercent", "presentation": "http://xbrl.sec.gov/cef/role/N2", "lang": "en-us", "role": "label", "Incentive Fees [Percent]" }, { "auth_ref": "r874", "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": "en-us", "role": "label", "Income Statement [Abstract]" }, { "auth_ref": "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationAxis", "presentation": "http://ocsl.com/role/PortfolioInvestmentsRollForwardintheChangesinFairValueDetails", "lang": "en-us", "role": "label", "Income Statement Location [Axis]", "label": "Income Statement Location [Axis]", "documentation": "Information by location in the income statement." }, { "auth_ref": "r249", "r250", "r599", "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationDomain", "presentation": "http://ocsl.com/role/PortfolioInvestmentsRollForwardintheChangesinFairValueDetails", "lang": "en-us", "role": "label", "Income Statement Location [Domain]", "label": "Income Statement Location [Domain]", "documentation": "Location in the income statement." }, { "auth_ref": "r250", "r599", "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureAbstract", "lang": "en-us", "role": "label", "Income Tax Disclosure [Abstract]" }, { "auth_ref": "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureTextBlock", "presentation": "http://ocsl.com/role/TaxableDistributableIncomeandDividendDistributions", "lang": "en-us", "role": "label", "Taxable/Distributable Income and Dividend Distributions", "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information." }, { "auth_ref": "r164", "r349", "r355", "r356", "r361", "r363", "r369", "r370", "r371", "r510", "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "presentation": "http://ocsl.com/role/TaxableDistributableIncomeandDividendDistributionsNarrativeDetails", "lang": "en-us", "role": "label", "Income tax expense", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." }, { "auth_ref": "r124", "r131", "r178", "r179", "r196", "r354", "r366", "r483", "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxPolicyTextBlock", "presentation": "http://ocsl.com/role/SignificantAccountingPoliciesPolicies", "lang": "en-us", "role": "label", "Income Taxes", "label": "Income Tax, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." }, { "auth_ref": "r146", "r350", "r351", "r356", "r357", "r360", "r362", "r497", "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "crdr": "debit", "calculation": "http://ocsl.com/role/ConsolidatedStatementofCashFlows", "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 15.0 }, { "presentation": "http://ocsl.com/role/ConsolidatedStatementofCashFlows", "lang": "en-us", "role": "label", "Increase (decrease) in accounts payable, accrued expenses and other liabilities", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid." }, { "auth_ref": "r5", "us-gaap_IncreaseDecreaseInBrokerageReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInBrokerageReceivables", "crdr": "credit", "calculation": "http://ocsl.com/role/ConsolidatedStatementofCashFlows", "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 16.0 }, { "presentation": "http://ocsl.com/role/ConsolidatedStatementofCashFlows", "lang": "en-us", "role": "label", "Increase (decrease) in due from broker", "label": "Increase (Decrease) in Receivable from Broker-Dealer and Clearing Organization", "documentation": "The increase (decrease) during the reporting period in the total amount due to the entity related to activities and operations with other broker-dealers, and clearing organizations, including deposits." }, { "auth_ref": "r5", "ocsl_IncreaseDecreaseInDirectorFeesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://ocsl.com/20240630", "localname": "IncreaseDecreaseInDirectorFeesPayable", "crdr": "debit", "calculation": "http://ocsl.com/role/ConsolidatedStatementofCashFlows", "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 }, { "presentation": "http://ocsl.com/role/ConsolidatedStatementofCashFlows", "lang": "en-us", "role": "label", "Increase (decrease) in director fees payable", "label": "Increase (Decrease) in Director Fees Payable", "documentation": "Increase (Decrease) in Director Fees Payable" }, { "auth_ref": "OCSL_IncreaseDecreaseInDueFromPortfolioCompanies": { "xbrltype": "monetaryItemType", "nsuri": "http://ocsl.com/20240630", "localname": "IncreaseDecreaseInDueFromPortfolioCompanies", "crdr": "debit", "calculation": "http://ocsl.com/role/ConsolidatedStatementofCashFlows", "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 6.0 }, { "presentation": "http://ocsl.com/role/ConsolidatedStatementofCashFlows", "lang": "en-us", "role": "label", "Increase (decrease) in due to affiliate", "label": "Increase (Decrease) in Due to Affiliates", "documentation": "The increase (decrease) in obligations owed to an entity that is controlling, under the control of, or within the same control group as the reporting entity by means of direct or indirect ownership." }, { "auth_ref": "r5", "us-gaap_IncreaseDecreaseInIncentiveFeePayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInIncentiveFeePayable", "crdr": "debit", "presentation": "http://ocsl.com/role/RelatedPartyTransactionsDetails", "lang": "en-us", "role": "label", "Accrued capital gains incentive fees expensed (reversed)", "label": "Increase (Decrease) in Incentive Fee Payable", "documentation": "Amount of increase (decrease) in fee payable for management of operations based on performance under arrangement, including, but not limited to, investment." }, { "auth_ref": "r1066", "us-gaap_IncreaseDecreaseInInterestAndDividendsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInInterestAndDividendsReceivable", "crdr": "credit", "calculation": "http://ocsl.com/role/ConsolidatedStatementofCashFlows", "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 19.0 }, { "presentation": "http://ocsl.com/role/ConsolidatedStatementofCashFlows", "lang": "en-us", "role": "label", "Increase (decrease) in interest, dividends and fees receivable", "label": "Increase (Decrease) in Interest and Dividends Receivable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount due to the entity in the form of unpaid interest and dividends." }, { "auth_ref": "r5", "us-gaap_IncreaseDecreaseInInterestPayableNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInInterestPayableNet", "crdr": "debit", "calculation": "http://ocsl.com/role/ConsolidatedStatementofCashFlows", "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 9.0 }, { "presentation": "http://ocsl.com/role/ConsolidatedStatementofCashFlows", "lang": "en-us", "role": "label", "Increase (decrease) in interest payable", "label": "Increase (Decrease) in Interest Payable, Net", "documentation": "The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity." }, { "auth_ref": "r5", "us-gaap_IncreaseDecreaseInManagementAndIncentiveFeesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInManagementAndIncentiveFeesPayable", "crdr": "debit", "calculation": "http://ocsl.com/role/ConsolidatedStatementofCashFlows", "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 }, { "presentation": "http://ocsl.com/role/ConsolidatedStatementofCashFlows", "lang": "en-us", "role": "label", "Increase (decrease) in base management fee and incentive fee payable", "label": "Increase (Decrease) in Management and Incentive Fees Payable", "documentation": "Amount of increase (decrease) in fees payable for management of fund or trust and management of operations based on performance under arrangement, including, but not limited to, investment." }, { "auth_ref": "r1066", "us-gaap_IncreaseDecreaseInOperatingAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingAssetsAbstract", "presentation": "http://ocsl.com/role/ConsolidatedStatementofCashFlows", "lang": "en-us", "role": "label", "Changes in operating assets and liabilities", "label": "Increase (Decrease) in Operating Assets [Abstract]" }, { "auth_ref": "us-gaap_IncreaseDecreaseInOtherOperatingAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherOperatingAssets", "crdr": "credit", "calculation": "http://ocsl.com/role/ConsolidatedStatementofCashFlows", "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 4.0 }, { "presentation": "http://ocsl.com/role/ConsolidatedStatementofCashFlows", "lang": "en-us", "role": "label", "Increase (decrease) in other assets", "label": "Increase (Decrease) in Other Operating Assets", "documentation": "Amount of increase (decrease) in operating assets classified as other." }, { "auth_ref": "r5", "us-gaap_IncreaseDecreaseInPayablesUnderRepurchaseAgreements": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInPayablesUnderRepurchaseAgreements", "crdr": "debit", "calculation": "http://ocsl.com/role/ConsolidatedStatementofCashFlows", "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 20.0 }, { "presentation": "http://ocsl.com/role/ConsolidatedStatementofCashFlows", "lang": "en-us", "role": "label", "Increase (decrease) in payables from unsettled


```

transactions", "label": "Increase (Decrease) in Payables under Repurchase Agreements", "documentation": "The increase (decrease) during the reporting period in the liability under agreements to repurchase securities that were sold." } } }, "auth_ref": { "r5" } }, "us-gaap_IncreaseDecreaseInReceivablesUnderRepurchaseAgreements": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInReceivablesUnderRepurchaseAgreements", "crdr": "credit", "calculation": { "http://ocsl.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": { "http://ocsl.com/role/ConsolidatedStatementofCashFlows": { "lang": { "en-us": { "role": { "terseLabel": "(Increase) decrease in receivables from unsettled transactions", "label": "Increase (Decrease) in Receivables under Repurchase Agreements", "documentation": "The increase (decrease) during the reporting period in the total amount due the entity under agreements to sell and repurchase securities." } } }, "auth_ref": { "r5" } }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "IndividualAxis", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Individual", "label": "Individual Axis", "documentation": "The increase (decrease) during the reporting period in the total amount due the entity under agreements to sell and repurchase securities." } } }, "auth_ref": { "r822", "r831", "r912", "r931", "r939", "r943", "r951" } } } } } } } } }, "ocsl_IndustrialMachinerySuppliesComponentsMember": { "xbrltype": "domainItemType", "nsuri": "http://ocsl.com/20240630", "localname": "IndustrialMachinerySuppliesComponentsMember", "presentation": { "http://ocsl.com/role/PortfolioInvestmentsPortfolioofInvestmentsbyIndustryDetails": { "lang": { "en-us": { "role": { "terseLabel": "Industrial Machinery & Supplies & Components", "label": "Industrial Machinery & Supplies & Components [Member]", "documentation": "Industrial Machinery & Supplies & Components" } } }, "auth_ref": { "r11", "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "auth_ref": { "r949" } } }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": { "r811", "r955" } } }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc": { "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Adopted", "label": "Insider Trading Policies and Procedures Adopted [Flag]" } } }, "auth_ref": { "r811", "r955" } } }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc": { "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Not Adopted", "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]" } } }, "auth_ref": { "r811", "r955" } } } } } } } } }, "ocsl_InsuranceBrokersMember": { "xbrltype": "domainItemType", "nsuri": "http://ocsl.com/20240630", "localname": "InsuranceBrokersMember", "presentation": { "http://ocsl.com/role/PortfolioInvestmentsPortfolioofInvestmentsbyIndustryDetails": { "lang": { "en-us": { "role": { "terseLabel": "Insurance Brokers", "label": "Insurance Brokers [Member]", "documentation": "Insurance Brokers" } } }, "auth_ref": { "r11", "ocsl_IntegratedOilGasMember": { "xbrltype": "domainItemType", "nsuri": "http://ocsl.com/20240630", "localname": "IntegratedOilGasMember", "presentation": { "http://ocsl.com/role/PortfolioInvestmentsPortfolioofInvestmentsbyIndustryDetails": { "lang": { "en-us": { "role": { "terseLabel": "Integrated Oil & Gas", "label": "Integrated Oil & Gas [Member]", "documentation": "Integrated Oil & Gas" } } }, "auth_ref": { "r11", "ocsl_IntegratedTelecommunicationServicesMember": { "xbrltype": "domainItemType", "nsuri": "http://ocsl.com/20240630", "localname": "IntegratedTelecommunicationServicesMember", "presentation": { "http://ocsl.com/role/PortfolioInvestmentsPortfolioofInvestmentsbyIndustryDetails": { "lang": { "en-us": { "role": { "terseLabel": "Integrated Telecommunication Services", "label": "Integrated Telecommunication Services [Member]", "documentation": "Integrated Telecommunication Services" } } }, "auth_ref": { "r11", "ocsl_InteractiveMediaServicesMember": { "xbrltype": "domainItemType", "nsuri": "http://ocsl.com/20240630", "localname": "InteractiveMediaServicesMember", "presentation": { "http://ocsl.com/role/PortfolioInvestmentsPortfolioofInvestmentsbyIndustryDetails": { "lang": { "en-us": { "role": { "terseLabel": "Interactive Media & Services", "label": "Interactive Media & Services [Member]", "documentation": "Interactive Media & Services" } } }, "auth_ref": { "r11", "us-gaap_InterestAndDebtExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestAndDebtExpense", "crdr": "debit", "presentation": { "http://ocsl.com/role/BorrowingsNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Interest expense inclusive of fees", "label": "Interest and Debt Expense", "documentation": "Interest and debt related expenses associated with nonoperating financing activities of the entity." } } }, "auth_ref": { "r9" } } }, "us-gaap_InterestAndDividendIncomeOperating": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestAndDividendIncomeOperating", "crdr": "credit", "presentation": { "http://ocsl.com/role/Schedule1214ScheduleofInvestmentsinandAdvancesToAffiliatesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Amount\u00a0of Interest, Fees or Dividends Credited\u00a0in Income", "label": "Interest and Dividend Income Operating", "documentation": "Represents the total of interest and dividend income, including any amortization and accretion (as applicable) of discounts and premiums, earned from (1) loans and leases whether held-for-sale or held-in-portfolio; (2) investment securities; (3) federal funds sold; (4) securities purchased under agreements to resell; (5) investments in banker's acceptances, commercial paper, or certificates of deposit; (6) dividend income; or (7) other investments not otherwise specified herein." } } }, "auth_ref": { "r116", "r1087" } } }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpense", "crdr": "debit", "calculation": { "http://ocsl.com/role/PortfolioInvestmentsSummarizedStatementofOperationsInformationDetails": { "parentTag": "us-gaap_InvestmentIncomeInvestmentExpense", "weight": -1.0, "order": 2.0 } }, "http://ocsl.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_InvestmentIncomeInvestmentExpense", "weight": -1.0, "order": 3.0 } }, "presentation": { "http://ocsl.com/role/PortfolioInvestmentsSummarizedStatementofOperationsInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Interest expense", "label": "Interest Expense", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense." } } }, "auth_ref": { "r67", "r122", "r150", "r195", "r409", "r600", "r902", "r1052" } } }, "us-gaap_InterestExpenseDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpenseDebt", "crdr": "debit", "calculation": { "http://ocsl.com/role/BorrowingsComponentsofInterestandOtherDebtExpensesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://ocsl.com/role/BorrowingsComponentsofInterestandOtherDebtExpensesDetails": { "lang": { "en-us": { "role": { "totalLabel": "Total interest expense", "label": "Interest Expense, Debt", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt." } } }, "auth_ref": { "r90", "r286", "r294", "r777", "r778" } } }, "us-gaap_InterestExpenseDebtExcludingAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpenseDebtExcludingAmortization", "crdr": "debit", "calculation": { "http://ocsl.com/role/BorrowingsComponentsofInterestandOtherDebtExpensesDetails": { "parentTag": "us-gaap_InterestExpenseDebt", "weight": -1.0, "order": 1.0 } }, "presentation": { "http://ocsl.com/role/BorrowingsComponentsofInterestandOtherDebtExpensesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Coupon interest", "label": "Interest Expense, Debt, Excluding Amortization", "documentation": "Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs." } } }, "auth_ref": { "r92", "r287", "r777", "r778" } } } } } } } } }, "ocsl_InterestExpenseEffectOffInterestRateSwap": { "xbrltype": "monetaryItemType", "nsuri": "http://ocsl.com/20240630", "localname": "InterestExpenseEffectOffInterestRateSwap", "crdr": "debit", "calculation": { "http://ocsl.com/role/BorrowingsComponentsofInterestandOtherDebtExpensesDetails": { "parentTag": "us-gaap_InterestExpenseDebt", "weight": -1.0, "order": 3.0 } }, "presentation": { "http://ocsl.com/role/BorrowingsComponentsofInterestandOtherDebtExpensesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Effect of interest rate swap", "label": "Interest Expense, Effect Of Interest Rate Swap", "documentation": "Interest Expense, Effect Of Interest Rate Swap" } } }, "auth_ref": { "r11", "cecf_InterestExpensesOnBorrowingsPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cecf/2023", "localname": "InterestExpensesOnBorrowingsPercent", "presentation": { "http://xbrl.sec.gov/cecf/role/N2": { "lang": { "en-us": { "role": { "label": "Interest Expenses on Borrowings [Percent]" } } }, "auth_ref": { "r873" } } }, "us-gaap_InterestIncomeDepositsWithFinancialInstitutions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestIncomeDepositsWithFinancialInstitutions", "crdr": "credit", "calculation": { "http://ocsl.com/role/ConsolidatedStatementsofOperations": { "parentTag": "ocsl_InterestIncomeOperatingIncludingDeposits", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://ocsl.com/role/ConsolidatedStatementsofOperations": { "lang": { "en-us": { "role": { "terseLabel": "Interest on cash and cash equivalents", "label": "Interest Income, Deposits with Financial Institutions", "documentation": "Interest income derived from funds deposited with both domestic and foreign financial institutions including funds in money market and other accounts." } } }, "auth_ref": { "r121", "r132", "r133" } } }, "us-gaap_InterestIncomeOperating": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestIncomeOperating", "crdr": "credit", "calculation": { "http://ocsl.com/role/PortfolioInvestmentsSummarizedStatementofOperationsInformationDetails": { "parentTag": "us-gaap_GrossInvestmentIncomeOperating", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://ocsl.com/role/PortfolioInvestmentsSummarizedStatementofOperationsInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Interest income", "label": "Interest Income, Operating", "documentation": "Amount of operating interest income, including, but not limited to, amortization and accretion of premiums and discounts on securities." } } }, "auth_ref": { "r87", "r591", "r722", "r724", "r801", "r802", "r1079" } } }, "ocsl_InterestIncomeOperatingIncludingDeposits": { "xbrltype": "monetaryItemType", "nsuri": "http://ocsl.com/20240630", "localname": "InterestIncomeOperatingIncludingDeposits", "crdr": "credit", "calculation": { "http://ocsl.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_GrossInvestmentIncomeOperating", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://ocsl.com/role/ConsolidatedStatementsofOperations": { "lang": { "en-us": { "role": { "totalLabel": "Total interest income", "label": "Interest Income, Operating, Including Deposits", "documentation": "Interest Income, Operating, Including Deposits" } } }, "auth_ref": { "r11", "us-gaap_InterestIncomeOperatingPaidInCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "local
```

"InterestRateSwapMaturing2029Member", "presentation": {"http://ocsl.com/role/ConsolidatedScheduleofInvestmentsDerivatives": {"lang": {"en-us": {"role": {"terseLabel": "Interest Rate Swap Maturing 2029", "label": "Interest Rate Swap Maturing 2029 [Member]", "documentation": "Interest Rate Swap Maturing 2029"} } } } }, "auth_ref": {"us-gaap-InterestRateSwapMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestRateSwapMember", "presentation": {"http://ocsl.com/role/BorrowingsNarrativeDetails": {"http://ocsl.com/role/ConsolidatedScheduleofInvestmentsDerivatives": {"http://ocsl.com/role/DerivativeInstrumentsScheduleofForeignCurrencyForwardContractsandInterestRateSwapDetails": {"lang": {"en-us": {"role": {"terseLabel": "Interest rate swap", "label": "Interest Rate Swap [Member]", "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period." } } } }, "auth_ref": {"r762", "r795", "r796"} } }, "ocsl-InternetServicesInfrastructureMember": {"xbrltype": "domainItemType", "nsuri": "http://ocsl.com/20240630", "localname": "InternetServicesInfrastructureMember", "presentation": {"http://ocsl.com/role/PortfolioInvestmentsPortfolioofInvestmentsbyIndustryDetails": {"lang": {"en-us": {"role": {"terseLabel": "Internet Services & Infrastructure", "label": "Internet Services & Infrastructure [Member]", "documentation": "Internet Services & Infrastructure"} } } } }, "auth_ref": {"cef-IntervalFundFlag": {"xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "IntervalFundFlag", "presentation": {"http://xbrl.sec.gov/cef/role/N2": {"lang": {"en-us": {"role": {"label": "Interval Fund [Flag]", "auth_ref": {"r835"} } } } } }, "ocsl-InvestmentAdvisoryAgreementIncentiveRatePreIncentiveFeeNetInvestmentIncomeBelowCatchUpMember": {"xbrltype": "domainItemType", "nsuri": "http://ocsl.com/20240630", "localname": "InvestmentAdvisoryAgreementIncentiveRatePreIncentiveFeeNetInvestmentIncomeBelowCatchUpMember", "presentation": {"http://ocsl.com/20240630", "localname": "InvestmentAdvisoryAgreementIncentiveRatePreIncentiveFeeNetInvestmentIncomeBelowCatchUpMember", "presentation": {"http://ocsl.com/role/RelatedPartyTransactionsDetails": {"lang": {"en-us": {"role": {"terseLabel": "Investment Advisory Agreement Incentive Rate Pre Incentive Fee Net Investment Income Below Catch Up", "label": "Investment Advisory Agreement - Incentive Rate, Pre-Incentive Fee Net Investment Income Below Catch Up [Member]", "documentation": "Investment Advisory Agreement - Incentive Rate, Pre-Incentive Fee Net Investment Income Below Catch Up"} } } } }, "auth_ref": {"ocsl-InvestmentAdvisoryAgreementIncentiveRatePreIncentiveFeeNetInvestmentIncomeExceedsCatchUpThresholdMember": {"xbrltype": "domainItemType", "nsuri": "http://ocsl.com/20240630", "localname": "InvestmentAdvisoryAgreementIncentiveRatePreIncentiveFeeNetInvestmentIncomeExceedsCatchUpThresholdMember", "presentation": {"http://ocsl.com/role/RelatedPartyTransactionsDetails": {"lang": {"en-us": {"role": {"terseLabel": "Investment Advisory Agreement Incentive Rate Quarterly Catch Up Threshold", "label": "Investment Advisory Agreement - Incentive Rate, Quarterly Catch-Up Threshold [Member]", "documentation": "Investment Advisory Agreement - Incentive Rate, Quarterly Catch-Up Threshold"} } } } }, "auth_ref": {"ocsl-InvestmentAdvisoryAgreementIncentiveRateRealizedCapitalGainsMember": {"xbrltype": "domainItemType", "nsuri": "http://ocsl.com/20240630", "localname": "InvestmentAdvisoryAgreementIncentiveRateRealizedCapitalGainsMember", "presentation": {"http://ocsl.com/role/RelatedPartyTransactionsDetails": {"lang": {"en-us": {"role": {"terseLabel": "Investment Advisory Agreement - Incentive Rate, Realized Capital Gains", "label": "Investment Advisory Agreement - Incentive Rate, Realized Capital Gains [Member]", "documentation": "Investment Advisory Agreement - Incentive Rate, Realized Capital Gains"} } } } }, "auth_ref": {"ocsl-InvestmentAdvisoryAgreementMember": {"xbrltype": "domainItemType", "nsuri": "http://ocsl.com/20240630", "localname": "InvestmentAdvisoryAgreementMember", "presentation": {"http://ocsl.com/role/RelatedPartyTransactionsDetails": {"lang": {"en-us": {"role": {"terseLabel": "Investment Advisory Agreement", "label": "Investment Advisory Agreement [Member]", "documentation": "Investment Advisory Agreement"} } } } }, "auth_ref": {"ocsl-InvestmentAdvisoryAgreementIncentiveRateRealizedCapitalGainsMember": {"xbrltype": "domainItemType", "nsuri": "http://ocsl.com/20240630", "localname": "InvestmentAdvisoryAgreementIncentiveRateRealizedCapitalGainsMember", "presentation": {"http://ocsl.com/role/RelatedPartyTransactionsDetails": {"lang": {"en-us": {"role": {"terseLabel": "Investment", "label": "Investment, Affiliated Issuer, Control and Affiliate", "documentation": "Investment, Affiliated Issuer, Control and Affiliate [Member]", "auth_ref": {"us-gaap-InvestmentAffiliatedIssuerControlledMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentAffiliatedIssuerControlledMember", "presentation": {"http://ocsl.com/role/ConsolidatedScheduleofInvestments": {"http://ocsl.com/role/ConsolidatedStatementsOfAssetsandLiabilities": {"http://ocsl.com/role/ConsolidatedStatementsOfAssetsandLiabilitiesParentetical": {"http://ocsl.com/role/ConsolidatedStatementsOfOperations": {"http://ocsl.com/role/Schedule1214ScheduleofInvestmentsinandAdvancetoAffiliatesDetails": {"lang": {"en-us": {"role": {"terseLabel": "Control investments", "label": "Investment, Affiliated Issuer, Controlled [Member]", "documentation": "Controlled affiliated issuer of investment." } } } }, "auth_ref": {"r493", "r518", "r558", "r560", "r567", "r583", "r593", "r594", "r725"} } }, "us-gaap-InvestmentAffiliatedIssuerMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentAffiliatedIssuerMember", "presentation": {"http://ocsl.com/role/ConsolidatedStatementsOfAssetsandLiabilities": {"http://ocsl.com/role/ConsolidatedStatementsOfAssetsandLiabilitiesParentetical": {"http://ocsl.com/role/ConsolidatedStatementsOfOperations": {"http://ocsl.com/role/Schedule1214ScheduleofInvestmentsinandAdvancetoAffiliatesDetails": {"lang": {"en-us": {"role": {"terseLabel": "Affiliate investments", "label": "Investment, Affiliated Issuer [Member]", "documentation": "Affiliated issuer of investment." } } } }, "auth_ref": {"r542", "r596", "r604", "r610", "r717", "r720", "r1037"} } }, "us-gaap-InvestmentAffiliatedIssuerNoncontrolledMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentAffiliatedIssuerNoncontrolledMember", "presentation": {"http://ocsl.com/role/ConsolidatedScheduleofInvestments": {"http://ocsl.com/role/Schedule1214ScheduleofInvestmentsinandAdvancetoAffiliatesDetails": {"lang": {"en-us": {"role": {"terseLabel": "Affiliate Investments", "label": "Investment, Affiliated Issuer, Noncontrolled [Member]", "documentation": "Noncontrolled affiliated issuer of investment." } } } }, "auth_ref": {"r493", "r518", "r559", "r561", "r568", "r583", "r593", "r594", "r705", "r716", "r717", "r719", "r720", "r724", "r725", "r729", "r730", "r731"} } }, "us-gaap-InvestmentBankingAdvisoryBrokerageAndUnderwritingFeesAndCommissions": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentBankingAdvisoryBrokerageAndUnderwritingFeesAndCommissions", "presentation": {"http://ocsl.com/role/BorrowingsNarrativeDetails": {"lang": {"en-us": {"role": {"terseLabel": "Underwriting commissions", "label": "Investment Banking, Advisory, Brokerage, and Underwriting Fees and Commissions", "documentation": "Amount of fees and commissions from banking, advisory, brokerage, and securities underwriting activities. Activities include, but are not limited to, underwriting securities, private placements of securities, investment advisory and management services, merger and acquisition services, sale and servicing of mutual funds, and other related consulting fees." } } } }, "auth_ref": {"r117"} } }, "us-gaap-InvestmentBasisSpreadVariableRate": {"xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentBasisSpreadVariableRate", "presentation": {"http://ocsl.com/role/ConsolidatedScheduleofInvestments": {"http://ocsl.com/role/PortfolioInvestmentsNarrativeDetails": {"http://ocsl.com/role/PortfolioInvestmentsPortfolioListingDetails": {"http://ocsl.com/role/Schedule1214ScheduleofInvestmentsinandAdvancetoAffiliatesDetails": {"lang": {"en-us": {"role": {"terseLabel": "Investment, basis spread, variable rate (as a percent)", "label": "Investment, Basis Spread, Variable Rate", "documentation": "Percentage added to reference rate used to compute variable rate on investment." } } } }, "auth_ref": {"r635", "r656", "r660", "r713"} } }, "ocsl-InvestmentChangeInMarketQuotesOrLiquidityMember": {"xbrltype": "domainItemType", "nsuri": "http://ocsl.com/20240630", "localname": "InvestmentChangeInMarketQuotesOrLiquidityMember", "presentation": {"http://ocsl.com/role/PortfolioInvestmentsRollForwardintheChangesinFairValueDetails": {"lang": {"en-us": {"role": {"terseLabel": "Investment, Change in Market Quotes or Liquidity", "label": "Investment, Change in Market Quotes or Liquidity [Member]", "documentation": "Investment, Change in Market Quotes or Liquidity"} } } } }, "auth_ref": {"us-gaap-InvestmentCompanyAbstract": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentCompanyAbstract", "lang": {"en-us": {"role": {"label": "Investment Company [Abstract]", "auth_ref": {"ocsl-InvestmentCompanyAccumulatedOverdistributedEarningsMember": {"xbrltype": "domainItemType", "nsuri": "http://ocsl.com/20240630", "localname": "InvestmentCompanyAccumulatedOverdistributedEarningsMember", "presentation": {"http://ocsl.com/role/ShareDataandNetAssetsScheduleofChangesinNetAssetsDetails": {"lang": {"en-us": {"role": {"terseLabel": "Accumulated Overdistributed Earnings", "label": "Investment Company, Accumulated Overdistributed Earnings [Member]", "documentation": "Investment Company, Accumulated Overdistributed Earnings"} } } } }, "auth_ref": {"dei-InvestmentCompanyActFileNumber": {"xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "InvestmentCompanyActFileNumber", "presentation": {"http://xbrl.sec.gov/cef/role/N2": {"lang": {"en-us": {"role": {"label": "Investment Company Act File Number", "auth_ref": {"r835", "r902", "r903", "r904"} } } } }, "dei-InvestmentCompanyActRegistration": {"xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "InvestmentCompanyActRegistration", "presentation": {"http://xbrl.sec.gov/cef/role/N2": {"lang": {"en-us": {"role": {"label": "Investment Company Act Registration", "auth_ref": {"r917"} } } } }, "ocsl-InvestmentCompanyAverageLongTermDebtOutstandingPerShare": {"xbrltype": "perShareItemType", "nsuri": "http://ocsl.com/20240630", "localname": "InvestmentCompanyAverageLongTermDebtOutstandingPerShare", "presentation": {"http://ocsl.com/role/FinancialHighlightsDetails": {"lang": {"en-us": {"role": {"terseLabel": "Average debt per share (dollars per share)", "label": "Investment Company, Average Long-Term Debt Outstanding Per Share", "documentation": "Investment Company, Average Long-Term Debt Outstanding Per Share"} } } } }, "auth_ref": {"ocsl-InvestmentCompanyCapitalShareTransactionsIncreaseDecrease": {"xbrltype": "monetaryItemType", "nsuri": "http://ocsl.com/20240630", "localname": "InvestmentCompanyCapitalShareTransactionsIncreaseDecrease", "presentation": {"http://ocsl.com/role/ConsolidatedStatementsOfChangesinNetAssets": {"parentTag": {"us-gaap-StockholdersEquityPeriodIncreaseDecrease": {"weight": 1.0, "order": 3.0}, "presentation": {"http://ocsl.com/role/ConsolidatedStatementsOfChangesinNetAssets": {"lang": {"en-us": {"role": {"terseLabel": "Net increase (decrease) in net assets from capital share transactions", "label": "Investment Company, Capital Share Transactions, Increase (Decrease)", "documentation": "Investment Company, Capital Share Transactions, Increase (Decrease)" } } } }, "auth_ref": {"us-gaap-InvestmentCompanyCapitalShareTransactionsStockIssuedAbstract": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentCompanyCapitalShareTransactionsStockIssuedAbstract", "presentation": {"http://ocsl.com/role/ConsolidatedStatementsOfChangesinNetAssets": {"lang": {"en-us": {"role": {"terseLabel": "Capital share transactions", "label": "Investment Company, Capital Share Transactions, Stock Issued [Abstract]", "auth_ref": {"us-gaap-InvestmentCompanyChangesInNetAssetsLineItems": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentCompanyChangesInNetAssetsLineItems", "presentation": {"http://ocsl.com/role/ShareDataandNetAssetsNarrativeDetails": {"http://ocsl.com/role/ShareDataandNetAssetsScheduleofChangesinNetAssetsDetails": {"http://ocsl.com/role/ShareDataandNetAssetsScheduleofCommonStockIssuedandSoldDetails": {"http://ocsl.com/role/ShareDataandNetAssetsScheduleofDistributionsDetails": {"lang": {"en-us": {"role": {"terseLabel": "Investment Company, Changes in Net Assets [Table]", "label": "Investment Company, Change in Net Assets [Table]", "documentation": "Disclosure of information about change in net assets (equity) of investment company." } } } }, "auth_ref": {"r521", "r535", "r740", "r742", "r743", "r744"} } }, "us-gaap-InvestmentCompanyChangesInNetAssetsTableTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentCompanyChangesInNetAssetsTableTextBlock", "presentation": {"http://ocsl.com/role/ShareDataandNetAssetsTables": {"lang": {"en-us": {"role": {"terseLabel": "Schedule of Changes in Net Assets", "label": "Investment Company, Change in Net Assets [Table Text Block]", "documentation": "Tabular disclosure of change in net assets (equity) of investment company." } } } }, "auth_ref": {"r1040", "r1042", "r1081", "r1082", "r1083", "r1084", "r1085"} } }, "ocsl-InvestmentCompanyComponentsOfDistributableEarningsAccumulatedLossesTableTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://ocsl.com/20240630", "localname": "InvestmentCompanyComponentsOfDistributableEarningsAccumulatedLossesTableTextBlock", "presentation": {"http://ocsl.com/role/TaxableDistributableIncomeandDividendDistributionsTables": {"lang": {"en-us": {"role": {"terseLabel": "Schedule of Components of Accumulated Overdistributed Earnings", "label": "Investment Company, Components Of Distributable Earnings (Accumulated Losses) [Table Text Block]", "documentation": "Investment Company, Components Of Distributable Earnings (Accumulated Losses)" } } } }, "auth_ref": {"us-gaap-InvestmentCompanyContractualFeeWaived": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentCompanyContractualFeeWaived", "presentation": {"http://ocsl.com/role/RelatedPartyTransactionsDetails": {"lang": {"en-us": {"role": {"terseLabel": "Investment company, contractual fee waived", "label": "Investment Company, Contractual Fee Waived", "documentation": "Amount of fee contractually waived by investment company." } } } }, "auth_ref": {"r516", "r594"} } }, "ocsl-InvestmentCompanyContractualFeeWaivedPerQuarter": {"xbrltype": "monetaryItemType",

```
"uri": "http://ocsl.com/20240630/", "localname": "InvestmentCompanyContractualFeeWaivedPerQuarter", "crdr": "credit", "presentation": "I",  
"http://ocsl.com/role/RelatedPartyTransactionsDetails"} | "lang": { "en-us": { "role": { "terseLabel": "Contractual fee waived, per quarter", "label": "Investment Company,  
Contractual Fee Waived, Per Quarter", "documentation": "Investment Company, Contractual Fee Waived, Per Quarter" } } }, "auth_ref": "I-1",  
"ocsl:InvestmentCompanyContractualFeeWaivedPeriod": { "xbrltype": "durationItemType", "nsuri": "http://ocsl.com/20240630/", "localname":  
"InvestmentCompanyContractualFeeWaivedPeriod", "presentation": "I", "http://ocsl.com/role/RelatedPartyTransactionsDetails"} | "lang": { "en-us": { "role": { "terseLabel":  
"Contractual fee waived, period otherwise receivable (in years)", "label": "Investment Company, Contractual Fee Waived, Period", "documentation": "Investment Company,  
Contractual Fee Waived, Period" } } }, "auth_ref": "I-1", "us-gaap:InvestmentCompanyDistributableEarningsLossAccumulatedCapitalLossCarryforward": { "xbrltype":  
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023/", "localname": "InvestmentCompanyDistributableEarningsLossAccumulatedCapitalLossCarryforward", "crdr":  
"debit", "presentation": "I", "http://ocsl.com/role/TaxableDistributableIncomeandDividendDistributionsNarrativeDetails"} | "lang": { "en-us": { "role": { "verboseLabel":  
"Undistributed ordinary income, net", "label": "Investment Company, Distributable Earnings (Loss), Accumulated Capital Loss Carryforward", "documentation": "Amount  
of accumulated undistributed deficit from capital loss carryforward of investment company." } } }, "auth_ref": "r509"}, "us-  
gaap:InvestmentCompanyDistributableEarningsLossAccumulatedLongTermCapitalGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023/  
", "localname": "InvestmentCompanyDistributableEarningsLossAccumulatedLongTermCapitalGainLoss", "crdr": "credit", "calculation": {  
"http://ocsl.com/role/TaxableDistributableIncomeandDividendDistributionsComponentsOfAccumulatedOverdistributedEarningsDetails": { "parentTag": "us-  
gaap_RetainedEarningsAccumulatedDeficit", "weight": 1.0, "order": 2.0 } }, "presentation": "I",  
"http://ocsl.com/role/TaxableDistributableIncomeandDividendDistributionsComponentsOfAccumulatedOverdistributedEarningsDetails"} | "lang": { "en-us": { "role": {  
"terseLabel": "Net realized capital losses", "label": "Investment Company, Distributable Earnings (Loss), Accumulated Long-Term Capital Gain (Loss)", "documentation":  
"Amount of accumulated undistributed earnings (deficit) from long-term capital gain (loss) of investment company." } } }, "auth_ref": "r508"}, "us-  
gaap:InvestmentCompanyDistributableEarningsLossAccumulatedOrdinaryIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023/  
", "localname": "InvestmentCompanyDistributableEarningsLossAccumulatedOrdinaryIncomeLoss", "crdr": "credit", "calculation": {  
"http://ocsl.com/role/TaxableDistributableIncomeandDividendDistributionsComponentsOfAccumulatedOverdistributedEarningsDetails": { "parentTag": "us-  
gaap_RetainedEarningsAccumulatedDeficit", "weight": 1.0, "order": 3.0 } }, "presentation": "I",  
"http://ocsl.com/role/TaxableDistributableIncomeandDividendDistributionsComponentsOfAccumulatedOverdistributedEarningsDetails"} | "lang": { "en-us": { "role": {  
"terseLabel": "Undistributed ordinary income, net", "label": "Investment Company, Distributable Earnings (Loss), Accumulated Ordinary Income (Loss)", "documentation":  
"Amount of accumulated undistributed earnings (deficit) from ordinary income (loss) of investment company." } } }, "auth_ref": "r507"}, "ocsl:InvestmentCompanyDistributableEarningsLossAccumulatedUnrealizedGainsLosses": { "xbrltype": "monetaryItemType", "nsuri": "http://ocsl.com/20240630/  
", "localname": "InvestmentCompanyDistributableEarningsLossAccumulatedUnrealizedGainsLosses", "crdr": "credit", "calculation": {  
"http://ocsl.com/role/TaxableDistributableIncomeandDividendDistributionsComponentsOfAccumulatedOverdistributedEarningsDetails": { "parentTag": "us-  
gaap_RetainedEarningsAccumulatedDeficit", "weight": 1.0, "order": 1.0 } }, "presentation": "I",  
"http://ocsl.com/role/TaxableDistributableIncomeandDividendDistributionsComponentsOfAccumulatedOverdistributedEarningsDetails"} | "lang": { "en-us": { "role": {  
"terseLabel": "Unrealized gains, net", "label": "Investment Company, Distributable Earnings (Loss), Accumulated Unrealized Gains (Losses)", "documentation":  
"Investment Company, Distributable Earnings (Loss), Accumulated Unrealized Gains (Losses)" } } }, "auth_ref": "I-1",  
"ocsl:InvestmentCompanyDistributableEarningsLossBeforeDeductions": { "xbrltype": "monetaryItemType", "nsuri": "http://ocsl.com/20240630/", "localname":  
"InvestmentCompanyDistributableEarningsLossBeforeDeductions", "crdr": "credit", "calculation": {  
"http://ocsl.com/role/TaxableDistributableIncomeandDividendDistributionsReconciliationOfNetIncreaseDecreaseInNetAssetsResultingFromOperationsDetails": {  
"parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": "I",  
"http://ocsl.com/role/TaxableDistributableIncomeandDividendDistributionsReconciliationOfNetIncreaseDecreaseInNetAssetsResultingFromOperationsDetails"} | "lang": {  
"en-us": { "role": { "totalLabel": "Taxable/Distributable Income", "label": "Investment Company, Distributable Earnings (Loss), Before Deductions", "documentation":  
"Investment Company, Distributable Earnings (Loss), Before Deductions" } } }, "auth_ref": "I-1", "us-gaap:InvestmentCompanyDistributionToShareholdersAbstract": {  
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023/", "localname": "InvestmentCompanyDistributionToShareholdersAbstract", "presentation": "I",  
"http://ocsl.com/role/ConsolidatedStatementsofChangesInNetAssets": { "lang": { "en-us": { "role": { "terseLabel": "Stockholder transactions", "label": "Investment  
Company, Distribution To Shareholders [Abstract]" } } }, "auth_ref": "I-1", "us-gaap:InvestmentCompanyDistributionToShareholdersPerShare": { "xbrltype":  
"perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023/", "localname": "InvestmentCompanyDistributionToShareholdersPerShare", "presentation": "I",  
"http://ocsl.com/role/FinancialHighlightsDetails": { "http://ocsl.com/role/ShareDataandNetAssetsScheduleofDistributionsDetails"} | "lang": { "en-us": { "role": {  
"terseLabel": "Amount per share (in dollars per share)", "negatedTerseLabel": "Distributions of net investment income to stockholders (dollars per share)", "label":  
"Investment Company, Distribution To Shareholders, Per Share", "documentation": "Per share or unit amount of distribution to shareholders. Includes, but is not limited  
to, dividend and capital gain. Excludes distribution for tax return of capital." } } }, "auth_ref": "r517", "r520", "r521", "r619"}, "us-gaap:InvestmentCompanyExpenseAfterReductionOffFeeWaiverAndReimbursement": { "xbrltype":  
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023/", "localname": "InvestmentCompanyExpenseAfterReductionOffFeeWaiverAndReimbursement", "crdr": "debit",  
"presentation": "I", "http://ocsl.com/role/ShareDataandNetAssetsScheduleofDistributionsDetails"} | "lang": { "en-us": { "role": { "terseLabel": "Cash Distribution", "label": "Investment  
Company, Dividend Distribution", "documentation": "Amount of dividend distribution from ordinary income and capital gain. Excludes distribution for tax return of  
capital." } } }, "auth_ref": "r517", "r520", "r521", "r619"}, "us-gaap:InvestmentCompanyExpenseAfterReductionOffFeeWaiverAndReimbursement": { "xbrltype":  
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023/", "localname": "InvestmentCompanyExpenseAfterReductionOffFeeWaiverAndReimbursement", "crdr": "debit",  
"calculation": { "http://ocsl.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_NetInvestmentIncome", "weight": -1.0, "order": 1.0 } },  
"presentation": "I", "http://ocsl.com/role/ConsolidatedStatementsofOperations"} | "lang": { "en-us": { "role": { "totalLabel": "Net expenses", "label": "Investment Company,  
Expense, after Reduction of Fee Waiver and Reimbursement", "documentation": "Amount, after reimbursement and fee waiver, of expense for generation of investment  
income classified as operating." } } }, "auth_ref": "r1057"}, "ocsl:InvestmentCompanyExpenseRatioNetExpenses": { "xbrltype": "percentItemType", "nsuri":  
"http://ocsl.com/20240630/", "localname": "InvestmentCompanyExpenseRatioNetExpenses", "presentation": "I", "http://ocsl.com/role/FinancialHighlightsDetails"} | "lang": {  
"en-us": { "role": { "terseLabel": "Ratio of net expenses to average net assets", "label": "Investment Company, Expense Ratio, Net Expenses", "documentation":  
"Investment Company, Expense Ratio, Net Expenses" } } }, "auth_ref": "I-1", "ocsl:InvestmentCompanyExpenseRatioTotalExpenses": { "xbrltype": "percentItemType",  
"nsuri": "http://ocsl.com/20240630/", "localname": "InvestmentCompanyExpenseRatioTotalExpenses", "presentation": "I", "http://ocsl.com/role/FinancialHighlightsDetails"} |  
"lang": { "en-us": { "role": { "terseLabel": "Ratio of total expenses to average net assets", "label": "Investment Company, Expense Ratio, Total Expenses", "documentation":  
"Investment Company, Expense Ratio, Total Expenses" } } }, "auth_ref": "I-1", "ocsl:InvestmentCompanyFinancialCommitmentToInvesteeAggregateAmount": { "xbrltype":  
"monetaryItemType", "nsuri": "http://ocsl.com/20240630/", "localname": "InvestmentCompanyFinancialCommitmentToInvesteeAggregateAmount", "crdr": "credit",  
"presentation": "I", "http://ocsl.com/role/PortfolioInvestmentsNarrativeDetails"} | "lang": { "en-us": { "role": { "terseLabel": "Financial commitment to investee, aggregate  
amount", "label": "Investment Company, Financial Commitment To Investee, Aggregate Amount", "documentation": "Investment Company, Financial Commitment To  
Investee, Aggregate Amount" } } }, "auth_ref": "I-1", "ocsl:InvestmentCompanyFinancialCommitmentToInvesteeByCompanyAndCounterpartyAggregateAmount": {  
"xbrltype": "monetaryItemType", "nsuri": "http://ocsl.com/20240630/", "localname": "InvestmentCompanyFinancialCommitmentToInvesteeByCompanyAndCounterpartyAggregateAmount", "crdr":  
"credit", "presentation": "I", "http://ocsl.com/role/PortfolioInvestmentsNarrativeDetails"} | "lang": { "en-us": { "role": { "terseLabel": "Financial commitment to investee by company and counterparty,  
aggregate amount", "label": "Investment Company, Financial Commitment To Investee By Company And Counterparty, Aggregate Amount", "documentation":  
"Investment Company, Financial Commitment To Investee By Company And Counterparty, Aggregate Amount" } } }, "auth_ref": "I-1",  
"ocsl:InvestmentCompanyFinancialCommitmentToInvesteeByCounterpartyAggregateAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://ocsl.com/20240630/  
", "localname": "InvestmentCompanyFinancialCommitmentToInvesteeByCounterpartyAggregateAmount", "crdr": "credit", "presentation": "I",  
"http://ocsl.com/role/PortfolioInvestmentsNarrativeDetails"} | "lang": { "en-us": { "role": { "terseLabel": "Financial commitment to investee by counterparty, aggregate  
amount", "label": "Investment Company, Financial Commitment To Investee By Counterparty, Aggregate Amount", "documentation": "Investment Company, Financial  
Commitment To Investee By Counterparty, Aggregate Amount" } } }, "auth_ref": "I-1", "us-gaap:InvestmentCompanyFinancialCommitmentToInvesteeFutureAmount": {  
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023/", "localname": "InvestmentCompanyFinancialCommitmentToInvesteeFutureAmount", "crdr":  
"credit", "presentation": "I", "http://ocsl.com/role/CommitmentsandContingenciesNarrativeDetails",  
"http://ocsl.com/role/CommitmentsandContingenciesScheduleofUnfundedCommitmentsbyInvestmentDetails", "http://ocsl.com/role/PortfolioInvestmentsNarrativeDetails"} |  
"lang": { "en-us": { "role": { "terseLabel": "Unfunded commitments", "label": "Investment Company, Financial Support To Investee Contractually Required, Not Provided,  
Amount", "documentation": "Amount of financial support committed by investment company to investee that is contractually required but not provided." } } }, "auth_ref":  
"r512"}, "us-gaap:InvestmentCompanyFinancialHighlightsRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023/", "localname":  
"InvestmentCompanyFinancialHighlightsRollForward", "presentation": "I", "http://ocsl.com/role/FinancialHighlightsDetails"} | "lang": { "en-us": { "role": { "terseLabel":  
"Investment Company, Financial Highlights [Roll Forward]", "label": "Investment Company, Financial Highlights [Roll Forward]", "documentation": "A roll forward is a  
reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": "I-1", "us-  
gaap:InvestmentCompanyFinancialHighlightsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023/", "localname":  
"InvestmentCompanyFinancialHighlightsTableTextBlock", "presentation": "I", "http://ocsl.com/role/FinancialHighlightsTables",  
"http://ocsl.com/role/PortfolioInvestmentsTables"} | "lang": { "en-us": { "role": { "terseLabel": "Schedule of Portfolio Composition", "verboseLabel": "Schedule of Financial  
Highlights", "label": "Investment Company, Financial Highlights [Table Text Block]", "documentation": "Tabular disclosure of financial highlights. Includes, but is not  
limited to, per share information, income and expense ratios, total return, capital commitment and fee waiver." } } }, "auth_ref": "r522"}, "us-  
gaap:Invest
```

```

(Depreciation), Per Share", "documentation": "Investment Company, Gain (Loss) On Unrealized Appreciation (Depreciation), Per Share" } } }, "auth_ref": "r141" }, "us-gaap:InvestmentCompanyInvestmentIncomeLossPerShare": { "xbrlType": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentCompanyInvestmentIncomeLossPerShare", "presentation": { "http://ocsl.com/role/ConsolidatedStatementsOfOperations", "http://ocsl.com/role/FinancialHighlightsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Net investment income per common share - basic and diluted (in dollars per share)", "verboseLabel": "Net investment income (in dollars per share)", "label": "Investment Company, Investment Income (Loss), Per Share", "documentation": "Per share or unit amount, after investment expense, of dividend and interest investment income (loss).", "parentTag": "us-gaap:InvestmentCompanyInvestmentIncomeLossRatio": { "xbrlType": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentCompanyInvestmentIncomeLossRatio", "presentation": { "http://ocsl.com/role/FinancialHighlightsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Ratio of net investment income to average net assets", "label": "Investment Company, Investment Income (Loss) Ratio", "documentation": "Percentage of investment income (loss) to average net assets.", "parentTag": "us-gaap:InvestmentCompanyInvestmentOwnedFairValueMeasurementInput": { "xbrlType": "decimalItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentCompanyInvestmentOwnedFairValueMeasurementInput", "presentation": { "http://ocsl.com/role/PortfolioInvestmentsSignificantUnobservableInputsForLevel3InvestmentsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Investments at fair value, measurement input", "label": "Investment Company, Investment Owned, Measurement Input", "documentation": "Value of input used to measure investment owned by investment company.", "parentTag": "us-gaap:InvestmentCompanyInvestmentsSold": { "xbrlType": "monetaryItemType", "nsuri": "http://ocsl.com/20240630", "localname": "InvestmentCompanyInvestmentsSold", "crdr": "credit", "presentation": { "http://ocsl.com/role/PortfolioInvestmentsNarrativeDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Investments sold", "label": "Investment Company, Investments Sold", "documentation": "Investment Company, Investments Sold", "parentTag": "us-gaap:InvestmentCompanyMarketValuePerShare": { "xbrlType": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentCompanyMarketValuePerShare", "presentation": { "http://ocsl.com/role/FinancialHighlightsDetails" }, "lang": { "en-us": { "role": { "periodStartLabel": "Per share market value at beginning of period (in dollars per share)", "periodEndLabel": "Per share market value at end of period (in dollars per share)", "label": "Investment Company, Market Value, Per Share", "documentation": "Market value per share of investment portfolio by investment company. Includes, but is not limited to, per unit, membership interest, or other ownership interest.", "parentTag": "us-gaap:InvestmentCompanyNetAssetsRollForward": { "xbrlType": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentCompanyNetAssetsRollForward", "presentation": { "http://ocsl.com/role/ConsolidatedStatementsOfChangesInNetAssets", "http://ocsl.com/role/ShareDataAndNetAssetsScheduleOfChangesInNetAssetsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Investment Company, Net Assets [Roll Forward]", "label": "Investment Company, Net Assets [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "parentTag": "us-gaap:InvestmentCompanyNonconsolidatedSubsidiaryAxis": { "xbrlType": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentCompanyNonconsolidatedSubsidiaryAxis", "presentation": { "http://ocsl.com/role/PortfolioInvestmentsNarrativeDetails", "http://ocsl.com/role/PortfolioInvestmentsPortfolioListingDetails", "http://ocsl.com/role/PortfolioInvestmentsSummarizedBalanceSheetInformationDetails", "http://ocsl.com/role/PortfolioInvestmentsSummarizedStatementOfOperationsInformationDetails", "http://ocsl.com/role/PortfolioInvestmentsSummaryOfPortfolioDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Investment Company, Nonconsolidated Subsidiary [Axis]", "label": "Investment Company, Nonconsolidated Subsidiary [Axis]", "documentation": "Information by nonconsolidated subsidiary of investment company. Excludes information consolidated by reporting entity.", "parentTag": "us-gaap:InvestmentCompanyNonconsolidatedSubsidiaryDomain": { "xbrlType": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentCompanyNonconsolidatedSubsidiaryDomain", "presentation": { "http://ocsl.com/role/PortfolioInvestmentsNarrativeDetails", "http://ocsl.com/role/PortfolioInvestmentsPortfolioListingDetails", "http://ocsl.com/role/PortfolioInvestmentsSummarizedBalanceSheetInformationDetails", "http://ocsl.com/role/PortfolioInvestmentsSummarizedStatementOfOperationsInformationDetails", "http://ocsl.com/role/PortfolioInvestmentsSummaryOfPortfolioDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Investment Company, Nonconsolidated Subsidiary [Domain]", "label": "Investment Company, Nonconsolidated Subsidiary [Domain]", "documentation": "Nonconsolidated subsidiary of investment company. Excludes information consolidated by reporting entity.", "parentTag": "us-gaap:InvestmentCompanyNonconsolidatedSubsidiaryLineItems": { "xbrlType": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentCompanyNonconsolidatedSubsidiaryLineItems", "presentation": { "http://ocsl.com/role/PortfolioInvestmentsNarrativeDetails", "http://ocsl.com/role/PortfolioInvestmentsPortfolioListingDetails", "http://ocsl.com/role/PortfolioInvestmentsSummarizedBalanceSheetInformationDetails", "http://ocsl.com/role/PortfolioInvestmentsSummarizedStatementOfOperationsInformationDetails", "http://ocsl.com/role/PortfolioInvestmentsSummaryOfPortfolioDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Investment Company, Nonconsolidated Subsidiary [Line Items]", "label": "Investment Company, Nonconsolidated Subsidiary [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "parentTag": "us-gaap:InvestmentCompanyNonconsolidatedSubsidiarySummarizedFinancialInformationTableTextBlock": { "xbrlType": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentCompanyNonconsolidatedSubsidiarySummarizedFinancialInformationTableTextBlock", "presentation": { "http://ocsl.com/role/PortfolioInvestmentsTables", "http://ocsl.com/role/PortfolioInvestmentsSummarizedFinancialInformation", "http://ocsl.com/role/PortfolioInvestmentsSummarizedStatementOfOperationsInformation", "http://ocsl.com/role/PortfolioInvestmentsSummaryOfPortfolioDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of Summarized Financial Information", "label": "Investment Company, Nonconsolidated Subsidiary, Summarized Financial Information [Table Text Block]", "documentation": "Tabular disclosure of summarized financial information for nonconsolidated subsidiary of investment company. Excludes information consolidated by reporting entity.", "parentTag": "us-gaap:InvestmentCompanyNonconsolidatedSubsidiaryTable": { "xbrlType": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentCompanyNonconsolidatedSubsidiaryTable", "presentation": { "http://ocsl.com/role/PortfolioInvestmentsNarrativeDetails", "http://ocsl.com/role/PortfolioInvestmentsPortfolioListingDetails", "http://ocsl.com/role/PortfolioInvestmentsSummarizedBalanceSheetInformationDetails", "http://ocsl.com/role/PortfolioInvestmentsSummarizedStatementOfOperationsInformationDetails", "http://ocsl.com/role/PortfolioInvestmentsSummaryOfPortfolioDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Investment Company, Nonconsolidated Subsidiary [Table]", "label": "Investment Company, Nonconsolidated Subsidiary [Table]", "documentation": "Disclosure of information about nonconsolidated subsidiary of investment company. Excludes information consolidated by reporting entity.", "parentTag": "us-gaap:InvestmentCompanyNumberOfBorrowers": { "xbrlType": "integerItemType", "nsuri": "http://ocsl.com/20240630", "localname": "InvestmentCompanyNumberOfBorrowers", "presentation": { "http://ocsl.com/role/PortfolioInvestmentsNarrativeDetails", "http://ocsl.com/role/PortfolioInvestmentsSummaryOfPortfolioDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Number of borrowers", "label": "Investment Company, Number Of Borrowers", "documentation": "Investment Company, Number Of Borrowers", "parentTag": "us-gaap:InvestmentCompanyPartFeeWaived": { "xbrlType": "monetaryItemType", "nsuri": "http://ocsl.com/20240630", "localname": "InvestmentCompanyPartFeeWaived", "crdr": "credit", "calculation": { "http://ocsl.com/role/ConsolidatedStatementsOfOperations": { "parentTag": "us-gaap:InvestmentCompanyExpenseAfterReductionOffFeeWaiverAndReimbursement": { "weight": -1.0, "order": 3.0 }, "presentation": { "http://ocsl.com/role/ConsolidatedStatementsOfOperations": { "http://ocsl.com/role/RelatedPartyTransactionsDetails" }, "lang": { "en-us": { "role": { "negatedLabel": "Part I incentive fees waived", "terseLabel": "Part I incentive fees waived", "label": "Investment Company, Part I Fee Waived", "documentation": "Investment Company, Part I Fee Waived", "parentTag": "us-gaap:InvestmentCompanyPortfolioTurnoverRatio": { "xbrlType": "percentItemType", "nsuri": "http://ocsl.com/20240630", "localname": "InvestmentCompanyPortfolioTurnoverRatio", "presentation": { "http://ocsl.com/role/FinancialHighlightsDetails", "http://ocsl.com/role/PortfolioInvestmentsSummaryOfPortfolioDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Ratio of portfolio turnover to average investments at fair value", "label": "Investment Company, Portfolio Turnover Ratio", "documentation": "Investment Company, Portfolio Turnover Ratio", "parentTag": "us-gaap:InvestmentCompanyProvisionBenefitForTaxesOnRealizedAndUnrealizedGainsLossesPerShare": { "xbrlType": "perShareItemType", "nsuri": "http://ocsl.com/20240630", "localname": "InvestmentCompanyProvisionBenefitForTaxesOnRealizedAndUnrealizedGainsLossesPerShare", "presentation": { "http://ocsl.com/role/FinancialHighlightsDetails", "http://ocsl.com/role/PortfolioInvestmentsSummaryOfPortfolioDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Provision benefit for taxes on realized and unrealized gains (losses) (in dollars per share)", "label": "Investment Company, (Provision) Benefit For Taxes On Realized And Unrealized Gains (Losses), Per Share", "documentation": "Investment Company, (Provision) Benefit For Taxes On Realized And Unrealized Gains (Losses), Per Share", "parentTag": "us-gaap:InvestmentCompanyRealizedGainsLossesAndNetUnrealizedAppreciationDepreciationTextBlock": { "xbrlType": "textBlockItemType", "nsuri": "http://ocsl.com/20240630", "localname": "InvestmentCompanyRealizedGainsLossesAndNetUnrealizedAppreciationDepreciationTextBlock", "presentation": { "http://ocsl.com/role/RealizedGainsLossesAndNetUnrealizedAppreciationOrDepreciation", "http://ocsl.com/role/ShareDataAndNetAssetsScheduleOfChangesInNetAssetsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Realized Gains or Losses and Net Unrealized Appreciation or Depreciation", "label": "Investment Company, Realized Gains (Losses) And Net Unrealized Appreciation (Depreciation) [Text Block]", "documentation": "Investment Company, Realized Gains (Losses) And Net Unrealized Appreciation (Depreciation)", "parentTag": "us-gaap:InvestmentCompanyRegistrationAmendment": { "xbrlType": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "InvestmentCompanyRegistrationAmendment", "presentation": { "http://xbrl.sec.gov/cef/role/N2", "http://xbrl.sec.gov/cef/role/N2/I", "lang": { "en-us": { "role": { "label": "Investment Company Registration Amendment", "documentation": "Investment Company Registration Amendment Number", "parentTag": "us-gaap:InvestmentCompanyRegistrationAmendmentNumber": { "xbrlType": "sequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "InvestmentCompanyRegistrationAmendmentNumber", "presentation": { "http://xbrl.sec.gov/cef/role/N2", "http://xbrl.sec.gov/cef/role/N2/I", "lang": { "en-us": { "role": { "label": "Investment Company Registration Amendment Number", "documentation": "Investment Company Registration Amendment Number", "parentTag": "us-gaap:InvestmentCompanySeniorSecurityIndebtednessAssetCoverageRatio": { "xbrlType": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentCompanySeniorSecurityIndebtednessAssetCoverageRatio", "presentation": { "http://ocsl.com/role/FinancialHighlightsDetails", "http://ocsl.com/role/PortfolioInvestmentsSummaryOfPortfolioDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Asset coverage ratio", "label": "Investment Company, Senior Security, Indebtedness, Asset Coverage Ratio", "documentation": "Percentage of total assets less all liabilities and indebtedness not represented by senior security to senior security representing indebtedness.", "parentTag": "us-gaap:InvestmentCompanyShareholderTransactionsIncreaseDecrease": { "xbrlType": "monetaryItemType", "nsuri": "http://ocsl.com/20240630", "localname": "InvestmentCompanyShareholderTransactionsIncreaseDecrease", "crdr": "credit", "calculation": { "http://ocsl.com/role/ConsolidatedStatementsOfChangesInNetAssets": { "parentTag": "us-gaap:StockholdersEquityPeriodIncreaseDecrease": { "weight": 1.0, "order": 1.0 }, "presentation": { "http://ocsl.com/role/ConsolidatedStatementsOfChangesInNetAssets", "http://ocsl.com/role/ShareDataAndNetAssetsScheduleOfChangesInNetAssetsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Net increase (decrease) in net assets from stockholder transactions", "verboseLabel": "Distributions to stockholders", "label": "Investment Company, Shareholder Transactions, Increase (Decrease)", "documentation": "Investment Company, Shareholder Transactions, Increase (Decrease)", "parentTag": "us-gaap:InvestmentCompanyTotalReturn": { "xbrlType": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentCompanyTotalReturn", "presentation": { "http://ocsl.com/role/FinancialHighlightsDetails", "http://ocsl.com/role/PortfolioInvestmentsSummaryOfPortfolioDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Total return", "label": "Investment Company, Total Return", "documentation": "Percentage increase (decrease
```

```
"http://ocsl.com/role/Schedule1214ScheduleofInvestmentsinandAdvancetoAffiliatesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Investment, Identifier [Axis]", "label": "Investment, Identifier [Axis]", "documentation": "Identification of investment in security, including, but not limited to, name, title, and other identifying information." } } }, "auth_ref": { "r537", "r538", "r539", "r544", "r545", "r546", "r551", "r552", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r642", "r643", "r644", "r645", "r646", "r648", "r649", "r650", "r652", "r654", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r667", "r668", "r669", "r670", "r671", "r672", "r673", "r674", "r676", "r677", "r678", "r681", "r682", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r712", "r713", "r714", "r715", "r717", "r718", "r720", "r721", "r722", "r723", "r725", "r726", "r727", "r728", "r730", "r732", "r733", "r734", "r789" } }, "us-gaap-InvestmentIncomeExpense": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentIncomeExpense", "crdr": "debit", "calculation": { "http://ocsl.com/role/ConsolidatedStatementsOfOperations": { "parentTag": "us-gaap-InvestmentCompanyExpenseAfterReductionOfWaiverAndReimbursement", "weight": 1.0, "order": 1.0 }, "http://ocsl.com/role/PortfolioInvestmentsSummarizedStatementOfOperationsInformationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://ocsl.com/role/ConsolidatedStatementsOfOperations": { "totalLabel": "Total expenses", "label": "Investment Income Expense", "documentation": "Amount of expenses related to the generation of investment income." } }, "auth_ref": { "r91", "r802", "r1034" } }, "us-gaap-InvestmentIncomeOperatingAfterExpenseAndTax": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentIncomeOperatingAfterExpenseAndTax", "crdr": "credit", "calculation": { "http://ocsl.com/role/ConsolidatedStatementsOfOperations": { "parentTag": "us-gaap-NetIncomeLoss", "weight": 1.0, "order": 1.0 }, "http://ocsl.com/role/ConsolidatedStatementsOfChangesInNetAssets": { "parentTag": "us-gaap-NetIncomeLoss", "weight": 1.0, "order": 4.0 } }, "presentation": { "http://ocsl.com/role/ConsolidatedStatementsOfChangesInNetAssets": { "totalLabel": "Net investment income", "terseLabel": "Net investment income", "verboseLabel": "Net investment income", "label": "Investment Income, Operating, after Expense and Tax", "documentation": "Amount, after expense and tax, of investment income classified as operating. Excludes realized and unrealized gain (loss) on investment." } }, "auth_ref": { "r519", "r602", "r617", "r803" } }, "us-gaap-InvestmentInterestRate": { "xbrlType": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentInterestRate", "presentation": { "http://ocsl.com/role/ConsolidatedScheduleofInvestments": { "totalLabel": "Investment interest rate (as a percent)", "label": "Investment Interest Rate", "documentation": "Rate of interest on investment." } }, "auth_ref": { "r634", "r635", "r655", "r656", "r660", "r661", "r712", "r713", "r789", "r993", "r995" } }, "us-gaap-InvestmentInterestRateFloor": { "xbrlType": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentInterestRateFloor", "presentation": { "http://ocsl.com/role/PortfolioInvestmentsNarrativeDetails": { "totalLabel": "Investment interest rate, floor (as a percent)", "label": "Investment Interest Rate, Floor", "documentation": "Minimum rate of interest on investment." } }, "auth_ref": { "r1069", "r1072", "r1075", "r1078" } }, "us-gaap-InvestmentInterestRatePaidInKind": { "xbrlType": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentInterestRatePaidInKind", "presentation": { "http://ocsl.com/role/ConsolidatedScheduleofInvestments": { "totalLabel": "Investment interest rate, paid in kind (as a percent)", "label": "Investment Interest Rate, Paid in Kind", "documentation": "Rate of interest paid in kind on investment." } }, "auth_ref": { "r635", "r656", "r660", "r713" } }, "us-gaap-InvestmentIssuerAffiliationAxis": { "xbrlType": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentIssuerAffiliationAxis", "presentation": { "http://ocsl.com/role/ConsolidatedScheduleofInvestments": { "totalLabel": "Investment issuer affiliation", "label": "Investment Issuer Affiliation", "documentation": "Information by affiliation of issuer of investment." } }, "auth_ref": { "r493", "r518", "r542", "r553", "r567", "r568", "r593", "r594", "r595", "r596", "r603", "r604", "r609", "r610", "r640", "r641", "r647", "r675", "r679", "r680", "r716", "r717", "r719", "r720", "r724", "r725", "r729", "r730", "r731" } }, "us-gaap-InvestmentIssuerAffiliationDomain": { "xbrlType": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentIssuerAffiliationDomain", "presentation": { "http://ocsl.com/role/ConsolidatedScheduleofInvestments": { "totalLabel": "Investment issuer affiliation domain", "label": "Investment Issuer Affiliation Domain", "documentation": "Affiliation of issuer of investment." } }, "auth_ref": { "r493", "r518", "r542", "r553", "r567", "r568", "r593", "r594", "r595", "r596", "r603", "r604", "r609", "r610", "r640", "r641", "r647", "r675", "r679", "r680", "r716", "r717", "r719", "r720", "r724", "r725", "r729", "r730", "r731" } }, "us-gaap-InvestmentIssuerNameAxis": { "xbrlType": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentIssuerNameAxis", "presentation": { "http://ocsl.com/role/PortfolioInvestmentsNarrativeDetails": { "totalLabel": "Investment issuer name", "label": "Investment Issuer Name", "documentation": "Information by name of issuer of investment." } }, "auth_ref": { "r1070", "r1073", "r1076", "r1080" } }, "us-gaap-InvestmentIssuerNameDomain": { "xbrlType": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentIssuerNameDomain", "presentation": { "http://ocsl.com/role/PortfolioInvestmentsNarrativeDetails": { "totalLabel": "Investment issuer name domain", "label": "Investment Issuer Name Domain", "documentation": "Name of issuer of investment." } }, "auth_ref": { "r1070", "r1073", "r1076", "r1080" } }, "cecf-InvestmentObjectivesAndPracticesTextBlock": { "xbrlType": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "InvestmentObjectivesAndPracticesTextBlock", "presentation": { "http://xbrl.sec.gov/cef/role/N2": { "totalLabel": "Investment objectives and practices", "label": "Investment Objectives and Practices [Text Block]", "documentation": "Investment objectives and practices." } }, "auth_ref": { "r888" } }, "ocsl-InvestmentOwnedAndMoneyMarketFundsPercentOfNetAssets": { "xbrlType": "percentItemType", "nsuri": "http://ocsl.com/20240630", "localname": "InvestmentOwnedAndMoneyMarketFundsPercentOfNetAssets", "presentation": { "http://ocsl.com/role/ConsolidatedScheduleofInvestments": { "totalLabel": "Investment owned and money market funds, percent of net assets (as a percent)", "label": "Investment Owned And Money Market Funds, Percent of Net Assets", "documentation": "Investment Owned And Money Market Funds, Percent of Net Assets." } }, "auth_ref": { "r1070", "r1073", "r1076", "r1080" } }, "us-gaap-InvestmentOwnedAtCost": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentOwnedAtCost", "crdr": "debit", "calculation": { "http://ocsl.com/role/ConsolidatedScheduleofInvestments": { "parentTag": "ocsl-InvestmentOwnedAtCostAndMoneyMarketFundsAtCarryingValue", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://ocsl.com/role/ConsolidatedScheduleofInvestments": { "totalLabel": "Investment owned at cost", "label": "Investment Owned Cost", "documentation": "Cost of the investment." } }, "auth_ref": { "r493", "r544", "r545", "r644", "r654", "r672", "r730", "r789", "r804", "r1046" } }, "ocsl-InvestmentOwnedAtCostAndMoneyMarketFundsAtCarryingValue": { "xbrlType": "monetaryItemType", "nsuri": "http://ocsl.com/20240630", "localname": "InvestmentOwnedAtCostAndMoneyMarketFundsAtCarryingValue", "crdr": "debit", "calculation": { "http://ocsl.com/role/ConsolidatedScheduleofInvestments": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://ocsl.com/role/ConsolidatedScheduleofInvestments": { "totalLabel": "Investment owned at cost and money market funds, at carrying value", "label": "Investment Owned At Cost And Money Market Funds, At Carrying Value", "documentation": "Investment Owned At Cost And Money Market Funds, At Carrying Value." } }, "auth_ref": { "r1070", "r1073", "r1076", "r1080" } }, "cecf-InvestmentOwnedAtFairValueAndMoneyMarketFundsAtCarryingValue": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentOwnedAtFairValueAndMoneyMarketFundsAtCarryingValue", "crdr": "debit", "calculation": { "http://ocsl.com/role/ConsolidatedScheduleofInvestments": { "parentTag": "us-gaap-Assets", "weight": 1.0, "order": 1.0 }, "http://ocsl.com/role/ConsolidatedScheduleofInvestments": { "parentTag": "ocsl-InvestmentOwnedAtFairValueAndMoneyMarketFundsAtCarryingValue", "weight": 1.0, "order": 2.0 }, "http://ocsl.com/role/PortfolioInvestmentsScheduleofFinancialInstrumentsCarriedAtFairValueDetails": { "parentTag": "us-gaap-AssetsFairValueDisclosure", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://ocsl.com/role/ConsolidatedScheduleofInvestments": { "totalLabel": "Investment owned at fair value", "label": "Investment Owned At Fair Value", "documentation": "Investment Owned At Fair Value." } }, "auth_ref": { "r1070", "r1073", "r1076", "r1080" } }, "us-gaap-InvestmentOwnedAtFairValue": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentOwnedAtFairValue", "crdr": "debit", "calculation": { "http://ocsl.com/role/ConsolidatedScheduleofInvestments": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://ocsl.com/role/ConsolidatedScheduleofInvestments": { "totalLabel": "Investment owned at fair value", "label": "Investment Owned At Fair Value", "documentation": "Investment Owned At Fair Value." } }, "auth_ref": { "r1070", "r1073", "r1076", "r1080" } }, "cecf-InvestmentOwnedBalancePrincipalAmount": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentOwnedBalancePrincipalAmount", "crdr": "debit", "presentation": { "http://ocsl.com/role/ConsolidatedScheduleofInvestments": { "totalLabel": "Investment owned balance principal amount", "label": "Investment Owned Balance, Principal Amount", "documentation": "Amount of principal of investment owned." } }, "auth_ref": { "r537", "r548", "r638", "r669", "r715", "r789" } }, "ocsl-InvestmentOwnedBalanceShareTradingDays": { "xbrlType": "durationItemType", "nsuri": "http://ocsl.com/20240630", "localname": "InvestmentOwnedBalanceShareTradingDays", "presentation": { "http://ocsl.com/role/ConsolidatedScheduleofInvestmentsParentetical": { "totalLabel": "Investment owned balance, shares, VWAP threshold (in dollars per share)", "label": "Investment Owned Balance, Share, VWAP, Threshold", "documentation": "Investment owned balance, shares, VWAP threshold (in dollars per share)."} }, "auth_ref": { "r1070
```

[illegible]


```
"http://xbrl.sec.gov/cef/2023", "localname": "LatestPremiumDiscountToNAVPercent", "presentation": "http://xbrl.sec.gov/cef/role/N2", "lang": "en-us", "role": "label", "terseLabel": "Latest Premium (Discount) to NAV [Percent]", "auth_ref": "r900", "cefLatestSharePrice": "http://xbrl.sec.gov/cef/role/N2", "perShareItem": "http://xbrl.sec.gov/cef/2023", "localname": "LatestSharePrice", "presentation": "http://xbrl.sec.gov/cef/role/N2", "lang": "en-us", "role": "label", "terseLabel": "Latest Share Price (Deprecated 2023-01-31)", "auth_ref": "r900", "deiLegalEntityAxis": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LegalEntityAxis", "presentation": "http://ocsl.com/role/PortfolioInvestmentsNarrativeDetails", "lang": "en-us", "role": "label", "Legal Entity Axis", "terseLabel": "Legal Entity Axis", "documentation": "The set of legal entities associated with a report.", "auth_ref": "I", "ocslLeisureFacilitiesMember": "http://xbrl.sec.gov/20240630", "localname": "LeisureFacilitiesMember", "presentation": "http://ocsl.com/role/PortfolioInvestmentsPortfolioInvestmentsByIndustryDetails", "lang": "en-us", "role": "label", "terseLabel": "Leisure Facilities", "label": "Leisure Facilities [Member]", "documentation": "Leisure Facilities", "auth_ref": "I", "ocslLeisureProductsMember": "http://xbrl.sec.gov/20240630", "localname": "LeisureProductsMember", "presentation": "http://ocsl.com/role/PortfolioInvestmentsPortfolioInvestmentsByIndustryDetails", "lang": "en-us", "role": "label", "terseLabel": "Leisure Products", "label": "Leisure Products [Member]", "documentation": "Leisure Products", "auth_ref": "I", "us-gaapLiabilities": "http://fasb.org/us-gaap/2023", "localname": "Liabilities", "crdr": "credit", "calculation": "http://ocsl.com/role/ConsolidatedStatementsOfAssetsAndLiabilities", "parentTag": "us-gaapLiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0, "http://ocsl.com/role/PortfolioInvestmentsSummarizedBalanceSheetInformationDetails", "parentTag": "us-gaapLiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0, "presentation": "http://ocsl.com/role/ConsolidatedStatementsOfAssetsAndLiabilities", "http://ocsl.com/role/PortfolioInvestmentsSummarizedBalanceSheetInformationDetails", "lang": "en-us", "role": "totalLabel", "Total liabilities", "label": "Liabilities", "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "auth_ref": "r20", "r163", "r238", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r373", "r374", "r375", "r399", "r562", "r768", "r804", "r1005", "r1022", "r1023", "us-gaapLiabilitiesAbstract": "http://xbrl.sec.gov/20240630", "localname": "LiabilitiesAbstract", "presentation": "http://ocsl.com/role/ConsolidatedStatementsOfAssetsAndLiabilities", "lang": "en-us", "role": "label", "terseLabel": "Liabilities", "label": "Liabilities [Abstract]", "auth_ref": "I", "us-gaapLiabilitiesAndStockholdersEquity": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": "http://ocsl.com/role/ConsolidatedStatementsOfAssetsAndLiabilities", "parentTag": null, "weight": null, "order": null, "root": true, "http://ocsl.com/role/PortfolioInvestmentsSummarizedBalanceSheetInformationDetails", "parentTag": null, "weight": null, "order": null, "root": true, "presentation": "http://ocsl.com/role/ConsolidatedStatementsOfAssetsAndLiabilities", "http://ocsl.com/role/PortfolioInvestmentsSummarizedBalanceSheetInformationDetails", "lang": "en-us", "role": "totalLabel", "Total liabilities and net assets", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "auth_ref": "r84", "r114", "r474", "r785", "r986", "r1001", "r1018", "us-gaapLiabilitiesFairValueDisclosure": "http://xbrl.sec.gov/20240630", "localname": "LiabilitiesFairValueDisclosure", "crdr": "credit", "calculation": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesFairValueDisclosure", "parentTag": null, "weight": null, "order": null, "root": true, "http://ocsl.com/role/PortfolioInvestmentsScheduledFinancialInstrumentsCarriedAtFairValueDetails", "parentTag": null, "weight": null, "order": null, "root": true, "presentation": "http://ocsl.com/role/PortfolioInvestmentsScheduledFinancialInstrumentsCarriedAtFairValueDetails", "lang": "en-us", "role": "totalLabel", "Total liabilities at fair value", "label": "Liabilities, Fair Value Disclosure", "documentation": "Fair value of financial and nonfinancial obligations.", "auth_ref": "r60", "ocslLiftBrandsHoldingsIncMember": "http://xbrl.sec.gov/20240630", "localname": "LiftBrandsHoldingsIncMember", "presentation": "http://ocsl.com/role/RealizedGainsLossesAndNetUnrealizedAppreciationDepreciationAggregateNetRealizedGainsDetails", "lang": "en-us", "role": "label", "terseLabel": "Lift Brands Holdings, Inc.", "label": "Lift Brands Holdings, Inc. [Member]", "documentation": "Lift Brands Holdings, Inc.", "auth_ref": "I", "us-gaapLineOfCredit": "http://xbrl.sec.gov/20240630", "localname": "LineOfCredit", "crdr": "credit", "calculation": "http://ocsl.com/role/PortfolioInvestmentsSummarizedBalanceSheetInformationDetails", "parentTag": "us-gaapLiabilities", "weight": 1.0, "order": 2.0, "http://ocsl.com/role/ConsolidatedStatementsOfAssetsAndLiabilities", "parentTag": "us-gaapLiabilities", "weight": 1.0, "order": 4.0, "presentation": "http://ocsl.com/role/BorrowingsNarrativeDetails", "http://ocsl.com/role/ConsolidatedStatementsOfAssetsAndLiabilities", "http://ocsl.com/role/PortfolioInvestmentsSummarizedBalanceSheetInformationDetails", "lang": "en-us", "role": "label", "terseLabel": "Credit facilities payable", "verboseLabel": "Senior credit facility payable", "label": "Long-Term Line of Credit", "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.", "auth_ref": "r17", "r113", "r1032", "ocslLineOfCreditFacilityAccordionFeatureIncreaseLimit": "http://xbrl.sec.gov/20240630", "localname": "LineOfCreditFacilityAccordionFeatureIncreaseLimit", "crdr": "credit", "presentation": "http://ocsl.com/role/BorrowingsNarrativeDetails", "lang": "en-us", "role": "label", "terseLabel": "Accordion feature, increase limit", "label": "Line of Credit Facility, Accordion Feature, Increase Limit", "documentation": "Line of Credit Facility, Accordion Feature, Increase Limit", "auth_ref": "I", "us-gaapLineOfCreditFacilityAxis": "http://xbrl.sec.gov/20240630", "localname": "LineOfCreditFacilityAxis", "presentation": "http://ocsl.com/role/SignificantAccountingPoliciesDetails", "lang": "en-us", "role": "label", "terseLabel": "Lender Name [Axis]", "label": "Lender Name [Axis]", "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.", "auth_ref": "r19", "r984", "us-gaapLineOfCreditFacilityFairValueOfAmountOutstanding": "http://xbrl.sec.gov/20240630", "localname": "LineOfCreditFacilityFairValueOfAmountOutstanding", "crdr": "credit", "presentation": "http://ocsl.com/role/BorrowingsNarrativeDetails", "lang": "en-us", "role": "label", "terseLabel": "Fair value", "label": "Line of Credit Facility, Fair Value of Amount Outstanding", "documentation": "Fair value of the amount outstanding under the credit facility.", "auth_ref": "r398", "us-gaapLineOfCreditFacilityInterestRateDuringPeriod": "http://xbrl.sec.gov/20240630", "localname": "LineOfCreditFacilityInterestRateDuringPeriod", "presentation": "http://ocsl.com/role/BorrowingsNarrativeDetails", "lang": "en-us", "role": "label", "terseLabel": "Interest rate (as a percent)", "label": "Line of Credit Facility, Interest Rate During Period", "documentation": "The effective interest rate during the reporting period.", "auth_ref": "r19", "us-gaapLineOfCreditFacilityLenderDomain": "http://xbrl.sec.gov/20240630", "localname": "LineOfCreditFacilityLenderDomain", "presentation": "http://ocsl.com/role/SignificantAccountingPoliciesDetails", "lang": "en-us", "role": "label", "terseLabel": "Line of Credit Facility, Lender Domain", "label": "Line of Credit Facility, Lender Domain", "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.", "auth_ref": "r19", "r984", us-gaapLineOfCreditFacilityLineItems": "http://xbrl.sec.gov/20240630", "localname": "LineOfCreditFacilityLineItems", "presentation": "http://ocsl.com/role/BorrowingsNarrativeDetails", "lang": "en-us", "role": "label", "terseLabel": "Line of Credit Facility Line Items", "label": "Line of Credit Facility Line Items", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "auth_ref": "r984", us-gaapLineOfCreditFacilityMaximumBorrowingCapacity": "http://xbrl.sec.gov/20240630", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": "http://ocsl.com/role/BorrowingsNarrativeDetails", "http://ocsl.com/role/PortfolioInvestmentsNarrativeDetails", "lang": "en-us", "role": "label", "terseLabel": "Borrowing capacity", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "auth_ref": "r19", "ocslLineOfCreditFacilityMaximumBorrowingCapacitySubjectToExpiration": "http://xbrl.sec.gov/20240630", "localname": "LineOfCreditFacilityMaximumBorrowingCapacitySubjectToExpiration", "crdr": "credit", "presentation": "http://ocsl.com/role/BorrowingsNarrativeDetails", "lang": "en-us", "role": "label", "terseLabel": "Borrowing capacity subject to expiration", "label": "Line of Credit Facility, Maximum Borrowing Capacity Subject to Expiration", "documentation": "Line of Credit Facility, Maximum Borrowing Capacity Subject to Expiration", "auth_ref": "I", "us-gaapLineOfCreditFacilityTable": "http://xbrl.sec.gov/20240630", "localname": "LineOfCreditFacilityTable", "presentation": "http://ocsl.com/role/BorrowingsNarrativeDetails", "lang": "en-us", "role": "label", "terseLabel": "Line of Credit Facility Table", "label": "Line of Credit Facility Table", "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.", "auth_ref": "r19", "r984", us-gaapLineOfCreditFacilityUnusedCapacityCommitmentFeePercentage": "http://xbrl.sec.gov/20240630", "localname": "LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage", "presentation": "http://ocsl.com/role/BorrowingsNarrativeDetails", "lang": "en-us", "role": "label", "terseLabel": "Unused capacity, commitment fee (as a percent)", "label": "Line of Credit Facility, Unused Capacity, Commitment Fee Percentage", "documentation": "The fee, expressed as a percentage of the line of credit facility, for available but unused credit arranged under the credit facility.", "auth_ref": "I", "ocslLineOfCreditFacilityUnusedCapacityCommitmentFeeThresholdPercentage": "http://xbrl.sec.gov/20240630", "localname": "LineOfCreditFacilityUnusedCapacityCommitmentFeeThresholdPercentage", "presentation": "http://ocsl.com/role/BorrowingsNarrativeDetails", "lang": "en-us", "role": "label", "terseLabel": "Commitment fee, unused capacity threshold percentage (as a percent)", "label": "Line of Credit Facility, Unused Capacity, Commitment Fee, Threshold Percentage", "documentation": "Line of Credit Facility, Unused Capacity, Commitment Fee, Threshold Percentage", "auth_ref": "I", "us-gaapLineOfCreditFacilityMember": "http://xbrl.sec.gov/20240630", "localname": "LineOfCreditFacilityMember", "presentation": "http://ocsl.com/role/PortfolioInvestmentsNarrativeDetails", "lang": "en-us", "role": "label", "terseLabel": "Line of Credit", "label": "Line of Credit [Member]", "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.", "auth_ref": "I", "cefLoanServicingFeesPercent": "http://xbrl.sec.gov/cef/role/N2", "lang": "en-us", "role": "label", "Loan Servicing Fees Percent", "auth_ref": "r874", deiLocalPhoneNumber": "http://xbrl.sec.gov/dei/2023",
```

```

"terseLabel": "Weighted average outstanding debt", "label": "Long-Term Debt, Average Amount Outstanding", "documentation": "Average amount outstanding of long-term debt.", "xbrl": "http://xbrl.sec.gov/cef/2023", "localname": "LongTermDebtDividendsAndCovenantsTextBlock", "presentation": "http://xbrl.sec.gov/cef/role/N2", "lang": "en-us", "role": "label", "Long Term Debt, Dividends and Covenants [Text Block]", "auth_ref": "r851", "us-gaap": "LongTermDebtFairValue", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtFairValue", "crdr": "credit", "presentation": "http://ocsl.com/role/BorrowingsNarrativeDetails", "http://ocsl.com/role/PortfolioInvestmentsScheduleofFinancialInstrumentsDisclosedbutCarriedatFairValueDetails", "lang": "en-us", "role": "terseLabel", "Fair Value", "label": "Long-Term Debt, Fair Value", "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.", "auth_ref": "r1", "cef": "LongTermDebtIssuanceAndSubstitutionTextBlock", "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "LongTermDebtIssuanceAndSubstitutionTextBlock", "presentation": "http://xbrl.sec.gov/cef/role/N2", "lang": "en-us", "role": "label", "Long Term Debt, Issuance and Substitution [Text Block]", "auth_ref": "r852", "cef": "LongTermDebtPrincipal", "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "LongTermDebtPrincipal", "presentation": "http://xbrl.sec.gov/cef/role/N2", "lang": "en-us", "role": "label", "Long Term Debt, Principal", "auth_ref": "r849", "cef": "LongTermDebtRightsLimitedByOtherSecuritiesTextBlock", "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "LongTermDebtRightsLimitedByOtherSecuritiesTextBlock", "presentation": "http://xbrl.sec.gov/cef/role/N2", "lang": "en-us", "role": "label", "Long Term Debt, Rights Limited by Other Securities [Text Block]", "auth_ref": "r853", "cef": "LongTermDebtStructuringTextBlock", "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "LongTermDebtStructuringTextBlock", "presentation": "http://xbrl.sec.gov/cef/role/N2", "lang": "en-us", "role": "label", "Long Term Debt, Structuring [Text Block]", "auth_ref": "r850", "cef": "LongTermDebtTableTextBlock", "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "LongTermDebtTableTextBlock", "presentation": "http://xbrl.sec.gov/cef/role/N2", "lang": "en-us", "role": "label", "Long Term Debt [Table Text Block]", "auth_ref": "r849", "cef": "LongTermDebtTitleTextBlock", "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "LongTermDebtTitleTextBlock", "presentation": "http://xbrl.sec.gov/cef/role/N2", "lang": "en-us", "role": "label", "Long Term Debt, Title [Text Block]", "auth_ref": "r849", "us-gaap": "LongTermDebtTypeAxis", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtTypeAxis", "presentation": "http://ocsl.com/role/BorrowingsNarrativeDetails", "http://ocsl.com/role/PortfolioInvestmentsNarrativeDetails", "lang": "en-us", "role": "terseLabel", "Long-Term Debt, Type [Axis]", "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt.", "auth_ref": "r22", "us-gaap": "LongTermDebtTypeDomain", "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtTypeDomain", "presentation": "http://ocsl.com/role/BorrowingsNarrativeDetails", "http://ocsl.com/role/PortfolioInvestmentsNarrativeDetails", "lang": "en-us", "role": "terseLabel", "Long-Term Debt, Type [Domain]", "label": "Long-Term Debt, Type [Domain]", "documentation": "Type of long-term debt arrangement such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "auth_ref": "r22", "cef": "LowestPriceOrBid", "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "LowestPriceOrBid", "presentation": "http://xbrl.sec.gov/cef/role/N2", "lang": "en-us", "role": "label", "Lowest Price or Bid", "auth_ref": "r894", "cef": "LowestPriceOrBidNav", "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "LowestPriceOrBidNav", "presentation": "http://xbrl.sec.gov/cef/role/N2", "lang": "en-us", "role": "label", "Lowest Price or Bid, NAV", "auth_ref": "r898", "cef": "LowestPriceOrBidPremiumDiscountToNavPercent", "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "LowestPriceOrBidPremiumDiscountToNavPercent", "presentation": "http://xbrl.sec.gov/cef/role/N2", "lang": "en-us", "role": "label", "Lowest Price or Bid, Premium Discount to NAV [Percent]", "auth_ref": "r899", "ocsl": "ManagementAndIncentiveFeePayable", "xbrltype": "monetaryItemType", "nsuri": "http://ocsl.com/20240630", "localname": "ManagementAndIncentiveFeePayable", "crdr": "credit", "calculation": "http://ocsl.com/role/ConsolidatedStatementsOfAssetsandLiabilities", "parentTag": "us-gaap:Liabilities", "weight": 1.0, "order": 3.0, "presentation": "http://ocsl.com/role/ConsolidatedStatementsOfAssetsandLiabilities", "http://ocsl.com/role/RelatedPartyTransactionsDetails", "lang": "en-us", "role": "terseLabel", "Base management fee and incentive fee payable", "label": "Management And Incentive Fee Payable", "documentation": "Management And Incentive Fee Payable", "auth_ref": "r1", "us-gaap": "ManagementAndServiceFeesBaseRate", "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ManagementAndServiceFeesBaseRate", "presentation": "http://ocsl.com/role/RelatedPartyTransactionsDetails", "lang": "en-us", "role": "terseLabel", "Base management fee rate (as a percent)", "label": "Management And Service Fees, Base Rate", "documentation": "Base rate for management and service fees under arrangement to manage operations, including, but not limited to, investment.", "auth_ref": "r1059", "us-gaap": "ManagementAndServiceFeesIncentiveRate", "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ManagementAndServiceFeesIncentiveRate", "presentation": "http://ocsl.com/role/RelatedPartyTransactionsDetails", "lang": "en-us", "role": "terseLabel", "Management incentive rate (as a percent)", "label": "Management and Service Fees, Incentive Rate", "documentation": "Rate based on performance for management and service fees under arrangement to manage operations, including, but not limited to, investment.", "auth_ref": "r1059", "ocsl": "ManagementAndServiceFeesInvestmentsPercentageThreshold", "xbrltype": "percentItemType", "nsuri": "http://ocsl.com/20240630", "localname": "ManagementAndServiceFeesInvestmentsPercentageThreshold", "presentation": "http://ocsl.com/role/RelatedPartyTransactionsDetails", "lang": "en-us", "role": "terseLabel", "Base management fee, threshold (as a percent)", "label": "Management And Service Fees, Investments Percentage Threshold", "documentation": "Management And Service Fees, Investments Percentage Threshold", "auth_ref": "r1", "us-gaap": "ManagementFeeExpense", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ManagementFeeExpense", "crdr": "debit", "calculation": "http://ocsl.com/role/ConsolidatedStatementsOfOperations", "parentTag": "us-gaap:InvestmentIncomeInvestmentExpense", "weight": 1.0, "order": 5.0, "presentation": "http://ocsl.com/role/ConsolidatedStatementsOfOperations", "http://ocsl.com/role/RelatedPartyTransactionsDetails", "lang": "en-us", "role": "terseLabel", "Base management fee", "label": "Management Fee Expense", "documentation": "Amount of expense for investment management fee, including, but not limited to, expense in connection with research, selection, supervision, and custody of investment.", "auth_ref": "r69", "r594", "r802", "r1051", "cef": "ManagementFeeNotBasedOnNetAssetsNoteTextBlock", "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "ManagementFeeNotBasedOnNetAssetsNoteTextBlock", "presentation": "http://xbrl.sec.gov/cef/role/N2", "lang": "en-us", "role": "label", "Management Fee not based on Net Assets, Note [Text Block]", "auth_ref": "r872", "cef": "ManagementFeesPercent", "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "ManagementFeesPercent", "presentation": "http://xbrl.sec.gov/cef/role/N2", "lang": "en-us", "role": "label", "Management Fees [Percent]", "auth_ref": "r871", "us-gaap": "MarketApproachValuationTechniqueMember", "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MarketApproachValuationTechniqueMember", "presentation": "http://ocsl.com/role/PortfolioInvestmentsSignificantUnobservableInputsforLevel3InvestmentsDetails", "lang": "en-us", "role": "terseLabel", "Market Yield", "label": "Valuation, Market Approach [Member]", "documentation": "Valuation approach using price and other relevant information generated by market transaction involving identical or comparable asset, liability, or group of assets and liabilities.", "auth_ref": "r13", "srt": "MaximumMember", "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MaximumMember", "presentation": "http://ocsl.com/role/BorrowingsNarrativeDetails", "http://ocsl.com/role/ConsolidatedScheduleofInvestmentsParentetical", "http://ocsl.com/role/PortfolioInvestmentsPortfolioListingDetails", "http://ocsl.com/role/PortfolioInvestmentsSignificantUnobservableInputsforLevel3InvestmentsDetails", "lang": "en-us", "role": "terseLabel", "Maximum", "label": "Maximum [Member]", "auth_ref": "r253", "r254", "r255", "r256", "r319", "r452", "r484", "r549", "r550", "r634", "r655", "r661", "r662", "r712", "r760", "r761", "r770", "r779", "r784", "r786", "r1007", "r1024", "r1025", "r1026", "r1027", "r1028", "r1029", "ced": "MeasureAxis", "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ced/2023", "localname": "MeasureAxis", "presentation": "http://xbrl.sec.gov/ced/role/PvpDisclosure", "lang": "en-us", "role": "terseLabel", "Measure", "label": "Measure [Axis]", "auth_ref": "r923", "ced": "MeasureName", "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ced/2023", "localname": "MeasureName", "presentation": "http://xbrl.sec.gov/ced/role/PvpDisclosure", "lang": "en-us", "role": "terseLabel", "Name", "label": "Measure Name", "auth_ref": "r923", "ocsl": "MeasurementInputAssetMultipleMember", "xbrltype": "domainItemType", "nsuri": "http://ocsl.com/20240630", "localname": "MeasurementInputAssetMultipleMember", "presentation": "http://ocsl.com/role/PortfolioInvestmentsSignificantUnobservableInputsforLevel3InvestmentsDetails", "lang": "en-us", "role": "terseLabel", "Asset Multiple", "label": "Measurement Input, Asset Multiple [Member]", "documentation": "Measurement Input, Asset Multiple", "auth_ref": "r1", "ocsl": "MeasurementInputBrokerQuotedPriceMember", "xbrltype": "domainItemType", "nsuri": "http://ocsl.com/20240630", "localname": "MeasurementInputBrokerQuotedPriceMember", "presentation": "http://ocsl.com/role/PortfolioInvestmentsSignificantUnobservableInputsforLevel3InvestmentsDetails", "lang": "en-us", "role": "terseLabel", "Broker Quoted Price", "label": "Measurement Input, Broker Quoted Price [Member]", "documentation": "Measurement Input, Broker Quoted Price", "auth_ref": "r1", "us-gaap": "MeasurementInputEbitdaMultipleMember", "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputEbitdaMultipleMember", "presentation": "http://ocsl.com/role/PortfolioInvestmentsSignificantUnobservableInputsforLevel3InvestmentsDetails", "lang": "en-us", "role": "terseLabel", "EBITDA Multiple", "label": "Measurement Input, EBITDA Multiple [Member]", "documentation": "Measurement input using earnings before interest, tax, depreciation and amortization (EBITDA) multiple.", "auth_ref": "r1017", "ocsl": "MeasurementInputMarketYieldMember", "xbrltype": "domainItemType", "nsuri": "http://ocsl.com/20240630", "localname": "MeasurementInputMarketYieldMember", "presentation": "http://ocsl.com/role/PortfolioInvestmentsSignificantUnobservableInputsforLevel3InvestmentsDetails", "lang": "en-us", "role": "terseLabel", "Market Yield", "label": "Measurement Input, Market Yield [Member]", "documentation": "Measurement Input, Market Yield", "auth_ref": "r1", "us-gaap": "MeasurementInputRevenueMultipleMember", "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputRevenueMultipleMember", "presentation": "http://ocsl.com/role/PortfolioInvestmentsSignificantUnobservableInputsforLevel3
```

"r550","r634","r655","r661","r662","r712","r760","r761","r770","r779","r784","r786","r1007","r1024","r1025","r1026","r1027","r1028","r1029"}},
"ecsd_MnpiDiscTimedForCompValFlag":{"xbrltype":"booleanItemType","nsuri":"http://xbrl.sec.gov/ecd/2023","localname":"MnpiDiscTimedForCompValFlag",
"presentation":{"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"},"lang":{"en-us":{"role":{"terseLabel":"MNPI Disclosure Timed for Compensation Value",
"label":"MNPI Disclosure Timed for Compensation Value [Flag] }}}},"auth_ref":{"r942"},"us-gaap_MoneyMarketFundsAtCarryingValue":{"xbrltype":
"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2023","localname":"MoneyMarketFundsAtCarryingValue","crdr":{"debit"},"calculation":{"
"http://ocsl.com/role/ConsolidatedScheduleofInvestments":{"parentTag":{"ocsl_InvestmentOwnedAtCostAndMoneyMarketFundsAtCarryingValue","weight":1.0,"order":
1.0},"presentation":{"http://ocsl.com/role/ConsolidatedScheduleofInvestments"},"lang":{"en-us":{"role":{"terseLabel":"Money market funds, at carrying value",
"label":"Money Market Funds, at Carrying Value"},"documentation":"Investment in short-term money market instruments (such as commercial paper, banker's
acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of
cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original
maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For
example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note
purchased three years ago does not become a cash equivalent when its remaining maturity is three months."}}},"auth_ref":{"r1111},
"ocsl_MoneyMarketFundsPercentOfNetAssets":{"xbrltype":"percentItemType","nsuri":"http://ocsl.com/20240630","localname":
"MoneyMarketFundsPercentOfNetAssets","presentation":{"http://ocsl.com/role/ConsolidatedScheduleofInvestments"},
"http://ocsl.com/role/PortfolioInvestmentsNarrativeDetails"},"lang":{"en-us":{"role":{"terseLabel":"Money market funds, percent of net assets (as a percent)",
"label":"Money Market Funds, Percent Of Net Assets"},"documentation":"Money Market Funds, Percent Of Net Assets }}}},"auth_ref":{"r1111},
"ocsl_MoviesEntertainmentMember":{"xbrltype":"domainItemType","nsuri":"http://ocsl.com/20240630","localname":"MoviesEntertainmentMember","presentation":{"
"http://ocsl.com/role/PortfolioInvestmentsPortfolioofInvestmentsbyIndustryDetails"},"lang":{"en-us":{"role":{"terseLabel":"Movies & Entertainment"},"label":
"Movies & Entertainment [Member]"},"documentation":"Movies & Entertainment }}}},"auth_ref":{"r1111},"ecsd_MtrlTermsOfTrdArrTextBlock":{"xbrltype":
"textBlockItemType","nsuri":"http://xbrl.sec.gov/ecd/2023","localname":"MtrlTermsOfTrdArrTextBlock","presentation":{"
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"},"lang":{"en-us":{"role":{"terseLabel":"Material Terms of Trading Arrangement"},"label":"Material Terms
of Trading Arrangement [Text Block] }}}},"auth_ref":{"r950"},"ocsl_MultiSectorHoldingsMember":{"xbrltype":"domainItemType","nsuri":
"http://ocsl.com/20240630","localname":"MultiSectorHoldingsMember","presentation":{"
"http://ocsl.com/role/PortfolioInvestmentsPortfolioofInvestmentsbyIndustryDetails"},"lang":{"en-us":{"role":{"terseLabel":"Multi-Sector Holdings"},"label":"Multi-
Sector Holdings [Member]"},"documentation":"Multi-Sector Holdings }}}},"auth_ref":{"r1111},"ecsd_NamedExecutiveOfficersFnTextBlock":{"xbrltype":
"textBlockItemType","nsuri":"http://xbrl.sec.gov/ecd/2023","localname":"NamedExecutiveOfficersFnTextBlock","presentation":{"
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"},"lang":{"en-us":{"role":{"terseLabel":"Named Executive Officers, Footnote"},"label":"Named Executive Officers,
Footnote [Text Block] }}}},"auth_ref":{"r924"},"us-gaap_NetAssetValuePerShare":{"xbrltype":"perShareItemType","nsuri":"http://fasb.org/us-gaap/2023",
"localname":"NetAssetValuePerShare","presentation":{"http://ocsl.com/role/ConsolidatedStatementsOfAssetsandLiabilitiesParenthetical"},
"http://ocsl.com/role/ConsolidatedStatementsOfChangesInNetAssets"},"http://xbrl.sec.gov/cef/role/N2"},"lang":{"en-us":{"role":{"label":"NAV Per Share",
"terseLabel":"Net asset value per common share (in dollars per share)","periodStartLabel":"Net asset value per share at beginning of period (in dollars per share)",
"periodEndLabel":"Net asset value per share at end of period (in dollars per share)","documentation":"Net asset value per
share or per unit of investments in certain entities that calculate net asset value per share. Includes, but is not limited to, by unit, membership interest, or other
ownership interest. Investment includes, but is not limited to, investment in certain hedge funds, venture capital funds, private equity funds, real estate partnerships or
funds. Excludes fair value disclosure."}}},"auth_ref":{"r1111,"r1112","r1113","r1114","r1115","r1116","r1117","r1118","r1119","r1120","r1121","r1122","r1123","r1124","r1125"},
"us-gaap_NetCashProvidedByUsedInFinancingActivities":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2023","localname":
"NetCashProvidedByUsedInFinancingActivities","crdr":{"debit"},"calculation":{"http://ocsl.com/role/ConsolidatedStatementofCashFlows":{"parentTag":{"us-
gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect","weight":1.0,"order":3.0}},
"presentation":{"http://ocsl.com/role/ConsolidatedStatementofCashFlows"},"lang":{"en-us":{"role":{"totalLabel":"Net cash provided by (used in) financing
activities"},"label":"Net Cash Provided by (Used in) Financing Activities"},"documentation":"Amount of cash inflow (outflow) from financing activities, including
discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment;
borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."}}},
"auth_ref":{"r1155"},"us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract":{"xbrltype":"stringItemType","nsuri":"http://fasb.org/us-gaap/2023",
"localname":"NetCashProvidedByUsedInFinancingActivitiesAbstract","presentation":{"http://ocsl.com/role/ConsolidatedStatementofCashFlows"},"lang":{"en-us":{"
"role":{"terseLabel":"Financing activities"},"label":"Net Cash Provided by (Used in) Financing Activities [Abstract] }}}},"auth_ref":{"r1111,"us-
gaap_NetCashProvidedByUsedInOperatingActivities":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2023","localname":
"NetCashProvidedByUsedInOperatingActivities","calculation":{"http://ocsl.com/role/ConsolidatedStatementofCashFlows":{"parentTag":{"us-
gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect","weight":1.0,"order":2.0}},
"presentation":{"http://ocsl.com/role/ConsolidatedStatementofCashFlows"},"lang":{"en-us":{"role":{"totalLabel":"Net cash provided by (used in) operating
activities"},"label":"Net Cash Provided by (Used in) Operating Activities"},"documentation":"Amount of cash inflow (outflow) from operating activities, including
discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."}}}},
"auth_ref":{"r93","r94","r95"},"us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract":{"xbrltype":"stringItemType","nsuri":"http://fasb.org/us-
gaap/2023","localname":"NetCashProvidedByUsedInOperatingActivitiesAbstract","presentation":{"http://ocsl.com/role/ConsolidatedStatementofCashFlows"},"lang":{"
"en-us":{"role":{"terseLabel":"Operating activities"},"label":"Net Cash Provided by (Used in) Operating Activities [Abstract] }}}},"auth_ref":{"r1111},
"cef_NetExpenseOverAssetsPercent":{"xbrltype":"percentItemType","nsuri":"http://xbrl.sec.gov/cef/2023","localname":"NetExpenseOverAssetsPercent",
"presentation":{"http://xbrl.sec.gov/cef/role/N2"},"lang":{"en-us":{"role":{"label":"Net expense over Assets [Percent]"},"auth_ref":{"r874"},"us-
gaap_NetIncomeLoss":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2023","localname":"NetIncomeLoss","crdr":{"credit"},"calculation":{"
"http://ocsl.com/role/TaxableDistributableIncomeandDividendDistributionsReconciliationofNetIncreaseDecreaseinNetAssetsResultingfromOperationsDetails":{"
"parentTag":{"ocsl_InvestmentCompanyDistributableEarningsLossBeforeDeductions"},"weight":1.0,"order":1.0},
"http://ocsl.com/role/ConsolidatedStatementsOfChangesInNetAssets":{"parentTag":{"us-gaap_StockholdersEquityPeriodIncreaseDecrease"},"weight":1.0,"order":2.0},
"http://ocsl.com/role/ConsolidatedStatementofCashFlows":{"parentTag":{"us-gaap_NetCashProvidedByUsedInOperatingActivities"},"weight":1.0,"order":3.0},
"http://ocsl.com/role/ConsolidatedStatementsOfOperations":{"parentTag":null,"weight":null,"order":null,"root":true},
"http://ocsl.com/role/PortfolioInvestmentsSummarizedStatementofOperationsInformationDetails":{"parentTag":null,"weight":null,"order":null,"root":true}},
"presentation":{"http://ocsl.com/role/ConsolidatedStatementofCashFlows","http://ocsl.com/role/ConsolidatedStatementsOfChangesInNetAssets",
"http://ocsl.com/role/ConsolidatedStatementsOfOperations"},"http://ocsl.com/role/PortfolioInvestmentsSummarizedStatementofOperationsInformationDetails",
"http://ocsl.com/role/ShareDataandNetAssetsScheduleofBasicandDilutedEarningsPerShareDetails",
"http://ocsl.com/role/TaxableDistributableIncomeandDividendDistributionsReconciliationofNetIncreaseDecreaseinNetAssetsResultingfromOperationsDetails",
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"},"lang":{"en-us":{"role":{"totalLabel":"Net increase (decrease) in net assets resulting from operations"},"terseLabel":
"Net increase (decrease) in net assets resulting from operations"},"verboseLabel":"Net increase (decrease) in net assets resulting from operations"},"netLabel":"Net
increase (decrease) in net assets resulting from operations"},"label":"Net Income (Loss) Attributable to Parent"},"documentation":"The portion of profit or loss for the
period, net of income taxes, which is attributable to the parent."}}},"auth_ref":{"r85","r95","r115","r135","r144","r145","r149","r163","r170","r172","r173",
"r174","r175","r178","r179","r184","r194","r197","r199","r201","r238","r257","r258","r259","r260","r261","r262","r263","r264","r265","r388","r399","r475",
"r588","r616","r618","r619","r679","r802","r1005"},"us-gaap_NetIncomeLossAttributableToReportingEntityAbstract":{"xbrltype":"stringItemType","nsuri":
"http://fasb.org/us-gaap/2023","localname":"NetIncomeLossAttributableToReportingEntityAbstract","presentation":{"
"http://ocsl.com/role/ConsolidatedStatementsOfChangesInNetAssets"},"lang":{"en-us":{"role":{"terseLabel":"Operations"},"label":"Net Income (Loss), Including
Portion Attributable to Noncontrolling Interest [Abstract] }}}},"auth_ref":{"r1111,"us-gaap_NetInvestmentIncome":{"xbrltype":"monetaryItemType","nsuri":
"http://fasb.org/us-gaap/2023","localname":"NetInvestmentIncome","crdr":{"credit"},"calculation":{"http://ocsl.com/role/ConsolidatedStatementsOfOperations":{"
"parentTag":{"us-gaap_InvestmentIncomeOperatingAfterExpenseAndTax"},"weight":1.0,"order":1.0},
"http://ocsl.com/role/PortfolioInvestmentsSummarizedStatementofOperationsInformationDetails":{"parentTag":{"us-gaap_NetIncomeLoss"},"weight":1.0,"order":3.0},
"presentation":{"http://ocsl.com/role/ConsolidatedStatementsOfOperations"},
"http://ocsl.com/role/PortfolioInvestmentsSummarizedStatementofOperationsInformationDetails"},"lang":{"en-us":{"role":{"totalLabel":"Net investment income
before taxes"},"label":"Net Investment Income"},"documentation":"Amount, after investment expense, of income earned from investments in securities and real estate.
Includes, but is not limited to, real estate investment, policy loans, dividends, and interest. Excludes realized gain (loss) on investments."}}},"auth_ref":{"r125",
"r478","r479","r601","r802"},"ocsl_NetRealizedGainsLossesAbstract":{"xbrltype":"stringItemType","nsuri":"http://ocsl.com/20240630","localname":
"NetRealizedGainsLossesAbstract","presentation":{"http://ocsl.com/role/ConsolidatedStatementsOfOperations"},"lang":{"en-us":{"role":{"terseLabel":"Realized
gains (losses)","label":"Net Realized Gains (Losses) [Abstract]"},"documentation":"Net Realized Gains (Losses)"},"auth_ref":{"r1111,"us-
gaap_NewAccountingPronouncementsPolicyPolicyTextBlock":{"xbrltype":"textBlockItemType","nsuri":"http://fasb.org/us-gaap/2023","localname":
"NewAccountingPronouncementsPolicyPolicyTextBlock","presentation":{"http://ocsl.com/role/SignificantAccountingPoliciesPolicies"},"lang":{"en-us":{"role":{"
"terseLabel":"Recently Adopted Accounting Pronouncements"},"label":"New Accounting Pronouncements, Policy [Policy Text Block]"},"documentation":"Disclosure of
accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the
expected or actual impact."}}},"auth_ref":{"r1111},"cef_NewCefOrBdcRegistrantFlag":{"xbrltype":"booleanItemType","nsuri":"http://xbrl.sec.gov/cef/2023","localname":
"NewCefOrBdcRegistrantFlag","presentation":{"http://xbrl.sec.gov/cef/role/N2"},"lang":{"en-us":{"role":{"label":"New CEF or BDC Registrant [Flag] }}}},
"auth_ref":{"r835"},"dei_NewEffectiveDateForPreviousFiling":{"xbrltype":"booleanItemType","nsuri":"http://xbrl.sec.gov/dei/2023","localname":
"NewEffectiveDateForPreviousFiling","presentation":{"http://xbrl.sec.gov/cef/role/N2"},"lang":{"en-us":{"role":{"label":"New Effective Date for Previous Filing" }} }
"auth_ref":{"r835","r902","r903","r904"},"cef_NoPublicTradingTextBlock":{"xbrltype":"textBlockItemType","nsuri":"http://xbrl.sec.gov/cef/2023","localname":
"NoPublicTradingTextBlock","presentation":{"http://xbrl.sec.gov/cef/role/N2"},"lang":{"en-us":{"role":{"label":"No Public Trading [Text Block] }}}},"auth_ref":{"
"r897"},"dei_NoSubstantiveChanges462c":{"xbrltype":"booleanItemType","nsuri":"http://xbrl.sec.gov/dei/2023","localname":"NoSubstantiveChanges462c",
"presentation":{"http://xbrl.sec.gov/cef/role/N2"},"lang":{"en-us":{"role":{"label":"No Substantive Changes, 462(c) }}}},"auth_ref":{"r961"},"dei_NoSubstantiveChanges462cFileNumber":{"xbrltype":
"fileNumberItemType","nsuri":"http://xbrl.sec.gov/dei/2023","localname":
"NoSubstantiveChanges462cFileNumber","presentation":{"http://xbrl.sec.gov/cef/role/N2"},"lang":{"en-us":{"role":{"label":"No Substantive Changes, 462(c), File
Number }}}},"auth_ref":{"r961"},"cef_NoTradingHistoryTextBlock":{"xbrltype":"textBlockItemType","nsuri":"http://xbrl.sec.gov/cef/2023","localname":
"NoTradingHistoryTextBlock","presentation":{"http://xbrl.sec.gov/cef/role/N2"},"lang":{"en-us":{"role":{"label":"No Trading History [Text Block] }}}},"auth_ref":
"r901"},"ocsl_NonAccrualStatusDebtSecuritiesMember":{"xbrltype":"domainItemType","nsuri":"http://ocsl.com/20240630","localname":
"NonAccrualStatusDebtSecuritiesMember","presentation":{"http://ocsl.com/role/SignificantAccountingPoliciesDetails"},"lang":{"en-us":{"role":{"terseLabel":"Non-
Accrual Status, Debt Securities"},"label":"Non-Accrual Status, Debt Securities [Member]"},"documentation":"Non-Accrual Status, Debt Securities" }}},"auth_ref":{"r1111},
"ecsd_NonGaapMeasureDescriptionTextBlock":{"xbrltype":"textBlockItemType","nsuri":"http://xbrl.sec.gov/ecd/2023","localname":
"NonGaapMeasureDescriptionTextBlock","presentation":{"http://xbrl.sec.gov/ecd/role/PvpDisclosure"},"lang":{"en-us":{"role":{"terseLabel":"Non-GAAP Measure
Description"},"label":"Non-GAAP Measure Description [Text Block] }}}},"auth_ref":{"r923"},"ecsd_NonNeosMember":{"xbrltype":"domainItemType","nsuri":
"http://xbrl.sec.gov/ecd/2023","localname":"NonNeosMember","presentation":{"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"},"lang":{"en-us":{"role":{"
"terseLabel":"Non-NEOs"},"label":"Non-NEOs [Member] }}}},"auth_ref":{"r819","r831","r912","r931","r939"},"ecsd_NonPeeoNeoAvgCompActuallyPaidAmt":{"xbrltype":
"monetaryItemType","nsuri":"http://xbrl.sec.gov/ecd/2023","localname":"NonPeeoNeoAvgCompActuallyPaidAmt","presentation":{"
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"},"lang":{"en-us":{"role":{"terseLabel":"Non-Peeo NEO Average Compensation Actually Paid Amount"},"label":"Non-PEO
NEO Average Compensation Actually Paid Amount" }}},"auth_ref":{"r921"},"ecsd_NonPeeoNeoAvgTotalCompAmt":{"xbrltype":"monetaryItemType","nsuri":

```

"uri": "http://xbrl.sec.gov/cecd/2023", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": { "http://xbrl.sec.gov/cecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Total Compensation Amount", "label": "Non-PEO NEO Average Total Compensation Amount" } } } }, "auth_ref": { "r920" } }, "cd": "NonPeoNeoMember", "xbrltype": { "domainItemType": "nsuri": "http://xbrl.sec.gov/cecd/2023", "localname": "NonPeoNeoMember", "presentation": { "http://xbrl.sec.gov/cecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO", "label": "Non-PEO NEO [Member]" } } } }, "auth_ref": { "r931" } }, "cd": "NonRule10b51ArrAdoptedFlag", "xbrltype": { "booleanItemType": "nsuri": "http://xbrl.sec.gov/cecd/2023", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": { "http://xbrl.sec.gov/cecd/role/InsiderTradingArrangements": { "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted", "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } } }, "auth_ref": { "r950" } }, "cd": "NonRule10b51ArrFrmtdFlag", "xbrltype": { "booleanItemType": "nsuri": "http://xbrl.sec.gov/cecd/2023", "localname": "NonRule10b51ArrFrmtdFlag", "presentation": { "http://xbrl.sec.gov/cecd/role/InsiderTradingArrangements": { "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated", "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } } }, "auth_ref": { "r950" } }, "us-gaap": "NonUsMember", "xbrltype": { "domainItemType": "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonUsMember", "presentation": { "http://ocsl.com/role/PortfolioInvestmentsPortfolioCompositionDetails": { "lang": { "en-us": { "role": { "terseLabel": "International", "label": "Non-US [Member]" } } } }, "documentation": { "Countries excluding the United States of America (US)" } }, "auth_ref": { "r1067", "r1071", "r1074", "r1077" } }, "ocsl": "NoncashFinancingItemsAbstract", "xbrltype": { "stringItemType": "nsuri": "http://ocsl.com/20240630", "localname": "NoncashFinancingItemsAbstract", "presentation": { "http://ocsl.com/role/ConsolidatedStatementOfCashFlows": { "lang": { "en-us": { "role": { "terseLabel": "Non-cash financing activities", "label": "Noncash Financing Items [Abstract]" } } } }, "documentation": { "Noncash Financing Items" } }, "auth_ref": { "r11", "us-gaap": "NoninterestExpenseDirectorsFees", "xbrltype": { "monetaryItemType": "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoninterestExpenseDirectorsFees", "crdr": "debit", "calculation": { "http://ocsl.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap:InvestmentIncomeInvestmentExpense", "weight": 1.0, "order": 7.0 } }, "presentation": { "http://ocsl.com/role/ConsolidatedStatementsofOperations": { "lang": { "en-us": { "role": { "terseLabel": "Directors fees", "label": "Noninterest Expense Directors Fees", "documentation": { "Noninterest expense related to directors' fees which are fees paid by an Entity to its directors. Directors' fees may be paid in addition to salary and other benefits." } } } }, "auth_ref": { "r119" } }, "us-gaap": "NortheastRegionMember", "xbrltype": { "domainItemType": "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NortheastRegionMember", "presentation": { "http://ocsl.com/role/PortfolioInvestmentsPortfolioCompositionDetails": { "lang": { "en-us": { "role": { "terseLabel": "Northeast", "label": "US Northeast Region [Member]", "documentation": { "Region of United States of America (US) designated as Northeast." } } } }, "auth_ref": { "r1067", "r1071", "r1074", "r1077" } }, "us-gaap": "NorthwestRegionMember", "xbrltype": { "domainItemType": "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NorthwestRegionMember", "presentation": { "http://ocsl.com/role/PortfolioInvestmentsPortfolioCompositionDetails": { "lang": { "en-us": { "role": { "terseLabel": "Northwest", "label": "US Northwest Region [Member]", "documentation": { "Region of United States of America (US) designated as Northwest." } } } }, "auth_ref": { "r1067", "r1071", "r1074", "r1077" } }, "us-gaap": "NotesPayable", "xbrltype": { "monetaryItemType": "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NotesPayable", "crdr": "credit", "calculation": { "http://ocsl.com/role/PortfolioInvestmentsSummarizedBalanceSheetInformationDetails": { "parentTag": "us-gaap:Liabilities", "weight": 1.0, "order": 4.0 } }, "presentation": { "http://ocsl.com/role/PortfolioInvestmentsSummarizedBalanceSheetInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Notes payable at fair value", "label": "Notes Payable", "documentation": { "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer." } } } }, "auth_ref": { "r17", "r113", "r1032" } }, "ocsl": "NumberOfBoardOfDirectors", "xbrltype": { "integerItemType": "nsuri": "http://ocsl.com/20240630", "localname": "NumberOfBoardOfDirectors", "presentation": { "http://ocsl.com/role/PortfolioInvestmentsNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Number of board of directors", "label": "Number Of Board Of Directors", "documentation": { "Number Of Board Of Directors" } } } }, "auth_ref": { "r11", "ocsl": "NumberOfBoardOfDirectorsSelectedByCompany", "xbrltype": { "integerItemType": "nsuri": "http://ocsl.com/20240630", "localname": "NumberOfBoardOfDirectorsSelectedByCompany", "presentation": { "http://ocsl.com/role/PortfolioInvestmentsNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Number of board of directors selected by company", "label": "Number Of Board Of Directors Selected By Company", "documentation": { "Number Of Board Of Directors Selected By Company" } } } }, "auth_ref": { "r11", "ocsl": "NumberOfBoardOfDirectorsSelectedByCounterparty", "xbrltype": { "integerItemType": "nsuri": "http://ocsl.com/20240630", "localname": "NumberOfBoardOfDirectorsSelectedByCounterparty", "presentation": { "http://ocsl.com/role/PortfolioInvestmentsNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Number of board of directors selected by counterparty", "label": "Number Of Board Of Directors Selected By Counterparty", "documentation": { "Number Of Board Of Directors Selected By Counterparty" } } } }, "auth_ref": { "r11", "ocsl": "NumberOfInvestmentCommitteeMembersSelectedByCompany", "xbrltype": { "integerItemType": "nsuri": "http://ocsl.com/20240630", "localname": "NumberOfInvestmentCommitteeMembersSelectedByCompany", "presentation": { "http://ocsl.com/role/PortfolioInvestmentsNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Number of investment committee members selected by company", "label": "Number Of Investment Committee Members Selected By Company", "documentation": { "Number Of Investment Committee Members Selected By Company" } } } }, "auth_ref": { "r11", "ocsl": "NumberOfInvestmentCommitteeMembersSelectedByCounterparty", "xbrltype": { "integerItemType": "nsuri": "http://ocsl.com/20240630", "localname": "NumberOfInvestmentCommitteeMembersSelectedByCounterparty", "presentation": { "http://ocsl.com/role/PortfolioInvestmentsNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Number of investment committee members selected by counterparty", "label": "Number Of Investment Committee Members Selected By Counterparty", "documentation": { "Number Of Investment Committee Members Selected By Counterparty" } } } }, "auth_ref": { "r11", "ocsl": "NumberOfInvestments", "xbrltype": { "integerItemType": "nsuri": "http://ocsl.com/20240630", "localname": "NumberOfInvestments", "presentation": { "http://ocsl.com/role/SignificantAccountingPoliciesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Number of investments", "label": "Number of Investments", "documentation": { "Number of Investments" } } } }, "auth_ref": { "r11", "ocsl": "OCISlickJVLLCMember", "xbrltype": { "domainItemType": "nsuri": "http://ocsl.com/20240630", "localname": "OCISlickJVLLCMember", "presentation": { "http://ocsl.com/role/PortfolioInvestmentsNarrativeDetails": { "http://ocsl.com/role/PortfolioInvestmentsPortfolioListingDetails", "http://ocsl.com/role/PortfolioInvestmentsSummarizedBalanceSheetInformationDetails", "http://ocsl.com/role/PortfolioInvestmentsSummarizedStatementOfOperationsInformationDetails", "http://ocsl.com/role/PortfolioInvestmentsSummaryofPortfolioDetails": { "lang": { "en-us": { "role": { "terseLabel": "OCISlick JV LLC", "label": "OCISlick JV LLC [Member]", "documentation": { "OCISlick JV LLC" } } } }, "auth_ref": { "r11", "ocsl": "OSI2CitibankFacilityMember", "xbrltype": { "domainItemType": "nsuri": "http://ocsl.com/20240630", "localname": "OSI2CitibankFacilityMember", "presentation": { "http://ocsl.com/role/BorrowingsNarrativeDetails": { "http://ocsl.com/role/PortfolioInvestmentsScheduleoffinancialInstrumentsDisclosedbutCarriedatFairValueDetails", "http://xbrl.sec.gov/cefd/role/N2": { "lang": { "en-us": { "role": { "terseLabel": "OSI2 Citibank Facility payable", "label": "OSI2 Citibank Facility [Member]", "documentation": { "OSI2 Citibank Facility" } } } }, "auth_ref": { "r11", "ocsl": "OaktreeStrategicIncomeCorporationMergerMember", "xbrltype": { "domainItemType": "nsuri": "http://ocsl.com/20240630", "localname": "OaktreeStrategicIncomeCorporationMergerMember", "presentation": { "http://ocsl.com/role/RelatedPartyTransactionsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Oaktree Strategic Income Corporation Merger", "label": "Oaktree Strategic Income Corporation Merger [Member]", "documentation": { "Oaktree Strategic Income Corporation Merger" } } } }, "auth_ref": { "r11", "ocsl": "OaktreeStrategicIncomeHIncMergerMember", "xbrltype": { "domainItemType": "nsuri": "http://ocsl.com/20240630", "localname": "OaktreeStrategicIncomeHIncMergerMember", "presentation": { "http://ocsl.com/role/RelatedPartyTransactionsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Oaktree Strategic Income H, Inc. Merger", "label": "Oaktree Strategic Income H, Inc. Merger [Member]", "documentation": { "Oaktree Strategic Income H, Inc. Merger" } } } }, "auth_ref": { "r11", "ocsl": "OaktreeStrategicIncomeHIncMergerYearOneMember", "xbrltype": { "domainItemType": "nsuri": "http://ocsl.com/20240630", "localname": "OaktreeStrategicIncomeHIncMergerYearOneMember", "presentation": { "http://ocsl.com/role/RelatedPartyTransactionsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Oaktree Strategic Income H, Inc. Merger, Year One", "label": "Oaktree Strategic Income H, Inc. Merger, Year One [Member]", "documentation": { "Oaktree Strategic Income H, Inc. Merger, Year One" } } } }, "auth_ref": { "r11", "ocsl": "OaktreeStrategicIncomeHIncMergerYearTwoMember", "xbrltype": { "domainItemType": "nsuri": "http://ocsl.com/20240630", "localname": "OaktreeStrategicIncomeHIncMergerYearTwoMember", "presentation": { "http://ocsl.com/role/RelatedPartyTransactionsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Oaktree Strategic Income H, Inc. Merger, Year Two", "label": "Oaktree Strategic Income H, Inc. Merger, Year Two [Member]", "documentation": { "Oaktree Strategic Income H, Inc. Merger, Year Two" } } } }, "auth_ref": { "r11", "ocsl": "OfficeServicesSuppliesMember", "xbrltype": { "domainItemType": "nsuri": "http://ocsl.com/20240630", "localname": "OfficeServicesSuppliesMember", "presentation": { "http://ocsl.com/role/PortfolioInvestmentsPortfolioofInvestmentsbyIndustryDetails": { "lang": { "en-us": { "role": { "terseLabel": "Office Services & Supplies", "label": "Office Services & Supplies [Member]", "documentation": { "Office Services & Supplies" } } } }, "auth_ref": { "r11", "ocsl": "OilGasStorageTransportationMember", "xbrltype": { "domainItemType": "nsuri": "http://ocsl.com/20240630", "localname": "OilGasStorageTransportationMember", "presentation": { "http://ocsl.com/role/PortfolioInvestmentsPortfolioofInvestmentsbyIndustryDetails": { "lang": { "en-us": { "role": { "terseLabel": "Oil & Gas Storage & Transportation", "label": "Oil & Gas Storage & Transportation [Member]", "documentation": { "Oil & Gas Storage & Transportation" } } } }, "auth_ref": { "r11", "us-gaap": "OpenForwardForeignCurrencyContractIdentifierAxis", "xbrltype": { "stringItemType": "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OpenForwardForeignCurrencyContractIdentifierAxis", "presentation": { "http://ocsl.com/role/ConsolidatedScheduleofInvestmentsDerivatives": { "http://ocsl.com/role/DerivativeInstrumentsScheduleofforeignCurrencyForwardContractsandInterestRateSwapDetails": { "lang": { "en-us": { "role": { "terseLabel": "Open Forward Foreign Currency Contract, Identifier [Axis]", "label": "Open Forward Foreign Currency Contract, Identifier [Axis]", "documentation": { "Identification of contract for foreign currency transaction at fixed rate at future date, including, but not limited
```

"textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "OtherExpensesNoteTextBlock", "presentation": "http://xbrl.sec.gov/cef/role/N2", "lang": "en-us", "role": "label", "Other Expenses, Note [Text Block]", "auth_ref": "r870", "cef_OtherFeederFundExpensesPercent": "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "OtherFeederFundExpensesPercent", "presentation": "http://xbrl.sec.gov/cef/role/N2", "lang": "en-us", "role": "label", "Other Feeder Fund Expenses [Percent]", "auth_ref": "r874", "us-gaap_OtherGeneralAndAdministrativeExpense": "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherGeneralAndAdministrativeExpense", "crdr": "debit", "presentation": "http://ocsl.com/role/RelatedPartyTransactionsDetails", "lang": "en-us", "role": "terseLabel": "General and administrative expenses", "label": "Other General and Administrative Expense", "documentation": "Amount of general and administrative expense classified as other.", "auth_ref": "r88", "r1058", "us-gaap_OtherIncome": "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherIncome", "crdr": "credit", "calculation": "http://ocsl.com/role/PortfolioInvestmentsSummarizedStatementOfOperationsInformationDetails", "parentTag": "us-gaap_GrossInvestmentIncomeOperating", "weight": 1.0, "order": 2.0, "presentation": "http://ocsl.com/role/PortfolioInvestmentsSummarizedStatementOfOperationsInformationDetails", "lang": "en-us", "role": "terseLabel": "Other income/Fee income", "label": "Other Income", "documentation": "Amount of revenue and income classified as other.", "auth_ref": "r482", "r592", "r723", "r724", "r726", "us-gaap_OtherLiabilities": "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilities", "crdr": "credit", "calculation": "http://ocsl.com/role/PortfolioInvestmentsSummarizedBalanceSheetInformationDetails", "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0, "http://ocsl.com/role/ConsolidatedStatementsOfAssetsandLiabilities": "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0, "presentation": "http://ocsl.com/role/ConsolidatedStatementsOfAssetsandLiabilities", "http://ocsl.com/role/PortfolioInvestmentsSummarizedBalanceSheetInformationDetails", "http://ocsl.com/role/RelatedPartyTransactionsDetails", "lang": "en-us", "role": "terseLabel": "Due to affiliate", "verboseLabel": "Other Liabilities", "label": "Other Liabilities", "documentation": "Amount of liabilities classified as other.", "auth_ref": "r72", "r467", "r558", "r559", "r804", "r1049", "cef_OtherMasterFundExpensesPercent": "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "OtherMasterFundExpensesPercent", "presentation": "http://xbrl.sec.gov/cef/role/N2", "lang": "en-us", "role": "label", "Other Master Fund Expenses [Percent]", "auth_ref": "r874", "ocsl_OtherNetMember": "xbrltype": "domainItemType", "nsuri": "http://ocsl.com/20240630", "localname": "OtherNetMember", "presentation": "http://ocsl.com/role/RealizedGainsorLossesandNetUnrealizedAppreciationorDepreciationAggregateNetRealizedGainsDetails", "lang": "en-us", "role": "terseLabel": "Other net", "label": "Other Net [Member]", "documentation": "Other Net", "auth_ref": "I", "ecd_OtherPerfMeasureAmt": "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OtherPerfMeasureAmt", "presentation": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": "en-us", "role": "terseLabel": "Other Performance Measure, Amount", "label": "Other Performance Measure, Amount", "auth_ref": "r923", "cef_OtherSecuritiesTableTextBlock": "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "OtherSecuritiesTableTextBlock", "presentation": "http://xbrl.sec.gov/cef/role/N2", "lang": "en-us", "role": "label", "Other Securities [Table Text Block]", "auth_ref": "r854", "cef_OtherSecurityDescriptionTextBlock": "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "OtherSecurityDescriptionTextBlock", "presentation": "http://xbrl.sec.gov/cef/role/N2", "lang": "en-us", "role": "label", "Other Security Description [Text Block]", "auth_ref": "r854", "cef_OtherSecurityTitleTextBlock": "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "OtherSecurityTitleTextBlock", "presentation": "http://xbrl.sec.gov/cef/role/N2", "lang": "en-us", "role": "label", "Other Security Title [Text Block]", "auth_ref": "r854", "ocsl_OtherSpecializedREITsMember": "xbrltype": "domainItemType", "nsuri": "http://ocsl.com/20240630", "localname": "OtherSpecializedREITsMember", "presentation": "http://ocsl.com/role/PortfolioInvestmentsPortfolioofInvestmentsbyIndustryDetails", "lang": "en-us", "role": "terseLabel": "Other Specialized REITs", "label": "Other Specialized REITs [Member]", "documentation": "Other Specialized REITs", "auth_ref": "I", "ocsl_OtherSpecialtyRetailMember": "xbrltype": "domainItemType", "nsuri": "http://ocsl.com/20240630", "localname": "OtherSpecialtyRetailMember", "presentation": "http://ocsl.com/role/PortfolioInvestmentsPortfolioofInvestmentsbyIndustryDetails", "lang": "en-us", "role": "terseLabel": "Other Specialty Retail", "label": "Other Specialty Retail [Member]", "documentation": "Other Specialty Retail", "auth_ref": "I", "cef_OtherTransactionExpense1Percent": "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "OtherTransactionExpense1Percent", "calculation": "http://xbrl.sec.gov/cef/role/Item3Te", "parentTag": "cef_OtherTransactionExpensesPercent", "weight": 1.0, "order": 1.0, "presentation": "http://xbrl.sec.gov/cef/role/N2", "lang": "en-us", "role": "label", "Other Transaction Expense 1 [Percent]", "auth_ref": "r869", "cef_OtherTransactionExpense2Percent": "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "OtherTransactionExpense2Percent", "calculation": "http://xbrl.sec.gov/cef/role/Item3Te", "parentTag": "cef_OtherTransactionExpensesPercent", "weight": 1.0, "order": 2.0, "presentation": "http://xbrl.sec.gov/cef/role/N2", "lang": "en-us", "role": "label", "Other Transaction Expense 2 [Percent]", "auth_ref": "r869", "cef_OtherTransactionExpense3Percent": "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "OtherTransactionExpense3Percent", "calculation": "http://xbrl.sec.gov/cef/role/Item3Te", "parentTag": "cef_OtherTransactionExpensesPercent", "weight": 1.0, "order": 3.0, "presentation": "http://xbrl.sec.gov/cef/role/N2", "lang": "en-us", "role": "label", "Other Transaction Expense 3 [Percent]", "auth_ref": "r869", "cef_OtherTransactionExpensesAbstract": "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "OtherTransactionExpensesAbstract", "presentation": "http://xbrl.sec.gov/cef/role/N2", "lang": "en-us", "role": "label", "Other Transaction Expenses [Abstract]", "auth_ref": "r869", "cef_OtherTransactionExpensesPercent": "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "OtherTransactionExpensesPercent", "calculation": "http://xbrl.sec.gov/cef/role/Item3Te", "parentTag": null, "weight": null, "order": null, "root": true, "presentation": "http://xbrl.sec.gov/cef/role/N2", "lang": "en-us", "role": "label", "Other Transaction Expenses [Percent]", "auth_ref": "r869", "cef_OtherTransactionFeesBasisMaximum": "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "OtherTransactionFeesBasisMaximum", "presentation": "http://xbrl.sec.gov/cef/role/N2", "lang": "en-us", "role": "label", "Other Transaction Fees Basis, Maximum", "auth_ref": "r869", "cef_OtherTransactionFeesBasisMaximumPercent": "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "OtherTransactionFeesBasisMaximumPercent", "presentation": "http://xbrl.sec.gov/cef/role/N2", "lang": "en-us", "role": "label", "Other Transaction Fees Basis, Maximum [Percent]", "auth_ref": "r869", "cef_OtherTransactionFeesBasisNoteTextBlock": "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "OtherTransactionFeesBasisNoteTextBlock", "presentation": "http://xbrl.sec.gov/cef/role/N2", "lang": "en-us", "role": "label", "Other Transaction Fees Basis, Note [Text Block]", "auth_ref": "r869", "cef_OtherTransactionFeesNoteTextBlock": "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "OtherTransactionFeesNoteTextBlock", "presentation": "http://xbrl.sec.gov/cef/role/N2", "lang": "en-us", "role": "label", "Other Transaction Fees, Note [Text Block]", "auth_ref": "r869", "ecd_OutstandingAggtErrCompAmt": "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingAggtErrCompAmt", "presentation": "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "lang": "en-us", "role": "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount", "label": "Outstanding Aggregate Erroneous Compensation Amount", "auth_ref": "r917", "r929", "r910", "r937", "ecd_OutstandingRecoveryCompAmt": "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryCompAmt", "presentation": "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "lang": "en-us", "role": "terseLabel": "Compensation Amount", "label": "Outstanding Recovery Compensation Amount", "auth_ref": "r820", "r832", "r913", "r940", "ecd_OutstandingRecoveryIndName": "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryIndName", "presentation": "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "lang": "en-us", "role": "terseLabel": "Name", "label": "Outstanding Recovery, Individual Name", "auth_ref": "r820", "r832", "r913", "r940", "cef_OutstandingSecuritiesTableTextBlock": "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "OutstandingSecuritiesTableTextBlock", "presentation": "http://xbrl.sec.gov/cef/role/N2", "lang": "en-us", "role": "label", "Outstanding Securities [Table Text Block]", "auth_ref": "r855", "cef_OutstandingSecurityAuthorizedShares": "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "OutstandingSecurityAuthorizedShares", "presentation": "http://xbrl.sec.gov/cef/role/N2", "lang": "en-us", "role": "label", "Outstanding Security, Authorized [Shares]", "auth_ref": "r857", "cef_OutstandingSecurityHeldShares": "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "OutstandingSecurityHeldShares", "presentation": "http://xbrl.sec.gov/cef/role/N2", "lang": "en-us", "role": "label", "Outstanding Security, Held [Shares]", "auth_ref": "r858", "cef_OutstandingSecurityNotHeldShares": "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "OutstandingSecurityNotHeldShares", "presentation": "http://xbrl.sec.gov/cef/role/N2", "lang": "en-us", "role": "label", "Outstanding Security, Not Held [Shares]", "auth_ref": "r859", "cef_OutstandingSecurityTitleTextBlock": "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "OutstandingSecurityTitleTextBlock", "presentation": "http://xbrl.sec.gov/cef/role/N2", "lang": "en-us", "role": "label", "Outstanding Security, Title [Text Block]", "auth_ref": "r856", "ocsl_PtDevelopmentLLCMember": "xbrltype": "domainItemType", "nsuri": "http://ocsl.com/20240630", "localname": "PtDevelopmentLLCMember", "presentation": "http://ocsl.com/role/RealizedGainsorLossesandNetUnrealizedAppreciationorDepreciationAggregateNetRealizedGainsDetails", "lang": "en-us", "role": "terseLabel": "P&L Development LLC", "label": "P&L Development LLC [Member]", "documentation": "P&L Development LLC", "auth_ref": "I", "ocsl_PackagedFoodsMeatsMember": "xbrltype": "domainItemType", "nsuri": "http://ocsl.com/20240630", "localname": "PackagedFoodsMeatsMember", "presentation": "http://ocsl.com/role/PortfolioInvestmentsPortfolioofInvestmentsbyIndustryDetails", "lang": "en-us", "role": "terseLabel": "Packaged Foods & Meats", "label": "Packaged Foods & Meats [Member]", "documentation": "Packaged Foods & Meats", "auth_ref": "I", "ocsl_PaperPlasticPackagingProductsMaterialsMember": "xbrltype": "domainItemType", "nsuri": "http://ocsl.com/20240630", "localname": "PaperPlasticPackagingProductsMaterialsMember", "presentation": "http://ocsl.com/role/PortfolioInvestmentsPortfolioofInvestmentsbyIndustryDetails", "lang": "en-us", "role": "terseLabel": "Paper & Plastic Packaging Products & Materials", "label": "Paper & Plastic Packaging Products & Materials [Member]", "documentation": "Paper & Plastic Packaging Products & Materials", "auth_ref": "I", "ocsl_PassengerAirlinesMember": "xbrltype": "domainItemType", "nsuri": "http://ocsl.com/20240630", "localname": "PassengerAirlinesMember", "presentation": "http://ocsl.com/role/PortfolioInvestmentsPortfolioofInvestmentsbyIndustryDetails", "lang": "en-us", "role": "terseLabel": "Passenger Airlines", "label": "Passenger Airlines [Member]", "documentation": "Passenger Airlines", "auth_ref": "I", "ecd_PayVsPerformanceDisclosureLineItems": "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PayVsPerformanceDisclosureLineItems", "lang": "en-us", "role": "label", "Pay vs Performance Disclosure [Line Items]", "auth_ref": "r919", "us-gaap_PayableInvestmentPurchase": "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PayableInvestmentPurchase", "crdr": "credit", "calculation": "http://ocsl.com/role/ConsolidatedStatementsOfAssetsandLiabilities", "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 7.0, "presentation": "http://ocsl.com/role/ConsolidatedStatementsOfAssetsandLiabilities", "lang": "en-us", "role": "terseLabel": "Payables from unsettled transactions", "label": "Payable, Investment, Purchase", "documentation": "Amount of payable for purchase of investment.", "auth_ref": "r554", "r739", "r804", "us-gaap_PaymentsForPurchaseOfInvestmentOperatingActivity": "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForPurchaseOfInvestmentOperatingActivity", "crdr": "credit", "calculation": "http://ocsl.com/role/ConsolidatedStatementofCashFlows", "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 21.0, "presentation": "http://ocsl.com/role/ConsolidatedStatementofCashFlows", "http://ocsl.com/role/PortfolioInvestmentsNarrativeDetails", "lang": "en-us", "role": "negatedTerseLabel": "Purchases of investments", "terseLabel": "Cash consideration for purchase of investments", "label": "Payment for Purchase, Investment, Operating Activity", "documentation": "Amount of cash outflow for acquisition of investment, classified as operating activity. Includes, but is not limited to, funding, origination, drawdown, and participation in investment.", "auth_ref": "r1066", "us-gaap_PaymentsForRepurchaseOfCommonStock": "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForRepurchaseOfCommonStock", "crdr": "credit", "calculation": "http://ocsl.com/role/ConsolidatedStatementofCashFlows", "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 7.0, "presentation": "http://ocsl.com/role/ConsolidatedStatementofCashFlows", "lang": "en-us", "role": "negatedTerseLabel": "Repurchases of common stock under dividend reinvestment plan", "label": "Payments for Repurchase of Common Stock", "documentation": "The cash outflow to reacquire common stock during the period.", "auth_ref": "r27", "us-gaap_PaymentsOfDebtIssuanceCosts": "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsOfDebtIssuanceCosts", "crdr": "credit", "calculation": "http://ocsl.com/role/ConsolidatedStatementofCashFlows", "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 5.0, "presentation": "http://ocsl.com/role/ConsolidatedStatementofCashFlows", "lang": "en-us", "role": "negatedLabel": "Deferred financing costs paid", "label": "Payments of Debt Issuance Costs", "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.", "auth_ref": "r29", "us-gaap_PaymentsOfDividendsCommonStock": "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsOfDividendsCommonStock", "crdr": "credit", "calculation": "http://ocsl.com/role/ConsolidatedStatementofCashFlows", "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 3.0, "presentation": "http://ocsl.com/role/ConsolidatedStatementofCashFlows", "lang": "en-us", "role": "negatedTerseLabel": "Distributions paid in cash", "label": "Payments of Ordinary Dividends, Common Stock", "documentation": "Amount of cash outflow in the form of ordinary dividends to

common shareholders of the parent entity." } } } , "auth_ref": { "r27" } } } , "us-gaap PaymentsOfStockIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsOfStockIssuanceCosts", "crdr": "credit", "calculation": { "http://ocsl.com/role/ConsolidatedStatementOfCashFlows", "parentTag": "us-gaap NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 6.0 } } } , "presentation": { "http://ocsl.com/role/ConsolidatedStatementOfCashFlows", "parentTag": "us-gaap NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 6.0 } } } , "presentation": { "http://ocsl.com/role/ShareDataandNetAssetsScheduleofCommonStockIssuedandSoldDetails" } } } , "lang": { "en-us": { "role": { "negatedTerseLabel": "Deferred offering costs paid", "verboseLabel": "Placement Agent Fees", "label": "Payments of Stock Issuance Costs", "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security." } } } , "auth_ref": { "r26" } } } , "ecd PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupIssuersFnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Peer Group Issuers, Footnote", "label": "Peer Group Issuers, Footnote [Text Block]", "auth_ref": { "r22" } } } } , "ecd PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Peer Group Total Shareholder Return Amount", "label": "Peer Group Total Shareholder Return Amount", "auth_ref": { "r22" } } } } , "ecd PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoActuallyPaidCompAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "terseLabel": "PEO Actually Paid Compensation Amount", "label": "PEO Actually Paid Compensation Amount", "auth_ref": { "r21" } } } } , "ecd PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "terseLabel": "PEO", "label": "PEO [Member]", "auth_ref": { "r931" } } } } , "ecd PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoName", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "terseLabel": "PEO Name", "label": "PEO Name", "auth_ref": { "r924" } } } , "ecd PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoTotalCompAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "terseLabel": "PEO Total Compensation Amount", "label": "PEO Total Compensation Amount", "auth_ref": { "r920" } } } } , "ocsl PercentageOfTotalAssetsRepresentingNonQualifyingAssets": { "xbrltype": "percentItemType", "nsuri": "http://ocsl.com/20240630", "localname": "PercentageOfTotalAssetsRepresentingNonQualifyingAssets", "presentation": { "http://ocsl.com/role/ConsolidatedScheduleofInvestmentsParenthetical", "lang": { "en-us": { "role": { "terseLabel": "Percentage of total assets representing non-qualifying assets (as a percent)", "label": "Percentage Of Total Assets Representing Non-Qualifying Assets", "documentation": "Percentage Of Total Assets Representing Non-Qualifying Assets", "auth_ref": { "r920" } } } } , "ocsl PercentageOfTotalAssetsRepresentingQualifyingAssets": { "xbrltype": "percentItemType", "nsuri": "http://ocsl.com/20240630", "localname": "PercentageOfTotalAssetsRepresentingQualifyingAssets", "presentation": { "http://ocsl.com/role/ConsolidatedScheduleofInvestmentsParenthetical", "lang": { "en-us": { "role": { "terseLabel": "Percentage of total assets representing qualifying assets (as a percent)", "label": "Percentage Of Total Assets Representing Qualifying Assets", "documentation": "Percentage Of Total Assets Representing Qualifying Assets", "auth_ref": { "r920" } } } } , "domainItemType": { "nsuri": "http://ocsl.com/20240630", "localname": "PersonalCareProductsMember", "presentation": { "http://ocsl.com/role/PortfolioInvestmentsPortfolioofInvestmentsbyIndustryDetails", "lang": { "en-us": { "role": { "terseLabel": "Personal Care Products", "label": "Personal Care Products [Member]", "documentation": "Personal Care Products", "auth_ref": { "r920" } } } } , "ocsl PharmaceuticalsMember": { "xbrltype": "domainItemType", "nsuri": "http://ocsl.com/20240630", "localname": "PharmaceuticalsMember", "presentation": { "http://ocsl.com/role/PortfolioInvestmentsPortfolioofInvestmentsbyIndustryDetails", "lang": { "en-us": { "role": { "terseLabel": "Pharmaceuticals", "label": "Pharmaceuticals [Member]", "documentation": "Pharmaceuticals", "auth_ref": { "r920" } } } } , "dei PostEffectiveAmendment": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PostEffectiveAmendment", "presentation": { "http://xbrl.sec.gov/dei/role/N2", "lang": { "en-us": { "role": { "label": "Post-Effective Amendment", "auth_ref": { "r805" } } } } , "dei PostEffectiveAmendmentNumber": { "xbrltype": "sequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PostEffectiveAmendmentNumber", "presentation": { "http://xbrl.sec.gov/dei/role/N2", "lang": { "en-us": { "role": { "label": "Post-Effective Amendment Number", "documentation": "Amendment number to registration statement under the Securities Act of 1933 before the registration becomes effective.", "auth_ref": { "r805" } } } } , "dei PreEffectiveAmendment": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreEffectiveAmendment", "presentation": { "http://xbrl.sec.gov/dei/role/N2", "lang": { "en-us": { "role": { "label": "Pre-Effective Amendment", "auth_ref": { "r805" } } } } , "dei PreEffectiveAmendmentNumber": { "xbrltype": "sequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreEffectiveAmendmentNumber", "presentation": { "http://xbrl.sec.gov/dei/role/N2", "lang": { "en-us": { "role": { "label": "Pre-Effective Amendment Number", "documentation": "Amendment number to registration statement under the Securities Act of 1933 before the registration becomes effective.", "auth_ref": { "r805" } } } } , "us-gaap PreferredStockLiquidationPreference": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockLiquidationPreference", "presentation": { "http://xbrl.sec.gov/cef/role/N2", "lang": { "en-us": { "role": { "label": "Preferred Stock Liquidating Preference", "documentation": "The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share.", "auth_ref": { "r43", "r44", "r78", "r983", "r1009" } } } } , "cef PreferredStockRestrictionsArrearageTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "PreferredStockRestrictionsArrearageTextBlock", "presentation": { "http://xbrl.sec.gov/cef/role/N2", "lang": { "en-us": { "role": { "label": "Preferred Stock Restrictions, Arrearage [Text Block]", "auth_ref": { "r845" } } } } , "cef PreferredStockRestrictionsOtherTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "PreferredStockRestrictionsOtherTextBlock", "presentation": { "http://xbrl.sec.gov/cef/role/N2", "lang": { "en-us": { "role": { "label": "Preferred Stock Restrictions, Other [Text Block]", "auth_ref": { "r846" } } } } , "cef PrimaryShelfFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "PrimaryShelfFlag", "presentation": { "http://xbrl.sec.gov/cef/role/N2", "lang": { "en-us": { "role": { "label": "Primary Shelf Flag", "auth_ref": { "r835" } } } } , "cef PrimaryShelfQualifiedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "PrimaryShelfQualifiedFlag", "presentation": { "http://xbrl.sec.gov/cef/role/N2", "lang": { "en-us": { "role": { "label": "Primary Shelf Qualified [Flag]", "auth_ref": { "r835" } } } } , "us-gaap ProceedsFromDebtNetOfIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromDebtNetOfIssuanceCosts", "crdr": "debit", "presentation": { "http://ocsl.com/role/BorrowingsNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Net proceeds", "label": "Proceeds from Debt, Net of Issuance Costs", "documentation": "The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.", "auth_ref": { "r153" } } } } , "us-gaap ProceedsFromDispositionOfInvestmentOperatingActivity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromDispositionOfInvestmentOperatingActivity", "crdr": "debit", "calculation": { "http://ocsl.com/role/ConsolidatedStatementOfCashFlows", "parentTag": "us-gaap NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } } } , "presentation": { "http://ocsl.com/role/ConsolidatedStatementOfCashFlows", "parentTag": "us-gaap NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } } } , "terseLabel": "Proceeds from the sales and repayments of investments", "verboseLabel": "Cash consideration for sale of investments", "label": "Proceeds from Disposition of Investment, Operating Activity", "documentation": "Amount of cash inflow from sale of investment, classified as operating activity. Includes, but is not limited to, repayment, principal payment, paydown, and maturity of investment.", "auth_ref": { "r1066" } } } , "us-gaap ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "calculation": { "http://ocsl.com/role/ConsolidatedStatementOfCashFlows", "parentTag": "us-gaap NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 4.0 } } } , "presentation": { "http://ocsl.com/role/ConsolidatedStatementOfCashFlows", "parentTag": "us-gaap NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 4.0 } } } , "lang": { "en-us": { "role": { "terseLabel": "Shares issued under the 'at the market' offering", "verboseLabel": "Gross Proceeds", "label": "Proceeds from Issuance of Common Stock", "documentation": "The cash inflow from the additional capital contribution to the entity.", "auth_ref": { "r4" } } } } , "ocsl ProceedsFromIssuanceOfCommonStockNet": { "xbrltype": "monetaryItemType", "nsuri": "http://ocsl.com/20240630", "localname": "ProceedsFromIssuanceOfCommonStockNet", "crdr": "debit", "presentation": { "http://ocsl.com/role/ShareDataandNetAssetsScheduleofCommonStockIssuedandSoldDetails", "lang": { "en-us": { "role": { "terseLabel": "Net proceeds excluding offering costs", "label": "Proceeds From Issuance Of Common Stock, Net", "documentation": "Proceeds From Issuance Of Common Stock, Net", "auth_ref": { "r4" } } } } , "us-gaap ProceedsFromLongTermLinesOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromLongTermLinesOfCredit", "crdr": "debit", "calculation": { "http://ocsl.com/role/ConsolidatedStatementOfCashFlows", "parentTag": "us-gaap NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } } } , "presentation": { "http://ocsl.com/role/ConsolidatedStatementOfCashFlows", "parentTag": "us-gaap NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } } } , "lang": { "en-us": { "role": { "terseLabel": "Borrowings under credit facilities", "label": "Proceeds from Long Term Lines of Credit", "documentation": "The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.", "auth_ref": { "r25" } } } } , "us-gaap ProceedsFromRepaymentsOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromRepaymentsOfDebt", "crdr": "debit", "presentation": { "http://ocsl.com/role/PortfolioInvestmentsSummarizedBalanceSheetInformationDetails", "lang": { "en-us": { "role": { "terseLabel": "Net proceeds", "label": "Proceeds from (Repayments of) Debt", "documentation": "The net cash inflow or outflow in aggregate debt due to repayments and proceeds from additional borrowings.", "auth_ref": { "r861" } } } } , "us-gaap ProfessionalFees": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProfessionalFees", "crdr": "debit", "calculation": { "http://ocsl.com/role/ConsolidatedStatementsOfOperations", "parentTag": "us-gaap InvestmentIncomeInvestmentExpense", "weight": 1.0, "order": 1.0 } } } , "presentation": { "http://ocsl.com/role/ConsolidatedStatementsOfOperations", "parentTag": "us-gaap InvestmentIncomeInvestmentExpense", "weight": 1.0, "order": 1.0 } } } , "lang": { "en-us": { "role": { "terseLabel": "Professional fees", "label": "Professional Fees", "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.", "auth_ref": { "r802", "r1053", "r1058" } } } } , "cef ProspectusLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "ProspectusLineItems", "lang": { "en-us": { "role": { "label": "Prospectus [Line Items]", "auth_ref": { "r835" } } } } , "cef ProspectusTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "ProspectusTable", "presentation": { "http://xbrl.sec.gov/cef/role/N2", "lang": { "en-us": { "role": { "label": "Prospectus", "auth_ref": { "r835" } } } } , "cef PurposeOfFeeTableNoteTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "PurposeOfFeeTableNoteTextBlock", "presentation": { "http://xbrl.sec.gov/cef/role/N2", "lang": { "en-us": { "role": { "label": "Purpose of Fee Table, Note [Text Block]", "auth_ref": { "r861" } } } } , "ecd PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTable", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure", "label": "Pay vs Performance Disclosure [Table]", "auth_ref": { "r919" } } } } , "ecd PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTableTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure, Table", "label": "Pay vs Performance [Table Text Block]", "auth_ref": { "r919" } } } } , "ocsl RadiologyPartnersIncMember": { "xbrltype": "domainItemType", "nsuri": "http://ocsl.com/20240630", "localname": "RadiologyPartnersIncMember", "presentation": { "http://ocsl.com/role/RealizedGainsorLossesandNetUnrealizedAppreciationorDepreciationAggregateNetRealizedGainsDetails", "lang": { "en-us": { "role": { "terseLabel": "Radiology Partners Inc", "label": "Radiology Partners Inc [Member]", "documentation": "Radiology Partners Inc", "auth_ref": { "r1077", "r1078", "r1079", "r1080", "r1081", "r1082", "r1083", "r1084", "r1085", "r1086", "r1087", "r1088", "r1089", "r1090", "r1091", "r1092", "r1093", "r1094", "r1095", "r1096", "r1097", "r1098", "r1099", "r1100", "r1101", "r1102", "r1103", "r1104", "r1105", "r1106", "r1107", "r1108", "r1109", "r1110", "r1111", "r1112", "r1113", "r1114", "r1115", "r1116", "r1117", "r1118", "r1119", "r1120", "r1121", "r1122", "r1123", "r1124", "r1125", "r1126", "r1127", "r1128", "r1129", "r1130", "r1131", "r1132", "r1133", "r1134", "r1135", "r1136", "r1137", "r1138", "r1139", "r1140", "r1141", "r1142", "r1143", "r1144", "r1145", "r1146", "r1147", "r1148", "r1149", "r1150", "r1151", "r1152", "r1153", "r1154", "r1155", "r1156", "r1157", "r1158", "r1159", "r1160", "r1161", "r1162", "r1163", "r1164", "r1165", "r1166", "r1167", "r1168", "r1169", "r1170", "r1171", "r1172", "r1173", "r1174", "r1175", "r1176", "r1177", "r1178", "r1179", "r1180", "r1181", "r1182", "r1183", "r1184", "r1185", "r1186", "r1187", "r1188", "r1189", "r1190", "r1191", "r1192", "r1193", "r1194", "r1195", "r1196", "r1197", "r1198", "r1199", "r1200", "r1201", "r1202", "r1203", "r1204", "r1205", "r1206", "r1207", "r1208", "r1209", "r1210", "r1211", "r1212", "r1213", "r1214", "r1215", "r1216", "r1217", "r1218", "r1219", "r1220", "r1221", "r1222", "r1223", "r1224", "r1225", "r1226", "r1227", "r1228", "r1229", "r1230", "r1231", "r1232", "r1233", "r1234", "r1235", "r1236", "r1237", "r1238", "r1239", "r1240", "r1241", "r1242", "r1243", "r1244", "r1245", "r1246", "r1247", "r1248", "r1249", "r1250", "r1251", "r1252", "r1253", "r1254", "r1255", "r1256", "r1257", "r1258", "r1259", "r1260", "r1261", "r1262", "r1263", "r1264", "r1265", "r1266", "r1267", "r1268", "r1269", "r1270", "r1271", "r1272", "r1273", "r1274", "r1275", "r1276", "r1277", "r1278", "r1279", "r1280", "r1281", "r1282", "r1283", "r1284", "r1285", "r1286", "r1287", "r1288", "r1289", "r1290", "r1291", "r1292", "r1293", "r1294", "r1295", "r1296", "r1297", "r1298", "r1299", "r1300", "r1301", "r1302", "r1303", "r1304", "r1305", "r1306", "r1307", "r1308", "r1309", "r1310", "r1311", "r1312", "r1313", "r1314", "r1315", "r1316", "r1317", "r1318", "r1319", "r1320", "r1321", "r1322", "r1323", "r1324", "r1325", "r1326", "r1327", "r1328", "r1329", "r1330", "r1331", "r1332", "r1333", "r1334", "r1335", "r1336", "r1337", "r1338", "r1339", "r1340", "r1341", "r1342", "r1343", "r1344", "r1345", "r1346", "r1347", "r1348", "r1349", "r1350", "r1351", "r1352", "r1353", "r1354", "r1355", "r1356", "r1357", "r1358", "r1359", "r1360", "r1361", "r1362", "r1363", "r1364", "r1365", "r1366", "r1367", "r1368", "r1369", "r1370", "r1371", "r1372", "r1373", "r1374", "r1375", "r1376", "r1377", "r1378", "r1379", "r1380", "r1381", "r1382", "r1383", "r1384", "r1385", "r1386", "r1387", "r1388", "r1389", "r1390", "r1391", "r1392", "r1393", "r1394", "r1395", "r1396", "r1397", "r1398", "r1399", "r1400", "r1401", "r1402", "r1403", "r1404", "r1405", "r1406", "r1407", "r1408", "r1409", "r1410", "r1411", "r1412", "r1413", "r1414", "r1415", "r1416", "r1417", "r1418", "r1419", "r1420", "r1421", "r1422", "r1423", "r1424", "r1425", "r1426", "r1427", "r1428", "r1429", "r1430", "r1431", "r1432", "r1433", "r1434", "r1435", "r1436", "r1437", "r1438", "r1439", "r1440", "r1441", "r1442", "r1443", "r1444", "r1445", "r1446", "r1447", "r1448", "r1449", "r1450", "r1451", "r1452", "r1453", "r1454", "r1455", "r1456", "r1457", "r1458", "r1459", "r1460", "r1461", "r1462", "r1463", "r1464", "r1465", "r1466", "r1467", "r1468", "r1469", "r1470", "r1471", "r1472", "r1473", "r1474", "r1475", "r1476", "r1477", "r1478", "r1479", "r1480", "r1481", "r1482", "r1483", "r1484", "r1485", "r1486", "r1487", "r1488", "r1489", "r1490", "r1491", "r1492", "r1493", "r1494", "r1495", "r1496", "r1497", "r1498", "r1499", "r1500", "r1501", "r1502", "r1503", "r1504", "r1505", "r1506", "r1507", "r1508", "r1509", "r1510", "r1511", "r1512", "r1513", "r1514", "r1515", "r1516", "r1517", "r1518", "r1519", "r1520", "r1521", "r1522", "r1523", "r1524", "r1525", "r1526", "r1527", "r1528", "r1529", "r1530", "r1531", "r1532", "r1533", "r1534", "r1535", "r1536", "r1537", "r1538", "r1539", "r1540", "r1541", "r1542", "r1543", "r1544", "r1545", "r1546", "r1547", "r1548", "r1549", "r1550", "r1551", "r1552", "r1553", "r1554", "r1555", "r1556", "r1557", "r1558", "r1559", "r1560", "r1561", "r1562", "r1563", "r1564", "r1565", "r1566", "r1567", "r1568", "r1569", "r1570", "r1571", "r1572", "r1573", "r1574", "r1575", "r1576", "r1577", "r1578", "r1579", "r1580", "r1581", "r1582", "r1583", "r1584", "r1585", "r1586", "r1587", "r1588", "r1589", "r1590", "r1591", "r1592", "r1593", "r1594", "r1595", "r1596", "r1597", "r1598", "r1599", "r1600", "r1601", "r1602", "r1603", "r1604", "r1605", "r1606", "r1607", "r1608", "r1609", "r1610", "r1611", "r1612", "r1613", "r1614", "r1615", "r1616", "r1617", "r1618", "r1619", "r1620", "r1621", "r1622", "r1623", "r1624", "r1625", "r1626", "r1627", "r1628", "r1629", "r1630", "r1631", "r1632", "r1633", "r1634", "r1635", "r1636", "r1637", "r1638", "r1639", "r1640", "r1641", "r1642", "r1643", "r1644", "r1645", "r1646", "r1647", "r1648", "r1649", "r1650", "r1651", "r1652", "r1653", "r1654", "r1655", "r1656", "r1657", "r1658", "r1659", "r1660", "r1661", "r1662", "r1663", "r1664", "r1665", "r1666", "r1667", "r1668", "r1669", "r1670", "r1671", "r1672", "r1673", "r1674", "r1675", "r1676", "r1677", "r1678", "r1679", "r1680", "r1681", "r1682", "r1683", "r1684", "r1685", "r1686", "r1687", "r1688", "r1689", "r1690", "r1691", "r1692", "r1693", "r1694", "r1695", "r1696", "r1697", "r1698", "r1699", "r1700", "r1701", "r1702", "r1703", "r1704", "r1705", "r1706", "r1707", "r1708", "r1709", "r1710", "r1711", "r1712", "r1713", "r1714", "r1715", "r1716", "r1717", "r1718", "r1719", "r1720", "r1721", "r1722", "r1723", "r1724", "r1725", "r1726", "r1727", "r1728", "r1729", "r1730", "r1731", "r1732", "r1733", "r1734", "r1735", "r1736", "r1737", "r1738", "r1739", "r1740", "r1741", "r1742", "r1743", "r1744", "r1745", "r1746", "r1747", "r1748", "r1749", "r1750", "r1751", "r1752", "r1753", "r1754", "r1755", "r1756", "r1757", "r1758", "r1759", "r1760", "r1761", "r1762", "r1763", "r1764", "r1765", "r1766", "r1767", "r1768", "r1769", "r1770", "r1771", "r1772", "r1773", "r1774", "r1775", "r1776", "r1777", "r1778", "r1779", "r1780", "r1781", "r1782", "r1783", "r1784", "r1785", "r1786", "r1787", "r1788", "r1789", "r1790", "r1791", "r1792", "r1793", "r1794", "r1795", "r1796", "r1797", "r1798", "r1799", "r1800", "r1801", "r1802", "r1803", "r1804", "r1805", "r1806", "r1807", "r1808", "r1809", "r1810", "r1811", "r1812", "r1813", "r1814", "r1815", "r1816", "r1817", "r1818", "r1819", "r1820", "r1821", "r1822", "r1823", "r1824", "r1825", "r1826", "r1827", "r1828", "r1829", "r1830", "r1831", "r1832", "r1833", "r1834", "r1835", "r1836", "r1837", "r1838", "r1839", "r1840", "r1841", "r1842", "r1843", "r1844", "r1845", "r1846", "r1847", "r1848", "r1849", "r1850", "r1851", "r1852", "r1853", "r1854", "r1855", "r1856", "r1857", "r1858", "r1859", "r1860", "r1861", "r1862", "r1863", "r1864", "r1865", "r1866", "r1867", "r1868", "r1869", "r1870", "r1871", "r1872", "r1873", "r1874", "r1875", "r1876", "r1877", "r1878", "r1879", "r1880", "r1881", "r1882", "r1883", "r1884", "r1885", "r1886", "r1887", "r1888", "r1889", "r1890", "r1891", "r1892", "r1893", "r1894", "r1895", "r1896", "r1897", "r1898", "r1899", "r1900", "r1901", "r1902", "r1903", "r1904", "r1905", "r1906", "r1907", "r1908", "r1909", "r1910", "r1911", "r1912", "r1913", "r1914", "r1915", "r1916", "r1917", "r1918", "r1919", "r1920", "r1921", "r1922", "r1923", "r1924", "r1925", "r1926", "r1927", "r1928", "r1929", "r1930", "r1931", "r1932", "r1933", "r1934", "r1935", "r1936", "r1937", "r1938", "r1939", "r1940", "r1941", "r1942", "r1943", "r1944", "r1945", "r1946", "r1947", "r1948", "r1949", "r1950", "r1951", "r1952", "r1953", "r1954", "r1955", "r1956", "r1957", "r1958", "r1959", "r1960", "r1961", "r1962", "r1963", "r1964", "r1965", "r1966", "r1967", "r1968", "r1969", "r1970", "r1971", "r1972", "r1973", "r1974", "r1975", "r1976", "r1977", "r1978", "r1979", "r1980", "r1981", "r1982", "r1983", "r1984", "r1985", "r1986", "r1987", "r1988", "r1989", "r1990", "r1991", "r1992", "r1993", "r1994", "r1995", "r1996", "r1997", "r1998", "r1999", "r2000", "r2001", "r2002", "r2003", "r2004", "r2005", "r2006", "r2007", "r2008", "r2009", "r2010", "r2011", "r2012", "r2013", "r2014", "r2015", "r2016", "r2017", "r2018", "r2019", "r2020", "r2021", "r2022", "r2023", "r2024", "r2025", "r2026", "r2027", "r2028", "r2029", "r2030", "r2031", "r2032", "r2033", "r2034", "r2035", "r2036", "r2037", "r2038", "r2039", "r2040", "r2041", "r2042", "r2043", "r2044", "r2045", "r2046", "r2047", "r2048", "r2049", "r2050", "r2051", "r2052", "r2053", "r2054", "r2055", "r2056", "r2057", "r2058", "r2059", "r2060", "r2061", "r2062", "r2063", "r2064", "r2065", "r2066", "r2067", "r2068", "r2069", "r2070", "r2071", "r2072", "r2073", "r2074", "r2075", "r2076", "r2077", "r2078", "r2079", "r2080", "r2081", "r2082", "r2083", "r2084", "r2085", "r2086", "r2087", "r2088", "r2089", "r2090", "r2091", "r2092", "r2093", "r2094", "r2095", "r2096", "r2097", "r2098", "r2099", "r2100", "r2101", "r2102", "r2103", "r2104", "r2105", "r2106", "r2107", "r2108", "r2109", "r


```

RealEstateOperatingCompaniesMember", "presentation": "http://ocsl.com/role/PortfolioInvestmentsPortfolioofInvestmentsbyIndustryDetails", "lang": "en-us", "role": "terseLabel", "Real Estate Operating Companies", "label": "Real Estate Operating Companies [Member]", "documentation": "Real Estate Operating Companies", "auth_ref": "us-gaap_RealEstateSectorMember", "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RealEstateSectorMember", "presentation": "http://ocsl.com/role/PortfolioInvestmentsPortfolioofInvestmentsbyIndustryDetails", "lang": "en-us", "role": "terseLabel", "Real Estate Development", "label": "Real Estate Sector [Member]", "documentation": "Sector of the economy consisting of companies engaged in real estate business activities", "auth_ref": "r772", "r1067", "r1071", "r1074", "r1077", "ocsl_RealEstateServicesMember", "xbrltype": "domainItemType", "nsuri": "http://ocsl.com/20240630", "localname": "RealEstateServicesMember", "presentation": "http://ocsl.com/role/PortfolioInvestmentsPortfolioofInvestmentsbyIndustryDetails", "lang": "en-us", "role": "terseLabel", "Real Estate Services", "label": "Real Estate Services [Member]", "documentation": "Real Estate Services", "auth_ref": "us-gaap_RealizedAndUnrealizedGainLossInvestmentAndDerivativeOperatingTaxExpenseBenefit", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RealizedAndUnrealizedGainLossInvestmentAndDerivativeOperatingTaxExpenseBenefit", "crdr": "debit", "calculation": "http://ocsl.com/role/ConsolidatedStatementsOfOperations", "parentTag": "us-gaap_RealizedAndUnrealizedGainLossInvestmentDerivativeAndForeignCurrencyTransactionOperatingAfterTax", "weight": -1.0, "order": 1.0, "http://ocsl.com/role/ConsolidatedStatementsOfChangesInNetAssets", "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 1.0, "presentation": "http://ocsl.com/role/ConsolidatedStatementsOfChangesInNetAssets", "http://ocsl.com/role/ConsolidatedStatementsOfOperations", "http://ocsl.com/role/ShareDataandNetAssetsScheduleofChangesinNetAssetsDetails", "http://ocsl.com/role/TaxableDistributableIncomeandDividendDistributionsNarrativeDetails", "lang": "en-us", "role": "negatedTerseLabel", "(Provision) benefit for taxes on realized and unrealized gains (losses)", "negatedLabel": "(Provision) benefit for taxes on realized and unrealized gains (losses)", "terseLabel": "(Provision) benefit for taxes on realized and unrealized gains (losses)", "label": "Gain (Loss). Investment and Derivative. Operating. Tax Expense (Benefit).", "documentation": "Amount of income tax expense (benefit) from realized and unrealized gain (loss) on investment and derivative, classified as operating. Investment includes, but is not limited to, debt and equity securities, security sold short, real estate, and commodity", "auth_ref": "r1054", "r1062", "us-gaap_RealizedAndUnrealizedGainLossInvestmentDerivativeAndForeignCurrencyTransactionOperatingAfterTax", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RealizedAndUnrealizedGainLossInvestmentDerivativeAndForeignCurrencyTransactionOperatingAfterTax", "crdr": "credit", "calculation": "http://ocsl.com/role/ConsolidatedStatementsOfOperations", "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 2.0, "presentation": "http://ocsl.com/role/ConsolidatedStatementsOfOperations", "lang": "en-us", "role": "totalLabel", "Net realized and unrealized gains (losses), net of taxes", "label": "Gain (Loss). Investment and Derivative. Operating. and Foreign Currency Transaction, after Tax", "documentation": "Amount, after tax, of realized and unrealized gain (loss) on investment and derivative, classified as operating, and foreign currency transaction. Investment includes, but is not limited to, debt and equity securities, security sold short, real estate, and commodity", "auth_ref": "r615", "r1039", "r1063", "r1086", "us-gaap_RealizedGainLossInvestmentAndDerivativeOperatingBeforeTax", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RealizedGainLossInvestmentAndDerivativeOperatingBeforeTax", "crdr": "credit", "calculation": "http://ocsl.com/role/ConsolidatedStatementofCashFlows", "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 2.0, "http://ocsl.com/role/ConsolidatedStatementsOfOperations", "parentTag": "us-gaap_RealizedAndUnrealizedGainLossInvestmentDerivativeAndForeignCurrencyTransactionOperatingAfterTax", "weight": 1.0, "order": 3.0, "http://ocsl.com/role/ConsolidatedStatementsOfChangesInNetAssets", "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 3.0, "presentation": "http://ocsl.com/role/ConsolidatedStatementsOfCashFlows", "http://ocsl.com/role/ConsolidatedStatementsOfChangesInNetAssets", "http://ocsl.com/role/ConsolidatedStatementsOfCashFlows", "lang": "en-us", "role": "totalLabel", "Net realized gains (losses)", "terseLabel": "Net realized gains (losses)", "negatedTerseLabel": "Net realized (gains) losses", "label": "Realized Gain (Loss). Investment and Derivative. Operating, before Tax", "documentation": "Amount, before tax, of realized gain (loss) on investment and derivative, classified as operating. Investment includes, but is not limited to, debt and equity securities, security sold short, real estate, and commodity", "auth_ref": "r586", "r746", "r802", "r1060", "us-gaap_RealizedGainLossInvestmentDerivativeAndForeignCurrencyTransactionPriceChangeOperatingBeforeTax", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RealizedGainLossInvestmentDerivativeAndForeignCurrencyTransactionPriceChangeOperatingBeforeTax", "crdr": "credit", "presentation": "http://ocsl.com/role/Schedule1214ScheduleofInvestmentsinandAdvancetoAffiliatesDetails", "lang": "en-us", "role": "terseLabel", "Net Realized Gain (Loss)", "label": "Realized Gain (Loss). Investment, Derivative, and Foreign Currency Transaction Price Change, Operating, before Tax", "documentation": "Amount, before tax, of realized gain (loss) on investment, derivative, and foreign currency transaction on investment and derivative from change in market price, classified as operating. Investment includes, but is not limited to, debt and equity securities, security sold short, real estate, and commodity", "auth_ref": "r586", "r746", "r1060", "us-gaap_ReceivableInvestmentSale", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReceivableInvestmentSale", "crdr": "debit", "calculation": "http://ocsl.com/role/ConsolidatedStatementsOfAssetsandLiabilities", "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 8.0, "presentation": "http://ocsl.com/role/ConsolidatedStatementsOfAssetsandLiabilities", "lang": "en-us", "role": "terseLabel", "Receivables from unsettled transactions", "label": "Receivable. Investment. Sale", "documentation": "Amount of receivable from sale of investment", "auth_ref": "r572", "r629", "r804", "us-gaap_ReceivablesFromBrokersDealersAndClearingOrganizations", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReceivablesFromBrokersDealersAndClearingOrganizations", "crdr": "debit", "calculation": "http://ocsl.com/role/ConsolidatedStatementsOfAssetsandLiabilities", "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 7.0, "presentation": "http://ocsl.com/role/ConsolidatedStatementsOfAssetsandLiabilities", "http://ocsl.com/role/DerivativeInstrumentsNarrativeDetails", "lang": "en-us", "role": "terseLabel", "Due from broker", "label": "Receivable from Broker-Dealer and Clearing Organization", "documentation": "Amount receivable from broker-dealers and clearing organizations, including, but not limited to, securities failed-to-deliver, certain deposits for securities borrowed, open transactions, good faith and margin deposits, commissions and floor brokerage receivables", "auth_ref": "r7", "ocsl_ReconciliationToTheConsolidatedStatementsOfAssetsandLiabilitiesAbstract", "xbrltype": "stringItemType", "nsuri": "http://ocsl.com/20240630", "localname": "ReconciliationToTheConsolidatedStatementsOfAssetsandLiabilitiesAbstract", "presentation": "http://ocsl.com/role/ConsolidatedStatementofCashFlows", "lang": "en-us", "role": "terseLabel", "Reconciliation to the Consolidated Statements of Assets and Liabilities", "label": "Reconciliation To The Consolidated Statements Of Assets And Liabilities [Abstract]", "documentation": "Reconciliation To The Consolidated Statements Of Assets And Liabilities", "auth_ref": "ecd_RecoveryOfErrCompDisclosureLineItems", "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": "en-us", "role": "label", "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]", "auth_ref": "r912", "r924", "r905", "r932", "ecf_RegisteredClosedEndFundFlag", "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecf/2023", "localname": "RegisteredClosedEndFundFlag", "presentation": "http://xbrl.sec.gov/ecf/role/N2", "lang": "en-us", "role": "label", "Registered Closed-End Fund [Flag]", "auth_ref": "r835", "us-gaap_RelatedPartyDomain", "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyDomain", "presentation": "http://ocsl.com/role/RelatedPartyTransactionsDetails", "lang": "en-us", "role": "terseLabel", "Related Party [Domain]", "label": "Related Party. Type [Domain]", "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests", "auth_ref": "r318", "r416", "r417", "r557", "r558", "r559", "r560", "r561", "r583", "r585", "r630", "us-gaap_RelatedPartyTransactionAxis", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionAxis", "presentation": "http://ocsl.com/role/RelatedPartyTransactionsDetails", "lang": "en-us", "role": "terseLabel", "Related Party Transaction [Axis]", "label": "Related Party Transaction [Axis]", "documentation": "Information by type of related party transaction", "auth_ref": "r416", "r417", "r1021", "us-gaap_RelatedPartyTransactionDomain", "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionDomain", "presentation": "http://ocsl.com/role/RelatedPartyTransactionsDetails", "lang": "en-us", "role": "terseLabel", "Related Party Transaction [Domain]", "label": "Related Party Transaction [Domain]", "documentation": "Transaction between related party", "auth_ref": "us-gaap_RelatedPartyTransactionLineItems", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionLineItems", "presentation": "http://ocsl.com/role/RelatedPartyTransactionsDetails", "lang": "en-us", "role": "terseLabel", "Related Party Transaction [Line Items]", "label": "Related Party Transaction [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table", "auth_ref": "r595", "r596", "r599", "ocsl_RelatedPartyTransactionNumberOfComponents", "xbrltype": "integerItemType", "nsuri": "http://ocsl.com/20240630", "localname": "RelatedPartyTransactionNumberOfComponents", "presentation": "http://ocsl.com/role/RelatedPartyTransactionsDetails", "lang": "en-us", "role": "terseLabel", "Number of components", "label": "Related Party Transaction, Number Of Components", "documentation": "Related Party Transaction, Number Of Components", "auth_ref": "ocsl_RelatedPartyTransactionTerminationNoticePeriod", "xbrltype": "durationItemType", "nsuri": "http://ocsl.com/20240630", "localname": "RelatedPartyTransactionTerminationNoticePeriod", "presentation": "http://ocsl.com/role/RelatedPartyTransactionsDetails", "lang": "en-us", "role": "terseLabel", "Related party transaction, termination, notice period", "label": "Related Party Transaction, Termination, Notice Period", "documentation": "Related Party Transaction, Termination, Notice Period", "auth_ref": "us-gaap_RelatedPartyTransactionsAbstract", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsAbstract", "lang": "en-us", "role": "label", "Related Party Transactions [Abstract]", "auth_ref": "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": "http://ocsl.com/role/RelatedPartyTransactionsDetails", "lang": "en-us", "role": "terseLabel", "Related Party [Axis]", "label": "Related Party. Type [Axis]", "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests", "auth_ref": "r318", "r416", "r417", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r557", "r558", "r559", "r560", "r561", "r583", "r585", "r630", "r1021", "us-gaap_RelatedPartyTransactionsDisclosureTextBlock", "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": "http://ocsl.com/role/RelatedPartyTransactions", "lang": "en-us", "role": "terseLabel", "Related Party Transactions", "label": "Related Party Transactions Disclosure [Text Block]", "documentation":
```

```

Restatement does not require Recovery, "label": "Restatement Does Not Require Recovery [Text Block]" } } }, "auth_ref": "r821", "r833", "r914", "r941" } } },
"ocsl:RestaurantsMember": { "xbrltype": "domainItemType", "nsuri": "http://ocsl.com/role/20240630", "localname": "RestaurantsMember", "presentation": {
"http://ocsl.com/role/PortfolioInvestmentsPortfolioInvestmentsIndustryDetails": { "lang": "en-us", "role": "terseLabel", "label": "Restaurants
[Member]", "documentation": "Restaurants" } } }, "auth_ref": { "us-gaap:RestrictedCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023",
"localname": "RestrictedCash", "crdr": "debit", "calculation": { "http://ocsl.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "us-
gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "weight": 1.0, "order": 2.0 },
"http://ocsl.com/role/ConsolidatedStatementofAssetsandLiabilities": { "parentTag": "us-gaap:Assets", "weight": 1.0, "order": 9.0 } }, "presentation": {
"http://ocsl.com/role/ConsolidatedStatementofCashFlows": { "http://ocsl.com/role/ConsolidatedStatementofAssetsandLiabilities":
"http://ocsl.com/role/PortfolioInvestmentsNarrativeDetails": { "http://ocsl.com/role/PortfolioInvestmentsSummarizedBalanceSheetInformationDetails",
"http://ocsl.com/role/SignificantAccountingPoliciesDetails": { "lang": "en-us", "role": "terseLabel", "label": "Restricted Cash and Cash Equivalents Items [Line Items]", "documentation": "Line
items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or
many axes to the table." } } }, "auth_ref": { "r1033" } }, "us-gaap:RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://ocsl.com/role/ConsolidatedStatementofAssetsandLiabilities": {
"parentTag": "us-gaap:StockholdersEquity", "weight": 1.0, "order": 2.0 },
"http://ocsl.com/role/TaxableDistributableIncomeandDividendDistributionsComponentsofAccumulatedOverdistributedEarningsDetails": { "parentTag": null, "weight":
null, "order": null, "root": true } }, "presentation": { "http://ocsl.com/role/ConsolidatedStatementsofAssetsandLiabilities":
"http://ocsl.com/role/TaxableDistributableIncomeandDividendDistributionsComponentsofAccumulatedOverdistributedEarningsDetails": { "lang": "en-us", "role": "terseLabel", "label": "Accumulated overdistributed earnings", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": { "r81", "r104", "r473", "r488", "r489", "r506", "r565", "r783" } },
"cef:ReturnAtMinusFivePercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "ReturnAtMinusFivePercent", "presentation": {
"http://xbrl.sec.gov/cef/role/N2": { "lang": "en-us", "role": "label", "Return at Minus Five [Percent]" } } }, "auth_ref": { "r893" } }, "cef:ReturnAtMinusTenPercent": {
"xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "ReturnAtMinusTenPercent", "presentation": { "http://xbrl.sec.gov/cef/role/N2": {
"lang": "en-us", "role": "label", "Return at Minus Ten [Percent]" } } }, "auth_ref": { "r893" } }, "cef:ReturnAtPlusFivePercent": { "xbrltype": "percentItemType",
"nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "ReturnAtPlusFivePercent", "presentation": { "http://xbrl.sec.gov/cef/role/N2": { "lang": "en-us", "role": "label",
"Return at Plus Five [Percent]" } } }, "auth_ref": { "r893" } }, "cef:ReturnAtPlusTenPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023",
"localname": "ReturnAtPlusTenPercent", "presentation": { "http://xbrl.sec.gov/cef/role/N2": { "lang": "en-us", "role": "label", "Return at Plus Ten [Percent]" } } },
"auth_ref": { "r893" } }, "cef:ReturnAtZeroPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "ReturnAtZeroPercent",
"presentation": { "http://xbrl.sec.gov/cef/role/N2": { "lang": "en-us", "role": "label", "Return at Zero [Percent]" } } }, "auth_ref": { "r893" } }, "us-
gaap:RevenueFromContractWithCustomerAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerAbstract",
"lang": "en-us", "role": "label", "Revenue from Contract with Customer [Abstract]" } } }, "auth_ref": { "us-
gaap:RevenuesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenuesAbstract", "presentation": {
"http://ocsl.com/role/ConsolidatedStatementsofOperations": { "lang": "en-us", "role": "terseLabel", "label": "Revenues [Abstract]" } } }, "auth_ref": {
"us-gaap:RevolvingCreditFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevolvingCreditFacilityMember",
"presentation": { "http://ocsl.com/role/BorrowingsNarrativeDetails": { "http://ocsl.com/role/PortfolioInvestmentsNarrativeDetails": { "lang": "en-us", "role": "terseLabel", "label": "Revolving Credit Facility [Member]", "documentation": "Arrangement in which loan proceeds can continuously be
obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount." } } }, "auth_ref": {
"cef:RightsLimitedByOtherSecuritiesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "RightsLimitedByOtherSecuritiesTextBlock", "presentation": { "http://xbrl.sec.gov/cef/role/N2": { "lang": "en-us", "role": "label", "Rights Limited by Other Securities
[Text Block]" } } }, "auth_ref": { "r848" } }, "cef:RightsSubjectToOtherThanMajorityVoteTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://xbrl.sec.gov/cef/2023", "localname": "RightsSubjectToOtherThanMajorityVoteTextBlock", "presentation": { "http://xbrl.sec.gov/cef/role/N2": { "lang": "en-us", "role": "label", "Rights Subject to Other than Majority Vote [Text Block]" } } }, "auth_ref": { "r847" } }, "cef:RiskAxis": { "xbrltype": "stringItemType", "nsuri":
"http://xbrl.sec.gov/cef/2023", "localname": "RiskAxis", "presentation": { "http://xbrl.sec.gov/cef/role/N2": { "lang": "en-us", "role": "label", "Risk [Axis]" } } },
"auth_ref": { "cef:RiskFactorsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "RiskFactorsTableTextBlock",
"presentation": { "http://xbrl.sec.gov/cef/role/N2": { "lang": "en-us", "role": "label", "Risk Factors [Table Text Block]" } } }, "auth_ref": { "r889" } },
"cef:RiskTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "RiskTextBlock", "presentation": {
"http://xbrl.sec.gov/cef/role/N2": { "lang": "en-us", "role": "label", "Risk [Text Block]" } } }, "auth_ref": { "us-gaap:RisksAndUncertaintiesAbstract": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RisksAndUncertaintiesAbstract", "lang": "en-us", "role": "label", "Risks and Uncertainties
[Abstract]" } } }, "auth_ref": { "ecd:Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrAdoptedFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements": { "lang": "en-us", "role": "terseLabel", "label": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": { "r950" } }, "ecd:Rule10b51ArrTrmndFlag": { "xbrltype":
"booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrTrmndFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements": { "lang": "en-us", "role": "terseLabel", "label": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": { "r950" } }, "ocsl:SLFJVIFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://ocsl.com/20240630",
"localname": "SLFJVIFacilityMember", "presentation": { "http://ocsl.com/role/PortfolioInvestmentsNarrativeDetails": { "http://xbrl.sec.gov/cef/role/N2": { "lang": "en-us", "role": "terseLabel", "label": "SLF JV I Facility [Member]", "documentation": "SLF JV I Facility" } } }, "auth_ref": { "ocsl:SLFJVILLCMember": { "xbrltype": "domainItemType", "nsuri": "http://ocsl.com/20240630", "localname": "SLFJVILLCMember", "presentation": {
"http://ocsl.com/role/PortfolioInvestmentsNarrativeDetails": { "lang": "en-us", "role": "terseLabel", "label": "SLF JV I LLC [Member]", "documentation": "SLF JV I LLC" } } }, "auth_ref": { "ocsl:SLFJVIMember": { "xbrltype": "domainItemType", "nsuri": "http://ocsl.com/20240630", "localname": "SLFJVIMember", "presentation": { "http://ocsl.com/role/PortfolioInvestmentsNarrativeDetails": { "http://ocsl.com/role/PortfolioInvestmentsPortfolioListingDetails":
"http://ocsl.com/role/PortfolioInvestmentsSummarizedBalanceSheetInformationDetails": { "http://ocsl.com/role/PortfolioInvestmentsSummaryofPortfolioDetails": { "lang": "en-us", "role": "terseLabel", "label": "SLF JV I Member", "documentation": "SLF JV I" } } }, "auth_ref": { "ocsl:SLFJVINotesMember": { "xbrltype": "domainItemType", "nsuri": "http://ocsl.com/20240630", "localname": "SLFJVINotesMember", "presentation": {
"http://ocsl.com/role/PortfolioInvestmentsNarrativeDetails": { "http://ocsl.com/role/PortfolioInvestmentsSummarizedStatementofOperationsInformationDetails": { "http://xbrl.sec.gov/cef/role/N2": { "lang": "en-us", "role": "terseLabel", "label": "SLF JV I Notes [Member]", "documentation": "SLF JV I Notes" } } }, "auth_ref": { "us-gaap:SaleOfStockConsiderationReceivedOnTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockConsiderationReceivedOnTransaction", "crdr": "debit", "presentation": {
"http://ocsl.com/role/ShareDataandNetAssetsScheduleofCommonStockIssuedandSoldDetails": { "lang": "en-us", "role": "terseLabel", "label": "Sale of Stock: Consideration Received on Transaction", "documentation": "Cash received on stock transaction after deduction of issuance costs." } } }, "auth_ref": { "ocsl:SaleOfStockConsiderationReceivedOnTransactionExcludingOfferingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://ocsl.com/20240630", "localname": "SaleOfStockConsiderationReceivedOnTransactionExcludingOfferingCosts", "crdr": "debit", "presentation": {
"http://ocsl.com/role/ShareDataandNetAssetsScheduleofCommonStockIssuedandSoldDetails": { "lang": "en-us", "role": "terseLabel", "label": "Sale of Stock: Consideration Received on Transaction, Excluding Offering Costs", "documentation": "Sale of Stock, Consideration Received on Transaction, Excluding Offering Costs" } } }, "auth_ref": { "ocsl:SaleOfStockMaximumAggregateOfferingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://ocsl.com/20240630", "localname": "SaleOfStockMaximumAggregateOfferingAmount", "crdr": "debit", "presentation": {
"http://ocsl.com/role/ShareDataandNetAssetsScheduleofCommonStockIssuedandSoldDetails": { "lang": "en-us", "role": "terseLabel", "label": "Sale of Stock: Maximum Aggregate Offering Amount", "documentation": "Sale of Stock, Maximum Aggregate Offering Amount" } } }, "auth_ref": { "us-gaap:SaleOfStockNameOffTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockNameOffTransactionDomain", "presentation": { "http://ocsl.com/role/ShareDataandNetAssetsNarrativeDetails":
"http://ocsl.com/role/ShareDataandNetAssetsScheduleofCommonStockIssuedandSoldDetails": { "lang": "en-us", "role": "terseLabel", "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": { "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "presentation": { "http://ocsl.com/role/ShareDataandNetAssetsNarrativeDetails":
"http://ocsl.com/role/ShareDataandNetAssetsScheduleofCommonStockIssuedandSoldDetails": { "lang": "en-us", "role": "terseLabel", "label": "Number of shares issued (in shares)", "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction." } } }, "auth_ref": { "us-gaap:SaleOfStockPricePerShare": { "xbrltype": "perShareItemType", "nsuri":
```

"http://ocsl.com/role/PortfolioInvestmentsNarrativeDetails"-I,"lang":{"en-us":{"role":{"terseLabel":"Investment Name [Axis]","label":"Investment Name [Axis]"} } },"auth_ref":{"r235","r236","r237"} },"us-gaap_ScheduleOfInvestmentsAbstract":{"xbrltype":"stringItemType","nsuri":"http://fasb.org/us-gaap/2023","localname":"ScheduleOfInvestmentsAbstract","lang":{"en-us":{"role":{"label":"Schedule of Investments [Abstract]"} } },"auth_ref":{"r235","r236","r237"} },"us-gaap_ScheduleOfInvestmentsLineItems":{"xbrltype":"stringItemType","nsuri":"http://fasb.org/us-gaap/2023","localname":"ScheduleOfInvestmentsLineItems","presentation":{"http://ocsl.com/role/ConsolidatedScheduleOfInvestments","http://ocsl.com/role/ConsolidatedScheduleOfInvestmentsDerivatives","http://ocsl.com/role/ConsolidatedScheduleOfInvestmentsParentetical","http://ocsl.com/role/PortfolioInvestmentsCompositionOfInvestmentsDetails","http://ocsl.com/role/PortfolioInvestmentsPortfolioCompositionDetails","http://ocsl.com/role/PortfolioInvestmentsPortfolioOfInvestmentsByIndustryDetails","http://ocsl.com/role/PortfolioInvestmentsScheduleOfFinancialInstrumentsCarriedatFairValueDetails","http://ocsl.com/role/PortfolioInvestmentsScheduleOfFinancialInstrumentsDisclosedbutCarriedatFairValueDetails","http://ocsl.com/role/RealizedGainsorLossesandNetUnrealizedAppreciationorDepreciationAggregateNetRealizedGainsDetails","http://ocsl.com/role/RealizedGainsorLossesandNetUnrealizedAppreciationorDepreciationNarrativeDetails","http://ocsl.com/role/Schedule1214ScheduleofInvestmentsandAdvancesToAffiliatesDetails"} },"lang":{"en-us":{"role":{"terseLabel":"Tersera Therapeutics LLC","label":"Schedule of Investments [Line Items]","documentation":"Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } },"auth_ref":{"r631","r632","r633","r634","r635","r636","r637","r638","r639","r640","r641","r642","r643","r644","r645","r646","r647","r648","r649","r650","r652","r654","r658","r659","r660","r661","r662","r663","r664","r665","r667","r668","r669","r670","r671","r672","r673","r674","r675","r676","r677","r678","r679","r680","r681","r682","r683","r684","r685","r686","r687","r688","r689","r690","r691","r692","r693","r694","r695","r696","r697","r698","r699","r700","r701","r702","r703","r704","r705","r706","r707","r708","r709","r710","r711","r712","r713","r714","r715","r716","r717","r718","r719","r720","r721","r722","r723","r724","r725","r726","r727","r728","r729","r730","r731","r732","r733","r734"} },"us-gaap_ScheduleOfInvestmentsTable":{"xbrltype":"stringItemType","nsuri":"http://fasb.org/us-gaap/2023","localname":"ScheduleOfInvestmentsTable","presentation":{"http://ocsl.com/role/ConsolidatedScheduleOfInvestments","http://ocsl.com/role/ConsolidatedScheduleOfInvestmentsDerivatives","http://ocsl.com/role/ConsolidatedScheduleOfInvestmentsParentetical","http://ocsl.com/role/PortfolioInvestmentsCompositionOfInvestmentsDetails","http://ocsl.com/role/PortfolioInvestmentsPortfolioCompositionDetails","http://ocsl.com/role/PortfolioInvestmentsPortfolioOfInvestmentsByIndustryDetails","http://ocsl.com/role/PortfolioInvestmentsScheduleOfFinancialInstrumentsCarriedatFairValueDetails","http://ocsl.com/role/PortfolioInvestmentsScheduleOfFinancialInstrumentsDisclosedbutCarriedatFairValueDetails","http://ocsl.com/role/RealizedGainsorLossesandNetUnrealizedAppreciationorDepreciationAggregateNetRealizedGainsDetails","http://ocsl.com/role/RealizedGainsorLossesandNetUnrealizedAppreciationorDepreciationNarrativeDetails"} },"lang":{"en-us":{"role":{"terseLabel":"Schedule of Investments [Table]","label":"Schedule of Investments [Table]","documentation":"Disclosure of information about investments owned by investment company." } },"auth_ref":{"r631","r632","r633","r634","r635","r636","r637","r638","r639","r640","r641","r642","r643","r644","r645","r646","r647","r648","r649","r650","r652","r654","r658","r659","r660","r661","r662","r663","r664","r665","r667","r668","r669","r670","r671","r672","r673","r674","r675","r676","r677","r678","r679","r680","r681","r682","r683","r684","r685","r686","r687","r688","r689","r690","r691","r692","r693","r694","r695","r696","r697","r698","r699","r700","r701","r702","r703","r704","r705","r706","r707","r708","r709","r710","r711","r712","r713","r714","r715","r716","r717","r718","r719","r720","r721","r722","r723","r724","r725","r726","r727","r728","r729","r730","r731","r732","r733","r734"} },"us-gaap_ScheduleOfRealizedGainLossTableTextBlock":{"xbrltype":"textBlockItemType","nsuri":"http://fasb.org/us-gaap/2023","localname":"ScheduleOfRealizedGainLossTableTextBlock","presentation":{"http://ocsl.com/role/RealizedGainsorLossesandNetUnrealizedAppreciationorDepreciationTables"} },"lang":{"en-us":{"role":{"terseLabel":"Schedule of Aggregate Net Realized Gains","label":"Schedule of Realized Gain (Loss) [Table Text Block]","documentation":"Tabular disclosure of the proceeds from sales of available-for-sale securities and the gross realized gains and gross realized losses that have been included in earnings as a result of those sales." } },"auth_ref":{"r997"} },"us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable":{"xbrltype":"stringItemType","nsuri":"http://fasb.org/us-gaap/2023","localname":"ScheduleOfRelatedPartyTransactionsByRelatedPartyTable","presentation":{"http://ocsl.com/role/RelatedPartyTransactionsDetails"} },"lang":{"en-us":{"role":{"terseLabel":"Schedule of Related Party Transactions, by Related Party [Table]","label":"Schedule of Related Party Transactions, by Related Party [Table]","documentation":"Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } },"auth_ref":{"r69","r70","r595","r596","r599"} },"us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable":{"xbrltype":"stringItemType","nsuri":"http://fasb.org/us-gaap/2023","localname":"ScheduleOfRestrictedCashAndCashEquivalentsTable","presentation":{"http://ocsl.com/role/SignificantAccountingPoliciesDetails"} },"lang":{"en-us":{"role":{"terseLabel":"Restrictions on Cash and Cash Equivalents [Table]","label":"Restrictions on Cash and Cash Equivalents [Table]","documentation":"Disclosure of information about cash and cash equivalents restricted as to withdrawal or usage." } },"auth_ref":{"r16","r109","r1033"} },"us-gaap_ScheduleOfSaleOfStockBySubsidiaryOrEquityMethodInvesteeDisclosureTextBlock":{"xbrltype":"textBlockItemType","nsuri":"http://fasb.org/us-gaap/2023","localname":"ScheduleOfSaleOfStockBySubsidiaryOrEquityMethodInvesteeDisclosureTextBlock","presentation":{"http://ocsl.com/role/ShareDataandNetAssetsTables"} },"lang":{"en-us":{"role":{"terseLabel":"Schedule of Common Stock Issued and Sold","label":"Schedule of Sale of Stock by Subsidiary or Equity Method Investee Disclosure [Table Text Block]","documentation":"Tabular disclosure of sales of stock or previously unissued stock made by subsidiary or equity method investee to investors outside the consolidated group. This includes stock issued in a business combination in exchange for shares of an acquired entity." } },"auth_ref":{"r235","r236","r237"} },"us-gaap_SecuredDebt":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2023","localname":"SecuredDebt","crdr":{"credit":"calculation"},"http://ocsl.com/role/PortfolioInvestmentsSummarizedBalanceSheetInformationDetails":{"parentTag":"us-gaap_Liabilities","weight":1.0,"order":3.0 },"presentation":{"http://ocsl.com/role/PortfolioInvestmentsSummarizedBalanceSheetInformationDetails"} },"lang":{"en-us":{"role":{"terseLabel":"Secured borrowings","label":"Secured Debt","documentation":"Carrying value as of the balance sheet date, including the current and noncurrent portions, of collateralized debt obligations (with maturities initially due after one year or beyond the operating cycle, if longer). Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower." } },"auth_ref":{"r17","r113","r1032"} },"ocsl_SecuredOvernightFinancingRateMember":{"xbrltype":"domainItemType","nsuri":"http://ocsl.com/20240630","localname":"SecuredOvernightFinancingRateMember","presentation":{"http://ocsl.com/role/BorrowingsNarrativeDetails","http://ocsl.com/role/PortfolioInvestmentsNarrativeDetails"} },"lang":{"en-us":{"role":{"terseLabel":"Secured Overnight Financing Rate","label":"Secured Overnight Financing Rate [Member]","documentation":"Secured Overnight Financing Rate"} } },"auth_ref":{"r235","r236","r237"} },"us-gaap_SecuredOvernightFinancingRateSoftOvernightIndexSwapRateMember":{"xbrltype":"domainItemType","nsuri":"http://fasb.org/us-gaap/2023","localname":"SecuredOvernightFinancingRateSoftOvernightIndexSwapRateMember","presentation":{"http://ocsl.com/role/BorrowingsNarrativeDetails"} },"lang":{"en-us":{"role":{"terseLabel":"Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate","label":"Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]","documentation":"Fixed rate on U.S. dollar, constant-notional interest rate swap that has its variable rate leg referenced to Secured Overnight Financing Rate (SOFR) with no additional spread over SOFR on variable-rate leg." } } },"auth_ref":{"r1015"} },"cef_Security12bTitle":{"xbrltype":"securityTitleItemType","nsuri":"http://xbrl.sec.gov/cef/2023","localname":"Security12bTitle","presentation":{"http://ocsl.com/role/Cover"} },"lang":{"en-us":{"role":{"label":"Title of 12(b) Security","terseLabel":"Title of 12(b) Security","documentation":"Title of a 12(b) registered security." } } },"auth_ref":{"r806"} },"cef_SecurityDividendsTextBlock":{"xbrltype":"textBlockItemType","nsuri":"http://xbrl.sec.gov/cef/2023","localname":"SecurityDividendsTextBlock","presentation":{"http://xbrl.sec.gov/cef/role/N2"} },"lang":{"en-us":{"role":{"label":"Security Dividends [Text Block]"} } },"auth_ref":{"r838"} },"cef_SecurityExchangeName":{"xbrltype":"edgarExchangeCodeItemType","nsuri":"http://xbrl.sec.gov/cef/2023","localname":"SecurityExchangeName","presentation":{"http://ocsl.com/role/Cover"} },"lang":{"en-us":{"role":{"label":"Security Exchange Name","terseLabel":"Security Exchange Name","documentation":"Name of the Exchange on which a security is registered." } } },"auth_ref":{"r808"} },"cef_SecurityLiabilitiesTextBlock":{"xbrltype":"textBlockItemType","nsuri":"http://xbrl.sec.gov/cef/2023","localname":"SecurityLiabilitiesTextBlock","presentation":{"http://xbrl.sec.gov/cef/role/N2"} },"lang":{"en-us":{"role":{"label":"Security Liabilities [Text Block]"} } },"auth_ref":{"r841"} },"cef_SecurityLiquidationRightsTextBlock":{"xbrltype":"textBlockItemType","nsuri":"http://xbrl.sec.gov/cef/2023","localname":"SecurityLiquidationRightsTextBlock","presentation":{"http://xbrl.sec.gov/cef/role/N2"} },"lang":{"en-us":{"role":{"label":"Security Liquidation Rights [Text Block]"} } },"auth_ref":{"r840"} },"cef_SecurityObligationsOfOwnershipTextBlock":{"xbrltype":"textBlockItemType","nsuri":"http://xbrl.sec.gov/cef/2023","localname":"SecurityObligationsOfOwnershipTextBlock","presentation":{"http://xbrl.sec.gov/cef/role/N2"} },"lang":{"en-us":{"role":{"label":"Security Obligations of Ownership [Text Block]"} } },"auth_ref":{"r843"} },"cef_SecurityPreemptiveAndOtherRightsTextBlock":{"xbrltype":"textBlockItemType","nsuri":"http://xbrl.sec.gov/cef/2023","localname":"SecurityPreemptiveAndOtherRightsTextBlock","presentation":{"http://xbrl.sec.gov/cef/role/N2"} },"lang":{"en-us":{"role":{"label":"Security Preemptive and Other Rights [Text Block]"} } },"auth_ref":{"r842"} },"cef_SecurityTitleTextBlock":{"xbrltype":"textBlockItemType","nsuri":"http://xbrl.sec.gov/cef/2023","localname":"SecurityTitleTextBlock","presentation":{"http://xbrl.sec.gov/cef/role/N2"} },"lang":{"en-us":{"role":{"label":"Security Title [Text Block]"} } },"auth_ref":{"r837"} },"cef_SecurityVotingRightsTextBlock":{"xbrltype":"textBlockItemType","nsuri":"http://xbrl.sec.gov/cef/2023","localname":"SecurityVotingRightsTextBlock","presentation":{"http://xbrl.sec.gov/cef/role/N2"} },"lang":{"en-us":{"role":{"label":"Security Voting Rights [Text Block]"} } },"auth_ref":{"r839"} } },"srt_SegmentGeographicalDomain":{"xbrltype":"domainItemType","nsuri":"http://fasb.org/srt/2023","localname":"SegmentGeographicalDomain","presentation":{"http://ocsl.com/role/PortfolioInvestmentsPortfolioCompositionDetails"} },"lang":{"en-us":{"role":{"terseLabel":"Geographical [Domain]","label":"Geographical [Domain]"} } },"auth_ref":{"r202","r203","r539","r543","r545","r640","r637","r679","r731","r750","r751","r752","r753","r754","r755","r756","r757","r758","r763","r780","r789","r1010","r1035"} },"ocsl_SeniorCreditFacilityMember":{"xbrltype":"domainItemType","nsuri":"http://ocsl.com/20240630","localname":"SeniorCreditFacilityMember","presentation":{"http://ocsl.com/role/PortfolioInvestmentsSummarizedStatementOfOperationsInformationDetails","http://xbrl.sec.gov/cef/role/N2"} },"lang":{"en-us":{"role":{"terseLabel":"Senior Credit Facility","label":"Senior Credit Facility [Member]","documentation":"Senior Credit Facility"} } },"auth_ref":{"r235","r236","r237"} },"ocsl_SeniorSecuredLoansMember":{"xbrltype":"domainItemType","nsuri":"http://ocsl.com/20240630","localname":"SeniorSecuredLoansMember","presentation":{"http://ocsl.com/role/PortfolioInvestmentsSummaryofPortfolioDetails"} },"lang":{"en-us":{"role":{"terseLabel":"Senior Secured Loans","label":"Senior Secured Loans [Member]","documentation":"Senior Secured Loans"} } },"auth_ref":{"r235","r236","r237"} },"cef_SeniorSecuritiesAmount":{"xbrltype":"monetaryItemType","nsuri":"http://xbrl.sec.gov/cef/2023","localname":"SeniorSecuritiesAmount","presentation":{"http://xbrl.sec.gov/cef/role/N2"} },"lang":{"en-us":{"role":{"label":"Senior Securities Amount (Deprecated 2023-01-31)"} } },"auth_ref":{"r880"} },"cef_SeniorSecuritiesAmt":{"xbrltype":"monetaryItemType","nsuri":"http://xbrl.sec.gov/cef/2023","localname":"SeniorSecuritiesAmt","presentation":{"http://ocsl.com/role/FinancialHighlightsDetails","http://xbrl.sec.gov/cef/role/N2"} },"lang":{"en-us":{"role":{"label":"Senior Securities Amount","terseLabel":"Senior Securities Amount","documentation":"Outstanding senior securities." } } },"auth_ref":{"r880"} },"cef_SeniorSecuritiesAverageMarketValuePerUnit":{"xbrltype":"perShareItemType","nsuri":"http://xbrl.sec.gov/cef/2023","localname":"SeniorSecuritiesAverageMarketValuePerUnit","presentation":{"http://xbrl.sec.gov/cef/role/N2"} },"lang":{"en-us":{"role":{"label":"Senior Securities Average Market Value per Unit"} } },"auth_ref":{"r883"} },"cef_SeniorSecuritiesAveragingMethodNoteTextBlock":{"xbrltype":"textBlockItemType","nsuri":"http://xbrl.sec.gov/cef/2023","localname":"SeniorSecuritiesAveragingMethodNoteTextBlock","presentation":{"http://xbrl.sec.gov/cef/role/N2"} },"lang":{"en-us":{"role":{"label":"Senior Securities Averaging Method, Note [Text Block]"} } },"auth_ref":{"r885"} },"cef_SeniorSecuritiesCoveragePerUnit":{"xbrltype":"perShareItemType","nsuri":"http://xbrl.sec.gov/cef/2023","localname":"SeniorSecuritiesCoveragePerUnit","presentation":{"http://xbrl.sec.gov/cef/role/N2"} },"lang":{"en-us":{"role":{"label":"Senior Securities Coverage per Unit (Deprecated 2023-01-31)"} } },"auth_ref":{"r881"} },"cef_SeniorSecuritiesCvgPerUnit":{"xbrltype":"perShareItemType","nsuri":"http://xbrl.sec.gov/cef/2023","localname":"SeniorSecuritiesCvgPerUnit","presentation":{"http://xbrl.sec.gov/cef/role/N2"} },"lang":{"en-us":{"role":{"label":"Senior Securities Coverage per Unit"} } },"auth_ref":{"r881"} },"cef_SeniorSecuritiesHeadingsNoteTextBlock":{"xbrltype":"textBlockItemType","nsuri":"http://xbrl.sec.gov/cef/2023","localname":"SeniorSecuritiesHeadingsNoteTextBlock","presentation":{"http://xbrl.sec.gov/cef/role/N2"} },"lang":{"en-us":{"role":{"label":"Senior Securities Headings, Note [Text Block]"} } },"auth_ref":{"r886"} },"cef_SeniorSecuritiesHighlightsAnnualizedNoteTextBlock":{"xbrltype":"textBlockItemType","nsuri":"http://xbrl.sec.gov/cef/2023","localname":"SeniorSecuritiesHighlightsAnnualizedNoteTextBlock","presentation":{"http://xbrl.sec.gov/cef/role/N2"} },"lang":{"en-us":{"role":{"label":"Senior Securities Highlights Annualized, Note [Text Block]"} } },"auth_ref":{"r877","r884"} },"cef_SeniorSecuritiesHighlightsAuditedNoteTextBlock":{"xbrltype":"textBlockItemType","nsuri":"http://xbrl.sec.gov/cef/2023","localname":"SeniorSecuritiesHighlightsAuditedNoteTextBlock","presentation":{"http://xbrl.sec.gov/cef/role/N2"} },"lang":{"en-us":{"role":{"label":"Senior Securities Highlights Audited, Note [Text Block]"} } },"auth_ref":{"r878","r884"} },"cef_SeniorSecuritiesInvoluntaryLiquidatingPreferencePerUnit":{"xbrltype":"perShareItemType","nsuri":"http://xbrl.sec.gov/cef/2023","localname":"SeniorSecuritiesInvoluntaryLiquidatingPreferencePerUnit","presentation":{"http://xbrl.sec.gov/cef/role/N2"} },"lang":{"en-us":{"role":{"label":"Senior Securities Involuntary Liquidating Preference per Unit (Deprecated 2023-01-31)"} } },"auth_ref":{"r882"} },"cef_SeniorSecuritiesNoteTextBlock":{"xbrltype":"textBlockItemType","nsuri":"http://xbrl.sec.gov/cef/2023","localname":"SeniorSecuritiesNoteTextBlock","presentation":{"http://xbrl.sec.gov/cef/role/N2"} },"lang":{"

"en-us": {"role": {"label": "Senior Securities Note [Text Block]" } } }, "auth_ref": {"r876": {"r884": {"cef_SeniorSecuritiesTableTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "SeniorSecuritiesTableTextBlock", "presentation": {"http://xbrl.sec.gov/cef/role/N2": {"lang": {"en-us": {"role": {"label": "Senior Securities [Table Text Block]" } } }, "auth_ref": {"r879": {"us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": {"http://xbrl.sec.gov/cef/role/AwardTimingDisclosure": {"lang": {"en-us": {"role": {"terseLabel": "All Award Types", "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": {"r320": {"r321": {"r322": {"r323": {"r324": {"r325": {"r326": {"r327": {"r328": {"r329": {"r330": {"r331": {"r332": {"r333": {"r334": {"r335": {"r336": {"r337": {"r338": {"r339": {"r340": {"r341": {"r342": {"r343": {"r344": {"r345": {"us-gaap_SharePrice": {"xbrltype": "xbrltype", "perShareItem": {"nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharePrice", "presentation": {"http://xbrl.sec.gov/cef/role/N2": {"lang": {"en-us": {"role": {"label": "Share Price", "documentation": "Price of a single share of a number of saleable stocks of a company." } } }, "auth_ref": {"cef_SharePriceTableTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "SharePriceTableTextBlock", "presentation": {"http://xbrl.sec.gov/cef/role/N2": {"lang": {"en-us": {"role": {"label": "Share Price [Table Text Block]" } } }, "auth_ref": {"r895": {"cef_SharePricesNotActualTransactionsTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "SharePricesNotActualTransactionsTextBlock", "presentation": {"http://xbrl.sec.gov/cef/role/N2": {"lang": {"en-us": {"role": {"label": "Share Prices Not Actual Transactions [Text Block]" } } }, "auth_ref": {"r896": {"cef_ShareholderTransactionExpensesTableTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "ShareholderTransactionExpensesTableTextBlock", "presentation": {"http://xbrl.sec.gov/cef/role/N2": {"lang": {"en-us": {"role": {"label": "Shareholder Transaction Expenses [Table Text Block]" } } }, "auth_ref": {"r860": {"ocsl_ShortTermCapitalLossCarryforwardMember": {"xbrltype": "domainItemType", "nsuri": "http://ocsl.com/20240630", "localname": "ShortTermCapitalLossCarryforwardMember", "presentation": {"http://ocsl.com/role/20240630": {"lang": {"en-us": {"role": {"terseLabel": "Short-Term Capital Loss Carryforward", "label": "Short-Term Capital Loss Carryforward [Member]", "documentation": "Short-Term Capital Loss Carryforward" } } }, "auth_ref": {"us-gaap_SignificantAccountingPoliciesTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": {"http://ocsl.com/role/SignificantAccountingPolicies": {"lang": {"en-us": {"role": {"terseLabel": "Significant Accounting Policies", "label": "Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": {"r96": {"r159": {"ocsl_SoftDrinksNonAlcoholicBeveragesMember": {"xbrltype": "domainItemType", "nsuri": "http://ocsl.com/20240630", "localname": "SoftDrinksNonAlcoholicBeveragesMember", "presentation": {"http://ocsl.com/role/PortfolioInvestmentsPortfolioInvestmentsbyIndustryDetails": {"lang": {"en-us": {"role": {"terseLabel": "Soft Drinks & Non-alcoholic Beverages", "label": "Soft Drinks & Non-alcoholic Beverages [Member]", "documentation": "Soft Drinks & Non-alcoholic Beverages" } } }, "auth_ref": {"us-gaap_SouthRegionMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SouthRegionMember", "presentation": {"http://ocsl.com/role/PortfolioInvestmentsPortfolioCompositionDetails": {"lang": {"en-us": {"role": {"terseLabel": "South", "label": "US South Region [Member]", "documentation": "Region of United States of America (US) designated as South." } } }, "auth_ref": {"r1067": {"r1071": {"r1074": {"r1077": {"us-gaap_SoutheastRegionMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SoutheastRegionMember", "presentation": {"http://ocsl.com/role/PortfolioInvestmentsPortfolioCompositionDetails": {"lang": {"en-us": {"role": {"terseLabel": "Southeast", "label": "US Southeast Region [Member]", "documentation": "Region of United States of America (US) designated as Southeast." } } }, "auth_ref": {"r1067": {"r1071": {"r1074": {"r1077": {"us-gaap_SouthwestRegionMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SouthwestRegionMember", "presentation": {"http://ocsl.com/role/PortfolioInvestmentsPortfolioCompositionDetails": {"lang": {"en-us": {"role": {"terseLabel": "Southwest", "label": "US Southwest Region [Member]", "documentation": "Region of United States of America (US) designated as Southwest." } } }, "auth_ref": {"r1067": {"r1071": {"r1074": {"r1077": {"ocsl_SpecializedFinanceMember": {"xbrltype": "domainItemType", "nsuri": "http://ocsl.com/20240630", "localname": "SpecializedFinanceMember", "presentation": {"http://ocsl.com/role/PortfolioInvestmentsPortfolioInvestmentsbyIndustryDetails": {"lang": {"en-us": {"role": {"terseLabel": "Specialized Finance", "label": "Specialized Finance [Member]", "documentation": "Specialized Finance" } } }, "auth_ref": {"ocsl_SpecialtyChemicalsMember": {"xbrltype": "domainItemType", "nsuri": "http://ocsl.com/20240630", "localname": "SpecialtyChemicalsMember", "presentation": {"http://ocsl.com/role/PortfolioInvestmentsPortfolioInvestmentsbyIndustryDetails": {"lang": {"en-us": {"role": {"terseLabel": "Specialty Chemicals", "label": "Specialty Chemicals [Member]", "documentation": "Specialty Chemicals" } } }, "auth_ref": {"us-gaap_StatementClassOfStockAxis": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": {"http://ocsl.com/role/ShareDataandNetAssetsNarrativeDetails": {"http://xbrl.sec.gov/cef/role/N2": {"lang": {"en-us": {"role": {"label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": {"r132": {"r139": {"r140": {"r141": {"r163": {"r182": {"r183": {"r185": {"r187": {"r192": {"r193": {"r238": {"r257": {"r259": {"r260": {"r261": {"r264": {"r265": {"r296": {"r297": {"r299": {"r302": {"r309": {"r399": {"r502": {"r503": {"r504": {"r505": {"r521": {"r524": {"r526": {"r527": {"r528": {"r529": {"r530": {"r531": {"r532": {"r533": {"r534": {"r536": {"r564": {"r589": {"r620": {"r740": {"r741": {"r742": {"r743": {"r744": {"r668": {"r983": {"r991": {"us-gaap_StatementEquityComponentsAxis": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": {"http://ocsl.com/role/ShareDataandNetAssetsScheduleofChangesinNetAssetsDetails": {"lang": {"en-us": {"role": {"terseLabel": "Equity Components [Axis]", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": {"r11": {"r24": {"r134": {"r147": {"r148": {"r149": {"r167": {"r168": {"r169": {"r171": {"r177": {"r179": {"r189": {"r239": {"r240": {"r310": {"r346": {"r347": {"r348": {"r363": {"r364": {"r378": {"r379": {"r380": {"r381": {"r382": {"r383": {"r386": {"r402": {"r403": {"r404": {"r405": {"r406": {"r407": {"r412": {"r485": {"r486": {"r487": {"r521": {"r620": {"srt_StatementGeographicalAxis": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "StatementGeographicalAxis", "presentation": {"http://ocsl.com/role/PortfolioInvestmentsPortfolioCompositionDetails": {"lang": {"en-us": {"role": {"terseLabel": "Geographical [Axis]", "label": "Geographical [Axis]", "documentation": "Information by geographical area." } } }, "auth_ref": {"r202": {"r203": {"r539": {"r543": {"r545": {"r640": {"r657": {"r679": {"r731": {"r747": {"r750": {"r751": {"r752": {"r753": {"r754": {"r755": {"r756": {"r757": {"r758": {"r763": {"r780": {"r789": {"r1010": {"r1035": {"us-gaap_StatementLineItems": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": {"http://ocsl.com/role/ConsolidatedStatementsofAssetsandLiabilities": {"http://ocsl.com/role/ConsolidatedStatementsofAssetsandLiabilitiesParenthetical": {"http://ocsl.com/role/ConsolidatedStatementsofOperations": {"lang": {"en-us": {"role": {"terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": {"r167": {"r168": {"r169": {"r189": {"r453": {"r493": {"r536": {"r553": {"r557": {"r558": {"r559": {"r560": {"r561": {"r564": {"r567": {"r568": {"r569": {"r570": {"r571": {"r574": {"r575": {"r576": {"r577": {"r579": {"r580": {"r581": {"r582": {"r583": {"r585": {"r593": {"r594": {"r603": {"r604": {"r605": {"r606": {"r607": {"r608": {"r609": {"r610": {"r611": {"r612": {"r613": {"r614": {"r620": {"r791": {"us-gaap_StatementOfCashFlowsAbstract": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "presentation": {"http://us-gaap_StatementOfFinancialPositionAbstract": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "presentation": {"http://us-gaap_StatementOfStockholdersEquityAbstract": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "presentation": {"http://us-gaap_StatementTable": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": {"http://ocsl.com/role/ConsolidatedStatementsofAssetsandLiabilities": {"http://ocsl.com/role/ConsolidatedStatementsofAssetsandLiabilitiesParenthetical": {"http://ocsl.com/role/ConsolidatedStatementsofOperations": {"lang": {"en-us": {"role": {"terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": {"r167": {"r168": {"r169": {"r189": {"r453": {"r493": {"r536": {"r553": {"r557": {"r558": {"r559": {"r560": {"r561": {"r564": {"r567": {"r568": {"r569": {"r570": {"r571": {"r574": {"r575": {"r576": {"r577": {"r579": {"r580": {"r581": {"r582": {"r583": {"r585": {"r593": {"r594": {"r603": {"r604": {"r605": {"r606": {"r607": {"r608": {"r609": {"r610": {"r611": {"r612": {"r613": {"r614": {"r620": {"r791": {"ced_StkPrCsrEstimationMethodTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ced/2023", "localname": "StkPrCsrEstimationMethodTextBlock", "presentation": {"http://xbrl.sec.gov/ced/role/ErrCompDisclosure": {"lang": {"en-us": {"role": {"terseLabel": "Stock Price or TSR Estimation Method", "label": "Stock Price or TSR Estimation Method [Text Block]" } } }, "auth_ref": {"r816": {"r820": {"r909": {"r936": {"us-gaap_StockAppreciationRightsSARSMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockAppreciationRightsSARSMember", "presentation": {"http://xbrl.sec.gov/ced/role/AwardTimingDisclosure": {"lang": {"en-us": {"role": {"terseLabel": "Stock Appreciation Rights (SARs)", "label": "Stock Appreciation Rights (SARs) [Member]", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": {"ocsl_StockIssuedAcquisition": {"xbrltype": "monetaryItemType", "nsuri": "http://ocsl.com/20240630", "localname": "StockIssuedAcquisition", "presentation": {"http://ocsl.com/role/ConsolidatedStatementofCashFlows": {"lang": {"en-us": {"role": {"terseLabel": "Issuance of shares in connection with the OS12 Merger", "label": "Stock Issued, Acquisition", "documentation": "Stock Issued, Acquisition" } } }, "auth_ref": {"ocsl_StockIssuedDividendReinvestmentPlan": {"xbrltype": "monetaryItemType", "nsuri": "http://ocsl.com/20240630", "localname": "StockIssuedDividendReinvestmentPlan", "presentation": {"http://ocsl.com/role/ConsolidatedStatementofCashFlows": {"lang": {"en-us": {"role": {"terseLabel": "Issuance of common stock under dividend reinvestment plan", "label": "Stock Issued, Dividend Reinvestment Plan", "documentation": "Stock Issued, Dividend Reinvestment Plan" } } }, "auth_ref": {"us-gaap_StockIssuedDuringPeriodSharesAcquisitions": {"xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesAcquisitions", "presentation": {"http://ocsl.com/role/ShareDataandNetAssetsScheduleofChangesinNetAssetsDetails": {"lang": {"en-us": {"role": {"terseLabel": "Issuance of common stock in connection with the OS12 Merger (in shares)", "label": "Stock Issued During Period, Shares, Acquisitions", "documentation": "Number of shares of stock issued during the period pursuant to acquisitions." } } }, "auth_ref": {"us-gaap_StockIssuedDuringPeriodSharesDividendReinvestmentPlan": {"xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesDividendReinvestmentPlan", "presentation": {"http://ocsl.com/role/ShareDataandNetAssetsNarrativeDetails": {"http://ocsl.com/role/ShareDataandNetAssetsScheduleofChangesinNetAssetsDetails": {"http://ocsl.com/role/ShareDataandNetAssetsScheduleofDistributionsDetails": {"lang": {"en-us": {"role": {"terseLabel": "Issuance of common stock under dividend reinvestment plan (in shares)", "label": "DRIPu00a0Shares Issued (in shares)", "documentation": "Number of shares issued during the period from a dividend reinvestment plan (DRIP). A dividend reinvestment plan allows the shareholders to reinvest dividends paid to them by the entity on new issues of stock by the entity." } } }, "auth_ref": {"r11": {"r620": {"r742": {"us-gaap_StockIssuedDuringPeriodSharesNewIssues": {"xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": {"http://ocsl.com/role/ShareDataandNetAssetsScheduleofChangesinNetAssetsDetails": {"lang": {"en-us": {"role": {"terseLabel": "Issuance of common stock in connection with the 'at the market' offering (in shares)", "label": "Stock Issued During Period, Shares, New Issues", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": {"r11": {"r78": {"r79": {"r104": {"r502": {"r620": {"r741": {"us-gaap_StockIssuedDuringPeriodValueAcquisitions": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueAcquisitions", "presentation": {"http://ocsl.com/role/ConsolidatedStatementsofChangesinNetAssets": {"parentTag": "ocsl_InvestmentCompanyCapitalShareTransactionsIncreaseDecrease", "weight": 1.0, "order": 1.0, "presentation": {"http://ocsl.com/role/ConsolidatedStatementsofChangesinNetAssets": {"http://ocsl.com/role/ShareDataandNetAssetsScheduleofChangesinNetAssetsDetails": {"lang": {"en-us": {"role": {"terseLabel": "Issuance of common stock in connection with the OS12 Merger", "label": "Stock Issued During Period, Value, Acquisitions", "documentation": "Value of stock issued pursuant to acquisitions during the period." } } }, "auth_ref": {"r11": {"r24": {"r104": {"us-gaap_StockIssuedDuringPeriodValueDividendReinvestmentPlan": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueDividendReinvestmentPlan", "presentation": {"http://ocsl.com/role/ConsolidatedStatementsofChangesinNetAssets": {"parentTag": "ocsl_InvestmentCompanyCapitalShareTransactionsIncreaseDecrease", "weight": 1.0, "order": 3.0, "presentation": {"http://ocsl.com/role/ConsolidatedStatementsofChangesinNetAssets": {"http://ocsl.com/role/ShareDataandNetAssetsScheduleofDistributionsDetails": {"lang": {"en-us": {"role": {"terseLabel": "Issuance of common stock under dividend reinvestment plan", "label": "DRIPu00a0Shares Value", "documentation": "Value of stock issued during the period from a dividend reinvestment plan (DRIP). A dividend reinvestment plan allows the holder of the stock to reinvest dividends paid to them by the entity on new issues of stock by the entity." } } }, "auth_ref": {"r11": {"r521":

```

"r620": "r742", "r790": "r803" }}, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "calculation": { "http://ocsl.com/role/ConsolidatedStatementsOfChangesInNetAssets": { "parentTag": "ocsl_InvestmentCompanyCapitalShareTransactionsIncreaseDecrease", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://ocsl.com/role/ConsolidatedStatementsOfChangesInNetAssets": { "http://ocsl.com/role/ShareDataandNetAssetsScheduleofChangesinNetAssetsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock in connection with the \"at the market\" offering", "label": "Stock Issued During Period, Value, New Issues", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": { "r11": "r78", "r79": "r104", "r521": "r620", "r741": "r803" } }, "us-gaap_StockRepurchasedDuringPeriodShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRepurchasedDuringPeriodShares", "presentation": { "http://ocsl.com/role/ShareDataandNetAssetsScheduleofChangesinNetAssetsDetails": { "lang": { "en-us": { "role": { "negatedTerseLabel": "Repurchase of common stock under dividend reinvestment plan (in shares)", "label": "Stock Repurchased During Period, Shares", "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock." } } }, "auth_ref": { "r11": "r78", "r79": "r104", "r505": "r620", "r743": { "us-gaap_StockRepurchasedDuringPeriodValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRepurchasedDuringPeriodValue", "crdr": "debit", "calculation": { "http://ocsl.com/role/ConsolidatedStatementsOfChangesinNetAssets": { "parentTag": "ocsl_InvestmentCompanyCapitalShareTransactionsIncreaseDecrease", "weight": -1.0, "order": 4.0 } }, "presentation": { "http://ocsl.com/role/ConsolidatedStatementsOfChangesinNetAssets": { "http://ocsl.com/role/ShareDataandNetAssetsScheduleofChangesinNetAssetsDetails": { "lang": { "en-us": { "role": { "negatedTerseLabel": "Repurchase of common stock under dividend reinvestment plan", "label": "Stock Repurchased During Period, Value", "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock." } } }, "auth_ref": { "r11": "r78", "r79": "r104", "r521": "r620", "r743", "r803" } } }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://ocsl.com/role/ConsolidatedStatementsOfAssetsandLiabilities": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://ocsl.com/role/ConsolidatedStatementsOfAssetsandLiabilities": { "http://ocsl.com/role/ConsolidatedStatementsOfChangesinNetAssets": { "http://ocsl.com/role/ShareDataandNetAssetsScheduleofChangesinNetAssetsDetails": { "lang": { "en-us": { "role": { "totalLabel": "Total net assets (equivalent to $18.19 and $19.63 per common share as of June 30, 2024 and September 30, 2023, respectively) (Note 1)", "periodStartLabel": "Net assets at beginning of period", "periodEndLabel": "Net assets at end of period", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": { "r79": "r82", "r83": "r98", "r566": "r584", "r622": "r623", "r785": "r804", "r986": "r1001", "r1018": "r1064" } }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityAbstract", "presentation": { "http://ocsl.com/role/ConsolidatedStatementsOfAssetsandLiabilities": { "lang": { "en-us": { "role": { "terseLabel": "Net assets", "label": "Equity, Attributable to Parent [Abstract]", "auth_ref": { "us-gaap_StockholdersEquityNoteAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteAbstract", "lang": { "en-us": { "role": { "label": "Stockholders' Equity Note [Abstract]", "auth_ref": { "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": { "http://ocsl.com/role/ShareDataandNetAssets": { "lang": { "en-us": { "role": { "terseLabel": "Share Data and Net Assets", "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": { "r101": "r161", "r295": "r297", "r298": "r299", "r300": "r301", "r302": "r303", "r304": "r305", "r306": "r308", "r310": "r385", "r624": "r626", "r745" } } }, "us-gaap_StockholdersEquityNoteStockSplitConversionRatio": { "xbrltype": "pureItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteStockSplitConversionRatio", "presentation": { "http://ocsl.com/role/ConsolidatedStatementsOfChangesinNetAssets": { "http://ocsl.com/role/ConsolidatedStatementsOfOperations": { "http://ocsl.com/role/FinancialHighlightsDetails": { "http://ocsl.com/role/ShareDataandNetAssetsNarrativeDetails": { "http://ocsl.com/role/SignificantAccountingPoliciesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Stock split, conversion ratio", "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio", "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one." } } }, "auth_ref": { "r18" } }, "us-gaap_StockholdersEquityPeriodIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityPeriodIncreaseDecrease", "calculation": { "http://ocsl.com/role/ConsolidatedStatementsOfChangesinNetAssets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://ocsl.com/role/ConsolidatedStatementsOfChangesinNetAssets": { "lang": { "en-us": { "role": { "totalLabel": "Total increase (decrease) in net assets", "label": "Stockholders' Equity, Period Increase (Decrease)", "documentation": "The increase (decrease) in stockholders' equity during the period." } } }, "auth_ref": { "r11": "r104", "r621": "r744", "r803": "r1038" } } }, "us-gaap_SubordinatedDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubordinatedDebtMember", "presentation": { "http://ocsl.com/role/PortfolioInvestmentsSignificantUnobservableInputsforLevel3InvestmentsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Subordinated Debt", "label": "Subordinated Debt [Member]", "documentation": "This element represents domestic or foreign subordinated debt. Subordinated debt has a lower priority of repayment in liquidation of the entity's assets." } } }, "auth_ref": { "us-gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventLineItems", "presentation": { "http://ocsl.com/role/SubsequentEventsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event [Line Items]", "label": "Subsequent Event [Line Items]", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } } }, "auth_ref": { "r408": "r420" } }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventMember", "presentation": { "http://ocsl.com/role/RelatedPartyTransactionsDetails": { "http://ocsl.com/role/SubsequentEventsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": { "r408": "r420" } }, "us-gaap_SubsequentEventTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTable", "presentation": { "http://ocsl.com/role/SubsequentEventsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event [Table]", "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued." } } }, "auth_ref": { "r408": "r420" } }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeAxis", "presentation": { "http://ocsl.com/role/RelatedPartyTransactionsDetails": { "http://ocsl.com/role/SubsequentEventsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Axis]", "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": { "r408": "r420" } }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeDomain", "presentation": { "http://ocsl.com/role/RelatedPartyTransactionsDetails": { "http://ocsl.com/role/SubsequentEventsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Domain]", "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": { "r408": "r420" } }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]", "auth_ref": { "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsTextBlock", "presentation": { "http://ocsl.com/role/SubsequentEvents": { "lang": { "en-us": { "role": { "terseLabel": "Subsequent Events", "label": "Subsequent Events [Text Block]", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": { "r419": "r421" } }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsidiarySaleOfStockAxis", "presentation": { "http://ocsl.com/role/ShareDataandNetAssetsNarrativeDetails": { "http://ocsl.com/role/ShareDataandNetAssetsScheduleofCommonStockIssuedandSoldDetails": { "lang": { "en-us": { "role": { "terseLabel": "Sale of Stock [Axis]", "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": { "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalCashFlowInformationAbstract", "presentation": { "http://ocsl.com/role/ConsolidatedStatementofCashFlows": { "lang": { "en-us": { "role": { "terseLabel": "Supplemental information", "label": "Supplemental Cash Flow Information [Abstract]", "auth_ref": { "ocsl_SyndicatedFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://ocsl.com/20240630", "localname": "SyndicatedFacilityMember", "presentation": { "http://ocsl.com/role/BorrowingsNarrativeDetails": { "http://ocsl.com/role/PortfolioInvestmentsScheduleofFinancialInstrumentsDisclosedbutCarriedatFairValueDetails": { "http://xbrl.sec.gov/cef/role/N2": { "lang": { "en-us": { "role": { "terseLabel": "Syndicated Facility payable", "label": "Syndicated Facility [Member]", "documentation": "Syndicated Facility" } } }, "auth_ref": { "ocsl_SystemsSoftwareMember": { "xbrltype": "domainItemType", "nsuri": "http://ocsl.com/20240630", "localname": "SystemsSoftwareMember", "presentation": { "http://ocsl.com/role/PortfolioInvestmentsPortfolioofInvestmentsbyIndustryDetails": { "lang": { "en-us": { "
```


presentation": f"http://ocsl.com/role/RealizedGainsLossesandNetUnrealizedAppreciationorDepreciationAggregateNetRealizedGainsDetails" l,"lang": f"en-us": f"role": f"terseLabel": "Thrasio, LLC" l,"label": "Thrasio, LLC [Member]", "documentation": "Thrasio, LLC" } } }, "auth_ref": f"cf.TotalAnnualExpensesPercent" f"xlbrtype": "percentItem" f"nsuri": "http://xbrl.sec.gov/cecf/2023" f"localname": "TotalAnnualExpensesPercent" f"presentation": f"http://xbrl.sec.gov/cecf/role/N2" l,"lang": f"en-us": f"role": f"label": "Total Annual Expenses [Percent]" } } }, "auth_ref": f"r873" l,"ecd.TotalShareholderRtnAmt": f"xlbrtype": "monetaryItemType" f"nsuri": "http://xbrl.sec.gov/ecd/2023" f"localname": "TotalShareholderRtnAmt" f"presentation": f"http://xbrl.sec.gov/ecd/role/PvpDisclosure" l,"lang": f"en-us": f"role": f"terseLabel": "Total Shareholder Return Amount" l,"label": "Total Shareholder Return Amount" } } }, "auth_ref": f"r923" l,"ecd.TotalShareholderRtnVsPeerGroupTextBlock": f"xlbrtype": "textBlockItemType" f"nsuri": "http://xbrl.sec.gov/ecd/2023" f"localname": "TotalShareholderRtnVsPeerGroupTextBlock" f"presentation": f"http://xbrl.sec.gov/ecd/role/PvpDisclosure" l,"lang": f"en-us": f"role": f"terseLabel": "Total Shareholder Return Vs Peer Group" l,"label": "Total Shareholder Return Vs Peer Group [Text Block]" } } }, "auth_ref": f"r929" l,"ecd.TradingArrAxis": f"xlbrtype": "stringItemType" f"nsuri": "http://xbrl.sec.gov/ecd/2023" f"localname": "TradingArrAxis" f"presentation": f"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" l,"lang": f"en-us": f"role": f"terseLabel": "Trading Arrangement" l,"label": "Trading Arrangement [Axis]" } } }, "auth_ref": f"r949" l,"ecd.TradingArrByIndTable": f"xlbrtype": "stringItem" f"nsuri": "http://xbrl.sec.gov/ecd/2023" f"localname": "TradingArrByIndTable" f"presentation": f"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" l,"lang": f"en-us": f"role": f"terseLabel": "Trading Arrangements by Individual" l,"label": "Trading Arrangements by Individual [Table]" } } }, "auth_ref": f"r951" l,"dei.TradingSymbol": f"xlbrtype": "tradingSymbolItemType" f"nsuri": "http://xbrl.sec.gov/dei/2023" f"localname": "TradingSymbol" f"presentation": f"http://ocsl.com/role/Cover" l,"lang": f"en-us": f"role": f"label": "Trading Symbol" l,"terseLabel": "Trading Symbol" l,"documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": f"us-gaap.TransfersAndServicingOffFinancialInstrumentsTypesOffFinancialInstrumentsDomain" f"xlbrtype": "domainItemType" f"nsuri": "http://fasb.org/us-gaap/2023" f"localname": "TransfersAndServicingOffFinancialInstrumentsTypesOffFinancialInstrumentsDomain" f"presentation": f"http://ocsl.com/role/PortfolioInvestmentsCompositionofInvestmentsDetails" f"http://ocsl.com/role/PortfolioInvestmentsNarrativeDetails" f"http://ocsl.com/role/PortfolioInvestmentsScheduleofFinancialInstrumentsCarriedatFairValueDetails" f"http://ocsl.com/role/PortfolioInvestmentsScheduleofFinancialInstrumentsDisclosedbutCarriedatFairValueDetails" f"http://ocsl.com/role/PortfolioInvestmentsSignificantUnobservableInputsforLevel3InvestmentsDetails" f"http://ocsl.com/role/SignificantAccountingPoliciesDetails" l,"lang": f"en-us": f"role": f"terseLabel": "Financial Instruments [Domain]" l,"label": "Financial Instruments [Domain]" l,"documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": f"r205" f"r206" f"r207" f"r208" f"r209" f"r210" f"r211" f"r212" f"r213" f"r214" f"r215" f"r216" f"r217" f"r218" f"r219" f"r220" f"r221" f"r222" f"r223" f"r224" f"r225" f"r226" f"r227" f"r228" f"r229" f"r230" f"r231" f"r232" f"r233" f"r234" f"r291" f"r307" f"r384" f"r422" f"r423" f"r424" f"r425" f"r426" f"r427" f"r428" f"r429" f"r430" f"r431" f"r432" f"r433" f"r434" f"r435" f"r436" f"r437" f"r438" f"r439" f"r440" f"r441" f"r442" f"r443" f"r444" f"r445" f"r446" f"r447" f"r448" f"r449" f"r450" f"r451" f"r476" f"r971" f"r972" f"r973" f"r974" f"r975" f"r976" f"r977" f"r997" f"r998" f"r999" f"1000" l,"ecd.TrdArrAdoptionDate": f"xlbrtype": "stringItemType" f"nsuri": "http://xbrl.sec.gov/ecd/2023" f"localname": "TrdArrAdoptionDate" f"presentation": f"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" l,"lang": f"en-us": f"role": f"terseLabel": "Adoption Date" l,"label": "Trading Arrangement Adoption Date" } } }, "auth_ref": f"r952" l,"ecd.TrdArrDuration": f"xlbrtype": "durationItemType" f"nsuri": "http://xbrl.sec.gov/ecd/2023" f"localname": "TrdArrDuration" f"presentation": f"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" l,"lang": f"en-us": f"role": f"terseLabel": "Arrangement Duration" l,"label": "Trading Arrangement Duration" } } }, "auth_ref": f"r953" l,"ecd.TrdArrIndName": f"xlbrtype": "stringItemType" f"nsuri": "http://xbrl.sec.gov/ecd/2023" f"localname": "TrdArrIndName" f"presentation": f"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" l,"lang": f"en-us": f"role": f"terseLabel": "Name" l,"label": "Trading Arrangement Individual Name" } } }, "auth_ref": f"r951" l,"ecd.TrdArrIndTitle": f"xlbrtype": "stringItemType" f"nsuri": "http://xbrl.sec.gov/ecd/2023" f"localname": "TrdArrIndTitle" f"presentation": f"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" l,"lang": f"en-us": f"role": f"terseLabel": "Title" l,"label": "Trading Arrangement Individual Title" } } }, "auth_ref": f"r951" l,"ecd.TrdArrSecuritiesAggAvailAmt": f"xlbrtype": "sharesItemType" f"nsuri": "http://xbrl.sec.gov/ecd/2023" f"localname": "TrdArrSecuritiesAggAvailAmt" f"presentation": f"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" l,"lang": f"en-us": f"role": f"terseLabel": "Aggregate Available" l,"label": "Trading Arrangement Securities Aggregate Available Amount" } } }, "auth_ref": f"r954" l,"ecd.TrdArrTerminationDate": f"xlbrtype": "stringItemType" f"nsuri": "http://xbrl.sec.gov/ecd/2023" f"localname": "TrdArrTerminationDate" f"presentation": f"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" l,"lang": f"en-us": f"role": f"terseLabel": "Termination Date" l,"label": "Trading Arrangement Termination Date" } } }, "auth_ref": f"r952" l,"us-gaap.UnamortizedDebtIssuanceExpense": f"xlbrtype": "monetaryItemType" f"nsuri": "http://fasb.org/us-gaap/2023" f"localname": "UnamortizedDebtIssuanceExpense" f"crdr": "debit" f"calculation": f"http://ocsl.com/role/BorrowingsComponentsoftheCarryingValueofNotesDetails" f"parentTag": "us-gaap.LongTermDebt" f"weight": 1.0 f"order": 4.0 l,"presentation": f"http://ocsl.com/role/BorrowingsComponentsoftheCarryingValueofNotesDetails" f"http://ocsl.com/role/ConsolidatedStatementsOfAssetsandLiabilitiesParentetical" l,"lang": f"en-us": f"role": f"terseLabel": "Unamortized financing costs" l,"negatedTerseLabel": "Unamortized financing costs" l,"label": "Unamortized Debt Issuance Expense" l,"documentation": "The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset." } } }, "auth_ref": f"cf.UnderwritersCompensationPercent" f"xlbrtype": "percentItemType" f"nsuri": "http://xbrl.sec.gov/cecf/2023" f"localname": "UnderwritersCompensationPercent" f"presentation": f"http://xbrl.sec.gov/cecf/role/N2" l,"lang": f"en-us": f"role": f"label": "Underwriters Compensation [Percent]" } } }, "auth_ref": f"r869" l,"ecd.UndrlygSecurityMktPriceChngPct": f"xlbrtype": "pureItemType" f"nsuri": "http://xbrl.sec.gov/ecd/2023" f"localname": "UndrlygSecurityMktPriceChngPct" f"presentation": f"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" l,"lang": f"en-us": f"role": f"terseLabel": "Underlying Security Market Price Change" l,"label": "Underlying Security Market Price Change, Percent" } } }, "auth_ref": f"r948" l,"us-gaap.UnrealizedGainLossInvestmentAndDerivativeOperatingBeforeTax": f"xlbrtype": "monetaryItemType" f"nsuri": "http://fasb.org/us-gaap/2023" f"localname": "UnrealizedGainLossInvestmentAndDerivativeOperatingBeforeTax" f"crdr": "credit" f"calculation": f"http://ocsl.com/role/ConsolidatedStatementsOfOperations" f"parentTag": "us-gaap.RealizedandUnrealizedGainLossInvestmentDerivativeandForeignCurrencyTransactionOperatingAfterTax" f"weight": 1.0 f"order": 2.0 l,"http://ocsl.com/role/ConsolidatedStatementsOfChangesinNetAssets": f"parentTag": "us-gaap.NetIncomeLoss" f"weight": 1.0 f"order": 2.0 l,"http://ocsl.com/role/ConsolidatedStatementofCashFlows": f"parentTag": "us-gaap.NetCashProvidedByUsedinOperatingActivities" f"weight": 1.0 f"order": 10.0 l,"presentation": f"http://ocsl.com/role/ConsolidatedStatementofCashFlows" f"http://ocsl.com/role/ConsolidatedStatementsOfChangesinNetAssets" f"http://ocsl.com/role/ConsolidatedStatementsOfOperations" l,"lang": f"en-us": f"role": f"totalLabel": "Net unrealized appreciation (depreciation)" l,"label": "Net unrealized appreciation (depreciation)" l,"terseLabel": "Net unrealized appreciation (depreciation)" l,"documentation": "Amount, before tax, of unrealized gain (loss) from investment and derivative, classified as operating. Investment includes, but is not limited to, debt and equity securities, security sold short, real estate, and commodity." } } }, "auth_ref": f"r587" f"r746" f"r802" f"r1061" l,"us-gaap.UnrealizedGainLossOnDerivatives": f"xlbrtype": "monetaryItemType" f"nsuri": "http://fasb.org/us-gaap/2023" f"localname": "UnrealizedGainLossOnDerivatives" f"crdr": "credit" f"calculation": f"http://ocsl.com/role/ConsolidatedStatementsOfOperations" f"parentTag": "us-gaap.UnrealizedGainLossInvestmentAndDerivativeOperatingBeforeTax" f"weight": 1.0 f"order": 2.0 l,"presentation": f"http://ocsl.com/role/ConsolidatedStatementsOfOperations" l,"lang": f"en-us": f"role": f"terseLabel": "Foreign currency forward contracts" l,"label": "Unrealized Gain (Loss) on Derivatives" l,"documentation": "The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period." } } }, "auth_ref": f"r6" f"r611" f"r612" f"r613" f"r614" f"r689" l,"us-gaap.UnsecuredDebt": f"xlbrtype": "monetaryItemType" f"nsuri": "http://fasb.org/us-gaap/2023" f"localname": "UnsecuredDebt" f"crdr": "credit" f"calculation": f"http://ocsl.com/role/ConsolidatedStatementsOfAssetsandLiabilities" f"parentTag": "us-gaap.Liabilities" f"weight": 1.0 f"order": 1.0 l,"presentation": f"http://ocsl.com/role/ConsolidatedStatementsOfAssetsandLiabilities" l,"lang": f"en-us": f"role": f"terseLabel": "Unsecured notes payable (net of \$5,468 and \$7,076 of unamortized financing costs as of June 30, 2024 and September 30, 2023, respectively)" l,"label": "Unsecured Debt" l,"documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of uncollateralized debt obligations (with maturities initially due after one year or beyond the operating cycle if longer)" } } }, "auth_ref": f"r17" f"r113" f"r1032" l,"ocsl.UnsettledInvestmentTransactionsPolicyTextBlock": f"xlbrtype": "textBlockItemType" f"nsuri": "http://ocsl.com/20240630" f"localname": "UnsettledInvestmentTransactionsPolicyTextBlock" f"presentation": f"http://ocsl.com/


```
{ "xbrlType": "domainItemType", "nsuri": "http://ocsl.com/20240630", "localname": "WPCPPHoldingsLLCMember", "presentation": [ { "http://ocsl.com/role/RealizedGainsOrLossesandNetUnrealizedAppreciationorDepreciationAggregateNetRealizedGainsDetails": { "lang": { "en-us": { "role": { "terseLabel": "WP CPP Holdings LLC", "label": "WP CPP Holdings LLC Member", "documentation": "W P C P P Holdings L L C"} } }, "auth ref": { "cecfWaiversAndReimbursementsOfFeesPercent": { "xbrlType": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "WaiversAndReimbursementsOfFeesPercent", "presentation": { "http://xbrl.sec.gov/cef/role/N2": { "lang": { "en-us": { "role": { "label": "Waivers and Reimbursements of Fees [Percent]" } } }, "auth ref": { "r874": { "cecfWarrantsOrRightsCalledAmount": { "xbrlType": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "WarrantsOrRightsCalledAmount", "presentation": { "http://xbrl.sec.gov/cef/role/N2": { "lang": { "en-us": { "role": { "label": "Warrants or Rights Called Amount" } } }, "auth ref": { "r854": { "cecfWarrantsOrRightsCalledPeriodDate": { "xbrlType": "dateItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "WarrantsOrRightsCalledPeriodDate", "presentation": { "http://xbrl.sec.gov/cef/role/N2": { "lang": { "en-us": { "role": { "label": "Warrants or Rights Called Period [Date]" } } }, "auth ref": { "r854": { "cecfWarrantsOrRightsCalledTitleTextBlock": { "xbrlType": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "WarrantsOrRightsCalledTitleTextBlock", "presentation": { "http://xbrl.sec.gov/cef/role/N2": { "lang": { "en-us": { "role": { "label": "Warrants or Rights Called Title" } } }, "auth ref": { "r854": { "cecfWarrantsOrRightsExercisePrice": { "xbrlType": "perShareItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "WarrantsOrRightsExercisePrice", "presentation": { "http://xbrl.sec.gov/cef/role/N2": { "lang": { "en-us": { "role": { "label": "Warrants or Rights Exercise Price" } } }, "auth ref": { "r854": { "scrtWeightedAverageMember": { "xbrlType": "domainItemType", "nsuri": "http://fasb.org/serf/2023", "localname": "WeightedAverageMember", "presentation": { "http://ocsl.com/role/PortfolioInvestmentsSummaryofPortfolioDetails": { "lang": { "en-us": { "role": { "terseLabel": "Weighted Average", "label": "Weighted Average [Member]" } } }, "auth ref": { "r760": { "us-gaap-WeightedAverageNumberofDilutedSharesOutstanding": { "xbrlType": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberofDilutedSharesOutstanding", "presentation": { "http://ocsl.com/role/ConsolidatedStatementsofOperations": { "http://ocsl.com/role/ShareDataandNetAssetsScheduledofBasicandDilutedEarningsPerShareDetails": { "lang": { "en-us": { "role": { "terseLabel": "Weighted average common shares outstanding - diluted (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth ref": { "r181": { "us-gaap-WeightedAverageNumberofSharesOutstandingBasic": { "xbrlType": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberofSharesOutstandingBasic", "presentation": { "http://ocsl.com/role/ShareDataandNetAssetsScheduledofBasicandDilutedEarningsPerShareDetails": { "lang": { "en-us": { "role": { "terseLabel": "Weighted average common shares outstanding - basic (in shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth ref": { "r180": { "us-gaap-WeightedAverageNumberofSharesOutstandingDilutedDisclosureItemsAbstract": { "xbrlType": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberofSharesOutstandingDilutedDisclosureItemsAbstract", "presentation": { "http://ocsl.com/role/ShareDataandNetAssetsScheduledofBasicandDilutedEarningsPerShareDetails": { "lang": { "en-us": { "role": { "terseLabel": "Earnings (loss) per common share \u2014 basic and diluted", "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]" } } }, "auth ref": { "ocslWellsFargoBankNAMember": { "xbrlType": "domainItemType", "nsuri": "http://ocsl.com/20240630", "localname": "WellsFargoBankNAMember", "presentation": { "http://ocsl.com/role/SignificantAccountingPoliciesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Wells Fargo Bank, N.A.", "label": "Wells Fargo Bank, N.A. [Member]", "documentation": "Wells Fargo Bank, N.A." } } }, "auth ref": { "us-gaap-WestRegionMember": { "xbrlType": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WestRegionMember", "presentation": { "http://ocsl.com/role/PortfolioInvestmentsPortfolioCompositionDetails": { "lang": { "en-us": { "role": { "terseLabel": "West", "label": "US West Region [Member]", "documentation": "Region of United States of America (US) designated as West." } } }, "auth ref": { "r1077": { "ocslWirelessTelecommunicationServicesMember": { "xbrlType": "domainItemType", "nsuri": "http://ocsl.com/20240630", "localname": "WirelessTelecommunicationServicesMember", "presentation": { "http://ocsl.com/role/PortfolioInvestmentsPortfolioInvestmentsbyIndustryDetails": { "lang": { "en-us": { "role": { "terseLabel": "Wireless Telecommunication Services", "label": "Wireless Telecommunication Services [Member]", "documentation": "Wireless Telecommunication Services" } } }, "auth ref": { "ocslZephyrBidcoLimitedMember": { "xbrlType": "domainItemType", "nsuri": "http://ocsl.com/20240630", "localname": "ZephyrBidcoLimitedMember", "presentation": { "http://ocsl.com/role/RealizedGainsOrLossesandNetUnrealizedAppreciationorDepreciationAggregateNetRealizedGainsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Zephyr Bidco Limited", "label": "Zephyr Bidco Limited [Member]", "documentation": "Zephyr Bidco Limited" } } }, "auth ref": { "stdRef": { "r0": { "role": { "http://fasb.org/us-gaap/role/ref/legacyRef": { "Name": "Accounting Standards Codification", "Section": "15", "Paragraph": "12", "Subparagraph": "(f)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481410/810-10-15-12"}, "r1": { "role": { "http://fasb.org/us-gaap/role/ref/legacyRef": { "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"}, "r2": { "role": { "http://fasb.org/us-gaap/role/ref/legacyRef": { "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "59", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-59"}, "r3": { "role": { "http://fasb.org/us-gaap/role/ref/legacyRef": { "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481877/830-230-45-1"}, "r4": { "role": { "http://fasb.org/us-gaap/role/ref/legacyRef": { "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"}, "r5": { "role": { "http://fasb.org/us-gaap/role/ref/legacyRef": { "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"}, "r6": { "role": { "http://fasb.org/us-gaap/role/ref/legacyRef": { "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"}, "r7": { "role": { "http://fasb.org/us-gaap/role/ref/legacyRef": { "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "SubTopic": "20", "Topic": "940", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481833/940-20-45-3"}, "r8": { "role": { "http://fasb.org/us-gaap/role/ref/legacyRef": { "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480463/815-10-45-5"}, "r9": { "role": { "http://fasb.org/us-gaap/role/ref/legacyRef": { "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "20", "Topic": "835", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483013/835-20-50-1"}, "r10": { "role": { "http://fasb.org/us-gaap/role/ref/legacyRef": { "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "30", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479910/205-30-50-1"}, "r11": { "role": { "http://fasb.org/us-gaap/role/ref/legacyRef": { "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"}, "r12": { "role": { "http://fasb.org/us-gaap/role/ref/legacyRef": { "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480431/815-10-50-2"}, "r13": { "role": { "http://fasb.org/us-gaap/role/ref/legacyRef": { "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"}, "r14": { "role": { "http://fasb.org/us-gaap/role/ref/legacyRef": { "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"}, "r15": { "role": { "http://fasb.org/us-gaap/role/ref/legacyRef": { "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"}, "r16": { "role": { "http://fasb.org/us-gaap/role/ref/legacyRef": { "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"}, "r17": { "role": { "http://fasb.org/us-gaap/role/ref/legacyRef": { "Name": "Accounting
```

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

"Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fash.org/1943274/2147480032/946-320-S99-2", "r1072": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fash.org/1943274/2147480032/946-320-S99-2", "r1073": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fash.org/1943274/2147480032/946-320-S99-2", "r1074": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))", "Publisher": "FASB", "URI": "https://asc.fash.org/1943274/2147480032/946-320-S99-3", "r1075": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fash.org/1943274/2147480032/946-320-S99-3", "r1076": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fash.org/1943274/2147480032/946-320-S99-3", "r1077": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fash.org/1943274/2147480032/946-320-S99-6", "r1078": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fash.org/1943274/2147480032/946-320-S99-6", "r1079": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column E)(Footnote 6)(a))", "Publisher": "FASB", "URI": "https://asc.fash.org/1943274/2147480032/946-320-S99-6", "r1080": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fash.org/1943274/2147480032/946-320-S99-6", "r1081": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fash.org/1943274/2147481004/946-505-50-1", "r1082": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fash.org/1943274/2147481004/946-505-50-2", "r1083": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fash.org/1943274/2147481004/946-505-50-2", "r1084": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fash.org/1943274/2147481004/946-505-50-2", "r1085": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fash.org/1943274/2147481004/946-505-50-2", "r1086": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "37", "Publisher": "FASB", "URI": "https://asc.fash.org/1943274/2147480228/946-830-45-37", "r1087": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "39", "Publisher": "FASB", "URI": "https://asc.fash.org/1943274/2147480228/946-830-45-39"}, ZIP 02 0001414932-24-000012-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001414932-24-000012-xbrl.zip M4SL#H0 (+RB UB9H+>@%?MV>P<>L-V-H- TRXBK#8S XHM=&WLOSWMVSVBMGN ?@5WIHBKOSUPL+9AKJGZOB/AZA:CKXJZFUFIF EK!M6j0= +ZHNNC#GfS2zRSGtX9fEHLMEFIY#LQ1->I+V/HK-FZBXKAXAW-MO.jPZOXUXJ J3SYVJFHUZ->M-L.I.WJ?7@Q YDE UXG BHO5G MOIS7D4Z#=J33U)JCW^++>G-J.V.9FFO.U2.ZS:MGI5O6UU.M6N#!+6SO.K'3ZZ3.NOUEV>=O=C.XJEUAIQWXL&R=MFO=L=NKA7IW.T|> MC=Mff#5WVLVF+.#ZT: f767EQOF KS.OFOJOKFEJUH&=KF8CBMM MJYIK5 MN0HKURZRUT3PLEH.GI4HXIT 3-T O.77H jO?K.OU=376J52 M-2-Y m-zpOG-yz=:08Q?xUS -JD Wt.-t.6217 >48I MWVCY ESAR4662 WM N7BI+ TATZ=32180KHAY3YS Z-Z->- Wf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mPJ-5IOYO5.MON#.IGH -CYZ=8T=fIEUIQU33.?<KYK1#RR023)=8f MUWXJ M9XSJK 8'B-+L @NO16C.K UCAR7WIXE+f QXOLOQ?<S1 JZ CJY L:(O-M/EY=S96IGNW-GP L?>I2=WOW'H V3Q9M BL_MNA _2BR=VWW2_-#3-.5+ Q1"HNO">H2WE9P+U+L3 Z5ZE<Z5ZG M7%VRKYNQ\$+9DBT6W.80KMZXIL-XL39.YL HS5GY699SJB TVAP9#HEMH M6d(f1371+l5)=O.VE6;l5>6%JT&T(%V5-P=MMVUT.F=XJ1616<&TSY#<&<LTZJUP2P2O5.OLOZ|>.@>O.VIDX<9GBORI?6KSXYZ/UOH IGCF |>+X M & % ! /VP-AHTL?1.18WBLSOO56/8J9|<+1?OWYI=>H8SS3 U ML<H J XM\$W=Y=y IV.X-27)VQJ JK&S5ZRIE 4H U Q>O.PIONE.8 MR BHIIU<3PDNDNM3L 59FUU/YI/IQ TA&G DXIG67 5Y9N%3F/U OIZ.QO M<#A SR6253TG?5&J OG9GL JS WNSZNKOIEY WAQOZY OHKSI5Z MAZ L3EY =>L WT8ZW YIH(YVUEI3+M .#C6 MY N J}>10KIS +>96QEFLE+FO3.C023).JS WYT HW2A?>Y=OGWCZBUO/Q@3 M.W.H9I3Q|=FL07 U=OVL MMX.#(CT(OHQHZMA4 IQH QWGGS h156MN5Ki8I6GWHPIM47IAZZ5AKHFH M5=WZYLV VM6KUUVU.WZ+>(OI6P@CZH? BOQ:>7>WYYAVIOS(E3HOY)>YUHV MI%OSA6STAC(WKBQE?FSKHC=T=K8+YVN %-3#.D9 ULQ.7U9#XB.6+-R M8W17NF9WCK+9UD?DCI?R2=?<3B2 2+K8<=>GUI?6UE7GF<IC UE<+ MAZVP?3>.>M%.HKY777#:#29@:EL?2&UY: 4'AVO. <%=<1-G??PF(INJO MKRFVK+/T JB# KM9V .9'L9\$ ~OO69PR<+!>.YNOW>R(I<I MTFV@9V TKL+S.D=I2..O.1.2W4ARI_XN OKVE M-9-C I3J).Y.B ID_Q-%9%\$&6KGKT TH-HEEDHIY3C4+1.ETZ#%>+7WT?<\$2M)>(BLXPELU M-P.2Q3@Z6YT=-5OG WXCHONFTUIDMC3JTYF.E.G TEIMDO4HXWPZBDPLL 1 MQ7HNVE42KVI3C4W2DWSJF QLO.F6-VHJ9J->HNPZUGU5)W<772?9BOGIL MCF AI&LUF@>+OKXKEG.SRBU3<+!>8Z-R

B2>^KB>^*ZP>4BGY-M15++/-Z-HJY(8%;J^7&P^?>F^YV@D3DZJH83K-99B*9<(4^ON8-HP4D6-MFJ2^D+WD)^IU8&%;>2&->
5M>45N9LD(R>PZA;XKG609@46MKU(8;C.NUFI-M1)6TG>74V5YVH5E=216R;0;#GZJ<3WTH9EV-FS0HL=CN1^E6&H1^F6H1-M5T(Q?>S1V;M(7EC^IDQYX5Q7LP(+T\$Z4VZ?H
H7ZALPM5J15HFYBF+L1E-2-L^D67=IRJ38;1)(9E)F17&9-M.PY+5T15%;(3^N7L=KEFVJ81@J<L^M^Y-2NP9;A=HROE2<+Z.K5GEC-MJCR?
^CK<^INEQ5@>DITSGOQ2.MJRP>9.U@<=JKDC1DS-MJRP>N:59AH@<=HJ<I3^NE^M^A4A+V+N=2^M^L5@<=L^>O5%T7A9:(L.MGI>^>HXZ>+100?@9IEKL)B-^KGU@NP0H%P5+
M05XJ+I^3JL%2K9>^*+2F.K:K4-C:Q:0:A4+99*16=SOR(2^GS@Q:V768;5%6I-MC=0EPU^KPM1+ZJ-A4=9+U;8KYZS;J^U^,M01M1^I^SDP>+Q9FT:2^%
3^7F#U>H6NBWWT7-ZH-R;#ZWC-MD<0K5?#>F/(QZFR3N?)(FK-5>0KHH-RK+<=L-R;#^SAT/K-1AD5G-2=3MO)M=LS#-U-UFL4=RF5L-G
QS="R=C1^5L=JGZV1^A/JC21^@=^%145(K^C4%M#HO/BFH0#,@=5B^5G1#1J(MZ%NO7H;WYI^@2^NT^5JZ&V^RK-UN1-BPS&XC)+V27QH.Z6EW1-N/IP=
ML^S-IAJPI&P@-I^V1>N>22C+^%258.YDK&ZWWT^R&L>@.6J^TP^H<70.6MQ&TE^D#1^RH&XP&Z490CDS14@DJ176215^C>+>
MW<^%KN=25B4^I^P>^%U23<G;.#M^D4HLK-L+RMS^61%ACBNP1.C)1^QROFI(2.M7RMSFE9F5<Z40>2)CBX(^UQ1.2^1^>KSA@2I>EON^/HU^WN.GDI^Q@O-T
MJB-YW&@RO=62IDQ\$Z.BDA80\$7BPS7F-NXO(RF3IS'O^=(S)PRU8'O^<M-1W-^F>FHE.K>L^J8BYNETV;3.O88DU\$;O:PF<5S^>9@/L^XPX@^WX>P6.Q<+Y>NE&8N6/+
4CY+2K>?MV0&SLM<7C0Q<@<+P^IXO3^<=^<1G>^%EFEX\$LS7N-P&C^I9.O40/H4U^M1^H1#(C@<@WNI-2^VA7XV^53H-M^K-19Z^99GZ^PCK>+I=60WQ5020^T^#44A6
M20YVJN2K\$9LSAI<+1AJO1J1.99@8XHK^A^9ANIP&X^%V2.S9YH@L+L1.KM6%1C@0+E+9^HJH+^#3>@B5<1YF.N7V1(K/P2^W^%XNE^X>J3J1)MBI(^73K^I
^#Z12XQYAc<Q^I2>^BUDT70H^D1+1+8L+1<65IV?P^216 M^3YGLIY^62QPOAH-V%6F=9XR516C0LVZ.D^<^Q^T^RPD^R^X;H503/2>M^GT1^4L^X.SICIS-
^#GKQ8SH-HEB710-PK-^JHPL^Q17PBU1^FOQ1^VN2^OIO3W-X7.WY5STS1="74X2)8 M.D&P^HM@^4ZD.ZZ^=9J1<^>5>WB92^N=8\$2YBK72@/G815-1F845DX/
MASY6?APKEG@-VHFID3Z-7YTK=08I^YJ9#5IGYPN1?%Z\$QNI=2&S.OX93 M%D.X4I+^%IZZ2<+^27X+2&OUSY^&2;1VWPMB^Y553SOZ.N:KYH1D8^91H
M60)0YU@.0T^Q^PIKGL>5Z^M1+L^H^K>I7^76Z-1SU^NG.%ZH9%;JU>=HLEO+EG22^2#I-0I/BH/3H-MG6@BEH.G/W>Rf@ABICT2C5/G^Q^Y^>2&TO2C^2K9W\$/
M9P.N1E1&YJH1A<4.CP0249UHQZ^M^J^U^Y9E7W^RRG-UE30-6ZMUG.%K0@E+9^HJH+^#3>@B5<1YF.N7V1(K/P2^W^%XNE^X>J3J1)MBI(^73K^I
^#Z12XQYAc<Q^I2>^BUDT70H^D1+1+8L+1<65IV?P^216 M^3YGLIY^62QPOAH-V%6F=9XR516C0LVZ.D^<^Q^T^RPD^R^X;H503/2>M^GT1^4L^X.SICIS-
^#GKQ8SH-HEB710-PK-^JHPL^Q17PBU1^FOQ1^VN2^OIO3W-X7.WY5STS1="74X2)8 M.D&P^HM@^4ZD.ZZ^=9J1<^>5>WB92^N=8\$2YBK72@/G815-1F845DX/
MASY6?APKEG@-VHFID3Z-7YTK=08I^YJ9#5IGYPN1?%Z\$QNI=2&S.OX93 M%D.X4I+^%IZZ2<+^27X+2&OUSY^&2;1VWPMB^Y553SOZ.N:KYH1D8^91H
M60)0YU@.0T^Q^PIKGL>5Z^M1+L^H^K>I7^76Z-1SU^NG.%ZH9%;JU>=HLEO+EG22^2#I-0I/BH/3H-MG6@BEH.G/W>Rf@ABICT2C5/G^Q^Y^>2&TO2C^2K9W\$/
M9P.N1E1&YJH1A<4.CP0249UHQZ^M^J^U^Y9E7W^RRG-UE30-6ZMUG.%K0@E+9^HJH+^#3>@B5<1YF.N7V1(K/P2^W^%XNE^X>J3J1)MBI(^73K^I
^#Z12XQYAc<Q^I2>^BUDT70H^D1+1+8L+1<65IV?P^216 M^3YGLIY^62QPOAH-V%6F=9XR516C0LVZ.D^<^Q^T^RPD^R^X;H503/2>M^GT1^4L^X.SICIS-
^#GKQ8SH-HEB710-PK-^JHPL^Q17PBU1^FOQ1^VN2^OIO3W-X7.WY5STS1="74X2)8 M.D&P^HM@^4ZD.ZZ^=9J1<^>5>WB92^N=8\$2YBK72@/G815-1F845DX/
MASY6?APKEG@-VHFID3Z-7YTK=08I^YJ9#5IGYPN1?%Z\$QNI=2&S.OX93 M%D.X4I+^%IZZ2<+^27X+2&OUSY^&2;1VWPMB^Y553SOZ.N:KYH1D8^91H
M60)0YU@.0T^Q^PIKGL>5Z^M1+L^H^K>I7^76Z-1SU^NG.%ZH9%;JU>=HLEO+EG22^2#I-0I/BH/3H-MG6@BEH.G/W>Rf@ABICT2C5/G^Q^Y^>2&TO2C^2K9W\$/
M9P.N1E1&YJH1A<4.CP0249UHQZ^M^J^U^Y9E7W^RRG-UE30-6ZMUG.%K0@E+9^HJH+^#3>@B5<1YF.N7V1(K/P2^W^%XNE^X>J3J1)MBI(^73K^I
^#Z12XQYAc<Q^I2>^BUDT70H^D1+1+8L+1<65IV?P^216 M^3YGLIY^62QPOAH-V%6F=9XR516C0LVZ.D^<^Q^T^RPD^R^X;H503/2>M^GT1^4L^X.SICIS-
^#GKQ8SH-HEB710-PK-^JHPL^Q17PBU1^FOQ1^VN2^OIO3W-X7.WY5STS1="74X2)8 M.D&P^HM@^4ZD.ZZ^=9J1<^>5>WB92^N=8\$2YBK72@/G815-1F845DX/
MASY6?APKEG@-VHFID3Z-7YTK=08I^YJ9#5IGYPN1?%Z\$QNI=2&S.OX93 M%D.X4I+^%IZZ2<+^27X+2&OUSY^&2;1VWPMB^Y553SOZ.N:KYH1D8^91H
M60)0YU@.0T^Q^PIKGL>5Z^M1+L^H^K>I7^76Z-1SU^NG.%ZH9%;JU>=HLEO+EG22^2#I-0I/BH/3H-MG6@BEH.G/W>Rf@ABICT2C5/G^Q^Y^>2&TO2C^2K9W\$/
M9P.N1E1&YJH1A<4.CP0249UHQZ^M^J^U^Y9E7W^RRG-UE30-6ZMUG.%K0@E+9^HJH+^#3>@B5<1YF.N7V1(K/P2^W^%XNE^X>J3J1)MBI(^73K^I
^#Z12XQYAc<Q^I2>^BUDT70H^D1+1+8L+1<65IV?P^216 M^3YGLIY^62QPOAH-V%6F=9XR516C0LVZ.D^<^Q^T^RPD^R^X;H503/2>M^GT1^4L^X.SICIS-
^#GKQ8SH-HEB710-PK-^JHPL^Q17PBU1^FOQ1^VN2^OIO3W-X7.WY5STS1="74X2)8 M.D&P^HM@^4ZD.ZZ^=9J1<^>5>WB92^N=8\$2YBK72@/G815-1F845DX/
MASY6?APKEG@-VHFID3Z-7YTK=08I^YJ9#5IGYPN1?%Z\$QNI=2&S.OX93 M%D.X4I+^%IZZ2<+^27X+2&OUSY^&2;1VWPMB^Y553SOZ.N:KYH1D8^91H
M60)0YU@.0T^Q^PIKGL>5Z^M1+L^H^K>I7^76Z-1SU^NG.%ZH9%;JU>=HLEO+EG22^2#I-0I/BH/3H-MG6@BEH.G/W>Rf@ABICT2C5/G^Q^Y^>2&TO2C^2K9W\$/
M9P.N1E1&YJH1A<4.CP0249UHQZ^M^J^U^Y9E7W^RRG-UE30-6ZMUG.%K0@E+9^HJH+^#3>@B5<1YF.N7V1(K/P2^W^%XNE^X>J3J1)MBI(^73K^I
^#Z12XQYAc<Q^I2>^BUDT70H^D1+1+8L+1<65IV?P^216 M^3YGLIY^62QPOAH-V%6F=9XR516C0LVZ.D^<^Q^T^RPD^R^X;H503/2>M^GT1^4L^X.SICIS-
^#GKQ8SH-HEB710-PK-^JHPL^Q17PBU1^FOQ1^VN2^OIO3W-X7.WY5STS1="74X2)8 M.D&P^HM@^4ZD.ZZ^=9J1<^>5>WB92^N=8\$2YBK72@/G815-1F845DX/
MASY6?APKEG@-VHFID3Z-7YTK=08I^YJ9#5IGYPN1?%Z\$QNI=2&S.OX93 M%D.X4I+^%IZZ2<+^27X+2&OUSY^&2;1VWPMB^Y553SOZ.N:KYH1D8^91H
M60)0YU@.0T^Q^PIKGL>5Z^M1+L^H^K>I7^76Z-1SU^NG.%ZH9%;JU>=HLEO+EG22^2#I-0I/BH/3H-MG6@BEH.G/W>Rf@ABICT2C5/G^Q^Y^>2&TO2C^2K9W\$/
M9P.N1E1&YJH1A<4.CP0249UHQZ^M^J^U^Y9E7W^RRG-UE30-6ZMUG.%K0@E+9^HJH+^#3>@B5<1YF.N7V1(K/P2^W^%XNE^X>J3J1)MBI(^73K^I
^#Z12XQYAc<Q^I2>^BUDT70H^D1+1+8L+1<65IV?P^216 M^3YGLIY^62QPOAH-V%6F=9XR516C0LVZ.D^<^Q^T^RPD^R^X;H503/2>M^GT1^4L^X.SICIS-
^#GKQ8SH-HEB710-PK-^JHPL^Q17PBU1^FOQ1^VN2^OIO3W-X7.WY5STS1="74X2)8 M.D&P^HM@^4ZD.ZZ^=9J1<^>5>WB92^N=8\$2YBK72@/G815-1F845DX/
MASY6?APKEG@-VHFID3Z-7YTK=08I^YJ9#5IGYPN1?%Z\$QNI=2&S.OX93 M%D.X4I+^%IZZ2<+^27X+2&OUSY^&2;1VWPMB^Y553SOZ.N:KYH1D8^91H
M60)0YU@.0T^Q^PIKGL>5Z^M1+L^H^K>I7^76Z-1SU^NG.%ZH9%;JU>=HLEO+EG22^2#I-0I/BH/3H-MG6@BEH.G/W>Rf@ABICT2C5/G^Q^Y^>2&TO2C^2K9W\$/
M9P.N1E1&YJH1A<4.CP0249UHQZ^M^J^U^Y9E7W^RRG-UE30-6ZMUG.%K0@E+9^HJH+^#3>@B5<1YF.N7V1(K/P2^W^%XNE^X>J3J1)MBI(^73K^I
^#Z12XQYAc<Q^I2>^BUDT70H^D1+1+8L+1<65IV?P^216 M^3YGLIY^62QPOAH-V%6F=9XR516C0LVZ.D^<^Q^T^RPD^R^X;H503/2>M^GT1^4L^X.SICIS-
^#GKQ8SH-HEB710-PK-^JHPL^Q17PBU1^FOQ1^VN2^OIO3W-X7.WY5STS1="74X2)8 M.D&P^HM@^4ZD.ZZ^=9J1<^>5>WB92^N=8\$2YBK72@/G815-1F845DX/
MASY6?APKEG@-VHFID3Z-7YTK=08I^YJ9#5IGYPN1?%Z\$QNI=2&S.OX93 M%D.X4I+^%IZZ2<+^27X+2&OUSY^&2;1VWPMB^Y553SOZ.N:KYH1D8^91H
M60)0YU@.0T^Q^PIKGL>5Z^M1+L^H^K>I7^76Z-1SU^NG.%ZH9%;JU>=HLEO+EG22^2#I-0I/BH/3H-MG6@BEH.G/W>Rf@ABICT2C5/G^Q^Y^>2&TO2C^2K9W\$/
M9P.N1E1&YJH1A<4.CP0249UHQZ^M^J^U^Y9E7W^RRG-UE30-6ZMUG.%K0@E+9^HJH+^#3>@B5<1YF.N7V1(K/P2^W^%XNE^X>J3J1)MBI(^73K^I
^#Z12XQYAc<Q^I2>^BUDT70H^D1+1+8L+1<65IV?P^216 M^3YGLIY^62QPOAH-V%6F=9XR516C0LVZ.D^<^Q^T^RPD^R^X;H503/2>M^GT1^4L^X.SICIS-
^#GKQ8SH-HEB710-PK-^JHPL^Q17PBU1^FOQ1^VN2^OIO3W-X7.WY5STS1="74X2)8 M.D&P^HM@^4ZD.ZZ^=9J1<^>5>WB92^N=8\$2YBK72@/G815-1F845DX/
MASY6?APKEG@-VHFID3Z-7YTK=08I^YJ9#5IGYPN1?%Z\$QNI=2&S.OX93 M%D.X4I+^%IZZ2<+^27X+2&OUSY^&2;1VWPMB^Y553SOZ.N:KYH1D8^91H
M60)0YU@.0T^Q^PIKGL>5Z^M1+L^H^K>I7^76Z-1SU^NG.%ZH9%;JU>=HLEO+EG22^2#I-0I/BH/3H-MG6@BEH.G/W>Rf@ABICT2C5/G^Q^Y^>2&TO2C^2K9W\$/
M9P.N1E1&YJH1A<4.CP0249UHQZ^M^J^U^Y9E7W^RRG-UE30-6ZMUG.%K0@E+9^HJH+^#3>@B5<1YF.N7V1(K/P2^W^%XNE^X>J3J1)MBI(^73K^I
^#Z12XQYAc<Q^I2>^BUDT70H^D1+1+8L+1<65IV?P^216 M^3YGLIY^62QPOAH-V%6F=9XR516C0LVZ.D^<^Q^T^RPD^R^X;H503/2>M^GT1^4L^X.SICIS-
^#GKQ8SH-HEB710-PK-^JHPL^Q17PBU1^FOQ1^VN2^OIO3W-X7.WY5STS1="74X2)8 M.D&P^HM@^4ZD.ZZ^=9J1<^>5>WB92^N=8\$2YBK72@/G815-1F845DX/
MASY6?APKEG@-VHFID3Z-7YTK=08I^YJ9#5IGYPN1?%Z\$QNI=2&S.OX93 M%D.X4I+^%IZZ2<+^27X+2&OUSY^&2;1VWPMB^Y553SOZ.N:KYH1D8^91H
M60)0YU@.0T^Q^PIKGL>5Z^M1+L^H^K>I7^76Z-1SU^NG.%ZH9%;JU>=HLEO+EG22^2#I-0I/BH/3H-MG6@BEH.G/W>Rf@ABICT2C5/G^Q^Y^>2&TO2C^2K9W\$/
M9P.N1E1&YJH1A<4.CP0249UHQZ^M^J^U^Y9E7W^RRG-UE30-6ZMUG.%K0@E+9^HJH+^#3>@B5<1YF.N7V1(K/P2^W^%XNE^X>J3J1)MBI(^73K^I
^#Z12XQYAc<Q^I2>^BUDT70H^D1+1+8L+1<65IV?P^216 M^3YGLIY^62QPOAH-V%6F=9XR516C0LVZ.D^<^Q^T^RPD^R^X;H503/2>M^GT1^4L^X.SICIS-
^#GKQ8SH-HEB710-PK-^JHPL^Q17PBU1^FOQ1^VN2^OIO3W-X7.WY5STS1="74X2)8 M.D&P^HM@^4ZD.ZZ^=9J1<^>5>WB92^N=8\$2YBK72@/G815-1F845DX/
MASY6?APKEG@-VHFID3Z-7YTK=08I^YJ9#5IGYPN1?%Z\$QNI=2&S.OX93 M%D.X4I+^%IZZ2<+^27X+2&OUSY^&2;1VWPMB^Y553SOZ.N:KYH1D8^91H
M60)0YU@.0T^Q^PIKGL>5Z^M1+L^H^K>I7^76Z-1SU^NG.%ZH9%;JU>=HLEO+EG22^2#I-0I/BH/3H-MG6@BEH.G/W>Rf@ABICT2C5/G^Q^Y^>2&TO2C^2K9W\$/
M9P.N1E1&YJH1A<4.CP0249UHQZ^M^J^U^Y9E7W^RRG-UE30-6ZMUG.%K0@E+9^HJH+^#3>@B5<1YF.N7V1(K/P2^W^%XNE^X>J3J1)MBI(^73K^I
^#Z12XQYAc<Q^I2>^BUDT70H^D1+1+8L+1<65IV?P^216 M^3YGLIY^62QPOAH-V%6F=9XR516C0LVZ.D^<^Q^T^RPD^R^X;H503/2>M^GT1^4L^X.SICIS-
^#GKQ8SH-HEB710-PK-^JHPL^Q17PBU1^FOQ1^VN2^OIO3W-X7.WY5STS1="74X2)8 M.D&P^HM@^4ZD.ZZ^=9J1<^>5>WB92^N=8\$2YBK72@/G815-1F845DX/
MASY6?APKEG@-VHFID3Z-7YTK=08I^YJ9#5IGYPN1?%Z\$QNI=2&S.OX93 M%D.X4I+^%IZZ2<+^27X+2&OUSY^&2;1VWPMB^Y553SOZ.N:KYH1D8^91H
M60)0YU@.0T^Q^PIKGL>5Z^M1+L^H^K>I7^76Z-1SU^NG.%ZH9%;JU>=HLEO+EG22^2#I-0I/BH/3H-MG6@BEH.G/W>Rf@ABICT2C5/G^Q^Y^>2&TO2C^2K9W\$/
M9P.N1E1&YJH1A<4.CP0249UHQZ^M^J^U^Y9E7W^RRG-UE30-6ZMUG.%K0@E+9^HJH+^#3>@B5<1YF.N7V1(K/P2^W^%XNE^X>J3J1)MBI(^73K^I
^#Z12XQYAc<Q^I2>^BUDT70H^D1+1+8L+1<65IV?P^216 M^3YGLIY^62QPOAH-V%6F=9XR516C0LVZ.D^<^Q^T^RPD^R^X;H503/2>M^GT1^4L^X.SICIS-
^#GKQ8SH-HEB710-PK-^JHPL^Q17PBU1^FOQ1^VN2^OIO3W-X7.WY5STS1="74X2)8 M.D&P^HM@^4ZD.ZZ^=9J1<^>5>WB92^N=8\$2YBK72@/G815-1F845DX/
MASY6?APKEG@-VHFID3Z-7YTK=08I^YJ9#5IGYPN1?%Z\$QNI=2&S.OX93 M%D.X4I+^%IZZ2<+^27X+2&OUSY^&2;1VWPMB^Y553SOZ.N:KYH1D8^91H
M60)0YU@.0T^Q^PIKGL>5Z^M1+L^H^K>I7^76Z-1SU^NG.%ZH9%;JU>=HLEO+EG22^2#I-0I/BH/3H-MG6@BEH.G/W>Rf@ABICT2C5/G^Q^Y^>2&TO2C^2K9W\$/
M9P.N1E1&YJH1A<4.CP0249UHQZ^M^J^U^Y9E7W^RRG-UE30-6ZMUG.%K0@E+9^HJH+^#3>@B5<1YF.N7V1(K/P2^W^%XNE^X>J3J1)MBI(^73K^I
^#Z12XQYAc<Q^I2>^BUDT70H^D1+1+8L+1<65IV?P^216 M^3YGLIY^62QPOAH-V%6F=9XR516C0LVZ.D^<^Q^T^RPD^R^X;H503/2>M^GT1^4L^X.SICIS-
^#GKQ8SH-HEB710-PK-^JHPL^Q17PBU1^FOQ1^VN2^OIO3W-X7.WY5STS1="74X2)8 M.D&P^HM@^4ZD.ZZ^=9J1<^>5>WB92^N=8\$2YBK72@/G815-1F845DX/
MASY6?APKEG@-VHFID3Z-7YTK=08I^YJ9#5IGYPN1?%Z\$QNI=2&S.OX93 M%D.X4I+^%IZZ2<+^27X+2&OUSY^&2;1VWPMB^Y553SOZ.N:KYH1D8^91H
M60)0YU@.0T^Q^PIKGL>5Z^M1+L^H^K>I7^76Z-1SU^NG.%ZH9%;JU>=HLEO+EG22^2#I-0I/BH/3H-MG6@BEH.G/W>Rf@ABICT2C5/G^Q^Y^>2&TO2C^2K9W\$/
M9P.N1E1&YJH1A<4.CP0249UHQZ^M^J^U^Y9E7W^RRG-UE30-6ZMUG.%K0@E+9^HJH+^#3>@B5<1YF.N7V1(K/P2^W^%XNE^X>J3J1)MBI(^73K^I
^#Z12XQYAc<Q^I2>^BUDT70H^D1+1+8L+1<65IV?P^216 M^3YGLIY^62QPOAH-V%6F=9XR516C0LVZ.D^<^Q^T^RPD^R^X;H503/2>M^GT1^4L^X.SICIS-
^#GKQ8SH-HEB710-PK-^JHPL^Q17PBU1^FOQ1^VN2^OIO3W-X7.WY5STS1="74X2)8 M.D&P^HM@^4ZD.ZZ^=9J1<^>5>WB92^N=8\$2YBK72@/G815-1F845DX/
MASY6?APKEG@-VHFID3Z-7YTK=08I^YJ9#5IGYPN1?%Z\$QNI=2&S.OX93 M%D.X4I+^%IZZ2<+^27X+2&OUSY^&2;1VWPMB^Y553SOZ.N:KYH1D8^91H
M60)0YU@.0T^Q^PIKGL>5Z^M1+L^H^K>I7^76Z-1SU^NG.%ZH9%;JU>=HLEO+EG22^2#I-0I/BH/3H-MG6@BEH.G/W>Rf@ABICT2C5/G^Q^Y^>2&TO2C^2K9W\$/
M9P.N1E1&YJH1A<4.CP0249UHQZ^M^J^U^Y9E7W^RRG-UE30-6ZMUG.%K0@E+9^HJH+^#3>@B5<1YF.N7V1(K/P2^W^%XNE^X>J3J1)MBI(^73K^I
^#Z12XQYAc<Q^I2>^BUDT70H^D1+1+8L+1<65IV?P^216 M^3YGLIY^62QPOAH-V%6F=9XR516C0LVZ.D^<^Q^T^RPD^R^X;H503/2>M^GT1^4L^X.SICIS-
^#GKQ8SH-HEB710-PK-^JHPL^Q17PBU1^FOQ1^VN2^OIO3W-X7.WY5STS1="74X2)8 M.D&P^HM@^4ZD.ZZ^=9J1<^>5>WB92^N=8\$2YBK72@/G815-1F845DX/
MASY6?APKEG@-VHFID3Z-7YTK=08I^YJ9#5IGYPN1?%Z\$QNI=2&S.OX93 M%D.X4I+^%IZZ2<+^27X+2&OUSY^&2;1VWPMB^Y553SOZ.N:KYH1D8^91H
M60)0YU@.0T^Q^PIKGL>5Z^M1+L^H^K>I7^76Z-1SU^NG.%ZH9%;JU>=HLEO+EG22^2#I-0I/BH/3H-MG6@BEH.G/W>Rf@ABICT2C5/G^Q^Y^>2&TO2C^2K9W\$/
M9P.N1E1&YJH1A<4.CP0249UHQZ^M^J^U^Y9E7W^RRG-UE30-6ZMUG.%K0@E+9^HJH+^#3>@B5<1YF.N7V1(K/P2^W^%XNE^X>J3J1)MBI(^73K^I
^#Z12XQYAc<Q^I2>^BUDT70H^D1+1+8L+1<65IV?P^216 M^3YGLIY^62QPOAH-V%6F=9XR516C0LVZ.D^<^Q^T^RPD^R^X;H503/2>M^GT1^4L^X.SICIS-
^#GKQ8SH-HEB710-PK-^JHPL^Q17PBU1^FOQ1^VN2^OIO3W-X7.WY5STS1="74X2)8 M.D&P^HM@^4ZD.ZZ^=9J1<^>5>WB92^N=8\$2YBK72@/G815-1F845DX/
MASY6?APKEG@-VHFID3Z-7YTK=08I^YJ9#5IGYPN1?%Z\$QNI=2&S.OX93 M%D.X4I+^%IZZ2<+^27X+2&OUSY^&2;1VWPMB^Y553SOZ.N:KYH1D8^91H
M60)0YU@.0T^Q^PIKGL>5Z^M1+L^H^K>I7^76Z-1SU^NG.%ZH9%;JU>=HLEO+EG22^2#I-0I/BH/3H-MG6@BEH.G/W>Rf@ABICT2C5/G^Q^Y^>2&TO2C^2K9W\$/
M9P.N1E1&YJH1A<4.CP0249UHQZ^M^J^U^Y9E7W^RRG-UE30-6ZMUG.%K0@E+9^HJH+^#3>@B5<1YF.N7V1(K/P2^W^%XNE^X>J3J1)MBI(^73K^I
^#Z12XQYAc<Q^I2>^BUDT70H^D1+1+8L+1<65IV?P^216 M^3YGLIY^62QPOAH-V%6F=9XR516C0LVZ.D^<^Q^T^RPD^R^X;H503/2>M^GT1^4L^X.SICIS-
^#GKQ8SH-HEB710-PK-^JHPL^Q17PBU1^FOQ1^VN2^OIO3W-X7.WY5STS1="74X2)8 M.D&P^HM@^4ZD.ZZ^=9J1<^>5>WB92^N=8\$2YBK72@/G815-1F845DX/
MASY6?APKEG@-VHFID3Z-7YTK=08I^YJ9#5IGYPN1?%Z\$QNI=2&S.OX93 M%D.X4I+^%IZZ2<+^27X+2&OUSY^&2;1VWPMB^Y553SOZ.N:KYH1D8^91H
M60)0YU@.0T^Q^PIKGL>5Z^M1+L^H^K>I7^76Z-1SU^NG.%ZH9%;JU>=HLEO+EG22^2#I-0I/BH/3H-MG6@BEH.G/W>Rf@ABICT2C5/G^Q^Y^>2&TO2C^2K9W\$/
M9P.N1E1&YJH1A<4.CP0249UHQZ^M^J^U^Y9E7W^RRG-UE30-6ZMUG.%K0@E+9^HJH+^#3>@B5<1YF.N7V1(K/P2^W^%XNE^X>J3J1)MBI(^73K^I
^#Z12XQYAc<Q^I2>^BUDT70H^D1+1+8L+1<65IV?P^216 M^3YGLIY^62QPOAH-V%6F=9XR516C0LVZ.D^<^Q^T^RPD^R^X;H503/2>M^GT1^4L^X.SICIS-
^#GKQ8SH-HEB710-PK-^JHPL^Q17PBU1^FOQ1^VN2^OIO3W-X7.WY5STS1="74X2)8 M.D&P^HM@^4ZD.ZZ^=9J1<^>5>WB92^N=8\$2YBK72@/G815-1F845DX/
MASY6?APKEG@-VHFID3Z-7YTK=08I^YJ9#5IGYPN1?%Z\$QNI=2&S.OX93 M%D.X4I+^%IZZ2<+^27X+2&OUSY^&2;1VWPMB^Y553SOZ.N:KYH1D8^91H
M60)0YU@.0T^Q^PIKGL>5Z^M1+L^H^K>I7^76Z-1SU^NG.%ZH9%;JU>=HLEO+EG22^2#I-0I/BH/3H-MG6@BEH.G/W>Rf@ABICT2C5/G^Q^Y^>2&TO2C^2K9W\$/
M9P.N1E1&YJH1A<4.CP0249UHQZ^M^J^U^Y9E7W^RRG-UE30-6ZMUG.%K0@E+9^HJH+^#3>@B5<1YF.N7V1(K/P2^W^%XNE^X>J3J1)MBI(^73K^I
^#Z12XQYAc<Q^I2>^BUDT70H^D1+1+8L+1<65IV?P^216 M^3YGLIY^62QPOAH-V%6F=9XR516C0LVZ.D^<^Q^T^RPD^R^X;H503/2>M^GT1^4L^X.SICIS-
^#GKQ8SH-HEB710-PK-^JHPL^Q17PBU1^FOQ1^VN2^OIO3W-X7.WY5STS1="74X2)8 M.D&P^HM@^4ZD.ZZ^=9J1<^>5>WB92^N=8\$2YBK72@/G815-1F845DX/
MASY6?APKEG@-VHFID3Z-7YTK=08I^YJ9#5IGYPN1?%Z\$QNI=2&S.OX93 M%D.X4I+^%IZZ2<+^27X+2&OUSY^&2;1VWPMB^Y553SOZ.N:KYH1D8^91H
M60)0YU@.0T^Q^PIKGL>5Z^M1+L^H^K>I7^76Z-1SU^NG.%ZH9%;JU>=HLEO+EG22^2#I-0I/BH/3H-MG6@BEH.G/W>Rf@ABICT2C5/G^Q^Y^>2&TO2C^2K9W\$/
M9P.N1E1&YJH1A<4.CP0249UHQZ^M^J^U^Y9E7W^RRG-UE30-6ZMUG.%K0@E+9^HJH+^#3>@B5<1YF.N7V1(K/P2^W^%XNE^X>J3J1)MBI(^73K^I
^#Z12XQYAc<Q^I2>^BUDT70H^D1+1+8L+1<65IV?P^216 M^3YGLIY^62QPOAH-V%6F=9XR516C0LVZ.D^<^Q^T^RPD^R^X;H503/2>M^GT1^4L^X.SICIS-
^#GKQ8SH-HEB710-PK-^JHPL^Q17PBU1^FOQ1^VN2^OIO3W-X7.WY5STS1="74X2)8 M.D&P^HM@^4ZD.ZZ^=9J1<^>5>WB92^N=8\$2YBK72@/G815-

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

07:28:1L:BC:YH:0&CK:40HQZ&@:M) (J) *4*124:BFDU:10Z:9D&") HUHT2OYWEKG@: SUDR&B1:HfZMAR&3F6:SH%:M:0090T1@5+1N67:Q14\$Z) 12, 07M6Y9
M4D+H06&@BXA.2S1056Q018155&Z4+Q1Z>1F35:TOR8KVV403&3W45HSR79&+&XFX:86:CL:9N7S02X7ZG41+16):H<0JZ2MRA M=CfP
9S2M4A%+1%7<61NFR5B=1J5H51&4&1<R. DD2@<G8+SNP10%#HfZ<=>9%#H7U1W45040BEN62K MR=U&=1H)H8Z7D+@>PZZPY30U "?1("U43(33f)
H1A1DZH9(81 MT) *5>Z8 46TAD1S<D%G5X1H11@7:T4=55Z>Z>A16H4H1203U3<1 P-O013+1HHR=3233=\$R\$&Z&A9Q1Z1M'O C11+1H<@fZM CO+1"IN%G2O1
M0+U3 14M<=HJGY=NA< 1Q4(1)<2XZ&ZX0<(GV:PD1PC7H:UPO<@1MSR01:Z) (E7-1<9%#HfL1P<)"1P67&V&H7:W@RP1871KCF&5#1&14M M-7A 2A0+@1"1P
P#A2T7U1"J1X#009>(O1.KE& G1P&E/6-UICHUB91?MZT MI/61.38(JS2?)O F.R<P>H1QV:85#7@Z5 A@7-10EX44 \$T-XN:C>Y39=1@LW3K3M#1+\$>2-1OZ4S 9JP*
#02Z<1>VW1P?+11(CO)2B*#BDGZ4G:Q-N<=MX'XBO:MCV1?&:CHH=V&:OJCI=>1DD-WX3&W+HNCV(IGN8:WHR&DP MF?&C.VCC.COOQFT\$S:1R1-MZ5D8?
Q12D1Y08&8.34X=1X0/MNYPD1DD55&4\$1 M1DX+O&1>1H7D?#4K H4C1P181&4&AD1=&+F+N8Y&C&F+EAR4D>M<A8 M<=>QEW3)+1X8VTS4D#7&2?
&G#15"=W7/U7CIBG&Z&B=-FR.CWNT&N+6 M9HNA30<29QTD03.3V). MB1A20ZSKZ> PO1K.VOC 4P4X>104E9H.Z7)P M'DM-2=>JH0:EBD.(17M&1G
<SYHUW+2IE/HU7E1WGGU1@:P.KGTY<C1O.410N4466 M-4+BSLE.YEEHR.KUF1@>E17M.1.G2&+1ADR31(=EE&5%((<1+1@23** MZ9X5==(\$21G F2L2Z?
"OM(C1D/H'OMA_Z #E4S9@Z&+Q&SF15M:ND) =B'M-(11R)D&1H@.J1T2%=O+8M8-"L1&Y12/H2HN%MAE'H=601FF6T>31=1N'M'T0UCC2C@K1%".YS.N#&LN7H1
M<=>4P7M1DU31M71JKM6+BSY7F@>16:6#5R0MF1/JZQ1"1N5N7R1+>V D65 M<=& MN/CJWL:9P'K51F0EZO@B1B10+>FHW2756 \$F1Z>W2W?F1=1K9<>
MU 9+71HWZ051JKH7ZAO&A1A6C@NNG>+30M0&1H1:1@5A1YA"1JK'KV MF>D1KCG71CJW9Y0Z1K1AWY1+1QWIK+>FHC8A#&EX0&5C5+14Y5 O81=
M'MLO1X1"JN<@<6V125W1'13F8V>EUPBXG3VX2N<= 25;1U0:3.HF14+>YQ%HH<1E12W@ MWAAL1K(1+L'012 9316Z->N=XX:FI+&A<7T&=>125QK1H2IHR0P1 M-
@1A NU(8 "M1WZ9141MW1=>Z33FCB:R1D>2S<16C>Y"U=10H1B9T9200?&1:3&5:2SS1LE10E28 MDGVA 13U10 11@GR14551R91>4 5L714G:Q&ELW 1R3&SDYD.V1A1W@%D
M8A5@T3+OX&H.LH'D(K=IP"%%C/HGW=P48D%W1.7\$<CO<14X(WC1+6HPBO:61J2H"LR:(PN3O)-OHXCFB?+I<D.A.S1H\$<36DY1F MBDEAEX>T0=S+1+M1?
ZD>=&E&F1R0P2D19>5>B0 DXH140\$+1@<0Y3Z@A=1+8 N6:RG<10"0"6"S- MXQ&5R<74T1?1\$P1T7@1B>G0C1D?<A1P 1X&8DH.#3@XZ M>C>D79D(E#&1)=#71KB)?
W10"0\$M SW2B19Q1EC M.RCE1A1@.(152U7?M10 KVMT T10W16C0Q5W0?<R4E=19208E10.(O M151U1@1DZ&8DR)D1H15066%T1@>#1A PK1VGP1?27
1#GM JN=41 6W M+H%44V+829:2K2X=ECVKZOGU@QJX'SI<C=D2 3FDUWT2K1+ EUAM&B&T MH
?9H.A1H(HSXR#40:="U5\$11&823G.&@.101DQKA8#B\$Q.CGRQ3&3F M+8T?M BTE1HP&1.A=AM/1(8M)<873Z1W1="AGY19T?2H.TGL&@<S 4\$Q
MX 5MNH1W+6P7D=>%9%W?Y7519JX<3C1U16GEO11.W1U1F&S+R 3=>H+1M2>17FXHOBZ740&B?AC 3VZH#P>1T21P.71+1YXG3M8#<WY9#RQ1-YB1
MRJF'BZ EL1 8KXVW0914V.O0>:CBY?1 16-8M?71 8.1O.29H18=81FX MQ4K(3.O4BYD>N%#JNX1(HNH2GH5HJH1E&8 L2)P@<@E4G3HRW6="149 M-
4&5&KA.HY1+A1D25B61J4.A10?>?>K>+1@00Q021 IEEL MG3P:AG&PV<@<O&AYBN&=&.B&X.CQO4L.FT&4T02DF4X N 7Q4BE105 MKH1E41T1O?>
10&H&5SGGR-9">1\$<9E9?CR&6&ZW@K&B.N1 B545BT1.H M4+1A="E8X%1T21&Y1E P>8Y@RBYK4A0R1.MY CX9PI<=&61JRA0T3?0\$?>JN&L51D1"AHG18/
X10+U1O.H.NU1"V6X1MY7319S96S 1MU&S.O.O#D=1.2V'H2+Y1+<GM7MTWY17M1&51 0'V8QIDR&AK<A09.9P1TD3Y0."65:1D52J8K#/?>#1>#>H.L81" G6<
#FP=>B3@H MRKK HB1T1FLB.="#\$8@< 9/1+1+1.10908"1AKH9 T10?R L5 N%11 MG6N61BC+K1E?#S+DYL7C1+7K1+121)WR"&86
M(O:61Q7002Z2A@T39A2.2&@>H.H M8="1AY8F.OPT<T&R<O.Q.R"R124E1EFMU4F49ZD9B1 BE+HP2"<MMW01>2 M1K&@&R@>4MOAPN=>\$\$577NOC*1 600@<2G-
D@RKED132D2Z2R207V7 CD* M81ZY1C1X241 92V.&@>DH(H"Q1M21(11 COHOC14"& C"HPH1@<715 ME.EUB7?2Z3G1O10H17R9?
91@< JY1M1W5<3C1%>L31AS7F3Q1.N15KR< MH0B1@<CG&SXMX221 TGT<@<16Z?PQ.9"15M Q3HT2+MNDR1<#>H C31O 1M1X%K64?>
XNLB@GCE1+109AE.Z8WU 3F6S1)1\$10 N56%G1B1BP7&KNH7>19(ELH MLZ(R2.RM9Y 4%<M F&?>.B?Z1O616T6.1+P1L.N=7M LW1S AIK143QW>M.H1H9?>
YEOG<A1@6<=>?1MHG+Y4XH0=14 MAF1+NZ<@f1FC 31%<B6A1G1Y.E06<80K7?0HC1+1JZP.A%G1<C12K1B M&A@<618NY1MBEW=>(A1W\$1.0581.7F4\$6 W&+A*6F?
HY1E<=>D>G.E1T121 M+Q>1P21WY1+ZR6F121C< (KR5Y1.M21SFPFHQOGZMS1W9D9<5ME 7H11X O= \$H6W1HHP=>51S)<0D>WG.2?>OH M1?
ODNF 1.63.IN.J1N56PZBVBD1V1V4USFEA1.P1S1L 57L06.(11 M37T.<@+11570TYLB.15E5H-Y3XF1-V@-15R6H1DDBHK1BA U2310XO>00L MWJD2ZS18<P.
&#2 K3PN<="M61GCE17S1.8"V@2B1P2(EMTGT6?G325 AY&N7G32N.S1L 9.H1&3Q?7SKU.MR.U1HKOJO1"=1R1=S(C&E.F1+&0@<4@<@KZSP1\$&X1ZS 1996AES>1.&
ME0 C.%)1" \$\$\$\$6D1@11@>=>RCC0)21D1.LR'F&Z69?&Q16?<Z&@11<@<X6?D 9PB5\$NA.M1#H1F1@<1.5>=>J51)W5>1+1A1C9PL#?G<1@>#21N1%.(1+11"00
<21+1EYOT1151P1"CLY1M1%#N7.S18W1KD1\$S:9#=>33+699)> OXW1T19M:="FOW1S>2.SC<Y71B188 M9D1+1WRN(X%1
(SR9T.FSKT1H1CG1XGA1O&O1J 3511 1GPH&B1>@<XO1U71D. MB911131TK.EW125M3F9AIR)>#&

[illegible]

[illegible]

Q0%+Q.9/-+1.5D\$;29HLO7Z%-UT77N;EG.0%EIV-M1<*OGAN;I>>S(FTZ@H4%0R9XF96(C*G4P)91F^@5U>0JSS;@R9:28&M;K;KDXV@R9(2*HK0)*9@B*K4\$.\$%-J
(S\$E@7@C;M6;PPY@A1L3.3@SNH*RHCAIR3V0%?2ID;XSXSMDI3TU>^H-A4\$6<D-M7FAH#53S@-Q0^@M8>H>P>2D;1R1P#L#VLC0L8J-8JR#TH12(RR-
\$MALIN;6PB4B26.35KJ-1J9XTLH0%0%0%0%1L-MF(RXPXR#R#TDP9T9#R#Z=-Z=L7>4&NB7FRMBJHJEH<PR<CJ(CET+2N0
M6&B;B;M9\$4UUY0%154-B42.6DP;MVF9^N)MV.E;R08-M0B&F5&9%0Q;9AR#F8U@45\$P9<05>9R.D;B;H@6RH(FN<KIU5<\$U>E.M;4M;+7-TMFTUTV#A;NIR-
WNGZBDIF;QKWAGIE(KI;L\$DK1@G&M;GX<H^>N2J>17PTTTOBSUM;Q&P#DS)80U@%P2ZVIM#63<5<Q2\$3^<MDP2SICU@EXI>QJIS<E+>VXIKI-
@DE/MJ/8G/E5H4RL<C5CEIQ1?=-MI@US2T(E-7TA#14DCLK58X/N#LD4/4/S+X!>=55V-MG67H=BGAL32551%>OUIKZ1%&8SKIP45=N;K4H9#Q@>7Z9<4*#J>+8
MGBV>W<G-SW3T7M6#K#T7V0B7/B>WTKJLH<LEJN3#=-OY<@5V3B5TJ-MJFC-2KD+2KGC;K#AM5LLI9&@>@RYDDYF.R5G9H048813SGXOEMG1#RYK7M^2<IG0H1
=>W<C#U0I@P#L#WS2MTH+YX00/5L<@KXWFL+>2M1M(L#N;D#9-M.YB2<F5S;X@L?21#E6;19H1#-STJ;B<0*0AME1\$SI/QRUE6-TG*
M42WU#>#88IRHRC+FM@D#J#S68EV%=<=1FR2;S<9ES<@POL;0)2&*>MOW#1KRIKXIS#LGB<^>1/W5Z+M^T3-TWL29.T66@10-TM#WU#LO"0?>T-MK?>
M2VLE26I74JZ<F.OW-1+6L1B;T.(B)M#>IH05(08B<=>#SKRJIR-M-^>O@R+AQO5N.RP231=>1\$D#5.VI7FE8>+7%ZSWO6@OMLFBUJ#>M03P>#(7B3Z+>
+V+>Z6A?>1X2*RI?>SF7GH@H\$-7-R6ICL;BCT<N%>SO-M)T1*MO<*>+L-80J9Z@>#VD?I2B&V9(SI&51.75>+5+7.Y9#M-2D6ELE90-M<(X+L1Q4>-0D1KPZS@S7
QVTFV9<1-9)IR9A4-Q&M&D.85437UV#>+XC-OP-MO&K(L(RI@Q9MYFJRL+EN)ZUG<4-MN-0K1-N+GAN#LH13JMDWE?>01<=>GMI<4>6CCH=HJ3BWK#W#>72-R
M#121B1ML+1<=3YWZL2>3HMV;H<H-EN12>=ISM-TN#L#I2UHQ08T-M3Z3>3A1H(JH16)F\$H1Z7TU29650Q(00K6G5K.PYIAR@>9<1
<03@2>64AL#XNM<5ZLNT557P<L4XLNW#M-PM93N9F<GHWI0T05>2RWK5.VNTAL8FI2PZ584A+<((9>SLDZ)91-MWSV#>0^14G)DMDWSS#H4XIM3?>
Q1F+>A9B1QI#LVB@>#KHJ0NE14AEB2-MT75<YRV#H49^>H29.9E+VJ-ZG&KAI6.EUN6(M.0%<539.41/GD-M&?>D.54S@X=N<K@I92ID8S<KTL<I23>P>
9D06UB2.0:Q1?>LOWI06K1Y-MGSSGK#K0M.TAMBOD<27-M.Y0P400-E-OR+U>QYDXB0?M2GY+6-Q<^9M2>HJ3LMIF>=FFV.I4W-ME%Z-2W>@>
=>M4CY7.2L-17TZD5YRNS1Q#>#665S@QW#17YSB#RKHFH-M05;G7V0-70Z%5YENIG4ZC6EQK#9U2NF34Z-VU5URNFHC3%HMGI+VW-M<P#EJW-M<+I#<3^C?>
0.#)HJ-U0D-VI2QI#EMERZ#NUGLST#>#&N>N\$U-M7DG@>HBYK6<0FFPEC#MG6\$X@>V-LH1(JED&X#>?K79VFUTWJ4A<@3HCY<MEX7-BXRD3X6#>IM@APICIBH62?>
J.K6YJH024UEBYN.GCH9G<S81+0-M9G9L2&K%>WOHQW3W>WZ3Y3M+1.U9+QSHO4GZX6S5F-T7H/3F(K;0IS>M0.V7910I@>(QPSQ.VKY1>X#>X-S-O-M1KKZ6>+>
APIX3-ID9-I4R-HJ3-DH-HKIOH#>W6Q0#>1%>7LO&65T0#>M#YMBHML#YV4CU;K#>5<XJX9%<@JCUZWZ#N:9ZL08.VI7.51C6C-MBMR#7E9-
G+>=(^U<@J5T_OINX00I@JPL&U4#5W=f.M.5<X3XOGQ?>25NX;YD.G:Z5C85S#GH5C#>VU(C42?>J@>ZZBDLU"RC?>MQO@F?>P=W=0\$1;H#A<S#HV2?>WW/%
H2.U@&F96B55U00=6(1#N?)>MAIF-Y0.YN<^>=>Z>=7-GKV7?&T#PPF#N2-6W1A35=V91+P2%>17\$M2>W0P2?4#B@>D3F8)T2==L.M#>VXT@>#AX<^>
%91OIQC3<3#>#>H#L#MX2.95>6GHM.W5X9HYU#(X-ACLO&A8;A#>L4BDM+>+?C2?6901K<1MY\$E#>#&8TQ9#BX60U#>#7R5IN2B(G.SA0<5C>=>7Z;ZB3IR<P%?>
+1YE+1#CMWGRRL9Y3N1<91\$>#>97A;7-7L<^>@>17@>5L<7S-1#>L-1#>D-MX<EIBCZ94DQO<Z+>A#&2;ICN(XOVN)A-ZH<1>5SL#Y-LCL@>BTBP.
M10.AG<QSZ81D13<CRHJ.BP5A50#>E.>=>@L#D8A0TKW8MU46G5?7R.MYV5>T.Y.FE.WDE?>?X1<=>#BYIPRSWP8@>#Y.D.T.OBD<^>A.HJ3>=>#TRZ-MB<P>D3#>H0B?>
T.HT7Y533I#>F#H<A-WOTAU#>GNBWI.D2.T6&6<@21.8-MD1A37D8/2HSZID<1DK-M2@>^HMB8IP5\$>L\$80T.T0GK#>A#4#0BF8\$A4#BIR#551-
1#B2D1+8V<2>1Y2(0G1Z<G#4Q3XSXDE?>F#>67QI@>C#C#VH-HEX9.T">@>HL=HJ2X&MDY.T7.Q+WOQ15%>0EAS3.CYX&@>6A91-D@80@>FC2?T#8IMG."OZ<OY<^>
M#HFAAZP#>=>1>4Z0B#H#O1<4>5VPD#H<F>P>T9P9D>1+1<5#A4Z<G.N-MR#XA-UW18>+&@>B.P71#<P4>=>#YB>27SYU#IR>@>B&S&@>VR.N-M.G7-MMG0?>
6&M;4.13FLJKJ7.YMRC8B8Y5<H#HYZ-QI8RIS(MY<4>V#>B#M<2X5X43.3%>X(C#HGO>N#4<@>PQ7377DILLH#>CLT2.2)3#>D-M5H1U#4J5H1LDO-
U#PRRHH#>S#>K<@>YHHR4H71#1EZ03#>M#XO1#TQ5T5G6C4.HJH1#YQZOM.EOXHO<#>=>83.91A-M2V1Z.T.H8G1.PGHL1.8&AIBD.OBW3>A(A.R0#PCVJ(CWV15#>F16
M#M1-CQ&F0.QXFB&M#>Y3YV1K620#>E.A#>=>X&LH9#>1XV1#1@>V3.2DI.M#>T7X45A36+>RF#01Q2.GMRHQV#>B#>S#P1#>J@>2&4BRZ#A8<3#>Z>=>H0MO-1^ZXO.5-
&MJP8MLK#>55RR9#8#>UO<=>MDR0@>G2?>7Y.5RX<=>1PDWM&S;ZN.94U#Y1X<05&20Q/F7-F.E.CQ#H4M2NXXRUOH>=>J.#O.K=>?X
GSEI.F."53G6+>1PQI>D\$>UO<@>(RE)6C.M.35=U10#A1XYE.FIT8RW5;3H>3<8C3DLE&QI@>SOVU.9#IX3.PKN1HA=MECN?2EYK#H5+M3#>C+>A)KJ
(HQLT.BK&O8J9#>+CZ.M7+AP1BLZV.9J6D.ZGLF<C=IW+>==66G#AA6JFE<=>CC>GBRLL#M1JB&S9;Z>1VHJXWSN<@TVO>2V35A2Z6.DDNMBW-=>(C4A6Z<^>
=>K&M.1#12A#VZ+>+SY.M4WP7V#>1W(9517<G<=>=>KIG1VZ61K#>PB-ABU@>SD?DE&SX3YVZ<8NVL#M60W#>3Z6BDS81+GG7+2W31.BHVH#>
R.H5

[illegible]

[illegible]

[illegible]

1+5X%Y%0H1XBFX%BP60R(R\$K(EV%N%SC6Q2V8)EG6SS1D5+8-18<=>M%J(G21.7.00IXV1<77S>BR35=17@5:8"SRMG6BIS(5HP3C)&N047LWN/%_2RZE7H6-0J>?>797U-MC<^CZ7&4BAK8IGNZ&KINW&W2Z<?>02ARDP00<@/G/M/LR6XFP/A07<22MQ0U4-AE1W4A&A1P2_Q0+T+<=>J=1+<7E-Q-M+Y1
FWO_RJ=&RE94IC(=K(=D(TT1MP5Y,6P17W75X6+X=C7H1A8 MP2M%>55U(TBP>OBRRNRAN7Z(WB_1M26.0UEFZ=>S'G\$0=&S17W642&ZKN?
MQ73XH83>?>YU1PE1%>K%>RJR1R7E1J5N7.(1AFD&8L-M+X-E1G<-MEA271)&NM2&E&U+1PT+N/8-L1V>?>14W14V31%81A2R)APM135-(74)-<MU5UB'H'=>
6J9N<9-35'KJ>VJR>51W1H_1"8P0WZQ'EY9'F'EC1A+1K1<MVJ9-F91WP>:KEU9Q&S=>19_3KQC%>U\$#>+V2_PQ%Q'G\$4+UWS40-41=
M0.9.R1J17ZGPR.3H7U%>G14KE7_7X1<1N4XW_1Y1ZW_MQY7=EHJ01&QY=>2L1N)9M(K&MK3.MZM%VHKGC05M75.B+>8B^N+UP2'A9_&@>MPL1'1M=>5.51VWNZ'
MP_+1.7.NB>?>1=173+?>1'J>GL+1'CW+0HX&G3U_CX+17Y.60B-7W-W1M5&E'>DP23XELV.C'>M29-2V3N6DWP?SUBAB-MD?P7H&7M5\$&S'EJWGTS'>C3'K06E01LW?>
7_EH_MV17U34<@31_>5_ZRICZU_1.F8S7?>/KG1N<?>17OF2-T9X=VQ_KT_4_M711R0RYV+1PH1VOVM+H'U'7U?>+1079F\$YJDK6=>U2^CO_1K1FT1WKM_A'
14104UHL1=M+E=>T.M.60717N8T(4=)6%10BU1J>13DW/NG.0-BO514W>?>UQ1/QPM=>R2_1PN1LG.V^<@H'X'G'0U11U'<@>?>1W'471+L5U01^M'Y&M'M'PW'
1413BW&WBR6C&9CD<=>@1X12K1<=>147+20VJ21<Q23%>W=M-M+S<=>URH13JED39?>1D19<5W=>@3SRKS6P?>7F5F<RCS'V4D1Y_1KTC1&M+M1Z&V21T'
T3_1=5.N9M5MFJ1VC=>TMC62'F3E1V>=>1B3K_6TA&S13V1C6H.M9>=>1KM'1HQ'<Q'>7LX&4&=OK&SC88-R&E6@>F_YCNSN<Q>910CLK1<M%N_6P=PD1ZTTF_B
MA1+QXB=>M504.W102=>W'K1FW7Y.20.9H_1LH01D&1AWZJ1P<C7V615+>Z.M7.KW1L51A1<=>91HMTCE1(D_7)KTLN14UEU&WK1010Y1/19=>#51M51MCV.M'1H'Z'
98UM2107\$?1<@10L1'KV37A<1^162=>G1'G1Y8S5Y%>1E_9_YN0+V%_M17Z31'6ROV1+SMV.B7('0SDLC'>LK2^UO#>JL7EVV10'^>06LT>+>=<1A_MCI'RW_RL716->?>UO?
>C7V1VP1W62GG5<=>1TW7'HKR<=>F.8TAW21SFZ3N1=>K1K<@>Q84Y^WNN%>E4T1=>B\$>M25F<@5+2K^>M'Z25M=>C&W'M0W.WK0P^>A\$>M&IMZA>=>XQV=>O.Q?
WT(4.M1.H1G13Z.HBRO1K<@>1Z#>E=>62CCV%>5C13MEN1-61FN-M1A>=>KFZ+<@>C0<6Q>B+1^C'>CKOQ621<@>VROH1JQ2L1AUX.OJN1712?>10<M'LEMD200B.5
M1A<O>U3V^>_>P.V&1?>_>UO<@>N.613J<6T_P'2FM?>=>G6G24A<1H_1'0O>=>8C81M_6M001X71HOU'P'OGC_WMXM_OBG^>Y'N2>OHRUN1L1P_C7:5Y&M&315.FEJZ_MV1
#D1L14<=>?>16BHC1P%>M&W&A1Y_C7UJO_G71(GO'^>=>#>AZT_L22N14<=>@>B8H1_X8>SSCPO5U_MJ1'61&G<+X3&KB921861BM13=>UFSMT1.N1Z&J1H1&6W&X)36KA>CB?
8_#>A+L&VZ71'>#_MIT<3>11P65NOW0/N<=>O'800-W?>?<#18%8KC1(91'?<=>M'J@6L&CH@>N'PP1+AH#&031LT=<=>30XOI:XF%OAW+ARF&W1\$3/ND00HZS
MR&P)NR+?2Z.R.M'=>?>1=7CGMSZ8F1P8A-37WR_7.N1N<=>@>UP9PX_>S2MM'K&K<@>L1BF=>+<@>0AG3KB4&0@=>#7?1D1HPFMD1E'>#>BSVAT31JSE.M'>S_ZBH
@RBP_<=>Z>=>EY26PVY1Z>BX21A>17>=>=>4&RKR&H4<=>=>Q_M819N1UUG1_EG<1_0>_DRI1P112N1X^W1^>XCD.2E'K1MOICBOL71<=>1^W1L%>14^%U@>=>
<1QX<111CE0&S&W81^>1TTLMS31DYJO+11770X<=>E&T33ZVW_>=>=>#2C1B1>=>X&XD&K&6&81TE9'>M=M+GW721W'F1P_K6ZD'KME.PSYKL15.7MF\$64MQ0161'G+O1G+Q.V>
(BK'H_MEF+BZ0101>1B1H_D2#>#1K7ZG6G18H7ZFE5NS&K4Y=>QRO_X1'FK1G1E'Y_MMSW+H72H'UFA'3316101L1^2%>U@1YQ_0&K=>B.H14&43G1+>=<L3_<
M_<G.N7R8=>=9YD86>_K9<X?LA_M'61XP55M#>JLY65%5C<1^N-6Z'ZG0U2VJ9>N-5UO+V>@>7CB304W'>V%_M&R1J12R>N\$NKZP7P;PW&CAA?>J.YOHV'BA1?>
R8599-3'>WG_HKS+P&M1.MB.<@>P+1A<F597K@_FC6BF1W5NS&K41.QW17C#0'>7R09FQ<5P.R875+X'00@H1D1E5OCH1P1>?>3#H1P'N^<@>Q2=P'K1K'>MOT+?>
SNA4#>=>7&8731&907V1DEX1PSH9.3C5V%>_>VFW1H1P1/E@=>+D<1@>MW_>#>A&N=>=>=>TE063FSQ5Q1V+L59G1J.M1@>=>1P>V721P^>=>ZRK.MD1=>=<7@>B_<
'4#7=YZR+>GOKUL+RW'MM>WB2H&M+>+F&X4D>1A1>H1V1+VHKMKBW0X<@>U?721M0F<1O1>N1<=>M8G123&4<=>13X44&VEFEZ=>@1BYVS(2F)3.GD-MY&HM8-
4M7431Y1<11-8#>M24X)>@Z0@>VM1M1L141CZ<@>HOXS.U'M'EQ_111^1X<_CKP1'X&Z59H5CU.H1W1C1N'50B0<?>4?>WIT<2?>MFR.MMF<
1:QLPWY9(&KT_Z1L_2_#>+V>=>1F%7N1+>1Y9N9W4@>1G#<=<1'Q.XH(1+M=03<0X0).H-7)T'P<=>TJ<6L&@>81'8PP#K6%<+&@>=>9A_1S2LYK8U9\$2
M^N_>#>+1110>O>CH^>7_>61>+>?>9D1P6P8PNWCP1_01>1^1^>9BP7@>O_M7B1W&H1&#>JYQ3G^>91J^1P'>#>?>1^>+<@>C&OFOZ1=>B2H#>K1H1W1H1'981W468-
#1BU<=>1A2P6V1W17.NQAYNS1>1^>E'A1E1G<7.01R<14'M2P&AD132N6#U'>M'UTY=>81+1J1MW2W&PH12C1<@>HP@>1L71P7R'>=>#>F00K'YOP'>SOQPT#>=>
N12MV.Z1.RRO.M74P@1MD\$1X>=>20Q>=>E8A5QO<GT9Y3B1ZW1'1MBE721D11K1A<=>Z-T1<=>Y1<=>=>=>OGYH861)WE(2171)19S1V4M=OY
M16K191&S&UK1EHWT3EL+11>=>40@>CUN78F.BN:0?>?>N&K15.L5<6'CO'>M1S<=>=>1S1^>105

[illegible]

M>#N=,H42>*TH4RIT:8:8R6M%>|/J8)S#NNIHWBS<+I> MRW)U2F*E.W9)8FU,|L<+,\$*FTH/FT/LH(FUH>62TF)H3**A)00:J M7:U18=XBHJ.HJ*1@&1Y-HM-1:01BHJB0@12450AT@R5Y%2E>#NHHU1-1M2&0JZO^PHV>W8584R>,N=N*ODJL=F=D*3(=W,2*02**A\$6,EG6(G97B MK- C">=&7Y1L.H.E*>VIRI64*B\$&A0)PKPJ6*U00Q@1 HTH(B^PGEI8&U6B9P M\$<G2.R.H.E=4Y\$K3&7Y>7:11P,38D1,|MAH2A?>COQ^QHJK&.&1?2?>J MT2TAUPY\$S0,|>E\$CG0X<R+>E172Y?H>A5R1DAB.D0Z*YAGW.MR@KK49>DYL.HFE.E509R=RWB*L.M5D&@XONOUX8RN>NFS0)6%EM,85%G.M\$&+0#L- E)M.OK.0MBHINV%&7\$G*720|<./P\$6=P")4G*ET\$P<+NB/UH/-M+9B-8WO.&T2RETFS40OTS,7M0P*F=*)L.M2S\$@<K*DV<%HN1=5*RE8Y\$A>H/L (TU2HXJ|^+TAD? P*GOL@Y@R.A1*9&# M0L1=4X@J4LG-0181Y@<SK>1599MQLH&6^W1D)P^1Y^/X07^1/1TG-G.M6<C\$+VP\$+ISK.E&V&E*#ZSMH9HW7K^HY5 H6>@DL@B4RQ\$XBJH01DZ M3A^HJH.NSSB22 O=Y6UJE107H8H<+X\$01\$5AZI0XQD\$<02U \$>#J K-ME<U7 L.O2(ZFFH>60.G\$YV2P? R&L F1+>174ET1H^YR1\$32>J@E|>E M04W/L ORB# EW99GB-W\$>9%U20N=N.O.H1Y&19-W<=<2%L5\$9TIP@U%0KN6%EF3UM9%9DNN(\$*2-B:11 M20KH2R^NM- %*P08=150EOR83A<=>XMGIAAK^992R9>=>@C UYH>+7+1M.M|>@XQ^FM+>YH>OYAE\$5&@<02L5E&&(WD31H0^E1=1=7H18H\$*G^F.MRIDTJQ?2-2IYW)0091? M;CD<<(21R1H@<BRBZ<5-E/CZ1F&S\$WA7=^+1M&/%X0@1WIRSEZ17X/(+WUK839\$&N@JVG?FA@Y^Y^@NO^ERY,SB:9+NZY-M,> f\$9>4^Y19>41OS/>7UO.PHM\$1K^O@<6&5/6%SO&0K?PY>9:MF5D/IN\$= M.L+>#KW-T.C/EOMD/8G2Y<5.11#<G1?3YR=5>J=ZW9Z-XUMY>0GI-OYY?E=HV-1N&% IY>7MZ|J1?215>T1?2PC\$G89 ,/LOT+2CC% M^XOA)3\$>S^<6 N^L\$GX&7L F1Y^J Q9^TWMX,D12>9XSRL^2=24G=1?>|M|>7=UWKXWSX+>1&X\$YB\$=A3E>.,|W#F? WU=Z6W^GJ<+2E+1^JUN=H M\$E1U7Y>S8&N^RZUBRT/R^7B7A#?>OHL->OD \$M2^TW@>+18@<32.N M\$A>%T9BQ(438P\$).LNE1PD^7Y<+>M)0D0R4D.V4VOUE. M38IE9N>S>G1K\$W0Y%419.MA22,X3\$V.Q.4^B2NC.OU<=>=>SWUZH^7CL\$NUH18U91U)NOYOT(Z2+>J C.MG<1B166)HQS52H0=>V@N.N2C=>3\$C.G0?L#E.N.NV-PE5P, \$Q7P.M.OY16+R0^F*K& FSLXL+8R>(\$15131H^<009H>73)QXCETN.EFC*&D+M?I6".S|@U-@/+7@<\$5VJIG@VF5,Z\$<43M;JWZ4FV6,9IAU^H-0ADB^2G^7\$U M1HVP^Y.Y.L.HR85<ISE.815G-H/J(E.N80\$<@2^N^CQO.Y14<@2#2WE?Y^M@EJ(#!U^D>920N2EY\$SMK<C8R\$>?>?C.U#D.J@QZK^80-LH0&+H(F M+J)5H|H+FZ^WLYG.L1?17UK>QO XISV8VQ1.T1\$5EXO MMKJ201ZK1>J.A2^T8(1+1A=M)K0/YE4X^1.9H@<GW>QV?)A5^W0\$<2527P.M.Q5>+2@>1Y^>U%01 \$55GZM^1(#DK)|<=>=>P.YTGH4Z0^Z30H1J\$@<M.O.WW=ML-1F?>P^W.MP<8\$>A1+L5-3<4J1D\$171H(REXYLMX1Z^0DOIMWRYO=<@JGL@1=12KB^ MMH010RR766#P.O.G1\$<4V09T4B7401.5>^9(\$%<T4P1H40^QDH@<SHN)M+FGX.R^RD>2FIAB3=+1)LA^<E/HJBHYKX1G/2P&H^0Q/OEHJ(H8B^0&8<C< M3#1.12775SUVK1^L\$3NH.LE.7B-69ZP^XV62H1U>#6W0.K.N9WJ9G.M.FH9E-G.Z^/HUK12#&+&,IM8E.Q02+O>#UC\$49LD^IQ216IV#>.)M=N536W-MBTRR70U D9\$QFUR154B01D(L.FDVNWJQD>6HR70UXL501A.MJ.U.GG.M6^IYN?H=U%80L.O19/U%IG<A^+S<+FULO/ST^SIN^YV+T M+J)5H|H+FZ^WLYG.L1?17UK>QO XISV8VQ1.T1\$5EXO MMKJ201ZK1>J.A2^T8(1+1A=M)K0/YE4X^1.9H@<GW>QV?)A5^W0\$<2527P.M.Q5>+2@>1Y^>U%01 \$55GZM^1(#DK)|<=>=>P.YTGH4Z0^Z30H1J\$@<M.O.WW=ML-1F?>P^W.MP<8\$>A1+L5-3<4J1D\$171H(REXYLMX1Z^0DOIMWRYO=<@JGL@1=12KB^ MMH010RR766#P.O.G1\$<4V09T4B7401.5>^9(\$%<T4P1H40^QDH@<SHN)M+FGX.R^RD>2FIAB3=+1)LA^<E/HJBHYKX1G/2P&H^0Q/OEHJ(H8B^0&8<C< M3#1.12775SUVK1^L\$3NH.LE.7B-69ZP^XV62H1U>#6W0.K.N9WJ9G.M.FH9E-G.Z^/HUK12#&+&,IM8E.Q02+O>#UC\$49LD^IQ216IV#>.)M=N536W-MBTRR70U D9\$QFUR154B01D(L.FDVNWJQD>6HR70UXL501A.MJ.U.GG.M6^IYN?H=U%80L.O19/U%IG<A^+S<+FULO/ST^SIN^YV+T M+J)5H|H+FZ^WLYG.L1?17UK>QO XISV8VQ1.T1\$5EXO MMKJ201ZK1>J.A2^T8(1+1A=M)K0/YE4X^1.9H@<GW>QV?)A5^W0\$<2527P.M.Q5>+2@>1Y^>U%01 \$55GZM^1(#DK)|<=>=>P.YTGH4Z0^Z30H1J\$@<M.O.WW=ML-1F?>P^W.MP<8\$>A1+L5-3<4J1D\$171H(REXYLMX1Z^0DOIMWRYO=<@JGL@1=12KB^ MMH010RR766#P.O.G1\$<4V09T4B7401.5>^9(\$%<T4P1H40^QDH@<SHN)M+FGX.R^RD>2FIAB3=+1)LA^<E/HJBHYKX1G/2P&H^0Q/OEHJ(H8B^0&8<C< M3#1.12775SUVK1^L\$3NH.LE.7B-69ZP^XV62H1U>#6W0.K.N9WJ9G.M.FH9E-G.Z^/HUK12#&+&,IM8E.Q02+O>#UC\$49LD^IQ216IV#>.)M=N536W-MBTRR70U D9\$QFUR154B01D(L.FDVNWJQD>6HR70UXL501A.MJ.U.GG.M6^IYN?H=U%80L.O19/U%IG<A^+S<+FULO/ST^SIN^YV+T M+J)5H|H+FZ^WLYG.L1?17UK>QO XISV8VQ1.T1\$5EXO MMKJ201ZK1>J.A2^T8(1+1A=M)K0/YE4X^1.9H@<GW>QV?)A5^W0\$<2527P.M.Q5>+2@>1Y^>U%01 \$55GZM^1(#DK)|<=>=>P.YTGH4Z0^Z30H1J\$@<M.O.WW=ML-1F?>P^W.MP<8\$>A1+L5-3<4J1D\$171H(REXYLMX1Z^0DOIMWRYO=<@JGL@1=12KB^ MMH010RR766#P.O.G1\$<4V09T4B7401.5>^9(\$%<T4P1H40^QDH@<SHN)M+FGX.R^RD>2FIAB3=+1)LA^<E/HJBHYKX1G/2P&H^0Q/OEHJ(H8B^0&8<C< M3#1.12775SUVK1^L\$3NH.LE.7B-69ZP^XV62H1U>#6W0.K.N9WJ9G.M.FH9E-G.Z^/HUK12#&+&,IM8E.Q02+O>#UC\$49LD^IQ216IV#>.)M=N536W-MBTRR70U D9\$QFUR154B01D(L.FDVNWJQD>6HR70UXL501A.MJ.U.GG.M6^IYN?H=U%80L.O19/U%IG<A^+S<+FULO/ST^SIN^YV+T M+J)5H|H+FZ^WLYG.L1?17UK>QO XISV8VQ1.T1\$5EXO MMKJ201ZK1>J.A2^T8(1+1A=M)K0/YE4X^1.9H@<GW>QV?)A5^W0\$<2527P.M.Q5>+2@>1Y^>U%01 \$55GZM^1(#DK)|<=>=>P.YTGH4Z0^Z30H1J\$@<M.O.WW=ML-1F?>P^W.MP<8\$>A1+L5-3<4J1D\$171H(REXYLMX1Z^0DOIMWRYO=<@JGL@1=12KB^ MMH010RR766#P.O.G1\$<4V09T4B7401.5>^9(\$%<T4P1H40^QDH@<SHN)M+FGX.R^RD>2FIAB3=+1)LA^<E/HJBHYKX1G/2P&H^0Q/OEHJ(H8B^0&8<C< M3#1.12775SUVK1^L\$3NH.LE.7B-69ZP^XV62H1U>#6W0.K.N9WJ9G.M.FH9E-G.Z^/HUK12#&+&,IM8E.Q02+O>#UC\$49LD^IQ216IV#>.)M=N536W-MBTRR70U D9\$QFUR154B01D(L.FDVNWJQD>6HR70UXL501A.MJ.U.GG.M6^IYN?H=U%80L.O19/U%IG<A^+S<+FULO/ST^SIN^YV+T M+J)5H|H+FZ^WLYG.L1?17UK>QO XISV8VQ1.T1\$5EXO MMKJ201ZK1>J.A2^T8(1+1A=M)K0/YE4X^1.9H@<GW>QV?)A5^W0\$<2527P.M.Q5>+2@>1Y^>U%01 \$55GZM^1(#DK)|<=>=>P.YTGH4Z0^Z30H1J\$@<M.O.WW=ML-1F?>P^W.MP<8\$>A1+L5-3<4J1D\$171H(REXYLMX1Z^0DOIMWRYO=<@JGL@1=12KB^ MMH010RR766#P.O.G1\$<4V09T4B7401.5>^9(\$%<T4P1H40^QDH@<SHN)M+FGX.R^RD>2FIAB3=+1)LA^<E/HJBHYKX1G/2P&H^0Q/OEHJ(H8B^0&8<C< M3#1.12775SUVK1^L\$3NH.LE.7B-69ZP^XV62H1U>#6W0.K.N9WJ9G.M.FH9E-G.Z^/HUK12#&+&,IM8E.Q02+O>#UC\$49LD^IQ216IV#>.)M=N536W-MBTRR70U D9\$QFUR154B01D(L.FDVNWJQD>6HR70UXL501A.MJ.U.GG.M6^IYN?H=U%80L.O19/U%IG<A^+S<+FULO/ST^SIN^YV+T M+J)5H|H+FZ^WLYG.L1?17UK>QO XISV8VQ1.T1\$5EXO MMKJ201ZK1>J.A2^T8(1+1A=M)K0/YE4X^1.9H@<GW>QV?)A5^W0\$<2527P.M.Q5>+2@>1Y^>U%01 \$55GZM^1(#DK)|<=>=>P.YTGH4Z0^Z30H1J\$@<M.O.WW=ML-1F?>P^W.MP<8\$>A1+L5-3<4J1D\$171H(REXYLMX1Z^0DOIMWRYO=<@JGL@1=12KB^ MMH010RR766#P.O.G1\$<4V09T4B7401.5>^9(\$%<T4P1H40^QDH@<SHN)M+FGX.R^RD>2FIAB3=+1)LA^<E/HJBHYKX1G/2P&H^0Q/OEHJ(H8B^0&8<C< M3#1.12775SUVK1^L\$3NH.LE.7B-69ZP^XV62H1U>#6W0.K.N9WJ9G.M.FH9E-G.Z^/HUK12#&+&,IM8E.Q02+O>#UC\$49LD^IQ216IV#>.)M=N536W-MBTRR70U D9\$QFUR154B01D(L.FDVNWJQD>6HR70UXL501A.MJ.U.GG.M6^IYN?H=U%80L.O19/U%IG<A^+S<+FULO/ST^SIN^YV+T M+J)5H|H+FZ^WLYG.L1?17UK>QO XISV8VQ1.T1\$5EXO MMKJ201ZK1>J.A2^T8(1+1A=M)K0/YE4X^1.9H@<GW>QV?)A5^W0\$<2527P.M.Q5>+2@>1Y^>U%01 \$55GZM^1(#DK)|<=>=>P.YTGH4Z0^Z30H1J\$@<M.O.WW=ML-1F?>P^W.MP<8\$>A1+L5-3<4J1D\$171H(REXYLMX1Z^0DOIMWRYO=<@JGL@1=12KB^ MMH010RR766#P.O.G1\$<4V09T4B7401.5>^9(\$%<T4P1H40^QDH@<SHN)M+FGX.R^RD>2FIAB3=+1)LA^<E/HJBHYKX1G/2P&H^0Q/OEHJ(H8B^0&8<C< M3#1.12775SUVK1^L\$3NH.LE.7B-69ZP^XV62H1U>#6W0.K.N9WJ9G.M.FH9E-G.Z^/HUK12#&+&,IM8E.Q02+O>#UC\$49LD^IQ216IV#>.)M=N536W-MBTRR70U D9\$QFUR154B01D(L.FDVNWJQD>6HR70UXL501A.MJ.U.GG.M6^IYN?H=U%80L.O19/U%IG<A^+S<+FULO/ST^SIN^YV+T M+J)5H|H+FZ^WLYG.L1?17UK>QO XISV8VQ1.T1\$5EXO MMKJ201ZK1>J.A2^T8(1+1A=M)K0/YE4X^1.9H@<GW>QV?)A5^W0\$<2527P.M.Q5>+2@>1Y^>U%01 \$55GZM^1(#DK)|<=>=>P.YTGH4Z0^Z30H1J\$@<M.O.WW=ML-1F?>P^W.MP<8\$>A1+L5-3<4J1D\$171H(REXYLMX1Z^0DOIMWRYO=<@JGL@1=12KB^ MMH010RR766#P.O.G1\$<4V09T4B7401.5>^9(\$%<T4P1H40^QDH@<SHN)M+FGX.R^RD>2FIAB3=+1)LA^<E/HJBHYKX1G/2P&H^0Q/OEHJ(H8B^0&8<C< M3#1.12775SUVK1^L\$3NH.LE.7B-69ZP^XV62H1U>#6W0.K.N9WJ9G.M.FH9E-G.Z^/HUK12#&+&,IM8E.Q02+O>#UC\$49LD^IQ216IV#>.)M=N536W-MBTRR70U D9\$QFUR154B01D(L.FDVNWJQD>6HR70UXL501A.MJ.U.GG.M6^IYN?H=U%80L.O19/U%IG<A^+S<+FULO/ST^SIN^YV+T M+J)5H|H+FZ^WLYG.L1?17UK>QO XISV8VQ1.T1\$5EXO MMKJ201ZK1>J.A2^T8(1+1A=M)K0/YE4X^1.9H@<GW>QV?)A5^W0\$<2527P.M.Q5>+2@>1Y^>U%01 \$55GZM^1(#DK)|<=>=>P.YTGH4Z0^Z30H1J\$@<M.O.WW=ML-1F?>P^W.MP<8\$>A1+L5-3<4J1D\$171H(REXYLMX1Z^0DOIMWRYO=<@JGL@1=12KB^ MMH010RR766#P.O.G1\$<4V09T4B7401.5>^9(\$%<T4P1H40^QDH@<SHN)M+FGX.R^RD>2FIAB3=+1)LA^<E/HJBHYKX1G/2P&H^0Q/OEHJ(H8B^0&8<C< M3#1.12775SUVK1^L\$3NH.LE.7B-69ZP^XV62H1U>#6W0.K.N9WJ9G.M.FH9E-G.Z^/HUK12#&+&,IM8E.Q02+O>#UC\$49LD^IQ216IV#>.)M=N536W-MBTRR70U D9\$QFUR154B01D(L.FDVNWJQD>6HR70UXL501A.MJ.U.GG.M6^IYN?H=U%80L.O19/U%IG<A^+S<+FULO/ST^SIN^YV+T M+J)5H|H+FZ^WLYG.L1?17UK>QO XISV8VQ1.T1\$5EXO MMKJ201ZK1>J.A2^T8(1+1A=M)K0/YE4X^1.9H@<GW>QV?)A5^W0\$<2527P.M.Q5>+2@>1Y^>U%01 \$55GZM^1(#DK)|<=>=>P.YTGH4Z0^Z30H1J\$@<M.O.WW=ML-1F?>P^W.MP<8\$>A1+L5-3<4J1D\$171H(REXYLMX1Z^0DOIMWRYO=<@JGL@1=12KB^ MMH010RR766#P.O.G1\$<4V09T4B7401.5>^9(\$%<T4P1H40^QDH@<SHN)M+FGX.R^RD>2FIAB3=+1)LA^<E/HJBHYKX1G/2P&H^0Q/OEHJ(H8B^0&8<C< M3#1.12775SUVK1^L\$3NH.LE.7B-69ZP^XV62H1U>#6W0.K.N9WJ9G.M.FH9E-G.Z^/HUK12#&+&,IM8E.Q02+O>#UC\$49LD^IQ216IV#>.)M=N536W-MBTRR70U D9\$QFUR154B01D(L.FDVNWJQD>6HR70UXL501A.MJ.U.GG.M6^IYN?H=U%80L.O19/U%IG<A^+S<+FULO/ST^SIN^YV+T M+J)5H|H+FZ^WLYG.L1?17UK>QO XISV8VQ1.T1\$5EXO MMKJ201ZK1>J.A2^T8(1+1A=M)K0/YE4X^1.9H@<GW>QV?)A5^W0\$<2527P.M.Q5>+2@>1Y^>U%01 \$55GZM^1(#DK)|<=>=>P.YTGH4Z0^Z30H1J\$@<M.O.WW=ML-1F?>P^W.MP<8\$>A1+L5-3<4J1D\$171H(REXYLMX1Z^0DOIMWRYO=<@JGL@1=12KB^ MMH010RR766#P.O.G1\$<4V09T4B7401.5>^9(\$%<T4P1H40^QDH@<SHN)M+FGX.R^RD>2FIAB3=+1)LA^<E/HJBHYKX1G/2P&H^0Q/OEHJ(H8B^0&8<C< M3#1.12775SUVK1^L\$3NH.LE.7B-69ZP^XV62H1U>#6W0.K.N9WJ9G.M.FH9E-G.Z^/HUK12#&+&,IM8E.Q02+O>#UC\$49LD^IQ216IV#>.)M=N536W-MBTRR70U D9\$QFUR154B01D(L.FDVNWJQD>6HR70UXL501A.MJ.U.GG.M6^IYN?H=U%80L.O19/U%IG<A^+S<+FULO/ST^SIN^YV+T M+J)5H|H+FZ^WLYG.L1?17UK>QO XISV8VQ1.T1\$5EXO MMKJ201ZK1>J.A2^T8(1+1A=M)K0/YE4X^1.9H@<GW>QV?)A5^W0\$<2527P.M.Q5>+2@>1Y^>U%01 \$55GZM^1(#DK)|<=>=>P.YTGH4Z0^Z30H1J\$@<M.O.WW=ML-1F?>P^W.MP<8\$>A1+L5-3<4J1D\$171H(REXYLMX1Z^0DOIMWRYO=<@JGL@1=12KB^ MMH010RR766#P.O.G1\$<4V09T4B7401.5>^9(\$%<T4P1H40^QDH@<SHN)M+FGX.R^RD>2FIAB3=+1)LA^<E/HJBHYKX1G/2P&H^0Q/OEHJ(H8B^0&8<C< M3#1.12775SUVK1^L\$3NH.LE.7B-69ZP^XV62H1U>#6W0.K.N9WJ9G.M.FH9E-G.Z^/HUK12#&+&,IM8E.Q02+O>#UC\$49LD^IQ216IV#>.)M=N536W-MBTRR70U D9\$QFUR154B01D(L.FDVNWJQD>6HR70UXL501A.MJ.U.GG.M6^IYN?H=U%80L.O19/U%IG<A^+S<+FULO/ST^SIN^YV+T M+J)5H|H+FZ^WLYG.L1?17UK>QO XISV8VQ1.T1\$5EXO MMKJ201ZK1>J.A2^T8(1+1A=M)K0/YE4X^1.9H@<GW>QV?)A5^W0\$<2527P.M.Q5>+2@>1Y^>U%01 \$55GZM^1(#DK)|<=>=>P.YTGH4Z0^Z30H1J\$@<M.O.WW=ML-1F?>P^W.MP<8\$>A1+L5-3<4J1D\$171H(REXYLMX1Z^0DOIMWRYO=<@JGL@1=12KB^ MMH010RR766#P.O.G1\$<4V09T4B7401.5>^9(\$%<T4P1H40^QDH@<SHN)M+FGX.R^RD>2FIAB3=+1)LA^<E/HJBHYKX1G/2P&H^0Q/OEHJ(H8B^0&8<C< M3#1.12775SUVK1^L\$3NH.LE.7B-69ZP^XV62H1U>#6W0.K.N9WJ9G.M.FH9E-G.Z^/HUK12#&+&,IM8E.Q02+O>#UC\$49LD^IQ216IV#>.)M=N536W-MBTRR70U D9\$QFUR154B01D(L.FDVNWJQD>6HR70UXL501A.MJ.U.GG.M6^IYN?H=U%80L.O19/U%IG<A^+S<+FULO/ST^SIN^YV+T M+J)5H|H+FZ^WLYG.L1?17UK>QO XISV8VQ1.T1\$5EXO MMKJ201ZK1>J.A2^T8(1+1A=M)K0/YE4X^1.9H@<GW>QV?)A5^W0\$<2527P.M.Q5>+2@>1Y^>U%01 \$55GZM^1(#DK)|<=>=>P.YTGH4Z0^Z30H1J\$@<M.O.WW=ML-1F?>P^W.MP<8\$>A1+L5-3<4J1D\$171H(REXYLMX1Z^0DOIMWRYO=<@JGL@1=12KB^ MMH010RR766#P.O.G1\$<4V09T4B7401.5>^9(\$%<T4P1H40^QDH@<SHN)M+FGX.R^RD>2FIAB3=+1)LA^<E/HJBHYKX1G/2P&H^0Q/OEHJ(H8B^0&8<C< M3#1.12775SUVK1^L\$3NH.LE.7B-69ZP^XV62H1U>#6W0.K.N9WJ9G.M.FH9E-G.Z^/HUK12#&+&,IM8E.Q02+O>#UC\$49LD^IQ216IV#>.)M=N536W-MBTRR70U D9\$QFUR154B01D(L.FDVNWJQD>6HR70UXL501A.MJ.U.GG.M6^IYN?H=U%80L.O19/U%IG<A^+S<+FULO/ST^SIN^YV+T M+J)5H|H+FZ^WLYG.L1?17UK>QO XISV8VQ1.T1\$5EXO MMKJ201ZK1>J.A2^T8(1+1A=M)K0/YE4X^1.9H@<GW>QV?)A5^W0\$<2527P.M.Q5>+2@>1Y^>U%01 \$55GZM^1(#DK)|<=>=>P.YTGH4Z0^Z30H1J\$@<M.O.WW=ML-1F?>P^W.MP<8\$>A1+L5-3<4J1D\$171H(REXYLMX1Z^0DOIMWRYO=<@JGL@1=12KB^ MMH010RR766#P.O.G1\$<4V09T4B7401.5>^9(\$%<T4P1H40^QDH@<SHN)M+FGX.R^RD>2FIAB3=+1)LA^<E/HJBHYKX1G/2P&H^0Q/OEHJ(H8B^0&8<C< M3#1.12775SUVK1^L\$3NH.LE.7B-69ZP^XV62H1U>#6W0.K.N9WJ9G.M.FH9E-G.Z^/HUK12#&+&,IM8E.Q02+O>#UC\$49LD^IQ216IV#>.)M=N536W-MBTRR70U D9\$QFUR154B01D(L.FDVNWJQD>6HR70UXL501A.MJ.U.GG.M6^IYN?H=U%80L.O19/U%IG<A^+S<+FULO/ST^SIN^YV+T M+J)5H|H+FZ^WLYG.L1?17UK>QO XISV8VQ1.T1\$5EXO MMKJ201ZK1>J.A2^T8(1+1A=M)K0/YE4X^1.9H@<GW>QV?)A5^W0\$<2527P.M.Q5>+2@>1Y^>U%01 \$55GZM^1(#DK)|<=>=>P.YTGH4Z0^Z30H1J\$@<M.O.WW=ML-1F?>P^W.MP<8\$>A1+L5-3<4J1D\$171H(REXYLMX1Z^0DOIMWRYO=<@JGL@1=12KB^ MMH010RR766#P.O.G1\$<4V09T4B7401.5>^9(\$%<T4P1H40^QDH@<SHN)M+FGX.R^RD>2FIAB3=+1)LA^<E/HJBHYKX1G/2P&H^0Q/OEHJ(H8B^0&8<C< M3#1.12775SUVK1^L\$3NH.LE.7B-69ZP^XV62H1U>#6W0.K.N9WJ9G.M.FH9E-G.Z^/HUK12#&+&,IM8E.Q02+O>#UC\$49LD^IQ216IV#>.)M=N536W-MBTRR70U D9\$QFUR154B01D(L.FDVNWJQD>6HR70UXL501A.MJ.U.GG.M6^IYN?H=U%80L.O19/U%IG<A^+S<+FULO/ST^SIN^YV+T M+J)5H|H+FZ^WLYG.L1?17UK>QO XISV8VQ1.T1\$5EXO MMKJ201ZK1>J.A2^T8(1+1A=M)K0/YE4X^1.9H@<GW>QV?)A5^W0\$<2527P.M.Q5>+2@>1Y^>U%01 \$55GZM^1(#DK)|<=>=>P.YTGH4Z0^Z30H1J\$@<M.O.WW=ML-1F?>P^W.MP<8\$>A1+L5-3<4J1D\$171H(REXYLMX1Z^0DOIMWRYO=<@JGL@1=12KB^ MMH010RR766#P.O.G1\$<4V09T4B7401.5>^9(\$%<T4P1H40^QDH@<SHN)M+FGX.R^RD>2FIAB3=+1)LA^<E/HJBHYKX1G/2P&H^0Q/OEHJ(H8B^0&8<C< M3#1.12775SUVK1^L\$3NH.LE.7B-69ZP^XV62H1U>#6W0.K.N9WJ9G.M.FH9E-G.Z^/HUK12#&+&,IM8E.Q02+O>#UC\$49LD^IQ216IV#>.)M=N536W-MBTRR70U D9\$QFUR154B01D(L.FDVNWJQD>6HR70UXL501A.MJ.U.GG.M6^IYN?H=U%80L.O19/U%IG<A^+S<+FULO/ST^SIN^YV+T M+J)5H|H+FZ^WLYG.L1?17UK>QO XISV8VQ1.T1\$5EXO MMKJ201ZK1>J.A2^T8(1+1A=M)K0/YE4X^1.9H@<GW>QV?)A5^W0\$<2527P.M.Q5>+2@>1Y^>U%01 \$55GZM^1(#DK)|<=>=>P.YTGH4Z0^Z30H1J\$@<M.O.WW=ML-1F?>P^W.MP<8\$>A1+L5-3<4J1D\$171H(REXYLMX1Z^0DOIMWRYO=<@JGL@1=12KB^ MMH010RR766#P.O.G1\$<4V09T4B7401.5>^9(\$%<T4P1H40^QDH@<SHN)M+FGX.R^RD>2FIAB3=+1)LA^<E/HJBHYKX1G/2P&H^0Q/OEHJ(H8B^0&8<C< M3#1.12775SUVK1^L\$3NH.LE.7B-69ZP^XV62H1U>#6W0.K.N9WJ9G.M.FH9E-G.Z^/HUK12#&+&,IM8E.Q02+O>#UC\$49LD^IQ216IV#>.)M=N536W-MBTRR70U D9\$QFUR154B01D(L.FDVNWJQD>6HR70UXL501A.MJ.U.GG.M6^IYN?H=U%80L.O19/U%IG<A^+S<+FULO/ST^SIN^YV+T M+J)5H|H+FZ^WLYG.L1?17UK>QO XISV8VQ1.T1\$5EXO MMKJ201ZK1>J.A2^T8(1+1A=M)K0/YE4X^1.9H@<GW>QV?)A5^W0\$<2527P.M.Q5>+2@>1Y^>U%01 \$55GZM^1(#DK)|<=>=>P.YTGH4Z0^Z30H1J\$@<M.O.WW=ML-1F?>P^W.MP<8\$>A1+L5-3<4J1D\$171H(REXYLMX1Z^0DOIMWRYO=<@JGL@1=12KB^ MMH010RR766#P.O.G1\$<4V09T4B7401.5>^9(\$%<T4P1H40^QDH@<SHN)M+FGX.R^RD>2FIAB3=+1)LA^<E/HJBHYKX1G/2P&H^0Q/OEHJ(H8B^0&8<C< M3#1.12775SUVK1^L\$3NH.LE.7B-69ZP^XV62H1U>#6W0.K.N9WJ9G.M.FH9E-G.Z^/HUK12#&+&,IM8E.Q02+O>#UC\$49LD^IQ216IV#>.)M=N536W-MBTRR70U D9\$QFUR154B01D(L.FDVNWJQD>6HR70UXL501A.MJ.U.GG.M6^IYN?H=U%80L.O19/U%IG<A^+S<+FULO/ST^SIN^YV+T M+J)5H|H+FZ^WLYG.L1?17UK>QO XISV8VQ1.T1\$5EXO MMKJ201ZK1>J.A2^T8(1+1A=M)K0/YE4X^1.9H@<GW>QV?)A5^W0\$<2527P.M.Q5>+2@>1Y^>U%01 \$55GZM^1(#DK)|<=>=>P.YTGH4Z0^Z30H1

[illegible]

0-0MN"SET^@U0%FITBU+WB:40IE9+H,3,9DUTY9"Y5(-;v75EM*^<=1?LE15'Z310XKWZ3+@Q"+G*LO'X(^2/G/GI-MM?I
73XP1+IPGGS,2E7IVPRX:4,4V"MINW>POQFB,SPQ=5%"H8?E4D1MBA4)(sX7=M+1T7Z1/S12IX2924/^-HRC(^(^YX04/ UJX6=T5LX9VSPC?M#799,+AV,*#-Z07,
(GNMS5NOYB" DPH216(4)56R:4s=>K1 U, _OM,K12:8-9-%56ZH4V1D3,2,QPDCD7CQJ7Z0,5+P,099?BZ+K>B<XMM+M,X,Y+L">+>XPBK32PN/H990%4G
ML,C1WX12T1Q10B,W1J3,+>#NRI1Y980M+K4(-C^SBB:CL:4)=/S(5?P+M=NA/K QX91V,4L QAS5H+FOKA,WK4(2<852P2,3YHHHC08 6":4:SPAZB<C^I/M-5B1:
=1X4(XNPQW:5C^s1+Y"J4105@O%OE@ #X3,"SP1:AC7:G6(N7L M,K#EAI= B 6X^&K1Q53DL2B1+T2HLPL>LR+T,SGOF,13GIEH12B7S,P2X&H&GMS?U>U,5->6,K&M?
+UJOKZDDDE(C,0^XPT2:(P,T56Q2+7+ORS2S&I830-#D=1P2X45T4,K^C=E.MOCYBDHD#4%SRPY10RXHOB&1H,7(Q/EP458=D9,J,M 7-2?W1^AQ.E=1+K*="2AK"#1Z:
5PCH,OP, GW861GW867D822>G.G.F, ICF13>10%K^Y1^XV,NR5?Y3^1P^C M^Ys.0=30(3T?=>#B,5)4L#CB^YJY1-I83M,M1HT6BQT?WBWJAO^HB MHF(HXNN)+H
MU,F(4YQY2)<0=IZA:THHH@#Y0,1ZPN3105ER+KFUY+GEETE,RIM:4>H9P,M=-1C28)6G_2^QO?>+>S0=H^9HP,PD,G=IMNU?2P(TJ0V@X@NR8L%L%NIZ
MSH,51X?C(YCTVOCMMDP)>/19C6W1Z,7>=>OC6TJK M-PA"DAVY=81-&P/2SH5IW7XP2-6LZN2873ZFC6FT1XBWBZ?<K^JGFG+MAMGHJX19SHOD1C?>+>H&U<
="M=1X?2HH,6(G6/RK19S^>ARVJ@P&Z,3=X M^C-V>2SIBG?2EMAP/AB9U,3FG6WEI7P2B+2OJ1F%I,RY)1+1@W021^@J2F,M2P1C=30P,PL4E,0:12S?5T%?712
X=Q?7MsQ%UQJ>XW4^KTC9Y9F\$OC=C-W2L M&F+U,Y01F,YG31A,G^&+4,4U510@&"5/LB+YJ,E M&DC%Y/Y/X@0H,2,5>>5D=(HO^U3Z5,1#CEE9E48;2C0W%
(EG+<K5?G-D MWCC ,16IN=0=)5,5PYUHO-DS>2C1 3C,W&H6D>BDHSSK^H-@JFC7L12M2U9;EEFK@&H?P^!\$HT,9^<0-X392K1C16N/19(10>+J6=95&AW4)?
XMDN?>>>4MO^#F6Y?C=GO+PC9D3N1VU,1L=IREFRJ, #H9S>1YV%9CMV-ME1VUWDDP#M@VW&K#Z,700S0U0^@+>+IUA;A9?2>=14GT^NMH1A&=8F*
M25GV<9>_PYMA@CJWZD;YCG;H0KZEPJ,LLKK6697MJBZB"W4YIPCV31^UZ A) MZ0>+>Z1Z1C 1J(1T^WLL 7)6BK1^CZ1P,UT@N87R15?XZ+V:V53
M5,1MGF7@<SLN^RS>G5WL@1 8NK "H2P=O@NH@IMZ4F4LL(K?;G(50MHJB RMZHQW?W^HNDUS=K^3NJ9N,U@PUZ1C\$T16^9E7150=181V10.N->U1
UD,=ZXY2ZXY2^XC41455&646G>D,IPAT21^>MW+54P,5B1V7E6&KOM^4G M<8#M^1J2J^C4>G5X>07%TQ1KP87C^YV1YO=A1861@/XCVNF9@<-2RW8C?
M39,M120L^U4MM6G1C(LZU9910G/9RV?>#>UK=54P6W6fXIC>6>6C^4G1G^5<1X&S, &A312YXWQ,1,7T,1#ZKRKC^CI,
ME4ELMXTS"N=DU,RC=>RS8IAK^LGD^IB,21^H^Z:6MBXMBP-ZPV99_-+MS8;ZE>B251R-M1NY28+5L,0=0_0@0m%2GLSC"E.DL1+1)KA-MEE(416>Z"WL^R^H^EV@H;
=<8(322,54 38H,(Z-LQVZ7XQJ>I92,K^1^Y1WLMBRRBICPTJ,ISENMID?<,"OPK05?3E%K41FA@&G/2TIE/AlK&NUK4>7T2CV1HP M,
12=VEBEAQ^NNAREUS2X9R^A^8IK^M^?716L,E B8K4ARTPGR0D5?BH^JID MW27H=58B4%W8Y74%M^CX&V,3U5U;HCY\$ A8^O&P^"01
M,12@Q,K^%+77ZL^>Z^5TN4AM9KTY^YU,8Q?Z7BGJ&Q^G5GUD=A^4712Ms?1ME81L1E,2MABP2<#D=R(RM61M&1@&8FM9%58B?HRC^IN<+1&@^KVH^H F
M/Z+&41^N@<X2BW,782X UXB)YAMO-B6XZ?>+>J1,18NS^F^Q%,19^&MX2#)?,NIM=POFO\$U1L-T8Y=SYFA4@XALEEUH9?NT,MF&BB#(N4=>9FJH,LHJB9,0,C,5-
EDPZMT MD1614(H^1H19>1D14\$2PM1+4C^5IZR1YTHDE@<I^V^CTJHMT+1VY@&+<U\$ M@GVYM,21:7.WHDH0SA,IS166B0H9\$SA3F1@79-K
MD1LAWL9LQ\$=8W4MQ31#1QY^M,6,9-1,KKMD-RT@=>#,>Y+WQI>=SO3S@ MG2(E GJN:EW+2T2%8QH2%LEGO M4FNGN1P+<E^IV^M=EH49ZQ53^GH6^?>
#<K 6IDH872%Z GL(4@15K2,L D MC6M1^ZBBU-8P2^D,^1^M=>HPB EQOOS=>57^ C,5JN:1L, DG, &5HIUSBU702IBLS=ZA^Y56C<2C&10C<441%
^D0B9/G,W^=B,D&S,1HH^F7H1&M^>V102WQAH^W^1^W^<C150L>8YVS6KXK00<#<0HFX\$2 (H&3010HHE^57^0 M62,971=U,JQ0@6>L&+L2^17Z%L+1K^<
YSHZYZK4C41=1B72T-7TX^4A^Q MZ&0%&OMBV+ES5FH0NRFH3ZUC?R2MKND,D@ID,UDI@YMC2^MRC&#1M19X1&#&M8,ME18KC71^,MJGJINK1(KE)ODI
YS&#&N\$M,OIE), MGIY,TRRR0MBD9ANGM<@F2S169K,8U390CSFK@<FVW16MF6+1(ZR1N0U;(5R6P0MF=<@R520531210E8570PB8N+1^F06>2, &G&82
M,9-G, WAEENY@G1S9F,2BMRR22M71-81NKY\$M,M, Q%&HJG0K^M@<D\$5 M,3K1+662U^<B=PEKS<Z3F,K^U^H\$3W8, %AG&21980S,7%K>0TUDU,1+6+1M>5<4Q/N3W
41P04 7-1>A21KXLP1^EPOH&S+>JHW^=<NZ><+T^Q&E, &MYH156,5(WD9,Q45^>9F8,SU+>1^NJEN9,K^H>D<618M^ZMLXWD1=R54S MKT@O>G>+>+JFEL
H,4UDX1L7&Z,T8, N1_Q06,TKFF7W31T=OD)^>+M^3HCAYW,T26ZQ^YA+O1FV, &0D0,&H23H3VZRY0&,&585Y1K,F5,Y7V1D7,59:>=<H^E%CO^3HA<,>ML,F1V^9^K^5DVYH
613,8B1=H04IT9^ZB04ATFK02?756P56FRETE^K M+25J,UE7,MAK0=O,CSVY,E,CH31802\$M16=>6?76, \$7QRT^GDI,K M3,S>YG E,Q
G&B^<IBX1)/G4Y2^INAL80J/32^@XC<+A,TO>+7PGIX70Y", MWV\$AAAF2F=6W9,7^E)>+>1,QLB=MI (W69RV12YDI,B=T,D,N,+8D;NB,M^"
9KJ4T2EAO+>1336P0(<^E M3>3+M6G9R1U?2,RVSYMT, 8GDCQ?QGQSHB M>1W4DWCQ,^HJ#8& E4YE12^<D, QK^%XSXHG1^#0K^A<T#8% HPB@<B
N,KY#A7S1,1YVGK 75C61KX5C>=9N17, N4SSR1UR(KJLFP&MH 77B,^7M^>85T241, D&Y7C)S1),15%MN,C511B>=<8NLR3C1Q^PO,Y1M+1,^1^2^Q MO,218
1\$KX&625B>=<R10,&4Q,20:&AGOH^Y%0,NGFZMH)^>#>N@<O M<6-K,1613>3J8ML1ICZ-MEL=W6H1U^0&BA814H1,6+>UWFF18^>LRO,S
M10DMHG6>HX^WEL80L,14W:B@IW7HAY6G&K<+N^N, N^>D1H2^58A,"G55 M,^RRO^EE>+>1,1%,67^8A=CGA(53008R=>=W1%YMYU,N73?7 GMOX^+9P=IV+&A
ML,PP-810@25(,G610J\$Z2>7IM^KQ+<F4=2X,^),D5G@H%813F,0^R10M04ZF M,<^),PL3="4MK,IUQU^9M,10F+<OKIAM,15L^14HB7D22V^M/E0F ZGL/52F MH^?
%DK,KAJL^E65,%51^>98,<^&gt

7P:7W:DS:5WN=MJ50/<^#QBVKQK35 R5&0/<^Y^SKS=76K3/<^&R/,0X23-KI1M>..671+!<^\$=W9.K6GVI:UAF*#.IPNW8GFZ"BX50-PD1YN/!<-M2
L"XHL=+BU@R07P2HA<MIPPI349Q<^B|<+D0UR6%ZGZSGP(TG MJHT20N>0:0:6LCLX+!#0/GIV/F.HJHX<*<^%#NU&OAR
M-Y@:FWF.8WCY12..5G.N.WDG>+P3V655#..19I.162K0&S..9+1&2137&E13 MTL>2>A|B-KLELFP(OQYZJDW<C*MHZ2>+!0QMSWJS |>DJO<#H|IV:W0GZVL
FVOCF#M2#XY#SIK&K<^M1ML34S2/<^E.RORR/..15B&S(2>+P3PTFY=0*ZALMH|D6MNMZ14B..M1*IXS?>+F>YF9?DN:>GBFO>XL#<^FL6:>%OCBD-R6 ZS3?PU9-NAE
M<^U..1+1&5DZ=14\$(1L7GCAVYNZ3AH.X(UT.R8H|<^0<^QVBP2PM1<^M0|OPB(G)Y<^M..1=16I64M0I?R?P..P.D.18Y?H?0)9.8.%>+!>4="M
|<^!AHQPIZ.C5<^8|>WM*<^H.A.P.0.XCC03<^*!>WN*(HHL<^LXLVT(F<^M05&OC<^1N/EJF4Q1ZU(UT.O?P*<^4<^U.M%8.EP.CXP?P|/OPL?2
1FN\$N2I4O&F%>^UOZBNY=>M5M7GYB.C9(FANV@.M@/)/Y:6^P|@SVH|@.CJ98P+3.ME)?>J0A<=2?XIW\$R1C2YH|<HJ6K1#>MOF5<^1.XA&M8MPD<^T0HUHZ1<2&Q5?P1
@NLT.C|@>056X1K08N#08..M6M44T@J<^PENFVN|XTF&Q9I05Q1+G<^((A4.1<^TMSF21SO0<^MOYJ14J.M40EUG#61<^V3K
<8.9>+!&=>51H2K0P|Q7:72IDK|>+IRCL<8.9>+!&#3+P7.MIM<^W@>+&Y7=XTZPT02C&A.OVBK<^Y1?2=>2JX1+Y..U2D1&^MN.P1
M3(NPJOHCQ6P|<^6<^SR16>9VQ<^6B|<X7U.X@>=>M0H0A4YQ<^8EA(E"SWH1&9A.4B|N<^0X3%2TQIFR31?>B-B61NCLAY32>M-R Z1%(C&^JOA<^JCG
20.)>WNK&^B#0K&#9W1.AB3LSZ108?>HUK1.MD&KREFU|6|?>LLYBR2<^0.%S|<N.X8.E&HJ<^L6GUOK.2R?>+!>OGU4R9D
M.O2C(RA)6<3QJLW?>OADK#AV0RI&Sf\$U&M%54V4.2(Cf&^J.VJVF2UAD<^+&+?>0.D?>U93?>+!>EKJ9RRR>RWY?>E%Y7>+!54WV9>.>C.%Q
M\$P>OX>X|Z3|J3?>M2K?F6&FVXZ>4YOA.HC\$SWFW|+!<N7.N83G?E" M9L2K4H|<7M6W/GS(4F.>..5XO1O.MR>QONFMP|<W7&K\$!<U\$0L5U1VLU
M6AE137.DPOUDBA(I#<K%Q07L>7H.EHX7?>J3|<0>G0>M..+!>JQXTEI815/<^MHHB3&+19T?>FVGT4829W?>P1D5/>..J3?>2.315C|L.N<^JETH4<=21.2<6YX+
(M6Z25..4M+4V10RXL6.M@5?>5<^1YQCA?>P2|>R&R8R<803?>PYFYKGOUQOX<^03<^?>7P2B|>..FV2<^C8Z3SURX>9AL>?>..13?>N.M53F5PHAN42GOAE|3<^KDA&|SHHTF?X
&X\$W49P76>?>Z?>..1<89|F8#>*<^R.MR9TZRQ.X5|6..05N<^U#3.R.9?>WMQ9S<^0WYX<^N2MIA.P15M%P5A<^1<^6NIA.M4|H4V.OVMZ<^XYS90#WZ?>#1
M&1F\$LO8X2HRS\$B?>N76|N?>+94IE<^216Q?>5<^I<0M(MD(T)V?>H.CUC@V9.L68..C(DH|M&BZ>+W290..MMJOV?O4\$ST<^<^<^TL19+!
(T+>H4."R">5=>FRCF?>C%9SINDF8GHE|<M.8Y|>..E=DD|H..>09>N7AO.H3?F?>P>56|<TBQ|84DPBDW?>M.YIEF?>H|HY1>>>817?>1|ROQ/6?>S8|>..61/0V/NFP-%
?BP6C3K3U.MQ4<0+H1+8GK<^\$Y2X<^+6+8U|Z7|112?>EYVA%<XJ2D|>R.%C|>8LH5%QZ3.E%<^&|353>+!>MBH1F3K5+A.R.
H|<715H1Z>+!>Y.O.SY<^XO1XJF7RCSU<^1K<0M.MBRNS.H87>KJPGGB1H4P95C|<1<81<^08L8|>..>B#N1FZ.4XO<^K287H01.8B<^8|>?>FJ9H
MH98<^WYRTPW7?>=>M0HLX<^1<30?>+!>L9K|>6|PHZ(FE?>G=BOPKBIJTG.G1#<M?Z?>B2#>=<^C6%5<^U<^T.Y4UEH79XN(M2M|E<^P?>Q?>
..BT\$P\$N20<^1#<^J>..ASZ.WH1+BX8H|H+ETD|6M3\$1QV82F.263|>8.CJFN.K16.C6#K?>258X&|<T.M.A39V?T?>6.TU|R.M.U?22<^51YX|MW5?>Q.#&11(FL2:40E<^<?
K%8&K|E&S&#%K|<0=KQ0&X|H|HJD3:VH<^J4M166G6Y3.>?N9.P@<NP0?P?>2L.M%>..RE+>WHAU9A9C7Q|>2A>NAT9X<^E9A&B3>*>3IGNFO|C83H<^IN2O|U%>
M"WB41U.V4P|<N2B8|ESCUT.E#NAK&152V<^2%>0.6KLCY=M<^H6V9JIB6.M2L|E6|K|<+08+1>55C&B<^<^V3F74P.DYGS|H.G|>90R<^KLCB.FFAWR?238&|<
MD9Y2H|<Q.7160?>3#>G|U%6#J#J|H(MTAH|<6|>V10Y(MK1<^Z<^Z&E..M6L.B2J|<66G%>?>?>P2F33K8AHG7.U.K.OBDHGA)8#..|H|<Q=B..%Y<^X6X?>5#>M.L?>0KPI?>U?>
Q\$CQ01N1KHUP<^QM1YQ&0W?>P2L7E?>Z.N.50%<^56F4Z29S<^<M9.YX<^EEL52B|O|<10XR\$>S.DWXM&T.SSHAQ.FV.5<^U655AY20.?9RG<^4<^T.MAR>=>X<^K.T45|V3|HDA?>67.
12.HJ2.E<6.K.2|>N2B9R(6S|XB2E1F0RGC8+JW=>5C?>74JN\$6IK.M.F|>50<^>5\$#2BP\$M3=<^U\$>+!<^N5VTC9EWK|YXNP57T=Y-X=60\$N#V.B"MO9"RP1H3U7B_XW
C&Z+>+3FMZ?21#E5<^|V97?>MO"R/..7U|>..&XEEF>8T.M=MA8|A+FR9<^O>
(A.FAIRW3C.EYDUUION2G16<^E|P1+|WKLH\$PQF3=>..L&4?>MHL1#K5\$REINS2D155(GQ?RXI2.M0?>TQIF<^N5DOTTFF<^+>284NZUZ.C|D6L<^CPUOH<^0S<^PGU*
=<#>9.1GG3A.MD?>M.V6ZL#>..Z?>E7QXPRR6#>..1#<^S|HJOT0H1V.P?>N"8VQO0C?DAN01R?>M.V.M8HK6GCC9<^ZK14Q+R4<^X4<^<N(W.AJ2C&3H1H?>Y>|<^<^P6U1A.M2
H.H12.D4RCF|H519Y?<^2VAGL2.L1+>2<^CGM|<^16X.E5\$W|K(F.E)D.MX?O=RB#<^1&BNH6|RW:2.M?GB|<=<^..N&K|H0|O9GV4<^<C|HFTV|865<
M..8=>6AV|BXL1R8HJG2&K&8EFN1H.9=GBA1.VZ=UU.2U=>YREBF?>7C?>LUX\$SL.YIU\$8DVIEA|..83CAA2.R46P.H0|X?>D&1A|HLO= M?>
?>DG.TJZ7T7T.H&?>TUM=>P6PEFC&U6J2VX3+8+C=A<6(|>?>YKOD<^FIT.M)+F/S9Q.POZ|<S=>..AK9/XEUA>5E6.WHP&#>S|<N8+L98.=TGO8-
Q<^HMCW?>7MKDK&VN<^CP8>+>SX1Y|AYAL4R?>P>2L.SB3W=<^X.LM9?2T10?>7#JL.M.M0?>N3.1Y4A<^0.LR|LF|<M.WV+>H|C|F.M|L<^H&F=FWA?>..80.
M|H

[illegible]

#G@7(LJA#93&_YM /FD@VC.M.IT84H6I3; %J%IDAX2*RS3/M..2A584IV#04WA7PHS>@+I.G9TM7F5 MOVLI"RJ05XQD9(-JBY*13KV72OI(OX#GA
PR9I(M"QO.&_I2M2A.Y1..ME#91YJYJYTP"IS..(J)KJ&K"J4N"J.BE#.9S..R)DMPW..M<65?E?@0D M3QR12>..Y)1..I.C4@B2*(VQ"&_C.Q I.GD1NP LB.WKSFH.5IFYM&#
M0)M2LZ.(ACURH.G.57..(6D#B9J790H1F5O9&<+>Y.B-3(BU4VQ2C9YI) MHEWB./9.B.0..+7NP0?NTM/AL/D)NJA.RB31+5-H9B1A.A=15LW"0I..ML2FNB1\$2.
H0C&HG=-2FV?TX.TZ.TGC&PNV!

DD;PWPMEC-X+DRWC?E.F.M.>.(FT?YQ(J98RQ9C.6?51<83R.J)1-L.KK..C69Ib)@?H(C)S.OHV.Y..MDD44W0?VF@H7?E.V9.=9\$WA914<."MZHIM<U11?Y.JDW?20DIZ5&
PH7/G.ML/FQI.E9_UV<C919M"O.E."<X1WY9B5D2?14D)K.YSWM"Q"O.VY?Z50W.MI(O&_XDN6?J.HRSY4KQ0A2=H2?A6?TIMPIDB8W"09U@<+>3?0H2>?1L#
M5b;SCA9J>FP@<4)QW2%ZK.V=3*OG-"0GXJYB?0?7?IDPK!PD.7IP7H.MML7!>9N.MIUC?<3?E1"IOXY?&P6S*8L<124.W1J59W@0@RZ9NKP.5N@-KFCFHNZ<M?>
ZDNE"8J&GV1@QUDK5NAL(LYKA.MWIGS)/AW.D<Y?OS.M=ID5H/VWV>PF&T.9<4LZ8H&%(H7C/Q)9)DXHLEP=2WRQ.U9#1+1YV>
MW@<..G%W1W@W1CND.T.M.(M(S6GA)?)PYI=PYIX4?W.L=1A4D)M&L.V1=1>MF>..16X..C#BX#?>70B2=ZISGLVKXN1B5>KU.U>6.M9M2SIK@.WQ<4<L.EB4?W>X9?>
9FXIASZ<01..(LP6L"BX151"TW..N.M..2?>20X2I3CUX160W?>4<F28*3BH"W.B10.81YOD.M.M.G6?4.(EO"AG5D)MY.PPS.YXL?@.D<9VBOND.Y.7U>.SPK9DR?..0?<
HX5WZ/G..R9.M26<..TLX528500.PD..9ENL(RT.S1UXH6?Y4.Z1#%G@<(B24.VB)<+>M&BPM.MX.Y.6S(CN((?2?>ZZK8?>?)Y.ZL?C.G.F:FKIGP?T~M%NFVX /MO~)
(HXOL?@4MXIUPIVE453&W57?@70?=\$\$.R7>TNP(580P>R6P8L?M~M%"/+B9(WZ5%GAR.UW!E7.7P(O)0?#0<+UEIOK?>C48..8R3.MP.
7~E"WRM;A@>S>+5MVLV?>W.7H5%(IX%?@?H#CL/OV.@<+1Y.JD)S1.6?>4VC.MM95Y2TSIK4.N?F.D=

MGE>A#..T>?>TS1905V7F?6?>+5M&G?>@?FQ?>K80T8?>M?>ZRM(G30K0CZ.P6CIX@90UB8?>M?>C_ QXVGP=IKMT/BL.S@.3GWX".SDI.S19TWYO"IP%<
BIY=<..Z\$80Y"MACCGMF8V.TEH?3BB1L?>?"5P.9>.OHY0.L35%<?>2@2.YHJ>+QV.T4V?>Z1.MH"HS.B0>258H/H?E?Q@.U&WOP&P&R31@.X.RH1.7W..9W7C.G7\$B33?U..
M/RZ?2HYYN(D8B5?EL.A.M1P6F.LWD6&B7=6WYK&V<FO>G>1.M&RMOQ6IR?E1\$64Q0?>T..J910#..11W?>1.S&K.E.LMJ?31R3L.8PW..PWLHVMXTDZ1)>K/E?N~G"9
LBFB#>+9)Y?>V9F%5."%\$1(DA6QXPLD4.MN55FUE-9.M3KAP1>5KQZ.ITTMO!H%5A<3>?>4!>5?YTE..%<4)3JL&GL77&GSU:07S.M?BP=9K?>
RFXZ5WZ>KBD=.Y053KQK.OWGJY#9&OLM7E<C?Q..JRD6GV18BBN)MH!>2L_OR>..09.2EGT6D.N186WDD2=(7EA1+FEZ..@<3?>QV<Q&QINN?E..MN631KNZ..?
T.K.U?>0@Y+G16F9M241FV3?J5G.LHS<P.3>..MTL<P&G&X1V7>Y?>16MRIA2&=HKK.S%1Q#6.61NAR<..(11.71.V.UG5?>
M3G51A33@<T..M.CM.P@02W86A1OS4DYB7D36?>2/E>1@1%<..MN2L31Y5U18R9>@9X8.1Y96S19H#N?S4)UA7H5CVAZM08>@<F7XHBV
MM.A1X32H1H"CC9?Z.OHUVX(N.OGGUQOB7136?>1&G6RE1.E.1G#3?<@9.M26?>@SP.8GRK.OBSHXQ3?T?(8278C4..X1YUN1Z>..?G"AG19?>#?Q@<(4581AA1%\$(X75">
IXT1=139RNON4FH9PT.I0.V<4W~#9ISBE*A1HZI>B/B/P\$V1O.MTOE~M\$X(E1\$.VW.F.+P@6B8LOWX#..0HGJ3R7-05TH~OHL7HK&\$F<..HMT?Z.MKD)H%<0K>1?>
~N@0?>X.CC?Y.05XW#?Y@Y9XK8WPRYC..MI6X5QK.RKA.M.@3ASDNT?IG<#?FV?>..BS2H8GQ2198K%=<U7AN1?>..81B?>Z?BP5>Z.M5~<?>6CGM@.(UME6\$?>
R.F+H2XMYU5#\$(ZZZ=1+1T+W?>47.MNH.X24P?>S>W.NAL+3?>Z.GH3?>5&BZ\$V~M=<+H?WQD.50R07R.Z.M.J.U00B16CRX?U@/B&9Q0@81R>4..5@0<8?3V<T
1EF3.14LFTFQ?>10.D.WX~BSIA785@<X1?2P201H1(GYQ?38BCD4)OQJXSKF.HCL.V8~H16<B5.M0(2)K@FC.SN..FRH?HX1LGM=1.LX.NEIG1513681?>2#1)TYSHOLK?>7=I
M0Z?>K..FY46T?>Q.D.7X~UG<XV78?>M.181?>#%IA(N@I.C19W?>BB..1%G..%5=<+6+Z110GMD?L.M9?>1Z)O&4.Z=2DQ1H1?>P.EH.E.CYL3381A.7G1&DPEZ=<P)9V+QZ1
MBZU<~YOMDLCK(1\$X?2VL07=1-UO>A"GD20=\$S.N.3IOK1H6G9.5J#1.M.R/EYT5.#P>T.4.Z1C6F(Y..1THU4.Z-1C5H(V#ZF?>PV@V8.M/B@1)&1J8?>
<X8R0149?A0<=<?KDP?C6B?A1+45P?2H61#?0F<?>6.QQX.MW@<XW>1+X+30N=<..1L4M55ZK2R05?>3H6YX".15Z?>4Q4.UAQ30?>0..GC8.ZX7T?DQ=<#?DH+KF.MZ
ZIFYH0KY=<D.P&CMQTC2TW>?>P.U.M.#.29P?>K~M#@<..6.55Z?>Y?Q(I.MX)QW\$B)EN?UYM+D.M.MM.LIC1V14?>SPLP2H0?>S&ROWH&R31@11LUFT6V3.M.2W\$>.
1#9DRL6S1@<..5.7BP5=V&#?8BT5)0.#>1..G6161IRCAG+IR+A.MK+T"O?GMI9B8K7H1#2?>YGC5?>WOISPC@Q1LPR31<+~<+C7EAU47N)F+MAFSB3?>P<?>
121B181L?>1UQV.G2H1Z?>MR521AP>..S."O'UFG?>M?>WBA01A.IS@G21@.G.O1HES?>Q?>E.P?>P.2.Q.2.MOZ2JQR@PV2?>
@.80)>H+1WCM~+1+HMN.DS13HIPJYO<L-9Q)@E1W~HLL?>M@E.JNE1534.FAR">..<GB1>GU+52?>S"R1P?SR"K4H1&H1<~NJRFDD1M>1+2D..2WS>..)(H8U+K&P?>
A>~>8&?>U81@<(RXN0MH0&?>B.HQ6.MB.OYB50?O7W.KA."K&QV?2FW>D55Y?>ZS1E?>7Q+<C..7A3&?>V.Y.TY.M?>F?>1G?>W1S?7?>4\$6N?>XFTY?>H
>6WP5UA4N1Z6+<B6A?>..E.MR&U4LE1U+KQB8B10YU+X.U.OGF?2MSA0?>H1E?Q?>A=1?>..MPPN=?>7#?>M1?Y0H5MXXK&P&SBW95LHJ1?>K~<~<~>S.JNFE49?GW~M.O?>
*8.PHJALUD34P<?>D0>3.PM.P?>CX1>89?>1>0HDM?R<?>1>5UMBE?>R6W18&+<?>Q(O1.25IC?>XDY1?>=<MZ?>3F1T<3J.GYL90.F48E?>H..BQ3F2V9-0G=YT45T?>1Y4?08R
11?86V7Y.MPXPH#<?>ZV.G.Q+X?>7.2Q61A#<E?>E29.D?>5K?>ED15?>K?>S7H5386EG1?>7G>U>M1V.36X.NA&X?>Q?>15.X0N1H4@<10G12P3Y3K27H5T?>0>H52.4G01+441?&gt

Q-LSAX4-0V-PTC\$^2WBI43ITL8X9A.&Z4#^%+J-MAR-70:AF.)?Q-U/86.2ITFZ^Q+JKTCH-M3KL3-7I+OJTOH0P>3B+5U)H\|)ZC.0>3E\$:\$^=+@+G'05X><%"5^G(#MC
YT8P.U.-+WY0QI:YZO4^JS#-2VNN5K6V8:G<^L^I05&921H4=,Q^-\$M>P?2J1HP:PIV&R-MIX@&&^#55A/GH^O^ZY\$%\$%=-MU:HF+FO^K02=R^Z#QLH-KH-M?
2YKBGX?T%>2&L^Y8:WY\$6KWI^XN^W6:0VL3C%:P%U:U4-M=B-0^X@L^K062HEG^B3):UD9>XKUJ^#8)Q)<^>IP=G+V5J=NI9V&^VYHA/L:NEV&^LX4HE8@HKK>^X
MX4L^HY?@LZ+)>48A\$@^X18W3.0S^ZB1..391+^805)D&^<^KIG.LMKRJI^=T6(29DB5I\$5-7ZN^YM4UW42YN1IN4MDW:~^R>SIX@+Z\$ESIH
MIJ8IS^77J3+LQ(L14DQ\$%X)GIL/60=C R/P5Z<#^X#7G^G1Z>M03KH1VHL5J\$2S6A0N5YPP^44=U+<^KY>~^2.24)HOGP/ANPIX@-IW^WJ^*ME3?

```

E:IBS>B4N1J9:41V2W8:1974>AD17QAK:RK1>*<PW5N<B:MGCEIP:MP>VPLI&J&KPK7KMR:LX92>GCMXZSHI>L>SNKT5>@ACF(CBM*2
MEU>@IOL&C13U1)<=>P@O: H*#7EIQOAVI: C>=>5MU>OM4SEB8*V+I/N%0.5NC<XXVB@NO&HJT/O&C>=>L69Y4 MRTSC%>R3>?>FDI:0>@IU@24R:3@=>ZRFH
KH1KO M0#>CAN6S AQV1*H M1#>PH2:B5194VM#0%>B68RQXOY5*R^>2+L:P:02I4Z6S5W>ZL 3P$N:4Z551>OIE@%80>8X&:00@&H/3>ZOG*Q>A M3C*F:
10I92O>Y+S>YGL3<=>Z286#>7216R#>H IAYGNHNSY396N<N<C1>M2>L7$5&4&KB<C L&E&41>K3AX:5%+1O.Z&P1>O>K>=>10>24 K*UO>X&E@+G D>FFJME#99%>(0SE
<GB27#>835J5: F8+1 M276X%<A1>OB3MAG:HYB1B>C1P2R61XJH1BO8 FJ>E BBP2U DTD:BYV M0%41UF2+1H1F+FCB<=>FYUEUK:HK2KPYH61&S1HJ:40M%1CZLXE
M%G63>W=>H@L D30J<L9LRN<F4$J2+014M0J7ZATFYBZ&J:~N9F 88 M:W=RR6WU7075:~0Z10N2%>=>C18P6P:XL&E53G0>YHJ:CA1MH+>QD2 MSL<ZTEL&XVU<
A?1>3UR5%>H@NE0B1:5*IS6+R<@03IS5B=>M@-MIV4%>G2:>2+>OWU<X<+>LQSD5LRA4#Z>=>M66LK2%>V<H1K:BLKAH3+>8HJ&S6NDYDYGOF:G<
<L&B1J&GR6%W1+>=MSL:G:ST>F9U:MSZNY9Y3Z1662:1HPU<3Y+>S9RE D+>W=FXG394>:MCJKZ<1E00RYK&JH2R2>L7>P20>@DVTVB3X9HM?
L1@>N94A<0>PJP M:W:4 C1L2DK96D VGT*PWGNB&YE0T<15+V1PT9D@N1U<VM80L0*8FZ MQPSH&:ZX>1>95S10Q<6V>M21&1B6FABQ04PUA15L1U>O:6 M66G
X1RL<41J15V<4E L4U1B+>=LL1&1 L17MK9>S14L<0003+>P9G:M:B6M%M68+>1 U9LF4L137G5SH&P: C9GLU U RCVJ<F3:T8H10>X9H<@ M7KL W:K4D&UW:~V?F
RD2175&C&K6G5C2V0G<#X1A41#03 F2M% M* M669=>3&H8 0*6K<+SNX<#L F1ZME1>V6I0IRG 7RP8165V1P2:1=>IGB8KX<45N8B>=>EG>CX3H1 MYPVW1&=>X*N5JH:
I2#>910F@>?>A1(TZ.OY:>@S M+55+>PK2 WFDMMG:IE 7H+G<=>4+>F5FO1YHX49?>2N6Z:31155 W M0T<31@>16:K680<3CBP13JZ&YGC124>5GDN815<1S:
<~VYMU/6>=>U<U: B%Y%>3%>H2 M4K<IES6U94?Z&L@>MVA:O QTV:MLC104A+BSL0+>H 6J@<L16T W*KL P@B50HM2 G.V06E4.805 YAS@E1 MD0*5H15 FB>A@>9:1&
W422P1>ID:H10<0+U<74U:~8X2XMM2D/2BK7=B MNCOW1<=>2S0EFTD:SN04255S<CWO>UT1&G<G0 R:~%QYA:4VOIC01<5G RD1~MW57RL F:Y1C55
RTB3F1<L O/8< &W4GJZMG2S:W31L8H<NK%>DAMS M51H1@DDRX13NKV:V2D4PU>=>3 M<~0%>5:~922M601WU9HM1~12Z@R<
U$ IR~M:WU<O>=>1O7+L5&S>=>W RHHX602A.0LP6 MH%E2 DCSOE@ YHHH48Y&E A<O YVYF01U M7%>@HMC6CU1 M&R8OY>#8
5>JHPI@EP&L&H28JZW15V1&S7ZNL15&M+THXZBE/HH M:O>9>X<Q I&RDVW0L:~0>YVO>=>LYSD+H E7F31KK<@>S MYBW7~>H<=>8+?2 MRBH:6T?
(FTH1@U&S1041500#F6K512V1A4Z 1M41QSQ%>Y PR<K<U<U< MEBS00 IV/G:7#6HGE1 U M@HS~ELD+>#04M1@>L DEMX27ZY N M1#>T~O VA7*6<~ESJD*46V H
MU08H/W:~U O@>157X1U1NHU=>2 V1&80K<795YV&S17HK=>~1~2EY4E9F1E1QT MHP 1 9X M#R+> KYE+>WU%>U1D5>
5DAY<=>77>15E21>0:JHBC8H01&H1LPU<L12+2U1C+>6 09&4<Z M5919D= 50Z1H1M1F7+>2 D0Q17ERJUE9P A&I2BNQ@JQF3HGA&S#HJL$Y2H M:Y'W$>
DHBUC&KG6>@KYV1U<F@U ANL1 OJDI&X1<=>0251>4 O M1<S= 6&505919&D+>2U=>=>U<L5+>1U@>HM6 F1CT:1452>@PYP*00ZZ%>QW MS(H14S1>2ZJZKB=>
>J>@>H M>=>IY&S4&E0E9F1F1OG:W0Z*OL7X M3HGLIE@3#7Z8.0V<K<L7Y:6HHCX MBY+XFN1C<F1<~VWTOQ10%>PIPV P<S2: M/@>516<=>E1G2<=>H10
MG4>9.7%>L>EM05* MC>=>M21DZDZ1P9C#1DPKC<81O14V:P2HUA370V~>2 MW<3>~JY<0V1V55>0 E185G<HJ1>M#1+268TYU>@KECAU9HUK4&E1L MLW*AA<
KF60H4+2 G6@>H3C<3X5P1>J1 OVSVCFT5B1&FN<S1+ CVL M C&KJW:FP1<K JXZV5D&52A1F7>10P2X:M1H F2G9R<EY55F2P1X3UA M&@>S1<+>14 10BW:
L3 P.COP M C.P7V A:YX.65=25MS67>2YGO JWWV<S+>HYL M C<DM7&S<=>=>L&S1H M2X$> AH=>R<M=O%>D M<6$>0<~Y*#8<~ZJ1 10E97UW XSV5Y?
<MKJ+>=>=>DWA6BWSW>5G4Z&SMWH10Z>7&H1KJ 241 51 /EY>=>O&B4 M.S L39674 M190TH<N 5Y&JRUU><3@>AMM6Z&S2RWO 07~WP*0UOMJL MWHLK1WY
M O3&#AP1 B.O9W1>+>254+HY>?>N1BXWH1OD>0>1&6 INGGW7T>7T1L M2&K1G I/W ZN:5&L33<6J>Y4 8#71RYKSR16:FWLWYXOKB=W7J?>@LN/MO?52
5: OF/5?WNIWJZ1O1+>?7 CY>N2BKV9 +XNOJ?>I M15M9A:~Y7KSV0ZV0616K1G106N5VE>2YFJ U U U U O9~AI>=>?>3K7O~G=>#%
IEP60M M1W T~U1GULY<Y5T63 3ZXBD<OM M&U&SBMNY<IR~>N1:AG69?>8GGY&E1<4>Y1<1613>G 9FB2:0&8BP1 M G6H6XZ51 3AC*G2YB503YF?
3@K&L&R&BMYD:4WU1<E32><16H02/G5 MFH1 N3MHV:~YVHA:HEH6&=>6Z99H1R0 SG<25XK1E: 193?2%>VAB MS1H2154V0&BIC<=>C Z>~92QGBR6?9>DTYH@&
L KE0:UMH:5FN<=>CS M1770B>=>K1L S572<EAT>=>M N3<@I6N K02#3014R3<6 B~P X?1556C2 NDB M%<L1(H12W)>=>A1<+>334 NPH<00%>=>CLU9<=>F07X N01 C3S?
W>=>M3R0P62S<N1<CL&B1Y12&81SW B42>D80L<U1H08&52 W+>DD9<H N R M&S<2P1DDB M1<=>H1Y1Z/7T1P8JG AIROK<REF>V15M)V$>P0<4BDE L M N
ZAGVD:KXBJHSQ4<+>NKM/DQ?G<=>*&IG1O/JI-ET17YR13W RD2:86K9: M1E*AD12J1Y1@M0 CG<7<IG<0OOR?>HORI QGED6IRO*#A7HR) B53
MM<3>3D66 M6J1P0%>50K0GGG&A9>M5NMWTF0Q<9>G9BV2Y1919667?P1Q> M42 M M B S17R&J72L3X90B7 WDS+>E KU(KA>=>=>98H%<2G>)>CE3 TO M&9D<P<
KH6 S7P&A4 K&ZKZ1U1Y39XSU0Q~>#R1P1+>T&9 LRNN2 MFOY0 M>QL1W6RX&I9R
```


[illegible]

M1<0%3f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l6D2LTRT: R9=>9MH44V1:HI<G=QZ1+M357P.RG\$W<#>^4+JN#>+52F>=>="N8^W1W<Z^U97K9VPUU<LJ.GJK.M5>)>@PD>89@BYHU<B.E9LJZ=>0%YR:NBBI\$RIT>U> MLEWUGZ2N5+V4HK<1=1AKGB@<KX.%>2%>10WL7<?>C@J.GJBM&=>DK3E3P<M\$9S>=>#VU23U33<?>5>6JRVU3<GCH19TXI>UO>JEML'JDUN<1>0>.BfJ< M1@<M>:Hf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tH.W 0G.V2<=UL<_>GJG66-10Q07U0<1U>O>X.MJ1<@<KN:P<CS#>+181Y.CS/GN14E6P+H<X.M+G1H.M1<_>D&R2.Y<=>UOR'P&RT1/OZ1FMT1'MCO?T3X9Q<F79H+Q1@<VfH.V.1U M3+1/HQOZ<3'9MR'1LOFLS1.N=S.GR02M9Y.M<=>W.EAV\$<0L1.3H>1S+P:1T5B+P.E.PH7@>H6@<K'QUAF>P=>T8\$>5U/1+D.MRR7B78-6161602&C5.AN<C>C:RGJ'(JN'Y\$E6W8YT 2>YB>BIAB/4+E.&=6 M<_>HUHJE4 052-3A/8Q6I(PZLV@>9Z+>_B.M9Q02>\$>S30.38HF.I>+>\$>=Z<1521C\$4RT.Z6Y0\$54HR874>AL>=>8BZ8Z&M.ZP3A3<^> IV64<959VH/VGORK.M.MKID00B1<KCS08N3>Z^>9@ISJSE64LX4A1'ED@I26I6CV86<0113P&TL&I#<M<=>EQEF.OCOQ<=>=<UNH'>Ll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

R3LL1ROBL>06L.R:B7<1.F.MX<Q'KXJHE1=>6L.XX<3MPVC=2+EQ9'NR'XIRGZT.UK72@<1'>KE1@<PIF<_<MAOS.BQ7B9.W2> %<SR>97982Q6B<_>DF.RXF).<#>#KKT&#<W&S<P\$<1G3.IV.MOFIXCK\$>=9'WN@<HRHS1'<KA'>0.X.E014.A1.SZR137+6.2D1G.BE.MOJ

6RN2'G.PVMXA1@<10V1D.CDF.M03R<2AY=KX% M%>'T/L<14DQD'Y4BZ(XN&A+GFA#<8'U3KOB1@8R10X2'N#>.LLD.XD:D1(W.MGDOQ0<57Ff. *81%<DC%<3B<10'4LZRD<6V'>@>2^>TAW@<H2G7Y22UT5<@<KU.MA@<(E.O2+0.ZG%<P1O1.6%YR>W8K2T<_>HJ'<C1'<H'K<_>WEOT0H>F'>R&S&MX.M6 IGO80L714GH<2V1=FIJB6\$>=>2ZP1="U;7R.F31+>SM8\$SR18.T30D&=>=<=<MD>V=>R\$1+PE/3:FEV@<+RQ%>1%PCS'F631U'<?>OT12'>8"QOF@<KDT9-M7)C< B'CH:R7A<_>2.HX8'>D7=>57.ECDAR11GIHF\$<A&22IZ>_>X>BNO.M=>#>7>V1>2Y<+5Y1(39B<4H>Z<2%76VFA<1>4>8>S'J1=<18>7=>M2OHT'<^<OZ@<11#<OA.X1XKS1 (1A4'>M2<8ZDP<_8MS.CB0>7>@<LH1'>@<M'YA=>P\$<F6@<1>1WNF+KJ8HZN15GME7PIQ057S01<_>#>Y1=>N1B1N+X8TG@<1H9.A71P\$<1JRC<_<9Y2.V2WVB.S3 M<_>M=X L.W+T&1G1G5=>6\$1<^>7RQG'1JQO5<1U.E0EKGUT>IBN6.MCLIB'Y\$K4M3NMOC13P0657JYVW<=>ZJN6<ZG7.040<H2X10UD\$1A.MF\$<SHK2>7>Y\$?> 55Z8J06/AV<^<OKIN7L5=EKBZV<8A397I@<T.M.LMD<1<_>2.M%<0>Y'1.R330.B73.8<_>2FV1.2<_>1.M2'<K<=>^<G=71\$B2AS1.R<_>#<KRX(A=>#H'<1@<1+>18>8A0)>1'>1'>C1H1 M2.LXO<^>3TLB9LVEV+KTH1BDN<1VUPGB0<2+>UCUV7.D:JANG+>8V.U<_>0BC.M<_>U04BLC\$<@<D12@<0N7=>=<B9>S6COW&E.DMY<=<6I>=>CV9+3?QF'2.K@<4 M1&4202FB'S5CUL<M9Y1J2I>OGP1I'<5W'MFQ0I%>AXWQ&B1B1O07RYT.MY<_>=>1.22H88Y@<140K&DT'5T112>5>9GH0<_>1R7&SD8'UDH.H'< <=<2>D<1HJ1'<KA=>U'<1'>=<9>#>4.Y.M-LPIN82VYN(DG/T2T2)<_>22Y17W<5A>=>=>((KKI1'<D24&R&#<PVT+>@%6 M04'<R2D2C32D2.BXV)8.1=>_>TEI7.CU<_>1M@<+>ZLF3<KB#<1J1>17=>M4H066.B@<OFU1PDS<0.MWJ1<=>#CN+1V1?+>1>2XB0<_>G12UF<O<_>1+>1+1+3J M6YA.K@<1@<W.G.F11<01@<1V7&L13>2.6ZUW<335.MCBZ<6)2JH06GR1N'W1+>A@<HP%22U4A2W4'<C)>7H+A>=>2'<KS6<AO+M<_> /AM+1MG/9L9WZC<15DE.V7&QIG2B1'<@<PU1'>?U46>UAFPP9<_>MD1.WH5NOKX=6&@<73WN+1R71'<1>.8OET/DGG.M9IOS>3AHP6.KAN6WDAIBU<_>2H1D- D7C2CPI1.352X'<HUG>=>1WQJ.MVB.M<_>TB<1UW&Q.H.(1A=>0T%>2>+>8N1K4M.MK<P%<V'<KQX<1'>U<2V7HOP9+>1A6P1/PF+QD'Y8KH1+>4>2%WIDH9D6W M1Q0DLAPR1LIZP.ZB:BTIF<C1'>EQH726VENH7T2E&TS1'>P<OID.RZ<3<_>M<_<4M5V1Q23030HH.ZAFH9ZQ.ABE)PG+<HYUKM6<_>#362XA=E<=>+5X1P4KX<8 M=1LR5522+1JATOS1&0#<0<+>5>584<DX07T>2.DN6V4<_>1.N.AO<EL.MMV12E1H51<_<6U1.BU1Y<37V7V6>G&31?>2V'1<1J'<X%>=>+>O1(1WY<9>1M1+>F%Z'XOM<_>2% 1448R<15XE0FD5F29>X'<MG1P<@<U8#>4)K&831.M=G1O<_<CQ\$<M>?>EL149E0.83'HY<_<F1<_<616H25=>U'>T'8QYUT+D.SZIDRNM. M1KIR\$<P7'>#D:J6\$KO.NA1)TTMO=>=>+19U1T'<X<1'>MG8P.HG\$<5\$%>HUD8.3'XC.<8%<U34>6JL181SFN#AW1(67K1'<1'>?>S<1G<_<GOEL6-7J'<G5M&18FOU'>? @01'D0&0=>S2C10N.MKE1W1'>=>ANCI&MG18+<6>=>9&LA)UX\$1HPT.B4N&E.S1\$<=>M04'<AO&M1A1+>FWT.BP5.3W<1'<C'<G<_>#<6P>PB>18D'<MK2=>B2CT&6PMZB WB90>=>S\$<XO3Z<_<TPKG2C.Z.MD.7M23C5111#<1L1NU<7UVERD7M2TO@<ZJ1'>HDE.RPLMN'63V/WDOQ<2VY18&^X71ZKXOYV1'>+>+X.MLBMI810H'IDN<4C?> W3X1'<7W1'>T7.M50WZU11<34X'<1'>@<W6Z<(<2A4TUPOW1%<1M>520FD1F'25KGL1'>N>7P.MODY1'>+>H@<10FU/CCD18<5XK1O21H'OR.UE+>X.M6.MF&R<N=N. f51A'<PPWD>=<69Q00\$<S.Y#>1M5>X8+<QHGD+63J2(0D0JO<_<AKT<AB.MG5=>KN=>=>XRV28RW.LOI#6AIG9W1B<_>T7T'6WOW17N<18'>E.2(5ON0=>6Z M7>=>RAIO\$19L&N1A<_>@>7&H1+>5>2A<2X617GW1%LAONV4IUJN(FPH04#<M)25Y<5.RRR(HFID20'<QOYP'<1'>?>5\$1I7<=>6BK1Y8181'<L14G71'>1<=>f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

[illegible]

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~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

Mk6-7*Z TM65JYKWK3R;WNUJPG.Z/6NICA6*4(=K6OV(ZVYV;U-PEG/LG=%P.28)&=&G(2-MNH(HD8)4"-2(L#(#+8(WJU@F?G=%GEU\$.JLR#/-=GWK)?^?JG>4*M3H
M#=#&WM=2@%H1-OESOB+3IF&&=-WF4AKU7MF#N)-%ZL83FTSBMTF.D.VG5-M2UMYVSRJL-6YXA<+%;@ONW50.W9^T8;IMZB<-O1.%YHJ3C0?>W-77A.X\$%
MIW#BP1.IU="&4Z>4QOE5-MUZ3;EIGHM7R&F^=-7=(D-V(ND2D-NB=ZTCHRI;F-MK36.9715^7ZJ S2IGR)?JY%G.(PC2#E;HNSIAAHN#*=-L1//W>Q
M'OZ<SD81?>Q-M.1+@3<1^>L^>M1+GZXQ;S+Y;F'K(GOUEVU.WL^VECK%QV1+/P2G(F-MN>=&S4.-ZIF06HA%5;RBRZ/NEALE^C7.QA^>W-NRNF;Z=^T2^F1?
J-MN%GZF^N=JL-^R?PGG.90-1%?I18-G'SZ0YWF5-NH;93XK<<=R0)OI-M1J3-&L@Y^Y;JC9J#^>3K;f-B+^V^ILFZ;^/I(3;T3X-G-W?0P74 M(G;ILZ#H/XVLL);8V>8&T6S>/\$
4^&61^>A^>K^> & MW-JV^T^>381>9& MU4f-ZK2-E06%05SL-OIRGR-VWD6J?>^=V16O.6M-P^9H^4DHUO)-5V MYJ4P5TD^08AED?^YES&MYGL#-&96S^Y^VM79A-#0.W^
<<69XNP1F7^H<4-8 M1^>^/R@L=1^>@Y+I2>30HXYB>9LEFWE<=^>Y6L1?J^YOU^>F-SV15?>L1.MH1#&S)@S0T81#>1)UOBND^HC0^S0DLV1^J3IN&F^T2@HG^IPY
KKGDB+U+U-1MWA(15;1C\$%>037&54-K15#81XPWA^J.OQ%JP2-^>OYV6;R;TY+CBJWGS MYVW?Q>L<2^L^N-562
MDT1^2@W@>LHDIE1010^>5^>L^>C^>TQX&9FQO^>3K=ISG9BU^V^IN&T^QO^>1^/ICI=D<Q-ME^>QEN;O6G?C7JZUFUKU/JK9^GGJ916GX#=#9-F01P3^?>HHSBN-LRX-MU?<S:1)2OH\$108.%-OH%#44X238S==<7R<^>XK51^FIKDIQVRDEK&LVTSD41-MIG7+Z1>6TR.7.312\$Y>?7LG.7/-M^BJ1+S<^>Y.G.0#4#61PWG@4<MP&=>
<#>J#>=N55D2^3WVJC^ZVR7G.U#&3177^>KYA-SPM>0OR3XQO M13V>^>C^>JZ/^HES^>JC@>W-L2L^>#<=1^>P^>(OD1^>FE3-4844FLHY9-M.C&S&XMG^NS9>L&XU>R;8-
GC<3#1+^>=100Q0-1.9)RUXJZ10FN20C<=MOJ;F3-10G?JL=>4&X-M1QJ1=>2)Q1-L-0.9^>WFE1=U=5TPR8/-M>1@TV7E23&XQ1A3VX<1^>1.%X1#>8"-
>9AD;08D)BX2M38\$%>S;P51-M9N1JST1F7/GLAK#J?>WS@66J%-PFBK19H.GCQX0^>+>O(VP)OZ1H.C6%BE-MO<^>1^>Y9106ZQ(O>U>12^>K1J^>J-4
C^WN05UA1WZSR9F<=>R3^>89^>R1+>N-M2<^>2.6731(P1G^>X3%-1>J^>ADY5T3MUU?TYP(1-AVU;42B)>2-1N(C1.M)JH1-0+>45515M6N1J4:04.74(S16-C.FI
ISH^>L6>DY#1)FON82D^>.%XE-8N+^>561Y53.>=I7+(03@3(4P2\$%>@MG@B2C\$E-GX9Q&4)XSZQ.GZX3^>TX&3>LQ8NGU#B;H>^>I@I<Q?P^>G.QQ-M^H61AX+
I2>0K<=>B>301P^>9P1E=IYV1^>0GET<=1^>+JY86.RV^>C1OFLORN0U3D64EM^>Y(5F&BP4^>0S 18EO)4-M^P=SO9FUB5?
Z7Z=>P=US2-1^>W@>+>N8E-N>+>1^>UJWJ3LH3>=M#3>E-BZIK=>C^>PKRZJHNI=1^>5L13^>AUI^>P+L#=>@>C>J^>W7YK=P>+>UOKX>#>M^>UZ^>H^>7
1GCVRG<3M12>1^>C^>CB^>YRN@JSE/D16R6^>1H%>.(SZG4B1B-MQ&^>2AEYH0S.4EG@1+>U01H9R@-E97<K1LGZ3-716\$61\$2Q-7Y22=F;1J7-M5?U0-50-
Y-1A5;5TV1F51V;UPD0>981PK4)-TIG&S^>F01S0650N#81ZM1^>K^>+>NZ4IK9U61=>4TG1Y)1EP>815QK3Q-T1-RG^>4R1RZB;
(1:E=54%2C=6^>F;IR106A=CD/3AC#>UNVX1^>1OZZE4.O-M9_PD-1HK?>C>N-K4TC@>(4TA1L^>4@936^>12^>26^>AAR^>(3.R1=)SNVFX1^>MK%FPI^>^>L@9N>=>#6#3-
500H3>1LC=E<3-1^>IAL2R-M^>XU-M^>T_S^>T^>9-MJK&ZD^>072L^K1Q003^>2^>Y166G^>0ME5OY1^>Y1OZE1^>7Y1>LJY>5W1A26>
MX0B3;KY^>N^>@>R1VY<3TFE50>>019N1W4+K1<=JES0HJ2P4A2AN1R.CN.R5M1^>M8C17Y HHJNYXVS^>Y^>VT%DLN1&=>7N28X<^>6^>2S&ZK;1=>E4DF19)?
M>A=Z^>04^>HTB-R;E(C2^K.HY1(Q5UEH01SU01E-2^>H01Q4RE0G^>C^>N:G0O-M-0JBZ7V62VALH;N#1=6#>117(\$<^>C1^>A.NJG3E=WXE-4KXG.Z>=>^>Y7.6D
M^>91H10G.9S)M^>F1<@>81E^>F50Q9Q24F&42^>M-MOVU<^>1F^>W7VWU9^>7-15=J>+>J^>A-U0^>PD2H-14M0ME1T(OA<^>XTGB+^>2^>PC.MPG12Y-
AC4S>RKD1/W;P>Y^>RV<^>_S@FTR&JNRAJHM^>^>PTPU\$1>^>_BI^>X-M28(DT41#UB4X1X7951^>f&F.EY.^>5L>5.C1Y+J^>1C4Q=I/2-608?M^>M6E1JD.Y;D10#M^>^>89DOWA)Q-
2NEY401FNR+^>1^>31E^>NY96<+>@16.7BR>?W.Y6Z51SH^>NEG^>?MM^>VX52=>=<J1.35M1<9P^>J1+G.S^>PC551D^>YH187>+1X7N;1W;UC1&=80-1^>MP0?21M631B#2LQ^>
<62FZ9(ZH604(M^>B&=>ZHLH^>Z06KG0T^>03KN8D;HCD-M.OH1E1V^>J1^>H02;E^>7^>4^>8^>G^>1^>@AGT6;1M^>AF8A^>2&E1=^>L^>ZQAF&S^>MY-Q60D<1^>)HMDX3E\$90T^>
>LAO>+16&S9H6^>Y^>PL^>f&1&X)7^>B64B1P-V-MKM^>X160<3N8<6&E&X18X3NS7?>+>Q>K1^>VDUW^>7G9KY1^>UQ5FEP^>@<A-MB;T8=1U6^>RE_5Q
JHXFE^>X4&66G>0T1EUV&=67^>@>OK^>TSL^>S&#>MOD.MZV1&S^>JRV<=>UWV^>14J1-LRM9Z1&S^>B@6L01^>W^>S^>YQMRZ>^>25GCI1^>U=>
MGODS1V^>A-RI#>CV6A+D<1^>YC01H^>CV1)SH1VUPCO^>PJ^>^>U1=E4@8@>JN1^>M9T=O17-57^>RV-M8P1C2EB6T33Q#2JM1^>1=-J^>T5^>Q>X>=>B-N60;J.P^>1/59.P=TD+110(G)?@
M^>U10S^>O15#>6JGP;1VB^>N0G^>WUHH^>1^>J@PR-5Y1U1O^>EY1B16(QO^>EGD1H^>16H7^>IS^>PZ&1^>408^>T^>K20-A#1WH1FXS-MM7>=>910Q^>D1V^>+7F1@>1?
68X<6...URP064UVR^>FES.#6&=>15R>+>G^>M^>M2^>W=IS.M-PZ1B>1^>KOH1^>1^>@M61^>47^>SNH1^>L1CBG&S/EQ#5&D(2A8-M+1^>@>Q6A1^>1^>95FCZ&U>5>0SF.72CF(E1L5TAP
6NY-F6+?>2LASI+1-M^>Q.5.LHI=>E5^>V1O^>#>W>UB:1B<+>221C9.%TFH1-0Q3@1^>E3E1M131SY@>(P1S<S1N123^>S(B311^>75SQ1Q1G#2P=>C^K1^>N1+>1^>JH1-712@J
M1W^>J&02KG1^>R^>JHE.W-21-NA-4-0.35X8%J9-GRMP;2MFJ>=3@&M^>52^>J90+J19-.E5L1N4L5R<1^>F^>ZZ^>Y29A<5J1J2=RA59>Z5^>H^>K^>M^>K&B<0_Q_#D#>
2-M=1^>C1^>5UFW;@>V1^>F>+>K<=<@>1A-XB.^>16^>MG#>K&1VZ-APT(SV1BD5WA>=F3-.06N^>O>M<1(H1^>TAQ1T^>#>8-HYBC1\$<=>0L^>1^>G^>DQ^K^>=<=>51P2^>XLP^>7U6Y;WD
M#1^>2S1^>#6#>21^>H0<^>MPU;&Z6P.3F1<0+7-5^>1K.S41Y0&S^>S^>FL@>1^>MJSK1UE1<9K1<=>08C5ZTL12W^>^>EN;S^>ON;J1^>7^>3^>3^>+16>=U7B5+JL=1^>#M-D
+1A+1A>2^>F811^>+1^>81T7.FBE1K&EV1K.K^>1^>1^>@2=>4T>SS@62<190#>.M9&K&N1^>CHRCU@3(R8D<=>S-98G2JAF51EAF^>F^>ZHYR1=Q1^>=>H^>HFKYM=TP-MG1Y^>ZQ^>1^>W6?
+45_EK_Z^>BN05B^>1^>2(G1^>ZY1RN<=>#>3BU80&1^>31ZLFZC1QORD-2B-MYX3Z01^>+>V1H8Q.05X^>E%>@5J1^>N2SG1=9^>@>F-2C&G&N1^>@>US&K2T09^>X-M06#Y\$
##>Z1.E1&9K1+>8#1^>V=86S1B1^>+>GBYH&T1^>8Y1BMW6>MW1000^>ZG8T1^>M9^>Q2^>W1?>=<@>A-E&G&H8A)1^>F1^>0B(XQ^>5^>4^>A(A&S-
&#>ZA^>URAK^>R^>R0F^>WMEH6Z310+Z#>Q15JDI0JH2691RLAF04Q-M.X3\$%7)FKHDO<NB^>YHRIDFOA(>N2^>F-UM9.76^>33681^>UR1N8^>LNA0VO=>MX^>E7F1^>
(=<#>F56N^>F01N8+1^>Z1Z1^>^>8X18DE&4(015D1^>=>SXC&B-M^>4<1^>2V1^>5-9D-C.SKV1^>L1V250^>E1H^>W^>X^>C^>@>95&F3^>1^>C)2P1K1BH8^>M71^>N&G1H0J1^>(#.5:6*^>PL61C^>
6B0^KVX\$<A^>3WS5J^>435&S^>YQMSK&^>MZ=ZG=Z1V10-Y^>14G&S^>Y95BGS^>5.OH8REV8ATV834CCP-2H1S1<-VH&M^>C>S.F5^>2M^>1^>4ZQ;QUM53=2-W04&EHA1K1M-
1^>U>915.O1N^>7>5<=>1^>Q1^>JdS^>1)1^>F#>60L^>1^>8HAHBP&A-8-1GZ1L^>R14U1H^>M-M^>W2(S;PUU1^>169-RS>=>@Y^>0^>0^>A^>IN^>X^>A^>S^>Y1^>U^>10G1^>7^>^>W2K6
M1^>GES1H^>=>P61D>T7^>1^>Y&M19Z8V-M8^>ZJH^>D40(1^>1^>J^>E1<=<@>D3OR1A1^>EG.G.G1K(O14^>X^>H1F=1^>M80.B.(B8>Y^>128.66CFD&29@>S.H83?<L^>F^>0L^>IM.<=>1^>LDK@>9^>HK>Q-M31^>3>SOHR5>3FB.T^>%>@Y^>1^>P10%)^>1^>SEL-3YV553U-60M%L#_BO#W^>1^>M^>VC^>CA=1.9<CZ@>B<=<1^>1^>TWB(Q.355\$7#^>#^>EL-
J7>=>601M-4^>CJ&E<W^>H^>5^>1&K2P41M1+16%>E6Z^>1UHMMKEA\$>_U1^>Q2>7^>CAASKJG24N51QO^>X^>H^>A121\$^>C^>HZE-MH>8E.(D1X16^>)W^>J5N^>N^>V1YX57V3\$>=>
#>BZ5HEMEW^>261T1^>#>=U5^>P#>M^>(OE^>H1B-15EPR6&1735^>3^>RN.41H^>1^>X^>2B1F1^>21^>ITWR=>U1^>Q7-E31NG
M=YNRRW1QO.T^>Q-LWV1YAGH1N^>C=05?>7^>L18QOQ^>1NS=>XG1+081JZ-MB11^>H1&4YH1V3>Q89F9>1G16<UY^>#7#A+1JY17LV^>X^>X1Z^>+>0>1^>3^>FRD0Q-M1HZN&M9
Q1L5-1^>#1^>P1L^>17^>JX7^>W@10@>Z081^>F4W^>N^>X^>R^>W^>S^>U^>A^>@>W^>S^>E^>H^>Z^>M1^>R^>K^>1^>G^>F^>Y^>78T^>S^>S^>GH1^>L^>W^>X^>K^>0-J50Q-M^>K^>EZUG>61TZW-CWT7/7Z1
M5F%>@T1@>@GSY.Y^>Q)BC(HTB-288&F86<3XF;RJ72N-#>JRM&KZN-M0%5S=>44;U>@Z&5X1OD&YS;1F4E.K0)2C^>9#81N^>V3K^>1^>H1M1W^>Y^>2C_#M
M1^>9^>W^>1^>1613USH31Y1+1(N0B1B^>M^>4231VD-M.K.E14B13-2Y1AC^>3^>+>MDDUCL(H;2AF%1^>J^>1^>Q3>6^>15M1-EC^>B^>XO-M0095V167E>+>0-P7^>1AQT^>#G1E1XIVS^>+<^>
1^>X^>Y3+6<K1KY1NMD1TSL&=>MEGR41SD0^>@P1DG0H14J1^>AC^>32<1J0@>K5/73^>S1J&0.O.NCJ1^>=>1YMH1^>=>QY5JAS0^>1^>S^>F1PFP^>40B1A1@>B^>D103691^>45T
1^>9>66>3^>H1H^>95^>T^>XGH1H1EAYT^>F1Z1Z663#B1N1-^>R^>FUSD^>1^>E-MHU<6EJ7WU1^>U1^>X5.C6&G<D-2^>3WC1^>1^>FZ0W^>V1PL1^>TH1E1@>1@1^>Q1^>8.2C.6+H^>G+1^>4C3
M1W^>1&R1G1+FL+Y-WM8^>L1X5OU1^>S1MCI7^>QOQ^>Y21^>FNE^>Y^>E^>H^>U^>D^>1^>4M1M-42E9G-03U9-M1E=KX^>E&=>4W44L^>A^>F1^>1^>U&O1^>2C^>1^>XQ11Y8L&^>4TAAF61^>5^>@>1^>K1^>1^>G9MNOEC015-M+
1^>H^>K^>F3MS1^>@>1^>EH91X@3.2%>S^>R^>X^>P^>V1^>Y9Y-L19WR7^>TCE^>S13^>90=>W-M^>1^>1&7^>X01^>91K^>1^>+7Z1^>FB51D^>XG^>C1<40>8A^>XH4^>5H1^>?>91Z1^>1A-MZC^>O0LH1H1W4B>=>Y0.S1H2KF
0%>SEM+>8161^>1^>J91^>1^>481Q1&1^>5=4+1^>1^>M1>9>#>10B24>2F1^>1^>14B1D1^>4B11^>51H1^>C1H15+3W.W1Z^>1^>HX#^>7ZS<^>VW=1U81T^>K4<=<=2^>M1+>C-KNW5&E^>F^>
(K1S<=>6K1C1^>M^>ZLEMY17J^>21H^>K885185-EV1H^>P9;EN1U1S^>X^>T+>3^>G15H1Y1^>MGM1^>9M^>F1^>1^>O+>1^>K1^>2E1^>=>P241H1Q+833FD1^>2>SW6W-M11^>A<=<1^>Q3^>7T2
Q1^>1^>M^>KPN^>S^>D(G1TE^>7^>V^>VQ91X1^>T1G6Y0ZNL9-MW0921F6T1B215H1A+>6^>97G1N=RL1C^>7FW-M-167?_#M^>V/S-600P^>@YCXH5PU.
%>S&G&BDOAH1^>PL&BOS.#S.F.E.D1MY-M231T05WZP.812G^>QOJ^>21^>FNE^>Y^>E^>H^>U^>D^>1^>4M1M-42E9G-03U9-M1E=KX^>E&=>4W44L^>A^>F1^>1^>U&O1^>2C^>1^>XQ11Y8L&^>4TAAF61^>5^>@>1^>K1^>1^>G9MNOEC015-M+
1^>H^>K^>F3MS1^>@>1^>EH91X@3.2%>S^>R^>X^>P^>V1^>Y9Y-L19WR7^>TCE^>S13^>90=>W-M^>1^>1&7^>X01^>91K^>1^>+7Z1^>FB51D^>XG^>C1<40>8A^>XH4^>5H1^>?>91Z1^>1A-MZC^>O0LH1H1W4B>=>Y0.S1H2KF
0%>SEM+>8161^>1^>J91^>1^>481Q1&1^>5=4+1^>1^>M1>9>#>10B24>2F1^>1^>14B1D1^>4B11^>51H1^>C1H15+3W.W1Z^>1^>HX#^>7ZS<^>VW=1U81T^>K4<=<=2^>M1+>C-KNW5&E^>F^>
(K1S<=>6K1C1^>M^>ZLEMY17J^>21H^>K885185-EV1H^>P9;EN1U1S^>X^>T+>3^>G15H1Y1^>MGM1^>9M^>F1^>1^>O+>1^>K1^>2E1^>=>P241H1Q+833FD1^>2>SW6W-M11^>A<=<1^>Q3^>7T2
Q1^>1^>M^>KPN^>S^>D(G1TE^>7^>V^>VQ91X1^>T1G6Y0ZNL9-MW0921F6T1B215H1A+>6^>97G1N=RL1C^>7FW-M-167?_#M^>V/S-600P^>@YCXH5PU.
%>S&G&BDOAH1^>PL&BOS.#S.F.E.D1MY-M231T05WZP.812G^>QOJ^>21^>FNE^>Y^>E^>H^>U^>D^>1^>4M1M-42E9G-03U9-M1E=KX^>E&=>4W44L^>A^>F1^>1^>U&O1^>2C^>1^>XQ11Y8L&^>4TAAF61^>5^>@>1^>K1^>1^>G9MNOEC015-M+
1^>H^>K^>F3MS1^>@>1^>EH91X@3.2%>S^>R^>X^>P^>V1^>Y9Y-L19WR7^>TCE^>S13^>90=>W-M^>1^>1&7^>X01^>91K^>1^>+7Z1^>FB51D^>XG^>C1<40>8A^>XH4^>5H1^>?>91Z1^>1A-MZC^>O0LH1H1W4B>=>Y0.S1H2KF
0%>SEM+>8161^>1^>J91^>1^>481Q1&1^>5=4+1^>1^>M1>9>#>10B24>2F1^>1^>14B1D1^>4B11^>51H1^>C1H15+3W.W1Z^>1^>HX#^>7ZS<^>VW=1U81T^>K4<=<=2^>M1+>C-KNW5&E^>F^>
(K1S<=>6K1C1^>M^>ZLEMY17J^>21H^>K885185-EV1H^>P9;EN1U1S^>X^>T+>3^>G15H1Y1^>MGM1^>9M^>F1^>1^>O+>1^>K1^>2E1^>=>P241H1Q+833FD1^>2>SW6W-M11^>A<=<1^>Q3^>7T2
Q1^>1^>M^>KPN^>S^>D(G1TE^>7^>V^>VQ91X1^>T1G6Y0ZNL9-MW0921F6T1B215H1A+>6^>97G1N=RL1C^>7FW-M-167?_#M^>V/S-600P^>@YCXH5PU.
%>S&G&BDOAH1^>PL&BOS.#S.F.E.D1MY-M231T05WZP.812G^>QOJ^>21^>FNE^>Y^>E^>H^>U^>D^>1^>4M1M-42E9G-03U9-M1E=KX^>E&=>4W44L^>A^>F1^>1^>U&O1^>2C^>1^>XQ11Y8L&^>4TAAF61^>5^>@>1^>K1^>1^>G9MNOEC015-M+
1^>H^>K^>F3MS1^>@>1^>EH91X@3.2%>S^>R^>X^>P^>V1^>Y9Y-L19WR7^>TCE^>S13^>90=>W-M^>1^>1&7^>X01^>91K^>1^>+7Z1^>FB51D^>XG^>C1<40>8A^>XH4^>5H1^>?>91Z1^>1A-MZC^>O0LH1H1W4B>=>Y0.S1H2KF
0%>SEM+>8161^>1^>J91^>1^>481Q1&1^>5=4+1^>1^>M1>9>#>10B24>2F1^>1^>14B1D1^>4B11^>51H1^>C1H15+3W.W1Z^>1^>HX#^>7ZS<^>VW=1U81T^>K4<=<=2^>M1+>C-KNW5&E^>F^>
(K1S<=>6K1C1^>M^>ZLEMY17J^>21H^>K885185-EV1H^>P9;EN1U1S^>X^>T+>3^>G15H1Y1^>MGM1^>9M^>F1^>1^>O+>1^>K1^>2E1^>=>P241H1Q+833FD1^>2>SW6W-M11^>A<=<1^>Q3^>7T2
Q1^>1^>M^>KPN^>S^>D(G1TE^>7^>V^>VQ91X1^>T1G6Y0ZNL9-MW0921F6T1B215H1A+>6^>97G1N=RL1C^>7FW-M-167?_#M^>V/S-600P^>@YCXH5PU.
%>S&G&BDOAH1^>PL&BOS.#S.F.E.D1MY-M231T05WZP.812G^>QOJ^>21^>FNE^>Y^>E^>H^>U^>D^>1^>4M1M-42E9G-03U9-M1E=KX^>E&=>4W44L^>A^>F1^>1^>U&O1^>2C^>1^>XQ11Y8L&^>4TAAF61^>5^>@>1^>K1^>1^>G9MNOEC015-M+
1^>H^>K^>F3MS1^>@>1^>EH91X@3.2%>S^>R^>X^>P^>V1^>Y9Y-L19WR7^>TCE^>S13^>90=>W-M^>1^>1&7^>X01^>91K^>1^>+7Z1^>FB51D^>XG^>C1<40>8A^>XH4^>5H1^>?>91Z1^>1A-MZC^>O0LH1H1W4B>=>Y0.S1H2KF
0%>SEM+>8161^>1^>J91^>1^>481Q1&1^>5=4+1^>1^>M1>9>#>10B24>2F1^>1^>14B1D1^>4B11^>51H1^>C1H15

[illegible]

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~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~59OU^>@>WT@>S\$123I4^> (02Y7#>D<=>I@2K0I(4_54^>ZZ?W:2+LB^>E MOI^>#ZJ_>^>D^>G^>RYZ^>AD^>I^>TZ>=>6.WD^KIN^>XC-NH3M^>I^>P\$9:~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

12V3H>K4"/U=%1*DP4C^>F8W2+4VP(CZISRK(BJ1J+JHOO^+R=UY MW.2LNF^+JZEGWC=EGE7448PXQ)3)T(H>6D(0H(CQD(2,9S&C1.Q5#B8
MV%W/L+>R5.3IO(LN0+/#5L@EQ=10HCZ2PAH66E4%#DhG0.@C/FQB=A MTEP@+^142@8XON_0%F2JX=X057^EOL"/3=%55>E55K+BR?C-(Q>B*SE@MG
(0)EIH(CBH)HA0Y.K(O91FUFNMVTV_K2S3J25?0=>B/CMJYTT(K>HKV2?0%3WVC/PJ.INR0T7T.TX^CULZ5B_M#1-9IH?F2)QVBI.X^>XW3F8^A(GSGC.KN^F
6IC.OZG31CBH?8.&5 MMW.FWVR-053#Z7.^1A.8D.OF^B^U+1.L.D9Q<LW_X3>B=RY3?W3P^8P.MS2)G+L669CDY8&1^9F6C7E9J5^K^2V2V+US7+G^<M=5)Q5EL?2
2(CU;T(^>^CD..8PK%V84RG_H4G(f^F^M^H^NKYEQH_39)^UG_M?;3J>YTU;T69/8KY%<C4^M^M@Q^<X.8+A5^B9;S.B.088NT?SIRY^M/TMP/TPU+LT=6IW>UA/AM.
L63(31Q^#D#W#A33HVBI).##F02^AGHJ21 MQ05AWILL0JHT^#.D&A&X8(HA2F1^>0FD%P^#IF13<2>AAV.%@LL^H^M=M=<%.XIN(R>FB.RB8F>SOET D1+Y:.(@T)I
<7>W5E5^@/(QI.TF2>2 M1^>2E+66Q>FG759>MT_187J54S8&?JF5JFJFACOHEW?%#UYLRLMUIP65%F>%OD10%5M-OR0.
1%#0H1R.H721H1+>Y?ZBNDM^ZD/M^M@=>7NK2A*0PAZXIR_1X&5&8JQASP.TS_1YWSF@LZ(H15.24)Q^GD^M^M=O+>2W2.Y<04HVSF82^W0^U(I^#5^OD^N?2
LX1^SKTROB^7U/L^Z/Z.MYVR31TL64%7XL312+41HWUD=97^0TIO01295V1+>AS.FIL@_1GW3.M%<WYGGPTUOI>M^D>2.HC4R35^+1>QF5^OW>L15/176UP<1X5-7
MA<)>EG7^#^1+1/O6+.%\$PI^+>J>8WFU(RL_10XKS^3>KKW0LOQ5^XW41 MUOP^ K&*8TPI^50(0C>7B2)^<G/211.PH#.(P277.IS.S.L10_94I.OU
MRP/QYE/L^SMHJNR_M2^4X#L627^CJ^K=>2V58+7W<1 MHL.U;B1GN6KH?7D>9JAWOQA0&+^1IM65@+6S)6IN.YTAMOX6@/44B MERK=>C(TC.
N1.06NIMH83F41OX1P+L.HA8&5%#QC^TDHSAQAF^U2LIGL M^S7J1%#62P99#1/7TH?>NJM210BOU.0JFKI2FEZA^TREGH5YGO@C%<1H MKRUY(=1WD%>JC^B?2
5AY)=E^7J3=E^&HHGT>W9EIH@1^XD3>2D^>FGR_M1.M^Q1TZ_Y.K1^7^AZD/RM33^N^O=EL3H_1CV3^X(CR&).L1.%V%81^>3M^8^>X%M^>M6H.FTD?>
LYG11H=3^F90F?Y>1/NKJXW25Q9014G6VBTY1Z^>YD^>76Y^M^>1%=>3=1.LHL%<107QI8R.SY2I./8Q(O4\$4^1(Z3^>3MS6^C1^MLPK9TOI?>1^M^C.H.<19.3VGLY
(=^1^1P7LG)>Q%5U77Q3KJ11^<^> MG39R6CSPH1?KSP0^<K13>41\$8H#(L.56%&)2QR(4Y0I&G<F.W4.MXB(12KREI>E8^\$=>759Q4/O17>2WM(Q?7EOPLC3>&)>7?2
Z.WENUX1@6^M?2.QIB>^>D?W7^N2U.SWFA^MFEUY1H(5YX4>7J09Y.Y.(4H93.W29.M^BQ/FF1EQ?>R5PW0F/O2M^M^M200-.UM^B1>V6G=17^S9MU K&7^SMVHA0
MW.9K8X1.UHA^<17>1.O*E>SGCJUH8H^>WON.UJ380DA>Y^A51.W1^MFR>0^MB9VH51L^>@3>91<0W^1XOFE.NCT?>LRTI3YD.LVGL525P
M^<1@>X7WWT71?>2RRNY^PKXB5^H^PV.(T)^1^<4>LP2IF^>Z^>G^>9T.MD7G67.100Y^<CK^AE.(5MUKP3336U@>F8R^<?>Z^A1)>A1YD1H41.UTTF^M#>.D1.7%G27H
H^C1>IA>G^<G7D1Z^N1.OB\$1(5R6P^UFG.BR&PSR.M@<3&O&A=SY6^<1>25>0&A^6X1^1M^1J8A1^478KW.PN?<Q&X^1Z9AB1JHFLYOZ
M7)3U\$1=5_84_BB1B7_63.KX.PY^<(LAYC%>E.APCYFH5.I(96Z1.MMJ.VZZZ#(B.BVJRE^J.ZI>O8\$1M^332)M12@4)04>1+L.IU&A3SU^T.M^+LLTN
N386&=L^D1^<6&U^QJR.EJ^NMMH332+5^PSE<.(D8214+1+3.M1.G^>D02G>CJ1^>P8P02K012L10R9K^<P6M^N.Z3CZ8^1KX3^7LKPQ4^C6KD^M167^M919(61DM.
3L5=>R/5E^83P^2L66B^P>+P2.SAYV^N^86(LY1B^M70^<1.R3RTB1^VGZ3>0=>V1GX12AGZOW^+>SB6U2Q37QCW+1(2)XWLP^V6G^1MNB8?2^5H3M
<1.EUU<1211M6NK4_74P4190OU^OZ60.%K51.MOK9XM31^>155E1.D0.IQ^E13=819MU^MUS16R1RX^<RM5-VYF>?QG2L^M^H32S^<JHW41^A^U^VJ^J22B10IUF
1^BGJ2V^WA9N0+ZNA\$S^<K^<K&MB2NP.TC?SP1><.&U91=>%@>.FDEQPCPNLT0>ZLW1.H5R(MH8>Q5T^IX.MN5>2.R5G66714UF42^4351A^XMG64^KEY^Y)
+TY2B&^A1&..8HBB.^9)MC#EUF0V1T9P9C4JR40EV#(=AQ<@98^1WE0M.Y.XJBFA^E\$OL153D9%>H.Z.M>6JR6JN^TJNX.IY.L^?U1U3?L&3S@TU512.KI9#F?2
WR4G^M5X%20C1M9UZO0R@<13D1^4H0>4^>936>@DD9^CA6G^1YJS.K\$>7#<80+1Q^H1M.#H0N^NIEB60=4.KN212G.O>U7H^OIP&L^TS^01+FD^>XOJNF^G6H0
MW.3.6L0^R83P^V\$1^DIAZ^Z50R54310JNIZTGFXX7X0YMEJ5^>QY1L^TW.MX03R45&S.GR92.(13.Y.41HXF@IAW#P33^>0%8.KH>?>4J19).T.XJ^F^X^M6^702PV^M#>6
M9=>0H1FL<K^1H01)51<06.MK6JE^OQY2C%>JTS3D^OV4&G^VRWLN^FA#7J^JIE7>+1>1P\$G^Q981Y1PUN1.M7&7&B3F1=><8GUP41H0>6^NWXQ.7H1S^M&LMD^>
(06I^<8YK^<1^1)BIB0^0.A6\$5^<U^<1D+2^>1D^>3P^>G^>9JER&M6G6V1H0^<1^FMXU01^\$>H(HL74^1>OBE+FTL0\$3^>7<@92)7B7B
ME^%AY1@Q.7^JP.^630XHHV14U5.FP9Q%>M76>3IB.O^<CKT1M^F/S.MZ4FX6^70Z?#P1GXZ.YCZW7.F@Y678Y^Y\$>^RG-6^GL?HWGOKXJ@HR5Y
MCB0&N1J6Y1Q21^<@<3S.71+1^TH^C^>O=J(7019F.O^M^M8U7^<377^T^125>=>5T.R^Y^?M0<8^<1^<7MH)X1MA4<1ZVXX1.M^G4JONPRIV37^?JG10F7F8^6^D<+1%U
<ARYD)AMHPX22%&EN21R41>1.M^VEKT91H1V1VWWEH1G71DN3^<1^<0%>@.EL1P^Y^50/75^FSP.9I4^>V1& MKKH-U^>@Y0.PTTIMH00^<D^S^S6&S(OPT
M1+1JL^H1EJRAM^QM.CY3F^XV\$BE^<+A1J^>ZS_8Q%(HHY^Y2^D.LH_1+KY.MB^<K&S^AB^<B^<G^<C^<B^<PDI(9.FRBLF>12FU1A30^R^<6N3^>2^<4G#?2
CX1DBCR>BF30378F81.M^>1J2CR^<M621^<0#>..676TQ.<6&.MB1UHT18<+>0.G80T7(0PP^8P1M1H0^M^4&S5Y^300/6^1A.C^>19>34VJR^DEQ5=>1UJ1D1^..6&?T1>#(1
MYOY+<.<Y^GB\$>4U1XN&UK@F^<S^M0Z^+W&14^RW^<D^W^75)OIS#0^<(XR(W24.#+08A<X^>U.^86G53+MN^DEL^PG)=XW02RBS.W..8E/H=6CQ0+
(N^#HJFX^501CB.^@4\$01CZB.M^HEH1Q0^>D36.GY.ZDUV1SZB1CG1E1M^F7W&C0Z2IRA^KKX^#@O^<CKR6^M^B^EDHON1ChG@Y.6N^33V1K13173H
T=0+H4^<#&4(0^SIF&S^BADES^M^<403K.DW700<64.9)9?2^4U53&A^>N^1F>27EW7FJX+AA4>3WTM@AF^R.8^HW29JENHHKS.C9I2Z^N^E?2
Q<63H@9&Z^LLA1\$7NVI^AF^M2F+>201F5@/CED^FD^M2^DKZ1(X\$QIEG0R9X>)>LR^<41^65K7^E.M15%UE^Z1^>X^HK59M1^P^FGC^E6LO@
(3AE^#708J7CAJ1>94IB.(H1P21MS41)20^>10=>35.GD^1(LN=>#%ZYX7K09Z>1^1^UR^FUZ^>10J2>1@U.M1TZU0U1H1^BKM^ONR#6#
ALL1UGN1OEVI5=UFHB1W>AXU1067%?M/6^>2Y1W91&1%RX?>GC=57QNEJE(AWG.OAG8.(NDB>.>WD0)0GV.\$^MK1^>G6E+W=RP9.?>LS1^>B61E2633>#PPHGU9H
^MM61+1^<Q1>2^MRY^>#<Q>VIB>1V087HTG<@D1=M^?V;5#<1K^MYU14^Z1..S^Y1LFWJ8LFV1^XV1P^?17QGT^1(C415V8T1^?>7@?>M^Y^<@R1
(81Q0=>=;K>1P11HGOH2N3K<45B+K^10T1&1.L(E4\$P3M^1B)12F0>@5Z(W20.F5N05G62RVI^F.V^XU5+.%SGW.FZ>#5^<X1JU.MK^TVKHPR^<1^<89&.<67-
7B2RL.MQ21S=<@TX84)1UVKKE7JHC^<0^/3>=LA^O^GA41XU58P.Y4.@8%591O<D^>K6KJ508&JY=1TKLE^#>19=1K61^>1?7^M8/HU^<V^B#><5H0Y07IRX^P1Q6?
N5A1350.MJF1M="55Q74FB@<1^<BW@X^M^>7&81A.EK<3GS^>SN\$1^>@A&Q9WR18D1&JE.LRE^SH.\$&55C&H2F\$MHHN^YK^
(A.^D@S^>WTR&51^U1D9%#T.G(BPZ^1^1T.9P6M.WB1P15Y2^>3^MOLPYSECWDD0EK)G7IK^C.LM+6IW@>47(\$W>EB^U=YT20N^N^O>Z^UP95QF.MN^33D=S(C^ZAS8#?>
H8ZX?>^>AUGO?>V>1^7LMB1M1D1^IAKK^<1^69>U1R^M^<A01Z^1^D1^PLBCHO>#>#?TSPOH.M2^<W^H<G^>V1P^AHM5^>QEU82HU(U^>M^H^<AB>B)VQ.O.G/S?2^57
55(N12YU1LHBD^E.MCLB1%<9>GIN^Q^U1T^%>@J(S.D.0^B2>5)Z.N^108H1YUS120>1J2B1L.M.MF8^2IQR\$^VR584^Z<1=(X13H1\$E1=1^J1LH@MX1KPI3^5DG
M4+WG&FV1(EJH^SLX^<1S8M^K^<1F1^>3^M^MEEW=>8)OYJ77^L1GRZTKMQW.MH+E^<3B^<N^TU=U>C^<17H1A^KJ5>P6QV^PET
2^CYTPR4K2537^<000RLK>N6(1A=^Y^HBI@<A^>M1^1#E<58%?T>HTC@GEVCI<3N^1Z>U4^Y061/E=5MIM&6147B58><M\$SIMRE(O.H+O=V1F^>=9N1+
<&GTEVYT+MYVVO(472G.%DFR.V73CBNPEV379141Y1J9XIF.ZIA1Z^<X71KW)3^>?>=M1+U3S21>M>Z^1^#X^WQ4KPL=>F^>H^>1A+TS0IRUCD40>DEAV180K#>1L.M-O^>
2QE>51FK&EA&)(0)F&(0H1H5%>2&F8>)P%\$5.HE4^7F1V9186^<HQ.MA^1T^P^<G^<EU8(1+1K@M^S^K&A1YT3M7+32G>?>Q/1J3O^1BZOW1^N1^MS1Q^&MS13@<EE
>2>2&S+>G<768C34^K^<U60.C1+6LU1^Q2TN^<N6S.M^9QC15+VY1YA9D9N241&(SD)TCQ+L=16U501.PT^711P411J1D1
M1BQ>XQ^?71V5^J81>WHX)UKV^>59P^1UBL&2D1LY^OSIADG15Z18WYKYZ.MS6FV1H^<4N^E^X11V^G21_78H3@)>1J71(8RM1DPY6^NEGK13>1^4M7
MH_4MX>1=>EFHK0@<Q>#E^\$13Y3IR1SP^MS1^>+G.CIR.G^>2>LY14?>1>TW3&^>7D9E1F&8.13^52.C^>VY(1^MPC1F1PCN1J^EY20H8_30L^19XSG1PK1D7LOU>1
ME^O+KW9E^7.EVEHR^<1^>5^55C^>1(1@2@.51G)6R^XB=>SY(G)2QV0)4M5^R4@9E5WXXC4^98^B^F2N9PBZVDE\$VM.4+>#>@1?&?>@15P^OGM^Q.TWF
1064Y5YHRNG1=JOE1MPWP^X?>@VR1P^>0.45\$AJ^Z95353QW.@JZ>D1^R.M1A^OEU^F4^>0^DQV1Q^>WR>5>@>155E3TUG1^WFTFMQ>L&S^BC^NTC271^MTW87M^*
(S341VW1.TNEW1%<G)8^X^<FP7)ZH@1^>Q.3E1P5.G1M^255^?W^MZZSF5YK(03N10\$S^>10Q>1QV1^<OYX&7DJ8HHY1Q1^>V>O75QGR8.M3UECQIP(BHD)0.5540?
5T44J3PB70>6P^>#>1^>ZV1RW>N1^>IGSQ0^>6F^MWR&@<C^7P0?>1V^RIND1L61O=>1V^RVR7^<S0Z^1J^EHA4^<K.C1C6G^>1^M8DBAB64+>1^>F1+1^>R^>VTM165G>
11.9X&6^<XN1O>1%Y.B5G+>>N1^>M2B<=>N^>F^>W1R61PICPE.(0AD\$1F410XR)WV44&1L1^O.M5K61JMD01J8^<G^KQ3S^<GN1H&51PEH\$>BVGK^16+1MH+
(9^>4EM^M=>1^>C>B@4L^>S&&F1&4CR5N.P3Y1NML9RM.P1P0\$1HW0>RB1<..M8Y^H<1^<#21>>JG<X^LW>DKL^>@1^>472&@81+1T4RS^41R@3D^<L^>@US
M1X149>TA3J61A4O^>O=V1R^>Y&5+71Z.^8V1AFR34YGS&S^D.99+5E1%M^DP=1+51647L1T^>M2B^>M2QD^Y7SR+(5=.S1A^#H+Z&^1^M1B0PHIR&C^>4D3M23=(2(S?
U2)11HDPW5%6FENH1J^1^M41764^XFSN0Q^>Q^>NW^Q392W1X0R18>?>E97H4+Y^>40)4LRT^<CD#1>M9^>B5B^89K^E2>1D^<HPC^>1^HJBK1.29%1^>#1^>CTB^P.Z2
3CD193MZA<%Z&KURP^H?T^>^>MUM5183^>Q\$U&CDDP65\$5\$1^<Q^>@R4U^HEG&1FZ.(C(OA4D13H&10BRE^(F97>M^>2K^>K^>Q^>6R^>P^>MLDARF10H1^M^MGS
Y11^>32^>N0L^>2^>T^>1KOHZ&77121\$7)QWXA&SE1(41_Q\$M^F^>Q^>OF^>M4M15^<1KBZ&9E..>RZWK&PKPOS4UH^Y&?PD=>#>KUFM<5C>21522GTDYF^S
MH#.%T99UQX13X&15\$YDL1%O1NE1^>3STW.9P+CP14^>YIT>QOE)M.TWQ/OE<3T4UP.Z1QA&10X^L14A&M.%512L^R^>KJB^Y>B1HLY9^MAM_RG16S#^E4
<G&Z1@<(3^>FTB1^>D)3^<Q.9Z48^8D1^A1P^GRWS^O^>S^>M1&F1UW0A43=>Y^>M1&F1UW0A40.GVY.F5J7R1JLRN00<9)TF17U1H^F55XD4P^M85E.Y+>
<6F1Q1V1>LDS1QSYL1=1>Y9DQ1N^>T81@1YVS341^16A1^A1H61U1M^&9QFC091\$41.G^>P^>N1^<C^>B88\$1P2SK6^>D1K^>1H21G1N^F521K^>N1M^T95U<5N+^?>
N1K^M.BP178\$1A21>1^E^Z18@WSTFEXME1&IKGO^CT1=V>514^M1R^>723DQ^WQSM1U1^>1^>FWXNR1V^>W1G1^>1^>X1B+8<2^>DEHBY1+82<6<3^R.MA^HE^M^>1^>C5(979341^%1K
O^2M&5T8N^<E^>G0V151719?>T^>FZYGQXR16B51^Z1G(F1Q0^>1Q3^>ZL^>X2^>C6B^AK1^>G6DQ\$X61.MWY^<@Y3).8^>P+@<CMOXX1^3J6?
#SOVP19)M11UFLN?P^<@4R8)1Z=>MA^P>1E=>BY@1K^8Y^>9EKG2&1^>RD7C\$M0%19G3ZNA1A1J1^>DIW14P3%138HHZ32Q
ML8Z68>9J9>49R8+>6VH0#5@1Q8M9B8X^K^<B1N1\$?>FM/JX26K=W1\$Y^M^8X151.7^<HH1A^<M^<MW0YX^>@1A&RSD^>#M81RPU\$N^>V^<=>OZAWRD^<NFE_<6T1^<@>1
1Z0563YV5M^21UK1>5VQ=>M09NG.MV1DR88>..@CG7C=>R2=1^1D7V^H^HE18YV+1^>2K^>04Q^>61XKMQO^>N;N.
(CZ4O^>#PZ2E\$1A1&41REB91^>4YV91NTC1^>R<O5(R1E51MRJH^>R82667K1^>V1Y^X3YV%>PCN=25BGW+4OM1V+1^>X1G<1%1J\$S.@93115.H1M^Q?2EY^>S00&5T1QO?>
>@>X0923Z>NTOG^E1V.YK.SI&1&WNSZ1R^<1^>MD8.X^72H^<6V^>O5S.D1FY.R^<H1G@E^>1^>1YV^4X5>8<#SARDM^WZ&@>Q8\$1K^>65TO^FEA0
MLB)MK1+>CMU&9K1&C^<WC^<PI^<HTM142Q0\$)I3@1H1&B.ZCSE10R15W^A.M45@>T555^%J1.O19V^>213@CY^<RD_331^>H^>NER001Z&).\$<1@ER4P^1M^>#D17L\$>
<<1V^>1^>E&FT^>GEKH^A1^<V5C9Z^>Z0^>6\$G\$>1^>W1F1E+Z1A.M1L.SK4^<J&M@N^>J1^>7M^<1^>5^>Y012^>AM^>ST1WQ^>08G&U^>H^>Q1^<C^>1&C6G^>6^>S1^>MU1P91^>KEP1^>#>OB
0^<LVN2^>IKOD^>1^>P7^>P^>V2F&G^>S.D.HDZMD04C.M6C.G.RUGO^>J8&2E1^>1E13+1>2>1R^>G+V1O^<6^>U1S1^>TP&B^>8ME5^>21^>MXBCLBUU^>#>9R.Z^>JDL_51JN7^>MMP?
41O1^>570<1%>C=>1^>P1YH1G1RE1A1P1^<98+>1^>Q.RF\$2GULZ1G1G0^K01M^>89SCL9>D1K^>R1LN>WH1=>SJKK^>@>7Y1X3C7M1L0NRE&1^<C.G4F37@M^>
POYES15A1^>2^>ZW1PYM1^>1%)11&8^>M^>VU.A1YS@>O>6151CT.M^>R^>#EXN>1^>O1W1L\$^>GH1^>44Y+0Q4O^>HOZ1A51%<6^>J1YFMOSW^>6^<1@>MNA9W^>36^>90EG50
P=>#POT8>FE^>F8NBU^>5^>N06CE&9>1CMR.T=062^>8H1^>MK8BRKMY0R81FK4H1^>5S+BI^>SZ+1=>P7BZ^>H^>Q2F^<1C66>6>X0G2JRWKHSE5+H3DDMDI&1N^>
BIDCA13^>AL^>GS^>0H5N+SUZ^>FHSN0FEXMO>14YBR17&N^>NYZ^>M1^>J0+>AOV&SGLZ1R^>BC4D91M^>7^>1^>B7EC&APGZ(1^>1240NKK&WXOR^K.M7^>WM=M1C1A+
X1&E1+PKCY1PM1^>HK41^>E0H1^>U1M^>RF.MST(H7^>WMU5PSX^>X1AUB4N^>1^>81QD2RTA&1^>TA&#>0T13VAB=3K2>1^>2FEG=1^>M^>108>7^>HWG^>1^>
BGY+1^>P41^>K^>BIBRR20C^>N45^>9Q?2^>H&6&1G^>O(S31M^<62^>4DW^>3^>U^>X&1^>MA^>S1LS1%<6K^<47^>5ZG642ML^>Z1^>X1A^>W^>1^>B5YD1YH^>GD1XC1N^>#(M28
>@>B1^>8TY<1^>(H121=1X)01U9N1RJMED^>E^>H1^>L&1&=>V681V1M60310=>M^>Y^>N34BCGVCY2Z&4N35K^>H1^>C^>Z2O<1^>V1N5S^>B9JUL^>(TQM14^>M2^>C2Q^>P^>
1P^>JN3G1A^>1JL6/63BX%\$7X^>7H1>RQ#>501@T^>?>6%QO.M18W0Z^>X^>W91AM=>G085^>B1FGL^>E^>C\$>1V(9)XAE1V17HU^>0)O^>1^>7MH.5^>O>Z>Z6)8\$KY^>E^>@1A+1^>6
<1&5\$>61PPE^>A^>7\$SBR.UQ>14<1^>M6ZQ^>O^>D^>HAIHCODET18ZT4&F6F8M^>H1^>HF771UDQY=U^>?%USA1&H1^>MBP^>1^>BB&Q1Y3.64^>R^>FL1^>R1^>G1H1^>H^>R^>MF9=>1
17DRGVC5M^>1N^>GF344H1^>G^>2^>WXY^>7^>V73O^>MDEP1^>N4<4^>9&41LW1^>H1&H1W1^>H1DPT1^>1&BYL>1^>T91^>MDM=>K&D>B7AT1G121HOZW1%1A2
YU1XL1<4W41^>RUPY^>3PYVBO^>NMPH^>BXO^>EM.G1O9&^>YHGDQ2P2R^>P7H.F(N^>A^>V1F016=>DDHK3NU&V4^>M+L^>M^>F^>F^>O1^>Z^>RZK1^>140FZ^>QM.G^>H1^>
W^K^<O^<C^<S^<X6771^>71^>51M^>SH1HA55=>D^>U5MP^>1H(KT41^>3^>8RG^>S2P@1^>V1016^>433C6&1^>L1@C^>M^>O.H1L^>G&L(DN^>4^>M946H6V175FEM^>P>=>%6WS&V^>O7
MWRK^>O^>E2A^>X47.CG#D+>@VXVZ^>#>84)GWH>YA251^>21\$1>JG.6YMXB^>MS^>J1^>JH^>G1403.N0R0FEZ^>CMN^>D^>TF&Q>WYTFZ58&61&53&O1H1
MA44YD#=>K)HODX.K^<1^>NGC7^>IV^>Z^>@>V8AA)FAD164>MSO49^>4S^K1^>@YRR>=>B^>3F&EEG^>GOL12T1^>1DM6PPB012T\$>=>K^>K^>M^>O^>1^>W^>1^>10H4%>+W^>1^>
YPIW6B1@1F4G^>F0NF1@>PRV^>1^>F1U1^>U1=1^>2VN1^>01SX@R1^>8A^>2R^>H19H^>U^>Y95R&GSW19D^>D^>KL17^>=>4NN^>Y^>MU=>A0BB7E^>FEE^>1^>3FD^>M^>5?
>@>N^>N^>DN1^>EL1G1W^>1^>FUV7B13010NLMK41^>1K<8@RS.V1^>1F5O1MT^>P22D1Q^>#8&30U^>BT1S^>1^>XN1F1W7S^>M9W0H^>HS9^>F3YU1^>@LH60^>9=>DVO?
A1^>M^>1@1^>1%70B0^>961^>5^>M^>UZFZ5W55&8X31P>0>1^>L^>Y614Z^>KA^>XW7H1D1^>4H^>4BHS1^>@P23T^>MXR^>1FM1^>1^>U&=>=>V^>K^>1^>XADR^KOOH41U13^>?>CJH0G^>OGD^>1^>
W51H&8^>D^>M>3^>V^>T^>PP=1X94A>R7^>5^>F^>5KZ^>QZ^>+0.K1^>A^>Y^>U137JHM^K1^>M^>ZUM^>1^>+1O31V1HB6E^>1^>A

0156A M138 QH \$I(03VSM.VLFY)AI#> -?2MS5;A1.GEE QSS05PGH1U1Z"1XK M">@91+25LOCIXYFJ)1FYWT+20;1<@985J6I1U ML0TSGR86 HC<&5Y.0M
M46FFTS;PQ/D0G3+1L1EGZ9W X7L0Q5R1088B*FXKJ1XEL*CI*CH93+1M*PW+2993;+1RSCX(400EYKBSPI9<PFU)Y2H1<#77Y< #&71(0I25Z<F\$H
MJS<#14%DX70<0.B6YPH=0>+14=955;+10G3&B=8K14L 1S_>0 MJO V3G.600+1RSCX(NTQ45+1F 7#1F 6Z0L0L1L1Y+AKR"H5N_%5L
M:L8"RDX"<LGN<H121.9>+XN0Y>G+2F5UQORV0< MB F%<Z+L9C6"> EBUH6 H>+XFBMD9G.D_7>#765WU7<X40YV)F.PK#P
0+H<+6FOP117<SPZSDNOX0>GNJXKXW4 MVS=6_1=EIJ5<I2Z0.5144SN1HDDP<@ XON190.IQ095H1F3<6SXW07>>MJO<Q><1UL1<1<1A_<DWF7CFO1<Q
Y=5#90)SIS3_17ZO1&2V2;1+QKZ<Z M&P9ZSD_+<F127=H_%1K&L1+N.R1Y12IDR H57X5U;=&K\$<+,>@>=UDL<A1 M1+>H.H094.10?&S<F 1=WHH1#80;1<0H1?
IRY=AC916R<3<EB2SQZ8 M5I9BON1Y 1.DC01Y;QH<A1I:BNP&B<QSDX8+L @L%W<X1GG.TNJ;>8K<Y>F>LJ<@>+YWKX3J3?3822N1F;BVJHH;C
MG_18N1P1<3X22W6.32WPFN;W>GJHK.YK.64<919R(4S1R11<1PJR 9Q M9Y0.30B*U=W\$<@>NX&DX<QD85W 1J2W+1;WLP52OMW_#1(EN.CGOC<ADH
MDRR;TEZ0XVJKB<L1W+1<@>CG.70PNSDP4+1U1.5<K/C6Y7KZFR0<0 MHA#=#>=S2_>0K0Q1Q1A:EGC(DH<R<@>MW&C1P_>BC
P6=>=72B18Z+01<8IMBZ1RXZ3G.YS>K(RA1<0 M/P<@>G.M1J9P 4EQ0QL7G7274P4PQUGJ(JMR71BQG116<#C<@>APANIHSLG79ET2X> MIFEKOPPPNN%Q02(H(G E/7?158)
<JNPKBA<K<#>FA0Q0> XAK<C_1#W6.721250 MYE1QM1DOUEFM3LBRE1+ADPFWZ.KB203&H4<0(O8.L0ID?D.12RFBF<PKE<5# M<L8#YCC<2<T1VP_Q7/MW%/P6FW=
MH4_1Y56M2U_HZ09RA1B;B.ZJAKD WSI<QJ0GG<R M&H2QE1H9.P1041<UXC(H<ZX>+V.N3V0UOP<@>FRD?>K0#UVSS&F=>=<H(RB1<5XK01W1<34H
M67G<C<#89%>QRX<Y1LJGK0B87 MZ1ANOO.FWB1 7G5<29;+XY7M2273<@>2+FH(OIB"K61YMN45.N3(1 M1=8<Z?B1=P"=FV"U<4U1H_3Z=8D\$?>
G3R1533UL95%4<_P.GB<@>PDJ1<LNL1?>M2P.TV-S M_>T N<K<K7F9.7L B1_5N15R7Q6R.Z<MPG>+J18J3C5A<@>E.6FVX8<S2G1 M<E&G1E1E=>=>
R1C7UXB78<C.<0T1=1F+K41Y9)H1.SDHM2P1V<K<S M RPP">1VD1E.9TUD ZABH1H<Q0L1FG_<@>QTX#87<?%FE7=13M%1<39H1 M8F6Y1E1E=>2G*ZWRT<1?>
YXHZK51F2A2T<#>1<@>(C1G16BZ8ZK U M&WPOH>_T<1P4.D.H0.L0G1F7F&_E1N5N03K1B>2&M<4#5N3Y\$Y A0=LYG ML(4YXXTIN1:1VEK>0.DXGT?>B1AX10<1
MAXNY"ZPLR8+6Y<GDJDO 5DV&A/6G02E M08?>#<4/FAK<K5<1Z1<+4/<@>1TNT 6_76WY3CH:G76P<K12Y+BA M1=1?>2.711U<MLT91=6
MHWK<N<ATV5<+6B2Y1M9K0_V1ZXKK64<#C3M<C<YH1041Z3?>3<OKDUV92(3?>3. MX4.A0YV90K1Y1W1GT_Y5X5 M<SWH%G19551H/MHX<0:MT=1%
Z1P1S<C7ENVAE5;F7<G1L.TPDWC%HO<M0S5<1ZQ1Z<1T1R4G<H1IEZ=81Q(UL15E1<1<1N_1Y1V1=>X(ZPI<K M01?>1R1C<?>X.E171?>0DPF<71T(RN4)
(G6C421<JL82551H<Q1OHI1F%&6.9_4<87717_5 N>1N18R4L2 M10.5U0R7.9?Q1<1N1L1U:FW=1B85.MX<S6G1CX2.50L K<0#8M1H1A<Y<C M MEG<
>295.F17<1U(GZ3F<@>#<K&H1<X3Y1M2>0&S<1E1QW<F.Y1J9XPI3?>E MU<K>=9R1JL?>03#561P<P.NNH18Y2VEBH<G0U.Z.D0>(MH.S.V.28Y<9V-HN
MW.5B=>G\$<@>P.H1JK<@>1W1U/M<MY1(G<#<P.1.DY1Z+D3S717L M<S<WCWD5.6.5U M<=6JSAK70 M+<C.MH1<?FID.MH1>7.S165 M1"95P9>RQ51#1+Y)
(G.ZS5<#>+5P4Y291<46>9Q(56EN521B1_04R*=>M44FA W#M V77M VV1<R+N X H 7?>2<8Z1R71<BG:5HB<BDG40/= AW<6HFAK M2NO1+1&?>WC\$< MG1ZXP#M
_UT4<1 M5<C1N1=>1"2D.D0F<0121%55%K<07% M1Y11<@>N&TP MUD0G<#<LJG10 R<ZYA1T<2<X1K1C41<@>GR<S<D0V 1WZXA1XCA1X<@>F1RAH5M183A1+1P
0_SZKPJGV1L#6%<08Y1R0N1<)<S<K5W01<5F02Q<@>IV M41<E1V1=>Z<X<ABGHQ<FTPU<#X1B?>541H1R71<CK<P1CWB1R1UX0ER
MSHH53JH1H43<AHSB<363D14M?>P16G<_KFOAHJH8<2<4VEO0K1W3 M8EGW53208H1<3Y_0<_5B7LZ<F9Q<YVD#6L=>_VP.DC1U<22CA1X<@>C.P1YHHW-48<
K#<C45P1<(A00D1?>V=PK+U1<#<E.YNA1LBY1Q1XB:MZ7K MU3K1W3<1?>E=>57QF<@>K0B9P.F2(3017<6%IYAYQ1R<C91#11 MBP9B1A<#17C M1N46>?>
Y<591YH0C1F<9H/D<@>UTU=>77F<OJUGO<@>PD9 M1T1B81<+<K.G.FSY1H1X:5ADHEPM>U<@>#1P<Z M&TOG53.FA1DZ3161<E=>F=>2Q.2B<4E01T6Y<M1 M#H;
W04<@>C<B<X<1H/7?>52BY<LLP0M(X)>213AY<X1F XG1.GWL1R1ZP M1<A1AXZ4H1Y QP+ZU2<@>4Q1L1.D P<#<C1<@>16XW3G1V1ADP?>2KH M1E1P1Q1B6<C4=4G;
IX-B1<2B2V71H1L1<1U(2F1TUD06<#<L002) M41S20BXL43R<?>P066WGL19.7W N4A K05<QSCU1H1X X1IAZ X0ST6E.6L C1X51Y3M<+>4AN3UXH1E10Q;
(HEM=>8&3<T9G<=Z1LS1R<41_0#>DH<G1G1<3 E M.W.W30.GWU>+1JDSOP 6B<YNK81<@>Y1H1<8UO<OSCA<+&@>10.2 M.L1<K1P1U<04MHKK?>
X<77<2<+1U9K131<G9S?>51K1<+&2T93E=<H71 M1B39.K0M<Z4Z<+>1JYIG1Y(YMK<*<L1L1=1<G=91PPMN1XGE(EU6510 M1X(S31Q11K1
(&&W22<04MVE+>F 0=5Q57K6X"H.S.DW\$<#<@>M+1/YWGB2>_D M#CBP11#982@> M3%T&4R1CY). Z<Q ?(FM<P%TNWE1AXO\$8.4RD<6#A8MKX=AI/ONAC(9.1
M.EEGE74DB6<(N2<+1Y1J<1J57>+1V1J1<@>TS19.EBK.YES&R<S2 M77>+>@>ZD7?>1<@>N1&6L1?>1U<X1F<+>RAN<0%>#X72<@>EP2201NX1E1M<G66XBDP1
J2A55GF<+>(5AB6L1<+>S<3

[illegible]

[illegible]

<4L&.PE9PXH16.IWJS#<@*Q&IAH(=,AT?M^VR^S,F^UC:V-MCQ06A-M^JH18.04(ZN822(UB&XT-MA%FGVO/KRT4>VL7SD/9WF-?C^E^M)*4
M(LP^XY\$SG^U^L^F2HYK9C9+<9#32/1#W^A^9SR4HB)NB^P^B^H^H^N^M^J>0.7JSHPT\$*0@<\$22?C4/P.C3L# M^+H8QN0."PEI=E79^505^+M MKW^>A+XOK?
\$4J55MOPN0IFM0KKXKL^S^H^<+<(ZHUS/K^K\$6G2T4H9(LM(A)+1JNN522^J%GNMY%6.A#0919V%6SHUWV0.3K^=BYPF^MY4< MJY^A5F7?@JDB^>#42
8BD2YU2G^IFU^R@91M5PQ&B=KH<?T^OUVDENEX-MDAO-A-N-WY\$S=74XTF017VOYN5M\$+24X\$^GYN7L#=-Q&M-X.8K6@T.91M-D-M.CON60B^>B^>BOX^Q7Q4(S75L^<
(\$:L+!#)SEQZ\$F!/@-M/LSF^TQ^N90?010#HDO.8<8#YP)8GZL4X\H(<)C:B\I/<4^>FP@ MYK\$^17.@|@B-C8#9VVRZ@8%92G>OJOOXA9_B@E#%#%\$HDL3!E8T8:>4Y;#&I
912U8ZD#Z5DQD.8I^V75W8^V16K\$YJHIMLYD^EKA\$@LGMRE:Q&E^M&?^JXG%12P45LH3V3V5^>#AN\$<-CR^GWJ29^PHY1^ISB;U3+G^20^?P^D
ME)JU^1>9&L+!<Q7^>1#H9U@B@D:FAA-E^QHU2@PPH8733E^M\$+6>^>HJG%12P45LH3V3V5^>#AN\$<-CR^GWJ29^PHY1^ISB;U3+G^20^?P^D
56F4V49K4!X^X8RIA^M^+TQ4@=V\$Z^PGR<."WSM^JWN^MSY7+Z=;1H0/1^XWQO^M^SATB^HA8\$H8Q19+^S2_1\$^>T^<O^X^Z^R76@^*47L3>Q>2^M+!^ASHBCA&Q6
6#D4)LOUAWTSJ.12Z+2(1#3W513J5A2^287A^9JT^*^MU3H^=DEQW7H^WVWOD>Y%<=>MAW^?H18M^6RIRIA/1ZIS1.05JH1^>IWA@A.05Y\$O^Q^>2.2/4_!<A?2# M
^D^&N#\$)<5G6FL59;^TFI>FQJ^KCL^NH>?7XQ=O.^?XT5W^UTI@8;2.(M80&8<-(B3JQ\$^E^1/(^>RT^5WZY):CJ=[KB39@5)A%5CAKIDUF\$Z\$Z:EOL^MO8MH^>G>1^<
<#A7E^GX@<\$5D18YV9Q0E^M+K\$3261.04U7D0>4C7BUE8&7^M^5^>VHIMLOMXQ&S^&N?P^>OQ>59IS<<@D&N(OU\$H^XJ^B6G^I^V@JBN90^_QI#W20^<
MR099Q&0\$1%YCWU^Y^TCL^M&DK1F4D7D^PEO)HTS1#)L91^K8V@.GC%DF2(\$Z\$A\$0H2^>P>6LQO-M^YATW@<+T01^>EYIJO10^>J^TJM-803FO)PQJZ<+M>Q>3@1
N0^TFP^H1A^W\$M^SXH^H(4^?2^BIBJ52.1BM@/CPVP^Q1231S^I-SNICA^>1\$1^?AOH^C4&S^M6W^M^Q^?C^B.1H(C)2Q^H^1PP&T^#W^510IQ14PM^X^""Z;7CQ>1Q?AWG
MW^IQ2I^_SG\$-6TCSIA^@OC+4HQ^B2I^YQ^4DY4U1%1M^DQRUBBFICUPH^<EKKX4H^?5EYG^*^DICI^6XHI^%B!)<QNTI\$<
MY5MSJV5NPI>SD:AS%COL<*2;12!OE)+7K!8^243(<@Q5D^H^H/D4M@R=ML2+IV0%""4^<RKVUSNTZ^<(E%6@1>?>\$6XX-W^/ZK74@Q=T)^K^<@&00)U-E^<.<M7Y9K6^<
FUTPFD^FLIO3U^N\$SX\$C(1B^P8YV7CB)UDH08J2><N&M^LX^C^MY6_54H1=8^%?X3L7^Y+Y>A=O.GL=C6ZY<L\$8ICG0A^0A^A5J^USTFO^M<+CA&9M^>O^Q^TWMW1A0
^110#<FOLJY>3U^@16B3^<QI(1^9M9CT^<?<3W4H6D28^M0R^BT@M^WMS^SNP2PM^<LN^44Y0M(OQK^>#ZD4A8\$>><5%>A^<XG7VFX^MG<
=RIUE6I\$^CXV^R8L^_OOIGC2UV\$S^X&J7R6G^>^>21.0LU390GL^I^AB9_M^*^<+OZMW30^>W^D\$^>U^OOOV^<O^PI^D5="ZZ08^ISD^19BD>8A(N9^M86#2^G#23/GH1^>J
K\$<@<PULH\$U^>Z=WI1P^>V4VBS6^<CZJ1^M%52^P^L^RS-)M=6CU^NAD\$7M4^9CQ0^>BUBV1P^CX=HGIN760/2B1P^B^M^D)24H^<1
Z_#GDK&QD4HROAN1^1S12#1^OZNRZES^B^AL9ODYFSDJHC@/H^M^C4N^F237^HSXJG4@8/GJ^7BB>-476LH0HR^93I85B(HCWVD&D%=UGUE0^ML14D8>Q<
^OSTF^<4L=0D5%JASBGAKDF^W&S\$5%=<^JZ1+3FX3Y^<P232YI^MH^654^<D^H^IBVEX^<1^>7^M^COYN^E^<@MS8)J^_OYK^<R^H^K^<6=E75^M^V4^10^M^<@WEZV4>=<O
LY^52YV1@J95_654^88HRYQ\$1^4YI3E#E#1^MY9>01.Q4A.G^1+1&X9^Y2^7H^K^=EOL\$^<O+>2Y9G1F2^>RHE22YHV^<L^M^#V.C^MH9C@Q8(QG^EW^Y^H\$%<AF\$S^CE0B
40AWM^N1QJ.9H4+4+M^J^4H1V54^L^I^W^<5%0\$0(DT)^B^M^E^Y^FK&ES^Y0^M3^Z^F+>J4HD.416F=(5CZTH/<1M^12V53+>^#1+!@^P^TH9^3GDP8^<A&S^M5T&S^X^<(\$R8:
Q10I#^<CZB14R1@J^H^H^WV_>2U^W^N&A^129%+>D^G^>MHG^Q3+>22B1X0B^QD=O4H7XP^>?74BIBW\$JW^U^OPD^>Y8B1P\$KAC^E^M^<P4N^E^<NZE^C^40GHJ1^<
Z70^Q@DJH^H(="W"?^>1=+X=9^A^+L^<M^#HB&Z1#^A1\$M0TL4EKW4+PZ>JHU5XW27^<TW^M^A^ZTM^?3WZR^HJB^AVW^G442P\$^<55P^FF^I=I2^Y^P^K^W0^L\$0H1
M^>9^<XRFJ79>=169HG&SUC^<872>?>IQCDX^X2K&K555132N1@JHT>+>K^MO1F^<6N&A^Z^N02^_OG^JQ\$4^9ZT^>2ER^M^+E^<DN^<V6\$<6^AO^CUO^>PIZ4G^5&W81^<8#<^=
I3SRVGO6\$5BBQPA9^VP8T^<G6B^<B^>?>?>8J2T^D1^57L^<O^I^P2T^UN1^MH788&B7\$G^>G>1@Y6HVH^<O^<P^J99>?EIVQW&S^E4&S^H&H^<^<
M^<#&^<HJXIE^S^SORQ87SV^<+>P^>PAE^+>O^GLK1^VZ_>78C^<H^H5HH^M9^AL&3X^4Y2HN4L^<C^PCE^H^@<F3J\$-3Y^<M^#>0^<RTQZ>V7L^<N^<L^<V^<A^<OOOF^<S^W4BPM3A9A3W^<
M^<B5(P9Q^<ZLW^T\$0\$D1= M^>6EER^JYKJL2\$=U^Q^L^<EM^<K^GHS^""PAS^#<#5\$#<TBE@<@<C\$1^<N^<M^<V4^<M^<YU^<1589(C^<AK^54^<
(9TGCU<+16H^LDBB^>)+>6>?>N%45> MQ2HLG?5H1%0MA#1@2L^SY>@BI?%DG^H^EX^Z9Z^6MCD^FWRT5+<8X>+<6)20H^M8>+H^F3+AK9+C@<SUO0@?HZA^WAKI
<#F\$Z;G15^<76Y^<N^<611^<WH^HWO^<8^M^KD^CP3EE^T^W&H^F^IN&+<+<8^CZ^<P^<O^<K^<P^RG^<W>?> R0KH9\$ZQ^<79<C^<Y8^M86C^P^1MOB^<C^<N^<C14L^0ZB^31L^G^H="XA7
YH^>0^20^A1B^3%F10^<F10^<Q\$F^D^<TR\$>=>06>?Z1+3W4H6B^ABW^JB98^>Z>CH>?O^<K^<3>P^<VZ>M^<S^<K^F8ANW^NR^VUT124N^<8AY^S^WEI&E^<Y^WBP^<KH^<6^G
5LDM^+7ZK^M^<Z^N^M^U^E2\$AX+<@?8L^DN&10^<E+O1S^D0^<Y^>20&S^3^<1^<R^<M^<4S^H&B^<48PIO^<M^<X^<FOZR2HSU0H^<J^<95XJ^D^<B^<4^<77:5FRI&7^<7^<V
(L^<Y^<L^<8&U^<H^<MWU@<1^<U@<46G6><?>FV^<H^<1^<MU^<D^<X^<P54^<Z^<7A132N^M\$C^_9R^P5V1805^MA2I
(^M@<N3>63P^<X8<+4R3^<K^<A1P^<K^<2A^<+3Y5^<B^5^<OJA>D1^<H>W66^<V^<MBEUAT^<13^<O18PPOGR&H^<UADS%3/f>C2(6^<RQ^<F^<
%<^<DN+KR\$S^<^<V^<O^<1^<#^<Y^<W<+J(19&S^<F^<P^<DBI^<Q^<S1VU^<M3)ZPA^<4UN712Z^<V12^<C1V^<F1^<+H6XJ^<N^<CLNH^<J6\$C^<^<R1FM\$<F1^<P2RXK^<X>HH7@<(S+<158F^<A^<B
M^<^<O1P^<P^<C02B26Z^<R^<V^<Y^<21^<M^<S^<XT^<65^<OY\$^<00V^<@>WP^<VMG7^<54C^<BDP^<04&F&7^<MAU^<O16^<G^<C4H^<111P^<C^<RUP^<=>2+>^<Z^<N^<UONN^<E^<MM^<M^<8W^<E^<F^<M^<
EP(W^<F\$<G^<41^<@ZNP9B^<V76K&4^<S8^<21^<MX6^<QO^<V^<X^<H^<L^<+>Y^<Y8^<L^<B1D^<N^<+>Y^<R^<E1^<31^<O^<D1^<G^<E^<B^<#^<Q^<M^<E^<8E^<=15^<Z^<M^<7^<Z^<A1^<B^<L^<M^<1^<H^<W\$<=>10^<U^<Y^<C^<D^<S^<Y^<4^<
<=<0&Y^<4U^<G^<5J3PT^<H^<M^<U^<M^<3^<7^<6^<7^<C^<U8^<W^<Y^<KQ9^<58^<B18\$^<1^<Y^<4^<""7^<1@Y^<U^<DQ88^<5194^<M^<FDB8^<A^<OAJ^<^<FNI^<+<C^<M^<U^<M^<X^<C^<Z^<13^<^<R2I^<=<
(ZMU^<KG^<E^<K>A1^<Y^<M^<K^<3^<4X^<L^<0\$O^<S^<AR22F47^<Y^<2A3^<F2^<W^<Z^<U^<C^<U^<+>(<4O^<X^<FD^<W^<A^<Y^<@<6^<G^<M^<1^<N^<W^<+AV^<""@<D6I^<F^<Y^<K^<FPJ^<V^<C^<Y
8RVB^<+1AJ^<Y^<VH81^<P^<Q^<7^<M^<8&K^<7^<M^<1^<Q^<7^<L^<O8^<9^<U^<B^<D^<B^<61^<31X^<27BRFIDH^<@PR^K^<+^<1^<AW5Y^<""@<42=71^<M2NNA^<9AN5^<^<WY9P6^<?>3=+<SR^<WT^<1^<44BHH^<
P^<23<+<1^<OUI1B^<@P^<SLE^<MST^<OJ^<H3^<Q^<E7E7^<S^<Q^<ZVA^<2^<W^<R7Y12^<6013^<ZMP2^<U^<Q^<K^<1^<P^<+1^<7SDE^<+<8&.<Q2^<UJ^<H0^<U^<16AV^<WH^<
(M^<VEW^<F18^<C&8^<QF^<M580^<^<T3P^<M1SEV^<Z^<MJEI^<P^<Y^<P1^<A18^<M^<Q^<R^<Q^<S^<56^<NM^<N^<MOGIB^<#<^<XVP^<C^<J^<EPJ^<Y^<K^<L^<2^<S^<9P^<V95^<""<K^<M^<AZ3^<U^<YA^<XW^<6^<+WJ^<83^<MT2>+<6
<10^<30^<GYH^<Z^<A8^<O^<8^<A1^<V1^<L^<U^<#^<XNHHC17^<D^<WU4>15^<M^<T^<H^<C^<Y^<D^<S^<B3353P^<B0R^<D^<12H^<H^<Q^<92^<U^<Y^<K4@<17^<A1J2^<=HHI^<+<K5^<D^<G^<M^<7^<C^<X2^<S&2^<=5^<KAS5^<""N^<JH
L362LX2^<W^<Y^<ZQ^<1E47+>^<JK^<P^K^<Z^<M^<O^<Y01^<MR^<Y01^<18?^<Y^<=U^<R^<L^<33^<Y^<+>CUP0U^<A^<N90I8RRJGNT^<?31+WB9145^<GX^<#^<A^<#^<AC831^<TF^<D^<+1RQ^<M^<)=@PG82FC&
IVXZ12G^<O^<P61^<7^<G^<@XWJ2^<Y5PP^<@<6^<3TH^<CBU^<M^<F^<E^<Y^<Y^<9^<M^<1^<D^<W^<6^<1^<M^<K^<M^<LVU^<M^<7%<@<MASP^<MA^<N^<D^<P^<90^<F^<DU^<41S^<15^<XV^<+V
ME201Z50^<+1671^<M^<H^<D^<7C^<2^<1^<2^>M^<Y^<12^<T^<AS1B^<Y09W72Y2^<F^<Q^<O^<N^<#^<PPD^<M^<K^<H^<S^<P^<#^<M^<#^<D809^<8D^<DC6A^<M^<#^<V^<XPY3^<G^<F^<1C^<U^<U^<N^<H^<L^<_<S^<)>\$3AN^<S^<X^<P^<CB
L&4&Z^<RBA^<P^<CB^<C^<7%<L^<R^<2&S^<G^<+VR6^<=>?>55^<M^<P^<+L^<64Y^<#^<1^<Y^<+>V^<M^<V^<D^<S^<Z^<S2^<910^<S^<1^<Q31^<+>9U3^<V^<N3^<D^<C^<2^<W^<A^<Q00^<M^<H^<RTD^<08?2^<Q^<+W^<G^<H^<S^<^<
ED&Y5N^<14^<S^<L^<W^<S^<D^<S^<W^<Y^<X^<A^<P^<P^<L^<5^<U^<W^<7^<G^<A^<M^<L^<W^<D^<S^<P^<H^<D^<F^<6^<H4^<4S^<E501^<EDN^<@<Q^<#^<54HH6^<H1
=R^<NYK^<C^<H^<+<K^<N120^<H^<90^<1^<@<ND^<,\$H^<Z^<B5YAA^<G5IE^<I^<U^<L^<6^<H^<+<C^<L6^<#RZK^<+<GN^<+R^<M^<TXW^<V^<V^<#^<I^<P^<H8P^<#>QVD^<+G^<FQ2^<DH^<N^<4#^<5W^<E0^<W^<=T\$<
L^<KOP^<N^<FGFJ^<P^<K^<I^<W^<H^<M^<H^<9S^<I^<V^<M^<D^<B^<E^<N^<9^<N^<K^<L^<M^<1^<Q^<=6^<M^<P^<C^<O^<F^<T^<U^<K^<V^<G^<F^<O^<P^<J^<H^<^<+<W^<L^<N^<1^<H^<N^<71^<E^<=Y^<9/561^<1^<AWK^<^<Y^<P^<M^<55^<M3818^<S^<ER^<H^<+<
O^<17M1^<26LZ^<P^<+<J^<8^<+<S^<U^<=30Y1^<W^<292U^<Y3\$3^<M^<P3Y^<H^<V^<Y^<O10^<GE^<A^<V^<I^<Y^<V^<Y^<K^<H^<S^<6^<64^<F^<03^<H^<Z1^<6FH^K^>?>2%<146G^<CEB^>?>2%<06B^<T^<5%<M^<L^<+<X^<P52^<QOCV!
(^<U^<H^<H^<S^<S^<O1^<U44^<H12^<S^<HEH^<Y^<A^<U^<U5^<5^<M^<D^<O^<A^<W^<6^<0T^>49N^<M^<T^<K1^<+<E^<V^<+>4C@<R^<45\$K^<A^<B^<I^<Q^<Y^<YH^<70\$<=10H^<M^<8^<C^<D^<L^<+>2Y1H^<H^<J^<K^<S^<8^<O^<T15^<U^<U49^<S^<V^<YOS^<M^<P^<W1^<^<
#1L51\$<Q^<U^<Y^<T2^>S^<Z^<E^<Q^<R^<A^<P^<I^<L^<U^<#^<XNHHC17^<D^<WU4>15^<M^<T^<H^<C^<Y^<D^<S^<B3353P^<B0R^<D^<12H^<H^<Q^<92^<U^<Y^<K4@<17^<A1J2^<=HHI^<+<K5^<D^<G^<M^<7^<C^<X2^<S&2^<=5^<KAS5^<""N^<JH
L362LX2^<W^<Y^<ZQ^<1E47+>^<JK^<P^K^<Z^<M^<O^<Y01^<MR^<Y01^<18?^<Y^<=U^<R^<L^<33^<Y^<+>CUP0U^<A^<N90I8RRJGNT^<?31+WB9145^<GX^<#^<A^<#^<AC831^<TF^<D^<+1RQ^<M^<)=@PG82FC&
IVXZ12G^<O^<P61^<7^<G^<@XWJ2^<Y5PP^<@<6^<3TH^<CBU^<M^<F^<E^<Y^<Y^<9^<M^<1^<D^<W^<6^<1^<M^<K^<M^<LVU^<M^<7%<@<MASP^<MA^<N^<D^<P^<90^<F^<DU^<41S^<15^<XV^<+V
ME201Z50^<+1671^<M^<H^<D^<7C^<2^<1^<2^>M^<Y^<12^<T^<AS1B^<Y09W72Y2^<F^<Q^<O^<N^<#^<PPD^<M^<K^<H^<S^<P^<#^<M^<#^<D809^<8D^<DC6A^<M^<#^<V^<XPY3^<G^<F^<1C^<U^<U^<N^<H^<L^<_<S^<)>\$3AN^<S^<X^<P^<CB
L&4&Z^<RBA^<P^<CB^<C^<7%<L^<R^<2&S^<G^<+VR6^<=>?>55^<M^<P^<+L^<64Y^<#^<1^<Y^<+>V^<M^<V^<D^<S^<Z^<S2^<910^<S^<1^<Q31^<+>9U3^<V^<N3^<D^<C^<2^<W^<A^<Q00^<M^<H^<RTD^<08?2^<Q^<+W^<G^<H^<S^<^<
ED&Y5N^<14^<S^<L^<W^<S^<D^<S^<W^<Y^<X^<A^<P^<P^<L^<5^<U^<W^<7^<G^<A^<M^<L^<W^<D^<S^<P^<H^<D^<F^<6^<H4^<4S^<E501^<EDN^<@<Q^<#^<54HH6^<H1
=R^<NYK^<C^<H^<+<K^<N120^<H^<90^<1^<@<ND^<,\$H^<Z^<B5YAA^<G5IE^<I^<U^<L^<6^<H^<+<C^<L6^<#RZK^<+<GN^<+R^<M^<TXW^<V^<V^<#^<I^<P^<H8P^<#>QVD^<+G^<FQ2^<DH^<N^<4#^<5W^<E0^<W^<=T\$<
L^<KOP^<N^<FGFJ^<P^<K^<I^<W^<H^<M^<H^<9S^<I^<V^<M^<D^<B^<E^<N^<9^<N^<K^<L^<M^<1^<Q^<=6^<M^<P^<C^<O^<F^<T^<U^<K^<V^<G^<F^<O^<P^<J^<H^<^<+<W^<L^<N^<1^<H^<N^<71^<E^<=Y^<9/561^<1^<AWK^<^<Y^<P^<M^<55^<M3818^<S^<ER^<H^<+<
O^<17M1^<26LZ^<P^<+<J^<8^<+<S^<U^<=30Y1^<W^<292U^<Y3\$3^<M^<P3Y^<H^<V^<Y^<O10^<GE^<A^<V^<I^<Y^<V^<Y^<K^<H^<S^<6^<64^<F^<03^<H^<Z1^<6FH^K^>?>2%<146G^<CEB^>?>2%<06B^<T^<5%<M^<L^<+<X^<P52^<QOCV!
(^<U^<H^<H^<S^<S^<O1^<U44^<H12^<S^<HEH^<Y^<A^<U^<U5^<5^<M^<D^<O^<A^<W^<6^<0T^>49N^<M^<T^<K1^<+<E^<V^<+>4C@<R^<45\$K^<A^<B^<I^<Q^<Y^<YH^<70\$<=10H^<M^<8^<C^<D^<L^<+>2Y1H^<H^<J^<K^<S^<8^<O^<T15^<U^<U49^<S^<V^<YOS^<M^<P^<W1^<^<
#1L51\$<Q^<U^<Y^<T2^>S^<Z^<E^<Q^<R^<A^<P^<I^<L^<U^<#^<XNHHC17^<D^<WU4>15^<M^<T^<H^<C^<Y^<D^<S^<B3353P^<B0R^<D^<12H^<H^<Q^<92^<U^<Y^<K4@<17^<A1J2^<=HHI^<+<K5^<D^<G^<M^<7^<C^<X2^<S&2^<=5^<KAS5^<""N^<JH
L362LX2^<W^&lt

M6G7%+*.*PK@;WOZ%;P.DL6@>*P@NDVH+2(C%A.BQ1-0JUDVN7,,2V-DK-MLM0IXOV4VA7/G;G;42OL<&W3P8#*0J=8PS2AL@#N/W~\$..GMDF MJH< #>%B'MFBNVXKI
90AB7%+*A1.M3A!BP@;LZB&AC@SDBLFKWQ9;-M-Y-VI@#*2DA1@T100@%-D-JNGC!*FNIL^L7-=O2U=@;"NOB.2.T6T8=-QQ MG.N.V.F?#
AN/A..WMKHIV=GL<GINGNIT(OAZVTH9LA>=>DI0 VP=)08!"M"LY."NURF=T-QSGFG19JSOUA0LI=JE10->WS D17:QJMS-I-M-JLK8K*Q\$WLV#8#*>228_07J2_G^-Y%
200Y.#10?<*>K'ADRM6Q<RG.M.NQ:DIWYERJFL5%"EYF(Y24EO5/SFM^F2PF6'ADG&8>IG4.&TCM'GWIC3=XQXJ.NNT32M30AG'DBT770.7ICZ7?H(I';67L1<+<
(O6H.MB.QFSC9RIVEG<s<@H%;&N2Q/L7+8-L42=>X=F(AO)=ZL:P1ST4K+=S.M\F=C9V4K6+=AI^DL<CW1>Y@fM.;@9^XTM'H*BA8<0C(LN?
WHHHG<#.3.Y%5DX.JP<D5.0%0Y7&U-MO.-=C>J2;W++QIN5.D.QF>HT^+A\L*WA6-T=F#^>6UW%\$L^2.5)CH.M)-N#SJZ>+B8 F^Al@XCQSL00&M*8
U.PF9.FKOW=F34H1L5>@Z MD&S(GE&GAC+KK62D.5TM3.S'DFK1K74OIFR.M36A5931FE>YB9DJ4^?>I9^CYG&RG6GVPI5=9747L8&GG6B=QY(H'6P2P4.L-L^IP.2
Q>+V\$GE R-IH1L81Q'O'ADI8>=CE^>|AT.IY^IMAT.M#1L129#UM5<C@>SDYHJ3T-.A.H-FE).ON5DO7^VKEX/C02=327GOL55 M3<AM9GK&VM^L<
<67W.L1WBOD@K'G.WJ+27E|^#=GWZIN.RZ-BI@3V_-S9 M+4MP5.GV/L-ONWTF2IEZ.A.BU^)=HL\$IN-M2WC3G^PJ8WHL-WZ-UGO-L"(GI3^102P.\$%M
S+.(6IREZ\$Z.MFA@JP.OBRWL+L65X.S(QZS.V.S.R.C?)#=\$\$>\$N:1MU5AM.HLY\$Z>M7AY6G L EBW)=F+3H B.\$6\$1=J>2IOHL.Z3180B59^HOWZ2DK<>88^@M
MSO)HL7P0Q/MX2.L96DK<.8L@:*SGY8.IP^XJ.^F.FE)KH%.8^0Q7^I=(P.E.F MB@3:6NMJ9D.)HP M=CK@1C+A^WF63LPHJL<9A:O)@5.(TG)H^S1^t<l&V%>Z.#B.BC!
MK9J.XJ^K+I46>V3^P+&7@5<6A9G6PUHFWWWL&PWLEWK RKX2BH<I4G6 MVHMS)91.#D+ESH4."BS9Y.6U78.AGN^#547EZZ&A4@0&.
^ZIACUO9^IK\$JVL^WUO MOHQX^WDVI.W.L+GE/F+E2H^7QMHD&B1+FO52P USG(=EYAFZBF QOLJ9G./6\$>2R/H7.T2RO"N9Q^97/+>M4/L\$CVB=%O;
(ELKR#D5MB6<--<=S1E7\$N/TQ/RMD MQ8S7R1(>D>#M.'BZP9-[5^I01G/L.08)7A7E^Y DRHJK@QGBBEUV38.(TD)EQO(L)>@<IR^M OKI!
OE^I=(ZX3KL102GNSN>V-H EIN^PS6KD>|PN3?*(SK(S0T=26GMVQM^2.9M.9I4YI@LHML^0L.7F."KB.EI.ORS
M^XMMXYZL104UB7C<XU)@>C/OY.5I@<HPLZ^O#P^HF.M.I4C415.%PCW%=SY^IPWHIF6<6-WF^SZz>CS.F.HLY&OOXY.YD102P.\$%M @ S+; 6^F /+^+^H \$ IP IO8W-
L+65X.S(R7S V.S.R.(T?>#\$P M>#:"1MU5C;ALWS^WO5I RFMB 5EJN+M8M;@HG =>+W.8REAORUDM82ZY M(ZG+ZM+W2EIN);0 VTMUPIK";F.^HW,Z/5-IRTF M1?
5H8IU.PM6)512@EJ LTYLXZ/35>"NW?T.215E^IF5:.55/H W&6-WL M.7-PYO(FQ4)-ODJM.JP1066705<0KIEZW M.5.VL6\$516M^>.FXNPQ^UBQ>.
H1@<6308TRIS& NRO7^4A7W/283GM9LH Mj6RIS^PP2Z-K3I=HJ2?(@C/I)^@G^I\$S)OBNN^718^01>J5P2P2_X^ME(FI^+<R>ZL%^ALLZ^#@08;
<@QUK9P>J.IN^I%)S PIL6.5G80U<3YW M7FE.49.Z2BJ.LHYEOV^T.KK.GEM1 G67 T2P^)*KJ6^N9^5<69+NF0& MD9=K8J(GYF^+4^FV%>#BLIM-G5J
X^);/VP5<6\$1@/32=B3.X6GD<3A/M2R03DP99FDX I>3^YV=895<Z\$K=N.B/76X/G.K-(K\$V9)(22VS&V-X@=#N\$SLOL4)<N^HSH6^526L^42LM@B.;7BM\$*+<
OG0/N8^7&4LUID<SG.4JV.W@H&F#=-.T0I8#A? MSDOTHS6:ZZ RIQM(LJ3&Z57N\$L+X9IM)@-W9#A^SICGD&<@NF(ID75R M7=725)Vv@Q107H#?
NJR.M<18V34P>#<HX)22.30%78^NBW3+NBXUPU MSOIHGC3>K+<(5CE46LA.(64.5A1.N8ZC)=M-P40/F7HJ59/(69M+V92
M\$C3M^>4(DY?>JMG6SKD(KFCVQOUEJ@) KENG<S7W:L SJRR #1#M=09/M5PA6QV@1^L^VT&YA58ZUX^23:RGH+D>E^M.E21>^#56\$5.3C^+Y=DY7 MWMWTUL .G.G
^HJG2>S/X T- TX.=XAL XH(KPQ.SR.KJN/HLOS.HX.MLB.WC4CMN>D)5HJHOI JOOO-ZN MK^ZV=EU LI.M8\$W3JOV6/GISL MX2E^HF<S^>V6DL&G2^K<@HJ
M.+2+2X.LQ<=>^3IW-IP1)Z.E.GID:X+Z+(P^H^NH H LCLWR8# MR^QIZB._W2X2WU6V@A.VODEPNE FA7XH^M+RBYSWA TEW7.W^4\$SLA0#% @
S+;6)F@<MDT@<4 JW9L M L C L & C B=(X8\$!<S L8X%<I C^D4\$LL A0#% @ S+;6>+<@&0);&\$.14 (<+M+Z.;&ICY U=0IAD@<T0 @ %M @08.V%>TR.#
T.#85.%H86(N<KUL4\$1 A0#% @ S+;6^72>V M0 <0 +14 I(BH^I C#SP>N:"1M4\$1 A0#% @ S+; M6%;1 OF+1 P 6B JP (+D<I C#R.5)P C.P.C.R.
^@Q.AO+FA75L+M O4 Q0 (<VB_UAYOP2.^@0 ^41<-"67E")0 M8W-L+65X.S(R7S V.S.R.(T?>#\$P>\$N:"1M4\$1 A0#% @ *H L@(<W L\$> \$!end XML 93.ocsl-20240630-htm.xml
IDAE: XBRL DOCUMENT MEMBER0001414932 2023-10-012024-06-30 0001414932 2024-07-00 0001414932 us-gaap:InvestmentAffiliatedIssuerMember 2024-06-30
0001414932 us-gaap:InvestmentAffiliatedIssuerMember 2023-09-30 0001414932 us-gaap:InvestmentAffiliatedIssuerMember 2024-06-30 0001414932 us-
gaap:InvestmentUnaffiliatedIssuerMember 2023-09-30 0001414932 us-gaap:InvestmentUnaffiliatedIssuerMember 2024-06-30 0001414932 us-
gaap:InvestmentUnaffiliatedIssuerMember 2023-09-30 0001414932 us-gaap:InvestmentUnaffiliatedIssuerMember 2024-06-30 0001414932 us-
gaap:InvestmentAffiliatedIssuerMember 2023-09-30 0001414932 us-gaap:InvestmentAffiliatedIssuerMember 2023-04-012023-06-30
0001414932 us-gaap:InvestmentAffiliatedIssuerMember 2023-10-012024-06-30 0001414932 us-gaap:InvestmentAffiliatedIssuerMember 2022-10-012023-06-30
0001414932 us-gaap:InvestmentAffiliatedIssuerMember 2024-04-012024-06-30 0001414932 us-gaap:InvestmentAffiliatedIssuerMember 2023-04-012023-06-30
0001414932 us-gaap:InvestmentUnaffiliatedIssuerMember 2023-10-012024-06-30 0001414932 us-gaap:InvestmentUnaffiliatedIssuerMember 2022-10-012023-06-30
0001414932 us-gaap:InvestmentUnaffiliatedIssuerMember 2024-04-012024-06-30 0001414932 us-gaap:InvestmentUnaffiliatedIssuerMember 2023-04-012023-06-30
0001414932 us-gaap:InvestmentUnaffiliatedIssuerMember 2023-10-012024-06-30 0001414932 us-gaap:InvestmentUnaffiliatedIssuerMember 2022-10-012023-06-30
0001414932 2024-04-012024-06-30 0001414932 2023-04-012023-06-30 0001414932 2022-10-012023-06-30 0001414932 2023-01-012023-06-30 0001414932 2024-03-31
0001414932 2023-03-31 0001414932 2022-09-30 0001414932 2023-06-30 0001414932 C5 Technology Holdings, LLC, Data Processing & Outsourced Services, Preferred Equity 2024-06-30 0001414932 Continental Intermodal
Group LP, Oil & Gas Storage & Transportation, Preferred Equity 2024-06-30 0001414932 Continental Intermodal Group LP, Oil & Gas Storage & Transportation, Common
Stock 2024-06-30 0001414932 Dominion Diagnostics, LLC, Health Care Services, First Lien Term Loan 2024-06-30 0001414932 Dominion Diagnostics, LLC, Health Care
Services, First Lien Revolver 2024-06-30 0001414932 Dominion Diagnostics, LLC, Health Care Services, Common Stock 2024-06-30 00014

Services, First Lien Term Loan 2024-06-30 0001414932 Eagleview Technology Corporation, Application Software, Second Lien Term Loan 2024-06-30 0001414932
Everus Holdings, Inc., Application Software, First Lien Term Loan 1 2024-06-30 0001414932 Everus Holdings, Inc., Application Software, First Lien Term Loan 2 2024-
06-30 0001414932 Everus Holdings, Inc., Application Software, First Lien Revolver 2024-06-30 0001414932 EOS Fitness Opco Holdings, LLC, Leisure Facilities,
Preferred Equity 2024-06-30 0001414932 EOS Fitness Opco Holdings, LLC, Leisure Facilities, Common Stock 2024-06-30 0001414932 Establishment Labs Holdings Inc.,
Health Care Technology, First Lien Term Loan 1 2024-06-30 0001414932 Establishment Labs Holdings Inc., Health Care Technology, First Lien Term Loan 2 2024-06-30
0001414932 Establishment Labs Holdings Inc., Health Care Technology, First Lien Term Loan 3 2024-06-30 0001414932 Establishment Labs Holdings Inc., Health Care
Technology, First Lien Term Loan 4 2024-06-30 0001414932 Evergreen IX Borrower 2023, LLC, Application Software, First Lien Term Loan 2024-06-30 0001414932
Evergreen IX Borrower 2023, LLC, Application Software, First Lien Revolver 2024-06-30 0001414932 Eyesouth Eye Care Holdco LLC, Health Care Services, First Lien
Term Loan 2 2024-06-30 0001414932 Eyesouth Eye Care Holdco LLC, Health Care Services, First Lien Term Loan 2 2024-06-30 0001414932 Eyesouth Eye Care Holdco
LLC, Health Care Services, Common Stock 1 2024-06-30 0001414932 Eyesouth Eye Care Holdco LLC, Health Care Services, Common Stock 2 2024-06-30 0001414932
Fairbridge Strategic Capital Funding LLC, Real Estate Operating Companies, First Lien Term Loan 2024-06-30 0001414932 Fairbridge Strategic Capital Funding LLC, Real
Estate Operating Companies, Warrants 2024-06-30 0001414932 Finastra USA, Inc., Application Software, First Lien Term Loan 2024-06-30 0001414932 Finastra
USA, Inc., Application Software, First Lien Revolver 2024-06-30 0001414932 Finthriv Software Intermediate Holdings, Inc., Health Care Technology, First Lien Term
Loan 2024-06-30 0001414932 FINThrive Software Intermediate Holdings, Inc., Health Care Technology, Second Lien Term Loan 2024-06-30 0001414932 Fortress
Biotech, Inc., Biotechnology, First Lien Term Loan 2024-06-30 0001414932 Fortress Biotech, Inc., Biotechnology, Warrants 2024-06-30 0001414932 Frontier
Communications Holdings, LLC, Integrated Telecommunication Services, Fixed Rate Bond 2024-06-30 0001414932 Frontier Issuer LLC, Specialized Finance, CLO Notes
2024-06-30 0001414932 Galileo Parent, Inc., Aerospace & Defense, First Lien Term Loan 2024-06-30 0001414932 Galileo Parent, Inc., Aerospace & Defense, First Lien
Revolver 2024-06-30 0001414932 GoldenTree Loan Management EUR CLO 2-DAC, Multi-Sector Holdings, CLO Notes 2024-06-30 0001414932 Grove Hotel Parcel Owner,
LLC, Hotels, Resorts & Cruise Lines, First Lien Term Loan 1 2024-06-30 0001414932 Grove Hotel Parcel Owner, LLC, Hotels, Resorts & Cruise Lines, First Lien Term Loan
2 2024-06-30 0001414932 Grove Hotel Parcel Owner, LLC, Hotels, Resorts & Cruise Lines, First Lien Revolver 2024-06-30 0001414932 Harbor Purchaser Inc., Education
Services, First Lien Term Loan 2024-06-30 0001414932 Harrow, Inc., Pharmaceuticals, First Lien Term Loan 1 2024-06-30 0001414932 Harrow, Inc., Pharmaceuticals,
First Lien Term Loan 2 2024-06-30 0001414932 Harrow, Inc., Pharmaceuticals, First Lien Term Loan 3 2024-06-30 0001414932 Horizon Aircraft Finance I Ltd.,
Specialized Finance, CLO Notes 2024-06-30 0001414932 HPS Loan Management 10-2016, Multi-Sector Holdings, CLO Notes 2024-06-30 0001414932 Husky Injection
Molding Systems Ltd., Industrial Machinery & Supplies & Components, Fixed Rate Bond 2024-06-30 0001414932 IAMGOLD Corporation, Gold, Second Lien Term Loan
2024-06-30 0001414932 Icefall Parent, Inc., Application Software, First Lien Term Loan 2024-06-30 0001414932 Icefall Parent, Inc., Application Software, First Lien
Revolver 2024-06-30 0001414932 iCEMs, Inc., Application Software, First Lien Term Loan 1 2024-06-30 0001414932 iCEMs, Inc., Application Software, First Lien Term
Loan 2 2024-06-30 0001414932 iCEMs, Inc., Application Software, First Lien Term Loan 3 2024-06-30 0001414932 iCEMs, Inc., Application Software, First Lien Revolver
2024-06-30 0001414932 Impel Pharmaceuticals Inc., Health Care Technology, First Lien Term Loan 1 2024-06-30 0001414932 Impel Pharmaceuticals Inc., Health Care
Technology, First Lien Term Loan 2 2024-06-30 0001414932 Impel Pharmaceuticals Inc., Health Care Technology, First Lien Term Loan 3 2024-06-30 0001414932 Impel
Pharmaceuticals Inc., Health Care Technology, First Lien Term Loan 4 2024-06-30 0001414932 Impel Pharmaceuticals Inc., Health Care Technology, Warrants 2024-06-
30 0001414932 Innocoll Pharmaceuticals Limited, Health Care Technology, Warrants 2024-06-30 0001414932 Integral Development Corporation, Diversified Financial
Services, Warrants 2024-06-30 0001414932 Inventus Power, Inc., Electrical Components & Equipment, First Lien Term Loan 2024-06-30 0001414932 Inventus Power,
Inc., Electrical Components & Equipment, First Lien Revolver 2024-06-30 0001414932 INW Manufacturing, LLC, Personal Care Products, First Lien Term Loan 2024-06-
30 0001414932 IPC Corp., Application Software, First Lien Term Loan 2024-06-30 0001414932 Kings Buyer, LLC, Environmental & Facilities Services, First Lien Term
Loan 1 2024-06-30 0001414932 Kings Buyer, LLC, Environmental & Facilities Services, First Lien Term Loan 2 2024-06-30 0001414932 Kings Buyer, LLC, Environmental
& Facilities Services, First Lien Revolver 1 2024-06-30 0001414932 Kings Buyer, LLC, Environmental & Facilities Services, First Lien Revolver 2 2024-06-30 0001414932
LABL, Inc., Office Services & Supplies, First Lien Term Loan 2024-06-30 0001414932 Latam Airlines Group S.A., Passenger Airlines, First Lien Term Loan 2024-06-30
0001414932 Learfield Communications, LLC, Movies & Entertainment, First Lien Term Loan 2024-06-30 0001414932 Lightbox Intermediate, L.P., Real Estate Services,
First Lien Term Loan 2024-06-30 0001414932 Liquid Environmental Solutions Corporation, Environmental & Facilities Services, Second Lien Term Loan 1 2024-06-30
0001414932 Liquid Environmental Solutions Corporation, Environmental & Facilities Services, Second Lien Term Loan 2 2024-06-30 0001414932 Liquid Environmental
Solutions Corporation, Environmental & Facilities Services, Common Stock 2024-06-30 0001414932 LSL Holdco, LLC, Health Care Distributors, First Lien Term Loan 1
2024-06-30 0001414932 LSL Holdco, LLC, Health Care Distributors, First Lien Term Loan 2 2024-06-30 0001414932 LSL Holdco, LLC, Health Care Distributors, First Lien
Revolver 2024-06-30 0001414932 Marinus Pharmaceuticals, Inc., Pharmaceuticals, First Lien Term Loan 1 2024-06-30 0001414932 Marinus Pharmaceuticals, Inc.,
Pharmaceuticals, First Lien Term Loan 2 2024-06-30 0001414932 Marinus Pharmaceuticals, Inc., Pharmaceuticals, First Lien Term Loan 3 2024-06-30 0001414932
Mesoblast, Inc., Biotechnology, First Lien Term Loan 2024-06-30 0001414932 Mesoblast, Inc., Biotechnology, Warrants 1 2024-06-30 0001414932 Mesoblast, Inc.,
Biotechnology, Warrants 2 2024-06-30 0001414932 MHE Intermediate Holdings, LLC, Diversified Support Services, First Lien Term Loan 1 2024-06-30 0001414932 MHE
Intermediate Holdings, LLC, Diversified Support Services, First Lien Term Loan 2 2024-06-30 0001414932 MHE Intermediate Holdings, LLC, Diversified Support Services,
First Lien Revolver 2024-06-30 0001414932 Mindbody, Inc., Internet Services & Infrastructure, First Lien Term Loan 1 2024-06-30 0001414932 Mindbody, Inc., Internet
Services & Infrastructure, First Lien Term Loan 2 2024-06-30 0001414932 Mindbody, Inc., Internet Services & Infrastructure, First Lien Revolver 2024-06-30 0001414932
Minotaur Acquisition, Inc., Financial Exchanges & Data, First Lien Term Loan 1 2024-06-30 0001414932 Minotaur Acquisition, Inc., Financial Exchanges & Data, First
Lien Term Loan 2 2024-06-30 0001414932 Minotaur Acquisition, Inc., Financial Exchanges & Data, First Lien Term Loan 3 2024-06-30 0001414932 Minotaur Acquisition,
Inc., Financial Exchanges & Data, First Lien Revolver 2024-06-30 0001414932 Modena Buyer LLC, Application Software, First Lien Term Loan 2024-06-30 0001414932
Monotype Imaging Holdings Inc., Application Software, First Lien Term Loan 1 2024-06-30 0001414932 Monotype Imaging Holdings Inc., Application Software, First Lien
Term Loan 2 2024-06-30 0001414932 Monotype Imaging Holdings Inc., Application Software, First Lien Revolver 2024-06-30 0001414932 Mosaic Companies, LLC, Home
Improvement Retail, First Lien Term Loan 2024-06-30 0001414932 MRI Software LLC, Application Software, First Lien Term Loan 1 2024-06-30 0001414932 MRI
Software LLC, Application Software, First Lien Term Loan 2 2024-06-30 0001414932 MRI Software LLC, Application Software, First Lien Term Loan 3 2024-06-30
0001414932 MRI Software LLC, Application Software, First Lien Revolver 2024-06-30 0001414932 NeuaG, LLC, Fertilizers & Agricultural Chemicals, First Lien Term Loan
2024-06-30 0001414932 Next Holdco, LLC, Health Care Technology, First Lien Term Loan 1 2024-06-30 0001414932 Next Holdco, LLC, Health Care Technology, First
Lien Term Loan 2 2024-06-30 0001414932 Next Holdco, LLC, Health Care Technology, First Lien Revolver 2024-06-30 0001414932 NN, Inc., Industrial Machinery &
Supplies & Components, First Lien Term Loan 2024-06-30 0001414932 NN, Inc., Industrial Machinery & Supplies & Components, Warrants 1 2024-06-30 0001414932 NN,
Inc., Industrial Machinery & Supplies & Components, Warrants 2 2024-06-30 0001414932 Northwoods Capital 25 Ltd, Multi-Sector Holdings, CLO Notes 2024-06-30
0001414932 OFSI Fund Ltd, Multi-Sector Holdings, CLO Notes 2024-06-30 0001414932 Oranje Holdco, Inc., Systems Software, First Lien Term Loan 1 2024-06-30
0001414932 Oranje Holdco, Inc., Systems Software, First Lien Term Loan 2 2024-06-30 0001414932 Oranje Holdco, Inc., Systems Software, First Lien Revolver 2024-06-
30 0001414932 OTG Management, LLC, Airport Services, First Lien Term Loan 2024-06-30 0001414932 OTG Management, LLC, Airport Services, Common Stock 2024-06-
30 0001414932 OZIM XXIII Ltd, Multi-Sector Holdings, CLO Notes 2024-06-30 0001414932 Performance Health Holdings, Inc., Health Care Distributors, First Lien Term
Loan 2024-06-30 0001414932 PetVet Care Centers, LLC, Health Care Services, First Lien Term Loan 1 2024-06-30 0001414932 PetVet Care Centers, LLC, Health Care
Services, First Lien Term Loan 2 2024-06-30 0001414932 PetVet Care Centers, LLC, Health Care Services, First Lien Revolver 2024-06-30 0001414932 PetVet Care
Centers, LLC, Health Care Services, Preferred Equity 2024-06-30 0001414932 Pluralsight, LLC, Application Software, First Lien Term Loan 2024-06-30 0001414932
Pluralsight, LLC, Application Software, First Lien Revolver 2024-06-30 0001414932 PPW Aero Buyer, Inc., Aerospace & Defense, First Lien Term Loan 1 2024-06-30
0001414932 PPW Aero Buyer, Inc., Aerospace & Defense, First Lien Term Loan 2 2024-06-30 0001414932 PPW Aero Buyer, Inc., Aerospace & Defense, First Lien Revolver
2024-06-30 0001414932 PRGX Global, Inc., Data Processing & Outsourced Services, First Lien Term Loan 2024-06-30 0001414932 PRGX Global, Inc., Data Processing &
Outsourced Services, First Lien Revolver 2024-06-30 0001414932 PRGX Global, Inc., Data Processing & Outsourced Services, Common Stock 2024-06-30 0001414932
Profrac Holdings II, LLC, Industrial Machinery & Supplies & Components, First Lien Floating Rate Bond 2024-06-30 0001414932 Protein For Pets Opco, LLC, Packaged
Foods & Meats, First Lien Term Loan 2024-06-30 0001414932 Protein For Pets Opco, LLC, Packaged Foods & Meats, First Lien Revolver 2024-06-30 0001414932 Quantum
Bidco Limited, Food Distributors, First Lien Term Loan 1 2024-06-30 0001414932 Quantum Bidco Limited, Food Distributors, First Lien Term Loan 2 2024-06-30
0001414932 QuorumLabs, Inc., Application Software, Preferred Equity 2024-06-30 0001414932 Relativity ODA LLC, Application Software, First Lien Term Loan 2024-06-
30 0001414932 Relativity ODA LLC, Application Software, First Lien Revolver 2024-06-30 0001414932 RumbleOn, Inc., Automotive Retail, First Lien Term Loan 1 2024-
06-30 0001414932 RumbleOn, Inc., Automotive Retail, First Lien Term Loan 2 2024-06-30 0001414932 RumbleOn, Inc., Automotive Retail, Warrants 2024-06-30
0001414932 Salus Workers' Compensation, LLC, Diversified Financial Services, First Lien Term Loan 2024-06-30 0001414932 Salus Workers' Compensation, LLC,
Diversified Financial Services, First Lien Revolver 2024-06-30 0001414932 Salus Workers' Compensation, LLC, Diversified Financial Services, Warrants 2024-06-30
0001414932 Saratoga, Diversified Financial Services, Credit Linked Notes 2024-06-30 0001414932 SCGH Salt Holdings Inc., Diversified Chemicals, Fixed Rate Bond 2024-
06-30 0001414932 Scilex Holding Co, Biotechnology, Common Stock 2024-06-30 0001414932 scPharmaceuticals Inc., Pharmaceuticals, First Lien Term Loan 1 2024-06-
30 0001414932 scPharmaceuticals Inc., Pharmaceuticals, First Lien Term Loan 2 2024-06-30 0001414932 scPharmaceuticals Inc., Pharmaceuticals, First Lien Term Loan
3 2024-06-30 0001414932 scPharmaceuticals Inc., Pharmaceuticals, Warrants 2024-06-30 0001414932 Seres Therapeutics, Inc., Biotechnology, First Lien Term Loan 1
2024-06-30 0001414932 Seres Therapeutics, Inc., Biotechnology, First Lien Term Loan 2 2024-06-30 0001414932 Seres Therapeutics, Inc., Biotechnology, First Lien Term
Loan 3 2024-06-30 0001414932 Seres Therapeutics, Inc., Biotechnology, First Lien Term Loan 4 2024-06-30 0001414932 Seres Therapeutics, Inc., Biotechnology,
Warrants 2024-06-30 0001414932 SM Wellness Holdings, Inc., Health Care Services, First Lien Term Loan 2024-06-30 0001414932 SM Wellness Holdings, Inc., Health
Care Services, Second Lien Term Loan 2024-06-30 0001414932 Soreson Communications, LLC, Communications Equipment, First Lien Term Loan 2024-06-30
0001414932 Soreson Communications, LLC, Communications Equipment, First Lien Revolver 2024-06-30 0001414932 Sorrento Therapeutics, Inc., Biotechnology,
Common Stock 2024-06-30 0001414932 Spanx, LLC, Apparel Retail, First Lien Term Loan 2024-06-30 0001414932 Spanx, LLC, Apparel Retail, First Lien Revolver 2024-
06-30 0001414932 SPX Flow, Inc., Industrial Machinery & Supplies & Components, Fixed Rate Bond 2024-06-30 0001414932 Staples, Inc., Office Services & Supplies,
First Lien Term Loan 2024-06-30 0001414932 Staples, Inc., Office Services & Supplies, Fixed Rate Bond 2024-06-30 0001414932 SumUp Holdings Luxembourg S.A.R.L.,
Diversified Financial Services, First Lien Term Loan 2024-06-30 0001414932 Superior Industries International, Inc., Auto Parts & Equipment, First Lien Term Loan 2024-
06-30 0001414932 Supreme Fitness Group NY Holdings, LLC, Leisure Facilities, First Lien Term Loan 1 2024-06-30 0001414932 Supreme Fitness Group NY Holdings,
LLC, Leisure Facilities, First Lien Term Loan 2 2024-06-30 0001414932 Supreme Fitness Group NY Holdings, LLC, Leisure Facilities, First Lien Term Loan 3 2024-06-30
0001414932 Supreme Fitness Group NY Holdings, LLC, Leisure Facilities, First Lien Revolver 2024-06-30 0001414932 SVP-Singer Holdings Inc., Home Furnishings, First
Lien Term Loan 2024-06-30 0001414932 Telephone and Date Systems, Inc., Wireless Telecommunication Services, First Lien Term Loan 1 2024-06-30 0001414932
Telephone and Date Systems, Inc., Wireless Telecommunication Services, First Lien Term Loan 2 2024-06-30 0001414932 Teletream Holdings Corporation, Application
Software, First Lien Term Loan 2024-06-30 0001414932 Teletream Holdings Corporation, Application Software, First Lien Revolver 2024-06-30 0001414932 Ten-X LLC,
Interactive Media & Services, First Lien Term Loan 2024-06-30 0001414932 THL Zinc Ventures Ltd, Diversified Metals & Mining, First Lien Term Loan 2024-06-30
0001414932 Thrasio, LLC, Broadline Retail, First Lien Term Loan 1 2024-06-30 0001414932 Thrasio, LLC, Broadline Retail, First Lien Term Loan 2 2024-06-30
0001414932 Thrasio, LLC, Broadline Retail, Common Stock 2024-06-30 0001414932 Touchstone Acquisition, Inc., Health Care Supplies, First Lien Term Loan 2024-06-30
0001414932 Trinitas CLO VI Ltd., Multi-Sector Holdings, CLO Notes 2024-06-30 0001414932 Trinitas CLO XV DAC, Multi-Sector Holdings, CLO Notes 2024-06-30
0001414932 Truck-Lite Co, LLC, Construction Machinery & Heavy Transportation Equipment, First Lien Term Loan 1 2024-06-30 0001414932 Truck-Lite Co, LLC,
Construction Machinery & Heavy Transportation Equipment, First Lien Term Loan 2 2024-06-30 0001414932 Truck-Lite Co, LLC, Construction Machinery & Heavy
Transportation Equipment, First Lien Revolver 2024-06-30 0001414932 Uniti Group LP, Cable & Satellite, Fixed Rate Bond 2024-06-30 0001414932 Verona Pharma, Inc.,
Pharmaceuticals, First Lien Term Loan 1 2024-06-30 0001414932 Verona Pharma, Inc., Pharmaceuticals, First Lien Term Loan 2 2024-06-30 0001414932 Verona Pharma,
Inc., Pharmaceuticals, First Lien Term Loan 3 2024-06-30 0001414932 Verona Pharma, Inc., Pharmaceuticals, First Lien Term Loan 4 2024-06-30 0001414932 Verona
Pharma, Inc., Pharmaceuticals, First Lien Term Loan 5 2024-06-30 0001414932 Verona Pharma, Inc., Pharmaceuticals, First Lien Term Loan 6 2024-06-30 0001414932
Win Brands Group LLC, Housewares & Specialties, First Lien Term Loan 2024-06-30 0001414932 Win Brands Group LLC, Housewares & Specialties, Warrants 2024-06-30
0001414932 Windstream Services II, LLC, Integrated Telecommunication Services, Common Stock 2024-06-30 0001414932 WP CPP Holdings, LLC, Aerospace & Defense,
First Lien Term Loan 2024-06-30 0001414932 WP CPP Holdings, LLC, Aerospace & Defense, First Lien Revolver 2024-06-30 0001414932 Zep Inc., Specialty Chemicals,
First Lien Term Loan 2024-06-30 0001414932 JP Morgan Prime Money Market Fund, Institutional Shares, Specialty Chemicals, First Lien Term Loan 2024-06-30
0001414932 Other cash accounts, Specialty Chemicals, First Lien Term Loan 2024-06-30 0001414932 EUR Foreign Currency Forward Contract, Maturing August 8, 2024

2024-06-30 0001414932 GBP Foreign Currency Forward Contract, Maturing August 8, 2024 2024-06-30 0001414932 us-gaap:ForeignExchangeForwardMember 2024-06-30 0001414932 ocsI:InterestRateSwapMaturing2027Member 2024-06-30 0001414932 ocsI:InterestRateSwapMaturing2029Member 2024-06-30 0001414932 us-gaap:InterestRateSwapMember 2024-06-30 0001414932 srt:MinimumMember 2024-06-30 0001414932 srt:MaximumMember 2024-06-30 0001414932 ocsI:EarnoutShareVestingTrancheTwoMember 2024-06-30 0001414932 ocsI:EarnoutShareVestingTrancheTwoMember 2023-10-01 2024-06-30 0001414932 C5 Technology Holdings, LLC, Data Processing & Outsourced Services, Common Stock 2023-09-30 0001414932 C5 Technology Holdings, LLC, Data Processing & Outsourced Services, Preferred Equity 2023-09-30 0001414932 Dominion Diagnostics, LLC, Health Care Services, First Lien Term Loan 1 2023-09-30 0001414932 Dominion Diagnostics, LLC, Health Care Services, First Lien Term Loan 2 2023-09-30 0001414932 Dominion Diagnostics, LLC, Health Care Services, First Lien Revolver 2023-09-30 0001414932 Dominion Diagnostics, LLC, Health Care Services, Common Stock 2023-09-30 0001414932 OCSi Glck JV LLC, Multi-Sector Holdings, Subordinated Debt 2023-09-30 0001414932 OCSi Glck JV LLC, Multi-Sector Holdings, Membership Interest 2023-09-30 0001414932 Senior Loan Fund IV I, LLC, Multi-Sector Holdings, Subordinated Debt 2023-09-30 0001414932 Senior Loan Fund IV I, LLC, Multi-Sector Holdings, Membership Interest 2023-09-30 0001414932 SIO2 Medical Products, Inc., Metal, Glass & Plastic Containers, First Lien Term Loan 2 2023-09-30 0001414932 SIO2 Medical Products, Inc., Metal, Glass & Plastic Containers, First Lien Term Loan 3 2023-09-30 0001414932 SIO2 Medical Products, Inc., Metal, Glass & Plastic Containers, Common Stock 2023-09-30 0001414932 SIO2 Medical Products, Inc., Metal, Glass & Plastic Containers, Warrants 2023-09-30 0001414932 Assembled Brands Capital LLC, Specialized Finance, First Lien Revolver 2023-09-30 0001414932 Assembled Brands Capital LLC, Specialized Finance, Common Stock 2023-09-30 0001414932 Assembled Brands Capital LLC, Specialized Finance, Preferred Equity 2023-09-30 0001414932 Assembled Brands Capital LLC, Specialized Finance, Warrants 2023-09-30 0001414932 Caregiver Services, Inc., Health Care Services, Preferred Equity 2023-09-30 0001414932 us-gaap:InvestmentAffiliatedIssuerNoncontrolledMember 2023-09-30 0001414932 107-109 Beech OAK22 LLC, Real Estate Development, First Lien Revolver 2023-09-30 0001414932 107 Fair Street LLC, Real Estate Development, First Lien Term Loan 2023-09-30 0001414932 112-126 Van Houten Real22 LLC, Real Estate Development, First Lien Term Loan 2023-09-30 0001414932 A.T. Holdings H Ltd., Biotechnology, First Lien Term Loan 2023-09-30 0001414932 A.T. Holdings H SARE, Biotechnology, First Lien Term Loan 2023-09-30 0001414932 Accupac, Inc., Personal Care Products, First Lien Term Loan 1 2023-09-30 0001414932 Accupac, Inc., Personal Care Products, First Lien Term Loan 2 2023-09-30 0001414932 Accupac, Inc., Personal Care Products, First Lien Revolver 2023-09-30 0001414932 Acquia Inc., Application Software, First Lien Term Loan 1 2023-09-30 0001414932 Acquia Inc., Application Software, First Lien Term Loan 2 2023-09-30 0001414932 Acquia Inc., Application Software, First Lien Revolver 2023-09-30 0001414932 ADB Companies, LLC, Construction & Engineering, First Lien Term Loan 1 2023-09-30 0001414932 ADB Companies, LLC, Construction & Engineering, First Lien Term Loan 2 2023-09-30 0001414932 ADB Companies, LLC, Construction & Engineering, First Lien Term Loan 3 2023-09-30 0001414932 ADC Therapeutics SA, Biotechnology, First Lien Term Loan 1 2023-09-30 0001414932 ADC Therapeutics SA, Biotechnology, First Lien Term Loan 2 2023-09-30 0001414932 ADC Therapeutics SA, Biotechnology, Warrants 2023-09-30 0001414932 AI Sirona (Luxembourg) Acquisition S.a.r.l., Pharmaceuticals, First Lien Term Loan 2023-09-30 0001414932 AIP RD Buyer Corp., Distributors, Second Lien Term Loan 2023-09-30 0001414932 AIP RD Buyer Corp., Distributors, Common Stock 2023-09-30 0001414932 AirStrip Technologies, Inc., Application Software, Warrants 2023-09-30 0001414932 All Web Leads, Inc., Advertising, First Lien Term Loan 2023-09-30 0001414932 Altice France S.A., Integrated Telecommunication Services, Fixed Rate Bond 2023-09-30 0001414932 Alto Pharmacy Holdings, Inc., Health Care Technology, First Lien Term Loan 2023-09-30 0001414932 Alto Pharmacy Holdings, Inc., Health Care Technology, Warrants 2023-09-30 0001414932 Alvogen Pharma US, Inc., Pharmaceuticals, First Lien Term Loan 2023-09-30 0001414932 Alvotech Holdings S.A., Biotechnology, Fixed Rate Bond 1 2023-09-30 0001414932 Alvotech Holdings S.A., Biotechnology, Fixed Rate Bond 2 2023-09-30 0001414932 Alvotech Holdings S.A., Biotechnology, Fixed Rate Bond 3 2023-09-30 0001414932 Alvotech Holdings S.A., Biotechnology, Fixed Rate Bond 4 2023-09-30 0001414932 Alvotech Holdings S.A., Biotechnology, Common Stock 1 2023-09-30 0001414932 Alvotech Holdings S.A., Biotechnology, Common Stock 2 2023-09-30 0001414932 American Auto Auction Group, LLC, Consumer Finance, Second Lien Term Loan 2023-09-30 0001414932 American Tire Distributors, Inc., Distributors, First Lien Term Loan 2023-09-30 0001414932 Amplify Fincio Pty Ltd., Movies & Entertainment, Second Lien Term Loan 2023-09-30 0001414932 Anastasia Parent, LLC, Personal Care Products, First Lien Term Loan 2023-09-30 0001414932 Ardonagh Midco 3 PLC, Insurance Brokers, First Lien Term Loan 1 2023-09-30 0001414932 Ardonagh Midco 3 PLC, Insurance Brokers, First Lien Term Loan 2 2023-09-30 0001414932 Ardonagh Midco 3 PLC, Insurance Brokers, First Lien Term Loan 3 2023-09-30 0001414932 Ardonagh Midco 3 PLC, Insurance Brokers, First Lien Term Loan 4 2023-09-30 0001414932 Ardonagh Midco 3 PLC, Insurance Brokers, First Lien Term Loan 5 2023-09-30 0001414932 ASP-R-PAC Acquisition Co LLC, Paper & Plastic Packaging Products & Materials, First Lien Term Loan 2023-09-30 0001414932 ASP-R-PAC Acquisition Co LLC, Paper & Plastic Packaging Products & Materials, First Lien Revolver 2023-09-30 0001414932 Astra Acquisition Corp., Application Software, First Lien Term Loan 2023-09-30 0001414932 athenahealth Group Inc., Health Care Technology, Preferred Equity 2023-09-30 0001414932 ATNX SPV, LLC, Pharmaceuticals, First Lien Term Loan 2023-09-30 0001414932 Aurora Lux Fincio S.A.R.L., Airport Services, First Lien Term Loan 2023-09-30 0001414932 Avalara, Inc., Application Software, First Lien Term Loan 2023-09-30 0001414932 Avalara, Inc., Application Software, First Lien Revolver 2023-09-30 0001414932 The Avery, Real Estate Operating Companies, First Lien Term Loan 2023-09-30 0001414932 The Avery, Real Estate Operating Companies, Subordinated Debt Term Loan 2023-09-30 0001414932 BAART Programs, Inc., Health Care Services, First Lien Term Loan 1 2023-09-30 0001414932 BAART Programs, Inc., Health Care Services, First Lien Term Loan 2 2023-09-30 0001414932 BAART Programs, Inc., Health Care Services, Second Lien Term Loan 1 2023-09-30 0001414932 BAART Programs, Inc., Health Care Services, Second Lien Term Loan 2 2023-09-30 0001414932 BAART Programs, Inc., Health Care Services, Second Lien Term Loan 3 2023-09-30 0001414932 Berner Food & Beverage, LLC, Soft Drinks & Non-alcoholic Beverages, First Lien Term Loan 2023-09-30 0001414932 Berner Food & Beverage, LLC, Soft Drinks & Non-alcoholic Beverages, First Lien Revolver 2023-09-30 0001414932 BioXcel Therapeutics, Inc., Pharmaceuticals, First Lien Term Loan 1 2023-09-30 0001414932 BioXcel Therapeutics, Inc., Pharmaceuticals, First Lien Term Loan 2 2023-09-30 0001414932 BioXcel Therapeutics, Inc., Pharmaceuticals, First Lien Term Loan 3 2023-09-30 0001414932 BioXcel Therapeutics, Inc., Pharmaceuticals, First Lien Term Loan 4 2023-09-30 0001414932 BioXcel Therapeutics, Inc., Pharmaceuticals, First Lien Term Loan 5 2023-09-30 0001414932 BioXcel Therapeutics, Inc., Pharmaceuticals, First Lien Term Loan 6 2023-09-30 0001414932 BioXcel Therapeutics, Inc., Pharmaceuticals, Warrants 2023-09-30 0001414932 Blackhawk Network Holdings, Inc., Data Processing & Outsourced Services, Second Lien Term Loan 2023-09-30 0001414932 Blumenthal Temecula, LLC, Automotive Retail, First Lien Term Loan 2023-09-30 0001414932 Blumenthal Temecula, LLC, Automotive Retail, Preferred Equity 1 2023-09-30 0001414932 Blumenthal Temecula, LLC, Automotive Retail, Preferred Equity 2 2023-09-30 0001414932 Blumenthal Temecula, LLC, Automotive Retail, Common Stock 2023-09-30 0001414932 Cadence Aerospace, LLC, Aerospace & Defense, First Lien Term Loan 1 2023-09-30 0001414932 Cadence Aerospace, LLC, Aerospace & Defense, First Lien Term Loan 2 2023-09-30 0001414932 Cadence Aerospace, LLC, Aerospace & Defense, First Lien Term Loan 3 2023-09-30 0001414932 Cadence Aerospace, LLC, Aerospace & Defense, First Lien Term Loan 4 2023-09-30 0001414932 Clear Channel Outdoor Holdings, Inc., Advertising, Fixed Rate Bond 1 2023-09-30 0001414932 Clear Channel Outdoor Holdings, Inc., Advertising, Fixed Rate Bond 2 2023-09-30 0001414932 Condor Merger Sub Inc., Systems Software, Fixed Rate Bond 2023-09-30 0001414932 Continental Intermodal Group LP, Oil & Gas Storage & Transportation, First Lien Term Loan 2023-09-30 0001414932 Continental Intermodal Group LP, Oil & Gas Storage & Transportation, Warrants 2023-09-30 0001414932 Conviva Inc., Application Software, Preferred Equity 2023-09-30 0001414932 Coupa Holdings, LLC, Application Software, First Lien Term Loan 1 2023-09-30 0001414932 Coupa Holdings, LLC, Application Software, First Lien Term Loan 2 2023-09-30 0001414932 Coupa Holdings, LLC, Application Software, First Lien Revolver 2023-09-30 0001414932 Covetrus, Inc., Health Care Distributors, First Lien Term Loan 2023-09-30 0001414932 Coyote Buyer, LLC, Specialty Chemicals, First Lien Term Loan 2023-09-30 0001414932 Coyote Buyer, LLC, Specialty Chemicals, First Lien Revolver 2023-09-30 0001414932 CPC Acquisition Corp., Specialty Chemicals, Second Lien Term Loan 2023-09-30 0001414932 Delta Leasing SPV II LLC, Specialized Finance, Subordinated Debt Term Loan 2023-09-30 0001414932 Delta Leasing SPV II LLC, Specialized Finance, Preferred Equity 2023-09-30 0001414932 Delta Leasing SPV II LLC, Specialized Finance, Common Stock 2023-09-30 0001414932 Delta Leasing SPV II LLC, Specialized Finance, Warrants 2023-09-30 0001414932 Dialyze Holdings, LLC, Health Care Equipment, First Lien Term Loan 2023-09-30 0001414932 Dialyze Holdings, LLC, Health Care Equipment, Subordinated Debt Term Loan 2023-09-30 0001414932 Dialyze Holdings, LLC, Health Care Equipment, Warrants 2023-09-30 0001414932 Digital AI Software Holdings, Inc., Application Software, First Lien Revolver 2023-09-30 0001414932 DirecTV Financing, LLC, Cable & Satellite, First Lien Term Loan 2023-09-30 0001414932 DTI Holdco, Inc., Research & Consulting Services, First Lien Term Loan 2023-09-30 0001414932 Eagleview Technology Corporation, Application Software, Second Lien Term Loan 2023-09-30 0001414932 EOS Fitness Opco Holdings, LLC, Leisure Facilities, Preferred Equity 2023-09-30 0001414932 EOS Fitness Opco Holdings, LLC, Leisure Facilities, Common Stock 2023-09-30 0001414932 Establishment Labs Holdings Inc., Health Care Technology, First Lien Term Loan 1 2023-09-30 0001414932 Establishment Labs Holdings Inc., Health Care Technology, First Lien Term Loan 2 2023-09-30 0001414932 Establishment Labs Holdings Inc., Health Care Technology, First Lien Term Loan 3 2023-09-30 0001414932 Establishment Labs Holdings Inc., Health Care Technology, First Lien Term Loan 4 2023-09-30 0001414932 Evergreen IX Borrower 2023, LLC, Application Software, First Lien Term Loan 2023-09-30 0001414932 Evergreen IX Borrower 2023, LLC, Application Software, First Lien Revolver 2023-09-30 0001414932 Fairbridge Strategic Capital Funding LLC, Real Estate Operating Companies, First Lien Term Loan 2023-09-30 0001414932 Fairbridge Strategic Capital Funding LLC, Real Estate Operating Companies, Warrants 2023-09-30 0001414932 Finastra USA, Inc., Application Software, First Lien Term Loan 2023-09-30 0001414932 Finastra USA, Inc., Application Software, First Lien Revolver 2023-09-30 0001414932 FINThrive Software Intermediate Holdings, Inc., Health Care Technology, Second Lien Term Loan 2023-09-30 0001414932 Fortress Biotech, Inc., Biotechnology, First Lien Term Loan 2023-09-30 0001414932 Fortress Biotech, Inc., Biotechnology, Warrants 2023-09-30 0001414932 Frontier Communications Holdings, LLC, Integrated Telecommunication Services, Fixed Rate Bond 2023-09-30 0001414932 Galileo Parent, Inc., Aerospace & Defense, First Lien Term Loan 2023-09-30 0001414932 Galileo Parent, Inc., Aerospace & Defense, First Lien Revolver 2023-09-30 0001414932 Gibson Brands, Inc., Leisure Products, First Lien Term Loan 2023-09-30 0001414932 GoldenTree Loan Management EUR CLO 2 DAC, Multi-Sector Holdings, CLO Notes 2023-09-30 0001414932 Grove Hotel Parcel Owner, LLC, Hotels, Resorts & Cruise Lines, First Lien Term Loan 1 2023-09-30 0001414932 Grove Hotel Parcel Owner, LLC, Hotels, Resorts & Cruise Lines, First Lien Term Loan 2 2023-09-30 0001414932 Grove Hotel Parcel Owner, LLC, Hotels, Resorts & Cruise Lines, First Lien Revolver 2023-09-30 0001414932 Harbor Purchaser Inc., Education Services, First Lien Term Loan 2023-09-30 0001414932 Harrow, Inc., Pharmaceuticals, First Lien Term Loan 1 2023-09-30 0001414932 Harrow, Inc., Pharmaceuticals, First Lien Term Loan 2 2023-09-30 0001414932 Horizon Aircraft Finance I Ltd., Specialized Finance, CLO Notes 2023-09-30 0001414932 IAMGOLD Corporation, Gold, Second Lien Term Loan 2023-09-30 0001414932 iCIMS, Inc., Application Software, First Lien Term Loan 1 2023-09-30 0001414932 iCIMS, Inc., Application Software, First Lien Term Loan 2 2023-09-30 0001414932 iCIMS, Inc., Application Software, First Lien Revolver 2023-09-30 0001414932 Impel Pharmaceuticals Inc., Health Care Technology, First Lien Term Loan 1 2023-09-30 0001414932 Impel Pharmaceuticals Inc., Health Care Technology, First Lien Term Loan 2 2023-09-30 0001414932 Impel Pharmaceuticals Inc., Health Care Technology, First Lien Term Loan 3 2023-09-30 0001414932 Impel Pharmaceuticals Inc., Health Care Technology, Warrants 2023-09-30 0001414932 Innocell Pharmaceuticals Limited, Health Care Technology, First Lien Term Loan 2023-09-30 0001414932 Integral Development Corporation, Diversified Financial Services, Warrants 2023-09-30 0001414932 Inventus Power, Inc., Electrical Components & Equipment, First Lien Term Loan 2023-09-30 0001414932 Inventus Power, Inc., Electrical Components & Equipment, First Lien Revolver 2023-09-30 0001414932 INW Manufacturing, LLC, Personal Care Products, First Lien Term Loan 2023-09-30 0001414932 IPC Corp., Application Software, First Lien Term Loan 2023-09-30 0001414932 Ivanti Software, Inc., Application Software, Second Lien Term Loan 2023-09-30 0001414932 Kings Buyer, LLC, Environmental & Facilities Services, First Lien Term Loan 1 2023-09-30 0001414932 Kings Buyer, LLC, Environmental & Facilities Services, First Lien Revolver 1 2023-09-30 0001414932 Kings Buyer, LLC, Environmental & Facilities Services, First Lien Term Loan 2 2023-09-30 0001414932 Kings Buyer, LLC, Environmental & Facilities Services, First Lien Revolver 2 2023-09-30 0001414932 Latam Airlines Group S.A., Passenger Airlines, First Lien Term Loan 2023-09-30 0001414932 Lift Brands Holdings, Inc., Leisure Facilities, Common Stock 2023-09-30 0001414932 Lightbox Intermediate, L.P., Real Estate Services, First Lien Term Loan 2023-09-30 0001414932 Liquid Environmental Solutions Corporation, Environmental & Facilities Services, Second Lien Term Loan 1 2023-09-30 0001414932 Liquid Environmental Solutions Corporation, Environmental & Facilities Services, Second Lien Term Loan 2 2023-09-30 0001414932 Liquid Environmental Solutions Corporation, Environmental & Facilities Services, Common Stock 2023-09-30 0001414932 LSL Holdco, LLC, Health Care Distributors, First Lien Term Loan 1 2023-09-30 0001414932 LSL Holdco, LLC, Health Care Distributors, First Lien Revolver 2023-09-30 0001414932 Marinus Pharmaceuticals, Inc., Pharmaceuticals, First Lien Term Loan 1 2023-09-30 0001414932 Marinus Pharmaceuticals, Inc., Pharmaceuticals, First Lien Term Loan 2 2023-09-30 0001414932 Marinus Pharmaceuticals, Inc., Pharmaceuticals, First Lien Term Loan 3 2023-09-30 0001414932 Mesoblast, Inc., Biotechnology, First Lien Term Loan 2023-09-30 0001414932 Mesoblast, Inc., Biotechnology, Warrants 1 2023-09-30 0001414932 Mesoblast, Inc., Biotechnology, Warrants 2 2023-09-30 0001414932 MHE Intermediate Holdings, LLC, Diversified Support Services, First Lien Term Loan 1 2023-09-30 0001414932 MHE Intermediate Holdings, LLC, Diversified Support Services, First Lien Term Loan 2 2023-09-30 0001414932 MHE Intermediate Holdings, LLC, Diversified Support Services, First Lien Revolver 2023-09-30 0001414932 Mindbody, Inc., Internet Services & Infrastructure, First Lien Term Loan 1 2023-09-30 0001414932 Mindbody, Inc., Internet Services & Infrastructure, First Lien Term Loan 2 2023-09-30 0001414932 Mindbody, Inc., Internet Services & Infrastructure, First Lien Revolver 2023-09-30 0001414932 MND Holdings III Corp., Other Specialty Retail, First Lien Term Loan 2023-09-30 0001414932 MND Holdings III Corp., Other Specialty Retail, First Lien Revolver 2023-09-30 0001414932 Mosaic Companies, LLC, Home Improvement Retail, First Lien Term Loan 2023-09-30 0001414932 MRI Software LLC, Application Software, First Lien

Term Loan 1 2023-09-30 0001414932 MRI Software LLC, Application Software, First Lien Term Loan 2 2023-09-30 0001414932 MRI Software LLC, Application Software, First Lien Revolver 2023-09-30 0001414932 Navisite, LLC, Data Processing & Outsourced Services, Second Lien Term Loan 2023-09-30 0001414932 NeuAG, LLC, Fertilizers & Agricultural Chemicals, First Lien Term Loan 2023-09-30 0001414932 NFP Corp., Diversified Financial Services, Fixed Rate Bond 2023-09-30 0001414932 NN, Inc., Industrial Machinery & Supplies & Components, First Lien Term Loan 2023-09-30 0001414932 NN, Inc., Industrial Machinery & Supplies & Components, Warrants 1 2023-09-30 0001414932 NN, Inc., Industrial Machinery & Supplies & Components, Warrants 2 2023-09-30 0001414932 OEConnection LLC, Application Software, Second Lien Term Loan 2023-09-30 0001414932 Oranje Holdco, Inc., Systems Software, First Lien Term Loan 2023-09-30 0001414932 Oranje Holdco, Inc., Systems Software, First Lien Revolver 2023-09-30 0001414932 OTG Management, LLC, Airport Services, First Lien Term Loan 1 2023-09-30 0001414932 OTG Management, LLC, Airport Services, First Lien Term Loan 2 2023-09-30 0001414932 OTG Management, LLC, Airport Services, First Lien Term Loan 3 2023-09-30 0001414932 P & I Development, LLC, Pharmaceuticals, Fixed Rate Bond 2023-09-30 0001414932 Park Place Technologies, LLC, Internet Services & Infrastructure, First Lien Term Loan 2023-09-30 0001414932 Performance Health Holdings, Inc., Health Care Distributors, First Lien Term Loan 2023-09-30 0001414932 Planview Parent, Inc., Application Software, Second Lien Term Loan 2023-09-30 0001414932 Pluralsight, LLC, Application Software, First Lien Term Loan 2023-09-30 0001414932 Pluralsight, LLC, Application Software, First Lien Revolver 2023-09-30 0001414932 PPW Aero Buyer, Inc., Aerospace & Defense, First Lien Term Loan 2023-09-30 0001414932 PPW Aero Buyer, Inc., Aerospace & Defense, First Lien Revolver 2023-09-30 0001414932 PRGX Global, Inc., Data Processing & Outsourced Services, First Lien Term Loan 2023-09-30 0001414932 PRGX Global, Inc., Data Processing & Outsourced Services, Common Stock 2023-09-30 0001414932 Profrac Holdings II, LLC, Industrial Machinery & Supplies & Components, First Lien Term Loan 1 2023-09-30 0001414932 Profrac Holdings II, LLC, Industrial Machinery & Supplies & Components, First Lien Term Loan 2 2023-09-30 0001414932 Quantum Bidco Limited, Food Distributors, First Lien Term Loan 2023-09-30 0001414932 Quorum Labs, Inc., Application Software, Preferred Equity 2023-09-30 0001414932 Relativity ODA LLC, Application Software, First Lien Term Loan 2023-09-30 0001414932 Relativity ODA LLC, Application Software, First Lien Revolver 2023-09-30 0001414932 RumbleOn, Inc., Automotive Retail, First Lien Term Loan 1 2023-09-30 0001414932 RumbleOn, Inc., Automotive Retail, First Lien Term Loan 2 2023-09-30 0001414932 RumbleOn, Inc., Automotive Retail, Warrants 2023-09-30 0001414932 Salus Workers' Compensation, LLC, Diversified Financial Services, First Lien Term Loan 2023-09-30 0001414932 Salus Workers' Compensation, LLC, Diversified Financial Services, Warrants 2023-09-30 0001414932 Scilex Holding Co., Biotechnology, Common Stock 2023-09-30 0001414932 SCP Eye Care Services, LLC, Health Care Services, Second Lien Term Loan 1 2023-09-30 0001414932 SCP Eye Care Services, LLC, Health Care Services, Second Lien Term Loan 2 2023-09-30 0001414932 SCP Eye Care Services, LLC, Health Care Services, Common Stock 2023-09-30 0001414932 scPharmaceuticals Inc., Pharmaceuticals, First Lien Term Loan 1 2023-09-30 0001414932 scPharmaceuticals Inc., Pharmaceuticals, First Lien Term Loan 2 2023-09-30 0001414932 scPharmaceuticals Inc., Pharmaceuticals, First Lien Term Loan 3 2023-09-30 0001414932 scPharmaceuticals Inc., Pharmaceuticals, Warrants 2023-09-30 0001414932 Seres Therapeutics, Inc., Biotechnology, First Lien Term Loan 1 2023-09-30 0001414932 Seres Therapeutics, Inc., Biotechnology, First Lien Term Loan 2 2023-09-30 0001414932 Seres Therapeutics, Inc., Biotechnology, First Lien Term Loan 3 2023-09-30 0001414932 Seres Therapeutics, Inc., Biotechnology, First Lien Term Loan 4 2023-09-30 0001414932 Seres Therapeutics, Inc., Biotechnology, Warrants 2023-09-30 0001414932 ShareThis, Inc., Application Software, Warrants 2023-09-30 0001414932 SM Wellness Holdings, Inc., Health Care Services, First Lien Term Loan 2023-09-30 0001414932 SM Wellness Holdings, Inc., Health Care Services, Second Lien Term Loan 2023-09-30 0001414932 SonicWall US Holdings Inc., Technology Distributors, Second Lien Term Loan 2023-09-30 0001414932 Sorrento Therapeutics, Inc., Biotechnology, Common Stock 2023-09-30 0001414932 Spanx, LLC, Apparel Retail, First Lien Term Loan 2023-09-30 0001414932 Spanx, LLC, Apparel Retail, First Lien Revolver 2023-09-30 0001414932 SumUp Holdings Luxembourg S.A.R.L., Diversified Financial Services, First Lien Term Loan 2023-09-30 0001414932 Superior Industries International, Inc., Auto Parts & Equipment, First Lien Term Loan 2023-09-30 0001414932 Supreme Fitness Group NY Holdings, LLC, Leisure Facilities, First Lien Term Loan 1 2023-09-30 0001414932 Supreme Fitness Group NY Holdings, LLC, Leisure Facilities, First Lien Term Loan 2 2023-09-30 0001414932 Supreme Fitness Group NY Holdings, LLC, Leisure Facilities, First Lien Revolver 2023-09-30 0001414932 SVP-Singer Holdings Inc., Home Furnishings, First Lien Term Loan 2023-09-30 0001414932 Tacala, LLC, Restaurants, Second Lien Term Loan 2023-09-30 0001414932 Tahoe Bidco B.V., Application Software, First Lien Term Loan 2023-09-30 0001414932 Tahoe Bidco B.V., Application Software, First Lien Revolver 2023-09-30 0001414932 Teletream Holdings Corporation, Application Software, First Lien Term Loan 2023-09-30 0001414932 Teletream Holdings Corporation, Application Software, First Lien Revolver 2023-09-30 0001414932 Ten-X LLC, Interactive Media & Services, First Lien Term Loan 2023-09-30 0001414932 TGNR HoldCo LLC, Integrated Oil & Gas, Subordinated Debt 2023-09-30 0001414932 THL Zinc Ventures Ltd, Diversified Metals & Mining, First Lien Term Loan 2023-09-30 0001414932 Thrasio, LLC, Broadline Retail, First Lien Term Loan 2023-09-30 0001414932 Thrasio, LLC, Broadline Retail, Preferred Equity 1 2023-09-30 0001414932 Thrasio, LLC, Broadline Retail, Preferred Equity 2 2023-09-30 0001414932 Thrasio, LLC, Broadline Retail, Preferred Equity 3 2023-09-30 0001414932 Thrasio, LLC, Broadline Retail, Preferred Equity 4 2023-09-30 0001414932 Touchstone Acquisition, Inc., Health Care Supplies, First Lien Term Loan 2023-09-30 0001414932 Trinitas CLO XV DAC, Multi-Sector Holdings, CLO Notes 2023-09-30 0001414932 Uniti Group LP, Other Specialized REITs, Fixed Rate Bond 1 2023-09-30 0001414932 Uniti Group LP, Other Specialized REITs, Fixed Rate Bond 2 2023-09-30 0001414932 Virgin Pulse, Inc., Application Software, Second Lien Term Loan 2023-09-30 0001414932 Win Brands Group LLC, Housewares & Specialties, First Lien Term Loan 1 2023-09-30 0001414932 Win Brands Group LLC, Housewares & Specialties, First Lien Term Loan 2 2023-09-30 0001414932 Win Brands Group LLC, Housewares & Specialties, Warrants 2023-09-30 0001414932 Windstream Services II, LLC, Integrated Telecommunication Services, Common Stock 2023-09-30 0001414932 WP CPP Holdings, LLC, Aerospace & Defense, First Lien Term Loan 2023-09-30 0001414932 WWEX Uni Topco Holdings, LLC, Air Freight & Logistics, Second Lien Term Loan 2023-09-30 0001414932 Zephyr Bidco Limited, Specialized Finance, Second Lien Term Loan 2023-09-30 0001414932 Zep Inc., Specialty Chemicals, First Lien Term Loan 2023-09-30 0001414932 J.P. Morgan Prime Money Market Fund, Institutional Shares 2023-09-30 0001414932 Other cash accounts 2023-09-30 0001414932 EUR Foreign Currency Forward Contract, Maturing November 9, 2023 2023-09-30 0001414932 GBP Foreign Currency Forward Contract, Maturing November 9, 2023 2023-09-30 0001414932 us-gaap:ForeignExchangeForwardMember 2023-09-30 0001414932 ocs:InterestRateSwapMaturing2027Member 2023-09-30 0001414932 ocs:InterestRateSwapMaturing2029Member 2023-09-30 0001414932 srt:MinimumMember 2023-09-30 0001414932 srt:MaximumMember 2023-09-30 0001414932 ocs:EarnoutShareVestingTrancheOneMember 2023-09-30 0001414932 ocs:EarnoutShareVestingTrancheTwoMember 2022-10-012023-09-30 0001414932 ocs:EarnoutShareVestingTrancheTwoMember 2022-10-012023-09-30 0001414932 ocs:InvestmentOwnedFairValueMemberocs:InvestmentTypeConcentrationRiskMemberocs:NonAccrualStatusDebtSecuritiesMember 2024-06-30 0001414932 ocs:InvestmentOwnedCostMemberocs:InvestmentTypeConcentrationRiskMemberocs:NonAccrualStatusDebtSecuritiesMember 2023-10-012024-06-30 0001414932 ocs:InvestmentOwnedFairValueMemberocs:InvestmentTypeConcentrationRiskMemberocs:NonAccrualStatusDebtSecuritiesMember 2023-10-012024-06-30 0001414932 ocs:InvestmentOwnedFairValueMemberocs:InvestmentTypeConcentrationRiskMemberocs:NonAccrualStatusDebtSecuritiesMember 2023-09-30 0001414932 ocs:InvestmentOwnedCostMemberocs:InvestmentTypeConcentrationRiskMemberocs:NonAccrualStatusDebtSecuritiesMember 2022-10-012023-09-30 0001414932 ocs:InvestmentOwnedFairValueMemberocs:InvestmentTypeConcentrationRiskMemberocs:NonAccrualStatusDebtSecuritiesMember 2022-10-012023-09-30 0001414932 ocs:DeutscheBankTrustCompanyAmericasMember 2024-06-30 0001414932 ocs:WellsFargoBankNAMember 2023-09-30 0001414932 2022-01-012022-12-31 0001414932 2023-01-012023-12-31 0001414932 ocs:SLFJVILLCMember 2024-06-30 0001414932 ocs:OCSIGlickVILLCMember 2024-06-30 0001414932 ocs:TheIVsMember 2024-06-30 0001414932 ocs:SLFJVILLCMember 2023-09-30 0001414932 ocs:OCSIGlickVILLCMember 2023-09-30 0001414932 ocs:InvestmentOwnedAtFairValueMemberocs:InvestmentTypeConcentrationRiskMemberocs:DebtSecuritiesSeniorSecuredMember 2023-10-012024-06-30 0001414932 ocs:InvestmentOwnedAtFairValueMemberocs:InvestmentTypeConcentrationRiskMemberocs:DebtSecuritiesSubordinatedIncludingJVDebtInstrumentsMember 2023-10-012024-06-30 0001414932 ocs:InvestmentOwnedAtFairValueMemberocs:InvestmentTypeConcentrationRiskMemberocs:DebtSecuritiesSeniorSecuredMember 2022-10-012023-09-30 0001414932 ocs:InvestmentOwnedAtFairValueMemberocs:InvestmentTypeConcentrationRiskMemberocs:DebtSecuritiesSubordinatedIncludingJVDebtInstrumentsMember 2022-10-012023-09-30 0001414932 us-gaap:DebtSecuritiesMember 2024-06-30 0001414932 us-gaap:DebtSecuritiesMember 2023-09-30 0001414932 us-gaap:EquitySecuritiesMember 2024-06-30 0001414932 us-gaap:EquitySecuritiesMember 2023-09-30 0001414932 ocs:DebtSecuritiesJVMember 2024-06-30 0001414932 ocs:DebtSecuritiesJVMember 2023-09-30 0001414932 ocs:DebtSecuritiesFloatingRateMember 2024-06-30 0001414932 ocs:DebtSecuritiesFloatingRateMember 2023-09-30 0001414932 ocs:DebtSecuritiesFixedRateMember 2024-06-30 0001414932 ocs:DebtSecuritiesFixedRateMember 2023-09-30 0001414932 us-gaap:FairValueInputsLevel1Memberocs:DebtSecuritiesSeniorSecuredMember 2024-06-30 0001414932 us-gaap:FairValueInputsLevel3Memberocs:DebtSecuritiesSeniorSecuredMember 2024-06-30 0001414932 us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberocs:DebtSecuritiesSeniorSecuredMember 2024-06-30 0001414932 ocs:DebtSecuritiesSeniorSecuredMember 2024-06-30 0001414932 us-gaap:FairValueInputsLevel1Memberocs:DebtSecuritiesSubordinatedIncludingJVDebtInstrumentsMember 2024-06-30 0001414932 us-gaap:FairValueInputsLevel3Memberocs:DebtSecuritiesSubordinatedIncludingJVDebtInstrumentsMember 2024-06-30 0001414932 us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberocs:DebtSecuritiesSubordinatedIncludingJVDebtInstrumentsMember 2024-06-30 0001414932 ocs:DebtSecuritiesSubordinatedIncludingJVDebtInstrumentsMember 2024-06-30 0001414932 us-gaap:FairValueInputsLevel1Memberocs:EquitySecuritiesPreferredMember 2024-06-30 0001414932 us-gaap:FairValueInputsLevel2Memberocs:EquitySecuritiesPreferredMember 2024-06-30 0001414932 us-gaap:FairValueInputsLevel3Memberocs:EquitySecuritiesPreferredMember 2024-06-30 0001414932 us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberocs:EquitySecuritiesPreferredMember 2024-06-30 0001414932 ocs:EquitySecuritiesPreferredMember 2024-06-30 0001414932 us-gaap:FairValueInputsLevel1Memberocs:EquitySecuritiesCommonAndWarrantsIncludingJVInvestmentsMember 2024-06-30 0001414932 us-gaap:FairValueInputsLevel2Memberocs:EquitySecuritiesCommonAndWarrantsIncludingJVInvestmentsMember 2024-06-30 0001414932 us-gaap:FairValueInputsLevel3Memberocs:EquitySecuritiesCommonAndWarrantsIncludingJVInvestmentsMember 2024-06-30 0001414932 us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberocs:EquitySecuritiesCommonAndWarrantsIncludingJVInvestmentsMember 2024-06-30 0001414932 ocs:EquitySecuritiesCommonAndWarrantsIncludingJVInvestmentsMember 2023-09-30 0001414932 us-gaap:FairValueInputsLevel1Member 2024-06-30 0001414932 us-gaap:FairValueInputsLevel2Member 2023-09-30 0001414932 us-gaap:FairValueInputsLevel3Member 2023-09-30 0001414932 us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberocs:EquitySecuritiesPreferredMember 2023-09-30 0001414932 ocs:EquitySecuritiesPreferredMember 2023-09-30 0001414932 us-gaap:FairValueInputsLevel1Memberocs:DebtSecuritiesSeniorSecuredMember 2023-09-30 0001414932 us-gaap:FairValueInputsLevel3Memberocs:DebtSecuritiesSeniorSecuredMember 2023-09-30 0001414932 us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberocs:DebtSecuritiesSeniorSecuredMember 2023-09-30 0001414932 ocs:DebtSecuritiesSeniorSecuredMember 2023-09-30 0001414932 us-gaap:FairValueInputsLevel1Memberocs:DebtSecuritiesSubordinatedIncludingJVDebtInstrumentsMember 2023-09-30 0001414932 us-gaap:FairValueInputsLevel2Memberocs:DebtSecuritiesSubordinatedIncludingJVDebtInstrumentsMember 2023-09-30 0001414932 us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberocs:DebtSecuritiesSubordinatedIncludingJVDebtInstrumentsMember 2023-09-30 0001414932 ocs:DebtSecuritiesSubordinatedIncludingJVDebtInstrumentsMember 2023-09-30 0001414932 us-gaap:FairValueInputsLevel1Memberocs:EquitySecuritiesPreferredMember 2023-09-30 0001414932 us-gaap:FairValueInputsLevel2Memberocs:EquitySecuritiesPreferredMember 2023-09-30 0001414932 us-gaap:FairValueInputsLevel3Memberocs:EquitySecuritiesPreferredMember 2023-09-30 0001414932 us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberocs:EquitySecuritiesPreferredMember 2023-09-30 0001414932 ocs:EquitySecuritiesPreferredMember 2023-09-30 0001414932 us-gaap:FairValueInputsLevel1Memberocs:EquitySecuritiesCommonAndWarrantsIncludingJVInvestmentsMember 2023-09-30 0001414932 us-gaap:FairValueInputsLevel2Memberocs:EquitySecuritiesCommonAndWarrantsIncludingJVInvestmentsMember 2023-09-30 0001414932 us-gaap:FairValueInputsLevel3Memberocs:EquitySecuritiesCommonAndWarrantsIncludingJVInvestmentsMember 2023-09-30 0001414932 us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberocs:EquitySecuritiesCommonAndWarrantsIncludingJVInvestmentsMember 2023-09-30 0001414932 ocs:EquitySecuritiesCommonAndWarrantsIncludingJVInvestmentsMember 2023-09-30 0001414932 us-gaap:FairValueInputsLevel1Member 2023-09-30 0001414932 us-gaap:FairValueInputsLevel2Member 2023-09-30 0001414932 us-gaap:FairValueInputsLevel3Member 2023-09-30 0001414932 us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember 2023-09-30 0001414932 ocs:DebtSecuritiesSeniorSecuredMember 2024-03-31 0001414932

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

ocsl:InvestmentOwnedAtFairValueMemberocsl:InvestmentSectorConcentrationRiskMemberocsl:LeisureProductsMember 2022-10-012023-09-30 0001414932
ocsl:InvestmentOwnedAtFairValueMemberocsl:TechnologyDistributorsMember 2024-06-30 0001414932
ocsl:InvestmentOwnedAtFairValueMemberocsl:InvestmentSectorConcentrationRiskMemberocsl:TechnologyDistributorsMember 2023-10-012024-06-30 0001414932
ocsl:InvestmentOwnedAtFairValueMemberocsl:TechnologyDistributorsMember 2023-09-30 0001414932
ocsl:InvestmentOwnedAtFairValueMemberocsl:InvestmentSectorConcentrationRiskMemberocsl:TechnologyDistributorsMember 2022-10-012023-09-30 0001414932
ocsl:InvestmentOwnedAtFairValueMember 2024-06-30 0001414932 ocsl:InvestmentOwnedAtFairValueMemberocsl:InvestmentSectorConcentrationRiskMember 2023-10-012024-06-30 0001414932 ocsl:InvestmentOwnedAtFairValueMember 2023-09-30 0001414932
ocsl:InvestmentOwnedAtFairValueMemberocsl:InvestmentSectorConcentrationRiskMember 2022-10-012023-09-30 0001414932 ocsl:SLFJVMember 2024-06-30 0001414932 ocsl:SLFJVMember 2023-09-30 0001414932 ocsl:SLFJVMemberocsl:KemperMember 2024-06-30 0001414932 ocsl:SLFJVMemberocsl:KemperMember 2023-09-30 0001414932 us-gaap:RevolvingCreditFacilityMemberocsl:SLFJVIFacilityMemberocsl:SLFJVMemberus-gaap:LineOfCreditMember 2024-06-30 0001414932 us-gaap:RevolvingCreditFacilityMemberocsl:SLFJVIFacilityMemberocsl:SLFJVMemberus-gaap:LineOfCreditMemberocsl:SecuredOvernightFinancingRateMemberocsl:UntilNovember32023Member 2023-10-012024-06-30 0001414932 us-gaap:RevolvingCreditFacilityMemberocsl:SLFJVIFacilityMemberocsl:SLFJVMemberus-gaap:LineOfCreditMember 2023-09-30 0001414932 ocsl:SLFJVMember 2024-06-30 0001414932 ocsl:SLFJVMember 2023-09-30 0001414932 ocsl:SLFJVNotesMemberocsl:SLFJVMember 2024-06-30 0001414932 ocsl:SLFJVNotesMemberocsl:SLFJVMember 2023-09-30 0001414932 ocsl:SLFJVILLCMemberocsl:SLFJVMember 2024-06-30 0001414932 ocsl:SLFJVILLCMemberocsl:SLFJVMember 2023-09-30 0001414932 srt:WeightedAverageMemberocsl:SLFJVMember 2024-06-30 0001414932 srt:WeightedAverageMemberocsl:SLFJVMember 2024-06-30 0001414932 srt:WeightedAverageMemberocsl:SLFJVMember 2023-09-30 0001414932 ocsl:SLFJVMember Largest Exposure To A Single Borrower 2024-06-30 0001414932 ocsl:SLFJVMember Largest Exposure To A Single Borrower 2023-09-30 0001414932 ocsl:SLFJVMember Five Largest Loan Exposures To Borrowers 2024-06-30 0001414932 ocsl:SLFJVMember Five Largest Loan Exposures To Borrowers 2023-09-30 0001414932 ocsl:SLFJVMember Access CIG, LLC, First Lien Term Loan 2024-06-30 0001414932 ocsl:SLFJVMember ADB Companies, LLC, First Lien Term Loan 1 2024-06-30 0001414932 ocsl:SLFJVMember ADB Companies, LLC, First Lien Term Loan 2 2024-06-30 0001414932 ocsl:SLFJVMember Avogen Pharma US, Inc., First Lien Term Loan 2024-06-30 0001414932 ocsl:SLFJVMember American Tire Distributors, Inc., First Lien Term Loan 2024-06-30 0001414932 ocsl:SLFJVMember Artera Services LLC, First Lien Term Loan 2024-06-30 0001414932 ocsl:SLFJVMember ASP-R-PAC Acquisition Co LLC, First Lien Revolver 2024-06-30 0001414932 ocsl:SLFJVMember ASP-R-PAC Acquisition Co LLC, First Lien Term Loan 2024-06-30 0001414932 ocsl:SLFJVMember Astra Acquisition Corp., First Lien Term Loan 1 2024-06-30 0001414932 ocsl:SLFJVMember Astra Acquisition Corp., First Lien Term Loan 2 2024-06-30 0001414932 ocsl:SLFJVMember Asurion, LLC, First Lien Term Loan 1 2024-06-30 0001414932 ocsl:SLFJVMember Asurion, LLC, First Lien Term Loan 2 2024-06-30 0001414932 ocsl:SLFJVMember athenahealth Group Inc., First Lien Term Loan 2024-06-30 0001414932 ocsl:SLFJVMember Aurora Lux Finco S.A.R.L., First Lien Term Loan 2024-06-30 0001414932 ocsl:SLFJVMember BAART Programs, Inc., First Lien Term Loan 1 2024-06-30 0001414932 ocsl:SLFJVMember BAART Programs, Inc., First Lien Term Loan 2 2024-06-30 0001414932 ocsl:SLFJVMember Bausch + Lomb Corporation, First Lien Term Loan 2024-06-30 0001414932 ocsl:SLFJVMember C5 Technology Holdings, LLC, Common Stock 2024-06-30 0001414932 ocsl:SLFJVMember C5 Technology Holdings, LLC, Common Stock 2024-06-30 0001414932 ocsl:SLFJVMember C5 Technology Holdings, LLC, Preferred Equity 2024-06-30 0001414932 ocsl:SLFJVMember Centerline Communications, LLC, First Lien Term Loan 1 2024-06-30 0001414932 ocsl:SLFJVMember Centerline Communications, LLC, First Lien Term Loan 2 2024-06-30 0001414932 ocsl:SLFJVMember Centerline Communications, LLC, First Lien Revolver 2024-06-30 0001414932 ocsl:SLFJVMember Centerline Communications, LLC, First Lien Term Loan 3 2024-06-30 0001414932 ocsl:SLFJVMember Cloud Software Group, Inc., First Lien Term Loan 2024-06-30 0001414932 ocsl:SLFJVMember Covetrus, Inc., First Lien Term Loan 2024-06-30 0001414932 ocsl:SLFJVMember Crown Subsea Communications Holding, Inc., First Lien Term Loan 2024-06-30 0001414932 ocsl:SLFJVMember Curium Bidco S.a.r.l., First Lien Term Loan 2024-06-30 0001414932 ocsl:SLFJVMember Dealer Tire Financial, LLC, First Lien Term Loan 2024-06-30 0001414932 ocsl:SLFJVMember DirecTV Financing, LLC, First Lien Term Loan 2024-06-30 0001414932 ocsl:SLFJVMember DTI Holdco, Inc., First Lien Term Loan 2024-06-30 0001414932 ocsl:SLFJVMember Eagle Parent Corp., First Lien Term Loan 2024-06-30 0001414932 ocsl:SLFJVMember Frontier Communications Holdings, LLC, First Lien Term Loan 1 2024-06-30 0001414932 ocsl:SLFJVMember Frontier Communications Holdings, LLC, First Lien Term Loan 2 2024-06-30 0001414932 ocsl:SLFJVMember Harbor Purchaser Inc., First Lien Term Loan 2024-06-30 0001414932 ocsl:SLFJVMember Husky Injection Molding Systems Ltd., First Lien Term Loan 2024-06-30 0001414932 ocsl:SLFJVMember Indivior Finance S.A.R.L., First Lien Term Loan 2024-06-30 0001414932 ocsl:SLFJVMember INW Manufacturing, LLC, First Lien Term Loan 2024-06-30 0001414932 ocsl:SLFJVMember KDC/ONE Development Corp Inc, First Lien Term Loan 2024-06-30 0001414932 ocsl:SLFJVMember LABEL, Inc., First Lien Term Loan 2024-06-30 0001414932 ocsl:SLFJVMember LaserAway Intermediate Holdings II, LLC, First Lien Term Loan 2024-06-30 0001414932 ocsl:SLFJVMember Lightbox Intermediate, L.P., First Lien Term Loan 2024-06-30 0001414932 ocsl:SLFJVMember McAfee Corp., First Lien Term Loan 2024-06-30 0001414932 ocsl:SLFJVMember Mitchell International, Inc., First Lien Term Loan 2024-06-30 0001414932 ocsl:SLFJVMember Peraton Corp., First Lien Term Loan 2024-06-30 0001414932 ocsl:SLFJVMember PetSmart LLC, First Lien Term Loan 2024-06-30 0001414932 ocsl:SLFJVMember Pluralsight, LLC, First Lien Revolver 2024-06-30 0001414932 ocsl:SLFJVMember Pluralsight, LLC, First Lien Term Loan 2024-06-30 0001414932 ocsl:SLFJVMember Renaissance Holding Corp., First Lien Term Loan 2024-06-30 0001414932 ocsl:SLFJVMember SCIH Salt Holdings Inc., First Lien Term Loan 2024-06-30 0001414932 ocsl:SLFJVMember Shearer's Foods LLC, First Lien Term Loan 2024-06-30 0001414932 ocsl:SLFJVMember SHO Holding I Corporation, First Lien Term Loan 1 2024-06-30 0001414932 ocsl:SLFJVMember SHO Holding I Corporation, First Lien Term Loan 2 2024-06-30 0001414932 ocsl:SLFJVMember SM Wellness Holdings, Inc., First Lien Term Loan 2024-06-30 0001414932 ocsl:SLFJVMember Southern Veterinary Partners, LLC, First Lien Term Loan 1 2024-06-30 0001414932 ocsl:SLFJVMember SPX Flow, Inc., LLC, First Lien Term Loan 2024-06-30 0001414932 ocsl:SLFJVMember Staples, Inc., First Lien Term Loan 2024-06-30 0001414932 ocsl:SLFJVMember Star Parent, Inc., First Lien Term Loan 2024-06-30 0001414932 ocsl:SLFJVMember Supply One Inc, First Lien Term Loan 2024-06-30 0001414932 ocsl:SLFJVMember Swissport Stratosphere USA LLC, First Lien Term Loan 2024-06-30 0001414932 ocsl:SLFJVMember Tacala, LLC, First Lien Term Loan 2024-06-30 0001414932 ocsl:SLFJVMember Touchstone Acquisition, Inc., First Lien Term Loan 2024-06-30 0001414932 ocsl:SLFJVMember Trident TPI Holdings, Inc., First Lien Term Loan 2024-06-30 0001414932 ocsl:SLFJVMemberocsl:A30DaySOFRMember 2023-10-012024-06-30 0001414932 ocsl:SLFJVMemberocsl:A90DaySOFRMember 2023-10-012024-06-30 0001414932 srt:MinimumMemberocsl:SLFJVMember 2024-06-30 0001414932 srt:MaximumMemberocsl:SLFJVMember 2024-06-30 0001414932 ocsl:SLFJVMember Access CIG, LLC, First Lien Term Loan 2023-09-30 0001414932 ocsl:SLFJVMember ADB Companies, LLC, First Lien Term Loan 1 2023-09-30 0001414932 ocsl:SLFJVMember ADB Companies, LLC, First Lien Term Loan 2 2023-09-30 0001414932 ocsl:SLFJVMember Altice France S.A., First Lien Term Loan 2023-09-30 0001414932 ocsl:SLFJVMember Avogen Pharma US, Inc., First Lien Term Loan 2023-09-30 0001414932 ocsl:SLFJVMember American Rock Salt Company LLC, First Lien Term Loan 2023-09-30 0001414932 ocsl:SLFJVMember American Tire Distributors, Inc., First Lien Term Loan 2023-09-30 0001414932 ocsl:SLFJVMember Amplify Finco Pty Ltd., First Lien Term Loan 2023-09-30 0001414932 ocsl:SLFJVMember Anastasia Parent, LLC, First Lien Term Loan 2023-09-30 0001414932 ocsl:SLFJVMember ASP-R-PAC Acquisition Co LLC, First Lien Revolver 2023-09-30 0001414932 ocsl:SLFJVMember ASP-R-PAC Acquisition Co LLC, First Lien Term Loan 2023-09-30 0001414932 ocsl:SLFJVMember Astra Acquisition Corp., First Lien Term Loan 2023-09-30 0001414932 ocsl:SLFJVMember Asurion, LLC, First Lien Term Loan 1 2023-09-30 0001414932 ocsl:SLFJVMember Asurion, LLC, First Lien Term Loan 2 2023-09-30 0001414932 ocsl:SLFJVMember Asurion, LLC, Second Lien Term Loan 2023-09-30 0001414932 ocsl:SLFJVMember athenahealth Group Inc., First Lien Term Loan 2023-09-30 0001414932 ocsl:SLFJVMember Aurora Lux Finco S.A.R.L., First Lien Term Loan 2023-09-30 0001414932 ocsl:SLFJVMember BAART Programs, Inc., First Lien Term Loan 1 2023-09-30 0001414932 ocsl:SLFJVMember BAART Programs, Inc., First Lien Term Loan 2 2023-09-30 0001414932 ocsl:SLFJVMember C5 Technology Holdings, LLC, Common Stock 2023-09-30 0001414932 ocsl:SLFJVMember C5 Technology Holdings, LLC, Preferred Equity 2023-09-30 0001414932 ocsl:SLFJVMember Centerline Communications, LLC, First Lien Term Loan 1 2023-09-30 0001414932 ocsl:SLFJVMember Centerline Communications, LLC, First Lien Term Loan 2 2023-09-30 0001414932 ocsl:SLFJVMember Centerline Communications, LLC, First Lien Revolver 2023-09-30 0001414932 ocsl:SLFJVMember Centerline Communications, LLC, First Lien Term Loan 3 2023-09-30 0001414932 ocsl:SLFJVMember Covetrus, Inc., First Lien Term Loan 2023-09-30 0001414932 ocsl:SLFJVMember Curium Bidco S.a.r.l., First Lien Term Loan 2023-09-30 0001414932 ocsl:SLFJVMember DirecTV Financing, LLC, First Lien Term Loan 2023-09-30 0001414932 ocsl:SLFJVMember DTI Holdco, Inc., First Lien Term Loan 2023-09-30 0001414932 ocsl:SLFJVMember Gibson Brands, Inc., First Lien Term Loan 2023-09-30 0001414932 ocsl:SLFJVMember Harbor Purchaser Inc., First Lien Term Loan 2023-09-30 0001414932 ocsl:SLFJVMember Indivior Finance S.A.R.L., First Lien Term Loan 2023-09-30 0001414932 ocsl:SLFJVMember INW Manufacturing, LLC, First Lien Term Loan 2023-09-30 0001414932 ocsl:SLFJVMember KDC/ONE Development Corp Inc, First Lien Term Loan 2023-09-30 0001414932 ocsl:SLFJVMember LABEL, Inc., First Lien Term Loan 2023-09-30 0001414932 ocsl:SLFJVMember LaserAway Intermediate Holdings II, LLC, First Lien Term Loan 2023-09-30 0001414932 ocsl:SLFJVMember Lightbox Intermediate, L.P., First Lien Term Loan 2023-09-30 0001414932 ocsl:SLFJVMember McAfee Corp., First Lien Term Loan 2023-09-30 0001414932 ocsl:SLFJVMember Mindbody, Inc., First Lien Revolver 2023-09-30 0001414932 ocsl:SLFJVMember Mindbody, Inc., First Lien Term Loan 2023-09-30 0001414932 ocsl:SLFJVMember Mitchell International, Inc., First Lien Term Loan 2023-09-30 0001414932 ocsl:SLFJVMember MRI Software LLC, First Lien Revolver 2023-09-30 0001414932 ocsl:SLFJVMember MRI Software LLC, First Lien Term Loan 1 2023-09-30 0001414932 ocsl:SLFJVMember MRI Software LLC, First Lien Term Loan 2 2023-09-30 0001414932 ocsl:SLFJVMember Northern Star Industries Inc., First Lien Term Loan 2023-09-30 0001414932 ocsl:SLFJVMember OECConnection LLC, First Lien Term Loan 2023-09-30 0001414932 ocsl:SLFJVMember Park Place Technologies, LLC, First Lien Term Loan 2023-09-30 0001414932 ocsl:SLFJVMember Planview Parent, Inc., First Lien Term Loan 2023-09-30 0001414932 ocsl:SLFJVMember Planview Parent, Inc., Second Lien Term Loan 2023-09-30 0001414932 ocsl:SLFJVMember Pluralsight, LLC, First Lien Revolver 2023-09-30 0001414932 ocsl:SLFJVMember Pluralsight, LLC, First Lien Term Loan 2023-09-30 0001414932 ocsl:SLFJVMember Renaissance Holding Corp., First Lien Term Loan 2023-09-30 0001414932 ocsl:SLFJVMember SHO Holding I Corporation, First Lien Term Loan 1 2023-09-30 0001414932 ocsl:SLFJVMember SHO Holding I Corporation, First Lien Term Loan 2 2023-09-30 0001414932 ocsl:SLFJVMember SM Wellness Holdings, Inc., First Lien Term Loan 2023-09-30 0001414932 ocsl:SLFJVMember Southern Veterinary Partners, LLC, First Lien Term Loan 2023-09-30 0001414932 ocsl:SLFJVMember Spanx, LLC, First Lien Term Loan 2023-09-30 0001414932 ocsl:SLFJVMember SPX Flow, Inc., First Lien Term Loan 2023-09-30 0001414932 ocsl:SLFJVMember Star Parent, Inc., First Lien Term Loan 2023-09-30 0001414932 ocsl:SLFJVMember TIBCO Software Inc., First Lien Term Loan 2023-09-30 0001414932 ocsl:SLFJVMember Touchstone Acquisition, Inc., First Lien Term Loan 2023-09-30 0001414932 ocsl:SLFJVMember Veritas US Inc., First Lien Term Loan 2023-09-30 0001414932 ocsl:SLFJVMember Windstream Services II, LLC, First Lien Term Loan 2023-09-30 0001414932 ocsl:SLFJVMember WP CPP Holdings, LLC, First Lien Term Loan 2023-09-30 0001414932 ocsl:SLFJVMember Total Portfolio Investments, First Lien Term Loan 2023-09-30 0001414932 ocsl:SLFJVMemberocsl:A30DaySOFRMember 2022-10-012023-09-30 0001414932 ocsl:SLFJVMemberocsl:A90DaySOFRMember 2022-10-012023-09-30 0001414932 ocsl:SLFJVMemberocsl:A30DayLIBORMember 2022-10-012023-09-30 0001414932 srt:MinimumMemberocsl:SLFJVMember 2023-09-30 0001414932 srt:MaximumMemberocsl:SLFJVMember 2023-09-30 0001414932 ocsl:SLFJVNotesMember 2024-06-30 0001414932 ocsl:SLFJVNotesMember 2023-09-30 0001414932 ocsl:SLFJVNotesMember 2024-04-012024-06-30 0001414932 ocsl:SLFJVNotesMember 2023-10-012024-06-30 0001414932 ocsl:SLFJVNotesMember 2023-04-012023-06-30 0001414932 ocsl:SLFJVNotesMember 2022-10-012023-06-30 0001414932 ocsl:SLFJVILLCMember 2024-06-30 0001414932 ocsl:SLFJVILLCMember 2024-04-012024-06-30 0001414932 ocsl:SLFJVILLCMember 2023-10-012024-06-30 0001414932 ocsl:SLFJVILLCMember 2023-04-012023-06-30 0001414932 ocsl:SLFJVILLCMember 2022-10-012023-06-30 0001414932 ocsl:SLFJVILLCMember 2022-10-012023-06-30 0001414932 ocsl:SLFJVMember 2023-10-012023-06-30 0001414932 ocsl:SLFJVMember 2023-04-012023-06-30 0001414932 ocsl:SLFJVMember 2022-10-012023-06-30 0001414932 ocsl:SeniorCreditFacilityMemberocsl:SLFJVMember 2024-04-012024-06-30 0001414932 ocsl:SeniorCreditFacilityMemberocsl:SLFJVMember 2023-04-012023-06-30 0001414932 ocsl:SeniorCreditFacilityMemberocsl:SLFJVMember 2022-10-012023-06-30 0001414932 ocsl:SLFJVNotesMemberocsl:SLFJVMember 2024-04-012024-06-30 0001414932 ocsl:SLFJVNotesMemberocsl:SLFJVMember 2023-10-012024-06-30 0001414932 ocsl:SLFJVNotesMemberocsl:SLFJVMember 2023-04-012023-06-30 0001414932 ocsl:SLFJVNotesMemberocsl:SLFJVMember 2022-10-012023-06-30 0001414932 ocsl:OC SIGlickJVLLCMember 2021-03-19 0001414932 ocsl:OC SIGlickJVLLCMemberocsl:OC SIGlickJVLLCMember 2024-06-30 0001414932 ocsl:OC SIGlickJVLLCMemberocsl:OC SIGlickJVLLCMember 2023-09-30 0001414932 ocsl:OC SIGlickJVLLCMemberocsl:OC SIGlickJVLLCMember 2024-06-30 0001414932 ocsl:OC SIGlickJVLLCMember 2023-09-30 0001414932 us-gaap:RevolvingCreditFacilityMemberocsl:GlickJVFacilityMemberocsl:OC SIGlickJVLLCMemberus-gaap:LineOfCreditMember 2024-06-30 0001414932 us-gaap:RevolvingCreditFacilityMemberocsl:GlickJVFacilityMemberocsl:OC SIGlickJVLLCMemberus-gaap:LineOfCreditMember 2024-06-30 0001414932 us-gaap:RevolvingCreditFacilityMemberocsl:GlickJVFacilityMemberocsl:OC SIGlickJVLLCMemberus-gaap:LineOfCreditMember 2023-09-30 0001414932 ocsl:OC SIGlickJVLLCMember 2024-06-30 0001414932 ocsl:OC SIGlickJVLLCMember 2023-09-30 0001414932 ocsl:OC SIGlickJVLLCMemberocsl:SeniorSecuredLoansMember 2024-06-30 0001414932 ocsl:OC SIGlickJVLLCMemberocsl:SeniorSecuredLoansMember 2023-09-30 0001414932 srt:WeightedAverageMemberocsl:OC SIGlickJVLLCMember 2024-06-30 0001414932 srt:WeightedAverageMemberocsl:OC SIGlickJVLLCMember 2023-09-30 0001414932

0001414932 ocsl:OCISlickJVLLCMember Largest Loan Exposure To A Single Borrower 2024-06-30 0001414932 ocsl:OCISlickJVLLCMember Largest Loan Exposure To A Single Borrower 2023-09-30 0001414932 ocsl:OCISlickJVLLCMember Five Largest Loan Exposures To Borrowers 2024-06-30 0001414932 ocsl:OCISlickJVLLCMember Access CIG, LLC, First Lien Term Loan 2024-06-30 0001414932 ocsl:OCISlickJVLLCMember ADB Companies, LLC, First Lien Term Loan 1 2024-06-30 0001414932 ocsl:OCISlickJVLLCMember ADB Companies, LLC, First Lien Term Loan 2 2024-06-30 0001414932 ocsl:OCISlickJVLLCMember Alvoen Pharma US, Inc., First Lien Term Loan 2024-06-30 0001414932 ocsl:OCISlickJVLLCMember American Fire Distributors, Inc., First Lien Term Loan 2024-06-30 0001414932 ocsl:OCISlickJVLLCMember Artera Services LLC, First Lien Term Loan 2024-06-30 0001414932 ocsl:OCISlickJVLLCMember ASP-R-PAC Acquisition Co LLC, First Lien Revolver 2024-06-30 0001414932 ocsl:OCISlickJVLLCMember Astra Acquisition Corp., First Lien Term Loan 1 2024-06-30 0001414932 ocsl:OCISlickJVLLCMember Astra Acquisition Corp., First Lien Term Loan 2 2024-06-30 0001414932 ocsl:OCISlickJVLLCMember Asurion, LLC, First Lien Term Loan 1 2024-06-30 0001414932 ocsl:OCISlickJVLLCMember Asurion, LLC, First Lien Term Loan 2 2024-06-30 0001414932 ocsl:OCISlickJVLLCMember athenahealth Group Inc., First Lien Term Loan 2024-06-30 0001414932 ocsl:OCISlickJVLLCMember Aurora Lux Fincos S.A.R.L., First Lien Term Loan 2024-06-30 0001414932 ocsl:OCISlickJVLLCMember BAART Programs, Inc., First Lien Term Loan 1 2024-06-30 0001414932 ocsl:OCISlickJVLLCMember BAART Programs, Inc., First Lien Term Loan 2 2024-06-30 0001414932 ocsl:OCISlickJVLLCMember Bausch + Lomb Corporation, First Lien Term Loan 2024-06-30 0001414932 ocsl:OCISlickJVLLCMember Cloud Software Group, Inc., First Lien Term Loan 2024-06-30 0001414932 ocsl:OCISlickJVLLCMember Covetrus, Inc., First Lien Term Loan 2024-06-30 0001414932 ocsl:OCISlickJVLLCMember Crown Subsea Communications Holding, Inc., First Lien Term Loan 2024-06-30 0001414932 ocsl:OCISlickJVLLCMember Curium Bidco S.A.R.L., First Lien Term Loan 2024-06-30 0001414932 ocsl:OCISlickJVLLCMember Dealer Tire Financial, LLC, First Lien Term Loan 2024-06-30 0001414932 ocsl:OCISlickJVLLCMember DirecTV Financing, LLC, First Lien Term Loan 2024-06-30 0001414932 ocsl:OCISlickJVLLCMember DTI Holco, Inc., First Lien Term Loan 2024-06-30 0001414932 ocsl:OCISlickJVLLCMember Eagle Parent Corp., First Lien Term Loan 2024-06-30 0001414932 ocsl:OCISlickJVLLCMember Frontier Communications Holdings, LLC, First Lien Term Loan 1 2024-06-30 0001414932 ocsl:OCISlickJVLLCMember Frontier Communications Holdings, LLC, First Lien Term Loan 2 2024-06-30 0001414932 ocsl:OCISlickJVLLCMember Harbor Purchaser Inc., First Lien Term Loan 2024-06-30 0001414932 ocsl:OCISlickJVLLCMember Husky Injection Molding Systems Ltd., First Lien Term Loan 2024-06-30 0001414932 ocsl:OCISlickJVLLCMember Indivior Finance S.A.R.L., First Lien Term Loan 2024-06-30 0001414932 ocsl:OCISlickJVLLCMember INW Manufacturing, LLC, First Lien Term Loan 2024-06-30 0001414932 ocsl:OCISlickJVLLCMember KDC/ONE Development Corp Inc, First Lien Term Loan 2024-06-30 0001414932 ocsl:OCISlickJVLLCMember LABI, Inc., First Lien Term Loan 2024-06-30 0001414932 ocsl:OCISlickJVLLCMember LaserAway Intermediate Holdings II, LLC, First Lien Term Loan 2024-06-30 0001414932 ocsl:OCISlickJVLLCMember OFConnection LLC, First Lien Term Loan 2024-06-30 0001414932 ocsl:OCISlickJVLLCMember Peraton Corp., First Lien Term Loan 2024-06-30 0001414932 ocsl:OCISlickJVLLCMember PetSmart LLC, First Lien Term Loan 2024-06-30 0001414932 ocsl:OCISlickJVLLCMember Pluralsight, LLC, First Lien Term Loan 2024-06-30 0001414932 ocsl:OCISlickJVLLCMember Pluralsight, LLC, First Lien Revolver 2024-06-30 0001414932 ocsl:OCISlickJVLLCMember Renaissance Holding Corp., First Lien Term Loan 2024-06-30 0001414932 ocsl:OCISlickJVLLCMember SCIH Salt Holdings Inc., First Lien Term Loan 2024-06-30 0001414932 ocsl:OCISlickJVLLCMember Shearer's Foods LLC, First Lien Term Loan 2024-06-30 0001414932 ocsl:OCISlickJVLLCMember SHO Holding I Corporation, First Lien Term Loan 1 2024-06-30 0001414932 ocsl:OCISlickJVLLCMember SHO Holding I Corporation, First Lien Term Loan 2 2024-06-30 0001414932 ocsl:OCISlickJVLLCMember SHO Holding I Corporation, First Lien Term Loan 3 2024-06-30 0001414932 ocsl:OCISlickJVLLCMember Southern Veterinary Partners, LLC, First Lien Term Loan 2024-06-30 0001414932 ocsl:OCISlickJVLLCMember SPX Flow, Inc., First Lien Term Loan 2024-06-30 0001414932 ocsl:OCISlickJVLLCMember Staples, Inc., First Lien Term Loan 2024-06-30 0001414932 ocsl:OCISlickJVLLCMember Star Parent, Inc., First Lien Term Loan 2024-06-30 0001414932 ocsl:OCISlickJVLLCMember Supply One Inc., First Lien Term Loan 2024-06-30 0001414932 ocsl:OCISlickJVLLCMember Swissport Stratosphere Usa LLC, First Lien Term Loan 2024-06-30 0001414932 ocsl:OCISlickJVLLCMember Tacala LLC, First Lien Term Loan 2024-06-30 0001414932 ocsl:OCISlickJVLLCMember Touchstone Acquisition, Inc., First Lien Term Loan 2024-06-30 0001414932 ocsl:OCISlickJVLLCMember Trident TPI Holdings, Inc., First Lien Term Loan 2024-06-30 0001414932 ocsl:OCISlickJVLLCMember MaximumMemberocs:OCISlickJVLLCMember 2024-06-30 0001414932 ocsl:OCISlickJVLLCMember Access CIG, LLC, First Lien Term Loan 2023-09-30 0001414932 ocsl:OCISlickJVLLCMember ADB Companies, LLC, First Lien Term Loan 1 2023-09-30 0001414932 ocsl:OCISlickJVLLCMember ADB Companies, LLC, First Lien Term Loan 2 2023-09-30 0001414932 ocsl:OCISlickJVLLCMember Alvoen Pharma US, Inc., First Lien Term Loan 2023-09-30 0001414932 ocsl:OCISlickJVLLCMember American Rock Salt Company LLC, First Lien Term Loan 2023-09-30 0001414932 ocsl:OCISlickJVLLCMember American Fire Distributors, Inc., First Lien Term Loan 2023-09-30 0001414932 ocsl:OCISlickJVLLCMember Amplify Fincos Pty Ltd., First Lien Term Loan 2023-09-30 0001414932 ocsl:OCISlickJVLLCMember Amynta Agency Borrower Inc., First Lien Term Loan 2023-09-30 0001414932 ocsl:OCISlickJVLLCMember Anastasia Parent, LLC, First Lien Term Loan 2023-09-30 0001414932 ocsl:OCISlickJVLLCMember ASP-R-PAC Acquisition Co LLC, First Lien Term Loan 2023-09-30 0001414932 ocsl:OCISlickJVLLCMember ASP-R-PAC Acquisition Co LLC, First Lien Revolver 2023-09-30 0001414932 ocsl:OCISlickJVLLCMember Astra Acquisition Corp., First Lien Term Loan 2023-09-30 0001414932 ocsl:OCISlickJVLLCMember Asurion, LLC, First Lien Term Loan 1 2023-09-30 0001414932 ocsl:OCISlickJVLLCMember Asurion, LLC, First Lien Term Loan 2 2023-09-30 0001414932 ocsl:OCISlickJVLLCMember Asurion, LLC, Second Lien Term Loan 2023-09-30 0001414932 ocsl:OCISlickJVLLCMember athenahealth Group Inc., First Lien Term Loan 2023-09-30 0001414932 ocsl:OCISlickJVLLCMember Aurora Lux Fincos S.A.R.L., First Lien Term Loan 2023-09-30 0001414932 ocsl:OCISlickJVLLCMember BAART Programs, Inc., First Lien Term Loan 1 2023-09-30 0001414932 ocsl:OCISlickJVLLCMember BAART Programs, Inc., First Lien Term Loan 2 2023-09-30 0001414932 ocsl:OCISlickJVLLCMember Covetrus, Inc., First Lien Term Loan 2023-09-30 0001414932 ocsl:OCISlickJVLLCMember Curium Bidco S.A.R.L., First Lien Term Loan 2023-09-30 0001414932 ocsl:OCISlickJVLLCMember DirecTV Financing, LLC, First Lien Term Loan 2023-09-30 0001414932 ocsl:OCISlickJVLLCMember DTI Holco, Inc., First Lien Term Loan 2023-09-30 0001414932 ocsl:OCISlickJVLLCMember Gibson Brands, Inc., First Lien Term Loan 2023-09-30 0001414932 ocsl:OCISlickJVLLCMember Harbor Purchaser Inc., First Lien Term Loan 2023-09-30 0001414932 ocsl:OCISlickJVLLCMember Indivior Finance S.A.R.L., First Lien Term Loan 2023-09-30 0001414932 ocsl:OCISlickJVLLCMember INW Manufacturing, LLC, First Lien Term Loan 2023-09-30 0001414932 ocsl:OCISlickJVLLCMember KDC/ONE Development Corp Inc, First Lien Term Loan 2023-09-30 0001414932 ocsl:OCISlickJVLLCMember LaserAway Intermediate Holdings II, LLC, First Lien Term Loan 2023-09-30 0001414932 ocsl:OCISlickJVLLCMember MRI Software LLC, First Lien Revolver 2023-09-30 0001414932 ocsl:OCISlickJVLLCMember Northern Star Industries Inc., First Lien Term Loan 2023-09-30 0001414932 ocsl:OCISlickJVLLCMember OFConnection LLC, First Lien Term Loan 2023-09-30 0001414932 ocsl:OCISlickJVLLCMember Planview Parent, Inc., First Lien Term Loan 2023-09-30 0001414932 ocsl:OCISlickJVLLCMember Planview Parent, Inc., Second Lien Term Loan 2023-09-30 0001414932 ocsl:OCISlickJVLLCMember Pluralsight, LLC, First Lien Term Loan 2023-09-30 0001414932 ocsl:OCISlickJVLLCMember Pluralsight, LLC, First Lien Revolver 2023-09-30 0001414932 ocsl:OCISlickJVLLCMember SHO Holding I Corporation, First Lien Term Loan 1 2023-

gaap:RevolvingCreditFacilityMemberocsl:SyndicatedFacilityMemberus-gaap:LineOfCreditMember 2023-10-012024-06-30 0001414932 us-gaap:RevolvingCreditFacilityMemberocsl:SyndicatedFacilityMemberus-gaap:LineOfCreditMember 2023-04-012023-06-30 0001414932 us-gaap:RevolvingCreditFacilityMemberocsl:SyndicatedFacilityMemberus-gaap:LineOfCreditMember 2022-10-012023-06-30 0001414932 ocsl:CitibankFacilityMember 2023-10-012024-06-30 0001414932 us-gaap:RevolvingCreditFacilityMemberocsl:CitibankFacilityMemberus-gaap:LineOfCreditMember 2023-06-30 0001414932 us-gaap:RevolvingCreditFacilityMemberocsl:CitibankFacilityMemberus-gaap:LineOfCreditMember 2023-04-012023-06-30 0001414932 us-gaap:RevolvingCreditFacilityMemberocsl:CitibankFacilityMemberus-gaap:LineOfCreditMember 2022-10-012023-06-30 0001414932 ocsl:OSI2CitibankFacilityMember 2023-10-012024-06-30 0001414932 us-gaap:RevolvingCreditFacilityMemberocsl:OSI2CitibankFacilityMemberus-gaap:LineOfCreditMember 2024-06-30 0001414932 srt:MinimumMemberus-gaap:RevolvingCreditFacilityMemberocsl:OSI2CitibankFacilityMemberus-gaap:LineOfCreditMemberocsl:SecuredOvernightFinancingRateMember 2023-10-012024-06-30 0001414932 us-gaap:RevolvingCreditFacilityMemberocsl:OSI2CitibankFacilityMemberocsl:OSI2CitibankFacilityMemberus-gaap:LineOfCreditMemberocsl:SecuredOvernightFinancingRateMemberocsl:AfterReinvestmentPeriodMember 2023-10-012024-06-30 0001414932 us-gaap:RevolvingCreditFacilityMemberocsl:OSI2CitibankFacilityMemberus-gaap:LineOfCreditMember 2023-10-012024-06-30 0001414932 us-gaap:RevolvingCreditFacilityMemberocsl:OSI2CitibankFacilityMemberus-gaap:LineOfCreditMember 2023-09-30 0001414932 us-gaap:RevolvingCreditFacilityMemberocsl:OSI2CitibankFacilityMemberus-gaap:LineOfCreditMember 2023-06-30 0001414932 us-gaap:RevolvingCreditFacilityMemberocsl:OSI2CitibankFacilityMemberus-gaap:LineOfCreditMember 2024-04-012024-06-30 0001414932 us-gaap:RevolvingCreditFacilityMemberocsl:OSI2CitibankFacilityMemberus-gaap:LineOfCreditMember 2023-04-012023-06-30 0001414932 us-gaap:RevolvingCreditFacilityMemberocsl:OSI2CitibankFacilityMemberus-gaap:LineOfCreditMember 2023-01-232023-06-30 0001414932 ocsl:A2025NotesMember 2023-10-012024-06-30 0001414932 ocsl:A2025NotesMember 2020-02-252020-02-25 0001414932 ocsl:A2027NotesMember 2023-10-012024-06-30 0001414932 ocsl:A2027NotesMember 2021-05-182021-05-18 0001414932 us-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMember 2021-05-18 0001414932 us-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMemberocsl:LondonInterbankOfferedRateLIBOR1Member 2021-05-18 0001414932 us-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:SecuredOvernightFinancingRateSoftOvernightIndexSwapRateMember 2021-05-18 0001414932 ocsl:A2029NotesMember 2023-10-012024-06-30 0001414932 ocsl:A2029NotesMember 2023-08-15 0001414932 ocsl:A2029NotesMember 2023-08-152023-08-15 0001414932 ocsl:A2029NotesMemberus-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMember 2023-08-15 0001414932 ocsl:A2029NotesMemberus-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMember 2023-08-15 0001414932 us-gaap:SecuredOvernightFinancingRateSoftOvernightIndexSwapRateMember 2023-08-15 0001414932 ocsl:A2025NotesMember 2023-09-30 0001414932 ocsl:A2027NotesMember 2023-09-30 0001414932 ocsl:A2029NotesMember 2023-09-30 0001414932 ocsl:A2025NotesMember 2024-04-012024-06-30 0001414932 ocsl:A2025NotesMember 2023-04-012023-06-30 0001414932 ocsl:A2025NotesMember 2022-10-012023-06-30 0001414932 ocsl:A2027NotesMember 2023-04-012023-06-30 0001414932 ocsl:A2027NotesMember 2022-10-012023-06-30 0001414932 ocsl:ShortTermCapitalLossCarryforwardMember 2023-09-30 0001414932 ocsl:LongTermCapitalLossCarryforwardMember 2023-09-30 0001414932 ocsl:ThrasioLLCMember 2024-04-012024-06-30 0001414932 ocsl:OtherNetMember 2024-04-012024-06-30 0001414932 us-gaap:ForeignExchangeForwardMember 2023-04-012023-06-30 0001414932 ocsl:AdenAnaisMergerSubIncMember 2023-04-012023-06-30 0001414932 ocsl:RadiologyPartnersIncMember 2023-04-012023-06-30 0001414932 ocsl:WPCPPHoldingsLLCMember 2023-04-012023-06-30 0001414932 ocsl:TerseraTherapeuticsLLCMember 2023-04-012023-06-30 0001414932 ocsl:OtherNetMember 2023-04-012023-06-30 0001414932 ocsl:ThrasioLLCMember 2023-10-012024-06-30 0001414932 ocsl:AllWebLeadsIncMember 2023-10-012024-06-30 0001414932 ocsl:ContinentalIntermodalGroupLEMember 2023-10-012024-06-30 0001414932 ocsl:PLDevelopmentLLCMember 2023-10-012024-06-30 0001414932 ocsl:AmericanTireDistributorsInc.Member 2023-10-012024-06-30 0001414932 ocsl:ZephyrBideoLimitedMember 2023-10-012024-06-30 0001414932 ocsl:LiftBrandsHoldingsInc.Member 2023-10-012024-06-30 0001414932 ocsl:AlvotechMember 2023-10-012024-06-30 0001414932 ocsl:ArdonaghMidco3PLCMember 2023-10-012024-06-30 0001414932 us-gaap:ForeignExchangeForwardMember 2023-10-012024-06-30 0001414932 ocsl:OtherNetMember 2023-10-012024-06-30 0001414932 us-gaap:ForeignExchangeForwardMember 2022-10-012023-06-30 0001414932 ocsl:AdenAnaisMergerSubIncMember 2023-10-012023-06-30 0001414932 ocsl:RadiologyPartnersIncMember 2022-10-012023-06-30 0001414932 ocsl:CaravanaCo.Member 2022-10-012023-06-30 0001414932 ocsl:ASPUntifraxHoldingsIncMember 2022-10-012023-06-30 0001414932 ocsl:WPCPPHoldingsLLCMember 2022-10-012023-06-30 0001414932 ocsl:GlobalMedicalResponseIncMember 2022-10-012023-06-30 0001414932 ocsl:TerseraTherapeuticsLLCMember 2022-10-012023-06-30 0001414932 ocsl:OtherNetMember 2022-10-012023-06-30 0001414932 ocsl:ExitedInvestmentsMember 2024-04-012024-06-30 0001414932 us-gaap:ForeignExchangeForwardMember 2024-04-012024-06-30 0001414932 us-gaap:DebtSecuritiesMember 2024-04-012024-06-30 0001414932 us-gaap:DebtSecuritiesMember 2023-04-012023-06-30 0001414932 us-gaap:EquitySecuritiesMember 2024-04-012024-06-30 0001414932 us-gaap:DebtSecuritiesMember 2023-04-012023-06-30 0001414932 ocsl:ExitedInvestmentsMember 2023-04-012023-06-30 0001414932 us-gaap:EquitySecuritiesMember 2023-10-012024-06-30 0001414932 us-gaap:EquitySecuritiesMember 2023-10-012024-06-30 0001414932 us-gaap:ForeignExchangeForwardMember 2023-10-012024-06-30 0001414932 ocsl:ExitedInvestmentsMember 2023-10-012024-06-30 0001414932 us-gaap:DebtSecuritiesMember 2022-10-012023-06-30 0001414932 ocsl:ExitedInvestmentsMember 2022-10-012023-06-30 0001414932 us-gaap:EquitySecuritiesMember 2022-10-012023-06-30 0001414932 us-gaap:ForeignExchangeForwardMember 2022-10-012023-06-30 0001414932 ocsl:InvestmentAdvisoryAgreementMember 2024-06-30 0001414932 ocsl:InvestmentAdvisoryAgreementMember 2023-10-012024-06-30 0001414932 2019-05-022019-05-02 0001414932 2019-05-032019-05-03 0001414932 ocsl:OaktreeStrategicIncomeCorporationMergerMember 2021-03-192021-03-19 0001414932 ocsl:OaktreeStrategicIncomeHncMergerMember 2023-01-232023-01-23 0001414932 ocsl:OaktreeStrategicIncomeHncMergerYearOneMember 2023-01-232023-01-23 0001414932 ocsl:OaktreeStrategicIncomeHncMergerYearTwoMember 2023-01-232023-01-23 0001414932 2024-04-262024-04-26 0001414932 us-gaap:SubsequentEventMember 2024-07-012024-07-01 0001414932 ocsl:InvestmentAdvisoryAgreementMember 2024-04-012024-06-30 0001414932 ocsl:InvestmentAdvisoryAgreementMember 2023-04-012023-06-30 0001414932 ocsl:InvestmentAdvisoryAgreementMember 2022-10-012023-06-30 0001414932 ocsl:InvestmentAdvisoryAgreementIncentiveRatePreIncentiveFeeNetInvestmentIncomeBelowCatchUpMember 2023-10-012024-06-30 0001414932 ocsl:InvestmentAdvisoryAgreementIncentiveRateQuarterlyCatchUpThresholdMember 2023-10-012024-06-30 0001414932 ocsl:InvestmentAdvisoryAgreementIncentiveRatePreIncentiveFeeNetInvestmentIncomeExceedsCatchUpThresholdMember 2023-10-012024-06-30 0001414932 srt:AffiliatedEntityMember 2024-04-012024-06-30 0001414932 ocsl:InvestmentAdvisoryAgreementMembersrt:AffiliatedEntityMember 2024-04-012024-06-30 0001414932 ocsl:InvestmentAdvisoryAgreementMembersrt:AffiliatedEntityMember 2023-10-012024-06-30 0001414932 ocsl:InvestmentAdvisoryAgreementMembersrt:AffiliatedEntityMember 2022-10-012023-06-30 0001414932 ocsl:InvestmentAdvisoryAgreementIncentiveRateRealizedCapitalGainsMembersrt:AffiliatedEntityMember 2023-10-012024-06-30 0001414932 srt:AffiliatedEntityMember 2023-10-012024-06-30 0001414932 srt:AffiliatedEntityMember 2022-10-012023-06-30 0001414932 srt:AffiliatedEntityMember 2024-06-30 0001414932 srt:AffiliatedEntityMember 2023-09-30 0001414932 EUR Foreign Currency Forward Contract, Maturing May 9, 2024 2024-06-30 0001414932 GBP Foreign Currency Forward Contract, Maturing May 9, 2024 2024-06-30 0001414932 Interest rate swap, Maturing January 15, 2027 2023-09-30 0001414932 Interest rate swap, Maturing February 15, 2029 2024-06-30 0001414932 Interest rate swap, Maturing January 15, 2027 2023-09-30 0001414932 Interest rate swap, Maturing February 15, 2029 2023-09-30 0001414932 us-gaap:InterestRateSwapMember 2023-09-30 0001414932 ocsl:DebtAndEquityFinancingMember 2024-06-30 0001414932 ocsl:IVFinancingMember 2024-06-30 0001414932 ocsl:DebtAndEquityFinancingMember 2023-09-30 0001414932 ocsl:IVFinancingMember 2023-09-30 0001414932 107-109 Beech OAK22 LLC 2024-06-30 0001414932 107-109 Beech OAK22 LLC 2023-09-30 0001414932 Verona Pharma, Inc. 2024-06-30 0001414932 Verona Pharma, Inc. 2023-09-30 0001414932 OCSI Glick JV LLC 2024-06-30 0001414932 OCSI Glick JV LLC 2023-09-30 0001414932 PPW Aero Buyer, Inc. 2024-06-30 0001414932 PPW Aero Buyer, Inc. 2023-09-30 0001414932 PetVet Care Centers, LLC 2024-06-30 0001414932 PetVet Care Centers, LLC 2023-09-30 0001414932 Senior Loan Fund IV, LLC 2024-06-30 0001414932 Senior Loan Fund IV, LLC 2023-09-30 0001414932 BioXcel Therapeutics, Inc. 2024-06-30 0001414932 BioXcel Therapeutics, Inc. 2023-09-30 0001414932 Ampspec Parent LLC 2024-06-30 0001414932 Ampspec Parent LLC 2023-09-30 0001414932 Kings Buyer, LLC 2024-06-30 0001414932 Kings Buyer, LLC 2023-09-30 0001414932 Seres Therapeutics, Inc. 2024-06-30 0001414932 Seres Therapeutics, Inc. 2023-09-30 0001414932 Monotype Imaging Holdings Inc. 2024-06-30 0001414932 Monotype Imaging Holdings Inc. 2023-09-30 0001414932 Next Holdco, LLC 2024-06-30 0001414932 Next Holdco, LLC 2023-09-30 0001414932 ICGMs, Inc. 2024-06-30 0001414932 ICGMs, Inc. 2023-09-30 0001414932 Eyesouth Eye Care Holdco LLC 2024-06-30 0001414932 Eyesouth Eye Care Holdco LLC 2023-09-30 0001414932 MRI Software LLC 2024-06-30 0001414932 MRI Software LLC 2023-09-30 0001414932 Quantum Bideo Limited 2024-06-30 0001414932 Telephone and Data Systems, Inc. 2024-06-30 0001414932 Telephone and Data Systems, Inc. 2023-09-30 0001414932 Digital.AI Software Holdings, Inc. 2024-06-30 0001414932 Digital.AI Software Holdings, Inc. 2023-09-30 0001414932 Truck-Lite Co., LLC 2024-06-30 0001414932 Truck-Lite Co., LLC 2023-09-30 0001414932 Sorenson Communications, LLC 2024-06-30 0001414932 Sorenson Communications, LLC 2023-09-30 0001414932 Grove Hotel Parcel Owner, LLC 2024-06-30 0001414932 Grove Hotel Parcel Owner, LLC 2023-09-30 0001414932 Mindbody, Inc. 2024-06-30 0001414932 Mindbody, Inc. 2023-09-30 0001414932 scPharmaceuticals Inc. 2024-06-30 0001414932 scPharmaceuticals Inc. 2023-09-30 0001414932 SumUp Holdings Luxembourg 2024-06-30 0001414932 SumUp Holdings Luxembourg 2023-09-30 0001414932 Avalara, Inc. 2024-06-30 0001414932 Avalara, Inc. 2023-09-30 0001414932 107 Fair Street LLC 2024-06-30 0001414932 107 Fair Street LLC 2023-09-30 0001414932 Harrow, Inc. 2024-06-30 0001414932 Harrow, Inc. 2023-09-30 0001414932 Accupac, Inc. 2024-06-30 0001414932 Accupac, Inc. 2023-09-30 0001414932 Inventus Power, Inc. 2024-06-30 0001414932 Inventus Power, Inc. 2023-09-30 0001414932 Delta Leasing SPV II LLC 2024-06-30 0001414932 Delta Leasing SPV II LLC 2023-09-30 0001414932 Establishment Labs Holdings Inc. 2024-06-30 0001414932 Establishment Labs Holdings Inc. 2023-09-30 0001414932 WP CPP Holdings, LLC 2024-06-30 0001414932 WP CPP Holdings, LLC 2023-09-30 0001414932 Enverus Holdings, Inc. 2024-06-30 0001414932 Enverus Holdings, Inc. 2023-09-30 0001414932 PRGX Global, Inc. 2024-06-30 0001414932 PRGX Global, Inc. 2023-09-30 0001414932 Salus Workers' Compensation, LLC 2024-06-30 0001414932 Salus Workers' Compensation, LLC 2023-09-30 0001414932 Spanx, LLC 2024-06-30 0001414932 Spanx, LLC 2023-09-30 0001414932 Minotaur Acquisition, Inc. 2024-06-30 0001414932 Minotaur Acquisition, Inc. 2023-09-30 0001414932 Relativity ODA LLC 2024-06-30 0001414932 Relativity ODA LLC 2023-09-30 0001414932 Crewline Buyer, Inc. 2024-06-30 0001414932 Crewline Buyer, Inc. 2023-09-30 0001414932 Protein For Pets Opco, LLC 2024-06-30 0001414932 Protein For Pets Opco, LLC 2023-09-30 0001414932 Coupa Holdings, LLC 2024-06-30 0001414932 Coupa Holdings, LLC 2023-09-30 0001414932 Oranje Holdco, Inc. 2024-06-30 0001414932 Oranje Holdco, Inc. 2023-09-30 0001414932 MHE Intermediate Holdings, LLC 2024-06-30 0001414932 MHE Intermediate Holdings, LLC 2023-09-30 0001414932 Evergreen IX Borrower 2023, LLC 2024-06-30 0001414932 Evergreen IX Borrower 2023, LLC 2023-09-30 0001414932 Acquia Inc. 2024-06-30 0001414932 Acquia Inc. 2023-09-30 0001414932 Supreme Fitness Group NY Holdings, LLC 2024-06-30 0001414932 Supreme Fitness Group NY Holdings, LLC 2023-09-30 0001414932 Galileo Parent, Inc. 2024-06-30 0001414932 Galileo Parent, Inc. 2023-09-30 0001414932 Centralsquare Technologies, LLC 2024-06-30 0001414932 Centralsquare Technologies, LLC 2023-09-30 0001414932 112-126 Van Houten Real22 LLC 2024-06-30 0001414932 112-126 Van Houten Real22 LLC 2023-09-30 0001414932 Berner Food & Beverage, LLC 2024-06-30 0001414932 Berner Food & Beverage, LLC 2023-09-30 0001414932 Finastra USA, Inc. 2024-06-30 0001414932 Finastra USA, Inc. 2023-09-30 0001414932 Icefall Parent, Inc. 2024-06-30 0001414932 Icefall Parent, Inc. 2023-09-30 0001414932 SIO2 Medical Products, Inc. 2024-06-30 0001414932 SIO2 Medical Products, Inc. 2023-09-30 0001414932 LSL Holdco, LLC 2024-06-30 0001414932 LSL Holdco, LLC 2023-09-30 0001414932 Telestream Holdings Corporation 2024-06-30 0001414932 Telestream Holdings Corporation 2023-09-30 0001414932 All Web Leads, Inc. 2024-06-30 0001414932 All Web Leads, Inc. 2023-09-30 0001414932 ASP-RPAC Acquisition Co LLC 2024-06-30 0001414932 ASP-RPAC Acquisition Co LLC 2023-09-30 0001414932 ADB Companies, LLC 2024-06-30 0001414932 ADB Companies, LLC 2023-09-30 0001414932 Fairbridge Strategic Capital Funding LLC 2024-06-30 0001414932 Fairbridge Strategic Capital Funding LLC 2023-09-30 0001414932 MND Holdings III Corp 2024-06-30 0001414932 MND Holdings III Corp 2023-09-30 0001414932 Assembled Brands Capital LLC 2024-06-30 0001414932 Assembled Brands Capital LLC 2023-09-30 0001414932 Dominion Diagnostics, LLC 2024-06-30 0001414932 Dominion Diagnostics, LLC 2023-09-30 0001414932 OTG Management, LLC 2024-06-30 0001414932 OTG Management, LLC 2023-09-30 0001414932 ADC Therapeutics SA 2024-06-30 0001414932 ADC Therapeutics SA 2023-09-30 0001414932 Impel Pharmaceuticals Inc. 2024-06-30 0001414932 Impel Pharmaceuticals Inc. 2023-09-30 0001414932 SCP Eye Care Services, LLC 2024-06-30 0001414932 SCP Eye Care Services, LLC 2023-09-30 0001414932 Tahoe Bidco B.V. 2024-06-30 0001414932 Tahoe Bidco B.V. 2023-09-30 0001414932 Pluralsight, LLC 2024-06-30 0001414932 Pluralsight, LLC 2023-09-30 0001414932 Liquid Environmental Solutions Corporation 2024-06-30 0001414932 Liquid Environmental Solutions Corporation 2023-09-30 0001414932 Coyote Buyer, LLC 2024-06-30 0001414932 Coyote Buyer, LLC 2023-09-30 0001414932 ocsl:DistributionTypeQuarterlyMemberus-gaap:SubsequentEventMember 2024-07-262024-07-26 0001414932 C5 Technology Holdings, LLC. Data Processing & Outsourced Services, Common Stock 2023-10-012024-06-30 0001414932 C5 Technology Holdings, LLC. Data Processing & Outsourced Services, Preferred Equity 2023-10-012024-06-30 0001414932 Continental Intermodal Group LP, Oil & Gas Storage & Transportation, Preferred Equity 2023-10-012024-06-30 0001414932 Continental

[illegible]

36000-
50000.09500.14821162900001010200011629000261303422330000140320000.07280.128710000009670009900000.05750.11112237500022226000223750000.06000.11345
69000.690000.06000.123000-
1500004531144000048280000.08006724400066488000329490000.08004790000472300023470000.07000.11831081300010480000108130000.05500.10842047000192200
2300001000001090003990000.07250.12572717600026904000269400000.05250.10592032500019936000199510000.05250-41000-
390000.05500.1098973900012073000119420000.05500.10702123000253400025500006488766937500000.06000.11443232900032124000322000000.06500-34000-
110000.08250.13840.00508812000859600083050000.08250.13840.005029198000285030002751900020445412020003990000.10000.15332527900024698000243940000.1
71000-
1090009910193270002770000.05330.10652450000024500000245000000.0488168000015530001565000930778000180000.08750000.08750000.08750.11755212000502900
104000-1000006600013900010000.05250.10691810400017930000180790000.05000-35000-
150000.08751109000107200011400000.05750.11081378000013232000126740000.10756835000677100065040000.06500.10321884600020199000199450000.08000.1334
9000-760000.08252716400023170000150760000.07000.12322509400024366000243910000.07000-91000-
940000.09750.05440.09752561800025482000230560000.09750.05440.09751809000179800015900000.06000.11341978900019012000191260000.13005041900050006000
54000-
510000.05750.110812800042000460000.06502830000257300018080000.11002512000246300024650000.1100319800031340003138000000000456800045680004568000
74000-
200000.04000.09331948000019457000194820001.863288517100027072350002.08732929320003121703000373640003736400069950000699500000.07210731400010731
2000-
80000.06000.11552033000201300020270000.07000.12346400000633500063800000.07000.12342533200025288000252530000.07000.12721333000132200013240000.06
38000-
380002894017400060000.05000.08865500000602400058250000.07750.1317178730001765500017687000178701733000282600057159000000.085023562000227950009
13000-
230000.05250.10908490000816800064140002152320789000200740001222200012260000117950000.06000.11492950900029164000282840000.07250.126450470000496
108000-
780000.07301916300019163000183400000.12504641000464100041700000.05000.10653247000321600031690000.05000.10651261000126900012310000.08500.1415892
15000-130000.07500-20000-
200000.05000.10391475000014173000146160000.06000.11521801300017690000178120000.06000.11479330009200009180000.07757270004620003960000.03000.0700
41000-
410000.09005995000059950000599500003750030000.07250.12551174200011509000115110000.07250.12552580002340002340000.06750.121831074000291270001991
54000-700000.08000-27000-350000.05250.10671434700013871000136180000.06500.11897448000729600073010000.06500-82000-
790000.06500.12041432000139900014040000.04466808000549000058730000.08250.136223975000233100002332800000.07250.1263
2442700024135000235480000.07250.12633636000360200035740000.07250000.06750.12143770003340002960000.10750.16062661300026492000244840000.10750.160
99000-
860000.05750.11404455000042918000350460000.06500.11924058700039935000389630000.07250.12781393900012661000100940000.06500.1104167520001662300016
47000-
470000.09500.14952642200024920000275120002000001399000000.05000.10654524300044717000438860000.08500.13995403000534800051600000.08500.1399293900
5630003720000.06000.11422736000259500025580000.06000.11422349400023128000219670000.06000-41000-
1720000.11508568000849500081320000.11504284000424700040660000.11508568000849500081320000.08000.0175910600085800008013000259877
5450007800066817
23000330000.06000.11522012500019912000198230000.06000.11522631000258700025910000.06000.11429640009360009380000.07000.12525248000522000051640000
43000-
760000.07500.12894053800039873000398330000.07500.12831466000121500012820000.06750.12515455900054236000531680000.05500.1099139730001393600013685
28000-
470000.08500.13993033900038021000290070000.09500.14896460600064720000631850000.068810191000983100087430000.06880.12290.020073362000724590006969
42000-360000.10000.15672571200025615000250690000.10000-11000-
690000.10000.15641210000119300011690000.07754519000455000033050000.05000.10429676000951800095510000.06000.11572237500022189000218960000.07250.1
53000-540000.06500.120138414000379600003838000000.06500-34000-
30001000001090002480000.07250.12782450300024255000240810000.07250.12782819000279700027710000.05750.112146260005897000516660006488766937500000.0
43000-
470000.08250.13900.0050367070003548000345050000.08250.13900.005013504000130580001269400020445412020007560000.10000.152425558000247770002479100
95000-930009910193270001625000930778000130000.08750.14188010000779900077780000.08750-35000-
680001037310370009510000.08750.1175521200049870004990000.08750000.0875000537001750002580000.07880.12887191000693400069370000.07880.128826970002
29000-
220000.09750.15262342300023207000228140000.09750.15171861000184500018020000.06000.11321994700019013000191990000.11504984000489400047850000.1300
<div style="margin-top:6pt;text-indent:24.75pt">Oaktree Specialty Lending Corporation (together with its consolidated subsidiaries, the "Company") is a specialty finance company that looks to provide customized, one-stop credit solutions to companies with limited access to public or syndicated capital markets. The Company was formed in late 2007 and operates as a closed-end, externally managed, non-diversified management investment company that has elected to be regulated as a Business Development Company under the Investment Company Act. The Company has qualified and elected to be treated as a regulated investment company ("RIC") under the Internal Revenue Code of 1986, as amended (the "Code"), for U.S. federal income tax purposes.</div><div style="margin-top:6pt;text-indent:24.75pt">The Company's investment objective is to generate current income and capital appreciation by providing companies with flexible and innovative financing solutions, including first and second lien loans, unsecured and mezzanine loans, bonds, preferred equity and certain equity co-investments. The Company may also seek to generate capital appreciation and income through secondary investments at discounts to par in either private or syndicated transactions.</div><div style="margin-top:6pt;text-indent:24.75pt">The Company is externally managed by Oaktree Fund Advisors, LLC ("Oaktree"), pursuant to an investment advisory agreement between the Company and Oaktree (as amended and restated, the "Investment Advisory Agreement"). Oaktree is an affiliate of Oaktree Capital Management, L.P. ("OCM"), the Company's external investment adviser from October 17, 2017 through May 3, 2020. Oaktree Fund Administration, LLC ("Oaktree Administrator"), a subsidiary of OCM, provides certain administrative and other services necessary for the Company to operate pursuant to an administration agreement between the Company and Oaktree Administrator (the "Administration Agreement"). See Note 10. In 2019, Brookfield Corporation (f/k/a Brookfield Asset Management Inc.) ("Brookfield") acquired a majority economic interest in Oaktree Capital Group, LLC. Oaktree and its affiliates operate as an independent business within Brookfield, with their own product offerings and investment, marketing and support teams.</div><div style="margin-top:6pt;text-indent:24.75pt">On March 19, 2021, the Company acquired Oaktree Strategic Income Corporation ("OCIS") pursuant to that certain Agreement and Plan of Merger (the "OCIS Merger Agreement"), dated as of October 28, 2020, by and among OCIS, the Company, Lion Merger Sub, Inc., a wholly-owned subsidiary of the Company, and, solely for the limited purposes set forth therein, Oaktree. Pursuant to the OCIS Merger Agreement, OCIS was merged with and into the Company in a two-step transaction, with the Company as the surviving company (the "OCIS Merger").</div><div style="margin-top:6pt;text-indent:24.75pt">On January 23, 2023, the Company acquired Oaktree Strategic Income II, Inc. ("OSI2") pursuant to that certain Agreement and Plan of Merger (the "OSI2 Merger Agreement"), dated as of September 14, 2022, by and among OSI2, the Company, Project Superior Merger Sub, Inc., a wholly-owned subsidiary of the Company, and, solely for the limited purposes set forth therein, Oaktree. Pursuant to the OSI2 Merger Agreement, OSI2 was merged with and into the Company in a two-step transaction with the Company as the surviving company (the "OSI2 Merger"). Significant Accounting Policies</div><div style="margin-top:6pt;text-indent:11.25pt">Basis of Presentation:</div><div style="margin-top:6pt;text-indent:24.75pt">The Consolidated Financial Statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") and pursuant to the requirements for reporting on Form 10-Q and Regulation S-X. In the opinion of management, all adjustments of a normal recurring nature considered necessary for the fair presentation of the Consolidated Financial Statements have been made. All intercompany balances and transactions have been eliminated. The Company is an investment company following the accounting and reporting guidance in ASC Topic 946.Financial Services - Investment Companies("ASC 946").</div><div style="margin-top:6pt;text-indent:24.75pt">Certain prior period amounts have been reclassified to conform to the current period presentation. All per share amounts and common shares outstanding have been retroactively adjusted as necessary to reflect the Company's 1-for-3 reverse stock split completed on January 20, 2023 and effective as of the commencement of trading on January 23, 2023.</div><div style="margin-top:14pt;text-indent:11.25pt">Use of Estimates:</div><div style="margin-top:6pt;text-indent:24.75pt">The preparation of the financial statements in conformity with GAAP requires management to make certain estimates and assumptions affecting amounts reported in the financial statements and accompanying notes. These estimates are based on the information that is currently available to the Company and on various other assumptions that the Company believes to be reasonable under the circumstances. Changes in the economic and political environments, financial markets and any other parameters used in determining these estimates could cause actual results to differ and such differences could be material. Significant estimates include the valuation of investments and revenue recognition.</div><div style="margin-top:14pt;text-indent:11.25pt">Consolidation:</div><div style="margin-top:6pt;text-indent:24.75pt">The accompanying Consolidated Financial Statements include the accounts of Oaktree Specialty Lending Corporation and its consolidated subsidiaries. Each consolidated subsidiary is wholly-owned and, as such, consolidated into the Consolidated Financial Statements. Certain subsidiaries that hold investments are treated as pass through entities for U.S. federal income tax purposes. The assets of certain of the consolidated subsidiaries are not directly available to satisfy the claims of the creditors of Oaktree Specialty Lending Corporation or any of its other subsidiaries.</div><div style="margin-top:6pt;text-indent:24.75pt">As an investment company, portfolio investments held by the Company are not consolidated into the Consolidated Financial Statements but rather are included on the Statements of Assets and Liabilities as investments at fair value.</div><div style="text-indent:11.25pt">Fair Value Measurements:</div><div style="margin-top:6pt;text-indent:24.75pt">Oaktree, as the valuation designee of the Company's Board of Directors pursuant to Rule 2a-5 under the Investment Company Act, determines the fair value of the Company's assets on at least a quarterly basis in accordance with ASC 820. ASC 820 defines fair value as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. A liability's fair value is defined as the amount that would be paid to transfer the liability to a new obligor, not the amount that would be paid to settle the liability with the creditor. ASC 820 prioritizes the use of observable market prices over entity-specific inputs. Where observable prices or inputs are not available or reliable, valuation techniques are applied. These valuation techniques involve some level of management estimation and judgment, the degree of which is dependent on the price transparency for the investments or market and the investments'

complexity.

Level 1 — Unadjusted, quoted prices in active markets for identical assets or liabilities as of the measurement date.

Level 2 — Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data at the measurement date for substantially the full term of the assets or liabilities.

Level 3 — Unobservable inputs that reflect Oaktree's best estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model.

If inputs used to measure fair value fall into different levels of the fair value hierarchy, an investment's level is based on the lowest level of input that is significant to the fair value measurement. Oaktree's assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the investment.

This includes investment securities that are valued using "bid" and "ask" prices obtained from independent third party pricing services or directly from brokers. These investments may be classified as Level 3 because the quoted prices may be indicative in nature for securities that are in an inactive market, may be for similar securities or may require adjustments for investment-specific factors or restrictions.

Financial instruments with readily available quoted prices generally will have a higher degree of market price observability and a lesser degree of judgment inherent in measuring fair value. As such, Oaktree obtains and analyzes readily available market quotations provided by pricing vendors and brokers for all of the Company's investments for which quotations are available. In determining the fair value of a particular investment, pricing vendors and brokers use observable market information, including both binding and non-binding indicative quotations.

Oaktree seeks to obtain at least two quotations for the subject or similar securities, typically from pricing vendors. If Oaktree is unable to obtain two quotes from pricing vendors, or if the prices obtained from pricing vendors are not within Oaktree's set threshold, Oaktree seeks to obtain a quote directly from a broker making a market for the asset. Oaktree evaluates the quotations provided by pricing vendors and brokers based on available market information, including trading activity of the subject or similar securities, or by performing a comparable security analysis to ensure that fair values are reasonably estimated. Oaktree also performs back-testing of valuation information obtained from pricing vendors and brokers against actual prices received in transactions. In addition to ongoing monitoring and back-testing, Oaktree performs due diligence procedures over pricing vendors to understand their methodology and controls to support their use in the valuation process. Generally, Oaktree does not adjust any of the prices received from these sources.

If the quotations obtained from pricing vendors or brokers are determined to not be reliable or are not readily available, Oaktree values such investments using any of three different valuation techniques. The first valuation technique is the transaction precedent technique, which utilizes recent or expected future transactions of the investment to determine fair value, to the extent applicable. The second valuation technique is an analysis of the enterprise value ("EV") of the portfolio company. EV means the entire value of the portfolio company to a market participant, including the sum of the values of debt and equity securities used to capitalize the enterprise at a point in time. The EV analysis is typically performed to determine (i) the value of equity investments, (ii) whether there is credit impairment for debt investments and (iii) the value for debt investments that the Company is deemed to control under the Investment Company Act. To estimate the EV of a portfolio company, Oaktree analyzes various factors, including the portfolio company's historical and projected financial results, macroeconomic impacts on the company and competitive dynamics in the company's industry. Oaktree also utilizes some or all of the following information based on the individual circumstances of the portfolio company: (i) valuations of comparable public companies, (ii) recent sales of private and public comparable companies in similar industries or having similar business or earnings characteristics, (iii) purchase prices as a multiple of their earnings or cash flow, (iv) the portfolio company's ability to meet its forecasts and its business prospects, (v) a discounted cash flow analysis, (vi) estimated liquidation or collateral value of the portfolio company's assets and (vii) offers from third parties to buy the portfolio company. Oaktree may probability weight potential sale outcomes with respect to a portfolio company when uncertainty exists as of the valuation date. The third valuation technique is a market yield technique, which is typically performed for non-credit impaired debt investments. In the market yield technique, a current price is imputed for the investment based upon an assessment of the expected market yield for a similarly structured investment with a similar level of risk, and Oaktree considers the current contractual interest rate, the capital structure and other terms of the investment relative to risk of the company and the specific investment. A key determinant of risk, among other things, is the leverage through the investment relative to the EV of the portfolio company. As debt investments held by the Company are substantially illiquid with no active transaction market, Oaktree depends on primary market data, including newly funded transactions and industry specific market movements, as well as secondary market data with respect to high yield debt instruments and syndicated loans, as inputs in determining the appropriate market yield, as applicable.

In accordance with ASC 820-10, certain investments that qualify as investment companies in accordance with ASC 946 may be valued using net asset value as a practical expedient for fair value. Consistent with FASB guidance under ASC 820, these investments are excluded from the hierarchical levels. These investments are generally not redeemable.

Oaktree estimates the fair value of certain privately held warrants using a Black Scholes pricing model, which includes an analysis of various factors and subjective assumptions, including the current stock price (by using an EV analysis as described above), the expected period until exercise, expected volatility of the underlying stock price, expected dividends and the risk free rate. Changes in the subjective input assumptions can materially affect the fair value estimates.

Rule 2a-3 under the Investment Company Act permits boards of directors of registered investment companies and Business Development Companies to either (i) choose to determine fair value in good faith or (ii) designate a valuation designee tasked with determining fair value in good faith, subject to the board's oversight. The Company's Board of Directors has designated Oaktree to serve as its valuation designee effective September 9, 2022.

Oaktree undertakes a multi-step valuation process each quarter in connection with determining the fair value of the Company's investments.

The quarterly valuation process begins with each portfolio company or investment being initially valued by Oaktree's valuation team.

Preliminary valuations are then reviewed and discussed with management of Oaktree.

Separately, independent valuation firms prepare valuations of the Company's investments, on a selected basis, for which market quotations are not readily available or are readily available but deemed not reflective of the fair value of the investment, and submit the reports to the Company and provide such reports to Oaktree.

Oaktree compares and contrasts its preliminary valuations to the valuations of the independent valuation firms and prepares a valuation report for the Audit Committee.

The Audit Committee reviews the valuation report with Oaktree, and Oaktree responds and supplements the valuation report to reflect any discussions between Oaktree and the Audit Committee.

Oaktree, as valuation designee, determines the fair value of each investment in the Company's portfolio.

The fair value of the Company's investments as of June 30, 2024 and September 30, 2023 was determined by Oaktree, as the Company's valuation designee. The Company has and will continue to engage independent valuation firms to provide assistance regarding the determination of the fair value of a portion of its portfolio securities for which market quotations are not readily available or are readily available but deemed not reflective of the fair value of the investment each quarter.

Due to the inherent uncertainty of determining the fair value of investments that do not have a readily available market value, the fair value of the Company's investments may fluctuate from period to period. Because of the inherent uncertainty of valuation, these estimated values may differ significantly from the values that would have been reported had a ready market for the investments existed, and it is reasonably possible that the difference could be material.

With the exception of the line items entitled "deferred financing costs," "deferred offering costs," "other assets," "deferred tax liability," "credit facilities payable" and "unsecured notes payable," which are reported at amortized cost, all assets and liabilities approximate fair value on the Consolidated Statements of Assets and Liabilities. The carrying value of the line items titled "interest, dividends and fees receivable," "due from portfolio companies," "receivables from unsettled transactions," "due from broker," "accounts payable, accrued expenses and other liabilities," "base management fee and incentive fee payable," "due to affiliate," "interest payable" and "payables from unsettled transactions" approximate fair value due to their short maturities.

Foreign Currency Translation

The accounting records of the Company are maintained in U.S. dollars. All assets and liabilities denominated in foreign currencies are translated into U.S. dollars based on the prevailing foreign exchange rate on the reporting date. The Company does not isolate that portion of the results of operations resulting from changes in foreign exchange rates on investments from the fluctuations arising from changes in market prices of securities held. The Company's investments in foreign securities may involve certain risks, including foreign exchange restrictions, expropriation, taxation or other political, social or economic risks, all of which could affect the market and/or credit risk of the investment. In addition, changes in the relationship of foreign currencies to the U.S. dollar can significantly affect the value of these investments and therefore the earnings of the Company.

Derivative Instruments

The Company uses foreign currency forward contracts to reduce the Company's exposure to fluctuations in the value of foreign currencies. In a foreign currency forward contract, the Company agrees to receive or deliver a fixed quantity of one currency for another at a pre-determined price at a future date. Foreign currency forward contracts are marked-to-market at the applicable forward rate. Unrealized appreciation (depreciation) on foreign currency forward contracts is recorded within derivative assets or derivative liabilities on the Consolidated Statements of Assets and Liabilities by counterparty on a net basis, not taking into account

collateral posted which is recorded separately, if applicable. Purchases and settlements of foreign currency forward contracts having the same settlement date and counterparty are generally settled net and any realized gains or losses are recognized on the settlement date. The Company does not utilize hedge accounting with respect to foreign currency forward contracts and, as such, the Company recognizes its foreign currency forward contracts at fair value with changes included in the net unrealized appreciation (depreciation) on the Consolidated Statements of Operations.

Interest Rate Swaps

The Company uses interest rate swaps to hedge some of the Company's fixed rate debt. The Company designated the interest rate swaps as the hedging instruments in an effective hedge accounting relationship, and therefore the periodic payments are recognized as components of interest expense in the Consolidated Statements of Operations. Depending on the nature of the balance at period end, the fair value of each interest rate swap is either included as a derivative asset or derivative liability on the Company's Consolidated Statements of Assets and Liabilities. The change in fair value of the interest rate swaps is offset by a change in the carrying value of the fixed rate debt. Any amounts paid to the counterparty to cover collateral obligations under the terms of the interest rate swap agreements are included in due from broker on the Company's Consolidated Statements of Assets and Liabilities.

Investment Income

Interest income, adjusted for accretion of original issue discount ("OID"), is recorded on an accrual basis to the extent that such amounts are expected to be collected. The Company stops accruing interest on investments when it is determined that interest is no longer collectible. Investments that are expected to pay regularly scheduled interest in cash are generally placed on non-accrual status when there is reasonable doubt that principal or interest cash payments will be collected. Cash interest payments received on investments may be recognized as income or a return of capital depending upon management's judgment. A non-accrual investment is restored to accrual status if past due principal and interest are paid in cash and the portfolio company, in management's judgment, is likely to continue timely payment of its remaining obligations. As of June 30, 2024, there were eight investments on non-accrual status that in aggregate represented 5.7% and 3.7% of total debt investments at cost and fair value, respectively. As of September 30, 2023, there were four investments on non-accrual status that in aggregate represented 2.4% and 1.8% of total debt investments at cost and fair value, respectively.

PIK Interest Income

In connection with its investment in a portfolio company, the Company sometimes receives nominal cost equity that is valued as part of the negotiation process with the portfolio company. When the Company receives nominal cost equity, the Company allocates its cost basis in the investment between debt securities and the nominal cost equity at the time of origination. Any resulting discount from recording the loan, or otherwise purchasing a security at a discount, is accreted into interest income over the life of the loan. The Company's investments in debt securities may contain PIK interest provisions. PIK interest, which generally represents contractually deferred interest added to the loan balance that is generally due at the end of the loan term, is generally recorded on the accrual basis to the extent such amounts are expected to be collected. The Company generally ceases accruing PIK interest if there is insufficient value to support the accrual or if the Company does not expect the portfolio company to be able to pay all principal and interest due. The Company's decision to cease accruing PIK interest on a loan or debt security involves subjective judgments and determinations based on available information about a particular portfolio company, including whether the portfolio company is current with respect to its payment of principal and interest on its loans and debt securities; financial statements and financial projections for the portfolio company; the Company's assessment of the portfolio company's business development success; information obtained by the Company in connection with periodic formal update interviews with the portfolio company's management and, if appropriate, the private equity sponsor; and information about the general economic and market conditions in which the portfolio company operates. The Company's determination to cease accruing PIK interest is generally made well before the Company's full write-down of a loan or debt security. In addition, if it is subsequently determined that the Company will not be able to collect any previously accrued PIK interest, the fair value of the loans or debt securities would be reduced by the amount of such previously accrued, but uncollectible, PIK interest. The accrual of PIK interest on the Company's debt investments increases the recorded cost basis of these investments in the Consolidated Financial Statements including for purposes of computing the capital gains incentive fee payable by the Company to Oaktree. To maintain its status as a RIC, certain income from PIK interest may be required to be distributed to the Company's stockholders, even though the Company has not yet collected the cash and may never do so.

Fee Income

Oaktree or its affiliates may provide financial advisory services to portfolio companies and, in return, the Company may receive fees for capital structuring services. These fees are generally non-recurring and are recognized by the Company upon the investment closing date. The Company may also receive additional fees in the ordinary course of business, including servicing, amendment, exit and prepayment fees, which are classified as fee income and recognized as they are earned or the services are rendered.

Dividend Income

The Company generally recognizes dividend income on the ex-dividend date for public securities and the record date for private equity investments. Distributions received from private equity investments are evaluated to determine if the distribution should be recorded as dividend income or a return of capital. Generally, the Company will not record distributions from private equity investments as dividend income unless there are sufficient earnings at the portfolio company prior to the distribution. Distributions that are classified as a return of capital are recorded as a reduction in the cost basis of the investment.

Cash and Cash Equivalents and Restricted Cash

Cash and cash equivalents consist of demand deposits and highly liquid investments with maturities of three months or less when acquired. The Company places its cash and cash equivalents and restricted cash with financial institutions and, at times, cash held in bank accounts exceeds the Federal Deposit Insurance Corporation ("FDIC") insurance limit. Cash and cash equivalents are included on the Company's Consolidated Schedule of Investments and cash equivalents are classified as Level 1 assets.

As of June 30, 2024, included in restricted cash was \$11.0 million that was held at Deutsche Bank Trust Company Americas in connection with the OS12 Citibank Facility (as defined in Note 6, Borrowings). Pursuant to the terms of the OS12 Citibank Facility, the Company was restricted in terms of access to the \$11.0 million until the occurrence of the periodic distribution dates and, in connection therewith, the Company's submission of its required periodic reporting schedules and verifications of the Company's compliance with the terms of the OS12 Citibank Facility. As of September 30, 2023, included in restricted cash was \$9.1 million that was held at Deutsche Bank Trust Company Americas in connection with the OS12 Citibank Facility.

Due from Portfolio Companies

Due from portfolio companies consists of amounts payable to the Company from its portfolio companies, including proceeds from the sale of portfolio companies not yet received or being held in escrow and excluding those amounts attributable to interest, dividends or fees receivable. These amounts are recognized as they become payable to the Company.

Receivables/Payables from Unsettled Transactions

Receivables/payables from unsettled transactions consist of amounts receivable to or payable by the Company for transactions that have not settled at the reporting date.

Deferred Financing Costs

Deferred financing costs consist of fees and expenses paid in connection with the closing or amending of credit facilities and debt offerings. Deferred financing costs in connection with credit facilities are capitalized as an asset when incurred. Deferred financing costs in connection with all other debt arrangements are a direct deduction from the related debt liability when incurred. Deferred financing costs are amortized using the effective interest method over the term of the respective debt arrangement. This amortization expense is included in interest expense in the Consolidated Statements of Operations. Upon early termination or modification of a credit facility, all or a portion of unamortized fees related to such facility may be accelerated into interest expense. For extinguishments of the Company's unsecured notes payable, any unamortized deferred financing costs are deducted from the carrying amount of the debt in determining the gain or loss from the extinguishment.

Deferred Offering Costs

Legal fees and other costs incurred in connection with the Company's shelf registration statement are capitalized as deferred offering costs in the Consolidated Statements of Assets and Liabilities. To the extent any such costs relate to equity offerings, these costs are charged as a reduction of capital upon utilization. To the extent any such costs relate to debt offerings, these costs are treated as deferred financing costs and are amortized over the term of the respective debt arrangement. Any deferred offering costs that remain at the expiration of the shelf registration statement or when it becomes probable that an offering will not be completed are expensed.

Legal fees and other costs incurred in connection with the Company's shelf registration statement are capitalized as deferred offering costs in the Consolidated Statements of Assets and Liabilities. To the extent any such costs relate to equity offerings, these costs are charged as a reduction of capital upon utilization. To the extent any such costs relate to debt offerings, these costs are treated as deferred financing costs and are amortized over the term of the respective debt arrangement. Any deferred offering costs that remain at the expiration of the shelf registration statement or when it becomes probable that an offering will not be completed are expensed.

The Company has elected to be subject to tax as a RIC under Subchapter M of the Code and operates in a manner so as to qualify for the tax treatment applicable to RICs. In order to be subject to tax as a RIC, among other things, the Company is required to meet certain source of income and asset diversification requirements and timely distribute dividends to its stockholders of an amount generally at least equal to 90% of investment company taxable income, as defined by the Code and determined without regard to any deduction for dividends paid, for each taxable year. As a RIC, the Company is not subject to U.S. federal income tax on the portion of its taxable income and gains distributed currently to stockholders as a dividend. Depending on the level of taxable income earned during a taxable year, the Company may choose to retain taxable income in excess of current year dividend distributions and would distribute such taxable income in the next taxable year. The Company would then incur a 4% excise tax on such income, as required. To the extent that the Company determines that its estimated current year annual taxable income, determined on a calendar year basis, could exceed estimated current calendar year dividend distributions, the Company accrues excise tax, if any, on estimated excess taxable income as taxable income is earned. The Company anticipates timely distribution of its taxable income within the tax rules under Subchapter M of the Code. For calendar year 2022, the Company incurred \$0.1 million of excise tax. The Company did not incur any U.S. federal excise tax for calendar year 2023. The Company does not expect to incur a U.S. federal excise tax for calendar year 2024.

The Company holds certain portfolio investments through taxable subsidiaries. The purpose of the Company's taxable subsidiaries is to permit the Company to hold equity investments in portfolio companies which are "pass through" entities for U.S. federal income tax purposes in order to comply with the RIC tax requirements. The taxable subsidiaries are consolidated for financial reporting purposes, and portfolio investments held by them are included in the Company's Consolidated Financial Statements as portfolio investments and recorded at fair value. The taxable subsidiaries are not consolidated with the Company for U.S. federal income tax purposes and may generate income tax expense, or benefit, and the related tax assets and liabilities, as a result of their ownership of certain portfolio investments. This income tax expense, if any, would be reflected in the Company's Consolidated Statements of Operations. The Company uses the liability method to account for its taxable subsidiaries' income taxes. Using this method, the Company recognizes deferred tax assets and liabilities for the estimated future tax effects attributable to temporary differences between financial reporting and tax bases of assets and liabilities. In addition, the Company recognizes deferred tax benefits

associated with net operating loss carry forwards that it may use to offset future tax obligations. The Company measures deferred tax assets and liabilities using the enacted tax rates expected to apply to taxable income in the years in which it expects to recover or settle those temporary differences.

Accounting for Uncertainty in Income Taxes (ASC 740), provides guidance for how uncertain tax positions should be recognized, measured, presented and disclosed in the Company's Consolidated Financial Statements. ASC 740 requires the evaluation of tax positions taken or expected to be taken in the course of preparing the Company's tax returns to determine whether the tax positions are "more-likely-than-not" of being sustained by the applicable tax authority. Tax positions not deemed to meet the more-likely-than-not threshold are recorded as a tax benefit or expense in the current year. Management's determinations regarding ASC 740 may be subject to review and adjustment at a later date based upon factors including an ongoing analysis of tax laws, regulations and interpretations thereof. The Company recognizes the tax benefits of uncertain tax positions only where the position is "more-likely-than-not" to be sustained assuming examination by tax authorities. Management has analyzed the Company's tax positions and has concluded that no liability for unrecognized tax benefits should be recorded related to uncertain tax positions taken on returns filed for open tax years 2021, 2022 and 2023. The Company identifies its major tax jurisdictions as U.S. Federal and California, and the Company is not aware of any tax positions for which it is reasonably possible that the total amounts of unrecognized tax benefits will change materially in the next 12 months.

Recently Adopted Accounting Pronouncements

In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280), which improves reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. The amendments are effective for fiscal years beginning after December 15, 2023 and interim period within fiscal years beginning after December 15, 2024. The Company does not expect this guidance to materially impact its consolidated financial statements.

Basis of Presentation

The Consolidated Financial Statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") and pursuant to the requirements for reporting on Form 10-Q and Regulation S-X. In the opinion of management, all adjustments of a normal recurring nature considered necessary for the fair presentation of the Consolidated Financial Statements have been made. All intercompany balances and transactions have been eliminated. The Company is an investment company following the accounting and reporting guidance in ASC Topic 946.

Financial Services - Investment Companies

The Consolidated Financial Statements of the Company include the accounts of Oaktree Specialty Lending Corporation and its consolidated subsidiaries. Each consolidated subsidiary is wholly owned and, as such, consolidated into the Consolidated Financial Statements. Certain subsidiaries that hold investments are treated as pass through entities for U.S. federal income tax purposes. The assets of certain of the consolidated subsidiaries are not directly available to satisfy the claims of the creditors of Oaktree Specialty Lending Corporation or any of its other subsidiaries.

As an investment company, portfolio investments held by the Company are not consolidated into the Consolidated Financial Statements but rather are included on the Statements of Assets and Liabilities as investments at fair value.

Fair Value Measurements

Oaktree, as the valuation designee of the Company's Board of Directors pursuant to Rule 2a-5 under the Investment Company Act, determines the fair value of the Company's assets on at least a quarterly basis in accordance with ASC 820. ASC 820 defines fair value as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. A liability's fair value is defined as the amount that would be paid to transfer the liability to a new obligor, not the amount that would be paid to settle the liability with the creditor. ASC 820 prioritizes the use of observable market prices over entity-specific inputs. Where observable prices or inputs are not available or reliable, valuation techniques are applied. These valuation techniques involve some level of management estimation and judgment, the degree of which is dependent on the price transparency for the investments or market and the investments' complexity.

Hierarchical levels, defined by ASC 820 and directly related to the amount of subjectivity associated with the inputs to fair valuation of these assets and liabilities, are as follows:

Level 1 - Unadjusted quoted prices in active markets for identical assets or liabilities as of the measurement date.

Level 2 - Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data at the measurement date for substantially the full term of the assets or liabilities.

Level 3 - Unobservable inputs that reflect Oaktree's best estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model.

If inputs used to measure fair value fall into different levels of the fair value hierarchy, an investment's level is based on the lowest level of input that is significant to the fair value measurement. Oaktree's assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the investment.

Investment securities that are valued using "bid" and "ask" prices obtained from independent third party pricing services or directly from brokers. These investments may be classified as Level 3 because the quoted prices may be indicative in nature for securities that are in an inactive market, may be for similar securities or may require adjustments for investment-specific factors or restrictions.

Financial instruments with readily available quoted prices generally will have a higher degree of market price observability and a lesser degree of judgment inherent in measuring fair value. As such, Oaktree obtains and analyzes readily available market quotations provided by pricing vendors and brokers for all of the Company's investments for which quotations are available. In determining the fair value of a particular investment, pricing vendors and brokers use observable market information, including both binding and non-binding indicative quotations.

Oaktree seeks to obtain at least two quotations for the subject or similar securities, typically from pricing vendors. If Oaktree is unable to obtain two quotes from pricing vendors, or if the prices obtained from pricing vendors are not within Oaktree's set threshold, Oaktree seeks to obtain a quote directly from a broker making a market for the asset. Oaktree evaluates the quotations provided by pricing vendors and brokers based on available market information, including trading activity of the subject or similar securities, or by performing a comparable security analysis to ensure that fair values are reasonably estimated. Oaktree also performs back-testing of valuation information obtained from pricing vendors and brokers against actual prices received in transactions. In addition to ongoing monitoring and back-testing, Oaktree performs due diligence procedures over pricing vendors to understand their methodology and controls to support their use in the valuation process. Generally, Oaktree does not adjust any of the prices received from these sources.

If the quotations obtained from pricing vendors or brokers are determined to not be reliable or are not readily available, Oaktree values such investments using any of three different valuation techniques. The first valuation technique is the transaction precedent technique, which utilizes recent or expected future transactions of the investment to determine fair value, to the extent applicable. The second valuation technique is an analysis of the enterprise value ("EV") of the portfolio company. EV means the entire value of the portfolio company to a market participant, including the sum of the values of debt and equity securities used to capitalize the enterprise at a point in time. The EV analysis is typically performed to determine (i) the value of equity investments, (ii) whether there is credit impairment for debt investments and (iii) the value for debt investments that the Company is deemed to control under the Investment Company Act. To estimate the EV of a portfolio company, Oaktree analyzes various factors, including the portfolio company's historical and projected financial results, macroeconomic impacts on the company and competitive dynamics in the company's industry. Oaktree also utilizes some or all of the following information based on the individual circumstances of the portfolio company: (i) valuations of comparable public companies, (ii) recent sales of private and public comparable companies in similar industries or having similar business or earnings characteristics, (iii) purchase prices as a multiple of their earnings or cash flow, (iv) the portfolio company's ability to meet its forecasts and its business prospects, (v) a discounted cash flow analysis, (vi) estimated liquidation or collateral value of the portfolio company's assets and (vii) offers from third parties to buy the portfolio company. Oaktree may probability weight potential sale outcomes with respect to a portfolio company when uncertainty exists as of the valuation date. The third valuation technique is a market yield technique, which is typically performed for non-credit impaired debt investments. In the market yield technique, a current price is imputed for the investment based upon an assessment of the expected market yield for a similarly structured investment with a similar level of risk, and Oaktree considers the current contractual interest rate, the capital structure and other terms of the investment relative to risk of the company and the specific investment. A key determinant of risk, among other things, is the leverage through the investment relative to the EV of the portfolio company. As debt investments held by the Company are substantially illiquid with no active transaction market, Oaktree depends on primary market data, including newly funded transactions and industry-specific market movements, as well as secondary market data with respect to high-yield debt instruments and syndicated loans, as inputs in determining the appropriate market yield, as applicable.

In accordance with ASC 820-10, certain investments that qualify as investment companies in accordance with ASC 946 may be valued using net asset value as a practical expedient for fair value. Consistent with FASB guidance under ASC 820, these investments are excluded from the hierarchical levels. These investments are generally not redeemable.

Oaktree estimates the fair value of certain privately held warrants using a Black-Scholes pricing model, which includes an analysis of various factors and subjective assumptions, including the current stock price (by using an EV analysis as described above), the expected period until exercise, expected volatility of the underlying stock price, expected dividends and the risk free rate. Changes in the subjective input assumptions can materially affect the fair value estimates.

Rule 2a-5 under the Investment

Company Act permits boards of directors of registered investment companies and Business Development Companies to either (i) choose to determine fair value in good faith or (ii) designate a valuation designee tasked with determining fair value in good faith, subject to the board's oversight. The Company's Board of Directors has designated Oaktree to serve as its valuation designee effective September 8, 2023.

Oaktree undertakes a multi-step valuation process each quarter in connection with determining the fair value of the Company's investments:

The Audit Committee reviews the valuation report with Oaktree, and Oaktree responds and supplements the valuation report to reflect any discussions between Oaktree and the Audit Committee.

Separately, independent valuation firms prepare valuations of the Company's investments, on a selected basis, for which market quotations are not readily available or are readily available but deemed not reflective of the fair value of the investment, and submit the reports to the Company and provide such reports to Oaktree.

Oaktree compares and contrasts its preliminary valuations to the valuations of the independent valuation firms and prepares a valuation report for the Audit Committee.

Oaktree, as valuation designee, determines the fair value of each investment in the Company's portfolio.

The fair value of the Company's investments as of June 30, 2024 and September 30, 2023 was determined by Oaktree, as the Company's valuation designee. The Company has and will continue to engage independent valuation firms to provide assistance regarding the determination of the fair value of a portion of its portfolio securities for which market quotations are not readily available or are readily available but deemed not reflective of the fair value of the investment each quarter.

Due to the inherent uncertainty of determining the fair value of investments that do not have a readily available market value, the fair value of the Company's investments may fluctuate from period to period. Because of the inherent uncertainty of valuation, these estimated values may differ significantly from the values that would have been reported had a ready market for the investments existed, and it is reasonably possible that the difference could be material.

With the exception of the line items entitled "deferred financing costs," "deferred offering costs," "other assets," "deferred tax liability," "credit facilities payable" and "unsecured notes payable," which are reported at amortized cost, all assets and liabilities approximate fair value on the Consolidated Statements of Assets and Liabilities. The carrying value of the line items titled "interest, dividends and fees receivable," "due from portfolio companies," "receivables from unsettled transactions," "due from broker," "accounts payable, accrued expenses and other liabilities," "base management fee and incentive fee payable," "due to affiliate," "interest payable" and "payables from unsettled transactions" approximate fair value due to their short maturities.

Foreign Currency Translation

The accounting records of the Company are maintained in U.S. dollars. All assets and liabilities denominated in foreign currencies are translated into U.S. dollars based on the prevailing foreign exchange rate on the reporting date. The Company does not isolate that portion of the results of operations resulting from changes in foreign exchange rates on investments from the fluctuations arising from changes in market prices of securities held. The Company's investments in foreign securities may involve certain risks, including foreign exchange restrictions, expropriation, taxation or other political, social or economic risks, all of which could affect the market and/or credit risk of the investment. In addition, changes in the relationship of foreign currencies to the U.S. dollar can significantly affect the value of these investments and therefore the earnings of the Company.

Derivative Instruments

Foreign Currency Forward Contracts

The Company uses foreign currency forward contracts to reduce the Company's exposure to fluctuations in the value of foreign currencies. In a foreign currency forward contract, the Company agrees to receive or deliver a fixed quantity of one currency for another at a pre-determined price at a future date. Foreign currency forward contracts are marked-to-market at the applicable forward rate. Unrealized appreciation (depreciation) on foreign currency forward contracts is recorded within derivative assets or derivative liabilities on the Consolidated Statements of Assets and Liabilities by counterparty on a net basis, not taking into account collateral posted which is recorded separately, if applicable. Purchases and settlements of foreign currency forward contracts having the same settlement date and counterparty are generally settled net and any realized gains or losses are recognized on the settlement date. The Company does not utilize hedge accounting with respect to foreign currency forward contracts and, as such, the Company recognizes its foreign currency forward contracts at fair value with changes included in the net unrealized appreciation (depreciation) on the Consolidated Statements of Operations.

Investment Income

Interest Income

The Company uses interest rate swaps to hedge some of the Company's fixed rate debt. The Company designated the interest rate swaps as the hedging instruments in an effective hedge accounting relationship, and therefore the periodic payments are recognized as components of interest expense in the Consolidated Statements of Operations. Depending on the nature of the balance at period end, the fair value of each interest rate swap is either included as a derivative asset or derivative liability on the Company's Consolidated Statements of Assets and Liabilities. The change in fair value of the interest rate swaps is offset by a change in the carrying value of the fixed rate debt. Any amounts paid to the counterparty to cover collateral obligations under the terms of the interest rate swap agreements are included in due from broker on the Company's Consolidated Statements of Assets and Liabilities.

Investment Income

PIK Interest Income

The Company's investments in debt securities may contain PIK interest provisions. PIK interest, which generally represents contractually deferred interest added to the loan balance that is generally due at the end of the loan term, is generally recorded on the accrual basis to the extent that such amounts are expected to be collected. The Company stops accruing interest on investments when it is determined that interest is no longer collectible. Investments that are expected to pay regularly scheduled interest in cash are generally placed on non-accrual status when there is reasonable doubt that principal or interest cash payments will be collected. Cash interest payments received on investments may be recognized as income or a return of capital depending upon management's judgment. A non-accrual investment is restored to accrual status if past due principal and interest are paid in cash and the portfolio company, in management's judgment, is likely to continue timely payment of its remaining obligations. As of June 30, 2024, there were eight investments on non-accrual status that in aggregate represented 5.7% and 3.7% of total debt investments at cost and fair value, respectively. As of September 30, 2023, there were four investments on non-accrual status that in aggregate represented 2.4% and 1.8% of total debt investments at cost and fair value, respectively.

Fee Income

Oaktree or its affiliates may provide financial advisory services to portfolio companies and, in return, the Company may receive fees for capital structuring services. These fees are generally non-recurring and are recognized by the Company upon the investment closing date. The Company may also receive additional fees in the ordinary course of business, including servicing, amendment, exit and prepayment fees, which are classified as fee income and recognized as they are earned or the services are rendered.

Dividend Income

The Company generally recognizes dividend income on the ex-dividend date for public securities and the record date for private equity investments. Distributions received from private equity investments are evaluated to determine if the distribution should be recorded as dividend income or a return of capital. Generally, the Company will not record distributions from private equity investments as dividend income unless there are sufficient earnings at the portfolio company prior to the distribution. Distributions that are classified as a return of capital are recorded as a reduction in the cost basis of the investment.

Cash and Cash Equivalents and Restricted Cash

Cash and cash equivalents consist of demand deposits and highly liquid investments with maturities of three months or less when acquired. The Company places its cash and cash equivalents and restricted cash with financial institutions and, at times, cash held in bank accounts exceeds the Federal Deposit Insurance Corporation ("FDIC") insurance limit. Cash and cash equivalents are included on the Company's Consolidated Schedule of Investments and cash equivalents are classified as Level 1 assets.

top:14pt;text-indent:11.25pt">Due from Portfolio Companies:</div><div style="margin-top:4pt;text-indent:22.5pt">Due from portfolio companies consists of amounts payable to the Company from its portfolio companies, including proceeds from the sale of portfolio companies not yet received or being held in escrow and excluding those amounts attributable to interest, dividends or fees receivable. These amounts are recognized as they become payable to the Companye.g., principal payments on the scheduled amortization payment date.</div><div style="margin-top:14pt;text-indent:11.25pt">Receivables/Payables from Unsettled Transactions:</div><div style="margin-top:4pt;text-indent:22.5pt">Receivables/payables from unsettled transactions consist of amounts receivable to or payable by the Company for transactions that have not settled at the reporting date.</div><div style="margin-top:14pt;text-indent:11.25pt">Deferred Financing Costs:</div><div style="margin-top:4pt;text-indent:22.5pt">Deferred financing costs consist of fees and expenses paid in connection with the closing or amending of credit facilities and debt offerings. Deferred financing costs in connection with credit facilities are capitalized as an asset when incurred. Deferred financing costs in connection with all other debt arrangements are a direct deduction from the related debt liability when incurred. Deferred financing costs are amortized using the effective interest method over the term of the respective debt arrangement. This amortization expense is included in interest expense in the Consolidated Statements of Operations. Upon early termination or modification of a credit facility, all or a portion of unamortized fees related to such facility may be accelerated into interest expense. For extinguishments of the Company's unsecured notes payable, any unamortized deferred financing costs are deducted from the carrying amount of the debt in determining the gain or loss from the extinguishment.</div><div style="margin-top:4pt;text-indent:9pt">Deferred Offering Costs:</div><div style="margin-top:4pt;text-indent:22.5pt">Legal fees and other costs incurred in connection with the Company's shelf registration statement are capitalized as deferred offering costs in the Consolidated Statements of Assets and Liabilities. To the extent any such costs relate to equity offerings, these costs are charged as a reduction of capital upon utilization. To the extent any such costs relate to debt offerings, these costs are treated as deferred financing costs and are amortized over the term of the respective debt arrangement. Any</div><div style="margin-top:4pt">deferred offering costs that remain at the expiration of the shelf registration statement or when it becomes probable that an offering will not be completed are expensed.</div><div style="margin-top:14pt;text-indent:11.25pt">Income Taxes:</div><div style="margin-top:4pt;text-indent:22.5pt">The Company has elected to be subject to tax as a RIC under Subchapter M of the Code and operates in a manner so as to qualify for the tax treatment applicable to RICs. In order to be subject to tax as a RIC, among other things, the Company is required to meet certain source of income and asset diversification requirements and timely distribute dividends to its stockholders of an amount generally at least equal to 90% of investment company taxable income, as defined by the Code and determined without regard to any deduction for dividends paid, for each taxable year. As a RIC, the Company is not subject to U.S. federal income tax on the portion of its taxable income and gains distributed currently to stockholders as a dividend. Depending on the level of taxable income earned during a taxable year, the Company may choose to retain taxable income in excess of current year dividend distributions and would distribute such taxable income in the next taxable year. The Company would then incur a 4% excise tax on such income, as required. To the extent that the Company determines that its estimated current year annual taxable income, determined on a calendar year basis, could exceed estimated current calendar year dividend distributions, the Company accrues excise tax, if any, on estimated excess taxable income as taxable income is earned. The Company anticipates timely distribution of its taxable income within the tax rules under Subchapter M of the Code. For calendar year 2022, the Company incurred \$0.1 million of excise tax. The Company did not incur any U.S. federal excise tax for calendar year 2023. The Company does not expect to incur a U.S. federal excise tax for calendar year 2024.</div><div style="margin-top:4pt;text-indent:22.5pt">The Company holds certain portfolio investments through taxable subsidiaries. The purpose of the Company's taxable subsidiaries is to permit the Company to hold equity investments in portfolio companies which are "pass through" entities for U.S. federal income tax purposes in order to comply with the RIC tax requirements. The taxable subsidiaries are consolidated for financial reporting purposes, and portfolio investments held by them are included in the Company's Consolidated Financial Statements as portfolio investments and recorded at fair value. The taxable subsidiaries are not consolidated with the Company for U.S. federal income tax purposes and may generate income tax expense, or benefit, and the related tax assets and liabilities, as a result of their ownership of certain portfolio investments. This income tax expense, if any, would be reflected in the Company's Consolidated Statements of Operations. The Company uses the liability method to account for its taxable subsidiaries' income taxes. Using this method, the Company recognizes deferred tax assets and liabilities for the estimated future tax effects attributable to temporary differences between financial reporting and tax bases of assets and liabilities. In addition, the Company recognizes deferred tax benefits associated with net operating loss carry forwards that it may use to offset future tax obligations. The Company measures deferred tax assets and liabilities using the enacted tax rates expected to apply to taxable income in the years in which it expects to recover or settle those temporary differences.</div><div style="margin-bottom:9pt;margin-top:10pt;text-indent:22.5pt">FASB ASC Topic 740,Accounting for Uncertainty in Income Taxes("ASC 740"), provides guidance for how uncertain tax positions should be recognized, measured, presented and disclosed in the Company's Consolidated Financial Statements. ASC 740 requires the evaluation of tax positions taken or expected to be taken in the course of preparing the Company's tax returns to determine whether the tax positions are "more-likely-than-not" of being sustained by the applicable tax authority. Tax positions not deemed to meet the more-likely-than-not threshold are recorded as a tax benefit or expense in the current year. Management's determinations regarding ASC 740 may be subject to review and adjustment at a later date based upon factors including an ongoing analysis of tax laws, regulations and interpretations thereof. The Company recognizes the tax benefits of uncertain tax positions only where the position is "more-likely-than-not" to be sustained assuming examination by tax authorities. Management has analyzed the Company's tax positions and has concluded that no liability for unrecognized tax benefits should be recorded related to uncertain tax positions taken on returns filed for open tax years 2021, 2022 and 2023. The Company identifies its major tax jurisdictions as U.S. Federal and California, and the Company is not aware of any tax positions for which it is reasonably possible that the total amounts of unrecognized tax benefits will change materially in the next 12 months.</div>1000000<div style="margin-top:14pt;text-indent:11.25pt">Recently Adopted Accounting Pronouncements</div><div style="margin-bottom:9pt;margin-top:10pt;text-indent:22.5pt">In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280), which improves reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. The amendments are effective for fiscal years beginning after December 15, 2023 and interim period within fiscal years beginning after December 15, 2024. The Company does not expect this guidance to materially impact its consolidated financial statements.</div>Portfolio Investments<div style="margin-top:9pt;text-indent:22.5pt">As of June 30, 2024, 208.7% of net assets at fair value, or \$3.1 billion, was invested in 158 portfolio companies, including (i) \$138.5 million in subordinated notes and limited liability company ("LLC") equity interests of Senior Loan Fund JV I, LLC ("SLF JV I"), a joint venture through which the Company and Trinity Universal Insurance Company, a subsidiary of Kemper Corporation ("Kemper"), co-invest in senior secured loans of middle-market companies and other corporate debt securities and (ii) \$49.9 million in subordinated notes and LLC equity interests of OCSI-Glick JV LLC ("Glick JV") and, together with SLF JV I, the "JVs"), a joint venture through which the Company and GF Equity Funding 2014 LLC ("GF Equity Funding") co-invest primarily in senior secured loans of middle-market companies. As of June 30, 2024, 7.2% of net assets at fair value, or \$0.73 billion, was invested in cash and cash equivalents (including \$11.0 million of restricted cash). In comparison, as of September 30, 2023, 190.8% of net assets at fair value, or \$2.9 billion, was invested in 143 portfolio investments, including (i) \$141.5 million in subordinated notes and LLC equity interests of SLF JV I and (ii) \$50.0 million in subordinated notes and LLC equity interests of Glick JV. As of September 30, 2023, 9.6% of net assets at fair value, or \$145.5 million, was invested in cash and cash equivalents (including \$9.1 million of restricted cash). As of June 30, 2024, 86.0% of the Company's portfolio at fair value consisted of senior secured debt investments and 9.0% consisted of subordinated debt investments, including the debt investments in the JVs. As of September 30, 2023, 86.5% of the Company's portfolio at fair value consisted of senior secured debt investments and 7.5% consisted of subordinated debt investments, including the debt investments in the JVs.</div><div style="margin-top:6pt;text-indent:24.75pt">The Company also held equity investments in certain of its portfolio companies consisting of common stock, preferred stock, warrants or LLC equity interests. These instruments generally do not produce a current return but are held for potential investment appreciation and capital gain.</div><div style="margin-top:8pt;text-indent:24.75pt">During the three and nine months ended June 30, 2024, the Company recorded net realized losses of \$69.5 million and \$84.5 million, respectively. During the three and nine months ended June 30, 2023, the Company recorded net realized losses of \$10.6 million and \$19.9 million, respectively. During the three and nine months ended June 30, 2024, the Company recorded net unrealized appreciation (depreciation) of \$26.2 million and \$(24.1) million, respectively. During the three and nine months ended June 30, 2023, the Company recorded net unrealized depreciation of \$1.0 million and \$42.3 million, respectively.</div><div style="margin-top:8pt;text-indent:24.75pt">The composition of the Company's investments as of June 30, 2024 and September 30, 2023 at cost and fair value was as follows:</div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:1.0%"></td><td style="

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

<td colspan=

[illegible]

[illegible]

[illegible]

debt was exchanged for Level 3 common equity, (2) \$4.7 million of Level 3 subordinated debt was exchanged for Level 3 senior secured debt, (3) \$1.2 million of Level 3 preferred equity was exchanged for Level 3 common equity and (4) \$0.3 million of Level 3 common stock was converted to Level 1 common stock.

The following table provides a roll-forward in the changes in fair value from September 30, 2022 to June 30, 2023 for all investments for which Oaktree determined fair value using unobservable (Level 3) factors:

	September 30, 2022	June 30, 2023
Investments	\$1,910,606	\$1,958
Equity	\$1,910,606	\$1,958
Fair value as of September 30, 2022	\$1,910,606	\$1,958
Subordinated Debt (including debt investments in the JVs)	\$1,910,606	\$1,958
Preferred	\$1,910,606	\$1,958
Equity	\$1,910,606	\$1,958
Fair value as of June 30, 2023	\$1,910,606	\$1,958

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

Diversified Financial Services

Aerospace & Defense

Fertilizers & Agricultural Chemicals

Environmental Facilities Services

Personal Care Products

Health Care Distributors

Metal Glass & Plastic Containers

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

```
<table><tr><td colspan=
```


[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

total assets of \$390.8 million and \$376.1 million, respectively. SLF JV I's portfolio primarily consisted of senior secured loans to 49 and 48 portfolio companies as of June 30, 2024 and September 30, 2023, respectively. The portfolio companies in SLF JV I are in industries similar to those in which the Company may invest directly. As of June 30, 2024, the Company's investment in SLF JV I consisted of LLC equity interests and SLF JV I Notes of \$138.5 million in aggregate, at fair value. As of September 30, 2023, the Company's investment in SLF JV I consisted of LLC equity interests and SLF JV I Notes of \$141.5 million in aggregate, at fair value.

As of each of June 30, 2024 and September 30, 2023, the Company and Kemper had funded approximately \$190.5 million to SLF JV I, of which \$166.7 million was from the Company. As of each of June 30, 2024 and September 30, 2023, the Company had aggregate commitments to fund SLF JV I of \$13.1 million, of which approximately \$9.8 million was to fund additional SLF JV I Notes and approximately \$3.3 million was to fund LLC equity interests in SLF JV I.

Below is a summary of SLF JV I's portfolio, followed by a listing of the individual loans in SLF JV I's portfolio as of June 30, 2024 and September 30, 2023:

	June 30, 2024	September 30, 2023
Number of borrowers	49	48
Largest exposure to a single borrower (1)	\$11.161	\$11.286
Total of five largest loan exposures to borrowers (1)	\$53.328	\$54.051
Weighted average interest rate on senior secured loans (2)	9.83%	9.83%
Number of borrowers in SLF JV I	49	48
Largest exposure to a single borrower (1)	\$11.161	\$11.286
Total of five largest loan exposures to borrowers (1)	\$53.328	\$54.051

Portfolio Company

	June 30, 2024	September 30, 2023
Industry	PIK	PIK
Spread		
Maturity Date		
Shares		
Principal		
Cost		
Fair Value		
Access CIG, LLC		
Diversified Support Services		
First Lien Term Loan		
SOFRI		
First Lien Term Loan		
SOFRI		

[illegible]

[illegible]

[illegible]

Wireless Telecommunication Services

First Lien Term Loan

SOFRA

Centerline Communications, LLC

Wireless Telecommunication Services

First Lien Revolver

Cloud Software Group, Inc.

Covertrus, Inc.

Health Care Distributors

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

height:100%">249

Total expenses (1)

>8,165

Net investment income

<(319)>

(4,372)

<(3,784)>

(4,343)

SF JV I Notes issued to the Company and Kemper under FASB ASC Topic 825,

Financial Instruments - Fair Value Option

OCSI Glick JV LLC

On March 19, 2021, the Company became party to the LLC agreement of Glick JV.

The Company co-invests primarily in senior secured loans of middle-market companies with GF Equity Funding through the Glick JV. The Glick JV is managed by a four person Board of Directors, two of whom are selected by the Company and two of whom are selected by GF Equity Funding. The Glick JV is capitalized as transactions are completed, and portfolio decisions and investment decisions in respect of the Glick JV must be approved by the Glick JV investment committee, which consists of one representative selected by the Company and one representative selected by GF Equity Funding (with approval from a representative of each required). Since the Company does not have a controlling financial interest in the Glick JV, the Company does not consolidate the Glick JV.

The members provide capital to the Glick JV in exchange for LLC equity interests, and the Company and GF Debt Fundng 2014 LLC ("GF Debt Fundng"), an entity advised by affiliates of GF Equity Funding, provide capital to the Glick JV in exchange for subordinated notes issued by the Glick JV (the "Glick JV Notes"). As of June 30, 2024 and September 30, 2023, the Company and GF Equity Funding owned 87.5% and 12.5%, respectively, of the outstanding LLC equity interests, and the Company and GF Debt Fundng owned 87.5% and 12.5%, respectively, of the Glick JV Notes. The Glick JV is not an "eligible portfolio company" as defined in section 2(a)(46) of the Investment Company Act.

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

Interest Rate:

(1) Represents the interest rate as of September 30, 2023. All interest rates are payable in cash, unless otherwise noted.

(2) The interest rate on the principal balance outstanding for all of the floating rate loans is indexed to SOFR, which typically resets semi-annually, quarterly, or monthly at the borrower's option. The borrower may also elect to have multiple interest reset periods for each loan. For each of these loans, the Company has provided the applicable margin over the reference rates based on each respective credit agreement and the cash interest rate as of period end. As of September 30, 2023, the reference rates for the Glick JV's variable rate loans were the 30-day SOFR at 5.32% and the 90-day SOFR at 5.39%. Most loans include an interest floor, which generally ranges from 0% to 1%. SOFR-based contracts may include a credit spread adjustment that is charged in addition to the base rate and the stated spread.

(3) Represents the current determination of fair value as of September 30, 2023 utilizing a similar technique as the Company in accordance with ASC 820. However, the determination of such fair value is not included in the valuation process described elsewhere herein.

(4) This investment was held by both the Company and the Glick JV as of September 30, 2023.

(5) Investment had undrawn commitments. Unamortized fees are classified as unearned income which reduces cost basis, which may result in a negative cost basis. A negative fair value may result from the unfunded commitment being valued below par.

The cost and fair value of the Company's aggregate investment in the Glick JV was \$51.3 million and \$49.9 million, respectively, as of June 30, 2024. The cost and fair value of the Company's aggregate investment in the Glick JV was \$50.3 million and \$50.0 million, respectively, as of September 30, 2023. For the three and nine months ended June 30, 2024, the Company's investment in the Glick JV Notes earned interest income of \$1.8 million and \$5.4 million, respectively. For the three and nine months ended June 30, 2023, the Company's investment in the Glick JV Notes earned interest income of \$1.8 million and \$5.0 million, respectively. The Company did not earn dividend income for the three and nine months ended June 30, 2024 and 2023 with respect to its investment in the LLC equity interest of the Glick JV. As of June 30, 2024, the Glick JV Notes bore interest at a rate of one-month SOFR plus 4.50% per annum and will mature on October 20, 2029.

Below is certain summarized financial information for the Glick JV as of June 30, 2024 and September 30, 2023 and for the three and nine months ended June 30, 2024 and 2023:

	June 30, 2024	September 30, 2023
Total assets	\$12,119	\$13,343
Cash and cash equivalents	\$13,109	\$13,109
Restricted cash	\$13,109	\$13,109
Other assets	\$13,343	\$13,343
Total liabilities	\$4,655	\$4,655
Accounts payable	\$14	\$14
Accounts receivable	\$5,521	\$5,521
Prepaid expenses	\$146	\$146
Accrued expenses	\$146	\$146
Deferred revenue	\$146	\$146
Long-term debt	\$146	\$146
Senior credit facility payable	\$146	\$146
Total liabilities	\$4,655	\$4,655
Total assets less total liabilities	\$7,464	\$8,688

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

```
serif;font-size:7pt;font-weight:400;line-height:100%></td><td colspan=
```

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

```


| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |


```

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]


```
<div><table><tr><td style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman';sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;>7,517</span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:center;right;vertical-align:bottom"></td><td colspan=
```

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

400;line-height:100%;>First Lien Term Loan

SOFRA

Cable & Satellite

BFI Holdco, Inc.

Research & Consulting Services

Gibson Brands, Inc.

Leisure Products

Indivior Finance S.A.R.L.

Pharmaceuticals

INW Manufacturing, LLC

[illegible]

[illegible]

[illegible]

[illegible]

<table><tr><td colspan=

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

```
<div><table border=
```


[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412

413

414

415

416

417

418

419

420

421

422

423

424

425

426

427

428

429

430

431

432

433

434

435

436

437

438

439

440

441

442

443

444

445

446

447

448

449

450

451

452

453

454

455

456

457

458

459

460

461

462

463

464

465

466

467

468

469

470

471

472

473

474

475

476

477

478

479

480

481

482

483

484

485

486

487

488

489

490

491

492

493

494

495

496

497

498

499

500

501

502

503

504

505

506

507

508

509

510

511

512

513

514

515

516

517

518

519

520

521

522

523

524

525

526

527

528

529

530

531

532

533

534

535

536

537

538

539

540

541

542

543

544

545

546

547

548

549

550

551

552

553

554

555

556

557

558

559

560

561

562

563

564

565

566

567

568

569

570

571

572

573

574

575

576

577

578

579

580

581

582

583

584

585

586

587

588

589

590

591

592

593

594

595

596

597

598

599

600

601

602

603

604

605

606

607

608

609

610

611

612

613

614

615

616

617

618

619

620

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

size:10pt;font-style:italic;font-weight:400;line-height:120%"> Syndicated Facility</div><div>
</div><div style="text-indent:2.5pt">On November 30, 2017, the Company entered into a senior secured revolving credit facility (as amended and restated, the "Syndicated Facility") pursuant to a Senior Secured Revolving Credit Agreement with the lenders party thereto, ING Capital LLC, as administrative agent, ING Capital LLC, JPMorgan Chase Bank, N.A., BofA Securities, Inc., and MUFG Union Bank, </div><div>N.A., as joint lead arrangers and joint bookrunners, and JPMorgan Chase Bank, N.A. and Bank of America, N.A., as syndication agents. The Syndicated Facility provides that the Company may use the proceeds of the loans and issuances of letters of credit under the Syndicated Facility for general corporate purposes, including acquiring and funding leveraged loans, mezzanine loans, high-yield securities, convertible securities, preferred stock, common stock and other investments. The Syndicated Facility further allows the Company to request letters of credit from ING Capital LLC, as the issuing bank. </div><div style="text-indent:2.5pt">
</div><div style="text-indent:2.5pt">As of June 30, 2024, the size of the Syndicated Facility was \$1.218 billion. In addition, pursuant to an "accordion" feature, the Company may increase the size of the facility to up to the greater of \$1.25 billion and the Company's net worth, as defined in the facility, under certain circumstances. </div><div style="text-indent:2.5pt">
</div><div style="text-indent:2.5pt">As of June 30, 2024, (i) the period during which the Company may make drawings with respect to \$1.035 billion of commitments will expire on June 23, 2027 and the maturity date is June 23, 2028, (ii) the period during which the Company may make drawings with respect to the remaining commitments will expire on May 4, 2025 and the maturity date is May 4, 2026 and (iii) the interest rate margin for (a) SOFR loans (which may be 1- or 3-month, at the Company's option) was 2.00% plus a SOFR adjustment which ranges between 0.11448% and 0.26161% and (b) alternate base rate loans was 1.00%. </div><div style="text-indent:2.5pt">
</div><div style="text-indent:2.5pt">The Syndicated Facility is secured by substantially all of the Company's assets (excluding, among other things, investments held in and by certain subsidiaries of the Company (including OSI-2 Senior Lending SPV, LLC, or "OSI-2 SPV") or investments in certain portfolio companies of the Company) and guaranteed by certain subsidiaries of the Company. </div><div style="text-indent:2.5pt">
</div><div style="text-indent:2.5pt">The Syndicated Facility requires the Company to, among other things, (i) make representations and warranties regarding the collateral as well as each of the Company's portfolio companies' businesses, (ii) agree to certain indemnification obligations, and (iii) comply with various affirmative and negative covenants, reporting requirements and other customary requirements for similar revolving credit facilities, including covenants related to: (A) limitations on the incurrence of additional indebtedness and liens, (B) limitations on certain investments, (C) limitations on certain asset transfers and restricted payments, (D) maintaining a certain minimum stockholders' equity, (E) maintaining a ratio of total assets (less total liabilities) to total indebtedness, of the Company and its subsidiaries (subject to certain exceptions), of not less than 1.50 to 1.00, (F) maintaining a ratio of consolidated EBITDA to consolidated interest expense, of the Company and its subsidiaries (subject to certain exceptions), of not less than 2.25 to 1.00, (G) maintaining a minimum liquidity and net worth, and (H) limitations on the creation or existence of agreements that prohibit liens on certain properties of the Company and certain of its subsidiaries. The Syndicated Facility also includes usual and customary default provisions such as the failure to make timely payments under the facility, the occurrence of a change in control, and the failure by the Company to materially perform under the agreements governing the facility, which, if not complied with, could accelerate repayment under the facility. As of June 30, 2024, the Company was in compliance with all financial covenants under the Syndicated Facility. In addition to the asset coverage ratio described above, borrowings under the Syndicated Facility (and the incurrence of certain other permitted debt) are subject to compliance with a borrowing base that will apply different advance rates to different types of assets in the Company's portfolio. Each loan or letter of credit originated or assumed under the Syndicated Facility is subject to the satisfaction of certain conditions. </div><div style="text-indent:2.5pt">
</div><div style="text-indent:2.5pt">As of June 30, 2024 and September 30, 2023, the Company had \$505.0 million and \$430.0 million of borrowings outstanding under the Syndicated Facility, which had a fair value of \$505.0 million and \$430.0 million, respectively. The Company's borrowings under the Syndicated Facility bore interest at a weighted average interest rate of 7.576% and 6.584% for the nine months ended June 30, 2024 and 2023, respectively. For the three and nine months ended June 30, 2024, the Company recorded interest expense (inclusive of fees) of \$10.2 million and \$29.3 million, respectively, related to the Syndicated Facility. For the three and nine months ended June 30, 2023, the Company recorded interest expense (inclusive of fees) of \$14.3 million and \$37.4 million, respectively, related to the Syndicated Facility. </div><div style="margin-top:9pt">Citibank Facility </div><div style="margin-top:6pt;text-indent:24.75pt">On March 19, 2021, the Company became party to a revolving credit facility (as amended and/or restated from time to time, the "Citibank Facility") with OCIS Senior Funding LLC, the Company's wholly-owned, special purpose financing subsidiary, as the borrower, the Company, as collateral manager and seller, each of the lenders from time to time party thereto, Citibank, N.A., as administrative agent, and Wells Fargo Bank, National Association, as collateral agent and custodian. On May 25, 2023, in connection with an amendment to the OSI2 Citibank Facility, the Citibank Facility was terminated. </div><div style="margin-top:6pt;text-indent:24.75pt">As of June 30, 2024 and September 30, 2023, the Company did not have any borrowings outstanding under the Citibank Facility. The Company's borrowings under the Citibank Facility bore interest at a weighted average interest rate of 6.762% for the nine months ended June 30, 2023. For the three and nine months ended June 30, 2023, the Company recorded interest expense (inclusive of fees) of \$2.4 million and \$8.0 million, respectively, related to the Citibank Facility. </div><div style="margin-top:9pt">OSI2 Citibank Facility </div><div style="margin-top:6pt;text-indent:24.75pt">On January 23, 2023, as a result of the consummation of the OSI2 Merger, the Company became party to a revolving credit facility (as amended and/or restated from time to time, the "OSI2 Citibank Facility") with OSI 2 SPV, the Company's wholly-owned and consolidated subsidiary, as the borrower, the Company, as collateral manager, each of the lenders from time to time party thereto, Citibank, N.A., as administrative agent, and Deutsche Bank Trust Company Americas, as collateral agent. </div><div style="margin-top:6pt;text-indent:24.75pt">As of June 30, 2024, the Company was able to borrow up to \$400 million under the OSI2 Citibank Facility (subject to borrowing base and other limitations). As of June 30, 2024, the OSI2 Citibank Facility had a reinvestment period through May 25, 2027, during which advances may be made, and matures on January 26, 2029. Following the reinvestment period, OSI 2 SPV will be required to make certain mandatory amortization payments. Borrowings under the OSI2 Citibank Facility bear interest payable quarterly at a rate per year equal to SOFR plus 2.35% per annum. After the reinvestment period, the applicable spread is 3.35% per year. There is also a non-usage fee of 0.30% per year on the unused portion of the OSI2 Citibank Facility, payable quarterly; provided that if the unused portion of the OSI2 Citibank Facility is greater than 30% of the commitments under the OSI2 Citibank Facility, the non-usage fee will be based on an unused portion of 30% of the commitments under the OSI2 Citibank Facility. The OSI2 Citibank Facility is secured by a first priority security interest in substantially all of OSI 2 SPV's assets. As part of the OSI2 Citibank Facility, OSI 2 SPV is subject to certain limitations as to how borrowed funds may be used and the types of loans that are eligible to be acquired by OSI 2 SPV including restrictions on sector concentrations, loan size, tenor and minimum investment ratings (or estimated ratings). The OSI2 Citibank Facility also contains certain requirements relating to interest coverage, collateral quality and portfolio performance, certain violations of which could result in the acceleration of the amounts due under the OSI2 Citibank Facility. </div><div style="margin-top:6pt;text-indent:24.75pt">As of June 30, 2024 and September 30, 2023, the Company had \$285.0 million and \$280.0 million outstanding under the OSI2 Citibank Facility, which had a fair value of \$285.0 million and \$280.0 million, respectively. The Company's borrowings under the OSI2 Citibank Facility bore interest at a weighted average interest rate of 8.029% and 7.275% for the nine months ended June 30, 2024 and the period from January 23, 2023 to June 30, 2023, respectively. For the three and nine months ended June 30, 2024, the Company recorded interest expense (inclusive of fees) of \$6.1 million and \$18.1 million, respectively, related to the OSI2 Citibank Facility. For the three months ended June 30, 2023 and the period from January 23, 2023 to June 30, 2023, the Company recorded interest expense (inclusive of fees) of \$4.9 million and \$8.0 million, respectively, related to the OSI2 Citibank Facility. </div><div style="margin-top:10pt">2025 Notes</div><div style="margin-top:10pt;text-indent:22.5pt">On February 25, 2020, the Company issued \$300.0 million in aggregate principal amount of the 2025 Notes for net proceeds of \$293.0 million after deducting OID of \$2.5 million, underwriting commissions and discounts of \$3.0 million and offering costs of \$0.7 million. The OID on the 2025 Notes is amortized based on the effective interest method over the term of the 2025 Notes. </div><div style="margin-top:10pt;text-indent:22.5pt">The 2025 Notes were issued pursuant to an indenture, dated April 30, 2012, as supplemented by the fifth supplemental indenture, dated February 25, 2020 (collectively, the "2025 Notes Indenture"), between the Company and Deutsche Bank Trust Company Americas (the "Trustee"). The 2025 Notes are the Company's general unsecured obligations that rank senior in right of payment to all of the Company's existing and future indebtedness that is expressly subordinated in right of payment to the 2025 Notes. The 2025 Notes rank equally in right of payment with all of the Company's existing and future liabilities that are not so subordinated. The 2025 Notes effectively rank junior to any of the Company's secured indebtedness (including unsecured indebtedness that the Company later secures) to the extent of the value of the assets securing such indebtedness. The 2025 Notes rank structurally junior to all existing and future indebtedness (including trade payables) incurred by the Company's subsidiaries, financing vehicles or similar facilities. </div><div style="margin-top:10pt;text-indent:22.5pt">Interest on the 2025 Notes is paid semi-annually on February 25 and August 25 at a rate of 3.500% per annum. The 2025 Notes mature on February 25, 2025 and may be redeemed in whole or in part at any time or from time to time at the Company's option prior to maturity at par plus a "make-whole" premium, if applicable. In addition, holders of the 2025 Notes can require the Company to repurchase the 2025 Notes at 100% of their principal amount upon the occurrence of certain change of control events as described in the 2025 Notes Indenture. The 2025 Notes were issued in minimum denominations of \$2,000 and integral multiples of \$1,000 in excess thereof. During the three and nine months ended June 30, 2024, the Company did not repurchase any of the 2025 Notes in the open market. </div><div style="margin-top:10pt;text-indent:22.5pt">The 2025 Notes Indenture contains certain covenants, including covenants requiring the Company's compliance with the asset coverage requirements set forth in Section 18(a)(1)(A) as modified by Section 61(a)(1) and (2) of the Investment Company Act or any successor provisions (but giving effect to any exemptive relief granted to the Company by the U.S. Securities and Exchange Commission ("SEC")), as well as covenants requiring the Company to provide financial information to the holders of the 2025 Notes and the Trustee if the Company ceases to be subject to the reporting requirements of the </div><div style="margin-top:10pt">Securities Exchange Act of 1934, as amended (the "Exchange Act"). These covenants are subject to limitations and exceptions that are described in the 2025 Notes Indenture. </div><div style="margin-top:10pt">2027 Notes</div><div style="margin-top:10pt;text-indent:22.5pt">On May 18, 2021, the Company issued \$350.0 million in aggregate principal amount of the 2027 Notes for net proceeds of \$344.8 million after deducting OID of \$1.0 million, underwriting commissions and discounts of \$3.5 million and offering costs of \$0.7 million. The OID on the 2027 Notes is amortized based on the effective interest method over the term of the 2027 Notes. </div><div style="margin-top:10pt;text-indent:22.5pt">The 2027 Notes were issued pursuant to an indenture, dated April 30, 2012, as supplemented by the sixth supplemental indenture, dated May 18, 2021 (collectively, the "2027 Notes Indenture"), between the Company and the Trustee. The 2027 Notes are the Company's general unsecured obligations that rank senior in right of payment to all of the Company's existing and future indebtedness that is expressly subordinated in right of payment to the 2027 Notes. The 2027 Notes rank equally in right of payment with all of the Company's existing and future liabilities that are not so subordinated. The 2027 Notes effectively rank junior to any of the Company's secured indebtedness (including unsecured indebtedness that the Company later secures) to the extent of the value of the assets securing such indebtedness. The 2027 Notes rank structurally junior to all existing and future indebtedness (including trade payables) incurred by the Company's subsidiaries, financing vehicles or similar facilities. </div><div style="margin-top:10pt;text-indent:22.5pt">Interest on the 2027 Notes is paid semi-annually on January 15 and July 15 at a rate of 2.700% per annum. The 2027 Notes mature on January 15, 2027 and may be redeemed in whole or in part at any time or from time to time at the Company's option prior to maturity at par plus a "make-whole" premium, if applicable. In addition, holders of the 2027 Notes can require the Company to repurchase the 2027 Notes at 100% of their principal amount upon the

occurrence of certain change of control events as described in the 2027 Notes Indenture. The 2027 Notes were issued in minimum denominations of \$2,000 and integral multiples of \$1,000 in excess thereof. During the three and nine months ended June 30, 2024, the Company did not repurchase any of the 2027 Notes in the open market.

The 2027 Notes Indenture contains certain covenants, including covenants requiring the Company's compliance with the asset coverage requirements set forth in Section 18(a)(1)(A) as modified by Section 61(a)(1) and (2) of the Investment Company Act or any successor provisions (but giving effect to any exemptive relief granted to the Company by the SEC), as well as covenants requiring the Company to provide financial information to the holders of the 2027 Notes and the Trustee if the Company ceases to be subject to the reporting requirements of the Exchange Act. These covenants are subject to limitations and exceptions that are described in the 2027 Notes Indenture.

In connection with the 2027 Notes, the Company entered into an interest rate swap to more closely align the interest rates of its liabilities with its investment portfolio, which consists of predominately floating rate loans. Under the interest rate swap agreement, the Company receives a fixed interest rate of 2.700% and pays a floating interest rate of the three-month SOFR plus 1.658% plus a SOFR adjustment of 0.26161% on a notional amount of \$350.0 million. The Company designated the interest rate swap as the hedging instrument in an effective hedge accounting relationship. See Note 12 for more information regarding the interest rate swap.

The 2029 Notes mature on February 15, 2029 and may be redeemed in whole or in part at any time or from time to time at the Company's option prior to maturity at par plus a "make-whole" premium, if applicable, as follows:

Maturity Date	Interest Rate
February 15, 2029	SOFR + 1.658%
August 15, 2029	SOFR + 1.658% + 0.26161%

The Company designated the interest rate swap as the hedging instrument in an effective hedge accounting relationship. See Note 12 for more information regarding the interest rate swap.

The below table presents the components of the carrying value of the 2025 Notes, the 2027 Notes and the 2029 Notes as of June 30, 2024 and September 30, 2023:

Note Maturity	As of June 30, 2024	As of September 30, 2023
2025 Notes	\$350.0 million	\$350.0 million
2027 Notes	\$350.0 million	\$350.0 million
2029 Notes	\$350.0 million	\$350.0 million

Unamortized financing costs

Note Maturity	As of June 30, 2024	As of September 30, 2023
2025 Notes	\$350.0 million	\$350.0 million
2027 Notes	\$350.0 million	\$350.0 million
2029 Notes	\$350.0 million	\$350.0 million

[illegible]

[illegible]

[illegible]

[illegible]

underwriting commissions and discounts of \$3.5 million and offering costs of \$0.7 million. The OID on the 2027 Notes is amortized based on the effective interest method over the term of the 2027 Notes.

The 2027 Notes were issued pursuant to an indenture, dated April 30, 2012, as supplemented by the sixth supplemental indenture, dated May 18, 2021 (collectively, the "2027 Notes Indenture"), between the Company and the Trustee. The 2027 Notes are the Company's general unsecured obligations that rank senior in right of payment to all of the Company's existing and future indebtedness that is expressly subordinated in right of payment to the 2027 Notes. The 2027 Notes rank equally in right of payment with all of the Company's existing and future liabilities that are not so subordinated. The 2027 Notes effectively rank junior to any of the Company's secured indebtedness (including unsecured indebtedness that the Company later secures) to the extent of the value of the assets securing such indebtedness. The 2027 Notes rank structurally junior to all existing and future indebtedness (including trade payables) incurred by the Company's subsidiaries, financing vehicles or similar facilities.

Interest on the 2027 Notes is paid semi-annually on January 15 and July 15 at a rate of 2.700% per annum. The 2027 Notes mature on January 15, 2027 and may be redeemed in whole or in part at any time or from time to time at the Company's option prior to maturity at par plus a "make-whole" premium, if applicable. In addition, holders of the 2027 Notes can require the Company to repurchase the 2027 Notes at 100% of their principal amount upon the occurrence of certain change of control events as described in the 2027 Notes Indenture. The 2027 Notes were issued in minimum denominations of \$2,000 and integral multiples of \$1,000 in excess thereof. During the three and nine months ended June 30, 2024, the Company did not repurchase any of the 2027 Notes in the open market.

The 2027 Notes Indenture contains certain covenants, including covenants requiring the Company's compliance with the asset coverage requirements set forth in Section 18(a)(1)(A) as modified by Section 61(a)(1) and (2) of the Investment Company Act or any successor provisions (but giving effect to any exemptive relief granted to the Company by the SEC), as well as covenants requiring the Company to provide financial information to the holders of the 2027 Notes and the Trustee if the Company ceases to be subject to the reporting requirements of the Exchange Act. These covenants are subject to limitations and exceptions that are described in the 2027 Notes Indenture.

In connection with the 2027 Notes, the Company entered into an interest rate swap to more closely align the interest rates of its liabilities with its investment portfolio, which consists of predominately floating rate loans. Under the interest rate swap agreement, the Company receives a fixed interest rate of 2.700% and pays a floating interest rate of the three-month SOFR plus 1.658% plus a SOFR adjustment of 0.26161% on a notional amount of \$350.0 million. The Company designated the interest rate swap as the hedging instrument in an effective hedge accounting relationship. See Note 12 for more information regarding the interest rate swap.

2029 Notes

The 2029 Notes were issued pursuant to an indenture, dated April 30, 2012, as supplemented by the seventh supplemental indenture, dated August 15, 2023 (collectively, the "2029 Notes Indenture"), between the Company and the Trustee. The 2029 Notes are the Company's general unsecured obligations that rank senior in right of payment to all of the Company's existing and future indebtedness that is expressly subordinated in right of payment to the 2029 Notes. The 2029 Notes rank equally in right of payment with all of the Company's existing and future liabilities that are not so subordinated. The 2029 Notes effectively rank junior to any of the Company's secured indebtedness (including unsecured indebtedness that the Company later secures) to the extent of the value of the assets securing such indebtedness. The 2029 Notes rank structurally junior to all existing and future indebtedness (including trade payables) incurred by the Company's subsidiaries, financing vehicles or similar facilities.

Interest on the 2029 Notes is paid semi-annually on February 15 and August 15 at a rate of 7.100% per annum. The 2029 Notes mature on February 15, 2029 and may be redeemed in whole or in part at any time or from time to time at the Company's option prior to maturity at par plus a "make-whole" premium, if applicable. In addition, holders of the 2029 Notes can require the Company to repurchase the 2029 Notes at 100% of their principal amount upon the occurrence of certain change of control events as described in the 2029 Notes Indenture. The 2029 Notes were issued in minimum denominations of \$2,000 and integral multiples of \$1,000 in excess thereof. During the three and nine months ended June 30, 2024, the Company did not repurchase any of the 2029 Notes in the open market.

The 2029 Notes Indenture contains certain covenants, including covenants requiring the Company's compliance with the asset coverage requirements set forth in Section 18(a)(1)(A) as modified by Section 61(a)(1) and (2) of the Investment Company Act or any successor provisions (but giving effect to any exemptive relief granted to the Company by the SEC), as well as covenants requiring the Company to provide financial information to the holders of the 2029 Notes and the Trustee if the Company ceases to be subject to the reporting requirements of the Exchange Act. These covenants are subject to limitations and exceptions that are described in the 2029 Notes Indenture.

In connection with the 2029 Notes, the Company entered into an interest rate swap to more closely align the interest rates of its liabilities with its investment portfolio, which consists of predominately floating rate loans. Under the interest rate swap agreement, the Company receives a fixed interest rate of 7.100% and pays a floating interest rate of the three-month SOFR plus 3.1255% on a notional amount of \$300.0 million. The Company designated the interest rate swap as the hedging instrument in an effective hedge accounting relationship. See Note 12 for more information regarding the interest rate swap.

On November 30, 2017, the Company entered into a senior secured revolving credit facility (as amended and restated, the "Syndicated Facility") pursuant to a Senior Secured Revolving Credit Agreement with the lenders party thereto, ING Capital LLC, as administrative agent, ING Capital LLC, JPMorgan Chase Bank, N.A., BofA Securities, Inc., and MUFG Union Bank, N.A., as joint lead arrangers and joint bookrunners, and JPMorgan Chase Bank, N.A. and Bank of America, N.A., as syndication agents. The Syndicated Facility provides that the Company may use the proceeds of the loans and issuances of letters of credit under the Syndicated Facility for general corporate purposes, including acquiring and funding leveraged loans, mezzanine loans, high-yield securities, convertible securities, preferred stock, common stock and other investments. The Syndicated Facility further allows the Company to request letters of credit from ING Capital LLC, as the issuing bank.

As of June 30, 2024, the size of the Syndicated Facility was \$1.218 billion. In addition, pursuant to an "accordion" feature, the Company may increase the size of the facility to up to the greater of \$1.25 billion and the Company's net worth, as defined in the facility, under certain circumstances.

As of June 30, 2024, (i) the period during which the Company may make drawings with respect to \$1.035 billion of commitments will expire on June 23, 2027 and the maturity date is June 23, 2028, (ii) the period during which the Company may make drawings with respect to the remaining commitments will expire on May 4, 2025 and the maturity date is May 4, 2026 and (iii) the interest rate margin for (a) SOFR loans (which may be 1- or 3-month, at the Company's option) was 2.00% plus a SOFR adjustment which ranges between 0.11448% and 0.26161% and (b) alternate base rate loans was 1.00%.

The Syndicated Facility is secured by substantially all of the Company's assets (excluding, among other things, investments held in and by certain subsidiaries of the Company (including OSI 2 Senior Lending SPV, LLC, or "OSI 2 SPV") or investments in certain portfolio companies of the Company) and guaranteed by certain subsidiaries of the Company. Syndicated Facility 121800000012500000001035000000.0000.02000.00114480.00261610.0100. The Syndicated Facility requires the Company to, among other things, (i) make representations and warranties regarding the collateral as well as each of the Company's portfolio companies' businesses, (ii) agree to certain indemnification obligations, and (iii) comply with various affirmative and negative covenants, reporting requirements and other customary requirements for similar revolving credit facilities, including covenants related to: (A) limitations on the incurrence of additional indebtedness and liens, (B) limitations on certain investments, (C) limitations on certain asset transfers and restricted payments, (D) maintaining a certain minimum stockholders' equity, (E) maintaining a ratio of total assets (less total liabilities) to total indebtedness, of the Company and its subsidiaries (subject to certain exceptions), of not less than 1.50 to 1.00, (F) maintaining a ratio of consolidated EBITDA to consolidated interest expense, of the Company and its subsidiaries (subject to certain exceptions), of not less than 2.25 to 1.00, (G) maintaining a minimum liquidity and net worth, and (H) limitations on the creation or existence of agreements that prohibit liens on certain properties of the Company and certain of its subsidiaries. The Syndicated Facility also includes usual and customary default provisions such as the failure to make timely payments under the facility, the occurrence of a change in control, and the failure by the Company to materially perform under the agreements governing the facility, which, if not complied with, could accelerate repayment under the facility. As of June 30, 2024, the Company was in compliance with all financial covenants under the Syndicated Facility. In addition to the asset coverage ratio described above, borrowings under the Syndicated Facility (and the incurrence of certain other permitted debt) are subject to compliance with a borrowing base that will apply different advance rates to different types of assets in the Company's portfolio. Each loan or letter of credit originated or assumed under the Syndicated Facility is subject to the satisfaction of certain conditions: 1.502.25505000000.04300000000505000000.04300000000.075760.06584102000002930000014300000374000000. On March 19, 2021, the Company became party to a revolving credit facility (as amended and/or restated from time to time, the "Citibank Facility") with OCSE Senior Funding II LLC, the Company's wholly-owned, special purpose financing subsidiary, as the borrower, the Company, as collateral manager and seller, each of the lenders from time to time party thereto, Citibank, N.A., as administrative agent, and Wells Fargo Bank, National Association, as collateral agent and custodian. On May 25, 2023, in connection with an amendment to the OSI2 Citibank Facility, the Citibank Facility was terminated. Citibank Facility 0.06762240000000000000.

On January 23, 2023, as a result of the consummation of the OSI2 Merger, the Company became party to a revolving credit facility (as amended and/or restated from time to time, the "OSI2 Citibank Facility") with OSI 2 SPV, the Company's wholly-owned and consolidated subsidiary, as the borrower, the Company, as collateral manager, each of the lenders from time to time party thereto, Citibank, N.A., as administrative agent, and Deutsche Bank Trust Company Americas, as collateral agent.

As of June 30, 2024, the Company was able to borrow up to \$400 million under the OSI2 Citibank Facility (subject to borrowing base and other limitations). OSI2 Citibank Facility 4000000000. As of June 30, 2024, the OSI2 Citibank Facility had a reinvestment period through May 25, 2027, during which advances may be made, and matures on January 26, 2029. Following the reinvestment period, OSI 2 SPV will be required to make certain mandatory amortization payments. Borrowings under the OSI2 Citibank Facility bear interest payable quarterly at a rate per year equal to SOFR plus 2.35% per annum. After the reinvestment period, the applicable spread is 3.35% per year. There is also a non-usage fee of 0.50% per year on the unused portion of the OSI2 Citibank Facility, payable quarterly; provided that if the unused portion of the OSI2 Citibank Facility is greater than 30% of the commitments under the OSI2 Citibank Facility, the non-usage fee will be based on an unused portion of 30% of the commitments under the OSI2 Citibank Facility. The OSI2 Citibank Facility is secured by a first priority security interest in substantially all of OSI 2 SPV's assets. As part of the OSI2 Citibank Facility, OSI 2 SPV is subject to certain limitations as to how borrowed funds may be used and the types of loans that are eligible to be acquired by OSI 2 SPV including restrictions on sector concentrations, loan size, tenor and minimum investment ratings (or estimated ratings). The OSI2 Citibank Facility also contains certain requirements relating to interest coverage, collateral quality and portfolio performance, certain violations of which could result in the acceleration of the amounts due under the OSI2 Citibank Facility. 0.02350.03350.00500.300.302850000000.028000000002850000000.02800000000.080290.0727561000001810000049000008000000.

On February 25, 2020, the Company issued \$300.0 million in aggregate principal amount of the 2025 Notes for net proceeds of \$293.8 million after deducting OID of \$2.5 million, underwriting commissions and discounts of \$3.0 million and offering costs of \$0.7 million. The OID on the 2025 Notes is amortized based on the effective interest method over the term of the 2025 Notes.

The 2025 Notes were issued pursuant to an indenture, dated April 30, 2012, as supplemented by the fifth supplemental indenture, dated February 25, 2020 (collectively, the "2025 Notes Indenture"), between the Company and Deutsche Bank Trust Company Americas (the "Trustee"). The 2025 Notes are the Company's general unsecured obligations that rank senior in right of payment to all of the Company's existing and future indebtedness that is expressly subordinated in right of payment to the 2025 Notes. The 2025 Notes rank equally in right of payment with all of the Company's existing and future liabilities that are not so subordinated. The 2025 Notes effectively rank junior to any of the Company's secured indebtedness (including unsecured indebtedness that the Company

(including trade payables) to the extent of the value of the assets securing such indebtedness. The 2025 Notes rank structurally junior to all existing and future indebtedness (including trade payables) incurred by the Company's subsidiaries, financing vehicles or similar facilities. Interest on the 2025 Notes is paid semi-annually on February 25 and August 25 at a rate of 3.500% per annum. The 2025 Notes mature on February 25, 2025 and may be redeemed in whole or in part at any time or from time to time at the Company's option prior to maturity at par plus a "make-whole" premium, if applicable. In addition, holders of the 2025 Notes can require the Company to repurchase the 2025 Notes at 100% of their principal amount upon the occurrence of certain change of control events as described in the 2025 Notes Indenture. The 2025 Notes were issued in minimum denominations of \$2,000 and integral multiples of \$1,000 in excess thereof. During the three and nine months ended June 30, 2024, the Company did not repurchase any of the 2025 Notes in the open market.3000000002025 Notes293000000250000030000007000000.035001<div style="margin-top:10pt;text-indent:22.5pt">The 2025 Notes Indenture contains certain covenants, including covenants requiring the Company's compliance with the asset coverage requirements set forth in Section 18(a)(1)(A) as modified by Section 61(a)(1) and (2) of the Investment Company Act or any successor provisions (but giving effect to any exemptive relief granted to the Company by the U.S. Securities and Exchange Commission ("SEC")), as well as covenants requiring the Company to provide financial information to the holders of the 2025 Notes and the Trustee if the Company ceases to be subject to the reporting requirements of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). These covenants are subject to limitations and exceptions that are described in the 2025 Notes Indenture.</div style="margin-top:10pt;text-indent:22.5pt">On May 18, 2021, the Company issued \$350.0 million in aggregate principal amount of the 2027 Notes for net proceeds of \$344.8 million after deducting OID of \$1.0 million, underwriting commissions and discounts of \$3.5 million and offering costs of \$0.7 million. The OID on the 2027 Notes is amortized based on the effective interest method over the term of the 2027 Notes.</div style="margin-top:10pt;text-indent:22.5pt">The 2027 Notes were issued pursuant to an indenture, dated April 30, 2012, as supplemented by the sixth supplemental indenture, dated May 18, 2021 (collectively, the "2027 Notes Indenture"), between the Company and the Trustee. The 2027 Notes are the Company's general unsecured obligations that rank senior in right of payment to all of the Company's existing and future indebtedness that is expressly subordinated in right of payment to the 2027 Notes. The 2027 Notes rank equally in right of payment with all of the Company's existing and future liabilities that are not so subordinated. The 2027 Notes effectively rank junior to any of the Company's secured indebtedness (including unsecured indebtedness that the Company later secures) to the extent of the value of the assets securing such indebtedness. The 2027 Notes rank structurally junior to all existing and future indebtedness (including trade payables) incurred by the Company's subsidiaries, financing vehicles or similar facilities. Interest on the 2027 Notes is paid semi-annually on January 15 and July 15 at a rate of 2.700% per annum. The 2027 Notes mature on January 15, 2027 and may be redeemed in whole or in part at any time or from time to time at the Company's option prior to maturity at par plus a "make-whole" premium, if applicable. In addition, holders of the 2027 Notes can require the Company to repurchase the 2027 Notes at 100% of their principal amount upon the occurrence of certain change of control events as described in the 2027 Notes Indenture. The 2027 Notes were issued in minimum denominations of \$2,000 and integral multiples of \$1,000 in excess thereof. During the three and nine months ended June 30, 2024, the Company did not repurchase any of the 2027 Notes in the open market.3500000002027 Notes344800000100000035000007000000.027001The 2027 Notes Indenture contains certain covenants, including covenants requiring the Company's compliance with the asset coverage requirements set forth in Section 18(a)(1)(A) as modified by Section 61(a)(1) and (2) of the Investment Company Act or any successor provisions (but giving effect to any exemptive relief granted to the Company by the SEC), as well as covenants requiring the Company to provide financial information to the holders of the 2027 Notes and the Trustee if the Company ceases to be subject to the reporting requirements of the Exchange Act. These covenants are subject to limitations and exceptions that are described in the 2027 Notes Indenture.0.027000.016580.0026161350000000<div style="margin-top:10pt;text-indent:22.5pt">On August 15, 2023, the Company issued \$300.0 million in aggregate principal amount of the 2029 Notes for net proceeds of \$292.9 million after deducting OID of \$3.5 million, underwriting commissions and discounts of \$3.0 million and offering costs of \$0.6 million. The OID on the 2029 Notes is amortized based on the effective interest method over the term of the 2029 Notes.</div style="margin-top:10pt;text-indent:22.5pt">The 2029 Notes were issued pursuant to an indenture, dated April 30, 2012, as supplemented by the seventh supplemental indenture, dated August 15, 2023 (collectively, the "2029 Notes Indenture"), between the Company and the Trustee. The 2029 Notes are the Company's general unsecured obligations that rank senior in right of payment to all of the Company's existing and future indebtedness that is expressly subordinated in right of payment to the 2029 Notes. The 2029 Notes rank equally in right of payment with all of the Company's existing and future liabilities that are not so subordinated. The 2029 Notes effectively rank junior to any of the Company's secured indebtedness (including unsecured indebtedness that the Company later secures) to the extent of the value of the assets securing such indebtedness. The 2029 Notes rank structurally junior to all existing and future indebtedness (including trade payables) incurred by the Company's subsidiaries, financing vehicles or similar facilities.</div style="margin-top:10pt;text-indent:22.5pt">Interest on the 2029 Notes is paid semi-annually on February 15 and August 15 at a rate of 7.100% per annum. The 2029 Notes mature on February 15, 2029 and may be redeemed in whole or in part at any time or from time to time at the Company's option prior to maturity at par plus a "make-whole" premium, if applicable. In addition, holders of the 2029 Notes can require</div style="margin-top:10pt;text-indent:22.5pt">the Company to repurchase the 2029 Notes at 100% of their principal amount upon the occurrence of certain change of control events as described in the 2029 Notes Indenture. The 2029 Notes were issued in minimum denominations of \$2,000 and integral multiples of \$1,000 in excess thereof. During the three and nine months ended June 30, 2024, the Company did not repurchase any of the 2029 Notes in the open market.</div style="margin-top:10pt;text-indent:22.5pt">3000000002029 Notes292900000350000030000006000000.071001<div style="margin-top:10pt;text-indent:22.5pt">The 2029 Notes Indenture contains certain covenants, including covenants requiring the Company's compliance with the asset coverage requirements set forth in Section 18(a)(1)(A) as modified by Section 61(a)(1) and (2) of the Investment Company Act or any successor provisions (but giving effect to any exemptive relief granted to the Company by the SEC), as well as covenants requiring the Company to provide financial information to the holders of the 2029 Notes and the Trustee if the Company ceases to be subject to the reporting requirements of the Exchange Act. These covenants are subject to limitations and exceptions that are described in the 2029 Notes Indenture.</div style="margin-top:10pt;text-indent:22.5pt">In connection with the 2029 Notes, the Company entered into an interest rate swap to more closely align the interest rates of its liabilities with its investment portfolio, which consists of predominantly floating rate loans. Under the interest rate swap agreement, the Company receives a fixed interest rate of 7.100% and pays a floating interest rate of the three-month SOFR plus 3.125% on a notional amount of \$300.0 million. The Company designated the interest rate swap as the hedging instrument in an effective hedge accounting relationship. See Note 12 for more information regarding the interest rate swap.</div style="margin-top:10pt;text-indent:22.5pt">The below table presents the components of the carrying value of the 2025 Notes, the 2027 Notes and the 2029 Notes as of June 30, 2024 and September 30, 2023.</div style="margin-top:10pt;text-indent:22.5pt"><table border="1"><tr><th>Component</th><th>June 30, 2024</th><th>September 30, 2023</th></tr><tr><td>Principal</td><td>300.0</td><td>300.0</td></tr><tr><td>Accrued interest</td><td>0.0</td><td>0.0</td></tr><tr><td>Unamortized discounts and offering costs</td><td>(0.7)</td><td>(0.7)</td></tr><tr><td>Total</td><td>299.3</td><td>299.3</td></tr></table></div style="margin-top:10pt;text-indent:22.5pt">As of June 30, 2024, the Company's carrying value of the 2025 Notes, the 2027 Notes and the 2029 Notes is \$300.0 million, which is equal to the principal amount of the 2025 Notes, the 2027 Notes and the 2029 Notes. The carrying value of the 2025 Notes, the 2027 Notes and the 2029 Notes is equal to the principal amount of the 2025 Notes, the 2027 Notes and the 2029 Notes because the 2025 Notes, the 2027 Notes and the 2029 Notes are not subject to any discounts or offering costs. The carrying value of the 2025 Notes, the 2027 Notes and the 2029 Notes is equal to the principal amount of the 2025 Notes, the 2027 Notes and the 2029 Notes because the 2025 Notes, the 2027 Notes and the 2029 Notes are not subject to any discounts or offering costs. The carrying value of the 2025 Notes, the 2027 Notes and the 2029 Notes is equal to the principal amount of the 2025 Notes, the 2027 Notes and the 2029 Notes because the 2025 Notes, the 2027 Notes and the 2029 Notes are not subject to any discounts or offering costs. The carrying value of the 2025 Notes, the 2027 Notes and the 2029 Notes is equal to the principal amount of the 2025 Notes, the 2027 Notes and the 2029 Notes because the 2025 Notes, the 2027 Notes and the 2029 Notes are not subject to any discounts or offering costs. The carrying value of the 2025 Notes, the 2027 Notes and the 2029 Notes is equal to the principal amount of the 2025 Notes, the 2027 Notes and the 2029 Notes because the 2025 Notes, the 2027 Notes and the 2029 Notes are not subject to any discounts or offering costs. The carrying value of the 2025 Notes, the 2027 Notes and the 2029 Notes is equal to the principal amount of the 2025 Notes, the 2027 Notes and the 2029 Notes because the 2025 Notes, the 2027 Notes and the 2029 Notes are not subject to any discounts or offering costs. The carrying value of the 2025 Notes, the 2027 Notes and the 2029 Notes is equal to the principal amount of the 2025 Notes, the 2027 Notes and the 2029 Notes because the 2025 Notes, the 2027 Notes and the 2029 Notes are not subject to any discounts or offering costs. The carrying value of the 2025 Notes, the

[illegible]

[illegible]

[illegible]

[illegible]

Table 1: Taxable/Distributable Income

Year	2023	2024
Unrealized gains (losses)	\$0.2 million	\$0.1 million
Unrealized depreciation on investments	\$0.6 million	\$0.4 million
Net increase (decrease)	\$0.8 million	\$0.5 million

The Company's taxable income for the three and nine months ended June 30, 2024 is an estimate and will not be finally determined until the Company files its tax return for the fiscal year ending September 30, 2024. Therefore, the final taxable income may be different than the estimate.

The Company uses the liability method to account for its taxable subsidiaries' income taxes. Using this method, the Company recognizes deferred tax assets and liabilities for the estimated future tax effects attributable to temporary differences between financial reporting and tax bases of assets and liabilities. In addition, the Company recognizes deferred tax benefits associated with net loss carry forwards that it may use to offset future tax obligations. The Company measures deferred tax assets and liabilities using the enacted tax rates expected to apply to taxable income in the years in which it expects to recover or settle those temporary differences.

When assessing the realizability of deferred tax assets, the Company considers whether it is probable that some or all of the deferred tax assets will not be realized. In determining whether the deferred tax assets are realizable, the Company considers the period of expiration of the tax asset, historical and projected taxable income and tax liabilities for the tax jurisdiction in which the tax asset is located. The deferred tax asset recognized by the Company, as it relates to the higher tax basis in the carrying value of certain assets compared to the book basis of those assets, will be recognized in future years by these taxable entities. Deferred tax assets are based on the amount of the tax benefit that the Company's management has determined is more likely than not to be realized in future periods. In determining the realizability of this tax benefit, management considered numerous factors that will give rise to pre-tax income in future periods. Among these are the historical and expected future book and tax basis pre-tax income of the Company and unrealized gains in the Company's assets at the determination date. Based on these and other factors, the Company determined that, as of June 30, 2024, \$8.7 million of the \$8.7 million deferred tax assets would not more likely than not be realized in future periods.

For the three months ended June 30, 2024, the Company recognized a total expense for income tax related to realized and unrealized gains (losses) of \$0.2 million, which was composed primarily of a current income tax expense. For the three months ended June 30, 2023, the Company recognized a total expense for income tax related to realized and unrealized gains (losses) of \$0.1 million, which was composed of (i) a current income tax expense of approximately \$1.0 million and (ii) a deferred income tax benefit of approximately \$0.9 million, which resulted from unrealized depreciation on investments held by the Company's wholly-owned taxable subsidiaries.

For the nine months ended June 30, 2024, the Company recognized a total expense for income tax related to realized and unrealized gains (losses) of \$0.6 million, which was composed primarily of a current income tax expense. For the nine months ended June 30, 2023, the Company recognized a total benefit for income tax related to realized and unrealized gains (losses) of \$0.4 million, which was composed of (i) a current income tax expense of approximately \$0.6 million and (ii) a deferred income tax benefit of approximately \$1.0 million, which resulted from unrealized depreciation on investments held by the Company's wholly-owned taxable subsidiaries.

As of September 30, 2023, the Company's last tax year end, the components of accumulated overdistributed earnings on a tax basis were as follows:

Component	2023	2024
Unrealized gains (losses)	\$0.2 million	\$0.1 million
Unrealized depreciation on investments	\$0.6 million	\$0.4 million
Net increase (decrease)	\$0.8 million	\$0.5 million

The aggregate cost of investments for U.S. federal income tax purposes was \$3,070.0 million as of September 30, 2023. As of September 30, 2023, the aggregate gross unrealized appreciation for all investments in which there was an excess of value over cost for U.S. federal income tax purposes was \$729.5 million. As of September 30, 2023, the aggregate gross unrealized depreciation for all investments in which there was an excess of cost for U.S. federal income tax purposes over value was \$704.5 million. Net unrealized depreciation based on the aggregate cost of investments for U.S. federal income tax purposes was \$175.0 million.

Listed below is a reconciliation of "net increase (decrease)" in net assets resulting from operations to taxable income for the three and nine months ended June 30, 2024 and 2023.

Year	2023	2024
Unrealized gains (losses)	\$0.2 million	\$0.1 million
Unrealized depreciation on investments	\$0.6 million	\$0.4 million
Net increase (decrease)	\$0.8 million	\$0.5 million

[illegible]

[illegible]

Total, netOther, netTotal, net

Total, net	Other, net

Total, net

(1) This investment was denominated in foreign currency and the realized gain (loss) shown in this table includes gains (losses) due to foreign currency translation, which was offset by gains (losses) on foreign currency forward contracts.

During the nine months ended June 30, 2023, the Company recorded an aggregate net realized loss of \$19.9 million, which consisted of the following:

Total, net	Other, net

Total, net

Portfolio Company

Net Realized Gain (Loss)

Foreign currency forward contracts

Aden & Anais Merger Sub Inc.

Carvana Co.

Radiology Partners Inc.

Global Medical Response Inc.

Thrasio, LLC

ASP Unifrax Holdings Inc.

WP GPP Holdings LLC

Terresa Therapeutics LLC

Other, net

Net Unrealized Appreciation or Depreciation

Net unrealized appreciation or depreciation reflects the net change in the valuation of the portfolio pursuant to the Company's valuation guidelines and the reclassification of any prior period unrealized appreciation or depreciation.

During the three months ended June 30, 2024 and 2023, the Company recorded net unrealized appreciation (depreciation) of \$26.2 million and \$(1.0) million, respectively. For the three months ended June 30, 2024, this consisted of \$83.6 million of net unrealized appreciation related to exited investments (a portion of which resulted in a reclassification to realized losses) and \$1.1 million of net unrealized appreciation of foreign currency forward contracts, partially offset by \$38.6 million of net unrealized depreciation on debt investments and \$19.9 million of net unrealized depreciation on equity investments. For the three months ended June 30, 2023, this consisted of \$9.8 million of net unrealized depreciation on debt investments and \$0.8 million of net unrealized depreciation on equity investments, partially offset by \$5.0 million of net unrealized appreciation related to exited investments (a portion of which resulted in a reclassification to realized losses) and \$4.6 million of net unrealized appreciation of foreign currency forward contracts.

During the nine months ended June 30, 2024 and 2023, the Company recorded net unrealized depreciation of \$24.1 million and \$42.3 million, respectively. For the nine months ended June 30, 2024, this consisted of \$49.6 million of net unrealized depreciation on debt investments, \$30.5 million of net unrealized depreciation on equity investments and \$4.5 million of net unrealized depreciation of foreign currency forward contracts, partially offset by \$69.5 million of net unrealized appreciation related to exited investments (a portion of which resulted in a reclassification to realized losses). For the nine months ended June 30, 2023, this consisted of \$54.3 million of net unrealized depreciation on debt investments and \$4.8 million of net unrealized depreciation of foreign currency forward contracts, partially offset by \$11.8 million of net unrealized appreciation related to exited investments (a portion of which resulted in a reclassification to realized losses) and \$5.1 million of net unrealized appreciation on equity investments.

During the three months ended June 30, 2024, the Company recorded an aggregate net realized loss of \$69.5 million, which consisted of the following:

Total, net	Other, net

Total, net

Portfolio Company

Net Realized Gain (Loss)

Thrasio, LLC

Other, net

Net Unrealized Appreciation or Depreciation

Net unrealized appreciation or depreciation reflects the net change in the valuation of the portfolio pursuant to the Company's valuation guidelines and the reclassification of any prior period unrealized appreciation or depreciation.

During the three months ended June 30, 2024 and 2023, the Company recorded an aggregate net realized loss of \$10.6 million, which consisted of the following:

Total, net	Other, net

Total, net

[illegible]

color:#ccccff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top">Foreign currency forward contracts</td><td style="background-color:#ccccff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"></td><td style="background-color:#ccccff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top">(5.5)</td><td colspan="3" style="background-color:#ccccff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ccccff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top">Aden & Anais Merger Sub Inc.</td><td colspan="3" style="background-color:#ccccff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(5.2)</td><td colspan="3" style="background-color:#ccccff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ccccff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top">Carvana Co.</td><td colspan="3" style="background-color:#ccccff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(2.8)</td><td colspan="3" style="background-color:#ccccff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top">(4.2)</td><td colspan="3" style="background-color:#ccccff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top">ASP Unifrax Holdings Inc.</td><td colspan="3" style="background-color:#ccccff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(2.1)</td><td colspan="3" style="background-color:#ccccff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top">(2.8)</td><td colspan="3" style="background-color:#ccccff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top">WP CPP Holdings LLC</td><td colspan="3" style="background-color:#ccccff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(1.3)</td><td colspan="3" style="background-color:#ccccff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top">(3.0)</td><td colspan="3" style="background-color:#ccccff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top">(5.2)</td><td colspan="3" style="background-color:#ccccff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top">Other, net</td><td colspan="3" style="background-color:#ccccff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(3.0)</td><td colspan="3" style="background-color:#ccccff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top">(3.0)</td><td colspan="3" style="background-color:#ccccff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt">Total, net</div></td><td colspan="3" style="background-color:#ccccff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccccff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(19.9)</td><td colspan="3" style="background-color:#ccccff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>69500000-68500000-1000000-0-69500000-10600000-6300000-5200000-3800000-13000005200000800000-10600000-84500000-68500000-13400000-6800000-1900000-1800000-1700000-1400000480000046000002600000-1000000-0-84500000-19900000-5000000-5200000-4200000-2800000-2100000-1300000-05200000-05200000-3000000-0-1990000026200000-1000000836000001100000-38600000-19900000-9800000-8000005000004600000-24100000-42300000-49600000-30500000-450000060500000-54300000-4800000118000003100000Concentration of Credit Risks</div><td colspan="3" style="background-color:#ccccff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">The Company deposits its cash with financial institutions and at times such balances are in excess of the FDIC insurance limit. The Company limits its exposure to credit loss by depositing its cash with high credit quality financial institutions and monitoring their financial stability.</div>Related Party Transactions</div><td colspan="3" style="background-color:#ccccff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">As of June 30, 2024 and September 30, 2023, the Company had a liability on its Consolidated Statements of Assets and Liabilities in the amount of \$15.4 million and \$19.5 million, respectively, reflecting the unpaid portion of the base management fees and incentive fees payable to Oaktree.</div><div style="margin-top:14.75pt;padding-left:9pt">Investment Advisory Agreement</div><div style="margin-top:10pt;padding-right:13.5pt;text-indent:20.25pt">The investment advisory agreement with Oaktree was amended and restated on March 19, 2021 in connection with the closing of the OCSI Merger and on January 23, 2023 in connection with the closing of OS12 Merger. The term "Investment Advisory Agreement" refers collectively to the agreements with Oaktree.</div><div style="margin-top:10pt;padding-right:13.5pt;text-indent:20.25pt">Unless earlier terminated as described below, the Investment Advisory Agreement will remain in effect from year-to-year if approved annually by the Board of Directors of the Company or by the affirmative vote of the holders of a majority of the Company's outstanding voting securities, including, in either case, approval by a majority of the directors of the Company who are not interested persons. The Investment Advisory Agreement will automatically terminate in the event of its assignment. The Investment Advisory Agreement may be terminated by either party without penalty upon 60 days' written notice to the other. The Investment Advisory Agreement may also be terminated, without penalty, upon the vote of a majority of the outstanding voting securities of the Company.</div><div style="margin-top:14.75pt;padding-left:9pt">Base Management Fee</div><div style="margin-top:2.15pt;text-indent:20.25pt"></div><div style="text-indent:18pt">Under the Investment Advisory Agreement, the base management fee is calculated at an annual rate of 1.50% of total gross assets, including any investment made with borrowings, but excluding cash and cash equivalents. The base management fee is payable quarterly in arrears and the fee for any partial month or quarter is appropriately prorated. Effective May 3, 2019 and through June 30, 2024, the base management fee on the Company's gross assets, including any investments made with borrowings, but excluding any cash and cash equivalents, that exceed the product of (A) 200% and (B) the Company's net asset value will be 1.00%. For the avoidance of doubt, the 200% will be calculated in accordance with the Investment Company Act and will give effect to exemptive relief the Company received from the SEC with respect to debentures issued by a small business investment company subsidiary. In connection with the OCSI Merger, Oaktree waived an aggregate of \$6 million of base management fees otherwise payable to Oaktree in the two years following the closing of the OCSI Merger on March 19, 2021 at a rate of \$750,000 per quarter (with such amount appropriately prorated for any partial quarter). In connection with the OS12 Merger, Oaktree waived an aggregate of \$9.0 million of base management fees payable to Oaktree as follows: \$6.0 million at a rate of \$1.5 million per quarter (with such amount appropriately prorated for any partial quarter) in the first year following closing of the OS12 Merger on January 23, 2023 and \$3.0 million at a rate of \$750,000 per quarter (with such amount appropriately prorated for any partial quarter) in the second year following closing of the OS12 Merger.</div><div style="text-indent:18pt">On April 26, 2024, Oaktree waived additional base management fees such that the total amount of waived base management fees (including those waived in connection with the OS12 Merger described above) was \$1.5 million for each of</div><div>the three months ended March 31, 2024 and June 30, 2024. In addition, effective July 1, 2024, the base management fee is calculated (net of base management fees previously waived by Oaktree) at an annual rate of 1.00% of total gross assets, including any investments made with borrowings, but excluding cash and cash equivalents.</div><div style="margin-top:10pt;text-indent:22.5pt">For the three and nine months ended June 30, 2024, the base management fee incurred under the Investment Advisory Agreement was \$10.3 million (net of waiver) and \$30.4 million (net of waiver), respectively. For the three and nine months ended June 30, 2023, the base management fee incurred under the Investment Advisory Agreement was \$10.5 million (net of waiver) and \$29.4 million (net of waiver), respectively.</div><div style="margin-top:14.75pt;padding-left:9pt">Incentive Fee</div><div style="margin-top:14.75pt;text-indent:18pt">The incentive fee consists of two parts. Under the Investment Advisory Agreement, the first part of the incentive fee (the "incentive fee on income" or "Part I incentive fee") is calculated and payable quarterly in arrears based upon the "pre-incentive fee net investment income" of the Company for the immediately preceding quarter. The payment of the incentive fee on income is subject to payment of a preferred return to investors each quarter (i.e., a "hurdle rate"), expressed as a rate of return on the value of the Company's net assets at the end of the most recently completed quarter, of 1.50%, subject to a "catch up" feature.</div><div style="margin-top:14.75pt;text-indent:18pt">For this purpose, "pre-incentive fee net investment income" means interest income, dividend income and any other income (including any other fees such as commitment, origination, structuring, diligence and consulting fees or other fees that the Company receives from portfolio companies, other than fees for providing managerial assistance) accrued during the fiscal quarter, minus the Company's operating expenses for the quarter (including the base management fee, expenses payable under the Administration Agreement and any interest expense and dividends paid on any issued and outstanding preferred stock, but excluding the incentive fee). Pre-incentive fee net investment income includes, in the case of investments with a deferred interest feature (such as OID debt, instruments with PIK interest and zero coupon securities), accrued income that the Company has not yet received in cash. Pre-incentive fee net investment income does not include any realized capital gains, realized capital losses or unrealized capital appreciation or depreciation. In addition, pre-incentive fee net investment income does not include any amortization or accretion of any purchase premium or purchase discount to interest income resulting solely from merger-related accounting adjustments in connection with the assets acquired in the OCSI Merger or in the OS12 Merger, in each case, including any premium or discount paid for the acquisition of such assets, solely to the extent that the inclusion of such merger-related accounting adjustments, in the aggregate, would result in an increase in pre-incentive fee net investment income.</div><div style="text-indent:18pt">Under the Investment Advisory Agreement, the calculation of the incentive fee on income for each quarter is as follows:</div><div style="margin-top:2.15pt"></div><div style="padding-left:36pt;padding-right:20.25pt;text-indent:13.5pt">No incentive fee is payable to Oaktree in any quarter in which the Company's pre-incentive fee net investment income does not exceed the preferred return rate of 1.50% (the "preferred return") on net assets;</div><div></div>

"padding-left:36pt;padding-right:2.25pt;text-indent:-13.5pt">100% of the Company's pre-incentive fee net investment income, if any, that exceeds the preferred return but is less than or equal to 1.8182% in any fiscal quarter is payable to Oaktree. This portion of the incentive fee on income is referred to as the "catch-up" provision, and it is intended to provide Oaktree with an incentive fee of 17.5% on all of the Company's pre-incentive fee net investment income when the Company's pre-incentive fee net investment income exceeds 1.8182% on net assets in any fiscal quarter; and</div><div style="padding-left:36pt;padding-right:2.25pt;text-indent:-13.5pt">For any quarter in which the Company's pre-incentive fee net investment income exceeds 1.8182% on net assets, the incentive fee on income is equal to 17.5% of the amount of the Company's pre-incentive fee net investment income, as the preferred return and catch-up will have been achieved.</div><div style="text-indent:18pt">
There is no accumulation of amounts on the hurdle rate from quarter to quarter and accordingly there is no clawback of amounts previously paid if subsequent quarters are below the quarterly hurdle. For the three months ended June 30, 2024, Oaktree waived \$3.2 million of Part I incentive fees.</div><div style="text-indent:18pt">
For the three and nine months ended June 30, 2024, the first part of the incentive fee (incentive fee on income) incurred under the Investment Advisory Agreement was \$5.1 million (net of waiver) and \$22.6 million (net of waiver), respectively. For the three and nine months ended June 30, 2023, the first part of the incentive fee (incentive fee on income) incurred under the Investment Advisory Agreement was \$9.6 million and \$26.3 million, respectively.</div><div style="text-indent:18pt"><div style="text-indent:18pt">Under the Investment Advisory Agreement, the second part of the incentive fee (the "capital gains incentive fee") is determined and payable in arrears as of the end of each fiscal year (or upon termination of the Investment Advisory Agreement, as of the termination date) commencing with the fiscal year ended September 30, 2019 and equals 17.5% of the Company's realized capital gains, if any, on a cumulative basis from the beginning of the fiscal year ended September 30, 2019 through the end of each subsequent fiscal year, computed net of all realized capital losses and unrealized capital depreciation on a</div><div style="color:#000000;font-family:Times New Roman,sans-serif;font-size:10pt;font-weight:400;line-height:112%">cumulative basis, less the aggregate amount of any previously paid capital gain incentive fees under the Investment Advisory Agreement. Any realized capital gains, realized capital losses, unrealized capital appreciation and unrealized capital depreciation with respect to the Company's portfolio as of the end of the fiscal year ended September 30, 2018 are excluded from the calculations of the second part of the incentive fee. In addition, the calculation of realized capital gains, realized capital losses and unrealized capital depreciation does (1) not include any such amounts resulting solely from merger-related accounting adjustments in connection with the assets acquired in the OCSI Merger or in the OSI2 Merger, in each case, including any premium or discount paid for the acquisition of such assets, solely to the extent that the inclusion of such merger-related accounting adjustments, in the aggregate, would result in an increase in the capital gains incentive fee, (2) include any such amounts associated with the investments acquired in the OCSI Merger for the period from October 1, 2018 to the date of closing of the OCSI Merger, solely to the extent that the exclusion of such amounts, in the aggregate, would result in an increase in the capital gains incentive fee and (3) include any such amounts associated with the investments acquired in the OSI2 Merger for the period from August 6, 2018 to the date of closing of the OSI2 Merger, solely to the extent that the exclusion of such amounts, in the aggregate, would result in an increase in the capital gains incentive fee. As of June 30, 2024, the Company paid \$9.6 million of capital gains incentive fees cumulatively under the Investment Advisory Agreement (net of waivers). Part II incentive fees are contractually calculated and paid at the end of the fiscal year in accordance with the Investment Advisory Agreement, which, as described above, differs from Part II incentive fees accrued under GAAP. Hypothetically, if Part II incentive fees were calculated as of June 30, 2024 under the Investment Advisory Agreement, no Part II incentive fees would be payable.</div><div style="text-indent:18pt">
GAAP requires that the capital gains incentive fee accrual consider the cumulative aggregate unrealized capital appreciation in the calculation, as a capital gains incentive fee would be payable if such unrealized capital appreciation were realized on a theoretical "liquidation basis." A fee so calculated and accrued would not be payable under applicable law and may never be paid based upon the computation of capital gains incentive fees in subsequent periods. Amounts ultimately paid under the Investment Advisory Agreement will be consistent with the formula reflected in the Investment Advisory Agreement. This GAAP accrual is calculated using the aggregate cumulative realized capital gains and losses and aggregate cumulative unrealized capital depreciation included in the calculation of the capital gains incentive fee plus the aggregate cumulative unrealized capital appreciation. Any realized capital gains and losses and cumulative unrealized capital appreciation and depreciation with respect to the Company's portfolio as of the end of the fiscal year ended September 30, 2018 are excluded from the GAAP accrual. If such amount is positive at the end of a period, then GAAP requires the Company to record a capital gains incentive fee equal to 17.5% of such cumulative amount, less the aggregate amount of actual capital gains incentive fees payable or capital gains incentive fees accrued under GAAP in all prior periods. The resulting accrual for any capital gains incentive fee under GAAP in a given period may result in an additional expense if such cumulative amount is greater than in the prior period or a reversal of previously recorded expense if such cumulative amount is less than in the prior period. If such cumulative amount is negative, then there is no accrual. There can be no assurance that such unrealized capital appreciation will be realized in the future or any accrued capital gains incentive fee will become payable under the Investment Advisory Agreement. For the three and nine months ended June 30, 2024 and 2023, there were no accrued capital gains incentive fees. As of June 30, 2024, the total accrued capital gains incentive fee liability was zero.</div><div style="margin-top:14.75pt;padding-left:9pt">Indemnification</div><div style="text-indent:18pt">
The Investment Advisory Agreement provides that, absent willful misfeasance, bad faith or gross negligence in the performance of their respective duties or by reason of the reckless disregard of their respective duties and obligations, Oaktree and its officers, managers, partners, members (and their members, including the owners of their members), agents, employees, controlling persons and any other person or entity affiliated with it, are entitled to indemnification from the Company for any damages, liabilities, costs and expenses (including reasonable attorneys' fees and amounts reasonably paid in settlement) arising from the rendering of Oaktree's services under the Investment Advisory Agreement or otherwise as investment adviser.</div><div style="margin-top:14pt;text-indent:11.25pt">Administrative Services</div><div style="margin-top:14pt;text-indent:18pt">The Company is party to the Administration Agreement with Oaktree Administrator. Pursuant to the Administration Agreement, Oaktree Administrator provides administrative services to the Company necessary for the operations of the Company, which include providing office facilities, equipment, clerical, bookkeeping and record keeping services at such facilities and such other services as Oaktree Administrator, subject to review by the Company's Board of Directors, shall from time to time deem to be necessary or useful to perform its obligations under the Administration Agreement. Oaktree Administrator may, on behalf of the Company, conduct relations and negotiate agreements with custodians, trustees, depositories, attorneys, underwriters, brokers and dealers, corporate fiduciaries, insurers, banks and such other persons in any such other capacity deemed to be necessary or desirable. Oaktree Administrator makes reports to the Company's Board of Directors of its performance of obligations under the Administration Agreement and furnishes advice and recommendations with respect to such other aspects of the Company's business and affairs, in each case, as it shall determine to be desirable or as</div><div style="margin-top:14pt">reasonably required by the Company's Board of Directors; provided that Oaktree Administrator shall not provide any investment advice or recommendation.</div><div style="margin-top:14pt;text-indent:18pt">Oaktree Administrator also provides portfolio collection functions for interest income, fees and warrants and is responsible for the financial and other records that the Company is required to maintain and prepares, prints and disseminates reports to the Company's stockholders and all other materials filed with the SEC. In addition, Oaktree Administrator assists the Company in determining and publishing the Company's net asset value, overseeing the preparation and filing of the Company's tax returns, and generally overseeing the payment of the Company's expenses and the performance of administrative and professional services rendered to the Company by others. Oaktree Administrator may also offer to provide, on the Company's behalf, managerial assistance to the Company's portfolio companies.</div><div style="margin-top:14pt;text-indent:18pt">For providing these services, facilities and personnel, the Company reimburses Oaktree Administrator the allocable portion of overhead and other expenses incurred by Oaktree Administrator in performing its obligations under the Administration Agreement, including the Company's allocable portion of the rent of the Company's principal executive offices (which are located in a building owned by a Brookfield affiliate) at market rates and the Company's allocable portion of the costs of compensation and related expenses of its Chief Financial Officer, Chief Compliance Officer, their staffs and other non-investment professionals at Oaktree that perform duties for the Company. Such reimbursement is at cost, with no profit to, or markup by, Oaktree Administrator. The Administration Agreement may be terminated by either party without penalty upon 60 days' written notice to the other. The Administration Agreement may also be terminated, without penalty, upon the vote of a majority of the Company's outstanding voting securities.</div><div style="margin-top:14pt;text-indent:18pt">For the three months ended June 30, 2024 and 2023, the Company accrued administrative expenses of \$0.5 million and \$0.4 million, respectively, including \$0.1 million and \$0.1 million of general and administrative expenses, respectively. For the nine months ended June 30, 2024 and 2023, the Company accrued administrative expenses of \$1.3 million and \$1.2 million, respectively, including \$0.3 million and \$0.2 million of general and administrative expenses, respectively.</div><div style="margin-top:14pt;text-indent:18pt">As of June 30, 2024 and September 30, 2023, \$4.8 million and \$4.3 million, respectively, was included in "Due to affiliate" in the Consolidated Statements of Assets and Liabilities, reflecting the unpaid portion of administrative expenses and other reimbursable expenses payable to Oaktree Administrator.</div></div><div>154000001950000022P60D0.015020.01002600000002P2Y750000900000060000001500000300000075000015000000.01001030000030400000010500000294000000.015</div><div style="color:#000000;font-family:Times New Roman,sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Highlights</div><div style="margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.554%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.1%"&

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

~~there is less competition and thus potential for greater returns, for our new investment opportunities: (1) situational lending, which we define to include directly originated loans to non-sponsor companies that are hard to understand and value using traditional underwriting techniques, (2) select sponsor lending, which we define to include financing to support leveraged buyouts of companies with specialized sponsors that have expertise in certain industries, (3) stressed sector and rescue lending, which we define to include opportunistic private loans in industries experiencing stress or limited access to capital and (4) public credit, where we seek discounted, high quality public debt investments particularly in times of market dislocation.~~

~~As discussed in Note 2, the Company completed a 1-for-3 reverse stock split on January 20, 2023, effective as of the commencement of trading on January 23, 2023. The weighted average common shares outstanding and per share information reflect the reverse stock split on a retroactive basis as necessary. As discussed in Note 2, the Company completed a 1-for-3 reverse stock split on January 20, 2023, effective as of the commencement of trading on January 23, 2023. The weighted average common shares outstanding and per share information reflect the reverse stock split on a retroactive basis as necessary. Interest rates may be adjusted from period to period on certain term loans and revolving. These rate adjustments may be either temporary in nature due to tier pricing arrangements or financial or payment covenant violations in the original credit agreements or permanent in nature per loan amendment or waiver documents.~~

~~The interest rate on the principal balance outstanding for most of the floating rate loans is indexed to the secured overnight financing rate ("SOFR"), the euro interbank offered rate ("EURIBOR" or "E"), the sterling overnight index average ("SONIA") and/or an alternate base rate (e.g., prime rate), which typically resets semi-annually, quarterly, or monthly at the borrower's option. The borrower may also elect to have multiple interest reset periods for each loan. For each of these loans, the Company has provided the applicable margin over the reference rate based on each respective credit agreement and the cash interest rate as of period end. As of June 30, 2024, the reference rates for the Company's variable rate loans were the 30-day SOFR at 5.34%, the 90-day SOFR at 5.33%, the 180-day SOFR at 5.23%, the PRIME at 6.50%, the SONIA at 5.23% and the 90-day EURIBOR at 3.62%. Most loans include an interest floor, which generally ranges from 0% to 3.00%. SOFR and SONIA based contracts may include a credit spread adjustment that is charged in addition to the base rate and the stated spread. Principal includes accumulated payment in kind ("PIK") interest and is net of repayments, if any. "£" signifies the investment is denominated in British Pounds. "€" signifies the investment is denominated in Euros. All other investments are denominated in U.S. dollars. Control investments generally are defined by the Investment Company Act of 1940, as amended (the "Investment Company Act"), as investments in companies in which the Company owns more than 25% of the voting securities or maintains greater than 50% of the board representation. As defined in the Investment Company Act, the Company is deemed to be both an "Affiliated Person" of and to "Control" these portfolio companies as the Company owns more than 25% of the portfolio company's outstanding voting securities or has the power to exercise control over management or policies of such portfolio company (including through a management agreement). See Schedule 12-14 in the accompanying notes to the Consolidated Financial Statements for transactions during the nine months ended June 30, 2024 in which the issuer was both an Affiliated Person and a portfolio company that the Company is deemed to control. This investment represents a participation interest in the underlying securities shown. Investment is not a "qualifying asset" as defined under Section 55(a) of the Investment Company Act. Under the Investment Company Act, the Company may not acquire any non-qualifying asset unless, at the time the acquisition is made, qualifying assets represent at least 70% of the Company's total assets. As of June 30, 2024, qualifying assets represented 72.7% of the Company's total assets and non-qualifying assets represented 27.3% of the Company's total assets. Income producing through payment of dividends or distributions. This investment represents Seller Earn Out Shares in Alvotech SA. The Seller Earn Out Shares will vest if, at any time through June 16, 2027, the Alvotech SA common share price is at or above a volume weighted average price ("VWAP") of \$20.00 per share for any trading days within any trading day period.tenttwenty. See Note 3 in the accompanying notes to the Consolidated Financial Statements for portfolio composition. ("ASC 820"); As of June 30, 2024, these investments were categorized as Level 3 within the fair value hierarchy established by Financial Accounting Standards Board ("FASB") guidance under Accounting Standards Codification ("ASC") Topic 820, Fair Value Measurements and Disclosures. This investment was valued using net asset value as a practical expedient for fair value. Consistent with ASC 820, these investments are excluded from the hierarchical levels. Affiliate Investments generally are defined by the Investment Company Act as investments in companies in which the Company owns between 5% and 25% of the voting securities. Non-Control/Non-Affiliate investments are investments that are neither Control Investments nor Affiliate Investments. Investment had undrawn commitments. Unamortized fees are classified as unearned income which reduces cost basis, which may result in a negative cost basis. A negative fair value may result from the unfunded commitment being valued below par. This investment was on non-accrual status as of June 30, 2024. This investment represents a revenue interest financing term loan in which the Company receives periodic interest payments based on a percentage of revenues earned at the respective portfolio company over the life of the loan. This investment represents a credit default swap that functions, in substance, like a credit linked note and represents a credit risk transfer for a pool of reference assets owned by a bank. The Company fully funded margin up front and in return the Company receives periodic interest payments. The Company's risk of loss is limited to the principal amount disclosed herein. The reference assets are primarily composed of investment grade corporate debt. The Company may be exposed to counterparty risk, which could make it difficult for the Company to collect on obligations, thereby resulting in potentially significant losses. In addition, the Company only has a contractual relationship with the counterparty bank, and not with the reference obligors of the reference assets. Accordingly, the Company generally may have no right to directly enforce compliance by the reference obligors with the terms of the reference assets. The Company will not directly benefit from the reference assets and will not have the benefit of the remedies that would normally be available to a holder of such reference assets. In addition, in the event of the insolvency of the counterparty bank, the Company may be treated as a general creditor of such counterparty bank, and will not have any claim with respect to the reference assets. This investment was renamed during the three months ended June 30, 2024. For the periods prior to June 30, 2024, this investment was referenced as SCP Eye Care Services, LLC. All debt investments are income producing unless otherwise noted. All equity investments are non-income producing unless otherwise noted. See Note 3 in the accompanying notes to the Consolidated Financial Statements for portfolio composition by geographic region. Equity ownership may be held in shares or units of companies related to the portfolio companies. Each of the Company's investments is pledged as collateral under one or more of its credit facilities. A single investment may be divided into parts that are individually pledged as collateral to separate credit facilities. Interest rates may be adjusted from period to period on certain term loans and revolving. These rate adjustments may be either temporary in nature due to tier pricing arrangements or financial or payment covenant violations in the original credit agreements or permanent in nature per loan amendment or waiver documents.~~

~~The interest rate on the principal balance outstanding for most of the floating rate loans is indexed to SOFR, the London Interbank Offered Rate ("LIBOR" or "L"), SONIA and/or an alternate base rate (e.g., prime rate), which typically resets semi-annually, quarterly, or monthly at the borrower's option. The borrower may also elect to have multiple interest reset periods for each loan. For each of these loans, the Company has provided the applicable margin over the reference rate based on each respective credit agreement and the cash interest rate as of period end. All LIBOR and SOFR shown above is in U.S. dollars unless otherwise noted. As of September 30, 2023, the reference rates for the Company's variable rate loans were the 30-day SOFR at 5.23%, the 90-day SOFR at 5.23%, the 180-day SOFR at 5.47%, the 30-day LIBOR at 5.42%, the 90-day LIBOR at 5.65%, the 180-day LIBOR at 5.90%, the PRIME at 6.50%, the SONIA at 5.19%, the 30-day EURIBOR at 3.42%, the 90-day EURIBOR at 3.82% and the 180-day EURIBOR at 3.95%. Most loans include an interest floor, which generally ranges from 0% to 2.75%. SOFR and SONIA based contracts may include a credit spread adjustment that is charged in addition to the base rate and the stated spread. Principal includes accumulated PIK interest and is net of repayments, if any. "£" signifies the investment is denominated in British Pounds. "€" signifies the investment is denominated in Euros. All other investments are denominated in U.S. dollars. Control investments generally are defined by the Investment Company Act as investments in companies in which the Company owns more than 25% of the voting securities or maintains greater than 50% of the board representation. As defined in the Investment Company Act, the Company is deemed to be both an "Affiliated Person" of and to "Control" these portfolio companies as the Company owns more than 25% of the portfolio company's outstanding voting securities or has the power to exercise control over management or policies of such portfolio company (including through a management agreement). See Schedule 12-14 in the Company's annual report on Form 10-K for the year ended September 30, 2023 for transactions during the year ended September 30, 2023 in which the issuer was both an Affiliated Person and a portfolio company that the Company is deemed to control. This investment represents a participation interest in the underlying securities shown. Investment is not a "qualifying asset" as defined under Section 55(a) of the Investment Company Act. Under the Investment Company Act, the Company may not acquire any non-qualifying asset unless, at the time the acquisition is made, qualifying assets represent at least 70% of the Company's total assets. As of September 30, 2023, qualifying assets represented 74.3% of the Company's total assets and non-qualifying assets represented 25.7% of the Company's total assets. Income producing through payment of dividends or distributions. This investment represents Seller Earn Out Shares in Alvotech SA. One half of the Seller Earn Out Shares will vest if, at any time through June 16, 2027, the Alvotech SA common share price is at or above a VWAP of \$15.00 per share for any trading days within any trading day period, and the other half will vest, if at any time during such period, the common share price is at or above a VWAP of \$20.00 per share for any trading days within any trading day period.tenttwentytenttwenty. See Note 3 in the accompanying notes to the Consolidated Financial Statements for portfolio composition. As of September 30, 2023, these investments were categorized as Level 3 within the fair value hierarchy established by ASC 820. This investment was valued using net asset value as a practical expedient for fair value. Consistent with ASC 820, these investments are excluded from the hierarchical levels. Affiliate Investments generally are defined by the Investment Company Act as investments in companies in which the Company owns between 5% and 25% of the voting securities. Investment had undrawn commitments. Unamortized fees are classified as unearned income which reduces cost basis, which may result in a negative cost basis. A negative fair value may result from the unfunded commitment being valued below par. This investment was on non-accrual status as of September 30, 2023. This investment was renamed during the three months ended March 31, 2023. For periods prior to March 31, 2023, this investment was referenced as PFNY Holdings, LLC. This investment represents a revenue interest financing term loan in which the Company receives periodic interest payments based on a percentage of revenues earned at the respective portfolio company over the life of the loan.~~

~~1876%\$<\$>P@Q.CFR3^&719°C:4\$641#?J7GBZBE44:C4I4H<9.=T+)^&NW" @&TS M/ALZ8V> <#XT@K=&>&N(4^F\$ZP1+H9&B-8(EP,BZ%NCE+?&L 5Y7#W16^C, MJFK? #KGSRRHYG=DIS5P^X)XP3/QLU<6Z6 /-=#J M4+0^NAP:2^WE,QMGK^R>J)?_".6,_TC_8F.Y%DI&CEW18#1HBV3@WG^R,~~